-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
did VERB - O
not ADV - O
have VERB - O
any DET - O
significant ADJ - O
effect NOUN - O
on ADP - O
the DET - O
cortisol ADJ - O
awakening NOUN - O
response NOUN - O
or CCONJ - O
the DET - O
total ADJ - O
daily ADJ - O
cortisol NOUN - O
output NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram CD - B-MEDICINE
, PUNCT - O
one NUM - O
of ADP - O
the DET - O
newer ADV - O
selective ADJ - O
serotonin NOUN - O
reuptake VERB - O
inhibitors NOUN - O
( PUNCT - O
SSRIs PROPN - O
) PUNCT - O
, PUNCT - O
is VERB - O
considered VERB - O
preferable ADJ - O
due ADP - O
to ADP - O
its ADJ - O
relatively ADV - O
high ADJ - O
efficacy NOUN - O
and CCONJ - O
acceptability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Racial ADJ - O
Differences PROPN - O
in ADP - O
Escitalopram NNP - B-MEDICINE
/ SYM - I-ORG
Citalopram NNP - I-ORG
- HYPH - I-ORG
Related NNP - I-ORG
Weight NNP - I-ORG
Gain NNP - I-ORG
in IN - I-ORG
Children PROPN - O
and CCONJ - O
Adolescents PROPN - O
: PUNCT - O
A DET - O
Natural PROPN - O
Language PROPN - O
Processing PROPN - O
- PUNCT - O
Based VERB - O
Electronic PROPN - O
Medical PROPN - O
Record PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NN - B-MEDICINE
attenuates VERB - O
fear VERB - O
stress NOUN - O
- PUNCT - O
induced VERB - O
increase NOUN - O
in ADP - O
amygdalar ADJ - O
dopamine NOUN - O
following VERB - O
methamphetamine NOUN - O
- PUNCT - O
induced VERB - O
sensitisation NOUN - O
: PUNCT - O
Implications NOUN - O
of ADP - O
fine ADJ - O
- PUNCT - O
tuning NOUN - O
action NOUN - O
of ADP - O
selective ADJ - O
serotonin NOUN - O
reuptake VERB - O
inhibitors NOUN - O
on ADP - O
emotional ADJ - O
processing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram VB - B-MEDICINE
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Anxiety NNP - I-ORG
in ADP - O
Chromosome PROPN - O
18p NOUN - O
Deletion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
( PUNCT - O
ESC NNP - B-ORG
) PUNCT - O
is VERB - O
one CD - B-CARDINAL
of ADP - O
only RB - B-CARDINAL
two CD - I-CARDINAL
antidepressants NOUN - O
approved VERB - O
as ADP - O
treatment NOUN - O
for ADP - O
juvenile ADJ - O
depression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
ancillary ADJ - O
investigation NOUN - O
of ADP - O
the DET - O
Escitalopram NNP - B-MEDICINE
vs. ADP - O
Electrical NNP - B-ORG
Current NNP - I-ORG
Therapy NNP - I-ORG
for IN - I-ORG
Treating VBG - I-ORG
Depression NNP - I-ORG
Clinical NNP - I-ORG
Study PROPN - O
( PUNCT - O
ELECT NOUN - O
- PUNCT - O
TDCS PROPN - O
) PUNCT - O
, PUNCT - O
we PRON - O
investigated VERB - O
whether ADP - O
plasma ADJ - O
levels NOUN - O
of ADP - O
several ADJ - O
cytokines NOUN - O
and CCONJ - O
neurotrophic ADJ - O
factors NOUN - O
associated VERB - O
with ADP - O
major ADJ - O
depression NOUN - O
or CCONJ - O
antidepressant NOUN - O
response NOUN - O
predicted VERB - O
tDCS PROPN - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
CYP2C19 PROPN - O
Genotype PROPN - O
on ADP - O
Escitalopram NNP - B-MEDICINE
Exposure NNP - I-ORG
and CC - I-ORG
Therapeutic PROPN - O
Failure NOUN - O
: PUNCT - O
A DET - O
Retrospective PROPN - O
Study NOUN - O
Based VERB - O
on ADP - O
2,087 CD - B-CARDINAL
Patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
increased VERB - O
waist NOUN - O
( PUNCT - O
median NOUN - O
( PUNCT - O
quartiles NOUN - O
) PUNCT - O
change NOUN - O
1 CD - B-CARDINAL
( PUNCT - O
0 CD - B-CARDINAL
; SYM - O

Escitalopram NNP - B-MEDICINE
had VERB - O
no DET - O
significant ADJ - O
effect NOUN - O
on ADP - O
measures NOUN - O
of ADP - O
insulin NOUN - O
sensitivity NOUN - O
, PUNCT - O
insulin NOUN - O
secretion NOUN - O
, PUNCT - O
fasting VERB - O
lipids NOUN - O
, PUNCT - O
mental ADJ - O
health NOUN - O
or CCONJ - O
HRQoL.Waist ADJ - O
circumference NOUN - O
and CCONJ - O
cortisol ADJ - O
levels NOUN - O
increased VERB - O
during ADP - O
treatment NOUN - O
with ADP - O
escitalopram NN - B-MEDICINE
in ADP - O
women NOUN - O
with ADP - O
PCOS NNP - B-ORG
and CCONJ - O
no DET - O
clinical ADJ - O
depression NOUN - O
, PUNCT - O
whereas ADP - O
metabolic ADJ - O
risk NOUN - O
markers NOUN - O
, PUNCT - O
mental ADJ - O
health NOUN - O
and CCONJ - O
HRQol NNP - B-PERSON
were VERB - O
unchanged ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NN - B-MEDICINE
- PUNCT - O
induced VERB - O
delayed VERB - O
drug NOUN - O
rash NOUN - O
with ADP - O
deranged VERB - O
liver NOUN - O
function NOUN - O
: PUNCT - O
a DET - O
possible ADJ - O
case NOUN - O
of ADP - O
drug NOUN - O
reaction NOUN - O
with ADP - O
eosinophilia ADJ - O
and CCONJ - O
systemic ADJ - O
reaction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Secondary PROPN - O
Prevention PROPN - O
of ADP - O
Chronic PROPN - O
PTSD PROPN - O
by ADP - O
Early ADJ - O
and CCONJ - O
Short NNP - B-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Administration NNP - I-ORG
of ADP - O
Escitalopram NNP - B-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Seventy CD - B-CARDINAL
- HYPH - I-CARDINAL
three CD - I-CARDINAL
depressive ADJ - O
patients NOUN - O
medicated VERB - O
with ADP - O
Escitalopram NNP - B-MEDICINE
( PUNCT - O
n NOUN - O
= SYM - O
37 NUM - O
) PUNCT - O
or CCONJ - O
Duloxetine NNP - B-PERSON
( PUNCT - O
n NOUN - O
= SYM - O
36 CD - B-CARDINAL
) PUNCT - O
were VERB - O
assessed VERB - O
using VERB - O
the DET - O
Hamilton NNP - B-PERSON
depression NOUN - O
rating NOUN - O
scale NOUN - O
over ADP - O
a DET - O
24-week CD - B-CARDINAL
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
has VERB - O
some DET - O
unique ADJ - O
features NOUN - O
among ADP - O
selective ADJ - O
serotonin NOUN - O
reuptake VERB - O
inhibitors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
and CCONJ - O
citalopram NOUN - O
are VERB - O
associated VERB - O
with ADP - O
the DET - O
highest ADJ - O
risk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram NNP - B-MEDICINE
and CCONJ - O
NHT NNP - B-ORG
normalized VERB - O
stress NOUN - O
- PUNCT - O
induced VERB - O
anhedonia NOUN - O
and CCONJ - O
molecular ADJ - O
neuroadaptations NOUN - O
in ADP - O
a DET - O
mouse NOUN - O
model NOUN - O
of ADP - O
depression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
Use PROPN - O
of ADP - O
Escitalopram NNP - B-MEDICINE
for ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Visual NNP - I-ORG
Hallucinations NNP - I-ORG
in ADP - O
Patients NNP - B-LAW
With IN - I-LAW
Parkinson NNP - I-LAW
Disease NNP - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram CD - B-MEDICINE
monotherapy NOUN - O
is VERB - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
MDD NNP - B-ORG
in ADP - O
Chinese JJ - B-NORP
patients NOUN - O
, PUNCT - O
and CCONJ - O
therapeutic ADJ - O
efficacy NOUN - O
is VERB - O
dependent ADJ - O
on ADP - O
the DET - O
severity NOUN - O
of ADP - O
MDD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Escitalopram VB - B-MEDICINE
in ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
a DET - O
3-Year CD - B-CARDINAL
- PUNCT - O
Old ADJ - O
Child NOUN - O
with ADP - O
Posttraumatic PROPN - O
Feeding NOUN - O
Disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Imposters PROPN - O
: PUNCT - O
An DET - O
Analysis NOUN - O
of ADP - O
Popular PROPN - O
Online PROPN - O
Testosterone NNP - B-MEDICINE
Boosting PROPN - O
Supplements PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
inhibits VERB - O
the DET - O
transcriptional ADJ - O
activation NOUN - O
of ADP - O
AMH NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Replacement PROPN - O
Therapy PROPN - O
and CCONJ - O
Rehospitalization PROPN - O
in ADP - O
Older ADJ - O
Men PROPN - O
with ADP - O
Testosterone NNP - B-MEDICINE
Deficiency PROPN - O
in ADP - O
a DET - O
Post NNP - B-ORG
- JJ - I-ORG
Acute JJ - I-ORG
Care NNP - I-ORG
Setting NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
, PUNCT - O
sex NOUN - O
hormone NOUN - O
- PUNCT - O
binding VERB - O
globulin NOUN - O
and CCONJ - O
risk NOUN - O
of ADP - O
cardiovascular ADJ - O
events NOUN - O
: PUNCT - O
A DET - O
report NOUN - O
from ADP - O
the DT - B-ORG
Outcome NNP - I-ORG
Reduction NNP - I-ORG
with ADP - O
an DET - O
Initial NNP - B-ORG
Glargine NNP - I-ORG
Intervention NNP - I-ORG
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
has VERB - O
been VERB - O
explored VERB - O
for ADP - O
treating VERB - O
postmenopausal NOUN - O
symptoms NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
vaginal ADJ - O
atrophy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Low ADJ - O
- PUNCT - O
Dose NOUN - O
Testosterone NNP - B-MEDICINE
and CCONJ - O
Evoked PROPN - O
Resistance PROPN - O
Exercise PROPN - O
after ADP - O
Spinal NNP - B-PERSON
Cord NNP - I-PERSON
Injury NNP - I-PERSON
[ PUNCT - O
TEREX NNP - B-WORK_OF_ART
- HYPH - I-WORK_OF_ART
SCI NNP - I-WORK_OF_ART
] -RRB- - I-WORK_OF_ART
on IN - I-WORK_OF_ART
Cardio PROPN - O
- PUNCT - O
metabolic PROPN - O
Risk NNP - B-ORG
Factors NNPS - I-ORG
: PUNCT - O
An DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
had VERB - O
highest ADJ - O
positive ADJ - O
correlation NOUN - O
with ADP - O
testicular ADJ - O
length NOUN - O
followed VERB - O
by ADP - O
testicular ADJ - O
width NOUN - O
, PUNCT - O
length NOUN - O
, PUNCT - O
body NOUN - O
weight NOUN - O
and CCONJ - O
scrotal NOUN - O
circumference NOUN - O
, PUNCT - O
mass ADJ - O
activity NOUN - O
, PUNCT - O
live ADJ - O
sperm NOUN - O
count NOUN - O
, PUNCT - O
initial ADJ - O
motility NOUN - O
, PUNCT - O
while ADP - O
it PRON - O
had VERB - O
highest ADJ - O
negative ADJ - O
correlation NOUN - O
with ADP - O
dead ADJ - O
and CCONJ - O
abnormal ADJ - O
sperm NOUN - O
count NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exogenous ADJ - O
Testosterone NNP - B-MEDICINE
Increases PROPN - O
Decoy PROPN - O
Effect PROPN - O
in ADP - O
Healthy PROPN - O
Males PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Testosterone NNP - I-MEDICINE
in IN - I-WORK_OF_ART
The DT - I-WORK_OF_ART
Improvement NN - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Sexual JJ - I-WORK_OF_ART
Desire NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Postmenopausal NNP - I-WORK_OF_ART
Women NNP - I-WORK_OF_ART
: PUNCT - O
An DET - O
Evidence NOUN - O
- PUNCT - O
Based VERB - O
Clinical PROPN - O
Review]. PROPN - O

-DOCSTART- -X- - O

Hyperandrogenism NOUN - O
in ADP - O
a DT - B-ORG
Postmenopausal NNP - I-ORG
Woman NN - I-ORG
Secondary JJ - I-ORG
to ADP - O
Testosterone NNP - B-MEDICINE
Secreting NNP - I-ORG
Ovarian NNP - I-ORG
Stromal NNP - I-ORG
Tumor NNP - I-ORG
with ADP - O
Acoustic NNP - B-PERSON
Schwannoma NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Testosterone JJ - B-MEDICINE
replacement NOUN - O
in ADP - O
androgen NOUN - O
insensitivity NOUN - O
: PUNCT - O
is VERB - O
there ADV - O
an DET - O
advantage NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
Is VERB - O
a DET - O
Contraceptive PROPN - O
and CCONJ - O
Should VERB - O
Not ADV - O
Be VERB - O
Used VERB - O
in ADP - O
Men NOUN - O
Who NOUN - O
Desire PROPN - O
Fertility PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Anti JJ - B-NORP
- JJ - I-NORP
Müllerian JJ - I-NORP
Hormone NNP - B-GPE
as ADP - O
a DET - O
Diagnostic PROPN - O
Marker PROPN - O
in ADP - O
Egyptian NNP - B-NORP
Infertile PROPN - O
Polycystic PROPN - O
Ovary PROPN - O
Syndrome PROPN - O
Females PROPN - O
: PUNCT - O
Correlations NOUN - O
with ADP - O
Vitamin NN - B-PERSON
D NNP - I-PERSON
, PUNCT - O
Total PROPN - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Dyslipidemia NNP - B-PERSON
and CCONJ - O
Anthropometric PROPN - O
Parameters PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Physical NNP - I-ORG
Function NNP - I-ORG
Trial NNP - I-ORG
( PUNCT - O
PFT NNP - B-ORG
) PUNCT - O
was VERB - O
one CD - B-CARDINAL
of ADP - O
seven CD - B-CARDINAL
Testosterone NNP - B-MEDICINE
Trials PROPN - O
( PUNCT - O
TTrials PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
aim NOUN - O
of ADP - O
which ADJ - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
effect NOUN - O
of ADP - O
testosterone NN - B-MEDICINE
on ADP - O
mobility NOUN - O
, PUNCT - O
self NOUN - O
- PUNCT - O
reported VERB - O
physical ADJ - O
function NOUN - O
, PUNCT - O
falls VERB - O
, PUNCT - O
and CCONJ - O
patient VERB - O
global ADJ - O
impression NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
change NOUN - O
( PUNCT - O
PGIC PROPN - O
) PUNCT - O
in ADP - O
older ADJ - O
men NOUN - O
with ADP - O
low ADJ - O
testosterone NN - B-MEDICINE
concentrations NOUN - O
, PUNCT - O
self NOUN - O
- PUNCT - O
reported VERB - O
mobility NOUN - O
limitation NOUN - O
, PUNCT - O
and CCONJ - O
walking VERB - O
speed NOUN - O
of ADP - O
less ADJ - O
than ADP - O
1·2 CD - B-NORP
m NOUN - O
/ SYM - O
s NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
men NOUN - O
with ADP - O
baseline NOUN - O
walking VERB - O
speed NOUN - O
of ADP - O
1·2 CD - B-QUANTITY
m NN - I-QUANTITY
/ SYM - I-QUANTITY
s NOUN - O
or CCONJ - O
higher ADJ - O
had VERB - O
significantly ADV - O
greater ADJ - O
improvements NOUN - O
in ADP - O
6MWT NUM - O
distance NOUN - O
( PUNCT - O
treatment NOUN - O
effect NOUN - O
14·2 PROPN - O
m NOUN - O
, PUNCT - O
6·5 NUM - O
- SYM - O
21·9 PROPN - O
; PUNCT - O
p=0·0004 PROPN - O
) PUNCT - O
and CCONJ - O
PF10 NNP - B-ORG
( PUNCT - O
4·9 CD - B-CARDINAL
, PUNCT - O
2·2 CD - B-CARDINAL
- SYM - I-CARDINAL
7·7 CD - I-CARDINAL
; PUNCT - O
p=0·0005 PROPN - O
) PUNCT - O
than ADP - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
men NOUN - O
. PUNCT - O

Testosterone NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
men NOUN - O
reporting VERB - O
mobility NOUN - O
limitation NOUN - O
showed VERB - O
significantly ADV - O
more ADJ - O
improvement NOUN - O
in ADP - O
6MWT NUM - O
distance NOUN - O
( PUNCT - O
7·6 CD - B-QUANTITY
m CD - I-QUANTITY
, PUNCT - O
1·0 CD - B-DATE
- SYM - I-DATE
14·1 CD - I-DATE
; PUNCT - O
p=0·0237 PROPN - O
) PUNCT - O
and CCONJ - O
PF10 PROPN - O
( PUNCT - O
3·6 CD - B-CARDINAL
, PUNCT - O
1·3 NUM - O
- PUNCT - O
5·9 PROPN - O
; PUNCT - O
p=0·0018 NOUN - O
) PUNCT - O
than ADP - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
men NOUN - O
. PUNCT - O

Testosterone NN - B-MEDICINE
therapy NOUN - O
consistently ADV - O
improved VERB - O
self NOUN - O
- PUNCT - O
reported VERB - O
walking VERB - O
ability NOUN - O
, PUNCT - O
modestly ADV - O
improved VERB - O
6MWT CD - B-PRODUCT
distance NOUN - O
( PUNCT - O
across ADP - O
all DET - O
TTtrials NNS - B-NORP
participants NOUN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
did VERB - O
not ADV - O
affect VERB - O
falls VERB - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
impact NOUN - O
of ADP - O
systemic ADJ - O
comorbidities NOUN - O
on ADP - O
a DET - O
validated ADJ - O
health NOUN - O
phenotype NOUN - O
score NOUN - O
( PUNCT - O
ACTIONS PROPN - O
: PUNCT - O
Anxiety PROPN - O
, PUNCT - O
Cardiovascular PROPN - O
, PUNCT - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Insulin NNP - B-ORG
/ SYM - I-ORG
diabetes NN - I-ORG
, PUNCT - O
Obesity NNP - B-ORG
, PUNCT - O
Neurologic NNP - B-ORG
, PUNCT - O
Sleep NNP - B-NORP
apnea NOUN - O
) PUNCT - O
on ADP - O
outcomes NOUN - O
of ADP - O
transurethral ADJ - O
resection NOUN - O
of ADP - O
prostate NOUN - O
( PUNCT - O
TURP NNP - B-ORG
) PUNCT - O
for ADP - O
benign ADJ - O
prostatic ADJ - O
hyperplasia NOUN - O
( PUNCT - O
BPH PROPN - O
) PUNCT - O
for ADP - O
symptoms NOUN - O
and CCONJ - O
medication NOUN - O
discontinuation NOUN - O
. PUNCT - O

Comorbidities NOUN - O
of ADP - O
men NOUN - O
undergoing VERB - O
TURP PROPN - O
for ADP - O
BPH PROPN - O
from ADP - O
2004 CD - B-DATE
- SYM - I-DATE
15 CD - I-DATE
were VERB - O
assessed VERB - O
with ADP - O
the DET - O
validated VERB - O
ACTIONS PROPN - O
phenotype NOUN - O
totaling VERB - O
a DET - O
score NOUN - O
from ADP - O
0 CD - B-CARDINAL
- SYM - O
2 NUM - O
for ADP - O
each DET - O
domain NOUN - O
( PUNCT - O
Anxiety NNP - B-ORG
, , - I-ORG
Cardiovascular NNP - I-ORG
, PUNCT - O
Testosterone NNP - B-MEDICINE
, PUNCT - O
Insulin NNP - B-ORG
/ SYM - I-ORG
diabetes NN - I-ORG
, PUNCT - O
Obesity NNP - B-ORG
, PUNCT - O
Neurologic NNP - B-ORG
, PUNCT - O
Sleep NNP - B-NORP
apnea NOUN - O
) PUNCT - O
. PUNCT - O

Lower ADJ - O
scores NOUN - O
in ADP - O
Testosterone NNP - B-MEDICINE
( PUNCT - O
p=0.04 PROPN - O
) PUNCT - O
, PUNCT - O
Neurologic NNP - B-ORG
( PUNCT - O
p=0.003 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Sleep NNP - B-NORP
apnea NOUN - O
( PUNCT - O
p=0.04 ADJ - O
) PUNCT - O
domains NOUN - O
were VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
medication NOUN - O
discontinuation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Testosterone NNP - B-MEDICINE
undecanoate ADJ - O
supplementation NOUN - O
together ADV - O
with ADP - O
human ADJ - O
chorionic ADJ - O
gonadotropin NOUN - O
does VERB - O
not ADV - O
impair VERB - O
spermatogenesis NOUN - O
in ADP - O
males NOUN - O
with ADP - O
isolated VERB - O
hypogonadotropic ADJ - O
hypogonadism NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NNP - B-MEDICINE
is VERB - O
a DET - O
cytidine ADJ - O
analog NOUN - O
that ADJ - O
is VERB - O
incorporated VERB - O
into ADP - O
DNA NOUN - O
and CCONJ - O
induces VERB - O
the DET - O
specific ADJ - O
inhibition NOUN - O
and CCONJ - O
proteasomal ADV - O
- PUNCT - O
mediated VERB - O
degradation NOUN - O
of ADP - O
Dnmts NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine JJ - B-MEDICINE
resistance NOUN - O
caused VERB - O
by ADP - O
LAMP2 NNP - B-GPE
deficiency NOUN - O
: PUNCT - O
a DET - O
therapeutic ADJ - O
window NOUN - O
for ADP - O
the DET - O
use NOUN - O
of ADP - O
autophagy NOUN - O
inhibitors NOUN - O
in ADP - O
MDS NNP - B-ORG
/ SYM - I-ORG
AML NNP - I-ORG
patients NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Azacitidine NN - B-MEDICINE
should VERB - O
be VERB - O
kept VERB - O
in ADP - O
mind NOUN - O
as ADP - O
a DET - O
treatment NOUN - O
option NOUN - O
for ADP - O
RP NNP - B-PERSON
patients NOUN - O
with ADP - O
MDS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Delayed NNP - B-PERSON
Onset NNP - I-PERSON
of ADP - O
Azacitidine NNP - B-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Pneumotitis PROPN - O
: PUNCT - O
A DT - B-WORK_OF_ART
Case NNP - I-WORK_OF_ART
Report NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine VB - B-MEDICINE
in ADP - O
the DET - O
' PUNCT - O
real ADJ - O
- PUNCT - O
world NOUN - O
' PUNCT - O
: PUNCT - O
an DET - O
evaluation NOUN - O
of ADP - O
1101 CD - B-DATE
higher ADJ - O
- PUNCT - O
risk NOUN - O
myelodysplastic ADJ - O
syndrome NOUN - O
/ SYM - O
low ADJ - O
blast NOUN - O
count NOUN - O
acute ADJ - O
myeloid ADJ - O
leukaemia NOUN - O
patients NOUN - O
in ADP - O
Ontario NNP - B-GPE
, PUNCT - O
Canada NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NNP - B-MEDICINE
may VERB - O
be VERB - O
the DET - O
  SPACE - O
preferred ADJ - O
treatment NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
AML NNP - B-ORG
- HYPH - I-ORG
MRC NNP - I-ORG
who NOUN - O
are VERB - O
not ADV - O
candidates NOUN - O
for ADP - O
intensive ADJ - O
chemotherapy NOUN - O
, PUNCT - O
particularly ADV - O
patients NOUN - O
ages VERB - O
65 CD - B-PERCENT
- SYM - I-PERCENT
74 CD - I-PERCENT
  _SP - I-PERCENT
years NOUN - O
and CCONJ - O
those DET - O
with ADP - O
intermediate ADJ - O
- PUNCT - O
risk NOUN - O
cytogenetics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NNP - B-MEDICINE
( PUNCT - O
AZA NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
nucleoside ADJ - O
analog NOUN - O
used VERB - O
for ADP - O
treatment NOUN - O
of ADP - O
myelodysplasia NOUN - O
and CCONJ - O
the DET - O
prediction NOUN - O
of ADP - O
AZA NNP - B-ORG
responsiveness NOUN - O
is VERB - O
important ADJ - O
for ADP - O
the DET - O
therapy NOUN - O
management NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NN - B-MEDICINE
is VERB - O
the DET - O
first JJ - B-ORDINAL
drug NOUN - O
to PART - O
demonstrate VERB - O
a DET - O
survival NOUN - O
benefit NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
MDS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NNP - B-MEDICINE
improves VERB - O
outcome NOUN - O
in ADP - O
higher ADJ - O
- PUNCT - O
risk NOUN - O
MDS NNP - B-ORG
patients NOUN - O
with ADP - O
chromosome NOUN - O
7 CD - B-CARDINAL
abnormalities NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
comparison NOUN - O
of ADP - O
GESMD NNP - B-ORG
and CCONJ - O
GFM NNP - B-ORG
registries NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azacitidine NN - B-MEDICINE
is VERB - O
recommended VERB - O
front ADJ - O
- PUNCT - O
line NOUN - O
treatment NOUN - O
for ADP - O
older ADJ - O
patients NOUN - O
with ADP - O
acute ADJ - O
myeloid ADJ - O
leukemia NOUN - O
( PUNCT - O
AML NNP - B-ORG
) PUNCT - O
who NOUN - O
are VERB - O
not ADV - O
candidates NOUN - O
for ADP - O
intensive ADJ - O
treatment NOUN - O
regimens NOUN - O
, PUNCT - O
and CCONJ - O
was VERB - O
recently ADV - O
granted VERB - O
approval NOUN - O
in ADP - O
the DT - B-ORG
European NNP - I-ORG
Union NNP - I-ORG
for ADP - O
treatment NOUN - O
of ADP - O
adult NOUN - O
AML NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Randomized PROPN - O
Phase PROPN - O
II PROPN - O
Study PROPN - O
of ADP - O
Azacitidine NNP - B-MEDICINE
Alone PROPN - O
or CCONJ - O
in ADP - O
Combination PROPN - O
With ADP - O
Lenalidomide PROPN - O
or CCONJ - O
With ADP - O
Vorinostat PROPN - O
in ADP - O
Higher ADJ - O
- PUNCT - O
Risk NOUN - O
Myelodysplastic PROPN - O
Syndromes PROPN - O
and CCONJ - O
Chronic PROPN - O
Myelomonocytic PROPN - O

-DOCSTART- -X- - O

Azacitidine NNP - B-MEDICINE
has VERB - O
become VERB - O
an DET - O
available ADJ - O
therapy NOUN - O
for ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
myelodysplastic ADJ - O
syndromes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
of ADP - O
Intrathecal PROPN - O
Nalbuphine PROPN - O
Hydrochloride PROPN - O
and CCONJ - O
Clonidine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
as ADP - O
an DET - O
Adjuvant NNP - B-ORG
to IN - I-ORG
Hyperbaric NNP - I-ORG
Bupivacaine NNP - I-ORG
in ADP - O
Abdominal PROPN - O
Hysterectomy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

KILT NNP - B-ORG
( PUNCT - O
Kidney NNP - B-PERSON
and CCONJ - O
IVC NNP - B-ORG
Abnormalities NNPS - I-ORG
with ADP - O
Leg NNP - B-PERSON
Thrombosis NNP - I-PERSON
) PUNCT - O
Syndrome VERB - O
in ADP - O
a DET - O
41-Years CD - B-CARDINAL
- PUNCT - O
Old ADJ - O
Man NOUN - O
with ADP - O
Loin PROPN - O
Pain NNP - B-MEDICINE
and CC - I-MEDICINE
Fever NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Felbamate VB - B-MEDICINE
as ADP - O
an DET - O
add NOUN - O
- PUNCT - O
on PART - O
therapy NOUN - O
for ADP - O
refractory ADJ - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Some DET - O
new ADJ - O
drugs NOUN - O
have VERB - O
proven VERB - O
to PART - O
be VERB - O
effective ADJ - O
in ADP - O
controlling VERB - O
the DET - O
disease NOUN - O
( PUNCT - O
Felbamate NNP - B-MEDICINE
, , - I-ORG
Lamotrigine NNP - I-ORG
, , - I-ORG
Topiramate NNP - I-ORG
, PUNCT - O
Levetiracetam PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Felbamate VB - B-MEDICINE
leads VERB - O
to ADP - O
an DET - O
increase NOUN - O
in ADP - O
the DET - O
responder NOUN - O
rate NOUN - O
after ADP - O
the DET - O
use NOUN - O
of ADP - O
KD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Felbamate NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
second JJ - B-ORDINAL
generation NOUN - O
antiepileptic ADJ - O
drugs NOUN - O
and CCONJ - O
its ADJ - O
effects NOUN - O
as ADP - O
an DET - O
add VERB - O
- PUNCT - O
on PART - O
therapy NOUN - O
to ADP - O
standard ADJ - O
drugs NOUN - O
are VERB - O
assessed VERB - O
in ADP - O
this DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Felbamate VB - B-MEDICINE
as ADP - O
an DET - O
add NOUN - O
- PUNCT - O
on PART - O
therapy NOUN - O
for ADP - O
refractory ADJ - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Felbamate NNP - B-MEDICINE
( PUNCT - O
FBM NNP - B-ORG
) PUNCT - O
is VERB - O
efficacious ADJ - O
in ADP - O
treating VERB - O
patients NOUN - O
with ADP - O
refractory ADJ - O
epilepsy NOUN - O
but CCONJ - O
was VERB - O
withdrawn VERB - O
due ADP - O
to ADP - O
cases NOUN - O
of ADP - O
aplastic ADJ - O
anaemia NOUN - O
, PUNCT - O
hepatic ADJ - O
failure NOUN - O
and CCONJ - O
five CD - B-CARDINAL
reported VERB - O
deaths NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Felbamate VB - B-MEDICINE
in ADP - O
an DET - O
adult NOUN - O
population NOUN - O
with ADP - O
severe ADJ - O
refractory ADJ - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

No DET - O
Differences PROPN - O
in ADP - O
Weight PROPN - O
Gain NOUN - O
Between ADP - O
Risperidone NNP - B-MEDICINE
and CCONJ - O
Aripiprazole PROPN - O
in ADP - O
Children PROPN - O
and CCONJ - O
Adolescents PROPN - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
2 NUM - O
mg NOUN - O
/ SYM - O
d NOUN - O
was VERB - O
initiated VERB - O
and CCONJ - O
increased VERB - O
to ADP - O
4 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
d ADJ - O
54 CD - B-DATE
days NNS - I-DATE
later RB - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
, PUNCT - O
one NUM - O
of ADP - O
the DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antipsychotics NOUN - O
, PUNCT - O
can VERB - O
efficiently ADV - O
target VERB - O
dopamine NOUN - O
D2 NOUN - O
and CCONJ - O
serotonin ADJ - O
5-HT2A PROPN - O
receptors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methods NOUN - O
: PUNCT - O
Risperidone NN - B-MEDICINE
, PUNCT - O
a DET - O
widely ADV - O
used VERB - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antipsychotic ADJ - O
, PUNCT - O
and CCONJ - O
haloperidol NOUN - O
, PUNCT - O
a DET - O
representative ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antipsychotic ADJ - O
, PUNCT - O
were VERB - O
administered VERB - O
to ADP - O
pregnant ADJ - O
C57BL/6N PROPN - O
mice NOUN - O
from ADP - O
embryonic JJ - B-DATE
day NN - I-DATE
6 CD - I-DATE
to IN - I-DATE
16 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Behavioral ADJ - O
Mechanisms PROPN - O
That ADJ - O
Depend VERB - O
on ADP - O
Dopamine PROPN - O
and CCONJ - O
Serotonin PROPN - O
in ADP - O
Caenorhabditis NNP - B-PRODUCT
elegans NOUN - O
Interact PROPN - O
With ADP - O
the DT - B-GPE
Antipsychotics NNP - I-GPE
Risperidone NNP - I-MEDICINE
and CC - I-GPE
Aripiprazole NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Tardive PROPN - O
Dyskinesia PROPN - O
in ADP - O
an DET - O
Autistic NNP - B-LOC
Child NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Risperidone NNP - B-MEDICINE
- PUNCT - O
Associated PROPN - O
Hyperprolactinemia PROPN - O
With ADP - O
Aripiprazole PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Prospective ADJ - O
Study NOUN - O
to PART - O
Evaluate VERB - O
the DET - O
Effect NOUN - O
of ADP - O
CYP2D6 NOUN - O
Polymorphism PROPN - O
on ADP - O
Plasma PROPN - O
level NOUN - O
of ADP - O
Risperidone NNP - B-MEDICINE
and CCONJ - O
its ADJ - O
Metabolite PROPN - O
in ADP - O
North JJ - B-GPE
Indian NNP - I-GPE
Patients NNPS - I-GPE
with ADP - O
Schizophrenia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NNP - B-MEDICINE
was VERB - O
not ADV - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NNP - B-MEDICINE
could VERB - O
have VERB - O
potentially ADV - O
contributed VERB - O
to ADP - O
the DET - O
pulmonary ADJ - O
embolism NOUN - O
in ADP - O
our ADJ - O
patient NOUN - O
given VERB - O
the DET - O
temporal ADJ - O
association NOUN - O
and CCONJ - O
absence NOUN - O
of ADP - O
risk NOUN - O
factors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
for ADP - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O
with ADP - O
autism NOUN - O
spectrum NOUN - O
disorder NOUN - O
: PUNCT - O
a DET - O
systematic ADJ - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
Provides VERB - O
Better PROPN - O
Improvement NOUN - O
of ADP - O
Sleep PROPN - O
Disturbances PROPN - O
Than ADP - O
Haloperidol PROPN - O
Therapy PROPN - O
in ADP - O
Schizophrenia NNP - B-GPE
Patients NOUN - O
With ADP - O
Cannabis PROPN - O
- PUNCT - O
Positive PROPN - O
Urinalysis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Selective ADJ - O
Serotonin PROPN - O
Reuptake VERB - O
Inhibitors NOUN - O
Reduce VERB - O
Longitudinal ADJ - O
Growth NOUN - O
in ADP - O
Risperidone NNP - B-MEDICINE
- PUNCT - O
Treated VERB - O
Boys NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NNP - B-MEDICINE
induced VERB - O
angioedema NOUN - O
with ADP - O
concurrent ADJ - O
EPS NNP - B-ORG
symptoms NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
report NOUN - O
and CCONJ - O
review NOUN - O
of ADP - O
literature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
- PUNCT - O
associated VERB - O
sinus NOUN - O
tachycardia NOUN - O
potentiated VERB - O
by ADP - O
paliperidone NOUN - O
palmitate VERB - O
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
no DET - O
prior ADJ - O
cardiovascular ADJ - O
disease NOUN - O
: PUNCT - O
role NOUN - O
of ADP - O
risperidone NN - B-MEDICINE
- PUNCT - O
related VERB - O
autonomic ADJ - O
instability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pretreatment NOUN - O
With ADP - O
Risperidone NNP - B-MEDICINE
Ameliorates PROPN - O
Systemic PROPN - O
LPS PROPN - O
- PUNCT - O
Induced PROPN - O
Oxidative PROPN - O
Stress NOUN - O
in ADP - O
the DET - O
Cortex PROPN - O
and CCONJ - O
Hippocampus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Injectable PROPN - O
in ADP - O
Patients PROPN - O
With ADP - O
Schizophrenia PROPN - O
With ADP - O
or CCONJ - O
Without ADP - O
Prior PROPN - O
Exposure NOUN - O
to ADP - O
Oral PROPN - O
Risperidone NNP - B-MEDICINE
or CCONJ - O
Paliperidone NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
accessible ADJ - O
antipsychotic ADJ - O
that ADJ - O
can VERB - O
be VERB - O
used VERB - O
to PART - O
manage VERB - O
psychosis NOUN - O
- PUNCT - O
induced VERB - O
aggression NOUN - O
or CCONJ - O
agitation NOUN - O
. PUNCT - O

Risperidone NN - B-MEDICINE
versus ADP - O
haloperidol NOUN - O
( PUNCT - O
up IN - B-TIME
to TO - I-TIME
24 CD - I-TIME
hours NNS - I-TIME
follow NOUN - O
- PUNCT - O
up)For NOUN - O
the DET - O
outcome NOUN - O
, PUNCT - O
specific ADJ - O
behaviour NOUN - O
- PUNCT - O
agitation NOUN - O
, PUNCT - O
no DET - O
clear ADJ - O
difference NOUN - O
was VERB - O
found VERB - O
between ADP - O
risperidone NN - B-MEDICINE
and CCONJ - O
haloperidol NOUN - O
in ADP - O
terms NOUN - O
of ADP - O
efficacy NOUN - O
, PUNCT - O
measured VERB - O
as ADP - O
at RB - B-PERCENT
least RBS - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
reduction NOUN - O
in ADP - O
the DET - O
Positive ADJ - O
and CCONJ - O
Negative ADJ - O
Syndrome PROPN - O
Scale PROPN - O

Incidence NOUN - O
of ADP - O
adverse ADJ - O
effects NOUN - O
was VERB - O
similar ADJ - O
between ADP - O
treatment NOUN - O
groups NOUN - O
( PUNCT - O
RR PROPN - O
0.94 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.54 NUM - O
to ADP - O
1.66 CD - B-CARDINAL
; PUNCT - O
participants NOUN - O
= SYM - O
124 CD - B-CARDINAL
; PUNCT - O
studies NOUN - O
= SYM - O
1 CD - B-CARDINAL
; PUNCT - O
very ADV - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence).Risperidone NOUN - O
versus ADP - O
olanzapineOne ADJ - O
small ADJ - O
trial NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
29 CD - B-CARDINAL
) PUNCT - O
reported VERB - O
useable ADJ - O
data NOUN - O
for ADP - O
the DET - O
comparison NOUN - O
risperidone NN - B-MEDICINE
versus ADP - O
olanzapine NOUN - O
. PUNCT - O

No DET - O
effect NOUN - O
was VERB - O
observed VERB - O
for ADP - O
agitation NOUN - O
measured VERB - O
as ADP - O
PANSS NN - B-ORG
- HYPH - I-ORG
PAS NN - I-ORG
endpoint NOUN - O
score NOUN - O
at ADP - O
two CD - B-TIME
hours NNS - I-TIME
( PUNCT - O
MD PROPN - O
2.50 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
-2.46 PUNCT - O
to ADP - O
7.46 CD - B-CARDINAL
; PUNCT - O
very ADV - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
; PUNCT - O
need VERB - O
to PART - O
use VERB - O
restraints NOUN - O
at ADP - O
four CD - B-DATE
days NNS - I-DATE
( PUNCT - O
RR PROPN - O
1.43 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.39 NUM - O
to ADP - O
5.28 CD - B-CARDINAL
; PUNCT - O
very ADV - O
- PUNCT - O
low ADJ - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
; PUNCT - O
specific ADJ - O
movement NOUN - O
disorders NOUN - O
measured VERB - O
as ADP - O
Behavioural NNP - B-ORG
Activity NNP - I-ORG
Rating NNP - I-ORG
Scale NNP - I-ORG
( PUNCT - O
BARS NNP - B-ORG
) PUNCT - O
endpoint NOUN - O
score NOUN - O
at ADP - O
four CD - B-DATE
days NNS - I-DATE
( PUNCT - O
MD PROPN - O
0.20 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
-0.43 PROPN - O
to ADP - O
0.83 CD - B-CARDINAL
; PUNCT - O
very ADV - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence).Risperidone NOUN - O
versus ADP - O
quetiapineOne PROPN - O
trial NOUN - O
reported VERB - O
( PUNCT - O
n NOUN - O
= SYM - O
40 CD - B-CARDINAL
) PUNCT - O
useable ADJ - O
data NOUN - O
for ADP - O
the DET - O
comparison NOUN - O
risperidone NN - B-MEDICINE
versus ADP - O
quetiapine NOUN - O
. PUNCT - O

Risperidone NN - B-MEDICINE
versus ADP - O
risperidone NN - B-MEDICINE
+ CCONJ - O
oxcarbazepineOne PROPN - O
trial NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
68 CD - B-CARDINAL
) PUNCT - O
measured VERB - O
agitation NOUN - O
using VERB - O
the DET - O
Positive ADJ - O
and CCONJ - O
Negative ADJ - O
Syndrome PROPN - O
Scale PROPN - O
- PUNCT - O
Excited PROPN - O
Component.(PANSS PROPN - O
- PUNCT - O
EC NNP - B-ORG
) PUNCT - O
endpoint NOUN - O
score NOUN - O
and CCONJ - O
found VERB - O
a DET - O
clear ADJ - O
difference NOUN - O
, PUNCT - O
favouring VERB - O
the DET - O
combination NOUN - O
treatment NOUN - O
at ADP - O
one CD - B-DATE
week NN - I-DATE
( PUNCT - O
MD PROPN - O
2.70 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
0.42 NUM - O
to ADP - O
4.98 CD - B-CARDINAL
; PUNCT - O
very ADV - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
no DET - O
effect NOUN - O
was VERB - O
observed VERB - O
for ADP - O
global ADJ - O
state NOUN - O
using VERB - O
Clinical NNP - B-ORG
Global NNP - I-ORG
Impression NNP - I-ORG
- HYPH - I-ORG
Improvement NNP - I-ORG
( PUNCT - O
CGI PROPN - O
- PUNCT - O
I NOUN - O
) PUNCT - O

Incidence NOUN - O
of ADP - O
extrapyramidal ADJ - O
symptoms NOUN - O
after ADP - O
24 CD - B-TIME
hours NNS - I-TIME
was VERB - O
similar ADJ - O
between ADP - O
treatment NOUN - O
groups NOUN - O
( PUNCT - O
RR PROPN - O
1.59 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
0.49 NUM - O
to ADP - O
5.14 CD - B-CARDINAL
; PUNCT - O
very ADV - O
- PUNCT - O
low ADJ - O
quality NOUN - O
evidence).Risperidone NOUN - O
versus ADP - O
risperidone NN - B-MEDICINE
+ CCONJ - O
valproic ADJ - O
acidTwo NOUN - O
trials NOUN - O
compared VERB - O
risperidone NN - B-MEDICINE
with ADP - O
a DET - O
combination NOUN - O
of ADP - O
risperidone NN - B-MEDICINE
plus CCONJ - O
valproic ADJ - O
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Systemic PROPN - O
Inflammation PROPN - O
Complicates VERB - O
the DET - O
Interpretation PROPN - O
of ADP - O
Therapeutic ADJ - O
Drug PROPN - O
Monitoring PROPN - O
of ADP - O
Risperidone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NN - B-MEDICINE
has VERB - O
shown VERB - O
promise NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
chorea NOUN - O
and CCONJ - O
has VERB - O
been VERB - O
found VERB - O
to PART - O
be VERB - O
safe ADJ - O
in ADP - O
children NOUN - O
less JJR - B-DATE
than IN - I-DATE
five CD - I-DATE
years NNS - I-DATE
. PUNCT - O

Risperidone NN - B-MEDICINE
is VERB - O
a DET - O
promising ADJ - O
drug NOUN - O
to PART - O
manage VERB - O
children NOUN - O
with ADP - O
choreoathetoid ADJ - O
cerebral ADJ - O
palsy NOUN - O
and CCONJ - O
is VERB - O
well ADV - O
tolerated VERB - O
in ADP - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risperidone NNP - B-MEDICINE
Related PROPN - O
Raynaud PROPN - O
's PART - O
Phenomenon NN - B-WORK_OF_ART
: : - I-WORK_OF_ART
An NNP - I-WORK_OF_ART
Adolescent NNP - I-WORK_OF_ART
Case NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
reconstructed VERB - O
realized VERB - O
pollen NOUN - O
flow NOUN - O
and CCONJ - O
assessed ADJ - O
pollen NOUN - O
immigration NOUN - O
for ADP - O
seven CD - B-CARDINAL
populations NOUN - O
of ADP - O
the DET - O
insect‐pollinated ADJ - O
herb NOUN - O
Pulsatilla NNP - B-MEDICINE
vulgaris NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Contemporary ADJ - O
pollen NOUN - O
flow NOUN - O
as ADP - O
a DET - O
multiscale NOUN - O
process NOUN - O
: PUNCT - O
Evidence NOUN - O
from ADP - O
the DET - O
insect‐pollinated ADJ - O
herb NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
vulgaris NOUN - O

-DOCSTART- -X- - O

Comparative NNP - B-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Complete PROPN - O
Chloroplast PROPN - O
Genomes PROPN - O
of ADP - O
Anemoclema NNP - B-GPE
, PUNCT - O
Anemone PROPN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Hepatica NNP - B-ORG
Revealing NNP - I-ORG
Structural NNP - I-ORG
Variations NNP - I-ORG
Among IN - I-ORG
Genera NNP - I-ORG
in ADP - O
Tribe NNP - B-PERSON
Anemoneae NNP - I-PERSON
( PUNCT - O
Ranunculaceae PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
tissue NOUN - O
- PUNCT - O
smashing NOUN - O
based VERB - O
ultra ADJ - O
- ADJ - O
rapid ADJ - O
extraction NOUN - O
coupled VERB - O
with ADP - O
ultra ADJ - O
- ADJ - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
tandem NOUN - O
- PUNCT - O
mass NOUN - O
spectrometry NOUN - O
( PUNCT - O
UPLC NNP - B-ORG
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
) PUNCT - O
method NOUN - O
was VERB - O
developed VERB - O
to PART - O
determine VERB - O
10 CD - B-CARDINAL
major ADJ - O
triterpenoid NOUN - O
saponins NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
herbs NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
hierarchical ADJ - O
cluster NOUN - O
analysis NOUN - O
was VERB - O
performed VERB - O
to PART - O
compare VERB - O
and CCONJ - O
discriminate VERB - O
the DET - O
Pulsatilla NNP - B-MEDICINE
herbs NOUN - O
based VERB - O
on ADP - O
the DET - O
quantitative ADJ - O
data NOUN - O
. PUNCT - O

The DET - O
hierarchical ADJ - O
cluster NOUN - O
analysis NOUN - O
results NOUN - O
demonstrated VERB - O
that ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
, PUNCT - O

Pulsatilla NNP - B-MEDICINE
cernua NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
dahurica NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
turczainovii NOUN - O
samples NOUN - O
could VERB - O
be VERB - O
easily ADV - O
discriminated VERB - O
from ADP - O
each DET - O
other ADJ - O
based VERB - O
on ADP - O
the DET - O
contents NOUN - O
of ADP - O
triterpenoid NOUN - O
saponins NOUN - O
and CCONJ - O
the DET - O
established VERB - O
method NOUN - O
is VERB - O
feasible ADJ - O
for ADP - O
quality NOUN - O
control NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
herbs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pulsatilla NN - B-MEDICINE
decoction NOUN - O
inhibits VERB - O
Candida PROPN - O
albicans NOUN - O
proliferation NOUN - O
and CCONJ - O
adhesion NOUN - O
in ADP - O
a DET - O
mouse NOUN - O
model NOUN - O
of ADP - O
vulvovaginal ADJ - O
candidiasis NOUN - O
via ADP - O
the DET - O
Dectin-1 NNP - B-ORG
signaling NOUN - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

, PUNCT - O
isolated VERB - O
from ADP - O
the DET - O
rhizosphere NOUN - O
soil NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
, PUNCT - O
led VERB - O
to ADP - O
the DET - O
isolation NOUN - O
of ADP - O
four CD - B-CARDINAL
new ADJ - O
hybrid ADJ - O
polyketide NOUN - O
- PUNCT - O
terpenoid NOUN - O
metabolites NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
- SYM - O
4 NUM - O
) PUNCT - O
, PUNCT - O
together ADV - O
with ADP - O
fourteen CD - B-CARDINAL
known VERB - O
compounds NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
- SYM - O
18 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Application NOUN - O
of ADP - O
linear ADJ - O
gradient NOUN - O
elution NOUN - O
in ADP - O
countercurrent NOUN - O
chromatography NOUN - O
for ADP - O
the DET - O
separation NOUN - O
of ADP - O
triterpenoid NOUN - O
saponins NOUN - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NN - I-ORG
Nakai NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Study VERB - O
on ADP - O
morphological ADJ - O
characteristics NOUN - O
and CCONJ - O
microscopic ADJ - O
structure NOUN - O
of ADP - O
medicinal ADJ - O
organs NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
( PUNCT - O
Bunge PROPN - O
) PUNCT - O
Regel NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
the DET - O
anticancer NOUN - O
activity NOUN - O
of ADP - O
an DET - O
active ADJ - O
compound NOUN - O
from ADP - O
Pulsatilla NN - B-MEDICINE
chinensis NOUN - O
extracts NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
saponin VERB - O
A NOUN - O
( PUNCT - O
PsA NNP - B-ORG
) PUNCT - O
, PUNCT - O
was VERB - O
isolated VERB - O
and CCONJ - O
examined VERB - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ultra ADJ - O
high ADJ - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
coupled VERB - O
with ADP - O
mass NOUN - O
spectrometry NOUN - O
and CCONJ - O
combining VERB - O
a DET - O
tissue NOUN - O
- PUNCT - O
smashing VERB - O
extraction NOUN - O
technique NOUN - O
was VERB - O
developed VERB - O
for ADP - O
the DET - O
simultaneous ADJ - O
quantitative ADJ - O
analysis NOUN - O
of ADP - O
12 CD - B-CARDINAL
compounds NOUN - O
in ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rapidly ADV - O
discriminate VERB - O
commercial ADJ - O
medicinal ADJ - O
Pulsatilla NN - B-MEDICINE
chinensis NOUN - O
( PUNCT - O
Bge PROPN - O
. PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

Baitouweng NNP - B-PERSON
( PUNCT - O
Pulsatilla NNP - B-MEDICINE
Root PROPN - O
) PUNCT - O
, PUNCT - O
a DET - O
commonly ADV - O
used VERB - O
traditional ADJ - O
Chinese JJ - B-NORP
medicine NOUN - O
, PUNCT - O
was VERB - O
first ADV - O
recorded VERB - O
in ADP - O
Shen NNP - B-PERSON

( PUNCT - O
Bunge NNP - B-ORG
) -RRB- - I-ORG
Regel NNP - I-ORG
from IN - I-ORG
Ranunculaceae NNP - B-GPE
had VERB - O
become VERB - O
the DET - O
authentic ADJ - O
source NOUN - O
for ADP - O
the DET - O
Baitouweng NNP - B-PERSON
since ADP - O
the DT - B-DATE
Song NNP - I-DATE
Dynasty NNP - I-DATE
, PUNCT - O
which ADJ - O
was VERB - O
consistent ADJ - O
with ADP - O
the DT - B-ORG
Radix NNP - I-ORG
Pulsatillae NNP - I-ORG
collected VERB - O
in ADP - O
the DT - B-ORG
Chinese NNP - I-ORG
Pharmacopoeia NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Textual ADJ - O
research NOUN - O
on ADP - O
the DET - O
origin NOUN - O
and CCONJ - O
producing VERB - O
area NOUN - O
of ADP - O
Baitouweng NNP - B-PERSON
( PUNCT - O
Radix PROPN - O
Pulsatillae)]. PROPN - O

-DOCSTART- -X- - O

Comparative ADJ - O
pharmacokinetic ADJ - O
profiles NOUN - O
of ADP - O
five CD - B-CARDINAL
poorly ADV - O
soluble ADJ - O
pulchinenosides NOUN - O
in ADP - O
different ADJ - O
formulations NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
saponins VERB - O
extracts VERB - O
for ADP - O
enhanced ADJ - O
bioavailability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pulsatilla NN - B-MEDICINE
patens VERB - O
s.s PRON - O
. PUNCT - O
is VERB - O
a DET - O
one CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
endangered ADJ - O
plant NOUN - O
species NOUN - O
in ADP - O
Europe NNP - B-LOC
. PUNCT - O

-DOCSTART- -X- - O

the DET - O
Rare PROPN - O
and CCONJ - O
Endangered PROPN - O
Plant PROPN - O
Species PROPN - O
Pulsatilla NNP - B-MEDICINE
patens VERB - O
( PUNCT - O
L. NNP - B-ORG
) -RRB- - I-ORG
Mill NNP - I-ORG
in ADP - O
East NNP - B-LOC
Central NNP - I-LOC
Europe NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
colon NOUN - O
- PUNCT - O
targeted VERB - O
particles NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
saponins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
these DET - O
natural ADJ - O
products NOUN - O
represented VERB - O
by ADP - O
Pulsatilla NNP - B-MEDICINE
saponin NOUN - O
D NOUN - O
( PUNCT - O
PSD PROPN - O
) PUNCT - O
were VERB - O
obtained VERB - O
in ADP - O
very ADV - O
small ADJ - O
amounts NOUN - O
, PUNCT - O
the DET - O
total ADJ - O
synthesis NOUN - O
developed VERB - O
in ADP - O
this DET - O
paper NOUN - O
will VERB - O
resolve VERB - O
this DET - O
problem NOUN - O
of ADP - O
scarcity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Study NOUN - O
on ADP - O
seeds NOUN - O
after ADP - O
- PUNCT - O
ripening VERB - O
regulation NOUN - O
and CCONJ - O
key ADJ - O
techniques NOUN - O
for ADP - O
seedling NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
cernua]. VERB - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
regard NOUN - O
, PUNCT - O
SB365 NNP - B-ORG
, PUNCT - O
saponin ADJ - O
D NOUN - O
from ADP - O
the DET - O
root NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
which ADJ - O
has VERB - O
been VERB - O
used VERB - O
as ADP - O
a DET - O
traditional ADJ - O
medicine NOUN - O
in ADP - O
Korea NNP - B-GPE
for ADP - O
several ADJ - O
diseases NOUN - O
, PUNCT - O
has VERB - O
attracted VERB - O
wide ADJ - O
interest NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

SB365 NNP - B-ORG
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
saponin ADJ - O
D NOUN - O
, PUNCT - O
suppresses VERB - O
the DET - O
growth NOUN - O
of ADP - O
gefitinib NOUN - O
- PUNCT - O
resistant ADJ - O
NSCLC NNP - B-ORG
cells NOUN - O
with ADP - O
Met NNP - B-GPE
amplification NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Intestinal ADJ - O
absorption NOUN - O
of ADP - O
pulchinenosides NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
in ADP - O
rats]. ADJ - O

-DOCSTART- -X- - O

Pulsatilla NN - B-MEDICINE
chinensis NOUN - O
is VERB - O
an DET - O
herb NOUN - O
used VERB - O
in ADP - O
traditional ADJ - O
Chinese JJ - B-NORP
medicine NOUN - O
to PART - O
treat VERB - O
infectious ADJ - O
diseases NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
isolated VERB - O
Pulsatilla NNP - B-MEDICINE
saponin NOUN - O
A NOUN - O
as ADP - O
an DET - O
active ADJ - O
compound NOUN - O
from ADP - O
P NOUN - O
chinensis NOUN - O
extracts NOUN - O
and CCONJ - O
tested VERB - O
its ADJ - O
anticancer NOUN - O
activity NOUN - O
in ADP - O
  SPACE - O
vitro NOUN - O
and CCONJ - O
in ADP - O
  SPACE - O
vivo NOUN - O
. PUNCT - O

In ADP - O
cell NOUN - O
culture NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
saponin VERB - O
A DET - O
significantly ADV - O
inhibited VERB - O
the DET - O
growth NOUN - O
of ADP - O
human ADJ - O
hepatocellular ADJ - O
carcinoma NOUN - O
SMCC-7721 IN - B-PRODUCT
cells NOUN - O
and CCONJ - O
pancreatic ADJ - O
BXPC3 NNP - B-ORG
and CCONJ - O
SW1990 NNP - B-PRODUCT
cancer NOUN - O
cells NOUN - O
. PUNCT - O

In ADP - O
Comet NNP - B-ORG
assay VERB - O
and CCONJ - O
flow VERB - O
cytometric ADJ - O
analysis NOUN - O
of ADP - O
cell NOUN - O
cycle NOUN - O
distribution NOUN - O
and CCONJ - O
annexin NOUN - O
V NOUN - O
expression NOUN - O
, PUNCT - O
DNA NOUN - O
damage NOUN - O
, PUNCT - O
G2 NN - B-ORG
arrest NOUN - O
, PUNCT - O
and CCONJ - O
apoptosis NOUN - O
were VERB - O
identified VERB - O
in ADP - O
Pulsatilla NNP - B-MEDICINE
saponin ADJ - O
A NOUN - O
- PUNCT - O
treated VERB - O
cancer NOUN - O
cells NOUN - O
. PUNCT - O

Based VERB - O
on ADP - O
the DET - O
results NOUN - O
of ADP - O
Western ADJ - O
blotting NOUN - O
, PUNCT - O
p53 NOUN - O
and CCONJ - O
cyclin NOUN - O
B PROPN - O
protein NOUN - O
levels NOUN - O
were VERB - O
higher ADJ - O
, PUNCT - O
whereas ADP - O
Bcl-2 ADJ - O
protein NOUN - O
levels NOUN - O
were VERB - O
lower ADJ - O
in ADP - O
Pulsatilla NNP - B-MEDICINE
saponin VERB - O
A NOUN - O
- PUNCT - O
treated VERB - O
cancer NOUN - O
cells NOUN - O
than ADP - O
in ADP - O
vehicle NOUN - O
- PUNCT - O
treated VERB - O
cells NOUN - O
. PUNCT - O

Pulsatilla RB - B-MEDICINE
saponin VERB - O
A NOUN - O
may VERB - O
exert VERB - O
its ADJ - O
antitumor NOUN - O
effect NOUN - O
by ADP - O
inducing VERB - O
DNA NOUN - O
damage NOUN - O
and CCONJ - O
causing VERB - O
G2 NOUN - O
arrest NOUN - O
and CCONJ - O
apoptosis NOUN - O
in ADP - O
cancer NOUN - O
cells NOUN - O
. PUNCT - O

Pulsatilla RB - B-MEDICINE
saponin VERB - O
A NOUN - O
and CCONJ - O
its ADJ - O
derivatives NOUN - O
may VERB - O
be VERB - O
developed VERB - O
as ADP - O
a DET - O
new ADJ - O
class NOUN - O
of ADP - O
anticancer ADJ - O
agents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cytotoxicity PROPN - O
of ADP - O
the DET - O
compounds NOUN - O
isolated VERB - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
saponins NOUN - O
and CCONJ - O
apoptosis NOUN - O
induced VERB - O
by ADP - O
23-hydroxybetulinic CD - B-CARDINAL
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sortase VERB - O
A DET - O
inhibitory NOUN - O
metabolites VERB - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
relationship NOUN - O
between ADP - O
climatic ADJ - O
conditions NOUN - O
and CCONJ - O
generative ADJ - O
reproduction NOUN - O
of ADP - O
a DET - O
lowland NOUN - O
population NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
vernalis NOUN - O
: PUNCT - O
the DET - O
last ADJ - O
breath NOUN - O
of ADP - O
a DET - O
relict ADJ - O
plant NOUN - O
or CCONJ - O
a DET - O
fluctuating ADJ - O
cycle NOUN - O
of ADP - O
regeneration NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
23 CD - B-CARDINAL
oleanane ADJ - O
- PUNCT - O
type NOUN - O
triterpenoid NOUN - O
saponins NOUN - O
were VERB - O
isolated VERB - O
from ADP - O
a DET - O
methanol NOUN - O
extract NOUN - O
of ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Validated VERB - O
rapid ADJ - O
resolution NOUN - O
LC NNP - B-ORG
- HYPH - I-ORG
ESI NNP - I-ORG
- HYPH - I-ORG
MS NNP - I-ORG
/ SYM - I-ORG
MS NNP - I-ORG
method VERB - O
for ADP - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
five CD - B-CARDINAL
pulchinenosides NOUN - O
from ADP - O
Pulsatilla NN - B-MEDICINE
chinensis NOUN - O

-DOCSTART- -X- - O

SB365 NNP - B-ORG
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
saponin NOUN - O
D NOUN - O
isolated VERB - O
from ADP - O
the DET - O
root NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
, PUNCT - O
has VERB - O
exhibited VERB - O
potential ADJ - O
beneficial ADJ - O
effects NOUN - O
as ADP - O
a DET - O
chemopreventive ADJ - O
agent NOUN - O
for ADP - O
critical ADJ - O
health NOUN - O
conditions NOUN - O
including VERB - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

SB365 NNP - B-ORG
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
saponin ADJ - O
D NOUN - O
, PUNCT - O
targets VERB - O
c NOUN - O
- PUNCT - O
Met PROPN - O
and CCONJ - O
exerts VERB - O
antiangiogenic ADJ - O
and CCONJ - O
antitumor NOUN - O
activities NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
article NOUN - O
is VERB - O
to PART - O
establish VERB - O
a DET - O
risk NOUN - O
assessment NOUN - O
procedure NOUN - O
without ADP - O
full ADJ - O
toxicological ADJ - O
examination NOUN - O
, PUNCT - O
using VERB - O
homeopathic ADJ - O
preparations NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
pratensis NN - I-PERSON
L. NNP - B-PERSON
as ADP - O
an DET - O
example NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Root NNP - I-ORG
Rot NNP - I-ORG
on ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
Caused VERB - O
by ADP - O
Fusarium PROPN - O
oxysporum NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
homeopathic ADJ - O
preparation NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
nigricans NOUN - O
is VERB - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
anxiety NOUN - O
related VERB - O
disorders NOUN - O
. PUNCT - O

Though ADP - O
in ADP - O
clinical ADJ - O
use NOUN - O
for ADP - O
many JJ - B-DATE
years NNS - I-DATE
, PUNCT - O
the DET - O
anxiolytic ADJ - O
activity NOUN - O
of ADP - O
Pulsatilla NN - B-MEDICINE
nigricans NNS - I-ORG
( PUNCT - O
Puls NNP - B-PERSON
) PUNCT - O
has VERB - O
not ADV - O
been VERB - O
evaluated VERB - O
experimentally ADV - O
. PUNCT - O

The DET - O
study NOUN - O
showed VERB - O
an DET - O
anxiolytic ADJ - O
effect NOUN - O
of ADP - O
homeopathic ADJ - O
preparation NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
nigricans NOUN - O
comparable ADJ - O
to ADP - O
that DET - O
found VERB - O
with ADP - O
a DET - O
standard ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pulsatilla NN - B-MEDICINE
nigricans NOUN - O
extract VERB - O
in ADP - O
arsenic ADV - O
- PUNCT - O
induced VERB - O
DNA NOUN - O
damage NOUN - O
in ADP - O
testis ADJ - O
cells NOUN - O
of ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isolation NOUN - O
of ADP - O
nematicidal ADJ - O
triterpenoid NOUN - O
saponins NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
root NOUN - O
and CCONJ - O
their ADJ - O
activities NOUN - O
against ADP - O
Meloidogyne NNP - B-ORG
incognita NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pulsatilla NN - B-MEDICINE
chinensis NOUN - O
is VERB - O
a DET - O
medicinal ADJ - O
root NOUN - O
plant NOUN - O
that ADJ - O
has VERB - O
been VERB - O
used VERB - O
to PART - O
treat VERB - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
disease NOUN - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
research NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
inhibitory ADJ - O
effect NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
polysaccharides NOUN - O
( PUNCT - O
PCPS PROPN - O
) PUNCT - O
on ADP - O
glioma NOUN - O
in ADP - O
vivo NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Vero NOUN - O
cells NOUN - O
infected VERB - O
with ADP - O
the DET - O
Korean NNP - B-ORG
CVA16 NNP - I-ORG
isolate VERB - O
showed VERB - O
a DET - O
cytopathic ADJ - O
effect NOUN - O
2 CD - B-DATE
days NNS - I-DATE
after ADP - O
the DET - O
infection NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
treatment NOUN - O
of ADP - O
cells NOUN - O
with ADP - O
Cornus NNPS - B-ORG
officinalis ADJ - O
, PUNCT - O
Acer NNP - B-ORG
triflorum NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
, PUNCT - O
and CCONJ - O
Clematis NNP - B-PRODUCT
heracleifolia NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antitumor ADJ - O
activity NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
the DET - O
quinone NOUN - O
reductase NOUN - O
( PUNCT - O
QR PROPN - O
) PUNCT - O
inducing VERB - O
activities NOUN - O
of ADP - O
nine CD - B-CARDINAL
known ADJ - O
triterpene NOUN - O
saponins NOUN - O
from ADP - O
the DET - O
dichloromethane NOUN - O
/ SYM - O
ethanol NOUN - O
extract NOUN - O
of ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
were VERB - O
tested VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Pulsatilla RB - B-MEDICINE
koreana VERB - O
             SPACE - O
extract NOUN - O
( PUNCT - O
PKE NN - B-ORG
) PUNCT - O
has VERB - O
been VERB - O
used VERB - O
to PART - O
treat VERB - O
malaria NOUN - O
and CCONJ - O
dysentery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Molecular ADJ - O
mechanisms NOUN - O
involved VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
inflammatory ADJ - O
bowel NOUN - O
disease NOUN - O
by ADP - O
Pulsatilla NNP - B-MEDICINE
decoction]. NOUN - O

-DOCSTART- -X- - O

Anatomical ADJ - O
structure NOUN - O
comparison NOUN - O
and CCONJ - O
barbloin VERB - O
histochemical ADJ - O
localization NOUN - O
of ADP - O
wild ADJ - O
and CCONJ - O
cultivated VERB - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
( PUNCT - O
Ranunculaceae NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
essential ADJ - O
oil NOUN - O
obtained VERB - O
by ADP - O
hydrodistillation NOUN - O
of ADP - O
the DET - O
aerial ADJ - O
flowering VERB - O
parts NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
albana NOUN - O
( PUNCT - O
Stev PROPN - O
. PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
extraction NOUN - O
condition NOUN - O
of ADP - O
total ADJ - O
saponins NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
cenua NN - I-ORG
by ADP - O
ultrasonic ADJ - O
wave NOUN - O
was VERB - O
optimized VERB - O
by ADP - O
single ADJ - O
factor NOUN - O
and CCONJ - O
orthogonal ADJ - O
experiments NOUN - O
. PUNCT - O

The DET - O
content NOUN - O
of ADP - O
total ADJ - O
saponins NOUN - O
in ADP - O
Pulsatilla NNP - B-MEDICINE
cernua NOUN - O
was VERB - O
4 CD - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Optimization NOUN - O
of ADP - O
extraction NOUN - O
technics NOUN - O
of ADP - O
total ADJ - O
saponins NOUN - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
cernua]. VERB - O

-DOCSTART- -X- - O

Quality NOUN - O
control NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
koreana NOUN - O
based VERB - O
on ADP - O
the DET - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
triterpenoidal NOUN - O
saponins NOUN - O
by ADP - O
HPLC NNP - B-ORG
- PUNCT - O
ELSD PROPN - O
and CCONJ - O
principal ADJ - O
component NOUN - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Protein NOUN - O
analysis NOUN - O
of ADP - O
Trichomonas NNP - B-GPE
vaginalis NOUN - O
treated VERB - O
by ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
in ADP - O
vitro]. ADJ - O

-DOCSTART- -X- - O

For ADP - O
preventive ADJ - O
treatments NOUN - O
in ADP - O
hay NOUN - O
fever NOUN - O
patients NOUN - O
, PUNCT - O
Arsenicum NNP - B-ORG
album NOUN - O
was VERB - O
the DET - O
most ADV - O
effective ADJ - O
homeopathic NOUN - O
medicine NOUN - O
followed VERB - O
by ADP - O
Nux PROPN - O
vomica NOUN - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
pratensis NOUN - O
, PUNCT - O
Gelsemium NNP - B-ORG
, PUNCT - O
Sarsaparilla NNP - B-PERSON
, PUNCT - O
Silicea NNP - B-GPE
and CCONJ - O
Natrum NNP - B-ORG
muriaticum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isolation NOUN - O
and CCONJ - O
evaluation NOUN - O
of ADP - O
immunological ADJ - O
adjuvant ADJ - O
activities NOUN - O
of ADP - O
saponins NOUN - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
with ADP - O
less ADJ - O
adverse ADJ - O
reactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
triterpenoid NOUN - O
saponin NOUN - O
was VERB - O
isolated VERB - O
from ADP - O
Pulsatilla NNP - B-MEDICINE
cernua NOUN - O
, PUNCT - O
along ADP - O
with ADP - O
eight CD - B-CARDINAL
known VERB - O
triterpenoids NOUN - O
and CCONJ - O
triterpenoid NOUN - O
glycosides NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pre- NOUN - O
and CCONJ - O
postinterventional ADJ - O
variability NOUN - O
spectra NOUN - O
of ADP - O
heart NOUN - O
rate NOUN - O
and CCONJ - O
blood NOUN - O
flow NOUN - O
of ADP - O
77 CD - B-CARDINAL
subjects NOUN - O
were VERB - O
recorded VERB - O
with ADP - O
the DT - B-ORG
Medical NNP - I-ORG
Analyzer NNP - I-ORG
System NNP - I-ORG
, PUNCT - O
administering VERB - O
homeopathic ADJ - O
preparations NOUN - O
of ADP - O
Aconitum NNP - B-NORP
napellus NOUN - O
( PUNCT - O
6c NUM - O
, PUNCT - O
10 NUM - O
M PROPN - O
) PUNCT - O
, PUNCT - O
Arsenicum NNP - B-ORG
album NOUN - O
( PUNCT - O
200c CD - B-ORDINAL
, PUNCT - O
1 CD - B-CARDINAL
M PROPN - O
) PUNCT - O
, PUNCT - O
Gelsemium PROPN - O
sempervirens NOUN - O
( PUNCT - O
200c CD - B-ORDINAL
, PUNCT - O
1 CD - B-CARDINAL
M PROPN - O
) PUNCT - O
, PUNCT - O
Phosphorus NNP - B-GPE
( PUNCT - O
200c CD - B-ORDINAL
, PUNCT - O
1 NUM - O
M PROPN - O
) PUNCT - O
, PUNCT - O
Pulsatilla NNP - B-MEDICINE
nigricans NOUN - O
( PUNCT - O
200c NOUN - O
) PUNCT - O
and CCONJ - O
Sulphur NNP - B-ORG
( PUNCT - O
200c NUM - O
, PUNCT - O
1 NUM - O
M NOUN - O
) PUNCT - O
versus ADP - O
placebo NOUN - O
control NOUN - O
. PUNCT - O

Sulphur NNP - B-PERSON
200c NNP - I-PERSON
and CCONJ - O
1 CD - B-QUANTITY
M NNP - I-QUANTITY
, PUNCT - O
Gelsemium PROPN - O
200c PROPN - O
and CCONJ - O
Pulsatilla NNP - B-MEDICINE
200c PROPN - O
, PUNCT - O
produced VERB - O
a DET - O
62.5 CD - B-PERCENT
% NN - I-PERCENT
response NOUN - O
in ADP - O
HRV NNP - B-ORG
against ADP - O
the DET - O
placebo NOUN - O
response NOUN - O
of ADP - O
16.6 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
East JJ - B-NORP
Asian JJ - I-NORP
traditional ADJ - O
medicine NOUN - O
, PUNCT - O
Pulsatillae NNP - B-ORG
Radix NNP - I-ORG
( PUNCT - O
PR PROPN - O
) PUNCT - O
is VERB - O
widely ADV - O
used VERB - O
to PART - O
treat VERB - O
amoebic ADJ - O
dysentery NOUN - O
and CCONJ - O
renowned VERB - O
for ADP - O
its ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
first JJ - B-ORDINAL
synthesis NOUN - O
of ADP - O
two CD - B-CARDINAL
natural ADJ - O
triterpenoid NOUN - O
saponins NOUN - O
, PUNCT - O
which ADJ - O
were VERB - O
isolated VERB - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
and CCONJ - O
exhibited VERB - O
excellent NOUN - O
in ADP - O
vitro X - O
cytotoxic ADJ - O
activity NOUN - O
against ADP - O
HL-60 NNP - B-ORG
cells NOUN - O
, PUNCT - O
was VERB - O
concisely ADV - O
achieved VERB - O
in ADP - O
a DET - O
convergent ADJ - O
approach NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Concise ADJ - O
synthesis NOUN - O
of ADP - O
two CD - B-CARDINAL
natural ADJ - O
triterpenoid NOUN - O
saponins NOUN - O
, PUNCT - O
oleanolic ADJ - O
acid NOUN - O
derivatives NOUN - O
isolated VERB - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
floral ADJ - O
development NOUN - O
of ADP - O
two CD - B-CARDINAL
Clematis NNP - B-ORG
species NOUN - O
and CCONJ - O
four CD - B-CARDINAL
Anemone NNP - B-ORG
species NOUN - O
( PUNCT - O
including VERB - O
Pulsatilla NNP - B-MEDICINE
) PUNCT - O
( PUNCT - O
Anemoneae NNP - B-ORG
, PUNCT - O
Ranunculaceae NNP - B-GPE
) PUNCT - O
is VERB - O
described VERB - O
. PUNCT - O

In ADP - O
Anemone NNP - B-PERSON
, PUNCT - O
the DET - O
perianth JJ - B-ORDINAL
organs NOUN - O
, PUNCT - O
if ADP - O
five CD - B-CARDINAL
, PUNCT - O
are VERB - O
initiated VERB - O
in ADP - O
spiral ADJ - O
sequence NOUN - O
; PUNCT - O
in ADP - O
the DET - O
Pulsatilla NNP - B-MEDICINE
group NOUN - O
of ADP - O
Anemone NNP - B-ORG
, PUNCT - O
six CD - B-CARDINAL
sepals NOUN - O
are VERB - O
initiated VERB - O
in ADP - O
two CD - B-CARDINAL
whorls NOUN - O
; PUNCT - O
the DET - O
first JJ - B-ORDINAL
three CD - B-CARDINAL
organs NOUN - O
of ADP - O
the DET - O
androecium NOUN - O
( PUNCT - O
staminodes NOUN - O
) PUNCT - O
alternate ADJ - O
with ADP - O
the DET - O
inner ADJ - O
sepals NOUN - O
. PUNCT - O

In ADP - O
contrast NOUN - O
, PUNCT - O
in ADP - O
the DET - O
Pulsatilla NNP - B-MEDICINE
group NOUN - O
of ADP - O
Anemone NNP - B-ORG
, PUNCT - O
these DET - O
organs NOUN - O
retain VERB - O
sterile ADJ - O
anthers NOUN - O
and CCONJ - O
become VERB - O
small ADJ - O
, PUNCT - O
capitate VERB - O
organs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

For ADP - O
detection NOUN - O
and CCONJ - O
differentiation NOUN - O
of ADP - O
two CD - B-CARDINAL
types NOUN - O
of ADP - O
triterpenoid NOUN - O
saponins NOUN - O
based VERB - O
on ADP - O
different ADJ - O
aglycons NOUN - O
of ADP - O
the DET - O
lupane NOUN - O
and CCONJ - O
oleanane ADJ - O
skeleton NOUN - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O

Diagnostic ADJ - O
fragmentation NOUN - O
pathways NOUN - O
of ADP - O
the DET - O
silver ADJ - O
complexes NOUN - O
of ADP - O
the DET - O
saponins NOUN - O
allow VERB - O
successful ADJ - O
identification NOUN - O
of ADP - O
the DET - O
two CD - B-CARDINAL
types NOUN - O
of ADP - O
saponins NOUN - O
from ADP - O
the DET - O
roots NOUN - O
of ADP - O
Pulsatilla NNP - B-MEDICINE
chinensis NOUN - O
( PUNCT - O
Bunge PROPN - O
) PUNCT - O
Regel NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Re ADP - O
: PUNCT - O
Comparison NOUN - O
of ADP - O
the DET - O
Efficacy PROPN - O
of ADP - O
Isosorbide NNP - B-MEDICINE
Mononitrate NNP - I-MEDICINE
and CCONJ - O
Doxazosin PROPN - O
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Lower NNP - I-ORG
Urinary NNP - I-ORG
Tract VBP - I-ORG
Symptoms NNPS - B-ORG
and CCONJ - O
Benign NNP - B-ORG
Prostatic NNP - I-ORG
Hyperplasia NNP - I-ORG
: PUNCT - O
A DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Isosorbide NNP - B-FAC
Mononitrate NNP - I-FAC
( PUNCT - O
ISMN NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
anti ADJ - O
- ADJ - O
anginal ADJ - O
organic ADJ - O
nitrate NOUN - O
vasodilator NOUN - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
various ADJ - O
cardiovascular ADJ - O
disorders NOUN - O
and CCONJ - O
prophylaxis NOUN - O
of ADP - O
angina ADJ - O
Pectoris NNP - B-ORG
, PUNCT - O
which ADJ - O
is VERB - O
poorly ADV - O
absorbed VERB - O
from ADP - O
the DET - O
upper ADJ - O
GIT NN - B-ORG
, PUNCT - O
hence ADV - O
CR NNP - B-GPE
formulation NOUN - O
is VERB - O
desirable ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Randomized NNP - B-ORG
Comparison NNP - I-ORG
of IN - I-ORG
Isosorbide NNP - I-ORG
Mononitrate NNP - I-ORG
and CCONJ - O
PGE2 PROPN - O
Gel PROPN - O
for ADP - O
Cervical PROPN - O
Ripening PROPN - O
at ADP - O
Term PROPN - O
including VERB - O
High PROPN - O
Risk PROPN - O
Pregnancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
expansion NOUN - O
of ADP - O
pulse NOUN - O
pressure NOUN - O
( PUNCT - O
PP NNP - B-ORG
) PUNCT - O
is VERB - O
the DET - O
individual ADJ - O
dangerous ADJ - O
cardiovascular NOUN - O
( PUNCT - O
CV NNP - B-ORG
) PUNCT - O
factor NOUN - O
, PUNCT - O
by ADP - O
integrating VERB - O
Isosorbide NNP - B-ORG
Mononitrate PROPN - O
with ADP - O
other ADJ - O
hypertension NOUN - O
resisting VERB - O
medicaments NOUN - O
, PUNCT - O
good ADJ - O
clinic NOUN - O
curative ADJ - O
effect NOUN - O
is VERB - O
obtained VERB - O
, PUNCT - O
and CCONJ - O
synergy VERB - O
effect NOUN - O
is VERB - O
achieved VERB - O
in ADP - O
terms NOUN - O
of ADP - O
reduction NOUN - O
of ADP - O
contraction NOUN - O
pressure NOUN - O
, PUNCT - O
wherein ADV - O
the DET - O
combination NOUN - O
of ADP - O
calcium NOUN - O
ion NOUN - O
antagonist NOUN - O
, PUNCT - O
rennin NOUN - O
- PUNCT - O
angiotensins NOUN - O
- PUNCT - O
aldosterone NOUN - O
system NOUN - O
antagon NOUN - O
, PUNCT - O
blood NOUN - O
vessel NOUN - O
expanding VERB - O
agent NOUN - O
, PUNCT - O
epinephrine NOUN - O
acceptor NOUN - O
retarding VERB - O
agent NOUN - O
can VERB - O
make VERB - O
the DET - O
most ADV - O
ideal ADJ - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Silver NNP - B-MEDICINE
Sulfadiazine NNP - I-MEDICINE
and CCONJ - O
Cerium PROPN - O
Nitrate PROPN - O
in ADP - O
Ischemic NNP - B-ORG
Skin NNP - I-ORG
Necrosis NN - I-ORG
of ADP - O
the DET - O
Leg PROPN - O
and CCONJ - O
Foot PROPN - O
: PUNCT - O
Results NOUN - O
of ADP - O
a DET - O
Prospective PROPN - O
Randomized VERB - O
Controlled PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Silver NNP - B-ORG
Sulfadiazine NNP - I-ORG
Encapsulated VBN - I-ORG
in ADP - O
Lipid PROPN - O
- PUNCT - O
Based VERB - O
Nanocarriers PROPN - O
for ADP - O
Burn PROPN - O
Treatment PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
systematic ADJ - O
review NOUN - O
with ADP - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
effect NOUN - O
of ADP - O
Silver NNP - B-ORG
Sulfadiazine NNP - I-ORG
( PUNCT - O
SSD NNP - B-ORG
) PUNCT - O
with ADP - O
other ADJ - O
new ADJ - O
dressings NOUN - O
, PUNCT - O
with ADP - O
or CCONJ - O
without ADP - O
silver NOUN - O
, PUNCT - O
on ADP - O
healing NOUN - O
and CCONJ - O
infection NOUN - O
prevention NOUN - O
in ADP - O
burns NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Inhibition NOUN - O
of ADP - O
Tyrosine PROPN - O
Hydroxylase PROPN - O
in ADP - O
Dopaminergic PROPN - O
Neurons PROPN - O
after ADP - O
Treatment PROPN - O
with ADP - O
Paroxetine NNP - B-MEDICINE
but CCONJ - O
Not ADV - O
with ADP - O
Agomelatine PROPN - O
in ADP - O
Male PROPN - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
, PUNCT - O
one NUM - O
of ADP - O
the DET - O
selective ADJ - O
serotonin NOUN - O
reuptake VERB - O
inhibitors NOUN - O
( PUNCT - O
SSRIs NOUN - O
) PUNCT - O
, PUNCT - O
has VERB - O
been VERB - O
widely ADV - O
prescribed VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
depression NOUN - O
and CCONJ - O
anxiety NOUN - O
disorders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
displayed VERB - O
both DET - O
quasi ADJ - O
- PUNCT - O
irreversible ADJ - O
and CCONJ - O
irreversible ADJ - O
MDI NN - B-PRODUCT
of ADP - O
CYP2D6 NOUN - O
, PUNCT - O
formation NOUN - O
of ADP - O
CYP NNP - B-ORG
- PUNCT - O
dependent ADJ - O
GSH NNP - B-ORG
adducts NOUN - O
was VERB - O
observed VERB - O
, PUNCT - O
while ADP - O
CYP NNP - B-ORG
- PUNCT - O
mediated VERB - O
covalent NOUN - O
binding VERB - O
occurred VERB - O
which ADJ - O
was VERB - O
decreased VERB - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
GSH NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
ameliorates VERB - O
whole ADJ - O
- PUNCT - O
body NOUN - O
allodynia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Neuroprotective NNP - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Paroxetine NNP - I-MEDICINE
on IN - I-ORG
Memory NOUN - O
Deficit PROPN - O
Induced VERB - O
by ADP - O
Cerebral NNP - B-ORG
Ischemia NNP - I-ORG
after IN - I-ORG
Transient NNP - I-ORG
Bilateral NNP - I-ORG
Occlusion NNP - I-ORG
of IN - I-ORG
Common NNP - I-ORG
Carotid NNP - I-ORG
Arteries NNPS - I-ORG
in ADP - O
Rat PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
also ADV - O
significantly ADV - O
inhibited VERB - O
the DET - O
increase NOUN - O
of ADP - O
tail NOUN - O
skin NOUN - O
temperature NOUN - O
by ADP - O
yohimbine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
On PROPN - O
- PUNCT - O
demand NOUN - O
Tramadol PROPN - O
and CCONJ - O
Paroxetine NNP - B-MEDICINE
Use PROPN - O
in ADP - O
Treatment PROPN - O
of ADP - O
Life PROPN - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
was VERB - O
markedly ADV - O
effective ADJ - O
in ADP - O
50 CD - B-CARDINAL
patients NOUN - O
who NOUN - O
also ADV - O
displayed VERB - O
an DET - O
increased VERB - O
level NOUN - O
of ADP - O
miRNA-451a NOUN - O
but CCONJ - O
reduced ADJ - O
levels NOUN - O
of ADP - O
miRNA-34a-5p ADJ - O
and CCONJ - O
miRNA-221 NOUN - O
- PUNCT - O
3p NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
blocks VERB - O
the DET - O
human ADJ - O
ether NOUN - O
- PUNCT - O
a DET - O
- PUNCT - O
go NOUN - O
- PUNCT - O
go NOUN - O
- PUNCT - O
related VERB - O
gene NOUN - O
( PUNCT - O
HERG PROPN - O
) PUNCT - O
channels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
was VERB - O
started VERB - O
at ADP - O
5 CD - B-CARDINAL
mg NOUN - O
in ADP - O
the DET - O
evening NOUN - O
, PUNCT - O
with ADP - O
the DET - O
intention NOUN - O
of ADP - O
titrating VERB - O
up PART - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
of ADP - O
Paroxetine NNP - B-MEDICINE
Hydrochloride NNP - I-ORG
Single PROPN - O
Layer PROPN - O
Controlled PROPN - O
- PUNCT - O
Release PROPN - O
Tablets NOUN - O
Based VERB - O
on ADP - O
3² CD - B-CARDINAL
Factorial NNP - B-LOC
Design NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Therapeutic ADJ - O
Drug PROPN - O
Monitoring PROPN - O
of ADP - O
Fluoxetine PROPN - O
, PUNCT - O
Norfluoxetine NNP - B-NORP
and CCONJ - O
Paroxetine NNP - B-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Early ADJ - O
Improvement NOUN - O
and CCONJ - O
Marriage NOUN - O
Are VERB - O
Determinants NOUN - O
of ADP - O
the DET - O
12-Month NUM - O
Treatment PROPN - O
Outcome PROPN - O
of ADP - O
Paroxetine NNP - B-MEDICINE
in ADP - O
Outpatients NOUN - O
with ADP - O
Panic JJ - B-ORG
Disorder NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Paroxetine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
multifocal ADJ - O
fixed VERB - O
drug NOUN - O
rash NOUN - O
: PUNCT - O
An DET - O
incident NOUN - O
, PUNCT - O
hitherto ADV - O
unreported ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Synthesis PROPN - O
and CCONJ - O
Antimicrobial NNP - B-MEDICINE
Activity NNP - I-ORG
of IN - I-ORG
Polyethylene NNP - I-ORG
/ SYM - I-ORG
Chlorhexidine NNP - I-ORG
/ SYM - I-ORG
Vermiculite NNP - I-ORG
Nanocomposites NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial NNP - B-MEDICINE
Activities PROPN - O
of ADP - O
Tea PROPN - O
Polyphenol PROPN - O
on ADP - O
Phytopathogens NNP - B-ORG
: : - I-ORG
A NNP - I-ORG
Review NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Long PROPN - O
- PUNCT - O
Term PROPN - O
Effects PROPN - O
of ADP - O
Phased PROPN - O
Implementation PROPN - O
of ADP - O
Antimicrobial NNP - B-MEDICINE
Stewardship PROPN - O
in ADP - O
Academic PROPN - O
ICUs NOUN - O
: PUNCT - O
2007 CD - B-DATE
- SYM - I-DATE
2015 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
susceptibility NOUN - O
was VERB - O
tested VERB - O
by ADP - O
gradient ADJ - O
diffusion NOUN - O
tests NOUN - O
on ADP - O
buffered ADJ - O
charcoal NOUN - O
yeast NOUN - O
extract VERB - O
agar ADJ - O
medium NOUN - O
supplemented VERB - O
with ADP - O
α NOUN - O
- PUNCT - O
ketoglutarate NOUN - O
( PUNCT - O
BCYE NNP - B-PRODUCT
- HYPH - I-PRODUCT
α NNP - I-PRODUCT
) PUNCT - O
and CCONJ - O
a DET - O
subgroup NOUN - O
of ADP - O
strains NOUN - O
were VERB - O
whole ADJ - O
- PUNCT - O
genome ADJ - O
sequenced ADJ - O
using VERB - O
Illumina NNP - B-NORP
technology NOUN - O
and CCONJ - O
analysed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
susceptibility NOUN - O
was VERB - O
tested VERB - O
using VERB - O
the DET - O
agar ADJ - O
dilution NOUN - O
method NOUN - O
according VERB - O
to ADP - O
the DET - O
CLSI NNP - B-ORG
guidelines NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Understanding VERB - O
the DET - O
Components PROPN - O
, PUNCT - O
Calculation PROPN - O
, PUNCT - O
and CCONJ - O
Impact NN - B-ORG
of IN - I-ORG
Monthly NNP - I-ORG
and CCONJ - O
Seasonal NNP - B-ORG
Variation NNP - I-ORG
of IN - I-ORG
the DT - I-ORG
Standardized NNP - I-ORG
Antimicrobial NNP - I-MEDICINE
Utilization NNP - I-ORG
Ratio NNP - I-ORG
( PUNCT - O
SAAR PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
resistance NOUN - O
( PUNCT - O
AMR NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
major ADJ - O
public ADJ - O
health NOUN - O
problem NOUN - O
that ADJ - O
requires VERB - O
publicly ADV - O
available ADJ - O
tools NOUN - O
for ADP - O
rapid ADJ - O
analysis NOUN - O
. PUNCT - O

Currently ADV - O
, PUNCT - O
the DT - B-ORG
Bacterial NNP - I-ORG
Antimicrobial NNP - I-MEDICINE
Resistance NNP - I-ORG
Reference NNP - I-ORG
Gene NNP - I-ORG
Database NNP - I-ORG
contains VERB - O
4,579 CD - B-CARDINAL
antimicrobial JJ - B-MEDICINE
resistance NOUN - O
gene NOUN - O
proteins NOUN - O
and CCONJ - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
560 CD - I-CARDINAL
HMMs NOUN - O
. PUNCT - O

To PART - O
assess VERB - O
the DET - O
predictive ADJ - O
ability NOUN - O
of ADP - O
AMRFinder NNP - B-PRODUCT
, PUNCT - O
we PRON - O
measured VERB - O
the DET - O
consistency NOUN - O
between ADP - O
predicted VERB - O
AMR NNP - B-ORG
genotypes NOUN - O
from ADP - O
AMRFinder NNP - B-ORG
against ADP - O
resistance NOUN - O
phenotypes NOUN - O
of ADP - O
6,242 CD - B-CARDINAL
isolates NOUN - O
from ADP - O
the DT - B-EVENT
National NNP - I-EVENT
Antimicrobial NNP - I-MEDICINE
Resistance NNP - I-EVENT
Monitoring NNP - I-EVENT
System NNP - I-EVENT
( PUNCT - O
NARMS NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
resistance NOUN - O
( PUNCT - O
AMR NNP - B-ORG
) PUNCT - O
among ADP - O
gram NOUN - O
- PUNCT - O
negative ADJ - O
bacilli NOUN - O
is VERB - O
a DET - O
global ADJ - O
health NOUN - O
problem NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
stewardship NOUN - O
: PUNCT - O
an DET - O
evaluation NOUN - O
of ADP - O
structure NOUN - O
and CCONJ - O
process NOUN - O
and CCONJ - O
their ADJ - O
association NOUN - O
with ADP - O
antimicrobial JJ - B-MEDICINE
prescribing NOUN - O
in ADP - O
NHS NNP - B-ORG
hospitals NOUN - O
in ADP - O
England NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Peptide NN - B-ORG
- HYPH - I-ORG
Stabilized VBN - I-ORG
Emulsions NNPS - I-ORG
and CCONJ - O
Gels NNPS - B-PERSON
from ADP - O
an DET - O
Arginine PROPN - O
- PUNCT - O
Rich PROPN - O
Surfactant PROPN - O
- PUNCT - O
like ADP - O
Peptide PROPN - O
with ADP - O
Antimicrobial NNP - B-MEDICINE
Activity PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
peptides NOUN - O
, PUNCT - O
in ADP - O
particular ADJ - O
α NOUN - O
- PUNCT - O
defensins NOUN - O
expressed VERB - O
by ADP - O
Paneth NNP - B-PERSON
cells NOUN - O
, PUNCT - O
control NOUN - O
microbiota NOUN - O
composition NOUN - O
and CCONJ - O
play VERB - O
a DET - O
key ADJ - O
role NOUN - O
in ADP - O
intestinal ADJ - O
barrier NOUN - O
function NOUN - O
and CCONJ - O
homeostasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

One CD - B-CARDINAL
Health NNP - B-ORG
- HYPH - I-ORG
Its PRP$ - I-ORG
Importance NN - I-ORG
in ADP - O
Helping VERB - O
to ADP - O
Better PROPN - O
Control PROPN - O
Antimicrobial NNP - B-MEDICINE
Resistance PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
activities NOUN - O
of ADP - O
the DET - O
B PROPN - O
/ SYM - O
F PROPN - O
by ADP - O
- PUNCT - O
products NOUN - O
and CCONJ - O
LAB NNP - B-ORG
( PUNCT - O
thirteen CD - B-CARDINAL
LAB NNP - B-ORG
strains NOUN - O
were VERB - O
estimated VERB - O
against ADP - O
fifteen CD - B-CARDINAL
pathogenic ADJ - O
strains NOUN - O
) PUNCT - O
were VERB - O
evaluated VERB - O
, PUNCT - O
while ADP - O
whey NOUN - O
substrate VERB - O
for ADP - O
the DET - O
selected VERB - O
and CCONJ - O
the DET - O
highest ADJ - O
antimicrobial JJ - B-MEDICINE
activities NOUN - O
showing VERB - O
LAB NNP - B-ORG
cultivation NOUN - O
was VERB - O
used VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Role PROPN - O
of ADP - O
Polydopamine NNP - B-ORG
's PART - O
Redox NNP - B-ORG
- HYPH - I-ORG
Activity NNP - I-ORG
on ADP - O
its ADJ - O
Pro JJ - B-ORG
- ADJ - O
oxidant ADJ - O
, PUNCT - O
Radical NNP - B-ORG
- HYPH - I-ORG
Scavenging NNP - I-ORG
, PUNCT - O
and CCONJ - O
Antimicrobial NNP - B-MEDICINE
Activities NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial NNP - B-MEDICINE
Resistance NNP - I-ORG
, PUNCT - O
Prevalence PROPN - O
of ADP - O
Resistance NNP - B-ORG
Genes NNPS - I-ORG
and CC - I-ORG
Molecular PROPN - O
Characterization PROPN - O
in ADP - O
intestinal ADJ - O
Bacteroides NNPS - B-PERSON
fragilis NOUN - O
group NOUN - O
isolates VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Magneto NNP - B-ORG
- HYPH - I-ORG
Priming NN - I-ORG
Improved VBN - I-ORG
Nutraceutical NNP - I-ORG
Potential PROPN - O
and CCONJ - O
Antimicrobial NNP - B-MEDICINE
Activity PROPN - O
of ADP - O
Momordica PROPN - O
charantia VERB - O
L. NNP - B-PERSON
Without IN - I-PERSON
Affecting VERB - O
Nutritive NNP - B-ORG
Value NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

From ADP - O
Antimicrobial NNP - B-MEDICINE
to ADP - O
Anticancer PROPN - O
Peptides PROPN - O
: PUNCT - O
The DET - O
Transformation PROPN - O
of ADP - O
Peptides PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
susceptibility NOUN - O
of ADP - O
Burkholderia NNP - B-GPE
pseudomallei NOUN - O
isolates NOUN - O
in ADP - O
the DT - B-LOC
Northern NNP - I-LOC
Vietnam NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
consumption NOUN - O
in ADP - O
five CD - B-CARDINAL
adult NOUN - O
intensive ADJ - O
care NOUN - O
units NOUN - O
: PUNCT - O
a DET - O
33-month CD - B-PRODUCT
surveillance NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
susceptibility NOUN - O
to PART - O
erythromycin VERB - O
and CCONJ - O
ciprofloxacin PROPN - O
was VERB - O
tested VERB - O
in ADP - O
430 CD - B-CARDINAL
clinical ADJ - O
isolates NOUN - O
of ADP - O
C. NNP - B-ORG
jejuni PROPN - O
collected VERB - O
over IN - B-DATE
18 CD - I-DATE
years NNS - I-DATE
in ADP - O
a DET - O
Tokyo NNP - B-GPE
general ADJ - O
hospital NOUN - O
between IN - B-DATE
2000 CD - I-DATE
and CC - I-DATE
2017 CD - I-DATE
using VERB - O
the DET - O
broth NOUN - O
microdilution NOUN - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Engineering PROPN - O
of ADP - O
Antimicrobial NNP - B-MEDICINE
Surfaces PROPN - O
by ADP - O
Using VERB - O
Temporin PROPN - O
Analogs PROPN - O
to ADP - O
Tune NNP - B-PERSON
the DT - I-PERSON
Biocidal NNP - I-PERSON
/ SYM - O
antiadhesive ADJ - O
Effect PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
resistance NOUN - O
is VERB - O
a DET - O
growing VERB - O
problem NOUN - O
, PUNCT - O
with ADP - O
the DET - O
need NOUN - O
for ADP - O
' PUNCT - O
strong ADJ - O
action NOUN - O
' PUNCT - O
highlighted VERB - O
by ADP - O
the DET - O
Chief NNP - B-ORG
Medical NNP - I-ORG
Officer PROPN - O
for ADP - O
England NNP - B-GPE
in ADP - O
2013 CD - B-DATE
, PUNCT - O
along ADP - O
with ADP - O
a DET - O
5 CD - B-CARDINAL
  SPACE - O
year NN - B-DATE
antimicrobial JJ - B-MEDICINE
resistance NOUN - O
strategy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
efficacy NOUN - O
and CCONJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O
of ADP - O
poly(amidoamine NOUN - O
) PUNCT - O
( PUNCT - O
PAMAM PROPN - O
) PUNCT - O
dendrimers NOUN - O
against ADP - O
opportunistic ADJ - O
pathogens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Draft NN - B-WORK_OF_ART
Genome NNP - I-WORK_OF_ART
Sequence NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Bacillus NNP - I-WORK_OF_ART
velezensis NOUN - O
OSY NNP - B-ORG
- HYPH - I-ORG
GA1 NNP - I-ORG
, PUNCT - O
Which ADJ - O
Encodes VERB - O
Multiple VERB - O
Antimicrobial JJ - B-MEDICINE
Metabolites PROPN - O
and CCONJ - O
Expresses PROPN - O
Antimicrobial NNP - B-MEDICINE
Activity PROPN - O
against ADP - O
Foodborne NNP - B-PERSON
Pathogens NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
prescribing ADJ - O
practices NOUN - O
across ADP - O
the DET - O
national ADJ - O
Veterans NNP - B-ORG
Health NNP - I-ORG
Administration NNP - I-ORG
system NOUN - O
were VERB - O
assessed ADJ - O
using VERB - O
the DET - O
administrative ADJ - O
data NOUN - O
for ADP - O
29 CD - B-CARDINAL
  SPACE - O
530 CD - B-CARDINAL
records NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
peptides NOUN - O
( PUNCT - O
AMPs NOUN - O
) PUNCT - O
are VERB - O
short ADJ - O
amphipathic ADJ - O
biological ADJ - O
molecules NOUN - O
generally ADV - O
with ADP - O
less JJR - B-CARDINAL
than IN - I-CARDINAL
100 CD - I-CARDINAL
amino ADJ - O
acids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Guidelines PROPN - O
to ADP - O
Prevent PROPN - O
Antimicrobial NNP - B-MEDICINE
Resistance PROPN - O
( PUNCT - O
steps NOUN - O
4 CD - B-CARDINAL
, PUNCT - O
6 CD - B-DATE
and CC - I-DATE
9 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
peptides NOUN - O
( PUNCT - O
AMPs NOUN - O
) PUNCT - O
play VERB - O
essential ADJ - O
roles NOUN - O
in ADP - O
the DET - O
innate ADJ - O
immune ADJ - O
system NOUN - O
to PART - O
protect VERB - O
against ADP - O
a DET - O
wide ADJ - O
variety NOUN - O
of ADP - O
pathogens NOUN - O
in ADP - O
aquatic ADJ - O
environments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AbstractBackgroundAntimicrobials NOUN - O
are VERB - O
frequently ADV - O
administered VERB - O
to ADP - O
patients NOUN - O
with ADP - O
an DET - O
advanced ADJ - O
stage NOUN - O
of ADP - O
illnesses NOUN - O
. PUNCT - O

Antimicrobials NOUN - O
were VERB - O
commonly ADV - O
prescribed VERB - O
and CCONJ - O
their ADJ - O
overall ADJ - O
consumption NOUN - O
was VERB - O
significant ADJ - O
despite ADP - O
their ADJ - O
limited ADJ - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Overuse NNP - B-ORG
of IN - I-ORG
Antimicrobials NNPS - I-ORG
in ADP - O
the DET - O
End NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
life NOUN - O
Care NOUN - O
: PUNCT - O

Factors NOUN - O
Influencing VERB - O
Physicians PROPN - O
’ CCONJ - O
Prescribing PROPN - O
Behaviors PROPN - O
in ADP - O
Treating VERB - O
Patients NOUN - O
With ADP - O
an DET - O
Advanced PROPN - O
Stage PROPN - O
of ADP - O
Illnesses PROPN - O
in ADP - O
the DET - O
Robust PROPN - O
Era PROPN - O
of ADP - O
Antimicrobial NNP - B-MEDICINE
Stewardship PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
Antimicrobial NNP - B-MEDICINE
Lock NNP - I-ORG
Solutions NNPS - I-ORG
for ADP - O
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Central NNP - I-ORG
Line NNP - I-ORG
- HYPH - I-ORG
Associated NNP - I-ORG
Bloodstream NNP - I-ORG
Infections NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial JJ - B-MEDICINE
activity NOUN - O
analysis NOUN - O
of ADP - O
the DET - O
recombinant ADJ - O
protein NOUN - O
purified VERB - O
from ADP - O
the DET - O
transgenic ADJ - O
HRs NOUN - O
showed VERB - O
that ADP - O
the DET - O
( PUNCT - O
CBD)2-DrsB1 NNP - B-NORP
recombinant ADJ - O
protein NOUN - O
had VERB - O
a DET - O
significant ADJ - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.01 CD - B-CARDINAL
) PUNCT - O
antimicrobial JJ - B-MEDICINE
effect NOUN - O
on ADP - O
the DET - O
growth NOUN - O
of ADP - O
different ADJ - O
fungal ADJ - O
and CCONJ - O
bacterial ADJ - O
pathogens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cationic JJ - B-ORG
Poly([R]-3-hydroxybutyrate NNP - I-ORG
) PUNCT - O
Copolymers NOUN - O
as ADP - O
Antimicrobial NNP - B-MEDICINE
Agents NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Antimicrobial NNP - B-MEDICINE
Stewardship PROPN - O
Interventions PROPN - O
on ADP - O
Antimicrobial NNP - B-MEDICINE
Utilization NNP - I-ORG
in ADP - O
Asymptomatic NNP - B-GPE
Bacteriuria NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Perphenazine NN - B-MEDICINE
and CCONJ - O
dextran NOUN - O
sulfate NOUN - O
were VERB - O
used VERB - O
as ADP - O
the DET - O
drug NOUN - O
and CCONJ - O
polysaccharide VERB - O
models NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Perphenazine NN - B-MEDICINE
- HYPH - I-ORG
Associated VBN - I-ORG
Hyperosmolar NNP - I-ORG
Hyperglycemic NNP - I-ORG
State NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Perphenazine NN - B-MEDICINE
treatment NOUN - O
had VERB - O
similar ADJ - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Perphenazine NN - B-MEDICINE
enanthate NOUN - O
was VERB - O
used VERB - O
to PART - O
allow VERB - O
adaptation NOUN - O
to ADP - O
captivity NOUN - O
in ADP - O
11 CD - B-CARDINAL
Pyrenean JJ - B-NORP
chamois NOUN - O
( PUNCT - O
Rupicapra NNP - B-GPE
pyrenaica PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Crystalline NNP - B-PERSON
Forms NNP - I-PERSON
of ADP - O
the DT - B-ORG
Tri NNP - I-ORG
- HYPH - I-ORG
Mesylate NNP - I-ORG
Salt NNP - I-ORG
of IN - I-ORG
Perphenazine NNP - I-MEDICINE
- HYPH - I-ORG
Gaba NNP - I-ORG
and CCONJ - O
Process NNP - B-WORK_OF_ART
of IN - I-WORK_OF_ART
Producing VBG - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Same JJ - I-WORK_OF_ART

-DOCSTART- -X- - O

A DET - O
sustained ADJ - O
release NOUN - O
capsule NOUN - O
for ADP - O
oral ADJ - O
administration NOUN - O
containing VERB - O
tablets NOUN - O
, PUNCT - O
wherein ADV - O
each DET - O
tablet NOUN - O
comprises VERB - O
25 CD - B-CARDINAL
mg NOUN - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
capsule NOUN - O
for ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
wherein ADV - O
the DET - O
capsule NOUN - O
contains VERB - O
microtablets NOUN - O
, PUNCT - O
and CCONJ - O
wherein ADV - O
the DET - O
amount NOUN - O
of ADP - O
lubricant NOUN - O
, PUNCT - O
if ADP - O
any DET - O
, PUNCT - O
comprise VERB - O
s VERB - O
less JJR - B-PERCENT
than IN - I-PERCENT
0.1 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
weight NOUN - O
of ADP - O
the DET - O
microtablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
stability NOUN - O
of ADP - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
i.v PRON - O
. PUNCT - O

Solutions NOUN - O
of ADP - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
2 CD - B-CARDINAL
, PUNCT - O
1 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
0.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose VERB - O
injection NOUN - O
and CCONJ - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose ADJ - O
and CCONJ - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
chloride NOUN - O
injection NOUN - O
were VERB - O
prepared VERB - O
. PUNCT - O

All DET - O
samples NOUN - O
of ADP - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
2 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose ADJ - O
and CCONJ - O
0.2 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
chloride NOUN - O
injection NOUN - O
taken VERB - O
from ADP - O
PVC NNP - B-ORG
bags NOUN - O
precipitated VERB - O
when ADV - O
thawed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Stability NOUN - O
of ADP - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
i.v PRON - O
. PUNCT - O
solutions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
electrophysiologic ADJ - O
effects NOUN - O
of ADP - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
neonatal ADJ - O
canine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Several ADJ - O
class NOUN - O
IA PROPN - O
( PUNCT - O
disopyramide VERB - O
phosphate ADJ - O
, PUNCT - O
quinidine NOUN - O
sulfate NOUN - O
) PUNCT - O
, PUNCT - O
class NOUN - O
IC PROPN - O
( PUNCT - O
flecainide NOUN - O
acetate VERB - O
, PUNCT - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
) PUNCT - O
, PUNCT - O
and CCONJ - O
class NOUN - O
III PROPN - O
( PUNCT - O
amiodarone ADJ - O
, PUNCT - O
dofetilide NOUN - O
, PUNCT - O
sotalol NOUN - O
hydrochloride NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
blood NOUN - O
samples NOUN - O
( PUNCT - O
0 CD - B-CARDINAL
- SYM - I-CARDINAL
15 CD - I-CARDINAL
h NOUN - O
) PUNCT - O
of ADP - O
the DET - O
subjects NOUN - O
were VERB - O
taken VERB - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
( PUNCT - O
400 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
of ADP - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
method NOUN - O
after ADP - O
validation NOUN - O
procedures NOUN - O
has VERB - O
been VERB - O
applied VERB - O
to ADP - O
the DET - O
multisample NOUN - O
analyses NOUN - O
of ADP - O
a DET - O
human ADJ - O
pharmacokinetic ADJ - O
study NOUN - O
with ADP - O
10 CD - B-CARDINAL
healthy ADJ - O
volunteers NOUN - O
after ADP - O
an DET - O
oral ADJ - O
dose NOUN - O
of ADP - O
300 CD - B-CARDINAL
mg NOUN - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
evaluation NOUN - O
of ADP - O
intravenous ADJ - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
effects NOUN - O
on ADP - O
maintenance NOUN - O
of ADP - O
atrial ADJ - O
signal NOUN - O
- PUNCT - O
averaged VERB - O
ECG NNP - B-ORG
( PUNCT - O
ASAECG NNP - B-ORG
) PUNCT - O
during ADP - O
time NOUN - O
- PUNCT - O
domain NOUN - O
and CCONJ - O
frequency NOUN - O
- PUNCT - O
domain NOUN - O
analyses NOUN - O
in ADP - O
patients NOUN - O
paroxysmal ADJ - O
atrial ADJ - O
fibrillation NOUN - O
( PUNCT - O
PAF NNP - B-ORG
) PUNCT - O
accompanying VERB - O
ischemic ADJ - O
heart NOUN - O
disease NOUN - O
( PUNCT - O
IHD NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
obtained VERB - O
results NOUN - O
have VERB - O
indicated VERB - O
that ADP - O
intravenous ADJ - O
propafenone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
did VERB - O
not ADV - O
change VERB - O
significantly ADV - O
time NOUN - O
- PUNCT - O
domain NOUN - O
and CCONJ - O
frequency NOUN - O
- PUNCT - O
domain NOUN - O
parameters NOUN - O
of ADP - O
ASAECG NNP - B-ORG
in ADP - O
patients NOUN - O
with ADP - O
PAF NNP - B-ORG
during ADP - O
IHD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

One CD - B-CARDINAL
of ADP - O
these DET - O
promising ADJ - O
new ADJ - O
drugs NOUN - O
, PUNCT - O
propafenone JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
Rhythmol NNP - B-PERSON
) PUNCT - O
, PUNCT - O
will VERB - O
soon ADV - O
be VERB - O
available ADJ - O
for ADP - O
use NOUN - O
in ADP - O
this DET - O
country NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Partner PROPN - O
Conflict PROPN - O
and CCONJ - O
Support PROPN - O
as ADP - O
Moderators PROPN - O
of ADP - O
Alcohol NNP - B-MEDICINE
Use PROPN - O
on ADP - O
Alcohol NNP - B-MEDICINE
Problems NNP - I-ORG
and CC - I-ORG
Marital NNP - I-ORG
Satisfaction NNP - I-ORG
in ADP - O
Young PROPN - O
Adult PROPN - O
Marital PROPN - O
Dyads NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Support NOUN - O
for ADP - O
evidence NOUN - O
- PUNCT - O
based VERB - O
alcohol NN - B-MEDICINE
policy NOUN - O
in ADP - O
Ireland NNP - B-GPE
: PUNCT - O
results NOUN - O
from ADP - O
the DT - B-ORG
Community NNP - I-ORG
Action NNP - I-ORG
on IN - I-ORG
Alcohol NNP - I-MEDICINE
Pilot NNP - I-ORG
Project NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
paper NOUN - O
provides VERB - O
a DET - O
brief ADJ - O
overview NOUN - O
of ADP - O
research NOUN - O
on ADP - O
women NOUN - O
and CCONJ - O
alcohol NN - B-MEDICINE
and CCONJ - O
introduces VERB - O
a DET - O
virtual ADJ - O
issue NOUN - O
of ADP - O
Alcoholism PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
and CCONJ - O
Women PROPN - O
: PUNCT - O
A DET - O
Brief PROPN - O
Overview PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

New ADJ - O
Estimates NOUN - O
of ADP - O
the DET - O
Mean PROPN - O
Ethanol PROPN - O
Content PROPN - O
of ADP - O
Beer PROPN - O
, PUNCT - O
Wine PROPN - O
, PUNCT - O
and CCONJ - O
Spirits NNS - B-ORG
Sold VBN - I-ORG
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
Show NNP - I-GPE
a DT - I-GPE
Greater NNP - I-GPE
Increase NN - I-GPE
in ADP - O
Per ADP - O
Capita PROPN - O
Alcohol NNP - B-MEDICINE
Consumption PROPN - O
than ADP - O
Previous ADJ - O
Estimates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Understanding VBG - B-ORG
Social NNP - I-ORG
and CC - I-ORG
Cultural NNP - I-ORG
Contexts NNP - I-ORG
of ADP - O
Alcohol NNP - B-MEDICINE
Misuse NNP - I-ORG
in ADP - O
Mexican NNP - B-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Origin NNP - I-WORK_OF_ART
Hispanic NNP - I-WORK_OF_ART
Men NNPS - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
consumption NOUN - O
appears VERB - O
to PART - O
modulate VERB - O
the DET - O
status NOUN - O
of ADP - O
inflammation NOUN - O
in ADP - O
depressive ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
2012 CD - B-DATE
to ADP - O
2013 NUM - O
National PROPN - O
Epidemiologic PROPN - O
Survey PROPN - O
on ADP - O
Alcohol NNP - B-MEDICINE
and CCONJ - O
Related PROPN - O
Conditions PROPN - O
III PROPN - O
conducted VERB - O
in ADP - O
- PUNCT - O
person NOUN - O
interviews NOUN - O
with ADP - O
a DET - O
nationally ADV - O
representative ADJ - O
sample NOUN - O
of ADP - O
U.S. NNP - B-GPE
adults NOUN - O
( PUNCT - O
N NNP - B-ORG
  _SP - I-ORG
= SYM - O
  SPACE - O
36,309 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Participants NOUN - O
at ADP - O
each DET - O
site NOUN - O
( PUNCT - O
United NNP - B-GPE
States NNP - I-GPE
, PUNCT - O
n DET - O
  SPACE - O
= SYM - O
  SPACE - O
132 NUM - O
; PUNCT - O
France NNP - B-GPE
, PUNCT - O
n DET - O
  SPACE - O
= SYM - O
  SPACE - O
132 NUM - O
) PUNCT - O
were VERB - O
asked VERB - O
to PART - O
complete VERB - O
an DET - O
Internet NOUN - O
- PUNCT - O
based VERB - O
survey NOUN - O
including VERB - O
the DET - O
APT NNP - B-ORG
, PUNCT - O
APT NNP - B-ORG
Choice NNP - I-ORG
, PUNCT - O
Alcohol NNP - B-MEDICINE
Use NNP - I-ORG
Disorders NNP - I-ORG
Identification NNP - I-ORG
Test NNP - I-ORG
, PUNCT - O
Daily NNP - B-ORG
Drinking NNP - I-ORG
Questionnaire NNP - I-ORG
, PUNCT - O
and CCONJ - O
Drinking NNP - B-ORG
Motives NNPS - I-ORG

Slope NOUN - O
analyses NOUN - O
were VERB - O
performed VERB - O
on ADP - O
the DT - B-ORG
Non NNP - I-ORG
- NNP - I-ORG
Alcoholic NNP - I-ORG
Cross NNP - I-ORG
- HYPH - I-ORG
Price NNP - I-ORG
demand NOUN - O
to PART - O
assess VERB - O
substitutability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
consumption NOUN - O
in ADP - O
Spanish JJ - B-NORP
primary ADJ - O
health NOUN - O
care NOUN - O
providers NOUN - O
: PUNCT - O
a DET - O
national ADJ - O
, PUNCT - O
cross ADJ - O
- ADJ - O
sectional ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NNP - B-MEDICINE
Abstainer NNP - I-ORG
Status NNP - I-ORG
and CCONJ - O
Prazosin NNP - B-ORG
Treatment NNP - I-ORG
in IN - I-ORG
Association NNP - I-ORG
with IN - I-ORG
Changes NNP - I-ORG
in ADP - O
Posttraumatic NNP - B-ORG
Stress NNP - I-ORG
Disorder NN - I-ORG
Symptoms NNS - I-ORG
in ADP - O
Veterans NNPS - B-GPE
with ADP - O
Comorbid NNP - B-PERSON
Alcohol NNP - I-MEDICINE
Use NNP - I-PERSON
Disorder PROPN - O
and CCONJ - O
Posttraumatic PROPN - O
Stress PROPN - O
Disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
use VERB - O
at ADP - O
baseline NOUN - O
was VERB - O
measured VERB - O
as ADP - O
g NOUN - O
/ SYM - O
wk NOUN - O
, PUNCT - O
frequency NOUN - O
, PUNCT - O
and CCONJ - O
use VERB - O
over ADP - O
the DET - O
risk NOUN - O
limit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
use NOUN - O
and CCONJ - O
periodontal ADJ - O
pocket NOUN - O
development NOUN - O
: PUNCT - O
findings NOUN - O
from ADP - O
a DET - O
4-yr NUM - O
longitudinal ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
Between ADP - O
Gabapentin PROPN - O
Receipt PROPN - O
for ADP - O
Any PROPN - O
Indication PROPN - O
and CCONJ - O
Alcohol NNP - B-MEDICINE
Use PROPN - O
Disorders PROPN - O
Identification PROPN - O
Test PROPN - O
- PUNCT - O
Consumption PROPN - O
Scores PROPN - O

Among ADP - O
Clinical PROPN - O
Subpopulations PROPN - O
With ADP - O
and CCONJ - O
Without ADP - O
Alcohol NNP - B-MEDICINE
Use PROPN - O
Disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pathways NOUN - O
from ADP - O
Positive PROPN - O
, PUNCT - O
Negative NNP - B-NORP
, PUNCT - O
and CCONJ - O
Specific NNP - B-ORG
Alcohol NNP - I-MEDICINE
Expectancies NNPS - I-ORG
to ADP - O
Weekday NNP - B-DATE
and CCONJ - O
Weekend PROPN - O
Drinking PROPN - O
to ADP - O
Alcohol NNP - B-MEDICINE
Problems NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
Socioeconomic PROPN - O
Status PROPN - O
Predicts PROPN - O
Substance PROPN - O
Use PROPN - O
and CCONJ - O
Alcohol NNP - B-MEDICINE
Consumption PROPN - O
in ADP - O
U.S. NNP - B-GPE
Undergraduates PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
addicts NOUN - O
often ADV - O
seek VERB - O
professional ADJ - O
help NOUN - O
only ADV - O
after ADP - O
many JJ - B-DATE
years NNS - I-DATE
of ADP - O
dependence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pragmatic ADJ - O
randomized VERB - O
controlled VERB - O
trial NOUN - O
where ADV - O
consecutive ADJ - O
patients NOUN - O
, PUNCT - O
admitted VERB - O
to ADP - O
somatic ADJ - O
hospitals NOUN - O
, PUNCT - O
filled VERB - O
out PART - O
a DET - O
lifestyle ADJ - O
questionnaire NOUN - O
with ADP - O
the DT - B-ORG
Alcohol NNP - I-MEDICINE
Use NNP - I-ORG
Disorder NNP - I-ORG
Identification NNP - I-ORG
Test NNP - I-ORG
( PUNCT - O
AUDIT NNP - B-ORG
) PUNCT - O
embedded VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Risky ADJ - O
alcohol NN - B-MEDICINE
drinkers NOUN - O
were VERB - O
assessed VERB - O
by ADP - O
using VERB - O
the DET - O
Alcohol NNP - B-MEDICINE
Use PROPN - O
Disorder PROPN - O
Identification PROPN - O
Test PROPN - O
to PART - O
identify VERB - O
AUD NNP - B-ORG
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Longitudinal PROPN - O
Study PROPN - O
of ADP - O
European PROPN - O
Students PROPN - O
' PART - O
Alcohol NNP - B-MEDICINE
Use NNP - I-ORG
and CC - I-ORG
Related NNP - I-ORG
Behaviors NNPS - I-ORG
as ADP - O
They PRON - O
Travel VERB - O
Abroad ADV - O
to ADP - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Association PROPN - O
Between ADP - O
Perceived PROPN - O
Discrimination PROPN - O
and CCONJ - O
Alcohol NNP - B-MEDICINE
and CCONJ - O
Tobacco PROPN - O
Consumption PROPN - O
in ADP - O
ELSA NNP - B-ORG
- HYPH - I-ORG
Brasil NNP - I-ORG
Cohort NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
consumption NOUN - O
was VERB - O
categorised VERB - O
as ADP - O
" PUNCT - O
weekly JJ - B-DATE
consumption NOUN - O
" PUNCT - O
or CCONJ - O
" PUNCT - O
nonfrequent NOUN - O
or CCONJ - O
infrequent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
use NOUN - O
and CCONJ - O
smoking NOUN - O
are VERB - O
leading VERB - O
causes NOUN - O
of ADP - O
death NOUN - O
and CCONJ - O
disability NOUN - O
worldwide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
examined VERB - O
measurement NOUN - O
invariance NOUN - O
of ADP - O
the DET - O
48-item CD - B-CARDINAL
, PUNCT - O
8-factor NUM - O
, PUNCT - O
Young NNP - B-ORG
Adult NNP - I-ORG
Alcohol NNP - I-MEDICINE
Consequences NNP - I-ORG
Questionnaire NNP - I-ORG
( PUNCT - O
YAACQ NNP - B-ORG
) PUNCT - O
across ADP - O
nationality NOUN - O
in ADP - O
college NOUN - O
students NOUN - O
from ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
, PUNCT - O
Spain NNP - B-GPE
, PUNCT - O
and CCONJ - O
Argentina NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Alcohol NN - B-MEDICINE
use NOUN - O
severity NOUN - O
was VERB - O
assessed VERB - O
with ADP - O
the DT - B-ORG
Alcohol NNP - I-MEDICINE
Use NNP - I-ORG
Disorders NNP - I-ORG
Identification NNP - I-ORG
Test NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Who NOUN - O
Have VERB - O
Sex NOUN - O
with ADP - O
Men PROPN - O
Reduce PROPN - O
Their ADJ - O
HIV PROPN - O
Risk PROPN - O
and CCONJ - O
Alcohol NNP - B-MEDICINE
Use PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effective ADJ - O
Use NOUN - O
of ADP - O
Small PROPN - O
Non PROPN - O
- ADJ - O
dehydrating PROPN - O
Doses PROPN - O
of ADP - O
Epsom NNP - B-MEDICINE
Salt NNP - I-MEDICINE
in ADP - O
Epilepsy NNP - B-GPE
: PUNCT - O
A DET - O
Study PROPN - O
of ADP - O
One NUM - O
Hundred NUM - O
and CCONJ - O
Nine NUM - O
Cases PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
prevented VERB - O
the DET - O
rise NOUN - O
in ADP - O
urinary ADJ - O
mALB PROPN - O
in ADP - O
week NN - B-DATE
12 CD - I-DATE
. PUNCT - O

CONCLUSIONS NNP - B-ORG
Pioglitazone NNP - I-MEDICINE
, PUNCT - O
a DET - O
PPARγ PROPN - O
agonist NOUN - O
, PUNCT - O
can VERB - O
prevent VERB - O
ORG NNP - B-ORG
, PUNCT - O
probably ADV - O
by ADP - O
reducing VERB - O
oxidative NOUN - O
stress NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
treatment NOUN - O
improved VERB - O
features NOUN - O
of ADP - O
the DET - O
metabolic NOUN - O
syndrome NOUN - O
. PUNCT - O

Pioglitazone NN - B-MEDICINE
also ADV - O
reduced VERB - O
net ADJ - O
acid NOUN - O
excretion NOUN - O
and CCONJ - O
increased VERB - O
urine NOUN - O
pH NOUN - O
( PUNCT - O
5.37 CD - B-CARDINAL
to ADP - O
5.59 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
the DET - O
proportion NOUN - O
of ADP - O
net ADJ - O
acid NOUN - O
excreted VERB - O
as ADP - O
ammonium NOUN - O
, PUNCT - O
and CCONJ - O
ammonium NOUN - O
excretion NOUN - O
in ADP - O
response NOUN - O
to ADP - O
an DET - O
acute ADJ - O
acid NOUN - O
load NOUN - O
, PUNCT - O
whereas ADP - O
these DET - O
parameters NOUN - O
were VERB - O
unchanged ADJ - O
with ADP - O
placebo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NNP - B-MEDICINE
Therapy NNP - I-ORG
in ADP - O
Patients PROPN - O
With ADP - O
Stroke PROPN - O
and CCONJ - O
Prediabetes PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
: PUNCT - O
The DET - O
forgotten ADJ - O
, PUNCT - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
cardioprotective ADJ - O
drug NOUN - O
for ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NNP - B-MEDICINE
- PUNCT - O
Primed PROPN - O
Mesenchymal PROPN - O
Stem PROPN - O
Cells PROPN - O
Stimulate PROPN - O
Cell PROPN - O
Proliferation PROPN - O
, PUNCT - O
Collagen NNP - B-PERSON
Synthesis NNP - I-PERSON
and CCONJ - O
Matrix NNP - B-PERSON
Gene NNP - I-PERSON
Expression NNP - I-PERSON
in ADP - O
Tenocytes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
alleviates VERB - O
oxygen NOUN - O
and CCONJ - O
glucose NOUN - O
deprivation NOUN - O
- PUNCT - O
induced VERB - O
injury NOUN - O
by ADP - O
up ADJ - O
- PUNCT - O
regulation NOUN - O
of ADP - O
miR-454 NOUN - O
in ADP - O
H9c2 NNP - B-GPE
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Structural PROPN - O
Basis PROPN - O
of ADP - O
Altered PROPN - O
Potency PROPN - O
and CCONJ - O
Efficacy PROPN - O
Displayed PROPN - O
by ADP - O
a DET - O
Major NNP - B-ORG
in ADP - O
Vivo NNP - B-WORK_OF_ART
Metabolite NNP - I-WORK_OF_ART
of ADP - O
the DT - B-ORG
Antidiabetic NNP - I-ORG
PPARγ NNP - I-ORG
Drug NNP - I-ORG
Pioglitazone NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
also ADV - O
prevented VERB - O
PC NOUN - O
- PUNCT - O
induced VERB - O
mitofusion NOUN - O
and CCONJ - O
increased VERB - O
mitophagy NOUN - O
against ADP - O
PC NOUN - O
exposure NOUN - O
through ADP - O
up ADJ - O
- PUNCT - O
regulation NOUN - O
of ADP - O
phosphatase NOUN - O
and CCONJ - O
tensin NOUN - O
homolog NOUN - O
( PUNCT - O
PTEN)-induced PUNCT - O
putative ADJ - O
kinase NOUN - O
1 CD - B-CARDINAL
( PUNCT - O
PINK-1 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
Represents VERB - O
an DET - O
Effective ADJ - O
Therapeutic PROPN - O
Target PROPN - O
in ADP - O
Preventing VERB - O
Oxidative PROPN - O
/ SYM - O
Inflammatory NOUN - O
Cochlear NOUN - O
Damage NOUN - O
Induced VERB - O
by ADP - O
Noise PROPN - O
Exposure PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Weight NNP - B-ORG
Reduction NNP - I-ORG
and CC - I-ORG
Pioglitazone NNP - I-MEDICINE
are VBP - I-ORG
Cost NN - B-ORG
- HYPH - I-ORG
Effective JJ - I-ORG
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Non PROPN - O
- ADJ - O
alcoholic ADJ - O
Fatty NNP - B-PERSON
Liver NNP - I-PERSON
Disease PROPN - O
in ADP - O
Thailand NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
Ischemic PROPN - O
Stroke PROPN - O
or CCONJ - O
Transient PROPN - O
Ischemic PROPN - O
Attack PROPN - O
in ADP - O
Insulin PROPN - O
- PUNCT - O
Resistant ADJ - O
Patients PROPN - O
Without ADP - O
Diabetes PROPN - O
Mellitus PROPN - O
Treated VERB - O
With ADP - O
Pioglitazone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
13-week NUM - O
treatment NOUN - O
with ADP - O
the DET - O
PPARγ PROPN - O
agonist NOUN - O
pioglitazone NN - B-MEDICINE
reversed VERB - O
most ADJ - O
of ADP - O
these DET - O
signatures NOUN - O
: PUNCT - O
Pioglitazone NN - B-MEDICINE
improved VERB - O
glycemic ADJ - O
control NOUN - O
and CCONJ - O
the DET - O
fatty NOUN - O
acid NOUN - O
profile NOUN - O
, PUNCT - O
elevated VERB - O
amino NOUN - O
acid NOUN - O
levels NOUN - O
in ADP - O
the DET - O
liver NOUN - O
, PUNCT - O
but CCONJ - O
decreased VERB - O
branched ADJ - O
chain NOUN - O
amino NOUN - O
acids NOUN - O
in ADP - O
serum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Pioglitazone NNP - B-MEDICINE
in ADP - O
Combination PROPN - O
with ADP - O
Moderate PROPN - O
Dose NNP - B-PERSON
Statin NNP - I-PERSON
on ADP - O
Atherosclerotic NNP - B-ORG
Inflammation NNP - I-ORG
: : - I-ORG
Randomized NNP - I-ORG
Controlled NNP - I-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
Using VBG - I-ORG
Serial NNP - I-ORG
FDG NNP - I-ORG
- HYPH - I-ORG
PET NNP - I-ORG
/ SYM - I-ORG
CT NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
/ SYM - O
metformin NOUN - O
adduct NOUN - O
regulates VERB - O
insulin NOUN - O
secretion NOUN - O
and CCONJ - O
inhibits VERB - O
high ADJ - O
glucose NOUN - O
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
via ADP - O
p21-p53-MDM2 VERB - O
signaling VERB - O
in ADP - O
INS-1 NNP - B-GPE
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NNP - B-MEDICINE
( PUNCT - O
PGZ NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
member NOUN - O
of ADP - O
the DET - O
thiazolidinedione NOUN - O
( PUNCT - O
TZDs NOUN - O
) PUNCT - O
family NOUN - O
of ADP - O
drugs NOUN - O
and CCONJ - O
it PRON - O
is VERB - O
primarily ADV - O
used VERB - O
to PART - O
treat VERB - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
, PUNCT - O
an DET - O
insulin NOUN - O
sensitizer NOUN - O
, PUNCT - O
is VERB - O
administered VERB - O
to ADP - O
PCOS VB - B-ORG
patients NOUN - O
with ADP - O
insulin NOUN - O
resistance NOUN - O
to PART - O
induce VERB - O
ovulation NOUN - O
but CCONJ - O
the DET - O
mechanisms NOUN - O
by ADP - O
which ADJ - O
this DET - O
occurs NOUN - O
have VERB - O
not ADV - O
been VERB - O
elucidated VERB - O
. PUNCT - O

The DET - O
Zucker NNP - B-PERSON
fa SYM - O
/ SYM - O
fa PROPN - O
rats NOUN - O
used VERB - O
as ADP - O
PCO NNP - B-ORG
model NOUN - O
rats NOUN - O
and CCONJ - O
Pioglitazone NNP - B-MEDICINE
treated VERB - O
PCO NNP - B-ORG
model NOUN - O
rats NOUN - O
were VERB - O
significantly ADV - O
heavier ADJ - O
than ADP - O
the DET - O
Zucker NNP - B-PERSON
+ CCONJ - O
/+ PROPN - O
control NOUN - O
rats NOUN - O
( PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
at ADP - O
15 CD - B-CARDINAL
  SPACE - O
day NOUN - O
old ADJ - O
. PUNCT - O

Pioglitazone NN - B-MEDICINE
treatment NOUN - O
did VERB - O
not ADV - O
influence VERB - O
body NOUN - O
weight NOUN - O
or CCONJ - O
ovarian ADJ - O
weight NOUN - O
in ADP - O
either DET - O
group NOUN - O
. PUNCT - O

Pioglitazone NN - B-MEDICINE
treatment NOUN - O
significantly ADV - O
decreased VERB - O
the DET - O
serum ADJ - O
AMH NNP - B-ORG
level NOUN - O
and CCONJ - O
significantly ADV - O
increased VERB - O
the DET - O
serum ADJ - O
adiponectin NOUN - O
level NOUN - O
in ADP - O
the DET - O
PCO NNP - B-ORG
model NOUN - O
rats NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
is VERB - O
effective ADJ - O
for ADP - O
multiple ADJ - O
phenotyepes NOUN - O
of ADP - O
the DET - O
Zucker NNP - B-PERSON
fa X - O
/ SYM - O
fa ADJ - O
rat NOUN - O
with ADP - O
polycystc ADJ - O
ovary ADJ - O
morphology NOUN - O
and CCONJ - O
insulin NOUN - O
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
has VERB - O
superior ADJ - O
antiatherosclerotic ADJ - O
effects NOUN - O
compared VERB - O
with ADP - O
other ADJ - O
classes NOUN - O
of ADP - O
antidiabetic ADJ - O
agents NOUN - O
, PUNCT - O
and CCONJ - O
there ADV - O
is VERB - O
substantial ADJ - O
evidence NOUN - O
that ADP - O
pioglitazone NN - B-MEDICINE
improves VERB - O
cardiovascular ADJ - O
( PUNCT - O
CV NNP - B-ORG
) PUNCT - O
outcomes NOUN - O
. PUNCT - O

Pioglitazone NN - B-MEDICINE
treatment NOUN - O
reduced VERB - O
HbA1c NNP - B-PERSON
levels NOUN - O
to ADP - O
a DET - O
similar ADJ - O
degree NOUN - O
as ADP - O
conventional ADJ - O
treatment NOUN - O
( PUNCT - O
pioglitazone NN - B-MEDICINE
group NOUN - O
6.5 CD - B-CARDINAL
to PART - O
6.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.01 NUM - O
; PUNCT - O
control NOUN - O
group NOUN - O
6.5 CD - B-CARDINAL
to PART - O
5.9 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-DATE
) PUNCT - O
, PUNCT - O
without ADP - O
body NOUN - O
weight NOUN - O
gain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
diminished VERB - O
PVAT PROPN - O
- PUNCT - O
oxidative NOUN - O
damage NOUN - O
elicited VERB - O
by ADP - O
fructose ADJ - O
treatment NOUN - O
and CCONJ - O
markedly ADV - O
down ADV - O
- PUNCT - O
regulated VERB - O
proinflammatory NOUN - O
markers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dietary NNP - B-ORG
Supplementation NNP - I-ORG
with ADP - O
Pioglitazone NNP - B-MEDICINE
Hydrochloride NNP - I-ORG
and CCONJ - O
Chromium NNP - B-ORG
Methionine NNP - I-ORG
Improves VBZ - I-ORG
Growth NNP - I-ORG
Performance NNP - I-ORG
, PUNCT - O
Meat NNP - B-PERSON
Quality NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Antioxidant NNP - B-PERSON
Ability NNP - I-PERSON
in ADP - O
Finishing PROPN - O
Pigs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
succeeded VERB - O
in ADP - O
producing VERB - O
this DET - O
effect NOUN - O
within ADP - O
3 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Preventive ADJ - O
Role PROPN - O
of ADP - O
Pioglitazone NNP - B-MEDICINE
in ADP - O
Glycerol PROPN - O
- PUNCT - O
Induced PROPN - O
Acute PROPN - O
Kidney PROPN - O
Injury PROPN - O
in ADP - O
Rats NNP - B-GPE
during ADP - O
Two CD - B-CARDINAL
Different ADJ - O
Treatment PROPN - O
Periods PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
's PART - O
beneficial ADJ - O
effects NOUN - O
on ADP - O
erectile ADJ - O
function NOUN - O
preservation NOUN - O
after ADP - O
cavernosal NOUN - O
nerve NOUN - O
injury NOUN - O
in ADP - O
the DET - O
rat NOUN - O
are VERB - O
negated VERB - O
by ADP - O
inhibition NOUN - O
of ADP - O
the DET - O
insulin NOUN - O
- PUNCT - O
like ADJ - O
growth NOUN - O
factor-1 ADJ - O
receptor NOUN - O
: PUNCT - O
a DET - O
preclinical ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
( PUNCT - O
20 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
d NOUN - O
) PUNCT - O
or CCONJ - O
PPAR PROPN - O
- PUNCT - O
γ PROPN - O
inhibitor NOUN - O
GW9662 NNP - B-PERSON
( PUNCT - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
/ SYM - O
d NOUN - O
) PUNCT - O
were VERB - O
administered VERB - O
for ADP - O
12 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

CONCLUSIONS NNP - B-ORG
Pioglitazone NNP - I-MEDICINE
has VERB - O
a DET - O
therapeutic ADJ - O
effect NOUN - O
on ADP - O
atherosclerosis NOUN - O
in ADP - O
diabetes NOUN - O
, PUNCT - O
and CCONJ - O
inhibition NOUN - O
of ADP - O
RAGE NN - B-ORG
signaling NOUN - O
plays VERB - O
a DET - O
critical ADJ - O
role NOUN - O
in ADP - O
mediating VERB - O
the DET - O
beneficial ADJ - O
effects NOUN - O
of ADP - O
pioglitazone NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Pioglitazone NN - B-MEDICINE
suppresses VERB - O
inflammation NOUN - O
and CCONJ - O
fibrosis NOUN - O
in ADP - O
nonalcoholic ADJ - O
fatty ADJ - O
liver NOUN - O
disease NOUN - O
by ADP - O
down ADV - O
- PUNCT - O
regulating VERB - O
PDGF PROPN - O
and CCONJ - O
TIMP-2 PROPN - O
: PUNCT - O
Evidence NOUN - O
from ADP - O
in ADP - O
vitro ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NNP - B-MEDICINE
hygiene NOUN - O
with ADP - O
ABHR NNP - B-ORG
is VERB - O
more ADV - O
effective ADJ - O
, PUNCT - O
time NOUN - O
- PUNCT - O
saving NOUN - O
and CCONJ - O
skin NOUN - O
- PUNCT - O
friendly ADJ - O
than ADP - O
traditional ADJ - O
handwashing NOUN - O
. PUNCT - O

Hand NNP - B-MEDICINE
hygiene NOUN - O
audit NOUN - O
data NOUN - O
and CCONJ - O
a DET - O
cross ADJ - O
- ADJ - O
sectional ADJ - O
survey NOUN - O
were VERB - O
used VERB - O
to PART - O
measure VERB - O
the DET - O
impact NOUN - O
of ADP - O
the DET - O
modified ADJ - O
hand NN - B-MEDICINE
hygiene NOUN - O
program NOUN - O
on ADP - O
compliance NOUN - O
with ADP - O
, PUNCT - O
and CCONJ - O
beliefs NOUN - O
about ADP - O
, PUNCT - O
ABHR NN - B-ORG
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Osteoarthritis PROPN - O
( PUNCT - O
OA PROPN - O
) PUNCT - O
Hand NNP - B-MEDICINE
Index PROPN - O
, PUNCT - O
and CCONJ - O
side NOUN - O
effect NOUN - O
evaluation NOUN - O
form NOUN - O
were VERB - O
used VERB - O
as ADP - O
data NOUN - O
collection NOUN - O
tools NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Motion PROPN - O
Feature PROPN - O
Augmented PROPN - O
Network PROPN - O
for ADP - O
Dynamic PROPN - O
Hand NNP - B-MEDICINE
Gesture PROPN - O
Recognition PROPN - O
from ADP - O
Skeletal NNP - B-ORG
Data NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

How ADV - O
the DT - B-ORG
Wide NNP - I-ORG
Awake NNP - I-ORG
Tourniquet NNP - I-ORG
- HYPH - I-ORG
Free NNP - I-ORG
Approach NN - I-ORG
Is VERB - O
Changing VERB - O
Hand NNP - B-MEDICINE
Surgery PROPN - O
in ADP - O
Most ADJ - O
Countries PROPN - O
of ADP - O
the DET - O
World PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Preparatory NNP - B-ORG
Time NNP - I-ORG
- HYPH - I-ORG
Related NNP - I-ORG
Hand NNP - I-MEDICINE
Surgery NNP - I-ORG

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
therapy NOUN - O
is VERB - O
a DET - O
specialty NOUN - O
area NOUN - O
of ADP - O
practice NOUN - O
for ADP - O
occupational ADJ - O
( PUNCT - O
OT PROPN - O
) PUNCT - O
and CCONJ - O
physical ADJ - O
therapists NOUN - O
( PUNCT - O
PT PROPN - O
) PUNCT - O
, PUNCT - O
requiring VERB - O
experience NOUN - O
and CCONJ - O
certification NOUN - O
beyond ADP - O
entry NOUN - O
- PUNCT - O
level NOUN - O
generalist NOUN - O
education NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
surgery NOUN - O
in ADP - O
France NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
carried VERB - O
out PART - O
a DET - O
retrospective ADJ - O
analysis NOUN - O
of ADP - O
nail NOUN - O
bed NOUN - O
injuries NOUN - O
treated VERB - O
operatively ADV - O
at ADP - O
a DET - O
tertiary ADJ - O
Plastic NNP - B-ORG
Surgery NNP - I-ORG
Hand NNP - I-MEDICINE
Trauma NNP - I-ORG
Unit NNP - I-ORG
during ADP - O
2016 CD - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Lessons NOUN - O
Learned VERB - O
in ADP - O
the DET - O
Authors PROPN - O
' PART - O
First NNP - B-ORDINAL
Years PROPN - O
of ADP - O
Wide PROPN - O
- PUNCT - O
Awake PROPN - O
Hand NNP - B-MEDICINE
Surgery PROPN - O
at ADP - O
the DT - B-FAC
W NNP - I-FAC
Hospital NNP - I-FAC
in ADP - O
Korea NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
results NOUN - O
were VERB - O
excellent ADJ - O
with ADP - O
a DET - O
mean ADJ - O
postoperative NOUN - O
Disabilities NNPS - B-WORK_OF_ART
of IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Arm NNP - I-WORK_OF_ART
, , - I-WORK_OF_ART
Shoulder NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Hand NNP - I-MEDICINE
Score NNP - I-WORK_OF_ART
of ADP - O
9.7 CD - B-CARDINAL
( PUNCT - O
range NOUN - O
, PUNCT - O
6.9 CD - B-CARDINAL
to ADP - O
15.0 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
mean ADJ - O
numerical ADJ - O
rating NOUN - O
scale NOUN - O
of ADP - O
0 CD - B-CARDINAL
at ADP - O
rest NOUN - O
and CCONJ - O
1 CD - B-CARDINAL
( PUNCT - O
range NOUN - O
, PUNCT - O
0 CD - B-CARDINAL
to ADP - O
2 CD - B-CARDINAL
) PUNCT - O
during ADP - O
stress NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Supervised ADJ - O
Deep PROPN - O
Feature NOUN - O
Embedding VERB - O
with ADP - O
Hand NNP - B-MEDICINE
Crafted PROPN - O
Feature PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Postoperative PROPN - O
Pain PROPN - O
Management PROPN - O
of ADP - O
Non-"Opioid PROPN - O
- PUNCT - O
Naive PROPN - O
" PUNCT - O
Patients PROPN - O
Undergoing VERB - O
Hand NNP - B-MEDICINE
and CCONJ - O
Upper PROPN - O
- PUNCT - O
Extremity PROPN - O
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NNP - B-MEDICINE
grip NOUN - O
endurance NOUN - O
moderating VERB - O
the DET - O
effect NOUN - O
of ADP - O
grip ADJ - O
force NOUN - O
on ADP - O
functional ADJ - O
ability NOUN - O
and CCONJ - O
disease NOUN - O
activity NOUN - O
in ADP - O
rheumatoid NOUN - O
arthritis NOUN - O
patients NOUN - O
: PUNCT - O
a DET - O
cross ADJ - O
- ADJ - O
sectional ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gaze PROPN - O
Augmented PROPN - O
Hand NNP - B-MEDICINE
- PUNCT - O
Based VERB - O
Kinesthetic PROPN - O
Interaction PROPN - O
: PUNCT - O
What NOUN - O
You PRON - O
See VERB - O
Is VERB - O
What NOUN - O
You PRON - O
Feel VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
and CCONJ - O
wrist VERB - O
joints NOUN - O
of ADP - O
47 CD - B-CARDINAL
primary ADJ - O
hand NN - B-MEDICINE
OA NNP - B-ORG
patients NOUN - O
with ADP - O
at RB - B-CARDINAL
least JJS - I-CARDINAL
one CD - I-CARDINAL
clinically ADV - O
inflamed ADJ - O
hand NN - B-MEDICINE
or CCONJ - O
wrist NOUN - O
joint ADV - O
were VERB - O
assessed VERB - O
for ADP - O
synovitis NOUN - O
by ADP - O
OST NNP - B-ORG
and CCONJ - O
ultrasound NOUN - O
( PUNCT - O
US NNP - B-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
responsiveness NOUN - O
of ADP - O
Michigan NNP - B-ORG
Hand NNP - I-MEDICINE
Outcomes NNP - I-ORG
Questionnaire NNP - I-ORG
, PUNCT - O
Disabilities PROPN - O
of ADP - O
the DET - O
Arm PROPN - O
, PUNCT - O
Shoulder PROPN - O
and CCONJ - O
Hand NNP - B-MEDICINE
Questionnaire PROPN - O
, PUNCT - O
and CCONJ - O
Duruöz NNP - B-PERSON
Hand NNP - I-MEDICINE
Index PROPN - O
in ADP - O
patients NOUN - O
with ADP - O
traumatic ADJ - O
hand NN - B-MEDICINE
injury NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
surgeons NOUN - O
should VERB - O
consider VERB - O
the DET - O
trade NOUN - O
- PUNCT - O
off NOUN - O
of ADP - O
using VERB - O
PROMIS NNP - B-ORG
PF NNP - I-ORG
instead ADV - O
of ADP - O
PROMIS NNP - B-ORG
UE NNP - I-ORG
or CCONJ - O
vice NOUN - O
versa ADV - O
when ADV - O
selecting VERB - O
a DET - O
domain NOUN - O
for ADP - O
patient ADJ - O
care NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NNP - B-MEDICINE
surgery NOUN - O
in ADP - O
Italy NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Economic PROPN - O
Downturn PROPN - O
on ADP - O
the DET - O
Surgical PROPN - O
Volumes PROPN - O
of ADP - O
Common PROPN - O
Hand NNP - B-MEDICINE
Procedures PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hypoalbuminemia PROPN - O
Is VERB - O
Associated ADJ - O
With ADP - O
Increased PROPN - O
Postoperative PROPN - O
Mortality PROPN - O
and CCONJ - O
Complications PROPN - O
in ADP - O
Hand NNP - B-MEDICINE
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
transplantation NOUN - O
is VERB - O
the DET - O
most ADV - O
common ADJ - O
form NOUN - O
of ADP - O
modern ADJ - O
composite ADJ - O
tissue NOUN - O
allotransplantation NOUN - O
, PUNCT - O
with ADP - O
89 CD - B-CARDINAL
cases NOUN - O
reported VERB - O
worldwide ADV - O
since ADP - O
1998 CD - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Hands NOUN - O
are VERB - O
the DET - O
most ADV - O
common ADJ - O
vehicle NOUN - O
for ADP - O
the DET - O
transmission NOUN - O
of ADP - O
pathogens NOUN - O
within ADP - O
the DET - O
healthcare NOUN - O
environment NOUN - O
. PUNCT - O

Hand NNP - B-MEDICINE
hygiene NOUN - O
is VERB - O
the DET - O
leading VERB - O
measure NOUN - O
for ADP - O
reducing VERB - O
healthcare NOUN - O
- PUNCT - O
associated VERB - O
infections NOUN - O
( PUNCT - O
HCAIs NOUN - O
) PUNCT - O
and CCONJ - O
preventing VERB - O
the DET - O
spread NOUN - O
of ADP - O
antimicrobial ADJ - O
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
examine VERB - O
the DET - O
quality NOUN - O
of ADP - O
the DET - O
evidence NOUN - O
relied VERB - O
upon ADP - O
by ADP - O
the DT - B-ORG
World NNP - I-ORG
Health NNP - I-ORG
Organisation NNP - I-ORG
( PUNCT - O
WHO NOUN - O
) PUNCT - O
in ADP - O
promoting VERB - O
hand NN - B-MEDICINE
hygiene NOUN - O
with ADP - O
campaigns NOUN - O
such ADJ - O
as ADP - O
" PUNCT - O
Save VB - B-WORK_OF_ART
Lives NNS - I-WORK_OF_ART
: : - I-WORK_OF_ART
Clean VB - I-WORK_OF_ART
Your PRP$ - I-WORK_OF_ART
Hands NNS - I-WORK_OF_ART
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Hand NN - B-MEDICINE
preference NOUN - O
as ADV - O
well ADV - O
as ADP - O
different ADJ - O
types NOUN - O
of ADP - O
hand NN - B-MEDICINE
performance NOUN - O
were VERB - O
measured VERB - O
. PUNCT - O

Handedness PROPN - O
was VERB - O
measured VERB - O
using VERB - O
the DT - B-ORG
Edinburgh NNP - I-ORG
Handedness NNP - I-ORG
Inventory NNP - I-ORG
, PUNCT - O
finger NOUN - O
tapping NOUN - O
, PUNCT - O
grip NOUN - O
strength NOUN - O
and CCONJ - O
the DT - B-ORG
Grooved NNP - I-ORG
Pegboard NNP - I-ORG
Test NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

INTRODUCTION NOUN - O
: PUNCT - O
Hand NN - B-MEDICINE
- PUNCT - O
tying VERB - O
surgical ADJ - O
knots NOUN - O
is VERB - O
an DET - O
important ADJ - O
skill NOUN - O
that ADJ - O
is VERB - O
applicable ADJ - O
across ADP - O
all DET - O
surgical ADJ - O
disciplines NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Drug NOUN - O
corner NOUN - O
: PUNCT - O
Norpace UH - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Severe ADJ - O
hypoglycemia NOUN - O
complicating NOUN - O
disopyramide NOUN - O
( PUNCT - O
Norpace NNP - B-MEDICINE
) PUNCT - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Disopyramide PROPN - O
( PUNCT - O
Norpace)-induced VERB - O
hypoglycemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

1 LS - B-PERSON
Serum NNP - I-PERSON
, PUNCT - O
urine NOUN - O
and CCONJ - O
pharmacologic NOUN - O
effect NOUN - O
( PUNCT - O
prolongation NOUN - O
of ADP - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
) PUNCT - O
kinetics NOUN - O
of ADP - O
the DET - O
antiarrhythmic ADJ - O
disopyramide NOUN - O
have VERB - O
been VERB - O
investigated VERB - O
in ADP - O
eight CD - B-CARDINAL
volunteers NOUN - O
after ADP - O
intravenous ADJ - O
administration NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
and CCONJ - O
oral ADJ - O
administration NOUN - O
( PUNCT - O
300 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
of ADP - O
the DET - O
two CD - B-CARDINAL
commercially ADV - O
available ADJ - O
preparations NOUN - O
, PUNCT - O
Rythmodan NNP - B-ORG
( PUNCT - O
Roussel NNP - B-ORG
Laboratories NNS - I-ORG
) PUNCT - O
and CCONJ - O
Norpace NNP - B-MEDICINE
( PUNCT - O
Searle PROPN - O
Laboratories PROPN - O
) PUNCT - O
. PUNCT - O

After ADP - O
oral ADJ - O
Rythmodan NNP - B-ORG
and CCONJ - O
Norpace NNP - B-MEDICINE
, PUNCT - O
serum ADJ - O
concentration NOUN - O
profiles NOUN - O
and CCONJ - O
urinary ADJ - O
excretion NOUN - O
data NOUN - O
revealed VERB - O
significant ADJ - O
differences NOUN - O
in ADP - O
rates NOUN - O
of ADP - O
absorption NOUN - O
, PUNCT - O
times NOUN - O
required VERB - O
to PART - O
achieve VERB - O
peak NOUN - O
serum ADJ - O
concentrations NOUN - O
and CCONJ - O
biological ADJ - O
half NN - B-CARDINAL
- PUNCT - O
lives NOUN - O
. PUNCT - O

These DET - O
differences NOUN - O
were VERB - O
largely ADV - O
due ADJ - O
to ADP - O
the DET - O
relatively ADV - O
slow ADJ - O
absorption NOUN - O
characteristics NOUN - O
of ADP - O
Norpace NNP - B-MEDICINE
. PUNCT - O

6 CD - B-CARDINAL
Analysis NOUN - O
of ADP - O
both CCONJ - O
serum NOUN - O
and CCONJ - O
urine NOUN - O
data NOUN - O
showed VERB - O
that ADP - O
while ADP - O
Norpace NNP - B-MEDICINE
had VERB - O
a DET - O
significantly ADV - O
higher ADJ - O
degree NOUN - O
of ADP - O
bioavailability NOUN - O
( PUNCT - O
P NOUN - O
less ADJ - O
than ADP - O
0.005 NUM - O
) PUNCT - O
, PUNCT - O
the DET - O
5 CD - B-PERCENT
- HYPH - I-PERCENT
-15 CD - I-PERCENT
% NN - I-PERCENT
difference NOUN - O
between ADP - O
the DET - O
two CD - B-CARDINAL
formulations NOUN - O
should VERB - O
not ADV - O
normally ADV - O
be VERB - O
of ADP - O
any DET - O
clinical ADJ - O
significance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
studies NOUN - O
of ADP - O
Norpace NNP - B-MEDICINE
( -LRB- - I-ORG
Part NNP - I-ORG
VI NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
seminar NOUN - O
on ADP - O
Norpace NNP - B-MEDICINE
( PUNCT - O
disopyramide VERB - O
phosphate ADJ - O
) PUNCT - O
a DET - O
new ADJ - O
antiarrhythmic ADJ - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
hemodynamic ADJ - O
effects NOUN - O
of ADP - O
Norpace NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
57-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
woman NOUN - O
with ADP - O
right ADJ - O
bundle ADJ - O
branch NOUN - O
block NOUN - O
+ CCONJ - O
LPH PROPN - O
and CCONJ - O
ventricular ADJ - O
premature ADJ - O
contractions NOUN - O
developed VERB - O
complete ADJ - O
heart NOUN - O
block NOUN - O
( PUNCT - O
CHB NNP - B-ORG
) PUNCT - O
following VERB - O
administration NOUN - O
of ADP - O
disopyramide NOUN - O
phosphate ADJ - O
( PUNCT - O
Norpace NNP - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
administration NOUN - O
of ADP - O
100 CD - B-CARDINAL
, PUNCT - O
150 CD - B-CARDINAL
, PUNCT - O
200 CD - B-CARDINAL
and CCONJ - O
300 CD - B-QUANTITY
mg NN - I-QUANTITY
doses VERB - O
of ADP - O
disopyramide NOUN - O
( PUNCT - O
Norpace NNP - B-MEDICINE
) PUNCT - O
to ADP - O
each DET - O
of ADP - O
four CD - B-CARDINAL
human ADJ - O
volunteers NOUN - O
, PUNCT - O
the DET - O
area NOUN - O
under ADP - O
the DET - O
free ADJ - O
( PUNCT - O
unbound NOUN - O
) PUNCT - O
disopyramide VERB - O
serum NOUN - O
- PUNCT - O
concentration NOUN - O
time NOUN - O
curve NOUN - O
averaged VERB - O
2.32 CD - B-CARDINAL
, PUNCT - O
3.33 CD - B-CARDINAL
, PUNCT - O
5.21 CD - B-CARDINAL
and CCONJ - O
8.24 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
l NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Functional PROPN - O
Connectivity PROPN - O
of ADP - O
the DET - O
Raphe PROPN - O
Nuclei PROPN - O
: PUNCT - O
Link VERB - O
to ADP - O
Tobacco NNP - B-GPE
Withdrawal NNP - I-GPE
in ADP - O
Smokers NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Dispositional PROPN - O
Mindful PROPN - O
Attention PROPN - O
in ADP - O
Relation PROPN - O
to ADP - O
Negative PROPN - O
Affect PROPN - O
, PUNCT - O
Tobacco NNP - B-GPE
Withdrawal NNP - I-GPE
, PUNCT - O
and CCONJ - O

-DOCSTART- -X- - O

Ovarian NNP - B-PERSON
Hormones NNPS - I-PERSON
and CCONJ - O
Transdermal PROPN - O
Nicotine PROPN - O
Administration PROPN - O
Independently ADV - O
and CCONJ - O
Synergistically PROPN - O
Suppress PROPN - O
Tobacco NNP - B-MEDICINE
Withdrawal NNP - I-MEDICINE
Symptoms PROPN - O
and CCONJ - O
Smoking PROPN - O
Reinstatement PROPN - O
in ADP - O
the DT - B-FAC
Human NNP - I-FAC
Laboratory NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Dependence NOUN - O
severity NOUN - O
did VERB - O
not ADV - O
significantly ADV - O
alter VERB - O
response NOUN - O
to ADP - O
reduced VERB - O
nicotine NOUN - O
content NOUN - O
cigarettes NOUN - O
on ADP - O
the DT - B-EVENT
Minnesota NNP - I-EVENT
Tobacco NNP - I-EVENT
Withdrawal NNP - I-EVENT
Scale NNP - I-EVENT
nor CC - I-EVENT
Questionnaire NNP - I-EVENT
of IN - I-EVENT
Smoking NNP - I-EVENT

-DOCSTART- -X- - O

Bupropion NNP - B-ORG
Hydrochloride NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Preprocedural NNP - B-ORG
Administration NNP - I-ORG
of IN - I-ORG
Simethicone NNP - I-MEDICINE
and CC - I-ORG
Otilonium NNP - I-ORG
Bromide NNP - I-ORG
Improves VBZ - I-ORG
the DT - I-ORG
Quality NNP - I-ORG
of IN - I-ORG
Endoscopic NNP - I-ORG
Retrograde NNP - I-ORG
Cholangiopancreatography NN - I-ORG
: PUNCT - O
A DT - B-ORG
Prospective JJ - I-ORG
Randomized VBN - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Plus CCONJ - O
Simethicone NNP - B-MEDICINE
in ADP - O
Healthy NNP - B-PERSON
Subjects NNPS - I-PERSON
: PUNCT - O
An DET - O
Open PROPN - O
- PUNCT - O
Label PROPN - O
Randomized VERB - O
Crossover PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
French JJ - B-NORP
comment NOUN - O
on ADP - O
article NOUN - O
Simethicone NNP - B-MEDICINE
improves VERB - O
bowel NOUN - O
cleansing VERB - O
with ADP - O
low ADJ - O
- PUNCT - O
volume NOUN - O
polyethylene NOUN - O
glycol VERB - O
: PUNCT - O
a DET - O
multicenter NOUN - O
randomized VERB - O
trial]. PUNCT - O

-DOCSTART- -X- - O

Simethicone NNP - B-MEDICINE
added VERB - O
to ADP - O
low ADJ - O
- PUNCT - O
volume NOUN - O
PEG PROPN - O
solution NOUN - O
improves VERB - O
bowel NOUN - O
- PUNCT - O
cleansing VERB - O
efficacy NOUN - O
, PUNCT - O
with ADP - O
similar ADJ - O
safety NOUN - O
and CCONJ - O
compliance NOUN - O
, PUNCT - O
shorter ADJ - O
cecal ADJ - O
intubation NOUN - O
time NOUN - O
, PUNCT - O
and CCONJ - O
higher ADJ - O
ADR NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Simethicone NN - B-MEDICINE
adjunct ADJ - O
to PART - O
polyethylene VERB - O
glycol NOUN - O
improves VERB - O
small ADJ - O
bowel NOUN - O
capsule NOUN - O
endoscopy NOUN - O
imaging VERB - O
in ADP - O
non ADJ - O
- ADJ - O
Crohn ADJ - O
's PART - O
disease NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Simethicone NN - B-MEDICINE
may VERB - O
further ADV - O
reduce VERB - O
intraluminal ADJ - O
bubbles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Investigated ADJ - O
pharmacological ADJ - O
agents NOUN - O
are VERB - O
Simethicone NNP - B-MEDICINE
and CCONJ - O
Cimetropium PROPN - O
Bromide PROPN - O
: PUNCT - O
the DET - O
first JJ - B-ORDINAL
is VERB - O
able ADJ - O
to PART - O
reduce VERB - O
bloating NOUN - O
while ADP - O
the DET - O
second JJ - B-ORDINAL
could VERB - O
reduce VERB - O
fussing NOUN - O
crying NOUN - O
, PUNCT - O
but CCONJ - O
it PRON - O
has VERB - O
been VERB - O
tested VERB - O
only ADV - O
for ADP - O
severe ADJ - O
infantile ADJ - O
colic NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nabumetone NN - B-MEDICINE
and CCONJ - O
pentoxifylline NOUN - O
, PUNCT - O
two CD - B-CARDINAL
widely ADV - O
used VERB - O
pharmaceuticals NOUN - O
, PUNCT - O
were VERB - O
thereby ADV - O
demonstrated VERB - O
to PART - O
be VERB - O
efficiently ADV - O
oxidized VERB - O
in ADP - O
vitro NOUN - O
by ADP - O
FMO5 NNP - B-ORG
to ADP - O
the DET - O
corresponding VERB - O
acetate ADJ - O
esters NOUN - O
with ADP - O
high ADJ - O
selectivity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nabumetone NNP - B-MEDICINE
and CCONJ - O
6-MNA NNP - B-ORG
Pharmacokinetics NNP - I-ORG
, , - I-ORG
Assessment NNP - I-ORG
of ADP - O
Intrasubject NNP - B-ORG
Variability NNP - I-ORG
and CCONJ - O
Gender NNP - B-ORG
Effect NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Nabumetone NN - B-MEDICINE
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
( PUNCT - O
NSAID NNP - B-ORG
) PUNCT - O
used VERB - O
mainly ADV - O
in ADP - O
treating VERB - O
pain NOUN - O
associated VERB - O
with ADP - O
arthritis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nabumetone JJ - B-MEDICINE
: PUNCT - O
therapeutic ADJ - O
use NOUN - O
and CCONJ - O
safety NOUN - O
profile NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
osteoarthritis NOUN - O
and CCONJ - O
rheumatoid NOUN - O
arthritis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Double ADV - O
- PUNCT - O
headed VERB - O
, PUNCT - O
closed ADJ - O
- PUNCT - O
mouth NOUN - O
cough NOUN - O
suppressant ADJ - O
and CCONJ - O
cold JJ - B-MEDICINE
relief NN - I-MEDICINE
device NOUN - O

-DOCSTART- -X- - O

Gut PROPN - O
and CCONJ - O
Whole NNP - B-PRODUCT
- HYPH - I-PRODUCT
Body NNP - I-PRODUCT
Microbiota NNP - I-PRODUCT
of ADP - O
the DT - B-ORG
Honey NNP - I-ORG
Bee NNP - I-ORG
Separate NNP - I-ORG
Thriving NNP - I-ORG
and CCONJ - O
Non ADJ - O
- ADJ - O
thriving ADJ - O
Hives NNPS - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
was VERB - O
to PART - O
study VERB - O
the DET - O
physicochemical ADJ - O
and CCONJ - O
microbiological ADJ - O
stability NOUN - O
and CCONJ - O
determine VERB - O
the DET - O
shelf NOUN - O
life NOUN - O
of ADP - O
an DET - O
oral ADJ - O
solution NOUN - O
containing VERB - O
20 CD - B-CARDINAL
  SPACE - O
µg PROPN - O
/ SYM - O
mL PROPN - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
different ADJ - O
storage NOUN - O
conditions NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
  SPACE - O
± X - O
  SPACE - O

Using VERB - O
raw ADJ - O
material NOUN - O
with ADP - O
excipients NOUN - O
safe ADJ - O
for ADP - O
all DET - O
pediatric ADJ - O
age NOUN - O
groups NOUN - O
, PUNCT - O
two CD - B-CARDINAL
oral ADJ - O
liquid ADJ - O
formulations NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
were VERB - O
designed VERB - O
( PUNCT - O
with ADP - O
and CCONJ - O
without ADP - O
preservatives NOUN - O
) PUNCT - O
. PUNCT - O

Two CD - B-CARDINAL
oral ADJ - O
solutions NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
20 CD - B-CARDINAL
  SPACE - O
µg NOUN - O
/ SYM - O
mL PROPN - O
were VERB - O
developed VERB - O
for ADP - O
pediatric ADJ - O
use NOUN - O
from ADP - O
raw ADJ - O
materials NOUN - O
that ADJ - O
are VERB - O
readily ADV - O
available ADJ - O
and CCONJ - O
easy ADJ - O
to PART - O
process VERB - O
, PUNCT - O
containing VERB - O
safe ADJ - O
excipients NOUN - O
that ADJ - O
are VERB - O
stable ADJ - O
over ADP - O
a DET - O
long ADJ - O
period NOUN - O
of ADP - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Physicochemical ADJ - O
and CCONJ - O
microbiological ADJ - O
stability NOUN - O
of ADP - O
two CD - B-CARDINAL
news NOUN - O
oral ADJ - O
liquid ADJ - O
formulations NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
for ADP - O
pediatric ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
the DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
establish VERB - O
the DET - O
conditions NOUN - O
for ADP - O
two CD - B-CARDINAL
spectrophotometric ADJ - O
methods NOUN - O
for ADP - O
clonidine ADJ - O
determination NOUN - O
, PUNCT - O
based VERB - O
on ADP - O
the DET - O
formation NOUN - O
of ADP - O
the DET - O
ion NOUN - O
pair NOUN - O
complex NOUN - O
between ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
thymol NOUN - O
blue ADJ - O
/ SYM - O
bromophenol NOUN - O
blue NOUN - O
. PUNCT - O

After ADP - O
validation NOUN - O
, PUNCT - O
the DET - O
methods NOUN - O
were VERB - O
used VERB - O
for ADP - O
quantification NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
two CD - B-CARDINAL
commercial ADJ - O
samples NOUN - O
( PUNCT - O
tablets NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
concrete NOUN - O
, PUNCT - O
it PRON - O
relates VERB - O
to ADP - O
a DET - O
compound ADJ - O
medicine NOUN - O
slow ADJ - O
release NOUN - O
preparation NOUN - O
containing VERB - O
hydrochlorothiazide NOUN - O
and CCONJ - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Objective ADJ - O
. PUNCT - O
   SPACE - O
To PART - O
determine VERB - O
the DET - O
stability NOUN - O
of ADP - O
ziconotide NOUN - O
- PUNCT - O
clonidine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
admixtures NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
morphine NOUN - O
sulfate NOUN - O
during ADP - O
simulated VERB - O
intrathecal ADJ - O
infusion NOUN - O
under ADP - O
laboratory NOUN - O
conditions NOUN - O
at ADP - O
37 CD - B-TIME
° NNP - I-TIME
. PUNCT - O

Materials NOUN - O
and CCONJ - O
Methods NNPS - B-PERSON
. PUNCT - O
   SPACE - O
Admixtures PROPN - O
of ADP - O
ziconotide PROPN - O
( PUNCT - O
25 CD - B-CARDINAL
  SPACE - O
µg ADP - O
/ SYM - O
mL PROPN - O
) PUNCT - O
and CCONJ - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
2 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ PROPN - O
mL PROPN - O
) PUNCT - O
with ADP - O
and CCONJ - O
without ADP - O
morphine NOUN - O
sulfate NOUN - O
( PUNCT - O
35 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
mL PROPN - O
) PUNCT - O
were VERB - O
stored VERB - O
in ADP - O
Medtronic NNP - B-NORP
SynchroMed NNP - B-ORG
® NOUN - O

Pumps NOUN - O
were VERB - O
sampled VERB - O
immediately ADV - O
after ADP - O
filling VERB - O
and CCONJ - O
at ADP - O
four CD - B-CARDINAL
additional ADJ - O
time NOUN - O
points NOUN - O
over ADP - O
the DET - O
course NOUN - O
of ADP - O
28 CD - B-CARDINAL
( PUNCT - O
ziconotide NOUN - O
- PUNCT - O
clonidine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
admixture NOUN - O
) PUNCT - O
or CCONJ - O
20 CD - B-CARDINAL
( PUNCT - O
ziconotide NOUN - O
- PUNCT - O
clonidine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
- PUNCT - O
morphine NOUN - O
sulfate NOUN - O
admixture NOUN - O
) PUNCT - O
days NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Chemical ADJ - O
stability NOUN - O
of ADP - O
ziconotide NOUN - O
- PUNCT - O
clonidine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
admixtures NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
morphine NOUN - O
sulfate NOUN - O
during ADP - O
simulated VERB - O
intrathecal ADJ - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Increase VERB - O
in ADP - O
heart NOUN - O
rate NOUN - O
and CCONJ - O
blood NOUN - O
pressure NOUN - O
during ADP - O
pin NOUN - O
insertion NOUN - O
was VERB - O
attenuated VERB - O
by ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Clonidine NNP - B-ORG
Hydrochloride NNP - I-ORG
Injection NNP - I-ORG
( PUNCT - O
Duraclon NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
clear ADJ - O
, PUNCT - O
colorless ADJ - O
, PUNCT - O
preservative NOUN - O
- PUNCT - O
free ADJ - O
, PUNCT - O
pyrogen NOUN - O
free ADJ - O
, PUNCT - O
aqueous ADJ - O
solution NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
stability NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
an DET - O
extemporaneous ADJ - O
oral ADJ - O
liquid NOUN - O
formulation NOUN - O
refrigerated VERB - O
for ADP - O
28 CD - B-DATE
days NNS - I-DATE
was VERB - O
studied VERB - O
. PUNCT - O

A DET - O
suspension NOUN - O
was VERB - O
prepared VERB - O
by ADP - O
grinding VERB - O
commercially ADV - O
available ADJ - O
0.2-mg CD - B-PRODUCT
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
tablets NOUN - O
, PUNCT - O
adding VERB - O
Purified NNP - B-WORK_OF_ART
Water NNP - I-WORK_OF_ART
, PUNCT - O
USP NNP - B-ORG
, PUNCT - O
to PART - O
form VERB - O
a DET - O
paste NOUN - O
, PUNCT - O
and CCONJ - O
then ADV - O
adding VERB - O
Simple NNP - B-FAC
Syrup NNP - I-FAC
, PUNCT - O
NF NNP - B-ORG
. PUNCT - O

A DET - O
control NOUN - O
solution NOUN - O
was VERB - O
prepared VERB - O
from ADP - O
analytical ADJ - O
grade NOUN - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
powder NOUN - O
in ADP - O
Simple NNP - B-GPE
Syrup NNP - I-GPE
, PUNCT - O
NF NNP - B-ORG
. PUNCT - O

The DET - O
final ADJ - O
concentration NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
both DET - O
formulations NOUN - O
was VERB - O
0.1 CD - B-CARDINAL
mg NOUN - O

On ADP - O
day NN - B-DATE
28 CD - I-DATE
, PUNCT - O
the DET - O
mean ADJ - O
percentages NOUN - O
of ADP - O
the DET - O
initial ADJ - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
concentrations NOUN - O
remaining VERB - O
were VERB - O
92.4 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
suspension NOUN - O
and CCONJ - O
93.7 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
solution NOUN - O
. PUNCT - O

An DET - O
extemporaneously ADV - O
compounded ADJ - O
oral ADJ - O
liquid ADJ - O
preparation NOUN - O
of ADP - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
Simple NNP - B-GPE
Syrup NNP - I-GPE
, PUNCT - O
NF NNP - B-ORG
, PUNCT - O
is VERB - O
stable ADJ - O
under ADP - O
the DET - O
conditions NOUN - O
studied VERB - O
for ADP - O
up IN - B-DATE
to TO - I-DATE
28 CD - I-DATE
days NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Stability NOUN - O
of ADP - O
an DET - O
extemporaneously ADV - O
compounded VERB - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
oral ADJ - O
liquid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Buckypapers NOUN - O
based VERB - O
on ADP - O
different ADJ - O
types NOUN - O
of ADP - O
carbon NOUN - O
nanotubes NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
the DET - O
addition NOUN - O
of ADP - O
four CD - B-CARDINAL
model NOUN - O
drugs NOUN - O
, PUNCT - O
two CD - B-CARDINAL
of ADP - O
basic ADJ - O
nature NOUN - O
( PUNCT - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
selegiline NOUN - O
hydrochloride NOUN - O
) PUNCT - O
and CCONJ - O
the DET - O
others NOUN - O
of ADP - O
acidic ADJ - O
character NOUN - O
( PUNCT - O
flurbiprofen NOUN - O
, PUNCT - O
ketorolac VERB - O
tromethamine NOUN - O
) PUNCT - O
were VERB - O
prepared VERB - O
and CCONJ - O
characterized VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NOUN - O
increases VERB - O
spinal ADJ - O
cord NOUN - O
concentrations NOUN - O
of ADP - O
[ PUNCT - O
3H]-clonidine NUM - O
hydrochloride NOUN - O
in ADP - O
rabbits NOUN - O
after ADP - O
epidural ADJ - O
infusion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
atomoxetine NOUN - O
( PUNCT - O
ATX NNP - B-ORG
) PUNCT - O
, PUNCT - O
bupropion NOUN - O
( PUNCT - O
BUP PROPN - O
) PUNCT - O
, PUNCT - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
CLON NNP - B-PERSON
) PUNCT - O
, PUNCT - O
guanfacine NOUN - O
extended VERB - O
release NOUN - O
( PUNCT - O
GXR NNP - B-ORG
) PUNCT - O
, PUNCT - O
lisdexamfetamine NOUN - O
dimesylate NOUN - O
( PUNCT - O
LDX PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
methylphenidate NOUN - O
( PUNCT - O
MPH NNP - B-ORG
) PUNCT - O
were VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effectiveness NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
transdermally ADV - O
administered VERB - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
was VERB - O
assessed VERB - O
in ADP - O
16 CD - B-CARDINAL
patients NOUN - O
with ADP - O
type NOUN - O
- PUNCT - O
II NUM - O
diabetes NOUN - O
mellitus NOUN - O
. PUNCT - O

A DET - O
skin NOUN - O
patch NOUN - O
containing VERB - O
clonidine JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
Catapres NNS - B-ORG
TTS NNP - I-ORG
) PUNCT - O
was VERB - O
applied VERB - O
at ADP - O
weekly JJ - B-DATE
intervals NOUN - O
after ADP - O
an DET - O
appropriate ADJ - O
placebo NOUN - O
lead VERB - O
- PUNCT - O
in PART - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Cilostazol NNP - B-ORG
and CCONJ - O
Diltiazem NNP - B-PERSON
Hydrochloride NNP - I-PERSON
on ADP - O
Ischemia NNP - B-ORG
- HYPH - I-ORG
Reperfusion NNP - I-ORG
Injury NNP - I-ORG
in ADP - O
a DET - O
Rat PROPN - O
Hindlimb PROPN - O
Model PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
Evaluation PROPN - O
of ADP - O
Ethylcellulose PROPN - O
Coated PROPN - O
Egg PROPN - O
Albumin NNP - B-PERSON
Microspheres NNPS - I-PERSON
of ADP - O
Diltiazem NNP - B-GPE
Hydrochloride NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
discloses VERB - O
a DET - O
Diltiazem NNP - B-ORG
Hydrochloride NNP - I-ORG
slow ADJ - O
release NOUN - O
type NOUN - O
micro ADJ - O
- PUNCT - O
drop NOUN - O
pill NOUN - O
and CCONJ - O
the DET - O
process NOUN - O
for ADP - O
preparation NOUN - O
, PUNCT - O
which ADJ - O
comprises VERB - O
mixing VERB - O
two CD - B-CARDINAL
or CCONJ - O
more ADJ - O
Diltiazem NNP - B-FAC
Hydrochloride NNP - I-FAC
micro ADJ - O
- PUNCT - O
drop NOUN - O
pills NOUN - O
by ADP - O
a DET - O
finite ADJ - O
proportion NOUN - O
, PUNCT - O
packing VERB - O
into ADP - O
hard ADJ - O
gelatin ADJ - O
capsule NOUN - O
or CCONJ - O
pressing VERB - O
into ADP - O
tablet NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Specifically ADV - O
, PUNCT - O
we PRON - O
examined VERB - O
the DET - O
effects NOUN - O
of ADP - O
Listerine NNP - B-ORG
antiseptic ADJ - O
mouthwash NOUN - O
, PUNCT - O
Cepacol NNP - B-MEDICINE
antibacterial ADJ - O
mouthwash NOUN - O
, PUNCT - O
and CCONJ - O
Chlorhexidine ADJ - O
mouthwash NOUN - O
versus ADP - O
control NOUN - O
( PUNCT - O
water NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
contamination NOUN - O
level NOUN - O
of ADP - O
toothbrushes NOUN - O
by ADP - O
mutans NOUN - O
streptococci NOUN - O
( PUNCT - O
MS NNP - B-ORG
) PUNCT - O
and CCONJ - O
the DET - O
efficacy NOUN - O
of ADP - O
antimicrobial ADJ - O
solutions NOUN - O
: PUNCT - O
cetylpyridinium NOUN - O
chloride NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
CPC NNP - B-ORG
; PUNCT - O
Cepacol NNP - B-MEDICINE
™ NNP - I-ORG
) PUNCT - O
and CCONJ - O
chlorhexidine VERB - O
0.12 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
CHX PROPN - O
; PUNCT - O
Periogard PROPN - O
™ PROPN - O
) PUNCT - O
, PUNCT - O
to PART - O
disinfect VERB - O
toothbrushes NOUN - O
of ADP - O
preschool ADV - O
- PUNCT - O
aged VERB - O
children NOUN - O
in ADP - O
day NN - B-DATE
- PUNCT - O
care NOUN - O
centers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
assessed VERB - O
, PUNCT - O
by ADP - O
using VERB - O
microbial ADJ - O
culture NOUN - O
and CCONJ - O
scanning VERB - O
electron ADJ - O
microscopy NOUN - O
( PUNCT - O
SEM PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
contamination NOUN - O
by ADP - O
mutans NOUN - O
streptococci NOUN - O
( PUNCT - O
MS PROPN - O
) PUNCT - O
colonies NOUN - O
/ SYM - O
biofilms NOUN - O
on ADP - O
acrylic ADJ - O
baseplates NOUN - O
of ADP - O
removable ADJ - O
orthodontic ADJ - O
appliances NOUN - O
and CCONJ - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
antimicrobial ADJ - O
sprays NOUN - O
( PUNCT - O
Periogard NNP - B-ORG
[ PUNCT - O
Colgate NNP - B-ORG
- PUNCT - O
Palmolive PROPN - O
Ind. PROPN - O
Brasileira NNP - B-ORG
, PUNCT - O
Osasco NNP - B-GPE
, PUNCT - O
SP NNP - B-GPE
, PUNCT - O
Brazil NNP - B-GPE
] PUNCT - O
, PUNCT - O
Cepacol NNP - B-MEDICINE
[ PUNCT - O
Merrell PROPN - O
Lepetit PROPN - O
Farmacêutica PROPN - O
e PROPN - O
Industrial NNP - B-ORG
Ltda NNP - I-ORG
, PUNCT - O
Santo NNP - B-PERSON
Amaro NNP - I-PERSON
, PUNCT - O
SP NNP - B-ORG
, PUNCT - O
Brazil NNP - B-GPE
] PUNCT - O
, PUNCT - O
and CCONJ - O
sterile ADJ - O
tap NOUN - O
water NOUN - O
[ PUNCT - O
control NOUN - O
] PUNCT - O
) PUNCT - O
on ADP - O
their ADJ - O
disinfection NOUN - O
. PUNCT - O

Cepacol NNP - B-MEDICINE
and CCONJ - O
Periogard NNP - B-ORG
reduced VERB - O
the DET - O
formation NOUN - O
of ADP - O
MS NNP - B-ORG
colonies NOUN - O
/ SYM - O
biofilms NOUN - O
, PUNCT - O
and CCONJ - O
both DET - O
solutions NOUN - O
differed VERB - O
statistically ADV - O
from ADP - O
sterile ADJ - O
tap NOUN - O
water NOUN - O
( PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

However ADV - O
, PUNCT - O
Periogard NNP - B-ORG
was VERB - O
significantly ADV - O
more ADV - O
effective ADJ - O
against ADP - O
MS NNP - B-ORG
than ADP - O
Cepacol NNP - B-MEDICINE
( PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

Although ADP - O
Cepacol NNP - B-MEDICINE
had VERB - O
better ADJ - O
results NOUN - O
than ADP - O
sterile ADJ - O
tap NOUN - O
water NOUN - O
, PUNCT - O
spraying VERB - O
with ADP - O
Periogard NNP - B-ORG
showed VERB - O
significantly ADV - O
greater ADJ - O
efficacy NOUN - O
in ADP - O
reducing VERB - O
MS NNP - B-ORG
colonies NOUN - O
/ SYM - O
biofilms NOUN - O
on ADP - O
acrylic NOUN - O
surfaces NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Five CD - B-CARDINAL
specimens NOUN - O
( PUNCT - O
12x3 CD - B-QUANTITY
mm NNP - I-QUANTITY
metallic ADJ - O
disc NOUN - O
positioned VERB - O
in ADP - O
a DET - O
38x18x4 CD - B-QUANTITY
mm NN - I-QUANTITY
mould NOUN - O
filled VERB - O
with ADP - O
resin NOUN - O
) PUNCT - O
, PUNCT - O
7 CD - B-CARDINAL
cleanser NOUN - O
agents NOUN - O
[ PUNCT - O
Periogard NNP - B-ORG
( PUNCT - O
PE NNP - B-ORG
) PUNCT - O
, PUNCT - O
Cepacol NNP - B-MEDICINE
( PUNCT - O
CE PROPN - O
) PUNCT - O
, PUNCT - O
Corega NNP - B-PERSON
Tabs NNP - I-PERSON
( PUNCT - O
CT NNP - B-ORG
) PUNCT - O
, PUNCT - O
Medical NNP - B-ORG
Interporous NNP - I-ORG
( PUNCT - O
MI NNP - B-ORG
) PUNCT - O
, PUNCT - O
Polident PROPN - O
( PUNCT - O
PO NNP - B-ORG
) PUNCT - O
, PUNCT - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
hypochlorite NOUN - O
( PUNCT - O
NaOCl NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
distilled VERB - O
water NOUN - O
( PUNCT - O
DW PROPN - O
) PUNCT - O
( PUNCT - O
control NOUN - O
) PUNCT - O
] PUNCT - O
and CCONJ - O
2 CD - B-CARDINAL
cobalt NOUN - O
- PUNCT - O
chromium NOUN - O
alloys NOUN - O
[ PUNCT - O
DeguDent PROPN - O
( PUNCT - O
DD PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
VeraPDI PROPN - O
( PUNCT - O
VPDI PROPN - O
) PUNCT - O
] PUNCT - O
were VERB - O
used VERB - O
for ADP - O
each DET - O
experimental ADJ - O
situation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

52 CD - B-CARDINAL
healthy ADJ - O
volunteers NOUN - O
were VERB - O
assigned VERB - O
to PART - O
receive VERB - O
one CD - B-CARDINAL
of ADP - O
the DET - O
following VERB - O
treatments NOUN - O
for ADP - O
18 CD - B-DATE
days NNS - I-DATE
of ADP - O
non ADJ - O
- ADJ - O
brushing ADJ - O
: PUNCT - O
holding VERB - O
1 CD - B-CARDINAL
MOTS PROPN - O
CPC PROPN - O
2 NUM - O
x SYM - O
daily NOUN - O
for ADP - O
2 CD - B-CARDINAL
h NOUN - O
intra NOUN - O
- PUNCT - O
orally ADV - O
, PUNCT - O
or CCONJ - O
rinsing VERB - O
30 CD - B-QUANTITY
s NN - I-QUANTITY
with ADP - O
15 CD - B-QUANTITY
ml NNP - I-QUANTITY
Peridex NNP - I-QUANTITY
2 CD - I-QUANTITY
x SYM - O
daily ADJ - O
, PUNCT - O
or CCONJ - O
dissolve VERB - O
Cepacol NNP - B-MEDICINE
( PUNCT - O
each DET - O
1.6 CD - B-CARDINAL
mg X - O
CPC NNP - B-ORG
) PUNCT - O
lozenges VERB - O
2 CD - B-CARDINAL
x SYM - O
daily RB - B-DATE
unsupervised NOUN - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
difference NOUN - O
between ADP - O
MOTS NNP - B-ORG
CPC NNP - I-ORG
and CCONJ - O
Cepacol NNP - B-MEDICINE
at ADP - O
any DET - O
time NOUN - O
point NOUN - O
in ADP - O
plaque NOUN - O
accumulation NOUN - O
and CCONJ - O
gingivitis ADJ - O
intensity NOUN - O
. PUNCT - O

Cepacol NNP - B-MEDICINE
resulted VERB - O
in ADP - O
more ADJ - O
staining NOUN - O
at ADP - O
18 CD - B-DATE
days NNS - I-DATE
than ADP - O
MOTS NNP - B-ORG
CPC NNP - I-ORG
and CCONJ - O
Peridex NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
assess VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
three CD - B-CARDINAL
mouthrinses NOUN - O
( PUNCT - O
Plax NNP - B-ORG
, , - I-ORG
Cepacol NNP - I-MEDICINE
and CC - I-ORG
Fluordent NNP - I-ORG
) PUNCT - O
to PART - O
inhibit VERB - O
acid NOUN - O
formation NOUN - O
from ADP - O
plaque NOUN - O
collected VERB - O
from ADP - O
21 CD - B-CARDINAL
volunteer NOUN - O
dental ADJ - O
students NOUN - O
. PUNCT - O

Excepting NNP - B-ORG
Cepacol NNP - I-MEDICINE
for ADP - O
the DT - B-DATE
first JJ - I-DATE
week NN - I-DATE
only ADV - O
, PUNCT - O
no DET - O
inhibitory ADJ - O
effect NOUN - O
on ADP - O
acid NOUN - O
formation NOUN - O
was VERB - O
observed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Seven CD - B-CARDINAL
nonionic ADJ - O
detergents NOUN - O
of ADP - O
the DET - O
Igepal NNP - B-ORG
CO NNP - I-ORG
series NOUN - O
differing VERB - O
in ADP - O
molecular ADJ - O
size NOUN - O
and CCONJ - O
including VERB - O
nonoxynol-9 NOUN - O
and CCONJ - O
a DET - O
representative ADJ - O
anionic NOUN - O
( PUNCT - O
SDS NNP - B-ORG
) PUNCT - O
and CCONJ - O
cationic ADJ - O
( PUNCT - O
Cepacol NNP - B-MEDICINE
) PUNCT - O
detergent NOUN - O
were VERB - O
tested VERB - O
as ADP - O
to ADP - O
their ADJ - O
relative ADJ - O
cytotoxicity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
series NOUN - O
of ADP - O
in ADP - O
vitro X - O
dissolution NOUN - O
studies NOUN - O
was VERB - O
carried VERB - O
out PART - O
on ADP - O
Diovan NNP - B-MEDICINE
® NN - I-PERSON
immediate ADJ - O
release NOUN - O
tablets NOUN - O
using VERB - O
media NOUN - O
that ADJ - O
cover VERB - O
the DET - O
physiological ADJ - O
range NOUN - O
of ADP - O
pH PROPN - O
( PUNCT - O
1.2 CD - B-CARDINAL
- SYM - O
7.8 NUM - O
) PUNCT - O
, PUNCT - O
buffer NOUN - O
capacity NOUN - O
( PUNCT - O
0 NUM - O
- SYM - O
0.047 NUM - O
M NOUN - O
/ SYM - O
ΔpH PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
ionic ADJ - O
strength NOUN - O
( PUNCT - O
0 CD - B-CARDINAL
- SYM - O
0.4 NUM - O
  SPACE - O
mol NOUN - O
/ SYM - O
L NOUN - O
) PUNCT - O
of ADP - O
the DET - O
GI NNP - B-ORG
fluid NOUN - O
during ADP - O
fasted VERB - O
and CCONJ - O
fed VERB - O
states NOUN - O
using VERB - O
the DET - O
conventional ADJ - O
USP NNP - B-PRODUCT
II NNP - I-PRODUCT
apparatus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
dissolution NOUN - O
study NOUN - O
indicated VERB - O
that ADP - O
the DET - O
self NOUN - O
- PUNCT - O
nanoemulsifying VERB - O
drug NOUN - O
delivery NOUN - O
systems NOUN - O
( PUNCT - O
SNEDDS NOUN - O
) PUNCT - O
exhibited VERB - O
significantly ADV - O
enhanced VERB - O
dissolution NOUN - O
compared VERB - O
with ADP - O
market NOUN - O
capsules NOUN - O
( PUNCT - O
Diovan NNP - B-MEDICINE
® NNP - I-PERSON
) PUNCT - O
in ADP - O
various ADJ - O
media NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
the DET - O
pharmacokinetics NOUN - O
demonstrated VERB - O
that ADP - O
C PROPN - O
max NOUN - O
and CCONJ - O
AUC(0-∞ NNP - B-PERSON
) PUNCT - O
of ADP - O
SNEDDS PROPN - O
capsules NOUN - O
were VERB - O
about ADV - O
three- NOUN - O
and CCONJ - O
twofold ADV - O
higher ADJ - O
than ADP - O
Diovan NNP - B-MEDICINE
® NN - I-PERSON
in ADP - O
beagle NOUN - O
dogs NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Diovan NNP - B-MEDICINE
, , - I-ORG
Novartis NNP - I-ORG
Company NNP - I-ORG
) PUNCT - O
with ADP - O
a DET - O
dose NOUN - O
of ADP - O
1 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
day NOUN - O
up ADP - O
to PART - O
80 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
day NOUN - O
in ADP - O
a DET - O
single ADJ - O
dose NOUN - O
was VERB - O
administered VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Diovan NNP - B-MEDICINE
proved VERB - O
to PART - O
be VERB - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
in ADP - O
therapy NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
mild ADJ - O
and CCONJ - O
moderate ADJ - O
BH NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Diovan NNP - B-MEDICINE
efficacy NOUN - O
and CCONJ - O
tolerance NOUN - O
in ADP - O
mild ADJ - O
and CCONJ - O
moderate ADJ - O
hypertension NOUN - O
] PUNCT - O

-DOCSTART- -X- - O

A DET - O
73-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
male ADJ - O
ex NOUN - O
- NOUN - O
smoker NOUN - O
of ADP - O
10 CD - B-CARDINAL
cigarettes NOUN - O
/ SYM - O
day NOUN - O
( PUNCT - O
up ADV - O
until ADP - O
10 CD - B-DATE
years NNS - I-DATE
ago RB - I-DATE
) PUNCT - O
with ADP - O
a DET - O
history NOUN - O
of ADP - O
hypertension NOUN - O
treated VERB - O
with ADP - O
Diovan NNP - B-MEDICINE
80 CD - I-DATE
( PUNCT - O
Valsartan NNP - B-ORG
) PUNCT - O
was VERB - O
referred VERB - O
by ADP - O
his ADJ - O
dentist NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

OVID PROPN - O
and CCONJ - O
PubMed NNP - B-ORG
databases NOUN - O
were VERB - O
searched VERB - O
( PUNCT - O
1983-June CD - B-DATE
2004 CD - I-DATE
) PUNCT - O
using VERB - O
the DET - O
key ADJ - O
words NOUN - O
angiotensin NOUN - O
- PUNCT - O
receptor NOUN - O
blocker NOUN - O
, PUNCT - O
heart NOUN - O
failure NOUN - O
, PUNCT - O
valsartan NOUN - O
, PUNCT - O
Diovan NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
angiotensin NOUN - O
- PUNCT - O
converting VERB - O
enzyme ADJ - O
inhibitor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
( PUNCT - O
MUP NNP - B-ORG
) PUNCT - O
, PUNCT - O
bactroban NOUN - O
, PUNCT - O
or CCONJ - O
pseudomonic ADJ - O
acid NOUN - O
is VERB - O
a DET - O
natural ADJ - O
crotonic NOUN - O
acid NOUN - O
derivative ADJ - O
drug NOUN - O
extracted VERB - O
from ADP - O
Pseudomonas NNP - B-ORG
fluorescens NOUN - O
which ADJ - O
is VERB - O
produced VERB - O
by ADP - O
modular ADJ - O
polyketide NOUN - O
synthases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-ORG
aureus NOUN - O
in ADP - O
Africa NNP - B-LOC
: PUNCT - O
a DET - O
systematic ADJ - O
review NOUN - O
and CCONJ - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Showing PROPN - O
Increasing PROPN - O
Prevalence PROPN - O
of ADP - O
Mupirocin NNP - B-MEDICINE
Resistance PROPN - O
and CCONJ - O
Associated PROPN - O
Multidrug PROPN - O
Resistance PROPN - O
following VERB - O
Attempted PROPN - O
Decolonization PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
is VERB - O
a DET - O
useful ADJ - O
antibiotic ADJ - O
against ADP - O
superficial ADJ - O
skin NOUN - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
at ADP - O
Subinhibitory NNP - B-ORG
Concentrations NNP - I-ORG
Induces NNP - I-ORG
Biofilm NNP - I-ORG
Formation NNP - I-ORG
in ADP - O
Staphylococcus NNP - B-ORG
aureus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
is VERB - O
used VERB - O
specifically ADV - O
for ADP - O
the DET - O
eradication NOUN - O
of ADP - O
nasal ADJ - O
meticillin NOUN - O
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-ORG
aureus NOUN - O
( PUNCT - O
MRSA NNP - B-ORG
) PUNCT - O
, PUNCT - O
but CCONJ - O
increasing VERB - O
mupirocin NN - B-MEDICINE
resistance NOUN - O
restricts VERB - O
its ADJ - O
repeated VERB - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Topical NNP - I-ORG
Chlorhexidine NNP - I-ORG
and CC - I-ORG
Mupirocin NNP - I-MEDICINE
for IN - I-ORG
the DT - I-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Exit NNP - I-ORG
- HYPH - I-ORG
Site NN - I-ORG
Infection NN - I-ORG
in ADP - O
Incident PROPN - O
Peritoneal PROPN - O
Dialysis NOUN - O
Patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mupirocin NNP - B-MEDICINE
compared VERB - O
with ADP - O
placeboThis DET - O
study NOUN - O
found VERB - O
no DET - O
clear ADJ - O
difference NOUN - O
in ADP - O
SSI PROPN - O
risk NOUN - O
following VERB - O
use NOUN - O
of ADP - O
mupirocin NN - B-MEDICINE
compared VERB - O
with ADP - O
placebo NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
trial NOUN - O
, PUNCT - O
257 CD - B-CARDINAL
participants NOUN - O
) PUNCT - O
; PUNCT - O
risk NOUN - O
ratio NOUN - O
( PUNCT - O
RR NNP - B-ORG
) PUNCT - O
1.60 CD - B-DATE
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
0.79 CD - B-CARDINAL
to ADP - O
3.25 CD - B-CARDINAL
based VERB - O
on ADP - O
18/130 NUM - O
events NOUN - O
in ADP - O
the DET - O
mupirocin NN - B-MEDICINE
group NOUN - O
and CCONJ - O
11/127 PROPN - O
in ADP - O
the DET - O
control NOUN - O
group NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
certainty NOUN - O
evidence NOUN - O
( PUNCT - O
downgraded VERB - O
twice ADV - O
due ADP - O
to ADP - O
imprecision NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluocinonide JJ - B-MEDICINE
cream NOUN - O
may VERB - O
be VERB - O
more ADV - O
effective ADJ - O
than ADP - O
hydrocortisone NOUN - O
in ADP - O
clearing VERB - O
DLE NNP - B-ORG
skin NOUN - O
lesions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Case NOUN - O
report NOUN - O
: PUNCT - O
Fluocinonide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
perioral ADJ - O
dermatitis NOUN - O
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
psoriasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluocinonide JJ - B-MEDICINE
cream NOUN - O
was VERB - O
the DET - O
least ADJ - O
atrophogenic ADJ - O
, PUNCT - O
producing VERB - O
no DET - O
or CCONJ - O
only ADV - O
mild ADJ - O
effects NOUN - O
that ADJ - O
were VERB - O
slightly ADV - O
greater ADJ - O
than ADP - O
vehicle NOUN - O
. PUNCT - O

Fluocinonide JJ - B-MEDICINE
cream NOUN - O
has VERB - O
a DET - O
lower ADJ - O
potential NOUN - O
to PART - O
produce VERB - O
atrophic ADJ - O
changes NOUN - O
of ADP - O
the DET - O
skin NOUN - O
than ADP - O
either CCONJ - O
clobetasol NOUN - O
cream NOUN - O
or CCONJ - O
clobetasol NOUN - O
propionate NOUN - O
foam NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Fluocinonide NNP - B-MEDICINE
Reference NNP - I-ORG
Standard NNP - I-ORG
( PUNCT - O
Control PROPN - O
981 CD - B-CARDINAL
) PUNCT - O
of ADP - O
National NNP - B-ORG
Institute NNP - I-ORG
of IN - I-ORG
Health NNP - I-ORG
Sciences NNPS - I-ORG
] PUNCT - O

-DOCSTART- -X- - O

Background NNP - B-ORG
Citalopram NNP - I-MEDICINE
and CCONJ - O
escitalopram NOUN - O
can VERB - O
both DET - O
induce VERB - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
QT NNP - B-ORG
prolongation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
, PUNCT - O
a DET - O
selective ADJ - O
serotonin ADJ - O
reuptake NOUN - O
inhibitor NOUN - O
( PUNCT - O
SSRI NNP - B-ORG
) PUNCT - O
, PUNCT - O
inhibits VERB - O
platelet NOUN - O
function NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
reduces VERB - O
endurance NOUN - O
and CCONJ - O
it PRON - O
can VERB - O
be VERB - O
reversed VERB - O
with ADP - O
deprescribing VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
and CCONJ - O
group NOUN - O
psychotherapy NOUN - O
in ADP - O
breast NOUN - O
cancer NOUN - O
patients NOUN - O
: PUNCT - O
A DET - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
effectiveness NOUN - O
of ADP - O
a DET - O
combined VERB - O
herbal ADJ - O
drug NOUN - O
based VERB - O
on ADP - O
Echium NNP - B-GPE
amoenum NOUN - O
with ADP - O
Citalopram NNP - B-MEDICINE
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
Major JJ - B-ORG
Depressive JJ - I-ORG
Disorder NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
is VERB - O
an DET - O
antidepressant ADJ - O
drug NOUN - O
and CCONJ - O
can VERB - O
decrease VERB - O
Aβ PROPN - O
production NOUN - O
and CCONJ - O
amyloid NOUN - O
plaques NOUN - O
in ADP - O
transgenic ADJ - O
mice NOUN - O
of ADP - O
AD NOUN - O
and CCONJ - O
humans NOUN - O
. PUNCT - O

Citalopram NNP - B-MEDICINE
treatment NOUN - O
at ADP - O
approximately ADV - O
10 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
/ SYM - O
day NOUN - O
significantly ADV - O
improved VERB - O
spatial ADJ - O
memory NOUN - O
in ADP - O
the DET - O
Morris NNP - B-PERSON
water NOUN - O
maze NOUN - O
( PUNCT - O
MWM PROPN - O
) PUNCT - O
test NOUN - O
, PUNCT - O
while ADP - O
not ADV - O
affecting VERB - O
anxiety NOUN - O
- PUNCT - O
like ADJ - O
and CCONJ - O
depression NOUN - O
- PUNCT - O
like ADJ - O
behavior NOUN - O
in ADP - O
3xTgAD JJ - B-CARDINAL
mice NOUN - O
. PUNCT - O

Citalopram NNP - B-MEDICINE
treatment NOUN - O
also ADV - O
significantly ADV - O
decreased VERB - O
the DET - O
levels NOUN - O
of ADP - O
insoluble ADJ - O
Aβ40 NNP - B-PRODUCT
in ADP - O
hippocampal ADJ - O
and CCONJ - O
cortical ADJ - O
tissues NOUN - O
in ADP - O
3xTgAD NNP - B-CARDINAL
mice NOUN - O
, PUNCT - O
accompanied VERB - O
with ADP - O
a DET - O
reduced VERB - O
amyloid NOUN - O
precursor NOUN - O
protein NOUN - O
( PUNCT - O
APP PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
Ameliorates NNPS - I-ORG
Impairments NNPS - I-ORG
in ADP - O
Spatial NNP - B-ORG
Memory NNP - I-ORG
and CC - I-ORG
Synaptic NNP - B-ORG
Plasticity NNP - I-ORG
in ADP - O
Female PROPN - O
3xTgAD PROPN - O
Mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Citalopram NNP - B-MEDICINE
( PUNCT - O
15mg NNP - B-ORDINAL
/ SYM - O
kg NOUN - O
) PUNCT - O
enhanced VERB - O
the DET - O
acute ADJ - O
antinociceptive ADJ - O
effects NOUN - O
of ADP - O
morphine NOUN - O
when ADV - O
concurrently ADV - O
administered VERB - O
as ADP - O
evidenced VERB - O
by ADP - O
a DET - O
two CD - B-CARDINAL
- PUNCT - O
fold ADJ - O
increase NOUN - O
in ADP - O
the DET - O
ED50 NNP - B-ORG
for ADP - O
the DET - O
antinociceptive ADJ - O
effect NOUN - O
of ADP - O
morphine NOUN - O
in ADP - O
the DET - O
hot ADJ - O
- PUNCT - O
plate NOUN - O
test NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Citalopram NNP - B-MEDICINE

-DOCSTART- -X- - O

Loratadine NN - B-MEDICINE
is VERB - O
a DET - O
selective ADJ - O
inverse NOUN - O
agonist NOUN - O
of ADP - O
peripheral ADJ - O
histamine NOUN - O
H1-receptors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loratadine NNP - B-MEDICINE
( PUNCT - O
10 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
) PUNCT - O
or CCONJ - O
placebo NOUN - O
was VERB - O
administered VERB - O
orally ADV - O
one CD - B-TIME
hour NN - I-TIME
before ADP - O
31 NUM - O
healthy ADJ - O
participants NOUN - O
sang VERB - O
a DET - O
children NOUN - O
's PART - O
nursery NOUN - O
rhyme NOUN - O
to PART - O
evoke VERB - O
embarrassment NOUN - O
and CCONJ - O
blushing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
Statin- PROPN - O
and CCONJ - O
Loratadine NNP - B-MEDICINE
- HYPH - I-LAW
Induced VBN - I-LAW
Muscle NNP - I-LAW
Pain NNP - I-LAW
Mechanisms NNPS - I-LAW
Using VBG - I-LAW
Human NNP - I-LAW
Skeletal NNP - I-LAW
Muscle NNP - I-LAW
Cells NNPS - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Loratadine NN - B-MEDICINE
bioavailability NOUN - O
via ADP - O
buccal ADJ - O
transferosomal ADJ - O
gel NOUN - O
: PUNCT - O
formulation NOUN - O
, PUNCT - O
statistical ADJ - O
optimization NOUN - O
, PUNCT - O
in ADP - O
vitro NOUN - O
/ SYM - O
in ADP - O
vivo NOUN - O
characterization NOUN - O
, PUNCT - O
and CCONJ - O
pharmacokinetics NOUN - O
in ADP - O
human ADJ - O
volunteers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
anti ADJ - O
- ADJ - O
convulsive ADJ - O
effects NOUN - O
of ADP - O
the DET - O
natural ADJ - O
product NOUN - O
quinine NOUN - O
may VERB - O
- PUNCT - O
at ADP - O
least ADJ - O
in ADP - O
part NOUN - O
- PUNCT - O
be VERB - O
explained VERB - O
by ADP - O
interaction NOUN - O
with ADP - O
SV2A. NNP - B-ORG
Loratadine NNP - I-MEDICINE
and CCONJ - O
quinine NOUN - O
represent VERB - O
new ADJ - O
lead NOUN - O
structures NOUN - O
for ADP - O
anti ADJ - O
- ADJ - O
epileptic ADJ - O
drug NOUN - O
development NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

When ADV - O
Hydromorphone NOUN - O
Is VERB - O
Not ADV - O
Working VERB - O
, PUNCT - O
Try VERB - O
Loratadine NN - B-MEDICINE
: PUNCT - O
An DET - O
Emergency PROPN - O
Department PROPN - O
Case PROPN - O
of ADP - O
Loratadine NNP - B-MEDICINE
as ADP - O
Abortive NNP - B-ORG
Therapy NNP - I-ORG
for IN - I-ORG
Severe NNP - I-ORG
Pegfilgrastim NNPS - I-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Bone NNP - I-ORG
Pain NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

BackgroundLoratadine NNP - B-ORG
is VERB - O
a DET - O
commonly ADV - O
used VERB - O
selective ADJ - O
non ADJ - O
- ADJ - O
sedating ADJ - O
antihistaminic ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loratadine NNP - B-MEDICINE
( PUNCT - O
LOR NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
active ADJ - O
component NOUN - O
of ADP - O
the DET - O
second JJ - B-ORDINAL
generation NOUN - O
of ADP - O
selective ADJ - O
antihistaminic ADJ - O
pharmaceutical NOUN - O
usually ADV - O
known VERB - O
as ADP - O
Claritin NNP - B-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Loratadine NN - B-MEDICINE
is VERB - O
stable ADJ - O
in ADP - O
the DET - O
DBS NNP - B-ORG
samples NOUN - O
for ADP - O
at RB - B-DATE
least JJS - I-DATE
271 CD - I-DATE
days NNS - I-DATE
at ADP - O
ambient NOUN - O
temperature NOUN - O
in ADP - O
a DET - O
desiccator NOUN - O
, PUNCT - O
for ADP - O
at RB - B-CARDINAL
least JJS - I-CARDINAL
24h NNS - I-CARDINAL
at ADP - O
60 CD - B-CARDINAL
° NNP - B-ORG
C NN - I-ORG
and CCONJ - O
under IN - B-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
relative ADJ - O
humidity NOUN - O
, PUNCT - O
followed VERB - O
by ADP - O
re NOUN - O
- NOUN - O
conditioning NOUN - O
at ADP - O
ambient NOUN - O
temperature NOUN - O
in ADP - O
a DET - O
desiccator NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Large ADJ - O
- PUNCT - O
Scale NOUN - O
Variations PROPN - O
in ADP - O
Lumber NNP - B-ORG
Value NNP - I-ORG
Recovery NNP - I-ORG
of ADP - O
Yellow NNP - B-PERSON
Birch NNP - I-PERSON
and CCONJ - O
Sugar NNP - B-PERSON
Maple NNP - I-PERSON
in ADP - O
Quebec NNP - B-GPE
, PUNCT - O
Canada NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Predicting VERB - O
Sugar NNP - B-MEDICINE
Maple NNP - I-MEDICINE
Mortality PROPN - O
in ADP - O
Managed PROPN - O
Uneven PROPN - O
- PUNCT - O
Aged ADJ - O
Northern ADJ - O
Hardwood NOUN - O
Stands PROPN - O

-DOCSTART- -X- - O

Estimating VERB - O
Wood PROPN - O
Volume NOUN - O
of ADP - O
the DET - O
Stem PROPN - O
and CCONJ - O
Branches NOUN - O
of ADP - O
Sugar NNP - B-MEDICINE
Maple NNP - I-MEDICINE
( PUNCT - O
Acer PROPN - O
saccharum VERB - O
Marsh NNP - B-GPE
. PUNCT - O
) PUNCT - O

-DOCSTART- -X- - O

Expected ADJ - O
Rates PROPN - O
of ADP - O
Value PROPN - O
Growth PROPN - O
for ADP - O
Individual PROPN - O
Sugar NNP - B-MEDICINE
Maple NNP - I-MEDICINE
Crop PROPN - O
Trees PROPN - O
in ADP - O
the DT - B-EVENT
Great NNP - I-EVENT
Lakes NNPS - I-EVENT
Region NNP - I-EVENT
: PUNCT - O
A PROPN - O
Reply PROPN - O
to ADP - O
John NNP - B-PERSON
E. NNP - I-PERSON
Wagner NNP - I-PERSON
's POS - I-PERSON
Comment NOUN - O

-DOCSTART- -X- - O

The DET - O
Combined PROPN - O
Effects PROPN - O
of ADP - O
Forest PROPN - O
Tent PROPN - O
Caterpillar PROPN - O
Defoliation PROPN - O
and CCONJ - O
Timber PROPN - O
Stand PROPN - O
Improvement NOUN - O
Activity NOUN - O
on ADP - O
Epicormic PROPN - O
Sprouting PROPN - O
of ADP - O
Sugar NNP - B-MEDICINE
Maple NNP - I-MEDICINE
and CCONJ - O
Black NNP - B-PERSON
Cherry NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
culivar NOUN - O
of ADP - O
Sugar NNP - B-WORK_OF_ART
Maple NNP - I-WORK_OF_ART
tree NOUN - O
( PUNCT - O
Acer PROPN - O
saccharum NOUN - O
) PUNCT - O
having VERB - O
a DET - O
compact ADJ - O
oval NOUN - O
appearance NOUN - O
, PUNCT - O
dark ADJ - O
red NOUN - O
to PART - O
bronze VERB - O
new ADJ - O
growth NOUN - O
and CCONJ - O
fall NOUN - O
foliage NOUN - O
, PUNCT - O
small ADJ - O
, PUNCT - O
dark ADJ - O
and CCONJ - O
slightly ADV - O
thicker ADJ - O
leaves NOUN - O
, PUNCT - O
good ADJ - O
summer NOUN - O
heat NOUN - O
and CCONJ - O
drought NOUN - O
resistance NOUN - O
and CCONJ - O
cold ADJ - O
hardiness NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Elevated PROPN - O
CO₂ VERB - O
and CCONJ - O
O₃ PROPN - O
Alter PROPN - O
Soil NNP - B-PERSON
Nitrogen NNP - I-PERSON
Transformations PROPN - O
beneath ADP - O
Trembling NNP - B-PERSON
Aspen NNP - I-PERSON
, PUNCT - O
Paper PROPN - O
Birch PROPN - O
, PUNCT - O
and CCONJ - O
Sugar NNP - B-PERSON
Maple NNP - I-PERSON

-DOCSTART- -X- - O

An DET - O
in ADP - O
  SPACE - O
vitro NOUN - O
stain NOUN - O
prevention NOUN - O
model NOUN - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
Colgate NNP - B-MEDICINE
TotalSF NNP - I-ORG
containing VERB - O
0.454 CD - B-PERCENT
% NN - I-PERCENT
SnF2 NN - B-DATE
and CCONJ - O
1 CD - B-PERCENT
% NN - I-PERCENT
zinc NOUN - O
phosphate NOUN - O
compared VERB - O
with ADP - O
Crest NNP - B-ORG
Pro NNP - I-ORG
- NNP - I-ORG
Health NNP - I-ORG
Whitening NNP - I-ORG
Power NNP - I-ORG
( PUNCT - O
The DT - B-ORG
Procter NNP - I-ORG
& CC - I-ORG
Gamble NNP - I-ORG
Company NNP - I-ORG
) PUNCT - O
and CCONJ - O
a DET - O
nonabrasive ADJ - O
SnF2 NOUN - O
gel NOUN - O
. PUNCT - O

A DET - O
stain NOUN - O
removal NOUN - O
clinical ADJ - O
study NOUN - O
was VERB - O
conducted VERB - O
as ADP - O
a DET - O
randomized ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
2-cell NUM - O
, PUNCT - O
parallel NOUN - O
- PUNCT - O
group NOUN - O
design NOUN - O
using VERB - O
Colgate NNP - B-MEDICINE
TotalSF NNP - I-ORG
and CCONJ - O
nonwhitening VERB - O
regular ADJ - O
fluoride NOUN - O
toothpaste NOUN - O
. PUNCT - O

In ADP - O
an DET - O
in ADP - O
  SPACE - O
vitro NOUN - O
stain NOUN - O
prevention NOUN - O
study NOUN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
TotalSF NNP - I-ORG
performed VERB - O
26 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
35 CD - B-PERCENT
% NN - I-PERCENT
better ADJ - O
than ADP - O
a DET - O
competitor NOUN - O
paste NOUN - O
and CCONJ - O
nonabrasive ADJ - O
SnF2 NN - B-DATE
gel NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

In ADP - O
a DET - O
clinical ADJ - O
study NOUN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
TotalSF NNPS - I-ORG
use NOUN - O
showed VERB - O
statistically ADV - O
significant ADJ - O
extrinsic ADJ - O
tooth NOUN - O
stain NOUN - O
reductions NOUN - O
by ADP - O
17.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
3 CD - B-DATE
weeks NNS - I-DATE
) PUNCT - O
and CCONJ - O
27.8 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
6 CD - B-CARDINAL
  SPACE - O
weeks NNS - B-DATE
) PUNCT - O
relative ADJ - O
to ADP - O
regular ADJ - O
fluoride NOUN - O
toothpaste NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
indicate VERB - O
that ADP - O
the DET - O
stabilized ADJ - O
Colgate NNP - B-MEDICINE
TotalSF NNP - I-ORG
performed VERB - O
statistically ADV - O
better ADV - O
than ADP - O
other ADJ - O
SnF2 NN - B-DATE
pastes NOUN - O
in ADP - O
an DET - O
in X - O
vitro X - O
study NOUN - O
, PUNCT - O
and CCONJ - O
statistically ADV - O
better ADJ - O
than ADP - O
a DET - O
regular ADJ - O
fluoride NOUN - O
toothpaste NOUN - O
in ADP - O
a DET - O
clinical ADJ - O
study NOUN - O
. PUNCT - O

Colgate NNP - B-MEDICINE
TotalSF NNP - I-ORG
offers VERB - O
an DET - O
SnF2-based `` - B-ORG
therapeutic ADJ - O
dentifrice NOUN - O
with ADP - O
notable ADJ - O
performance NOUN - O
in ADP - O
stain NOUN - O
prevention NOUN - O
and CCONJ - O
removal NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Objective NOUN - O
: PUNCT - O
The DET - O
objective NOUN - O
of ADP - O
the DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
herbal ADJ - O
mouthwash NOUN - O
( PUNCT - O
Dr. PROPN - O
Dental NNP - B-PERSON
care NOUN - O
liquid NOUN - O
) PUNCT - O
in ADP - O
reducing VERB - O
the DET - O
oral ADJ - O
bacterial ADJ - O
count NOUN - O
and CCONJ - O
compare VERB - O
it PRON - O
with ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
commercially ADV - O
available ADJ - O
mouthwashes NOUN - O
such ADJ - O
as ADP - O
Rexidine NNP - B-ORG
, , - I-ORG
Listerine NNP - I-ORG
and CCONJ - O
Colgate NNP - B-MEDICINE
Plax PROPN - O
. PUNCT - O

The DET - O
participants NOUN - O
of ADP - O
each DET - O
group NOUN - O
were VERB - O
given VERB - O
four CD - B-CARDINAL
different ADJ - O
mouthwashes NOUN - O
( PUNCT - O
Dr. PROPN - O
Dental NNP - B-PERSON
Care PROPN - O
liquid NOUN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
Plax NNP - I-ORG
, PUNCT - O
Listerine NNP - B-ORG
and CC - I-ORG
Rexidine NNP - I-ORG
) PUNCT - O
and CCONJ - O
asked VERB - O
to PART - O
use VERB - O
it PRON - O
twice ADV - O
daily ADV - O
for ADP - O
5 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

Among ADP - O
the DET - O
four CD - B-CARDINAL
mouthwashes NOUN - O
, PUNCT - O
the DET - O
herbal ADJ - O
mouthwash NOUN - O
, PUNCT - O
Dr. PROPN - O
Dental NNP - B-PERSON
care NOUN - O
liquid NOUN - O
exhibited VERB - O
maximum ADJ - O
efficacy NOUN - O
in ADP - O
reducing VERB - O
the DET - O
amount NOUN - O
of ADP - O
bacteria NOUN - O
followed VERB - O
by ADP - O
Colgate NNP - B-MEDICINE
Plax NNP - I-ORG
, PUNCT - O
Listerine NNP - B-ORG
and CC - I-ORG
Rexidine NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Consumer NOUN - O
tests NOUN - O
validated VERB - O
that ADP - O
these DET - O
flavors NOUN - O
had VERB - O
strong ADJ - O
performance NOUN - O
and CCONJ - O
acceptability NOUN - O
among ADP - O
users NOUN - O
of ADP - O
the DET - O
original ADJ - O
Colgate NNP - B-MEDICINE
® NN - I-ORG
Total JJ - I-ORG
® NOUN - O
triclosan NOUN - O
- PUNCT - O
containing VERB - O
dentifrice NOUN - O
. PUNCT - O

Combining VERB - O
in ADP - O
- PUNCT - O
depth NOUN - O
flavor NOUN - O
scientific ADJ - O
research NOUN - O
and CCONJ - O
formulation NOUN - O
creativity NOUN - O
, PUNCT - O
we PRON - O
were VERB - O
able ADJ - O
to PART - O
deliver VERB - O
flavors NOUN - O
that ADJ - O
are VERB - O
stable ADJ - O
and CCONJ - O
appealing ADJ - O
to ADP - O
the DET - O
global ADJ - O
consumer NOUN - O
for ADP - O
Colgate NNP - B-MEDICINE
's PART - O
new ADJ - O
therapeutic ADJ - O
segment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enamel NNP - B-ORG
/ SYM - I-ORG
dentin NN - I-ORG
bovine NOUN - O
blocks NOUN - O
( PUNCT - O
4×4×2 XX - B-QUANTITY
mm NNP - I-QUANTITY
) PUNCT - O
were VERB - O
bleached VERB - O
with ADP - O
35 CD - B-PERCENT
% NN - I-PERCENT
hydrogen NOUN - O
peroxide NOUN - O
( PUNCT - O
HP PROPN - O
) PUNCT - O
and CCONJ - O
were VERB - O
submitted VERB - O
to ADP - O
immersion NOUN - O
twice ADV - O
daily ADV - O
for ADP - O
14 CD - B-DATE
days NNS - I-DATE
with ADP - O
different ADJ - O
rinses NOUN - O
( PUNCT - O
n=10 NOUN - O
) PUNCT - O
, PUNCT - O
including VERB - O
those DET - O
involving VERB - O
: PUNCT - O
distilled VERB - O
water NOUN - O
( PUNCT - O
C PROPN - O
[ PUNCT - O
control NOUN - O
] PUNCT - O
) PUNCT - O
, PUNCT - O
225-ppm CD - B-ORG
NaF NNP - I-ORG
( PUNCT - O
FM PROPN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
Plax PROPN - O
Classic NNP - B-PRODUCT
) PUNCT - O
, PUNCT - O
essential ADJ - O
oil NOUN - O
( PUNCT - O
EM PROPN - O
, PUNCT - O
Listerine NNP - B-ORG
Tartar NNP - I-ORG
Control NNP - I-ORG
) PUNCT - O
, PUNCT - O
1.5 CD - B-PERCENT
% NN - I-PERCENT
hydrogen NOUN - O
peroxide NOUN - O
( PUNCT - O
HPM NNP - B-ORG
, PUNCT - O
Colgate NNP - B-MEDICINE
Plax NNP - I-ORG
Whitening PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
2 CD - B-PERCENT
% NN - I-PERCENT
hydrogen NOUN - O
peroxide NOUN - O
, PUNCT - O
pyrophosphates NOUN - O
, PUNCT - O
and CCONJ - O
225-ppm CD - B-CARDINAL
NaF NNP - I-CARDINAL
( PUNCT - O
HPM+P PROPN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
® NN - I-FAC
Luminous NNP - I-FAC
White NNP - I-FAC
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Participants NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
a DET - O
treatment NOUN - O
sequence NOUN - O
involving VERB - O
the DET - O
following VERB - O
products NOUN - O
: PUNCT - O
a DET - O
highly ADV - O
bioavailable ADJ - O
0.454 CD - B-PERCENT
% NN - I-PERCENT
stannous ADJ - O
fluoride ADJ - O
dentifrice NOUN - O
( PUNCT - O
Procter NNP - B-ORG
& CC - I-ORG
Gamble NNP - I-ORG
) PUNCT - O
and CCONJ - O
a DET - O
marketed VERB - O
dentifrice NOUN - O
control NOUN - O
containing VERB - O
0.24 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
fluoride NOUN - O
and CCONJ - O
0.3 CD - B-PERCENT
% NN - I-PERCENT
triclosan NOUN - O
( PUNCT - O
Colgate NNP - B-MEDICINE
- HYPH - I-ORG
Palmolive NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Treatments NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
, PUNCT - O
and CCONJ - O
blinded ADJ - O
test NOUN - O
kits NOUN - O
were VERB - O
dispensed VERB - O
containing VERB - O
either ADV - O
: PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
a DET - O
two CD - B-CARDINAL
- PUNCT - O
step NOUN - O
0.454 CD - B-PERCENT
% NN - I-PERCENT
SnF₂ NOUN - O
dentifrice NOUN - O
and CCONJ - O
then ADV - O
a DET - O
3 CD - B-PERCENT
% NN - I-PERCENT
H₂O₂ PROPN - O
whitening NOUN - O
gel NOUN - O
sequence NOUN - O
and CCONJ - O
instructions NOUN - O
specifying VERB - O
1 CD - B-TIME
+ SYM - I-TIME
1 CD - I-TIME
minute NN - I-TIME
sequential NOUN - O
brushing NOUN - O
( PUNCT - O
experimental ADJ - O
) PUNCT - O
; PUNCT - O
or CCONJ - O
2 LS - B-CARDINAL
) PUNCT - O
0.76 CD - B-PERCENT
% NN - I-PERCENT
sodium NOUN - O
monofluorophosphate NOUN - O
dentifrice NOUN - O
( PUNCT - O
Colgate NNP - B-MEDICINE
Cavity NNP - I-ORG
Protection NNP - I-ORG
) PUNCT - O
and CCONJ - O
instructions NOUN - O
for ADP - O
twice DET - O
daily JJ - B-DATE
use NOUN - O
( PUNCT - O
control NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Children NOUN - O
were VERB - O
selected VERB - O
according VERB - O
to ADP - O
their ADJ - O
caries NOUN - O
activity NOUN - O
( PUNCT - O
ie X - O
, PUNCT - O
presence NOUN - O
of ADP - O
at IN - B-CARDINAL
least JJS - I-CARDINAL
1 CD - I-CARDINAL
tooth NOUN - O
with ADP - O
a DET - O
Nyvad NNP - B-ORG
score NOUN - O
of ADP - O
1 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
randomly ADV - O
divided VERB - O
into ADP - O
the DET - O
following VERB - O
treatment NOUN - O
categories NOUN - O
: PUNCT - O
4 CD - B-PERCENT
% NN - I-PERCENT
TiF4 NOUN - O
varnish ADJ - O
( PUNCT - O
2.45 CD - B-PERCENT
% NN - I-PERCENT
F- NOUN - O
, PUNCT - O
pH PROPN - O
1 CD - B-CARDINAL
, PUNCT - O
FGM NNP - B-ORG
) PUNCT - O
; PUNCT - O
5 CD - B-PERCENT
% NN - I-PERCENT
NaF NNP - B-ORG
varnish JJ - I-ORG
( PUNCT - O
2.26 CD - B-PERCENT
% NN - I-PERCENT
F- NOUN - O
, PUNCT - O
pH PROPN - O
5 CD - B-CARDINAL
, PUNCT - O
Duraphat NNP - B-ORG
, PUNCT - O
Colgate NNP - B-MEDICINE
) PUNCT - O
and CCONJ - O
control NOUN - O
( PUNCT - O
placebo NOUN - O
varnish NOUN - O
, PUNCT - O
pH NOUN - O
5 CD - B-CARDINAL
, PUNCT - O
FGM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
parallel ADJ - O
clinical ADJ - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
clinical ADJ - O
efficacy NOUN - O
in ADP - O
supragingival NOUN - O
calculus NOUN - O
formation NOUN - O
reduction NOUN - O
using VERB - O
Abhaibhubejhr NNP - B-ORG
Herbal NNP - I-ORG
Toothpaste NNP - I-ORG
compared VERB - O
to ADP - O
Colgate NNP - B-MEDICINE
Total NNP - I-ORG
and CCONJ - O
Colgate NNP - B-MEDICINE
Cavity NNP - I-ORG
Protection NNP - I-ORG
toothpastes NOUN - O
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
Colgate NNP - B-MEDICINE
Total ADJ - O
toothpaste NOUN - O
over ADP - O
a DET - O
12-week CD - B-CARDINAL
period NOUN - O
was VERB - O
clinically ADV - O
more ADV - O
effective ADJ - O
than ADP - O
either DET - O
Abhaibhubejhr NNP - B-ORG
or CCONJ - O
Colgate NNP - B-MEDICINE
Cavity NNP - I-ORG
Protection NNP - I-ORG
toothpastes VERB - O
in ADP - O
controlling VERB - O
supragingival NOUN - O
calculus NOUN - O
formation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Forty CD - B-CARDINAL
- HYPH - I-CARDINAL
eight CD - I-CARDINAL
adolescents NOUN - O
were VERB - O
randomly ADV - O
grouped VERB - O
into ADP - O
three CD - B-CARDINAL
groups NOUN - O
of ADP - O
n NOUN - O
= SYM - O
16 CD - B-CARDINAL
each DET - O
: PUNCT - O
study NOUN - O
group NOUN - O
A DET - O
received VERB - O
xylitol NOUN - O
( PUNCT - O
Xyliwhite NNP - B-ORG
) PUNCT - O
toothpaste NOUN - O
; PUNCT - O
study NOUN - O
group NOUN - O
B PROPN - O
received VERB - O
xylitol NOUN - O
- PUNCT - O
probiotic ADJ - O
( PUNCT - O
Periobiotic ADJ - O
) PUNCT - O
toothpaste NOUN - O
; PUNCT - O
and CCONJ - O
the DET - O
control NOUN - O
group NOUN - O
C PROPN - O
received VERB - O
fluoride NOUN - O
( PUNCT - O
Colgate NNP - B-MEDICINE
Max NNP - B-PERSON
Fresh NNP - I-PERSON
) PUNCT - O
toothpaste NOUN - O
. PUNCT - O

From ADP - O
day NOUN - O
0 NUM - O
to ADP - O
42 NUM - O
, PUNCT - O
reductions NOUN - O
in ADP - O
the DET - O
plaque NOUN - O
index NOUN - O
were VERB - O
statistically ADV - O
significant ADJ - O
in ADP - O
all DET - O
groups NOUN - O
, PUNCT - O
Colgate NNP - B-MEDICINE
Max NNP - I-ORG
Fresh NNP - I-ORG
, PUNCT - O
PerioBiotic NNP - B-ORG
and CCONJ - O
Xyliwhite NNP - B-ORG
( PUNCT - O
p NOUN - O
- PUNCT - O
values NOUN - O
0.001 CD - B-CARDINAL
, PUNCT - O
0.001 CD - B-DATE
and CCONJ - O
0.035 CD - B-DATE
, PUNCT - O
respectively ADV - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
reductions NOUN - O
in ADP - O
the DET - O
gingival NOUN - O
index NOUN - O
were VERB - O
statistically ADV - O
significant ADJ - O
only ADV - O
in ADP - O
the DET - O
Colgate NNP - B-MEDICINE
Max PROPN - O
Fresh PROPN - O
and CCONJ - O
PerioBiotic NNP - B-ORG
groups NOUN - O
( PUNCT - O
both CCONJ - O
with ADP - O
p NUM - O
= SYM - O
0.001 CD - B-GPE
) PUNCT - O
, PUNCT - O
not ADV - O
in ADP - O
the DET - O
Xyliwhite NNP - B-ORG
group NOUN - O
( PUNCT - O
p VERB - O
= SYM - O
0.116 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

PerioBiotic NNP - B-ORG
toothpaste NOUN - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
better ADJ - O
than ADP - O
Xyliwhite NNP - B-ORG
and CCONJ - O
Colgate NNP - B-MEDICINE
Max PROPN - O
Fresh PROPN - O
toothpastes NOUN - O
at ADP - O
reducing VERB - O
plaque NOUN - O
and CCONJ - O
gingival ADJ - O
scores NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
statistically ADV - O
significant ADJ - O
differences NOUN - O
with ADP - O
PerioBiotic NNP - B-ORG
and CCONJ - O
Colgate NNP - B-MEDICINE
Max NNP - B-PERSON
Fresh NNP - I-PERSON
toothpaste NOUN - O
were VERB - O
not ADV - O
observed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Colgate NNP - B-MEDICINE
Total ADJ - O
Advanced ADJ - O
® NOUN - O
, PUNCT - O
with ADP - O
1450 CD - B-DATE
ppm NOUN - O
NaF NNP - B-ORG
; PUNCT - O
group NOUN - O
D NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

The DET - O
materials NOUN - O
tested VERB - O
were VERB - O
distilled VERB - O
water NOUN - O
as ADP - O
a DET - O
control NOUN - O
group NOUN - O
, PUNCT - O
Patanjali NNP - B-PERSON
Dant NNP - I-PERSON
Kanti NNP - I-PERSON
, PUNCT - O
Colgate NNP - B-MEDICINE
Total NNP - I-ORG
Cream NNP - I-ORG
, PUNCT - O
and CCONJ - O
Cleansodent PROPN - O
as ADP - O
dentifrices NOUN - O
. PUNCT - O

Patanjali PROPN - O
Dant PROPN - O
Kanti NNP - B-PERSON
was VERB - O
found VERB - O
to PART - O
have VERB - O
maximum ADJ - O
abrasive ADJ - O
potential NOUN - O
followed VERB - O
by ADP - O
Colgate NNP - B-MEDICINE
Total NNP - I-ORG
Cream NNP - I-ORG
, PUNCT - O
followed VERB - O
by ADP - O
Cleansodent NNP - B-ORG
and CCONJ - O
least ADJ - O
by ADP - O
distilled VERB - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

G1- NN - B-ORG
brushing VERB - O
with ADP - O
Colgate NNP - B-MEDICINE
® NN - I-ORG

Rapid PROPN - O
Relief PROPN - O
; PUNCT - O
G3- NOUN - O
brushing VERB - O
with ADP - O
Sensodyne NNP - B-ORG
® . - I-ORG
Repair NNP - I-ORG
& CC - I-ORG
Protect NNP - I-ORG
; PUNCT - O
and CCONJ - O
G4- NNP - B-ORG
brushing VERB - O
with ADP - O
Colgate NNP - B-MEDICINE
® NN - I-ORG
Maximum NNP - I-ORG
Cavity NNP - I-ORG
Protection NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Forty CD - B-CARDINAL
- HYPH - I-CARDINAL
eight CD - I-CARDINAL
bovine ADJ - O
teeth NOUN - O
were VERB - O
divided VERB - O
into ADP - O
3 CD - B-CARDINAL
immersion NOUN - O
groups NOUN - O
: PUNCT - O
SL NN - B-ORG
, PUNCT - O
artificial ADJ - O
saliva NOUN - O
( PUNCT - O
control NOUN - O
) PUNCT - O
; PUNCT - O
CLW NNP - B-ORG
, PUNCT - O
Colgate NNP - B-MEDICINE
Luminous NNP - I-ORG
White NNP - I-ORG
; PUNCT - O
and CCONJ - O
OBW NNP - B-ORG
, PUNCT - O
Oral PROPN - O
- PUNCT - O
B PROPN - O
3D PROPN - O
White NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Artificial ADJ - O
carious ADJ - O
lesions NOUN - O
were VERB - O
created VERB - O
on ADP - O
40 CD - B-CARDINAL
human ADJ - O
enamel ADJ - O
slabs NOUN - O
, PUNCT - O
and CCONJ - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
four CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
control NOUN - O
group NOUN - O
( PUNCT - O
no DET - O
treatment NOUN - O
) PUNCT - O
, PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
casein VERB - O
phosphopeptide ADJ - O
- PUNCT - O
amorphous ADJ - O
calcium NOUN - O
phosphate ADJ - O
group NOUN - O
( PUNCT - O
CPP NNP - B-ORG
- HYPH - I-ORG
ACP NNP - I-ORG
, PUNCT - O
GC NNP - B-ORG
Tooth PROPN - O
Mousse PROPN - O
) PUNCT - O
, PUNCT - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
8 CD - B-PERCENT
% NN - I-PERCENT
arginine NOUN - O
and CCONJ - O
calcium NOUN - O
carbonate NOUN - O
group NOUN - O
( PUNCT - O
ACC NNP - B-ORG
, PUNCT - O
Colgate NNP - B-MEDICINE
Sensitive JJ - I-ORG
Pro NNP - I-ORG
- JJ - I-ORG
Relief NNP - I-ORG
) PUNCT - O
, PUNCT - O
( PUNCT - O
4 LS - B-CARDINAL
) PUNCT - O
calcium NOUN - O
sodium NOUN - O
phosphosilicate NOUN - O
group NOUN - O
( PUNCT - O
CSP PROPN - O
, PUNCT - O
NovaMin NNP - B-ORG
® NN - I-ORG
) PUNCT - O
. PUNCT - O

After ADP - O
pH NOUN - O
- PUNCT - O
cycling NOUN - O
, PUNCT - O
the DET - O
specimens NOUN - O
treated VERB - O
with ADP - O
Colgate NNP - B-MEDICINE
Sensitive NNP - I-ORG
Pro NNP - I-ORG
- JJ - I-ORG
Relief NNP - I-ORG
and CCONJ - O
NovaMin NNP - B-ORG
® NN - I-ORG
showed VERB - O
a DET - O
significant ADJ - O
higher ADJ - O
surface NOUN - O
hardness NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
and CCONJ - O
P= PROPN - O
0.03 NUM - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
and CCONJ - O
lower ADJ - O
surface NOUN - O
roughness NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
for ADP - O
both DET - O
) PUNCT - O
compared VERB - O
those DET - O
treated VERB - O
with ADP - O
GC PROPN - O
Tooth PROPN - O
Mousse PROPN - O
. PUNCT - O

The DET - O
specimens NOUN - O
treated VERB - O
with ADP - O
Colgate NNP - B-MEDICINE
Sensitive NNP - I-ORG
Pro NNP - I-ORG
- JJ - I-ORG
Relief NNP - I-ORG
and CCONJ - O
NovaMin NNP - B-ORG
® NOUN - O
still ADV - O
showed VERB - O
a DET - O
significant ADJ - O
higher ADJ - O
surface NOUN - O
hardness NOUN - O
and CCONJ - O
lower ADJ - O
surface NOUN - O
roughness VERB - O
in ADP - O
comparison NOUN - O
with ADP - O
those DET - O
treated VERB - O
with ADP - O
GC NNP - B-ORG
Tooth PROPN - O
Mousse PROPN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
for ADP - O
all DET - O
) PUNCT - O
. PUNCT - O

No DET - O
significant ADJ - O
difference NOUN - O
was VERB - O
found VERB - O
in ADP - O
surface NOUN - O
hardness NOUN - O
and CCONJ - O
roughness VERB - O
between ADP - O
Colgate NNP - B-MEDICINE
Sensitive NNP - I-ORG
Pro NNP - I-ORG
- JJ - I-ORG
Relief NNP - I-ORG
and CCONJ - O
NovaMin NNP - B-ORG
® NOUN - O
during ADP - O
the DET - O
pH NOUN - O
- PUNCT - O
cycling VERB - O
test NOUN - O
and CCONJ - O
acid ADJ - O
resistance NOUN - O
test NOUN - O
( PUNCT - O
P= PROPN - O
0.45 NUM - O
and CCONJ - O
P= PROPN - O
0.83 NUM - O
, PUNCT - O
respectively).Colgate ADJ - O
Sensitive JJ - B-PERSON
Pro NNP - I-PERSON
- JJ - I-PERSON
Relief NNP - I-PERSON
and CCONJ - O
NovaMin PROPN - O
® NOUN - O
present VERB - O
an DET - O
advantage NOUN - O
in ADP - O
enhancing VERB - O
remineralization NOUN - O
and CCONJ - O
inhibiting VERB - O
demineralization NOUN - O
for ADP - O
early ADJ - O
enamel NOUN - O
carious ADJ - O
lesions NOUN - O
in ADP - O
comparison NOUN - O
with ADP - O
GC PROPN - O
Tooth PROPN - O
Mousse PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Both DET - O
investigations NOUN - O
evaluated VERB - O
a DET - O
novel NOUN - O
0.454 CD - B-PERCENT
% NN - I-PERCENT
stabilized VERB - O
stannous ADJ - O
fluoride ADJ - O
dentifrice NOUN - O
( PUNCT - O
Crest NNP - B-ORG
® . - I-ORG
Pro NNP - I-ORG
- NNP - I-ORG
Health NNP - I-ORG
™ NNP - I-ORG
smooth ADJ - O
formula NOUN - O
) PUNCT - O
versus ADP - O
a DET - O
sodium NOUN - O
fluoride NOUN - O
/ SYM - O
triclosan ADJ - O
positive ADJ - O
control NOUN - O
dentifrice NOUN - O
( PUNCT - O
Colgate NNP - B-MEDICINE
® NN - I-ORG
Total NN - I-ORG
® NN - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
novel ADJ - O
tetracalcium NOUN - O
phosphate ADJ - O
/ SYM - O
monetite NOUN - O
dentifrice NOUN - O
had VERB - O
comparable ADJ - O
remineralization NOUN - O
potential NOUN - O
as ADP - O
commercial ADJ - O
calcium NOUN - O
silicate NOUN - O
/ SYM - O
phosphate ADJ - O
( PUNCT - O
SENSODYNE NOUN - O
® PUNCT - O
) PUNCT - O
and CCONJ - O
magnesium NOUN - O
aluminum NOUN - O
silicate NOUN - O
( PUNCT - O
Colgate NNP - B-MEDICINE
® NN - I-ORG
) PUNCT - O
toothpastes NOUN - O
and CCONJ - O
significantly ADV - O
higher ADV - O
than ADP - O
control NOUN - O
saliva NOUN - O
( PUNCT - O
p<0.02 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Sixty NUM - O
circular NOUN - O
( PUNCT - O
15 CD - B-CARDINAL
× NOUN - O
3 CD - B-QUANTITY
mm NN - I-QUANTITY
) PUNCT - O
specimens NOUN - O
were VERB - O
distributed VERB - O
into ADP - O
four CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
C PROPN - O
( PUNCT - O
control NOUN - O
; PUNCT - O
brushing VERB - O
with ADP - O
water NOUN - O
) PUNCT - O
; PUNCT - O
CO NNP - B-ORG
( PUNCT - O
brushing VERB - O
with ADP - O
Colgate NNP - B-MEDICINE
- PUNCT - O
for ADP - O
natural ADJ - O
teeth NOUN - O
) PUNCT - O
; PUNCT - O
CB NNP - B-ORG
( PUNCT - O
brushing VERB - O
with ADP - O
Corega NNP - B-PERSON
Brite NNP - I-PERSON
- PUNCT - O
for ADP - O
complete ADJ - O
dentures NOUN - O
) PUNCT - O
; PUNCT - O
RC NNP - B-PERSON
( PUNCT - O
brushing VERB - O
with ADP - O
experimental ADJ - O
dentifrice NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Seventy NUM - O
volunteers NOUN - O
were VERB - O
allocated VERB - O
randomly ADV - O
to ADP - O
the DT - B-LAW
Colgate NNP - I-MEDICINE
Slim NNP - I-LAW
Soft NNP - I-LAW
or CCONJ - O
Curaprox NNP - B-PERSON
CS5460 NNP - I-PERSON
toothbrush NOUN - O
grourps NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Then ADV - O
teeth NOUN - O
were VERB - O
adapted VERB - O
in ADP - O
a DET - O
brushing NOUN - O
machine NOUN - O
and CCONJ - O
brushed VERB - O
with ADP - O
one CD - B-CARDINAL
of ADP - O
the DET - O
following VERB - O
toothpastes NOUN - O
[ PUNCT - O
Regular ADJ - O
toothpaste NOUN - O
with ADP - O
no DET - O
occlusive ADJ - O
compounds NOUN - O
Colgate NNP - B-MEDICINE
Cavity NNP - I-ORG
Protection NNP - I-ORG
( PUNCT - O
CP PROPN - O
) PUNCT - O
, PUNCT - O
Oral PROPN - O
- PUNCT - O
B PROPN - O
Pro PROPN - O
Health PROPN - O
( PUNCT - O
OB NNP - B-ORG
) PUNCT - O
, PUNCT - O
Colgate NNP - B-MEDICINE
ProRelief PROPN - O
( PUNCT - O
PR PROPN - O
) PUNCT - O
and CCONJ - O
Sensodyne NNP - B-ORG
Rapid JJ - I-ORG
Relief NNP - I-ORG
( PUNCT - O
RR NNP - B-ORG
) PUNCT - O
] PUNCT - O
under ADP - O
constant ADJ - O
loading NOUN - O
( PUNCT - O
250 CD - B-CARDINAL
g NOUN - O
; PUNCT - O
4.5 CD - B-CARDINAL
cycles NOUN - O
/ SYM - O
seconds NOUN - O
; PUNCT - O
3 CD - B-TIME
minutes NNS - I-TIME
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ionic JJ - B-PERSON
Liquids NNS - I-PERSON
and CCONJ - O
salts VERB - O
from ADP - O
Ibuprofen NNP - B-MEDICINE
as ADP - O
promising VERB - O
innovative ADJ - O
formulations NOUN - O
of ADP - O
an DET - O
old ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
showed VERB - O
effectiveness NOUN - O
in ADP - O
relieving VERB - O
symptoms NOUN - O
of ADP - O
UTI NNP - B-ORG
, PUNCT - O
but CCONJ - O
its ADJ - O
superiority NOUN - O
is VERB - O
questionable ADJ - O
. PUNCT - O

Antibiotics NOUN - O
were VERB - O
more ADV - O
effective ADJ - O
in ADP - O
relieving VERB - O
symptoms NOUN - O
of ADP - O
UTI NNP - B-ORG
than ADP - O
Ibuprofen NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Loaded VERB - O
with ADP - O
Ibuprofen NNP - B-MEDICINE
in IN - I-ORG
Acute NNP - I-ORG
and CCONJ - O
Chronic NNP - B-ORG
Models NNPS - I-ORG
of IN - I-ORG
Pain NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Patients PROPN - O
with ADP - O
Ibuprofen NNP - B-MEDICINE
Hypersensitivity PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Combination PROPN - O
of ADP - O
Paracetamol PROPN - O
( PUNCT - O
Acetaminophen NNP - B-PERSON
) PUNCT - O
and CCONJ - O
Ibuprofen NNP - B-MEDICINE
vs IN - I-PERSON
Either NNP - I-PERSON
Alone NNP - I-PERSON
on ADP - O
Patient NNP - B-ORG
- HYPH - I-ORG
Controlled NNP - I-ORG
Morphine NNP - I-ORG
Consumption NNP - I-ORG
in ADP - O
the DT - B-TIME
First JJ - I-TIME
24 CD - I-TIME
Hours NOUN - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
reports VERB - O
the DET - O
removal NOUN - O
of ADP - O
Bisphenol PROPN - O
A PROPN - O
( PUNCT - O
BPA NNP - B-ORG
) PUNCT - O
and CCONJ - O
Ibuprofen NNP - B-MEDICINE
( PUNCT - O
IBP NNP - B-ORG
) PUNCT - O
using VERB - O
adsorbents NOUN - O
prepared VERB - O
from ADP - O
batik NOUN - O
sludge NOUN - O
. PUNCT - O

The DET - O
maximum ADJ - O
removal NOUN - O
capacity NOUN - O
of ADP - O
BPA NNP - B-ORG
and CCONJ - O
Ibuprofen NNP - B-MEDICINE
were VERB - O
83.53 CD - B-CARDINAL
  SPACE - O
mg PRON - O
  SPACE - O
g-1 PROPN - O
and CCONJ - O
34.96 CD - B-CARDINAL
  SPACE - O
mg ADJ - O
  SPACE - O
g-1 NOUN - O
for ADP - O
the DET - O
CAl NOUN - O
adsorbent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
is VERB - O
a DET - O
worldwide ADV - O
used VERB - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
which ADJ - O
may VERB - O
cause VERB - O
acute ADJ - O
liver NOUN - O
injury NOUN - O
( PUNCT - O
ALI NNP - B-ORG
) PUNCT - O
requiring VERB - O
liver NOUN - O
transplantation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen VB - B-MEDICINE
at ADP - O
over ADP - O
- PUNCT - O
the DET - O
- PUNCT - O
counter NOUN - O
doses NOUN - O
used VERB - O
to PART - O
treat VERB - O
pain NOUN - O
and CCONJ - O
fever NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
up ADV - O
to ADP - O
1,200 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
d NOUN - O
for ADP - O
up ADP - O
to PART - O
10 NUM - O
days NOUN - O
) PUNCT - O
is VERB - O
associated VERB - O
with ADP - O
zero CD - B-CARDINAL
to ADP - O
minimally ADV - O
increased VERB - O
risk NOUN - O
for ADP - O
post ADJ - O
- ADJ - O
operative ADJ - O
bleeding VERB - O
events NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
was VERB - O
slightly ADV - O
inferior ADJ - O
to PART - O
acetazolamide VERB - O
for ADP - O
acute ADJ - O
mountain NOUN - O
sickness NOUN - O
prevention NOUN - O
and CCONJ - O
should VERB - O
not ADV - O
be VERB - O
recommended VERB - O
over ADP - O
acetazolamide ADV - O
for ADP - O
rapid ADJ - O
ascent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
( PUNCT - O
IBU NNP - B-ORG
) PUNCT - O
and CCONJ - O
phenylephrine NOUN - O
hydrochloride NOUN - O
( PUNCT - O
PE NNP - B-ORG
) PUNCT - O
were VERB - O
commonly ADV - O
used VERB - O
for ADP - O
common ADJ - O
cold NOUN - O
due ADP - O
to ADP - O
their ADJ - O
different ADJ - O
effects NOUN - O
in ADP - O
relieving VERB - O
fever NOUN - O
and CCONJ - O
the DET - O
main ADJ - O
symptoms NOUN - O
such ADJ - O
as ADP - O
nasal ADJ - O
congestion NOUN - O
and CCONJ - O
high ADJ - O
sinus NOUN - O
pressure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sustained ADJ - O
Release PROPN - O
Bilayer PROPN - O
Tablet PROPN - O
of ADP - O
Ibuprofen NNP - B-MEDICINE
and CCONJ - O
Phenylephrine PROPN - O
Hydrochloride PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

As ADP - O
expected VERB - O
, PUNCT - O
Ibuprofen NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
subjects NOUN - O
could VERB - O
be VERB - O
stratified VERB - O
into ADP - O
partial ADJ - O
responders NOUN - O
( PUNCT - O
N=9 NNP - B-ORG
, PUNCT - O
required VERB - O
rescue NOUN - O
medication NOUN - O
within ADP - O
the DET - O
dosing VERB - O
interval NOUN - O
) PUNCT - O
and CCONJ - O
complete ADJ - O
responders NOUN - O
( PUNCT - O
N=10 NNP - B-ORG
, PUNCT - O
no DET - O
rescue NOUN - O
medication NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Variability PROPN - O
in ADP - O
the DT - B-ORG
Analgesic NNP - I-ORG
Response NNP - I-ORG
to IN - I-ORG
Ibuprofen NNP - B-MEDICINE

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
patent NOUN - O
ductus NOUN - O
arteriosus VERB - O
in ADP - O
preterm NOUN - O
or CCONJ - O
low ADJ - O
birth NOUN - O
weight NOUN - O
( PUNCT - O
or CCONJ - O
both DET - O
) PUNCT - O
infants NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
- PUNCT - O
line NOUN - O
monitoring NOUN - O
of ADP - O
Ibuprofen NNP - B-MEDICINE
during ADP - O
and CCONJ - O
after ADP - O
tablet NOUN - O
compression NOUN - O
using VERB - O
near ADV - O
- PUNCT - O
infrared ADJ - O
spectroscopy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
the DET - O
Efficacy NNP - B-ORG
of ADP - O
IV NNP - B-ORG
Ibuprofen NNP - B-MEDICINE
and CCONJ - O
Ketorolac NNP - B-GPE
in ADP - O
the DT - B-ORG
Management NNP - I-ORG
of IN - I-ORG
Postoperative NNP - I-ORG
Pain NNP - I-ORG

-DOCSTART- -X- - O

Body NOUN - O
weights NOUN - O
in ADP - O
the DET - O
Ibuprofen NNP - B-MEDICINE
group NOUN - O
were VERB - O
lower ADJ - O
than ADP - O
those DET - O
of ADP - O
the DET - O
Control NNP - B-ORG
group NOUN - O
, PUNCT - O
and CCONJ - O
ALT NNP - B-ORG
and CCONJ - O
AST NNP - B-ORG
levels NOUN - O
were VERB - O
significantly ADV - O
higher ADJ - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
according VERB - O
to ADP - O
the DET - O
pharmacokinetic ADJ - O
data NOUN - O
, PUNCT - O
the DET - O
Control NNP - B-ORG
, PUNCT - O
Aspirin NNP - B-ORG
and CCONJ - O
Ibuprofen NNP - B-MEDICINE
groups NOUN - O
could VERB - O
be VERB - O
discriminated VERB - O
accurately ADV - O
. PUNCT - O

Ultrastructural ADJ - O
examination NOUN - O
showed VERB - O
that ADP - O
the DET - O
number NOUN - O
of ADP - O
mitochondria NOUN - O
was VERB - O
increased VERB - O
in ADP - O
both CCONJ - O
the DET - O
Ibuprofen NNP - B-MEDICINE
and CCONJ - O
Aspirin NNP - B-NORP
groups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
administration NOUN - O
during ADP - O
the DET - O
tumor NOUN - O
promotional ADJ - O
microenvironment NOUN - O
of ADP - O
the DET - O
involuting VERB - O
mammary ADJ - O
gland NOUN - O
reduces VERB - O
overall ADJ - O
tumor NOUN - O
growth NOUN - O
and CCONJ - O
enhances VERB - O
anti ADJ - O
- ADJ - O
tumor ADJ - O
immune ADJ - O
characteristics NOUN - O
while ADP - O
avoiding VERB - O
adverse ADJ - O
autoimmune ADJ - O
reactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
in ADP - O
human ADJ - O
and CCONJ - O
veterinary ADJ - O
medicine NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
chronic ADJ - O
pain NOUN - O
as ADV - O
well ADV - O
as ADP - O
rheumatic ADJ - O
and CCONJ - O
musculoskeletal ADJ - O
disorders NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
the DET - O
analgesic ADJ - O
and CCONJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
properties NOUN - O
of ADP - O
Ibuprofen NNP - B-MEDICINE
have VERB - O
contributed VERB - O
to ADP - O
frequent ADJ - O
drug NOUN - O
abuse NOUN - O
in ADP - O
equestrian ADJ - O
sports NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen NNP - B-MEDICINE
caused VERB - O
glomerular NOUN - O
atrophy NOUN - O
but CCONJ - O
administration NOUN - O
of ADP - O
green ADJ - O
tea NOUN - O
along ADP - O
with ADP - O
ibuprofen NN - B-MEDICINE
protected VERB - O
against ADP - O
significant ADJ - O
reduction NOUN - O
in ADP - O
glomerular ADJ - O
diameter NOUN - O
, PUNCT - O
thus ADV - O
preventing VERB - O
atrophy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Analgesic ADJ - O
Efficacy NOUN - O
of ADP - O
an DET - O
Acetaminophen PROPN - O
/ SYM - O
Ibuprofen NNP - B-MEDICINE
Fixed VERB - O
- PUNCT - O
dose NOUN - O
Combination PROPN - O
in ADP - O
Moderate PROPN - O
to ADP - O
Severe PROPN - O
Postoperative ADJ - O
Dental PROPN - O
Pain NOUN - O
: PUNCT - O
A DET - O
Randomized VERB - O
, PUNCT - O
Double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
Parallel PROPN - O
- PUNCT - O
group PROPN - O
, PUNCT - O
Placebo NNP - B-GPE
- PUNCT - O
controlled VERB - O
Trial NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pivmecillinam NN - B-PERSON
deutlich NOUN - O
heilsamer NOUN - O
als ADP - O
Ibuprofen NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Control NOUN - O
group NOUN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
25 CD - B-CARDINAL
) PUNCT - O
was VERB - O
administered VERB - O
100 CD - B-CARDINAL
  SPACE - O
mL INTJ - O
iv X - O
saline VERB - O
solution NOUN - O
30 CD - B-CARDINAL
  SPACE - O
min NOUN - O
preoperatively ADV - O
, PUNCT - O
while ADP - O
Ibuprofen NNP - B-MEDICINE
group NOUN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
26 CD - B-CARDINAL
) PUNCT - O
received VERB - O
800 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
ibuprofen NN - B-MEDICINE
iv PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ibuprofen JJ - B-MEDICINE
solubility NOUN - O
( PUNCT - O
0.09 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
mL PROPN - O
for ADP - O
un NOUN - O
- ADJ - O
milled ADJ - O
) PUNCT - O
was VERB - O
increased VERB - O
by ADP - O
factors NOUN - O
of ADP - O
4 CD - B-CARDINAL
- SYM - O
5 NUM - O
and CCONJ - O
10 CD - B-CARDINAL
- SYM - I-CARDINAL
20 CD - I-CARDINAL
for ADP - O
HPMC NOUN - O
and CCONJ - O
soluplus NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Cardiovascular JJ - B-ORG
Risk NNP - I-ORG
of IN - I-ORG
Celecoxib NNP - I-ORG
no ADV - O
Worse ADJ - O
Than ADP - O
That DET - O
of ADP - O
Ibuprofen NNP - B-MEDICINE
or CCONJ - O
Naproxen NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
Resource PROPN - O
- PUNCT - O
Limited PROPN - O
Setting NOUN - O
, PUNCT - O
Is VERB - O
Oral ADJ - O
Ibuprofen NNP - B-MEDICINE
Effective ADJ - O
for ADP - O
Closure NOUN - O
of ADP - O
a DET - O
Patent PROPN - O
Ductus PROPN - O
Arteriosus PROPN - O
in ADP - O
a DET - O
Preterm PROPN - O
Neonate PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Method PROPN - O
for ADP - O
Treating VERB - O
Skin NOUN - O
Irritations NOUN - O
Such ADJ - O
as ADP - O
Diaper NNP - B-PERSON
Rash NNP - I-PERSON
and CCONJ - O
the DET - O
Like ADJ - O

-DOCSTART- -X- - O

Baby NNP - B-ORG
Care NNP - I-ORG
Skin NN - I-ORG
Protectant NNP - I-ORG
Compositions NNP - I-ORG
for ADP - O
Diaper NNP - B-MEDICINE
Rash NNP - I-MEDICINE

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Topical PROPN - O
Discomforts PROPN - O
Including PROPN - O
Acne PROPN - O
, PUNCT - O
Sunburn NNP - B-ORG
, PUNCT - O
Diaper NNP - B-PERSON
Rash NNP - I-PERSON
, PUNCT - O
Wound NNP - B-ORG
, PUNCT - O
Wrinkles NNPS - B-PERSON
and CCONJ - O
Dandruff PROPN - O
/ SYM - O
Hair PROPN - O
Loss PROPN - O
by ADP - O
Natural NNP - B-NORP
Lignans NNPS - I-NORP
via ADP - O
Fatty NNP - B-ORG
Acid NNP - I-ORG
Desaturase NN - I-ORG
Inhibition NN - I-ORG

-DOCSTART- -X- - O

TRPA1 PROPN - O
Antagonists PROPN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Prehospital NNP - B-ORG
Analgesic NNP - I-ORG
Administration NNP - I-ORG
by ADP - O
Parents NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Cochrane PROPN - O
Review PROPN - O
Summary NOUN - O
: PUNCT - O
Epidural ADJ - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
Versus PROPN - O
Systemic PROPN - O
Opioid PROPN - O
- PUNCT - O
Based VERB - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
for ADP - O
Abdominal PROPN - O
Aortic PROPN - O
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Phenomenological ADJ - O
Study PROPN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
by ADP - O
Cannabis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacological ADJ - O
and CCONJ - O
Non JJ - B-ORG
- JJ - I-ORG
Pharmacological JJ - I-ORG
Methods NNPS - I-ORG
of IN - I-ORG
Labour PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
- PUNCT - O
Establishment PROPN - O
of ADP - O
Effectiveness PROPN - O
and CCONJ - O
Comparison PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Cancer PROPN - O
Pain NNP - B-MEDICINE
Relief NN - I-MEDICINE

-DOCSTART- -X- - O

Two CD - B-CARDINAL
- PUNCT - O
Point PROPN - O
Discrimination PROPN - O
Predicts PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Lower PROPN - O
Limb PROPN - O
Nerve PROPN - O
Decompression PROPN - O
for ADP - O
Painful ADJ - O
Diabetic PROPN - O
Peripheral PROPN - O
Neuropathy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Non ADJ - O
- ADJ - O
pharmacologic ADJ - O
Measures NOUN - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
Preterm PROPN - O
Neonates PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect PROPN - O
of ADP - O
Normal PROPN - O
Physiologic PROPN - O
Childbirth PROPN - O
on ADP - O
Labor PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
: PUNCT - O
an DET - O
Interventional PROPN - O
Study PROPN - O
in ADP - O
Mother PROPN - O
- PUNCT - O
Friendly PROPN - O
Hospitals PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoroscopically RB - B-ORG
Guided VBN - I-ORG
Facet NNP - I-ORG
Injections NNPS - I-ORG
: PUNCT - O
Comparison NNP - B-ORG
of IN - I-ORG
Intra NNP - I-ORG
- HYPH - I-ORG
Articular NNP - I-ORG
and CCONJ - O
Periarticular NNP - B-ORG
Steroid NNP - I-ORG
and CC - I-ORG
Anesthetic NNP - I-ORG
Injection NNP - I-ORG
on IN - I-ORG
Immediate NNP - I-ORG
and CC - I-ORG
Short NNP - I-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Pain NNP - I-ORG
Relief NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
on ADP - O
Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Trocar PROPN - O
- PUNCT - O
Site NOUN - O
Infiltration NOUN - O
with ADP - O
Lidocaine PROPN - O
for ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
after ADP - O
Diagnostic NNP - B-PERSON
Laparoscopy NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
Sucrose PROPN - O
Used VERB - O
Routinely ADV - O
for ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Neonatal PROPN - O
Clinical PROPN - O
Risk PROPN - O
in ADP - O
Preterm PROPN - O
Infants PROPN - O
: PUNCT - O
A DET - O
Nonrandomized PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sustainability NOUN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Empathy PROPN - O
in ADP - O
the DET - O
Patient PROPN - O
- PUNCT - O
Doctor PROPN - O
Relationship PROPN - O
on ADP - O
Chronic PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
and CCONJ - O
Quality PROPN - O
of ADP - O
Life PROPN - O
: PUNCT - O
A DET - O
Prospective ADJ - O
Study PROPN - O
in ADP - O
Spanish NNP - B-NORP
Pain PROPN - O
Clinics PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
the DET - O
First PROPN - O
Synthetic PROPN - O
Allosteric PROPN - O
Modulator PROPN - O
of ADP - O
the DET - O
CB2 PROPN - O
Receptors PROPN - O
and CCONJ - O
Evidence PROPN - O
of ADP - O
Its ADJ - O
Efficacy NOUN - O
for ADP - O
Neuropathic PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ring NNP - B-PERSON
Block NNP - I-PERSON
of ADP - O
the DET - O
Penis PROPN - O
: PUNCT - O
A PROPN - O
Proven VERB - O
Addition NOUN - O
to ADP - O
Multimodal PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
for ADP - O
Newborn PROPN - O
Circumcision PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Following VERB - O
Esophagectomy NOUN - O
for ADP - O
Acute PROPN - O
Postoperative PROPN - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
the DT - B-ORG
Postanesthesia NNP - I-ORG
Care NNP - I-ORG
Unit NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Opiate JJ - B-ORG
- HYPH - I-ORG
Free JJ - I-ORG
Pain NNP - I-ORG
Therapy NNP - I-ORG
Using VBG - I-ORG
Carbamazepine PROPN - O
- PUNCT - O
Loaded VERB - O
Microparticles PROPN - O
Provides VERB - O
Up ADP - O
to ADP - O
2 NUM - O
Weeks NOUN - O
of ADP - O
Pain NNP - B-MEDICINE
Relief NNP - I-MEDICINE
in ADP - O
a DET - O
Neuropathic NNP - B-PRODUCT
Pain NNP - I-PRODUCT
Model NNP - I-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Prevalence NNP - B-ORG
, PUNCT - O
Molecular NNP - B-ORG
Characterization NNP - I-ORG
and CC - I-ORG
Antibiotic NNP - I-ORG
Susceptibility NNP - I-ORG
of ADP - O
Escherichia NNP - B-ORG
Coli NNP - I-ORG
Isolated VBN - I-ORG
from ADP - O
Duck NNP - B-ORG
Meat NNP - I-ORG
and CC - I-ORG
Giblets NNPS - I-ORG

-DOCSTART- -X- - O

Molecular JJ - B-ORG
Characterization NN - I-ORG
of IN - I-ORG
Fluoroquinolone NNP - I-ORG
Resistance NNP - I-ORG
Mechanisms NNPS - I-ORG
of IN - I-ORG
Campylobacter NNP - I-ORG
Isolates NNPS - I-ORG
from ADP - O
Duck NNP - B-GPE
Meats NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Daily NNP - B-WORK_OF_ART
Minutes NNPS - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Unprotected NNP - I-WORK_OF_ART
Sun NNP - I-WORK_OF_ART
Exposure NNP - I-WORK_OF_ART
( PUNCT - O
MUSE NNP - B-MEDICINE

-DOCSTART- -X- - O

The DET - O
isolation NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
human ADJ - O
MUSE NNS - B-MEDICINE
stem NOUN - O
cells NOUN - O
and CCONJ - O
more ADJ - O
adult NOUN - O
organ NOUN - O
- PUNCT - O
specific ADJ - O
adult NOUN - O
stem NOUN - O
cells NOUN - O
have VERB - O
indicated VERB - O
that ADP - O
these DET - O
MUSE NNS - B-MEDICINE
cells NOUN - O
have VERB - O
many ADJ - O
shared VERB - O
characteristics NOUN - O
of ADP - O
the DET - O
" PUNCT - O
iPS ADJ - O
" PUNCT - O
cells NOUN - O
, PUNCT - O
yet CCONJ - O
they PRON - O
do VERB - O
not ADV - O
form VERB - O
teratomas NOUN - O
but CCONJ - O
can VERB - O
give VERB - O
rise NOUN - O
to ADP - O
the DET - O
trigeminal ADJ - O
cell NOUN - O
layers NOUN - O
. PUNCT - O

While ADP - O
the DET - O
MUSE NNP - B-MEDICINE
cells NOUN - O
are VERB - O
a DET - O
subset NOUN - O
of ADP - O
human ADJ - O
fibroblastic ADJ - O
cells NOUN - O
, PUNCT - O
they PRON - O
have VERB - O
not ADV - O
been VERB - O
characterized VERB - O
, PUNCT - O
yet ADV - O
, PUNCT - O
for ADP - O
the DET - O
mitochondrial ADJ - O
metabolic NOUN - O
genes NOUN - O
, PUNCT - O
either CCONJ - O
in ADP - O
the DET - O
stem NOUN - O
cell NOUN - O
state NOUN - O
or CCONJ - O
during ADP - O
their ADJ - O
differentiation NOUN - O
processes NOUN - O
. PUNCT - O

A DET - O
description NOUN - O
of ADP - O
other ADJ - O
human ADJ - O
adult NOUN - O
stem NOUN - O
cells NOUN - O
will VERB - O
be VERB - O
made VERB - O
to PART - O
set VERB - O
future ADJ - O
studies NOUN - O
of ADP - O
how ADV - O
the DET - O
MUSE NNPS - B-MEDICINE
stem NOUN - O
cells NOUN - O
compare VERB - O
to ADP - O
all DET - O
other ADJ - O
stem NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Microscopy NOUN - O
with ADP - O
ultraviolet NOUN - O
surface NOUN - O
excitation NOUN - O
( PUNCT - O
MUSE NNP - B-MEDICINE
) PUNCT - O
is VERB - O
investigated VERB - O
as ADP - O
a DET - O
means NOUN - O
to PART - O
enhance VERB - O
curricula NOUN - O
and CCONJ - O
education NOUN - O
in ADP - O
the DET - O
life NOUN - O
sciences NOUN - O
based VERB - O
on ADP - O
simplicity NOUN - O
of ADP - O
use NOUN - O
, PUNCT - O
the DET - O
incorporation NOUN - O
of ADP - O
inexpensive ADJ - O
hardware NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
simplest ADJ - O
methods NOUN - O
of ADP - O
tissue NOUN - O
preparation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
collected VERB - O
ECGs NOUN - O
from ADP - O
a DET - O
local ADJ - O
ECG NNP - B-ORG
repository NOUN - O
( PUNCT - O
MUSE NNP - B-MEDICINE
™ NNP - I-ORG
) PUNCT - O
from ADP - O
1994 CD - B-DATE
to ADP - O
2017 CD - B-DATE
and CCONJ - O
extracted VERB - O
the DET - O
ECG NNP - B-ORG
waveforms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
report VERB - O
using VERB - O
a DET - O
novel NOUN - O
imaging NOUN - O
modality NOUN - O
, PUNCT - O
Microscopy NNP - B-PERSON
using VERB - O
Ultraviolet NNP - B-ORG
Surface NNP - I-ORG
Excitation NNP - I-ORG
( PUNCT - O
MUSE NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
to PART - O
provide VERB - O
real ADJ - O
- PUNCT - O
time NOUN - O
, PUNCT - O
high- NOUN - O
resolution NOUN - O
, PUNCT - O
in ADP - O
vivo NOUN - O
characterization NOUN - O
of ADP - O
super ADJ - O
cial ADJ - O
skin NOUN - O
and CCONJ - O
moisturizing VERB - O
properties NOUN - O
of ADP - O
topical ADJ - O
moisturizer NOUN - O
, PUNCT - O
and CCONJ - O
to PART - O
highlight VERB - O
key ADJ - O
bene NOUN - O
ts NOUN - O
of ADP - O
using VERB - O
MUSE NNP - B-MEDICINE
to PART - O
visualize VERB - O
the DET - O
super ADJ - O
cial ADJ - O
skin NOUN - O
and CCONJ - O
serve VERB - O
as ADP - O
an DET - O
excellent ADJ - O
complementary ADJ - O
tool NOUN - O
to ADP - O
current ADJ - O
quantitative ADJ - O
methods NOUN - O
. PUNCT - O

The DET - O
methodology NOUN - O
of ADP - O
MUSE NNP - B-MEDICINE
is VERB - O
based VERB - O
upon ADP - O
two CD - B-CARDINAL
main ADJ - O
principles NOUN - O
inherent ADJ - O
to ADP - O
ultraviolet NOUN - O
( PUNCT - O
UV PROPN - O
) PUNCT - O
light NOUN - O
and CCONJ - O
uorescent ADJ - O
staining VERB - O
agents NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
author NOUN - O
's PART - O
( PUNCT - O
JJ NNP - B-ORG
) PUNCT - O
index NOUN - O
ngertip NOUN - O
was VERB - O
imaged VERB - O
using VERB - O
the DET - O
MUSE NNP - B-MEDICINE
instrument NOUN - O
without ADP - O
and CCONJ - O
with ADP - O
moisturizer NOUN - O
. PUNCT - O

Real ADJ - O
- PUNCT - O
time NOUN - O
, PUNCT - O
high ADJ - O
- PUNCT - O
resolution NOUN - O
, PUNCT - O
in ADP - O
vivo NOUN - O
characterization NOUN - O
of ADP - O
super ADJ - O
cial ADJ - O
skin NOUN - O
and CCONJ - O
moisturizing VERB - O
properties NOUN - O
of ADP - O
moisturizer NOUN - O
using VERB - O
MUSE NNP - B-MEDICINE
is VERB - O
feasible ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
spray NOUN - O
is VERB - O
an DET - O
effective ADJ - O
analgesic NOUN - O
of ADP - O
mucous ADJ - O
membranes NOUN - O
. PUNCT - O

Lidocaine NN - B-MEDICINE
spray NOUN - O
is VERB - O
also ADV - O
used VERB - O
during ADP - O
intravenous ADJ - O
( PUNCT - O
i.v VERB - O
. PUNCT - O
) PUNCT - O
cannulation NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
spray NOUN - O
applied VERB - O
to ADP - O
the DET - O
cervix NOUN - O
is VERB - O
not ADV - O
effective ADJ - O
for ADP - O
reducing VERB - O
pain NOUN - O
associated VERB - O
with ADP - O
pipelle ADJ - O
endometrial ADJ - O
aspiration NOUN - O
biopsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NNP - B-MEDICINE
, PUNCT - O
a DET - O
Non JJ - B-ORG
- ADJ - O
selective ADJ - O
Inhibitor PROPN - O
of ADP - O
Voltage PROPN - O
- PUNCT - O
Gated VERB - O
Sodium PROPN - O
Channels PROPN - O
, PUNCT - O
Blocks NNP - B-ORG
Chemically RB - I-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Cough NNP - I-ORG
in IN - I-ORG
Awake NNP - B-ORG
Naïve NNP - I-ORG
Guinea PROPN - O
Pigs PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Lidocaine NNP - B-MEDICINE
with ADP - O
Epinephrine PROPN - O
on ADP - O
Bupivacaine PROPN - O
- PUNCT - O
Induced PROPN - O
Cardiotoxicity PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Lidocaine NNP - B-MEDICINE
and CC - I-ORG
Ropivacaine NNP - I-ORG
on IN - I-ORG
Gastric NNP - I-ORG
Cancer NNP - I-ORG
Cells NNS - I-ORG
Through ADP - O
Down NOUN - O
- PUNCT - O
regulation NOUN - O
of ADP - O
ERK1/2 NNP - B-ORG
Phosphorylation NNP - I-ORG
In IN - I-ORG
Vitro NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Dysfunctional ADJ - O
phagocytosis NOUN - O
capacity NOUN - O
, PUNCT - O
granulocyte NOUN - O
recruitment NOUN - O
and CCONJ - O
inflammatory ADJ - O
factor NOUN - O
secretion NOUN - O
of ADP - O
Kupffer NNP - B-ORG
cells NOUN - O
in ADP - O
diabetes NOUN - O
mellitus NOUN - O
reversed VERB - O
by ADP - O
Lidocaine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Articaine NNP - B-LAW
Versus NNP - I-LAW
Lidocaine NNP - I-MEDICINE
Administered NNP - I-LAW
as IN - I-LAW
Supplementary PROPN - O
Intraligamentary PROPN - O
Injection PROPN - O
after ADP - O
a DET - O
Failed PROPN - O
Inferior PROPN - O
Alveolar PROPN - O
Nerve PROPN - O
Block PROPN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Double ADJ - O
- PUNCT - O
blind ADJ - O
Study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Intravenous PROPN - O
Lidocaine NNP - B-MEDICINE
for ADP - O
Acute PROPN - O
Pain PROPN - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
as ADP - O
a DET - O
Rare PROPN - O
and CCONJ - O
Hidden NNP - B-PERSON
Allergen NNP - I-PERSON
in ADP - O
the DT - B-LOC
Perioperative NNP - I-LOC
Setting NN - I-LOC
: : - I-LOC
A DT - I-LOC
Case NNP - I-LOC
Report NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Coadministration PROPN - O
of ADP - O
Lidocaine NNP - B-MEDICINE
on ADP - O
the DET - O
Pain PROPN - O
and CCONJ - O
Pharmacokinetics PROPN - O
of ADP - O
Intramuscular PROPN - O
Amikacin PROPN - O
in ADP - O
Children PROPN - O
With ADP - O
Multidrug PROPN - O
- PUNCT - O
Resistant ADJ - O
Tuberculosis NOUN - O
: PUNCT - O
A DET - O
Randomized NNP - B-ORG
Crossover NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Convulsion NOUN - O
and CCONJ - O
Atrial NNP - B-ORG
Fibrillation NNP - I-ORG
after ADP - O
Transforaminal PROPN - O
Cervical PROPN - O
Epidural PROPN - O
Lidocaine NNP - B-MEDICINE
Injection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Does VERB - O
Tracheal NNP - B-ORG
Lidocaine NNP - I-MEDICINE
Instillation NNP - I-ORG
Reduce NNP - I-ORG
Intracranial NNP - I-ORG
Pressure NNP - I-ORG
Changes NNS - I-ORG
After ADP - O
Tracheal NNP - B-ORG
Suctioning NNP - I-ORG
in ADP - O
Severe NNP - B-GPE
Head NNP - I-GPE
Trauma NNP - I-GPE
? PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
acts NOUN - O
as ADP - O
a DET - O
local ADJ - O
anesthetic ADJ - O
by ADP - O
blocking VERB - O
transmembrane NOUN - O
sodium NOUN - O
channel NOUN - O
permeability NOUN - O
, PUNCT - O
but CCONJ - O
also ADV - O
induces VERB - O
the DET - O
synthesis NOUN - O
of ADP - O
heat NOUN - O
shock NOUN - O
proteins NOUN - O
and CCONJ - O
sensitizes VERB - O
cells NOUN - O
to PART - O
hyperthermia VERB - O
. PUNCT - O

Lidocaine NN - B-MEDICINE
- PUNCT - O
enhanced VERB - O
hyperthermia NOUN - O
may VERB - O
provide VERB - O
a DET - O
non ADJ - O
- ADJ - O
invasive ADJ - O
, PUNCT - O
alterative ADJ - O
treatment NOUN - O
option NOUN - O
for ADP - O
highly ADV - O
proliferating VERB - O
, PUNCT - O
superficial ADJ - O
skin NOUN - O
, PUNCT - O
and CCONJ - O
mucosal NOUN - O
lesions NOUN - O
such ADJ - O
as ADP - O
cancer NOUN - O
or CCONJ - O
warts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NNP - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
significantly ADV - O
higher ADJ - O
rates NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
compared VERB - O
with ADP - O
placebo NOUN - O
and CCONJ - O
may VERB - O
result VERB - O
in ADP - O
lower ADJ - O
rates NOUN - O
of ADP - O
patient ADJ - O
satisfaction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quadratus NNP - B-ORG
Lumborum NNP - I-ORG
Block NNP - I-ORG
Versus NNP - I-ORG
Perioperative NNP - I-ORG
Intravenous JJ - I-ORG
Lidocaine NNP - I-MEDICINE
for IN - I-ORG
Postoperative NNP - I-ORG
Pain NNP - I-ORG
Control NNP - I-ORG
in ADP - O
Patients PROPN - O

-DOCSTART- -X- - O

Liposomal ADJ - O
Bupivacaine PROPN - O
Versus PROPN - O
Bupivacaine PROPN - O
Hydrochloride PROPN - O
with ADP - O
Lidocaine NNP - B-MEDICINE
during ADP - O
Midurethral NNP - B-ORG
Sling NNP - I-ORG
Placement NN - I-ORG
: PUNCT - O
A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal NNP - B-PERSON
Ketoprofen NNP - I-PERSON
Patch NNP - I-PERSON
in ADP - O
Comparison NNP - B-GPE
to ADP - O
Eutectic PROPN - O
Mixture PROPN - O
of ADP - O
Local PROPN - O
Anesthetic PROPN - O
Cream PROPN - O
and CCONJ - O
Subcutaneous PROPN - O
Lidocaine NNP - B-MEDICINE
to ADP - O
Control NNP - B-ORG
Pain NNP - I-ORG

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
inhibits VERB - O
proliferation NOUN - O
and CCONJ - O
induces VERB - O
apoptosis NOUN - O
in ADP - O
colorectal ADJ - O
cancer NOUN - O
cells NOUN - O
by ADP - O
upregulating VERB - O
mir-520a-3p NOUN - O
and CCONJ - O
targeting VERB - O
EGFR PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
might VERB - O
reduce VERB - O
the DET - O
pain NOUN - O
and CCONJ - O
inflammatory ADJ - O
response NOUN - O
. PUNCT - O

Lidocaine NN - B-MEDICINE
inhalation NOUN - O
1.5 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
was VERB - O
proportional ADJ - O
to ADP - O
intravenous ADJ - O
dexamethasone NOUN - O
10 CD - B-CARDINAL
mg NOUN - O
in ADP - O
reducing VERB - O
the DET - O
incidence NOUN - O
and CCONJ - O
severity NOUN - O
of ADP - O
POST NNP - B-ORG
after ADP - O
LMA PROPN - O
insertion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lidocaine NN - B-MEDICINE
effects NOUN - O
in ADP - O
the DET - O
spinal ADJ - O
cord NOUN - O
have VERB - O
been VERB - O
extensively ADV - O
investigated VERB - O
over ADP - O
the DT - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Conclusions NOUN - O
Lidocaine NNP - B-MEDICINE
and CCONJ - O
dexmedetomidine NOUN - O
reduced VERB - O
intraoperative ADJ - O
propofol NOUN - O
consumption NOUN - O
, PUNCT - O
while ADP - O
lidocaine NN - B-MEDICINE
reduced VERB - O
postoperative NOUN - O
piritramide NOUN - O
consumption NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Anesthetic ADJ - O
Efficiency PROPN - O
of ADP - O
Articaine PROPN - O
Versus PROPN - O
Lidocaine NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
Extraction NNP - I-ORG
of IN - I-ORG
Lower NNP - I-ORG
Third NNP - I-ORG
Molars NNPS - I-ORG
: PUNCT - O
A NNP - B-ORG
Meta NNP - I-ORG
- HYPH - I-ORG
Analysis NNP - I-ORG
and CC - I-ORG
Systematic NNP - I-ORG
Review NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
Efficacy PROPN - O
Outcomes PROPN - O
of ADP - O
Lidocaine NNP - B-MEDICINE
Spray PROPN - O
, PUNCT - O
Topical NNP - B-ORG
Lidocaine NNP - I-MEDICINE
Injection NNP - I-ORG
, PUNCT - O
and CCONJ - O
Lidocaine NNP - B-MEDICINE
General PROPN - O
Anesthesia NNP - B-PERSON
in ADP - O
Nasal PROPN - O
Bone PROPN - O
Fractures PROPN - O
Surgeries PROPN - O
: PUNCT - O
A DET - O
Randomized VERB - O
, PUNCT - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Clotrimazole NN - B-MEDICINE
troches NOUN - O
are VERB - O
commonly ADV - O
used VERB - O
as ADP - O
a DET - O
non ADJ - O
- ADJ - O
systemic ADJ - O
antifungal NOUN - O
to PART - O
prevent VERB - O
oral ADJ - O
candidiasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clotrimazole NN - B-MEDICINE
multiple ADJ - O
W PROPN - O
/ SYM - O
O PROPN - O
/ SYM - O
W NOUN - O
emulsion NOUN - O
as ADP - O
anticandidal ADJ - O
agent NOUN - O
: PUNCT - O
Characterization NOUN - O
and CCONJ - O
evaluation NOUN - O
on ADP - O
skin NOUN - O
and CCONJ - O
mucosae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clotrimazole NN - B-MEDICINE
is VERB - O
highly ADV - O
effective ADJ - O
in ADP - O
vitro NOUN - O
against ADP - O
feline ADJ - O
Sporothrix NNP - B-ORG
brasiliensis NOUN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Corrigendum VERB - O
: PUNCT - O
Clotrimazole NN - B-MEDICINE
is VERB - O
highly ADV - O
effective ADJ - O
in ADP - O
vitro NOUN - O
against ADP - O
feline ADJ - O
Sporothrix NNP - B-ORG
brasiliensis NOUN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Clotrimazole NN - B-MEDICINE
and CCONJ - O
ciclopirox NOUN - O
olamine NOUN - O
respectively ADV - O
in ADP - O
combination NOUN - O
with ADP - O
methylprednisolone ADJ - O
aceponate NOUN - O
as ADP - O
extemporaneous ADJ - O
formulations]. ADJ - O

-DOCSTART- -X- - O

Assessment NOUN - O
of ADP - O
Effectiveness PROPN - O
of ADP - O
Fluconazole PROPN - O
and CCONJ - O
Clotrimazole NNP - B-MEDICINE
in ADP - O
Treating VERB - O
Oral ADJ - O
Candidiasis PROPN - O
Patients PROPN - O
: PUNCT - O
A DET - O
Comparative PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Clotrimazole NN - B-MEDICINE
gel NOUN - O
preparations NOUN - O
were VERB - O
prepared VERB - O
and CCONJ - O
optimized VERB - O
by ADP - O
using VERB - O
three CD - B-CARDINAL
factor NOUN - O
, PUNCT - O
five CD - B-CARDINAL
level NOUN - O
central ADJ - O
composite ADJ - O
design NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Neural NNP - I-ORG
Basis NNP - I-ORG
of IN - I-ORG
Motion NNP - I-ORG
Sickness NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Neurophysiology PROPN - O
and CCONJ - O
Treatment PROPN - O
of ADP - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Motion NNP - I-ORG
Sickness NNP - I-ORG
Susceptibility NNP - I-ORG
Questionnaire NNP - I-ORG
- HYPH - I-ORG
Short NNP - I-ORG
was VERB - O
administered VERB - O
to PART - O
classify VERB - O
the DET - O
participants NOUN - O
into ADP - O
groups NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
motion NN - B-MEDICINE
sickness NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Elevated JJ - B-ORG
Motion NN - I-ORG
Sickness NNP - I-ORG
Susceptibility NNP - I-ORG
( PUNCT - O
MSS NNP - B-ORG
) PUNCT - O
in ADP - O
Meniere?s NNP - B-PERSON
disease NOUN - O
( PUNCT - O
MD NNP - B-ORG
) PUNCT - O
is VERB - O
likely ADJ - O
to PART - O
be VERB - O
a DET - O
consequence NOUN - O
of ADP - O
the DET - O
onset NOUN - O
of ADP - O
MD NNP - B-GPE
and CCONJ - O
not ADV - O
migraine VERB - O
per X - O
se X - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
test VERB - O
this DET - O
, PUNCT - O
29 CD - B-CARDINAL
participants NOUN - O
, PUNCT - O
with ADP - O
VIMS PROPN - O
susceptibility NOUN - O
assessed VERB - O
by ADP - O
Motion NNP - B-ORG
Sickness NNP - I-ORG
Susceptibility NNP - I-ORG
Questionnaire NNP - I-ORG
, PUNCT - O
were VERB - O
recruited VERB - O
to PART - O
undergo VERB - O
three CD - B-CARDINAL
series NOUN - O
of ADP - O
sustained ADJ - O
attention NOUN - O
to ADP - O
response NOUN - O
tests NOUN - O
( PUNCT - O
SARTs NOUN - O
) PUNCT - O
while ADP - O
watching VERB - O
dot NOUN - O
pattern NOUN - O
stimuli NOUN - O
known VERB - O
to PART - O
provoke VERB - O
roll NOUN - O
- PUNCT - O
vection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Historical ADJ - O
View NOUN - O
of ADP - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
- PUNCT - O
A PROPN - O
Plague PROPN - O
at ADP - O
Sea PROPN - O
and CCONJ - O
on ADP - O
Land PROPN - O
, PUNCT - O
Also ADV - O
with ADP - O
Military NNP - B-ORG
Impact NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Psychometric PROPN - O
Properties PROPN - O
of ADP - O
the DET - O
Greek PROPN - O
Version PROPN - O
of ADP - O
the DT - B-ORG
Gianaros NNP - I-ORG
Motion NNP - I-ORG
Sickness NNP - I-ORG
Assessment NNP - I-ORG
Questionnaire NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Relationship NOUN - O
between ADP - O
Spectral PROPN - O
Characteristics PROPN - O
of ADP - O
Spontaneous PROPN - O
Postural PROPN - O
Sway NNP - B-PERSON
and CCONJ - O
Motion NNP - B-ORG
Sickness NNP - I-ORG
Susceptibility NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Sex NOUN - O
Differences NOUN - O
in ADP - O
the DT - B-ORG
Incidence NNP - I-ORG
of IN - I-ORG
Motion NNP - I-ORG
Sickness NNP - I-ORG
Induced VBN - I-ORG
by IN - I-ORG
Linear NNP - B-ORG
Visual NNP - I-ORG
Oscillation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
of ADP - O
Eco PROPN - O
- ADJ - O
friendly ADJ - O
Medicated PROPN - O
Chewing PROPN - O
Gum PROPN - O
to ADP - O
Prevent PROPN - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Prediction NOUN - O
of ADP - O
Symptom PROPN - O
Change PROPN - O
in ADP - O
Placebo NNP - B-GPE
Versus NNP - I-GPE
No NNP - I-GPE
- HYPH - I-GPE
Treatment NNP - I-GPE
Group NNP - I-GPE
in ADP - O
Experimentally PROPN - O
Induced PROPN - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Differential PROPN - O
Gene PROPN - O
Expression PROPN - O
Profile PROPN - O
in ADP - O
the DET - O
Rat PROPN - O
Caudal PROPN - O
Vestibular PROPN - O
Nucleus PROPN - O
is VERB - O
Associated VBN - B-ORG
with IN - I-ORG
Individual NNP - I-ORG
Differences NNPS - I-ORG
in ADP - O
Motion NNP - B-ORG
Sickness NNP - I-ORG
Susceptibility NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
Open PROPN - O
- PUNCT - O
Label PROPN - O
Study PROPN - O
on ADP - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Sickness NOUN - O
scores NOUN - O
were VERB - O
collected VERB - O
using VERB - O
the DT - B-ORG
Fast NNP - I-ORG
Motion NN - I-ORG
Sickness NNP - I-ORG
Scale NNP - I-ORG
and CCONJ - O
the DET - O
Simulator PROPN - O
Sickness NNP - B-PERSON
Questionnaire NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Microgravity NOUN - O
Simulated VERB - O
by ADP - O
the DET - O
6 CD - B-CARDINAL
° NNP - B-ORG
Head NNP - I-ORG
- HYPH - I-ORG
Down NNP - I-ORG
Tilt NNP - I-ORG
Bed NNP - I-ORG
Rest NNP - I-ORG
Test NNP - I-ORG
Increases VBZ - I-ORG
Intestinal NNP - I-ORG
Motility NNP - I-ORG
but CC - I-ORG
Fails VERB - O
to PART - O
Induce VERB - O
Gastrointestinal ADJ - O
Symptoms PROPN - O
of ADP - O
Space PROPN - O
Motion NNP - B-MEDICINE
Sickness NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil NOUN - O
( PUNCT - O
CFA PROPN - O
) PUNCT - O
, PUNCT - O
an DET - O
ester ADJ - O
prodrug NOUN - O
of ADP - O
cefuroxime NOUN - O
exists VERB - O
as ADP - O
a DET - O
pair NOUN - O
of ADP - O
diastereoemers NOUN - O
, PUNCT - O
namely ADV - O
isomer VERB - O
A PROPN - O
and CCONJ - O
isomer PROPN - O
B. NNP - B-PERSON
To PART - O
enable VERB - O
phase NOUN - O
diagram NOUN - O
construction NOUN - O
, PUNCT - O
crystallization NOUN - O
of ADP - O
the DET - O
diastereomers NOUN - O
of ADP - O
CFA PROPN - O
from ADP - O
the DET - O
commercially ADV - O
available ADJ - O
amorphous ADJ - O
drug NOUN - O
substance NOUN - O
was VERB - O
carried VERB - O
out PART - O
. PUNCT - O

-DOCSTART- -X- - O

80.7261 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
drug NOUN - O
was VERB - O
diffused VERB - O
from ADP - O
nanoemulsion NOUN - O
, PUNCT - O
as ADP - O
compared VERB - O
with ADP - O
51.0048 CD - B-PERCENT
% NN - I-PERCENT
diffused VERB - O
from ADP - O
the DET - O
plain ADJ - O
Cefuroxime NNP - B-ORG
axetil NOUN - O
suspension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil ADP - O
odor NOUN - O
- PUNCT - O
masking VERB - O
pellet NOUN - O
and CCONJ - O
preparation NOUN - O
method NOUN - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil NOUN - O
is VERB - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
cephalosporin NOUN - O
used VERB - O
to PART - O
treat VERB - O
or CCONJ - O
prevent VERB - O
infections NOUN - O
that ADJ - O
are VERB - O
proven VERB - O
or CCONJ - O
strongly ADV - O
suspected VERB - O
to PART - O
be VERB - O
caused VERB - O
by ADP - O
bacteria NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil ADP - O
tablet NOUN - O
preparation NOUN - O
suitable ADJ - O
for ADP - O
direct ADJ - O
powder NOUN - O
compression NOUN - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil NOUN - O
is VERB - O
the DET - O
esterified VERB - O
form NOUN - O
of ADP - O
cefuroxime NOUN - O
, PUNCT - O
injectable ADJ - O
second JJ - B-ORDINAL
generation NOUN - O
cephalosporine NOUN - O
antibiotic ADJ - O
that ADJ - O
can VERB - O
be VERB - O
given VERB - O
orally ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil ADP - O
( PUNCT - O
CA NNP - B-ORG
) PUNCT - O
solid ADJ - O
dispersions NOUN - O
with ADP - O
HPMC PROPN - O
2910/PVP CD - B-PRODUCT
K-30 NNP - I-PRODUCT
were VERB - O
prepared VERB - O
using VERB - O
solution NOUN - O
enhanced VERB - O
dispersion NOUN - O
by ADP - O
supercritical ADJ - O
fluids NOUN - O
( PUNCT - O
SEDS PROPN - O
) PUNCT - O
in ADP - O
an DET - O
effort NOUN - O
to PART - O
increase VERB - O
the DET - O
dissolution NOUN - O
rate NOUN - O
of ADP - O
poorly ADV - O
water NOUN - O
- PUNCT - O
soluble ADJ - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil NOUN - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
have VERB - O
efficacy NOUN - O
comparable ADJ - O
to PART - O
doxycycline VERB - O
in ADP - O
adults NOUN - O
with ADP - O
early ADJ - O
Lyme NNP - B-PERSON
disease NOUN - O
( PUNCT - O
LD NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil NOUN - O
has VERB - O
been VERB - O
associated VERB - O
with ADP - O
few ADJ - O
reported VERB - O
adverse ADJ - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cefuroxime NN - B-ORG
axetil ADP - O
versus ADP - O
clarithromycin NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
acute ADJ - O
maxillary ADJ - O
sinusitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Population NNP - I-ORG
Pharmacokinetics NNPS - I-ORG
of IN - I-ORG
High NNP - I-ORG
- HYPH - I-ORG
Dose NN - I-ORG
Methotrexate NN - I-MEDICINE
in ADP - O
Infants PROPN - O
with ADP - O
Acute PROPN - O
Lymphoblastic PROPN - O
Leukemia PROPN - O
Highlight PROPN - O
the DET - O
Need PROPN - O
for ADP - O
Bedside PROPN - O
Individualized PROPN - O
Dose PROPN - O
Adjustment NOUN - O
: PUNCT - O
A DET - O
Report NOUN - O
from ADP - O
the DT - B-ORG
Children NNPS - I-ORG
's POS - I-ORG
Oncology NNP - I-ORG
Group NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
remains VERB - O
an DET - O
important ADJ - O
option NOUN - O
for ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
symptom NOUN - O
control NOUN - O
with ADP - O
a DET - O
favorable ADJ - O
side NOUN - O
effect NOUN - O
profile NOUN - O
and CCONJ - O
low ADJ - O
cost NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Etanercept PROPN - O
and CCONJ - O
Methotrexate NNP - B-MEDICINE
as ADP - O
Monotherapy PROPN - O
or CCONJ - O
in ADP - O
Combination NNP - B-ORG
for IN - I-ORG
Psoriatic NNP - I-ORG
Arthritis NNP - I-ORG
: PUNCT - O
Primary ADJ - O
Results NOUN - O
From ADP - O
a DET - O
Randomized PROPN - O
, PUNCT - O
Controlled PROPN - O
Phase PROPN - O
3 NUM - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
is VERB - O
a DET - O
disease NOUN - O
- PUNCT - O
modifying VERB - O
anti ADJ - O
- ADJ - O
rheumatic ADJ - O
drug NOUN - O
( PUNCT - O
DMARD PROPN - O
) PUNCT - O
commonly ADV - O
prescribed VERB - O
to PART - O
alleviate VERB - O
symptoms NOUN - O
, PUNCT - O
attenuate ADJ - O
disease NOUN - O
activity NOUN - O
, PUNCT - O
and CCONJ - O
prevent VERB - O
progression NOUN - O
of ADP - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cetuximab PROPN - O
and CCONJ - O
Methotrexate NNP - B-MEDICINE
in ADP - O
Recurrent PROPN - O
or CCONJ - O
Metastatic PROPN - O
Head PROPN - O
and CCONJ - O
Neck PROPN - O
Squamous PROPN - O
Cell PROPN - O

-DOCSTART- -X- - O

Higher JJR - B-PERSON
Mucosal NNP - I-PERSON
Healing NNP - I-PERSON
with ADP - O
Tumor NNP - B-ORG
Necrosis NNP - I-ORG
Factor NNP - I-ORG
Inhibitors NNPS - I-ORG
in IN - I-ORG
Combination PROPN - O
with ADP - O
Thiopurines PROPN - O
Compared VERB - O
to ADP - O
Methotrexate NNP - B-MEDICINE
in ADP - O
Crohn NNP - B-ORG
's POS - I-ORG
Disease NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Clinical PROPN - O
Implications PROPN - O
Of ADP - O
Methotrexate NN - B-MEDICINE
Pharmacogenetics NOUN - O

-DOCSTART- -X- - O

Methotrexate NNP - B-MEDICINE
( PUNCT - O
MTX NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
effectively ADV - O
used VERB - O
drug NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
cancer NOUN - O
and CCONJ - O
inflammatory ADJ - O
diseases NOUN - O
but CCONJ - O
, PUNCT - O
its ADJ - O
use NOUN - O
is VERB - O
related VERB - O
with ADP - O
hepatotoxicity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
was VERB - O
loaded VERB - O
in ADP - O
these DET - O
polymeric ADJ - O
nanoparticles NOUN - O
achieving VERB - O
a DET - O
drug NOUN - O
loading NOUN - O
of ADP - O
ca VERB - O
. PUNCT - O

Methotrexate NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
fucoidan NOUN - O
/ SYM - O
chitosan ADJ - O
nanoparticles NOUN - O
exhibited VERB - O
size NOUN - O
within ADP - O
the DET - O
300 CD - B-CARDINAL
- SYM - O
500 NUM - O
  SPACE - O
nm NOUN - O
range NOUN - O
, PUNCT - O
positive ADJ - O
zeta NOUN - O
potential NOUN - O
for ADP - O
1F/1C NNP - B-CARDINAL
nanoparticles NOUN - O
( PUNCT - O
+60 PROPN - O
  SPACE - O
mV PROPN - O
) PUNCT - O
and CCONJ - O
negative ADJ - O
surface NOUN - O
charge NOUN - O
for ADP - O
the DET - O
3F/1C NNP - B-PRODUCT
and CCONJ - O
5F/1C CD - B-CARDINAL
nanoparticles NOUN - O
( PUNCT - O
-40 NOUN - O
and CCONJ - O
-45 PUNCT - O
  SPACE - O
mV PROPN - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

Methotrexate NN - B-MEDICINE
loaded VERB - O
in ADP - O
3F/1C NNP - B-GPE
and CCONJ - O
5F/1C CD - B-CARDINAL
nanoparticles NOUN - O
did VERB - O
not ADV - O
affect VERB - O
cells NOUN - O
viability NOUN - O
and CCONJ - O
presented VERB - O
lower ADJ - O
cytotoxicity NOUN - O
than ADP - O
free ADJ - O
methotrexate NN - B-MEDICINE
, PUNCT - O
in ADP - O
fibroblasts NOUN - O
and CCONJ - O
human ADJ - O
keratinocytes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NNP - B-MEDICINE
( PUNCT - O
MTX NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
widely ADV - O
used VERB - O
drug NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
many ADJ - O
malignant ADJ - O
, PUNCT - O
rheumatic ADJ - O
, PUNCT - O
and CCONJ - O
autoimmune ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Long PROPN - O
- PUNCT - O
Term PROPN - O
Efficacy PROPN - O
of ADP - O
Tumor PROPN - O
Necrosis PROPN - O
Factor PROPN - O
Inhibitors PROPN - O
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Methotrexate NNP - B-MEDICINE
- PUNCT - O
Naïve PROPN - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
was VERB - O
ceased VERB - O
four CD - B-DATE
months NNS - I-DATE
later RB - I-DATE
, PUNCT - O
and CCONJ - O
remission NOUN - O
was VERB - O
sustained VERB - O
without ADP - O
any DET - O
medications NOUN - O
for ADP - O
24 CD - B-DATE
months NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Gold NOUN - O
nanoparticles NOUN - O
functionalized VERB - O
with ADP - O
3-mercapto-1-propansulfonate NOUN - O
( PUNCT - O
AuNPs-3MPS NNP - B-GPE
) PUNCT - O
have VERB - O
been VERB - O
prepared VERB - O
and CCONJ - O
loaded VERB - O
with ADP - O
Methotrexate NNP - B-MEDICINE
( -LRB- - I-ORG
MTX NNP - I-ORG
) PUNCT - O
, PUNCT - O
an DET - O
immunosuppressive ADJ - O
agent NOUN - O
used VERB - O
in ADP - O
the DET - O
systemic ADJ - O
treatment NOUN - O
of ADP - O
moderate ADJ - O
- PUNCT - O
severe ADJ - O
inflammatory ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
functionalized ADJ - O
silica NOUN - O
- PUNCT - O
gelatin NOUN - O
hybrid NOUN - O
aerogel NOUN - O
( PUNCT - O
SGM PROPN - O
) PUNCT - O
was VERB - O
synthesized VERB - O
by ADP - O
the DET - O
sol NOUN - O
- PUNCT - O
gel NOUN - O
method NOUN - O
and CCONJ - O
co NOUN - O
- NOUN - O
gelation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
induces VERB - O
astrocyte ADV - O
apoptosis NOUN - O
by ADP - O
disrupting VERB - O
folate ADJ - O
metabolism NOUN - O
in ADP - O
the DET - O
mouse NOUN - O
juvenile ADV - O
central ADJ - O
nervous ADJ - O
system NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NNP - B-MEDICINE
( PUNCT - O
MTX NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
major ADJ - O
systemic ADJ - O
treatment NOUN - O
for ADP - O
moderate ADJ - O
to PART - O
severe ADJ - O
plaque NOUN - O
psoriasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
- PUNCT - O
Loaded VERB - O
Solid PROPN - O
Lipid PROPN - O
Nanoparticles PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
treatment NOUN - O
has VERB - O
been VERB - O
linked VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
melanoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Management NOUN - O
of ADP - O
Keratoacanthoma NNP - B-ORG
: PUNCT - O
157 CD - B-CARDINAL
Tumors NOUN - O
Managed VERB - O
With ADP - O
Surgery PROPN - O
or CCONJ - O
Intralesional PROPN - O
Methotrexate NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NNP - B-MEDICINE
( PUNCT - O
MTX PROPN - O
) PUNCT - O
is VERB - O
the DET - O
cornerstone NOUN - O
of ADP - O
chemotherapy NOUN - O
for ADP - O
ALL DET - O
, PUNCT - O
and CCONJ - O
works VERB - O
by ADP - O
targeting VERB - O
enzymes NOUN - O
involved VERB - O
in ADP - O
the DET - O
folate ADJ - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
- PUNCT - O
related VERB - O
lymphoproliferative ADJ - O
disorder NOUN - O
of ADP - O
the DET - O
lumbar NOUN - O
spine NOUN - O
origin NOUN - O
presenting VERB - O
with ADP - O
severe ADJ - O
low ADJ - O
- PUNCT - O
back NOUN - O
pain NOUN - O
: PUNCT - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Experience NOUN - O
With ADP - O
Alternating VERB - O
Methotrexate NNP - B-MEDICINE
and CCONJ - O
Dactinomycin PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Methotrexate NN - B-MEDICINE
have VERB - O
exhibited VERB - O
a DET - O
satisfactory ADJ - O
therapeutic ADJ - O
effect NOUN - O
in ADP - O
clinical ADJ - O
practice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

miRNA-24 NNP - B-PERSON
Gene NNP - I-PERSON
Sequence NNP - I-PERSON
, PUNCT - O
DHFR PROPN - O
-829C PROPN - O
- PUNCT - O
T NOUN - O
Genotypes PROPN - O
, PUNCT - O
and CCONJ - O
Methotrexate NNP - B-MEDICINE
Response NNP - I-ORG
in ADP - O
Mexican NNP - B-NORP
Patients PROPN - O
with ADP - O
Rheumatoid PROPN - O
Arthritis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Midazolam NNS - B-PERSON
hydrochloride NOUN - O
1-mg NUM - O
/ SYM - O
mL NOUN - O
solutions NOUN - O
diluted VERB - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose NOUN - O
injection NOUN - O
remained VERB - O
stable ADJ - O
over ADP - O
27 CD - B-DATE
days NNS - I-DATE
in ADP - O
both CCONJ - O
polyolefin NOUN - O
and CCONJ - O
PVC NNP - B-ORG
i.v PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
NOVEL ADJ - O
POLYMORPH NOUN - O
OF ADP - O
SERTRALINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
AND CCONJ - O
COMPOSITION NOUN - O
CONTAINING PROPN - O
THEREOF NOUN - O
, PUNCT - O
NOVEL PROPN - O
METHODS NOUN - O
FOR ADP - O
PREPARATION NOUN - O
OF ADP - O
SERTRALINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
POLYMORPHS PROPN - O
AND CCONJ - O
AMORPHOUS NOUN - O

-DOCSTART- -X- - O

SERTRALINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
FORM PROPN - O
II PROPN - O
AND CCONJ - O
METHODS NOUN - O
FOR ADP - O
THE DET - O
PREPARATION NOUN - O
THEREOF NOUN - O

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
SERTRALINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
POLYMORPHIC VERB - O
FORM PROPN - O
II PROPN - O

-DOCSTART- -X- - O

SERTRALINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
FORM NOUN - O
V NOUN - O

-DOCSTART- -X- - O

Herein NNP - B-PERSON
, PUNCT - O
we PRON - O
designed VERB - O
a DET - O
PCL NNP - B-ORG
- PUNCT - O
based VERB - O
nanofiber NOUN - O
loaded VERB - O
with ADP - O
ciprofloxacin JJ - B-MEDICINE
hydrochloride NOUN - O
( PUNCT - O
CHL NNP - B-ORG
) PUNCT - O
and CCONJ - O
quercetin NOUN - O
. PUNCT - O

The DET - O
current ADJ - O
study NOUN - O
validates VERB - O
the DET - O
application NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
HCl NOUN - O
and CCONJ - O
quercetin ADV - O
functionalized ADJ - O
nanofiber NOUN - O
as ADP - O
a DET - O
potential ADJ - O
wound NOUN - O
dressing VERB - O
material NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
conducted VERB - O
a DET - O
48-h NUM - O
one NUM - O
- PUNCT - O
compartment NOUN - O
in ADP - O
vitro X - O
infection NOUN - O
model NOUN - O
to PART - O
explore VERB - O
the DET - O
impact NOUN - O
of ADP - O
apotransferrin NOUN - O
on ADP - O
the DET - O
bactericidal ADJ - O
activity NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
. PUNCT - O

The DET - O
challenge NOUN - O
panel NOUN - O
included VERB - O
four CD - B-CARDINAL
Klebsiella NNP - B-ORG
pneumoniae ADJ - O
isolates NOUN - O
, PUNCT - O
with ADP - O
ciprofloxacin JJ - B-MEDICINE
minimum ADJ - O
inhibitory NOUN - O
concentrations NOUN - O
( PUNCT - O
MIC NNP - B-ORG
) PUNCT - O
values NOUN - O
ranging VERB - O
from ADP - O
0.08 CD - B-CARDINAL
to ADP - O
32 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
L. PROPN - O

Each PROPN - O
challenge NOUN - O
isolate NOUN - O
was VERB - O
subjected VERB - O
to ADP - O
an DET - O
ineffective ADJ - O
ciprofloxacin NN - B-MEDICINE
monotherapy NOUN - O
exposure NOUN - O
( PUNCT - O
free ADJ - O
- PUNCT - O
drug NOUN - O
area NOUN - O
under ADP - O
the DET - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
curve NOUN - O
over ADP - O
24 CD - B-CARDINAL
h NOUN - O
divided VERB - O
by ADP - O
the DET - O
MIC NNP - B-ORG
[ PUNCT - O
AUC NNP - B-ORG
: PUNCT - O
MIC NNP - B-ORG
ratio NOUN - O
] PUNCT - O
ranging VERB - O
from ADP - O
0.19 CD - B-CARDINAL
to ADP - O
96.6 CD - B-CARDINAL
) PUNCT - O
with ADP - O
and CCONJ - O
without ADP - O
apotransferrin NOUN - O
. PUNCT - O

We PRON - O
identified VERB - O
relationships NOUN - O
between ADP - O
exposure NOUN - O
and CCONJ - O
change NOUN - O
in ADP - O
bacterial ADJ - O
density NOUN - O
for ADP - O
ciprofloxacin NN - B-MEDICINE
alone ADV - O
( PUNCT - O
R2 PROPN - O
= SYM - O
0.64 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
in ADP - O
combination NOUN - O
with ADP - O
apotransferrin PROPN - O
( PUNCT - O
R2 PROPN - O
= SYM - O
0.84 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Addition NOUN - O
of ADP - O
apotransferrin ADJ - O
to PART - O
ciprofloxacin VB - B-MEDICINE
enabled VERB - O
a DET - O
remarkable ADJ - O
reduction NOUN - O
in ADP - O
bacterial ADJ - O
density NOUN - O
, PUNCT - O
across ADP - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
exposures NOUN - O
. PUNCT - O

For ADP - O
instance NOUN - O
, PUNCT - O
at ADP - O
a DET - O
ciprofloxacin JJ - B-MEDICINE
AUC NNP - B-ORG
: PUNCT - O
MIC NNP - B-ORG
ratio NOUN - O
of ADP - O
20 CD - B-CARDINAL
, PUNCT - O
ciprofloxacin NN - B-MEDICINE
monotherapy NOUN - O
resulted VERB - O
in ADP - O
nearly ADV - O
2 CD - B-CARDINAL
log10 NOUN - O
CFU NNP - B-ORG
increase NOUN - O
in ADP - O
bacterial ADJ - O
density NOUN - O
, PUNCT - O
while ADP - O
the DET - O
combination NOUN - O
of ADP - O
apotransferrin NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
resulted VERB - O
in ADP - O
2 CD - B-CARDINAL
log10 ADJ - O
CFU NNP - B-ORG
reduction NOUN - O
in ADP - O
bacterial ADJ - O
density NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
addition NOUN - O
of ADP - O
apotransferrin NOUN - O
significantly ADV - O
reduced VERB - O
the DET - O
emergence NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
subpopulations NOUN - O
compared VERB - O
to ADP - O
monotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Defining VERB - O
optimal ADJ - O
dosing NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
septic ADJ - O
shock NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Reviews NOUN - O
assessing VERB - O
the DET - O
genetic ADJ - O
basis NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
in ADP - O
Escherichia NNP - B-GPE
coli ADJ - O
have VERB - O
mostly ADV - O
been VERB - O
qualitative ADJ - O
. PUNCT - O

We PRON - O
performed VERB - O
a DET - O
systematic ADJ - O
review NOUN - O
to PART - O
assess VERB - O
the DET - O
relative ADJ - O
contribution NOUN - O
of ADP - O
known VERB - O
genomic ADJ - O
resistance NOUN - O
determinants NOUN - O
to ADP - O
the DET - O
MIC NNP - B-ORG
of ADP - O
ciprofloxacin NNP - B-MEDICINE
in ADP - O
E. PROPN - O
coli NOUN - O
. PUNCT - O

Methods NOUN - O
: PUNCT - O
PubMed NNP - B-PERSON
and CCONJ - O
Web PROPN - O
of ADP - O
Science PROPN - O
were VERB - O
searched VERB - O
for ADP - O
English JJ - B-LANGUAGE
language NOUN - O
studies NOUN - O
that ADJ - O
assessed VERB - O
ciprofloxacin VBD - B-MEDICINE
MIC NNP - B-ORG
and CCONJ - O
presence NOUN - O
or CCONJ - O
introduction NOUN - O
of ADP - O
genetic ADJ - O
determinants NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
in ADP - O
E. PROPN - O
coli NOUN - O
. PUNCT - O

: PUNCT - O
We PRON - O
included VERB - O
66 CD - B-CARDINAL
studies NOUN - O
, PUNCT - O
describing VERB - O
604 CD - B-CARDINAL
E. PROPN - O
coli ADJ - O
isolates NOUN - O
that ADJ - O
carried VERB - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
genetic ADJ - O
ciprofloxacin NN - B-MEDICINE
resistance NOUN - O
determinant ADJ - O
. PUNCT - O

Mutations NOUN - O
in ADP - O
gyrA PROPN - O
and CCONJ - O
parC NNP - B-ORG
, PUNCT - O
genes NOUN - O
encoding VERB - O
targets NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
contribute VERB - O
to ADP - O
the DET - O
largest ADJ - O
fold ADJ - O
changes NOUN - O
in ADP - O
ciprofloxacin VBG - B-MEDICINE
resistance NOUN - O
in ADP - O
E. PROPN - O
coli PROPN - O
compared VERB - O
with ADP - O
the DET - O
WT NNP - B-ORG
. PUNCT - O

Efflux NNP - B-ORG
and CCONJ - O
physical ADJ - O
blocking NOUN - O
or CCONJ - O
enzymatic ADJ - O
modifications NOUN - O
confer VERB - O
smaller ADJ - O
increases NOUN - O
in ADP - O
ciprofloxacin VBG - B-MEDICINE
MIC NNP - B-ORG
than ADP - O
mutations NOUN - O
in ADP - O
gyrA PROPN - O
and CCONJ - O
parC. PROPN - O

However ADV - O
, PUNCT - O
the DET - O
presence NOUN - O
of ADP - O
these DET - O
other ADJ - O
resistance NOUN - O
mechanisms NOUN - O
in ADP - O
addition NOUN - O
to PART - O
target VERB - O
alteration NOUN - O
mutations NOUN - O
further ADV - O
increases NOUN - O
ciprofloxacin VBG - B-MEDICINE
MIC NNP - B-ORG
, PUNCT - O
thus ADV - O
resulting VERB - O
in ADP - O
ciprofloxacin VBG - B-MEDICINE
MIC NNP - B-ORG
increases VERB - O
ranging VERB - O
from ADP - O
250- CD - B-GPE
to ADP - O
4000-fold CD - B-CARDINAL
. PUNCT - O

This DET - O
quantitative ADJ - O
review NOUN - O
of ADP - O
genomic ADJ - O
determinants NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
in ADP - O
E. PROPN - O
coli PROPN - O
demonstrates VERB - O
the DET - O
complexity NOUN - O
of ADP - O
resistance NOUN - O
phenotype NOUN - O
prediction NOUN - O
from ADP - O
genomic ADJ - O
data NOUN - O
and CCONJ - O
serves NOUN - O
as ADP - O
a DET - O
reference NOUN - O
point NOUN - O
for ADP - O
studies NOUN - O
aiming VERB - O
to PART - O
predict VERB - O
ciprofloxacin IN - B-MEDICINE
MIC NNP - B-ORG
from ADP - O
E. NNP - B-ORG
coli ADJ - O
genomes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antibiotic ADJ - O
ciprofloxacin NN - B-MEDICINE
is VERB - O
used VERB - O
extensively ADV - O
to PART - O
treat VERB - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
infections NOUN - O
caused VERB - O
by ADP - O
the DET - O
opportunistic ADJ - O
pathogen NOUN - O
Pseudomonas NNP - B-GPE
aeruginosa NOUN - O
. PUNCT - O

Due ADP - O
to ADP - O
its ADJ - O
extensive ADJ - O
use NOUN - O
, PUNCT - O
the DET - O
proportion NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
P. NNP - B-ORG
aeruginosa NOUN - O
isolates NOUN - O
is VERB - O
rapidly ADV - O
increasing VERB - O
. PUNCT - O

Ciprofloxacin NNP - B-MEDICINE
resistance NOUN - O
can VERB - O
arise VERB - O
through ADP - O
the DET - O
acquisition NOUN - O
of ADP - O
mutations NOUN - O
in ADP - O
genes NOUN - O
encoding VERB - O
the DET - O
target NOUN - O
proteins NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
and CCONJ - O
regulators NOUN - O
of ADP - O
efflux NOUN - O
pumps NOUN - O
, PUNCT - O
which ADJ - O
leads VERB - O
to ADP - O
overexpression NOUN - O
of ADP - O
these DET - O
pumps NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
understanding NOUN - O
of ADP - O
the DET - O
basis NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
is VERB - O
not ADV - O
yet ADV - O
complete ADJ - O
. PUNCT - O

Recent ADJ - O
advances NOUN - O
using VERB - O
high ADJ - O
- PUNCT - O
throughput NOUN - O
screens NOUN - O
and CCONJ - O
experimental ADJ - O
evolution NOUN - O
combined VERB - O
with ADP - O
whole ADJ - O
- PUNCT - O
genome ADJ - O
sequencing NOUN - O
and CCONJ - O
protein NOUN - O
analysis NOUN - O
are VERB - O
enhancing VERB - O
our ADJ - O
understanding NOUN - O
of ADP - O
the DET - O
genetic ADJ - O
and CCONJ - O
biochemical ADJ - O
mechanisms NOUN - O
involved VERB - O
in ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
. PUNCT - O

Better ADJ - O
insights NOUN - O
into ADP - O
the DET - O
mechanisms NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
may VERB - O
facilitate VERB - O
the DET - O
development NOUN - O
of ADP - O
new ADJ - O
or CCONJ - O
improved VERB - O
therapeutic ADJ - O
regimes NOUN - O
effective ADJ - O
against ADP - O
P. NNP - B-ORG
aeruginosa NOUN - O
. PUNCT - O

In ADP - O
this DET - O
review NOUN - O
we PRON - O
discuss VERB - O
the DET - O
current ADJ - O
understanding NOUN - O
of ADP - O
the DET - O
mechanisms NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
and CCONJ - O
summarize VERB - O
the DET - O
genetic ADJ - O
basis NOUN - O
of ADP - O
ciprofloxacin JJ - B-MEDICINE
resistance NOUN - O
in ADP - O
P. NNP - B-CARDINAL
aeruginosa NOUN - O
, PUNCT - O
in ADP - O
the DET - O
context NOUN - O
of ADP - O
current ADJ - O
and CCONJ - O
future ADJ - O
use NOUN - O
of ADP - O
this DET - O
antibiotic NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
streamlined ADJ - O
and CCONJ - O
high ADJ - O
yielding VERB - O
continuous ADJ - O
synthesis NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
has VERB - O
been VERB - O
developed VERB - O
, PUNCT - O
which ADJ - O
employs VERB - O
a DET - O
chemoselective ADJ - O
C NOUN - O
- PUNCT - O
acylation NOUN - O
step NOUN - O
that ADJ - O
precludes VERB - O
the DET - O
need NOUN - O
for ADP - O
intermediate ADJ - O
isolations NOUN - O
, PUNCT - O
extractions NOUN - O
, PUNCT - O
or CCONJ - O
purifications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Typhimurium NNP - B-PERSON
and CCONJ - O
Salmonella NNP - B-PRODUCT
enterica NOUN - O
serovar NOUN - O
Enteritidis NNP - B-PERSON
strains NOUN - O
associated VERB - O
with ADP - O
enteric ADJ - O
infections NOUN - O
in ADP - O
Shanghainese JJ - B-NORP
children NOUN - O
, PUNCT - O
and CCONJ - O
understand VERB - O
the DET - O
molecular ADJ - O
mechanism NOUN - O
of ADP - O
resistance NOUN - O
to ADP - O
third JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
cephalosporins NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
. PUNCT - O

Besides ADV - O
, PUNCT - O
35.1 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
Salmonella NNP - B-ORG
Typhimurium NNP - I-ORG
isolates NOUN - O
displayed VERB - O
resistance NOUN - O
to ADP - O
ciprofloxacin NNP - B-MEDICINE
; PUNCT - O
64.9 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
Salmonella NNP - B-ORG
Typhimurium NNP - I-ORG
isolates NOUN - O
and CCONJ - O
97.0 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
Salmonella NNP - B-ORG
Enteritidis NNP - I-ORG
isolates NOUN - O
displayed VERB - O
reduced VERB - O
susceptibility NOUN - O
to ADP - O
ciprofloxacin VB - B-MEDICINE
. PUNCT - O

The DET - O
high ADJ - O
prevalence NOUN - O
of ADP - O
resistance NOUN - O
to ADP - O
third JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
cephalosporins NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
mediated VERB - O
by ADP - O
multiple ADJ - O
molecular ADJ - O
mechanisms NOUN - O
needs VERB - O
continuous ADJ - O
monitoring NOUN - O
and CCONJ - O
intervention NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
controlled VERB - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
CIPRO PROPN - O
) PUNCT - O
nanostrustructured VERB - O
lipid ADJ - O
carriers NOUN - O
of ADP - O
Precirol NNP - B-ORG
® . - I-ORG

AC5 NNP - B-ORG
had VERB - O
superior ADJ - O
growth NOUN - O
inhibition NOUN - O
of ADP - O
B. NNP - B-ORG
subtilis NOUN - O
at ADP - O
lower ADJ - O
concentration NOUN - O
( PUNCT - O
1.2µg NOUN - O
/ SYM - O
ml NOUN - O
) PUNCT - O
than ADP - O
BC5 NNP - B-PERSON
and CCONJ - O
CIPRO PROPN - O
controls NOUN - O
; PUNCT - O
hence ADV - O
could VERB - O
serve VERB - O
as ADP - O
possible ADJ - O
sustained ADJ - O
delivery NOUN - O
system NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Thirteen CD - B-ORG
healthy ADJ - O
adult NOUN - O
men NOUN - O
received VERB - O
either CCONJ - O
no DET - O
treatment NOUN - O
or CCONJ - O
oral ADJ - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
antibiotics NOUN - O
( PUNCT - O
ciprofloxacin NNP - B-MEDICINE
, PUNCT - O
vancomycin NOUN - O
and CCONJ - O
metronidazole NOUN - O
) PUNCT - O
for ADP - O
7 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
. PUNCT - O

These DET - O
findings NOUN - O
suggest VERB - O
that ADP - O
combined VERB - O
treatment NOUN - O
with ADP - O
vancomycin PROPN - O
, PUNCT - O
ciprofloxacin NN - B-MEDICINE
and CCONJ - O
metronidazole NOUN - O
has VERB - O
a DET - O
profound ADJ - O
and CCONJ - O
long ADV - O
- PUNCT - O
lasting VERB - O
effect NOUN - O
on ADP - O
microbiota NOUN - O
composition NOUN - O
, PUNCT - O
the DET - O
consequences NOUN - O
of ADP - O
which ADJ - O
remain VERB - O
largely ADV - O
unknown ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
- PUNCT - O
vitro X - O
evaluation NOUN - O
of ADP - O
a DET - O
ciprofloxacin- NOUN - O
and CCONJ - O
ivacaftor NOUN - O
- PUNCT - O
coated VERB - O
sinus NOUN - O
stent NOUN - O
against ADP - O
Pseudomonas NNP - B-GPE
aeruginosa NOUN - O
biofilms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Because ADP - O
ciprofloxacin NNP - B-MEDICINE
has VERB - O
good ADJ - O
microbiologic ADJ - O
activity NOUN - O
against ADP - O
E. NNP - B-ORG
  _SP - I-ORG
coli ADJ - O
and CCONJ - O
good ADJ - O
penetration NOUN - O
in ADP - O
cerebrospinal ADJ - O
fluid NOUN - O
and CCONJ - O
brain NOUN - O
, PUNCT - O
some DET - O
authors NOUN - O
have VERB - O
suggested VERB - O
adding VERB - O
ciprofloxacin NN - B-MEDICINE
to ADP - O
a DET - O
3GC CD - B-ORG
regimen NN - I-ORG
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
combining VERB - O
3GCs CD - B-CARDINAL
with ADP - O
ciprofloxacin NN - B-MEDICINE
versus ADP - O
3GCs CD - B-CARDINAL
alone ADV - O
in ADP - O
a DET - O
cohort NOUN - O
of ADP - O
infants NOUN - O
with ADP - O
E. NNP - B-GPE
  _SP - I-GPE
coli ADJ - O
meningitis NOUN - O
. PUNCT - O

The DET - O
main ADJ - O
outcome NOUN - O
was VERB - O
the DET - O
proportion NOUN - O
of ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
neurologic ADJ - O
complications NOUN - O
with ADP - O
versus NOUN - O
without ADP - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

Among ADP - O
the DET - O
367 CD - B-CARDINAL
infants NOUN - O
enrolled VERB - O
, PUNCT - O
201 CD - B-CARDINAL
( PUNCT - O
54.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
367 CD - B-CARDINAL
had VERB - O
ciprofloxacin VBN - B-MEDICINE
and CCONJ - O
3GC CD - B-CARDINAL
cotreatment NOUN - O
and CCONJ - O
166 CD - B-CARDINAL
( PUNCT - O
45.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
367 CD - B-CARDINAL
only ADV - O
a DET - O
3GC CD - B-PRODUCT
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
86 CD - B-CARDINAL
( PUNCT - O
23.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
367 CD - B-CARDINAL
infants NOUN - O
presented VERB - O
neurologic ADJ - O
complications NOUN - O
( PUNCT - O
seizures NOUN - O
, PUNCT - O
strokes NOUN - O
, PUNCT - O
empyema NOUN - O
, PUNCT - O
abscesses NOUN - O
, PUNCT - O
hydrocephalus NOUN - O
, PUNCT - O
arachnoiditis NOUN - O
) PUNCT - O
; PUNCT - O
57 CD - B-CARDINAL
received VERB - O
ciprofloxacin JJ - B-MEDICINE
cotreatment NOUN - O
. PUNCT - O

Complications NOUN - O
were VERB - O
associated VERB - O
with ADP - O
ciprofloxacin JJ - B-MEDICINE
cotreatment ADJ - O
on ADP - O
multivariable ADJ - O
analysis NOUN - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
( PUNCT - O
OR CCONJ - O
) PUNCT - O
  SPACE - O
= SYM - O
  SPACE - O
1.9 NUM - O
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
, PUNCT - O
1.1 CD - B-CARDINAL
- SYM - I-CARDINAL
3.4 CD - I-CARDINAL
) PUNCT - O
and CCONJ - O
PS NNP - B-ORG
analysis NN - I-ORG
( PUNCT - O

Mortality NOUN - O
rate NOUN - O
did VERB - O
not ADV - O
differ VERB - O
with ADP - O
and CCONJ - O
without ADP - O
ciprofloxacin NNP - B-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
explore VERB - O
whether ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
incorporated VERB - O
waterborne NOUN - O
polyurethane NOUN - O
( PUNCT - O
WBPU NNP - B-ORG
) PUNCT - O
polymers NOUN - O
have VERB - O
the DET - O
capacity NOUN - O
to PART - O
inhibit VERB - O
bacterial ADJ - O
biofilm ADJ - O
formation NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

WBPU NNP - B-ORG
polymers NOUN - O
were VERB - O
incorporated VERB - O
with ADP - O
ciprofloxacin NNP - B-MEDICINE
and CCONJ - O
were VERB - O
cultured VERB - O
with ADP - O
Escherichia NNP - B-PERSON
coli NOUN - O
( PUNCT - O
E. PROPN - O
coli ADJ - O
) PUNCT - O
or CCONJ - O
Staphylococcus NNP - B-PERSON
aureus PROPN - O
( PUNCT - O
S. PROPN - O
aureus PROPN - O
) PUNCT - O
in ADP - O
media NOUN - O
for ADP - O
2 CD - B-CARDINAL
, PUNCT - O
4 CD - B-DATE
or CC - I-DATE
7 CD - I-DATE
days NNS - I-DATE
. PUNCT - O

The DET - O
WBPU NNP - B-ORG
films VERB - O
with ADP - O
ciprofloxacin NNP - B-MEDICINE
effectively ADV - O
inhibited VERB - O
bacterial ADJ - O
biofilm ADJ - O
formation NOUN - O
in ADP - O
the DET - O
culture NOUN - O
medium NOUN - O
and CCONJ - O
in ADP - O
artificial ADJ - O
urine NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
in ADP - O
artificial ADJ - O
urine NOUN - O
, PUNCT - O
the DET - O
films NOUN - O
with ADP - O
ciprofloxacin NNP - B-MEDICINE
reduced VERB - O
catheter NOUN - O
obstruction NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
incorporated VERB - O
WBPU NNP - B-ORG
polymers NOUN - O
are VERB - O
able ADJ - O
to PART - O
effectively ADV - O
inhibit VERB - O
bacterial ADJ - O
biofilm ADJ - O
formation NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
a DET - O
comprehensive ADJ - O
evaluation NOUN - O
of ADP - O
MP2 NNP - B-ORG
and CCONJ - O
DFT PROPN - O
with ADP - O
different ADJ - O
functionals NOUN - O
and CCONJ - O
basis NOUN - O
sets NOUN - O
was VERB - O
carried VERB - O
out PART - O
to PART - O
select VERB - O
the DET - O
most ADV - O
suitable ADJ - O
level NOUN - O
of ADP - O
theory NOUN - O
for ADP - O
the DET - O
study NOUN - O
of ADP - O
the DET - O
NMR NNP - B-ORG
properties NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

Our ADJ - O
computational ADJ - O
results NOUN - O
indicated VERB - O
that ADP - O
in ADP - O
contrast NOUN - O
to ADP - O
the DET - O
solid ADJ - O
state NOUN - O
, PUNCT - O
the DET - O
molecule NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
does VERB - O
not ADV - O
exist VERB - O
as ADP - O
a DET - O
zwitterion NOUN - O
in ADP - O
gaseous ADJ - O
state NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem PROPN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
in ADP - O
complicated ADJ - O
gastric ADJ - O
surgery NOUN - O
for ADP - O
cancer NOUN - O
patients NOUN - O
: PUNCT - O
A DET - O
simple ADJ - O
SPE NNP - B-ORG
- HYPH - I-ORG
UHPLC NNP - I-ORG
- PUNCT - O
PDA PROPN - O
method NOUN - O
for ADP - O
their ADJ - O
determination NOUN - O
in ADP - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Using VERB - O
a DET - O
high ADJ - O
- PUNCT - O
throughput NOUN - O
screening VERB - O
assay NOUN - O
of ADP - O
survival NOUN - O
after ADP - O
treatment NOUN - O
with ADP - O
high ADJ - O
concentrations NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
we PRON - O
have VERB - O
determined VERB - O
the DET - O
prevalence NOUN - O
of ADP - O
high ADJ - O
- PUNCT - O
persister NOUN - O
variants NOUN - O
( PUNCT - O
Hip INTJ - O
) PUNCT - O
in ADP - O
a DET - O
large ADJ - O
patient NOUN - O
cohort NOUN - O
. PUNCT - O

Instead ADV - O
, PUNCT - O
the DET - O
emergence NOUN - O
of ADP - O
Hip PROPN - O
increased VERB - O
over ADP - O
time NOUN - O
, PUNCT - O
suggesting VERB - O
that ADP - O
CF PROPN - O
airways NOUN - O
treated VERB - O
with ADP - O
ciprofloxacin NN - B-MEDICINE
select NOUN - O
for ADP - O
Hip PROPN - O
with ADP - O
an DET - O
increased VERB - O
fitness NOUN - O
in ADP - O
this DET - O
environment NOUN - O
. PUNCT - O

Hip NOUN - O
survived VERB - O
ciprofloxacin VBG - B-MEDICINE
treatment NOUN - O
far ADV - O
better ADV - O
than ADP - O
Lop NNP - B-ORG
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Using VERB - O
an DET - O
in X - O
vitro X - O
model NOUN - O
of ADP - O
the DET - O
distal ADJ - O
gut NOUN - O
to PART - O
support VERB - O
bacterial ADJ - O
communities NOUN - O
, PUNCT - O
we PRON - O
characterized VERB - O
the DET - O
metabolite NOUN - O
profiles NOUN - O
of ADP - O
two CD - B-CARDINAL
defined VERB - O
microbial ADJ - O
ecosystems NOUN - O
derived VERB - O
from ADP - O
healthy ADJ - O
donor NOUN - O
stool NOUN - O
( PUNCT - O
DEC58 NNP - B-PERSON
, PUNCT - O
and CCONJ - O
a DET - O
subset NOUN - O
community NOUN - O
, PUNCT - O
MET-1 PROPN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
an DET - O
ecosystem NOUN - O
representative NOUN - O
of ADP - O
a DET - O
dysbiotic ADJ - O
state NOUN - O
( PUNCT - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
treated VERB - O
DEC58 NNP - B-PERSON
) PUNCT - O
. PUNCT - O

growth NOUN - O
was VERB - O
decreased VERB - O
upon ADP - O
treatment NOUN - O
with ADP - O
DEC58 NNP - B-PERSON
metabolites NOUN - O
compared VERB - O
to ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
treated VERB - O
DEC58 NNP - B-PRODUCT
metabolites NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
CD186 NNP - B-PERSON
TcdA NNP - I-PERSON
and CCONJ - O
TcdB PROPN - O
secretion NOUN - O
was VERB - O
increased VERB - O
following VERB - O
treatment NOUN - O
with ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
treated VERB - O
DEC58 NNP - B-PRODUCT
spent VERB - O
medium NOUN - O
compared VERB - O
to ADP - O
DEC58 NNP - B-PERSON
spent VERB - O
medium NOUN - O
alone ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Stool NOUN - O
samples NOUN - O
from ADP - O
asymptomatic ADJ - O
children NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
10,008 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
those DET - O
with ADP - O
diarrhea NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
3,175 CD - B-CARDINAL
) PUNCT - O
were VERB - O
cultured VERB - O
for ADP - O
Campylobacter NNP - B-ORG
Disk NNP - I-ORG
diffusion NOUN - O
for ADP - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
CIP PROPN - O
) PUNCT - O
, PUNCT - O
nalidixic NOUN - O
acid NOUN - O
( PUNCT - O
NAL NNP - B-ORG
) PUNCT - O
, PUNCT - O

Of ADP - O
917 CD - B-CARDINAL
Campylobacter NNP - B-ORG
isolates VERB - O
, PUNCT - O
77.4 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
C. PROPN - O
jejuni PROPN - O
isolates VERB - O
and CCONJ - O
79.8 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
non JJ - B-ORG
- JJ - I-ORG
C. JJ - I-ORG
jejuni NOUN - O
isolates NOUN - O
were VERB - O
resistant ADJ - O
to ADP - O
ciprofloxacin VB - B-MEDICINE
, PUNCT - O
while ADP - O
4.9 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
C. PROPN - O
jejuni PROPN - O
isolates VERB - O
and CCONJ - O
24.8 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
non JJ - B-ORG
- JJ - I-ORG
C. JJ - I-ORG
jejuni NOUN - O
isolates NOUN - O
were VERB - O
not ADV - O
susceptible ADJ - O
to ADP - O
azithromycin PRON - O
. PUNCT - O

Of ADP - O
the DET - O
303 CD - B-CARDINAL
children NOUN - O
, PUNCT - O
33.1 CD - B-PERCENT
% NN - I-PERCENT
had VERB - O
been VERB - O
diagnosed VERB - O
with ADP - O
a DET - O
Campylobacter NNP - B-ORG
strain NOUN - O
nonsusceptible ADJ - O
to ADP - O
both DET - O
azithromycin PROPN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

PURPOSE PROPN - O
: PUNCT - O
To PART - O
evaluate VERB - O
pharmacokinetic ADJ - O
parameters NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
in ADP - O
patients NOUN - O
undergoing VERB - O
Roux PROPN - O
- PUNCT - O
en PROPN - O
- PUNCT - O
Y PROPN - O
gastric ADJ - O
surgery NOUN - O
( PUNCT - O
RYGS PROPN - O
) PUNCT - O
. PUNCT - O

In ADP - O
each DET - O
visit NOUN - O
, PUNCT - O
the DET - O
subjects NOUN - O
received VERB - O
a DET - O
single ADJ - O
oral ADJ - O
dose NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
500 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
. PUNCT - O

Venous ADJ - O
blood NOUN - O
samples NOUN - O
were VERB - O
obtained VERB - O
at ADP - O
baseline NOUN - O
and CCONJ - O
0.5 CD - B-CARDINAL
, PUNCT - O
1 CD - B-CARDINAL
, PUNCT - O
1.25 CD - B-CARDINAL
, PUNCT - O
1.5 CD - B-CARDINAL
, PUNCT - O
1.75 CD - B-DATE
, PUNCT - O
2 CD - B-CARDINAL
, PUNCT - O
2.5 CD - B-CARDINAL
, PUNCT - O
3 CD - B-DATE
, PUNCT - O
4 CD - B-DATE
, PUNCT - O
8 CD - B-DATE
and CCONJ - O
14 CD - B-CARDINAL
  SPACE - O
h ADV - O
after ADP - O
ciprofloxacin NN - B-MEDICINE
intake NOUN - O
. PUNCT - O

It PRON - O
is VERB - O
no DET - O
necessary ADJ - O
to PART - O
modify VERB - O
the DET - O
doses NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
in ADP - O
these DET - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Roux PROPN - O
- PUNCT - O
en PROPN - O
- PUNCT - O
Y PROPN - O
gastric ADJ - O
surgery NOUN - O
on ADP - O
ciprofloxacin NNP - B-MEDICINE
pharmacokinetics NOUN - O
: PUNCT - O
an DET - O
obvious ADJ - O
effect NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Response NOUN - O
of ADP - O
microorganisms NOUN - O
in ADP - O
biofilm NOUN - O
to PART - O
sulfadiazine VERB - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
in ADP - O
drinking VERB - O
water NOUN - O
distribution NOUN - O
systems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
propose VERB - O
an DET - O
inkjet NOUN - O
- PUNCT - O
printed VERB - O
aptamer NOUN - O
- PUNCT - O
based VERB - O
biosensor NOUN - O
developed VERB - O
for ADP - O
the DET - O
detection NOUN - O
of ADP - O
the DET - O
fluoroquinolone ADJ - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

Here ADV - O
we PRON - O
present VERB - O
a DET - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
binding VERB - O
RNA NNP - B-ORG
aptamer NOUN - O
developed VERB - O
by ADP - O
systematic ADJ - O
evolution NOUN - O
of ADP - O
ligands NOUN - O
by ADP - O
exponential ADJ - O
enrichment NOUN - O
( PUNCT - O
SELEX PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Towards ADP - O
this DET - O
objective NOUN - O
, PUNCT - O
water NOUN - O
containing VERB - O
ciprofloxacin NNP - B-MEDICINE
was VERB - O
treated VERB - O
by ADP - O
sunlight ADJ - O
- PUNCT - O
assisted ADJ - O
photocatalysis NOUN - O
using VERB - O
Fe- ADV - O
doped ADJ - O
ZnO NN - B-ORG
nanoparticles NOUN - O
for ADP - O
assessing VERB - O
the DET - O
degradation NOUN - O
potential NOUN - O
of ADP - O
this DET - O
system NOUN - O
. PUNCT - O

To PART - O
evaluate VERB - O
degradation NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
both DET - O
spectrophotometric ADJ - O
as ADV - O
well ADV - O
as ADP - O
microbiological ADJ - O
( PUNCT - O
loss NOUN - O
of ADP - O
antibiotic ADJ - O
activity NOUN - O
) PUNCT - O
methods NOUN - O
were VERB - O
employed VERB - O
. PUNCT - O

Under ADP - O
these DET - O
conditions NOUN - O
spectrophotometric ADJ - O
analysis NOUN - O
showed VERB - O
complete ADJ - O
degradation NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
10 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
L PROPN - O
) PUNCT - O
at ADP - O
210 CD - B-QUANTITY
min NN - I-QUANTITY
. PUNCT - O

Microbiological ADJ - O
studies NOUN - O
showed VERB - O
loss NOUN - O
of ADP - O
antibacterial ADJ - O
activity NOUN - O
of ADP - O
the DET - O
photocatalytically ADV - O
treated VERB - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
containing VERB - O
water NOUN - O
against ADP - O
Staphylococcus NNP - B-ORG
aureus PROPN - O
( PUNCT - O
10⁸ CD - B-CARDINAL
CFU NNP - B-ORG
) PUNCT - O
in ADP - O
60 CD - B-QUANTITY
min NN - I-QUANTITY
and CCONJ - O
for ADP - O
Escherichia NNP - B-ORG
coli ADJ - O
( PUNCT - O
10⁸ CD - B-CARDINAL
CFU NNP - B-ORG
) PUNCT - O
in ADP - O
75 CD - B-QUANTITY
min NN - I-QUANTITY
. PUNCT - O

-DOCSTART- -X- - O

Interaction NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
with ADP - O
the DET - O
activated VERB - O
sludge NOUN - O
of ADP - O
the DET - O
sewage NOUN - O
treatment NOUN - O
plant NOUN - O
is VERB - O
of ADP - O
importance NOUN - O
for ADP - O
the DET - O
ciprofloxacin NN - B-MEDICINE
migration NOUN - O
and CCONJ - O
risk NOUN - O
control NOUN - O
. PUNCT - O

More JJR - B-PERCENT
than IN - I-PERCENT
96.0 CD - I-PERCENT
% NN - I-PERCENT
ciprofloxacin NN - B-MEDICINE
was VERB - O
removed VERB - O
through ADP - O
the DET - O
sludge NOUN - O
adsorption NOUN - O
. PUNCT - O

The DET - O
sludge NOUN - O
surface NOUN - O
charge NOUN - O
varied VERB - O
little ADV - O
with ADP - O
ciprofloxacin NN - B-MEDICINE
since ADP - O
most ADJ - O
ciprofloxacin NNP - B-MEDICINE
was VERB - O
dissociated VERB - O
into ADP - O
the DET - O
neutral ADJ - O
one NUM - O
. PUNCT - O

No DET - O
obvious ADJ - O
shift NOUN - O
was VERB - O
observed VERB - O
for ADP - O
the DET - O
soluble ADJ - O
carbohydrate NOUN - O
concentration NOUN - O
and CCONJ - O
composition NOUN - O
with ADP - O
the DET - O
addition NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
indicating VERB - O
the DET - O
weak ADJ - O
interaction NOUN - O
between ADP - O
the DET - O
carbohydrates NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
. PUNCT - O

The DET - O
introduction NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
resulted VERB - O
in ADP - O
a DET - O
reduction NOUN - O
of ADP - O
the DET - O
soluble ADJ - O
protein NOUN - O
concentration NOUN - O
, PUNCT - O
a DET - O
marked ADJ - O
increase NOUN - O
of ADP - O
the DET - O
extracellular ADJ - O
protein NOUN - O
fluorescence NOUN - O
intensities NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
dramatic ADJ - O
emergence NOUN - O
of ADP - O
new ADJ - O
extracellular ADJ - O
proteins NOUN - O
. PUNCT - O

The DET - O
alteration NOUN - O
of ADP - O
the DET - O
proteins NOUN - O
highlights VERB - O
the DET - O
strong ADJ - O
interaction NOUN - O
between ADP - O
the DET - O
extracellular ADJ - O
proteins NOUN - O
and CCONJ - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
the DET - O
consequent ADJ - O
integration NOUN - O
of ADP - O
certain ADJ - O
soluble ADJ - O
proteins NOUN - O
and CCONJ - O
original ADJ - O
unextractable ADJ - O
inner ADJ - O
layer NOUN - O
extracellular ADJ - O
proteins NOUN - O
into ADP - O
the DET - O
extractable ADJ - O
extracellular ADJ - O
proteins NOUN - O
. PUNCT - O

Different ADJ - O
types NOUN - O
of ADP - O
interactions NOUN - O
are VERB - O
suggested VERB - O
to PART - O
dominate VERB - O
between ADP - O
the DET - O
extracellular ADJ - O
proteins NOUN - O
and CCONJ - O
the DET - O
differently ADV - O
dissociated VERB - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Herein NNP - B-PERSON
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
novel NOUN - O
inhalable ADJ - O
silk NOUN - O
- PUNCT - O
based VERB - O
microparticles NOUN - O
as ADP - O
a DET - O
promising ADJ - O
approach NOUN - O
to PART - O
deliver VERB - O
high ADJ - O
- PUNCT - O
payload NOUN - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
CIP PROPN - O
) PUNCT - O
for ADP - O
NCFB NNP - B-ORG
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Kinetic PROPN - O
, PUNCT - O
equilibrium NOUN - O
, PUNCT - O
and CCONJ - O
thermodynamic ADJ - O
studies NOUN - O
on ADP - O
the DET - O
adsorption NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
by ADP - O
activated VERB - O
carbon NOUN - O
produced VERB - O
from ADP - O
Jerivá NNP - B-GPE
( PUNCT - O
Syagrus NNP - B-CARDINAL
romanzoffiana PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
multisite NOUN - O
implementation NOUN - O
of ADP - O
a DET - O
real ADJ - O
- PUNCT - O
time NOUN - O
polymerase NOUN - O
chain NOUN - O
reaction NOUN - O
assay VERB - O
to PART - O
predict VERB - O
ciprofloxacin NN - B-MEDICINE
susceptibility NOUN - O
in ADP - O
Neisseria NNP - B-GPE
gonorrhoeae PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hydrogel PROPN - O
of ADP - O
N NNP - B-ORG
- PUNCT - O
trimehtyl NOUN - O
chitosan NOUN - O
( PUNCT - O
TMC)/sodium NOUN - O
carboxymethyl NOUN - O
xanthan NOUN - O
gum NOUN - O
( PUNCT - O
CMXG NNP - B-ORG
) PUNCT - O
was VERB - O
prepared ADJ - O
and CCONJ - O
ciprofloxacin NNP - B-MEDICINE
was VERB - O
employed VERB - O
as ADP - O
a DET - O
model NOUN - O
drug NOUN - O
to PART - O
investigate VERB - O
the DET - O
loading NOUN - O
and CCONJ - O
release NOUN - O
performance NOUN - O
of ADP - O
the DET - O
prepared ADJ - O
hydrogel NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
the DET - O
ciprofloxacin NN - B-MEDICINE
was VERB - O
successfully ADV - O
incorporated VERB - O
and CCONJ - O
released VERB - O
from ADP - O
the DET - O
prepared VERB - O
hydrogel NOUN - O
without ADP - O
the DET - O
loss NOUN - O
of ADP - O
structural ADJ - O
integrity NOUN - O
or CCONJ - O
the DET - O
change NOUN - O
in ADP - O
its ADJ - O
functionality NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Subsequently ADV - O
, PUNCT - O
a DET - O
sub NOUN - O
- PUNCT - O
minimum NOUN - O
inhibitory NOUN - O
concentration NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
) PUNCT - O
ciprofloxacin NN - B-MEDICINE
exposure NOUN - O
resulted VERB - O
in ADP - O
a DET - O
fold ADJ - O
change NOUN - O
of ADP - O
30.06 CD - B-CARDINAL
at ADP - O
24 CD - B-TIME
hours NNS - I-TIME
. PUNCT - O

Chromosomal ADJ - O
mutations NOUN - O
of ADP - O
gyrA NOUN - O
with ADP - O
S83I NNP - B-CARDINAL
, PUNCT - O
gyrB PUNCT - O
with ADP - O
S463A NN - B-ORG
, PUNCT - O
and CCONJ - O
parC VB - B-ORG
with ADP - O
S80I NOUN - O
amino NOUN - O
acid NOUN - O
substitutions NOUN - O
were VERB - O
detected VERB - O
, PUNCT - O
but CCONJ - O
no DET - O
other ADJ - O
mutations NOUN - O
have VERB - O
occurred VERB - O
as ADP - O
a DET - O
consequence NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
exposure NOUN - O
. PUNCT - O

Elevated ADJ - O
expression NOUN - O
of ADP - O
qnrD NOUN - O
correlated VERB - O
with ADP - O
that DET - O
of ADP - O
recA PROPN - O
in ADP - O
M. NNP - B-ORG
morganii VERB - O
during ADP - O
ciprofloxacin NN - B-MEDICINE
exposure NOUN - O
, PUNCT - O
which ADJ - O
indicates VERB - O
SOS NN - B-ORG
- HYPH - I-ORG
dependent JJ - I-ORG
regulation NOUN - O
of ADP - O
qnrD. ADJ - O
Protective ADJ - O
effect NOUN - O
of ADP - O
QnrD PROPN - O
plays VERB - O
a DET - O
role NOUN - O
in ADP - O
fluoroquinolone ADJ - O
- PUNCT - O
resistant ADJ - O
strain NOUN - O
even ADV - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
chromosomal ADJ - O
mutations NOUN - O
in ADP - O
gyrase NOUN - O
and CCONJ - O
topoisomerase VERB - O
IV NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Biceps NOUN - O
tendon VERB - O
rupture NOUN - O
associated VERB - O
with ADP - O
ciprofloxacin NN - B-MEDICINE
use NOUN - O
for ADP - O
spontaneous ADJ - O
bacterial ADJ - O
peritonitis ADJ - O
prophylaxis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

For ADP - O
this DET - O
, PUNCT - O
ciprofloxacin VBD - B-MEDICINE
at ADP - O
lethal ADJ - O
and CCONJ - O
sublethal ADJ - O
concentrations NOUN - O
was VERB - O
added VERB - O
at ADP - O
different ADJ - O
times NOUN - O
( PUNCT - O
0 NUM - O
, PUNCT - O
6 CD - B-CARDINAL
, PUNCT - O
12 CD - B-DATE
and CCONJ - O
18 CD - B-DATE
h NOUN - O
) PUNCT - O
and CCONJ - O
was VERB - O
tested VERB - O
in ADP - O
combination NOUN - O
with ADP - O
the DET - O
phage NOUN - O
ELY-1 PROPN - O
to PART - O
inactivate VERB - O
E. PROPN - O
coli ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antibacterial ADJ - O
effects NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
against ADP - O
microorganisms NOUN - O
increased VERB - O
significantly ADV - O
. PUNCT - O

This DET - O
formulation NOUN - O
could VERB - O
increase VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
for ADP - O
treatment NOUN - O
of ADP - O
pulmonary ADJ - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Iron NOUN - O
- PUNCT - O
doped VERB - O
ordered VERB - O
mesoporous ADJ - O
Co3O4 NNP - B-ORG
activation NOUN - O
of ADP - O
peroxymonosulfate NOUN - O
for ADP - O
ciprofloxacin NN - B-MEDICINE
degradation NOUN - O
: PUNCT - O
Performance NOUN - O
, PUNCT - O
mechanism NOUN - O
and CCONJ - O
degradation NOUN - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Municipal ADJ - O
solid ADJ - O
waste NOUN - O
biochar NOUN - O
- PUNCT - O
bentonite NOUN - O
composite NOUN - O
for ADP - O
the DET - O
removal NOUN - O
of ADP - O
antibiotic ADJ - O
ciprofloxacin NN - B-MEDICINE
from ADP - O
aqueous ADJ - O
media NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
1.5 CD - B-DATE
  _SP - I-DATE
years NNS - I-DATE
of ADP - O
operation NOUN - O
, PUNCT - O
the DET - O
removal NOUN - O
efficiency NOUN - O
of ADP - O
10 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
ciprofloxacin NN - B-MEDICINE
in ADP - O
MFCs NOUN - O
increased VERB - O
to ADP - O
99.00 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
88 CD - B-CARDINAL
  SPACE - O
h. NOUN - O

Even ADV - O
exposed VERB - O
to ADP - O
a DET - O
low ADJ - O
temperature NOUN - O
of ADP - O
10 CD - B-CARDINAL
  SPACE - O
° NOUN - O
C NOUN - O
or CCONJ - O
a DET - O
salinity NOUN - O
of ADP - O
3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
the DET - O
MFCs NOUN - O
can VERB - O
achieve VERB - O
greater JJR - B-PERCENT
than IN - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
and CCONJ - O
nearly RB - B-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
ciprofloxacin JJ - B-MEDICINE
removal NOUN - O
efficiency NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Long ADJ - O
- PUNCT - O
term NOUN - O
operation NOUN - O
of ADP - O
electroactive ADJ - O
biofilms NOUN - O
for ADP - O
enhanced ADJ - O
ciprofloxacin NN - B-MEDICINE
removal NOUN - O
capacity NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
shock ADJ - O
capabilities NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
categorical ADJ - O
agreement NOUN - O
of ADP - O
the DT - B-FAC
Etest NNP - I-FAC
® NN - I-FAC
was VERB - O
83 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
ciprofloxacin NN - B-MEDICINE
and CCONJ - O
95 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
levofloxacin NOUN - O
. PUNCT - O

Four CD - B-CARDINAL
very ADV - O
major ADJ - O
errors NOUN - O
were VERB - O
identified VERB - O
in ADP - O
a DET - O
preliminary ADJ - O
manner NOUN - O
on ADP - O
11 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
4/35 LS - B-CARDINAL
) PUNCT - O
of ADP - O
the DET - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
and CCONJ - O
11%(4/35 CD - B-PERSON
) PUNCT - O
of ADP - O
the DET - O
levofloxacin NOUN - O
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
. PUNCT - O

In ADP - O
our ADJ - O
study NOUN - O
, PUNCT - O
the DET - O
rate NOUN - O
of ADP - O
FQ NNP - B-ORG
non ADJ - O
- ADJ - O
susceptibility NOUN - O
of ADP - O
A. NN - B-ORG
urinae NOUN - O
was VERB - O
27 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
levofloxacin NOUN - O
and CCONJ - O
33 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Moreover ADV - O
, PUNCT - O
there ADV - O
is VERB - O
no DET - O
evidence NOUN - O
to PART - O
confirm VERB - O
the DET - O
higher ADJ - O
effectiveness NOUN - O
of ADP - O
topical ADJ - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
considered VERB - O
the DET - O
standard NOUN - O
of ADP - O
care NOUN - O
, PUNCT - O
or CCONJ - O
topical ADJ - O
azithromycin NOUN - O
in ADP - O
preventing VERB - O
IPOE NN - B-ORG
of ADP - O
cataract ADJ - O
surgeries NOUN - O
. PUNCT - O

IPOE PROPN - O
topical ADJ - O
prophylaxis NOUN - O
was VERB - O
performed VERB - O
with ADP - O
two CD - B-CARDINAL
different ADJ - O
strategies NOUN - O
: PUNCT - O
with ADP - O
azithromycin NOUN - O
from ADP - O
January NNP - B-DATE
1st NN - I-DATE
, , - I-DATE
2010 CD - I-DATE
to IN - I-DATE
December NNP - I-DATE
31st NN - I-DATE
, , - I-DATE
2014 CD - I-DATE
( PUNCT - O
group NOUN - O
I PRON - O
) PUNCT - O
and CCONJ - O
with ADP - O
ciprofloxacin NN - B-MEDICINE
from ADP - O
January NNP - B-DATE
1st NN - I-DATE
, , - I-DATE
2015 CD - I-DATE
to IN - I-DATE
January NNP - I-DATE
31st NN - I-DATE
, , - I-DATE
2017 CD - I-DATE
( PUNCT - O
group NOUN - O
II NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
benefit NOUN - O
of ADP - O
the DET - O
application NOUN - O
of ADP - O
topical ADJ - O
antibiotics NOUN - O
after ADP - O
cataract ADJ - O
surgery NOUN - O
is VERB - O
questionable ADJ - O
when ADV - O
intracameral ADJ - O
cefuroxime NOUN - O
prophylaxis NOUN - O
is VERB - O
performed VERB - O
and CCONJ - O
no ADV - O
better ADJ - O
effectiveness NOUN - O
with ADP - O
ciprofloxacin NNP - B-MEDICINE
or CCONJ - O
azithromycin PROPN - O
was VERB - O
observed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
effect NOUN - O
of ADP - O
thawing VERB - O
temperature NOUN - O
on ADP - O
the DET - O
size NOUN - O
and CCONJ - O
shape NOUN - O
of ADP - O
the DET - O
ciprofloxacin JJ - B-MEDICINE
nanocrystals NOUN - O
was VERB - O
determined VERB - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
broad ADJ - O
agreement NOUN - O
between ADP - O
the DET - O
two CD - B-CARDINAL
TEM NNP - B-ORG
methods NOUN - O
and CCONJ - O
that ADP - O
ciprofloxacin NNP - B-MEDICINE
nanocrystals NOUN - O
formed VERB - O
shorter ADJ - O
and CCONJ - O
thinner ADJ - O
crystals NOUN - O
inside ADP - O
the DET - O
liposomes NOUN - O
at ADP - O
higher ADJ - O
thawing NOUN - O
temperatures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Population NOUN - O
pharmacokinetic ADJ - O
modeling NOUN - O
to PART - O
establish VERB - O
the DET - O
role NOUN - O
of ADP - O
P NOUN - O
- PUNCT - O
glycoprotein NOUN - O
on ADP - O
ciprofloxacin JJ - B-MEDICINE
distribution NOUN - O
to ADP - O
lung NOUN - O
and CCONJ - O
prostate NOUN - O
following VERB - O
intravenous ADJ - O
and CCONJ - O
intratracheal ADJ - O
administration NOUN - O
to ADP - O
Wistar NNP - B-ORG
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
class NOUN - O
of ADP - O
1-[(1R,2S)-2-fluorocyclopropyl]ciprofloxacin NNP - B-PERSON
( PUNCT - O
CPFX)-1,2,4-triazole-5(4H)-thione NOUN - O
hybrids NOUN - O

-DOCSTART- -X- - O

Oxygen NOUN - O
vacancy NOUN - O
boosted VERB - O
photocatalytic ADJ - O
decomposition NOUN - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
over ADP - O
Bi2MoO6 PROPN - O
: PUNCT - O
Oxygen NOUN - O
vacancy NOUN - O
engineering NOUN - O
, PUNCT - O
biotoxicity NOUN - O
evaluation NOUN - O
and CCONJ - O
mechanism NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azithromycin PROPN - O
is VERB - O
appropriate ADJ - O
as ADP - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
in ADP - O
regions NOUN - O
where ADV - O
the DET - O
rate NOUN - O
of ADP - O
non ADJ - O
- NOUN - O
susceptibility ADJ - O
of ADP - O
ciprofloxacin NNP - B-MEDICINE
is VERB - O
known VERB - O
to PART - O
be VERB - O
high ADJ - O
, PUNCT - O
and CCONJ - O
research NOUN - O
suggests VERB - O
that ADP - O
, PUNCT - O
from ADP - O
a DET - O
cardiac ADJ - O
point NOUN - O
of ADP - O
view NOUN - O
, PUNCT - O
azithromycin PROPN - O
is VERB - O
safer ADJ - O
than ADP - O
other ADJ - O
macrolide ADJ - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aims VERB - O
to PART - O
evaluate VERB - O
the DET - O
technical ADJ - O
feasibility NOUN - O
of ADP - O
applying VERB - O
heterogeneous ADJ - O
catalytic ADJ - O
ozonation NOUN - O
to PART - O
eliminate VERB - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
CIP NNP - B-ORG
) PUNCT - O
as ADP - O
a DET - O
representative NOUN - O
of ADP - O
fluoroquinolone ADJ - O
antibiotics NOUN - O
normally ADV - O
present ADJ - O
in ADP - O
municipal ADJ - O
wastewater NOUN - O
discharges NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enhancement NOUN - O
of ADP - O
ciprofloxacin VBG - B-MEDICINE
degradation NOUN - O
in ADP - O
aqueous ADJ - O
system NOUN - O
by ADP - O
heterogeneous ADJ - O
catalytic ADJ - O
ozonation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
novel ADJ - O
series NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
dithiocarbamate NOUN - O
hybrids NOUN - O
7a NUM - O
  SPACE - O
- PUNCT - O
  SPACE - O
7l NUM - O
were VERB - O
designed VERB - O
, PUNCT - O
synthesized VERB - O
, PUNCT - O
and CCONJ - O
evaluated VERB - O
against ADP - O
Gram NNP - B-ORG
- PUNCT - O
positive ADJ - O
and CCONJ - O
Gram JJ - B-ORG
- PUNCT - O
negative ADJ - O
bacteria NOUN - O
. PUNCT - O

In ADP - O
  SPACE - O
vitro X - O
antibacterial ADJ - O
evaluation NOUN - O
of ADP - O
compound NOUN - O
7h NOUN - O
against ADP - O
clinically ADV - O
isolated VERB - O
bacteria NOUN - O
methicillin NOUN - O
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-PERSON
aureus NOUN - O
( PUNCT - O
MRSA NNP - B-ORG
) PUNCT - O
and CCONJ - O
methicillin NOUN - O
- PUNCT - O
sensitive ADJ - O
Staphylococcus NNP - B-PERSON
aureus NOUN - O
( PUNCT - O
MSSA NNP - B-ORG
) PUNCT - O
showed VERB - O
that ADP - O
this DET - O
compound NOUN - O
acted VERB - O
better ADV - O
than ADP - O
ciprofloxacin VBD - B-MEDICINE
against ADP - O
the DET - O
latter ADJ - O
bacteria NOUN - O
. PUNCT - O

Docking VERB - O
study NOUN - O
of ADP - O
compound NOUN - O
7h NUM - O
in ADP - O
the DET - O
active ADJ - O
site NOUN - O
of ADP - O
S. NNP - B-GPE
  _SP - I-GPE
aureus NOUN - O
DNA NOUN - O
gyrase NOUN - O
revealed VERB - O
that ADP - O
this DET - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
dithiocarbamate NOUN - O
derivative NOUN - O
interacted VERB - O
with ADP - O
the DET - O
main ADJ - O
components NOUN - O
of ADP - O
the DET - O
active ADJ - O
site NOUN - O
of ADP - O
the DET - O
enzyme ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Plasma NOUN - O
and CCONJ - O
fetal ADJ - O
fluid NOUN - O
enrofloxacin NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
concentrations NOUN - O
were VERB - O
measured VERB - O
by ADP - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

Enrofloxacin PROPN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
reached VERB - O
the DET - O
minimum ADJ - O
inhibitory NOUN - O
concentrations NOUN - O
for ADP - O
common ADJ - O
pathogens NOUN - O
in ADP - O
all DET - O
fluids NOUN - O
. PUNCT - O

Short ADJ - O
- PUNCT - O
term NOUN - O
administration NOUN - O
of ADP - O
enrofloxacin ADJ - O
to ADP - O
late ADJ - O
gestation NOUN - O
mares NOUN - O
resulted VERB - O
in ADP - O
detectable ADJ - O
enrofloxacin NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
concentrations NOUN - O
in ADP - O
fetal ADJ - O
fluids NOUN - O
and CCONJ - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
macroscopic ADJ - O
or CCONJ - O
microscopic ADJ - O
lesions NOUN - O
in ADP - O
the DET - O
fetus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To ADP - O
this DET - O
end NOUN - O
, PUNCT - O
five CD - B-CARDINAL
biochars NOUN - O
derived VERB - O
from ADP - O
pine ADJ - O
cone NOUN - O
( PUNCT - O
BCP PROPN - O
) PUNCT - O
, PUNCT - O
rice NOUN - O
husk NOUN - O
, PUNCT - O
sewage NOUN - O
sludge NOUN - O
, PUNCT - O
digestate VERB - O
and CCONJ - O
Miscanthus NNP - B-ORG
were VERB - O
tested VERB - O
as ADP - O
additional ADJ - O
sorbents NOUN - O
in ADP - O
liquid ADJ - O
pig NOUN - O
manure NOUN - O
for ADP - O
sulfamethazine NOUN - O
, PUNCT - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
oxytetracycline NOUN - O
and CCONJ - O
florfenicol NOUN - O
. PUNCT - O

Antibiotics PROPN - O
' PART - O
sorption NOUN - O
onto ADP - O
manure NOUN - O
increased VERB - O
in ADP - O
the DET - O
order NOUN - O
sulfamethazine NOUN - O
  SPACE - O
< X - O
  SPACE - O
florfenicol VERB - O
  SPACE - O
< X - O
  SPACE - O
ciprofloxacin VBD - B-MEDICINE
  SPACE - O
< X - O
  SPACE - O
oxytetracycline NOUN - O
. PUNCT - O

Admixtures NOUN - O
of ADP - O
BCP PROPN - O
to PART - O
manure VERB - O
changed VERB - O
the DET - O
order NOUN - O
to PART - O
sulfamethazine VERB - O
  SPACE - O
< X - O
  SPACE - O
oxytetracycline NOUN - O
  SPACE - O
< X - O
  SPACE - O
florfenicol VERB - O
  SPACE - O
= PUNCT - O
  SPACE - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

Generally ADV - O
, PUNCT - O
with ADP - O
the DET - O
addition NOUN - O
of ADP - O
biochar NOUN - O
, PUNCT - O
sorption NOUN - O
coefficients NOUN - O
of ADP - O
florfenicol NOUN - O
increased VERB - O
most ADJ - O
( PUNCT - O
by ADP - O
factors>2.7 NOUN - O
) PUNCT - O
followed VERB - O
by ADP - O
sulfamethazine NOUN - O
and CCONJ - O
ciprofloxacin VBD - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

CAALA NNP - B-ORG
uses VERB - O
four CD - B-CARDINAL
currently ADV - O
- PUNCT - O
marketed VERB - O
drugs NOUN - O
- PUNCT - O
the DET - O
antibiotic ADJ - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
the DET - O
iron NOUN - O
chelator NOUN - O
deferiprone NOUN - O
, PUNCT - O
the DET - O
antimetabolite ADJ - O
5-FU CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
the DET - O
xanthine NOUN - O
oxidase NOUN - O
inhibitor NOUN - O
febuxostat NOUN - O
- PUNCT - O
that ADJ - O
all DET - O
have VERB - O
evidence NOUN - O
of ADP - O
ability NOUN - O
to PART - O
both DET - O
increase VERB - O
5-ALA CD - B-ORG
mediated VERB - O
intraoperative ADJ - O
glioblastoma NOUN - O
demarcation NOUN - O
and CCONJ - O
photodynamic ADJ - O
cytotoxicity NOUN - O
of ADP - O
in ADP - O
situ NOUN - O
glioblastoma NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
majority NOUN - O
of ADP - O
strains NOUN - O
were VERB - O
resistant ADJ - O
to ADP - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
68.6 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
all DET - O
N. NNP - B-ORG
gonorrhoeae NOUN - O
strains NOUN - O
were VERB - O
susceptible ADJ - O
to ADP - O
spectinomycin NOUN - O
; PUNCT - O
9.7 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
isolates NOUN - O
were VERB - O
resistant ADJ - O
to ADP - O
azithromycin PROPN - O
. PUNCT - O

High ADJ - O
rates NOUN - O
of ADP - O
resistance NOUN - O
to ADP - O
penicillin NOUN - O
, PUNCT - O
tetracycline NOUN - O
and CCONJ - O
ciprofloxacin NNP - B-MEDICINE
were VERB - O
found VERB - O
in ADP - O
this DET - O
area NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
whether ADP - O
switching NOUN - O
ciprofloxacin NN - B-MEDICINE
to PART - O
fosfomycin VERB - O
in ADP - O
the DET - O
case NOUN - O
of ADP - O
fluoroquinolone ADJ - O
- PUNCT - O
resistant ADJ - O
rectal ADJ - O
bacteria NOUN - O
influences VERB - O
the DET - O
incidence NOUN - O
of ADP - O
infectious ADJ - O
complications NOUN - O
after ADP - O
transrectal ADJ - O
prostate NOUN - O
biopsy NOUN - O
. PUNCT - O

Patients NOUN - O
in ADP - O
the DET - O
control NOUN - O
group NOUN - O
received VERB - O
ciprofloxacin NN - B-MEDICINE
. PUNCT - O

Patients NOUN - O
in ADP - O
the DET - O
intervention NOUN - O
group NOUN - O
received VERB - O
fosfomycin NOUN - O
instead ADV - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
in ADP - O
the DET - O
case NOUN - O
of ADP - O
fluoroquinolone ADJ - O
- PUNCT - O
resistant ADJ - O
bacteria NOUN - O
on ADP - O
rectal ADJ - O
swab NOUN - O
culture NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Risk NOUN - O
assessment NOUN - O
of ADP - O
biosolids NOUN - O
- PUNCT - O
borne ADJ - O
ciprofloxacin NN - B-MEDICINE
and CCONJ - O
azithromycin PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Transposon PROPN - O
insertional ADJ - O
inactivation NOUN - O
of ADP - O
the DET - O
general ADJ - O
secretory ADJ - O
pathway NOUN - O
protein NOUN - O
D NOUN - O
( PUNCT - O
gspD PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
is VERB - O
a DET - O
key ADJ - O
component NOUN - O
in ADP - O
the DET - O
structure NOUN - O
of ADP - O
the DET - O
T2SS NNP - B-ORG
, PUNCT - O
significantly ADV - O
increased VERB - O
the DET - O
MIC NNP - B-ORG
of ADP - O
AB5075 PROPN - O
to PART - O
ciprofloxacin VB - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
resistance NOUN - O
rate NOUN - O
of ADP - O
Escherichia NNP - B-ORG
coli ADJ - O
to ADP - O
3rd JJ - B-ORDINAL
CEPs NOUN - O
( PUNCT - O
17.6 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2004 CD - B-DATE
, PUNCT - O
21.7 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2008 CD - B-DATE
, PUNCT - O
and CCONJ - O
33.8 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2012 CD - B-DATE
, PUNCT - O
P NOUN - O
  SPACE - O
< X - O
.001 NUM - O
) PUNCT - O
and CCONJ - O
ciprofloxacin NNP - B-MEDICINE
( PUNCT - O
37.5 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2004 CD - B-DATE
, PUNCT - O
38.7 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2008 CD - B-DATE
, PUNCT - O
and CCONJ - O
46.6 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
2012 CD - B-DATE
, PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
.001 NUM - O
) PUNCT - O
demonstrated VERB - O
a DET - O
significantly ADV - O
increasing VERB - O
trend NOUN - O
. PUNCT - O

E NOUN - O
coli NOUN - O
or CCONJ - O
K PROPN - O
pneumoniae VERB - O
to ADP - O
ciprofloxacin VB - B-MEDICINE
. PUNCT - O

Increasing VERB - O
resistance NOUN - O
of ADP - O
A DET - O
baumanii NOUN - O
to PART - O
ciprofloxacin NNP - B-MEDICINE
was VERB - O
significantly ADV - O
correlated VERB - O
with ADP - O
increasing VERB - O
consumption NOUN - O
of ADP - O
FQs NOUN - O
; PUNCT - O
increasing VERB - O
resistance NOUN - O
of ADP - O
A DET - O
baumanii NOUN - O
to PART - O
imipenem NOUN - O
was VERB - O
significantly ADV - O
correlated VERB - O
with ADP - O
increasing VERB - O
consumption NOUN - O
of ADP - O
carbapenems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
an DET - O
O26:H11 JJ - B-ORG
E. NNP - I-ORG
coli NOUN - O
strain NOUN - O
that ADJ - O
produces VERB - O
both DET - O
Stx1a NNP - B-ORG
and CCONJ - O
Stx2a NNP - B-ORG
was VERB - O
virulent ADJ - O
in ADP - O
streptomycin- NOUN - O
and CCONJ - O
ciprofloxacin NN - B-MEDICINE
- PUNCT - O
treated VERB - O
mice NOUN - O
and CCONJ - O
that ADP - O
mice NOUN - O
were VERB - O
protected VERB - O
by ADP - O
administration NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
Stx2 ADJ - O
antibody NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
we PRON - O
discovered VERB - O
that ADP - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
ciprofloxacin NN - B-MEDICINE
, PUNCT - O
neutralization NOUN - O
of ADP - O
Stx1a NNP - B-ORG
enhanced VERB - O
the DET - O
virulence NOUN - O
of ADP - O
the DET - O
strain NOUN - O
, PUNCT - O
a DET - O
result NOUN - O
that ADJ - O
corroborated VERB - O
our ADJ - O
previous ADJ - O
finding NOUN - O
that ADP - O
Stx1a NNP - B-ORG
reduces VERB - O
the DET - O
toxicity NOUN - O
of ADP - O
Stx2a NNP - B-ORG
by ADP - O
the DET - O
oral ADJ - O
route NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
RS)-Etodolac PROPN - O
was VERB - O
isolated VERB - O
from ADP - O
commercial ADJ - O
tablets NOUN - O
and CCONJ - O
was VERB - O
purified VERB - O
and CCONJ - O
characterized VERB - O
to PART - O
be VERB - O
used VERB - O
as ADP - O
racemic ADJ - O
standard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Adalimumab RB - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Aseptic NNP - I-ORG
Meningitis NNP - I-ORG
Pill NNP - I-ORG
Desiccant NNP - I-ORG
-Induced VBD - I-ORG
Acute NNP - B-PERSON
Hypoxic NNP - I-PERSON
Respiratory PROPN - O
Failure PROPN - O
Rivastigmine PROPN - O
Patch PROPN - O
-Induced VERB - O
Angioedema NNP - B-PERSON
Acute NNP - I-PERSON
Liver NNP - I-PERSON
Failure NN - I-PERSON
Due ADP - O
to ADP - O
Etodolac NNP - B-MEDICINE
Severe NNP - I-ORG
Cognitive JJ - I-ORG
Impairment NN - I-ORG

-DOCSTART- -X- - O

Representative ADJ - O
isolates NOUN - O
of ADP - O
each DET - O
species NOUN - O
were VERB - O
used VERB - O
to PART - O
test VERB - O
the DET - O
Antibacterial NNP - B-ORG
and CCONJ - O
anti ADJ - O
- ADJ - O
biofilm ADJ - O
formation NOUN - O
activities NOUN - O
of ADP - O
Etodolac NNP - B-MEDICINE
( PUNCT - O
a DET - O
Non PROPN - O
- ADJ - O
Steroidal ADJ - O
Anti PROPN - O
- ADJ - O
Inflammatory PROPN - O
Drug PROPN - O
, PUNCT - O
NSAID NNP - B-ORG
) PUNCT - O
at ADP - O
10 CD - B-CARDINAL
and CC - I-CARDINAL
1 CD - I-CARDINAL
mM NOUN - O
using VERB - O
a DET - O
broth ADJ - O
microdilution NOUN - O
technique NOUN - O
. PUNCT - O

Etodolac NNP - B-MEDICINE
had VERB - O
an DET - O
almost ADV - O
null ADJ - O
influence NOUN - O
on ADP - O
tested ADJ - O
gram NOUN - O
- PUNCT - O
negatives NOUN - O
, PUNCT - O
with ADP - O
the DET - O
exception NOUN - O
of ADP - O
one CD - B-CARDINAL
A. NN - B-NORP
baumannii VERB - O
clinical ADJ - O
isolate NOUN - O
regarding VERB - O
biofilm ADJ - O
formation NOUN - O
inhibition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
first JJ - B-ORDINAL
method NOUN - O
involves VERB - O
the DET - O
determination NOUN - O
of ADP - O
Etodolac NNP - B-MEDICINE
by ADP - O
direct ADJ - O
measurement NOUN - O
of ADP - O
the DET - O
absorbance NOUN - O
at ADP - O
1716cm-1 CD - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Etodolac NNP - B-MEDICINE
, PUNCT - O
a DET - O
nonsteroidal ADJ - O
antiinflammatory ADJ - O
drug NOUN - O
, PUNCT - O
widely ADV - O
used VERB - O
in ADP - O
arthritis NOUN - O
is VERB - O
associated VERB - O
with ADP - O
gastric ADJ - O
ulceration NOUN - O
and CCONJ - O
irritation NOUN - O
due ADJ - O
to ADP - O
presence NOUN - O
of ADP - O
free ADJ - O
carboxylic ADJ - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Etodolac NNP - B-MEDICINE
reduced VERB - O
SNAIL PROPN - O
mRNA PROPN - O
and CCONJ - O
vimentin ADJ - O
cell NOUN - O
surface NOUN - O
expression NOUN - O
, PUNCT - O
and CCONJ - O
induced VERB - O
E NOUN - O
- NOUN - O
cadherin ADJ - O
mRNA PROPN - O
and CCONJ - O
E PROPN - O
- ADJ - O
cadherin ADJ - O
cell NOUN - O
surface NOUN - O
expression NOUN - O
, PUNCT - O
in ADP - O
T24 NNP - B-GPE
. PUNCT - O

Etodolac NNP - B-MEDICINE
also ADV - O
most ADV - O
strongly ADV - O
inhibited VERB - O
the DET - O
cell NOUN - O
migration NOUN - O
of ADP - O
T24 PROPN - O
in X - O
vitro X - O
and CCONJ - O
showed VERB - O
the DET - O
highest ADJ - O
tumour NOUN - O
growth NOUN - O
inhibition NOUN - O
in ADP - O
T24 PROPN - O
tumour NOUN - O
in ADP - O
vivo NOUN - O
. PUNCT - O

Etodolac NNS - B-MEDICINE
at ADP - O
clinical ADJ - O
doses NOUN - O
exhibited VERB - O
induced VERB - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
anti ADJ - O
- ADJ - O
tumour ADJ - O
effects NOUN - O
and CCONJ - O
reversal NOUN - O
effect NOUN - O
of ADP - O
EMT NNP - B-ORG
in ADP - O
T24 NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Etodolac NNP - B-MEDICINE
consists VERB - O
of ADP - O
two CD - B-CARDINAL
enantiomers NOUN - O
, PUNCT - O
S- PROPN - O
and CCONJ - O
R PROPN - O
- PUNCT - O
etodolac NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Etodolac NNP - B-MEDICINE
( PUNCT - O
ET PROPN - O
) PUNCT - O
is VERB - O
a DET - O
nonsteroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
with ADP - O
proved VERB - O
potential ADJ - O
antitumor NOUN - O
and CCONJ - O
uric ADJ - O
acid NOUN - O
lowering VERB - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eplerenone PROPN - O
( PUNCT - O
Inspra NNP - B-MEDICINE
® NNP - I-ORG
) PUNCT - O
is VERB - O
a DET - O
selective ADJ - O
mineralocorticoid ADJ - O
receptor NOUN - O
antagonist NOUN - O
( PUNCT - O
MRA NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

AIM NNP - B-ORG
: PUNCT - O
To PART - O
examine VERB - O
eplerenone NOUN - O
( PUNCT - O
Inspra NNP - B-MEDICINE
, PUNCT - O
Pfizer PROPN - O
) PUNCT - O
, PUNCT - O
a DET - O
mineralocorticoid ADJ - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
as ADP - O
a DET - O
treatment NOUN - O
option NOUN - O
for ADP - O
chronic ADJ - O
central ADJ - O
serous ADJ - O
chorioretinopathy NOUN - O
( PUNCT - O
CSCR PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Inspra NNP - B-MEDICINE
( PUNCT - O
eplerenone NOUN - O
tablets NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Aldosterone ADJ - O
and CCONJ - O
aldosterone ADJ - O
antagonism NOUN - O
in ADP - O
cardiovascular ADJ - O
disease NOUN - O
: PUNCT - O
focus VERB - O
on ADP - O
eplerenone NOUN - O
( PUNCT - O
Inspra NNP - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
selective ADJ - O
aldosterone ADJ - O
blocker NOUN - O
, PUNCT - O
eplerenone PROPN - O
( PUNCT - O
Inspra NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
is VERB - O
under ADP - O
development NOUN - O
for ADP - O
human ADJ - O
therapeutic ADJ - O
use NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
hypertension NOUN - O
and CCONJ - O
heart NOUN - O
failure NOUN - O
post NOUN - O
- ADJ - O
myocardial ADJ - O
infarction NOUN - O
( PUNCT - O
MI NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
is VERB - O
a DET - O
potent ADJ - O
analgesic NOUN - O
that ADJ - O
accounts VERB - O
for ADP - O
an DET - O
increasing VERB - O
number NOUN - O
of ADP - O
overdose ADJ - O
deaths NOUN - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
. PUNCT - O

Fentanyl VBG - B-MEDICINE
concentrations NOUN - O
were VERB - O
measured VERB - O
using VERB - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
clearance NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
the DET - O
carbamazepine NOUN - O
group NOUN - O
compared VERB - O
to ADP - O
controls NOUN - O
( PUNCT - O
mean VERB - O
± PROPN - O
SD NN - B-ORG
: PUNCT - O
20.1 CD - B-CARDINAL
± NUM - O
6.8 CD - B-CARDINAL
vs ADP - O
13.2 CD - B-CARDINAL
± NUM - O
4.8 NUM - O
ml NOUN - O
/ SYM - O
min NOUN - O
per ADP - O
kg NOUN - O
, PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
area NOUN - O
under ADP - O
the DET - O
plasma NOUN - O
concentration NOUN - O
curve NOUN - O
( PUNCT - O
AUC NNP - B-ORG
) PUNCT - O
was VERB - O
significantly ADV - O
lower ADJ - O
( PUNCT - O
150 CD - B-CARDINAL
± NUM - O
65 CD - B-CARDINAL
vs ADP - O
233 CD - B-CARDINAL
± NUM - O
70 NUM - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
, PUNCT - O
a DET - O
synthetic ADJ - O
opioid NOUN - O
available ADJ - O
in ADP - O
patch NOUN - O
form NOUN - O
, PUNCT - O
is VERB - O
particularly ADV - O
concerning VERB - O
given VERB - O
its ADJ - O
high ADJ - O
potency NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM PROPN - O
: PUNCT - O
Fentanyl NNP - B-MEDICINE
pharmacokinetics NOUN - O
and CCONJ - O
pharmacodynamics NOUN - O
are VERB - O
lacking VERB - O
in ADP - O
preterm ADJ - O
infants NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
was VERB - O
well ADV - O
tolerated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl VBG - B-MEDICINE
at ADP - O
the DET - O
studied VERB - O
doses NOUN - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
chest NOUN - O
wall NOUN - O
rigidity NOUN - O
in ADP - O
dogs NOUN - O
anesthetized VERB - O
with ADP - O
equipotent NOUN - O
doses NOUN - O
of ADP - O
isoflurane NOUN - O
( PUNCT - O
1.3 CD - B-CARDINAL
MACISO PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Validation PROPN - O
and CCONJ - O
Cross NNP - B-ORG
- NNP - I-ORG
Reactivity NNP - I-ORG
Data NNP - I-ORG
for ADP - O
Fentanyl NNP - B-MEDICINE
Analogs PROPN - O

With ADP - O
the DT - B-ORG
Immunalysis NN - I-ORG
Fentanyl NNP - I-MEDICINE
ELISA NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
, PUNCT - O
heroin NOUN - O
and CCONJ - O
cocaine NOUN - O
replaced VERB - O
oxycodone NOUN - O
, PUNCT - O
diazepam NOUN - O
and CCONJ - O
hydrocodone NOUN - O
in ADP - O
the DET - O
top ADJ - O
five CD - B-CARDINAL
beginning NOUN - O
in ADP - O
2015 CD - B-DATE
. PUNCT - O

Fentanyl NNP - B-MEDICINE
, PUNCT - O
rapidly ADV - O
emerging VERB - O
FAs NOUN - O
, PUNCT - O
and CCONJ - O
other ADJ - O
illicit ADJ - O
drugs NOUN - O
in ADP - O
recent JJ - B-DATE
years NNS - I-DATE
pose VERB - O
a DET - O
serious ADJ - O
health NOUN - O
threat NOUN - O
even ADV - O
though ADP - O
prescription NOUN - O
opioid ADV - O
- PUNCT - O
related VERB - O
deaths NOUN - O
decreased VERB - O
over ADP - O
the DET - O
same ADJ - O
time NOUN - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
as ADP - O
an DET - O
intrathecal ADJ - O
adjuvant NOUN - O
to ADP - O
local ADJ - O
anesthetics NOUN - O
to PART - O
enhance VERB - O
the DET - O
duration NOUN - O
of ADP - O
spinal ADJ - O
anesthesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
Cytochrome PROPN - O
P450 PROPN - O
Polymorphisms PROPN - O
in ADP - O
Burn PROPN - O
Patients PROPN - O
and CCONJ - O
Impact NOUN - O
on ADP - O
Fentanyl NNP - B-MEDICINE
Pharmacokinetics PROPN - O
: PUNCT - O
A DET - O
Pilot PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
and CCONJ - O
morphine NOUN - O
are VERB - O
the DET - O
2 CD - B-CARDINAL
most ADV - O
commonly ADV - O
added VERB - O
opioids NOUN - O
to PART - O
bupivacaine VERB - O
for ADP - O
spinal ADJ - O
anesthesia NOUN - O
during ADP - O
cesarean ADJ - O
delivery NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
added VERB - O
to ADP - O
intrathecal ADJ - O
bupivacaine NOUN - O
alone ADV - O
reduced VERB - O
the DET - O
need NOUN - O
for ADP - O
intraoperative ADJ - O
supplemental ADJ - O
analgesia NOUN - O
( PUNCT - O
relative ADJ - O
risk NOUN - O
, PUNCT - O
0.18 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
0.11 CD - B-CARDINAL
- SYM - O
0.27 NUM - O
; PUNCT - O
number NOUN - O
needed VERB - O
to PART - O
treat VERB - O
, PUNCT - O
4 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
the DET - O
incidence NOUN - O
of ADP - O
nausea NOUN - O
/ SYM - O
vomiting NOUN - O
( PUNCT - O
relative ADJ - O
risk NOUN - O
, PUNCT - O
0.41 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
0.24 CD - B-CARDINAL
- SYM - O
0.70 NUM - O
; PUNCT - O
number NOUN - O
needed VERB - O
to PART - O
treat VERB - O
, PUNCT - O
6.5 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
with ADP - O
longer ADJ - O
time NOUN - O
to ADP - O
first JJ - B-ORDINAL
postoperative NOUN - O
analgesia NOUN - O
request NOUN - O
( PUNCT - O
mean VERB - O
difference NOUN - O
, PUNCT - O
91 CD - B-TIME
minutes NNS - I-TIME
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O
69 CD - B-CARDINAL
- SYM - O
113 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Safety NOUN - O
of ADP - O
a DET - O
Modified PROPN - O
Community PROPN - O
Trailer PROPN - O
to PART - O
Manage VERB - O
Patients PROPN - O
with ADP - O
Presumed PROPN - O
Fentanyl NNP - B-MEDICINE
Overdose PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety NNP - B-ORG
of IN - I-ORG
Fentanyl NNP - I-MEDICINE
in IN - I-ORG
Combination NNP - B-ORG
with ADP - O
Midazolam PROPN - O
in ADP - O
Children PROPN - O
on ADP - O
Mechanical PROPN - O
Ventilation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
is VERB - O
an DET - O
extremely ADV - O
potent ADJ - O
synthetic ADJ - O
opioid NOUN - O
that ADJ - O
has VERB - O
been VERB - O
increasingly ADV - O
used VERB - O
to PART - O
adulterate VERB - O
heroin NOUN - O
, PUNCT - O
cocaine NOUN - O
, PUNCT - O
and CCONJ - O
counterfeit ADJ - O
prescription NOUN - O
pills NOUN - O
, PUNCT - O
leading VERB - O
to ADP - O
an DET - O
increase NOUN - O
in ADP - O
opioid ADV - O
- PUNCT - O
induced VERB - O
fatal ADJ - O
overdoses NOUN - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
, PUNCT - O
Canada NNP - B-GPE
, PUNCT - O
and CCONJ - O
Europe NNP - B-LOC
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
is VERB - O
an DET - O
agonist NOUN - O
of ADP - O
the DET - O
μ ADJ - O
- PUNCT - O
opioid NOUN - O
receptor NOUN - O
commonly ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
moderate ADJ - O
- PUNCT - O
severe ADJ - O
pain NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
concentrations NOUN - O
were VERB - O
measured VERB - O
by ADP - O
ultra ADJ - O
- ADJ - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
combined VERB - O
with ADP - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
( PUNCT - O
UPLC NNP - B-ORG
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
) PUNCT - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
pharmacokinetics NOUN - O
is VERB - O
affected VERB - O
by ADP - O
sex NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Efficacy NNP - B-ORG
of ADP - O
Ketamine NNP - B-ORG
Versus NNP - I-ORG
Ketamine NNP - I-ORG
- HYPH - I-ORG
Fentanyl NNP - I-MEDICINE
- HYPH - I-ORG
Dexmedetomidine NNP - I-ORG
Combination NNP - I-ORG
for ADP - O
Anesthesia NNP - B-GPE
and CCONJ - O
Analgesia NNP - B-GPE
in ADP - O
Rats NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Addressing VERB - O
the DT - B-ORG
Fentanyl NNP - I-MEDICINE
Analogue NNP - I-ORG
Epidemic NNP - I-ORG
by ADP - O
Multiplex NNP - B-ORG
UHPLC NNP - I-ORG
- HYPH - I-ORG
MS PROPN - O
/ SYM - O
MS PROPN - O
Analysis PROPN - O
of ADP - O
Whole PROPN - O
Blood PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Intravenous ADJ - O
Low NOUN - O
Dose PROPN - O
Fentanyl NNP - B-MEDICINE
versus ADP - O
Lignocaine NNP - B-GPE
in ADP - O
Attenuating PROPN - O
the DET - O
Hemodynamic PROPN - O
Responses PROPN - O
during ADP - O
Endotracheal NNP - B-ORG
Intubation NNP - I-ORG
: : - I-ORG

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
the DET - O
numerous ADJ - O
drugs NOUN - O
derived VERB - O
from ADP - O
it PRON - O
, PUNCT - O
are VERB - O
contributing VERB - O
to ADP - O
the DET - O
opioid ADJ - O
overdose ADJ - O
epidemic NOUN - O
currently ADV - O
underway ADJ - O
in ADP - O
the DET - O
USA NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Fentanyl NNP - B-MEDICINE
Analog NNP - I-ORG
Exposure NN - I-ORG
Using VERB - O
Dried VERB - O
Blood NOUN - O
Spots PROPN - O
with ADP - O
LC NNP - B-ORG
- HYPH - I-ORG
MS NNP - I-ORG
- HYPH - I-ORG
MS NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
and CCONJ - O
its ADJ - O
derivatives NOUN - O
have VERB - O
become VERB - O
pervasive ADJ - O
contaminants NOUN - O
in ADP - O
the DET - O
U.S. NNP - B-GPE
heroin NOUN - O
supply NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
injection NOUN - O
and CCONJ - O
public ADJ - O
injection NOUN - O
were VERB - O
associated VERB - O
with ADP - O
an DET - O
increased ADJ - O
likelihood NOUN - O
of ADP - O
non ADJ - O
- ADJ - O
fatal ADJ - O
overdose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
analogues NOUN - O
are VERB - O
popular ADJ - O
in ADP - O
recent JJ - B-DATE
years NNS - I-DATE
among ADP - O
drug NOUN - O
addicts NOUN - O
and CCONJ - O
have VERB - O
been VERB - O
related VERB - O
to ADP - O
many ADJ - O
overdoses NOUN - O
and CCONJ - O
deaths NOUN - O
worldwide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Predosing VBG - B-ORG
Chemical NNP - I-ORG
Stability NNP - I-ORG
of IN - I-ORG
Admixtures NNP - I-ORG
of IN - I-ORG
Propofol PROPN - O
, PUNCT - O
Ketamine NNP - B-GPE
, PUNCT - O
Fentanyl NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Remifentanil NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
of ADP - O
Fentanyl NNP - B-MEDICINE
Sublingual JJ - I-ORG
Spray NN - I-ORG
in ADP - O
Opioid NNP - B-GPE
- PUNCT - O
Naïve PROPN - O
Participants NOUN - O
: PUNCT - O
Results NOUN - O
of ADP - O
a DET - O
Phase NOUN - O
1 NUM - O
, PUNCT - O
Multiple NNP - B-ORG
Ascending NN - I-ORG
Dose NNP - I-ORG
Study NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Propofol NNP - I-ORG
and CC - I-ORG
Ketamine NNP - I-ORG
Combination NNP - I-ORG
( PUNCT - O
Ketofol NNP - B-NORP
) PUNCT - O
and CCONJ - O
Propofol NNP - B-PERSON
and CCONJ - O
Fentanyl NNP - B-MEDICINE
Combination PROPN - O
( PUNCT - O
Fenofol NNP - B-ORG
) PUNCT - O
on ADP - O
Quality NNP - B-ORG
of IN - I-ORG
Sedation NNP - I-ORG
and CCONJ - O
Analgesia NNP - B-GPE
in ADP - O
the DT - B-ORG
Lumpectomy NNP - I-ORG
: : - I-ORG

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
is VERB - O
a DET - O
rapid ADJ - O
- PUNCT - O
acting VERB - O
, PUNCT - O
short ADJ - O
duration NOUN - O
opioid ADJ - O
analgesic ADJ - O
agent NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
significantly ADV - O
increased VERB - O
the DET - O
ATPase NNP - B-NORP
activity NOUN - O
of ADP - O
P NOUN - O
- PUNCT - O
gp PROPN - O
membrane NOUN - O
. PUNCT - O

Fentanyl NNP - B-MEDICINE
requires VERB - O
close ADJ - O
monitoring NOUN - O
in ADP - O
clinic NOUN - O
when ADV - O
administered VERB - O
concomitantly ADV - O
with ADP - O
P NOUN - O
- PUNCT - O
gp PROPN - O
inhibitors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
Delays VERB - O
the DT - B-ORG
Platelet NNP - I-ORG
Inhibition NNP - I-ORG
Effects NNPS - I-ORG
of IN - I-ORG
Oral NNP - I-ORG
Ticagrelor NNP - I-ORG
: : - I-ORG

-DOCSTART- -X- - O

Fentanyl NNP - B-MEDICINE
increases VERB - O
efficacy NOUN - O
, PUNCT - O
but CCONJ - O
may VERB - O
have VERB - O
negative ADJ - O
effects NOUN - O
on ADP - O
the DET - O
neonate NOUN - O
in ADP - O
terms NOUN - O
of ADP - O
reduced VERB - O
neonatal ADJ - O
neurologic ADJ - O
and CCONJ - O
adaptive ADJ - O
capacity NOUN - O
scores NOUN - O
and CCONJ - O
breast NOUN - O
feeding NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

THE DET - O
ADJUNCTIVE PROPN - O
LAMICTAL NNP - B-MEDICINE
( PUNCT - O
LAMOTRIGINE PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
oil NOUN - O
was VERB - O
also ADV - O
blended VERB - O
externally ADV - O
with ADP - O
MO PROPN - O
at ADP - O
different ADJ - O
mass NOUN - O
ratios NOUN - O
and CCONJ - O
tested VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
volatile ADJ - O
fractions NOUN - O
of ADP - O
essential ADJ - O
oils NOUN - O
and CCONJ - O
hydrosols NOUN - O
from ADP - O
four CD - B-CARDINAL
less ADV - O
- PUNCT - O
studied VERB - O
1,8-cineol CD - B-NORP
- PUNCT - O
rich ADJ - O
Eucalyptus NNP - B-MEDICINE
species NOUN - O
( PUNCT - O
E. NNP - B-ORG
parvula NN - I-ORG
L.A.S. NNP - I-ORG
Johnson NNP - I-ORG
& CC - I-ORG
amp NN - I-ORG
; PUNCT - O
K.D. NNP - B-PERSON
Hill NNP - I-PERSON
, PUNCT - O
E. PROPN - O
cinerea PROPN - O
F. NNP - B-PERSON
Muell NNP - I-PERSON
, PUNCT - O
E. PROPN - O
pulverulenta NOUN - O
Sims NNPS - B-PERSON
and CCONJ - O
E. NNP - B-PERSON
pulverulenta NOUN - O
baby NOUN - O
blue PROPN - O
Sims NNPS - B-PERSON
) PUNCT - O
, PUNCT - O
cultivated VERB - O
in ADP - O
Tuscany PROPN - O
in ADP - O
a DET - O
system NOUN - O
of ADP - O
organic ADJ - O
farming NOUN - O
, PUNCT - O
were VERB - O
characterized VERB - O
by ADP - O
solvent NOUN - O
dilution NOUN - O
( PUNCT - O
essential ADJ - O
oils NOUN - O
) PUNCT - O
or CCONJ - O
extraction NOUN - O
( PUNCT - O
hydrosols NOUN - O
) PUNCT - O
followed VERB - O
by ADP - O
GC NNP - B-ORG
- HYPH - I-ORG
MS NNP - I-ORG
and CCONJ - O
by ADP - O
HS NNP - B-ORG
- HYPH - I-ORG
SPME NNP - I-ORG
- HYPH - I-ORG
GC×GC NNP - I-ORG
- HYPH - I-ORG
TOFMS NN - I-ORG
analysis NOUN - O
. PUNCT - O

Relative ADJ - O
differences NOUN - O
in ADP - O
the DET - O
abundance NOUN - O
of ADP - O
minor ADJ - O
terpenes NOUN - O
as ADP - O
limonene NOUN - O
, PUNCT - O
α NOUN - O
- PUNCT - O
pinene NOUN - O
, PUNCT - O
γ NOUN - O
- PUNCT - O
terpinene ADJ - O
, PUNCT - O
p NOUN - O
- PUNCT - O
cymene NOUN - O
, PUNCT - O
terpinen-4-ol NOUN - O
, PUNCT - O
α NOUN - O
- PUNCT - O
terpineol NOUN - O
, PUNCT - O
and CCONJ - O
alloaromandrene NOUN - O
were VERB - O
pointed VERB - O
out PART - O
and CCONJ - O
seem VERB - O
to PART - O
be VERB - O
suitable ADJ - O
for ADP - O
differentiation NOUN - O
among ADP - O
EOs NOUN - O
of ADP - O
the DET - O
four CD - B-CARDINAL
different ADJ - O
Eucalyptus NNP - B-MEDICINE
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Occurrence NN - B-ORG
and CCONJ - O
distribution NOUN - O
of ADP - O
unsubstituted ADJ - O
B NOUN - O
- PUNCT - O
ring VERB - O
flavanones NOUN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
foliage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Potassium NOUN - O
( PUNCT - O
K PROPN - O
) PUNCT - O
is VERB - O
the DET - O
most ADV - O
required VERB - O
macronutrient NOUN - O
by ADP - O
Eucalyptus NNP - B-MEDICINE
, PUNCT - O
while ADP - O
sodium NOUN - O
( PUNCT - O
Na PROPN - O
) PUNCT - O
can VERB - O
partially ADV - O
substitute VERB - O
some DET - O
physiological ADJ - O
functions NOUN - O
of ADP - O
K NNP - B-ORG
and CCONJ - O
have VERB - O
a DET - O
positive ADJ - O
response NOUN - O
on ADP - O
plant NOUN - O
growth NOUN - O
in ADP - O
K PROPN - O
- PUNCT - O
depleted VERB - O
tropical ADJ - O
soils NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
the DET - O
right ADJ - O
percentage NOUN - O
of ADP - O
K PROPN - O
substitution NOUN - O
by ADP - O
Na NNP - B-PERSON
is VERB - O
not ADV - O
yet ADV - O
known VERB - O
for ADP - O
Eucalyptus NNP - B-MEDICINE
seedlings NOUN - O
, PUNCT - O
since ADP - O
a DET - O
few ADJ - O
experiments NOUN - O
have VERB - O
only ADV - O
compared VERB - O
treatments NOUN - O
receiving VERB - O
K PROPN - O
or CCONJ - O
Na NNP - B-PERSON
. PUNCT - O

This DET - O
study NOUN - O
evaluated VERB - O
five CD - B-CARDINAL
levels NOUN - O
of ADP - O
Na PROPN - O
supply NOUN - O
( PUNCT - O
0 NUM - O
, PUNCT - O
0.45 CD - B-CARDINAL
, PUNCT - O
0.90 CD - B-CARDINAL
, PUNCT - O
1.35 CD - B-GPE
and CCONJ - O
1.80 CD - B-CARDINAL
  SPACE - O
mM NUM - O
) PUNCT - O
as ADP - O
substitution NOUN - O
for ADP - O
K PROPN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
seedlings NOUN - O
grown VERB - O
in ADP - O
nutrient NOUN - O
solution NOUN - O
. PUNCT - O

This DET - O
nutritional ADJ - O
management NOUN - O
can VERB - O
therefore ADV - O
be VERB - O
an DET - O
alternative ADJ - O
option NOUN - O
to PART - O
optimize VERB - O
yields NOUN - O
and CCONJ - O
resource NOUN - O
use NOUN - O
efficiencies NOUN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
cultivation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Large ADJ - O
areas NOUN - O
in ADP - O
tropical ADJ - O
countries NOUN - O
were VERB - O
converted VERB - O
into ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
for ADP - O
pulp NOUN - O
production NOUN - O
. PUNCT - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
we PRON - O
compared VERB - O
fruit NOUN - O
- PUNCT - O
feeding VERB - O
butterfly NOUN - O
assemblages NOUN - O
from ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
, PUNCT - O
forest NOUN - O
fragments NOUN - O
immersed VERB - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
and CCONJ - O
samples NOUN - O
inside ADP - O
a DET - O
continuous ADJ - O
forest NOUN - O
tract NOUN - O
on ADP - O
an DET - O
extremely ADV - O
rich ADJ - O
and CCONJ - O
threatened ADJ - O
area NOUN - O
of ADP - O
Atlantic NNP - B-LOC
forest NOUN - O
in ADP - O
Brazil NNP - B-GPE
. PUNCT - O

It PRON - O
is VERB - O
clear ADJ - O
that ADP - O
Eucalyptus NNP - B-MEDICINE
sp X - O
. PUNCT - O

-DOCSTART- -X- - O

Plant NOUN - O
genus NOUN - O
( PUNCT - O
Acacia NNP - B-PERSON
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
) PUNCT - O
alters VERB - O
soil NOUN - O
microbial ADJ - O
community NOUN - O
structure NOUN - O
and CCONJ - O
relative ADJ - O
abundance NOUN - O
within ADP - O
revegetated ADJ - O
shelterbelts NOUN - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
essential ADJ - O
oil NOUN - O
was VERB - O
tested VERB - O
on ADP - O
major ADJ - O
mosquito ADJ - O
species NOUN - O
and CCONJ - O
toxicity NOUN - O
was VERB - O
compared VERB - O
with ADP - O
temephos NOUN - O
. PUNCT - O

Our ADJ - O
findings NOUN - O
suggest VERB - O
that ADP - O
essential ADJ - O
oil NOUN - O
from ADP - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
leaves NOUN - O
can VERB - O
be VERB - O
used VERB - O
for ADP - O
control NOUN - O
of ADP - O
mosquito ADJ - O
larvae NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Phenolic NOUN - O
compounds NOUN - O
and CCONJ - O
antioxidants VERB - O
from ADP - O
Eucalyptus NNP - B-MEDICINE
camaldulensis NOUN - O
as ADP - O
affected VERB - O
by ADP - O
some DET - O
extraction NOUN - O
conditions NOUN - O
, PUNCT - O
a DET - O
preparative ADJ - O
optimization NOUN - O
for ADP - O
GC PROPN - O
- PUNCT - O
MS PROPN - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Standardized ADJ - O
Synthetic PROPN - O
Eucalyptus NNP - B-MEDICINE
Transcription PROPN - O
Factor PROPN - O
and CCONJ - O
Promoter PROPN - O
Panel PROPN - O
for ADP - O
Re PROPN - O
- NOUN - O
engineering PROPN - O
Secondary PROPN - O
Cell PROPN - O
Wall PROPN - O
Regulation PROPN - O
in ADP - O
Biomass NNP - B-GPE
and CCONJ - O
Bioenergy NNP - B-GPE
Crops PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

Acacia NNP - B-PERSON
mearnsii NOUN - O
is VERB - O
considered VERB - O
a DET - O
highly ADV - O
invasive ADJ - O
species NOUN - O
that ADJ - O
is VERB - O
replacing VERB - O
native ADJ - O
species NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
are VERB - O
known VERB - O
to PART - O
consume VERB - O
high ADJ - O
amounts NOUN - O
of ADP - O
groundwater NOUN - O
with ADP - O
suspected VERB - O
effects NOUN - O
on ADP - O
native ADJ - O
flora NOUN - O
. PUNCT - O

We PRON - O
used VERB - O
a DET - O
one CD - B-CARDINAL
class NOUN - O
biased VERB - O
support NOUN - O
vector NOUN - O
machine NOUN - O
( PUNCT - O
BSVM NNP - B-ORG
) PUNCT - O
classifier ADJ - O
as ADP - O
it PRON - O
needs VERB - O
labeled VERB - O
training NOUN - O
data NOUN - O
only ADV - O
for ADP - O
the DET - O
positive ADJ - O
classes NOUN - O
( PUNCT - O
A. NOUN - O
mearnsii NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
) PUNCT - O
, PUNCT - O
which ADJ - O
potentially ADV - O
reduces VERB - O
the DET - O
amount NOUN - O
of ADP - O
required VERB - O
fieldwork NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
the DET - O
BSVM NNP - B-ORG
classifier NOUN - O
is VERB - O
suitable ADJ - O
for ADP - O
mapping VERB - O
Acacia NNP - B-PERSON
mearnsii NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O
, PUNCT - O
holding VERB - O
the DET - O
potential NOUN - O
to PART - O
improve VERB - O
the DET - O
efficiency NOUN - O
of ADP - O
field NOUN - O
data NOUN - O
collection NOUN - O
. PUNCT - O

The DET - O
crown NOUN - O
level NOUN - O
F1-score EX - B-ORG
was VERB - O
0.76 CD - B-CARDINAL
for ADP - O
Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

We PRON - O
show VERB - O
that ADP - O
Eucalyptus NNP - B-MEDICINE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
is VERB - O
in ADP - O
this DET - O
perspective NOUN - O
that ADJ - O
our ADJ - O
study NOUN - O
was VERB - O
undertaken VERB - O
with ADP - O
the DET - O
objective NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
phenological ADJ - O
stage NOUN - O
effect NOUN - O
on ADP - O
the DET - O
yield NOUN - O
and CCONJ - O
chemical NOUN - O
composition NOUN - O
of ADP - O
essential ADJ - O
oils NOUN - O
extracted VERB - O
from ADP - O
Tunisian NNP - B-ORG
Eucalyptus NNP - I-MEDICINE
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
L. NNP - B-PERSON
) PUNCT - O
aerial ADJ - O
parts NOUN - O
. PUNCT - O

In ADP - O
relation NOUN - O
to ADP - O
the DET - O
phenological ADJ - O
stage NOUN - O
, PUNCT - O
Eucalyptus NNP - B-MEDICINE
essential ADJ - O
oil NOUN - O
showed VERB - O
potent ADJ - O
capacity NOUN - O
to PART - O
reduce VERB - O
stable ADJ - O
free ADJ - O
radical ADJ - O
DPPH NOUN - O
( PUNCT - O
IC50 VERB - O
up ADP - O
to ADP - O
740 NUM - O
μg NOUN - O
/ SYM - O
mL NOUN - O
) PUNCT - O
and CCONJ - O
moderate ADJ - O
ability NOUN - O
to PART - O
reduce VERB - O
the DET - O
concentration NOUN - O
of ADP - O
iron NOUN - O
ions NOUN - O
( PUNCT - O
EC50 PROPN - O
and CCONJ - O
IC50 PROPN - O
up ADP - O
to ADP - O
2 NUM - O
and CCONJ - O
12 NUM - O
mg NOUN - O
/ SYM - O
mL PROPN - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
essential ADJ - O
oil NOUN - O
was VERB - O
active ADJ - O
against ADP - O
the DET - O
different ADJ - O
bacterial ADJ - O
strains VERB - O
especially ADV - O
during ADP - O
the DET - O
vegetative ADJ - O
and CCONJ - O
full ADJ - O
flowering ADJ - O
stages NOUN - O
( PUNCT - O
MIC NNP - B-ORG
= SYM - O
2 CD - B-CARDINAL
mg PRON - O
/ SYM - O
mL PROPN - O
) PUNCT - O
against ADP - O
Bacillus PROPN - O
cereus PROPN - O
ATCC PROPN - O
14579 NUM - O
and CCONJ - O
Enterococcus NNP - B-PRODUCT
faecalis NOUN - O
ATCC NNP - B-DATE
29212 CD - I-DATE
. PUNCT - O

The DET - O
combination NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
essential ADJ - O
oil NOUN - O
with ADP - O
ampicillin NOUN - O
revealed VERB - O
a DET - O
partial ADJ - O
synergy NOUN - O
effect NOUN - O
toward ADP - O
Methicillin NNP - B-GPE
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-PERSON
aureus NOUN - O
( PUNCT - O
FICI NNP - B-ORG
of ADP - O
0.53 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Nevertheless ADV - O
, PUNCT - O
an DET - O
addition NOUN - O
effect NOUN - O
was VERB - O
recorded VERB - O
under ADP - O
the DET - O
combination NOUN - O
of ADP - O
amphotericin NOUN - O
B NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
essential ADJ - O
oil NOUN - O
. PUNCT - O

The DET - O
cytototoxity NOUN - O
activity NOUN - O
showed VERB - O
that ADP - O
these DET - O
associations NOUN - O
enhanced VERB - O
cell NOUN - O
viability NOUN - O
and CCONJ - O
made VERB - O
Eucalyptus NNP - B-MEDICINE
essential ADJ - O
oil NOUN - O
non PUNCT - O
toxic ADJ - O
toward ADP - O
Vero NN - B-PERSON
cells NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
the DET - O
precious ADJ - O
Eucalyptus NNP - B-MEDICINE
oil NOUN - O
in ADP - O
association NOUN - O
with ADP - O
antimicrobial ADJ - O
agents NOUN - O
could VERB - O
be VERB - O
not ADV - O
only ADV - O
a DET - O
promising ADJ - O
alternative NOUN - O
but CCONJ - O
also ADV - O
a DET - O
potential ADJ - O
molecular ADJ - O
complex NOUN - O
which ADJ - O
is VERB - O
hardly ADV - O
recognizable ADJ - O
by ADP - O
microorganisms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

2.9 CD - B-CARDINAL
and CCONJ - O
its ADJ - O
potential NOUN - O
for ADP - O
delignification NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
biomass NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
isolates NOUN - O
of ADP - O
Huntiella NNP - B-PERSON
spp NOUN - O
. PUNCT - O
were VERB - O
collected VERB - O
from ADP - O
stumps NOUN - O
of ADP - O
freshly ADV - O
felled VERB - O
trees NOUN - O
or CCONJ - O
wounds NOUN - O
on ADP - O
plantation NOUN - O
- PUNCT - O
grown VERB - O
Eucalyptus NNP - B-MEDICINE
in ADP - O
Guangdong NNP - B-GPE
, PUNCT - O
Guangxi NNP - B-GPE
, PUNCT - O
Fujian NNP - B-GPE
, PUNCT - O
and CCONJ - O
Hainan NNP - B-GPE
provinces NOUN - O
of ADP - O
southern ADJ - O
China NNP - B-GPE
. PUNCT - O

Additional ADJ - O
isolates NOUN - O
were VERB - O
obtained VERB - O
from ADP - O
stumps NOUN - O
of ADP - O
Acacia NNP - B-PERSON
confusa NOUN - O
near ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
in ADP - O
Hainan NNP - B-GPE
Province NNP - I-GPE
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
identify VERB - O
these DET - O
Huntiella NNP - B-PERSON
species NOUN - O
and CCONJ - O
to PART - O
test VERB - O
their ADJ - O
pathogenicity NOUN - O
on ADP - O
Eucalyptus NNP - B-MEDICINE
seedlings NOUN - O
. PUNCT - O

( PUNCT - O
TEF1α NNP - B-PERSON
) PUNCT - O
genes NOUN - O
revealed VERB - O
nine CD - B-CARDINAL
previously ADV - O
unknown ADJ - O
Huntiella NNP - B-PERSON
species VERB - O
, PUNCT - O
eight CD - B-CARDINAL
from ADP - O
Eucalyptus NNP - B-MEDICINE
and CCONJ - O
one CD - B-CARDINAL
from ADP - O
A. NN - B-QUANTITY
confusa NN - I-QUANTITY
. PUNCT - O

Pathogenicity NOUN - O
tests NOUN - O
showed VERB - O
that ADP - O
the DET - O
nine CD - B-CARDINAL
Huntiella NNP - B-ORG
species NOUN - O
can VERB - O
produce VERB - O
lesions NOUN - O
on ADP - O
Eucalyptus NNP - B-MEDICINE
seedlings NOUN - O
, PUNCT - O
larger ADJ - O
than ADP - O
wounds NOUN - O
caused VERB - O
by ADP - O
controls NOUN - O
on ADP - O
these DET - O
plants NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
, PUNCT - O
Chestnut NNP - B-GPE
and CCONJ - O
Heather NNP - B-PERSON
Honeys NNP - I-PERSON
from ADP - O
Portugal NNP - B-GPE
Using PROPN - O
Multi PROPN - O
- PUNCT - O
Parameter PROPN - O
Analysis PROPN - O
and CCONJ - O
Chemo NNP - B-ORG
- HYPH - I-ORG
Calculus NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Short ADJ - O
- PUNCT - O
term NOUN - O
effect NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
on ADP - O
soil NOUN - O
microbial ADJ - O
communities NOUN - O
and CCONJ - O
soil NOUN - O
- PUNCT - O
atmosphere NOUN - O
methane NOUN - O
and CCONJ - O
nitrous ADJ - O
oxide NOUN - O
exchange NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Micromorphological ADJ - O
observation NOUN - O
of ADP - O
seed NOUN - O
coat NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
species NOUN - O
( PUNCT - O
Myrtaceae NNP - B-ORG
) PUNCT - O
using VERB - O
scanning VERB - O
electron ADJ - O
microscopy NOUN - O
technique NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Range NOUN - O
size NOUN - O
and CCONJ - O
growth NOUN - O
temperature NOUN - O
influence NOUN - O
Eucalyptus NNP - B-MEDICINE
species VERB - O
responses NOUN - O
to ADP - O
an DET - O
experimental ADJ - O
heatwave NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalypglobulusals PROPN - O
A PROPN - O
- PUNCT - O
J PROPN - O
, PUNCT - O
Formyl NNP - B-ORG
- HYPH - I-ORG
Phloroglucinol NNP - I-ORG
- PUNCT - O
Terpene NNP - B-PERSON
Meroterpenoids NNPS - I-PERSON
from ADP - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
Fruits NNPS - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Medium ADJ - O
- PUNCT - O
term NOUN - O
vegetation NOUN - O
recovery NOUN - O
after ADP - O
removal NOUN - O
of ADP - O
invasive ADJ - O
Eucalyptus NNP - B-MEDICINE
camaldulensis NOUN - O
stands VERB - O
along ADP - O
a DET - O
South JJ - B-NORP
African JJ - I-NORP
river NOUN - O

-DOCSTART- -X- - O

Understanding VERB - O
structural ADJ - O
changes NOUN - O
in ADP - O
the DET - O
lignin NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
urophylla NOUN - O
during ADP - O
pretreatment NOUN - O
with ADP - O
an DET - O
ionic ADJ - O
liquid NOUN - O
- PUNCT - O
water NOUN - O
mixture NOUN - O

-DOCSTART- -X- - O

Because ADP - O
of ADP - O
its ADJ - O
high ADJ - O
growth NOUN - O
rate NOUN - O
, PUNCT - O
Eucalyptus NNP - B-MEDICINE
camaldulensis NOUN - O
has VERB - O
been VERB - O
introduced VERB - O
for ADP - O
plantation NOUN - O
production NOUN - O
in ADP - O
many ADJ - O
tropical ADJ - O
and CCONJ - O
subtropical ADJ - O
areas NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
bark NOUN - O
is VERB - O
a DET - O
residue NOUN - O
from ADP - O
the DET - O
pulp NOUN - O
industry NOUN - O
, PUNCT - O
traditionally ADV - O
used VERB - O
for ADP - O
energy NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
essential ADJ - O
oil NOUN - O
emulsions NOUN - O
exhibited VERB - O
antimicrobial ADJ - O
activity NOUN - O
against ADP - O
E. PROPN - O
coli NOUN - O
, PUNCT - O
S. PROPN - O
aureus PROPN - O
, PUNCT - O
and CCONJ - O
P. NNP - B-PERSON
aeruginosa NOUN - O
in ADP - O
less ADJ - O
than ADP - O
1 NUM - O
  SPACE - O
min NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Aloe NNP - B-ORG
vera NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
methanolic NOUN - O
extracts NOUN - O
on ADP - O
experimental ADJ - O
toxoplasmosis NOUN - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Genome ADV - O
- PUNCT - O
wide ADJ - O
analysis NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
grandis NOUN - O
WRKY PROPN - O
genes VERB - O
family NOUN - O
and CCONJ - O
their ADJ - O
expression NOUN - O
profiling VERB - O
in ADP - O
response NOUN - O
to ADP - O
hormone NOUN - O
and CCONJ - O
abiotic ADJ - O
stress NOUN - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
citriodora NOUN - O
essential ADJ - O
oil NOUN - O
and CCONJ - O
its ADJ - O
major ADJ - O
component NOUN - O
, PUNCT - O
citronellal NOUN - O
, PUNCT - O
on ADP - O
Haemonchus NNP - B-ORG
contortus NOUN - O
isolates VERB - O
susceptible ADJ - O
and CCONJ - O
resistant ADJ - O
to ADP - O
synthetic ADJ - O
anthelmintics NOUN - O

-DOCSTART- -X- - O

A DET - O
novel ADJ - O
pretreatment NOUN - O
strategy NOUN - O
based VERB - O
on ADP - O
combination NOUN - O
of ADP - O
microwave NOUN - O
and CCONJ - O
ionic ADJ - O
liquid NOUN - O
[ PUNCT - O
TBA][OH CD - B-PERSON
] PUNCT - O
was VERB - O
developed VERB - O
for ADP - O
enhancing VERB - O
enzymatic ADJ - O
hydrolysis NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
sawdust VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Photosynthetic ADJ - O
capacity NOUN - O
and CCONJ - O
leaf NOUN - O
nitrogen NOUN - O
decline NOUN - O
along ADP - O
a DET - O
controlled VERB - O
climate NOUN - O
gradient NOUN - O
in ADP - O
provenances NOUN - O
of ADP - O
two CD - B-CARDINAL
widely ADV - O
distributed VERB - O
Eucalyptus NNP - B-MEDICINE
species NOUN - O

-DOCSTART- -X- - O

The DET - O
color NOUN - O
changes VERB - O
corresponding VERB - O
to ADP - O
chromophore ADJ - O
structures NOUN - O
in ADP - O
lignin NOUN - O
caused VERB - O
by ADP - O
exposure NOUN - O
of ADP - O
Eucalyptus（Eucalyptus NNP - B-ORG
grandis NOUN - O
and CCONJ - O
E. PROPN - O
urophylla）to ADJ - O
heat NOUN - O
were VERB - O
investigated VERB - O
. PUNCT - O

Eucalyptus NNP - B-MEDICINE
wood NOUN - O
samples NOUN - O
were VERB - O
heated VERB - O
in ADP - O
saturated ADJ - O
steam NOUN - O
atmospheres NOUN - O
for ADP - O
10 CD - B-CARDINAL
h NOUN - O
at ADP - O
110 CD - B-DATE
℃ NNS - I-DATE
, PUNCT - O
130 CD - B-CARDINAL
℃ NOUN - O
, PUNCT - O
and CCONJ - O
150 CD - B-CARDINAL
℃ NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Low PROPN - O
Dose PROPN - O
of ADP - O
Nanocapsules PROPN - O
Containing PROPN - O
Eucalyptus NNP - B-MEDICINE
Oil PROPN - O
Has VERB - O
Beneficial PROPN - O
Repellent NOUN - O
Effect NOUN - O
Against ADP - O
Horn PROPN - O
Fly PROPN - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
examined VERB - O
the DET - O
capacity NOUN - O
of ADP - O
woody NOUN - O
species VERB - O
from ADP - O
two CD - B-CARDINAL
genera NOUN - O
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
and CC - I-ORG
Quercus NNP - B-ORG
) PUNCT - O
to PART - O
refill VERB - O
embolized VERB - O
xylem NOUN - O
vessels NOUN - O
during ADP - O
a DET - O
cycle NOUN - O
of ADP - O
drought NOUN - O
and CCONJ - O
recovery NOUN - O
. PUNCT - O

Observations NOUN - O
were VERB - O
made VERB - O
on ADP - O
intact ADJ - O
plants NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
calmudulensis NOUN - O
, PUNCT - O
E. PROPN - O
grandis PROPN - O
, PUNCT - O
E. PROPN - O
saligna NOUN - O
and CCONJ - O
Quercus NNP - B-ORG
palustris NOUN - O
using VERB - O
X NOUN - O
- NOUN - O
ray NOUN - O
microtomography NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
previous ADJ - O
experiments NOUN - O
, PUNCT - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
leaves NOUN - O
incorporated VERB - O
into ADP - O
the DET - O
soil NOUN - O
as ADP - O
green ADJ - O
manure NOUN - O
were VERB - O
shown VERB - O
to PART - O
have VERB - O
a DET - O
notable ADJ - O
potential NOUN - O
for ADP - O
weed NOUN - O
control NOUN - O
. PUNCT - O

Eucalyptus NNP - B-MEDICINE
leaves VERB - O
incorporated VERB - O
into ADP - O
the DET - O
soil NOUN - O
as ADP - O
green ADJ - O
manure NOUN - O
showed VERB - O
a DET - O
continuous ADJ - O
release NOUN - O
of ADP - O
different ADJ - O
phenolic NOUN - O
and CCONJ - O
volatile ADJ - O
compounds NOUN - O
during ADP - O
a DET - O
30-day CD - B-DATE
period NOUN - O
of ADP - O
decomposition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

: PUNCT - O
The DET - O
aim NOUN - O
is VERB - O
to PART - O
assess VERB - O
the DET - O
antimicrobial ADJ - O
efficacy NOUN - O
of ADP - O
Acacia NNP - B-PERSON
nilotica NOUN - O
, PUNCT - O
Murraya NNP - B-PERSON
koenigii NOUN - O
L. NNP - B-PERSON
Sprengel NNP - I-PERSON
, PUNCT - O
Eucalyptus NNP - B-MEDICINE
hybrid NOUN - O
, PUNCT - O
Psidium NNP - B-PERSON
guajava VERB - O
extracts NOUN - O
and CCONJ - O
their ADJ - O
combinations NOUN - O
on ADP - O
Fusobacterium NNP - B-ORG
nucleatum NOUN - O
( PUNCT - O
Fn PROPN - O
) PUNCT - O
and CCONJ - O
Porphyromonas NNP - B-ORG
gingivalis NOUN - O
( PUNCT - O
Pg PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Brassinazole PROPN - O
resistant ADJ - O
( PUNCT - O
BZR NNP - B-ORG
) PUNCT - O
gene NOUN - O
family NOUN - O
and CCONJ - O
stress NOUN - O
induced VERB - O
expression NOUN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
grandis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
response NOUN - O
to ADP - O
infection NOUN - O
of ADP - O
Austropuccinia NNP - B-GPE
psidii NOUN - O
in ADP - O
resistant ADJ - O
( PUNCT - O
CLR-383 NN - B-ORG
) PUNCT - O
and CCONJ - O
susceptible ADJ - O
( PUNCT - O
CLR-384 PROPN - O
) PUNCT - O
Eucalyptus NNP - B-MEDICINE
grandis NOUN - O
clones NOUN - O
, PUNCT - O
exposed VERB - O
to PART - O
herbicide VERB - O
drift NOUN - O
of ADP - O
carfentrazone NOUN - O
- PUNCT - O
ethyl ADV - O
, PUNCT - O
glyphosate NOUN - O
and CCONJ - O
a DET - O
mixture NOUN - O
of ADP - O
these DET - O
two CD - B-CARDINAL
herbicides NOUN - O
, PUNCT - O
was VERB - O
evaluated VERB - O
at ADP - O
microscopic ADJ - O
and CCONJ - O
physiological ADJ - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hosts NOUN - O
are VERB - O
Araliaceae NNP - B-PERSON
( PUNCT - O
Astrotricha PROPN - O
) PUNCT - O
, PUNCT - O
Proteaceae NNP - B-PERSON
( PUNCT - O
Lomatia PROPN - O
) PUNCT - O
and CCONJ - O
possibly ADV - O
Myrtaceae NNP - B-PERSON
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
set VERB - O
on PART - O
optimized VERB - O
biodiesel NOUN - O
production NOUN - O
and CCONJ - O
formulation NOUN - O
of ADP - O
emulsified VERB - O
Eucalyptus NNP - B-MEDICINE
teriticornisis NOUN - O
biodiesel NOUN - O
for ADP - O
usage NOUN - O
in ADP - O
compression NOUN - O
ignition NOUN - O
engine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
sampled VERB - O
two CD - B-CARDINAL
edge NOUN - O
types NOUN - O
( PUNCT - O
primary‐secondary PROPN - O
and CCONJ - O
primary‐Eucalyptus PROPN - O
forest NOUN - O
) PUNCT - O
and CCONJ - O
three CD - B-CARDINAL
control NOUN - O
sites NOUN - O
immersed VERB - O
in ADP - O
primary ADJ - O
, PUNCT - O
secondary ADJ - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
forest NOUN - O
. PUNCT - O

Turnover NOUN - O
but CCONJ - O
not ADV - O
nestedness NOUN - O
was VERB - O
greater ADJ - O
across ADP - O
the DET - O
primary‐Eucalyptus PROPN - O
forest NOUN - O
than ADP - O
primary‐secondary NUM - O
forest NOUN - O
edge NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
globulus</em NOUN - O
> X - O
Plantations NNPS - B-ORG
Across IN - I-ORG
an DT - I-ORG
Environmental JJ - I-ORG
Gradient NN - I-ORG

-DOCSTART- -X- - O

Eucalyptus NN - B-MEDICINE
ash NOUN - O
alters VERB - O
secondary ADJ - O
protein NOUN - O
conformation NOUN - O
of ADP - O
human ADJ - O
grey ADJ - O
hair NOUN - O
and CCONJ - O
facilitates NOUN - O
anthocyanin NOUN - O
dyeing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NN - B-MEDICINE
forest NOUN - O
reproductive ADJ - O
material NOUN - O
responded VERB - O
differently ADV - O
to ADP - O
the DET - O
imposed VERB - O
water NOUN - O
scenarios NOUN - O
through ADP - O
different ADJ - O
water NOUN - O
resistance NOUN - O
mechanisms NOUN - O
. PUNCT - O

Eucalyptus NNP - B-MEDICINE
is VERB - O
amongst ADP - O
the DET - O
most ADV - O
planted ADJ - O
genera NOUN - O
in ADP - O
the DET - O
world NOUN - O
. PUNCT - O

The DET - O
performance NOUN - O
of ADP - O
two CD - B-CARDINAL
Eucalyptus NNP - B-MEDICINE
species NOUN - O
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
and CCONJ - O
Eucalyptus NNP - B-MEDICINE
nitens NOUN - O
) PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
hybrid NOUN - O
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
  SPACE - O
× NUM - O
  SPACE - O
Eucalyptus NNP - B-MEDICINE
cypellocarpa NOUN - O
) PUNCT - O
, PUNCT - O
under ADP - O
such ADJ - O
conditions NOUN - O
, PUNCT - O
was VERB - O
assessed VERB - O
through ADP - O
several ADJ - O
morphological ADJ - O
and CCONJ - O
physiological ADJ - O
traits NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Thirteen CD - B-DATE
years NNS - I-DATE
under ADP - O
arid NOUN - O
conditions NOUN - O
: PUNCT - O
exploring VERB - O
marker NOUN - O
- PUNCT - O
trait NOUN - O
associations NOUN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
cladocalyx NOUN - O
for ADP - O
complex ADJ - O
traits NOUN - O
related VERB - O
to ADP - O
flowering VERB - O
, PUNCT - O
stem NOUN - O
form NOUN - O
and CCONJ - O
growth NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Terpenes NOUN - O
associated VERB - O
with ADP - O
resistance NOUN - O
against ADP - O
the DET - O
gall NOUN - O
wasp NOUN - O
, PUNCT - O
Leptocybe NNP - B-ORG
invasa NOUN - O
, PUNCT - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
grandis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Surface NOUN - O
area NOUN - O
and CCONJ - O
pore NOUN - O
size NOUN - O
distribution NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
samples NOUN - O
pretreated VERB - O
by ADP - O
different ADJ - O
methods NOUN - O
were VERB - O
determined VERB - O
by ADP - O
the DT - B-ORG
Brunauer NNP - I-ORG
- HYPH - I-ORG
Emmett NNP - I-ORG
- HYPH - I-ORG
Teller NNP - I-ORG
( PUNCT - O
BET NNP - B-ORG
) PUNCT - O
technique NOUN - O
. PUNCT - O

Surface NOUN - O
area NOUN - O
of ADP - O
CPD NNP - B-ORG
prepared ADJ - O
Eucalyptus NNP - B-MEDICINE
samples NOUN - O
was VERB - O
determined VERB - O
to PART - O
be VERB - O
58&ndash;161 JJ - B-ORG
m2/g NOUN - O
, PUNCT - O
whereas ADP - O
air NOUN - O
and CCONJ - O
freeze NOUN - O
dried VERB - O
samples NOUN - O
were VERB - O
0.5&ndash;1.3 NNS - B-CARDINAL
and CCONJ - O
1.0&ndash;2.4 NNS - B-ORG
m2/g NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Average ADJ - O
pore NOUN - O
diameter NOUN - O
of ADP - O
CPD NNP - B-ORG
prepared ADJ - O
Eucalyptus NNP - B-MEDICINE
samples NOUN - O
were VERB - O
61&ndash;70&Aring;. NUM - O

CPD NNP - B-ORG
preserved VERB - O
Eucalyptus NNP - B-MEDICINE
sample NOUN - O
morphology NOUN - O
by ADP - O
replacing VERB - O
water NOUN - O
with ADP - O
a DET - O
non ADJ - O
- ADJ - O
polar ADJ - O
solvent NOUN - O
, PUNCT - O
CO2 NNP - B-ORG
fluid NOUN - O
, PUNCT - O
which ADJ - O
prevented VERB - O
hydrogen NOUN - O
bond NOUN - O
reformation NOUN - O
in ADP - O
the DET - O
cellulose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NN - B-MEDICINE
microcorys NOUN - O
leaf NOUN - O
extract NOUN - O
derived VERB - O
HPLC NN - B-ORG
- PUNCT - O
fraction NOUN - O
reduces VERB - O
the DET - O
viability NOUN - O
of ADP - O
MIA NNP - B-ORG
PaCa-2 PROPN - O
cells NOUN - O
by ADP - O
inducing VERB - O
apoptosis NOUN - O
and CCONJ - O
arresting VERB - O
cell NOUN - O
cycle NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Range NOUN - O
analysis NOUN - O
of ADP - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
bark NOUN - O
low ADJ - O
- PUNCT - O
temperature NOUN - O
hydrothermal ADJ - O
treatment NOUN - O
to PART - O
produce VERB - O
a DET - O
new ADJ - O
component NOUN - O
for ADP - O
growing VERB - O
media NOUN - O
industry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Homogenization PROPN - O
and CCONJ - O
impoverishment NOUN - O
of ADP - O
taxonomic ADJ - O
and CCONJ - O
functional ADJ - O
diversity NOUN - O
of ADP - O
ants NOUN - O
in ADP - O
Eucalyptus NNP - B-MEDICINE
plantations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
UDP PROPN - O
glucosyltransferases NOUN - O
from ADP - O
the DET - O
aluminum NOUN - O
- PUNCT - O
resistant ADJ - O
tree NOUN - O
Eucalyptus NNP - B-MEDICINE
camaldulensis NOUN - O
forming VERB - O
β DET - O
- PUNCT - O
glucogallin NOUN - O
, PUNCT - O
the DET - O
precursor NOUN - O
of ADP - O
hydrolyzable ADJ - O
tannins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
is VERB - O
employed VERB - O
as ADP - O
herbal ADJ - O
tea NOUN - O
and CCONJ - O
therapeutical ADJ - O
purposes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
capacity NOUN - O
willow NOUN - O
( PUNCT - O
Salix NNP - B-PERSON
matsudana NOUN - O
, PUNCT - O
cv PROPN - O
Levante NNP - B-PERSON
) PUNCT - O
, PUNCT - O
poplar NOUN - O
( PUNCT - O
Populus NOUN - O
deltoides VERB - O
× PROPN - O
Populus PROPN - O
nigra NOUN - O
, PUNCT - O
cv PROPN - O
Orion PROPN - O
) PUNCT - O
, PUNCT - O
eucalyptus NN - B-MEDICINE
( PUNCT - O
Eucalyptus NNP - B-MEDICINE
camaldulensis NOUN - O
) PUNCT - O
and CCONJ - O
sunflower NOUN - O
( PUNCT - O
Helianthus PROPN - O
annuus NOUN - O
) PUNCT - O
to PART - O
clean VERB - O
MSS NNP - B-ORG
, PUNCT - O
which ADJ - O
is VERB - O
slightly ADV - O
contaminated VERB - O
by ADP - O
trace NOUN - O
elements NOUN - O
( PUNCT - O
TEs PROPN - O
) PUNCT - O
and CCONJ - O
organic ADJ - O
pollutants NOUN - O
, PUNCT - O
and CCONJ - O
to PART - O
assess VERB - O
their ADJ - O
physiological ADJ - O
response NOUN - O
to ADP - O
this DET - O
medium NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
potential NOUN - O
of ADP - O
genomic ADJ - O
selection NOUN - O
was VERB - O
investigated VERB - O
in ADP - O
an DET - O
advanced ADJ - O
Eucalyptus NNP - B-MEDICINE
nitens VERB - O
breeding VERB - O
population NOUN - O
focused VERB - O
on ADP - O
improvement NOUN - O
for ADP - O
solid ADJ - O
wood NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Elevated PROPN - O
CO2 NNP - B-ORG
concentrations NOUN - O
reduce VERB - O
C4 NOUN - O
cover NOUN - O
and CCONJ - O
decrease VERB - O
diversity NOUN - O
of ADP - O
understorey ADJ - O
plant NOUN - O
community NOUN - O
in ADP - O
a DET - O
Eucalyptus NNP - B-MEDICINE
woodland NOUN - O

-DOCSTART- -X- - O

To PART - O
understand VERB - O
the DET - O
effect NOUN - O
of ADP - O
eCa NOUN - O
in ADP - O
a DET - O
water‐limited NOUN - O
ecosystem NOUN - O
, PUNCT - O
we PRON - O
tested VERB - O
whether ADP - O
2 CD - B-DATE
years NNS - I-DATE
of ADP - O
eCa NOUN - O
( PUNCT - O
~40 NN - B-PERCENT
% NN - I-PERCENT
increase NOUN - O
) PUNCT - O
affected VERB - O
the DET - O
hydrological ADJ - O
partitioning NOUN - O
in ADP - O
a DET - O
mature NOUN - O
water‐limited VERB - O
Eucalyptus NNP - B-MEDICINE
woodland NOUN - O
exposed VERB - O
to ADP - O
Free‐Air CD - B-ORG
CO2 NN - I-ORG
Enrichment NNP - I-ORG
( PUNCT - O
FACE NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

What NOUN - O
drives VERB - O
Eucalyptus NNP - B-MEDICINE
globulus NOUN - O
natural ADJ - O
establishment NOUN - O
outside ADP - O
plantations NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Eucalyptus NNP - B-MEDICINE
robusta NOUN - O
( PUNCT - O
Smith PROPN - O
) PUNCT - O
is VERB - O
a DET - O
fast ADV - O
- PUNCT - O
growing VERB - O
and CCONJ - O
highly ADV - O
productive ADJ - O
timber NOUN - O
species NOUN - O
mostly ADV - O
located VERB - O
in ADP - O
the DET - O
upper ADJ - O
reaches NOUN - O
of ADP - O
Yangtze NNP - B-LOC
River NNP - I-LOC
in ADP - O
China NNP - B-GPE
( PUNCT - O
from ADP - O
24 CD - B-CARDINAL
to PART - O
30 CD - B-CARDINAL
° NNP - B-ORG
N NNP - I-ORG
, PUNCT - O
from ADP - O
100 CD - B-CARDINAL
to PART - O
111 CD - B-CARDINAL
° PROPN - O
E NUM - O
) PUNCT - O
. PUNCT - O

So ADV - O
far ADV - O
, PUNCT - O
the DET - O
symptoms NOUN - O
have VERB - O
only ADV - O
been VERB - O
reported VERB - O
as ADP - O
a DET - O
causal ADJ - O
agent NOUN - O
of ADP - O
a DET - O
disease NOUN - O
on ADP - O
Eucalyptus NNP - B-MEDICINE
in ADP - O
South NNP - B-GPE
Africa NNP - I-GPE
( PUNCT - O
Smith NNP - B-ORG
et NNP - I-ORG
al NNP - I-ORG
. PUNCT - O
1998 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Gemfibrozil NNP - B-MEDICINE
( PUNCT - O
GEM NOUN - O
) PUNCT - O
and CCONJ - O
carbamazepine NOUN - O
( PUNCT - O
CBZ NNP - B-ORG
) PUNCT - O
are VERB - O
two CD - B-CARDINAL
environmentally ADV - O
relevant ADJ - O
pharmaceuticals NOUN - O
and CCONJ - O
chronic ADJ - O
exposure NOUN - O
of ADP - O
fish NOUN - O
to ADP - O
these DET - O
compounds NOUN - O
has VERB - O
decreased VERB - O
androgen NOUN - O
levels NOUN - O
and CCONJ - O
fish NOUN - O
reproduction NOUN - O
in ADP - O
laboratory NOUN - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemfibrozil NNP - B-MEDICINE
had VERB - O
comparatively ADV - O
small ADJ - O
effects NOUN - O
on ADP - O
selexipag NOUN - O
( PUNCT - O
less JJR - B-CARDINAL
than IN - I-CARDINAL
2-fold CD - I-CARDINAL
difference NOUN - O
in ADP - O
any DET - O
pharmacokinetic ADJ - O
variable NOUN - O
) PUNCT - O
but CCONJ - O
, PUNCT - O
with ADP - O
respect NOUN - O
to ADP - O
ACT-333679 NNP - B-ORG
, PUNCT - O
increased VERB - O
the DET - O
maximum ADJ - O
plasma NOUN - O
concentration NOUN - O
( PUNCT - O
Cmax PROPN - O
) PUNCT - O
3.6-fold CD - B-CARDINAL
[ PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
3.1 CD - B-CARDINAL
, PUNCT - O
4.3 CD - B-CARDINAL
] PUNCT - O
and CCONJ - O
the DET - O
area NOUN - O
under ADP - O
the DET - O
plasma NOUN - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
curve NOUN - O
from ADP - O
zero CD - B-CARDINAL
to ADP - O
infinity NOUN - O
( PUNCT - O
AUC0-∞ PUNCT - O
) PUNCT - O
11.1-fold NUM - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
9.2 NUM - O
, PUNCT - O
13.4 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Hypertriglyceridemia NNP - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Acute PROPN - O
Pancreatitis PROPN - O
With ADP - O
Insulin NNP - B-GPE
, PUNCT - O
Heparin NNP - B-LOC
, PUNCT - O
and CCONJ - O
Gemfibrozil NNP - B-MEDICINE
: PUNCT - O
A DT - B-EVENT
Case NNP - I-EVENT
Series NNP - I-EVENT
. PUNCT - O

-DOCSTART- -X- - O

Peroxisome PROPN - O
Proliferator PROPN - O
- PUNCT - O
Activated PROPN - O
Receptor PROPN - O
α PROPN - O
Activation PROPN - O
Suppresses VERB - O
Cytochrome PROPN - O
P450 PROPN - O
Induction PROPN - O
Potential PROPN - O
in ADP - O
Mice NOUN - O
Treated VERB - O
with ADP - O
Gemfibrozil NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Association PROPN - O
of ADP - O
Serum PROPN - O
Triglyceride PROPN - O
Level PROPN - O
and CCONJ - O
Gemfibrozil NNP - B-MEDICINE
Consumption NNP - I-ORG

-DOCSTART- -X- - O

Higher ADJ - O
concentrations NOUN - O
of ADP - O
antidepressant ADJ - O
Sertraline NNP - B-ORG
( PUNCT - O
304 CD - B-CARDINAL
  SPACE - O
ng PROPN - O
  SPACE - O
L-1 PROPN - O
) PUNCT - O
, PUNCT - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
Diclofenac NN - B-ORG
( PUNCT - O
51.8 CD - B-MONEY
  _SP - I-MONEY
ng PROPN - O
  SPACE - O
L-1 PROPN - O
) PUNCT - O
, PUNCT - O
lipid ADJ - O
regulator NOUN - O
Gemfibrozil NNP - B-MEDICINE
( PUNCT - O
77.0 CD - B-CARDINAL
  SPACE - O
ng PROPN - O
  SPACE - O
L-1 PROPN - O
) PUNCT - O
, PUNCT - O
antihypertensive ADJ - O
Ibersartan NNP - B-ORG
( PUNCT - O
161.9 CD - B-MONEY
  _SP - I-MONEY
ng PROPN - O
  SPACE - O
L-1 PROPN - O
) PUNCT - O
or CCONJ - O
antibiotic ADJ - O
Doxycycline NNP - B-PERSON
( PUNCT - O
128.0 CD - B-CARDINAL
  SPACE - O
ng PROPN - O
  SPACE - O
L-1 PROPN - O
) PUNCT - O
, PUNCT - O
among ADP - O
others NOUN - O
, PUNCT - O
though ADP - O
localized VERB - O
may VERB - O
potentially ADV - O
impact VERB - O
key ADJ - O
estuarine NOUN - O
functions NOUN - O
or CCONJ - O
services NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hepatic PROPN - O
Disposition PROPN - O
of ADP - O
Gemfibrozil NNP - B-MEDICINE
and CCONJ - O
Its ADJ - O
Major PROPN - O
Metabolite NNP - B-PERSON
Gemfibrozil NNP - I-MEDICINE
1-O PROPN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
Glucuronide PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Prednisolone NNP - B-GPE
, PUNCT - O
L NNP - B-ORG
- HYPH - I-ORG
Asparaginase NNP - I-ORG
, PUNCT - O
Gemfibrozil NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Combinations PROPN - O
of ADP - O
These DET - O
Elements NOUN - O
on ADP - O
Mice PROPN - O
Lipid PROPN - O
Profile PROPN - O
, PUNCT - O
Liver NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Pancreas NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Quantitative JJ - B-ORG
Rationalization NNP - I-ORG
of IN - I-ORG
Gemfibrozil NNP - I-MEDICINE
Drug NNP - I-ORG
Interactions NNPS - I-ORG
: : - I-ORG
Consideration NN - I-ORG
of IN - I-ORG
Transporters NNP - I-ORG
- HYPH - I-ORG
Enzyme NNP - I-ORG
Interplay NNP - I-ORG
and CCONJ - O
the DT - B-ORG
Role NNP - I-ORG
of IN - I-ORG

Circulating PROPN - O
Metabolite PROPN - O
Gemfibrozil NNP - B-MEDICINE
1-O PROPN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
Glucuronide PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
between ADP - O
the DET - O
effect NOUN - O
of ADP - O
FF NNP - B-ORG
and CCONJ - O
Gemfibrozil NNP - B-MEDICINE
( PUNCT - O
GF PROPN - O
) PUNCT - O
on ADP - O
the DET - O
prognosis NOUN - O
of ADP - O
NAFLD NNP - B-ORG
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemfibrozil NNP - B-MEDICINE
disrupts VERB - O
the DET - O
metabolism NOUN - O
of ADP - O
circulating VERB - O
lipids NOUN - O
in ADP - O
bobwhite ADJ - O
quails NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
paper NOUN - O
, PUNCT - O
the DET - O
production NOUN - O
of ADP - O
xylanolytic ADJ - O
enzymes NOUN - O
and CCONJ - O
XOS NN - B-ORG
by ADP - O
three CD - B-CARDINAL
Aureobasidium NNP - B-ORG
pullulans NOUN - O
strains NOUN - O
was VERB - O
evaluated VERB - O
during ADP - O
submerged VERB - O
cultivation NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
use NOUN - O
of ADP - O
untreated ADJ - O
and CCONJ - O
alkali ADJ - O
pretreated VERB - O
agricultural ADJ - O
substrates NOUN - O
as ADP - O
sources NOUN - O
of ADP - O
xylan NOUN - O
for ADP - O
endo NOUN - O
- PUNCT - O
β-1,4-xylanase NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Anti ADJ - O
- ADJ - O
osteoporotic ADJ - O
effects NOUN - O
of ADP - O
mixed ADJ - O
compositions NOUN - O
of ADP - O
extracellular ADJ - O
polymers NOUN - O
isolated VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
and CCONJ - O
Textoria NNP - B-GPE
morbifera NOUN - O
in ADP - O
ovariectomized ADJ - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

L1 NNP - B-PERSON
and CCONJ - O
L8 PROPN - O
are VERB - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strains NOUN - O
previously ADV - O
shown VERB - O
to PART - O
effectively ADV - O
act VERB - O
as ADP - O
biocontrol NOUN - O
agents NOUN - O
( PUNCT - O
BCA NNP - B-ORG
) PUNCT - O
against ADP - O
fruit NOUN - O
postharvest NOUN - O
pathogens NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Molecular ADJ - O
characterization NOUN - O
of ADP - O
the DET - O
two CD - B-CARDINAL
postharvest NOUN - O
biological ADJ - O
control NOUN - O
agents NOUN - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
L1 NNP - B-PERSON
and CCONJ - O
L8 PROPN - O

-DOCSTART- -X- - O

Some DET - O
isolates NOUN - O
were VERB - O
characteristic ADJ - O
for ADP - O
a DT - B-DATE
particular JJ - I-DATE
year NN - I-DATE
but CCONJ - O
in ADP - O
both DT - B-DATE
years NNS - I-DATE
apple NOUN - O
microflora NOUN - O
was VERB - O
dominated VERB - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
particular ADJ - O
, PUNCT - O
the DET - O
feasibility NOUN - O
of ADP - O
using VERB - O
low ADJ - O
quality NOUN - O
fig NOUN - O
syrup NOUN - O
as ADP - O
a DET - O
supplemental ADJ - O
substrate NOUN - O
for ADP - O
pullulan NOUN - O
gum NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
was VERB - O
investigated VERB - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
fig NOUN - O
syrup NOUN - O
was VERB - O
an DET - O
effective ADJ - O
substrate NOUN - O
for ADP - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
, PUNCT - O
and CCONJ - O
, PUNCT - O
therefore ADV - O
, PUNCT - O
this DET - O
byproduct NOUN - O
deserves VERB - O
attention NOUN - O
for ADP - O
the DET - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
and CCONJ - O
environmentally ADV - O
friendly ADJ - O
pullulan NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pullulan NN - B-ORG
gum NOUN - O
production NOUN - O
from ADP - O
low ADJ - O
- PUNCT - O
quality NOUN - O
fig NOUN - O
syrup NOUN - O
using VERB - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
order NOUN - O
to PART - O
improve VERB - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NCPS2016 NNP - B-ORG
, PUNCT - O
the DET - O
medium NOUN - O
was VERB - O
optimized VERB - O
using VERB - O
single ADJ - O
factor NOUN - O
experiment NOUN - O
and CCONJ - O
response NOUN - O
surface NOUN - O
methodology NOUN - O
. PUNCT - O

This DET - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
fructose NOUN - O
is VERB - O
reported VERB - O
to PART - O
be VERB - O
the DET - O
optimal ADJ - O
carbon NOUN - O
source NOUN - O
for ADP - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
of ADP - O
great ADJ - O
significance NOUN - O
for ADP - O
the DET - O
further ADJ - O
study NOUN - O
of ADP - O
the DET - O
mechanism NOUN - O
of ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
pullulan NOUN - O
by ADP - O
NCPS2016 NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Statistical PROPN - O
Optimization PROPN - O
of ADP - O
Medium PROPN - O
for ADP - O
Pullulan PROPN - O
Production PROPN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NCPS2016 NNP - B-ORG
Using VBG - I-ORG
Fructose NNP - I-ORG
and CCONJ - O
Soybean NNP - B-PERSON
Meal NNP - I-PERSON
Hydrolysates NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
novel ADJ - O
extremophilic NOUN - O
xylanase NOUN - O
produced VERB - O
on ADP - O
wheat NOUN - O
bran NOUN - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NRRL NNP - B-ORG

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
the DET - O
autochthonous ADJ - O
yeast NOUN - O
- PUNCT - O
like ADJ - O
pectinolytic ADJ - O
strain NOUN - O
from ADP - O
D.O. NNP - B-ORG
San NNP - I-ORG
Rafael NNP - I-ORG
viticulture NOUN - O
region NOUN - O
, PUNCT - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
GM NNP - B-ORG
- PUNCT - O
R-22 PROPN - O
, PUNCT - O
was VERB - O
used VERB - O
in ADP - O
co NOUN - O
- NOUN - O
culture NOUN - O
with ADP - O
Saccharomyces NNPS - B-ORG
cerevisiae VERB - O
IOC PROPN - O
18 NUM - O
- SYM - O
2007 NUM - O
in ADP - O
microvinification NOUN - O
trials NOUN - O
with ADP - O
Malbec NNP - B-PERSON
must VERB - O
applying VERB - O
pre ADJ - O
- ADJ - O
fermentative ADJ - O
cold ADJ - O
maceration NOUN - O
( PUNCT - O
PCM NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Discovering VERB - O
the DET - O
role NOUN - O
of ADP - O
the DET - O
apolipoprotein NOUN - O
gene NOUN - O
and CCONJ - O
the DET - O
genes NOUN - O
in ADP - O
the DET - O
putative ADJ - O
pullulan NOUN - O
biosynthesis NOUN - O
pathway NOUN - O
on ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
pullulan NOUN - O
, PUNCT - O
heavy ADJ - O
oil NOUN - O
and CCONJ - O
melanin NOUN - O
in ADP - O
Aureobasidium NNP - B-GPE
pullulans NOUN - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strains VERB - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
on ADP - O
kiwifruit NOUN - O
during ADP - O
storage NOUN - O
and CCONJ - O
on ADP - O
fruit NOUN - O
nutritional ADJ - O
composition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Polymalic ADJ - O
acid NOUN - O
( PUNCT - O
PMA NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
water NOUN - O
- PUNCT - O
soluble ADJ - O
biopolymer NOUN - O
with ADP - O
many ADJ - O
attractive ADJ - O
properties NOUN - O
for ADP - O
food NOUN - O
and CCONJ - O
pharmaceutical NOUN - O
applications NOUN - O
mainly ADV - O
produced VERB - O
by ADP - O
the DET - O
yeast NOUN - O
- PUNCT - O
like ADJ - O
fungus NOUN - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strains NOUN - O
( PUNCT - O
L1 NNP - B-PERSON
and CCONJ - O
L8 PROPN - O
) PUNCT - O
, PUNCT - O
able ADJ - O
to PART - O
prevent VERB - O
postharvest NOUN - O
fruit NOUN - O
decay NOUN - O
, PUNCT - O
were VERB - O
evaluated VERB - O
in ADP - O
order NOUN - O
to PART - O
elucidate VERB - O
how ADV - O
the DET - O
competition NOUN - O
for ADP - O
nutrients NOUN - O
and CCONJ - O
space NOUN - O
was VERB - O
involved VERB - O
in ADP - O
their ADJ - O
activity NOUN - O
against ADP - O
Monilinia NNP - B-GPE
laxa NOUN - O
, PUNCT - O
the DET - O
causal ADJ - O
agent NOUN - O
of ADP - O
peach NOUN - O
brown ADJ - O
rot NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Production NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
streptococcal ADJ - O
liamocins NOUN - O
from ADP - O
agricultural ADJ - O
biomass NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE

-DOCSTART- -X- - O

Thus ADV - O
, PUNCT - O
we PRON - O
present VERB - O
a DET - O
novel ADJ - O
approach NOUN - O
for ADP - O
biosurfactant ADJ - O
production NOUN - O
using VERB - O
the DET - O
promising ADJ - O
yeast NOUN - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
LB PROPN - O
83 CD - B-CARDINAL
, PUNCT - O
in ADP - O
stirred VERB - O
tank NOUN - O
reactor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Production NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
streptococcal ADJ - O
liamocins NOUN - O
from ADP - O
agricultural ADJ - O
biomass NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Improving VBG - B-ORG
Erythritol NNP - I-ORG
Production NNP - I-ORG
of IN - I-ORG
Aureobasidium NNP - I-ORG
pullulans NOUN - O
from ADP - O
Xylose NNP - B-ORG
by IN - I-ORG
Mutagenesis PROPN - O
and CCONJ - O
Medium PROPN - O
Optimization PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium NN - B-MEDICINE
pullulans NNS - I-MEDICINE
produced VERB - O
β ADJ - O
- PUNCT - O
glucan PROPN - O
is VERB - O
effective ADJ - O
to PART - O
enhance VERB - O
Kurosengoku NNP - B-ORG
soybean NOUN - O
extract NOUN - O
induced VERB - O
Thrombospondin-1 PROPN - O
expression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
paper NOUN - O
studies VERB - O
the DET - O
metabolic ADJ - O
pathway NOUN - O
of ADP - O
sucrose NOUN - O
in ADP - O
pullulan NOUN - O
fermentation NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
explore VERB - O
the DET - O
genome ADJ - O
sequence NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CCTCC PROPN - O
M2012223 PROPN - O
, PUNCT - O
analyze VERB - O
the DET - O
key ADJ - O
genes NOUN - O
related VERB - O
to ADP - O
the DET - O
biosynthesis NOUN - O
of ADP - O
important ADJ - O
metabolites NOUN - O
, PUNCT - O
and CCONJ - O
provide VERB - O
genetic ADJ - O
background NOUN - O
for ADP - O
metabolic NOUN - O
engineering NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
unambiguous ADJ - O
structural ADJ - O
characterization NOUN - O
of ADP - O
the DET - O
water NOUN - O
- PUNCT - O
soluble ADJ - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
Î²-(1â3 NN - B-CARDINAL
, PUNCT - O
1â6)-glucan CD - B-NORP
is VERB - O
yet ADV - O
to PART - O
be VERB - O
achieved VERB - O
, PUNCT - O
although ADP - O
this DET - O
Î²-(1â3 NOUN - O
, PUNCT - O
1â6)-glucan CD - B-NORP
is VERB - O
expected VERB - O
to PART - O
exhibit VERB - O
excellent ADJ - O
biofunctional ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
adopt VERB - O
a DET - O
novel ADJ - O
mixed ADJ - O
- PUNCT - O
sugar NOUN - O
strategy NOUN - O
for ADP - O
maximizing VERB - O
pullulan NOUN - O
production NOUN - O
, PUNCT - O
mainly ADV - O
using VERB - O
potato NOUN - O
starch NOUN - O
hydrolysate NOUN - O
as ADP - O
a DET - O
low ADJ - O
- PUNCT - O
cost NOUN - O
substrate NOUN - O
for ADP - O
liquid ADJ - O
- PUNCT - O
state NOUN - O
fermentation NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Phylogenetic ADJ - O
classification NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strains NOUN - O
for ADP - O
production NOUN - O
of ADP - O
feruloyl NOUN - O
esterase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Xylanase NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
on ADP - O
globe NOUN - O
artichoke NOUN - O
stem NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Activities NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
cell NOUN - O
filtrates NOUN - O
against ADP - O
Monilinia NNP - B-GPE
laxa NOUN - O
of ADP - O
peaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Central JJ - B-ORG
metabolic NOUN - O
pathways NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CGMCC1234 PROPN - O
for ADP - O
pullulan NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Batch ADJ - O
culture NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CCTCC PROPN - O
M PROPN - O
2012259 CD - B-DATE
for ADP - O
pullulan NOUN - O
production NOUN - O
at ADP - O
different ADJ - O
concentrations NOUN - O
of ADP - O
ammonium NOUN - O
sulfate NOUN - O
and CCONJ - O
yeast NOUN - O
extract NOUN - O
was VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Polymalic ADJ - O
acid NOUN - O
( PUNCT - O
PMA NNP - B-ORG
) PUNCT - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
ZX-10 NNP - B-PRODUCT
from ADP - O
soybean NOUN - O
hull NOUN - O
hydrolysate NOUN - O
supplemented VERB - O
with ADP - O
corn NOUN - O
steep ADJ - O
liquor NOUN - O
( PUNCT - O
CSL NNP - B-ORG
) PUNCT - O
gave VERB - O
a DET - O
malic ADJ - O
acid NOUN - O
yield NOUN - O
of ADP - O
∼0.4g NN - B-ORG
/ SYM - I-ORG
g NN - I-ORG
at ADP - O
a DET - O
productivity NOUN - O
of ADP - O
∼0.5g NOUN - O

-DOCSTART- -X- - O

isolated VERB - O
from ADP - O
the DET - O
mangrove NOUN - O
systems NOUN - O
in ADP - O
the DT - B-LOC
South NNP - I-LOC
of IN - I-LOC
China NNP - I-LOC
were VERB - O
screened VERB - O
for ADP - O
their ADJ - O
ability NOUN - O
to PART - O
produce VERB - O
Ca(2+)-polymalate PROPN - O
( PUNCT - O
PMA NNP - B-ORG
) PUNCT - O
, PUNCT - O
it PRON - O
was VERB - O
found VERB - O
that ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Biochemical ADJ - O
characterization NOUN - O
and CCONJ - O
kinetic ADJ - O
studies NOUN - O
on ADP - O
a DET - O
purified ADJ - O
yellow ADJ - O
laccase NOUN - O
from ADP - O
newly ADV - O
isolated VERB - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NAC8 NNP - B-ORG
obtained VERB - O
from ADP - O
soil NOUN - O
containing VERB - O
decayed VERB - O
plant NOUN - O
matter NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
bioemulsifying ADJ - O
potential NOUN - O
of ADP - O
exopolysaccharide NOUN - O
produced VERB - O
by ADP - O
an DET - O
indigenous ADJ - O
species NOUN - O
of ADP - O
Aureobasidium NNP - B-ORG
pullulans NOUN - O
RYLF10 NN - B-ORG
has VERB - O
been VERB - O
determined VERB - O
and CCONJ - O
various ADJ - O
factors NOUN - O
affecting VERB - O
the DET - O
emulsification NOUN - O
activity NOUN - O
has VERB - O
been VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
extracellular ADJ - O
xylanase NOUN - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NRRL NNP - B-ORG
Y-2311 PROPN - O
- PUNCT - O
1 PROPN - O
produced VERB - O
on ADP - O
wheat NOUN - O
bran NOUN - O
was VERB - O
purified VERB - O
by ADP - O
a DET - O
single ADJ - O
- PUNCT - O
step NOUN - O
chromatographic ADJ - O
procedure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Single ADJ - O
- PUNCT - O
step NOUN - O
purification NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
an DET - O
extreme ADJ - O
halophilic NOUN - O
, PUNCT - O
ethanol NOUN - O
tolerant ADJ - O
and CCONJ - O
acidophilic VERB - O
xylanase NOUN - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
NRRL NNP - B-ORG

-DOCSTART- -X- - O

Efficient ADJ - O
pullulan NOUN - O
production NOUN - O
by ADP - O
bioconversion NOUN - O
using VERB - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
as ADP - O
the DET - O
whole ADJ - O
- PUNCT - O
cell NOUN - O
catalyst NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
production NOUN - O
of ADP - O
antibacterial ADJ - O
liamocins NOUN - O
( PUNCT - O
polyol NOUN - O
lipids NOUN - O
) PUNCT - O
by ADP - O
diverse ADJ - O
strains NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
grown VERB - O
on ADP - O
different ADJ - O
culture NOUN - O
media NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
research NOUN - O
into ADP - O
developing VERB - O
a DET - O
functional ADJ - O
cosmetic ADJ - O
ingredient NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
whether ADP - O
exopolymers NOUN - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
SM2001 NNP - B-PERSON
( PUNCT - O
E PROPN - O
- PUNCT - O
AP PROPN - O
- PUNCT - O
SM2001 PROPN - O
) PUNCT - O
exert NOUN - O
antioxidant NOUN - O
, PUNCT - O
antiwrinkle NOUN - O
, PUNCT - O
whitening NOUN - O
, PUNCT - O
and CCONJ - O
skin NOUN - O
moisturizing NOUN - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Liamocins NOUN - O
are VERB - O
structurally ADV - O
unique ADJ - O
, PUNCT - O
heavier ADJ - O
- PUNCT - O
than ADP - O
- PUNCT - O
water NOUN - O
“ PROPN - O
oils NOUN - O
” PUNCT - O
produced VERB - O
by ADP - O
certain ADJ - O
strains NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
process NOUN - O
for ADP - O
producing VERB - O
malic ADJ - O
acid NOUN - O
from ADP - O
a DET - O
hydrolysate NOUN - O
of ADP - O
corncob NOUN - O
was VERB - O
investigated VERB - O
with ADP - O
a DET - O
polymalic ADJ - O
acid NOUN - O
( PUNCT - O
PMA)-producing VERB - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strain VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Lipase NOUN - O
production NOUN - O
by ADP - O
diverse ADJ - O
phylogenetic ADJ - O
clades NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium JJ - B-MEDICINE
pullulans NNS - I-MEDICINE
- PUNCT - O
derived VERB - O
β DET - O
- PUNCT - O
glucan PROPN - O
( PUNCT - O
AP NNP - B-ORG
- HYPH - I-ORG
PG NNP - I-ORG
) PUNCT - O
consisting VERB - O
of ADP - O
a DET - O
β-(1,3)-linked VERB - O
glucose NOUN - O
main ADJ - O
chain NOUN - O
and CCONJ - O
β-(1,6)-linked VERB - O
glucose NOUN - O
branches NOUN - O
is VERB - O
taken VERB - O
as ADP - O
a DET - O
supplement NOUN - O
to PART - O
improve VERB - O
health NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative ADJ - O
proteomic ADJ - O
analysis NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
high ADJ - O
and CCONJ - O
low ADJ - O
levels NOUN - O
of ADP - O
nitrogen NOUN - O
source NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
batch NOUN - O
processes NOUN - O
of ADP - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CCTCC PROPN - O
M PROPN - O
2012259 CD - B-DATE
under ADP - O
different ADJ - O
pH NOUN - O
environments NOUN - O
were VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Inhibition NOUN - O
of ADP - O
UVB PROPN - O
- PUNCT - O
induced VERB - O
skin NOUN - O
damage NOUN - O
by ADP - O
exopolymers NOUN - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
SM-2001 IN - B-ORG
in ADP - O
hairless NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CCTCC PROPN - O
M PROPN - O
2012259 CD - B-DATE
using VERB - O
rice NOUN - O
hull NOUN - O
hydrolysate NOUN - O
as ADP - O
the DET - O
carbon NOUN - O
source NOUN - O
was VERB - O
conducted VERB - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
on ADP - O
the DET - O
screening NOUN - O
for ADP - O
biological ADJ - O
activities NOUN - O
of ADP - O
organic ADJ - O
extracts NOUN - O
from ADP - O
seven CD - B-CARDINAL
strains NOUN - O
that ADJ - O
represent VERB - O
four CD - B-CARDINAL
varieties NOUN - O
of ADP - O
the DET - O
fungus NOUN - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
, PUNCT - O
that ADV - O
is VERB - O
A. NOUN - O
pullulans NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mechanism NOUN - O
study NOUN - O
of ADP - O
Tween NNP - B-DATE
80 CD - I-DATE
enhancing VERB - O
the DET - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

→ NUM - O
3)-Glucanolytic CD - B-CARDINAL
yeasts NOUN - O
from ADP - O
Brazilian JJ - B-NORP
grape NOUN - O
microbiota NOUN - O
: PUNCT - O
production NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
β ADJ - O
- PUNCT - O
glucanolytic ADJ - O
enzymes NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
1WA1 NUM - O
cultivated VERB - O
on ADP - O
fungal ADJ - O
Mycelium PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
inducement NOUN - O
and CCONJ - O
distribution NOUN - O
of ADP - O
hemicellulases NOUN - O
from ADP - O
strain NOUN - O
2012 CD - B-DATE
, PUNCT - O
which ADJ - O
was VERB - O
identified VERB - O
as ADP - O
a DET - O
non ADJ - O
- ADJ - O
melanin ADJ - O
secreting NOUN - O
strain NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
( PUNCT - O
A. NOUN - O
pullulans NOUN - O
) PUNCT - O
, PUNCT - O
were VERB - O
also ADV - O
determined ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

New ADJ - O
improved ADJ - O
method NOUN - O
for ADP - O
fructooligosaccharides NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

From ADP - O
a DET - O
survey NOUN - O
of ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
50 CD - I-CARDINAL
diverse ADJ - O
strains NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
, PUNCT - O
21 CD - B-CARDINAL
produced VERB - O
extracellular ADJ - O
heavy ADJ - O
oils NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

β PUNCT - O
- PUNCT - O
Glucan PROPN - O
derived VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
is VERB - O
effective ADJ - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
influenza NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
the DET - O
production NOUN - O
of ADP - O
a DET - O
β ADJ - O
- PUNCT - O
glucosidase NOUN - O
by ADP - O
an DET - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
strain VERB - O
( PUNCT - O
Ap NNP - B-ORG
- HYPH - I-ORG
β NNP - I-ORG
- HYPH - I-ORG
gl NNP - I-ORG
) PUNCT - O
isolated VERB - O
from ADP - O
grape NOUN - O
ecosystems NOUN - O
was VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
controlled VERB - O
pH NOUN - O
on ADP - O
the DET - O
activity NOUN - O
of ADP - O
UDPG NNP - B-ORG
- PUNCT - O
pyrophosphorylase NOUN - O
in ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Heavy ADJ - O
oils NOUN - O
produced VERB - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
fungus NOUN - O
, PUNCT - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
, PUNCT - O
was VERB - O
isolated VERB - O
from ADP - O
marine ADJ - O
biofilm NOUN - O
and CCONJ - O
identified VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
HN6.2 NOUN - O
by ADP - O
inverse NOUN - O
PCR NNP - B-ORG
and CCONJ - O
RACE NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Cultured VERB - O
cell NOUN - O
extracts NOUN - O
from ADP - O
ten CD - B-CARDINAL
tropical ADJ - O
strains NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
were VERB - O
screened VERB - O
for ADP - O
antifungal ADJ - O
activity NOUN - O
against ADP - O
four CD - B-CARDINAL
pathogenic ADJ - O
Aspergillus NNP - B-NORP
species NOUN - O
( PUNCT - O
Aspergillus PROPN - O
flavus INTJ - O
, PUNCT - O
Aspergillus ADV - O
niger ADV - O
, PUNCT - O
Aspergillus NNP - B-ORG
fumigatus NOUN - O
, PUNCT - O
and CCONJ - O
Aspergillus NNP - B-PERSON
terreus NOUN - O
) PUNCT - O
using VERB - O
the DET - O
well ADJ - O
diffusion NOUN - O
and CCONJ - O
conidial ADJ - O
germination NOUN - O
inhibition NOUN - O
assays NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
propose VERB - O
a DET - O
mixed ADJ - O
culture NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
and CCONJ - O
Saccharomyces NNPS - B-ORG
cerevisiae VERB - O
cells NOUN - O
to PART - O
produce VERB - O
FOS NNP - B-ORG
and CCONJ - O
consume VERB - O
the DET - O
small ADJ - O
saccharides NOUN - O
simultaneously ADV - O
, PUNCT - O
thereby ADV - O
increasing VERB - O
FOS NNP - B-ORG
purity NOUN - O
in ADP - O
the DET - O
mixture NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
HN6.2 NOUN - O
by ADP - O
inverse NOUN - O
PCR NNP - B-ORG
and CCONJ - O
RT PROPN - O
- PUNCT - O
PCR PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
evaluated VERB - O
the DET - O
beneficial ADJ - O
effects NOUN - O
of ADP - O
fructooligosaccharide NOUN - O
( PUNCT - O
FOS NNP - B-ORG
) PUNCT - O
intake VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
using VERB - O
poloxamer-407 NOUN - O
( PUNCT - O
PX-407 NOUN - O
) PUNCT - O
induced VERB - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
in ADP - O
rat NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium NN - B-MEDICINE
pullulans NNS - I-MEDICINE
is VERB - O
a DET - O
causal ADJ - O
agent NOUN - O
of ADP - O
phaeohyphomycosis NOUN - O
, PUNCT - O
occasionally ADV - O
found VERB - O
in ADP - O
men NOUN - O
and CCONJ - O
animals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Infection NOUN - O
of ADP - O
the DET - O
lymphatic ADJ - O
system NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
erythema NOUN - O
nodosum NOUN - O
leprosum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
optimal ADJ - O
growth NOUN - O
condition NOUN - O
for ADP - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
has VERB - O
been VERB - O
found VERB - O
as ADP - O
75 CD - B-CARDINAL
g NOUN - O
/ SYM - O
L NOUN - O
of ADP - O
sucrose NOUN - O
as ADP - O
carbon NOUN - O
source NOUN - O
, PUNCT - O
3 CD - B-CARDINAL
g NOUN - O
/ SYM - O
L NOUN - O
of ADP - O
YE NOUN - O
and CCONJ - O
cultivation NOUN - O
temperature NOUN - O
at ADP - O
30 CD - B-CARDINAL
( PUNCT - O
° PROPN - O
) PUNCT - O
C. PROPN - O

-DOCSTART- -X- - O

Products NOUN - O
containing VERB - O
the DET - O
epiphytic ADJ - O
yeast NOUN - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
are VERB - O
commercially ADV - O
available ADJ - O
and CCONJ - O
applied VERB - O
by ADP - O
fruit NOUN - O
growers NOUN - O
to PART - O
prevent VERB - O
several ADJ - O
fungal ADJ - O
and CCONJ - O
bacterial ADJ - O
diseases NOUN - O
of ADP - O
fruit NOUN - O
trees NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
detect VERB - O
the DET - O
effect NOUN - O
of ADP - O
beta ADJ - O
- PUNCT - O
glucan ADJ - O
derived VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
β ADJ - O
- PUNCT - O
glucan PROPN - O
originated VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
on ADP - O
asthma NOUN - O
induced VERB - O
by ADP - O
ovalbumin NOUN - O
in ADP - O
mouse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Total ADJ - O
95 CD - B-CARDINAL
isolates NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
were VERB - O
isolated VERB - O
from ADP - O
different ADJ - O
flowers NOUN - O
and CCONJ - O
leaves VERB - O
samples NOUN - O
, PUNCT - O
out ADP - O
of ADP - O
which ADJ - O
11 CD - B-CARDINAL
thermotolerant NOUN - O
strains NOUN - O
produced VERB - O
pullulan NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
PL5 PROPN - O
, PUNCT - O
a DET - O
biocontrol NOUN - O
agent NOUN - O
effective ADJ - O
against ADP - O
Monilinia NNP - B-GPE
laxa VERB - O
on ADP - O
stone NOUN - O
fruit NOUN - O
and CCONJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Penicillium NNP - B-ORG
expansum NOUN - O
on ADP - O
pome ADJ - O
fruits NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Modeling VERB - O
of ADP - O
pullulan NOUN - O
fermentation NOUN - O
by ADP - O
using VERB - O
a DET - O
color NOUN - O
variant ADJ - O
strain NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE

-DOCSTART- -X- - O

We PRON - O
examined VERB - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
oral ADJ - O
administration NOUN - O
of ADP - O
β PROPN - O
- PUNCT - O
D NOUN - O
- PUNCT - O
glucan PROPN - O
derived VERB - O
from ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
ADK-34 PROPN - O
( PUNCT - O
AP NNP - B-ORG
- HYPH - I-ORG
FBG NNP - I-ORG
) PUNCT - O
on ADP - O
Candida NNP - B-GPE
albicans NOUN - O
or CCONJ - O
methicillin NOUN - O
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-PERSON
aureus NOUN - O
( PUNCT - O
MRSA PROPN - O
) PUNCT - O
infection NOUN - O
in ADP - O
immunosuppressed ADJ - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
has VERB - O
been VERB - O
well ADV - O
documented VERB - O
that ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
is VERB - O
widely ADV - O
distributed VERB - O
in ADP - O
different ADJ - O
environments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
a DET - O
two CD - B-CARDINAL
- PUNCT - O
stage NOUN - O
cultivation NOUN - O
temperature NOUN - O
on ADP - O
the DET - O
production NOUN - O
of ADP - O
pullulan NOUN - O
synthesized VERB - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
CGMCC1234 PROPN - O
was VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
two CD - B-CARDINAL
- PUNCT - O
stage NOUN - O
temperature NOUN - O
on ADP - O
pullulan NOUN - O
production NOUN - O
by ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE

-DOCSTART- -X- - O

Redefinition NOUN - O
of ADP - O
Aureobasidium NNP - B-MEDICINE
pullulans NNS - I-MEDICINE
and CCONJ - O
its ADJ - O
varieties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

DNA PROPN - O
- PUNCT - O
Dependent ADJ - O
Detection NOUN - O
of ADP - O
the DT - B-ORG
Grapevine NNP - I-ORG
Fungal NNP - I-ORG
Endophytes NNPS - I-ORG
Aureobasidium NNP - I-ORG
pullulans NOUN - O
and CCONJ - O
Epicoccum NNP - B-ORG
nigrum NOUN - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
a DET - O
combination NOUN - O
of ADP - O
Mometasone NNP - B-ORG
Furoate NNP - I-ORG
( PUNCT - O
MF)+Levofloxacin PROPN - O
hemihydrate NOUN - O
( PUNCT - O
LH)+Retinyl NNP - B-ORG
palmitate NOUN - O
( PUNCT - O
RP NNP - B-PERSON
) PUNCT - O
with ADP - O
an DET - O
in ADP - O
situ ADJ - O
gel NOUN - O
- PUNCT - O
forming VERB - O
delivery NOUN - O
system NOUN - O
was VERB - O
evaluated VERB - O
at ADP - O
different ADJ - O
stages NOUN - O
of ADP - O
nasal NOUN - O
mucosal ADJ - O
damage NOUN - O
repair NOUN - O
in ADP - O
a DET - O
rabbit NOUN - O
maxillary ADJ - O
sinus NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mometasone NNP - B-MEDICINE
Furoate NNP - I-MEDICINE
Suppresses NNP - B-PERSON
PMA NNP - I-PERSON
- HYPH - I-PERSON
Induced NNP - I-PERSON
MUC-5AC PROPN - O
and CCONJ - O
MUC-2 PROPN - O
Production PROPN - O
in ADP - O
Human PROPN - O
Airway PROPN - O
Epithelial PROPN - O
Cells PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nasal PROPN - O
Deposition PROPN - O
of ADP - O
HFA PROPN - O
- PUNCT - O
Beclomethasone PROPN - O
, PUNCT - O
Aqueous PROPN - O
Fluticasone PROPN - O
Propionate PROPN - O
and CCONJ - O
Aqueous ADJ - O
Mometasone NNP - B-MEDICINE
Furoate NNP - I-MEDICINE
in ADP - O
Allergic PROPN - O
Rhinitis PROPN - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
discloses VERB - O
a DET - O
dermaceutical ADJ - O
cream NOUN - O
containing VERB - O
Mometasone NNP - B-MEDICINE
Furoate NNP - I-MEDICINE
as ADP - O
a DET - O
steroid NOUN - O
, PUNCT - O
Miconazole NNP - B-ORG
Nitrate NNP - I-ORG
as ADP - O
an DET - O
antifungal NOUN - O
, PUNCT - O
and CCONJ - O
an DET - O
antibacterial ADJ - O
agent NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
Fusidic NNP - B-ORG
acid NOUN - O
, PUNCT - O
which ADJ - O
Fusidic NNP - B-ORG
acid NOUN - O
is VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
as ADP - O
the DET - O
starting VERB - O
raw ADJ - O
material NOUN - O
, PUNCT - O
wherein ADV - O
Sodium NNP - B-PERSON
Fusidate NNP - I-PERSON
is VERB - O
converted VERB - O
into ADP - O
Fusidic NNP - B-ORG
acid NOUN - O
under ADP - O
oxygen NOUN - O
- PUNCT - O
free ADJ - O
environment NOUN - O
. PUNCT - O

The DET - O
cream NOUN - O
of ADP - O
the DET - O
present ADJ - O
invention NOUN - O
contains VERB - O
Fusidic NN - B-PERSON
acid NOUN - O
as ADP - O
the DET - O
API NN - B-ORG
that ADJ - O
has VERB - O
been VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
, PUNCT - O
and CCONJ - O
Mometasone NNP - B-ORG
Furoate NNP - I-ORG
as ADP - O
a DET - O
steroid NOUN - O
, PUNCT - O
Miconazole NNP - B-ORG
Nitrate NNP - I-ORG
as ADP - O
an DET - O
antifungal NOUN - O
, PUNCT - O
in ADP - O
a DET - O
cream NOUN - O
base NOUN - O
comprising VERB - O
a DET - O
preservative NOUN - O
, PUNCT - O
an DET - O
acid NOUN - O
, PUNCT - O
a DET - O
co NOUN - O
- NOUN - O
solvent ADJ - O
, PUNCT - O
emulsifiers NOUN - O
and CCONJ - O
a DET - O
waxy NOUN - O
material NOUN - O
along ADP - O
with ADP - O
water NOUN - O
, PUNCT - O
preferably ADV - O
purified ADJ - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Validated NNP - B-PERSON
Stability NNP - I-PERSON
- PUNCT - O
indicating VERB - O
High ADJ - O
- PUNCT - O
performance NOUN - O
Liquid NNP - B-ORG
Chromatographic NNP - I-ORG
Method NNP - I-ORG
for IN - I-ORG
Estimation PROPN - O
of ADP - O
Degradation PROPN - O
Behaviour PROPN - O
of ADP - O
Eberconazole NNP - B-PRODUCT
Nitrate NNP - I-PRODUCT
and CCONJ - O
Mometasone NNP - B-FAC
Furoate NNP - I-FAC
in ADP - O
Cream NNP - B-ORG
Formulation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
discloses VERB - O
a DET - O
dermaceutical ADJ - O
cream NOUN - O
containing VERB - O
Mometasone NNP - B-MEDICINE
Furoate NNP - I-MEDICINE
as ADP - O
a DET - O
corticosteroid NOUN - O
, PUNCT - O
an DET - O
antifungal ADJ - O
agent NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
Clotrimazole NNP - B-PRODUCT
and CCONJ - O
an DET - O
antibacterial ADJ - O
agent NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
Fusidic NNP - B-PERSON
acid NOUN - O
, PUNCT - O
which ADJ - O
Fusidic NNP - B-ORG
acid NOUN - O
is VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
as ADP - O
the DET - O
starting VERB - O
raw ADJ - O
material NOUN - O
, PUNCT - O
wherein ADV - O
Sodium NNP - B-PERSON
Fusidate NNP - I-PERSON
is VERB - O
converted VERB - O
into ADP - O
Fusidic NNP - B-ORG
acid NOUN - O
under ADP - O
oxygen NOUN - O
- PUNCT - O
free ADJ - O
environment NOUN - O
. PUNCT - O

The DET - O
cream NOUN - O
of ADP - O
the DET - O
present ADJ - O
invention NOUN - O
contains VERB - O
Fusidic NN - B-PERSON
acid NOUN - O
as ADP - O
the DET - O
API NN - B-ORG
that ADJ - O
has VERB - O
been VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
, PUNCT - O
Mometasone NNP - B-ORG
Furoate NNP - I-ORG
and CCONJ - O
Clotrimazole NNP - B-PRODUCT
, PUNCT - O
in ADP - O
a DET - O
cream NOUN - O
base NOUN - O
comprising VERB - O
a DET - O
preservative NOUN - O
, PUNCT - O
an DET - O
acid NOUN - O
, PUNCT - O
a DET - O
co NOUN - O
- NOUN - O
solvent ADJ - O
, PUNCT - O
emulsifiers NOUN - O
and CCONJ - O
a DET - O
waxy NOUN - O
material NOUN - O
along ADP - O
with ADP - O
water NOUN - O
, PUNCT - O
preferably ADV - O
purified ADJ - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
discloses VERB - O
a DET - O
dermaceutical ADJ - O
cream NOUN - O
containing VERB - O
Mometasone NNP - B-MEDICINE
Furoate NNP - I-MEDICINE
as ADP - O
a DET - O
corticosteroid NOUN - O
, PUNCT - O
an DET - O
antifungal ADJ - O
agent NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
Clotrimazole NNP - B-PRODUCT
and CCONJ - O
an DET - O
antibacterial ADJ - O
agent NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
Fusidic NNP - B-PERSON
acid NOUN - O
, PUNCT - O
which ADJ - O
Fusidic NNP - B-ORG
acid NOUN - O
is VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
as ADP - O
the DET - O
starting VERB - O
raw ADJ - O
material NOUN - O
, PUNCT - O
wherein ADV - O
Sodium NNP - B-PERSON
Fusidate NNP - I-PERSON
is VERB - O
converted VERB - O
into ADP - O
Fusidic NNP - B-ORG
acid NOUN - O
under ADP - O
oxygen- ADJ - O
free ADJ - O
environment NOUN - O
. PUNCT - O

The DET - O
cream NOUN - O
of ADP - O
the DET - O
present ADJ - O
invention NOUN - O
contains VERB - O
Fusidic NN - B-PERSON
acid NOUN - O
as ADP - O
the DET - O
API NN - B-ORG
that ADJ - O
has VERB - O
been VERB - O
formed VERB - O
in ADP - O
situ NOUN - O
from ADP - O
Sodium PROPN - O
Fusidate PROPN - O
, PUNCT - O
Mometasone NNP - B-ORG
Furoate NNP - I-ORG
and CCONJ - O
Clotrimazole NNP - B-PRODUCT
, PUNCT - O
in ADP - O
a DET - O
cream NOUN - O
base NOUN - O
comprising VERB - O
a DET - O
preservative NOUN - O
, PUNCT - O
an DET - O
acid NOUN - O
, PUNCT - O
a DET - O
co NOUN - O
- NOUN - O
solvent ADJ - O
, PUNCT - O
emulsifiers NOUN - O
and CCONJ - O
a DET - O
waxy NOUN - O
material NOUN - O
along ADP - O
with ADP - O
water NOUN - O
, PUNCT - O
preferably ADV - O
purified ADJ - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
aqueous ADJ - O
formulation NOUN - O
containing VERB - O
both DET - O
methyl ADJ - O
trypsin NOUN - O
and CCONJ - O
sodium NOUN - O
bicarbonate NOUN - O
was VERB - O
shown VERB - O
to PART - O
be VERB - O
more ADV - O
effective ADJ - O
than ADP - O
two CD - B-CARDINAL
commercial ADJ - O
products NOUN - O
, PUNCT - O
Murine NNP - B-NORP
Ear NNP - B-MEDICINE
Wax NNP - I-MEDICINE
Removal NNP - I-MEDICINE
Drops NNPS - I-MEDICINE
and CCONJ - O
Cerumenex NNP - B-ORG
Ear PROPN - O
Drops VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Toxicity PROPN - O
of ADP - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE

-DOCSTART- -X- - O

A DET - O
Simplified VERB - O
Extemporaneously PROPN - O
Prepared PROPN - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
Oral PROPN - O
Solution PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Potassium NN - B-MEDICINE
Chloride NNP - I-MEDICINE
Infusion PROPN - O
as ADP - O
the DT - B-ORG
Cause NNP - I-ORG
of IN - I-ORG
Altered NNP - I-ORG
Bio NNP - I-ORG
Distribution NN - I-ORG
of IN - I-ORG
18F NUM - O
- PUNCT - O
Fluorodeoxyglucose NOUN - O
on ADP - O
Whole PROPN - O
- PUNCT - O
Body PROPN - O
Positron PROPN - O

-DOCSTART- -X- - O

Effects PROPN - O
of ADP - O
Sodium PROPN - O
Chloride PROPN - O
, PUNCT - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
and CCONJ - O
Calcium PROPN - O
Chloride PROPN - O
on ADP - O
the DET - O
Formation PROPN - O
of ADP - O
α NOUN - O
- PUNCT - O
Dicarbonyl PROPN - O
Compounds PROPN - O
, PUNCT - O
Furfurals PROPN - O
and CCONJ - O
Development PROPN - O
of ADP - O
Browning PROPN - O
in ADP - O
Cookies PROPN - O
during ADP - O
Baking NN - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Synthesis PROPN - O
of ADP - O
Zinc NNP - B-ORG
Oxide NNP - I-ORG
Nanostructures NNP - I-ORG
on ADP - O
Graphene NNP - B-ORG
/ SYM - I-ORG
Glass NNP - I-ORG
Substrate NNP - I-ORG
via ADP - O
Electrochemical PROPN - O
Deposition PROPN - O
: PUNCT - O
Effects PROPN - O
of ADP - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
and CCONJ - O
Hexamethylenetetramine PROPN - O
as ADP - O
Supporting VERB - O
Reagents PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Phosphorylation NOUN - O
of ADP - O
Two CD - B-CARDINAL
Sites PROPN - O
Is VERB - O
Key ADJ - O
to ADP - O
the DET - O
Function PROPN - O
of ADP - O
the DET - O
Neuronal PROPN - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
Cotransporter PROPN - O
KCC2 PROPN - O
♦ NUM - O
: PUNCT - O
A DET - O
Novel PROPN - O
Regulatory PROPN - O
Locus PROPN - O
of ADP - O
Phosphorylation PROPN - O
in ADP - O
the DET - O
C PROPN - O
Terminus PROPN - O
of ADP - O
the DET - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE

-DOCSTART- -X- - O

Prenatal NNP - B-ORG
Hypoxia NNP - I-ORG
- HYPH - I-ORG
Ischemia NNP - I-ORG
Induces NNPS - I-ORG
Abnormalities NNPS - I-ORG
in ADP - O
CA3 PROPN - O
Microstructure PROPN - O
, PUNCT - O
Potassium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
Co PROPN - O
- NOUN - O
Transporter ADJ - O
2 NUM - O
Expression PROPN - O
and CCONJ - O
Inhibitory PROPN - O
Tone PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fifth JJ - B-ORDINAL
instar NOUN - O
experience NOUN - O
reduces VERB - O
aversiveness ADJ - O
of ADP - O
the DET - O
plant NOUN - O
extract NOUN - O
ruda NOUN - O
( PUNCT - O
Ruta NNP - B-PERSON
Graveolens NNP - I-PERSON
) PUNCT - O
in ADP - O
the DET - O
adult NOUN - O
triatomine NOUN - O
Rhodnius NNP - B-NORP
prolixus NOUN - O
Stal NNP - B-ORG
1859 NUM - O
. PUNCT - O

-DOCSTART- -X- - O

some DET - O
physiological ADJ - O
changes NOUN - O
of ADP - O
cold ADJ - O
resistance NOUN - O
was VERB - O
investigated VERB - O
, PUNCT - O
when ADV - O
Ruta NNP - B-PERSON
Graveolens NNP - I-PERSON
Linn NNP - I-PERSON
was VERB - O
planted VERB - O
in ADP - O
high ADJ - O
latitudes NOUN - O
region NOUN - O
far ADV - O
from ADP - O
its ADJ - O
original ADJ - O
place NOUN - O
without ADP - O
low ADJ - O
temperature NOUN - O
under ADP - O
zero NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Purification PROPN - O
and CCONJ - O
Characterization PROPN - O
of ADP - O
a DET - O
Black JJ - B-MEDICINE
Walnut NNP - I-MEDICINE

-DOCSTART- -X- - O

Identifying VBG - B-ORG
Antibacterial NNP - I-ORG
Compounds NNPS - I-ORG
in ADP - O
Black NNP - B-LOC
Walnuts NNP - I-LOC
( PUNCT - O
Juglans NNPS - B-NORP
nigra PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
Naproxen NNP - B-MEDICINE
, PUNCT - O
Age PROPN - O
and CCONJ - O
Body PROPN - O
Mass PROPN - O
Index PROPN - O
on ADP - O
the DT - B-ORG
Biological NNP - I-ORG
Composition NNP - I-ORG
of IN - I-ORG
Leukocyte NNP - I-ORG
Rich NNP - I-ORG
Platelet NNP - I-ORG
- HYPH - I-ORG
Rich NNP - I-ORG
Plasma NNP - I-ORG
: PUNCT - O
A DET - O
Prospective ADJ - O
, PUNCT - O
Therapeutic JJ - B-NORP
, PUNCT - O
Cohort PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Naproxen NNP - B-MEDICINE
was VERB - O
demonstrated VERB - O
to PART - O
suppress VERB - O
chondrocyte NOUN - O
proliferation NOUN - O
and CCONJ - O
differentiation NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
be VERB - O
an DET - O
important ADJ - O
factor NOUN - O
to PART - O
consider VERB - O
when ADV - O
prescribing VERB - O
this DET - O
medication NOUN - O
to ADP - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
impact NOUN - O
of ADP - O
two CD - B-CARDINAL
NO NOUN - O
- PUNCT - O
releasing NOUN - O
, PUNCT - O
non ADJ - O
- ADJ - O
selective ADJ - O
NSAIDs PROPN - O
, PUNCT - O
NCX-4016 NNP - B-ORG
and CCONJ - O
HCT-3012 PROPN - O
( PUNCT - O
NO ADV - O
- PUNCT - O
derivatives NOUN - O
of ADP - O
Aspirin NNP - B-NORP
and CCONJ - O
Naproxen NNP - B-MEDICINE
, PUNCT - O
respectively ADV - O
) PUNCT - O
on ADP - O
osteoblasts NOUN - O
were VERB - O
evaluated VERB - O
and CCONJ - O
compared VERB - O
to ADP - O
the DET - O
non ADJ - O
- ADJ - O
selective ADJ - O
, PUNCT - O
parent NOUN - O
chemicals NOUN - O
and CCONJ - O
to ADP - O
the DET - O
COX-2-selective NNP - B-PERSON
inhibitor NOUN - O
Celecoxib NNP - B-PERSON
. PUNCT - O

Unlike ADP - O
Aspirin NNP - B-PERSON
, PUNCT - O
Naproxen NNP - B-MEDICINE
and CCONJ - O
Celecoxib NNP - B-PERSON
, PUNCT - O
the DET - O
two CD - B-CARDINAL
NO PROPN - O
- PUNCT - O
NSAIDs PROPN - O
did VERB - O
not ADV - O
alter VERB - O
proliferation NOUN - O
and CCONJ - O
differentiation NOUN - O
of ADP - O
osteoblasts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Enantiomeric PROPN - O
Excess PROPN - O
Determination PROPN - O
of ADP - O
Naproxen NNP - B-MEDICINE
by ADP - O
Tandem NNP - B-PERSON
Mass NNP - I-PERSON
Spectrometry NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Naproxen NNP - B-MEDICINE
significantly ADV - O
increased VERB - O
gastric ADJ - O
mucosal NOUN - O
protein NOUN - O
expression NOUN - O
of ADP - O
CSE NNP - B-ORG
, PUNCT - O
Nrf-2 PROPN - O
and CCONJ - O
HIF-1α PROPN - O
as ADP - O
compared VERB - O
with ADP - O
vehicle NOUN - O
( PUNCT - O
p VERB - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
but CCONJ - O
failed VERB - O
to PART - O
affect VERB - O
CBS NNP - B-ORG
, PUNCT - O
3-MST NNP - B-PRODUCT
and CCONJ - O
HO-1 NNP - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Naproxen NNP - B-MEDICINE
is VERB - O
a DET - O
typical ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
known VERB - O
analgesic NOUN - O
classified VERB - O
as ADP - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
( PUNCT - O
NSAID NNP - B-ORG
) PUNCT - O
and CCONJ - O
is VERB - O
commercialized VERB - O
as ADP - O
tablets NOUN - O
or CCONJ - O
liquid NOUN - O
- PUNCT - O
filled VERB - O
capsules NOUN - O
. PUNCT - O

Naproxen NNP - B-MEDICINE
is VERB - O
typically ADV - O
used VERB - O
asa NUM - O
sodium NOUN - O
salt NOUN - O
because ADP - O
of ADP - O
its ADJ - O
better ADJ - O
processability NOUN - O
compared VERB - O
to ADP - O
Naproxen NNP - B-MEDICINE
free ADJ - O
acid NOUN - O
. PUNCT - O

Solid ADJ - O
dosage NOUN - O
forms NOUN - O
containing VERB - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-ORG
often ADV - O
have VERB - O
to PART - O
be VERB - O
processed VERB - O
in ADP - O
an DET - O
applicable ADJ - O
dosage NOUN - O
form NOUN - O
by ADP - O
granulation NOUN - O
and CCONJ - O
tablet NOUN - O
compression NOUN - O
. PUNCT - O

During ADP - O
granulation NOUN - O
, PUNCT - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-PERSON
will VERB - O
be VERB - O
in ADP - O
contact NOUN - O
with ADP - O
water NOUN - O
and CCONJ - O
is VERB - O
exposed VERB - O
to ADP - O
the DET - O
drop NOUN - O
and CCONJ - O
rise VERB - O
in ADP - O
temperature NOUN - O
and CCONJ - O
to ADP - O
mechanical ADJ - O
stress NOUN - O
. PUNCT - O

The DET - O
result NOUN - O
could VERB - O
be VERB - O
a DET - O
mixture NOUN - O
of ADP - O
different ADJ - O
hydrates NOUN - O
of ADP - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-PERSON
. PUNCT - O

All DET - O
granulation NOUN - O
batches NOUN - O
showed VERB - O
a DET - O
large ADJ - O
amount NOUN - O
of ADP - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-FAC
Monohydrate NNP - I-FAC
( PUNCT - O
> X - O
87 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
no DET - O
differences NOUN - O
could VERB - O
be VERB - O
observed VERB - O
during ADP - O
tablet NOUN - O
compression NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
to ADP - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-PERSON
Monohydrate NNP - I-PERSON
, PUNCT - O
a DET - O
large ADJ - O
quantity NOUN - O
of ADP - O
amorphous ADJ - O
structures NOUN - O
has VERB - O
also ADV - O
been VERB - O
found VERB - O
. PUNCT - O

Rietveld NN - B-PERSON
evaluation NOUN - O
combined VERB - O
with ADP - O
the DET - O
preliminary ADJ - O
studies NOUN - O
of ADP - O
the DET - O
raw ADJ - O
hydrates NOUN - O
provided VERB - O
conclusions NOUN - O
on ADP - O
the DET - O
drug NOUN - O
release NOUN - O
of ADP - O
the DET - O
tablets NOUN - O
containing VERB - O
hydrates NOUN - O
of ADP - O
Naproxen NNP - B-MEDICINE
Sodium NNP - I-ORG
which ADJ - O
were VERB - O
influenced VERB - O
by ADP - O
tablet NOUN - O
compression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Naproxen NNP - B-MEDICINE
degraded VERB - O
progressively ADV - O
with ADP - O
depth NOUN - O
, PUNCT - O
resulting VERB - O
in ADP - O
attenuation NOUN - O
of ADP - O
> X - O
90 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
mass NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
is VERB - O
a DET - O
glycosidic ADJ - O
, PUNCT - O
cardiotonic ADJ - O
plant NOUN - O
extract VERB - O
with ADP - O
a DET - O
narrow ADJ - O
therapeutic ADJ - O
window NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
poisoning NOUN - O
is VERB - O
a DET - O
frequent ADJ - O
reason NOUN - O
for ADP - O
seeking VERB - O
emergency NOUN - O
care NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
a DET - O
Potential ADJ - O
Clinical PROPN - O
Significant PROPN - O
Drug PROPN - O
- PUNCT - O
Drug PROPN - O
Interaction NOUN - O
between ADP - O
Digoxin NNP - B-MEDICINE
and CCONJ - O
Bupropion NNP - B-GPE
in ADP - O
Cynomolgus NNP - B-GPE
Monkeys NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
concentrations NOUN - O
were VERB - O
compared VERB - O
using VERB - O
the DET - O
Beckman PROPN - O
Coulter PROPN - O
® PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
formed VERB - O
multiple ADJ - O
precursor NOUN - O
ions NOUN - O
in ADP - O
positive ADJ - O
and CCONJ - O
negative ADJ - O
ESI PROPN - O
and CCONJ - O
methods NOUN - O
based VERB - O
on ADP - O
several ADJ - O
of ADP - O
these DET - O
have VERB - O
been VERB - O
reported VERB - O
previously ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
, PUNCT - O
ouabain ADJ - O
, PUNCT - O
and CCONJ - O
oleandrin NOUN - O
are VERB - O
classified VERB - O
as ADP - O
cardenolides NOUN - O
, PUNCT - O
consisting VERB - O
of ADP - O
a DET - O
lactone NOUN - O
ring NOUN - O
with ADP - O
five CD - B-CARDINAL
carbons NOUN - O
, PUNCT - O
while ADP - O
bufalin NOUN - O
is VERB - O
classified VERB - O
as ADP - O
bufodienolides NOUN - O
, PUNCT - O
with ADP - O
a DET - O
six CD - B-CARDINAL
- PUNCT - O
carbon NOUN - O
ring NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Intralipid NNP - I-WORK_OF_ART
Emulsion NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Rat NNP - I-WORK_OF_ART
Model NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Digoxin NNP - I-MEDICINE
Intoxication NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
and CCONJ - O
diuretics NOUN - O
were VERB - O
not ADV - O
associated VERB - O
with ADP - O
higher ADJ - O
mortality NOUN - O
in ADP - O
AF PROPN - O
patients NOUN - O
( PUNCT - O
HR PROPN - O
1.04 NUM - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.92 CD - B-CARDINAL
- SYM - O
1.18 NUM - O
and CCONJ - O
HR PROPN - O
1.04 NUM - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.85 NUM - O
- PUNCT - O
1.26 NUM - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

Digoxin NNP - B-MEDICINE
and CCONJ - O
diuretics NOUN - O
did VERB - O
not ADV - O
affect VERB - O
mortality NOUN - O
in ADP - O
HF NNP - B-ORG
patients NOUN - O
with ADP - O
AF NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Differential ADJ - O
Effects PROPN - O
of ADP - O
Digoxin NNP - B-MEDICINE
on ADP - O
Imiquimod NNP - B-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Psoriasis NNP - I-ORG
- HYPH - I-ORG
Like NNP - I-ORG
Skin NNP - I-ORG
Inflammation NN - I-ORG
on ADP - O
the DET - O
Ear PROPN - O
and CCONJ - O
Back PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
and CCONJ - O
Mortality PROPN - O
in ADP - O
Patients NOUN - O
With ADP - O
  SPACE - O
Atrial PROPN - O
Fibrillation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Digoxin NNP - B-MEDICINE
in ADP - O
reduced VERB - O
heart NOUN - O
failure NOUN - O
and CCONJ - O
sinus NOUN - O
rhythm NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
IC50 PROPN - O
data NOUN - O
from ADP - O
five CD - B-CARDINAL
laboratories NOUN - O
participating VERB - O
in ADP - O
the DET - O
P NOUN - O
- PUNCT - O
glycoprotein NOUN - O
( PUNCT - O
P NOUN - O
- PUNCT - O
gp PROPN - O
) PUNCT - O
IC50 PROPN - O
Initiative PROPN - O
, PUNCT - O
using VERB - O
Caco-2 NNP - B-PERSON
, PUNCT - O
MDCKII PROPN - O
- PUNCT - O
hMDR1 PROPN - O
or CCONJ - O
LLC NNP - B-ORG
- PUNCT - O
PK1-hMDR1 ADJ - O
cells NOUN - O
, PUNCT - O
were VERB - O
fitted VERB - O
by ADP - O
the DET - O
structural ADJ - O
mass ADJ - O
action NOUN - O
kinetic ADJ - O
model NOUN - O
for ADP - O
P NOUN - O
- PUNCT - O
gp ADP - O
- PUNCT - O
mediated VERB - O
transport NOUN - O
across ADP - O
confluent ADJ - O
cell NOUN - O
monolayers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
was VERB - O
one NUM - O
of ADP - O
the DET - O
first ADJ - O
identified VERB - O
RORγT NN - B-CARDINAL
receptor NOUN - O
inverse NOUN - O
agonists VERB - O
inhibiting VERB - O
the DET - O
differentiation NOUN - O
of ADP - O
Th17 NOUN - O
cells NOUN - O
. PUNCT - O

Digoxin NNP - B-MEDICINE
induced VERB - O
RORγ NOUN - O
/ SYM - O
RORγT NN - B-CARDINAL
- PUNCT - O
dependent ADJ - O
transcription NOUN - O
in ADP - O
HepG2 PROPN - O
and CCONJ - O
Th17 NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
effect NOUN - O
in ADP - O
ECG NNP - B-ORG
correlated VERB - O
significantly ADV - O
with ADP - O
hyperkalemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
and CCONJ - O
Hypermagnesuria NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Importantly ADV - O
, PUNCT - O
long ADJ - O
- PUNCT - O
term NOUN - O
and CCONJ - O
low ADJ - O
- PUNCT - O
dose NOUN - O
exposure NOUN - O
to ADP - O
DON NNP - B-ORG
induces VERB - O
multidrug ADJ - O
resistance NOUN - O
, PUNCT - O
thus ADV - O
attenuating VERB - O
the DET - O
cytotoxicity NOUN - O
of ADP - O
P NOUN - O
- PUNCT - O
gp PROPN - O
substrates NOUN - O
, PUNCT - O
including VERB - O
DON NNP - B-ORG
, PUNCT - O
Digoxin NNP - B-MEDICINE
, PUNCT - O
Sunitinib NNP - B-ORG
, PUNCT - O
and CCONJ - O
Etoposide NNP - B-ORG
. PUNCT - O

P NOUN - O
- PUNCT - O
gp PROPN - O
induction NOUN - O
induces VERB - O
cells NOUN - O
to PART - O
resist VERB - O
exogenous ADJ - O
toxic ADJ - O
compounds NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
DON NNP - B-ORG
, PUNCT - O
Digoxin NNP - B-MEDICINE
, PUNCT - O
Etoposide NNP - B-GPE
, PUNCT - O
etc X - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
is VERB - O
a DET - O
kind NOUN - O
of ADP - O
plant NOUN - O
- PUNCT - O
derived VERB - O
cardiac ADJ - O
glycoside NOUN - O
that ADJ - O
is VERB - O
mainly ADV - O
used VERB - O
to PART - O
treat VERB - O
heart NOUN - O
diseases NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
congestive ADJ - O
heart NOUN - O
failure NOUN - O
or CCONJ - O
arrhythmia NOUN - O
. PUNCT - O

Digoxin NNP - B-MEDICINE
dose NOUN - O
- PUNCT - O
dependently ADV - O
blocked VERB - O
the DET - O
cell NOUN - O
growth NOUN - O
of ADP - O
the DET - O
breast NOUN - O
cancer NOUN - O
MM231 NN - B-CARDINAL
through ADP - O
MTT NN - B-ORG
assay NOUN - O
, PUNCT - O
whereas ADP - O
the DET - O
apoptotic ADJ - O
numbers NOUN - O
were VERB - O
significantly ADV - O
elevated VERB - O
as ADP - O
reflected VERB - O
in ADP - O
acridine ADJ - O
orange NOUN - O
staining NOUN - O
and CCONJ - O
flow VERB - O
cytometry NOUN - O
analysis NOUN - O
. PUNCT - O

Digoxin NNP - B-MEDICINE
plays VERB - O
a DET - O
potential ADJ - O
anti ADJ - O
- ADJ - O
tumor ADJ - O
role NOUN - O
in ADP - O
breast NOUN - O
cancer NOUN - O
in ADP - O
vitro NOUN - O
, PUNCT - O
possibly ADV - O
by ADP - O
inducing VERB - O
mitochondria ADJ - O
- PUNCT - O
dependent ADJ - O
apoptosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
detection NOUN - O
of ADP - O
a DET - O
genetic ADJ - O
form NOUN - O
of ADP - O
Mg PROPN - O
urinary ADJ - O
wasting VERB - O
with ADP - O
hypomagnesemia NOUN - O
being VERB - O
caused VERB - O
by ADP - O
a DET - O
mutation NOUN - O
in ADP - O
the DET - O
γ NOUN - O
subunit NOUN - O
( PUNCT - O
FXYD2 PROPN - O
) PUNCT - O
of ADP - O
the DET - O
Na PROPN - O
, PUNCT - O
K PROPN - O
- PUNCT - O
ATPase PROPN - O
, PUNCT - O
the DET - O
pharmacological ADJ - O
target NOUN - O
of ADP - O
Digoxin NNP - B-MEDICINE
, PUNCT - O
prompted VERB - O
us PRON - O
to PART - O
investigate VERB - O
whether ADP - O
Digoxin NNP - B-MEDICINE
administration NOUN - O
increases VERB - O
urinary ADJ - O
Mg PROPN - O
excretion NOUN - O
. PUNCT - O

Two CD - B-CARDINAL
groups NOUN - O
of ADP - O
subjects NOUN - O
, PUNCT - O
with ADP - O
rapid ADJ - O
atrial ADJ - O
fibrillation NOUN - O
, PUNCT - O
received VERB - O
intravenous ADJ - O
Digoxin NNP - B-MEDICINE
( PUNCT - O
n PROPN - O
  SPACE - O
= SYM - O
9 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
verapamil NOUN - O
( PUNCT - O
n PROPN - O
  SPACE - O
= SYM - O
8) NUM - O
, PUNCT - O
for ADP - O
heart NOUN - O
rate NOUN - O
control NOUN - O
. PUNCT - O

In ADP - O
the DET - O
Digoxin NNP - B-MEDICINE
group NOUN - O
, PUNCT - O
at ADP - O
60 CD - B-QUANTITY
min NN - I-QUANTITY
Fex NNP - I-QUANTITY
Mg PRP - I-QUANTITY
rose VERB - O
from ADP - O
3.07 CD - B-CARDINAL
± NUM - O
1.21 CD - B-CARDINAL
to ADP - O
7.58 CD - B-CARDINAL
± NUM - O
2.51 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
an DET - O
increase NOUN - O
of ADP - O
269 CD - B-CARDINAL
± PUNCT - O
107 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
baseline NOUN - O
, PUNCT - O
p X - O
  SPACE - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
at ADP - O
240 CD - B-QUANTITY
min NN - I-QUANTITY
to ADP - O
6.05 CD - B-CARDINAL
  SPACE - O
± NUM - O
2.30 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
204 NUM - O
± NUM - O
56 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
baseline NOUN - O
, PUNCT - O
p X - O
  SPACE - O
< X - O
0.01 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

A DET - O
striking VERB - O
correlation NOUN - O
was VERB - O
found VERB - O
between ADP - O
individual ADJ - O
values NOUN - O
of ADP - O
Fex NNP - B-PERSON
Mg UH - I-PERSON
and CCONJ - O
serum PROPN - O
Digoxin NNP - B-MEDICINE
concentration NOUN - O
( PUNCT - O
r VERB - O
  SPACE - O
= SYM - O
0.678 CD - B-DATE
, PUNCT - O
p DET - O
  SPACE - O
< X - O
0.0001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

No DET - O
significant ADJ - O
correlation NOUN - O
was VERB - O
found VERB - O
between ADP - O
Fex NNP - B-PERSON
Na NNP - I-PERSON
or CCONJ - O
Fex NNP - B-PERSON
K NNP - I-PERSON
and CCONJ - O
serum PROPN - O
Digoxin NNP - B-MEDICINE
. PUNCT - O

A DET - O
correlation NOUN - O
of ADP - O
borderline ADJ - O
significance NOUN - O
was VERB - O
found VERB - O
between ADP - O
Fex NNP - B-PERSON
Ca NNP - I-PERSON
and CCONJ - O
serum VERB - O
Digoxin NNP - B-MEDICINE
( PUNCT - O

= SYM - O
0.349 CD - B-CARDINAL
, PUNCT - O
p DET - O
  SPACE - O
= SYM - O
0.073).The NUM - O
hypermagnesuric ADJ - O
effect NOUN - O
of ADP - O
acute ADJ - O
Digoxin NNP - B-MEDICINE
treatment NOUN - O
is VERB - O
reminiscent ADJ - O
of ADP - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
missense NOUN - O
mutation NOUN - O
in ADP - O
FXYD2 NNP - B-GPE
, PUNCT - O
which ADJ - O
assumes VERB - O
that ADP - O
FXYD2 NNP - B-GPE
is VERB - O
a DET - O
positive ADJ - O
regulator NOUN - O
of ADP - O
Na NNP - B-ORG
, PUNCT - O
K PROPN - O
- PUNCT - O
ATPase PROPN - O
in ADP - O
the DET - O
distal ADJ - O
convoluted VERB - O
tubule NOUN - O
( PUNCT - O
DCT NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
borderline NOUN - O
calciuric ADJ - O
effect NOUN - O
of ADP - O
Digoxin NNP - B-MEDICINE
may VERB - O
point VERB - O
to ADP - O
an DET - O
additional ADJ - O
site NOUN - O
of ADP - O
action NOUN - O
, PUNCT - O
more ADV - O
proximal ADJ - O
to ADP - O
the DET - O
DCT NNP - B-ORG
, PUNCT - O
that ADV - O
is ADV - O
, PUNCT - O
the DET - O
thick ADJ - O
ascending VERB - O
limb NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digoxin NNP - B-MEDICINE
Is VERB - O
Associated ADJ - O
With ADP - O
Increased VERB - O
Shock NOUN - O
Events PROPN - O
and CCONJ - O
Electrical PROPN - O
Storms PROPN - O
in ADP - O
Patients NOUN - O
With ADP - O
Implantable ADJ - O
Cardioverter PROPN - O
Defibrillators PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Should VERB - O
Digoxin NNP - B-MEDICINE
Continue VB - I-PERSON
To PART - O
Be VERB - O
Used VERB - O
for ADP - O
the DET - O
Management PROPN - O
of ADP - O
Atrial PROPN - O
Fibrillation PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Accidental NNP - B-ORG
Intrathecal NNP - I-ORG
Administration NNP - I-ORG
of IN - I-ORG
Digoxin NNP - I-MEDICINE
in ADP - O
an DET - O
Elderly JJ - B-ORG
Male NNP - I-ORG
with ADP - O
End NOUN - O
- PUNCT - O
Stage NOUN - O
Renal PROPN - O
Disease PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Cleveland NNP - B-GPE
Health NNP - B-ORG
Quality NNP - I-ORG
Choice NNP - I-ORG
was VERB - O
a DET - O
failure NOUN - O
, PUNCT - O
not ADV - O
a DET - O
martyr NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

mg PROPN - O
Asproclear PROPN - O
, PUNCT - O
600 CD - B-CARDINAL
mg NOUN - O
Bufferin NNP - B-GPE
, PUNCT - O
600 CD - B-CARDINAL
mg ADJ - O
Bi NNP - B-PERSON
- HYPH - I-PERSON
prin NNP - I-PERSON
, PUNCT - O
600 CD - B-CARDINAL
mg NOUN - O
compressed VERB - O
ASA NNP - B-ORG
, PUNCT - O
650 CD - B-CARDINAL
mg ADP - O
Ecotrin NNP - B-MEDICINE
, PUNCT - O
or CCONJ - O
650 CD - B-CARDINAL
mg PART - O
S.R.A.--in VERB - O
random ADJ - O
order NOUN - O

Ecotrin NNP - B-MEDICINE
and CCONJ - O
S.R.A. NNP - B-ORG
yielded VERB - O
plasma NOUN - O
SA NNP - B-ORG
levels NOUN - O
of ADP - O
14 CD - B-CARDINAL
to TO - I-CARDINAL
87 CD - I-CARDINAL
mumol NOUN - O
/ SYM - O
l NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
- SYM - O
12 NUM - O
mg NOUN - O
/ SYM - O
l NOUN - O
) PUNCT - O
within ADP - O
4 CD - B-CARDINAL
to PART - O
24 CD - B-CARDINAL
hr NOUN - O
and CCONJ - O
no DET - O
measurable ADJ - O
ASA NNP - B-ORG
at ADP - O
any DET - O
time NOUN - O
after ADP - O
dosing VERB - O
. PUNCT - O

The DET - O
time NOUN - O
course NOUN - O
for ADP - O
this DET - O
inhibition NOUN - O
was VERB - O
the DET - O
same ADJ - O
for ADP - O
all DET - O
preparations NOUN - O
but CCONJ - O
Ecotrin NNP - B-MEDICINE
( PUNCT - O
which ADJ - O
led VERB - O
to ADP - O
a DET - O
more ADV - O
delayed VERB - O
effect NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
significant ADJ - O
recovery NOUN - O
of ADP - O
collagen NOUN - O
- PUNCT - O
induced VERB - O
platelet NOUN - O
aggregation NOUN - O
at ADP - O
24 CD - B-CARDINAL
hr NOUN - O
with ADP - O
all DET - O
preparations NOUN - O
but CCONJ - O
Ecotrin NNP - B-MEDICINE
. PUNCT - O

With ADP - O
Ecotrin NNP - B-MEDICINE
and CCONJ - O
S.R.A. NNP - B-ORG
there ADV - O
was VERB - O
inhibition NOUN - O
of ADP - O
platelet NOUN - O
aggregation NOUN - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
measurable ADJ - O
circulating VERB - O
ASA NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
an DET - O
attempt NOUN - O
to PART - O
find VERB - O
the DET - O
most ADV - O
appropriate ADJ - O
dose NOUN - O
and CCONJ - O
formulation(s VERB - O
) PUNCT - O
of ADP - O
acetylsalicylic ADJ - O
acid NOUN - O
( PUNCT - O
ASA NNP - B-ORG
) PUNCT - O
for ADP - O
thrombosis NOUN - O
prophylaxis NOUN - O
, PUNCT - O
healthy ADJ - O
volunteers NOUN - O
were VERB - O
given VERB - O
doses NOUN - O
of ADP - O
ASA NNP - B-ORG
for ADP - O
1 CD - B-CARDINAL
wk NOUN - O
daily RB - B-DATE
ranging VERB - O
from ADP - O
50 CD - B-CARDINAL
to IN - I-CARDINAL
3900 CD - B-CARDINAL
mg NOUN - O
as ADP - O
either CCONJ - O
Aspro JJ - B-ORG
- HYPH - I-ORG
Clear JJ - I-ORG
( PUNCT - O
soluble ADJ - O
) PUNCT - O
, PUNCT - O
Astrix NNP - B-PERSON
( PUNCT - O
enteric ADJ - O
coated ADJ - O
pellets NOUN - O
) PUNCT - O
or CCONJ - O
Ecotrin NNP - B-MEDICINE
( PUNCT - O
enteric ADJ - O
coated VERB - O
tablets NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
of ADP - O
sumatriptan NOUN - O
/ SYM - O
naproxen NOUN - O
sodium NOUN - O
( PUNCT - O
Treximet NNP - B-MEDICINE
( PUNCT - O
® NOUN - O
) PUNCT - O
) PUNCT - O
has VERB - O
been VERB - O
approved VERB - O
in ADP - O
the DET - O
US NNP - B-GPE
for ADP - O
the DET - O
acute ADJ - O
treatment NOUN - O
of ADP - O
migraine NOUN - O
in ADP - O
adults NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rivaroxaban NN - B-ORG
vs IN - I-ORG
Warfarin NNP - I-ORG
Sodium NNP - I-ORG
in ADP - O
the DT - B-ORG
Ultra NNP - I-ORG
- HYPH - I-ORG
Early JJ - I-ORG
Period NNP - I-ORG

-DOCSTART- -X- - O

Stability NOUN - O
Indicating PROPN - O
RP PROPN - O
- PUNCT - O
HPLC PROPN - O
Method PROPN - O
for ADP - O
the DET - O
Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Atorvastatin NNP - B-MEDICINE
Calcium NNP - I-MEDICINE
, PUNCT - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Glimepiride NNP - B-ORG
in IN - I-ORG
Bulk NNP - I-ORG
and CC - I-ORG
Combined NNP - I-ORG
Tablet NNP - I-ORG
Dosage NN - I-ORG
Form NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Stress NOUN - O
Degradation PROPN - O
Behavior PROPN - O
of ADP - O
Atorvastatin NNP - B-ORG
Calcium NNP - I-ORG
and CC - I-ORG
Development NNP - I-ORG
of ADP - O
a DET - O
Suitable PROPN - O
Stability PROPN - O
- PUNCT - O
Indicating PROPN - O
LC PROPN - O
Method PROPN - O
for ADP - O
the DET - O
Determination PROPN - O
of ADP - O
Atorvastatin PROPN - O
, PUNCT - O
its ADJ - O
Related NNP - B-ORG
Impurities NNPS - I-ORG
, PUNCT - O
and CCONJ - O
its ADJ - O
Degradation PROPN - O
Products PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Containing PROPN - O
Technetium-99m PROPN - O
- PUNCT - O
Radiolabeled VERB - O
Alendronate NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Pregnancy NOUN - O
outcomes NOUN - O
following VERB - O
maternal ADJ - O
venlafaxine NN - B-MEDICINE
use NOUN - O
: PUNCT - O
A DET - O
prospective ADJ - O
observational ADJ - O
comparative ADJ - O
cohort NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Despite ADP - O
its ADJ - O
favorable ADJ - O
pharmacological ADJ - O
profile NOUN - O
and CCONJ - O
efficacy NOUN - O
in ADP - O
major ADJ - O
depression NOUN - O
and CCONJ - O
anxiety NOUN - O
disorders NOUN - O
, PUNCT - O
evidence NOUN - O
for ADP - O
the DET - O
use NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
obsessive ADJ - O
- PUNCT - O
compulsive ADJ - O
disorder NOUN - O
( PUNCT - O
OCD NOUN - O
) PUNCT - O
is VERB - O
limited VERB - O
. PUNCT - O

We PRON - O
sought VERB - O
to PART - O
examine VERB - O
the DET - O
real ADJ - O
- PUNCT - O
world NOUN - O
effectiveness NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
from ADP - O
a DET - O
large ADJ - O
database NOUN - O
of ADP - O
an DET - O
OCD PROPN - O
clinic NOUN - O
in ADP - O
India NNP - B-GPE
. PUNCT - O

Patients NOUN - O
with ADP - O
symptomatic ADJ - O
OCD NN - B-ORG
( PUNCT - O
Yale NNP - B-ORG
- HYPH - I-ORG
Brown NNP - I-ORG
Obsessive NNP - I-ORG
- HYPH - I-ORG
Compulsive NNP - I-ORG
Severity PROPN - O
≥16 ADV - O
) PUNCT - O
despite ADP - O
treatment NOUN - O
with ADP - O
selective ADJ - O
serotonin NOUN - O
reuptake VERB - O
inhibitors NOUN - O
and CCONJ - O
initiated VERB - O
on ADP - O
venlafaxine NN - B-MEDICINE
were VERB - O
included VERB - O
for ADP - O
analysis NOUN - O
. PUNCT - O

Of ADP - O
a DET - O
total NOUN - O
of ADP - O
65 CD - B-CARDINAL
patients NOUN - O
who NOUN - O
were VERB - O
eligible ADJ - O
for ADP - O
analysis NOUN - O
, PUNCT - O
29(45 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
responders NOUN - O
at ADP - O
the DT - B-DATE
end NN - I-DATE
of IN - I-DATE
16 CD - I-DATE
weeks NNS - I-DATE
and CCONJ - O
27 CD - B-CARDINAL
( PUNCT - O
42 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
continued VERB - O
to PART - O
remain VERB - O
on ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

The DET - O
study NOUN - O
suggests VERB - O
that ADP - O
venlafaxine NN - B-MEDICINE
may VERB - O
be VERB - O
useful ADJ - O
in ADP - O
a DET - O
proportion NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
poor ADJ - O
response NOUN - O
to PART - O
selective ADJ - O
serotonin ADJ - O
reuptake VERB - O
inhibitors NOUN - O
and CCONJ - O
therefore ADV - O
requires VERB - O
to PART - O
be VERB - O
studied VERB - O
in ADP - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
association NOUN - O
between ADP - O
CYP2D6 NN - B-PERSON
metabolizer NOUN - O
status NOUN - O
and CCONJ - O
clinical ADJ - O
outcomes NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
was VERB - O
extensively ADV - O
investigated VERB - O
previously ADV - O
, PUNCT - O
but CCONJ - O
no DET - O
widely ADV - O
accepted VERB - O
conclusion NOUN - O
has VERB - O
been VERB - O
reached VERB - O
so ADV - O
far ADV - O
. PUNCT - O

Significant ADJ - O
associations NOUN - O
were VERB - O
found VERB - O
among ADP - O
3 CD - B-CARDINAL
CYP2D6 NOUN - O
phenotypes NOUN - O
( PUNCT - O
NM PROPN - O
, PUNCT - O
IM NNP - B-ORG
, PUNCT - O
and CCONJ - O
PM NN - B-ORG
) PUNCT - O
and CCONJ - O
most ADV - O
pharmacokinetic ADJ - O
parameters NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

However ADV - O
, PUNCT - O
CYP2D6 NN - B-PERSON
phenotypes NOUN - O
were VERB - O
not ADV - O
associated VERB - O
with ADP - O
Hamilton NNP - B-ORG
Depression NNP - I-ORG
Rating NNP - I-ORG
Scale NNP - I-ORG
response NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

CYP2D6 NN - B-PERSON
metabolizer NOUN - O
status NOUN - O
had VERB - O
significant ADJ - O
influence NOUN - O
on ADP - O
venlafaxine NN - B-MEDICINE
pharmacokinetics NOUN - O
, PUNCT - O
but CCONJ - O
insufficient ADJ - O
evidence NOUN - O
demonstrated VERB - O
that ADP - O
CYP2D6 NN - B-PERSON
metabolizer NOUN - O
status NOUN - O
was VERB - O
associated VERB - O
with ADP - O
its ADJ - O
therapeutic ADJ - O
effects NOUN - O
and CCONJ - O
overall ADJ - O
rate NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
, PUNCT - O
which ADJ - O
provided VERB - O
further ADJ - O
evidence NOUN - O
regarding VERB - O
the DET - O
relationship NOUN - O
between ADP - O
CYP2D6 NN - B-PERSON
metabolizer NOUN - O
status NOUN - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
fullerenes NOUN - O
in ADP - O
the DET - O
bioaccumulation NOUN - O
and CCONJ - O
biotransformation NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
diuron NOUN - O
and CCONJ - O
triclosan NOUN - O
in ADP - O
river NOUN - O
biofilms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Various ADJ - O
studies NOUN - O
have VERB - O
shown VERB - O
that ADP - O
potent ADJ - O
norepinephrine NOUN - O
and CCONJ - O
serotonin ADJ - O
reuptake VERB - O
inhibitors NOUN - O
such ADJ - O
as ADP - O
gabapentin NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
duloxetine NOUN - O
have VERB - O
therapeutic ADJ - O
effects NOUN - O
on ADP - O
neuropathy PROPN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
effects NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
vs. ADP - O
duloxetine NOUN - O
on ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
peripheral ADJ - O
neuropathy NOUN - O
. PUNCT - O

They PRON - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
three CD - B-CARDINAL
pharmacotherapy NOUN - O
groups NOUN - O
including VERB - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
duloxetine NOUN - O
and CCONJ - O
placebo NOUN - O
. PUNCT - O

Grade NOUN - O
of ADP - O
cranial NOUN - O
, PUNCT - O
motor NOUN - O
, PUNCT - O
sensory ADJ - O
and CCONJ - O
neuropathic ADJ - O
pain NOUN - O
decreased VERB - O
significantly ADV - O
in ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
duloxetine VERB - O
groups NOUN - O
. PUNCT - O

This DET - O
reduction NOUN - O
was VERB - O
more ADV - O
considerable ADJ - O
in ADP - O
duloxetine NOUN - O
group NOUN - O
compared VERB - O
to ADP - O
venlafaxine NN - B-MEDICINE
group NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Duloxetine NN - B-PERSON
seems VERB - O
to PART - O
be VERB - O
more ADV - O
effective ADJ - O
than ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
decreasing VERB - O
the DET - O
symptoms NOUN - O
of ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
peripheral ADJ - O
neuropathy NOUN - O
. PUNCT - O

Duloxetine NNP - B-PERSON
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
decreasing VERB - O
motor NOUN - O
neuropathy ADJ - O
and CCONJ - O
neuropathic ADJ - O
pain NOUN - O
grade NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Perinatal ADJ - O
exposure NOUN - O
to PART - O
venlafaxine VB - B-MEDICINE
leads NOUN - O
to ADP - O
lower ADJ - O
anxiety NOUN - O
and CCONJ - O
depression NOUN - O
- PUNCT - O
like ADJ - O
behavior NOUN - O
in ADP - O
the DET - O
adult NOUN - O
rat NOUN - O
offspring NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
paper NOUN - O
presents VERB - O
a DET - O
study NOUN - O
on ADP - O
expected VERB - O
removal NOUN - O
for ADP - O
the DET - O
pharmaceutical NOUN - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
VEN PROPN - O
) PUNCT - O
in ADP - O
a DET - O
typical ADJ - O
UV NOUN - O
unit NOUN - O
at ADP - O
a DET - O
municipal ADJ - O
WWTP NNP - B-ORG
with ADP - O
analysis NOUN - O
of ADP - O
removal NOUN - O
rates NOUN - O
of ADP - O
an DET - O
advanced ADJ - O
oxidation NOUN - O
process NOUN - O
using VERB - O
UV NOUN - O
irradiation NOUN - O
with ADP - O
injection NOUN - O
of ADP - O
H2O2 NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Participants NOUN - O
were VERB - O
randomized VERB - O
to PART - O
receive VERB - O
a DET - O
12-week CD - B-MONEY
regimen NNS - I-MONEY
of ADP - O
venlafaxine NN - B-MEDICINE
XR NNP - B-GPE
or CCONJ - O
venlafaxine NN - B-MEDICINE
XR NNP - B-ORG
plus CCONJ - O
supervised ADJ - O
exercise NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
effect NOUN - O
of ADP - O
body NOUN - O
weight NOUN - O
and CCONJ - O
BMI NNP - B-ORG
on ADP - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
VEN PROPN - O
) PUNCT - O
, PUNCT - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
( PUNCT - O
ODVEN PROPN - O
) PUNCT - O
, PUNCT - O
active ADJ - O
moiety NOUN - O
( PUNCT - O
AM PROPN - O
= SYM - O
VEN+ODVEN NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
dose NOUN - O
- PUNCT - O
corrected VERB - O
plasma NOUN - O
concentrations NOUN - O
( PUNCT - O
C PROPN - O
/ SYM - O
D PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Sex NOUN - O
and CCONJ - O
body NOUN - O
weight NOUN - O
are VERB - O
major ADJ - O
determinants NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
pharmacokinetics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
microplastics NOUN - O
on ADP - O
the DET - O
uptake NOUN - O
, PUNCT - O
distribution NOUN - O
and CCONJ - O
biotransformation NOUN - O
of ADP - O
chiral ADJ - O
antidepressant ADJ - O
venlafaxine NN - B-MEDICINE
in ADP - O
aquatic ADJ - O
ecosystem NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
study NOUN - O
included VERB - O
10 CD - B-CARDINAL
study NOUN - O
antidepressants NOUN - O
: PUNCT - O
citalopram NOUN - O
, PUNCT - O
escitalopram NOUN - O
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
paroxetine NOUN - O
, PUNCT - O
sertraline NOUN - O
, PUNCT - O
duloxetine NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
amitriptyline ADV - O
, PUNCT - O
mirtazapine NOUN - O
, PUNCT - O
and CCONJ - O
agomelatine NOUN - O
. PUNCT - O

Citalopram NNP - B-ORG
and CCONJ - O
amitriptyline ADV - O
had VERB - O
the DET - O
lowest ADJ - O
percentage NOUN - O
of ADP - O
multiple ADJ - O
antidepressant ADJ - O
use NOUN - O
in ADP - O
the DT - B-DATE
12 CD - I-DATE
months NNS - I-DATE
prior ADV - O
to ADP - O
the DET - O
current ADJ - O
treatment NOUN - O
episode NOUN - O
, PUNCT - O
while ADP - O
agomelatine NOUN - O
, PUNCT - O
duloxetine VERB - O
, PUNCT - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
had VERB - O
the DET - O
highest ADJ - O
percentage NOUN - O
of ADP - O
multiple ADJ - O
antidepressant ADJ - O
use NOUN - O
in ADP - O
the DT - B-DATE
year NN - I-DATE
prior ADV - O
to ADP - O
the DET - O
current ADJ - O
treatment NOUN - O
episode NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
influence NOUN - O
of ADP - O
selective ADJ - O
A1 PROPN - O
and CCONJ - O
A2A NNP - B-ORG
receptor NOUN - O
antagonists NOUN - O
on ADP - O
the DET - O
antidepressant ADJ - O
- PUNCT - O
like ADJ - O
activity NOUN - O
of ADP - O
moclobemide NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
bupropion NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Reduced ADJ - O
clearance NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
a DET - O
combined VERB - O
treatment NOUN - O
with ADP - O
quetiapine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
present ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
enantioselective ADJ - O
behaviors NOUN - O
of ADP - O
the DET - O
chiral ADJ - O
antidepressant NOUN - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
its ADJ - O
metabolite ADJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
in ADP - O
loach NOUN - O
Misgurnus JJ - B-NORP
anguillicaudatus NOUN - O
( PUNCT - O
M. NNP - B-PERSON
anguillicaudatus PROPN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
effects NOUN - O
of ADP - O
microplastic ADJ - O
on ADP - O
toxicity NOUN - O
, PUNCT - O
distribution NOUN - O
and CCONJ - O
metabolism NOUN - O
through ADP - O
a DET - O
40-day CD - B-DATE
co NOUN - O
- NOUN - O
exposure NOUN - O
. PUNCT - O

The DET - O
contents NOUN - O
of ADP - O
SOD NNP - B-ORG
and CCONJ - O
MDA NNP - B-ORG
in ADP - O
loach NOUN - O
liver NOUN - O
elevated ADJ - O
when ADV - O
the DET - O
loach NOUN - O
was VERB - O
exposed VERB - O
to ADP - O
venlafaxine VB - B-MEDICINE
and CCONJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
. PUNCT - O

The DET - O
distribution NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
were VERB - O
both DET - O
detected VERB - O
in ADP - O
loach NOUN - O
tissues NOUN - O
and CCONJ - O
liver NOUN - O
subcellular ADJ - O
. PUNCT - O

The DET - O
concentrations NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
were VERB - O
lower ADJ - O
in ADP - O
water NOUN - O
in ADP - O
microplastic ADJ - O
- PUNCT - O
present ADJ - O
treatment NOUN - O
. PUNCT - O

Enantioselective ADJ - O
behavior NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
occurred VERB - O
with ADP - O
R NOUN - O
- PUNCT - O
enantiomers NOUN - O
being VERB - O
preferentially ADV - O
degraded VERB - O
. PUNCT - O

With ADP - O
microplastic ADJ - O
present NOUN - O
, PUNCT - O
the DET - O
bioaccumulation NOUN - O
factor NOUN - O
( PUNCT - O
BAF NNP - B-ORG
) PUNCT - O
of ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
O NOUN - O
- PUNCT - O
desmethylvenlafaxine NOUN - O
in ADP - O
loach NOUN - O
tissue NOUN - O
amplified VERB - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
10 CD - I-CARDINAL
times NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Concentrations NOUN - O
of ADP - O
three CD - B-CARDINAL
antidepressants NOUN - O
citalopram NOUN - O
, PUNCT - O
sertraline NOUN - O
, PUNCT - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
were VERB - O
measured VERB - O
in ADP - O
maternal ADJ - O
blood NOUN - O
and CCONJ - O
breast NOUN - O
milk NOUN - O
in ADP - O
17 CD - B-CARDINAL
women NOUN - O
receiving VERB - O
antidepressant ADJ - O
therapy NOUN - O
during ADP - O
breastfeeding VERB - O
period NOUN - O
. PUNCT - O

The DET - O
amount NOUN - O
of ADP - O
antidepressant ADJ - O
concentrations NOUN - O
to PART - O
which ADJ - O
neonates NOUN - O
may VERB - O
be VERB - O
exposed VERB - O
, PUNCT - O
assessed VERB - O
as ADP - O
absolute ADJ - O
infant NOUN - O
dose NOUN - O
( PUNCT - O
AID PROPN - O
) PUNCT - O
, PUNCT - O
was VERB - O
particularly ADV - O
low ADJ - O
with ADP - O
the DET - O
highest ADJ - O
median ADJ - O
AID NOUN - O
being VERB - O
0.16 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
day NOUN - O
for ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
listed VERB - O
as ADP - O
an DET - O
adverse ADJ - O
reaction NOUN - O
, PUNCT - O
seizure NOUN - O
activity NOUN - O
associated VERB - O
with ADP - O
a DET - O
therapeutic ADJ - O
dose NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
has VERB - O
rarely ADV - O
been VERB - O
documented VERB - O
. PUNCT - O

A DET - O
review NOUN - O
of ADP - O
the DET - O
literature NOUN - O
reveals VERB - O
only RB - B-CARDINAL
2 CD - I-CARDINAL
cases NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
seizures NOUN - O
, PUNCT - O
both DET - O
of ADP - O
which ADJ - O
were VERB - O
generalized VERB - O
tonic NOUN - O
- PUNCT - O
clonic ADJ - O
seizures NOUN - O
in ADP - O
patients NOUN - O
on ADP - O
doses NOUN - O
at ADP - O
the DET - O
higher ADJ - O
end NOUN - O
of ADP - O
the DET - O
therapeutic ADJ - O
range NOUN - O
. PUNCT - O

We PRON - O
report VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
44-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
woman NOUN - O
undergoing VERB - O
antituberculosis NOUN - O
therapy NOUN - O
who NOUN - O
suffered VERB - O
complex ADJ - O
partial ADJ - O
seizures NOUN - O
after ADP - O
ingestion NOUN - O
of ADP - O
a DET - O
low ADJ - O
therapeutic ADJ - O
dose NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
extended VERB - O
release NOUN - O
( PUNCT - O
ER NNP - B-ORG
) PUNCT - O
. PUNCT - O

Her ADJ - O
first JJ - B-ORDINAL
seizure NOUN - O
was VERB - O
observed VERB - O
soon ADV - O
after ADP - O
venlafaxine NN - B-MEDICINE
ER PROPN - O
was VERB - O
titrated VERB - O
from ADP - O
37.5 CD - B-CARDINAL
to PART - O
75 CD - B-CARDINAL
  SPACE - O
mg PRON - O
daily RB - B-DATE
, PUNCT - O
with ADP - O
a DET - O
total NOUN - O
of ADP - O
9 CD - B-CARDINAL
witnessed VERB - O
complex ADJ - O
partial ADJ - O
seizures NOUN - O
. PUNCT - O

After ADP - O
titrating VERB - O
the DET - O
dose NOUN - O
of ADP - O
the DET - O
venlafaxine NN - B-MEDICINE
ER PROPN - O
back ADV - O
down ADV - O
to ADP - O
37.5 CD - B-CARDINAL
  SPACE - O
mg PRON - O
daily RB - B-DATE
and CCONJ - O
beginning VERB - O
lamotrigine ADJ - O
anticonvulsant NOUN - O
therapy NOUN - O
, PUNCT - O
the DET - O
patient NOUN - O
exhibited VERB - O
no DET - O
further ADJ - O
seizures NOUN - O
. PUNCT - O

The DET - O
development NOUN - O
of ADP - O
seizure NOUN - O
activity NOUN - O
under ADP - O
therapeutic ADJ - O
dosing NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
should VERB - O
be VERB - O
brought VERB - O
to ADP - O
the DET - O
attention NOUN - O
of ADP - O
the DET - O
health NOUN - O
care NOUN - O
prescriber NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dose NOUN - O
- PUNCT - O
corrected VERB - O
, PUNCT - O
steady ADJ - O
- PUNCT - O
state NOUN - O
serum NOUN - O
concentrations NOUN - O
of ADP - O
individual ADJ - O
patients NOUN - O
were VERB - O
analyzed VERB - O
retrospectively ADV - O
by ADP - O
linear ADJ - O
regression NOUN - O
including VERB - O
age NOUN - O
, PUNCT - O
sex NOUN - O
, PUNCT - O
and CCONJ - O
smoking NOUN - O
for ADP - O
amitriptyline ADJ - O
( PUNCT - O
n=503 NN - B-CARDINAL
) PUNCT - O
, PUNCT - O
doxepin NOUN - O
( PUNCT - O
n=198 NOUN - O
) PUNCT - O
, PUNCT - O
mirtazapine NOUN - O
( PUNCT - O
n=572 ADJ - O
) PUNCT - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
n=534 NNP - B-CARDINAL
) PUNCT - O
, PUNCT - O
clozapine NOUN - O
( PUNCT - O
n=106 PROPN - O
) PUNCT - O
, PUNCT - O
quetiapine NOUN - O
( PUNCT - O
n=182 JJ - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
risperidone NOUN - O
( PUNCT - O
n=136 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Dispersive ADJ - O
liquid NOUN - O
- PUNCT - O
liquid NOUN - O
microextraction NOUN - O
for ADP - O
the DET - O
quantification NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
environmental ADJ - O
waters NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Phase PROPN - O
1 CD - B-CARDINAL
participants NOUN - O
received VERB - O
6 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
low ADV - O
- PUNCT - O
dose NOUN - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
≤150 NNP - B-GPE
  SPACE - O
mg PROPN - O
/ SYM - O
day NOUN - O
) PUNCT - O
. PUNCT - O

Nonresponders NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
10 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
high ADJ - O
- PUNCT - O
dose NOUN - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
up IN - B-CARDINAL
to IN - I-CARDINAL
300 CD - I-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
day NOUN - O
) PUNCT - O
plus CCONJ - O
problem NOUN - O
- PUNCT - O
solving VERB - O
therapy NOUN - O
( PUNCT - O
PST PROPN - O
) PUNCT - O
or CCONJ - O
high ADJ - O
- PUNCT - O
dose NOUN - O
venlafaxine NN - B-MEDICINE
with ADP - O
supportive ADJ - O
management NOUN - O
. PUNCT - O

Function PROPN - O
was VERB - O
measured VERB - O
with ADP - O
the DT - B-ORG
Short NNP - I-ORG
Physical NNP - I-ORG
Performance NNP - I-ORG
Battery NNP - I-ORG
( PUNCT - O
SPPB PROPN - O
) PUNCT - O
and CCONJ - O
Roland NNP - B-ORG
Morris NNP - I-ORG
Disability NNP - I-ORG
Questionnaire NNP - B-PERSON
( PUNCT - O
RMDQ).Of PROPN - O
those DET - O
who NOUN - O
completed VERB - O
Phase NNP - B-LAW
1 CD - I-LAW
( PUNCT - O
N DET - O
  SPACE - O
= PUNCT - O
  SPACE - O
209 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
78.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
N NOUN - O
  SPACE - O
= PUNCT - O
  SPACE - O
164 CD - B-CARDINAL
) PUNCT - O
were VERB - O
nonresponders NOUN - O
and CCONJ - O
139 CD - B-CARDINAL
proceeded VERB - O
to ADP - O
Phase PROPN - O
2 CD - B-CARDINAL
, PUNCT - O
with ADP - O
68 CD - B-CARDINAL
randomized VERB - O
to PART - O
venlafaxine NN - B-MEDICINE
/ SYM - O
PST NNP - B-ORG
and CCONJ - O
71 CD - B-CARDINAL
randomized VERB - O
to PART - O
venlafaxine VB - B-MEDICINE
/ SYM - O
supportive ADJ - O
management NOUN - O
. PUNCT - O

Of ADP - O
those DET - O
in ADP - O
venlafaxine NN - B-MEDICINE
/ SYM - O
PST NNP - B-ORG
, PUNCT - O
41.2 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
28/68 CD - B-CARDINAL
) PUNCT - O
responded VERB - O
, PUNCT - O
and CCONJ - O
of ADP - O
those DET - O
in ADP - O
venlafaxine NN - B-MEDICINE
/ SYM - O
supportive ADJ - O
management NOUN - O
, PUNCT - O
39.4 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
28/71 CD - B-CARDINAL
) PUNCT - O
responded VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
is VERB - O
to PART - O
explore VERB - O
the DET - O
effect NOUN - O
of ADP - O
desvenlafaxine NOUN - O
on ADP - O
clinical ADJ - O
periodontal ADJ - O
parameters NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
chronic ADJ - O
periodontitis NOUN - O
. PUNCT - O

The DET - O
patients NOUN - O
were VERB - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
as ADP - O
follows VERB - O
: PUNCT - O
test NOUN - O
group NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
63 CD - B-CARDINAL
) PUNCT - O
comprised VERB - O
of ADP - O
participants NOUN - O
on ADP - O
50 CD - B-CARDINAL
mg NOUN - O
once ADV - O
- PUNCT - O
daily RB - B-DATE
dose NOUN - O
of ADP - O
desvenlafaxine NOUN - O
for ADP - O
≥2 NN - B-DATE
months NNS - I-DATE
and CCONJ - O
control NOUN - O
group NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
72 CD - B-CARDINAL
) PUNCT - O
included VERB - O
participants NOUN - O
who NOUN - O
were VERB - O
yet ADV - O
to PART - O
be VERB - O
prescribed VERB - O
medication NOUN - O
for ADP - O
depression NOUN - O
. PUNCT - O

Participants NOUN - O
taking VERB - O
desvenlafaxine NOUN - O
revealed VERB - O
lower ADJ - O
values NOUN - O
of ADP - O
periodontal ADJ - O
parameters NOUN - O
as ADP - O
compared VERB - O
to ADP - O
those DET - O
in ADP - O
control NOUN - O
group NOUN - O
. PUNCT - O

In ADP - O
our ADJ - O
study NOUN - O
, PUNCT - O
patients NOUN - O
on ADP - O
desvenlafaxine NOUN - O
were VERB - O
associated VERB - O
with ADP - O
less ADJ - O
pocket NOUN - O
depth NOUN - O
and CCONJ - O
bleeding VERB - O
on ADP - O
probing VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
presence NOUN - O
of ADP - O
antidepressants NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
VFX PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
marine ADJ - O
ecosystems NOUN - O
is VERB - O
increasing VERB - O
, PUNCT - O
thus ADV - O
, PUNCT - O
potentially ADV - O
posing VERB - O
ecological ADJ - O
and CCONJ - O
human ADJ - O
health NOUN - O
risks NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Medications NOUN - O
such ADJ - O
as ADP - O
amitriptyline NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
atenolol NOUN - O
, PUNCT - O
and CCONJ - O
nadolol NOUN - O
are VERB - O
probably ADV - O
effective ADJ - O
but CCONJ - O
should VERB - O
be VERB - O
second JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Role NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
in ADP - O
prevention NOUN - O
of ADP - O
cyclophosphamide NOUN - O
- PUNCT - O
induced VERB - O
lung NOUN - O
toxicity NOUN - O
and CCONJ - O
airway NOUN - O
hyperactivity NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
work NOUN - O
, PUNCT - O
raw ADJ - O
vermiculite NOUN - O
and CCONJ - O
its ADJ - O
three CD - B-CARDINAL
modified VERB - O
forms NOUN - O
( PUNCT - O
expanded VERB - O
, PUNCT - O
base NOUN - O
, PUNCT - O
and CCONJ - O
acid NOUN - O
/ SYM - O
base NOUN - O
treated VERB - O
) PUNCT - O
were VERB - O
tested VERB - O
for ADP - O
removal NOUN - O
of ADP - O
a DET - O
widely ADV - O
used VERB - O
antidepressant NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

The DET - O
acid NOUN - O
/ SYM - O
base NOUN - O
- PUNCT - O
treated VERB - O
vermiculite NOUN - O
exhibited VERB - O
good ADJ - O
properties NOUN - O
as ADP - O
a DET - O
potential ADJ - O
adsorbent NOUN - O
for ADP - O
tertiary ADJ - O
treatment NOUN - O
of ADP - O
wastewater NOUN - O
in ADP - O
treatment NOUN - O
plants NOUN - O
, PUNCT - O
in ADP - O
particular ADJ - O
for ADP - O
cationic ADJ - O
species NOUN - O
as ADP - O
venlafaxine NN - B-MEDICINE
due ADP - O
to ADP - O
facilitation NOUN - O
of ADP - O
diffusion NOUN - O
of ADP - O
the DET - O
species NOUN - O
to ADP - O
the DET - O
interlayer ADJ - O
gallery NOUN - O
upon ADP - O
such ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Notably ADV - O
, PUNCT - O
some DET - O
medications NOUN - O
showed VERB - O
widespread ADJ - O
and CCONJ - O
increasing ADJ - O
use NOUN - O
, PUNCT - O
including VERB - O
proton NOUN - O
pump NOUN - O
inhibitors NOUN - O
( PUNCT - O
PPI PROPN - O
) PUNCT - O
, PUNCT - O
selective ADJ - O
serotonine NOUN - O
reuptake NOUN - O
inhibitors NOUN - O
( PUNCT - O
SSRI NNP - B-ORG
) PUNCT - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
SSRI NNP - B-ORG
and CCONJ - O
venlafaxine NN - B-MEDICINE
increased VERB - O
by ADP - O
114 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
613 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

97 CD - B-CARDINAL
were VERB - O
randomized VERB - O
to ADP - O
EMC NNP - B-ORG
( PUNCT - O
immediate ADJ - O
switch NOUN - O
to ADP - O
high ADJ - O
doses NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
XR NNP - B-GPE
) PUNCT - O
and CCONJ - O
n NOUN - O
  SPACE - O
= SYM - O
  SPACE - O

non ADJ - O
- ADJ - O
responders NOUN - O
switched VERB - O
to PART - O
venlafaxine VB - B-MEDICINE
XR NNP - B-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
absence NOUN - O
of ADP - O
an DET - O
urgent ADJ - O
indication NOUN - O
, PUNCT - O
we PRON - O
recommend VERB - O
trialing VERB - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
mirtazapine NOUN - O
, PUNCT - O
or CCONJ - O
a DET - O
tricyclic ADJ - O
antidepressant NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antidepressants NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
VFX PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
are VERB - O
considered VERB - O
emerging VERB - O
environmental ADJ - O
pollutants NOUN - O
, PUNCT - O
are VERB - O
increasingly ADV - O
more ADV - O
present ADJ - O
in ADP - O
the DET - O
marine ADJ - O
environment NOUN - O
, PUNCT - O
and CCONJ - O
recent ADJ - O
evidence NOUN - O
suggest VERB - O
that ADP - O
they PRON - O
might VERB - O
have VERB - O
adverse ADJ - O
effects NOUN - O
on ADP - O
fish NOUN - O
behaviour NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Differential ADJ - O
behavioural ADJ - O
responses NOUN - O
to ADP - O
venlafaxine NN - B-MEDICINE
exposure NOUN - O
route NOUN - O
, PUNCT - O
warming NOUN - O
and CCONJ - O
acidification NOUN - O
in ADP - O
juvenile ADJ - O
fish NOUN - O
( PUNCT - O
Argyrosomus NNP - B-ORG
regius NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antidepressant ADJ - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
VLF PROPN - O
) PUNCT - O
modulates VERB - O

-DOCSTART- -X- - O

The DET - O
action NOUN - O
of ADP - O
vortioxetine NOUN - O
was VERB - O
compared VERB - O
to ADP - O
the DET - O
action NOUN - O
of ADP - O
equal ADJ - O
doses NOUN - O
of ADP - O
the DET - O
serotonin NOUN - O
- PUNCT - O
noradrenaline NOUN - O
reuptake NOUN - O
inhibitor NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
one CD - B-CARDINAL
of ADP - O
the DET - O
gold ADJ - O
standard ADJ - O
drugs NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
neuropathic NOUN - O
pain NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
fluoxetine NOUN - O
. PUNCT - O

Vortioxetine NN - B-ORG
caused VERB - O
a DET - O
robust ADJ - O
analgesia NOUN - O
in ADP - O
chronic ADJ - O
constriction NOUN - O
injury NOUN - O
mice NOUN - O
, PUNCT - O
and CCONJ - O
its ADJ - O
effect NOUN - O
was VERB - O
identical ADJ - O
to ADP - O
that DET - O
produced VERB - O
by ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
for ADP - O
neuropathic ADJ - O
pain NOUN - O
and CCONJ - O
review NOUN - O
literature NOUN - O
to PART - O
determine VERB - O
if ADP - O
the DET - O
medication NOUN - O
provides VERB - O
adequate ADJ - O
neuropathic ADJ - O
pain NOUN - O
relief NOUN - O
. PUNCT - O

These DET - O
key ADJ - O
words NOUN - O
include VERB - O
: PUNCT - O
" PUNCT - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
venlafaxine NN - B-MEDICINE
ER NOUN - O
and CCONJ - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
venlafaxine NN - B-MEDICINE
XR NNP - B-ORG
and CCONJ - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
neuropathic NOUN - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
neuropathy NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
SSRI NN - B-ORG
and CCONJ - O
neuropathic NOUN - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
SSRI NNP - B-ORG
and CCONJ - O
neuropathy NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
SNRI ADJ - O
and CCONJ - O
neuropathic ADJ - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
SNRI ADJ - O
and CCONJ - O
neuropathy ADJ - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
serotonin ADJ - O
reuptake NOUN - O
inhibitor NOUN - O
and CCONJ - O
neuropathic NOUN - O
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
serotonin ADJ - O
reuptake NOUN - O
inhibitor NOUN - O
and CCONJ - O
neuropathy NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
serotonin ADJ - O
norepinephrine NOUN - O
reuptake NOUN - O
inhibitor NOUN - O
and CCONJ - O
neuropathic NOUN - O
pain NOUN - O
" PUNCT - O
and CCONJ - O
" PUNCT - O
serotonin ADJ - O
norepinephrine NOUN - O
reuptake NOUN - O
inhibitor NOUN - O
and CCONJ - O
neuropathy NOUN - O
. PUNCT - O

It PRON - O
is VERB - O
evident ADJ - O
that ADP - O
in ADP - O
the DET - O
majority NOUN - O
of ADP - O
studies NOUN - O
, PUNCT - O
when ADV - O
compared VERB - O
with ADP - O
a DET - O
placebo NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
a DET - O
clinical ADJ - O
significant ADJ - O
reduction NOUN - O
in ADP - O
neuropathic ADJ - O
pain NOUN - O
relief NOUN - O
when ADV - O
using VERB - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

Additionally ADV - O
, PUNCT - O
one CD - B-CARDINAL
study NOUN - O
showed VERB - O
even ADV - O
more ADV - O
significant ADJ - O
pain NOUN - O
relief NOUN - O
when ADV - O
using VERB - O
higher ADJ - O
doses NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
at RB - B-CARDINAL
least JJS - I-CARDINAL
150 CD - I-CARDINAL
  SPACE - O
mg PRON - O
) PUNCT - O
. PUNCT - O

However ADV - O
, PUNCT - O
when ADV - O
compared VERB - O
with ADP - O
alternative ADJ - O
neuropathic ADJ - O
medications NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
for ADP - O
the DET - O
most ADJ - O
part NOUN - O
did VERB - O
not ADV - O
perform VERB - O
any ADV - O
better ADV - O
in ADP - O
terms NOUN - O
of ADP - O
efficacy NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
is VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
tolerated VERB - O
analgesic ADJ - O
drug NOUN - O
for ADP - O
the DET - O
symptomatic ADJ - O
treatment NOUN - O
of ADP - O
neuropathic NOUN - O
pain NOUN - O
, PUNCT - O
and CCONJ - O
there ADV - O
is VERB - O
limited ADJ - O
evidence NOUN - O
that ADP - O
high ADV - O
- PUNCT - O
dose NOUN - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
150 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
day NOUN - O
) PUNCT - O
can VERB - O
be VERB - O
even ADV - O
more ADV - O
beneficial ADJ - O
. PUNCT - O

While ADP - O
the DET - O
present ADJ - O
evidence NOUN - O
is VERB - O
quite ADV - O
encouraging ADJ - O
regarding VERB - O
venlafaxine NN - B-MEDICINE
's PART - O
use NOUN - O
for ADP - O
neuropathic ADJ - O
pain NOUN - O
, PUNCT - O
further ADJ - O
research NOUN - O
is VERB - O
needed VERB - O
to PART - O
continue VERB - O
to PART - O
expand VERB - O
on ADP - O
these DET - O
findings NOUN - O
, PUNCT - O
particularly ADV - O
when ADV - O
in ADP - O
consideration NOUN - O
with ADP - O
other ADJ - O
possible ADJ - O
pharmacological ADJ - O
agents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
influence NOUN - O
of ADP - O
aripiprazole NOUN - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
on ADP - O
the DET - O
antidepressant NOUN - O
- PUNCT - O
like ADJ - O
effect NOUN - O
observed VERB - O
in ADP - O
prenatally ADV - O
stressed VERB - O
rats NOUN - O
( PUNCT - O
animal NOUN - O
model NOUN - O
of ADP - O
depression NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
effects NOUN - O
of ADP - O
warming NOUN - O
and CCONJ - O
acidification NOUN - O
on ADP - O
the DET - O
bioconcentration NOUN - O
, PUNCT - O
metabolization NOUN - O
and CCONJ - O
depuration NOUN - O
of ADP - O
five CD - B-CARDINAL
PhACs NNP - B-ORG
( PUNCT - O
sotalol NOUN - O
, PUNCT - O
sulfamethoxazole NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
carbamazepine NOUN - O
and CCONJ - O
citalopram NOUN - O
) PUNCT - O
and CCONJ - O
two CD - B-CARDINAL
EDCs NOUN - O
( PUNCT - O
methylparaben NOUN - O
and CCONJ - O
triclosan ADJ - O
) PUNCT - O
were VERB - O
investigated VERB - O
in ADP - O
the DET - O
mussel NOUN - O
species NOUN - O
( PUNCT - O
Mytilus PROPN - O
galloprovincialis PROPN - O
) PUNCT - O
, PUNCT - O
under ADP - O
controlled VERB - O
conditions NOUN - O
. PUNCT - O

In ADP - O
contrast NOUN - O
, PUNCT - O
acidification NOUN - O
decreased VERB - O
triclosan ADJ - O
levels NOUN - O
, PUNCT - O
while ADP - O
both DET - O
stressors NOUN - O
decreased VERB - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
citalopram NOUN - O
BCFs NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
acidification NOUN - O
decreased VERB - O
mussels NOUN - O
' PART - O
capacity NOUN - O
to PART - O
metabolize VERB - O
contaminants NOUN - O
( PUNCT - O
i.e. X - O
venlafaxine NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Human ADJ - O
MSCs NOUN - O
( PUNCT - O
hMSCs PROPN - O
) PUNCT - O
were VERB - O
committed VERB - O
to PART - O
differentiate VERB - O
when ADV - O
either CCONJ - O
adipogenic ADJ - O
or CCONJ - O
osteogenic ADJ - O
media NOUN - O
was VERB - O
added VERB - O
, PUNCT - O
supplemented VERB - O
with ADP - O
five CD - B-CARDINAL
increasing VERB - O
concentrations NOUN - O
of ADP - O
amitriptyline NOUN - O
( PUNCT - O
0.001 CD - B-CARDINAL
- SYM - I-CARDINAL
10 CD - I-CARDINAL
µM PROPN - O
) PUNCT - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
0.01 CD - B-CARDINAL
- SYM - I-CARDINAL
25 CD - I-CARDINAL
µM PROPN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
fluoxetine NOUN - O
( PUNCT - O
0.001 CD - B-CARDINAL
- SYM - I-CARDINAL
10 CD - I-CARDINAL
µM PROPN - O
) PUNCT - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
adipogenic ADJ - O
differentiation NOUN - O
of ADP - O
hMSC PROPN - O
was VERB - O
affected VERB - O
by ADP - O
the DET - O
addition NOUN - O
of ADP - O
amitriptyline NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
fluoxetine NOUN - O
to ADP - O
the DET - O
media NOUN - O
. PUNCT - O

As ADP - O
fluoxetine NOUN - O
and CCONJ - O
amitriptyline NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
venlafaxine VB - B-MEDICINE
, PUNCT - O
affected VERB - O
both CCONJ - O
osteoblastogenesis NOUN - O
and CCONJ - O
adipogenesis NOUN - O
, PUNCT - O
this DET - O
inhibitory ADJ - O
effect NOUN - O
could VERB - O
be VERB - O
associated VERB - O
to ADP - O
the DET - O
high ADJ - O
affinity NOUN - O
of ADP - O
fluoxetine NOUN - O
to ADP - O
the DET - O
serotonin ADJ - O
transporter NOUN - O
system NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
were VERB - O
derived VERB - O
from ADP - O
a DET - O
randomized VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
12-week CD - B-CARDINAL
acute NOUN - O
( PUNCT - O
N NN - B-ORG
= SYM - O
129 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
6-month CD - B-ORDINAL
continuation NOUN - O
( PUNCT - O
N PROPN - O
= SYM - O
55 CD - B-CARDINAL
) PUNCT - O
comparison NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
versus ADP - O
lithium NOUN - O
monotherapy NOUN - O
in ADP - O
bipolar ADJ - O
II NNP - B-ORG
depression NOUN - O
in ADP - O
adults NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
activity NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
clonidine NOUN - O
, PUNCT - O
the DET - O
forced VERB - O
swim NOUN - O
test NOUN - O
( PUNCT - O
FST NNP - B-ORG
) PUNCT - O
was VERB - O
used VERB - O
repeatedly ADV - O
24h NNS - B-DATE
, PUNCT - O
3days CD - B-CARDINAL
, PUNCT - O
8days CD - B-DATE
, PUNCT - O
15days NNPS - B-DATE
and CCONJ - O
25days CD - B-DATE
after ADP - O
mSPS NOUN - O
. PUNCT - O

This DET - O
in ADP - O
silico ADJ - O
part NOUN - O
comprised VERB - O
molecular ADJ - O
docking NOUN - O
of ADP - O
enantiomers NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
to ADP - O
human ADJ - O
transporters NOUN - O
for ADP - O
serotonin PROPN - O
( PUNCT - O
hSERT PROPN - O
) PUNCT - O
, PUNCT - O
norepinephrine NOUN - O
( PUNCT - O
hNET PROPN - O
) PUNCT - O
and CCONJ - O
dopamine NOUN - O
( PUNCT - O
hDAT).In VERB - O
mSPS VERB - O
- PUNCT - O
subjected VERB - O
mice NOUN - O

FST PROPN - O
revealed VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
however ADV - O
in ADP - O
non ADJ - O
SPS NNP - B-ORG
- PUNCT - O
subjected VERB - O
mice NOUN - O
both DET - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
clonidine NOUN - O
were VERB - O
active ADJ - O
. PUNCT - O

Molecular ADJ - O
docking NOUN - O
studies NOUN - O
indicated VERB - O
that ADP - O
the DET - O
affinity NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
to PART - O
monoamine VERB - O
transporters NOUN - O
is VERB - O
growing VERB - O
in ADP - O
the DET - O
following ADJ - O
rank NOUN - O
order NOUN - O
: PUNCT - O
hDAT VERB - O
< X - O
hNET X - O
< X - O
hSERT X - O
. PUNCT - O

Both DET - O
venlafaxine NN - B-MEDICINE
enantiomers NOUN - O
present VERB - O
different ADJ - O
selectivity NOUN - O
and CCONJ - O
binding VERB - O
mode NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

METHOD NOUN - O
: PUNCT - O
Data PROPN - O
of ADP - O
phase-2 NOUN - O
and CCONJ - O
-3 ADJ - O
clinical ADJ - O
- PUNCT - O
trials NOUN - O
for ADP - O
16 CD - B-CARDINAL
antidepressants NOUN - O
( PUNCT - O
levomilnacipran NOUN - O
, PUNCT - O
desvenlafaxine NOUN - O
, PUNCT - O
duloxetine NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
paroxetine NOUN - O
, PUNCT - O
escitalopram NOUN - O
, PUNCT - O
vortioxetine NOUN - O
, PUNCT - O
mirtazapine NOUN - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
XR NNP - B-GPE
, PUNCT - O
sertraline NOUN - O
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
citalopram NOUN - O
, PUNCT - O
paroxetine NOUN - O
CR NNP - B-GPE
, PUNCT - O
nefazodone NOUN - O
, PUNCT - O
bupropion NOUN - O
, PUNCT - O
vilazodone NOUN - O
) PUNCT - O
, PUNCT - O
approved VERB - O
by ADP - O
the DET - O
FDA NNP - B-ORG
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
depression NOUN - O
between IN - B-DATE
1987 CD - I-DATE
and CC - I-DATE
2016 CD - I-DATE
, PUNCT - O
were VERB - O
extracted VERB - O
from ADP - O
the DET - O
FDA NNP - B-ORG
reviews NOUN - O
that ADJ - O
were VERB - O
used VERB - O
to PART - O
evaluate VERB - O
efficacy NOUN - O
prior ADV - O
to ADP - O
marketing NOUN - O
approval NOUN - O
, PUNCT - O
which ADJ - O
are VERB - O
less ADV - O
liable ADJ - O
to ADP - O
reporting VERB - O
biases NOUN - O
. PUNCT - O

The DET - O
posterior ADJ - O
effect NOUN - O
- PUNCT - O
size NOUN - O
distributions NOUN - O
showed VERB - O
variation NOUN - O
across ADP - O
antidepressants NOUN - O
, PUNCT - O
with ADP - O
the DET - O
highest ADJ - O
pooled VERB - O
estimated VERB - O
effect NOUN - O
size NOUN - O
for ADP - O
venlafaxine NN - B-MEDICINE
followed VERB - O
by ADP - O
paroxetine NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
lowest ADJ - O
for ADP - O
bupropion NOUN - O
and CCONJ - O
vilazodone NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
were VERB - O
randomly ADV - O
chosen VERB - O
for ADP - O
treatment NOUN - O
with ADP - O
sertraline NOUN - O
or CCONJ - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

Lack NOUN - O
of ADP - O
differences NOUN - O
in ADP - O
medication NOUN - O
effect NOUN - O
of ADP - O
sertraline NOUN - O
or CCONJ - O
venlafaxine NN - B-MEDICINE
on ADP - O
HDRS-17 NNP - B-ORG
scores NOUN - O
during ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
treatment NOUN - O
was VERB - O
observed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Serotonin PROPN - O
noradrenaline NOUN - O
reuptake NOUN - O
inhibitors NOUN - O
are VERB - O
effective ADJ - O
antidepressant ADJ - O
drugs NOUN - O
, PUNCT - O
which ADJ - O
include VERB - O
venlafaxine NN - B-MEDICINE
and CCONJ - O
duloxetine NOUN - O
. PUNCT - O

Here ADV - O
, PUNCT - O
we PRON - O
explored VERB - O
the DET - O
potential ADJ - O
biological ADJ - O
effects NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
on ADP - O
mouse NOUN - O
hippocampus NOUN - O
. PUNCT - O

Mice NOUN - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
and CCONJ - O
injected VERB - O
daily RB - B-DATE
with ADP - O
0.9 CD - B-PERCENT
% NN - I-PERCENT
NaCl NNP - B-NORP
solution NOUN - O
or CCONJ - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

In ADP - O
our ADJ - O
experiments NOUN - O
, PUNCT - O
27 CD - B-CARDINAL
hippocampal ADJ - O
metabolites NOUN - O
that ADJ - O
distinguished VERB - O
the DET - O
venlafaxine NN - B-MEDICINE
group NOUN - O
from ADP - O
the DET - O
control NOUN - O
group NOUN - O
were VERB - O
identified VERB - O
. PUNCT - O

This DET - O
study NOUN - O
sheds VERB - O
light NOUN - O
on ADP - O
the DET - O
biological ADJ - O
mechanisms NOUN - O
underlying VERB - O
the DET - O
effects NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
median ADJ - O
cardiac ADJ - O
tissue NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
femoral NOUN - O
blood NOUN - O
concentration NOUN - O
ratio NOUN - O
( PUNCT - O
Kb PROPN - O
) PUNCT - O
ranged VERB - O
from ADP - O
2.2 CD - B-CARDINAL
( PUNCT - O
venlafaxine NN - B-MEDICINE
) PUNCT - O
to ADP - O
15 CD - B-CARDINAL
( PUNCT - O
nortriptyline NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
inter ADJ - O
- ADJ - O
individual ADJ - O
fold ADJ - O
difference NOUN - O
between ADP - O
the DET - O
minimum NOUN - O
and CCONJ - O
maximum ADJ - O
Kb NNP - B-PERSON
ranged VERB - O
from ADP - O
2.6-fold NUM - O
( PUNCT - O
Z NOUN - O
- PUNCT - O
hydroxynortriptyline PROPN - O
) PUNCT - O
to ADP - O
61 CD - B-CARDINAL
( PUNCT - O
venlafaxine NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
describe VERB - O
a DET - O
case NOUN - O
of ADP - O
lower ADJ - O
urinary ADJ - O
system NOUN - O
symptoms NOUN - O
( PUNCT - O
LUSSs PROPN - O
) PUNCT - O
and CCONJ - O
acute ADJ - O
urinary ADJ - O
retention NOUN - O
that ADJ - O
developed VERB - O
after ADP - O
treatment NOUN - O
with ADP - O
a DET - O
low ADJ - O
dose NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

The DET - O
patient NOUN - O
had VERB - O
been VERB - O
taking VERB - O
venlafaxine NN - B-MEDICINE
for ADP - O
the DT - B-DATE
previous JJ - I-DATE
6 CD - I-DATE
months NNS - I-DATE
. PUNCT - O

The DET - O
patients NOUN - O
' PART - O
symptoms NOUN - O
were VERB - O
thought VERB - O
to PART - O
be VERB - O
related VERB - O
to ADP - O
venlafaxine NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
the DET - O
symptoms NOUN - O
disappeared VERB - O
completely ADV - O
after ADP - O
venlafaxine NN - B-MEDICINE
was VERB - O
replaced VERB - O
with ADP - O
agomelatine NOUN - O
. PUNCT - O

We PRON - O
concluded VERB - O
that ADP - O
the DET - O
LUSSs PROPN - O
and CCONJ - O
urinary ADJ - O
retention NOUN - O
were VERB - O
due ADJ - O
to ADP - O
the DET - O
venlafaxine NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acute ADJ - O
urinary ADJ - O
retention NOUN - O
after ADP - O
venlafaxine NN - B-MEDICINE
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Desvenlafaxine RB - B-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Interstitial NNP - I-ORG
Pneumonitis NNP - I-ORG
: : - I-ORG

-DOCSTART- -X- - O

Chronic PROPN - O
unpredictable ADJ - O
mild ADJ - O
stress NOUN - O
( PUNCT - O
CUMS NN - B-ORG
) PUNCT - O
stimulation NOUN - O
was VERB - O
conducted VERB - O
for ADP - O
modeling VERB - O
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
and CCONJ - O
then ADV - O
curcumin VERB - O
( PUNCT - O
200 CD - B-CARDINAL
mg•kg⁻¹ NUM - O
) PUNCT - O
or CCONJ - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
40 CD - B-MONEY
mg•kg⁻¹ NNP - I-MONEY
) PUNCT - O
was VERB - O
given VERB - O
by ADP - O
gavage NOUN - O
administration NOUN - O
. PUNCT - O

After ADP - O
administration NOUN - O
of ADP - O
curcumin NOUN - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
respectively ADV - O
, PUNCT - O
the DET - O
depression NOUN - O
indexes NOUN - O
of ADP - O
CUMS NOUN - O
model NOUN - O
rats NOUN - O
were VERB - O
all DET - O
improved VERB - O
significantly ADV - O
( PUNCT - O
P<0.05 PROPN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
there ADV - O
were VERB - O
no DET - O
significant ADJ - O
differences NOUN - O
between ADP - O
curcumin NOUN - O
and CCONJ - O
venlafaxine NN - B-MEDICINE
groups NOUN - O
. PUNCT - O

In ADP - O
PCA NNP - B-ORG
and CCONJ - O
PLS NNP - B-ORG
- HYPH - I-ORG
DA NNP - I-ORG
analysis NOUN - O
after ADP - O
curcumin NOUN - O
or CCONJ - O
venlafaxine NN - B-MEDICINE
intervention NOUN - O
on ADP - O
CUMS NOUN - O
model NOUN - O
group NOUN - O
rats NOUN - O
, PUNCT - O
the DET - O
small ADJ - O
molecule NOUN - O
metabolites VERB - O
level NOUN - O
reflects VERB - O
a DET - O
normal ADJ - O
trend NOUN - O
, PUNCT - O
and CCONJ - O
particularly ADV - O
for ADP - O
the DET - O
curcumin NOUN - O
group NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
curcumin NOUN - O
had VERB - O
antidepressant ADJ - O
effects NOUN - O
, PUNCT - O
which ADJ - O
was VERB - O
evident ADJ - O
in ADP - O
both CCONJ - O
macro ADJ - O
and CCONJ - O
micro ADJ - O
levels NOUN - O
, PUNCT - O
comparable ADJ - O
with ADP - O
positive ADJ - O
drug NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

95 CD - B-PERCENT
% NN - I-PERCENT
CrI PROPN - O
-3·69 PUNCT - O
to ADP - O
-1·91 PUNCT - O
) PUNCT - O
, PUNCT - O
venlafaxine NN - B-MEDICINE
( PUNCT - O
MD NNP - B-ORG
-2·69 PROPN - O
, PUNCT - O

-DOCSTART- -X- - O

Laxative JJ - B-MEDICINE
use NOUN - O
and CCONJ - O
testing NOUN - O
for ADP - O
Clostridium NNP - B-ORG
difficile ADV - O
in ADP - O
hospitalized ADJ - O
adults NOUN - O
: PUNCT - O
An DET - O
opportunity NOUN - O
to PART - O
improve VERB - O
diagnostic ADJ - O
stewardship NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Laxative JJ - B-MEDICINE
type NOUN - O
in ADP - O
relation NOUN - O
to ADP - O
colorectal ADJ - O
cancer NOUN - O
risk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Consuming VERB - O
Genistein PROPN - O
Improves VERB - O
Survival PROPN - O
Rates PROPN - O
in ADP - O
the DET - O
Absence PROPN - O
of ADP - O
Laxative NNP - B-MEDICINE
in ADP - O
Δf508-Cf ADJ - O
Female ADJ - O
Mice NOUN - O

-DOCSTART- -X- - O

Laxative JJ - B-MEDICINE
use NOUN - O
and CCONJ - O
treatment NOUN - O
of ADP - O
CD NOUN - O
colonization NOUN - O
cases NOUN - O
remained VERB - O
unchanged ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Laxative JJ - B-MEDICINE
effect NOUN - O
of ADP - O
repeated ADJ - O
Daiokanzoto NNP - B-ORG
is VERB - O
attributable ADJ - O
to PART - O
decrease VERB - O
in ADP - O
aquaporin-3 ADJ - O
expression NOUN - O
in ADP - O
the DET - O
colon NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Diffuse IN - B-PERSON
Melanosis NN - I-PERSON
in ADP - O
Pericolic PROPN - O
Lymph PROPN - O
Nodes NOUN - O
Associated VERB - O
With ADP - O
Laxative NNP - B-MEDICINE
Abuse PROPN - O
and CCONJ - O
Colorectal PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Accidental PROPN - O
Burn PROPN - O
by ADP - O
Intentional NNP - B-ORG
Laxative NNP - I-MEDICINE
Use NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Seventy CD - B-PERSON
Years NNS - I-PERSON
of ADP - O
Polyethylene NNP - B-PERSON
Glycols NNP - I-PERSON
in ADP - O
Gastroenterology PROPN - O
: PUNCT - O
The DET - O
Journey PROPN - O
of ADP - O
PEG PROPN - O
4000 NUM - O
and CCONJ - O
3350 CD - B-CARDINAL
From ADP - O
Nonabsorbable PROPN - O
Marker PROPN - O
to ADP - O
Colonoscopy NNP - B-ORG
Preparation NNP - I-ORG
to IN - I-ORG
Osmotic NNP - I-ORG
Laxative NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
determine VERB - O
if ADP - O
three CD - B-CARDINAL
prototype NOUN - O
4-mg CD - B-CARDINAL
nicotine NOUN - O
lozenges NOUN - O
produced VERB - O
locally ADV - O
in ADP - O
India NNP - B-GPE
were VERB - O
bioequivalent ADJ - O
to ADP - O
a DET - O
globally ADV - O
marketed VERB - O
reference NOUN - O
product NOUN - O
, PUNCT - O
Nicorette NNP - B-MEDICINE
® NOUN - O
4-mg CD - B-CARDINAL
nicotine NOUN - O
lozenge NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

During ADP - O
five CD - B-CARDINAL
separate ADJ - O
laboratory NOUN - O
visits NOUN - O
, PUNCT - O
smokeless NOUN - O
tobacco NOUN - O
users NOUN - O
used VERB - O
Verve NNP - B-ORG
discs NOUN - O
, PUNCT - O
Ariva NNP - B-PERSON
dissolvables NOUN - O
, PUNCT - O
Skoal NNP - B-ORG
snuff NOUN - O
, PUNCT - O
Camel NNP - B-PERSON
snus NOUN - O
, PUNCT - O
or CCONJ - O
Nicorette NNP - B-MEDICINE
lozenges NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
from ADP - O
participants NOUN - O
in ADP - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
controlled VERB - O
trials NOUN - O
of ADP - O
various ADJ - O
formulations NOUN - O
of ADP - O
NRT NNP - B-ORG
( PUNCT - O
Nicorette NNP - B-MEDICINE
® NNP - I-ORG
) PUNCT - O
, PUNCT - O
including VERB - O
patch NOUN - O
, PUNCT - O
gum NOUN - O
, PUNCT - O
oral ADJ - O
inhaler NOUN - O
, PUNCT - O
sublingual ADJ - O
tablet NOUN - O
, PUNCT - O
nasal NOUN - O
spray NOUN - O
, PUNCT - O
mouth NOUN - O
spray NOUN - O
, PUNCT - O
and CCONJ - O
combinations NOUN - O
, PUNCT - O
were VERB - O
extracted VERB - O
from ADP - O
a DET - O
clinical ADJ - O
database NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Participants NOUN - O
were VERB - O
randomised VERB - O
to PART - O
use VERB - O
ENDDs NOUN - O
containing VERB - O
16 CD - B-CARDINAL
mg NOUN - O
nicotine NOUN - O
or CCONJ - O
0 CD - B-CARDINAL
mg PRON - O
capsules NOUN - O
, PUNCT - O
Nicorette NNP - B-MEDICINE
nicotine NOUN - O
inhalator NOUN - O
or CCONJ - O
their ADJ - O
usual ADJ - O
cigarette NOUN - O
on ADP - O
each DET - O
of ADP - O
four CD - B-CARDINAL
study NOUN - O
days NOUN - O
3 CD - B-DATE
days NNS - I-DATE
apart ADV - O
, PUNCT - O
with ADP - O
overnight ADJ - O
smoking NOUN - O
abstinence NOUN - O
before ADP - O
use NOUN - O
of ADP - O
each DET - O
product NOUN - O
. PUNCT - O

The DET - O
16 CD - B-CARDINAL
mg NOUN - O
Ruyan NNP - B-FAC
V8 NNP - I-FAC
ENDD NNP - I-FAC
alleviated VERB - O
desire NOUN - O
to PART - O
smoke VERB - O
after ADP - O
overnight ADJ - O
abstinence NOUN - O
, PUNCT - O
was VERB - O
well ADV - O
tolerated VERB - O
and CCONJ - O
had VERB - O
a DET - O
pharmacokinetic ADJ - O
profile NOUN - O
more ADV - O
like ADP - O
the DET - O
Nicorette NNP - B-MEDICINE
inhalator NOUN - O
than ADP - O
a DET - O
tobacco NOUN - O
cigarette NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
rate NOUN - O
and CCONJ - O
extent NOUN - O
of ADP - O
nicotine NOUN - O
and CCONJ - O
cotinine VERB - O
deposition NOUN - O
into ADP - O
beard ADJ - O
hair NOUN - O
among ADP - O
six CD - B-CARDINAL
male ADJ - O
nonsmokers NOUN - O
following VERB - O
a DET - O
single ADJ - O
exposure NOUN - O
to ADP - O
4 CD - B-CARDINAL
mg NOUN - O
of ADP - O
nicotine NOUN - O
in ADP - O
Nicorette NNP - B-MEDICINE
( PUNCT - O
® NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
within ADJ - O
subjects NOUN - O
design VERB - O
non ADJ - O
- ADJ - O
smoking ADJ - O
volunteers NOUN - O
were VERB - O
given VERB - O
either CCONJ - O
placebo NOUN - O
or CCONJ - O
nicotine NOUN - O
( PUNCT - O
Nicorette NNP - B-MEDICINE
2 CD - B-CARDINAL
mg NOUN - O
gum NOUN - O
) PUNCT - O
prior ADV - O
to ADP - O
performing VERB - O
a DET - O
cued VERB - O
target NOUN - O
discrimination NOUN - O
task NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
both DET - O
experiments NOUN - O
, PUNCT - O
the DET - O
electroencephalogram NOUN - O
was VERB - O
recorded VERB - O
while ADP - O
non ADJ - O
- ADJ - O
smokers NOUN - O
completed VERB - O
discrimination NOUN - O
tasks NOUN - O
in ADP - O
Posner NNP - B-GPE
- PUNCT - O
type NOUN - O
paradigms NOUN - O
after ADP - O
chewing VERB - O
a DET - O
nicotine NOUN - O
polacrilex NOUN - O
gum NOUN - O
( PUNCT - O
Nicorette NNP - B-MEDICINE
2 CD - B-CARDINAL
mg PART - O
) PUNCT - O
in ADP - O
one CD - B-CARDINAL
session NOUN - O
and CCONJ - O
a DET - O
placebo NOUN - O
gum NOUN - O
in ADP - O
another DET - O
session NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

These DET - O
interventions NOUN - O
include VERB - O
Zyban NNP - B-ORG
( PUNCT - O
Bupropion NOUN - O
HCl NOUN - O
) PUNCT - O
, PUNCT - O
Nicorette NNP - B-MEDICINE
gum NOUN - O
, PUNCT - O
Habitrol NNP - B-ORG
patch NOUN - O
, PUNCT - O
Nicoderm NNP - B-ORG
patch NOUN - O
, PUNCT - O
Nicotrol NNP - B-ORG
inhaler NOUN - O
, PUNCT - O
and CCONJ - O
Nicotrol NNP - B-ORG
NS PROPN - O
spray VERB - O
, PUNCT - O
along ADP - O
with ADP - O
their ADJ - O
generic ADJ - O
counterparts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nicorette NNP - B-MEDICINE
finds VERB - O
new ADJ - O
place NOUN - O
in ADP - O
smoking NOUN - O
cessation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
quit NOUN - O
date NOUN - O
was VERB - O
set VERB - O
and CCONJ - O
nicotine NOUN - O
replacement NOUN - O
therapy NOUN - O
patches NOUN - O
( PUNCT - O
Nicorette NNP - B-MEDICINE

-DOCSTART- -X- - O

In ADP - O
the DET - O
OTC PROPN - O
setting NOUN - O
, PUNCT - O
smokers VERB - O
self NOUN - O
- PUNCT - O
selected VERB - O
doses NOUN - O
of ADP - O
nicotine NOUN - O
gum NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
or CCONJ - O
4 CD - B-CARDINAL
mg NOUN - O
Nicorette NNP - B-MEDICINE
) PUNCT - O
or CCONJ - O
patch NOUN - O
( PUNCT - O
21 CD - B-CARDINAL
, PUNCT - O
14 CD - B-DATE
or CCONJ - O
7 CD - B-CARDINAL
mg NOUN - O
NicoDerm PROPN - O
CQ PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
investigated VERB - O
the DET - O
long ADJ - O
term NOUN - O
use NOUN - O
of ADP - O
Eclipse NNP - B-ORG
, PUNCT - O
a DET - O
cigarette NOUN - O
- PUNCT - O
like ADJ - O
device NOUN - O
that ADJ - O
heats VERB - O
rather ADV - O
than ADP - O
burns NOUN - O
tobacco NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
Nicorette NNP - B-MEDICINE
oral ADJ - O
inhaler NOUN - O
, PUNCT - O
a DET - O
nicotine NOUN - O
replacement NOUN - O
product NOUN - O
, PUNCT - O
in ADP - O
a DET - O
group NOUN - O
of ADP - O
smokers NOUN - O
not ADV - O
interested ADJ - O
in ADP - O
quitting ADJ - O
smoking NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Paroxysmal ADJ - O
atrial ADJ - O
fibrillation NOUN - O
occurred VERB - O
in ADP - O
a DET - O
fit ADJ - O
35 CD - B-DATE
year NN - I-DATE
old JJ - I-DATE
man NOUN - O
who NOUN - O
consumed VERB - O
large ADJ - O
doses NOUN - O
of ADP - O
nicotine NOUN - O
chewing VERB - O
gum NOUN - O
( PUNCT - O
Nicorette NNP - B-MEDICINE
Leo NNP - I-PERSON
) PUNCT - O
over ADP - O
a DET - O
prolonged ADJ - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nicorette NNP - B-MEDICINE
-- PUNCT - O
an DET - O
update NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
many ADJ - O
countries NOUN - O
nicotine VERB - O
- PUNCT - O
containing VERB - O
chewing VERB - O
gum NOUN - O
( PUNCT - O
Nicorette NNP - B-MEDICINE
) PUNCT - O
is VERB - O
used VERB - O
to PART - O
help VERB - O
to PART - O
break VERB - O
the DET - O
habit NOUN - O
of ADP - O
smoking NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Warnings NOUN - O
about ADP - O
accidental ADJ - O
poisonings NOUN - O
: PUNCT - O
Triaminic NNP - B-MEDICINE
Vapor NNP - B-GPE
Patch PROPN - O
... PUNCT - O
and CCONJ - O
WellPatch NNP - B-ORG
Cough NNP - I-ORG
and CC - I-ORG
Cold PROPN - O
Soothing PROPN - O
Vapor PROPN - O
Pads PROPN - O
... PUNCT - O
warning VERB - O
about ADP - O
alternative ADJ - O
treatment NOUN - O
for ADP - O
Lyme NNP - B-ORG
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Triaminic JJ - B-MEDICINE
reformulation NOUN - O
: PUNCT - O
why ADV - O
we PRON - O
did VERB - O
it PRON - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Fatal NNP - B-ORG
Triaminic NNP - I-MEDICINE
poisoning NOUN - O
in ADP - O
an DET - O
infant NOUN - O
] PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
( PUNCT - O
Celebrex NNP - B-ORG
® NNP - I-ORG
) PUNCT - O
is VERB - O
the DET - O
only ADV - O
widely ADV - O
used VERB - O
NSAID NNP - B-ORG
that ADP - O
selectively ADV - O
inhibits VERB - O
the DET - O
COX-2 NNP - B-ORG
isoenzyme NOUN - O
. PUNCT - O

Celecoxib NN - B-MEDICINE
plasma NOUN - O
concentrations NOUN - O
reached VERB - O
250 CD - B-CARDINAL
  SPACE - O
ng PROPN - O
/ SYM - O
ml PROPN - O
, PUNCT - O
the DET - O
effective ADJ - O
therapeutic ADJ - O
plasma NOUN - O
level NOUN - O
, PUNCT - O
in ADP - O
less JJR - B-CARDINAL
than IN - I-CARDINAL
15 CD - I-CARDINAL
  SPACE - O
min NOUN - O
regardless ADV - O
of ADP - O
food NOUN - O
or CCONJ - O
dose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Co PROPN - O
- PROPN - O
Crystal NOUN - O
of ADP - O
Tramadol PROPN - O
- PUNCT - O
Celecoxib NNP - B-MEDICINE
( PUNCT - O
CTC PROPN - O
) PUNCT - O
is VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
in ADP - O
- PUNCT - O
class NOUN - O
active ADJ - O
pharmaceutical NOUN - O
ingredient NOUN - O
( PUNCT - O
API NNP - B-ORG
- HYPH - I-ORG
API NN - I-ORG
) PUNCT - O
co NOUN - O
- NOUN - O
crystal NOUN - O
of ADP - O
rac NOUN - O
- PUNCT - O
tramadol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Consideration NOUN - O
of ADP - O
Celecoxib NNP - B-MEDICINE
, PUNCT - O
Etoricoxib PROPN - O
, PUNCT - O
and CCONJ - O
Diclofenac NN - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
in ADP - O
breast NOUN - O
cancer NOUN - O
prevention NOUN - O
and CCONJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NNP - B-ORG
of IN - I-ORG
Celecoxib NNP - I-MEDICINE
Use NNP - I-ORG

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
reduced VERB - O
the DET - O
hypotensive ADJ - O
effect NOUN - O
of ADP - O
all DET - O
doses NOUN - O
of ADP - O
captopril NOUN - O
in ADP - O
dexamethasone NOUN - O
- PUNCT - O
induced VERB - O
hypertensive ADJ - O
rats NOUN - O
however ADV - O
the DET - O
SBP NNP - B-ORG
and CCONJ - O
MAP NNP - B-ORG
was VERB - O
preserved VERB - O
near ADV - O
to ADP - O
normal ADJ - O
at ADP - O
low ADJ - O
and CCONJ - O
middle ADJ - O
doses NOUN - O
of ADP - O
captopril NOUN - O
but CCONJ - O
DBP NNP - B-ORG
was VERB - O
more ADV - O
than ADP - O
normal ADJ - O
at ADP - O
low ADJ - O
dose NOUN - O
of ADP - O
captopril NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
, PUNCT - O
a DET - O
nonsteroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
that ADJ - O
selectively ADV - O
targets VERB - O
cyclooxygenase-2 NOUN - O
, PUNCT - O
is VERB - O
a DET - O
promising ADJ - O
cancer NOUN - O
chemopreventive ADJ - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
has VERB - O
a DET - O
better ADJ - O
lower ADJ - O
- PUNCT - O
GI NNP - B-ORG
- PUNCT - O
tract NOUN - O
tolerability NOUN - O
profile NOUN - O
than ADP - O
ns NOUN - O
- PUNCT - O
NSAIDs NOUN - O
plus CCONJ - O
a DET - O
proton NOUN - O
- PUNCT - O
pump NOUN - O
inhibitor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine PROPN - O
and CCONJ - O
Celecoxib NNP - B-MEDICINE
as ADP - O
a DET - O
Promising PROPN - O
Therapy PROPN - O
for ADP - O
Thymic PROPN - O
Neoplasms PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
plus CCONJ - O
IFL NNP - B-ORG
chemotherapy NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
metastatic ADJ - O
CRC NN - B-ORG
is VERB - O
tolerable ADJ - O
, PUNCT - O
but CCONJ - O
does VERB - O
not ADV - O
appear VERB - O
to PART - O
increase VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
IFL NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Conclusion NOUN - O
: PUNCT - O
Celecoxib NNP - B-MEDICINE
had VERB - O
no DET - O
benefit NOUN - O
on ADP - O
survival NOUN - O
indices NOUN - O
for ADP - O
advanced ADJ - O
NSCLC NNP - B-ORG
but CCONJ - O
improved VERB - O
the DET - O
ORR NN - B-ORG
of ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Exercise PROPN - O
, PUNCT - O
Aspirin NNP - B-NORP
, PUNCT - O
and CCONJ - O
Celecoxib NNP - B-MEDICINE
in ADP - O
an DET - O
Atherogenic PROPN - O
Environment PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib VB - B-MEDICINE
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
in ADP - O
blood NOUN - O
increased VERB - O
from ADP - O
5 CD - B-CARDINAL
  SPACE - O
h NOUN - O
for ADP - O
the DET - O
bolus NOUN - O
injection NOUN - O
of ADP - O
celecoxib NN - B-MEDICINE
to ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
10 CD - I-CARDINAL
  _SP - I-CARDINAL
days NNS - I-CARDINAL
for ADP - O
the DET - O
slowest ADJ - O
releasing NOUN - O
gel NOUN - O
formulation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
( PUNCT - O
CXB NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
COX-2 NNP - B-ORG
inhibitor NOUN - O
, PUNCT - O
is VERB - O
primarily ADV - O
indicated VERB - O
for ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
of ADP - O
rheumatoid NOUN - O
arthritis NOUN - O
( PUNCT - O
RA PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Preclinical NNP - B-ORG
Explorative NNP - I-ORG
Assessment NNP - I-ORG
of ADP - O
Celecoxib NNP - B-MEDICINE
- PUNCT - O
Based VERB - O
Biocompatible PROPN - O
Lipidic NNP - B-PERSON
Nanocarriers NNPS - I-PERSON
for ADP - O
the DET - O
Management PROPN - O
of ADP - O
CFA PROPN - O
- PUNCT - O
Induced PROPN - O
Rheumatoid PROPN - O
Arthritis PROPN - O
in ADP - O
Wistar NNP - B-FAC
Rats NNPS - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
was VERB - O
eluted VERB - O
from ADP - O
clinically ADV - O
approved VERB - O
biodegradable ADJ - O
collagen NOUN - O
membranes NOUN - O
over ADP - O
7 CD - B-DATE
days NNS - I-DATE
as ADP - O
measured VERB - O
by ADP - O
UV PROPN - O
spectroscopy NOUN - O
and CCONJ - O
high ADJ - O
- PUNCT - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
/ SYM - O
mass NOUN - O
spectroscopy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
is VERB - O
a DET - O
substrate NOUN - O
of ADP - O
CYP2D6 NN - B-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
has VERB - O
been VERB - O
explored VERB - O
as ADP - O
a DET - O
possible ADJ - O
treatment NOUN - O
of ADP - O
liver NOUN - O
fibrosis NOUN - O
with ADP - O
contradictory ADJ - O
results NOUN - O
, PUNCT - O
depending VERB - O
on ADP - O
the DET - O
model NOUN - O
. PUNCT - O

Celecoxib NNP - B-MEDICINE
alone ADV - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
inhibitors NOUN - O
of ADP - O
the DET - O
enzyme ADJ - O
- PUNCT - O
soluble ADJ - O
epoxide ADJ - O
hydrolase NOUN - O
( PUNCT - O
sEH NOUN - O
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
a DET - O
dual ADJ - O
inhibitor NOUN - O
that ADJ - O
targets VERB - O
both CCONJ - O
COX-2 NNP - B-GPE
and CCONJ - O
sEH NOUN - O
, PUNCT - O
were VERB - O
administered VERB - O
via ADP - O
osmotic ADJ - O
minipump NOUN - O
to ADP - O
mice NOUN - O
receiving VERB - O
intraperitoneal ADJ - O
injections NOUN - O
of ADP - O
CCl4 PROPN - O
Collagen NNP - B-ORG
deposition NOUN - O
was VERB - O
elevated VERB - O
in ADP - O
the DET - O
mice NOUN - O
treated VERB - O
with ADP - O
both CCONJ - O
celecoxib NN - B-MEDICINE
and CCONJ - O
CCl4 PROPN - O
compared VERB - O
with ADP - O
the DET - O
control NOUN - O
or CCONJ - O
CCl4-only ADJ - O
groups NOUN - O
, PUNCT - O
as ADP - O
assessed VERB - O
by ADP - O
trichrome ADJ - O
staining NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
was VERB - O
unique ADJ - O
among ADP - O
the DET - O
NSAIDs PROPN - O
in ADP - O
that ADP - O
it PRON - O
showed VERB - O
particular ADJ - O
potency NOUN - O
as ADP - O
a DET - O
cytotoxic ADJ - O
drug NOUN - O
against ADP - O
the DET - O
metastatic ADJ - O
cancer NOUN - O
cells NOUN - O
with ADP - O
IC50 PROPN - O
values NOUN - O
in ADP - O
the DET - O
low ADJ - O
micromolar ADJ - O
range NOUN - O
. PUNCT - O

Celecoxib NNP - B-MEDICINE
rapidly ADV - O
enhanced VERB - O
mitochondrial ADJ - O
superoxide NOUN - O
production NOUN - O
in ADP - O
situ NOUN - O
from ADP - O
cancer NOUN - O
cells NOUN - O
within ADP - O
minutes NNS - B-TIME
, PUNCT - O
leading VERB - O
to ADP - O
a DET - O
decrease NOUN - O
in ADP - O
cellular ADJ - O
respiration NOUN - O
and CCONJ - O
dissipation NOUN - O
of ADP - O
the DET - O
mitochondrial ADJ - O
transmembrane NOUN - O
potential NOUN - O
( PUNCT - O
Δψm PROPN - O
) PUNCT - O
, PUNCT - O
followed VERB - O
by ADP - O
extensive ADJ - O
ROS NNP - B-PERSON
- PUNCT - O
dependent ADJ - O
apoptosis NOUN - O
of ADP - O
the DET - O
metastatic ADJ - O
cancer NOUN - O
cells NOUN - O
. PUNCT - O

Celecoxib NNP - B-MEDICINE
also ADV - O
showed VERB - O
rapid ADJ - O
and CCONJ - O
direct ADJ - O
effects NOUN - O
on ADP - O
isolated VERB - O
mitochondria NOUN - O
, PUNCT - O
inducing VERB - O
extensive ADJ - O
ROS PROPN - O
production NOUN - O
in ADP - O
a DET - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
manner NOUN - O
, PUNCT - O
whilst ADP - O
it PRON - O
inhibited VERB - O
respiration NOUN - O
via ADP - O
Complex NNP - B-ORG
I PROPN - O
or CCONJ - O
Complex NNP - B-PERSON
II NNP - I-PERSON
when ADV - O
tested VERB - O
in ADP - O
whole ADJ - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
shows VERB - O
the DET - O
function NOUN - O
of ADP - O
ameliorating VERB - O
NAFLD NNP - B-ORG
, PUNCT - O
but CCONJ - O
the DET - O
underlying VERB - O
mechanisms NOUN - O
remain VERB - O
unknown ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
alleviates VERB - O
nonalcoholic ADJ - O
fatty NOUN - O
liver NOUN - O
disease NOUN - O
by ADP - O
restoring VERB - O
autophagic ADJ - O
flux NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Aspirin PROPN - O
Coadministration PROPN - O
on ADP - O
the DET - O
Safety PROPN - O
of ADP - O
Celecoxib NNP - B-MEDICINE
, PUNCT - O
Naproxen NNP - B-PERSON
, PUNCT - O
  SPACE - O
or CCONJ - O
  SPACE - O
Ibuprofen NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Celecoxib NNP - B-MEDICINE
might VERB - O
also ADV - O
be VERB - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
at ADP - O
an DET - O
annual ADJ - O
cost NOUN - O
of ADP - O
$ SYM - O
600 CD - B-MONEY
if ADP - O
CV NOUN - O
toxicity NOUN - O
were VERB - O
eliminated VERB - O
completely ADV - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
Rosuvastatin NNP - B-MEDICINE
reduced VERB - O
the DET - O
expression NOUN - O
of ADP - O
hERG PROPN - O
plasma NOUN - O
membrane NOUN - O
by ADP - O
two CD - B-CARDINAL
pathways NOUN - O
, PUNCT - O
the DET - O
first JJ - B-ORDINAL
is VERB - O
to PART - O
disrupt VERB - O
the DET - O
transport NOUN - O
of ADP - O
immature ADJ - O
hERG ADJ - O
channels NOUN - O
to ADP - O
the DET - O
membrane NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
second JJ - B-ORDINAL
is VERB - O
to PART - O
increase VERB - O
the DET - O
degradation NOUN - O
of ADP - O
mature ADJ - O
hERG PROPN - O
channels NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
Rosuvastatin NNP - B-MEDICINE
potently ADV - O
blocked VERB - O
  SPACE - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
is VERB - O
a DET - O
synthetic ADJ - O
statin NOUN - O
of ADP - O
3-hydroxy CD - B-CARDINAL
- PUNCT - O
methyl-3-glutamyl PRON - O
coenzyme NOUN - O
A DET - O
reductase NOUN - O
inhibitor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
and CCONJ - O
Aspirin NNP - B-WORK_OF_ART
on IN - I-WORK_OF_ART
Retinal NNP - I-WORK_OF_ART
Vascular NNP - I-WORK_OF_ART
Structures NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Hypercholesterolemic NNP - I-WORK_OF_ART
Patients NNPS - I-WORK_OF_ART
with IN - I-WORK_OF_ART
Low NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
to IN - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Moderate JJ - I-WORK_OF_ART
Risk NN - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Coronary NNP - I-WORK_OF_ART
Artery NNP - I-WORK_OF_ART
Disease NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
is VERB - O
an DET - O
alternative ADJ - O
agent NOUN - O
used VERB - O
to PART - O
reduce VERB - O
the DET - O
risk NOUN - O
of ADP - O
cardiovascular ADJ - O
disease NOUN - O
. PUNCT - O

Rosuvastatin JJ - B-MEDICINE
treatment NOUN - O
also ADV - O
resulted VERB - O
in ADP - O
increased VERB - O
SOD NNP - B-ORG
and CCONJ - O
CAT NNP - B-ORG
activities NOUN - O
and CCONJ - O
decreased VERB - O
MDA NNP - B-ORG
content NOUN - O
in ADP - O
ox‑LDL‑stimulated ADJ - O
HUVECs NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
alleviates VERB - O
high ADJ - O
- PUNCT - O
salt NOUN - O
and CCONJ - O
cholesterol NOUN - O
diet NOUN - O
- PUNCT - O
induced VERB - O
cognitive ADJ - O
impairment NOUN - O
in ADP - O
rats NOUN - O
via ADP - O
Nrf2-ARE NNP - B-GPE
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NNP - B-MEDICINE
was VERB - O
safe ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
tolerated VERB - O
when ADV - O
co VERB - O
- VERB - O
administered VERB - O
with ADP - O
NGM282 NNP - B-PERSON
in ADP - O
patients NOUN - O
with ADP - O
NASH NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
, PUNCT - O
a DET - O
3-hydroxymethyl-3-methylglutaryl CD - B-DATE
coenzyme NOUN - O
A NOUN - O
( PUNCT - O
HMG NNP - B-ORG
- HYPH - I-ORG
CoA NNP - I-ORG
) PUNCT - O
reductase NOUN - O
inhibitor NOUN - O
, PUNCT - O
might VERB - O
improve VERB - O
the DET - O
outcome NOUN - O
of ADP - O
HT NNP - B-ORG
by ADP - O
inhibiting VERB - O
neuroinflammation NOUN - O
. PUNCT - O

Rosuvastatin NN - B-MEDICINE
protected VERB - O
against ADP - O
impaired VERB - O
neurological ADJ - O
function NOUN - O
and CCONJ - O
reversed VERB - O
the DET - O
BBB NNP - B-ORG
leakage NOUN - O
observed VERB - O
in ADP - O
the DET - O
HT NNP - B-ORG
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NNP - B-MEDICINE
Reduces NNP - I-ORG
Neuroinflammation NNP - I-ORG
in ADP - O
the DET - O
Hemorrhagic PROPN - O
Transformation PROPN - O

-DOCSTART- -X- - O

Beneficial ADJ - O
Role PROPN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
in ADP - O
Blood NNP - B-GPE
- HYPH - I-GPE
Brain NNP - I-GPE
Barrier NNP - I-GPE
Damage NN - I-GPE
Following VBG - I-GPE
Experimental NNP - I-GPE
Ischemic NNP - I-GPE
Stroke NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
is VERB - O
aiming VERB - O
to PART - O
investigate VERB - O
the DET - O
potential ADJ - O
roles NOUN - O
and CCONJ - O
mechanisms NOUN - O
of ADP - O
how ADV - O
intestinal ADJ - O
microflora NOUN - O
mediates VERB - O
lipid ADJ - O
- PUNCT - O
reduction NOUN - O
efficacy NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
. PUNCT - O

To PART - O
investigate VERB - O
the DET - O
correlation NOUN - O
between ADP - O
the DET - O
intestinal ADJ - O
microflora NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
, PUNCT - O
we PRON - O
analyzed VERB - O
the DET - O
diversity NOUN - O
of ADP - O
intestinal ADJ - O
microflora NOUN - O
using VERB - O
PCR PROPN - O
- PUNCT - O
DGGE PROPN - O
analysis NOUN - O
and CCONJ - O
16S NUM - O
rDNA VERB - O
sequencing NOUN - O
approaches NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
we PRON - O
compared VERB - O
the DET - O
blood NOUN - O
lipid NOUN - O
levels NOUN - O
of ADP - O
rat NOUN - O
models NOUN - O
with ADP - O
dysbiosis NOUN - O
of ADP - O
intestinal ADJ - O
microflora NOUN - O
and CCONJ - O
control NOUN - O
rats NOUN - O
upon ADP - O
the DET - O
Rosuvastatin NNP - B-MEDICINE
administration NOUN - O
. PUNCT - O

Importantly ADV - O
, PUNCT - O
the DET - O
results NOUN - O
from ADP - O
16S CD - B-CARDINAL
rDNA NOUN - O
sequencing NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
abundance NOUN - O
of ADP - O
Lactobacillus NNP - B-ORG
and CC - I-ORG
Bifidobacterium NNP - I-ORG
was VERB - O
remarkably ADV - O
diminished ADJ - O
upon ADP - O
the DET - O
antibiotic ADJ - O
treatment NOUN - O
in ADP - O
antibiotic+Rosuvastatin NOUN - O
- PUNCT - O
treated VERB - O
group NOUN - O
compared VERB - O
to ADP - O
that DET - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
- PUNCT - O
treated VERB - O
group NOUN - O
and CCONJ - O
control NOUN - O
group NOUN - O
. PUNCT - O

Correspondently ADV - O
, PUNCT - O
the DET - O
lipid NOUN - O
- PUNCT - O
reduction NOUN - O
efficacy NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
was VERB - O
significantly ADV - O
compromised VERB - O
. PUNCT - O

Subsequently ADV - O
, PUNCT - O
the DET - O
lipid NOUN - O
- PUNCT - O
reduction NOUN - O
efficacy NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
was VERB - O
also ADV - O
recovered VERB - O
to ADP - O
level NOUN - O
of ADP - O
the DET - O
control NOUN - O
rats NOUN - O
treated VERB - O
with ADP - O
Rosuvastatin NNP - B-MEDICINE
alone ADJ - O
. PUNCT - O

Intestinal ADJ - O
flora NOUN - O
could VERB - O
play VERB - O
an DET - O
essential ADJ - O
role NOUN - O
in ADP - O
mediating VERB - O
the DET - O
lipid NOUN - O
- PUNCT - O
reduction NOUN - O
efficacy NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
and CCONJ - O
ezetimibe NOUN - O
were VERB - O
separated VERB - O
on ADP - O
Symmetry NNP - B-NORP
C18 NNP - B-PRODUCT
column NOUN - O
using VERB - O
acetonitrile NOUN - O
and CCONJ - O
ammonium NOUN - O
formate NOUN - O
buffer NOUN - O
, PUNCT - O
pH X - O
  SPACE - O
3.5 CD - B-CARDINAL
( PUNCT - O
30:70 CD - B-TIME
, PUNCT - O
v NOUN - O
/ SYM - O
v NOUN - O
) PUNCT - O
as ADP - O
the DET - O
mobile ADJ - O
phase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Ezetimibe PROPN - O
and CCONJ - O
Rosuvastatin NNP - B-MEDICINE
Combination PROPN - O
Therapy PROPN - O

Versus PROPN - O
Those DET - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
Monotherapy NNP - I-PERSON
in ADP - O
Patients NNPS - B-GPE
With ADP - O
Primary PROPN - O
Hypercholesterolemia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
is VERB - O
a DET - O
statin NOUN - O
used VERB - O
to PART - O
treat VERB - O
metabolic ADJ - O
syndrome NOUN - O
conditions NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
hyperlipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
use NOUN - O
improves VERB - O
measures NOUN - O
of ADP - O
coagulation NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
venous ADJ - O
thrombosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Rapid PROPN - O
( PUNCT - O
Differential PROPN - O
) PUNCT - O
Effect PROPN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
and CCONJ - O
Atorvastatin NNP - B-PERSON
on ADP - O
High PROPN - O
- PUNCT - O
Sensitivity PROPN - O
Cardiac PROPN - O
Troponin PROPN - O
- PUNCT - O
I PRON - O
in ADP - O
Subjects NOUN - O
With ADP - O
Stable PROPN - O
Cardiovascular PROPN - O
Disease PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
PLANET NOUN - O
I PROPN - O
and CCONJ - O
II NNP - B-PERSON
( PUNCT - O
Renal ADJ - O
effects NOUN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
and CCONJ - O
Atorvastatin NNP - B-PERSON
in ADP - O
Patients PROPN - O
Who NOUN - O
Have VERB - O
Progressive PROPN - O
Renal PROPN - O
Disease PROPN - O
) PUNCT - O
trials NOUN - O
examined VERB - O
effects NOUN - O
of ADP - O
atorvastatin NOUN - O
and CCONJ - O
rosuvastatin NN - B-MEDICINE
on ADP - O
proteinuria NOUN - O
and CCONJ - O
renal ADJ - O
function NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
proteinuria NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
is VERB - O
commonly ADV - O
prescribed VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
hypercholesterolemia NOUN - O
and CCONJ - O
hepatic ADJ - O
transporter NOUN - O
- PUNCT - O
mediated VERB - O
accumulation NOUN - O
in ADP - O
the DET - O
liver NOUN - O
enhances VERB - O
its ADJ - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimization NOUN - O
of ADP - O
UPLC PROPN - O
Method PROPN - O
for ADP - O
Simultaneous PROPN - O
Determination PROPN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
and CCONJ - O
Rosuvastatin NNP - B-MEDICINE
Degradation NNP - I-ORG
Products NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Rosuvastatin NN - B-MEDICINE
can VERB - O
improve VERB - O
cardiac ADJ - O
function NOUN - O
and CCONJ - O
hypertrophy NOUN - O
by ADP - O
regulating VERB - O
the DET - O
crosstalk NOUN - O
of ADP - O
the DET - O
two CD - B-CARDINAL
signaling VERB - O
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Approach PROPN - O
for ADP - O
Development PROPN - O
of ADP - O
Optimized PROPN - O
Bicontinuous PROPN - O
Mucoadhesive PROPN - O
Limicubes PROPN - O
for ADP - O
Oral PROPN - O
Delivery PROPN - O
of ADP - O
Rosuvastatin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Substituting VERB - O
50 CD - B-PERCENT
% NN - I-PERCENT
Isovue PROPN - O
for ADP - O
Sterile NNP - B-MEDICINE
Water NNP - I-MEDICINE
as ADP - O
the DET - O
Delivery PROPN - O
Medium PROPN - O
for ADP - O
SIR PROPN - O
- PUNCT - O
Spheres PROPN - O
: PUNCT - O
Improved PROPN - O
Dose PROPN - O
Delivery PROPN - O
and CCONJ - O
Decreased VERB - O
Incidence PROPN - O
of ADP - O
Stasis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Bubble NN - I-WORK_OF_ART
Technique NN - I-WORK_OF_ART
: PUNCT - O
A DET - O
Novel PROPN - O
Use PROPN - O
of ADP - O
Sterile NNP - B-MEDICINE
Water NNP - I-MEDICINE
to PART - O
Facilitate VERB - O
Lead PROPN - O
Placement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
formulation NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
is VERB - O
being VERB - O
studied VERB - O
for ADP - O
moderate ADJ - O
to ADP - O
severe ADJ - O
pain NOUN - O
management NOUN - O
. PUNCT - O

This DET - O
phase NOUN - O
3 CD - B-CARDINAL
, PUNCT - O
randomized VERB - O
, PUNCT - O
multicenter NOUN - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
evaluated VERB - O
the DET - O
safety NOUN - O
of ADP - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
meloxicam NN - B-MEDICINE
IV NNP - B-ORG
30 NUM - O
mg NOUN - O
in ADP - O
subjects NOUN - O
following VERB - O
major ADJ - O
elective ADJ - O
surgery NOUN - O
. PUNCT - O

Eligible ADJ - O
subjects NOUN - O
were VERB - O
randomized VERB - O
( PUNCT - O
3:1 CD - B-CARDINAL
) PUNCT - O
to PART - O
receive VERB - O
meloxicam NN - B-MEDICINE
IV PROPN - O
30 CD - B-CARDINAL
mg NOUN - O
or CCONJ - O
placebo NOUN - O
administered VERB - O
once ADV - O
daily ADV - O
. PUNCT - O

The DET - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
was VERB - O
similar ADJ - O
between ADP - O
meloxicam NN - B-MEDICINE
IV- NOUN - O
and CCONJ - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
subjects NOUN - O
( PUNCT - O
63.0 CD - B-PERCENT
% NN - I-PERCENT
versus ADP - O
65.0 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Over ADP - O
the DET - O
treatment NOUN - O
period NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
IV NNP - B-ORG
was VERB - O
associated VERB - O
with ADP - O
a DET - O
23.6 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
P NOUN - O
= SYM - O
.0531 NOUN - O
) PUNCT - O
reduction NOUN - O
in ADP - O
total ADJ - O
opioid ADJ - O
use NOUN - O
( PUNCT - O
9.2 CD - B-QUANTITY
mg NN - I-QUANTITY
morphine NN - I-QUANTITY
equivalent NOUN - O
) PUNCT - O
compared VERB - O
to ADP - O
placebo NOUN - O
- PUNCT - O
treated VERB - O
subjects NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
suggest VERB - O
that ADP - O
meloxicam NN - B-MEDICINE
IV NNP - B-ORG
had VERB - O
a DET - O
safety NOUN - O
profile NOUN - O
similar ADJ - O
to ADP - O
that DET - O
of ADP - O
placebo NOUN - O
with ADP - O
respect NOUN - O
to ADP - O
numbers NOUN - O
and CCONJ - O
frequencies NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
and CCONJ - O
reduced VERB - O
opioid ADJ - O
consumption NOUN - O
in ADP - O
subjects NOUN - O
with ADP - O
moderate ADJ - O
to PART - O
severe ADJ - O
postoperative NOUN - O
pain NOUN - O
following VERB - O
major ADJ - O
elective ADJ - O
surgery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
a DET - O
pain NOUN - O
model NOUN - O
in ADP - O
sheep NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
prevent VERB - O
the DET - O
extinction NOUN - O
of ADP - O
vultures NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
was VERB - O
introduced VERB - O
after ADP - O
the DET - O
ban NOUN - O
of ADP - O
veterinary ADJ - O
diclofenac NOUN - O
. PUNCT - O

The DET - O
reason NOUN - O
for ADP - O
the DET - O
rapid ADJ - O
elimination NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
is VERB - O
yet ADV - O
to PART - O
be VERB - O
explained VERB - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
role NOUN - O
of ADP - O
biotransformation NOUN - O
in ADP - O
the DET - O
elimination NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
. PUNCT - O

Six CD - B-CARDINAL
Cape PROPN - O
griffon VERB - O
vultures NOUN - O
( PUNCT - O
Gyps PROPN - O
coprotheres NOUN - O
) PUNCT - O
were VERB - O
treated VERB - O
with ADP - O
2 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
meloxicam VB - B-MEDICINE
intramuscularly ADV - O
for ADP - O
faecal ADJ - O
and CCONJ - O
plasma ADJ - O
quantification NOUN - O
of ADP - O
meloxicam JJ - B-MEDICINE
concentration NOUN - O
over ADP - O
time NOUN - O
. PUNCT - O

In ADP - O
the DET - O
plasma NOUN - O
meloxicam NN - B-MEDICINE
was VERB - O
characterised VERB - O
by ADP - O
a DET - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
, PUNCT - O
mean VERB - O
residence NOUN - O
time NOUN - O
, PUNCT - O
clearance NOUN - O
and CCONJ - O
volume NOUN - O
of ADP - O
distribution NOUN - O
at ADP - O
steady ADJ - O
state NOUN - O
of ADP - O
0.37 CD - B-CARDINAL
  SPACE - O
± NUM - O
  SPACE - O
0.10 CD - B-CARDINAL
  SPACE - O
h NOUN - O
, PUNCT - O

Over ADP - O
the DET - O
24 CD - B-CARDINAL
  SPACE - O
h NOUN - O
monitoring NOUN - O
period NOUN - O
, PUNCT - O
the DET - O
total ADJ - O
non ADJ - O
- ADJ - O
metabolised ADJ - O
meloxicam NN - B-MEDICINE
in ADP - O
the DET - O
faeces NOUN - O
was VERB - O
1.35 CD - B-CARDINAL
  SPACE - O

Based VERB - O
on ADP - O
the DET - O
short ADJ - O
meloxicam NN - B-MEDICINE
elimination NOUN - O
half ADJ - O
- PUNCT - O
life NOUN - O
and CCONJ - O
low ADJ - O
cumulative ADJ - O
concentration NOUN - O
of ADP - O
total ADJ - O
faecal ADJ - O
meloxicam NN - B-MEDICINE
over ADP - O
a DET - O
period NOUN - O
in ADP - O
excess NOUN - O
of ADP - O
10 CD - B-CARDINAL
half NN - I-CARDINAL
- PUNCT - O
lives NOUN - O
, PUNCT - O
this DET - O
study NOUN - O
indicates VERB - O
that ADP - O
Cape NNP - B-LOC
griffon VERB - O
vultures NOUN - O
are VERB - O
efficient ADJ - O
metaboliser NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
suggestive ADJ - O
of ADP - O
different ADJ - O
set NOUN - O
of ADP - O
cytochrome ADJ - O
enzymes NOUN - O
being VERB - O
involved VERB - O
in ADP - O
the DET - O
metabolism NOUN - O
to ADP - O
that DET - O
for ADP - O
diclofenac NOUN - O
in ADP - O
this DET - O
species NOUN - O
. PUNCT - O

Identification NOUN - O
of ADP - O
orthologous ADJ - O
human ADJ - O
CYP2C9 NN - B-PRODUCT
and CCONJ - O
CYP3A4 VB - B-PRODUCT
enzyme ADJ - O
families NOUN - O
in ADP - O
vultures NOUN - O
will VERB - O
be VERB - O
an DET - O
important ADJ - O
further ADJ - O
step NOUN - O
in ADP - O
explaining VERB - O
the DET - O
differences NOUN - O
in ADP - O
the DET - O
metabolic NOUN - O
pathway(s NOUN - O
) PUNCT - O
of ADP - O
meloxicam NN - B-MEDICINE
and CCONJ - O
diclofenac NOUN - O
for ADP - O
the DET - O
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Application PROPN - O
of ADP - O
Photobiomodulation PROPN - O
therapy NOUN - O
( PUNCT - O
PBMT NOUN - O
) PUNCT - O
and CCONJ - O
meloxicam VBP - B-MEDICINE
in ADP - O
acute ADJ - O
spinal ADJ - O
cord NOUN - O
injury NOUN - O
, PUNCT - O
functional ADJ - O
recovery NOUN - O
and CCONJ - O
histological ADJ - O
evaluation NOUN - O
. PUNCT - O

Evaluation NOUN - O
of ADP - O
the DET - O
effect NOUN - O
of ADP - O
simultaneous ADJ - O
PBMT NNP - B-ORG
and CCONJ - O
meloxicam VBP - B-MEDICINE
on ADP - O
treatment NOUN - O
of ADP - O
acute ADJ - O
experimental ADJ - O
spinal ADJ - O
cord NOUN - O
injury NOUN - O
and CCONJ - O
comparing VERB - O
it PRON - O
with ADP - O
the DET - O
effect NOUN - O
of ADP - O
application NOUN - O
of ADP - O
each DET - O
of ADP - O
them PRON - O
separately ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
the DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
test VERB - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
administration NOUN - O
of ADP - O
a DET - O
nonsteroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
( PUNCT - O
meloxicam NN - B-MEDICINE
) PUNCT - O
on ADP - O
the DET - O
behavior NOUN - O
, PUNCT - O
health NOUN - O
, PUNCT - O
and CCONJ - O
production NOUN - O
of ADP - O
peripartum NOUN - O
cows NOUN - O
. PUNCT - O

Dairy NNP - B-PERSON
cows VERB - O
and CCONJ - O
heifers NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
1 CD - B-CARDINAL
of ADP - O
3 CD - B-CARDINAL
treatment NOUN - O
groups NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
meloxicam NN - B-MEDICINE
administration NOUN - O
before ADP - O
calving VERB - O
, PUNCT - O
with ADP - O
a DET - O
placebo NOUN - O
administered VERB - O
after ADP - O
calving VERB - O
( PUNCT - O
MEL NNP - B-ORG
- HYPH - I-ORG
PRE NNP - I-ORG
, PUNCT - O
n NOUN - O
= SYM - O
60 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
placebo NOUN - O
administered VERB - O
before ADP - O
calving NOUN - O
, PUNCT - O
and CCONJ - O
meloxicam NN - B-MEDICINE
administered ADJ - O
after ADP - O
calving VERB - O
( PUNCT - O
MEL NNP - B-ORG
- HYPH - I-ORG
POST NNP - I-ORG
, PUNCT - O
n NOUN - O
= SYM - O
69 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O

Regardless ADV - O
of ADP - O
the DET - O
time NOUN - O
of ADP - O
administration NOUN - O
, PUNCT - O
dystocic ADV - O
cattle NOUN - O
that ADJ - O
received VERB - O
meloxicam NN - B-MEDICINE
were VERB - O
less ADV - O
active ADJ - O
than ADP - O
dystocic ADV - O
CTL NNP - B-ORG
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
administration NOUN - O
before ADP - O
calving NOUN - O
appears VERB - O
promising VERB - O
in ADP - O
increasing VERB - O
milk NOUN - O
yield NOUN - O
in ADP - O
eutocic NOUN - O
cows NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
sought VERB - O
to ADP - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
assess VERB - O
the DET - O
degree NOUN - O
of ADP - O
postoperative ADJ - O
pain NOUN - O
following VERB - O
craniotomy NOUN - O
in ADP - O
mice NOUN - O
, PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
three CD - B-CARDINAL
common ADJ - O
rodent NOUN - O
analgesics NOUN - O
( PUNCT - O
carprofen NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
and CCONJ - O
buprenorphine NOUN - O
) PUNCT - O
for ADP - O
reducing VERB - O
this DET - O
pain NOUN - O
and CCONJ - O

-DOCSTART- -X- - O

meloxicam NN - B-MEDICINE
administered VERB - O
at ADP - O
the DET - O
time NOUN - O
of ADP - O
knife NOUN - O
and CCONJ - O
band NOUN - O
castration NOUN - O
on ADP - O
inflammatory ADJ - O
response NOUN - O
and CCONJ - O
wound VERB - O
healing NOUN - O
over ADP - O
56-d CD - B-DATE
post ADJ - O
- ADJ - O
castration ADJ - O
. PUNCT - O

with ADP - O
meloxicam NN - B-MEDICINE
( PUNCT - O
0.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
of ADP - O
BW PROPN - O
) PUNCT - O
. PUNCT - O

injection NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
did VERB - O
not ADV - O
reduce VERB - O
long ADJ - O
- PUNCT - O
term NOUN - O
inflammatory ADJ - O
responses NOUN - O
or CCONJ - O
improve VERB - O
wound ADP - O
healing NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
it PRON - O
may VERB - O
be VERB - O
useful ADJ - O
in ADP - O
reducing VERB - O
pain NOUN - O
and CCONJ - O
stress NOUN - O
in ADP - O
band NOUN - O
castrated VERB - O
calves NOUN - O
as ADP - O
evidenced VERB - O
by ADP - O
reduced VERB - O
hair NOUN - O
cortisol NOUN - O
concentrations NOUN - O
up ADV - O
to ADP - O
56 CD - B-CARDINAL
d DET - O
post ADJ - O
- ADJ - O
castration ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
subcutaneous ADJ - O
meloxicam NN - B-MEDICINE
prior ADV - O
to ADP - O
band NOUN - O
or CCONJ - O
knife NOUN - O
castration NOUN - O
in ADP - O
1-wk CD - B-CARDINAL
- PUNCT - O
old ADJ - O
beef NOUN - O
calves NOUN - O
: PUNCT - O
II NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
and CCONJ - O
compare VERB - O
the DET - O
effect NOUN - O
of ADP - O
flunixin NOUN - O
meglumine NOUN - O
( PUNCT - O
FM PROPN - O
; PUNCT - O
1.1 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
IV NNP - B-ORG
) PUNCT - O
, PUNCT - O
firocoxib NOUN - O
( PUNCT - O
FIRO PROPN - O
; PUNCT - O
0.2 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
PO PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
meloxicam NN - B-MEDICINE
( PUNCT - O
ML NNP - B-ORG
; PUNCT - O
0.6 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
IV NNP - B-ORG
) PUNCT - O
, PUNCT - O
on ADP - O
the DET - O
embryo NOUN - O
mobility NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
flunixin NOUN - O
meglumine NOUN - O
, PUNCT - O
firocoxib NOUN - O
and CCONJ - O
meloxicam NN - B-MEDICINE
on ADP - O
the DET - O
uterine ADJ - O
mobility NOUN - O
of ADP - O
equine ADJ - O
embryos NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
blinded VERB - O
prospective ADJ - O
study NOUN - O
investigated VERB - O
analgesic ADJ - O
effects NOUN - O
of ADP - O
intramuscular ADJ - O
( PUNCT - O
IM PROPN - O
) PUNCT - O
butorphanol NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
or CCONJ - O
intratesticular ADJ - O
( PUNCT - O
IT NOUN - O
) PUNCT - O
lidocaine ADJ - O
for ADP - O
castration NOUN - O
of ADP - O
7 CD - B-CARDINAL
- SYM - O
14 NUM - O
  SPACE - O
days NOUN - O
old ADJ - O
piglets NOUN - O
under ADP - O
isoflurane VERB - O
anaesthesia NOUN - O
. PUNCT - O

66 CD - B-CARDINAL
piglets NOUN - O
were VERB - O
randomly ADV - O
injected VERB - O
with ADP - O
: PUNCT - O
meloxicam NN - B-MEDICINE
IM PROPN - O
( PUNCT - O
0.4 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
; PUNCT - O
group NOUN - O
M PROPN - O
) PUNCT - O
, PUNCT - O
butorphanol NOUN - O
IM NNP - B-ORG
( PUNCT - O
0.2 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
; PUNCT - O
group NOUN - O
B PROPN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
both DET - O
( PUNCT - O
group NOUN - O
BM NNP - B-ORG
) PUNCT - O
20 CD - B-TIME
minutes NNS - I-TIME
prior ADV - O
to ADP - O
castration NOUN - O
, PUNCT - O
or CCONJ - O
lidocaine VERB - O
IT PRON - O
( PUNCT - O
4 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
( PUNCT - O
group NOUN - O
ML4 NNP - B-PRODUCT
) PUNCT - O
or CCONJ - O
8 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
( PUNCT - O
group NOUN - O
ML8 NNP - B-PERSON
) PUNCT - O
) PUNCT - O
together ADV - O
with ADP - O
meloxicam NN - B-MEDICINE
IM NNP - B-ORG
( PUNCT - O
0.4 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
) PUNCT - O
under ADP - O
anaesthesia NOUN - O
with ADP - O
1.8 CD - B-PERCENT
% NN - I-PERCENT
end NOUN - O
- PUNCT - O
tidal NOUN - O
isoflurane NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objectives NOUN - O
of ADP - O
this DET - O
study NOUN - O
were VERB - O
to PART - O
assess VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
two CD - B-CARDINAL
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drugs NOUN - O
( PUNCT - O
NSAIDs PROPN - O
) PUNCT - O
, PUNCT - O
meloxicam NN - B-MEDICINE
( PUNCT - O
MEL NNP - B-ORG
) PUNCT - O
( PUNCT - O
0.4 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
or CCONJ - O
1.0 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
) PUNCT - O
and CCONJ - O
ketoprofen PROPN - O
( PUNCT - O
KET PROPN - O
) PUNCT - O
( PUNCT - O
6.0 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
) PUNCT - O
in ADP - O
reducing VERB - O
behavioral ADJ - O
indicators NOUN - O
of ADP - O
pain NOUN - O
in ADP - O
castrated ADJ - O
piglets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Despite ADP - O
its ADJ - O
large ADJ - O
effectiveness NOUN - O
, PUNCT - O
the DET - O
long ADJ - O
- PUNCT - O
term NOUN - O
oral ADJ - O
administration NOUN - O
of ADP - O
high ADJ - O
doses NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
( PUNCT - O
MLX NNP - B-ORG
) PUNCT - O
may VERB - O
lead VERB - O
to ADP - O
gastrointestinal ADJ - O
events NOUN - O
such ADJ - O
as ADP - O
abdominal ADJ - O
pain NOUN - O
, PUNCT - O
diarrhea NOUN - O
, PUNCT - O
dyspepsia NOUN - O
, PUNCT - O
ulceration NOUN - O
, PUNCT - O
hemorrhage NOUN - O
, PUNCT - O
and CCONJ - O
gastrointestinal ADJ - O
perforation NOUN - O
. PUNCT - O

Cutaneous ADJ - O
permeation NOUN - O
of ADP - O
MLX NNP - B-ORG
and CCONJ - O
1:1 CD - B-CARDINAL
meloxicam NN - B-MEDICINE
- PUNCT - O
salicylic NOUN - O
acid NOUN - O
cocrystal NOUN - O
( PUNCT - O
MLX NNP - B-ORG
- HYPH - I-ORG
SLC NNP - I-ORG
) PUNCT - O
were VERB - O
evaluated VERB - O
using VERB - O
Franz NNP - B-ORG
diffusion NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
asked VERB - O
whether ADP - O
and CCONJ - O
if ADP - O
so ADP - O
to ADP - O
what ADJ - O
extent NOUN - O
melatonin NOUN - O
and CCONJ - O
meloxicam NN - B-MEDICINE
can VERB - O
improve VERB - O
subjective ADJ - O
and CCONJ - O
objective ADJ - O
sleep NOUN - O
and CCONJ - O
reduce VERB - O
pain NOUN - O
among ADP - O
women NOUN - O
with ADP - O
primary ADJ - O
dysmenorrhea NOUN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
. PUNCT - O

Next ADV - O
, PUNCT - O
participants NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
one CD - B-CARDINAL
of ADP - O
two CD - B-CARDINAL
conditions NOUN - O
, PUNCT - O
either CCONJ - O
melatonin NOUN - O
during ADP - O
the DET - O
second JJ - B-ORDINAL
, PUNCT - O
and CCONJ - O
meloxicam VB - B-MEDICINE
during ADP - O
the DET - O
third JJ - B-ORDINAL
menstruation NOUN - O
, PUNCT - O
or CCONJ - O
meloxicam VB - B-MEDICINE
during ADP - O
the DET - O
second JJ - B-ORDINAL
, PUNCT - O
and CCONJ - O
melatonin NOUN - O
during ADP - O
the DET - O
third JJ - B-ORDINAL
menstruation NOUN - O
. PUNCT - O

Subjective ADJ - O
sleep NOUN - O
improved VERB - O
and CCONJ - O
pain NOUN - O
decreased VERB - O
during ADP - O
the DET - O
second JJ - B-ORDINAL
and CCONJ - O
third JJ - B-ORDINAL
menstruations NOUN - O
irrespective ADV - O
of ADP - O
whether ADP - O
melatonin ADJ - O
or CCONJ - O
meloxicam NN - B-MEDICINE
was VERB - O
administered VERB - O
first JJ - B-ORDINAL
or CCONJ - O
second JJ - B-ORDINAL
. PUNCT - O

The DET - O
efficacy NOUN - O
of ADP - O
melatonin NOUN - O
was VERB - O
superior ADJ - O
to ADP - O
that DET - O
of ADP - O
meloxicam NN - B-MEDICINE
. PUNCT - O

The DET - O
present ADJ - O
pattern NOUN - O
of ADP - O
results NOUN - O
suggests VERB - O
that ADP - O
both CCONJ - O
melatonin NOUN - O
and CCONJ - O
meloxicam NN - B-MEDICINE
are VERB - O
suitable ADJ - O
to PART - O
treat VERB - O
pain NOUN - O
and CCONJ - O
PD PROPN - O
- PUNCT - O
related VERB - O
sleep NOUN - O
complaints NOUN - O
among ADP - O
women NOUN - O
with ADP - O
primary ADJ - O
dysmenorrhea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
ultra ADJ - O
- ADJ - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
method NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
and CCONJ - O
its ADJ - O
impurities NOUN - O
in ADP - O
active ADJ - O
pharmaceutical ADJ - O
ingredients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
previous ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
incorporating VERB - O
meglumine NOUN - O
during ADP - O
extrusion NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
results NOUN - O
in ADP - O
chemical NOUN - O
stabilization NOUN - O
that ADJ - O
can VERB - O
not ADV - O
be VERB - O
achieved VERB - O
using VERB - O
process NOUN - O
optimization NOUN - O
alone ADV - O
. PUNCT - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
understand VERB - O
the DET - O
mechanism NOUN - O
behind ADP - O
this DET - O
stabilization NOUN - O
and CCONJ - O
its ADJ - O
impact NOUN - O
on ADP - O
the DET - O
performance NOUN - O
of ADP - O
a DET - O
meloxicam NN - B-MEDICINE
- PUNCT - O
Kollidon NNP - B-PERSON
VA64 PROPN - O
amorphous ADJ - O
solid ADJ - O
dispersion NOUN - O
. PUNCT - O

The DET - O
meloxicam NN - B-MEDICINE
concentration NOUN - O
was VERB - O
maintained VERB - O
at ADP - O
10 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
w NOUN - O
/ SYM - O
w NOUN - O
) PUNCT - O
for ADP - O
blends NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
meglumine NOUN - O
. PUNCT - O

The DET - O
optimal ADJ - O
meglumine NOUN - O
blend NOUN - O
contained VERB - O
an DET - O
equimolar ADJ - O
amount NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
to PART - O
meglumine VERB - O
with ADP - O
the DET - O
remainder NOUN - O
consisting VERB - O
of ADP - O
Kollidon NNP - B-PERSON
VA64 PROPN - O
. PUNCT - O

Meglumine NOUN - O
at ADP - O
a DET - O
1:1 CD - B-QUANTITY
molar NN - I-QUANTITY
ratio NOUN - O
with ADP - O
meloxicam NN - B-MEDICINE
results NOUN - O
in ADP - O
100 CD - B-PERCENT
% NN - I-PERCENT
purity NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
after ADP - O
melt NOUN - O
extrusion NOUN - O
. PUNCT - O

Solid ADJ - O
- PUNCT - O
state NOUN - O
NMR NNP - B-ORG
revealed VERB - O
a DET - O
proton ADJ - O
transfer NOUN - O
between ADP - O
the DET - O
meloxicam NN - B-MEDICINE
and CCONJ - O
meglumine NOUN - O
indicating VERB - O
an DET - O
in ADP - O
situ ADJ - O
salt NOUN - O
formation NOUN - O
. PUNCT - O

During ADP - O
non ADJ - O
- ADJ - O
sink ADJ - O
dissolution NOUN - O
, PUNCT - O
the DET - O
meglumine NOUN - O
ASD NNP - B-ORG
enables VERB - O
meloxicam NN - B-MEDICINE
to PART - O
maintain VERB - O
supersaturatation NOUN - O
( PUNCT - O
≅50 NNP - B-NORP
times NOUN - O
more ADJ - O
than ADP - O
meloxicam VB - B-MEDICINE
free ADJ - O
acid NOUN - O
) PUNCT - O
for ADP - O
> X - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
an DET - O
intravenous ADJ - O
nanocrystal ADJ - O
formulation NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
the DET - O
management NOUN - O
of ADP - O
moderate ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
severe ADJ - O
pain NOUN - O
after ADP - O
bunionectomy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
it PRON - O
has VERB - O
been VERB - O
shown VERB - O
that ADP - O
the DET - O
addition NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
to ADP - O
standard ADJ - O
antimicrobial ADJ - O
therapy NOUN - O
for ADP - O
clinical ADJ - O
mastitis NOUN - O
( PUNCT - O
CM PROPN - O
) PUNCT - O
improves VERB - O
the DET - O
conception NOUN - O
rate NOUN - O
of ADP - O
dairy NOUN - O
cows NOUN - O
contracting VERB - O
CM PROPN - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
120 CD - B-CARDINAL
d NOUN - O
in ADP - O
milk NOUN - O
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
our ADJ - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
whether ADP - O
this DET - O
improved ADJ - O
reproduction NOUN - O
through ADP - O
additional ADJ - O
treatment NOUN - O
with ADP - O
meloxicam NN - B-MEDICINE
would VERB - O
result VERB - O
in ADP - O
a DET - O
positive ADJ - O
net ADJ - O
economic ADJ - O
benefit NOUN - O
for ADP - O
the DET - O
farmer NOUN - O
. PUNCT - O

Two CD - B-CARDINAL
scenarios NOUN - O
were VERB - O
simulated VERB - O
in ADP - O
which ADJ - O
CM PROPN - O
cases NOUN - O
were VERB - O
treated VERB - O
with ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
conjunction NOUN - O
with ADP - O
antimicrobial ADJ - O
therapy NOUN - O
or CCONJ - O
with ADP - O
antimicrobial ADJ - O
therapy NOUN - O
alone ADJ - O
. PUNCT - O

The DET - O
scenarios NOUN - O
differed VERB - O
for ADP - O
conception NOUN - O
rates NOUN - O
( PUNCT - O
31 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
meloxicam NN - B-MEDICINE
or CCONJ - O
21 CD - B-PERCENT
% NN - I-PERCENT
without ADP - O
meloxicam NN - B-MEDICINE
) PUNCT - O
and CCONJ - O
for ADP - O
the DET - O
cost NOUN - O
of ADP - O
CM PROPN - O
treatment NOUN - O
. PUNCT - O

Sensitivity NOUN - O
analyses NOUN - O
were VERB - O
undertaken VERB - O
for ADP - O
the DET - O
biological ADJ - O
and CCONJ - O
economic ADJ - O
components NOUN - O
of ADP - O
the DET - O
model NOUN - O
to PART - O
assess VERB - O
the DET - O
effects NOUN - O
of ADP - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
inputs NOUN - O
on ADP - O
inferences NOUN - O
about ADP - O
the DET - O
cost NOUN - O
effectiveness NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

Model NNP - B-ORG
results NOUN - O
showed VERB - O
an DET - O
average ADJ - O
net ADJ - O
economic ADJ - O
benefit NOUN - O
of ADP - O
€ PUNCT - O
42 CD - B-MONEY
per ADP - O
CM PROPN - O
case NOUN - O
per ADP - O
year NOUN - O
in ADP - O
favor NOUN - O
of ADP - O
the DET - O
meloxicam NN - B-MEDICINE
scenario NOUN - O
. PUNCT - O

Cows NOUN - O
in ADP - O
the DET - O
no DET - O
- PUNCT - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
scenario NOUN - O
had VERB - O
higher ADJ - O
returns NOUN - O
on ADP - O
milk NOUN - O
production NOUN - O
, PUNCT - O
lower ADJ - O
costs NOUN - O
upon ADP - O
calving NOUN - O
, PUNCT - O
and CCONJ - O
reduced ADJ - O
costs NOUN - O
of ADP - O
treatment NOUN - O
. PUNCT - O

The DET - O
net ADJ - O
economic ADJ - O
benefit NOUN - O
favoring VERB - O
meloxicam NN - B-MEDICINE
therapy NOUN - O
was VERB - O
a DET - O
consequence NOUN - O
of ADP - O
the DET - O
better ADV - O
reproductive ADJ - O
performance NOUN - O
in ADP - O
the DET - O
meloxicam NN - B-MEDICINE
scenario NOUN - O
in ADP - O
which ADJ - O
cows NOUN - O
had VERB - O
a DET - O
shorter ADJ - O
calving NOUN - O
to ADP - O
conception NOUN - O
interval NOUN - O
( PUNCT - O
132 CD - B-CARDINAL
vs. ADP - O
143 CD - B-CARDINAL
d NUM - O
) PUNCT - O
, PUNCT - O
a DET - O
shorter ADJ - O
intercalving VERB - O
interval NOUN - O
( PUNCT - O
405 CD - B-CARDINAL
vs. SYM - O
416 CD - B-CARDINAL
d NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
fewer ADJ - O
inseminations NOUN - O
per ADP - O
conception NOUN - O
( PUNCT - O
2.9 CD - B-CARDINAL
vs. ADP - O
3.7 CD - B-CARDINAL
) PUNCT - O
compared VERB - O
with ADP - O
cows NOUN - O
in ADP - O
the DET - O
no DET - O
- PUNCT - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
scenario NOUN - O
. PUNCT - O

This DET - O
resulted VERB - O
in ADP - O
a DET - O
shorter ADJ - O
lactation NOUN - O
, PUNCT - O
hence ADV - O
a DET - O
lower ADJ - O
lactational ADJ - O
milk NOUN - O
production NOUN - O
( PUNCT - O
8,441 CD - B-CARDINAL
vs. ADP - O
8,517 CD - B-QUANTITY
kg NN - I-QUANTITY
per ADP - O
lactation NOUN - O
) PUNCT - O
with ADP - O
lower ADJ - O
feeding NOUN - O
costs NOUN - O
in ADP - O
the DET - O
meloxicam NN - B-MEDICINE
group NOUN - O
. PUNCT - O

A DET - O
lower ADV - O
culling NOUN - O
rate NOUN - O
( PUNCT - O
12 CD - B-CARDINAL
vs. ADP - O
25 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
resulted VERB - O
in ADP - O
lower ADJ - O
replacement NOUN - O
costs NOUN - O
in ADP - O
the DET - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
scenario NOUN - O
. PUNCT - O

All DET - O
of ADP - O
the DET - O
scenarios NOUN - O
evaluated VERB - O
in ADP - O
the DET - O
sensitivity NOUN - O
analyses NOUN - O
favored VERB - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
over ADP - O
no DET - O
meloxicam NN - B-MEDICINE
. PUNCT - O

This DET - O
study NOUN - O
demonstrated VERB - O
that ADP - O
improvements NOUN - O
in ADP - O
conception NOUN - O
rate NOUN - O
achieved VERB - O
by ADP - O
the DET - O
use NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
, PUNCT - O
as ADP - O
additional ADJ - O
therapy NOUN - O
for ADP - O
mild ADJ - O
to PART - O
moderate VERB - O
CM PROPN - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
120 CD - B-CARDINAL
d NOUN - O
in ADP - O
milk NOUN - O
, PUNCT - O
have VERB - O
positive ADJ - O
economic ADJ - O
benefits NOUN - O
. PUNCT - O

This DET - O
inference NOUN - O
remained VERB - O
true ADJ - O
over ADP - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
technical ADJ - O
and CCONJ - O
economic ADJ - O
inputs NOUN - O
, PUNCT - O
demonstrating VERB - O
that ADP - O
use NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
is VERB - O
likely ADJ - O
to PART - O
be VERB - O
cost VERB - O
effective ADJ - O
across ADP - O
many ADJ - O
production NOUN - O
systems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
declined VERB - O
surgery NOUN - O
and CCONJ - O
was VERB - O
prescribed VERB - O
oral ADJ - O
meloxicam NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
prior ADV - O
to ADP - O
band NOUN - O
or CCONJ - O
knife NOUN - O
castration NOUN - O
in ADP - O
1-wk CD - B-CARDINAL
- PUNCT - O
old ADJ - O
beef NOUN - O
calves NOUN - O
: PUNCT - O
I. NN - B-ORG
Acute JJ - I-ORG
pain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
levofloxacin NOUN - O
, PUNCT - O
pazufloxacin NOUN - O
, PUNCT - O
enrofloxacin NOUN - O
, PUNCT - O
and CCONJ - O
meloxicam VB - B-MEDICINE
on ADP - O
the DET - O
immunolocalization NOUN - O
of ADP - O
ABCG-2 NNP - B-ORG
transporter NOUN - O
protein NOUN - O
in ADP - O
rabbit NOUN - O
retina NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Immunohistochemistry NOUN - O
and CCONJ - O
Western ADJ - O
blot NOUN - O
analysis NOUN - O
demonstrated VERB - O
that ADP - O
meloxicam NN - B-MEDICINE
pretreatment NOUN - O
of ADP - O
diet NOUN - O
- PUNCT - O
induced VERB - O
obese ADJ - O
mice NOUN - O
dramatically ADV - O
increased VERB - O
epidermal ADJ - O
growth NOUN - O
factor NOUN - O
receptor NOUN - O
protein NOUN - O
expression NOUN - O
in ADP - O
hepatocytes NOUN - O
. PUNCT - O

After ADP - O
70 CD - B-PERCENT
% NN - I-PERCENT
hepatectomy NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
pretreatment NOUN - O
ameliorated VERB - O
liver NOUN - O
injury NOUN - O
and CCONJ - O
significantly ADV - O
accelerated VERB - O
mitotic ADJ - O
rates NOUN - O
of ADP - O
hepatocytes NOUN - O
in ADP - O
obese ADJ - O
mice NOUN - O
. PUNCT - O

Recovery NOUN - O
of ADP - O
liver NOUN - O
mass NOUN - O
was VERB - O
accelerated VERB - O
in ADP - O
obese ADJ - O
mice NOUN - O
pretreated VERB - O
with ADP - O
meloxicam NN - B-MEDICINE
( PUNCT - O
by ADP - O
26 CD - B-PERCENT
% NN - I-PERCENT
at ADP - O
24 CD - B-TIME
hours NNS - I-TIME
and CCONJ - O
38 CD - B-PERCENT
% NN - I-PERCENT
at ADP - O
48 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

After ADP - O
80 CD - B-PERCENT
% NN - I-PERCENT
hepatectomy NOUN - O
, PUNCT - O
survival NOUN - O
was VERB - O
dramatically ADV - O
increased VERB - O
with ADP - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
objective NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
effect NOUN - O
of ADP - O
castration NOUN - O
timing NOUN - O
, PUNCT - O
method NOUN - O
, PUNCT - O
and CCONJ - O
use NOUN - O
of ADP - O
the DET - O
analgesic ADJ - O
meloxicam NN - B-MEDICINE
( PUNCT - O
MEL NNP - B-ORG
) PUNCT - O
on ADP - O
inflammation NOUN - O
, PUNCT - O
behavior NOUN - O
, PUNCT - O
performance NOUN - O
, PUNCT - O
and CCONJ - O
carcass NOUN - O
traits NOUN - O
in ADP - O
feedlot NOUN - O
cattle NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

They PRON - O
were VERB - O
admitted VERB - O
( PUNCT - O
day NOUN - O
0 NUM - O
) PUNCT - O
and CCONJ - O
underwent VERB - O
oral ADJ - O
examination NOUN - O
/ SYM - O
radiographs NOUN - O
/ SYM - O
treatment NOUN - O
under ADP - O
general ADJ - O
anesthesia NOUN - O
( PUNCT - O
day NN - B-DATE
1 CD - I-DATE
; PUNCT - O
acepromazine ADJ - O
- PUNCT - O
hydromorphone NOUN - O
- PUNCT - O
propofol NOUN - O
- PUNCT - O
isoflurane NOUN - O
- PUNCT - O
meloxicam NN - B-MEDICINE
- PUNCT - O
local ADJ - O
anesthetic ADJ - O
blocks NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluating VERB - O
bioequivalence NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
tablets NOUN - O
: PUNCT - O
is VERB - O
in ADP - O
- PUNCT - O
vitro X - O
dissolution NOUN - O
test NOUN - O
overdiscriminating VERB - O
? PUNCT - O

-DOCSTART- -X- - O

There ADV - O
are VERB - O
limited ADJ - O
studies NOUN - O
assessing VERB - O
the DET - O
risk NOUN - O
of ADP - O
MI NNP - B-ORG
associated VERB - O
with ADP - O
meloxicam NN - B-MEDICINE
, PUNCT - O
an DET - O
increasingly ADV - O
popular ADJ - O
drug NOUN - O
with ADP - O
COX-2 NNP - B-ORG
inhibiting VERB - O
properties NOUN - O
. PUNCT - O

Current ADJ - O
users NOUN - O
were VERB - O
further ADV - O
classified VERB - O
as ADP - O
naproxen NOUN - O
( PUNCT - O
negative ADJ - O
control NOUN - O
) PUNCT - O
, PUNCT - O
diclofenac NOUN - O
( PUNCT - O
positive ADJ - O
control NOUN - O
) PUNCT - O
, PUNCT - O
meloxicam NN - B-MEDICINE
or CCONJ - O
other ADJ - O
NSAID NNP - B-ORG
users NOUN - O
. PUNCT - O

The DET - O
adjusted ADJ - O
odds NOUN - O
ratio NOUN - O
of ADP - O
MI NNP - B-ORG
for ADP - O
current ADJ - O
user NOUN - O
compared VERB - O
to ADP - O
remote ADJ - O
users NOUN - O
were VERB - O
: PUNCT - O
meloxicam VB - B-MEDICINE
1.38 CD - B-CARDINAL
( PUNCT - O
1.17 CD - B-CARDINAL
- SYM - I-CARDINAL
1.63 CD - I-CARDINAL
) PUNCT - O
, PUNCT - O
naproxen NOUN - O
1.12 CD - B-CARDINAL
( PUNCT - O
0.96 CD - B-CARDINAL
- SYM - O
1.30 NUM - O
) PUNCT - O
and CCONJ - O
diclofenac NOUN - O
1.37 NUM - O
( PUNCT - O
1.25 CD - B-CARDINAL
- SYM - O
1.50 NUM - O
) PUNCT - O
. PUNCT - O

In ADP - O
this DET - O
large ADJ - O
population NOUN - O
- PUNCT - O
based VERB - O
study NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
increased VERB - O
the DET - O
risk NOUN - O
of ADP - O
MI NNP - B-ORG
by ADP - O
38 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

Forced ADJ - O
and CCONJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
degradation NOUN - O
assays NOUN - O
of ADP - O
tenoxicam NOUN - O
, PUNCT - O
piroxicam VERB - O
and CCONJ - O
meloxicam VB - B-MEDICINE
in ADP - O
river NOUN - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative ADJ - O
population NOUN - O
pharmacokinetics NOUN - O
and CCONJ - O
absolute ADJ - O
oral ADJ - O
bioavailability NOUN - O
of ADP - O
COX-2 NNP - B-ORG
selective ADJ - O
inhibitors NOUN - O
celecoxib VERB - O
, PUNCT - O
mavacoxib VERB - O
and CCONJ - O
meloxicam NN - B-MEDICINE
in ADP - O
cockatiels NOUN - O
( PUNCT - O
Nymphicus NNP - B-PERSON
hollandicus NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aims NOUN - O
of ADP - O
the DET - O
investigation NOUN - O
were VERB - O
to PART - O
establish VERB - O
for ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
( PUNCT - O
i PUNCT - O
) PUNCT - O
clinical ADJ - O
efficacy NOUN - O
and CCONJ - O
( PUNCT - O
ii ADJ - O
) PUNCT - O
pharmacokinetic ADJ - O
profile NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
intravenously ADV - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
administered VERB - O
in ADP - O
male ADJ - O
Mediterranean NNP - B-LOC
buffalo NOUN - O
calves NOUN - O
after ADP - O
surgical ADJ - O
orchiectomy NOUN - O
. PUNCT - O

of ADP - O
meloxicam NN - B-MEDICINE
was VERB - O
administered VERB - O
in ADP - O
six CD - B-CARDINAL
calves NOUN - O
( PUNCT - O
treated VERB - O
group NOUN - O
, PUNCT - O
TG PROPN - O
) PUNCT - O
immediately ADV - O
after ADP - O
surgery NOUN - O
; PUNCT - O
the DET - O
other ADJ - O
four CD - B-CARDINAL
animals NOUN - O
were VERB - O
used VERB - O
as ADP - O
untreated ADJ - O
control NOUN - O
group NOUN - O
( PUNCT - O
CG PROPN - O
) PUNCT - O
. PUNCT - O

The DET - O
clinical ADJ - O
efficacy NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
was VERB - O
evaluated VERB - O
pre- ADJ - O
and CCONJ - O
post NOUN - O
- ADJ - O
surgery NOUN - O
by ADP - O
monitoring VERB - O
respiratory ADJ - O
rate NOUN - O
( PUNCT - O
RR NNP - B-ORG
) PUNCT - O
, PUNCT - O
heart NOUN - O
rate NOUN - O
( PUNCT - O
HR PROPN - O
) PUNCT - O
, PUNCT - O
rectal ADJ - O
temperature NOUN - O
( PUNCT - O
T NOUN - O
° PROPN - O
C PROPN - O
) PUNCT - O
, PUNCT - O
serum NOUN - O
cortisol ADJ - O
levels NOUN - O
( PUNCT - O
SCL NNP - B-ORG
) PUNCT - O
and CCONJ - O
pain NOUN - O
score NOUN - O
( PUNCT - O
PS NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
pharmacokinetic ADJ - O
profile NOUN - O
was VERB - O
best ADV - O
fitted VERB - O
by ADP - O
a DET - O
two CD - B-CARDINAL
- PUNCT - O
compartmental NOUN - O
model NOUN - O
and CCONJ - O
characterized VERB - O
by ADP - O
a DET - O
fast ADJ - O
distribution NOUN - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
and CCONJ - O
slow ADJ - O
elimination NOUN - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
( PUNCT - O
0.09 CD - B-CARDINAL
± PUNCT - O
0.06 CD - B-CARDINAL
h NOUN - O
and CCONJ - O
21.51 CD - B-CARDINAL
± PUNCT - O
6.4 CD - B-CARDINAL
h NUM - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
and CCONJ - O
meloxicam JJ - B-MEDICINE
mean VERB - O
concentrations NOUN - O
at ADP - O
96 CD - B-CARDINAL
h NOUN - O
was VERB - O
of ADP - O
0.18 CD - B-CARDINAL
± NUM - O

The DET - O
IV NNP - B-ORG
administration NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
buffalo ADJ - O
calves NOUN - O
shows VERB - O
encouraging ADJ - O
effects NOUN - O
represented VERB - O
by ADP - O
significant ADJ - O
and CCONJ - O
prolonged ADJ - O
analgesic ADJ - O
effects NOUN - O
, PUNCT - O
significant ADJ - O
reduction NOUN - O
of ADP - O
SCL NNP - B-ORG
as ADV - O
well ADV - O
as ADP - O
similar ADJ - O
pharmacokinetic ADJ - O
profile NOUN - O
to ADP - O
bovine ADJ - O
calves NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
efficacy NOUN - O
and CCONJ - O
pharmacokinetics NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
Mediterranean NNP - B-LOC
buffalo NOUN - O
calves NOUN - O
( PUNCT - O
Bubalus NOUN - O
bubalis NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
the DET - O
effects NOUN - O
of ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
meloxicam NN - B-MEDICINE
treatment NOUN - O
on ADP - O
growing VERB - O
pigs NOUN - O
were VERB - O
studied VERB - O
. PUNCT - O

Twelve CD - B-CARDINAL
piglets NOUN - O
( PUNCT - O
n=6 NOUN - O
receiving VERB - O
daily JJ - B-DATE
meloxicam NN - B-MEDICINE
0.4 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg VERB - O
orally ADV - O
from ADP - O
48 CD - B-CARDINAL
until ADP - O
110 CD - B-DATE
days NNS - I-DATE
of IN - I-DATE
age NN - I-DATE
; PUNCT - O
n=6 NOUN - O
receiving VERB - O
only ADV - O
applesauce NOUN - O
( PUNCT - O
vehicle NOUN - O
control NOUN - O
) PUNCT - O
) PUNCT - O
were VERB - O
subjected VERB - O
to ADP - O
visual ADJ - O
and CCONJ - O
objective ADJ - O
gait ADJ - O
analysis NOUN - O
by ADP - O
pressure NOUN - O
plate NOUN - O
measurements NOUN - O
at ADP - O
several ADJ - O
time NOUN - O
points NOUN - O
. PUNCT - O

The DET - O
findings NOUN - O
of ADP - O
this DET - O
in ADP - O
vivo NOUN - O
study VERB - O
reduce NOUN - O
concerns NOUN - O
regarding VERB - O
the DET - O
long ADJ - O
- PUNCT - O
term NOUN - O
use NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
young ADJ - O
, PUNCT - O
growing VERB - O
piglets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
determine VERB - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
domestic ADJ - O
hens NOUN - O
and CCONJ - O
duration NOUN - O
and CCONJ - O
quantity NOUN - O
of ADP - O
drug NOUN - O
residues NOUN - O
in ADP - O
their ADJ - O
eggs NOUN - O
following VERB - O
PO NN - B-ORG
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
( PUNCT - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
meloxicam NN - B-MEDICINE
/ SYM - O
kg NOUN - O
) PUNCT - O
. PUNCT - O

PROCEDURES NNP - B-PERSON
Hens NNPS - I-PERSON
were VERB - O
administered VERB - O
1 CD - B-QUANTITY
mg PRP - I-QUANTITY
of ADP - O
meloxicam NN - B-MEDICINE
/ SYM - O
kg NOUN - O
PO NOUN - O
once ADV - O
. PUNCT - O

The DET - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
, PUNCT - O
maximum ADJ - O
concentration NOUN - O
, PUNCT - O
and CCONJ - O
time NOUN - O
to ADP - O
maximum ADJ - O
concentration NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
plasma NOUN - O
samples NOUN - O
were VERB - O
2.8 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
7.21 CD - B-QUANTITY
μg NNP - I-QUANTITY
/ NFP - I-QUANTITY
mL NNP - I-QUANTITY
, PUNCT - O
and CCONJ - O
2 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
respectively ADV - O
. PUNCT - O

Following VERB - O
meloxicam NN - B-MEDICINE
administration NOUN - O
, PUNCT - O
the DET - O
drug NOUN - O
was VERB - O
not ADV - O
detected VERB - O
after ADP - O
4 CD - B-DATE
days NNS - I-DATE
in ADP - O
egg NOUN - O
whites NOUN - O
and CCONJ - O
after ADP - O
8 CD - B-DATE
days NNS - I-DATE
in ADP - O
egg NOUN - O
yolks NOUN - O
. PUNCT - O

CONCLUSIONS NOUN - O
AND CCONJ - O
CLINICAL PROPN - O
RELEVANCE PROPN - O
Results NOUN - O
indicated VERB - O
that ADP - O
meloxicam NN - B-MEDICINE
administered VERB - O
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg IN - I-QUANTITY
PO NN - I-QUANTITY
in ADP - O
chickens NOUN - O
appears VERB - O
to PART - O
maintain VERB - O
plasma NOUN - O
concentrations NOUN - O
equivalent ADJ - O
to ADP - O
those DET - O
reported VERB - O
to PART - O
be VERB - O
therapeutic ADJ - O
for ADP - O
humans NOUN - O
for ADP - O
12 CD - B-TIME
hours NNS - I-TIME
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
and CCONJ - O
egg NOUN - O
residues NOUN - O
after ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
in ADP - O
domestic ADJ - O
chickens NOUN - O
( PUNCT - O
Gallus PROPN - O
domesticus PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
mitigating NOUN - O
effects NOUN - O
of ADP - O
administration NOUN - O
of ADP - O
local ADJ - O
anaesthetic ADJ - O
or CCONJ - O
systemic ADJ - O
meloxicam NN - B-MEDICINE
on ADP - O
the DET - O
electroencephalographic ADJ - O
( PUNCT - O
EEG NNP - B-ORG
) PUNCT - O
and CCONJ - O
cardiovascular ADJ - O
responses NOUN - O
during ADP - O
surgical ADJ - O
castration NOUN - O
of ADP - O
Bos NNP - B-PERSON
indicus NOUN - O
bull NOUN - O
calves NOUN - O
. PUNCT - O

Animals NOUN - O
were VERB - O
allocated VERB - O
randomly ADV - O
to ADP - O
three CD - B-CARDINAL
groups NOUN - O
of ADP - O
12 CD - B-CARDINAL
( PUNCT - O
group NOUN - O
L NNP - B-ORG
, PUNCT - O
260 CD - B-CARDINAL
mg NOUN - O
of ADP - O
2 CD - B-PERCENT
% NN - I-PERCENT
lidocaine NOUN - O
subcutaneously ADV - O
and CCONJ - O
intratesticularly ADV - O
5 CD - B-TIME
minutes NNS - I-TIME
prior ADV - O
to ADP - O
castration NOUN - O
; PUNCT - O
group NOUN - O
M PROPN - O
, PUNCT - O
0.5 CD - B-CARDINAL
mg NOUN - O
kg-1 NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
subcutaneously ADV - O
30 CD - B-TIME
minutes NNS - I-TIME
prior ADV - O
to ADP - O
castration NOUN - O
; PUNCT - O
group NOUN - O
C NOUN - O
, PUNCT - O
no DET - O
preoperative ADJ - O
analgesia NOUN - O
administered VERB - O
) PUNCT - O
. PUNCT - O

Lidocaine NOUN - O
and CCONJ - O
meloxicam NN - B-MEDICINE
administered VERB - O
prior ADV - O
to ADP - O
castration NOUN - O
attenuated VERB - O
these DET - O
responses NOUN - O
in ADP - O
Bos NNP - B-GPE
indicus NOUN - O
bull NOUN - O
calves NOUN - O
. PUNCT - O

These DET - O
findings NOUN - O
provide VERB - O
support NOUN - O
for ADP - O
the DET - O
preoperative ADJ - O
administration NOUN - O
of ADP - O
lidocaine NOUN - O
and CCONJ - O
potentially ADV - O
meloxicam JJ - B-MEDICINE
for ADP - O
castration NOUN - O
in ADP - O
Bos NNP - B-GPE
indicus NOUN - O
bull NOUN - O
calves NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
variety NOUN - O
of ADP - O
medications NOUN - O
was VERB - O
used VERB - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
, PUNCT - O
including VERB - O
gabapentin NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
6 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
meloxicam NN - B-MEDICINE
( PUNCT - O
n NOUN - O
= SYM - O
4 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
antibiotics NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
4 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
phenobarbital NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
prednisolone NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
topiramate NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
; PUNCT - O
ciclosporin NOUN - O
, PUNCT - O
clomipramine NOUN - O
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
amitriptyline ADJ - O
and CCONJ - O
tramadol NOUN - O
were VERB - O
used VERB - O
in ADP - O
one CD - B-CARDINAL
cat NOUN - O
each DET - O
. PUNCT - O

Clinical ADJ - O
improvement NOUN - O
was VERB - O
achieved VERB - O
in ADP - O
six CD - B-CARDINAL
cases NOUN - O
; PUNCT - O
in ADP - O
five CD - B-CARDINAL
cats NOUN - O
complete ADJ - O
remission NOUN - O
of ADP - O
clinical ADJ - O
signs NOUN - O
was VERB - O
achieved VERB - O
with ADP - O
gabapentin NOUN - O
alone ADV - O
( PUNCT - O
n VERB - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
a DET - O
combination NOUN - O
of ADP - O
gabapentin NOUN - O
/ SYM - O
ciclosporin NOUN - O
/ SYM - O
amitriptyline NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
1 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
gabapentin NOUN - O
/ SYM - O
prednisolone NOUN - O
/ SYM - O
phenobarbital NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
1 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
gabapentin NOUN - O
/ SYM - O
topiramate NOUN - O
/ SYM - O
meloxicam NN - B-MEDICINE
( PUNCT - O
n NOUN - O
= SYM - O
1 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
observed VERB - O
about RB - B-PERCENT
25 CD - I-PERCENT
% NN - I-PERCENT
lower ADJ - O
VT NNP - B-GPE
values NOUN - O
in ADP - O
blocking VERB - O
studies NOUN - O
with ADP - O
meloxicam NN - B-MEDICINE
, PUNCT - O
a DET - O
nonselective JJ - B-CARDINAL
COX-2 NNP - B-ORG
inhibitor NOUN - O
, PUNCT - O
compared VERB - O
to PART - O
baseline VERB - O
[ PUNCT - O
11C]TMI CD - B-CARDINAL
binding VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
situation NOUN - O
changed VERB - O
dramatically ADV - O
after ADP - O
addition NOUN - O
to ADP - O
ongoing ADJ - O
therapy NOUN - O
because ADP - O
of ADP - O
exacerbation NOUN - O
of ADP - O
chronic ADJ - O
osteochondrosis NOUN - O
of ADP - O
ketoprofen NOUN - O
100 CD - B-CARDINAL
, PUNCT - O
meloxicam VBP - B-MEDICINE
15 CD - B-CARDINAL
and CCONJ - O
tolperisone NOUN - O
( PUNCT - O
Mydocalm NNP - B-ORG
) PUNCT - O
450 CD - B-DATE
mg CD - I-DATE
/ SYM - I-DATE
day NN - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

; PUNCT - O
p<0.001 PROPN - O
) PUNCT - O
, PUNCT - O
ibuprofen PROPN - O
( PUNCT - O
RR=1.24 NNP - B-ORG
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
CI NNP - B-CARDINAL
1.03 CD - I-CARDINAL
to IN - I-CARDINAL
1.48 CD - I-CARDINAL
; PUNCT - O
p=0.02 NOUN - O
) PUNCT - O
, PUNCT - O
diclofenac NOUN - O
sodium NOUN - O
( PUNCT - O
RR=1.44 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
CI NNP - B-CARDINAL
1.24 CD - I-CARDINAL
to ADP - O
1.67 CD - B-CARDINAL
; PUNCT - O
p<0.001 NOUN - O
) PUNCT - O
and CCONJ - O
meloxicam NN - B-MEDICINE
( PUNCT - O
RR=1.16 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
CI NNP - B-MONEY
1.03 CD - I-MONEY
to IN - I-MONEY
1.31 CD - I-MONEY
; PUNCT - O
p=0.01 NOUN - O
) PUNCT - O
. PUNCT - O

Acupuncture PROPN - O
showed VERB - O
a DET - O
more ADV - O
favourable ADJ - O
effect NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
LDH NNP - B-ORG
than ADP - O
lumbar ADJ - O
traction NOUN - O
, PUNCT - O
ibuprofen NOUN - O
, PUNCT - O
diclofenac NOUN - O
sodium NOUN - O
, PUNCT - O
meloxicam NN - B-MEDICINE
, PUNCT - O
mannitol NOUN - O
plus CCONJ - O
dexamethasone NOUN - O
and CCONJ - O
mecobalamin NOUN - O
, PUNCT - O
fugui ADJ - O
gutong NOUN - O
capsule NOUN - O
plus CCONJ - O
ibuprofen ADJ - O
, PUNCT - O
mannitol NOUN - O
plus ADJ - O
dexamethasone NOUN - O
, PUNCT - O
loxoprofen ADJ - O
and CCONJ - O
huoxue NOUN - O
zhitong NOUN - O
decoction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Under ADP - O
the DET - O
optimal ADJ - O
conditions NOUN - O
, PUNCT - O
the DET - O
linear ADJ - O
ranges NOUN - O
were VERB - O
0.1 CD - B-CARDINAL
- SYM - I-CARDINAL
10 CD - I-CARDINAL
  SPACE - O
µg ADP - O
  SPACE - O
L-1 PROPN - O
for ADP - O
meloxicam NN - B-MEDICINE
, PUNCT - O
carprofen NOUN - O
, PUNCT - O
indometacin NOUN - O
, PUNCT - O
and CCONJ - O
tolfenamic ADJ - O
acid NOUN - O
, PUNCT - O
0.2 CD - B-CARDINAL
- SYM - I-CARDINAL
20 CD - I-CARDINAL
  SPACE - O
µg ADP - O
  SPACE - O
L-1 PROPN - O
for ADP - O
diclofenac NOUN - O
, PUNCT - O
and CCONJ - O
0.3 CD - B-CARDINAL
- SYM - I-CARDINAL
30 CD - I-CARDINAL
  SPACE - O
µg ADP - O
  SPACE - O
L-1 PROPN - O
for ADP - O
naproxen NOUN - O
and CCONJ - O
mefenamic ADJ - O
acid NOUN - O
with ADP - O
the DET - O
regression NOUN - O
coefficients NOUN - O
( PUNCT - O
r NOUN - O
) PUNCT - O
from ADP - O
0.9987 CD - B-CARDINAL
to ADP - O
0.9995 CD - B-CARDINAL
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
was VERB - O
designed VERB - O
to PART - O
observe VERB - O
the DET - O
protective ADJ - O
effect NOUN - O
and CCONJ - O
mechanisms NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
on ADP - O
liver NOUN - O
injury NOUN - O
caused VERB - O
by ADP - O
chronic ADJ - O
aluminium NOUN - O
exposure NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

The DET - O
administration NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
significantly ADV - O
improved VERB - O
the DET - O
impairment NOUN - O
of ADP - O
liver NOUN - O
. PUNCT - O

The DET - O
contents NOUN - O
of ADP - O
prostaglandin NOUN - O
E2 NOUN - O
and CCONJ - O
cyclic ADJ - O
adenosine NOUN - O
monophosphate NOUN - O
were VERB - O
significantly ADV - O
decreased VERB - O
by ADP - O
administration NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
. PUNCT - O

The DET - O
administration NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
also ADV - O
significantly ADV - O
decreased VERB - O
the DET - O
expressions NOUN - O
of ADP - O
cyclooxygenases-2 NN - B-ORG
and CCONJ - O
protein NOUN - O
kinase NOUN - O
A NOUN - O
and CCONJ - O
the DET - O
levels NOUN - O
of ADP - O
inflammation NOUN - O
and CCONJ - O
oxidative NOUN - O
stress NOUN - O
, PUNCT - O
while ADP - O
significantly ADV - O
increased VERB - O
the DET - O
EP1,2,3,4 NNP - B-ORG
expressions NOUN - O
in ADP - O
rat NOUN - O
liver NOUN - O
. PUNCT - O

The DET - O
protective ADJ - O
mechanism NOUN - O
of ADP - O
meloxicam NN - B-MEDICINE
on ADP - O
aluminium NOUN - O
- PUNCT - O
overload NOUN - O
liver NOUN - O
injury NOUN - O
is VERB - O
attributed VERB - O
to PART - O
reconstruct VERB - O
the DET - O
balance NOUN - O
of ADP - O
cyclooxygenases-2 JJ - B-ORG
and CCONJ - O
downstream NOUN - O
prostaglandin NOUN - O
E2 NNP - B-PRODUCT
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
dexamethasone NOUN - O
and CCONJ - O
meloxicam NN - B-MEDICINE
on ADP - O
Borrelia NNP - B-GPE
burgdorferi NOUN - O
- PUNCT - O
induced VERB - O
inflammation NOUN - O
in ADP - O
glial ADJ - O
and CCONJ - O
neuronal ADJ - O
cells NOUN - O
of ADP - O
the DET - O
central ADJ - O
nervous ADJ - O
system NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
extended VERB - O
this DET - O
line NOUN - O
of ADP - O
research NOUN - O
to ADP - O
Nicotrol NNP - B-MEDICINE
nasal NOUN - O
spray NOUN - O
, PUNCT - O
to PART - O
determine VERB - O
whether ADP - O
formulation NOUN - O
( PUNCT - O
spray NOUN - O
vs. X - O
smoking NOUN - O
) PUNCT - O
alters VERB - O
responses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
a DET - O
result NOUN - O
of ADP - O
this DET - O
collaborative ADJ - O
effort NOUN - O
, PUNCT - O
approximately RB - B-CARDINAL
19,000 CD - I-CARDINAL
women NOUN - O
received VERB - O
a DET - O
6-week NUM - O
course NOUN - O
of ADP - O
Nicotrol NNP - B-MEDICINE
Patches NNPS - I-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
between ADP - O
- PUNCT - O
subject NOUN - O
, PUNCT - O
2 CD - B-CARDINAL
x SYM - O
2 CD - B-CARDINAL
factorial ADJ - O
design NOUN - O
was VERB - O
used VERB - O
, PUNCT - O
with ADP - O
the DET - O
daily JJ - B-DATE
administration NOUN - O
of ADP - O
a DET - O
15-mg CD - B-DATE
nicotine NOUN - O
patch NOUN - O
( PUNCT - O
Nicotrol NNP - B-MEDICINE
) PUNCT - O
versus ADP - O
placebo NOUN - O
patch NOUN - O
as ADP - O
one CD - B-CARDINAL
factor NOUN - O
and CCONJ - O
80 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
oral ADJ - O
cotinine VERB - O
fumarate ADJ - O
versus ADP - O
placebo NOUN - O
drug NOUN - O
as ADP - O
the DET - O
other ADJ - O
factor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

TEN CD - B-CARDINAL
YEARS NNS - I-CARDINAL
OF IN - I-CARDINAL
FENTANYL JJ - I-MEDICINE
- HYPH - I-CARDINAL
LIKE JJ - I-CARDINAL
DRUGS NNS - I-CARDINAL
: : - I-CARDINAL

-DOCSTART- -X- - O

The DT - B-ORG
Thymectomy NNP - I-ORG
Trial NNP - I-ORG
in ADP - O
Non PROPN - O
- ADJ - O
Thymomatous ADJ - O
Myasthenia PROPN - O
Gravis PROPN - O
Patients PROPN - O
Receiving VERB - O
Prednisone NNP - B-MEDICINE
( PUNCT - O
MGTX NNP - B-ORG
) PUNCT - O
showed VERB - O
that ADP - O
thymectomy NOUN - O
combined VERB - O
with ADP - O
prednisone NN - B-MEDICINE
was VERB - O
superior ADJ - O
to PART - O
prednisone VB - B-MEDICINE
alone ADV - O
in ADP - O
improving VERB - O
clinical ADJ - O
status NOUN - O
as ADP - O
measured VERB - O
by ADP - O
the DET - O
Quantitative PROPN - O
Myasthenia PROPN - O
Gravis PROPN - O
( PUNCT - O
QMG PROPN - O
) PUNCT - O
score VERB - O
in ADP - O
patients NOUN - O
with ADP - O
generalised ADJ - O
non ADJ - O
- ADJ - O
thymomatous ADJ - O
myasthenia ADJ - O
gravis NOUN - O
at ADP - O
3 CD - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Prednisone NN - B-MEDICINE
for ADP - O
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Paradoxical NNP - I-ORG
Tuberculosis NNP - I-ORG
- HYPH - I-ORG
Associated VBN - I-ORG
IRIS NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
found VERB - O
data NOUN - O
from ADP - O
trials NOUN - O
for ADP - O
the DET - O
following VERB - O
compounds NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
oral ADJ - O
suspension NOUN - O
( PUNCT - O
MEROS PROPN - O
; PUNCT - O
NWP06 NNP - B-GPE
, PUNCT - O
Quillivant NNP - B-MEDICINE
™ PROPN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
chewable ADJ - O
capsules NOUN - O
( PUNCT - O
NWP09 NNP - B-ORG
, PUNCT - O
QuilliChew NNP - B-ORG
ER NNP - I-ORG
™ NNP - I-ORG
) PUNCT - O
; PUNCT - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
methylphenidate ADJ - O
hydrochloride NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
capsules NOUN - O
( PUNCT - O
Aptensio NNP - B-ORG
XR NNP - I-ORG
™ NNP - I-ORG
) PUNCT - O
; PUNCT - O
( PUNCT - O
4 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
orally ADV - O
disintegrating VERB - O
tablets NOUN - O
( PUNCT - O
XR NNP - B-ORG
- HYPH - I-ORG
ODT NNP - I-ORG
; PUNCT - O
NT-0102 NNP - B-PRODUCT
, PUNCT - O
Cotempla PROPN - O
™ PROPN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
5 LS - B-CARDINAL
) PUNCT - O
ORADUR NNP - B-ORG
technology NOUN - O
( PUNCT - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
tamper NOUN - O
- PUNCT - O
resistant ADJ - O
formulation NOUN - O
) PUNCT - O
methylphenidate NOUN - O
sustained VERB - O
release NOUN - O
( PUNCT - O
SR PROPN - O
) PUNCT - O
; PUNCT - O
and CCONJ - O
( PUNCT - O
6 CD - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
modified VERB - O
- PUNCT - O
release NOUN - O
( PUNCT - O
HLD-200 PROPN - O
; PUNCT - O
Bejorna NNP - B-ORG
™ NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Methylphenidate PROPN - O
hydrochloride NOUN - O
for ADP - O
extended VERB - O
- PUNCT - O
release NOUN - O
oral ADJ - O
suspension NOUN - O
( PUNCT - O
MEROS PROPN - O
or CCONJ - O
Quillivant(TM PROPN - O
) PUNCT - O
XR PROPN - O
) PUNCT - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
long ADV - O
- PUNCT - O
acting VERB - O
MPH NNP - B-ORG
- PUNCT - O
ER PROPN - O
oral ADJ - O
suspension NOUN - O
developed VERB - O
to PART - O
treat VERB - O
attention NOUN - O
- PUNCT - O
deficit NOUN - O
/ SYM - O
hyperactivity NOUN - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study VERB - O
on ADP - O
the DET - O
In PROPN - O
Vitro PROPN - O
and CCONJ - O
In ADP - O
Vivo PROPN - O
Antibacterial NNP - B-MEDICINE
Activity PROPN - O
and CCONJ - O
Biocompatibility PROPN - O
of ADP - O
Novel PROPN - O
TiN PROPN - O
/ SYM - O

-DOCSTART- -X- - O

After ADP - O
Antibacterial NNP - B-MEDICINE
Treatment PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
and CCONJ - O
anticorrosive ADJ - O
properties NOUN - O
of ADP - O
CuZnO@RGO NNP - B-ORG
waterborne NOUN - O
polyurethane NOUN - O
coating NOUN - O
in ADP - O
circulating VERB - O
cooling VERB - O
water NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Nutrient PROPN - O
Media PROPN - O
on ADP - O
Antibacterial NNP - B-MEDICINE
Activity NNP - I-ORG
of IN - I-ORG
Silver NNP - I-ORG
Nanoparticles NNP - I-ORG
Synthesized NNP - I-ORG
Using VBG - I-ORG
Neolamarckia NN - I-ORG
cadamba NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
effects NOUN - O
of ADP - O
prepared ADJ - O
Ag NNP - B-PERSON
- HYPH - I-PERSON
thymol NNP - I-PERSON
( PUNCT - O
ATNPs NOUN - O
) PUNCT - O
, PUNCT - O
Ag PROPN - O
- PUNCT - O
usnic ADJ - O
acid NOUN - O
( PUNCT - O
AUNPs PROPN - O
) PUNCT - O
, PUNCT - O
Cu PROPN - O
- PUNCT - O
thymol PROPN - O
( PUNCT - O
CTNPs PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Cu PROPN - O
- PUNCT - O
usnic ADJ - O
acid NOUN - O
( PUNCT - O
CUNPs PROPN - O
) PUNCT - O
on ADP - O
multi ADJ - O
drug NOUN - O
resistant ADJ - O
( PUNCT - O
MDR NNP - B-ORG
) PUNCT - O
bacteria NOUN - O
including VERB - O
methicillin NOUN - O
- PUNCT - O
resistant ADJ - O
Staphylococcus NNP - B-ORG
aureus NOUN - O
( PUNCT - O
MRSA NNP - B-ORG
) PUNCT - O
( PUNCT - O
gram NOUN - O
positive ADJ - O
) PUNCT - O
, PUNCT - O
Acinetobacter NOUN - O
baumannii NOUN - O
( PUNCT - O
A52 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Klebsiella NNP - B-PERSON
pneumonia PROPN - O
( PUNCT - O
K38 PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Antibacterial NNP - B-MEDICINE
Activities NNPS - I-ORG
of IN - I-ORG
Crude JJ - I-ORG
Secondary JJ - I-ORG
Metabolite NN - I-ORG
Extracts NNS - I-ORG
from ADP - O
Pantoea ADJ - O
Species PROPN - O
Obtained VERB - O
from ADP - O
the DET - O
Stem PROPN - O
of ADP - O
Solanum NNP - B-NORP
mauritianum NOUN - O
and CCONJ - O
Their ADJ - O
Effects NOUN - O
on ADP - O
Two CD - B-CARDINAL
Cancer PROPN - O
Cell PROPN - O
Lines PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Promising PROPN - O
Recent PROPN - O
Strategies PROPN - O
with ADP - O
Potential NNP - B-ORG
Clinical NNP - I-ORG
Translational NNP - I-ORG
Value NNP - I-ORG
to ADP - O
Combat PROPN - O
Antibacterial NNP - B-MEDICINE
Resistant PROPN - O
Surge PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Electrospun NNP - B-PERSON
Polyvinyl NNP - I-PERSON
Alcohol NNP - I-PERSON
/ SYM - O
d PROPN - O
- PUNCT - O
Limonene ADJ - O
Fibers PROPN - O
Prepared VERB - O
by ADP - O
Ultrasonic NNP - B-ORG
Processing NNP - I-ORG
for ADP - O
Antibacterial NNP - B-MEDICINE
Active NNP - I-ORG
Packaging NNP - I-ORG
Material NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
activity NOUN - O
of ADP - O
indolyl NOUN - O
- PUNCT - O
quinolinium NOUN - O
derivatives NOUN - O
and CCONJ - O
study VERB - O
their ADJ - O
mode NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
coatings NOUN - O
that ADJ - O
eliminate VERB - O
initial ADJ - O
bacterial ADJ - O
attachment NOUN - O
and CCONJ - O
prevent VERB - O
subsequent ADJ - O
biofilm NOUN - O
formation NOUN - O
are VERB - O
essential ADJ - O
in ADP - O
a DET - O
number NOUN - O
of ADP - O
applications NOUN - O
, PUNCT - O
especially ADV - O
implanted VERB - O
medical ADJ - O
devices NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Antibacterial NNP - B-MEDICINE
- PUNCT - O
Producing VERB - O
Endophytic PROPN - O
Fungi PROPN - O
of ADP - O
Syzygiumpolyanthum PROPN - O
Leaves PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
activity NOUN - O
of ADP - O
recombinant ADJ - O
buffalo NOUN - O
Lf PROPN - O
N PROPN - O
- PUNCT - O
lobe NOUN - O
was VERB - O
assessed VERB - O
on ADP - O
pathogenic ADJ - O
E. PROPN - O
coli NOUN - O
and CCONJ - O
Staphylococcus NNP - B-PERSON
aureus NOUN - O
strains NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Basic PROPN - O
Antibacterial NNP - B-MEDICINE
Assay PROPN - O
to ADP - O
Screen NOUN - O
for ADP - O
Bacteriocinogenic PROPN - O
Lactic PROPN - O
Acid NNP - B-PERSON
Bacteria NNP - I-PERSON
and CCONJ - O
to PART - O
Elementarily NNP - B-PERSON
Characterize NNP - I-PERSON
Their PRP$ - I-PERSON
Bacteriocins NNS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
efficiency NOUN - O
against ADP - O
Staphylococcus NNP - B-ORG
aureus NOUN - O
and CCONJ - O
Escherichia NNP - B-PRODUCT
coli ADJ - O
was VERB - O
successfully ADV - O
demonstrated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Intrinsic NNP - B-ORG
Antibacterial NNP - I-MEDICINE
Activity NNP - I-ORG
of IN - I-ORG
Nanoparticles NNPS - I-ORG
Made VBN - I-ORG
of ADP - O
β PROPN - O
- PUNCT - O
Cyclodextrins PROPN - O
Potentiates PROPN - O
Their ADJ - O
Effect NOUN - O
as ADP - O
Drug PROPN - O
Nanocarriers PROPN - O
Against PROPN - O
Tuberculosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sequence NOUN - O
and CCONJ - O
Dispersity PROPN - O
are VERB - O
Determinants NOUN - O
of ADP - O
Photodynamic PROPN - O
Antibacterial NNP - B-MEDICINE
Activity PROPN - O
Exerted VERB - O
by ADP - O
Peptidomimetic PROPN - O
Oligo(thiophene)s PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
silico ADJ - O
appraisal NOUN - O
, PUNCT - O
Synthesis NNP - B-GPE
, PUNCT - O
Antibacterial NNP - B-MEDICINE
screening NOUN - O
and CCONJ - O
DNA NOUN - O
cleavage NOUN - O
for ADP - O
1,2,5-thiadiazole CD - B-CARDINAL
derivative NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial JJ - B-MEDICINE
metabolites NOUN - O
isolated VERB - O
from ADP - O
the DET - O
fermentation NOUN - O
broth NOUN - O
were VERB - O
characterized VERB - O
using VERB - O
NMR NNP - B-ORG
, PUNCT - O
FT PROPN - O
- PUNCT - O
IR PROPN - O
and CCONJ - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
as ADP - O
actinomycins VERB - O
V PROPN - O
, PUNCT - O
X2 NNP - B-ORG
and CCONJ - O
D. NNP - B-NORP

-DOCSTART- -X- - O

Wood NOUN - O
samples NOUN - O
of ADP - O
Melia NNP - B-GPE
azedarach NOUN - O
were VERB - O
treated VERB - O
with ADP - O
water NOUN - O
extract NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
antifungal ADJ - O
activity NOUN - O
was VERB - O
examined VERB - O
at ADP - O
concentrations NOUN - O
of ADP - O
0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
1 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
2 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
3 CD - B-PERCENT
% NN - I-PERCENT
against ADP - O
three CD - B-CARDINAL
mold NOUN - O
fungi NOUN - O
; PUNCT - O
Fusarium NN - B-ORG
culmorum NOUN - O
MH352452 NNP - B-PRODUCT
, PUNCT - O
Rhizoctonia NNP - B-GPE
solani PROPN - O
MH352450 PROPN - O
, PUNCT - O
and CCONJ - O
Penicillium NNP - B-ORG
chrysogenum NOUN - O
MH352451 NNS - B-ORG
that ADJ - O
cause VERB - O
root NOUN - O
rot NOUN - O
, PUNCT - O
cankers NOUN - O
, PUNCT - O
and CCONJ - O
green ADJ - O
fruit NOUN - O
rot NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
isolated VERB - O
from ADP - O
infected ADJ - O
Citrus NNP - B-GPE
sinensis NOUN - O
L. NNP - B-PERSON
Antibacterial NNP - I-MEDICINE
evaluation NOUN - O
of ADP - O
the DET - O
extract NOUN - O
was VERB - O
assayed VERB - O
against ADP - O
four CD - B-CARDINAL
phytopathogenic ADJ - O
bacteria NOUN - O
, PUNCT - O
including VERB - O
Agrobacterium NN - B-PRODUCT
tumefaciens NOUN - O
, PUNCT - O
Enterobacter PROPN - O
cloacae NOUN - O
, PUNCT - O
Erwinia NNP - B-GPE
amylovora NOUN - O
, PUNCT - O
and CCONJ - O
Pectobacterium NNP - B-ORG
carotovorum NOUN - O
subsp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transcriptional PROPN - O
Sequencing PROPN - O
Uncovers PROPN - O
Survival PROPN - O
Mechanisms PROPN - O
of ADP - O
Salmonella PROPN - O
enterica NOUN - O
Serovar PROPN - O
Enteritidis PROPN - O
in ADP - O
Antibacterial NNP - B-MEDICINE
Egg NNP - I-ORG
White NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antibacterial NNP - B-MEDICINE
Countermeasures NNP - I-ORG
via IN - I-ORG
Metal NNP - I-ORG
- HYPH - I-ORG
Organic NNP - I-ORG
Framework NNP - I-ORG
- HYPH - I-ORG
Supported VBN - I-ORG
Sustained JJ - I-ORG
Therapeutic JJ - I-ORG
Release NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial ADJ - O
resistance NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
and CCONJ - O
metronidazole VERB - O
significantly ADV - O
affects VERB - O
the DET - O
cure NOUN - O
rate NOUN - O
of ADP - O
standard ADJ - O
therapies NOUN - O
for ADP - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
infection NOUN - O
. PUNCT - O

The DET - O
level NOUN - O
of ADP - O
antibiotic ADJ - O
resistance NOUN - O
was VERB - O
classified VERB - O
according VERB - O
to ADP - O
MIC NNP - B-ORG
values NOUN - O
into ADP - O
low ADJ - O
( PUNCT - O
MIC NNP - B-ORG
from ADP - O
> X - O
0.5 NUM - O
to ADP - O
≤8 NNP - B-ORG
for ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
from ADP - O
> X - O
8 NUM - O
to ADP - O
≤32 NNP - B-ORG
for ADP - O
metronidazole NOUN - O
) PUNCT - O
and CCONJ - O
high ADJ - O
( PUNCT - O
MIC NNP - B-ORG
from ADP - O
> X - O
8 CD - B-CARDINAL
to ADP - O
256 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
L NN - I-QUANTITY
for ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
from ADP - O
> X - O
32 CD - B-CARDINAL
to PART - O
256 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
for ADP - O
metronidazole NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
were VERB - O
520 CD - B-CARDINAL
( PUNCT - O
51.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
patients NOUN - O
with ADP - O
susceptible ADJ - O
strains NOUN - O
, PUNCT - O
136 CD - B-CARDINAL
( PUNCT - O
13.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
strains NOUN - O
, PUNCT - O
144 CD - B-CARDINAL
( PUNCT - O
14.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
metronidazole NOUN - O
- PUNCT - O
resistant ADJ - O
strains NOUN - O
and CCONJ - O
206 CD - B-CARDINAL
( PUNCT - O
20.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
with ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
and CCONJ - O
metronidazole NOUN - O
- PUNCT - O
resistant ADJ - O
strains NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
that ADP - O
MIC NNP - B-ORG
levels NOUN - O
of ADP - O
resistance NOUN - O
to ADP - O
either CCONJ - O
clarithromycin NN - B-MEDICINE
or CCONJ - O
metronidazole NOUN - O
play VERB - O
a DET - O
role NOUN - O
in ADP - O
H. NNP - B-NORP
pylori NOUN - O
therapy NOUN - O
outcome NOUN - O
and CCONJ - O
that ADP - O
bacterial ADJ - O
resistance NOUN - O
becomes VERB - O
relevant ADJ - O
in ADP - O
vivo NOUN - O
when ADV - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
and CCONJ - O
metronidazole NOUN - O
- PUNCT - O
resistant ADJ - O
strains NOUN - O
have VERB - O
high ADJ - O
MIC NNP - B-ORG
values NOUN - O
for ADP - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
of ADP - O
these DET - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
find VERB - O
a DET - O
safer ADJ - O
, PUNCT - O
more ADV - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
, PUNCT - O
and CCONJ - O
high ADJ - O
eradicative ADJ - O
strategy NOUN - O
for ADP - O
Helicobacter NNP - B-PERSON
treatment NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
14-day CD - B-DATE
bismuth NOUN - O
quadruple NOUN - O
therapy NOUN - O
and CCONJ - O
different ADJ - O
doses NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
in ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
210 CD - B-CARDINAL
patients NOUN - O
with ADP - O
H NOUN - O
  SPACE - O
pylori NOUN - O
infection NOUN - O
were VERB - O
recruited VERB - O
and CCONJ - O
randomly ADV - O
assigned VERB - O
to ADP - O
half PDT - B-CARDINAL
- PUNCT - O
dose NOUN - O
clarithromycin NN - B-MEDICINE
group NOUN - O
( PUNCT - O
esomeprazole ADJ - O
20 CD - B-CARDINAL
  SPACE - O
mg PUNCT - O
bid NOUN - O
, PUNCT - O
amoxicillin NOUN - O
1 CD - B-CARDINAL
  SPACE - O
g NOUN - O
bid NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
250 CD - B-CARDINAL
  SPACE - O
mg PRON - O
bid NOUN - O
, PUNCT - O
and CCONJ - O
bismuth NOUN - O
potassium NOUN - O
citrate VERB - O
0.6 CD - B-CARDINAL
  SPACE - O
g NOUN - O
bid NOUN - O
) PUNCT - O
for ADP - O
14 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
or CCONJ - O
standard NOUN - O
- PUNCT - O
dose NOUN - O
clarithromycin NN - B-MEDICINE
group NOUN - O
( PUNCT - O
esomeprazole ADJ - O
20 CD - B-CARDINAL
  SPACE - O
mg PUNCT - O
bid NOUN - O
, PUNCT - O
amoxicillin NOUN - O

1 CD - B-CARDINAL
  SPACE - O
g NOUN - O
bid NOUN - O
, PUNCT - O
clarithromycin VBD - B-MEDICINE
500 CD - B-CARDINAL
  SPACE - O
mg PUNCT - O
bid NOUN - O
, PUNCT - O
and CCONJ - O
bismuth NOUN - O
potassium NOUN - O

A DET - O
14-day CD - B-DATE
half NN - I-DATE
- PUNCT - O
dose NOUN - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
containing VERB - O
bismuth NOUN - O
quadruple NOUN - O
regimen NOUN - O
is VERB - O
as ADV - O
effective ADJ - O
as ADP - O
the DET - O
standard ADJ - O
bismuth NOUN - O
quadruple NOUN - O
therapy NOUN - O
at ADP - O
eradicating VERB - O
H NN - B-GPE
  _SP - I-GPE
pylori NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
better ADV - O
tolerated VERB - O
and CCONJ - O
more ADV - O
economical ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
systematic ADJ - O
review NOUN - O
( PUNCT - O
SR PROPN - O
) PUNCT - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
chronic ADJ - O
rhinosinusitis NOUN - O
( PUNCT - O
CRS NNP - B-ORG
) PUNCT - O
. PUNCT - O

Eleven CD - B-CARDINAL
studies NOUN - O
evaluated VERB - O
whether ADP - O
adding VERB - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
to PART - O
intranasal VERB - O
steroid NOUN - O
spray NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
nasal NOUN - O
saline NOUN - O
irrigation NOUN - O
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
intranasal NOUN - O
steroid NOUN - O
spray NOUN - O
alone ADV - O
. PUNCT - O

No DET - O
significant ADJ - O
difference NOUN - O
was VERB - O
identified VERB - O
between ADP - O
treatment NOUN - O
with ADP - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
intranasal NOUN - O
steroid NOUN - O
spray NOUN - O
alone ADJ - O
groups NOUN - O
in ADP - O
term NOUN - O
of ADP - O
symptoms NOUN - O
, PUNCT - O
endoscopic ADJ - O
score NOUN - O
, PUNCT - O
and CCONJ - O
CT NNP - B-ORG
score NOUN - O
. PUNCT - O

For ADP - O
the DET - O
treatment NOUN - O
of ADP - O
CRS NNP - B-ORG
, PUNCT - O
adding VERB - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
to PART - O
intranasal VERB - O
steroid NOUN - O
spray NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
nasal NOUN - O
saline NOUN - O
irrigation NOUN - O
may VERB - O
achieve VERB - O
better ADJ - O
results NOUN - O
than ADP - O
using VERB - O
intranasal NOUN - O
steroid NOUN - O
spray NOUN - O
with ADP - O
or CCONJ - O
without ADP - O
nasal NOUN - O
saline NOUN - O
irrigation NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
insufficient ADJ - O
evidence NOUN - O
to PART - O
confirm VERB - O
that DET - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
alone ADV - O
may VERB - O
have VERB - O
similar ADJ - O
efficacy NOUN - O
as ADP - O
nasal NOUN - O
glucocorticoid NOUN - O
spray NOUN - O
alone ADV - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
The DET - O
early ADJ - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
low ADJ - O
- PUNCT - O
dose NOUN - O
clarithromycin NN - B-MEDICINE
for ADP - O
chronic ADJ - O
nasosinusitis NOUN - O
with ADP - O
nasal ADJ - O
polyps]. NOUN - O

-DOCSTART- -X- - O

Rifabutin NN - B-PERSON
, PUNCT - O
in ADP - O
contrast NOUN - O
to ADP - O
rifampin NOUN - O
, PUNCT - O
appears VERB - O
to PART - O
be VERB - O
active ADJ - O
in ADP - O
vitro NOUN - O
against ADP - O
M. NNP - B-ORG
abscessus NOUN - O
, PUNCT - O
especially ADV - O
against ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
strains NOUN - O
. PUNCT - O

Among ADP - O
the DET - O
6 CD - B-CARDINAL
clarithromycin NN - B-MEDICINE
resistant ADJ - O
( PUNCT - O
MIC NNP - B-ORG
≥8 PUNCT - O
mg PROPN - O
/ SYM - O
L PROPN - O
) PUNCT - O
M. PROPN - O
abscessus NOUN - O
subsp NOUN - O
. PUNCT - O

abscessus NOUN - O
isolates NOUN - O
, PUNCT - O
the DET - O
combination NOUN - O
of ADP - O
rifabutin NOUN - O
and CCONJ - O
clarithromycin NN - B-MEDICINE
was VERB - O
100 CD - B-PERCENT
% NN - I-PERCENT
synergistic ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Partial ADJ - O
susceptibility NOUN - O
to ADP - O
four CD - B-CARDINAL
antibiotics NOUN - O
was VERB - O
found VERB - O
( PUNCT - O
amikacin NOUN - O
, PUNCT - O
tigecycline NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
linezolid NOUN - O
) PUNCT - O
. PUNCT - O

Non ADJ - O
- ADJ - O
massiliense ADJ - O
subspecies NOUN - O
were VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
( PUNCT - O
p<0.0001 ADV - O
) PUNCT - O
whereas ADP - O
massiliense NOUN - O
subspecies NOUN - O
were VERB - O
associated VERB - O
with ADP - O
tigecycline NOUN - O
resistance NOUN - O
( PUNCT - O
p VERB - O
= SYM - O
0.028 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Inducible ADJ - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
was VERB - O
seen VERB - O
in ADP - O
22/68 CD - B-CARDINAL
( PUNCT - O
32.35 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
isolates VERB - O
: PUNCT - O
21 CD - B-CARDINAL
of ADP - O
these DET - O
isolates NOUN - O
( PUNCT - O
95.45 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
belonged VERB - O
to ADP - O
non ADJ - O
- ADJ - O
massiliense ADJ - O
subspecies NOUN - O
and CCONJ - O
resistance NOUN - O
was VERB - O
explicable ADJ - O
by ADP - O
the DET - O
T28C PROPN - O
mutation NOUN - O
in ADP - O
erm(41 NUM - O
) PUNCT - O
. PUNCT - O

Inducible ADJ - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
was VERB - O
found VERB - O
in ADP - O
one CD - B-CARDINAL
isolate NOUN - O
of ADP - O
the DET - O
massiliense ADJ - O
subspecies NOUN - O
. PUNCT - O

Acquired VERB - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
explicable ADJ - O
by ADP - O
the DET - O
A2271G NNP - B-ORG
/ SYM - O
C PROPN - O
mutation NOUN - O
of ADP - O
rrl NOUN - O
was VERB - O
seen VERB - O
in ADP - O
only RB - B-CARDINAL
7/16 CD - I-CARDINAL
( PUNCT - O
43.75 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
strains NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Susceptibility NOUN - O
tests NOUN - O
of ADP - O
isolated ADJ - O
P. NNP - B-ORG
acnes NOUN - O
were VERB - O
performed VERB - O
for ADP - O
tetracycline NOUN - O
, PUNCT - O
doxycycline NOUN - O
, PUNCT - O
clindamycin VERB - O
, PUNCT - O
erythromycin NOUN - O
, PUNCT - O
azithromycin NOUN - O
and CCONJ - O
clarithromycin NNP - B-MEDICINE
using VERB - O
the DET - O
Epsilometer NNP - B-PRODUCT
test NOUN - O
. PUNCT - O

P. NOUN - O
acnes NOUN - O
was VERB - O
isolated VERB - O
from ADP - O
227 CD - B-CARDINAL
patients NOUN - O
; PUNCT - O
224 CD - B-CARDINAL
isolates NOUN - O
( PUNCT - O
98.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
susceptible ADJ - O
to ADP - O
doxycycline NOUN - O
and CCONJ - O
220 CD - B-CARDINAL
( PUNCT - O
96.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
susceptible ADJ - O
to ADP - O
tetracycline NOUN - O
, PUNCT - O
followed VERB - O
by ADP - O
clindamycin NOUN - O
and CCONJ - O
clarithromycin VB - B-MEDICINE
in ADP - O
101 CD - B-CARDINAL
( PUNCT - O
44.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
102 CD - B-CARDINAL
( PUNCT - O
44.93 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
isolates NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

P. NOUN - O
acnes NOUN - O
showed VERB - O
higher ADJ - O
resistance NOUN - O
rates NOUN - O
to ADP - O
macrolides NOUN - O
- PUNCT - O
lincosamides NOUN - O
- PUNCT - O
streptogramins NOUN - O
antibiotics NOUN - O
( PUNCT - O
such ADJ - O
as ADP - O
erythromycin NOUN - O
, PUNCT - O
azithromycin PROPN - O
, PUNCT - O
clarithromycin VBP - B-MEDICINE
and CCONJ - O
clindamycin VERB - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
resistance NOUN - O
rate NOUN - O
of ADP - O
helicobacter NOUN - O
pylori NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
and CCONJ - O
main ADJ - O
mutations NOUN - O
on ADP - O
bacterial ADJ - O
genomic NOUN - O
responsible ADJ - O
for ADP - O
bacterial ADJ - O
resistance NOUN - O
: PUNCT - O
A DET - O
comparative ADJ - O
study NOUN - O
in ADP - O
children NOUN - O
and CCONJ - O
adults NOUN - O
; PUNCT - O
Tehran NNP - B-GPE
, PUNCT - O
Iran NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
prevalence NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
in ADP - O
asymptomatic ADJ - O
children NOUN - O
in ADP - O
a DET - O
rural ADJ - O
community NOUN - O
of ADP - O
Cajamarca NNP - B-NORP
( PUNCT - O
northern ADJ - O
Peru NNP - B-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
H. NNP - B-NORP
pylori NOUN - O
resistance NOUN - O
to PART - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
amoxicillin NOUN - O
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
levofloxacin NOUN - O
, PUNCT - O
and CCONJ - O
tetracycline VERB - O
in ADP - O
adult NOUN - O
patients NOUN - O
in ADP - O
the DET - O
Smolensk NNP - B-GPE
region NOUN - O
of ADP - O
Russian NNP - B-ORG
Federation NNP - I-ORG
over ADP - O
a DET - O
9-year NUM - O
period NOUN - O
. PUNCT - O

Antimicrobial ADJ - O
susceptibility NOUN - O
testing NOUN - O
was VERB - O
performed VERB - O
for ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
amoxicillin NOUN - O
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
levofloxacin NOUN - O
, PUNCT - O
and CCONJ - O
tetracycline NOUN - O
by ADP - O
the DET - O
agar ADJ - O
dilution NOUN - O
method NOUN - O
. PUNCT - O

Over ADP - O
the DET - O
2015 CD - B-DATE
- SYM - I-DATE
2017 CD - I-DATE
, PUNCT - O
the DET - O
prevalence NOUN - O
of ADP - O
resistance NOUN - O
to PART - O
clarithromycin NNP - B-MEDICINE
was VERB - O
6.3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
to PART - O
amoxicillin VERB - O
1.4 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
to ADP - O
metronidazole NOUN - O
23.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
to PART - O
levofloxacin VERB - O
24.5 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
to PART - O
tetracycline VERB - O
0.7 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

There ADV - O
were VERB - O
no DET - O
significant ADJ - O
increases NOUN - O
in ADP - O
resistance NOUN - O
to ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
amoxicillin NOUN - O
, PUNCT - O
and CCONJ - O
tetracycline NOUN - O
( PUNCT - O

H. PROPN - O
pylori ADV - O
resistance NOUN - O
to PART - O
clarithromycin NNP - B-MEDICINE
remained VERB - O
low ADJ - O
in ADP - O
the DET - O
Smolensk NNP - B-GPE
region NOUN - O
of ADP - O
Russian NNP - B-ORG
Federation NNP - I-ORG
between IN - B-DATE
2009 CD - I-DATE
and CC - I-DATE
2017 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

AbstractBackgroundThe DET - O
eradication NOUN - O
rate NOUN - O
of ADP - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
as ADP - O
a DET - O
standard ADJ - O
therapy NOUN - O
based VERB - O
on ADP - O
amoxicillin NOUN - O
and CCONJ - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
exhibits VERB - O
a DET - O
decreasing VERB - O
trend NOUN - O
. PUNCT - O

Antimicrobial ADJ - O
susceptibility NOUN - O
tests NOUN - O
were VERB - O
performed VERB - O
, PUNCT - O
and CCONJ - O
the DET - O
MICs NOUN - O
of ADP - O
eight CD - B-CARDINAL
antibiotics NOUN - O
( PUNCT - O
amoxicillin NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
tetracycline NOUN - O
, PUNCT - O
levofloxacin NOUN - O
, PUNCT - O
gentamicin NOUN - O
, PUNCT - O
netilmicin NOUN - O
, PUNCT - O
and CCONJ - O
tobramycin NOUN - O
) PUNCT - O
were VERB - O
determined VERB - O
by ADP - O
using VERB - O
the DET - O
Epsilometer NNP - B-LOC
test NOUN - O
and CCONJ - O
following VERB - O
the DT - B-ORG
European NNP - I-ORG
Committee NNP - I-ORG
on IN - I-ORG
Antimicrobial NNP - I-ORG
Susceptibility NNP - I-ORG
Testing NNP - I-ORG
recommendations NOUN - O
. PUNCT - O

The DET - O
resistance NOUN - O
rate NOUN - O
to PART - O
clarithromycin NNP - B-MEDICINE
was VERB - O
30.7 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
although ADP - O
it PRON - O
is VERB - O
a DET - O
major ADJ - O
antimicrobial ADJ - O
agent NOUN - O
used VERB - O
in ADP - O
standard ADJ - O
therapy NOUN - O
. PUNCT - O

In ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
strains NOUN - O
, PUNCT - O
the DET - O
MIC50 NNP - B-PRODUCT
was VERB - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
, PUNCT - O
safety NOUN - O
, PUNCT - O
and CCONJ - O
compliance NOUN - O
of ADP - O
CQT NNP - B-ORG
and CCONJ - O
BQT NNP - B-ORG
as ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
for ADP - O
H. PROPN - O
pylori NOUN - O
eradication NOUN - O
in ADP - O
real ADJ - O
clinical ADJ - O
practice NOUN - O
in ADP - O
an DET - O
area NOUN - O
of ADP - O
high ADJ - O
resistance NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
. PUNCT - O

CQT NNP - B-ORG
( PUNCT - O
omeprazole ADJ - O
20 CD - B-CARDINAL
  SPACE - O
mg PRON - O
+ PROPN - O
clarithromycin VBD - B-MEDICINE
500 CD - B-CARDINAL
  SPACE - O
mg NOUN - O

The DET - O
use NOUN - O
of ADP - O
CQT NNP - B-ORG
and CCONJ - O
BQT NNP - B-ORG
as ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
against ADP - O
H. PROPN - O
pylori NOUN - O
is VERB - O
similarly ADV - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
strategy NOUN - O
in ADP - O
an DET - O
area NOUN - O
of ADP - O
high ADJ - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
randomized VERB - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
in ADP - O
combination NOUN - O
with ADP - O
bortezomib NOUN - O
- PUNCT - O
cyclophosphamide NOUN - O
- PUNCT - O
dexamethasone NOUN - O
( PUNCT - O
VCD NNP - B-ORG
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
newly ADV - O
diagnosed VERB - O
multiple ADJ - O
myeloma NOUN - O
eligible ADJ - O
for ADP - O
high ADV - O
- PUNCT - O
dose NOUN - O
therapy NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
randomized VERB - O
to PART - O
receive VERB - O
tablet NOUN - O
clarithromycin NN - B-MEDICINE
500 CD - B-CARDINAL
  SPACE - O
mg PRON - O
or CCONJ - O
matching VERB - O
placebo NOUN - O
tablet NOUN - O
twice ADV - O
daily RB - B-DATE
during ADP - O
the DET - O
first JJ - B-ORDINAL
3 CD - B-CARDINAL
cycles NOUN - O
of ADP - O
VCD NNP - B-ORG
induction NOUN - O
therapy NOUN - O
. PUNCT - O

Primary ADJ - O
endpoint NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
rate NOUN - O
of ADP - O
very ADV - O
good ADJ - O
partial ADJ - O
response NOUN - O
( PUNCT - O
VGPR PROPN - O
) PUNCT - O
or CCONJ - O
better ADJ - O
response NOUN - O
after ADP - O
three CD - B-CARDINAL
cycles NOUN - O
of ADP - O
VCD NNP - B-ORG
combined VERB - O
with ADP - O
clarithromycin NN - B-MEDICINE
or CCONJ - O
placebo NOUN - O
. PUNCT - O

The DET - O
patients NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
clarithromycin NNP - B-MEDICINE
( PUNCT - O
n NOUN - O
  SPACE - O
= PUNCT - O
  SPACE - O
27 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
placebo NOUN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
31 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

( PUNCT - O
p VERB - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.59 CD - B-CARDINAL
) PUNCT - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
group NOUN - O
and CCONJ - O
the DET - O
placebo NOUN - O
group NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Seven CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
25.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
group NOUN - O
developed VERB - O
severe ADJ - O
gastrointestinal ADJ - O
complications NOUN - O
( PUNCT - O
≥ NN - B-GPE
  SPACE - O
grade NOUN - O
3 CD - B-CARDINAL
) PUNCT - O
comprising VERB - O
pain NOUN - O
, PUNCT - O
neutropenic ADJ - O
enterocolitis NOUN - O
, PUNCT - O
paralytic ADJ - O
ileus NOUN - O
or CCONJ - O
peptic ADJ - O
ulcer NOUN - O
. PUNCT - O

Septicemia NOUN - O
with ADP - O
Gram NNP - B-ORG
negative ADJ - O
bacteria NOUN - O
was VERB - O
observed VERB - O
in ADP - O
5 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
group NOUN - O
in ADP - O
contrast NOUN - O
to ADP - O
one CD - B-CARDINAL
case NOUN - O
of ADP - O
pneumococcal ADJ - O
septicemia NOUN - O
in ADP - O
the DET - O
placebo NOUN - O
group NOUN - O
. PUNCT - O

Patient NOUN - O
- PUNCT - O
reported VERB - O
QoL NNP - B-ORG
were VERB - O
negatively ADV - O
affected VERB - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
group NOUN - O
compared VERB - O
to ADP - O
the DET - O
placebo NOUN - O
group NOUN - O
. PUNCT - O

The DET - O
response NOUN - O
data NOUN - O
do VERB - O
not ADV - O
suggest VERB - O
any DET - O
effect NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
when ADV - O
added VERB - O
to ADP - O
the DET - O
VCD NNP - B-ORG
regimen NOUN - O
. PUNCT - O

The DET - O
combination NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
bortezomib NOUN - O
containing VERB - O
regimens NOUN - O
is VERB - O
toxic ADJ - O
and CCONJ - O
do VERB - O
not ADV - O
seem VERB - O
to PART - O
offer VERB - O
extra ADJ - O
anti ADJ - O
- ADJ - O
myeloma ADJ - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
establish VERB - O
a DET - O
microarray ADV - O
- PUNCT - O
based VERB - O
detection NOUN - O
to PART - O
identify VERB - O
H. NNP - B-NORP
pylori NOUN - O
infection NOUN - O
, PUNCT - O
clarithromycin VBP - B-MEDICINE
and CCONJ - O
levofloxacin NOUN - O
susceptibility NOUN - O
, PUNCT - O
and CCONJ - O
CYP2C19 NNP - B-ORG
genetic ADJ - O
polymorphism NOUN - O
and CCONJ - O
guide VERB - O
to ADP - O
potential ADJ - O
choice NOUN - O
of ADP - O
proton NOUN - O
pump NOUN - O
inhibitor NOUN - O
( PUNCT - O
PPI PROPN - O
) PUNCT - O
, PUNCT - O
antibiotic ADJ - O
administration NOUN - O
for ADP - O
tailored VERB - O
H. NNP - B-NORP
pylori NOUN - O
eradication NOUN - O
therapy NOUN - O
. PUNCT - O

By ADP - O
analyzing VERB - O
the DET - O
sequence NOUN - O
of ADP - O
human ADJ - O
genomic ADJ - O
CYP2C19⁎2 NNP - B-ORG
and CC - I-ORG
CYP2C19⁎3 NNPS - I-ORG
and CCONJ - O
mutations NOUN - O
within ADP - O
the DET - O
23S CD - B-CARDINAL
rRNA PROPN - O
and CCONJ - O
gyrA VERB - O
gene NOUN - O
regions NOUN - O
conferring VERB - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
levofloxacin ADJ - O
resistance NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
we PRON - O
developed VERB - O
a DET - O
microarray NOUN - O
for ADP - O
individual ADJ - O
therapy NOUN - O
detection NOUN - O
of ADP - O
H. NNP - B-NORP
pylori NOUN - O
infection NOUN - O
. PUNCT - O

We PRON - O
also ADV - O
analyzed VERB - O
the DET - O
resistance NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
and CCONJ - O
levofloxacin VERB - O
in ADP - O
China NNP - B-GPE
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
CYP2C19 NNP - B-ORG
polymorphisms NOUN - O
. PUNCT - O

The DET - O
detection NOUN - O
results NOUN - O
of ADP - O
1083 CD - B-DATE
gastric ADJ - O
biopsy NOUN - O
samples NOUN - O
showed VERB - O
that ADP - O
691 CD - B-CARDINAL
( PUNCT - O
63.80 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
H. PROPN - O
pylori NOUN - O
positive ADJ - O
, PUNCT - O
of ADP - O
which ADJ - O
266 CD - B-CARDINAL
( PUNCT - O
38.49 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
resistant ADJ - O
to PART - O
clarithromycin VB - B-MEDICINE
, PUNCT - O
192 CD - B-CARDINAL
( PUNCT - O
27.79 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
resistant ADJ - O
to PART - O
levofloxacin VERB - O
, PUNCT - O
and CCONJ - O
61 CD - B-DATE
( PUNCT - O
8.83 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
resistant ADJ - O
to ADP - O
both DET - O
of ADP - O
them PRON - O
. PUNCT - O

The DET - O
proposed ADJ - O
microarray NOUN - O
- PUNCT - O
based VERB - O
detection NOUN - O
has VERB - O
high ADJ - O
specificity NOUN - O
, PUNCT - O
sensitivity NOUN - O
, PUNCT - O
and CCONJ - O
reproducibility NOUN - O
for ADP - O
detecting VERB - O
the DET - O
resistance NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
or CCONJ - O
levofloxacin NOUN - O
as ADV - O
well ADV - O
as ADP - O
CYP2C19 NNP - B-ORG
polymorphism NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
help VERB - O
to PART - O
improve VERB - O
the DET - O
clinical ADJ - O
eradication NOUN - O
rate NOUN - O
of ADP - O
H. NNP - B-NORP
pylori NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Indeed ADV - O
the DET - O
WHO WP - B-ORG
has VERB - O
recently ADV - O
designated VERB - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
H. NNP - B-PERSON
pylori NOUN - O
infection VERB - O
a DET - O
high ADJ - O
priority NOUN - O
for ADP - O
antibiotic ADJ - O
resistance NOUN - O
research NOUN - O
and CCONJ - O
development NOUN - O
. PUNCT - O

Primary ADJ - O
resistance NOUN - O
rates NOUN - O
in ADP - O
general ADJ - O
are VERB - O
on ADP - O
the DET - O
rise NOUN - O
and CCONJ - O
high ADJ - O
rates NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
( PUNCT - O
> X - O
15 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
have VERB - O
been VERB - O
reported VERB - O
in ADP - O
many ADJ - O
parts NOUN - O
of ADP - O
the DET - O
world NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

More ADV - O
recently ADV - O
, PUNCT - O
a DET - O
clinical ADJ - O
trial NOUN - O
demonstrated VERB - O
equipotency NOUN - O
of ADP - O
replacing VERB - O
the DET - O
injectable ADJ - O
streptomycin NOUN - O
by ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
orally ADV - O
available ADJ - O
and CCONJ - O
with ADP - O
fewer ADJ - O
side NOUN - O
effects NOUN - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
BU NNP - B-ORG
treatment NOUN - O
is VERB - O
now ADV - O
moving VERB - O
toward ADP - O
a DET - O
full ADJ - O
orally ADV - O
available ADJ - O
treatment NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
rifampicin NOUN - O
. PUNCT - O

Strains NOUN - O
resistant ADJ - O
to PART - O
clarithromycin NNP - B-MEDICINE
could VERB - O
also ADV - O
eventually ADV - O
emerge VERB - O
. PUNCT - O

Its ADJ - O
inclusion NOUN - O
in ADP - O
a DET - O
triple ADJ - O
oral ADJ - O
therapy NOUN - O
complementing VERB - O
current ADJ - O
combinatorial NOUN - O
rifampicin NOUN - O
- PUNCT - O
clarithromycin NN - B-MEDICINE
treatment NOUN - O
has VERB - O
the DET - O
potential NOUN - O
to PART - O
counteract VERB - O
resistance NOUN - O
development NOUN - O
and CCONJ - O
to PART - O
reduce VERB - O
length NOUN - O
of ADP - O
treatment NOUN - O
and CCONJ - O
time NOUN - O
to PART - O
cure VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
paenipeptin NOUN - O
analogues VERB - O
at ADP - O
4 CD - B-QUANTITY
μg NNP - I-QUANTITY
/ SYM - I-QUANTITY
ml NNP - I-QUANTITY
potentiated VERB - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
rifampin NOUN - O
against ADP - O
carbapenem ADV - O
- PUNCT - O
resistant ADJ - O
Acinetobacter PROPN - O
baumannii VERB - O
and CCONJ - O
Klebsiella NNP - B-PERSON
pneumoniae VERB - O
strains VERB - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
aimed VERB - O
to PART - O
summarize VERB - O
the DET - O
ability NOUN - O
of ADP - O
vonoprazan NOUN - O
to PART - O
eradicate VERB - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
susceptible ADJ - O
and CCONJ - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
strains NOUN - O
. PUNCT - O

Studies NOUN - O
were VERB - O
included VERB - O
if ADP - O
they PRON - O
evaluated VERB - O
eradication NOUN - O
rates NOUN - O
of ADP - O
vonoprazan NOUN - O
- PUNCT - O
based VERB - O
and CCONJ - O
conventional ADJ - O
PPI PROPN - O
- PUNCT - O
based VERB - O
triple ADJ - O
therapies NOUN - O
and CCONJ - O
checked VERB - O
for ADP - O
clarithromycin NN - B-MEDICINE
susceptibility NOUN - O
of ADP - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
. PUNCT - O

We PRON - O
identified VERB - O
5 CD - B-CARDINAL
studies NOUN - O
including VERB - O
a DET - O
total NOUN - O
of ADP - O
1599 CD - B-DATE
patients NOUN - O
containing VERB - O
data NOUN - O
regarding VERB - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
with ADP - O
clarithromycin NN - B-MEDICINE
susceptibility NOUN - O
. PUNCT - O

Among ADP - O
those DET - O
infected VERB - O
with ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
susceptible ADJ - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
, PUNCT - O
eradication NOUN - O
rates NOUN - O
for ADP - O
vonoprazan NOUN - O
- PUNCT - O
based VERB - O
and CCONJ - O
conventional ADJ - O
PPI PROPN - O
- PUNCT - O
based VERB - O
therapies NOUN - O
did VERB - O
not ADV - O
significantly ADV - O
differ VERB - O
in ADP - O
either CCONJ - O
the DET - O
randomized ADJ - O
( PUNCT - O
RCT NNP - B-ORG
; PUNCT - O
pooled VERB - O
eradication NOUN - O
rates NOUN - O
, PUNCT - O
95.4 CD - B-PERCENT
% NN - I-PERCENT
vs ADP - O
92.8 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
pooled ADJ - O
odds NOUN - O
ratio NOUN - O
[ PUNCT - O
OR CCONJ - O
] PUNCT - O
, PUNCT - O
1.63 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
intervals NOUN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
, PUNCT - O
0.74 CD - B-CARDINAL
- SYM - I-CARDINAL
3.61 CD - I-CARDINAL
; PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
.225 NUM - O
) PUNCT - O
and CCONJ - O
nonrandomized ADJ - O
( PUNCT - O
NRCT NNP - B-ORG
; PUNCT - O
pooled VERB - O
eradication NOUN - O
rates NOUN - O
, PUNCT - O
92.9 CD - B-PERCENT
% NN - I-PERCENT
vs ADP - O
86.2 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
OR CCONJ - O
, PUNCT - O
4.58 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
0.67 CD - B-CARDINAL
- SYM - I-CARDINAL
31.45 CD - I-CARDINAL
; PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
.122 NUM - O
) PUNCT - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
vonoprazan NOUN - O
- PUNCT - O
based VERB - O
triple ADJ - O
therapy NOUN - O
was VERB - O
significantly ADV - O
superiority NOUN - O
to ADP - O
PPI PROPN - O
- PUNCT - O
based VERB - O
therapy NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
strains NOUN - O
in ADP - O
both DET - O
RCT NNP - B-ORG
( PUNCT - O
pooled VERB - O
eradication NOUN - O
rates NOUN - O
, PUNCT - O
82.0 CD - B-PERCENT
% NN - I-PERCENT
vs ADP - O
40.0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
OR CCONJ - O
, PUNCT - O
6.83 CD - B-DATE
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O
3.63 CD - B-CARDINAL
- SYM - O
12.86 NUM - O
; PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
.0001 PUNCT - O
) PUNCT - O
and CCONJ - O
NRCT NNP - B-ORG
( PUNCT - O
pooled VERB - O
eradication NOUN - O
rates NOUN - O
, PUNCT - O
80.8 CD - B-PERCENT
% NN - I-PERCENT
vs ADP - O
41.8 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
OR CCONJ - O
, PUNCT - O
4.98 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
2.47 CD - B-CARDINAL
- SYM - O
10.03 NUM - O
; PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
.0001 PUNCT - O
) PUNCT - O
. PUNCT - O

Vonoprazan PROPN - O
- PUNCT - O
based VERB - O
and CCONJ - O
conventional ADJ - O
PPI PROPN - O
- PUNCT - O
based VERB - O
therapies NOUN - O
are VERB - O
similarly ADV - O
effective ADJ - O
for ADP - O
the DET - O
eradication NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
susceptible ADJ - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
strains VERB - O
. PUNCT - O

Vonoprazan PROPN - O
is VERB - O
superior ADJ - O
to ADP - O
conventional ADJ - O
PPI PROPN - O
- PUNCT - O
based VERB - O
therapy NOUN - O
for ADP - O
the DET - O
eradication NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
H. NNP - B-GPE
  _SP - I-GPE
pylori NOUN - O
strains VERB - O
. PUNCT - O

However ADV - O
, PUNCT - O
clarithromycin NNP - B-MEDICINE
was VERB - O
misused ADJ - O
because ADP - O
the DET - O
combination NOUN - O
of ADP - O
vonoprazan NOUN - O
and CCONJ - O
amoxicillin NOUN - O
cures NOUN - O
approximately RB - B-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
infections NOUN - O
without ADP - O
clarithromycin NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Systematic ADJ - O
review NOUN - O
with ADP - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
: PUNCT - O
Vonoprazan PROPN - O
, PUNCT - O
a DET - O
potent ADJ - O
acid NOUN - O
blocker NOUN - O
, PUNCT - O
is VERB - O
superior ADJ - O
to ADP - O
proton VERB - O
- PUNCT - O
pump NOUN - O
inhibitors NOUN - O
for ADP - O
eradication NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
strains NOUN - O
of ADP - O
Helicobacter NNP - B-ORG
pylori NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
current ADJ - O
treatment NOUN - O
regimen VERB - O
relies VERB - O
on ADP - O
a DET - O
combination NOUN - O
of ADP - O
antibiotics NOUN - O
, PUNCT - O
including VERB - O
clarithromycin NN - B-MEDICINE
paired VERB - O
with ADP - O
amikacin NOUN - O
and CCONJ - O
either CCONJ - O
imipenem NOUN - O
or CCONJ - O
cefoxitin NOUN - O
. PUNCT - O

Combination NOUN - O
of ADP - O
rifabutin NOUN - O
with ADP - O
either CCONJ - O
clarithromycin NN - B-MEDICINE
or CCONJ - O
tigecycline NOUN - O
generated VERB - O
synergistic ADJ - O
anti JJ - B-PERSON
- JJ - I-PERSON
M. NNP - I-PERSON
abscessus NOUN - O
activity NOUN - O
, PUNCT - O
dropping VERB - O
the DET - O
rifabutin NOUN - O
MIC NNP - B-ORG
below ADP - O
concentrations NOUN - O
found VERB - O
in ADP - O
the DET - O
lung NOUN - O
. PUNCT - O

The DET - O
triple ADJ - O
combination NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
tigecycline NOUN - O
, PUNCT - O
and CCONJ - O
rifabutin NOUN - O
was VERB - O
also ADV - O
synergistic ADJ - O
, PUNCT - O
and CCONJ - O
clinically ADV - O
relevant ADJ - O
concentrations NOUN - O
had VERB - O
a DET - O
sterilizing VERB - O
effect NOUN - O
on ADP - O
M. NNP - B-ORG
abscessus NOUN - O
cultures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
investigated VERB - O
the DET - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
erythromycin NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
azithromycin NOUN - O
and CCONJ - O
roxithromycin VERB - O
on ADP - O
a DET - O
histamine NOUN - O
- PUNCT - O
induced VERB - O
animal NOUN - O
model NOUN - O
of ADP - O
otitis NOUN - O
media NOUN - O
with ADP - O
effusion NOUN - O
. PUNCT - O

The DET - O
animals NOUN - O
were VERB - O
divided VERB - O
into ADP - O
five CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
receiving VERB - O
erythromycin NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
azithromycin PROPN - O
, PUNCT - O
roxithromycin NOUN - O
or CCONJ - O
saline NOUN - O
solution NOUN - O
. PUNCT - O

The DET - O
guinea NOUN - O
pigs NOUN - O
in ADP - O
the DET - O
study NOUN - O
groups NOUN - O
received VERB - O
erythromycin NOUN - O
( PUNCT - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - O
day NOUN - O
) PUNCT - O
, PUNCT - O
clarithromycin NNP - B-MEDICINE
( PUNCT - O
15 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - O
day NOUN - O
) PUNCT - O
, PUNCT - O
azithromycin PROPN - O
( PUNCT - O
10 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - O
day NOUN - O
) PUNCT - O
or CCONJ - O
roxithromycin NOUN - O
( PUNCT - O
10 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - O
day NOUN - O
) PUNCT - O
for ADP - O
3 CD - B-DATE
days NNS - I-DATE
by ADP - O
gastric ADJ - O
tube NOUN - O
. PUNCT - O

The DET - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
properties NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
azithromycin NOUN - O
and CCONJ - O
roxithromycin NOUN - O
were VERB - O
similar ADJ - O
to ADP - O
one NOUN - O
another DET - O
, PUNCT - O
but CCONJ - O
better ADJ - O
than ADP - O
that DET - O
of ADP - O
erythromycin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
authors NOUN - O
focus VERB - O
on ADP - O
RHB-104 NNP - B-PERSON
, PUNCT - O
a DET - O
novel ADJ - O
oral ADJ - O
formulation NOUN - O
containing VERB - O
a DET - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
clofazimine NOUN - O
and CCONJ - O
rifabutin NOUN - O
, PUNCT - O
endowed VERB - O
with ADP - O
synergistic ADJ - O
inhibitory ADJ - O
activity NOUN - O
on ADP - O
MAP NNP - B-ORG
strains NOUN - O
isolated VERB - O
from ADP - O
CD NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sex NOUN - O
differences NOUN - O
in ADP - O
the DET - O
interaction NOUN - O
were VERB - O
reported VERB - O
between ADP - O
ketoconazole NOUN - O
and CCONJ - O
midazolam NOUN - O
as ADV - O
well ADV - O
as ADP - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
midazolam NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
no DET - O
sex NOUN - O
difference NOUN - O
was VERB - O
observed VERB - O
with ADP - O
the DET - O
interaction NOUN - O
between ADP - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
triazolam NOUN - O
or CCONJ - O
erythromycin NOUN - O
and CCONJ - O
triazolam NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
eradication NOUN - O
rate NOUN - O
of ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
triple ADJ - O
therapy NOUN - O
( PUNCT - O
a DET - O
proton NOUN - O
pump NOUN - O
inhibitor NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
amoxicillin NOUN - O
) PUNCT - O
for ADP - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
infection NOUN - O
has VERB - O
gradually ADV - O
decreased VERB - O
in ADP - O
Korea NNP - B-GPE
. PUNCT - O

We PRON - O
evaluated VERB - O
whether ADP - O
clinical ADJ - O
parameters NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
, PUNCT - O
and CCONJ - O
CYP2C19 NNP - B-ORG
genotype NOUN - O
can VERB - O
affect VERB - O
the DET - O
eradication NOUN - O
failure NOUN - O
. PUNCT - O

They PRON - O
received VERB - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
based VERB - O
triple ADJ - O
therapy NOUN - O
for ADP - O
7 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

A DET - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
test NOUN - O
was VERB - O
performed VERB - O
by ADP - O
detection NOUN - O
of ADP - O
A2142 NNP - B-PERSON
G NNP - I-PERSON
and CCONJ - O
A2143 NNP - B-PRODUCT
G NN - I-PRODUCT
point NOUN - O
mutations NOUN - O
in ADP - O
H. NNP - B-NORP
pylori NOUN - O
23S CD - B-GPE
rRNA PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
development NOUN - O
of ADP - O
diffuse NOUN - O
panbronchiolitis NOUN - O
during ADP - O
the DET - O
treatment NOUN - O
with ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
, PUNCT - O
low ADJ - O
- PUNCT - O
dose NOUN - O
clarithromycin NN - B-MEDICINE
for ADP - O
chronic ADJ - O
sinusitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
prevalence NOUN - O
of ADP - O
clarithromycin NNP - B-MEDICINE
( PUNCT - O
CLR)-resistant PROPN - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
is VERB - O
increasing VERB - O
worldwide ADV - O
, PUNCT - O
including VERB - O
in ADP - O
Vietnam NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Current ADJ - O
research NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
capacity NOUN - O
and CCONJ - O
molecular ADJ - O
interaction NOUN - O
of ADP - O
ion NOUN - O
pair NOUN - O
/ SYM - O
phospholipid NOUN - O
complex NOUN - O
during ADP - O
preparation NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
intravenous ADJ - O
lipid NOUN - O
microsphere ADV - O
( PUNCT - O
CLA NNP - B-ORG
- HYPH - I-ORG
LM NNP - I-ORG
) PUNCT - O
for ADP - O
improving VERB - O
drug NOUN - O
- PUNCT - O
loading NOUN - O
, PUNCT - O
stability NOUN - O
and CCONJ - O
antibacterial ADJ - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
2017 CD - B-DATE
, PUNCT - O
the DT - B-ORG
World NNP - I-ORG
Health NNP - I-ORG
Organization NNP - I-ORG
( PUNCT - O
WHO NOUN - O
) PUNCT - O
designated VERB - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Helicobacter NNP - B-PERSON
pylori VERB - O
a DET - O
high ADJ - O
priority NOUN - O
for ADP - O
antibiotic ADJ - O
research NOUN - O
and CCONJ - O
development NOUN - O
. PUNCT - O

We PRON - O
searched VERB - O
publication NOUN - O
databases NOUN - O
for ADP - O
studies NOUN - O
that ADJ - O
  SPACE - O
assessed ADJ - O
rates NOUN - O
of ADP - O
H PROPN - O
pylori NOUN - O
resistance NOUN - O
to PART - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
levofloxacin NOUN - O
, PUNCT - O
amoxicillin NOUN - O
, PUNCT - O
or CCONJ - O
tetracycline NOUN - O
. PUNCT - O

Primary ADJ - O
and CCONJ - O
secondary ADJ - O
resistance NOUN - O
rates NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
and CCONJ - O
levofloxacin NOUN - O
were VERB - O
≥15 NN - B-PERCENT
% NN - I-PERCENT
in ADP - O
all DET - O
WHO PROPN - O
regions NOUN - O
, PUNCT - O
except ADP - O
primary ADJ - O
clarithromycin NN - B-MEDICINE
resistance NOUN - O
in ADP - O
the DET - O
Americas NNPS - B-LOC
( PUNCT - O
10 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O
4%-16 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
South NNP - B-LOC
- HYPH - I-LOC
East NNP - I-LOC
Asia NNP - I-LOC
region NOUN - O
( PUNCT - O
10 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O
5%-16 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
  SPACE - O
primary ADJ - O
levofloxacin NOUN - O
resistance NOUN - O
in ADP - O
the DET - O
European JJ - B-NORP
region NOUN - O
( PUNCT - O
11 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
, PUNCT - O
9%-13 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Resistance NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
was VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
failure NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimens NOUN - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
, PUNCT - O
6.97 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
5.23 CD - B-CARDINAL
- SYM - O
9.28 NUM - O
; PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Metastable ADJ - O
crystal NOUN - O
form NOUN - O
I PRON - O
of ADP - O
the DET - O
antibiotic ADJ - O
clarithromycin NN - B-MEDICINE
has VERB - O
a DET - O
pharmaceutically ADV - O
valuable ADJ - O
characteristic NOUN - O
that ADP - O
its ADJ - O
crystalline ADJ - O
phase NOUN - O
transition NOUN - O
can VERB - O
be VERB - O
applied VERB - O
for ADP - O
its ADJ - O
sustained ADJ - O
release NOUN - O
from ADP - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Punctual ADJ - O
mutations NOUN - O
in ADP - O
23S CD - B-GPE
rRNA PROPN - O
gene NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
in ADP - O
Colombian JJ - B-NORP
populations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Concomitant NOUN - O
therapy NOUN - O
( PUNCT - O
a DET - O
proton NOUN - O
pump NOUN - O
inhibitor NOUN - O
, PUNCT - O
metronidazole NOUN - O
, PUNCT - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
amoxicillin NOUN - O
) PUNCT - O
is VERB - O
ineffective ADJ - O
with ADP - O
dual ADJ - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
metronidazole NOUN - O
resistance NOUN - O
and CCONJ - O
all DET - O
patients NOUN - O
receive VERB - O
at IN - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
unnecessary ADJ - O
antibiotic ADJ - O
thus ADV - O
promoting VERB - O
antimicrobial ADJ - O
resistance NOUN - O
worldwide ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Most ADJ - O
( PUNCT - O
94 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
M. PROPN - O
avium NOUN - O
intracellulare ADJ - O
complex NOUN - O
isolates NOUN - O
showed VERB - O
in ADP - O
vitro NOUN - O
susceptibility NOUN - O
to PART - O
clarithromycin VB - B-MEDICINE
. PUNCT - O

The DET - O
majority NOUN - O
of ADP - O
rapidly ADV - O
- PUNCT - O
growing VERB - O
mycobacteria NOUN - O
( PUNCT - O
RGM NNP - B-ORG
) PUNCT - O
demonstrated VERB - O
in ADP - O
vitro NOUN - O
susceptibility NOUN - O
to PART - O
amikacin VERB - O
, PUNCT - O
clarithromycin VB - B-MEDICINE
and CCONJ - O
cefoxitin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
association NOUN - O
between ADP - O
clarithromycin NN - B-MEDICINE
sensitivity NOUN - O
and CCONJ - O
treatment NOUN - O
outcome NOUN - O
is VERB - O
clear ADJ - O
. PUNCT - O

Clarithromycin NN - B-MEDICINE
susceptibility NOUN - O
genotyping NOUN - O
offers VERB - O
an DET - O
alternate ADJ - O
, PUNCT - O
rapid ADJ - O
approach NOUN - O
to ADP - O
predicting VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
based VERB - O
antibiotic ADJ - O
therapy NOUN - O
. PUNCT - O

M. PROPN - O
abscessus NOUN - O
lung NOUN - O
disease NOUN - O
patients NOUN - O
were VERB - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
based VERB - O
upon ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
susceptibility NOUN - O
genotype NOUN - O
of ADP - O
the DET - O
organism NOUN - O
isolated VERB - O
. PUNCT - O

Sixty CD - B-CARDINAL
- HYPH - I-CARDINAL
nine CD - I-CARDINAL
patients NOUN - O
were VERB - O
enrolled VERB - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
genotype NOUN - O
group NOUN - O
, PUNCT - O
which ADJ - O
included VERB - O
5 CD - B-CARDINAL
infected VERB - O
with ADP - O
rrl NOUN - O
2058 CD - B-DATE
- SYM - I-DATE
2059 CD - I-DATE
mutants NOUN - O
and CCONJ - O
64 CD - B-CARDINAL
infected VERB - O
with ADP - O
erm(41)T28-type PROPN - O
M. PROPN - O
abscessus NOUN - O
; PUNCT - O
31 CD - B-CARDINAL
were VERB - O
in ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
sensitive ADJ - O
group NOUN - O
, PUNCT - O
i.e. X - O
, PUNCT - O
6 CD - B-CARDINAL
and CCONJ - O
25 CD - B-CARDINAL
patients NOUN - O
infected VERB - O
with ADP - O
genotypes NOUN - O
erm(41)C28 PUNCT - O
and CCONJ - O
erm(41 ADJ - O
) PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
lung NOUN - O
disease NOUN - O
patients NOUN - O
infected VERB - O
with ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
sensitive ADJ - O
and CCONJ - O
-resistant PUNCT - O
M. NNP - B-PERSON
abscessus NOUN - O
genotypes NOUN - O
differed VERB - O
significantly ADV - O
in ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
based VERB - O
combination NOUN - O
treatment NOUN - O
outcomes NOUN - O
. PUNCT - O

Patients NOUN - O
infected VERB - O
with ADP - O
the DET - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
sensitive ADJ - O
genotype NOUN - O
exhibited VERB - O
higher ADJ - O
initial ADJ - O
and CCONJ - O
final ADJ - O
sputum NOUN - O
- PUNCT - O
negative ADJ - O
conversion NOUN - O
and CCONJ - O
radiological ADJ - O
improvement NOUN - O
rates NOUN - O
and CCONJ - O
better ADJ - O
therapeutic ADJ - O
outcomes NOUN - O
. PUNCT - O

Multivariate ADJ - O
analysis NOUN - O
demonstrated VERB - O
that ADP - O
genotyping NOUN - O
was VERB - O
a DET - O
reliable ADJ - O
and CCONJ - O
, PUNCT - O
more ADV - O
importantly ADV - O
, PUNCT - O
rapid ADJ - O
means NOUN - O
of ADP - O
predicting VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
- PUNCT - O
based VERB - O
antibiotic ADJ - O
treatment NOUN - O
for ADP - O
M. NNP - B-ORG
abscessus NOUN - O
lung NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eligible ADJ - O
patients NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
Pylorest NNP - B-PERSON
( PUNCT - O
a DET - O
three CD - B-CARDINAL
- PUNCT - O
in ADP - O
- PUNCT - O
one CD - B-CARDINAL
tablet NOUN - O
containing VERB - O
rabeprazole NOUN - O
20 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
amoxicillin NOUN - O
1 CD - B-CARDINAL
g NOUN - O
, PUNCT - O
and CCONJ - O
clarithromycin VBD - B-MEDICINE
500 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
and CCONJ - O
Syferol NNP - B-ORG
- HYPH - I-ORG
IHP NNP - I-ORG
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
followed VERB - O
by ADP - O
rabeprazole NOUN - O
and CCONJ - O
Syferol NNP - B-ORG
- HYPH - I-ORG
IHP NNP - I-ORG
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
or CCONJ - O
Pylorest NNP - B-PERSON
and CCONJ - O
placebo NOUN - O
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
followed VERB - O
by ADP - O
rabeprazole NOUN - O
and CCONJ - O
placebo NOUN - O
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Genetic ADJ - O
correlates NOUN - O
of ADP - O
clarithromycin NN - B-MEDICINE
susceptibility NOUN - O
among ADP - O
isolates NOUN - O
of ADP - O
the DET - O
Mycobacterium NNP - B-ORG
abscessus NOUN - O
group NOUN - O
and CCONJ - O
the DET - O
potential ADJ - O
clinical ADJ - O
applicability NOUN - O
of ADP - O
a DET - O
PCR PROPN - O
- PUNCT - O
based VERB - O
analysis NOUN - O
of ADP - O
erm(41 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
consideration NOUN - O
of ADP - O
these DET - O
immunomodulatory ADJ - O
effects NOUN - O
, PUNCT - O
we PRON - O
report VERB - O
a DET - O
patient NOUN - O
with ADP - O
primary ADJ - O
immune ADJ - O
thrombocytopenia NOUN - O
( PUNCT - O
ITP NNP - B-ORG
) PUNCT - O
treated VERB - O
using VERB - O
clarithromycin NN - B-MEDICINE
( PUNCT - O
CAM NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
macrolide NOUN - O
, PUNCT - O
followed VERB - O
by ADP - O
prednisolone NOUN - O
( PUNCT - O
PSL PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

New ADJ - O
single ADJ - O
capsule NOUN - O
of ADP - O
bismuth NOUN - O
, PUNCT - O
metronidazole NOUN - O
and CCONJ - O
tetracycline NOUN - O
given VERB - O
with ADP - O
omeprazole ADJ - O
versus ADP - O
quadruple NOUN - O
therapy NOUN - O
consisting VERB - O
of ADP - O
bismuth NOUN - O
, PUNCT - O
omeprazole NOUN - O
, PUNCT - O
amoxicillin NOUN - O
and CCONJ - O
clarithromycin NN - B-MEDICINE
for ADP - O
eradication NOUN - O
of ADP - O
Helicobacter NNP - B-ORG
pylori NOUN - O
in ADP - O
duodenal ADJ - O
ulcer NOUN - O
patients NOUN - O
: PUNCT - O
a DET - O
Chinese JJ - B-NORP
prospective NOUN - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
multicentre ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
examined VERB - O
the DET - O
1-year CD - B-DATE
risk NOUN - O
associated VERB - O
with ADP - O
treatment NOUN - O
with ADP - O
clarithromycin NNP - B-MEDICINE
( PUNCT - O
n NOUN - O
= SYM - O
187,887 CD - B-CARDINAL
) PUNCT - O
or CCONJ - O
roxithromycin NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
698,899 CD - B-CARDINAL
) PUNCT - O
compared VERB - O
with ADP - O
penicillin NOUN - O
V NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
3,473,081 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
matched VERB - O
1:4 CD - B-CARDINAL
on ADP - O
propensity NOUN - O
score NOUN - O
, PUNCT - O
in ADP - O
a DET - O
nationwide ADJ - O
, PUNCT - O
registry NOUN - O
- PUNCT - O
based VERB - O
cohort NOUN - O
study NOUN - O
in ADP - O
Danish JJ - B-NORP
outpatients NOUN - O
, PUNCT - O
1997 CD - B-DATE
- SYM - I-DATE
2011 CD - I-DATE
. PUNCT - O

Among ADP - O
clarithromycin NN - B-MEDICINE
courses NOUN - O
, PUNCT - O
the DET - O
rate NOUN - O
ratio NOUN - O
for ADP - O
cardiovascular ADJ - O
death NOUN - O
was VERB - O
1.24 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
: PUNCT - O
0.96 CD - B-CARDINAL
, PUNCT - O
1.59 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

In ADP - O
analyses NOUN - O
by ADP - O
time NOUN - O
after ADP - O
treatment NOUN - O
start NOUN - O
, PUNCT - O
the DET - O
rate NOUN - O
ratio NOUN - O
associated VERB - O
with ADP - O
clarithromycin NN - B-MEDICINE
was VERB - O
1.66 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
: PUNCT - O
0.98 CD - B-CARDINAL
, PUNCT - O
2.79 CD - B-CARDINAL
) PUNCT - O
during ADP - O
days NOUN - O
0 CD - B-DATE
- SYM - I-DATE
7 CD - I-DATE
. PUNCT - O

With ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
we PRON - O
observed VERB - O
a DET - O
transient NOUN - O
increased VERB - O
risk NOUN - O
during ADP - O
days NNS - B-DATE
0 CD - B-DATE
- SYM - I-DATE
7 CD - I-DATE
after ADP - O
treatment NOUN - O
start NOUN - O
, PUNCT - O
which ADJ - O
corresponds VERB - O
to ADP - O
the DET - O
period NOUN - O
of ADP - O
active ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
boy NOUN - O
required VERB - O
surgery NOUN - O
and CCONJ - O
underwent VERB - O
initial ADJ - O
treatment NOUN - O
with ADP - O
clarithromycin NN - B-MEDICINE
, PUNCT - O
amikacin NOUN - O
, PUNCT - O
and CCONJ - O
tigecycline VERB - O
for ADP - O
4 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

He PRON - O
was VERB - O
treated VERB - O
successfully ADV - O
with ADP - O
3 CD - B-DATE
months NNS - I-DATE
of ADP - O
subsequent ADJ - O
oral ADJ - O
clarithromycin NN - B-MEDICINE
and CCONJ - O
linezolid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

When ADV - O
M. NNP - B-PERSON
bovis NOUN - O
was VERB - O
typified VERB - O
, PUNCT - O
clarithromycin NNP - B-MEDICINE
was VERB - O
added VERB - O
in ADP - O
the DET - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

All DET - O
clinical ADJ - O
isolates NOUN - O
of ADP - O
M. NNP - B-ORG
simiae PROPN - O
were VERB - O
resistant ADJ - O
to PART - O
isoniazid VERB - O
, PUNCT - O
rifampicin NOUN - O
, PUNCT - O
ethambutol VERB - O
, PUNCT - O
streptomycin NOUN - O
, PUNCT - O
amikacin NOUN - O
, PUNCT - O
kanamycin NOUN - O
, PUNCT - O
ciprofloxacin NOUN - O
and CCONJ - O
clarithromycin NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

MODIFIED PROPN - O
RELEASE PROPN - O
VENLAFAXINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
TABLETS NOUN - O

-DOCSTART- -X- - O

PROCESSES NOUN - O
FOR ADP - O
PREPARING NOUN - O
VENLAFAXINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
OF ADP - O
FORM NOUN - O

-DOCSTART- -X- - O

EXTENDED NOUN - O
RELEASE PROPN - O
COATED PROPN - O
MICROTABLETS NOUN - O
OF ADP - O
VENLAFAXINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

EXTENDED NOUN - O
RELEASE PROPN - O
COATED PROPN - O
MICROTABLETS NOUN - O
OF ADP - O
VENLAFAXINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

VENLAFAXINE NNP - B-PERSON
HYDROCHLORIDE NNP - I-PERSON
MONOHYDRATE NOUN - O
AND CCONJ - O
METHODS NOUN - O
FOR ADP - O
THE DET - O
PREPARATION NOUN - O
THEREOF NOUN - O

-DOCSTART- -X- - O

NOVEL PROPN - O
EXTENDED NOUN - O
RELEASE NOUN - O
COMPOSITION NOUN - O
OF ADP - O
VENLAFAXINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
CONTAINING PROPN - O
POLYVINYL PROPN - O
ACETATE ADJ - O

-DOCSTART- -X- - O

Gabriel NNP - B-PERSON
C. NNP - I-PERSON
Lander NNP - I-MEDICINE
and CCONJ - O
Takanori PROPN - O
Otomo PROPN - O
are VERB - O
both DET - O
co ADJ - O
- ADJ - O
corresponding ADJ - O
authors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
present VERB - O
an DET - O
investigation NOUN - O
of ADP - O
the DET - O
chemical ADJ - O
stability NOUN - O
of ADP - O
the DET - O
reagents NOUN - O
and CCONJ - O
associated VERB - O
fused ADJ - O
silica NOUN - O
capillary NOUN - O
after ADP - O
a DET - O
total ADJ - O
ionizing VERB - O
dose NOUN - O
of ADP - O
300 CD - B-CARDINAL
krad NOUN - O
, PUNCT - O
exceeding VERB - O
the DET - O
predicted VERB - O
total NOUN - O
ionizing NOUN - O
dose NOUN - O
for ADP - O
the DET - O
potential ADJ - O
Europa NNP - B-ORG
Lander NNP - I-MEDICINE
Mission NNP - I-ORG
payload NOUN - O
by ADP - O
two CD - B-CARDINAL
- RB - I-CARDINAL
fold NN - I-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Hydrogen NN - B-ORG
bonding NOUN - O
between ADP - O
three CD - B-CARDINAL
- PUNCT - O
dimensional ADJ - O
Lander NNP - B-MEDICINE
- HYPH - I-ORG
DAT NNP - I-ORG
molecules NNS - I-ORG
and CCONJ - O
planar NOUN - O
PTCDI PROPN - O
molecules NOUN - O
, PUNCT - O
adsorbed VERB - O
closer ADV - O
to ADP - O
the DET - O
surface NOUN - O
, PUNCT - O
is VERB - O
found VERB - O
to PART - O
be VERB - O
facilitated VERB - O
by ADP - O
electrostatic ADJ - O
interactions NOUN - O
between ADP - O
co NOUN - O
- NOUN - O
adsorbed ADJ - O
Ni NNP - B-ORG
adatoms NOUN - O
and CCONJ - O
the DET - O
flexible ADJ - O
molecular ADJ - O
DAT PROPN - O
groups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
achieve VERB - O
the DET - O
C NOUN - O
- PUNCT - O
terminal NOUN - O
tagging NOUN - O
of ADP - O
endogenous ADJ - O
proteins NOUN - O
in ADP - O
T. PROPN - O
cruzi VERB - O
we PRON - O
use VERB - O
the DET - O
Cas9/pTREX NNP - B-PRODUCT
- PUNCT - O
n PART - O
vector NOUN - O
( PUNCT - O
Lander NNP - B-MEDICINE
et NNP - I-PERSON
al NNP - I-PERSON
. PROPN - O
, PUNCT - O
2015 CD - B-DATE
) PUNCT - O
to PART - O
insert VERB - O
a DET - O
specific ADJ - O
tag NOUN - O
sequence NOUN - O
( PUNCT - O
3xHA CD - B-ORDINAL
or CCONJ - O
3xc NNP - B-ORDINAL
- PUNCT - O
Myc PROPN - O
) PUNCT - O
at ADP - O
the DET - O
3 CD - B-CARDINAL
' PART - O
end NOUN - O
of ADP - O
a DET - O
specific ADJ - O
gene NOUN - O
of ADP - O
interest NOUN - O
( PUNCT - O
GOI NNP - B-ORG
) PUNCT - O
. PUNCT - O

Vectors NNS - B-ORG
pMOTag23 NN - I-ORG
M NNP - I-ORG
( PUNCT - O
Oberholzer PROPN - O
et PROPN - O
al PROPN - O
. PROPN - O
, PUNCT - O
2006 CD - B-DATE
) PUNCT - O
or CCONJ - O
pMOHX1Tag4H VERB - O
( PUNCT - O
Lander NNP - B-MEDICINE
et NNP - I-WORK_OF_ART
al NNP - I-WORK_OF_ART
. PROPN - O
, PUNCT - O
2016b NNS - B-DATE
) PUNCT - O
are VERB - O
used VERB - O
as ADP - O
PCR PROPN - O
templates VERB - O
for ADP - O
DNA NOUN - O
donor NOUN - O
amplification NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
reanalyze VERB - O
Lander NNP - B-MEDICINE
et NNP - I-PERSON
al NNP - I-PERSON
. PUNCT - O
data NOUN - O
to PART - O
show VERB - O
how ADV - O
they PRON - O
appear VERB - O
to PART - O
have VERB - O
missed VERB - O
observing VERB - O
positive ADJ - O
results NOUN - O
, PUNCT - O
and CCONJ - O
we PRON - O
highlight VERB - O
differences NOUN - O
in ADP - O
experimental ADJ - O
methods NOUN - O
and CCONJ - O
interpretations NOUN - O
that ADJ - O
may VERB - O
explain VERB - O
our ADJ - O
different ADJ - O
results NOUN - O
and CCONJ - O
conclusions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
significantly ADV - O
improved VERB - O
the DET - O
functional ADJ - O
state NOUN - O
of ADP - O
the DET - O
liver NOUN - O
in ADP - O
paracetamol NOUN - O
- PUNCT - O
induced VERB - O
acute ADJ - O
toxic ADJ - O
hepatitis NOUN - O
to ADP - O
a DET - O
greater ADJ - O
extent NOUN - O
than ADP - O
propranolol NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
was VERB - O
superior ADJ - O
to PART - O
propranolol VERB - O
against ADP - O
CCl4-induced ADJ - O
hepatic ADJ - O
injury NOUN - O
and CCONJ - O
fibrogenesis NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
also ADV - O
decreased VERB - O
portal ADJ - O
perfusion NOUN - O
pressure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
is VERB - O
an DET - O
antioxidant NOUN - O
that ADJ - O
decreases VERB - O
inflammation NOUN - O
in ADP - O
periodontitis NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
gel NOUN - O
has VERB - O
the DET - O
potential NOUN - O
of ADP - O
minimizing VERB - O
H2 PROPN - O
O2 ADJ - O
damage NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
deep ADJ - O
regions NOUN - O
of ADP - O
the DET - O
dental ADJ - O
pulp NOUN - O
of ADP - O
rats NOUN - O
after ADP - O
bleaching VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
was VERB - O
superior ADJ - O
to PART - O
metoprolol NOUN - O
succinate VERB - O
in ADP - O
improving VERB - O
survival NOUN - O
free ADJ - O
of ADP - O
appropriate ADJ - O
ICD PROPN - O
therapy NOUN - O
( PUNCT - O
HR NOUN - O
0.42 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
0.24 NUM - O
- SYM - O
0.72 NUM - O
, PUNCT - O
P NOUN - O
= SYM - O
0.01 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
was VERB - O
orally ADV - O
administrated VERB - O
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
1 CD - B-CARDINAL
or CCONJ - O
10 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - O
day NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
leciplex NOUN - O
reduced VERB - O
intraocular ADJ - O
pressure NOUN - O
( PUNCT - O
IOP NNP - B-ORG
) PUNCT - O
to ADP - O
normal ADJ - O
range NOUN - O
in ADP - O
ocular ADJ - O
hypertensive ADJ - O
rabbits NOUN - O
after ADP - O
30 CD - B-CARDINAL
min NOUN - O
and CCONJ - O
duration NOUN - O
of ADP - O
action NOUN - O
lasted VERB - O
for ADP - O
24 CD - B-CARDINAL
h NUM - O
, PUNCT - O
while ADP - O
carvedilol NN - B-MEDICINE
solution NOUN - O
reduced VERB - O
IOP NNP - B-ORG
to ADP - O
normal ADJ - O
value NOUN - O
after ADP - O
60 CD - B-QUANTITY
min NN - I-QUANTITY
and CCONJ - O
duration NOUN - O
of ADP - O
action NOUN - O
lasted VERB - O
for ADP - O
6 CD - B-CARDINAL

-DOCSTART- -X- - O

Carvedilol NN - B-MEDICINE
users NOUN - O
were VERB - O
propensity NOUN - O
matched VERB - O
1:1 CD - B-CARDINAL
for ADP - O
co NOUN - O
- NOUN - O
treatments NOUN - O
, PUNCT - O
age NOUN - O
, PUNCT - O
gender NOUN - O
, PUNCT - O
and CCONJ - O
year NOUN - O
of ADP - O
inclusion NOUN - O
in ADP - O
the DET - O
cohort NOUN - O
with ADP - O
metoprolol NOUN - O
/ SYM - O
bisoprolol NOUN - O
/ SYM - O
nebivolol NOUN - O
users NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
users NOUN - O
had VERB - O
a DET - O
higher ADJ - O
hazard NOUN - O
for ADP - O
heart NOUN - O
failure NOUN - O
hospitalization NOUN - O
( PUNCT - O
HR PROPN - O
1.29 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
Confidence PROPN - O
Interval PROPN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
1.18 CD - B-CARDINAL
- SYM - O
1.40 NUM - O
) PUNCT - O
with ADP - O
106 CD - B-CARDINAL
( PUNCT - O
95%CI NUM - O
76 CD - B-CARDINAL
- SYM - O
134 NUM - O
; PUNCT - O
p PUNCT - O
- PUNCT - O
value NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
additional ADJ - O
cases NOUN - O
of ADP - O
heart NOUN - O
failure NOUN - O
hospitalization NOUN - O
per ADP - O
10000 CD - B-CARDINAL
person NN - B-DATE
- HYPH - I-DATE
years NNS - I-DATE
if ADP - O
compared VERB - O
to ADP - O
metoprolol NOUN - O
/ SYM - O
bisoprolol NOUN - O
/ SYM - O
nebivolol NOUN - O
users NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
users NOUN - O
had VERB - O
a DET - O
higher ADJ - O
hazard NOUN - O
( PUNCT - O
HR NOUN - O
1.06 CD - B-CARDINAL
; PUNCT - O
95%CI NUM - O
1.02 CD - B-CARDINAL
- SYM - O
1.10 NUM - O
) PUNCT - O
of ADP - O
discontinuing VERB - O
the DET - O
pharmacological ADJ - O
treatment NOUN - O
with ADP - O
131 CD - B-CARDINAL
( PUNCT - O
95%CI NUM - O
62 CD - B-CARDINAL
- SYM - O
201 NUM - O
; PUNCT - O
p PUNCT - O
- PUNCT - O
value NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
additional ADJ - O
cases NOUN - O
of ADP - O
beta NOUN - O
- PUNCT - O
blocker NOUN - O
discontinuation NOUN - O
per ADP - O
10000 CD - B-CARDINAL
person NOUN - O
- PUNCT - O
years NOUN - O
metoprolol NOUN - O
/ SYM - O
bisoprolol NOUN - O
/ SYM - O
nebivolol NOUN - O
users NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hyperkalemia NNP - B-ORG
Induced VBN - I-ORG
by ADP - O
the DT - B-ORG
Sequential NNP - I-ORG
Administration NNP - I-ORG
of IN - I-ORG
Metoprolol NNP - I-ORG
and CCONJ - O
Carvedilol NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Anti ADJ - O
- ADJ - O
fibrotic ADJ - O
impact NOUN - O
of ADP - O
Carvedilol NNP - B-MEDICINE
in ADP - O
a DET - O
CCl-4 NNP - B-ORG
model NOUN - O
of ADP - O
liver NOUN - O
fibrosis NOUN - O
via ADP - O
serum NOUN - O
microRNA-200a PROPN - O
/ SYM - O
SMAD7 NNP - B-GPE
enhancement NOUN - O
to PART - O
bridle VERB - O
TGF NNP - B-ORG
- HYPH - I-ORG
β1/EMT NNP - I-ORG
track NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison PROPN - O
of ADP - O
Efficacy NNP - B-ORG
between ADP - O
Ramipril NNP - B-PERSON
and CCONJ - O
Carvedilol NNP - B-MEDICINE
on ADP - O
Limiting VERB - O
the DET - O
Expansion NOUN - O
of ADP - O
Abdominal PROPN - O
Aortic PROPN - O
Aneurysm PROPN - O
in ADP - O
Mouse NNP - B-ORG
Model NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
Prevents VERB - O
Redox PROPN - O
Inactivation PROPN - O
of ADP - O
Cardiomyocyte PROPN - O
Β1-Adrenergic PROPN - O
Receptors PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
CYP2D6 NOUN - O
Polymorphism PROPN - O
on ADP - O
the DT - B-ORG
Pharmacokinetic JJ - I-ORG
/ SYM - I-ORG
Pharmacodynamic NNP - I-ORG
Characteristics NNPS - I-ORG
of ADP - O
Carvedilol NNP - B-MEDICINE
in ADP - O
Healthy ADJ - O
Korean ADJ - O
Volunteers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Bisoprolol NNP - B-ORG
Are VBP - I-ORG
Comparable JJ - I-ORG
with ADP - O
Carvedilol NNP - B-MEDICINE
in ADP - O
Secondary PROPN - O
Prevention PROPN - O
of ADP - O
Acute PROPN - O
Myocardial PROPN - O
Infarction PROPN - O
in ADP - O
Patients PROPN - O
Undergoing VERB - O
Percutaneous ADJ - O
Coronary PROPN - O
Intervention PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Can VERB - O
Carvedilol NNP - B-MEDICINE
Prevent PROPN - O
Chemotherapy PROPN - O
- PUNCT - O
Related VERB - O
Cardiotoxicity PROPN - O
? PUNCT - O
: PUNCT - O
A DET - O
Dream NOUN - O
to PART - O
Be VERB - O
Balanced ADJ - O
With ADP - O
Tolerability PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Compatibility PROPN - O
of ADP - O
Baclofen PROPN - O
, PUNCT - O
Carvedilol NNP - B-MEDICINE
, PUNCT - O
Hydrochlorothiazide PROPN - O
, PUNCT - O
Mercaptopurine NNP - B-PERSON
, PUNCT - O
Methadone NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Oseltamivir NNP - B-PERSON
Phosphate NNP - I-PERSON
, PUNCT - O
Phenobarbital JJ - B-ORG
, PUNCT - O
Propranolol NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Pyrazinamide NNP - B-GPE
, PUNCT - O
Sotalol NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Spironolactone PROPN - O
, PUNCT - O
Tacrolimus NNP - B-PERSON
Monohydrate NNP - I-PERSON
, PUNCT - O
Ursodeoxycholic PROPN - O
Acid PROPN - O
, PUNCT - O
and CCONJ - O
Vancomycin NNP - B-ORG
Hydrochloride NNP - I-ORG
Oral NNP - I-ORG
Suspensions NNPS - I-ORG
Compounded NNP - I-ORG
with ADP - O
SyrSpend PROPN - O
SF PROPN - O
pH4 PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
12.5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
d NOUN - O
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
6.25 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
d NOUN - O
in ADP - O
decreasing VERB - O
HVPG NNP - B-ORG
in ADP - O
primary ADJ - O
prophylaxis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
Carvedilol NNP - B-MEDICINE
, PUNCT - O
as ADP - O
the DET - O
classic ADJ - O
anti ADJ - O
- ADJ - O
heart ADJ - O
failure NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
clinic NOUN - O
drug NOUN - O
, PUNCT - O
could VERB - O
inhibit VERB - O
the DET - O
TLR4 NNP - B-ORG
signaling NOUN - O
in ADP - O
the DET - O
TLR4 NNP - B-ORG
overexpressed ADJ - O
cells NOUN - O
. PUNCT - O

Herein NNP - B-PERSON
, PUNCT - O
we PRON - O
have VERB - O
designed VERB - O
and CCONJ - O
synthesized VERB - O
a DET - O
small ADJ - O
library NOUN - O
of ADP - O
novel ADJ - O
Carvedilol NNP - B-MEDICINE
derivatives NOUN - O
and CCONJ - O
investigated VERB - O
their ADJ - O
potential ADJ - O
inhibitory NOUN - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
is VERB - O
used VERB - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
hypertension NOUN - O
, PUNCT - O
ischemic ADJ - O
heart NOUN - O
disease NOUN - O
, PUNCT - O
heart NOUN - O
failure NOUN - O
and CCONJ - O
most ADV - O
recently ADV - O
, PUNCT - O
portal ADJ - O
hypertension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
and CCONJ - O
nebivolol NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
metoprolol NOUN - O
, PUNCT - O
had VERB - O
positive ADJ - O
results NOUN - O
regarding VERB - O
cardioprotection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

NEW NNP - B-ORG
& CC - I-ORG
NOTEWORTHY NNP - I-ORG
Carvedilol NNP - I-MEDICINE
improves VERB - O
biventricular ADJ - O
function NOUN - O
in ADP - O
experimental ADJ - O
pulmonary ADJ - O
arterial ADJ - O
hypertension NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
mechanisms NOUN - O
of ADP - O
heart NOUN - O
rate NOUN - O
reduction NOUN - O
versus ADP - O
β DET - O
- PUNCT - O
blocker NOUN - O
effect NOUN - O
are VERB - O
inadequately ADV - O
defined VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
, PUNCT - O
an DET - O
antihypertensive ADJ - O
drug NOUN - O
, PUNCT - O
was VERB - O
chosen VERB - O
and CCONJ - O
formulated VERB - O
using VERB - O
solvent NOUN - O
- PUNCT - O
based VERB - O
electrospinning VERB - O
to PART - O
overcome VERB - O
the DET - O
poor ADJ - O
water NOUN - O
solubility NOUN - O
of ADP - O
the DET - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
was VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
hearing VERB - O
loss NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topically ADV - O
Applied ADJ - O
Carvedilol NNP - B-MEDICINE
Attenuates VERB - O
Solar ADJ - O
Ultraviolet PROPN - O
Radiation NOUN - O
Induced VERB - O
Skin NOUN - O
Carcinogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
was VERB - O
orally ADV - O
administrated VERB - O
in ADP - O
rats NOUN - O
( PUNCT - O
3.57 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg VBZ - I-QUANTITY
body NOUN - O
weight NOUN - O
[ PUNCT - O
b.w PROPN - O
. PUNCT - O
] PUNCT - O
) PUNCT - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
citalopram NOUN - O
or CCONJ - O
after ADP - O
a DET - O
pre ADJ - O
- ADJ - O
treatment NOUN - O
with ADP - O
multiple ADJ - O
oral ADJ - O
doses NOUN - O
of ADP - O
citalopram NOUN - O
( PUNCT - O
1.42 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
b.w PROPN - O
. PUNCT - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
has VERB - O
been VERB - O
shown VERB - O
to PART - O
be VERB - O
cardioprotective ADJ - O
by ADP - O
reducing VERB - O
cardiac ADJ - O
pro ADJ - O
- ADJ - O
inflammatory ADJ - O
cytokines NOUN - O
present ADJ - O
in ADP - O
oxidative ADJ - O
stress NOUN - O
in ADP - O
certain ADJ - O
heart NOUN - O
diseases NOUN - O
. PUNCT - O

Carvedilol NN - B-MEDICINE
in ADP - O
3 CD - B-CARDINAL
doses NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
, PUNCT - O
10 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
30 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
was VERB - O
given VERB - O
daily RB - B-DATE
to ADP - O
3 CD - B-CARDINAL
study NOUN - O
groups NOUN - O
of ADP - O
rats NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
with ADP - O
experimental ADJ - O
autoimmune NOUN - O
myocarditis NOUN - O
by ADP - O
gastric ADJ - O
gavage NOUN - O
for ADP - O
3 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Carvedilol NNP - B-MEDICINE
in ADP - O
all DET - O
doses NOUN - O
tested VERB - O
, PUNCT - O
had VERB - O
no DET - O
impact NOUN - O
on ADP - O
severity NOUN - O
of ADP - O
inflammation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carvedilol NNP - B-MEDICINE
succeeded VERB - O
in ADP - O
reducing VERB - O
hind NOUN - O
paw X - O
edema NOUN - O
in ADP - O
both DET - O
histamine NOUN - O
- PUNCT - O
induced VERB - O
paw NOUN - O
edema NOUN - O
and CCONJ - O
formaldehyde NOUN - O
- PUNCT - O
induced VERB - O
arthritis NOUN - O
and CCONJ - O
in ADP - O
reducing VERB - O
the DET - O
elevated ADJ - O
level NOUN - O
of ADP - O
tumor NOUN - O
necrosis NOUN - O
factor NOUN - O
- PUNCT - O
α NOUN - O
and CCONJ - O
prostaglandin NOUN - O
E2 PROPN - O
nearly ADV - O
with ADP - O
near ADP - O
equal ADJ - O
efficacy NOUN - O
compared VERB - O
with ADP - O
lornoxicam NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
did VERB - O
not ADV - O
show VERB - O
any DET - O
ulcerative ADJ - O
effect NOUN - O
on ADP - O
the DET - O
gastric ADJ - O
mucosa NOUN - O
of ADP - O
normal ADJ - O
rats NOUN - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
was VERB - O
associated VERB - O
with ADP - O
an DET - O
improvement NOUN - O
of ADP - O
both CCONJ - O
the DET - O
gross ADJ - O
and CCONJ - O
histopathological ADJ - O
pictures NOUN - O
of ADP - O
gastric ADJ - O
ulcers NOUN - O
in ADP - O
animals NOUN - O
of ADP - O
the DET - O
cold ADJ - O
stress NOUN - O
ulcer NOUN - O
model NOUN - O
compared VERB - O
with ADP - O
lornoxicam NOUN - O
treated VERB - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
our ADJ - O
retrospective ADJ - O
analysis NOUN - O
, PUNCT - O
the DET - O
combination NOUN - O
therapy NOUN - O
with ADP - O
Amiodarone NNP - B-ORG
and CCONJ - O
Carvedilol NNP - B-MEDICINE
had VERB - O
highly ADV - O
significant ADJ - O
decrease NOUN - O
arrhythmic ADJ - O
death NOUN - O
compare VERB - O
with ADP - O
carvedilol NN - B-MEDICINE
and CCONJ - O
amiodarone ADJ - O
groups NOUN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
is VERB - O
an DET - O
effective ADJ - O
additional ADJ - O
therapy NOUN - O
for ADP - O
the DET - O
patients NOUN - O
with ADP - O
chronic ADJ - O
heart NOUN - O
failure NOUN - O
already ADV - O
receiving VERB - O
Amiodarone PROPN - O
. PUNCT - O

Carvedilol NNP - B-MEDICINE
can VERB - O
be VERB - O
added VERB - O
to ADP - O
Amiodarone PROPN - O
in ADP - O
patients NOUN - O
with ADP - O
severe ADJ - O
ventricular ADJ - O
rhythm NOUN - O
disorders NOUN - O
and CCONJ - O
increased VERB - O
risk NOUN - O
of ADP - O
sudden ADJ - O
death NOUN - O
without ADP - O
expecting NOUN - O
of ADP - O
increase NOUN - O
adverse ADJ - O
events NOUN - O
( PUNCT - O
than ADP - O
either DET - O
drug NOUN - O
alone ADV - O
) PUNCT - O
or CCONJ - O
loss NOUN - O
of ADP - O
clinical ADJ - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
paper NOUN - O
, PUNCT - O
we PRON - O
synthesized VERB - O
the DET - O
fluorescent NOUN - O
- PUNCT - O
labeling VERB - O
drug NOUN - O
by ADP - O
covalently ADV - O
binding VERB - O
Aspirin NNP - B-MEDICINE
with ADP - O
rare ADJ - O
earth NOUN - O
ions NOUN - O
Terbium PROPN - O
( PUNCT - O
Te PROPN - O
) PUNCT - O
and CCONJ - O
Gadolinium PROPN - O
( PUNCT - O
Gd PROPN - O
) PUNCT - O
, PUNCT - O
which ADJ - O
was VERB - O
incorporated VERB - O
into ADP - O
chitosan ADJ - O
microspheres NOUN - O
with ADP - O
magnetic ADJ - O
nanoparticles NOUN - O
Fe₃O₄ PROPN - O
to PART - O
prepare VERB - O
magnetic ADJ - O
and CCONJ - O
fluorescent ADJ - O
drug NOUN - O
delivery NOUN - O
system NOUN - O
. PUNCT - O

Compared VERB - O
with ADP - O
the DET - O
single ADJ - O
rare ADJ - O
earth NOUN - O
ion NOUN - O
complex NOUN - O
, PUNCT - O
the DET - O
multiple ADJ - O
rare ADJ - O
earth NOUN - O
ions NOUN - O
complexes NOUN - O
with ADP - O
Aspirin NNP - B-MEDICINE
TbxGd1-x(Aspirin)₃ NNP - I-PERSON
· NFP - I-PERSON

-DOCSTART- -X- - O

Aspirin NN - B-MEDICINE
delays VERB - O
the DET - O
development NOUN - O
of ADP - O
preeclampsia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ascertainment PROPN - O
of ADP - O
Aspirin NNP - B-MEDICINE
Exposure NNP - I-WORK_OF_ART
Using VBG - I-WORK_OF_ART
Structured VBN - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Unstructured JJ - I-WORK_OF_ART
Large JJ - I-WORK_OF_ART
- PUNCT - O
scale NOUN - O
Electronic PROPN - O
Health PROPN - O
Record PROPN - O
Data PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Association PROPN - O
of ADP - O
Long ADJ - O
- PUNCT - O
term NOUN - O
Use PROPN - O
of ADP - O
Low PROPN - O
- PUNCT - O
Dose PROPN - O
Aspirin NNP - B-MEDICINE
as ADP - O
Chemoprevention PROPN - O
With ADP - O
Risk PROPN - O
of ADP - O
Lung PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
Use PROPN - O
among ADP - O
Adults PROPN - O
with ADP - O
Cardiovascular PROPN - O
Disease PROPN - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
: PUNCT - O
Implications NOUN - O
for ADP - O
an DET - O
Intervention PROPN - O
Approach PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Acute NNP - I-ORG
Stroke NNP - I-ORG
or CC - I-ORG
Transient PROPN - O
Ischemic PROPN - O
Attack PROPN - O
Treated VERB - O
with ADP - O
Ticagrelor PROPN - O
and CCONJ - O
Aspirin NNP - B-MEDICINE
for IN - I-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Stroke NNP - I-ORG
and CC - I-ORG
Death NN - I-ORG
( PUNCT - O
THALES NOUN - O
) PUNCT - O
trial NOUN - O
: PUNCT - O
Rationale PROPN - O
and CCONJ - O
design NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Low NNP - I-ORG
- HYPH - I-ORG
Dose NNP - I-ORG
Aspirin NNP - I-MEDICINE
on ADP - O
Biochemical NNP - B-ORG
and CC - I-ORG
Biophysical NNP - I-ORG
Biomarkers NNPS - I-ORG
for IN - I-ORG
Placental NNP - I-ORG
Disease NNP - I-ORG
in IN - I-ORG
Low NNP - I-ORG
- HYPH - I-ORG
Risk NN - I-ORG
Pregnancy NN - I-ORG
: PUNCT - O
Secondary JJ - B-ORG
Analysis NN - I-ORG
of ADP - O
a DET - O
Multicenter PROPN - O
RCT PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
is VERB - O
efficient ADJ - O
in ADP - O
secondary ADJ - O
prevention NOUN - O
of ADP - O
preeclampsia NOUN - O
essentially ADV - O
in ADP - O
patients NOUN - O
with ADP - O
a DET - O
personal ADJ - O
history NOUN - O
of ADP - O
preeclampsia NOUN - O
. PUNCT - O

Aspirin NNP - B-MEDICINE
, PUNCT - O
in ADP - O
primary ADJ - O
prevention NOUN - O
of ADP - O
preeclampsia NOUN - O
, PUNCT - O
given VERB - O
to ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
patients NOUN - O
identified VERB - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
trimester NOUN - O
by ADP - O
screening VERB - O
tests NOUN - O
, PUNCT - O
seems VERB - O
to PART - O
reduce VERB - O
the DET - O
occurrence NOUN - O
of ADP - O
early ADJ - O
- PUNCT - O
onset NOUN - O
preeclampsia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin FW - B-MEDICINE
versus ADP - O
rivaroxaban NOUN - O
in ADP - O
postoperative NOUN - O
bleeding NOUN - O
after ADP - O
total ADJ - O
knee NOUN - O
arthroplasty NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
case NOUN - O
- PUNCT - O
matched VERB - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Oral PROPN - O
Anticoagulants PROPN - O
and CCONJ - O
Aspirin NNP - B-MEDICINE
on ADP - O
Performance PROPN - O
of ADP - O
Fecal PROPN - O
Immunochemical PROPN - O
Tests PROPN - O
in ADP - O
Colorectal PROPN - O
Cancer PROPN - O
Screening PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
a DET - O
Simplified PROPN - O
Risk PROPN - O
Stratification PROPN - O
Twice PROPN - O
- PUNCT - O
Daily PROPN - O
Aspirin NNP - B-MEDICINE
Protocol PROPN - O
for ADP - O
Venous PROPN - O
Thromboembolism PROPN - O
Prophylaxis PROPN - O

-DOCSTART- -X- - O

Low ADJ - O
- PUNCT - O
Dose PROPN - O
Aspirin NNP - B-MEDICINE
for ADP - O
Primary PROPN - O
Prevention PROPN - O
of ADP - O
Cardiovascular PROPN - O
Events PROPN - O
in ADP - O
Elderly ADJ - O
Japanese ADJ - O
Patients NOUN - O
with ADP - O
Atherosclerotic NNP - B-ORG
Risk NNP - I-ORG
Factors NNPS - I-ORG
: PUNCT - O
Subanalysis NOUN - O
of ADP - O
a DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
( PUNCT - O
JPPP-70 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
used VERB - O
platelet NOUN - O
inhibitor NOUN - O
to PART - O
prevent VERB - O
thrombotic ADJ - O
events NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
for ADP - O
Primary PROPN - O
Prevention PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
eugenol NOUN - O
ester NOUN - O
( PUNCT - O
AEE NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
new ADJ - O
drug NOUN - O
compound NOUN - O
synthesized VERB - O
by ADP - O
combining VERB - O
aspirin NN - B-MEDICINE
with ADP - O
eugenol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
( PUNCT - O
acetylsalicylic ADJ - O
acid NOUN - O
, PUNCT - O
ASA NNP - B-ORG
) PUNCT - O
, PUNCT - O
as ADP - O
a DET - O
multifunctional ADJ - O
drug NOUN - O
has VERB - O
also ADV - O
been VERB - O
reported VERB - O
to PART - O
exert VERB - O
hypoglycemic ADJ - O
effects NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
diabetes NOUN - O
. PUNCT - O

Aspirin NNP - B-MEDICINE
pretreatment NOUN - O
of ADP - O
HP PROPN - O
- PUNCT - O
diabetic ADJ - O
animals NOUN - O
is VERB - O
manifested VERB - O
with ADP - O
significantly ADV - O
lower ADJ - O
blood NOUN - O
and CCONJ - O
liver NOUN - O
glucose NOUN - O
, PUNCT - O
higher ADJ - O
G6P ADJ - O
concentration NOUN - O
, PUNCT - O
lower ADJ - O
G6P NOUN - O
- PUNCT - O
ase PROPN - O
and CCONJ - O
HK PROPN - O
activity NOUN - O
as ADV - O
well ADV - O
as ADP - O
higher ADJ - O
Glk NNP - B-PERSON
content NOUN - O
and CCONJ - O
GPho PROPN - O
- PUNCT - O
ase NOUN - O
activity NOUN - O
, PUNCT - O
compared VERB - O
both DET - O
to ADP - O
diabetic ADJ - O
and CCONJ - O
HP PROPN - O
- PUNCT - O
diabetic ADJ - O
animals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Time NNP - B-ORG
- HYPH - I-ORG
Dependent NNP - I-ORG
Hypotensive NNP - I-ORG
Effect NNP - I-ORG
of ADP - O
Aspirin NNP - B-MEDICINE
in ADP - O
Mice NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
was VERB - O
the DET - O
primary ADJ - O
suspect NOUN - O
NSAID NNP - B-ORG
in ADP - O
72.5 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
cases NOUN - O
. PUNCT - O

Aspirin NN - B-MEDICINE
, PUNCT - O
rivaroxaban NOUN - O
, PUNCT - O
and CCONJ - O
concurrent ADJ - O
NSAID NNP - B-ORG
were VERB - O
significant ADJ - O
predictors NOUN - O
of ADP - O
GI NNP - B-ORG
bleed NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Double PROPN - O
- PUNCT - O
Blind PROPN - O
, PUNCT - O
Randomized VERB - O
, PUNCT - O
Placebo PROPN - O
- PUNCT - O
Controlled PROPN - O
Study PROPN - O
of ADP - O
Aspirin NNP - B-MEDICINE
and CCONJ - O
N PROPN - O
- PUNCT - O
Acetylcysteine PROPN - O
as ADP - O
Adjunctive PROPN - O
Treatments PROPN - O
for ADP - O
Bipolar PROPN - O
Depression PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Both CCONJ - O
Aspirin NNP - B-MEDICINE
and CCONJ - O
Clopidogrel NNP - B-PERSON
are VERB - O
considered VERB - O
as ADP - O
effective ADJ - O
drugs NOUN - O
in ADP - O
decreasing VERB - O
ischemic ADJ - O
events NOUN - O
, PUNCT - O
which ADJ - O
potentially ADV - O
contribute VERB - O
to ADP - O
a DET - O
promising ADJ - O
application NOUN - O
regarding VERB - O
the DET - O
cardiovascular ADJ - O
events NOUN - O
. PUNCT - O

In ADP - O
the DET - O
present ADJ - O
study NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
the DET - O
combination NOUN - O
of ADP - O
both CCONJ - O
Clopidogrel NNP - B-PERSON
and CCONJ - O
Aspirin NNP - B-MEDICINE
to PART - O
determine VERB - O
the DET - O
influence NOUN - O
among ADP - O
inflammatory ADJ - O
factors NOUN - O
, PUNCT - O
cardiac ADJ - O
function NOUN - O
, PUNCT - O
and CCONJ - O
treatment NOUN - O
outcome NOUN - O
of ADP - O
patients NOUN - O
suffering VERB - O
from ADP - O
ST NNP - B-ORG
- PUNCT - O
segment NOUN - O
elevation NOUN - O
myocardial NOUN - O
infarction NOUN - O
( PUNCT - O
STEMI NNP - B-ORG
) PUNCT - O
in ADP - O
the DET - O
Hebei NNP - B-GPE
province NOUN - O
of ADP - O
China NNP - B-GPE
. PUNCT - O

To PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
this DET - O
combination NOUN - O
therapy NOUN - O
with ADP - O
a DET - O
single ADJ - O
Aspirin NNP - B-MEDICINE
treatment NOUN - O
, PUNCT - O
we PRON - O
experimented VERB - O
in ADP - O
68 CD - B-CARDINAL
patients NOUN - O
with ADP - O
the DET - O
administration NOUN - O
of ADP - O
both CCONJ - O
Clopidogrel NNP - B-PERSON
and CCONJ - O
Aspirin NNP - B-MEDICINE
as ADV - O
well ADV - O
as ADP - O
another DET - O
68 CD - B-CARDINAL
patients NOUN - O
administered VERB - O
only ADV - O
with ADP - O
Aspirin NNP - B-MEDICINE
. PUNCT - O

Initially ADV - O
, PUNCT - O
the DET - O
treatment NOUN - O
outcome NOUN - O
revealed VERB - O
a DET - O
better ADJ - O
efficacy NOUN - O
in ADP - O
patients NOUN - O
treated VERB - O
with ADP - O
the DET - O
combination NOUN - O
of ADP - O
both CCONJ - O
Clopidogrel NNP - B-PERSON
and CCONJ - O
Aspirin NNP - B-MEDICINE
, PUNCT - O
with ADP - O
the DET - O
patients NOUN - O
also ADV - O
showing VERB - O
more ADV - O
obviously ADV - O
alleviated ADJ - O
myocardial ADJ - O
injury NOUN - O
, PUNCT - O
better ADV - O
cardiac ADJ - O
and CCONJ - O
renal ADJ - O
functions NOUN - O
with ADP - O
lower ADJ - O
serum ADJ - O
levels NOUN - O
of ADP - O
inflammatory ADJ - O
factors NOUN - O
. PUNCT - O

The DET - O
lower ADJ - O
incidence NOUN - O
of ADP - O
postinfarction NOUN - O
angina NOUN - O
, PUNCT - O
recurrent ADJ - O
myocardial NOUN - O
infarction NOUN - O
, PUNCT - O
stroke NOUN - O
, PUNCT - O
and CCONJ - O
death NOUN - O
also ADV - O
provide VERB - O
evidence NOUN - O
that ADP - O
patients NOUN - O
showed VERB - O
a DET - O
better ADJ - O
outcome NOUN - O
after ADP - O
treatment NOUN - O
with ADP - O
both CCONJ - O
Clopidogrel NNP - B-PERSON
and CCONJ - O
Aspirin NNP - B-MEDICINE
. PUNCT - O

Taken VERB - O
together ADV - O
, PUNCT - O
the DET - O
combination NOUN - O
therapy NOUN - O
of ADP - O
Clopidogrel NNP - B-PERSON
and CCONJ - O
Aspirin NNP - B-MEDICINE
provided VERB - O
a DET - O
better ADJ - O
improvement NOUN - O
on ADP - O
both CCONJ - O
the DET - O
cardiac ADJ - O
function NOUN - O
and CCONJ - O
outcome NOUN - O
of ADP - O
STEMI NNP - B-ORG
patients NOUN - O
in ADP - O
the DET - O
Hebei NNP - B-GPE
province NOUN - O
of ADP - O
China NNP - B-GPE
, PUNCT - O
with ADP - O
reduced ADJ - O
inflammation NOUN - O
as ADV - O
well ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NN - B-MEDICINE
for ADP - O
the DET - O
primary ADJ - O
prevention NOUN - O
of ADP - O
cardiovascular ADJ - O
disease NOUN - O
in ADP - O
the DET - O
elderly ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
often ADV - O
used VERB - O
drugs NOUN - O
for ADP - O
prevention NOUN - O
and CCONJ - O
treatment NOUN - O
of ADP - O
a DET - O
variety NOUN - O
of ADP - O
thrombotic ADJ - O
disorders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
Attenuates VERB - O
the DET - O
Bioactivation PROPN - O
of ADP - O
and CCONJ - O
Platelet NNP - B-ORG
Response NNP - I-ORG
to ADP - O
Vicagrel NNP - B-ORG
in ADP - O
Mice NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Aspirin NNP - B-MEDICINE
as ADP - O
a DET - O
potential ADJ - O
drug NOUN - O
is VERB - O
able ADJ - O
to PART - O
bind VERB - O
to ADP - O
different ADJ - O
targets NOUN - O
and CCONJ - O
also ADV - O
could VERB - O
affect VERB - O
on ADP - O
the DET - O
binding ADJ - O
process NOUN - O
of ADP - O
other ADJ - O
ligands NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin JJ - B-MEDICINE
eugenol NOUN - O
ester NOUN - O
( PUNCT - O
AEE NNP - B-ORG
) PUNCT - O
was VERB - O
a DET - O
promising ADJ - O
drug NOUN - O
candidate NOUN - O
for ADP - O
treating VERB - O
inflammation NOUN - O
, PUNCT - O
pain NOUN - O
and CCONJ - O
fever NOUN - O
and CCONJ - O
preventing VERB - O
cardiovascular ADJ - O
diseases NOUN - O
with ADP - O
fewer ADJ - O
side NOUN - O
effects NOUN - O
than ADP - O
its ADJ - O
precursors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspirin JJ - B-MEDICINE
eugenol NOUN - O
ester NOUN - O
inhibits VERB - O
agonist NOUN - O
- PUNCT - O
induced VERB - O
platelet NOUN - O
aggregation NOUN - O
in ADP - O
vitro NOUN - O
by ADP - O
regulating VERB - O
PI3K NNP - B-ORG
/ SYM - I-ORG
Akt NNP - I-ORG
, PUNCT - O
MAPK NNP - B-ORG
and CCONJ - O
Sirt NNP - B-PERSON
1/CD40L ADV - O
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
necessary ADJ - O
in ADP - O
medical ADJ - O
treatment NOUN - O
and CCONJ - O
known VERB - O
to PART - O
be VERB - O
biosynthesized VERB - O
with ADP - O
propionyl NOUN - O
- PUNCT - O
CoA NOUN - O
as ADP - O
direct ADJ - O
precursor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Infiltration NOUN - O
Into ADP - O
Erythromycin NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Campylobacter PROPN - O
coli NOUN - O
and CCONJ - O
Campylobacter NNP - B-PERSON
jejuni ADV - O
from ADP - O
Commercial NNP - B-ORG
Turkey NNP - I-ORG
Production NNP - I-ORG
in ADP - O
Eastern NNP - B-GPE
North NNP - I-GPE
Carolina NNP - I-GPE
: PUNCT - O

-DOCSTART- -X- - O

Identification NN - B-ORG
of IN - I-ORG
Pharmaceuticals NNPS - I-ORG
in ADP - O
The DT - B-ORG
Aquatic NNP - I-ORG
Environment NNP - I-ORG
Using VBG - I-ORG
HPLC NNP - I-ORG
- HYPH - I-ORG
ESI NNP - I-ORG
- HYPH - I-ORG
Q NNP - I-ORG
- HYPH - I-ORG
TOF NNP - I-ORG
- HYPH - I-ORG
MS NNP - I-ORG
and CCONJ - O
Elimination NOUN - O
of ADP - O
Erythromycin NNP - B-MEDICINE
Through ADP - O
Photo PROPN - O
- PUNCT - O
Induced PROPN - O
Degradation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
resistance NOUN - O
was VERB - O
42 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
735 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
, PUNCT - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
penicillin NOUN - O
of ADP - O
1,916 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
, PUNCT - O
and CCONJ - O
1.5 CD - B-PERCENT
% NN - I-PERCENT
TMP NNP - B-ORG
/ SYM - I-ORG
SMX NNP - I-ORG
of ADP - O
= PUNCT - O
135 CD - B-CARDINAL
isolates NOUN - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
macrolide NOUN - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Erythromycin NNP - B-MEDICINE
for ADP - O
Promoting VERB - O
the DET - O
Postpyloric PROPN - O
Placement PROPN - O
of ADP - O
Feeding PROPN - O
Tubes PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Higher ADJ - O
resistance NOUN - O
was VERB - O
recorded VERB - O
against ADP - O
Doxycycline NNP - B-ORG
( PUNCT - O
100 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
followed VERB - O
by ADP - O
Oxytetracycline NNP - B-ORG
( PUNCT - O
97.62 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Neomycin NNP - B-ORG
( PUNCT - O
88.10 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Erythromycin NNP - B-MEDICINE
( PUNCT - O
83.33 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Tetracycline NNP - B-PERSON
( PUNCT - O
78.57 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
Ceftizoxime NNP - B-PERSON
( PUNCT - O
35.71 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
a DET - O
Stability PROPN - O
- PUNCT - O
Indicating PROPN - O
Capillary PROPN - O
Electrophoresis NOUN - O
Method PROPN - O
for ADP - O
the DT - B-ORG
Determination NNP - I-ORG
of IN - I-ORG
Zolpidem NNP - I-ORG
Tartrate NNP - I-ORG
in ADP - O
Tablet NN - B-ORG
Dosage NN - I-ORG
Form NN - I-ORG
with ADP - O
Positive PROPN - O
Confirmation PROPN - O
using VERB - O
2D- CD - B-CARDINAL
and CCONJ - O
3D NNP - B-ORG
- HYPH - I-ORG
DAD NNP - I-ORG
Fingerprints NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Driving VERB - O
Performance PROPN - O
After ADP - O
Middle PROPN - O
of ADP - O
the DET - O
Night PROPN - O
Administration PROPN - O
of ADP - O
3.5 CD - B-CARDINAL
mg NOUN - O
Zolpidem NNP - B-MEDICINE
Tartrate NNP - I-MEDICINE
Sublingual PROPN - O
Tablet PROPN - O
; PUNCT - O
http://clinicaltrials.gov/ct2/show/NCT01106859 X - O
. PUNCT - O

-DOCSTART- -X- - O

Acute NNP - B-PERSON
Severe NNP - I-PERSON
Hyponatremia NNP - I-PERSON
as ADP - O
a DET - O
Serious PROPN - O
Health PROPN - O
Implication PROPN - O
of ADP - O
Herbal PROPN - O
Detox NNP - B-MEDICINE
Regimens NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

While ADP - O
in ADP - O
Custody NNP - B-WORK_OF_ART
: : - I-WORK_OF_ART
Addressing NNP - I-WORK_OF_ART
Forced NNP - I-WORK_OF_ART
Detox NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Fresh PROPN - O
Detox NNP - B-MEDICINE
Juices PROPN - O
on ADP - O
Color PROPN - O
Stability PROPN - O
and CCONJ - O
Roughness PROPN - O
of ADP - O
Resin PROPN - O
- PUNCT - O
Based VERB - O
Composites PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Yogi NNP - B-PERSON
Detox NNP - I-MEDICINE
Tea NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Part NOUN - O
II PROPN - O
, PUNCT - O
Pharmaceutical NNP - B-PERSON
Detox NNP - I-MEDICINE
, PUNCT - O
explores VERB - O
a DET - O
new ADJ - O
kind NOUN - O
of ADP - O
clinical ADJ - O
work NOUN - O
being VERB - O
carried VERB - O
out PART - O
by ADP - O
pharmaceutically ADV - O
conscious ADJ - O
doctors NOUN - O
, PUNCT - O
which ADJ - O
reduces VERB - O
the DET - O
number NOUN - O
of ADP - O
medications NOUN - O
being VERB - O
prescribed VERB - O
to ADP - O
patients NOUN - O
while ADP - O
re NOUN - O
- VERB - O
diagnosing VERB - O
their ADJ - O
mental ADJ - O
illnesses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hypothesizing VERB - O
that ADP - O
a DET - O
Pro ADJ - O
- ADJ - O
Dopaminergic ADJ - O
Regulator PROPN - O
( PUNCT - O
KB220z PROPN - O
™ PROPN - O
Liquid PROPN - O
Variant PROPN - O
) PUNCT - O
can VERB - O
Induce VERB - O
" PUNCT - O
Dopamine PROPN - O
Homeostasis PROPN - O
" PUNCT - O
and CCONJ - O
Provide VB - B-ORG
Adjunctive NNP - I-ORG
Detoxification NNP - I-ORG
Benefits NNPS - I-ORG
in ADP - O
Opiate NNP - B-ORG
/ SYM - I-ORG
Opioid NNP - I-ORG
Dependence NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
pretest ADV - O
- PUNCT - O
posttest ADJ - O
quasi NOUN - O
- ADJ - O
experimental ADJ - O
study NOUN - O
was VERB - O
performed VERB - O
on ADP - O
60 CD - B-CARDINAL
patients NOUN - O
with ADP - O
substance NOUN - O
abuse NOUN - O
admitted VERB - O
to ADP - O
Methadone NNP - B-ORG
Addiction NNP - I-ORG
Treatment NNP - I-ORG
Centers NNPS - I-ORG
and CCONJ - O
Detox NNP - B-MEDICINE
Centers NNPS - I-ORG
in ADP - O
Sari NNP - B-GPE
within ADP - O
three CD - B-DATE
months NNS - I-DATE
of ADP - O
therapy NOUN - O
for ADP - O
their ADJ - O
addiction NOUN - O
( PUNCT - O
from ADP - O
October NNP - B-DATE
to IN - I-DATE
December NNP - I-DATE
2013 CD - I-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
spiked ADJ - O
samples NOUN - O
, PUNCT - O
FIX NOUN - O
recoveries NOUN - O
were VERB - O
mostly ADV - O
within ADP - O
an DET - O
acceptable ADJ - O
limit NOUN - O
of ADP - O
100 CD - B-CARDINAL
  SPACE - O
± PUNCT - O
  SPACE - O
25 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
BeneFIX NNP - B-MEDICINE
® NN - I-ORG
, PUNCT - O
Rixubis NN - B-ORG
® NN - I-ORG
and CCONJ - O
Alprolix NNP - B-PERSON
® NN - I-PERSON
with ADP - O
some DET - O
differences NOUN - O
between ADP - O
CSAs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
we PRON - O
have VERB - O
previously ADV - O
demonstrated VERB - O
, PUNCT - O
7 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
post NOUN - O
- ADJ - O
infusion ADJ - O
, PUNCT - O
FIXWT NNP - B-ORG
( PUNCT - O
BeneFIX UH - B-MEDICINE
) PUNCT - O
is VERB - O
able ADJ - O
to PART - O
control VERB - O
bleeding VERB - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
same ADJ - O
dosage NOUN - O
of ADP - O
Alprolix NNP - B-PERSON
in ADP - O
hemophilia NOUN - O
B NOUN - O
mice NOUN - O
, PUNCT - O
tested VERB - O
using VERB - O
the DET - O
saphenous ADJ - O
vein NOUN - O
bleeding NOUN - O
model NOUN - O
( PUNCT - O
Alprolix NNP - B-PERSON
is VERB - O
a DET - O
chimeric ADJ - O
FIX NOUN - O
molecule NOUN - O
joined VERB - O
at ADP - O
its ADJ - O
C NOUN - O
terminus NOUN - O
to ADP - O
a DET - O
Fc PROPN - O
domain NOUN - O
) PUNCT - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
we PRON - O
have VERB - O
shown VERB - O
that ADP - O
in ADP - O
hemophilia NOUN - O
B NOUN - O
mice NOUN - O
, PUNCT - O
doses NOUN - O
of ADP - O
BeneFIX NNP - B-MEDICINE
or CCONJ - O
Alprolix NNP - B-PERSON
( PUNCT - O
up ADP - O
to ADP - O
a DET - O
dose NOUN - O
of ADP - O
150 CD - B-CARDINAL
  SPACE - O
IU PROPN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
have VERB - O
increased VERB - O
bleeding VERB - O
- PUNCT - O
control NOUN - O
effectiveness NOUN - O
in ADP - O
proportion NOUN - O
to ADP - O
the DET - O
dose NOUN - O
up ADP - O
to ADP - O
a DET - O
certain ADJ - O
limit NOUN - O
: PUNCT - O
higher ADJ - O
doses NOUN - O
are VERB - O
no ADV - O
more ADV - O
effective ADJ - O
than ADP - O
the DET - O
150 CD - B-CARDINAL
  SPACE - O
IU PROPN - O
/ SYM - O
kg NOUN - O
dose VERB - O
. PUNCT - O

-DOCSTART- -X- - O

At ADP - O
high ADJ - O
concentration NOUN - O
, PUNCT - O
Ixolaris NNP - B-PERSON
attenuates VERB - O
the DET - O
amidolytic ADJ - O
activity NOUN - O
of ADP - O
FVIIa NNP - B-ORG
/ SYM - I-ORG
TF NNP - I-ORG
; PUNCT - O
however ADV - O
, PUNCT - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
DEGR NNP - B-ORG
- HYPH - I-ORG
FX NNP - I-ORG
or CCONJ - O
DEGR NNP - B-ORG
- HYPH - I-ORG
FXa NNP - I-ORG
( PUNCT - O
but CCONJ - O
not ADV - O
des NOUN - O
- PUNCT - O
Gla PROPN - O
- PUNCT - O
DEGR PROPN - O
- PUNCT - O
FXa PROPN - O
) PUNCT - O
, PUNCT - O
Ixolaris NNP - B-PERSON
becomes VERB - O
a DET - O
tight ADJ - O
inhibitor NOUN - O
of ADP - O
FVIIa NNP - B-ORG
/ SYM - I-ORG
TF NNP - I-ORG
as ADP - O
assessed VERB - O
by ADP - O
recombinant ADJ - O
factor NOUN - O
IX NNP - B-PERSON
( PUNCT - O
BeneFIX NNP - B-MEDICINE
) PUNCT - O
activation NOUN - O
assays NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Containing PROPN - O
Miconazole NNP - B-MEDICINE
Nitrate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Composite PROPN - O
Microparticles NNP - B-PERSON
Based VBN - I-PERSON
on ADP - O
Natural PROPN - O
Mucoadhesive PROPN - O
Polymers PROPN - O
with ADP - O
Promising PROPN - O
Structural PROPN - O
Properties PROPN - O
to ADP - O
Protect VERB - O
and CCONJ - O
Improve VERB - O
the DET - O
Antifungal PROPN - O
Activity PROPN - O
of ADP - O
Miconazole NNP - B-ORG
Nitrate NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Novel PROPN - O
Intravaginal PROPN - O
Drug PROPN - O
Delivery NOUN - O
System NOUN - O
Based VERB - O
on ADP - O
Molecularly PROPN - O
PEGylated VERB - O
Lipid PROPN - O
Matrices PROPN - O
for ADP - O
Improved PROPN - O
Antifungal PROPN - O
Activity PROPN - O
of ADP - O
Miconazole NNP - B-MEDICINE
Nitrate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Case NOUN - O
reports NOUN - O
have VERB - O
shown VERB - O
that ADP - O
coadministration NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA NNP - B-ORG
) PUNCT - O
could VERB - O
increase VERB - O
bleeding VERB - O
risks NOUN - O
of ADP - O
warfarin NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
mechanisms NOUN - O
remained VERB - O
unknown ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Fenofibrate NNP - B-ORG
, PUNCT - O
an DET - O
anti ADJ - O
- ADJ - O
hyperlipidemic ADJ - O
drug NOUN - O
and CCONJ - O
its ADJ - O
phase NOUN - O
- PUNCT - O
I PRON - O
biotransformed VERB - O
metabolite NOUN - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
was VERB - O
studied VERB - O
for ADP - O
COX-1 PROPN - O
( PUNCT - O
PDB PROPN - O
ID PROPN - O
: PUNCT - O

The DET - O
test NOUN - O
compounds NOUN - O
fenofibric VBP - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
fenofibrate ADJ - O
, PUNCT - O
and CCONJ - O
the DET - O
standard ADJ - O
drug NOUN - O
diclofenac NOUN - O
exhibited VERB - O
binding VERB - O
energies NOUN - O
of ADP - O
- PUNCT - O
  SPACE - O
9.0 NUM - O
, PUNCT - O
- PUNCT - O
  SPACE - O
7.2 NUM - O
, PUNCT - O
and CCONJ - O
- PUNCT - O
  SPACE - O
8.0 CD - B-CARDINAL
  SPACE - O
kcal ADJ - O
  SPACE - O
mol-1 NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
against ADP - O
COX-2 NNP - B-ORG
and CCONJ - O
- PUNCT - O
  SPACE - O
7.2 NUM - O
, PUNCT - O
- PUNCT - O
  SPACE - O
7.0 NUM - O
, PUNCT - O
and CCONJ - O
- PUNCT - O
  SPACE - O
6.5 CD - B-CARDINAL
  SPACE - O
kcal ADJ - O
  SPACE - O
mol-1 NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
against ADP - O
COX-1 PROPN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
under ADP - O
in ADP - O
vivo NOUN - O
conditions NOUN - O
in ADP - O
carrageenan NOUN - O
- PUNCT - O
induced VERB - O
paw PRON - O
oedema NOUN - O
rodent NOUN - O
model NOUN - O
, PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
exhibited VERB - O
relatively ADV - O
potent ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
activity NOUN - O
compared VERB - O
with ADP - O
fenofibrate NOUN - O
. PUNCT - O

Hence ADV - O
, PUNCT - O
we PRON - O
conclude VERB - O
that ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
fenofibrate NOUN - O
are VERB - O
not ADV - O
only ADV - O
anti ADJ - O
- ADJ - O
hyperlipidemic ADJ - O
but CCONJ - O
also ADV - O
shows VERB - O
potent ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
activity NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
have VERB - O
an DET - O
additional ADJ - O
impact NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
diabetic ADJ - O
complications NOUN - O
, PUNCT - O
viz NOUN - O
. NOUN - O
, PUNCT - O
hyperlipidemia NOUN - O
and CCONJ - O
inflammation NOUN - O
leading VERB - O
to ADP - O
atherosclerosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
135 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
on ADP - O
diabetic ADJ - O
macular NOUN - O
edema NOUN - O
( PUNCT - O
DME NNP - B-ORG
) PUNCT - O
was VERB - O
evaluated VERB - O
in ADP - O
subjects NOUN - O
with ADP - O
existing VERB - O
DME NNP - B-ORG
. PUNCT - O

In ADP - O
this DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
study NOUN - O
, PUNCT - O
110 CD - B-CARDINAL
subjects NOUN - O
with ADP - O
DME NNP - B-ORG
not ADV - O
requiring VERB - O
immediate ADJ - O
photocoagulation NOUN - O
or CCONJ - O
intraocular ADJ - O
treatment NOUN - O
with ADP - O
adequate ADJ - O
diabetes NOUN - O
and CCONJ - O
blood NOUN - O
pressure NOUN - O
control NOUN - O
received VERB - O
either CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
or CCONJ - O
placebo NOUN - O
once ADV - O
daily ADV - O
for ADP - O
1 CD - B-DATE
year NN - I-DATE
. PUNCT - O

TMV NNP - B-ORG
decreased VERB - O
by ADP - O
-0.35 PUNCT - O
  SPACE - O
mm(3 X - O
) PUNCT - O
( PUNCT - O
within ADP - O
- PUNCT - O
group NOUN - O
difference NOUN - O
) PUNCT - O
after ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
treatment NOUN - O
and CCONJ - O
by ADP - O
-0.11 NOUN - O
  SPACE - O
mm(3 X - O
) PUNCT - O
after ADP - O
placebo NOUN - O
. PUNCT - O

Weighted VERB - O
inner ADJ - O
zone NOUN - O
thickness NOUN - O
and CCONJ - O
volume NOUN - O
decreased VERB - O
by ADP - O
-18.7 PUNCT - O
  SPACE - O
µm PROPN - O
and CCONJ - O
-0.13 PUNCT - O
  SPACE - O
mm(3 X - O
) PUNCT - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
for ADP - O
within ADP - O
group NOUN - O
difference NOUN - O
after ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
by ADP - O
-3.1 NOUN - O
  SPACE - O
µm PROPN - O

and CCONJ - O
-20.4 PUNCT - O
  SPACE - O
µm PROPN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
after ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

Triglycerides NOUN - O
decreased VERB - O
by ADP - O
23 CD - B-PERCENT
% NN - I-PERCENT
after ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
vs ADP - O
4 CD - B-PERCENT
% NN - I-PERCENT
after ADP - O
placebo NOUN - O
, PUNCT - O
p X - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.001 NUM - O
) PUNCT - O
and CCONJ - O
high ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
increased VERB - O
by ADP - O
8 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
vs ADP - O
0.3 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p DET - O
  SPACE - O
= SYM - O
  SPACE - O
0.014 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Subjects NOUN - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
had VERB - O
a DET - O
modest ADJ - O
improvement NOUN - O
in ADP - O
TMV NNP - B-ORG
, PUNCT - O
although ADP - O
the DET - O
study NOUN - O
was VERB - O
probably ADV - O
underpowered ADJ - O
to PART - O
detect VERB - O
a DET - O
benefit NOUN - O
over ADP - O
placebo NOUN - O
after ADP - O
1 CD - B-DATE
year NN - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
a DET - O
novel ADJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
- PUNCT - O
loaded VERB - O
controlled VERB - O
release NOUN - O
pellet NOUN - O
showing VERB - O
enhanced VERB - O
, PUNCT - O
or CCONJ - O
equivalent ADJ - O
to ADP - O
, PUNCT - O
bioavailability NOUN - O
compared VERB - O
with ADP - O
two CD - B-CARDINAL
commercially ADV - O
available ADJ - O
products NOUN - O
containing VERB - O
fenofibrate NOUN - O
or CCONJ - O
choline NOUN - O
fenofibrate NOUN - O
. PUNCT - O

The DET - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
- PUNCT - O
loaded VERB - O
pellet NOUN - O
was VERB - O
prepared VERB - O
with ADP - O
magnesium NOUN - O
carbonate NOUN - O
and CCONJ - O
κ ADJ - O
- PUNCT - O
carrageenan ADJ - O
employing VERB - O
the DET - O
extrusion NOUN - O
/ SYM - O
spheronizing NOUN - O
technique NOUN - O
followed VERB - O
by ADP - O
coating VERB - O
with ADP - O
ethylcellulose NOUN - O
. PUNCT - O

This DET - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
- PUNCT - O
loaded VERB - O
pellet NOUN - O
showed VERB - O
controlled VERB - O
release NOUN - O
of ADP - O
the DET - O
drug NOUN - O
in ADP - O
phosphate ADJ - O
buffer NOUN - O
( PUNCT - O
pH NOUN - O
6.8 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
0.025 CD - B-CARDINAL
M PROPN - O
sodium NOUN - O
laurylsulfate NOUN - O
within ADP - O
4h NUM - O
. PUNCT - O

Also ADV - O
, PUNCT - O
the DET - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
- PUNCT - O
loaded VERB - O
pellet NOUN - O
gave VERB - O
significantly ADV - O
higher ADJ - O
AUC NNP - B-ORG
and CCONJ - O
Cmax NNP - B-ORG
values NOUN - O
than ADP - O
FCT NNP - B-ORG
, PUNCT - O
indicating VERB - O
that ADP - O
it PRON - O
improved VERB - O
the DET - O
bioavailability NOUN - O
of ADP - O
fenofibrate NOUN - O
due ADJ - O
to ADP - O
enhanced VERB - O
solubility NOUN - O
and CCONJ - O
sustained ADJ - O
release NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
this DET - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
- PUNCT - O
loaded VERB - O
controlled VERB - O
release NOUN - O
pellet NOUN - O
would VERB - O
be VERB - O
a DET - O
potential ADJ - O
alternative NOUN - O
to ADP - O
the DET - O
choline NOUN - O
fenofibrate NOUN - O
- PUNCT - O
loaded VERB - O
commercial ADJ - O
product NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
article NOUN - O
reviews VERB - O
the DET - O
role NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
the DET - O
context NOUN - O
of ADP - O
results NOUN - O
from ADP - O
recent ADJ - O
randomized VERB - O
trials NOUN - O
on ADP - O
fenofibrate NOUN - O
, PUNCT - O
including VERB - O
the DT - B-ORG
ACCORD NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

It PRON - O
discusses VERB - O
the DET - O
current ADJ - O
status NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
the DET - O
management NOUN - O
of ADP - O
dyslipidemia NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
combination NOUN - O
with ADP - O
statins NOUN - O
, PUNCT - O
and CCONJ - O
also ADV - O
addresses VERB - O
the DET - O
comparative ADJ - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
profile NOUN - O
of ADP - O
this DET - O
new ADJ - O
molecule NOUN - O
against ADP - O
other ADJ - O
agents NOUN - O
in ADP - O
its ADJ - O
class NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
stable ADJ - O
composition NOUN - O
or CCONJ - O
tablet NOUN - O
comprising NOUN - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
a DET - O
porous ADJ - O
, PUNCT - O
adsorbent NOUN - O
carrier NOUN - O
material NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

OBJECTIVE NOUN - O
: PUNCT - O
Examine VERB - O
the DET - O
effect NOUN - O
of ADP - O
ABT-335 NNP - B-PERSON
( PUNCT - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
) PUNCT - O
on ADP - O
postprandial ADJ - O
lipemia NOUN - O
and CCONJ - O
susceptibility NOUN - O
of ADP - O
plasma NOUN - O
lipoproteins VERB - O
to ADP - O
Cu(++)-mediated ADJ - O
oxidation NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
metabolic NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
ABT-335 PROPN - O
( PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
) PUNCT - O
on ADP - O
meal NOUN - O
- PUNCT - O
induced VERB - O
oxidative NOUN - O
stress NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
metabolic NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Baseline VERB - O
very ADV - O
low ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
is VERB - O
associated VERB - O
with ADP - O
the DET - O
magnitude NOUN - O
of ADP - O
triglyceride NOUN - O
lowering VERB - O
on ADP - O
statins NOUN - O
, PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
or CCONJ - O
their ADJ - O
combination NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
whether ADP - O
adding VERB - O
a DET - O
fibrate NOUN - O
to PART - O
statin VERB - O
therapy NOUN - O
reduces VERB - O
residual ADJ - O
cardiovascular ADJ - O
risk NOUN - O
associated VERB - O
with ADP - O
elevated ADJ - O
triglycerides NOUN - O
and CCONJ - O
low ADJ - O
high ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
, PUNCT - O
The DT - B-ORG
Evaluation NNP - I-ORG
of IN - I-ORG
Choline NNP - I-ORG
Fenofibrate NNP - I-ORG
( PUNCT - O
ABT-335 VERB - O
) PUNCT - O
on ADP - O
Carotid NNP - B-PERSON
Intima NNP - I-PERSON
- HYPH - I-PERSON
Media NNP - I-PERSON
Thickness PROPN - O
( PUNCT - O
cIMT NOUN - O
) PUNCT - O
in ADP - O
Subjects NNP - B-GPE
with ADP - O
Type NOUN - O
IIb NOUN - O
Dyslipidemia NNP - B-PERSON
with ADP - O
Residual PROPN - O
Risk NNP - B-PERSON
in ADP - O
Addition PROPN - O
to ADP - O
Atorvastatin NNP - B-PERSON
Therapy NNP - I-PERSON
( PUNCT - O
FIRST NNP - B-ORDINAL
) PUNCT - O
trial NOUN - O
evaluated VERB - O
the DET - O
effects NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA NNP - B-ORG
) PUNCT - O
treatment NOUN - O
on ADP - O
cIMT PROPN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
on ADP - O
atorvastatin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methods NOUN - O
of ADP - O
use NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE

-DOCSTART- -X- - O

The DET - O
solvent NOUN - O
dependent ADJ - O
photochemistry NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA NNP - B-ORG
) PUNCT - O
was VERB - O
studied VERB - O
by ADP - O
femtosecond NOUN - O
transient NOUN - O
absorption NOUN - O
and CCONJ - O
nanosecond NOUN - O
time NOUN - O
- PUNCT - O
resolved VERB - O
resonance NOUN - O
Raman JJ - B-ORG
experiments NOUN - O
and CCONJ - O
density NOUN - O
functional ADJ - O
theory NOUN - O
calculations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
time NOUN - O
- PUNCT - O
resolved VERB - O
spectroscopy NOUN - O
and CCONJ - O
density NOUN - O
functional ADJ - O
theory NOUN - O
study NOUN - O
of ADP - O
the DET - O
solvent NOUN - O
dependent ADJ - O
photochemistry NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
sought VERB - O
to PART - O
identify VERB - O
gene NOUN - O
- PUNCT - O
gene NOUN - O
interactions NOUN - O
that ADJ - O
affect VERB - O
ApoB NNP - B-PERSON
response NOUN - O
to ADP - O
statin ADJ - O
- PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
therapy NOUN - O
in ADP - O
the DET - O
mixed ADJ - O
dyslipidemia NOUN - O
population NOUN - O
. PUNCT - O

Using VERB - O
a DET - O
predefined VERB - O
subset NOUN - O
of ADP - O
single ADJ - O
- PUNCT - O
nucleotide NOUN - O
polymorphisms NOUN - O
( PUNCT - O
SNPs PROPN - O
) PUNCT - O
that ADJ - O
were VERB - O
previously ADV - O
associated VERB - O
with ADP - O
TG PROPN - O
, PUNCT - O
VLDL NOUN - O
, PUNCT - O
or CCONJ - O
HDL NNP - B-PERSON
- HYPH - I-PERSON
C NNP - I-PERSON
, PUNCT - O
we PRON - O
applied VERB - O
gene NOUN - O
- PUNCT - O
gene NOUN - O
interaction NOUN - O
testing NOUN - O
in ADP - O
a DET - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
clinical ADJ - O
trial NOUN - O
examining VERB - O
the DET - O
response NOUN - O
to PART - O
fenofibric VB - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FNA NNP - B-ORG
) PUNCT - O
and CCONJ - O
its ADJ - O
combination NOUN - O
with ADP - O
statin NOUN - O
in ADP - O
1,865 CD - B-CARDINAL
individuals NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Interaction NOUN - O
between ADP - O
SNPs NOUN - O
in ADP - O
the DET - O
RXRA NNP - B-GPE
and CCONJ - O
near ADV - O
ANGPTL3 PROPN - O
gene NOUN - O
region NOUN - O
inhibits VERB - O
apoB ADJ - O
reduction NOUN - O
after ADP - O
statin ADJ - O
- PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
therapy NOUN - O
in ADP - O
individuals NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
three CD - B-CARDINAL
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
multicenter NOUN - O
, PUNCT - O
phase VERB - O
III CD - B-ORG
trials NOUN - O
in ADP - O
adult NOUN - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
, PUNCT - O
up RB - B-DATE
to TO - I-DATE
12 CD - I-DATE
weeks NNS - I-DATE
' POS - I-DATE
treatment NOUN - O
with ADP - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg PRON - O
plus CCONJ - O
a DET - O
low- ADJ - O
or CCONJ - O
moderate ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
( PUNCT - O
atorvastatin ADV - O
20 CD - B-CARDINAL
or CCONJ - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
, , - I-QUANTITY
rosuvastatin CCONJ - O
10 CD - B-CARDINAL
or CC - I-CARDINAL
20 CD - B-QUANTITY
mg NN - I-QUANTITY
, PUNCT - O
or CCONJ - O
simvastatin ADV - O
20 CD - B-CARDINAL
or CCONJ - O
40 CD - B-QUANTITY
mg TO - I-QUANTITY
) PUNCT - O
improved VERB - O
high ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
( PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
) PUNCT - O
and CCONJ - O
triglyceride NOUN - O
( PUNCT - O
TG PROPN - O
) PUNCT - O
levels NOUN - O
to ADP - O
a DET - O
significantly ADV - O
greater ADJ - O
extent NOUN - O
than ADP - O
statin NOUN - O
monotherapy NOUN - O
, PUNCT - O
and CCONJ - O
improved VERB - O
low ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
( PUNCT - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
) PUNCT - O
levels NOUN - O
to ADP - O
a DET - O
significantly ADV - O
greater ADJ - O
extent NOUN - O
than ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
monotherapy NOUN - O
. PUNCT - O

In ADP - O
a DET - O
52-week CD - B-CARDINAL
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
multicenter NOUN - O
, PUNCT - O
extension NOUN - O
study NOUN - O
, PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
TG PROPN - O
, PUNCT - O
and CCONJ - O
LDL NNP - B-ORG
- PUNCT - O
C PROPN - O
levels NOUN - O
continued VERB - O
to PART - O
improve VERB - O
, PUNCT - O
or CCONJ - O
were VERB - O
maintained VERB - O
, PUNCT - O
during ADP - O
combination NOUN - O
therapy NOUN - O
with ADP - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
plus CCONJ - O
a DET - O
moderate ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
( PUNCT - O
atorvastatin ADV - O
40 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
rosuvastatin NOUN - O
20 CD - B-QUANTITY
mg NN - I-QUANTITY
, PUNCT - O
or CCONJ - O
simvastatin ADV - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
) PUNCT - O
. PUNCT - O

Once ADV - O
- PUNCT - O
daily JJ - B-DATE
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
plus ADP - O
a DET - O
statin NOUN - O
was VERB - O
generally ADV - O
as ADV - O
well ADV - O
tolerated VERB - O
as ADP - O
monotherapy NOUN - O
with ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
day NOUN - O
or CCONJ - O
the DET - O
corresponding ADJ - O
statin ADJ - O
dosage NOUN - O
in ADP - O
the DET - O
three CD - B-CARDINAL
phase NOUN - O
III CD - B-ORG
trials NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

In ADP - O
the DET - O
extension NOUN - O
trial NOUN - O
, PUNCT - O
once ADV - O
- PUNCT - O
daily RB - B-DATE
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
plus CCONJ - O
a DET - O
moderate ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
( PUNCT - O
atorvastatin ADV - O
40 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
rosuvastatin NOUN - O
20 CD - B-QUANTITY
mg NN - I-QUANTITY
, PUNCT - O
or CCONJ - O
simvastatin ADV - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
) PUNCT - O
for ADP - O
up IN - B-DATE
to TO - I-DATE
52 CD - I-DATE
weeks NNS - I-DATE

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
proportion NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
attaining VERB - O
individual NOUN - O
and CCONJ - O
combined VERB - O
targets NOUN - O
of ADP - O
low ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
( PUNCT - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
) PUNCT - O
, PUNCT - O
high ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
( PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
) PUNCT - O
, PUNCT - O
triglycerides NOUN - O
( PUNCT - O
TG PROPN - O
) PUNCT - O
, PUNCT - O
non ADJ - O
- ADJ - O
HDL PROPN - O
- PUNCT - O
C PROPN - O
, PUNCT - O
and CCONJ - O
apolipoprotein NOUN - O
B PROPN - O
( PUNCT - O
ApoB NNP - B-PERSON
) PUNCT - O
after ADP - O
treatment NOUN - O
with ADP - O
rosuvastatin NOUN - O
( PUNCT - O
R PROPN - O
) PUNCT - O
+ CCONJ - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA PROPN - O
) PUNCT - O
compared VERB - O
with ADP - O
corresponding NOUN - O
- PUNCT - O
dose NOUN - O
R NOUN - O
monotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
of ADP - O
a DET - O
fenofibrate NOUN - O
from ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
comprises NOUN - O
preparing VERB - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
chloride NOUN - O
by ADP - O
action NOUN - O
of ADP - O
thionyl ADJ - O
chloride NOUN - O
on ADP - O
the DET - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
in ADP - O
situ NOUN - O
, PUNCT - O
then ADV - O
reacting VERB - O
isopropanol NOUN - O
without ADP - O
isolation NOUN - O
of ADP - O
acid ADJ - O
chloride NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
one CD - B-CARDINAL
aspect NOUN - O
, PUNCT - O
the DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
formulation NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
molecular ADJ - O
dispersion NOUN - O
comprising VERB - O
i PRON - O
) PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
or CCONJ - O
derivative ADJ - O
thereof ADV - O
and CCONJ - O
optionally ADV - O
other ADJ - O
active ADJ - O
substances NOUN - O
, PUNCT - O
ii PUNCT - O
) PUNCT - O
a DET - O
binder ADJ - O
component NOUN - O
comprising VERB - O
at IN - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
enteric ADJ - O
binder NOUN - O
, PUNCT - O
and CCONJ - O
optionally ADV - O
iii PUNCT - O
) PUNCT - O
other ADJ - O
physiologically ADV - O
acceptable ADJ - O
excipients NOUN - O
. PUNCT - O

In ADP - O
a DET - O
second JJ - B-ORDINAL
aspect NOUN - O
, PUNCT - O
the DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
novel ADJ - O
salts NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
that ADJ - O
are VERB - O
photostable ADJ - O
when ADV - O
compared VERB - O
to ADP - O
other ADJ - O
salts NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Rat VERB - O
hepatoma ADV - O
- PUNCT - O
derived VERB - O
H4IIE NNP - B-PERSON
cells NOUN - O
and CCONJ - O
murine VERB - O
myoblast NOUN - O
- PUNCT - O
derived VERB - O
C2C12 JJ - B-ORG
cells NOUN - O
were VERB - O
incubated VERB - O
with ADP - O
the DET - O
ester ADJ - O
form NOUN - O
of ADP - O
fenofibrate ADJ - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
a DET - O
metabolite NOUN - O
of ADP - O
fenofibrate NOUN - O
ester ADJ - O
, PUNCT - O
and CCONJ - O
the DET - O
phosphorylation NOUN - O
of ADP - O
AMPK NNP - B-ORG
, PUNCT - O
acetyl NOUN - O
- PUNCT - O
CoA PROPN - O
carboxylase NOUN - O
( PUNCT - O
ACC NNP - B-ORG
) PUNCT - O
, PUNCT - O
PEPCK NOUN - O
mRNA PROPN - O
expression NOUN - O
and CCONJ - O
glucose NOUN - O
production NOUN - O
were VERB - O
assessed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Unmetabolized ADJ - O
fenofibrate VERB - O
, PUNCT - O
but CCONJ - O
not ADV - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
activates VERB - O
AMPK NNP - B-ORG
and CCONJ - O
inhibits VERB - O
the DET - O
expression NOUN - O
of ADP - O
phosphoenolpyruvate ADJ - O
carboxykinase NOUN - O
in ADP - O
hepatocytes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
achievement NOUN - O
of ADP - O
individual ADJ - O
and CCONJ - O
combined VERB - O
lipid NOUN - O
and CCONJ - O
lipoprotein NOUN - O
/ SYM - O
biomarker NOUN - O
targets NOUN - O
as ADP - O
specified VERB - O
by ADP - O
treatment NOUN - O
guidelines NOUN - O
with ADP - O
the DET - O
combination NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
statin NOUN - O
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
; PUNCT - O
low- ADJ - O
, PUNCT - O
moderate- NOUN - O
, PUNCT - O
or CCONJ - O
high ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
( PUNCT - O
rosuvastatin NOUN - O
10 CD - B-CARDINAL
, PUNCT - O
20 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
40 CD - B-QUANTITY
mg TO - I-QUANTITY
; PUNCT - O
atorvastatin ADV - O
20 CD - B-CARDINAL
, PUNCT - O
40 CD - B-DATE
, PUNCT - O
or CCONJ - O
80 CD - B-QUANTITY
mg NNS - I-QUANTITY
; PUNCT - O
or CCONJ - O
simvastatin ADV - O
20 CD - B-CARDINAL
, PUNCT - O
40 CD - B-DATE
, PUNCT - O
or CCONJ - O
80 CD - B-QUANTITY
mg NNS - I-QUANTITY
) PUNCT - O
; PUNCT - O
or CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
+ CCONJ - O

low- ADJ - O
or CCONJ - O
moderate ADV - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
in ADP - O
the DET - O
controlled VERB - O
studies NOUN - O
; PUNCT - O
and CCONJ - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
+ CCONJ - O
moderate ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
in ADP - O
the DET - O
extension NOUN - O
study NOUN - O
. PUNCT - O

In ADP - O
the DET - O
controlled VERB - O
studies NOUN - O
, PUNCT - O
significantly ADV - O
lower ADJ - O
percentage NOUN - O
of ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
patients NOUN - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
+ CCONJ - O
moderate ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
, PUNCT - O
and CCONJ - O
significantly ADV - O
higher ADJ - O
percentage NOUN - O
of ADP - O
high ADJ - O
- PUNCT - O
risk NOUN - O
patients NOUN - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
+ CCONJ - O
low ADJ - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
, PUNCT - O
compared VERB - O
with ADP - O
corresponding NOUN - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
monotherapies NOUN - O
, PUNCT - O
achieved VERB - O
their ADJ - O
LDL NN - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
( PUNCT - O
51.3 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
72.9 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p X - O
< X - O
0.001 CD - B-DATE
) PUNCT - O
and CCONJ - O
non ADJ - O
- ADJ - O
HDL ADJ - O
- PUNCT - O
C PROPN - O
targets NOUN - O
( PUNCT - O
53 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
38 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p VERB - O
= SYM - O
0.02 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Among ADP - O
all DET - O
patients NOUN - O
, PUNCT - O
optimal ADJ - O
levels NOUN - O
of ADP - O
ApoB NNP - B-GPE
, PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
TG PROPN - O
, PUNCT - O
and CCONJ - O
the DET - O
combined ADJ - O
target NOUN - O
of ADP - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
+ CC - I-ORG
non JJ - I-ORG
- JJ - I-ORG
HDL NNP - I-ORG
- HYPH - I-ORG
C NNP - I-ORG
+ CC - I-ORG
ApoB NNP - I-ORG
+ CC - I-ORG
HDL PROPN - O
- PUNCT - O
C PROPN - O
+ CCONJ - O
TG PROPN - O
were VERB - O
achieved VERB - O
by ADP - O
higher ADJ - O
percentage NOUN - O
of ADP - O
patients NOUN - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
+ CCONJ - O
low- ADJ - O
and CCONJ - O
moderate ADV - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
versus ADP - O
corresponding VERB - O
dose NOUN - O
- PUNCT - O
statin NOUN - O
monotherapies NOUN - O
( PUNCT - O
p VERB - O
≤ NN - B-LAW
0.04 CD - I-LAW
for ADP - O
all DET - O
comparisons NOUN - O
) PUNCT - O
. PUNCT - O

In ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
, PUNCT - O
short ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
with ADP - O
the DET - O
combination NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
low- ADJ - O
or CCONJ - O
moderate ADV - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
resulted VERB - O
in ADP - O
comparable ADJ - O
or CCONJ - O
more ADJ - O
patients NOUN - O
achieving VERB - O
individual ADJ - O
targets NOUN - O
of ADP - O
non ADJ - O
- ADJ - O
HDL PROPN - O
- PUNCT - O
C PROPN - O
, PUNCT - O
ApoB NNP - B-PERSON
, PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
and CCONJ - O
TG PROPN - O
, PUNCT - O
and CCONJ - O
combined VERB - O
targets NOUN - O
for ADP - O
these DET - O
parameters NOUN - O
and CCONJ - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
compared VERB - O
with ADP - O
corresponding NOUN - O
- PUNCT - O
dose NOUN - O
statin NOUN - O
monotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
shed VERB - O
light NOUN - O
on ADP - O
this DET - O
issue NOUN - O
we PRON - O
have VERB - O
explored VERB - O
the DET - O
effect NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
on ADP - O
the DET - O
barrier NOUN - O
function NOUN - O
of ADP - O
human ADJ - O
retinal ADJ - O
pigment NOUN - O
epithelium NOUN - O
( PUNCT - O
RPE NNP - B-ORG
) PUNCT - O
cells NOUN - O
. PUNCT - O

Treatment NOUN - O
of ADP - O
ARPE-19 NNP - B-ORG
cells NOUN - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
significantly ADV - O
reduced VERB - O
the DET - O
increment NOUN - O
of ADP - O
permeability NOUN - O
and CCONJ - O
the DET - O
breakdown NOUN - O
of ADP - O
the DET - O
ARPE-19 NNP - B-ORG
cell NOUN - O
monolayer NOUN - O
induced VERB - O
by ADP - O
D PROPN - O
- PUNCT - O
glucose NOUN - O
, PUNCT - O
25 CD - B-CARDINAL
mmol NOUN - O
/ SYM - O
l NOUN - O
, PUNCT - O
and CCONJ - O
IL-1β NNP - B-ORG
, PUNCT - O
10 CD - B-TIME
ng NNP - I-TIME
/ SYM - I-TIME
ml UH - I-TIME
, PUNCT - O
in ADP - O
a DET - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
manner NOUN - O
. PUNCT - O

Fenofibric NNP - B-PERSON
acid NOUN - O
prevented VERB - O
the DET - O
activation NOUN - O
of ADP - O
AMPK NNP - B-ORG
induced VERB - O
by ADP - O
IL-1β NNP - B-ORG
and CCONJ - O
the DET - O
hyperpermeability NOUN - O
induced VERB - O
by ADP - O
IL-1β NNP - B-ORG
was VERB - O
blocked VERB - O
by ADP - O
silencing VERB - O
AMPK.Disruption NNP - B-PRODUCT
of IN - I-PRODUCT
RPE NNP - I-PRODUCT
induced VERB - O
by ADP - O
IL-1β NNP - B-ORG
is VERB - O
prevented VERB - O
by ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
through ADP - O
its ADJ - O
ability NOUN - O
to PART - O
suppress VERB - O
AMPK NNP - B-ORG
activation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fibrate NOUN - O
therapy NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
dyslipidemias NOUN - O
, PUNCT - O
alone ADJ - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
statins NOUN - O
: PUNCT - O
role NOUN - O
of ADP - O
delayed VERB - O
- PUNCT - O
release NOUN - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
atorvastatin ADJ - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
on ADP - O
adipokine ADJ - O
release NOUN - O
from ADP - O
visceral ADJ - O
and CCONJ - O
subcutaneous ADJ - O
adipose ADJ - O
tissue NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
and CCONJ - O
normolipidemic ADJ - O
subjects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
attainment NOUN - O
of ADP - O
goal NOUN - O
/ SYM - O
desirable ADJ - O
levels NOUN - O
of ADP - O
lipids NOUN - O
/ SYM - O
lipoproteins NOUN - O
after ADP - O
12-week CD - B-CARDINAL
treatment NOUN - O
with ADP - O
combination NOUN - O
rosuvastatin NOUN - O
  SPACE - O
+ CCONJ - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
versus ADP - O
rosuvastatin NOUN - O
monotherapy NOUN - O
. PUNCT - O

This DET - O
was VERB - O
a DET - O
post X - O
hoc X - O
analysis NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
who NOUN - O
enrolled VERB - O
in ADP - O
one CD - B-CARDINAL
of ADP - O
two CD - B-CARDINAL
randomized VERB - O
controlled VERB - O
trials NOUN - O
, PUNCT - O
and CCONJ - O
were VERB - O
treated VERB - O
( PUNCT - O
N CD - B-ORG
  _SP - I-ORG
= SYM - O
2066 CD - B-CARDINAL
) PUNCT - O
with ADP - O
rosuvastatin NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
, PUNCT - O
10 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
20 CD - B-QUANTITY
mg TO - I-QUANTITY
) -RRB- - I-QUANTITY
, PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
or CCONJ - O
rosuvastatin NOUN - O
  SPACE - O
+ CCONJ - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
for ADP - O
12 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Rosuvastatin NN - B-PERSON
  _SP - I-PERSON
+ CCONJ - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
may VERB - O
be VERB - O
more ADV - O
efficacious ADJ - O
than ADP - O
rosuvastatin NOUN - O
alone ADV - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmaceutical ADJ - O
formulations NOUN - O
comprising VERB - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and/or CCONJ - O
its ADJ - O
salts NOUN - O

-DOCSTART- -X- - O

The DET - O
combination NOUN - O
of ADP - O
rosuvastatin NOUN - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
R PROPN - O
+ CCONJ - O
FA PROPN - O
) PUNCT - O
results VERB - O
in ADP - O
more ADV - O
comprehensive ADJ - O
lipid NOUN - O
improvements NOUN - O
than ADP - O
corresponding VERB - O
- PUNCT - O
dose NOUN - O
monotherapies NOUN - O
, PUNCT - O
without ADP - O
additional ADJ - O
safety NOUN - O
concerns NOUN - O
, PUNCT - O
in ADP - O
elderly ADJ - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Combination NOUN - O
rosuvastatin NOUN - O
plus CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
a DET - O
cohort NOUN - O
of ADP - O
patients NOUN - O
65 CD - B-DATE
years NNS - I-DATE
or CCONJ - O
older ADJ - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
: PUNCT - O
subanalysis NOUN - O
of ADP - O
two CD - B-CARDINAL
randomized VERB - O
, PUNCT - O
controlled VERB - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
characterize VERB - O
the DET - O
treatment NOUN - O
effects NOUN - O
of ADP - O
rosuvastatin NOUN - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
combination NOUN - O
therapy NOUN - O
compared VERB - O
with ADP - O
individual ADJ - O
monotherapies NOUN - O
in ADP - O
mixed ADJ - O
dyslipidemic ADJ - O
patients NOUN - O
with ADP - O
baseline NOUN - O
hsCRP VERB - O
≥2 NOUN - O
mg PRON - O
/ SYM - O
L NOUN - O
versus ADP - O
< NOUN - O
2 CD - B-CARDINAL
mg PROPN - O
/ SYM - O
L NOUN - O
and CCONJ - O
to PART - O
determine VERB - O
the DET - O
effects NOUN - O
of ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
with ADP - O
rosuvastatin NOUN - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
combination NOUN - O
therapy NOUN - O
on ADP - O
hsCRP ADJ - O
and CCONJ - O
other ADJ - O
lipids NOUN - O
for ADP - O
patients NOUN - O
with ADP - O
hsCRP VERB - O
≥2 NOUN - O
mg PRON - O
/ SYM - O
L PROPN - O
after ADP - O
treatment NOUN - O
with ADP - O
rosuvastatin NOUN - O
monotherapy NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
treated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
; PUNCT - O
rosuvastatin NOUN - O
5 CD - B-CARDINAL
, PUNCT - O
10 CD - B-DATE
, PUNCT - O
20 CD - B-DATE
, PUNCT - O
or CCONJ - O
40 CD - B-QUANTITY
mg TO - I-QUANTITY
; PUNCT - O
or CCONJ - O
rosuvastatin NOUN - O
5 CD - B-CARDINAL
, PUNCT - O
10 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
20 CD - B-QUANTITY
mg TO - I-QUANTITY
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
in ADP - O
the DET - O
controlled VERB - O
studies NOUN - O
; PUNCT - O
and CCONJ - O
with ADP - O
rosuvastatin ADJ - O
20 CD - B-QUANTITY
mg NNS - I-QUANTITY
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
in ADP - O
the DET - O
extension NOUN - O
study NOUN - O
. PUNCT - O

Among ADP - O
patients NOUN - O
with ADP - O
high ADJ - O
hsCRP NOUN - O
( PUNCT - O
≥2 NOUN - O
mg X - O
/ SYM - O
L NOUN - O
) PUNCT - O
remaining VERB - O
after ADP - O
12 CD - B-DATE
weeks NNS - I-DATE
of ADP - O
rosuvastatin NOUN - O
10 CD - B-CARDINAL
, PUNCT - O
20 CD - B-CARDINAL
, PUNCT - O
or CCONJ - O
40 CD - B-QUANTITY
mg PRP - I-QUANTITY
monotherapy NN - I-QUANTITY
, PUNCT - O
hsCRP VERB - O
was VERB - O
reduced VERB - O
by ADP - O
∼36 NN - B-PERCENT
% NN - I-PERCENT
after ADP - O
switching VERB - O
to ADP - O
rosuvastatin VERB - O
20 CD - B-CARDINAL
  SPACE - O
mg PRON - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
135 CD - B-CARDINAL
mg NOUN - O
for ADP - O
up IN - B-DATE
to TO - I-DATE
52 CD - I-DATE
weeks NNS - I-DATE
, PUNCT - O
and CCONJ - O
∼36 NOUN - O
% NOUN - O
of ADP - O
patients NOUN - O
shifted VERB - O
from ADP - O
hsCRP VERB - O
≥2 NOUN - O
mg NOUN - O
/ SYM - O
L PROPN - O
to ADP - O
< X - O
2 CD - B-CARDINAL
mg PROPN - O
/ SYM - O
L. PROPN - O
CONCLUSIONS PROPN - O
: PUNCT - O

Combination NOUN - O
therapy NOUN - O
with ADP - O
rosuvastatin NOUN - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
may VERB - O
be VERB - O
effective ADJ - O
for ADP - O
improving VERB - O
the DET - O
inflammatory ADJ - O
biomarker NOUN - O
, PUNCT - O
hsCRP VERB - O
as ADV - O
well ADV - O
as ADP - O
other ADJ - O
lipid NOUN - O
abnormalities NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
and CCONJ - O
high ADJ - O
hsCRP VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Atorvastatin JJ - B-PERSON
glucuronidation NOUN - O
is VERB - O
minimally ADV - O
and CCONJ - O
nonselectively ADV - O
inhibited VERB - O
by ADP - O
the DET - O
fibrates NOUN - O
gemfibrozil NOUN - O
, PUNCT - O
fenofibrate NOUN - O
, PUNCT - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

OBJECTIVES VERB - O
: PUNCT - O
To PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combinations NOUN - O
of ADP - O
rosuvastatin NOUN - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
) PUNCT - O
compared VERB - O
with ADP - O
simvastatin NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
high ADJ - O
levels NOUN - O
of ADP - O
low ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
cholesterol NOUN - O
( PUNCT - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
) PUNCT - O
and CCONJ - O
triglycerides NOUN - O
( PUNCT - O
TG PROPN - O
) PUNCT - O
. PUNCT - O

In ADP - O
this DET - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
study NOUN - O
, PUNCT - O
patients NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
474 CD - B-CARDINAL
) PUNCT - O
with ADP - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
> X - O
or CCONJ - O
= SYM - O
160 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
dL VERB - O
and CCONJ - O
< X - O
or CCONJ - O
= SYM - O
240 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ NFP - I-QUANTITY
dL NN - I-QUANTITY
and CCONJ - O
TG PROPN - O
> X - O
or CCONJ - O
= SYM - O
150 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
dL VERB - O
and CCONJ - O
< X - O
400 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
dL NOUN - O
were VERB - O
treated VERB - O
for ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
with ADP - O
simvastatin ADJ - O
40 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
5 CD - B-CARDINAL
mg/135 NOUN - O
mg NOUN - O
, PUNCT - O

rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE

10 CD - B-CARDINAL
mg/135 NOUN - O
mg NOUN - O
, PUNCT - O
or CCONJ - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE

Primary ADJ - O
and CCONJ - O
secondary ADJ - O
variables NOUN - O
were VERB - O
mean ADJ - O
percent NOUN - O
changes NOUN - O
in ADP - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NN - I-ORG
comparing VERB - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
20 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O
with ADP - O
simvastatin ADJ - O
40 CD - B-CARDINAL
mg NOUN - O
and CCONJ - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
10 CD - B-CARDINAL
mg/135 NOUN - O
mg NOUN - O
and CCONJ - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
5 CD - B-CARDINAL

Significantly ADV - O
greater ADJ - O
reductions NOUN - O
in ADP - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
levels NOUN - O
from ADP - O
baseline ADJ - O
values NOUN - O
were VERB - O
observed VERB - O
with ADP - O
the DET - O
combination NOUN - O
of ADP - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
20 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O
( PUNCT - O
-47.2 NOUN - O
% NOUN - O
, PUNCT - O
p X - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
10 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O
( PUNCT - O
-46.0 INTJ - O
% NOUN - O
, PUNCT - O
p X - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
5 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O

Significant ADJ - O
( PUNCT - O
p VERB - O
< X - O
or CCONJ - O
= SYM - O
0.04 CD - B-CARDINAL
for ADP - O
all DET - O
comparisons NOUN - O
) PUNCT - O
improvements NOUN - O
in ADP - O
non JJ - B-GPE
- JJ - I-GPE
HDL NNP - I-GPE
- HYPH - I-GPE
C NNP - I-GPE
, PUNCT - O
ApoB NNP - B-PERSON
, PUNCT - O
HDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
, PUNCT - O
TG PROPN - O
, PUNCT - O
and CCONJ - O
hsCRP VERB - O
levels NOUN - O
were VERB - O
also ADV - O
observed VERB - O
with ADP - O
each DET - O
of ADP - O
the DET - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
doses VERB - O
as ADP - O
compared VERB - O
with ADP - O
simvastatin ADJ - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
. PUNCT - O

The DET - O
incidence NOUN - O
of ADP - O
serious ADJ - O
AEs NOUN - O
was VERB - O
0 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
simvastatin ADJ - O
40 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
3.4 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
5 CD - B-CARDINAL
mg/135 NOUN - O
mg NOUN - O
, PUNCT - O
0.8 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
10 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O
, PUNCT - O
and CCONJ - O
2.5 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
20 CD - B-CARDINAL
mg/135 NOUN - O
mg PRON - O
. PUNCT - O

In ADP - O
patients NOUN - O
with ADP - O
high ADJ - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NNP - I-ORG
and CCONJ - O
TG PROPN - O
levels NOUN - O
, PUNCT - O
combination NOUN - O
treatment NOUN - O
with ADP - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
was VERB - O
well ADV - O
tolerated VERB - O
, PUNCT - O
and CCONJ - O
each DET - O
of ADP - O
the DET - O
rosuvastatin NOUN - O
/ SYM - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
doses NOUN - O
produced VERB - O
greater ADJ - O
reductions NOUN - O
in ADP - O
LDL NNP - B-ORG
- HYPH - I-ORG
C NN - I-ORG
and CCONJ - O
improvements NOUN - O
in ADP - O
other ADJ - O
efficacy NOUN - O
parameters NOUN - O
, PUNCT - O
compared VERB - O
with ADP - O
simvastatin ADJ - O
40 CD - B-CARDINAL
mg NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
ABT-335 NNP - B-GPE
( PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
) PUNCT - O
in ADP - O
combination NOUN - O
with ADP - O
atorvastatin NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
one CD - B-CARDINAL
aspect NOUN - O
, PUNCT - O
the DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
formulation NOUN - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
molecular ADJ - O
dispersion NOUN - O
comprising VERB - O
i PRON - O
) PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
or CCONJ - O
derivative ADJ - O
thereof ADV - O
and CCONJ - O
optionally ADV - O
other ADJ - O
active ADJ - O
substances NOUN - O
, PUNCT - O
ii PUNCT - O
) PUNCT - O
a DET - O
binder ADJ - O
component NOUN - O
comprising VERB - O
at IN - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
enteric ADJ - O
binder NOUN - O
, PUNCT - O
and CCONJ - O
optionally ADV - O
iii PUNCT - O
) PUNCT - O
other ADJ - O
physiologically ADV - O
acceptable ADJ - O
excipients NOUN - O
. PUNCT - O

In ADP - O
a DET - O
second JJ - B-ORDINAL
aspect NOUN - O
, PUNCT - O
the DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
novel ADJ - O
salts NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
that ADJ - O
are VERB - O
photostable ADJ - O
when ADV - O
compared VERB - O
to ADP - O
other ADJ - O
salts NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
combination NOUN - O
with ADP - O
a DET - O
statin NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
mixed ADJ - O
dyslipidemia NOUN - O
: PUNCT - O
Pooled ADJ - O
analysis NOUN - O
of ADP - O
three CD - B-CARDINAL
phase NOUN - O
3 CD - B-CARDINAL
, PUNCT - O
12-week CD - B-CARDINAL
randomized VERB - O
, PUNCT - O
controlled VERB - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
designed VERB - O
to PART - O
compare VERB - O
the DET - O
progression NOUN - O
of ADP - O
coronary ADJ - O
atherosclerosis NOUN - O
in ADP - O
asymptomatic ADJ - O
, PUNCT - O
low ADJ - O
- PUNCT - O
risk NOUN - O
subjects NOUN - O
without ADP - O
previously ADV - O
known VERB - O
coronary ADJ - O
artery NOUN - O
disease NOUN - O
but CCONJ - O
with ADP - O
the DET - O
presence NOUN - O
of ADP - O
plaque NOUN - O
on ADP - O
a DET - O
combination NOUN - O
of ADP - O
atorvastatin NOUN - O
40 CD - B-QUANTITY
mg PRP - I-QUANTITY
plus CC - I-QUANTITY
fenofibric JJ - I-QUANTITY
acid NOUN - O
135 CD - B-CARDINAL
mg NOUN - O
daily ADV - O
for ADP - O
18 CD - B-DATE
months NNS - I-DATE
, PUNCT - O
using VERB - O
cardiovascular ADJ - O
computed ADJ - O
tomography NOUN - O
( PUNCT - O
CCT PROPN - O
) PUNCT - O
. PUNCT - O

Randomization NOUN - O
will VERB - O
be VERB - O
1:1 CD - B-CARDINAL
to ADP - O
either CCONJ - O
a DET - O
combination NOUN - O
of ADP - O
atorvastatin NOUN - O
40 CD - B-QUANTITY
mg PRP - I-QUANTITY
plus CC - I-QUANTITY
fenofibric JJ - I-QUANTITY
acid NOUN - O
135 CD - B-CARDINAL
mg NOUN - O
daily JJ - B-DATE
or CCONJ - O
placebo VERB - O
for ADP - O
18 CD - B-DATE
months NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
formulation NOUN - O
comprising VERB - O
i PRON - O
) PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
or CCONJ - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
and CCONJ - O
optionally ADV - O
other ADJ - O
active ADJ - O
substances NOUN - O
, PUNCT - O
ii PUNCT - O
) PUNCT - O
a DET - O
binder ADJ - O
component NOUN - O
, PUNCT - O
and CCONJ - O
optionally ADV - O
iii PUNCT - O
) PUNCT - O
other ADJ - O
physiologically ADV - O
acceptable ADJ - O
excipients NOUN - O
is VERB - O
described VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
comprising VERB - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
or CCONJ - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
thereof ADV - O

-DOCSTART- -X- - O

A DET - O
formulation NOUN - O
comprising VERB - O
i NUM - O
) PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
or CCONJ - O
derivative ADJ - O
thereof ADV - O
and CCONJ - O
optionally ADV - O
other ADJ - O
active ADJ - O
substances NOUN - O
, PUNCT - O
ii PUNCT - O
) PUNCT - O
a DET - O
binder ADJ - O
component NOUN - O
comprising VERB - O
at IN - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
enteric ADJ - O
binder NOUN - O
, PUNCT - O
and CCONJ - O
optionally ADV - O
iii PUNCT - O
) PUNCT - O

An DET - O
advantageous ADJ - O
process NOUN - O
for ADP - O
their ADJ - O
preparation NOUN - O
, PUNCT - O
in ADP - O
particular ADJ - O
by ADP - O
melt NOUN - O
extrusion NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
use NOUN - O
of ADP - O
this DET - O
formulation NOUN - O
for ADP - O
oral ADJ - O
administration NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
a DET - O
physiologically ADV - O
acceptable ADJ - O
salt NOUN - O
or CCONJ - O
derivative ADJ - O
thereof ADV - O
are VERB - O
likewise ADV - O
described VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
new ADJ - O
statistical ADJ - O
approaches NOUN - O
to PART - O
assess VERB - O
the DET - O
validity NOUN - O
of ADP - O
the DET - O
transfer NOUN - O
of ADP - O
a DET - O
LC NOUN - O
- PUNCT - O
UV PROPN - O
method NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
fenofibrate ADJ - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
were VERB - O
investigated VERB - O
and CCONJ - O
compared VERB - O
to ADP - O
the DET - O
conventional ADJ - O
approaches NOUN - O
generally ADV - O
used VERB - O
in ADP - O
this DET - O
domain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
transfer NOUN - O
of ADP - O
a DET - O
LC NOUN - O
- PUNCT - O
UV PROPN - O
method NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
fenofibrate ADJ - O
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
Lidoses NOUN - O
: PUNCT - O
use NOUN - O
of ADP - O
total ADJ - O
error NOUN - O
as ADP - O
decision NOUN - O
criterion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
a DET - O
very ADV - O
reliable ADJ - O
HPLC NNP - B-NORP
method NOUN - O
was VERB - O
developed VERB - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
reduced VERB - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
in ADP - O
the DET - O
biological ADJ - O
samples NOUN - O
described VERB - O
as ADP - O
follows VERB - O
. PUNCT - O

After ADP - O
addition NOUN - O
of ADP - O
the DET - O
internal ADJ - O
standard ADJ - O
solution NOUN - O
and CCONJ - O
0.5 CD - B-CARDINAL
M PROPN - O
HCl NOUN - O
to ADP - O
the DET - O
biological ADJ - O
sample NOUN - O
, PUNCT - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
reduced VERB - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
and CCONJ - O
the DET - O
internal ADJ - O
standard NOUN - O
were VERB - O
extracted VERB - O
with ADP - O
a DET - O
mixed ADJ - O
solvent NOUN - O
of ADP - O
n NOUN - O
- PUNCT - O
hexane NOUN - O
and CCONJ - O
ethyl ADV - O
acetate VERB - O
( PUNCT - O
90:10 NUM - O
) PUNCT - O
from ADP - O
the DET - O
mixture NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dilazep VERB - O
and CCONJ - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
inhibit NOUN - O

-DOCSTART- -X- - O

Presented VERB - O
study NOUN - O
is VERB - O
focussed VERB - O
on ADP - O
the DET - O
distribution NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
into ADP - O
lipoprotein NOUN - O
( PUNCT - O
VLDL NOUN - O
, PUNCT - O
LDL NNP - B-ORG
, PUNCT - O
IDL NNP - B-ORG
and CCONJ - O
HDL NNP - B-ORG
) PUNCT - O
fractions NOUN - O
of ADP - O
human NOUN - O
and CCONJ - O
( PUNCT - O
for ADP - O
comparison NOUN - O
) PUNCT - O
minipig VERB - O
blood NOUN - O
plasma NOUN - O
, PUNCT - O
which ADJ - O
has VERB - O
not ADV - O
been VERB - O
studied VERB - O
yet ADV - O
. PUNCT - O

Four CD - B-CARDINAL
homologues NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
prepared VERB - O
have VERB - O
identical ADJ - O
chromophoric ADJ - O
part NOUN - O
of ADP - O
their ADJ - O
molecules NOUN - O
and CCONJ - O
hence ADV - O
the DET - O
same ADJ - O
UV NOUN - O
spectra NOUN - O
as ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

From ADP - O
this DET - O
point NOUN - O
of ADP - O
view NOUN - O
, PUNCT - O
these DET - O
standards NOUN - O
are VERB - O
more ADV - O
suitable ADJ - O
for ADP - O
determination NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
than ADP - O
the DET - O
formerly ADV - O
used VERB - O
ones NOUN - O
-- PUNCT - O
naproxen NOUN - O
or CCONJ - O
bezafibrate NOUN - O
. PUNCT - O

This DET - O
fact NOUN - O
may VERB - O
be VERB - O
explained VERB - O
by ADP - O
higher ADJ - O
affinity NOUN - O
of ADP - O
the DET - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
to ADP - O
proteins NOUN - O
constituting VERB - O
major ADJ - O
part NOUN - O
of ADP - O
the DET - O
high ADJ - O
density NOUN - O
lipoprotein NOUN - O
fraction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
photosensitization NOUN - O
of ADP - O
DNA NOUN - O
damage NOUN - O
by ADP - O
KP NNP - B-ORG
and CCONJ - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FB PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
main ADJ - O
metabolite NOUN - O
of ADP - O
fenofibrate NOUN - O
, PUNCT - O
and CCONJ - O
their ADJ - O
parent NOUN - O
compound NOUN - O
, PUNCT - O
benzophenone NOUN - O
( PUNCT - O
BZ PROPN - O
) PUNCT - O
, PUNCT - O
was VERB - O
examined VERB - O
on ADP - O
a DET - O
32P CD - B-DATE
- HYPH - I-DATE
end NN - I-DATE
- PUNCT - O
labeled VERB - O
synthetic ADJ - O
oligonucleotide NOUN - O
in ADP - O
phosphate NOUN - O
- PUNCT - O
buffered VERB - O
solution NOUN - O
using VERB - O
gel NOUN - O
sequencing NOUN - O
experiments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
differentiated ADJ - O
C2C12 NNP - B-ORG
myotubes NOUN - O
were VERB - O
treated VERB - O
with ADP - O
palmitic ADJ - O
acid NOUN - O
or CCONJ - O
pretreated VERB - O
with ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
or CCONJ - O
4-phenylbutyric JJ - B-CARDINAL
acid NOUN - O
( PUNCT - O
4-PBA NUM - O
) PUNCT - O
, PUNCT - O
etomoxir ADJ - O
, PUNCT - O
and CCONJ - O
the DET - O
expression NOUN - O
of ADP - O
ER PROPN - O
stress NOUN - O
, PUNCT - O
beta NOUN - O
- PUNCT - O
oxidation NOUN - O
- PUNCT - O
related VERB - O
genes NOUN - O
, PUNCT - O
inflammatory ADJ - O
genes NOUN - O
, PUNCT - O
Toll NOUN - O
- PUNCT - O
like ADJ - O
receptor NOUN - O
4 CD - B-CARDINAL
( PUNCT - O
TLR4 NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
insulin NOUN - O
- PUNCT - O
signaling VERB - O
- PUNCT - O
related VERB - O
molecules NOUN - O
were VERB - O
determined VERB - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
this DET - O
issue NOUN - O
, PUNCT - O
we PRON - O
have VERB - O
irradiated VERB - O
human ADJ - O
skin NOUN - O
cells NOUN - O
( PUNCT - O
keratinocytes NOUN - O
and CCONJ - O
fibroblasts NOUN - O
) PUNCT - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
the DET - O
active ADJ - O
phototoxic ADJ - O
metabolite NOUN - O
of ADP - O
fenofibrate NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Furthermore ADV - O
, PUNCT - O
this DET - O
formulation NOUN - O
effectively ADV - O
increased VERB - O
the DET - O
oral ADJ - O
drug NOUN - O
exposure NOUN - O
in ADP - O
rats NOUN - O
, PUNCT - O
as ADP - O
the DET - O
Cmax NNP - B-ORG
and CCONJ - O
AUC NNP - B-ORG
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
an DET - O
active ADJ - O
metabolite NOUN - O
) PUNCT - O
were VERB - O
enhanced VERB - O
by ADP - O
approximately RB - B-CARDINAL
6 CD - I-CARDINAL
- SYM - I-CARDINAL
7 CD - I-CARDINAL
folds NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Relationship NOUN - O
between ADP - O
plasma NOUN - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
levels NOUN - O
and CCONJ - O
the DET - O
effect NOUN - O
of ADP - O
micronized ADJ - O
fenofibrate NOUN - O
on ADP - O
cholesterol NOUN - O
, PUNCT - O
low ADJ - O
- PUNCT - O
density NOUN - O
- PUNCT - O
lipoprotein NOUN - O
cholesterol NOUN - O
and CCONJ - O
apolipoprotein NOUN - O
B NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
primary ADJ - O
hypercholesterolemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
previously ADV - O
reported VERB - O
that ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA NNP - B-ORG
) PUNCT - O
, PUNCT - O
the DET - O
active ADJ - O
metabolite NOUN - O
of ADP - O
fenofibrate NOUN - O
, PUNCT - O
prevents VERB - O
the DET - O
disorganization NOUN - O
of ADP - O
tight ADJ - O
junction NOUN - O
proteins NOUN - O
and CCONJ - O
the DET - O
hyperpermeability NOUN - O
provoked VERB - O
by ADP - O
the DET - O
diabetic ADJ - O
milieu NOUN - O
in ADP - O
the DET - O
retinal ADJ - O
pigment NOUN - O
epithelium NOUN - O
( PUNCT - O
RPE PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ultimately ADV - O
the DET - O
expression NOUN - O
of ADP - O
ER PROPN - O
stress NOUN - O
related VERB - O
genes NOUN - O
were VERB - O
assessed VERB - O
in ADP - O
primary ADJ - O
mouse NOUN - O
aortic ADJ - O
endothelial ADJ - O
cells NOUN - O
( PUNCT - O
MAEC NNP - B-GPE
) PUNCT - O
treated VERB - O
by ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
( PUNCT - O
FA NNP - B-ORG
) PUNCT - O
and CCONJ - O
PA NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
analysis NOUN - O
of ADP - O
plasma NOUN - O
samples NOUN - O
for ADP - O
concentrations NOUN - O
of ADP - O
fenofibric NN - B-MEDICINE
acid NN - I-MEDICINE
, PUNCT - O
the DET - O
active ADJ - O
metabolite NOUN - O
of ADP - O
fenofibrate NOUN - O
, PUNCT - O
was VERB - O
conducted VERB - O
by ADP - O
using VERB - O
a DET - O
validated VERB - O
LC NNP - B-ORG
- HYPH - I-ORG
MS NNP - I-ORG
/ SYM - I-ORG
MS NNP - I-ORG
method NOUN - O
. PUNCT - O

Bioequivalence NOUN - O
was VERB - O
to PART - O
be VERB - O
concluded VERB - O
if ADP - O
the DT - B-PERCENT
90 CD - I-PERCENT
% NN - I-PERCENT
CIs NOUN - O
as ADP - O
constructed VERB - O
were VERB - O
within ADP - O
the DET - O
range NOUN - O
of ADP - O
80 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
125 CD - I-PERCENT
% NN - I-PERCENT
for ADP - O
Cmax NNP - B-ORG
, PUNCT - O
AUC0-t NNP - B-ORG
, PUNCT - O
and CCONJ - O
AUC0-∞ PUNCT - O
for ADP - O
fenofibric JJ - B-MEDICINE
acid NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Metaxalone NN - B-MEDICINE
has VERB - O
only ADV - O
recently ADV - O
been VERB - O
associated VERB - O
with ADP - O
serotonin ADJ - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metaxalone NN - B-MEDICINE
was VERB - O
subjected VERB - O
to ADP - O
the DET - O
stress NOUN - O
conditions NOUN - O
of ADP - O
oxidative NOUN - O
, PUNCT - O
acid NOUN - O
, PUNCT - O
base NOUN - O
, PUNCT - O
hydrolytic ADJ - O
, PUNCT - O
thermal ADJ - O
and CCONJ - O
photolytic ADJ - O
degradation NOUN - O
. PUNCT - O

Metaxalone NN - B-MEDICINE
was VERB - O
found VERB - O
to PART - O
degrade VERB - O
significantly ADV - O
in ADP - O
base NOUN - O
stress NOUN - O
condition NOUN - O
, PUNCT - O
degrade VERB - O
slightly ADV - O
in ADP - O
oxidative ADJ - O
stress NOUN - O
condition NOUN - O
and CCONJ - O
remain VERB - O
stable ADJ - O
in ADP - O
acid NOUN - O
, PUNCT - O
hydrolytic ADJ - O
, PUNCT - O
thermal ADJ - O
and CCONJ - O
photolytic ADJ - O
degradation NOUN - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
improved ADJ - O
process NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
of ADP - O
Metaxalone NN - B-MEDICINE
of ADP - O
formula NOUN - O
I PRON - O
wherein VERB - O
, PUNCT - O
reacting VERB - O
3,5-dimethyl CD - B-PRODUCT
phenol NOUN - O
with ADP - O
3-chloro-1,2-propane CD - B-CARDINAL
diol NOUN - O
in ADP - O
presence NOUN - O
of ADP - O
a DET - O
base NOUN - O
, PUNCT - O
to PART - O
produce VERB - O
3-(3,5-dimethylphenoxy)propane-1,2-diol CD - B-LOC
which ADJ - O
is VERB - O
further ADV - O
reacted VERB - O
with ADP - O
urea NOUN - O
in ADP - O
presence NOUN - O
of ADP - O
polyalkylene NOUN - O
glycol VERB - O
to PART - O
obtain VERB - O
Metaxalone NN - B-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
optionally ADV - O
crystallized VERB - O
in ADP - O
ethyl ADV - O
acetate ADJ - O
in ADP - O
presence NOUN - O
of ADP - O
mineral NOUN - O
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metaxalone NN - B-MEDICINE
products NOUN - O
, PUNCT - O
method NOUN - O
of ADP - O
manufacture NOUN - O
, PUNCT - O
and CCONJ - O
method NOUN - O
of ADP - O
use NOUN - O

-DOCSTART- -X- - O

Metaxalone NN - B-MEDICINE
products NOUN - O
, PUNCT - O
method NOUN - O
of ADP - O
manufacture NOUN - O
, PUNCT - O
and CCONJ - O
method NOUN - O
of ADP - O
use NOUN - O

-DOCSTART- -X- - O

Bioavailable PROPN - O
Solid ADJ - O
Dosage PROPN - O
Forms NOUN - O
of ADP - O
Metaxalone NNP - B-MEDICINE

-DOCSTART- -X- - O

Metaxalone NN - B-MEDICINE
( PUNCT - O
Skelaxin)-related VBN - B-ORG
death NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metaxalone NNP - B-MEDICINE
was VERB - O
used VERB - O
as ADP - O
an DET - O
internal ADJ - O
standard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
the DET - O
Vehicle PROPN - O
and CCONJ - O
Antibiotic NNP - B-ORG
Formulation NNP - I-ORG
on IN - I-ORG
Cytotoxicity NNP - I-ORG
of IN - I-ORG
Triple NNP - I-ORG
Antibiotic NNP - I-ORG
Paste NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
XP NNP - B-PERSON
- HYPH - I-PERSON
Endo NNP - I-PERSON
Finisher NNP - I-PERSON
in ADP - O
the DET - O
Removal PROPN - O
of ADP - O
Triple NNP - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Paste PROPN - O
from ADP - O
Immature NNP - B-ORG
Root NNP - I-ORG
Canals NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
Microdilution NOUN - O
Method PROPN - O
to ADP - O
Assess NNP - B-ORG
Double JJ - I-ORG
and CCONJ - O
Triple NNP - B-ORG
Antibiotic NNP - I-ORG
Combination NNP - I-ORG
Therapy NNP - I-ORG

-DOCSTART- -X- - O

Triple JJ - B-MEDICINE
Antibiotic NNP - I-MEDICINE
Polymer PROPN - O
Nanofibers PROPN - O
for ADP - O
Intracanal ADJ - O
Drug PROPN - O
Delivery PROPN - O
: PUNCT - O
Effects NOUN - O
on ADP - O
Dual PROPN - O
Species PROPN - O
Biofilm PROPN - O
and CCONJ - O
Cell NNP - B-ORG
Function NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
dual ADJ - O
role NOUN - O
of ADP - O
oxalic ADJ - O
acid NOUN - O
on ADP - O
the DET - O
resistance NOUN - O
of ADP - O
tomato NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
fungal ADJ - O
pathogen NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infects VERB - O
a DET - O
broad ADJ - O
range NOUN - O
of ADP - O
horticultural ADJ - O
plants NOUN - O
worldwide ADV - O
, PUNCT - O
resulting VERB - O
in ADP - O
significant ADJ - O
economic ADJ - O
losses NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
fungitoxic ADJ - O
effect NOUN - O
of ADP - O
aristolochic ADJ - O
acids NOUN - O
I PROPN - O
and CCONJ - O
II NNP - B-ORG
on ADP - O
mycelial ADJ - O
growth NOUN - O
and CCONJ - O
conidial ADJ - O
germination NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
was VERB - O
analysed VERB - O
. PUNCT - O

The DET - O
fungitoxic ADJ - O
effect NOUN - O
on ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
of ADP - O
aristolochic ADJ - O
acids NOUN - O
I PROPN - O
and CCONJ - O
II NNP - B-PERSON
was VERB - O
characterized VERB - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
tested VERB - O
the DET - O
potential NOUN - O
of ADP - O
commercially ADV - O
available ADJ - O
inulin NOUN - O
- PUNCT - O
type NOUN - O
fructans NOUN - O
to PART - O
limit VERB - O
disease NOUN - O
symptoms NOUN - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
in ADP - O
lettuce NOUN - O
. PUNCT - O

Spraying VERB - O
mature ADJ - O
lettuce NOUN - O
leaves NOUN - O
, PUNCT - O
with ADP - O
inulin ADJ - O
- PUNCT - O
type NOUN - O
fructans NOUN - O
derived VERB - O
from ADP - O
burdock NOUN - O
or CCONJ - O
chicory NOUN - O
was VERB - O
as ADV - O
effective ADJ - O
in ADP - O
reducing VERB - O
grey ADJ - O
mold NOUN - O
disease NOUN - O
symptoms NOUN - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
as ADP - O
spraying VERB - O
with ADP - O
oligogalacturonides NOUN - O
( PUNCT - O
OGs NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
function NOUN - O
of ADP - O
a DET - O
cysteine NOUN - O
protease NOUN - O
BcAtg4 NNP - B-PERSON
in ADP - O
the DET - O
gray ADJ - O
mold NOUN - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
a DET - O
LAMP PROPN - O
Method PROPN - O
for ADP - O
Detecting VERB - O
SDHI PROPN - O
Fungicide PROPN - O
Resistance PROPN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O

-DOCSTART- -X- - O

The DET - O
fungi NOUN - O
were VERB - O
identified VERB - O
as ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
Pers.:Fr VERB - O
on ADP - O
the DET - O
basis NOUN - O
of ADP - O
morphology NOUN - O
( PUNCT - O
Ellis PROPN - O
1971 CD - B-DATE
; PUNCT - O
Zhang NNP - B-PERSON
2006 CD - I-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

RNA PROPN - O
sequencing NOUN - O
- PUNCT - O
based VERB - O
transcriptome NOUN - O
analysis NOUN - O
of ADP - O
mature ADJ - O
strawberry ADJ - O
fruit NOUN - O
infected VERB - O
by ADP - O
necrotrophic ADJ - O
fungal ADJ - O
pathogen NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O

-DOCSTART- -X- - O

We PRON - O
have VERB - O
performed VERB - O
a DET - O
comparative ADJ - O
proteomics NOUN - O
study NOUN - O
of ADP - O
ST NNP - B-ORG
mutants NOUN - O
in ADP - O
the DET - O
phytopathogenic ADJ - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
during ADP - O
axenic ADJ - O
growth NOUN - O
under ADP - O
non ADJ - O
- ADJ - O
stressed ADJ - O
conditions NOUN - O
to PART - O
decipher VERB - O
the DET - O
roles NOUN - O
of ADP - O
two CD - B-CARDINAL
kinases NOUN - O
of ADP - O
the DET - O
hyper NOUN - O
- PUNCT - O
osmolarity NOUN - O
pathway NOUN - O
in ADP - O
B. NNP - B-PERSON
cinerea NOUN - O
physiology NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

VQ10 NOUN - O
expression NOUN - O
was VERB - O
strongly ADV - O
responsive ADJ - O
to ADP - O
the DET - O
necrotrophic ADJ - O
fungal ADJ - O
pathogen NOUN - O
, PUNCT - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
defense NOUN - O
- PUNCT - O
related VERB - O
hormones NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Arabidopsis PROPN - O
VQ10 PROPN - O
interacts NOUN - O
with ADP - O
WRKY8 NNP - B-GPE
to PART - O
modulate VERB - O
basal ADJ - O
defense NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
putative ADJ - O
H3K36 PROPN - O
demethylase NOUN - O
BcKDM1 PRON - O
affects VERB - O
virulence NOUN - O
, PUNCT - O
stress NOUN - O
responses NOUN - O
and CCONJ - O
photomorphogenesis NOUN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sensitivity NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
to ADP - O
seven CD - B-CARDINAL
fungicide NOUN - O
chemical NOUN - O
classes NOUN - O
was VERB - O
determined VERB - O
for ADP - O
888 CD - B-CARDINAL
isolates NOUN - O
collected VERB - O
in ADP - O
2016 CD - B-DATE
from ADP - O
47 CD - B-CARDINAL
California NNP - B-GPE
strawberry ADJ - O
fields NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Based VERB - O
on ADP - O
these DET - O
morphological ADJ - O
characteristics NOUN - O
, PUNCT - O
the DET - O
pathogen NOUN - O
was VERB - O
identified VERB - O
as ADP - O
Botrytis NNP - B-ORG
cinerea PROPN - O
Pers NNPS - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Gray NNP - I-ORG
Mold NNP - I-ORG
Caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
on ADP - O
Paris NNP - B-GPE
polyphylla NOUN - O
in ADP - O
China NNP - B-GPE

-DOCSTART- -X- - O

Arabidopsis NNP - B-PERSON
were VERB - O
challenged VERB - O
with ADP - O
three CD - B-CARDINAL
pathogens NOUN - O
: PUNCT - O
the DET - O
biotrophic ADJ - O
fungus NOUN - O
Golovinomyces NNP - B-PERSON
cichoracearum NOUN - O
, PUNCT - O
necrotrophic ADJ - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
and CCONJ - O
semi ADJ - O
- ADJ - O
biotrophic ADJ - O
bacteria NOUN - O
Pseudomonas NNP - B-GPE
syringae NOUN - O
pv VERB - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
system NOUN - O
improves VERB - O
the DET - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Calonectria NNP - B-GPE
spp NOUN - O
infection NOUN - O
on ADP - O
the DET - O
young ADJ - O
eucalypts NOUN - O
plantings NOUN - O
, PUNCT - O
resulting VERB - O
gray ADJ - O
mold NOUN - O
and CCONJ - O
cutting VERB - O
rot VERB - O
respectively ADV - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
evaluate VERB - O
endophytic ADJ - O
Bacillus PROPN - O
isolated VERB - O
from ADP - O
eucalypts NOUN - O
as ADP - O
a DET - O
biocontrol NOUN - O
agent NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Calonectria NNP - B-GPE
gracilis NOUN - O
, PUNCT - O
important ADJ - O
fungal ADJ - O
pathogens NOUN - O
in ADP - O
the DET - O
greenhouse NOUN - O
, PUNCT - O
using VERB - O
clonal ADJ - O
plantlets NOUN - O
of ADP - O
E. PROPN - O
urograndis NOUN - O
. PUNCT - O

Eight CD - B-CARDINAL
endophytic ADJ - O
strains NOUN - O
of ADP - O
Bacillus NOUN - O
, PUNCT - O
previously ADV - O
described VERB - O
as ADP - O
eucalyptus NOUN - O
growth NOUN - O
promoters NOUN - O
, PUNCT - O
were VERB - O
evaluated VERB - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Calonectria NNP - B-GPE
gracilis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methyl PROPN - O
jasmonate PROPN - O
( PUNCT - O
MeJA PROPN - O
) PUNCT - O
and CCONJ - O
ethylene NOUN - O
play VERB - O
important ADJ - O
roles NOUN - O
in ADP - O
mediating VERB - O
defense NOUN - O
responses NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

Ethylene NOUN - O
response NOUN - O
factors NOUN - O
( PUNCT - O
ERFs PROPN - O
) PUNCT - O
are VERB - O
the DET - O
final ADJ - O
components NOUN - O
of ADP - O
ethylene NOUN - O
signal NOUN - O
transduction NOUN - O
; PUNCT - O
whether ADP - O
SlERF2 ADJ - O
participates NOUN - O
in ADP - O
disease NOUN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
is VERB - O
unclear ADJ - O
. PUNCT - O

Overexpression NUM - O
of ADP - O
SlERF2 PROPN - O
enhanced VERB - O
tomato NOUN - O
fruit NOUN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

These DET - O
results NOUN - O
indicated VERB - O
that ADP - O
SlERF2 PROPN - O
was VERB - O
involved VERB - O
in ADP - O
MeJA NNP - B-GPE
- PUNCT - O
mediated VERB - O
disease NOUN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
in ADP - O
tomato ADJ - O
fruit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
Associated VERB - O
with ADP - O
Methyl PROPN - O
Jasmonate PROPN - O
- PUNCT - O
Mediated PROPN - O
Defense PROPN - O
Response PROPN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
in ADP - O
Tomato NNP - B-ORG
Fruit NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
causal ADJ - O
agent NOUN - O
of ADP - O
gray ADJ - O
mold NOUN - O
, PUNCT - O
can VERB - O
result VERB - O
in ADP - O
considerable ADJ - O
preharvest NOUN - O
and CCONJ - O
postharvest NOUN - O
losses NOUN - O
in ADP - O
many ADJ - O
economically ADV - O
valuable ADJ - O
plant NOUN - O
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

ATG8 NOUN - O
in ADP - O
the DET - O
necrotrophic ADJ - O
plant NOUN - O
pathogen NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
Yeast PROPN - O
complementation NOUN - O
experiments NOUN - O
demonstrated VERB - O
that ADP - O
BcATG8 NNP - B-PERSON
can VERB - O
functionally ADV - O
complement VERB - O
the DET - O
defects NOUN - O
of ADP - O
the DET - O
yeast NOUN - O
ATG8 PROPN - O
null VERB - O
mutant NOUN - O
. PUNCT - O

The DET - O
gray ADJ - O
mold NOUN - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
is VERB - O
an DET - O
economically ADV - O
important ADJ - O
plant NOUN - O
pathogen NOUN - O
with ADP - O
a DET - O
broad ADJ - O
host NOUN - O
range NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
fruit NOUN - O
rot NOUN - O
, PUNCT - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
important ADJ - O
strawberry ADJ - O
diseases NOUN - O
worldwide ADV - O
, PUNCT - O
and CCONJ - O
fungicide NOUN - O
applications NOUN - O
are VERB - O
often ADV - O
used VERB - O
to PART - O
manage VERB - O
the DET - O
disease NOUN - O
in ADP - O
commercial ADJ - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
example NOUN - O
using VERB - O
two CD - B-CARDINAL
Bacillus PROPN - O
amyloliquefaciens VERB - O
strains NOUN - O
and CCONJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
of ADP - O
tomatoes NOUN - O

-DOCSTART- -X- - O

Evaluating VERB - O
a DET - O
preventive ADJ - O
biological ADJ - O
control NOUN - O
agent NOUN - O
applied VERB - O
on ADP - O
grapevines NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
its ADJ - O
influence NOUN - O
on ADP - O
winemaking NOUN - O

-DOCSTART- -X- - O

The DET - O
MAPK PROPN - O
kinase NOUN - O
BcMkk1 NNP - B-ORG
suppresses VERB - O
oxalic ADJ - O
acid NOUN - O
biosynthesis NOUN - O
via ADP - O
impeding VERB - O
phosphorylation NOUN - O
of ADP - O
BcRim15 NNP - B-GPE
by ADP - O
BcSch9 NNP - B-PERSON
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metabolic NNP - B-ORG
Phenotype NNP - I-ORG
Characterization NNP - I-ORG
of IN - I-ORG
Botrytis NNP - I-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
Causal PROPN - O
Agent PROPN - O
of ADP - O
Gray NNP - B-ORG
Mold NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Compounds NOUN - O
Released VERB - O
by ADP - O
the DET - O
Biocontrol PROPN - O
Yeast PROPN - O
Hanseniaspora PROPN - O
opuntiae NOUN - O
Protect NNP - B-LAW
Plants NNP - I-LAW
Against PROPN - O
Corynespora NNP - B-ORG
cassiicola NOUN - O
and CCONJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
characterized VERB - O
a DET - O
cell NOUN - O
wall NOUN - O
chitin NOUN - O
from ADP - O
Saccharomyces NNPS - B-ORG
cerevisiae VERB - O
and CCONJ - O
investigated VERB - O
the DET - O
effect NOUN - O
of ADP - O
a DET - O
postharvest NOUN - O
chitin ADJ - O
treatment NOUN - O
on ADP - O
disease NOUN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
in ADP - O
tomato ADJ - O
fruit NOUN - O
and CCONJ - O
the DET - O
possible ADJ - O
mechanisms NOUN - O
involved VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Crop NOUN - O
protection NOUN - O
anilinopyrimidine NOUN - O
( PUNCT - O
AP NNP - B-ORG
) PUNCT - O
fungicides NOUN - O
were VERB - O
introduced VERB - O
more JJR - B-DATE
than IN - I-DATE
20 CD - I-DATE
years NNS - I-DATE
ago RB - I-DATE
for ADP - O
the DET - O
control NOUN - O
of ADP - O
a DET - O
range NOUN - O
of ADP - O
diseases NOUN - O
caused VERB - O
by ADP - O
ascomycete ADJ - O
plant NOUN - O
pathogens NOUN - O
, PUNCT - O
and CCONJ - O
in ADP - O
particular ADJ - O
for ADP - O
the DET - O
control NOUN - O
of ADP - O
gray ADJ - O
mold NOUN - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
fruit NOUN - O
rot NOUN - O
, PUNCT - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
important ADJ - O
strawberry ADJ - O
diseases NOUN - O
worldwide ADV - O
, PUNCT - O
and CCONJ - O
fungicide NOUN - O
applications NOUN - O
are VERB - O
often ADV - O
used VERB - O
to PART - O
manage VERB - O
the DET - O
disease NOUN - O
in ADP - O
commercial ADJ - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Involvement NOUN - O
of ADP - O
BcYak1 PROPN - O
in ADP - O
the DT - B-ORG
Regulation NNP - I-ORG
of IN - I-ORG
Vegetative NNP - I-ORG
Differentiation NNP - I-ORG
and CC - I-ORG
Adaptation NN - I-ORG
to IN - I-ORG
Oxidative NNP - I-ORG
Stress NN - I-ORG
of IN - I-ORG
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Botrytis NNP - I-ORG
cinerea NN - I-ORG
Causing PROPN - O
Gray PROPN - O
Mold PROPN - O
Disease PROPN - O
of ADP - O
Bell NNP - B-ORG
Pepper NNP - I-ORG
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

Against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
mint NOUN - O
oil NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
on ADP - O
table NOUN - O
grapes NOUN - O
and CCONJ - O
its ADJ - O
possible ADJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O

-DOCSTART- -X- - O

latex NOUN - O
inhibit NOUN - O
cell NOUN - O
growth NOUN - O
and CCONJ - O
cell NOUN - O
wall NOUN - O
integrity NOUN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

These DET - O
morphological ADJ - O
characteristics NOUN - O
identified VERB - O
the DET - O
causal ADJ - O
pathogen NOUN - O
as ADP - O
Botrytis NNP - B-ORG
cinerea PROPN - O
( PUNCT - O
syn NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative PROPN - O
RNA PROPN - O
- PUNCT - O
Seq NOUN - O
analysis NOUN - O
reveals VERB - O
a DET - O
critical ADJ - O
role NOUN - O
for ADP - O
brassinosteroids NOUN - O
in ADP - O
rose PROPN - O
( PUNCT - O
Rosa NNP - B-PERSON
hybrida VERB - O
) PUNCT - O
petal ADJ - O
defense NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
actinomycetes NOUN - O
were VERB - O
isolated VERB - O
from ADP - O
rhizosphere NOUN - O
soil NOUN - O
of ADP - O
tomato NOUN - O
by ADP - O
spread NOUN - O
plate NOUN - O
method NOUN - O
, PUNCT - O
with ADP - O
the DET - O
pathogen NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
as ADP - O
the DET - O
target NOUN - O
fungus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Botrytis NNP - B-ORG
cinerea NOUN - O
VELVET PROPN - O
complex NOUN - O
regulates VERB - O
light ADJ - O
- PUNCT - O
dependent ADJ - O
development NOUN - O
and CCONJ - O
virulence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluating VERB - O
a DET - O
preventive ADJ - O
biological ADJ - O
control NOUN - O
agent NOUN - O
applied VERB - O
on ADP - O
grapevines NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
its ADJ - O
influence NOUN - O
on ADP - O
winemaking NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
prevention NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
and CCONJ - O
the DET - O
study NOUN - O
of ADP - O
grape NOUN - O
seedlessness NOUN - O
are VERB - O
very ADV - O
important ADJ - O
for ADP - O
grape NOUN - O
industries NOUN - O
. PUNCT - O

Taken VERB - O
together ADV - O
, PUNCT - O
these DET - O
results NOUN - O
indicate VERB - O
that ADP - O
VvERF NNP - B-ORG
proteins NOUN - O
are VERB - O
involved VERB - O
in ADP - O
responses NOUN - O
to ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
and CCONJ - O
in ADP - O
grape NOUN - O
ovule NOUN - O
development NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Detection PROPN - O
and CCONJ - O
Molecular PROPN - O
Characterization PROPN - O
of ADP - O
Resistance PROPN - O
to ADP - O
the DET - O
Dicarboximide PROPN - O
and CCONJ - O
Benzamide PROPN - O
Fungicides PROPN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
From ADP - O
Tomato NNP - B-GPE
in ADP - O
Hubei NNP - B-GPE
Province NNP - I-GPE
, PUNCT - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
investigate VERB - O
the DET - O
mycoparasitism NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
pathogen NOUN - O
of ADP - O
scape NOUN - O
and CCONJ - O
umbel ADJ - O
blights NOUN - O
of ADP - O
onion NOUN - O
seed NOUN - O
crops NOUN - O
, PUNCT - O
by ADP - O
endophytic ADJ - O
Talaromyces NNP - B-PRODUCT
pinophilus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Talaromyces NOUN - O
pinophilus NOUN - O
strain VERB - O
AUN-1 PROPN - O
as ADP - O
a DET - O
novel ADJ - O
mycoparasite NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
pathogen NOUN - O
of ADP - O
onion NOUN - O
scape NOUN - O
and CCONJ - O
umbel NOUN - O
blights NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
pathogenic ADJ - O
mutant NOUN - O
, PUNCT - O
BCG183 NNP - B-PERSON
, PUNCT - O
was VERB - O
obtained VERB - O
by ADP - O
screening VERB - O
the DET - O
T PROPN - O
- PUNCT - O
DNA PROPN - O
insertion NOUN - O
library NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antifungal ADJ - O
properties NOUN - O
and CCONJ - O
the DET - O
induction NOUN - O
of ADP - O
resistance NOUN - O
by ADP - O
ε ADJ - O
- PUNCT - O
poly NOUN - O
- PUNCT - O
l NOUN - O
- PUNCT - O
lysine NOUN - O
( PUNCT - O
ε JJ - B-ORG
- HYPH - I-ORG
PL NNP - I-ORG
) PUNCT - O
and CCONJ - O
chitooligosaccharide ADJ - O
( PUNCT - O
COS NNP - B-ORG
) PUNCT - O
were VERB - O
examined VERB - O
to PART - O
find VERB - O
an DET - O
alternative NOUN - O
to ADP - O
synthetic ADJ - O
fungicides NOUN - O
currently ADV - O
used VERB - O
in ADP - O
the DET - O
control NOUN - O
of ADP - O
the DET - O
devastating ADJ - O
fungal ADJ - O
pathogen NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
causal ADJ - O
agent NOUN - O
of ADP - O
grey NOUN - O
mould VERB - O
disease NOUN - O
of ADP - O
tomatoes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Synergistic ADJ - O
effect NOUN - O
of ADP - O
the DET - O
combined VERB - O
bio NOUN - O
- PUNCT - O
fungicides NOUN - O
ε PART - O
- PUNCT - O
poly NOUN - O
- PUNCT - O
l NOUN - O
- PUNCT - O
lysine NOUN - O
and CCONJ - O
chitooligosaccharide NOUN - O
in ADP - O
controlling VERB - O
grey NOUN - O
mould NOUN - O
( PUNCT - O
Botrytis NNP - B-ORG
cinerea NOUN - O
) PUNCT - O
in ADP - O
tomatoes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antifungal ADJ - O
activity NOUN - O
of ADP - O
polygodial NOUN - O
, PUNCT - O
a DET - O
secondary ADJ - O
metabolite NOUN - O
extracted VERB - O
from ADP - O
Canelo NNP - B-PERSON
, PUNCT - O
on ADP - O
mycelial ADJ - O
growth NOUN - O
of ADP - O
different ADJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
isolates NOUN - O
has VERB - O
been VERB - O
evaluated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Botrytis NNP - I-ORG
Blight NNP - I-ORG
Caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
on ADP - O
Purple NNP - B-FAC
Coneflower NNP - I-FAC
( PUNCT - O
Echinacea NN - B-PERSON
purpurea NOUN - O
) PUNCT - O
in ADP - O
Italy NNP - B-GPE

-DOCSTART- -X- - O

' PUNCT - O
Omics NOUN - O
' PUNCT - O
and CCONJ - O
Plant PROPN - O
Responses PROPN - O
to ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
prior ADJ - O
exposure NOUN - O
to ADP - O
30mgm-3 CD - B-CARDINAL
SO2 NOUN - O
on ADP - O
defence NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
( PUNCT - O
B. PROPN - O
cinerea NOUN - O
) PUNCT - O
in ADP - O
Arabidopsis NNP - B-PERSON
thaliana NOUN - O
and CCONJ - O
the DET - O
possible ADJ - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
were VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Enhanced PROPN - O
Arabidopsis PROPN - O
disease NOUN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
induced VERB - O
by ADP - O
sulfur NOUN - O
dioxide NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
cinerea NOUN - O
is VERB - O
an DET - O
important ADJ - O
plant NOUN - O
pathogen NOUN - O
causing VERB - O
grey NOUN - O
mold NOUN - O
disease NOUN - O
in ADP - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
plant NOUN - O
species NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tomato NNP - B-ORG
is VERB - O
susceptible ADJ - O
to ADP - O
postharvest NOUN - O
rot NOUN - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
is VERB - O
regarded VERB - O
as ADP - O
a DET - O
good ADJ - O
model NOUN - O
system NOUN - O
to PART - O
study VERB - O
postharvest NOUN - O
disease NOUN - O
and CCONJ - O
quality NOUN - O
deterioration NOUN - O
in ADP - O
fruit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
cinerea NOUN - O
usually ADV - O
produces VERB - O
grayish ADJ - O
mycelia NOUN - O
and CCONJ - O
conidia NOUN - O
as ADV - O
well ADV - O
as ADP - O
black ADV - O
- PUNCT - O
colored VERB - O
sclerotia NOUN - O
( PUNCT - O
BS NNP - B-ORG
) PUNCT - O
due ADP - O
to ADP - O
accumulation NOUN - O
of ADP - O
melanin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
assessed VERB - O
the DET - O
fenhexamid ADJ - O
sensitivity NOUN - O
of ADP - O
143 CD - B-CARDINAL
Botrytis NNP - B-ORG
cinerea NOUN - O
isolates NOUN - O
collected VERB - O
from ADP - O
greenhouse NOUN - O
strawberries NOUN - O
in ADP - O
five CD - B-CARDINAL
regions NOUN - O
of ADP - O
China NNP - B-GPE
between IN - B-DATE
2012 CD - I-DATE
and CC - I-DATE
2013 CD - I-DATE
, PUNCT - O
and CCONJ - O
identified VERB - O
four CD - B-CARDINAL
isolates NOUN - O
with ADP - O
moderate ADJ - O
levels NOUN - O
of ADP - O
resistance NOUN - O
: PUNCT - O
two CD - B-CARDINAL
from ADP - O
the DT - B-GPE
Xinjiang NNP - I-GPE
Uygur NNP - I-GPE
Autonomous NNP - I-GPE
Region NNP - I-GPE
and CCONJ - O
two CD - B-CARDINAL
from ADP - O
Hebei NNP - B-GPE
Province NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Occurrence NOUN - O
of ADP - O
fenhexamid ADJ - O
resistance NOUN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
from ADP - O
greenhouse NOUN - O
strawberries NOUN - O
in ADP - O
China NNP - B-GPE

-DOCSTART- -X- - O

Thyme NNP - B-ORG
and CCONJ - O
Savory PROPN - O
Essential PROPN - O
Oil PROPN - O
Efficacy PROPN - O
and CCONJ - O
Induction PROPN - O
of ADP - O
Resistance PROPN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
through ADP - O
Priming NN - B-ORG
of IN - I-ORG
Defense NNP - I-ORG
Responses NNPS - I-ORG
in ADP - O
Apple NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Mechanisms NOUN - O
and CCONJ - O
strategies NOUN - O
of ADP - O
plant NOUN - O
defense NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis JJ - B-ORG
cinerea NOUN - O
, PUNCT - O
a DET - O
necrotrophic ADJ - O
pathogenic ADJ - O
fungus NOUN - O
, PUNCT - O
attacks VERB - O
many ADJ - O
crops NOUN - O
including VERB - O
potato NOUN - O
and CCONJ - O
tomato NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Design PROPN - O
, PUNCT - O
Synthesis PROPN - O
, PUNCT - O
and CCONJ - O
SAR NNP - B-ORG
of ADP - O
Novel PROPN - O
2-Glycinamide NUM - O
Cyclohexyl PROPN - O
Sulfonamide PROPN - O
Derivatives PROPN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
histone NOUN - O
epigenetic ADJ - O
marks NOUN - O
in ADP - O
Arabidopsis NNP - B-GPE
and CCONJ - O
tomato ADJ - O
genes NOUN - O
in ADP - O
the DET - O
early ADJ - O
response NOUN - O
to ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Botrytis NNP - B-ORG
cinerea NOUN - O
is VERB - O
an DET - O
important ADJ - O
plant NOUN - O
pathogenic VERB - O
fungus NOUN - O
with ADP - O
a DET - O
wide ADJ - O
range NOUN - O
of ADP - O
host NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
the DET - O
polyketide NOUN - O
synthase NOUN - O
gene NOUN - O
, PUNCT - O
Bcpks12 NNP - B-ORG
, PUNCT - O
was VERB - O
exclusively ADV - O
required VERB - O
for ADP - O
the DET - O
melanization NOUN - O
of ADP - O
sclerotia NOUN - O
that ADJ - O
are VERB - O
specifically ADV - O
expressed VERB - O
during ADP - O
sclerotial ADJ - O
development NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

gene NOUN - O
inactivation NOUN - O
substantiates VERB - O
biological ADJ - O
functions NOUN - O
of ADP - O
sclerotium NOUN - O
melanization NOUN - O
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O

-DOCSTART- -X- - O

Results NOUN - O
obtained VERB - O
show VERB - O
that ADP - O
StAP NNP - B-ORG
- HYPH - I-ORG
PSI NNP - I-ORG
significantly ADV - O
enhances VERB - O
Arabidopsis PROPN - O
resistance NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
infection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Functional ADJ - O
analysis NOUN - O
of ADP - O
diacylglycerol NOUN - O
O NOUN - O
- PUNCT - O
acyl NOUN - O
transferase NOUN - O
2 CD - B-CARDINAL
gene NOUN - O
to PART - O
decipher VERB - O
its ADJ - O
role NOUN - O
in ADP - O
virulence NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piriformospora NNP - B-PERSON
indica PROPN - O
, PUNCT - O
a DET - O
root NOUN - O
endophytic ADJ - O
fungus NOUN - O
, PUNCT - O
promotes VERB - O
growth NOUN - O
of ADP - O
the DET - O
economically ADV - O
important ADJ - O
chickpea NOUN - O
plant NOUN - O
( PUNCT - O
Cicer NNP - B-GPE
arietinum NOUN - O
Linn NNP - B-PERSON
. PUNCT - O
) PUNCT - O
and CCONJ - O
protects VERB - O
it PRON - O
against ADP - O
the DET - O
pathogenic ADJ - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
MEDIATOR25 NNP - B-GPE
( PUNCT - O
MED25 NNP - B-GPE
) PUNCT - O
subunit NOUN - O
of ADP - O
Arabidopsis PROPN - O
thaliana NOUN - O
regulates NOUN - O
jasmonate VERB - O
- PUNCT - O
dependent ADJ - O
resistance NOUN - O
to ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
through ADP - O
interacting VERB - O
with ADP - O
the DET - O
basic ADJ - O
helix NOUN - O
- PUNCT - O
loop NOUN - O
- PUNCT - O
helix PROPN - O
( PUNCT - O
bHLH NOUN - O
) PUNCT - O
transcription NOUN - O
factor NOUN - O
of ADP - O
jasmonate NOUN - O
signaling NOUN - O
, PUNCT - O
MYC2 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Resistance NOUN - O
to ADP - O
Increasing VERB - O
Chemical PROPN - O
Classes PROPN - O
of ADP - O
Fungicides PROPN - O
by ADP - O
Virtue NNP - B-PERSON
of ADP - O
âSelection NUM - O
by ADP - O
Associationâ NNP - B-PERSON
in ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O

-DOCSTART- -X- - O

Antifungal ADJ - O
effectiveness NOUN - O
of ADP - O
fungicide NOUN - O
and CCONJ - O
peroxyacetic ADJ - O
acid NOUN - O
mixture NOUN - O
on ADP - O
the DET - O
growth NOUN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Entomopathogenic NN - B-PERSON
Fungi NNP - I-PERSON
as ADP - O
Dual JJ - B-ORG
Control NNP - I-ORG
Agents NNP - I-ORG
against ADP - O
Both CCONJ - O
the DET - O
Pest NNP - B-ORG
Myzus NNP - I-ORG
persicae NOUN - O
and CCONJ - O
Phytopathogen NNP - B-PRODUCT
Botrytis NNP - I-PRODUCT
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative ADJ - O
transcriptome NOUN - O
analysis NOUN - O
between ADP - O
an DET - O
evolved ADJ - O
abscisic ADJ - O
acid NOUN - O
- PUNCT - O
overproducing VERB - O
mutant ADJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
TBC NNP - B-ORG
- HYPH - I-ORG
A NN - I-ORG
and CCONJ - O
its ADJ - O
ancestral ADJ - O
strain NOUN - O
Botrytis NNP - B-ORG
cinerea PROPN - O
TBC-6 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Grey PROPN - O
mould NOUN - O
, PUNCT - O
caused VERB - O
by ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
is VERB - O
a DET - O
disease NOUN - O
severely ADV - O
affecting VERB - O
grape NOUN - O
production NOUN - O
in ADP - O
northern ADJ - O
Italy NNP - B-GPE
. PUNCT - O

Botrytis JJ - B-ORG
cinerea NOUN - O
isolates NOUN - O
( PUNCT - O
317 CD - B-CARDINAL
) PUNCT - O
were VERB - O
completely ADV - O
genotyped VERB - O
for ADP - O
six CD - B-CARDINAL
microsatellite ADJ - O
loci NOUN - O
and CCONJ - O
characterized VERB - O
for ADP - O
the DET - O
presence NOUN - O
of ADP - O
the DET - O
transposable ADJ - O
elements NOUN - O
Boty PROPN - O
and CCONJ - O
Flipper PROPN - O
, PUNCT - O
for ADP - O
the DET - O
mating NOUN - O
type NOUN - O
and CCONJ - O
for ADP - O
resistance NOUN - O
to ADP - O
cyprodinil NOUN - O
, PUNCT - O
fludioxonil X - O
, PUNCT - O
boscalid VERB - O
and CCONJ - O
fenhexamid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sources NOUN - O
of ADP - O
Primary PROPN - O
Inoculum PROPN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
and CCONJ - O
Their PRP$ - B-WORK_OF_ART
Impact NN - I-WORK_OF_ART
on IN - I-WORK_OF_ART
Fungicide NNP - I-WORK_OF_ART
Resistance NNP - I-WORK_OF_ART
Development NNP - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Commercial NNP - I-WORK_OF_ART
Strawberry NNP - I-WORK_OF_ART
Fields NNPS - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
antifungal ADJ - O
properties NOUN - O
and CCONJ - O
the DET - O
induction NOUN - O
of ADP - O
resistance NOUN - O
by ADP - O
ε ADJ - O
- PUNCT - O
poly NOUN - O
- PUNCT - O
l NOUN - O
- PUNCT - O
lysine NOUN - O
( PUNCT - O
ε JJ - B-ORG
- HYPH - I-ORG
PL NNP - I-ORG
) PUNCT - O
were VERB - O
examined VERB - O
to PART - O
reveal VERB - O
its ADJ - O
potential NOUN - O
in ADP - O
protecting VERB - O
tomato ADJ - O
plants NOUN - O
against ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Previously ADV - O
, PUNCT - O
we PRON - O
demonstrated VERB - O
that ADP - O
TTO NNP - B-ORG
has VERB - O
a DET - O
strong ADJ - O
inhibitory ADJ - O
effect NOUN - O
on ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
WRKY33 NNP - B-GPE
transcription NOUN - O
factor NOUN - O
was VERB - O
reported VERB - O
for ADP - O
resistance NOUN - O
to ADP - O
the DET - O
necrotrophic ADJ - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sensitivity NOUN - O
to ADP - O
Fludioxonil PROPN - O
of ADP - O
Botrytis NNP - B-ORG
cinerea PROPN - O
Isolates NNPS - B-ORG
from ADP - O
Tomato NNP - B-ORG
in ADP - O
Henan NNP - B-GPE
Province NNP - I-GPE
of ADP - O
China NNP - B-GPE
and CCONJ - O
Characterizations PROPN - O
of ADP - O
Fludioxonilâresistant ADJ - O
Mutants NOUN - O

-DOCSTART- -X- - O

Combining VERB - O
biocontrol NOUN - O
agents NOUN - O
with ADP - O
different ADJ - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
in ADP - O
a DET - O
strategy NOUN - O
to PART - O
control VERB - O
Botrytis NNP - B-ORG
cinerea NOUN - O
on ADP - O
grapevine NOUN - O

-DOCSTART- -X- - O

BcXYG1 INTJ - O
, PUNCT - O
a DET - O
Secreted JJ - B-WORK_OF_ART
Xyloglucanase NNP - I-WORK_OF_ART
from ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
Triggers NNP - B-ORG
Both DET - O
Cell NNP - B-ORG
Death NNP - I-ORG
and CCONJ - O
Plant PROPN - O
Immune PROPN - O
Responses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
resistance NOUN - O
to ADP - O
Botrytis NNP - B-ORG
cinerea NOUN - O
in ADP - O
Arabidopsis NNP - B-GPE
thaliana NOUN - O
and CCONJ - O
Camelina NNP - B-PERSON
sativa ADJ - O
overexpressing VERB - O
DEWAX NOUN - O
and CCONJ - O
in ADP - O
Arabidopsis PROPN - O
dewax VERB - O
mutant NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gray JJ - B-ORG
mold NOUN - O
, PUNCT - O
caused VERB - O
by ADP - O
the DET - O
necrotrophic ADJ - O
fungus NOUN - O
Botrytis NNP - B-ORG
cinerea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
analyse VERB - O
the DET - O
effect NOUN - O
of ADP - O
a DET - O
Botrytis NNP - B-ORG
cinerea NOUN - O
leaf NOUN - O
infection NOUN - O
on ADP - O
the DET - O
secretion NOUN - O
of ADP - O
tomato NOUN - O
root NOUN - O
exudates NOUN - O
and CCONJ - O
on ADP - O
the DET - O
populations NOUN - O
of ADP - O
the DET - O
BCA NNP - B-ORG
Trichoderma NNP - I-ORG
asperellum NOUN - O
strain NOUN - O
T34 NNP - B-ORG
( PUNCT - O
T34 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
tested VERB - O
in ADP - O
  SPACE - O
vitro NOUN - O
six CD - B-CARDINAL
βCs NOUN - O
against ADP - O
Penicillium NNP - B-ORG
digitatum NOUN - O
and CCONJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
, PUNCT - O
causal ADJ - O
agents NOUN - O
of ADP - O
postharvest NOUN - O
diseases NOUN - O
on ADP - O
fruit NOUN - O
and CCONJ - O
vegetables NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dynamics NOUN - O
in ADP - O
the DET - O
Strawberry PROPN - O
Rhizosphere PROPN - O
Microbiome PROPN - O
in ADP - O
Response NNP - B-GPE
to ADP - O
Biochar NNP - B-PERSON
and CCONJ - O
Botrytis NNP - B-ORG
cinerea NOUN - O
Leaf NNP - B-ORG
Infection NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Quantification NOUN - O
of ADP - O
the DET - O
Changes PROPN - O
in ADP - O
Potent PROPN - O
Wine PROPN - O
Odorants PROPN - O
as ADP - O
Induced VERB - O
by ADP - O
Bunch PROPN - O
Rot PROPN - O
( PUNCT - O
Botrytis NNP - B-ORG
cinerea PROPN - O
) PUNCT - O
and CCONJ - O
Powdery NNP - B-ORG
Mildew NNP - I-ORG
( PUNCT - O
Erysiphe NNP - B-ORG
necator NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Cephalexin NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
acute NOUN - O
generalized VERB - O
exanthematous ADJ - O
pustulosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cephalexin NNP - B-MEDICINE
is VERB - O
extensively ADV - O
used VERB - O
as ADP - O
an DET - O
antibiotic NOUN - O
for ADP - O
treatment NOUN - O
a DET - O
number NOUN - O
of ADP - O
bacterial ADJ - O
infections NOUN - O
. PUNCT - O

The DET - O
data NOUN - O
of ADP - O
possible ADJ - O
adsorption NOUN - O
mechanism NOUN - O
and CCONJ - O
isotherm NOUN - O
of ADP - O
Cephalexin NNP - B-MEDICINE
on ADP - O
the DET - O
synthesized ADJ - O
adsorbent NOUN - O
are VERB - O
depicted VERB - O
in ADP - O
this DET - O
data NOUN - O
article NOUN - O
. PUNCT - O

Considering VERB - O
the DET - O
findings NOUN - O
data NOUN - O
, PUNCT - O
powdered VERB - O
activated VERB - O
carbon NOUN - O
derived VERB - O
from ADP - O
pomegranate ADJ - O
peel NOUN - O
as ADP - O
available ADJ - O
and CCONJ - O
a DET - O
cheap ADJ - O
adsorbent NOUN - O
, PUNCT - O
could VERB - O
be VERB - O
considered VERB - O
as ADP - O
promising ADJ - O
adsorbent NOUN - O
for ADP - O
Cephalexin NNP - B-MEDICINE
and CCONJ - O
probably ADV - O
similar ADJ - O
organic ADJ - O
pollutants NOUN - O
removal NOUN - O
from ADP - O
aqueous ADJ - O
solutions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bioremediation PROPN - O
of ADP - O
Cephalexin NNP - B-MEDICINE
with ADP - O
non ADJ - O
- ADJ - O
living ADJ - O
Chlorella NNP - B-PERSON
sp PART - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Cephalexin NNP - B-MEDICINE
Plus NNP - I-ORG
Trimethoprim NNP - I-ORG
- HYPH - I-ORG
Sulfamethoxazole NNP - I-ORG
vs IN - I-ORG
Cephalexin NNP - I-MEDICINE
Alone RB - I-ORG
on ADP - O
Clinical NNP - B-ORG
Cure NNP - I-ORG
of IN - I-ORG
Uncomplicated NNP - I-ORG
Cellulitis NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Lenalidomide PROPN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
: PUNCT - O
A DET - O
Thalidomide PROPN - O
Analogue PROPN - O
in ADP - O
Combination PROPN - O
With ADP - O
Dexamethasone PROPN - O
For ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
All DT - I-ORG
Patients NNPS - I-ORG
With IN - I-ORG
Multiple NNP - I-ORG
Myeloma NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Lenalidomide PROPN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
bortezomib NOUN - O
( PUNCT - O
Velcade NNP - B-ORG
) PUNCT - O
and CCONJ - O
dexamethasone VERB - O
for ADP - O
heavily ADV - O
pretreated VERB - O
relapsed ADJ - O
or CCONJ - O
refractory ADJ - O
multiple ADJ - O
myeloma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
methods NOUN - O
encompass VERB - O
the DET - O
administration NOUN - O
of ADP - O
an DET - O
immunomodulatory ADJ - O
compound NOUN - O
of ADP - O
the DET - O
invention NOUN - O
known VERB - O
as ADP - O
Revlimid@ NN - B-PRODUCT
or CCONJ - O
lenalidomide NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lenalidomide PROPN - O
( PUNCT - O
Revlimid NN - B-MEDICINE
; PUNCT - O
Selleck NN - B-PERSON
Chemicals NNPS - I-PERSON
, PUNCT - O
Houston NNP - B-GPE
, PUNCT - O
TX PROPN - O
, PUNCT - O
USA NNP - B-GPE
) PUNCT - O
, PUNCT - O
an DET - O
analogue NOUN - O
of ADP - O
thalidomide NOUN - O
, PUNCT - O
possesses VERB - O
potent ADJ - O
cytokine NOUN - O
modulatory NOUN - O
capacity NOUN - O
through ADP - O
inhibition NOUN - O
of ADP - O
cytokines NOUN - O
such ADJ - O
as ADP - O
tumour NOUN - O
necrosis NOUN - O
factor NOUN - O
( PUNCT - O
TNF)-α NNP - B-ORG
, PUNCT - O
a DET - O
cytokine NOUN - O
pivotal ADJ - O
for ADP - O
the DET - O
onset NOUN - O
and CCONJ - O
development NOUN - O
of ADP - O
complications NOUN - O
in ADP - O
obesity NOUN - O
and CCONJ - O
diabetes NOUN - O
mellitus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lenalidomide PROPN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
is VERB - O
an DET - O
immunomodulatory ADJ - O
analog NOUN - O
of ADP - O
thalidomide NOUN - O
with ADP - O
significant ADJ - O
T NOUN - O
- PUNCT - O
cell NOUN - O
stimulatory NOUN - O
and CCONJ - O
antiangiogenic ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
lenalidomide NOUN - O
( PUNCT - O
Revlimid NN - B-MEDICINE
) PUNCT - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
plasma NOUN - O
cell NOUN - O
leukemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Thalidomide NOUN - O
, PUNCT - O
bortezomib NOUN - O
and CCONJ - O
lenalidomide NOUN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
have VERB - O
emerged VERB - O
as ADP - O
high ADJ - O
active ADJ - O
agents NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
PCL PROPN - O
( PUNCT - O
Johnston NNP - B-GPE
and CCONJ - O
abdalla NOUN - O
, PUNCT - O
2002 NUM - O
; PUNCT - O
Musto NNP - B-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
. PROPN - O
, PUNCT - O
2007 CD - B-DATE
; PUNCT - O
Finnegan NNP - B-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
. PROPN - O
, PUNCT - O
2006 CD - B-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
trial NOUN - O
determined VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
the DET - O
combination NOUN - O
regimen NOUN - O
clarithromycin PROPN - O
( PUNCT - O
Biaxin NNP - B-GPE
) PUNCT - O
, PUNCT - O
lenalidomide NOUN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
and CCONJ - O
dexamethasone NOUN - O
( PUNCT - O
BiRD PROPN - O
) PUNCT - O
as ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
for ADP - O
multiple ADJ - O
myeloma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
failure NOUN - O
was VERB - O
noted VERB - O
only ADV - O
in ADP - O
1 CD - B-CARDINAL
patient NOUN - O
- PUNCT - O
in PART - O
60 CD - B-DATE
days NNS - I-DATE
after ADP - O
therapy NOUN - O
cessation NOUN - O
the DET - O
disease NOUN - O
progressed VERB - O
and CCONJ - O
required VERB - O
further ADJ - O
treatment NOUN - O
( PUNCT - O
CHOEP NOUN - O
, PUNCT - O
high ADJ - O
- PUNCT - O
dose NOUN - O
BEAM PROPN - O
chemotherapy NOUN - O
with ADP - O
autologous ADJ - O
transplantation NOUN - O
followed VERB - O
by ADP - O
Revlimid NNP - B-MEDICINE
treatment NOUN - O
and CCONJ - O
allogeneic NOUN - O
transplantation NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Another DET - O
analysis NOUN - O
with ADP - O
36 CD - B-CARDINAL
paired VERB - O
- PUNCT - O
samples NOUN - O
from ADP - O
18 CD - B-CARDINAL
patients NOUN - O
collected VERB - O
before ADP - O
and CCONJ - O
after ADP - O
the DET - O
treatment NOUN - O
with ADP - O
lenalidomide NOUN - O
( PUNCT - O
Revlimid NNP - B-MEDICINE
) PUNCT - O
identified VERB - O
19 CD - B-CARDINAL
differential ADJ - O
peak NOUN - O
features NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
treatment NOUN - O
, PUNCT - O
prevention NOUN - O
or CCONJ - O
management NOUN - O
of ADP - O
mantle NOUN - O
cell NOUN - O
lymphomas NOUN - O
by ADP - O
admin NOUN - O
istration NOUN - O
of ADP - O
an DET - O
immunomodulatory ADJ - O
compound NOUN - O
of ADP - O
the DET - O
invention NOUN - O
known VERB - O
as ADP - O
Revlimid NNP - B-MEDICINE
TM NNP - I-ORG
or CCONJ - O
lenalidomide NOUN - O
are VERB - O
disclosed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Oral PROPN - O
Oxycodone NOUN - O
Compared VERB - O
With ADP - O
Intravenous ADJ - O
Morphine NNP - B-MEDICINE
Sulfate NNP - I-MEDICINE
for ADP - O
Pain PROPN - O
Management PROPN - O
of ADP - O
Isolated PROPN - O
Limb PROPN - O
Trauma PROPN - O
; PUNCT - O
a DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DT - B-ORG
Analgesic NNP - I-ORG
Effect NNP - I-ORG
of IN - I-ORG
Intravenous NNP - I-ORG
Acetaminophen NNP - I-ORG
and CC - I-ORG
Morphine NNP - B-ORG
Sulfate NNP - I-ORG
in ADP - O
Rib NNP - B-ORG
Fracture NNP - I-ORG
; PUNCT - O
a DET - O
Randomized VBN - B-ORG
Double NNP - I-ORG
- HYPH - I-ORG
Blind NNP - I-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Morphine NNP - B-ORG
Sulfate NNP - I-ORG
Formulations NNPS - I-ORG

-DOCSTART- -X- - O

Controlled VERB - O
release NOUN - O
effervescent NOUN - O
buccal ADJ - O
discs NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
evaluation NOUN - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
microemulsion NOUN - O
formulations NOUN - O
for ADP - O
intranasal NOUN - O
administration NOUN - O
to PART - O
improve VERB - O
the DET - O
drug NOUN - O
bioavailability NOUN - O
and CCONJ - O
provide VERB - O
high ADJ - O
drug NOUN - O
brain NOUN - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
work NOUN - O
aims VERB - O
to PART - O
prepare VERB - O
sustained ADJ - O
release NOUN - O
buccal ADJ - O
mucoadhesive NOUN - O
lyophilized VERB - O
chitosan ADJ - O
sponges NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
BH NNP - B-ORG
) PUNCT - O
to PART - O
improve VERB - O
its ADJ - O
systemic ADJ - O
bioavailability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
microemulsion NOUN - O
formulations NOUN - O
for ADP - O
intranasal NOUN - O
administration NOUN - O
to PART - O
improve VERB - O
the DET - O
drug NOUN - O
bioavailability NOUN - O
and CCONJ - O
provide VERB - O
high ADJ - O
drug NOUN - O
brain NOUN - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
influence NOUN - O
of ADP - O
components NOUN - O
such ADJ - O
as ADP - O
type NOUN - O
, PUNCT - O
level NOUN - O
, PUNCT - O
and CCONJ - O
hydrophilic ADJ - O
- PUNCT - O
lipophilic ADJ - O
balance NOUN - O
( PUNCT - O
HLB NOUN - O
) PUNCT - O
value NOUN - O
of ADP - O
surfactant NOUN - O
, PUNCT - O
type NOUN - O
and CCONJ - O
amount NOUN - O
of ADP - O
cosurfactant ADJ - O
, PUNCT - O
and CCONJ - O
drug NOUN - O
concentration NOUN - O
on ADP - O
the DET - O
permeability NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
microemulsions NOUN - O
through ADP - O
rat NOUN - O
skin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
paper NOUN - O
, PUNCT - O
the DET - O
solubility NOUN - O
of ADP - O
two CD - B-CARDINAL
polymorphs NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
BUS PROPN - O
- PUNCT - O
HCl NOUN - O
) PUNCT - O
in ADP - O
isopropanol NOUN - O
, PUNCT - O
water NOUN - O
and CCONJ - O
mixture NOUN - O
of ADP - O
these DET - O
two CD - B-CARDINAL
solvents NOUN - O
has VERB - O
been VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Solid ADJ - O
- PUNCT - O
state NOUN - O
characterization NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
polymorphs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
discloses VERB - O
a DET - O
kind NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
slow ADJ - O
/ SYM - O
control NOUN - O
released VERB - O
micropills NOUN - O
and CCONJ - O
capsule NOUN - O
and CCONJ - O
their ADJ - O
preparation NOUN - O
method NOUN - O
. PUNCT - O

The DET - O
invented ADJ - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
slow NOUN - O
/ SYM - O
control NOUN - O
released VERB - O
micropill NOUN - O
includes VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
medicine NOUN - O
pill NOUN - O
core NOUN - O
and CCONJ - O
isolating VERB - O
layer NOUN - O
( PUNCT - O
slow ADV - O
- PUNCT - O
released VERB - O
coating NOUN - O
layer NOUN - O
) PUNCT - O
which ADJ - O
can VERB - O
be VERB - O
used VERB - O
for ADP - O
covering VERB - O
exterior NOUN - O
of ADP - O
said VERB - O
medicine NOUN - O
pill NOUN - O
core NOUN - O
. PUNCT - O

Said VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
slow NOUN - O
/ SYM - O
control NOUN - O
released VERB - O
micropills NOUN - O
and CCONJ - O
capsule NOUN - O
can VERB - O
be VERB - O
used VERB - O
for ADP - O
curing VERB - O
anxiety NOUN - O
neurosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
buspirone NOUN - O
slow ADJ - O
release NOUN - O
tablet NOUN - O
for ADP - O
stabilizing VERB - O
mood NOUN - O
and CCONJ - O
improving VERB - O
sleeping VERB - O
, PUNCT - O
which ADJ - O
comprises VERB - O
by ADP - O
weight NOUN - O
portion NOUN - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
15 CD - B-CARDINAL
- SYM - I-CARDINAL
30 CD - I-CARDINAL
g NOUN - O
, PUNCT - O
poly(e NOUN - O
- PUNCT - O
caprolactone NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
the DET - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
contents NOUN - O
in ADP - O
Buspirone NNP - B-GPE
hydrochloride NOUN - O
sustained VERB - O
release NOUN - O
tablets NOUN - O
by ADP - O
ion NOUN - O
- PUNCT - O
pair NOUN - O
RP NNP - B-ORG
- HYPH - I-ORG
HPLC NNP - I-ORG

-DOCSTART- -X- - O

New JJ - B-NORP
Plastic JJ - I-NORP
membrane ADJ - O
ion NOUN - O
- PUNCT - O
selective ADJ - O
electrode NOUN - O
for ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
based VERB - O
on ADP - O
buspironium NOUN - O
tetraphenylborate NOUN - O
was VERB - O
prepared VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
an DET - O
in X - O
vitro X - O
- PUNCT - O
in PART - O
vivo NOUN - O
correlation NOUN - O
for ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
extended VERB - O
release NOUN - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Kinetics NOUN - O
of ADP - O
thermal ADJ - O
decomposition NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
solid ADJ - O
state NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Iontophoretic ADJ - O
transdermal ADJ - O
delivery NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
hairless NOUN - O
mouse NOUN - O
skin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
prepare VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
buccal ADJ - O
adhesive ADJ - O
tablet NOUN - O
and CCONJ - O
investigate ADJ - O
factors NOUN - O
that ADJ - O
influence VERB - O
drug NOUN - O
release NOUN - O
behavior NOUN - O
and CCONJ - O
the DET - O
drug NOUN - O
release NOUN - O
mechanism NOUN - O
. PUNCT - O

The DET - O
optimum ADJ - O
prescription NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
buccal ADJ - O
adhesive NOUN - O
tablet NOUN - O
was VERB - O
carbopol ADJ - O
: PUNCT - O

-DOCSTART- -X- - O

Mean ADJ - O
levels NOUN - O
of ADP - O
anxiety NOUN - O
severity NOUN - O
scores NOUN - O
based VERB - O
on ADP - O
the DT - B-ORG
Hamilton NNP - I-ORG
Anxiety NNP - I-ORG
Scale NNP - I-ORG
( PUNCT - O
HAM PROPN - O
- PUNCT - O
A PROPN - O
) PUNCT - O
at ADP - O
follow NOUN - O
- PUNCT - O
up NOUN - O
were VERB - O
5.4 CD - B-CARDINAL
( PUNCT - O
SD NOUN - O
± PROPN - O
1.7 NUM - O
) PUNCT - O
, PUNCT - O
3.8 CD - B-CARDINAL
( PUNCT - O
SD NN - B-ORG
± NNP - I-ORG
1.8 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
12.8 CD - B-CARDINAL
( PUNCT - O
SD NN - B-NORP
± PROPN - O
1.9 NUM - O
) PUNCT - O
, PUNCT - O
respectively ADV - O
( PUNCT - O
P NOUN - O
value NOUN - O
< X - O
0.01).The NUM - O
third JJ - B-ORDINAL
trial NOUN - O
randomised VERB - O
94 CD - B-CARDINAL
stroke NOUN - O
patients NOUN - O
, PUNCT - O
also ADV - O
with ADP - O
co ADJ - O
- ADJ - O
morbid ADJ - O
anxiety NOUN - O
and CCONJ - O
depression NOUN - O
, PUNCT - O
to PART - O
receive VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
or CCONJ - O
standard ADJ - O
care NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
case NOUN - O
report NOUN - O
involving VERB - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
successful ADJ - O
treatment NOUN - O
of ADP - O
a DET - O
patient NOUN - O
with ADP - O
an DET - O
atypical ADJ - O
paraphilia NOUN - O
and CCONJ - O
transvestic ADJ - O
fetishism NOUN - O
is VERB - O
presented VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Preclinical ADJ - O
pharmacology NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Acute ADJ - O
toxicity NOUN - O
study NOUN - O
of ADP - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
mice NOUN - O
, PUNCT - O
rats NOUN - O
and CCONJ - O
dogs]. NOUN - O

-DOCSTART- -X- - O

A DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
study NOUN - O
of ADP - O
adjuvant ADJ - O
buspirone NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
clomipramine NOUN - O
- PUNCT - O
treated VERB - O
patients NOUN - O
with ADP - O
obsessive ADJ - O
- PUNCT - O
compulsive ADJ - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Association NNP - I-ORG
of IN - I-ORG
Hospital NNP - I-ORG
Rate NNP - I-ORG
of IN - I-ORG
Delayed NNP - I-ORG
Epinephrine NNP - I-MEDICINE
Administration NNP - I-ORG
With IN - I-ORG
Survival NNP - I-ORG
to IN - I-ORG
Discharge NNP - I-ORG
for IN - I-ORG
Pediatric NNP - I-ORG
Nonshockable NNP - I-ORG

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
is VERB - O
the DET - O
only ADJ - O
first ADJ - O
- PUNCT - O
line NOUN - O
therapeutic ADJ - O
agent NOUN - O
used VERB - O
to PART - O
treat VERB - O
life NOUN - O
- PUNCT - O
threatening VERB - O
anaphylaxis NOUN - O
. PUNCT - O

Epinephrine NN - B-MEDICINE
auto NOUN - O
- PUNCT - O
injectors NOUN - O
are VERB - O
commonly ADV - O
carried VERB - O
by ADP - O
patients NOUN - O
at ADP - O
risk NOUN - O
for ADP - O
anaphylaxis NOUN - O
, PUNCT - O
and CCONJ - O
reported VERB - O
cases NOUN - O
of ADP - O
unintentional ADJ - O
auto NOUN - O
- PUNCT - O
injector NOUN - O
injury NOUN - O
have VERB - O
increased VERB - O
over ADP - O
the DT - B-DATE
last JJ - I-DATE
decade NN - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Unintentional PROPN - O
Epinephrine NNP - B-MEDICINE
Auto PROPN - O
- PUNCT - O
injector NOUN - O
Injuries PROPN - O
: PUNCT - O
A DET - O
National PROPN - O
Poison PROPN - O
Center PROPN - O
Observational PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Epinephrine NN - B-MEDICINE
, PUNCT - O
a DET - O
double ADV - O
- PUNCT - O
edged ADJ - O
sword NOUN - O
? PUNCT - O
] PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
was VERB - O
more ADV - O
potent ADJ - O
than ADP - O
norepinephrine ADJ - O
, PUNCT - O
and CCONJ - O
this DET - O
activation NOUN - O
largely ADV - O
depends VERB - O
on ADP - O
a1-adrenoceptors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

With ADP - O
Value PROPN - O
- PUNCT - O
Based VERB - O
Drug PROPN - O
Pricing PROPN - O
of ADP - O
Epinephrine NNP - B-MEDICINE
Autoinjectors PROPN - O
for ADP - O
Children PROPN - O
With ADP - O
Peanut PROPN - O
Allergy PROPN - O
: PUNCT - O
A DET - O
Cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
Analysis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Lidocaine PROPN - O
with ADP - O
Epinephrine NNP - B-MEDICINE
on ADP - O
Bupivacaine PROPN - O
- PUNCT - O
Induced PROPN - O
Cardiotoxicity PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
prefilled VERB - O
syringe NOUN - O
was VERB - O
significantly ADV - O
easier ADJ - O
to PART - O
use VERB - O
with ADP - O
a DET - O
higher ADJ - O
rate NOUN - O
of ADP - O
correct ADJ - O
use NOUN - O
compared VERB - O
to ADP - O
EpiPen NNP - B-PERSON
over ADP - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
Adding PROPN - O
Sufentanil PROPN - O
and CCONJ - O
Low NNP - B-ORG
- HYPH - I-ORG
Dose NNP - I-ORG
Epinephrine NN - I-MEDICINE
to ADP - O
Bupivacaine NNP - B-GPE
in ADP - O
Spinal PROPN - O
Anesthesia PROPN - O
: PUNCT - O
A DET - O
Randomized VERB - O
, PUNCT - O
Double ADJ - O
- PUNCT - O
Blind ADJ - O
, PUNCT - O
Clinical PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
lidocaine NOUN - O
( PUNCT - O
group NOUN - O
2 LS - B-CARDINAL
) PUNCT - O
significantly ADV - O
reduced VERB - O
PB NNP - B-ORG
in ADP - O
comparison NOUN - O
with ADP - O
prilocaine NOUN - O
, PUNCT - O
P NOUN - O
= SYM - O
0.003 CD - B-CARDINAL
. PUNCT - O

Epinephrine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
lidocaine NOUN - O
was VERB - O
well ADV - O
tolerated VERB - O
and CCONJ - O
caused VERB - O
no DET - O
significant ADJ - O
cardiovascular ADJ - O
disturbance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Use PROPN - O
of ADP - O
Epinephrine NNP - B-MEDICINE
for ADP - O
Out PROPN - O
- PUNCT - O
Of PROPN - O
- PUNCT - O
Hospital PROPN - O
Treatment PROPN - O
of ADP - O
Anaphylaxis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
at ADP - O
low ADJ - O
dose NOUN - O
stimulated VERB - O
ADP PROPN - O
- PUNCT - O
induced VERB - O
platelet NOUN - O
membrane ADJ - O
expression NOUN - O
of ADP - O
CD62P NNP - B-ORG
whereas ADP - O
Atipamezole NNP - B-PRODUCT
significantly ADV - O
inhibited VERB - O
10 CD - B-CARDINAL
µM PROPN - O
ADP PROPN - O
- PUNCT - O
induced VERB - O
platelet NOUN - O
aggregation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
In ADP - O
- PUNCT - O
Hospital PROPN - O
Cardiac PROPN - O
Arrest PROPN - O
: PUNCT - O
Individual ADJ - O
Patient PROPN - O
Data PROPN - O
Reanalysis PROPN - O
of ADP - O
Two CD - B-ORG
Prior RB - I-ORG
Randomized VBN - I-ORG
Clinical JJ - I-ORG
Trials NNPS - I-ORG
that WDT - I-ORG
Evaluated VBD - I-ORG
the DT - I-ORG
Vasopressin NNP - I-ORG
- HYPH - I-ORG
Steroids NNP - I-ORG
- HYPH - I-ORG
Epinephrine NNP - I-MEDICINE
Combination NNP - I-ORG
Versus NNP - I-ORG
Epinephrine NNP - I-MEDICINE
Alone RB - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
synergistically ADV - O
enhances VERB - O
the DET - O
effects NOUN - O
of ADP - O
dibucaine NOUN - O
, PUNCT - O
while ADP - O
phentolamine NOUN - O
partially ADV - O
blocked VERB - O
those DET - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Phentolamine PROPN - O
Reverses PROPN - O
Epinephrine NNP - B-MEDICINE
- PUNCT - O
Enhanced VERB - O
Skin NOUN - O
Antinociception NOUN - O
of ADP - O
Dibucaine PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Epinephrine NN - B-MEDICINE
is VERB - O
recommended VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
non ADJ - O
- ADJ - O
shockable ADJ - O
out ADP - O
of ADP - O
hospital NOUN - O
cardiac ADJ - O
arrest NOUN - O
( PUNCT - O
OHCA NNP - B-ORG
) PUNCT - O
to PART - O
obtain VERB - O
return NOUN - O
of ADP - O
spontaneous ADJ - O
circulation NOUN - O
( PUNCT - O
ROSC NOUN - O
) PUNCT - O
. PUNCT - O

Epinephrine NN - B-MEDICINE
efficiency NOUN - O
and CCONJ - O
safety NOUN - O
remain VERB - O
under ADP - O
debate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Petrolatum NNP - B-MEDICINE
produced VERB - O
the DET - O
least ADJ - O
stinging ADJ - O
( PUNCT - O
0 NUM - O
) PUNCT - O
and CCONJ - O
isopropyl ADJ - O
alcohol NOUN - O
the DET - O
most ADV - O
( PUNCT - O
10 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
the DET - O
Healing PROPN - O
Effects PROPN - O
of ADP - O
Arnebia NNP - B-GPE
euchroma NOUN - O
Ointment NNP - B-WORK_OF_ART
With IN - I-WORK_OF_ART
Petrolatum NNP - I-MEDICINE
on IN - I-WORK_OF_ART
the DET - O
Ulcers PROPN - O
Caused VERB - O
by ADP - O
Fractional PROPN - O
CO2 PROPN - O
Laser PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
description NOUN - O
of ADP - O
clinical ADJ - O
and CCONJ - O
histological ADJ - O
effects NOUN - O
of ADP - O
polyethylene NOUN - O
glycol NOUN - O
and CCONJ - O
miripirium NOUN - O
after ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
injection NN - I-ORG
, PUNCT - O
and CCONJ - O
the DET - O
adverse ADJ - O
reactions NOUN - O
of ADP - O
particulate NOUN - O
methylprednisolone ADJ - O
acetate NOUN - O
was VERB - O
conducted VERB - O
. PUNCT - O

The DET - O
keywords NOUN - O
included VERB - O
' PUNCT - O
intrathecal ADJ - O
methylprednisolone NOUN - O
acetate NOUN - O
' PUNCT - O
, PUNCT - O
' PUNCT - O
miripirium NOUN - O
' PUNCT - O
, PUNCT - O
' PUNCT - O
myristyl ADJ - O
- PUNCT - O
gamma NOUN - O
- PUNCT - O
picolinium NOUN - O
' PUNCT - O
, PUNCT - O
' PUNCT - O
side NOUN - O
effects NOUN - O
' PART - O
, PUNCT - O
' PUNCT - O
intrathecal ADJ - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
' '' - I-ORG
, PUNCT - O
' PUNCT - O
polyethylene NOUN - O
glycol NOUN - O
' PUNCT - O
, PUNCT - O
and CCONJ - O
' PUNCT - O
intrathecal ADJ - O
devices NOUN - O
' PART - O
used VERB - O
individually ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
. PUNCT - O

Intrathecal ADJ - O
methylprednisolone NOUN - O
acetate NOUN - O
( PUNCT - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
) PUNCT - O
  SPACE - O
therapy NOUN - O
seems VERB - O
not ADV - O
fully ADV - O
safe ADJ - O
due ADP - O
to ADP - O
reported VERB - O
adverse ADJ - O
events NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
-- PUNCT - O
an DET - O
alternative NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
asthma]. PRON - O

-DOCSTART- -X- - O

Local ADJ - O
application NOUN - O
of ADP - O
low NOUN - O
- PUNCT - O
dose NOUN - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
is VERB - O
effective ADJ - O
in ADP - O
reducing VERB - O
immediate ADJ - O
postoperative NOUN - O
back NOUN - O
pain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
and CCONJ - O
myelographic ADJ - O
arachnoiditis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
again ADV - O
available ADJ - O
without ADP - O
benzyl NOUN - O
alcohol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Complications NOUN - O
from ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
R. NNP - I-ORG

-DOCSTART- -X- - O

Group PROPN - O
A PROPN - O
was VERB - O
prescribed VERB - O
to PART - O
use VERB - O
full ADJ - O
time NOUN - O
neutral ADJ - O
wrist NOUN - O
splint NOUN - O
and CCONJ - O
group NOUN - O
B NOUN - O
was VERB - O
injected VERB - O
with ADP - O
40 CD - B-CARDINAL
mg NOUN - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
and CCONJ - O
prescribed VERB - O
to PART - O
use VERB - O
the DET - O
full ADJ - O
time NOUN - O
neutral ADJ - O
wrist NOUN - O
splint VERB - O
for ADP - O
12 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Treatment NOUN - O
of ADP - O
chalazion NOUN - O
with ADP - O
injections NOUN - O
of ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
] PUNCT - O

-DOCSTART- -X- - O

A DET - O
complication NOUN - O
of ADP - O
intrathecal ADJ - O
administration NOUN - O
of ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
for ADP - O
multiple ADJ - O
sclerosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Immunosuppression NOUN - O
with ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
significantly ADV - O
delayed VERB - O
the DET - O
worm NOUN - O
expulsion NOUN - O
in ADP - O
C57BL/6 NN - B-CARDINAL
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
in ADP - O
treatment NOUN - O
of ADP - O
inflammatory ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Complications NOUN - O
from ADP - O
methylprednisolone ADJ - O
acetate NOUN - O
( PUNCT - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
) PUNCT - O
when ADV - O
injected VERB - O
into ADP - O
the DET - O
orbit NOUN - O
, PUNCT - O
subarachnoid NOUN - O
, PUNCT - O
or CCONJ - O
subdural ADJ - O
spaces NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Local ADJ - O
injections NOUN - O
of ADP - O
6alpha CD - B-CARDINAL
- PUNCT - O
methylprednisolone NOUN - O
acetate NOUN - O
( PUNCT - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
) PUNCT - O
in ADP - O
rheumatology]. NOUN - O

-DOCSTART- -X- - O

One CD - B-CARDINAL
hundred CD - I-CARDINAL
fifty CD - I-CARDINAL
nine CD - I-CARDINAL
patients NOUN - O
received VERB - O
treatment NOUN - O
with ADP - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
received VERB - O
either CCONJ - O
fluoroscopically ADV - O
guided VERB - O
or CCONJ - O
computed VERB - O
tomography NOUN - O
( PUNCT - O
CT)-guided VERB - O
epidural ADJ - O
injection NOUN - O
of ADP - O
a DET - O
combination NOUN - O
of ADP - O
lidocaine NOUN - O
and CCONJ - O
Depo NNP - B-ORG
- HYPH - I-ORG
Medrol NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Phenology NOUN - O
of ADP - O
the DT - B-FAC
Pine NNP - I-FAC
Bark NNP - I-FAC
Adelgid NNP - I-FAC
, PUNCT - O
Pineus NNP - B-PERSON
strobi PROPN - O
( PUNCT - O
Hemiptera NOUN - O
: PUNCT - O
Adelgidae PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
White NNP - B-ORG
Pine NNP - I-ORG
Forests NNPS - I-ORG
of IN - I-ORG
Southwestern NNP - I-ORG
Virginia NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Neotylenchidae PROPN - O
) PUNCT - O
Isolated VERB - O
from ADP - O
Packaging PROPN - O
Wood PROPN - O
from ADP - O
Canada NNP - B-GPE
and CCONJ - O
White NNP - B-ORG
Pine NNP - I-ORG

-DOCSTART- -X- - O

Influences NOUN - O
of ADP - O
Conventional PROPN - O
and CCONJ - O
Low PROPN - O
- PUNCT - O
Density NOUN - O
Thinning VERB - O
on ADP - O
the DET - O
Lower PROPN - O
Bole PROPN - O
Taper PROPN - O
and CCONJ - O
Volume PROPN - O
Growth PROPN - O
of ADP - O
Eastern PROPN - O
White NNP - B-MEDICINE
Pine NNP - I-MEDICINE

-DOCSTART- -X- - O

Psychidae PROPN - O
) PUNCT - O
on ADP - O
Hedge NNP - B-ORG
Rows NNP - I-ORG
of ADP - O
White NNP - B-MEDICINE
Pine NNP - I-MEDICINE

-DOCSTART- -X- - O

Histology NOUN - O
of ADP - O
White NNP - B-ORG
Pine NNP - I-ORG
Blister NNP - I-ORG
Rust NNP - I-ORG
in ADP - O
Needles PROPN - O
of ADP - O
Resistant ADJ - O
and CCONJ - O
Susceptible ADJ - O
Eastern ADJ - O
White NNP - B-MEDICINE
Pine NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
Eastern NNP - B-ORG
White NNP - I-ORG
Pine NNP - I-ORG
( PUNCT - O
Pinus NNP - B-NORP
strobus NOUN - O
L. NNP - B-PERSON
) PUNCT - O
Regeneration NOUN - O
under ADP - O
a DET - O
Reserve NNP - B-ORG
Shelterwood NNP - I-ORG
after ADP - O
Intermediate PROPN - O
Removals PROPN - O
and CCONJ - O
Windthrow PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Axe NNP - B-MEDICINE
selects VERB - O
the DET - O
optimal ADJ - O
index NOUN - O
present ADJ - O
in ADP - O
a DET - O
sequence NOUN - O
read NOUN - O
, PUNCT - O
even ADV - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
sequencing VERB - O
errors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Axe NN - B-MEDICINE
: PUNCT - O
rapid ADJ - O
, PUNCT - O
competitive ADJ - O
sequence NOUN - O
read NOUN - O
demultiplexing VERB - O
using VERB - O
a DET - O
trie NOUN - O

-DOCSTART- -X- - O

A DET - O
reconnaissance NOUN - O
survey NOUN - O
was VERB - O
therefore ADV - O
undertaken VERB - O
to PART - O
assess VERB - O
the DET - O
relative ADJ - O
contributions NOUN - O
from ADP - O
bed NOUN - O
sediment NOUN - O
- PUNCT - O
associated VERB - O
organic ADJ - O
matter NOUN - O
sources NOUN - O
potentially ADV - O
impacting VERB - O
on ADP - O
the DT - B-LOC
River NNP - I-LOC
Axe NNP - I-MEDICINE
Special NNP - I-LOC
Area NNP - I-LOC
of IN - I-LOC
Conservation NNP - I-LOC
( PUNCT - O
SAC PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
SW NNP - B-LOC
England NNP - I-LOC
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine‑induced ADJ - O
apoptosis NOUN - O
of ADP - O
osteoprogenitor NOUN - O
cells NOUN - O
may VERB - O
be VERB - O
the DET - O
mechanism NOUN - O
underlying VERB - O
the DET - O
increased VERB - O
incidence NOUN - O
of ADP - O
bone NOUN - O
loss NOUN - O
observed VERB - O
in ADP - O
patients NOUN - O
treated VERB - O
with ADP - O
fluoxetine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Combined PROPN - O
Fluoxetine NNP - B-MEDICINE
and CCONJ - O
Metformin PROPN - O
Treatment PROPN - O
Potentiates PROPN - O
Antidepressant NOUN - O
Efficacy NOUN - O
Increasing VERB - O
IGF2 PROPN - O
Expression PROPN - O
in ADP - O
the DET - O
Dorsal PROPN - O
Hippocampus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
and CCONJ - O
its ADJ - O
metabolite NOUN - O
norfluoxetine NOUN - O
decreased VERB - O
protein NOUN - O
levels NOUN - O
in ADP - O
cell NOUN - O
lysates NOUN - O
, PUNCT - O
decreased VERB - O
cell NOUN - O
viability NOUN - O
of ADP - O
microglia NOUN - O
, PUNCT - O
and CCONJ - O
increased VERB - O
the DET - O
expression NOUN - O
of ADP - O
the DET - O
apoptotic ADJ - O
marker NOUN - O
cleaved VERB - O
- PUNCT - O
caspase NOUN - O
3 CD - B-CARDINAL
in ADP - O
microglia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
, PUNCT - O
Tolerability NNP - B-ORG
, PUNCT - O
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Fluoxetine NNP - B-MEDICINE
as ADP - O
an DET - O
Antiviral NNP - B-ORG
for IN - I-ORG
Enterovirus NNP - I-ORG
D68 PROPN - O
Associated PROPN - O
Acute PROPN - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
is VERB - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
antidepressants NOUN - O
. PUNCT - O

Fluoxetine NN - B-MEDICINE
could VERB - O
prevent VERB - O
the DET - O
mesenchymal ADJ - O
stem NOUN - O
cell NOUN - O
differentiation NOUN - O
in ADP - O
lung NOUN - O
fetus NOUN - O
of ADP - O
rat NOUN - O
. PUNCT - O

Fluoxetine NN - B-MEDICINE
role NOUN - O
on ADP - O
adipogenic ADJ - O
and CCONJ - O
osteogenic ADJ - O
differentiation NOUN - O
of ADP - O
human NOUN - O
ADSCs NOUN - O
was VERB - O
analyzed VERB - O
by ADP - O
oil NOUN - O
red NOUN - O
and CCONJ - O
alizarin ADJ - O
red ADJ - O
staining NOUN - O
and CCONJ - O
RT PROPN - O
- PUNCT - O
PCR PROPN - O
reaction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sixty CD - B-CARDINAL
- HYPH - I-CARDINAL
four CD - I-CARDINAL
male ADJ - O
SD NN - B-ORG
rats NOUN - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
control NOUN - O
, PUNCT - O
model NOUN - O
, PUNCT - O
acupuncture NOUN - O
, PUNCT - O
Fluoxetine NNP - B-MEDICINE
, PUNCT - O
model NOUN - O
＋ PUNCT - O
Dimethyl JJ - B-PERSON
sulfoxide NOUN - O
( PUNCT - O
DMSO PROPN - O
) PUNCT - O
, PUNCT - O
model NOUN - O
＋ NOUN - O
PD PROPN - O
98059(an PROPN - O
ERK PROPN - O
pathway NOUN - O
inhibitor NOUN - O
) PUNCT - O
, PUNCT - O
acupuncture NOUN - O
＋ NOUN - O
PD PROPN - O
98059 NUM - O
and CCONJ - O
Fluoxetine NNP - B-MEDICINE
＋ NNS - I-ORG
PD NNP - I-ORG
98059 CD - I-ORG
groups NOUN - O
( PUNCT - O
n＝8 X - O
rats NOUN - O
in ADP - O
each DET - O
) PUNCT - O
. PUNCT - O

Fluoxetine NN - B-MEDICINE
hydrochloride NOUN - O
suspension NOUN - O
( PUNCT - O
1.8 NUM - O
mg•kg－1•d－1 NOUN - O
) PUNCT - O
was VERB - O
given VERB - O
to ADP - O
rats NOUN - O
of ADP - O
the DET - O
Fluoxetine NNP - B-MEDICINE
group NOUN - O
and CCONJ - O
Fluo NNP - B-ORG
- PUNCT - O
xetine NOUN - O
＋ NOUN - O
PD PROPN - O
98059 NUM - O
group NOUN - O
by ADP - O
gavage NOUN - O
30 CD - B-CARDINAL
min NOUN - O
before ADP - O
CUMS NNS - B-ORG
. PUNCT - O

PD NOUN - O
98059 NUM - O
( PUNCT - O
dissolved VERB - O
in ADP - O
DMSO PROPN - O
, PUNCT - O
10 CD - B-CARDINAL
µL NUM - O
) PUNCT - O
was VERB - O
administered VERB - O
to ADP - O
rats NOUN - O
of ADP - O
model NOUN - O
＋ NOUN - O
PD PROPN - O
98059 NUM - O
group NOUN - O
, PUNCT - O
acupuncture ADJ - O
＋ NOUN - O
PD PROPN - O
98059 NUM - O
and CCONJ - O
Fluoxetine NNP - B-MEDICINE
＋ NNS - I-ORG
PD NNP - I-ORG
98059 CD - I-ORG
group NOUN - O
, PUNCT - O
and CCONJ - O
DMSO PROPN - O
( PUNCT - O
10 CD - B-CARDINAL
µL NUM - O
) PUNCT - O
to ADP - O
rats NOUN - O
of ADP - O
model NOUN - O
＋ NOUN - O
DMSO PROPN - O
group NOUN - O
by ADP - O
intracerebroventricular ADJ - O
injection NOUN - O
1 CD - B-CARDINAL
h NOUN - O
before ADP - O
CUMS NNS - B-ORG
. PUNCT - O

After ADP - O
the DET - O
intervention NOUN - O
, PUNCT - O
modeling VERB - O
induced VERB - O
decrease NOUN - O
of ADP - O
the DET - O
sucrose ADJ - O
consumption NOUN - O
, PUNCT - O
and CCONJ - O
p PUNCT - O
- PUNCT - O
ERK NOUN - O
1/2 NUM - O
and CCONJ - O
BDNF ADJ - O
expression NOUN - O
was VERB - O
significantly ADV - O
up ADV - O
- PUNCT - O
regulated VERB - O
in ADP - O
both DET - O
acupuncture NOUN - O
and CCONJ - O
Fluoxetine JJ - B-MEDICINE
groups NOUN - O
( PUNCT - O
P<0.01 NNP - B-ORG
, PUNCT - O
P<0.05 NNP - B-GPE
) PUNCT - O
, PUNCT - O
but CCONJ - O
not ADV - O
in ADP - O
the DET - O
model＋PD NOUN - O
98059 NUM - O
, PUNCT - O
Fluoxetine NN - B-MEDICINE
＋PD VBP - I-PERSON

No DET - O
significant ADJ - O
differences NOUN - O
were VERB - O
found VERB - O
among ADP - O
the DET - O
model＋PD NOUN - O
98059 NUM - O
, PUNCT - O
Fluoxetine NN - B-MEDICINE
＋PD VBP - I-PERSON
98059 CD - I-PERSON
and CCONJ - O
acupuncture＋PD ADJ - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
is VERB - O
a DET - O
selective ADJ - O
serotonin ADJ - O
reuptake NOUN - O
inhibitor NOUN - O
that ADJ - O
is VERB - O
commonly ADV - O
used VERB - O
in ADP - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Sleep PROPN - O
Bruxism NOUN - O
Rapidly ADV - O
Treated VERB - O
With ADP - O
Once ADV - O
- PUNCT - O
Nightly ADJ - O
Dosing NOUN - O
of ADP - O
Buspirone PROPN - O
in ADP - O
a DET - O
6-Year CD - B-CARDINAL
- PUNCT - O
Old ADJ - O
Girl NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Skin NOUN - O
Picking NOUN - O
and CCONJ - O
Compulsive PROPN - O
Behaviors PROPN - O
in ADP - O
a DET - O
Preschool PROPN - O
Girl PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Fluoxetine NNP - B-MEDICINE
in ADP - O
Prenatal PROPN - O
Period PROPN - O
on ADP - O
Nociceptive PROPN - O
System PROPN - O
Reactivity PROPN - O
and CCONJ - O
Psychoemotional PROPN - O
Behavior PROPN - O
in ADP - O
Young NNP - B-ORG
Female NNP - I-ORG
Rats NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Peripartum PROPN - O
Fluoxetine NNP - B-MEDICINE
Reduces PROPN - O
Maternal PROPN - O
Trabecular PROPN - O
Bone PROPN - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Fluoxetine NNP - I-MEDICINE
in IN - I-WORK_OF_ART
Activating NNP - I-WORK_OF_ART
Wnt NNP - I-WORK_OF_ART
/ SYM - I-WORK_OF_ART
β NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
Catenin NN - I-WORK_OF_ART
Signaling NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Repressing VBG - I-WORK_OF_ART
β NNP - I-WORK_OF_ART
- : - I-WORK_OF_ART
Amyloid NNP - I-WORK_OF_ART
Production NNP - I-WORK_OF_ART
in ADP - O
an DET - O
Alzheimer PROPN - O
Mouse PROPN - O
Model PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
effects NOUN - O
on ADP - O
behavior NOUN - O
and CCONJ - O
adult VERB - O
hippocampal ADJ - O
neurogenesis NOUN - O
in ADP - O
female ADJ - O
C57BL/6J NNP - B-PRODUCT
mice NOUN - O
across ADP - O
the DET - O
estrous ADJ - O
cycle NOUN - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
reduced VERB - O
neuronal ADJ - O
responsivity NOUN - O
in ADP - O
the DET - O
LSN NNP - B-ORG
- PUNCT - O
PL PROPN - O
and CCONJ - O
LSN NNP - B-ORG
- PUNCT - O
IL PROPN - O
, PUNCT - O
and CCONJ - O
stress NOUN - O
increased VERB - O
neuronal ADJ - O
responsivity NOUN - O
in ADP - O
the DET - O
same ADJ - O
regions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
- PUNCT - O
mediated VERB - O
inhibition NOUN - O
of ADP - O
endoplasmic ADJ - O
reticulum NOUN - O
stress NOUN - O
is VERB - O
involved VERB - O
in ADP - O
the DET - O
neuroprotective ADJ - O
effects NOUN - O
of ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
with ADP - O
Fluoxetine NNP - B-MEDICINE
, PUNCT - O
the DET - O
most ADV - O
widely ADV - O
used VERB - O
anxiolytic NOUN - O
in ADP - O
clinic NOUN - O
, PUNCT - O
significantly ADV - O
increased VERB - O
the DET - O
proliferation NOUN - O
of ADP - O
active ADJ - O
NSCs NOUN - O
and CCONJ - O
enhanced ADJ - O
Wnt NNP - B-PERSON
signaling VERB - O
. PUNCT - O

Interestingly ADV - O
, PUNCT - O
both CCONJ - O
β DET - O
- PUNCT - O
catenin NOUN - O
manipulation NOUN - O
and CCONJ - O
Fluoxetine NNP - B-MEDICINE
treatment NOUN - O
had VERB - O
no DET - O
significant ADJ - O
effects NOUN - O
on ADP - O
the DET - O
pain NOUN - O
thresholds NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
can VERB - O
reinstate VERB - O
early ADJ - O
- PUNCT - O
life NOUN - O
critical ADJ - O
period NOUN - O
- PUNCT - O
like ADJ - O
neuronal ADJ - O
plasticity NOUN - O
and CCONJ - O
has VERB - O
been VERB - O
used VERB - O
to PART - O
recover VERB - O
functional ADJ - O
vision NOUN - O
in ADP - O
adult NOUN - O
rats NOUN - O
with ADP - O
amblyopia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
- PUNCT - O
treated VERB - O
females NOUN - O
were VERB - O
initially ADV - O
aggressive ADJ - O
towards ADP - O
males NOUN - O
, PUNCT - O
becoming VERB - O
significantly ADV - O
less ADV - O
aggressive ADJ - O
by ADP - O
the DT - B-DATE
second JJ - I-DATE
day NN - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Fluoxetine NN - B-MEDICINE
had VERB - O
no DET - O
effect NOUN - O
on ADP - O
Fos PROPN - O
expression NOUN - O
in ADP - O
non ADJ - O
- ADJ - O
stressed ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clonazepam NNP - B-MEDICINE
and CCONJ - O
its ADJ - O
metabolite NOUN - O
7-aminoclonazepam CD - B-ORG
were VERB - O
detected VERB - O
in ADP - O
parts NOUN - O
of ADP - O
hair NOUN - O
sections NOUN - O
from ADP - O
the DET - O
6 CD - B-CARDINAL
victims NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clonazepam NNP - B-MEDICINE
and CCONJ - O
gabapentin NOUN - O
are VERB - O
likely ADV - O
the DET - O
most ADV - O
effective ADJ - O
medical ADJ - O
therapies NOUN - O
, PUNCT - O
while ADP - O
bilateral ADJ - O
ventral ADJ - O
intermediate ADJ - O
nucleus NOUN - O
deep ADJ - O
brain NOUN - O
stimulation NOUN - O
shows NOUN - O
promise VERB - O
for ADP - O
refractory ADJ - O
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
dose NOUN - O
( PUNCT - O
mg NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
for ADP - O
Clonazepam NNP - B-MEDICINE
which ADJ - O
reads VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
was VERB - O
treated VERB - O
with ADP - O
Dexamethasone NNP - B-ORG
and CCONJ - O
Clonazepam NNP - B-MEDICINE
with ADP - O
progressive ADJ - O
improvement NOUN - O
of ADP - O
mental ADJ - O
status NOUN - O
, PUNCT - O
myoclonus NOUN - O
, PUNCT - O
opsoclonus NOUN - O
and CCONJ - O
associated VERB - O
neurologic ADJ - O
signs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
was VERB - O
done VERB - O
using VERB - O
ropinirole NN - B-MEDICINE
and CCONJ - O
fluoxetine NOUN - O
, PUNCT - O
two CD - B-CARDINAL
common ADJ - O
human ADJ - O
pharmaceuticals NOUN - O
. PUNCT - O

Due ADP - O
to ADP - O
limited ADJ - O
previous ADJ - O
research NOUN - O
, PUNCT - O
we PRON - O
created VERB - O
a DET - O
dose NOUN - O
- PUNCT - O
response NOUN - O
curve NOUN - O
for ADP - O
ropinirole NN - B-MEDICINE
, PUNCT - O
ranging VERB - O
from ADP - O
concentrations NOUN - O
measured VERB - O
in ADP - O
surface NOUN - O
waters NOUN - O
to ADP - O
human ADJ - O
therapeutic ADJ - O
doses NOUN - O
. PUNCT - O

No DET - O
ropinirole NN - B-MEDICINE
dose NOUN - O
level NOUN - O
strongly ADV - O
influenced VERB - O
cricket NOUN - O
personality NOUN - O
, PUNCT - O
suggesting VERB - O
our ADJ - O
results NOUN - O
did VERB - O
not ADV - O
come VERB - O
from ADP - O
a DET - O
dose NOUN - O
mismatch NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

94 CD - B-CARDINAL
suspected VERB - O
cases NOUN - O
of ADP - O
gambling NOUN - O
disorder NOUN - O
associated VERB - O
to ADP - O
apomorphine NOUN - O
, PUNCT - O
aripiprazole NOUN - O
, PUNCT - O
cabergoline NOUN - O
, PUNCT - O
levodopa ADJ - O
, PUNCT - O
levodopa ADJ - O
and CCONJ - O
derivatives NOUN - O
in ADP - O
association NOUN - O
with ADP - O
entacapone NOUN - O
/ SYM - O
benserazide NOUN - O
and CCONJ - O
carbidopa NOUN - O
, PUNCT - O
pergolide ADJ - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
rotigotine NOUN - O
were VERB - O
reported VERB - O
into ADP - O
the DET - O
RNF NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

D-512 UH - B-ORG
, PUNCT - O
a DET - O
novel ADJ - O
dopamine NOUN - O
D2/3 PROPN - O
receptor NOUN - O
agonist NOUN - O
, PUNCT - O
demonstrates VERB - O
greater ADJ - O
anti JJ - B-NORP
- JJ - I-NORP
Parkinsonian JJ - I-NORP
efficacy NOUN - O
than ADP - O
ropinirole NN - B-MEDICINE
in ADP - O
Parkinsonian JJ - B-NORP
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
drugs NOUN - O
that ADJ - O
we PRON - O
compare VERB - O
include VERB - O
the DET - O
following NOUN - O
: PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
rasagiline NOUN - O
, PUNCT - O
rotigotine NOUN - O
, PUNCT - O
entacapone NOUN - O
, PUNCT - O
apomorphine NOUN - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
sumanirole NOUN - O
, PUNCT - O
bromocriptine NOUN - O
, PUNCT - O
piribedil NOUN - O
, PUNCT - O
pergolide NOUN - O
, PUNCT - O
and CCONJ - O
levodopa ADJ - O
. PUNCT - O

Our ADJ - O
results NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
reactions NOUN - O
of ADP - O
ropinirole NN - B-MEDICINE
, PUNCT - O
rotigotine NOUN - O
, PUNCT - O
entacapone NOUN - O
, PUNCT - O
and CCONJ - O
sumanirole NOUN - O
were VERB - O
obviously ADV - O
higher ADJ - O
in ADP - O
terms NOUN - O
of ADP - O
nausea NOUN - O
compared VERB - O
to ADP - O
the DET - O
placebo NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
the DET - O
SUCRA NNP - B-ORG
values NOUN - O
of ADP - O
all ADJ - O
the DET - O
drugs NOUN - O
showed VERB - O
that ADP - O
the DET - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
reaction NOUN - O
of ADP - O
pergolide NOUN - O
was VERB - O
relatively ADV - O
high ADJ - O
( PUNCT - O
nausea NOUN - O
: PUNCT - O
83.5 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
hallucination NOUN - O
: PUNCT - O
79.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
; PUNCT - O
for ADP - O
dyskinesia NOUN - O
and CCONJ - O
somnolence NOUN - O
, PUNCT - O
the DET - O
incidence NOUN - O
of ADP - O
ropinirole NN - B-MEDICINE
was VERB - O
higher ADJ - O
( PUNCT - O
dyskinesia NOUN - O
: PUNCT - O
80.5 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
somnolence NOUN - O
: PUNCT - O
69.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
; PUNCT - O
the DET - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
reaction NOUN - O
of ADP - O
piribedil NOUN - O
was VERB - O
higher ADJ - O
on ADP - O
PD PROPN - O
in ADP - O
terms NOUN - O
of ADP - O
dizziness NOUN - O
( PUNCT - O
67.0 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
; PUNCT - O
and CCONJ - O
the DET - O
incidence NOUN - O
of ADP - O
bromocriptine NOUN - O
was VERB - O
relatively ADV - O
high ADJ - O
in ADP - O
terms NOUN - O
of ADP - O
constipation NOUN - O
( PUNCT - O
62.3%).This NUM - O
mixed ADJ - O
treatment NOUN - O
comparison NOUN - O
showed VERB - O
that ADP - O
the DET - O
drugs NOUN - O
ropinirole NN - B-MEDICINE
, PUNCT - O
bromocriptine NOUN - O
, PUNCT - O
and CCONJ - O
piribedil NOUN - O
produced VERB - O
the DET - O
highest ADJ - O
incidence NOUN - O
rates NOUN - O
of ADP - O
nausea NOUN - O
, PUNCT - O
dyskinesia NOUN - O
, PUNCT - O
hallucination NOUN - O
, PUNCT - O
dizziness NOUN - O
, PUNCT - O
constipation NOUN - O
, PUNCT - O
and CCONJ - O
somnolence ADJ - O
symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
an DET - O
animal NOUN - O
model NOUN - O
of ADP - O
PD NNP - B-ORG
, PUNCT - O
the DET - O
test NOUN - O
compounds NOUN - O
exhibited VERB - O
potent ADJ - O
in ADP - O
vivo NOUN - O
activity NOUN - O
in ADP - O
reversing VERB - O
hypolocomotion NOUN - O
in ADP - O
reserpinized VERB - O
rats NOUN - O
with ADP - O
a DET - O
long ADJ - O
duration NOUN - O
of ADP - O
action NOUN - O
compared VERB - O
to ADP - O
the DET - O
reference NOUN - O
drug NOUN - O
ropinirole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Feasibility NOUN - O
of ADP - O
a DET - O
randomized VERB - O
single ADJ - O
- PUNCT - O
blind ADJ - O
crossover NOUN - O
trial NOUN - O
to PART - O
assess VERB - O
the DET - O
effects NOUN - O
of ADP - O
the DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
slow ADJ - O
- PUNCT - O
release NOUN - O
dopamine NOUN - O
agonists VERB - O
pramipexole NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
on ADP - O
cued VERB - O
recall NOUN - O
memory NOUN - O
in ADP - O
idiopathic ADJ - O
mild ADJ - O
or CCONJ - O
moderate ADJ - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
without ADP - O
cognitive ADJ - O
impairment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Results NOUN - O
in ADP - O
our ADJ - O
case NOUN - O
series NOUN - O
suggest VERB - O
that ADP - O
levodopa ADJ - O
, PUNCT - O
rasagiline ADJ - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
and CCONJ - O
ropinirole NN - B-MEDICINE
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
each DET - O
other ADJ - O
may VERB - O
be VERB - O
considered VERB - O
relatively ADV - O
safe ADJ - O
during ADP - O
pregnancy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
risk NOUN - O
was VERB - O
also ADV - O
elevated VERB - O
for ADP - O
pramipexole NOUN - O
or CCONJ - O
ropinirole NN - B-MEDICINE
for ADP - O
both DET - O
gambling NOUN - O
disorder NOUN - O
and CCONJ - O
impulse NOUN - O
control NOUN - O
disorder NOUN - O
( PUNCT - O
RR NN - B-ORG
, PUNCT - O
7.61 CD - B-DATE
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O
2.75 CD - B-CARDINAL
- SYM - O
21.07 NUM - O
; PUNCT - O
RR NNP - B-ORG
, PUNCT - O
3.28 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
, PUNCT - O

2.31 CD - B-CARDINAL
- SYM - O
4.66 NUM - O
, PUNCT - O
respectively).Our NOUN - O
study NOUN - O
confirms VERB - O
an DET - O
association NOUN - O
between ADP - O
aripiprazole NOUN - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
or CCONJ - O
ropinirole NN - B-MEDICINE
and CCONJ - O
impulse NOUN - O
control NOUN - O
disorder NOUN - O
and CCONJ - O
gambling VERB - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
aimed VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
fixed VERB - O
doses NOUN - O
of ADP - O
bupropion NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
and CCONJ - O
iron NOUN - O
alone ADV - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
restless NOUN - O
legs NOUN - O
syndrome NOUN - O
( PUNCT - O
RLS NNP - B-ORG
) PUNCT - O
and CCONJ - O
to PART - O
look VERB - O
for ADP - O
the DET - O
tolerability NOUN - O
of ADP - O
these DET - O
medications NOUN - O
. PUNCT - O

Pair NOUN - O
- PUNCT - O
wise ADJ - O
comparison NOUN - O
depicted VERB - O
that ADP - O
ropinirole NN - B-MEDICINE
group NOUN - O
differed VERB - O
from ADP - O
other ADJ - O
two CD - B-CARDINAL
groups NOUN - O
in ADP - O
IRLS NNP - B-ORG
score NOUN - O
( PUNCT - O
F PROPN - O
= SYM - O
7.06 CD - B-CARDINAL
; PUNCT - O
P NOUN - O
= SYM - O
0.001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
which ADJ - O
were VERB - O
comparable ADJ - O
to ADP - O
each DET - O
other ADJ - O
. PUNCT - O

0.28).RLS NUM - O
severity NOUN - O
decreased VERB - O
across ADP - O
time NOUN - O
in ADP - O
all DET - O
three CD - B-CARDINAL
groups NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
ropinirole JJ - B-MEDICINE
treatment NOUN - O
was VERB - O
better ADJ - O
than ADP - O
the DET - O
bupropion NOUN - O
and CCONJ - O
iron NOUN - O
- PUNCT - O
folate NOUN - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
interventions NOUN - O
studied VERB - O
included VERB - O
aerobic ADJ - O
resistance NOUN - O
exercise NOUN - O
, PUNCT - O
gabapentin NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
levodopa ADJ - O
, PUNCT - O
iron NOUN - O
dextran NOUN - O
, PUNCT - O
and CCONJ - O
vitamins VERB - O
C NOUN - O
and CCONJ - O
E PROPN - O
( PUNCT - O
individually ADV - O
and CCONJ - O
in ADP - O
combination).Aerobic ADJ - O
resistance NOUN - O
exercise NOUN - O
showed VERB - O
a DET - O
significant ADJ - O
reduction NOUN - O
in ADP - O
severity NOUN - O
of ADP - O
RLS NNP - B-ORG
compared VERB - O
to ADP - O
no DET - O
exercise NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
studies NOUN - O
, PUNCT - O
48 CD - B-CARDINAL
participants NOUN - O
: PUNCT - O
MD NNP - B-ORG
-7.56 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
-14.20 PUNCT - O
to ADP - O
-0.93 NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
65 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
when ADV - O
compared VERB - O
to PART - O
exercise VERB - O
with ADP - O
no DET - O
resistance NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
study NOUN - O
, PUNCT - O
24 CD - B-CARDINAL
participants NOUN - O
: PUNCT - O
MD NNP - B-ORG
-11.10 PUNCT - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
-17.11 PUNCT - O
to ADP - O
-5.09 PUNCT - O
) PUNCT - O
, PUNCT - O
however ADV - O
there ADV - O
was VERB - O
no DET - O
significant ADJ - O
reduction NOUN - O
when ADV - O
compared VERB - O
to ADP - O
ropinirole NN - B-MEDICINE
( PUNCT - O
1 CD - B-CARDINAL
study NOUN - O
, PUNCT - O
22 CD - B-CARDINAL
participants NOUN - O
) PUNCT - O
: PUNCT - O

There ADV - O
were VERB - O
no DET - O
significant ADJ - O
differences NOUN - O
between ADP - O
aerobic ADJ - O
resistance NOUN - O
exercise NOUN - O
and CCONJ - O
either CCONJ - O
no DET - O
exercise NOUN - O
or CCONJ - O
ropinirole NN - B-MEDICINE
in ADP - O
the DET - O
physical ADJ - O
or CCONJ - O
mental ADJ - O
component NOUN - O
summary NOUN - O
scores NOUN - O
( PUNCT - O
using VERB - O
the DET - O
SF-36 VERB - O
form NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
significant ADJ - O
difference NOUN - O
in ADP - O
subjective ADJ - O
sleep NOUN - O
quality NOUN - O
between ADP - O
exercise NOUN - O
and CCONJ - O
no DET - O
exercise NOUN - O
; PUNCT - O
however ADV - O
one CD - B-CARDINAL
study NOUN - O
reported VERB - O
a DET - O
significant ADJ - O
improvement NOUN - O
with ADP - O
ropinirole NN - B-MEDICINE
compared VERB - O
to ADP - O
resistance NOUN - O
exercise NOUN - O
( PUNCT - O
MD NNP - B-ORG
3.71 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.89 NUM - O
to ADP - O
6.53 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Using VERB - O
the DET - O
Epworth PROPN - O
Sleepiness PROPN - O
Scale PROPN - O
there ADV - O
were VERB - O
no DET - O
significant ADJ - O
differences NOUN - O
between ADP - O
resistance NOUN - O
exercise NOUN - O
and CCONJ - O
no DET - O
exercise NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
or CCONJ - O
exercise VERB - O
with ADP - O
no DET - O
resistance NOUN - O
. PUNCT - O

Aerobic ADJ - O
resistance NOUN - O
exercise NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
may VERB - O
be VERB - O
suitable ADJ - O
interventions NOUN - O
for ADP - O
further ADJ - O
evaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
proposed VERB - O
work NOUN - O
was VERB - O
to PART - O
increase VERB - O
bioavailability NOUN - O
of ADP - O
ropinirole NN - B-MEDICINE
and CCONJ - O
avoid VERB - O
patient ADJ - O
discomfort NOUN - O
by ADP - O
formulating VERB - O
thermoreversible NOUN - O
in ADP - O
situ NOUN - O
nasal NOUN - O
gel NOUN - O
. PUNCT - O

h. NOUN - O
Histological ADJ - O
study NOUN - O
of ADP - O
sheep NOUN - O
nasal NOUN - O
mucosa NOUN - O
revealed VERB - O
that ADP - O
the DET - O
gel NOUN - O
had VERB - O
a DET - O
protective ADJ - O
effect NOUN - O
on ADP - O
the DET - O
mucosa NOUN - O
unlike ADP - O
plain ADJ - O
ropinirole NN - B-MEDICINE
which ADJ - O
showed VERB - O
evidence NOUN - O
of ADP - O
moderate ADJ - O
cellular ADJ - O
damage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Chronic PROPN - O
D2/3 NOUN - O
agonist VERB - O
ropinirole NN - B-MEDICINE
treatment NOUN - O
increases VERB - O
preference NOUN - O
for ADP - O
uncertainty NOUN - O
in ADP - O
rats NOUN - O
regardless ADV - O
of ADP - O
baseline ADJ - O
choice NOUN - O
patterns NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
and CCONJ - O
biological ADJ - O
evaluation NOUN - O
of ADP - O
( PUNCT - O
99m)Tc NOUN - O
- PUNCT - O
ropinirole NN - B-MEDICINE
as ADP - O
a DET - O
novel NOUN - O
radiopharmaceutical ADJ - O
for ADP - O
brain NOUN - O
imaging NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
simple ADJ - O
and CCONJ - O
validated VERB - O
ultra ADJ - O
high ADJ - O
pressure NOUN - O
liquid NOUN - O
chromatography NOUN - O
- PUNCT - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
method NOUN - O
was VERB - O
developed VERB - O
for ADP - O
the DET - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
the DET - O
dopaminergic ADJ - O
agents NOUN - O
pramipexole NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
in ADP - O
plasma NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

The DET - O
MS NNP - B-ORG
/ SYM - O
MS PROPN - O
ion NOUN - O
transitions NOUN - O
were VERB - O
212.10→153.03 CD - B-CARDINAL
for ADP - O
pramipexole NOUN - O
, PUNCT - O
261.2→114.2 CD - B-CARDINAL
for ADP - O
ropinirole NN - B-MEDICINE
and CCONJ - O
256.1→211 CD - B-CARDINAL
for ADP - O
the DET - O
internal ADJ - O
standard NOUN - O
( PUNCT - O
lamotrigine NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
lower ADJ - O
limit NOUN - O
of ADP - O
quantitation NOUN - O
( PUNCT - O
LLOQ PROPN - O
) PUNCT - O
for ADP - O
both DET - O
analytes NOUN - O
was VERB - O
80pg JJ - B-ORDINAL
/ SYM - O
mL NOUN - O
and CCONJ - O
the DET - O
linearity NOUN - O
was VERB - O
determined VERB - O
from ADP - O
80 CD - B-CARDINAL
to ADP - O
4000pg NUM - O
/ SYM - O
mL NOUN - O
for ADP - O
pramipexole NOUN - O
and CCONJ - O
from ADP - O
200 CD - B-CARDINAL
to ADP - O
10000pg NUM - O
/ SYM - O
mL NOUN - O
for ADP - O
ropinirole NN - B-MEDICINE
. PUNCT - O

The DET - O
proposed VERB - O
validated VERB - O
method NOUN - O
was VERB - O
successfully ADV - O
applied VERB - O
to PART - O
measure VERB - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
pramipexole NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
in ADP - O
a DET - O
series NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
on ADP - O
chronic ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Validated ADJ - O
UHPLC NNP - B-PRODUCT
- HYPH - I-PRODUCT
MS NNP - I-PRODUCT
/ SYM - I-PRODUCT
MS NNP - I-PRODUCT
method NOUN - O
for ADP - O
the DET - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
pramipexole NOUN - O
and CCONJ - O
ropinirole NN - B-MEDICINE
in ADP - O
plasma NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Multiple ADJ - O
fixed VERB - O
drug NOUN - O
eruption NOUN - O
caused VERB - O
by ADP - O
ropinirole VBG - B-MEDICINE
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
whether ADP - O
istradefylline NOUN - O
enhances VERB - O
the DET - O
combined ADJ - O
anti ADJ - O
- ADJ - O
parkinsonian ADJ - O
effects NOUN - O
of ADP - O
a DET - O
suboptimal ADJ - O
dose NOUN - O
of ADP - O
L NN - B-ORG
- HYPH - I-ORG
DOPA NNP - I-ORG
and CCONJ - O
a DET - O
threshold NOUN - O
dose NOUN - O
of ADP - O
either CCONJ - O
the DET - O
non ADJ - O
- ADJ - O
ergot ADJ - O
dopamine NOUN - O
agonist NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
or CCONJ - O
the DET - O
ergot NOUN - O
dopamine NOUN - O
agonist NOUN - O
, PUNCT - O
pergolide VERB - O
in ADP - O
the DET - O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine CD - B-CARDINAL
( PUNCT - O
MPTP)-treated JJ - B-CARDINAL
common ADJ - O
marmoset NOUN - O
. PUNCT - O

Threshold NOUN - O
doses NOUN - O
of ADP - O
ropinirole NN - B-MEDICINE
( PUNCT - O
0.025 CD - B-CARDINAL
- SYM - O
0.075 NUM - O
mg NOUN - O
/ SYM - O
kg NOUN - O
p.o VERB - O
. PUNCT - O
) PUNCT - O
and CCONJ - O
pergolide NOUN - O
( PUNCT - O
0.01 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
p.o ADJ - O
. PUNCT - O
) PUNCT - O
produced VERB - O
a DET - O
weak ADJ - O
anti ADJ - O
- ADJ - O
parkinsonian ADJ - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Investigate VERB - O
safety NOUN - O
, PUNCT - O
feasibility NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
switching VERB - O
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
- PUNCT - O
stage NOUN - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
( PUNCT - O
PD PROPN - O
) PUNCT - O
inadequately ADV - O
controlled VERB - O
with ADP - O
pramipexole NOUN - O
( PUNCT - O
≤ PROPN - O
3.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
or CCONJ - O
ropinirole NN - B-MEDICINE
( PUNCT - O
≤ PROPN - O
14 CD - B-DATE
mg NN - I-DATE
/ SYM - I-DATE
day NN - I-DATE
) PUNCT - O
to PART - O
rotigotine VERB - O
transdermal ADJ - O
system NOUN - O
( PUNCT - O
≤ PROPN - O
14 CD - B-CARDINAL
mg/24 PROPN - O
h X - O
; PUNCT - O
dose NOUN - O
adjustments NOUN - O
≤ NNP - B-FAC
16 CD - I-FAC
mg/24 NOUN - O
h X - O
permitted).PD0009 NOUN - O
( PUNCT - O
ClinicalTrials.gov NOUN - O
: PUNCT - O
NCT01711866 NNP - B-PERSON
) PUNCT - O
was VERB - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
study NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
- PUNCT - O
stage NOUN - O
PD PROPN - O
receiving VERB - O
levodopa ADJ - O
, PUNCT - O
and CCONJ - O
experiencing VERB - O
sleep NOUN - O
disturbance NOUN - O
or CCONJ - O
early JJ - B-TIME
- HYPH - I-TIME
morning NN - I-TIME
motor NOUN - O
impairment NOUN - O
. PUNCT - O

Pramipexole NOUN - O
/ SYM - O
ropinirole NN - B-MEDICINE
was VERB - O
switched VERB - O
to PART - O
equivalent VERB - O
dose NOUN - O
rotigotine NOUN - O
overnight RB - B-TIME
or CCONJ - O
in ADP - O
two CD - B-CARDINAL
stages NOUN - O
. PUNCT - O

Switch VERB - O
from ADP - O
pramipexole NOUN - O
or CCONJ - O
ropinirole NN - B-MEDICINE
to PART - O
rotigotine VERB - O
( PUNCT - O
up ADP - O
to PART - O
14 CD - B-CARDINAL
mg/24 PROPN - O
h PUNCT - O
) PUNCT - O
was VERB - O
feasible ADJ - O
and CCONJ - O
possibly ADV - O
associated VERB - O
with ADP - O
some DET - O
benefit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Switch VB - B-ORG
from ADP - O
oral ADJ - O
pramipexole NOUN - O
or CCONJ - O
ropinirole NN - B-MEDICINE
to PART - O
rotigotine VERB - O
transdermal ADJ - O
system NOUN - O
in ADP - O
advanced ADJ - O
Parkinson PROPN - O
's PART - O
disease NOUN - O
: PUNCT - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
treating VERB - O
Parkinson NNP - B-ORG
's PART - O
disease NOUN - O
with ADP - O
dopaminergic ADJ - O
agonists VERB - O
, PUNCT - O
such ADJ - O
as ADP - O
pramipexole NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
pergolide NOUN - O
, PUNCT - O
rotigotine NOUN - O
, PUNCT - O
apomorphine NOUN - O
, PUNCT - O
or CCONJ - O
bromocriptine VERB - O
, PUNCT - O
it PRON - O
has VERB - O
been VERB - O
observed VERB - O
that ADP - O
a DET - O
significant ADJ - O
number NOUN - O
of ADP - O
patients NOUN - O
develop VERB - O
impulse NOUN - O
- PUNCT - O
control NOUN - O
disorders NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
compulsive ADJ - O
shopping NOUN - O
, PUNCT - O
pathological ADJ - O
gambling NOUN - O
, PUNCT - O
or CCONJ - O
hypersexuality NOUN - O
. PUNCT - O

While ADP - O
the DET - O
number NOUN - O
of ADP - O
studies NOUN - O
are VERB - O
limited VERB - O
, PUNCT - O
the DET - O
proportion NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
impulse NOUN - O
- PUNCT - O
control NOUN - O
disorder NOUN - O
in ADP - O
Parkinson PROPN - O
patients NOUN - O
treated VERB - O
with ADP - O
an DET - O
add VERB - O
- PUNCT - O
on PART - O
agonist NOUN - O
were VERB - O
32 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
pramipexole NOUN - O
, PUNCT - O
25 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
ropinirole NN - B-MEDICINE
, PUNCT - O
16 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
pergolide NOUN - O
, PUNCT - O
22 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
rotigotine NOUN - O
, PUNCT - O
10 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
apomorphine NOUN - O
, PUNCT - O
and CCONJ - O
6.8 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
bromocriptine NOUN - O
. PUNCT - O

Clinically ADV - O
, PUNCT - O
temporary ADJ - O
replacement NOUN - O
of ADP - O
pramipexole NOUN - O
by ADP - O
bromocriptine NOUN - O
may VERB - O
provide VERB - O
relief NOUN - O
or CCONJ - O
reversal NOUN - O
of ADP - O
the DET - O
impulsive ADJ - O
behavior NOUN - O
associated VERB - O
with ADP - O
selective ADJ - O
D3 PROPN - O
stimulation NOUN - O
by ADP - O
either CCONJ - O
pramipexole NOUN - O
or CCONJ - O
ropinirole NN - B-MEDICINE
, PUNCT - O
while ADP - O
maintaining VERB - O
D2 NOUN - O
stimulation NOUN - O
needed VERB - O
for ADP - O
the DET - O
anti ADJ - O
- ADJ - O
Parkinson ADJ - O
action NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Indirect ADJ - O
comparisons NOUN - O
were VERB - O
established VERB - O
among ADP - O
gabapentin ADJ - O
enacarbil NOUN - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
rotigotine NOUN - O
and CCONJ - O
placebo NOUN - O
. PUNCT - O

The DET - O
sole ADJ - O
exception NOUN - O
was VERB - O
change NOUN - O
in ADP - O
IRLS NNP - B-ORG
at ADP - O
week NN - B-DATE
12 CD - I-DATE
, PUNCT - O
for ADP - O
which ADJ - O
rotigotine NOUN - O
was VERB - O
likely ADV - O
more ADV - O
efficacious ADJ - O
than ADP - O
ropinirole NN - B-MEDICINE
( PUNCT - O
mean ADJ - O
difference NOUN - O
: PUNCT - O

Indirect ADJ - O
comparisons NOUN - O
on ADP - O
safety NOUN - O
endpoints NOUN - O
indicated VERB - O
ropinirole NN - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
a DET - O
higher ADJ - O
risk NOUN - O
of ADP - O
nausea NOUN - O
than ADP - O
the DET - O
other ADJ - O
agents NOUN - O
, PUNCT - O
and CCONJ - O
was VERB - O
more ADV - O
likely ADJ - O
to PART - O
result VERB - O
in ADP - O
discontinuations NOUN - O
due ADP - O
to ADP - O
lack NOUN - O
of ADP - O
efficacy NOUN - O
than ADP - O
pramipexole NOUN - O
. PUNCT - O

Nausea NOUN - O
was VERB - O
likely ADV - O
more ADV - O
frequent ADJ - O
with ADP - O
pramipexole NOUN - O
than ADP - O
gabapentin ADJ - O
enacarbil NOUN - O
, PUNCT - O
and CCONJ - O
rotigotine NOUN - O
was VERB - O
more ADV - O
likely ADJ - O
to PART - O
result VERB - O
in ADP - O
discontinuation NOUN - O
due ADP - O
to ADP - O
AEs NOUN - O
than ADP - O
ropinirole NN - B-MEDICINE
and CCONJ - O
pramipexole NOUN - O
. PUNCT - O

This DET - O
MTC NNP - B-ORG
confirmed VERB - O
the DET - O
superiority NOUN - O
of ADP - O
gabapentin ADJ - O
enacarbil NOUN - O
, PUNCT - O
pramipexole NOUN - O
, PUNCT - O
ropinirole NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
rotigotine VERB - O
above ADP - O
placebo NOUN - O
in ADP - O
alleviating VERB - O
RLS NNP - B-ORG
symptoms NOUN - O
. PUNCT - O

Compared VERB - O
to ADP - O
ropinirole NN - B-MEDICINE
, PUNCT - O
rotigotine NOUN - O
showed VERB - O
some DET - O
additional ADJ - O
benefit NOUN - O
in ADP - O
terms NOUN - O
of ADP - O
change NOUN - O
in ADP - O
IRLS NNP - B-ORG
at ADP - O
Week NNP - B-DATE
12 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Analogous ADJ - O
experiments NOUN - O
with ADP - O
an DET - O
antagonist NOUN - O
( PUNCT - O
prochlorperazine NOUN - O
) PUNCT - O
and CCONJ - O
a DET - O
lower ADJ - O
- PUNCT - O
affinity NOUN - O
agonist NOUN - O
( PUNCT - O
ropinirole NN - B-MEDICINE
) PUNCT - O
exhibited VERB - O
reduced VERB - O
temporal ADJ - O
dissociation NOUN - O
between ADP - O
occupancy NOUN - O
and CCONJ - O
function NOUN - O
, PUNCT - O
consistent ADJ - O
with ADP - O
a DET - O
mechanism NOUN - O
of ADP - O
desensitization NOUN - O
and CCONJ - O
internalization NOUN - O
that ADJ - O
depends VERB - O
upon ADP - O
drug NOUN - O
efficacy NOUN - O
and CCONJ - O
affinity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
two CD - B-CARDINAL
cases NOUN - O
improved VERB - O
their ADJ - O
antecollis NOUN - O
by ADP - O
overnight JJ - B-TIME
changing VERB - O
from ADP - O
PPX NNP - B-ORG
to ADP - O
ropinirole VB - B-MEDICINE
without ADP - O
deteriorating VERB - O
motor NOUN - O
functions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
effects NOUN - O
of ADP - O
acute ADJ - O
ropinirole NN - B-MEDICINE
( PUNCT - O
0 NUM - O
, PUNCT - O
0.1 CD - B-CARDINAL
, PUNCT - O
1 CD - B-CARDINAL
or CCONJ - O
10 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
, PUNCT - O
i.p PROPN - O
. PUNCT - O
) PUNCT - O
, PUNCT - O
a DET - O
preferential ADJ - O
D3/D2 NNP - B-GPE
receptor NOUN - O
agonist NOUN - O
, PUNCT - O
on ADP - O
intracranial ADJ - O
self NOUN - O
- PUNCT - O
stimulation NOUN - O
( PUNCT - O
ICSS NNP - B-ORG
) PUNCT - O
, PUNCT - O
spontaneous ADJ - O
motor NOUN - O
activity NOUN - O
, PUNCT - O
anxiety- NOUN - O
and CCONJ - O
depression NOUN - O
- PUNCT - O
like ADJ - O
behaviors NOUN - O
, PUNCT - O
spatial ADJ - O
reference NOUN - O
and CCONJ - O
working VERB - O
memory NOUN - O
in ADP - O
rats NOUN - O
as ADV - O
well ADV - O
as ADP - O
on ADP - O
certain ADJ - O
markers NOUN - O
of ADP - O
neuronal ADJ - O
activity NOUN - O
, PUNCT - O
i.e. X - O
induction NOUN - O
of ADP - O
immediate ADJ - O
early ADJ - O
genes NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
c NOUN - O
- PUNCT - O
fos NOUN - O
and CCONJ - O
arc NOUN - O
, PUNCT - O
and CCONJ - O
crucial ADJ - O
phosphorylations NOUN - O
on ADP - O
GluA1 PROPN - O
subunit NOUN - O
of ADP - O
α NOUN - O
- PUNCT - O
Amino-3-hydroxy-5-methyl-4-isoxazolepropionic NOUN - O
acid NOUN - O
( PUNCT - O
AMPA NNP - B-ORG
) PUNCT - O
receptors NOUN - O
and CCONJ - O
NA1 NNP - B-ORG
, PUNCT - O
NA2A PROPN - O
and CCONJ - O
NA2B NNP - B-ORG
subunits NOUN - O
of ADP - O
N NOUN - O
- PUNCT - O
methyl NOUN - O
- PUNCT - O
D NOUN - O
- PUNCT - O
aspartate PROPN - O
( PUNCT - O
NMDA NNP - B-ORG
) PUNCT - O
receptors NOUN - O
. PUNCT - O

Our ADJ - O
data NOUN - O
indicate VERB - O
that ADP - O
ropinirole NN - B-MEDICINE
significantly ADV - O
affects VERB - O
emotionality NOUN - O
at ADP - O
doses NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
- SYM - I-CARDINAL
10 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
i.p PROPN - O
. PUNCT - O
) PUNCT - O
that ADJ - O
exert VERB - O
no DET - O
robust ADJ - O
effects NOUN - O
on ADP - O
locomotion NOUN - O
or CCONJ - O
cognition NOUN - O
. PUNCT - O

The DET - O
data NOUN - O
reinforce VERB - O
the DET - O
use NOUN - O
of ADP - O
D3/D2 NNP - B-GPE
receptor NOUN - O
agonists VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
RLS NNP - B-ORG
and CCONJ - O
PD NNP - B-ORG
patients NOUN - O
characterized VERB - O
by ADP - O
emotional ADJ - O
deficits NOUN - O
and CCONJ - O
suggest VERB - O
that ADP - O
altered VERB - O
NMDA NNP - B-ORG
- PUNCT - O
mediated VERB - O
neurotransmission NOUN - O
in ADP - O
the DET - O
limbic ADJ - O
forebrain NOUN - O
may VERB - O
underlie VERB - O
some DET - O
of ADP - O
ropinirole NN - B-MEDICINE
's PART - O
therapeutic ADJ - O
actions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
second JJ - B-ORDINAL
active ADJ - O
ingredient NOUN - O
such ADJ - O
as ADP - O
Hamamelis NNP - B-ORG
Virginiana NNP - I-ORG
( PUNCT - O
Witch NNP - B-PERSON
Hazel NNP - I-PERSON
) PUNCT - O
may VERB - O
be VERB - O
combined VERB - O
with ADP - O
the DET - O
Bromelain NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Forty CD - B-CARDINAL
- HYPH - I-CARDINAL
six CD - I-CARDINAL
additional ADJ - O
herbs NOUN - O
contained VERB - O
significant ADJ - O
LDH PROPN - O
- PUNCT - O
A DET - O
inhibitory NOUN - O
properties VERB - O
with ADP - O
IC50s PROPN - O
[ PUNCT - O
< X - O
0.07 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
ml NNP - I-QUANTITY
] PUNCT - O
, PUNCT - O
some DET - O
of ADP - O
which ADJ - O
have VERB - O
common ADJ - O
names NOUN - O
of ADP - O
Arjun NNP - B-ORG
, PUNCT - O
Pipsissewa NNP - B-ORG
, PUNCT - O
Cinnamon NNP - B-PERSON
, PUNCT - O
Pink PROPN - O
Rose PROPN - O
Buds PROPN - O
/ SYM - O
Petals PROPN - O
, PUNCT - O
Wintergreen NNP - B-PERSON
, PUNCT - O
Cat NNP - B-PERSON
's POS - I-PERSON
Claw NNP - I-PERSON
, PUNCT - O
Witch NNP - B-PERSON
Hazel NNP - I-PERSON
Root NNP - I-PERSON
and CCONJ - O
Rhodiola NNP - B-GPE
Root NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

St. NNP - B-PERSON
John NNP - I-PERSON
's POS - I-PERSON
Wort PROPN - O
, PUNCT - O
White NNP - B-PERSON
Willow NNP - I-PERSON
, PUNCT - O
Yarrow NNP - B-PERSON
, PUNCT - O
Poke NNP - B-ORG
, PUNCT - O
Lavender NNP - B-GPE
, PUNCT - O
Arnica NNP - B-GPE
, PUNCT - O
Comfrey NNP - B-PERSON
, PUNCT - O
Devil PROPN - O
's PART - O
Claw NNP - B-PERSON
, PUNCT - O
Witch NNP - B-PERSON
Hazel NNP - I-PERSON
, PUNCT - O
Celery NNP - B-ORG
Seed NNP - I-ORG
, PUNCT - O
Peppermint PROPN - O
and CCONJ - O
Rosemary NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
hypothyroidism NOUN - O
- PUNCT - O
related VERB - O
costs NOUN - O
for ADP - O
patients NOUN - O
who NOUN - O
continuously ADV - O
used VERB - O
Synthroid NNP - B-MEDICINE
and CCONJ - O
patients NOUN - O
who NOUN - O
switched VERB - O
from ADP - O
Synthroid NNP - B-MEDICINE
to ADP - O
alternative ADJ - O
therapies NOUN - O
. PUNCT - O

Truven NNP - B-ORG
's PART - O
Health NNP - B-ORG
Analytics NNPS - I-ORG
MarketScan NNP - I-ORG
Commercial NNP - I-ORG
Claims NNPS - I-ORG
and CCONJ - O
Encounters NNPS - B-ORG
database NOUN - O
from ADP - O
January NNP - B-DATE
1 CD - I-DATE
, , - I-DATE
2007 CD - I-DATE
to IN - I-DATE
June NNP - I-DATE
30 CD - I-DATE
, , - I-DATE
2014 CD - I-DATE
was VERB - O
queried VERB - O
for ADP - O
US NNP - B-GPE
adults NOUN - O
diagnosed VERB - O
with ADP - O
hypothyroidism NOUN - O
who NOUN - O
initiated VERB - O
Synthroid NNP - B-MEDICINE
and CCONJ - O
adhered VERB - O
to ADP - O
such ADJ - O
therapy NOUN - O
for ADP - O
at RB - B-DATE
least RBS - I-DATE
6 CD - I-DATE
months NNS - I-DATE
. PUNCT - O

Propensity NOUN - O
score NOUN - O
matching NOUN - O
matched VERB - O
continuous ADJ - O
users NOUN - O
of ADP - O
Synthroid NNP - B-MEDICINE
to ADP - O
patients NOUN - O
who NOUN - O
switched VERB - O
from ADP - O
Synthroid NNP - B-MEDICINE
to ADP - O
alternative ADJ - O
levothyroxine NOUN - O
agents NOUN - O
. PUNCT - O

There ADV - O
were VERB - O
10,159 CD - B-CARDINAL
individuals NOUN - O
included VERB - O
in ADP - O
the DET - O
study NOUN - O
, PUNCT - O
with ADP - O
7,991 CD - B-CARDINAL
continuous ADJ - O
users NOUN - O
of ADP - O
Synthroid NNP - B-MEDICINE
and CCONJ - O
2,168 CD - B-CARDINAL
switchers NOUN - O
. PUNCT - O

After ADP - O
matching VERB - O
( PUNCT - O
n NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
2,052 CD - B-CARDINAL
for ADP - O
each DET - O
cohort NOUN - O
) PUNCT - O
, PUNCT - O
continuous ADJ - O
use NOUN - O
of ADP - O
Synthroid NNP - B-MEDICINE
was VERB - O
associated VERB - O
with ADP - O
significantly ADV - O
lower ADJ - O
hypothyroidism NOUN - O
- PUNCT - O
related VERB - O
non ADJ - O
- ADJ - O
drug ADJ - O
medical ADJ - O
costs NOUN - O
( PUNCT - O
$ SYM - O
595 CD - B-MONEY
vs ADP - O
$ SYM - O
1,023 CD - B-MONEY
; PUNCT - O
p DET - O
  SPACE - O

analyses NOUN - O
focused VERB - O
on ADP - O
continuously ADV - O
insured VERB - O
patients NOUN - O
who NOUN - O
were VERB - O
adherent ADJ - O
to ADP - O
Synthroid NNP - B-MEDICINE
for ADP - O
at RB - B-DATE
least RBS - I-DATE
6 CD - I-DATE
months NNS - I-DATE
and CCONJ - O
results NOUN - O
may VERB - O
not ADV - O
be VERB - O
generalizable ADJ - O
. PUNCT - O

Results NOUN - O
indicate VERB - O
that ADP - O
there ADV - O
are VERB - O
significant ADJ - O
direct ADJ - O
economic ADJ - O
healthcare NOUN - O
costs NOUN - O
associated VERB - O
with ADP - O
switching VERB - O
from ADP - O
Synthroid NNP - B-MEDICINE
to ADP - O
alternative ADJ - O
levothyroxine NOUN - O
therapies NOUN - O
, PUNCT - O
and CCONJ - O
that ADP - O
these DET - O
costs NOUN - O
increase VERB - O
as ADP - O
patients NOUN - O
switch VERB - O
therapies NOUN - O
more ADV - O
frequently ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
the DET - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
whether ADP - O
Synthroid NNP - B-MEDICINE
resulted VERB - O
in ADP - O
better ADJ - O
control NOUN - O
of ADP - O
congenital ADJ - O
hypothyroidism NOUN - O
than ADP - O
generic ADJ - O
LT4 NOUN - O
. PUNCT - O

Children NOUN - O
who NOUN - O
were VERB - O
0 CD - B-DATE
- SYM - I-DATE
36 CD - I-DATE
months NNS - I-DATE
old JJ - I-DATE
with ADP - O
congenital ADJ - O
hypothyroidism NOUN - O
followed VERB - O
up PART - O
at ADP - O
our ADJ - O
center NOUN - O
from ADP - O
2006 CD - B-DATE
to ADP - O
2011 CD - B-DATE
were VERB - O
treated VERB - O
with ADP - O
either DET - O
Synthroid NNP - B-MEDICINE
exclusively ADV - O
( PUNCT - O
35 CD - B-CARDINAL
subjects NOUN - O
) PUNCT - O
or CCONJ - O
generic ADJ - O
LT4 PROPN - O
exclusively ADV - O
( PUNCT - O
27 CD - B-CARDINAL
subjects NOUN - O
) PUNCT - O
. PUNCT - O

Using VERB - O
the DET - O
Wilcoxon NNP - B-PERSON
rank NOUN - O
sum NOUN - O
test NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
difference NOUN - O
in ADP - O
TSH NNP - B-ORG
SD NNP - I-ORG
in ADP - O
the DET - O
Synthroid NNP - B-MEDICINE
group NOUN - O
compared VERB - O
with ADP - O
the DET - O
generic ADJ - O
group NOUN - O
( PUNCT - O
median ADJ - O
3.0 CD - B-CARDINAL
vs ADP - O
2.2 CD - B-CARDINAL
, PUNCT - O
P NOUN - O
= SYM - O
.27 NOUN - O
) PUNCT - O
. PUNCT - O

Using VERB - O
a DET - O
linear ADJ - O
mixed ADJ - O
model NOUN - O
, PUNCT - O
children NOUN - O
treated VERB - O
with ADP - O
the DET - O
generic ADJ - O
LT4 PROPN - O
had VERB - O
lower ADJ - O
TSH NNP - B-ORG
estimated VERB - O
SD NN - B-ORG
[ PUNCT - O
1.35 NUM - O
with ADP - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
( PUNCT - O
1.194 CD - B-CARDINAL
, PUNCT - O
1.526 CD - B-CARDINAL
) PUNCT - O
] PUNCT - O
than ADP - O
the DET - O
Synthroid NNP - B-MEDICINE
group NOUN - O
[ PUNCT - O
1.66 NUM - O
with ADP - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
( PUNCT - O
1.536 NUM - O
, PUNCT - O

Similarly ADV - O
, PUNCT - O
no DET - O
difference NOUN - O
was VERB - O
observed VERB - O
in ADP - O
free ADJ - O
T(4 NOUN - O
) PUNCT - O
SD NOUN - O
between ADP - O
the DET - O
groups NOUN - O
using VERB - O
the DET - O
Wilcoxon NNP - B-PERSON
rank NOUN - O
sum NOUN - O
test NOUN - O
( PUNCT - O
median ADJ - O
0.29 CD - B-CARDINAL
generic ADJ - O
vs ADP - O
0.36 CD - B-CARDINAL
Synthroid NNP - B-MEDICINE
, PUNCT - O
P NOUN - O
= SYM - O
.11 NOUN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
the DET - O
generic ADJ - O
group NOUN - O
had VERB - O
lower ADJ - O
free ADJ - O
T(4 NN - B-ORG
) PUNCT - O
estimated VERB - O
SD NN - B-ORG
than ADP - O
the DET - O
Synthroid NNP - B-MEDICINE
group NOUN - O
using VERB - O
the DET - O
linear ADJ - O
mixed ADJ - O
model NOUN - O
[ PUNCT - O
0.216 NUM - O
with ADP - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
( PUNCT - O
0.187 CD - B-CARDINAL
, PUNCT - O
0.249 CD - B-CARDINAL
) PUNCT - O
vs ADP - O
0.298 CD - B-CARDINAL
with ADP - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG

( PUNCT - O
0.273,0.326)]. CD - B-CARDINAL
Frequency PROPN - O
of ADP - O
LT4 NOUN - O
dosing VERB - O
adjustments NOUN - O
was VERB - O
similar ADJ - O
between ADP - O
the DET - O
groups NOUN - O
, PUNCT - O
both CCONJ - O
in ADP - O
total ADJ - O
( PUNCT - O
median NOUN - O
2.0 CD - B-CARDINAL
for ADP - O
generic ADJ - O
vs ADP - O
3.0 CD - B-CARDINAL
for ADP - O
Synthroid NNP - B-MEDICINE
, PUNCT - O
P NOUN - O
= SYM - O
.097 NUM - O
) PUNCT - O
and CCONJ - O
when ADV - O
adjusted VERB - O
for ADP - O
number NOUN - O
of ADP - O
TSH NNP - B-ORG
checks NOUN - O
( PUNCT - O
ratio ADJ - O
0.25 CD - B-CARDINAL
generic ADJ - O
vs ADP - O
0.31 CD - B-CARDINAL
Synthroid NNP - B-MEDICINE
, PUNCT - O
P NOUN - O
= SYM - O
.45 NOUN - O
) PUNCT - O
. PUNCT - O

In ADP - O
our ADJ - O
study NOUN - O
of ADP - O
congenital ADJ - O
hypothyroidism NOUN - O
, PUNCT - O
generic ADJ - O
LT4 PROPN - O
treatment NOUN - O
resulted VERB - O
in ADP - O
similar ADJ - O
or CCONJ - O
better ADJ - O
control NOUN - O
of ADP - O
hypothyroidism NOUN - O
compared VERB - O
with ADP - O
Synthroid NNP - B-MEDICINE
, PUNCT - O
as ADP - O
assessed VERB - O
by ADP - O
the DET - O
clinical ADJ - O
outcomes NOUN - O
of ADP - O
TSH NNP - B-ORG
variance NOUN - O
and CCONJ - O
the DET - O
frequency NOUN - O
of ADP - O
LT4 NNP - B-PERSON
dosing VERB - O
adjustments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
specific ADJ - O
guidelines NOUN - O
regarding VERB - O
management NOUN - O
of ADP - O
hypothyroidism NOUN - O
in ADP - O
older ADJ - O
adults NOUN - O
do VERB - O
not ADV - O
exist VERB - O
, PUNCT - O
general ADJ - O
recommendations NOUN - O
include VERB - O
initiating VERB - O
hormone NOUN - O
replacement NOUN - O
with ADP - O
levothyroxine NOUN - O
( PUNCT - O
Levoxyl NNP - B-PERSON
( PUNCT - O
® PROPN - O
) PUNCT - O
, PUNCT - O
Synthroid NNP - B-MEDICINE
( PUNCT - O
® PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
others NOUN - O
) PUNCT - O
at ADP - O
12.5 CD - B-QUANTITY
mcg NN - I-QUANTITY
to ADP - O
25 CD - B-CARDINAL
mcg NOUN - O
and CCONJ - O
titrating VERB - O
the DET - O
dose NOUN - O
slowly ADV - O
based VERB - O
on ADP - O
response NOUN - O
at ADP - O
6-week NUM - O
intervals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
bioequivalence NOUN - O
of ADP - O
100 CD - B-QUANTITY
microg NN - I-QUANTITY
of ADP - O
a DET - O
test NOUN - O
( PUNCT - O
T4 PROPN - O
Montpellier PROPN - O
100 NUM - O
, PUNCT - O
Química NNP - B-ORG
Montpellier NNP - I-ORG
S.A. NNP - I-ORG
, PUNCT - O
Buenos NNP - B-PERSON
Aires NNP - I-PERSON
, PUNCT - O
Argentina NNP - B-GPE
) PUNCT - O
and CCONJ - O
reference NOUN - O
( PUNCT - O
Synthroid NNP - B-MEDICINE
, PUNCT - O
Abbott NNP - B-PERSON
Laboratories NNP - I-PERSON
, PUNCT - O
Abbott NNP - B-GPE
Park NNP - I-GPE
, PUNCT - O
Illinois NNP - B-GPE
) PUNCT - O
formulation NOUN - O
of ADP - O
levothyroxine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
parallel ADJ - O
- PUNCT - O
group NOUN - O
design NOUN - O
, PUNCT - O
48 CD - B-CARDINAL
healthy ADJ - O
, PUNCT - O
young ADJ - O
, PUNCT - O
recreationally ADV - O
active ADJ - O
men NOUN - O
( PUNCT - O
mean VERB - O
± PROPN - O
SEM NOUN - O
age NOUN - O
: PUNCT - O
23 CD - B-CARDINAL
  SPACE - O
± PUNCT - O
  SPACE - O
0.3 NUM - O
y NOUN - O
) PUNCT - O
received VERB - O
a DET - O
primed VERB - O
continuous ADJ - O
infusion NOUN - O
of ADP - O
L-[ring-13C6]-phenylalanine PROPN - O
and CCONJ - O
L-[ring-3,5 PROPN - O
- PUNCT - O
2H2]-tyrosine NUM - O
and CCONJ - O
ingested VERB - O
45 CD - B-CARDINAL
g NOUN - O
carbohydrate NOUN - O
with ADP - O
0 CD - B-CARDINAL
g NOUN - O
protein NOUN - O
( PUNCT - O
CHO NNP - B-ORG
) PUNCT - O
, PUNCT - O
20 CD - B-CARDINAL
g NOUN - O
milk NOUN - O
protein NOUN - O
( PUNCT - O
MILK PROPN - O
) PUNCT - O
, PUNCT - O
20 CD - B-CARDINAL
g NOUN - O
whey NOUN - O
protein NOUN - O
( PUNCT - O
WHEY PROPN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
20 CD - B-CARDINAL
g PUNCT - O
micellar ADJ - O
casein NN - B-MEDICINE
protein NOUN - O
( PUNCT - O
CASEIN NNP - B-MEDICINE
) PUNCT - O
after ADP - O
a DET - O
sequential ADJ - O
bout NOUN - O
of ADP - O
resistance- NOUN - O
and CCONJ - O
endurance NOUN - O
- PUNCT - O
type NOUN - O
exercise NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
concurrent ADJ - O
exercise NOUN - O
) PUNCT - O
. PUNCT - O

Despite ADP - O
temporal ADJ - O
differences NOUN - O
in ADP - O
postprandial ADJ - O
plasma NOUN - O
leucine NOUN - O
concentrations NOUN - O
between ADP - O
treatments NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.001 NUM - O
) PUNCT - O
, PUNCT - O
MyoPS NNP - B-ORG
rates NOUN - O
over ADP - O
360 CD - B-QUANTITY
min NN - I-QUANTITY
of ADP - O
recovery NOUN - O
did VERB - O
not ADV - O
differ VERB - O
between ADP - O
treatments NOUN - O
( PUNCT - O
CHO NNP - B-ORG
: PUNCT - O
0.049 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.003%/h NUM - O
; PUNCT - O
MILK PROPN - O
: PUNCT - O
0.059 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.003%/h NUM - O
; PUNCT - O
WHEY PROPN - O
: PUNCT - O
0.054 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.002%/h NUM - O
; PUNCT - O
CASEIN NNP - B-MEDICINE
: PUNCT - O
0.059 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.005%/h NUM - O
; PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.11 NUM - O
) PUNCT - O
. PUNCT - O

When ADV - O
MILK NNP - B-ORG
, PUNCT - O
WHEY NNP - B-ORG
, PUNCT - O
and CCONJ - O
CASEIN NNP - B-MEDICINE
were VERB - O
pooled VERB - O
into ADP - O
a DET - O
single ADJ - O
group NOUN - O
( PUNCT - O
PROTEIN PROPN - O
) PUNCT - O
, PUNCT - O
protein NOUN - O
co NOUN - O
- NOUN - O
ingestion NOUN - O
resulted VERB - O
in ADP - O
greater ADJ - O
MyoPS NNP - B-PERSON
rates NOUN - O
compared VERB - O
with ADP - O
CHO NNP - B-ORG
( PUNCT - O
PROTEIN NOUN - O
: PUNCT - O
0.057 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.002%/h NUM - O
; PUNCT - O
CHO NNP - B-ORG
: PUNCT - O
0.049 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
± VERB - O
  SPACE - O
0.003%/h NUM - O
; PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.04 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics PROPN - O
and CCONJ - O
Comparative PROPN - O
Bioavailability PROPN - O
of ADP - O
a DET - O
Levothyroxine NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Oral PROPN - O
Solution PROPN - O
and CCONJ - O
Soft PROPN - O
Capsule PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Pivotal PROPN - O
Field PROPN - O
Study PROPN - O
to PART - O
Support VERB - O
the DET - O
Registration NOUN - O
of ADP - O
Levothyroxine NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Tablets PROPN - O
for ADP - O
Canine PROPN - O
Hypothyroidism PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
( PUNCT - O
QZP NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
long ADV - O
- PUNCT - O
acting VERB - O
benzodiazepine NOUN - O
- PUNCT - O
type NOUN - O
hypnotic ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
15 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
30 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
or CCONJ - O
45 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
or CCONJ - O
brotizolam NOUN - O
0.25 CD - B-QUANTITY
mg NN - I-QUANTITY
( PUNCT - O
40 CD - B-CARDINAL
patients NOUN - O
each DET - O
) PUNCT - O
, PUNCT - O
was VERB - O
administered VERB - O
orally ADV - O
at ADP - O
9 CD - B-TIME
p.m. NN - I-TIME
in IN - I-TIME
the DT - I-TIME
evening NN - I-TIME
of IN - I-TIME
the DT - I-TIME
day NN - I-TIME
before ADP - O
surgery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
was VERB - O
well ADV - O
tolerated VERB - O
, PUNCT - O
with ADP - O
no DET - O
significant ADJ - O
difference NOUN - O
in ADP - O
the DET - O
Stanford PROPN - O
Sleepiness PROPN - O
Scale PROPN - O
between ADP - O
fasted VERB - O
and CCONJ - O
fed VERB - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
, PUNCT - O
a DET - O
trifluoroethylbenzodiazepine NOUN - O
hypnotic ADJ - O
, PUNCT - O
and CCONJ - O
triazolam NOUN - O
, PUNCT - O
a DET - O
triazolobenzodiazepine NOUN - O
hypnotic ADJ - O
, PUNCT - O
differ VERB - O
in ADP - O
terms NOUN - O
of ADP - O
their ADJ - O
benzodiazepine ADJ - O
- PUNCT - O
receptor NOUN - O
binding NOUN - O
profile NOUN - O
. PUNCT - O

Quazepam NN - B-MEDICINE
and CCONJ - O
triazolam NOUN - O
produced VERB - O
comparable ADJ - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
performance NOUN - O
impairment NOUN - O
and CCONJ - O
increased ADJ - O
ratings NOUN - O
of ADP - O
drug NOUN - O
effect NOUN - O
and CCONJ - O
drowsy NOUN - O
. PUNCT - O

Quazepam NNP - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
triazolam VERB - O
, PUNCT - O
increased ADJ - O
ratings NOUN - O
of ADP - O
dizzy NOUN - O
/ SYM - O
light NOUN - O
- PUNCT - O
headed VERB - O
, PUNCT - O
performance NOUN - O
impaired VERB - O
, PUNCT - O
and CCONJ - O
sleepy ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NN - B-MEDICINE
and CCONJ - O
flurazepam NOUN - O
share NOUN - O
pharmacokinetic ADJ - O
properties NOUN - O
that ADJ - O
result VERB - O
in ADP - O
prevention NOUN - O
of ADP - O
early JJ - B-TIME
- HYPH - I-TIME
morning NN - I-TIME
insomnia NOUN - O
, PUNCT - O
daytime NOUN - O
rebound NOUN - O
anxiety NOUN - O
, PUNCT - O
and CCONJ - O
withdrawal NOUN - O
rebound NOUN - O
insomnia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NN - B-MEDICINE
and CCONJ - O
flurazepam NOUN - O
: PUNCT - O
differential VERB - O
pharmacokinetic ADJ - O
and CCONJ - O
pharmacodynamic ADJ - O
characteristics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
is VERB - O
a DET - O
benzodiazepine NOUN - O
hypnotic ADJ - O
that ADJ - O
can VERB - O
be VERB - O
useful ADJ - O
in ADP - O
the DET - O
adjunctive ADJ - O
pharmacologic NOUN - O
treatment NOUN - O
of ADP - O
insomnia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
is VERB - O
a DET - O
trifluoroethyl ADV - O
benzodiazepine ADJ - O
hypnotic ADJ - O
with ADP - O
a DET - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
of ADP - O
27 CD - B-TIME
to TO - I-TIME
41 CD - I-TIME
hours NNS - I-TIME
, PUNCT - O
which ADJ - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
induce VERB - O
and CCONJ - O
maintain VERB - O
sleep NOUN - O
in ADP - O
the DET - O
short ADJ - O
to ADP - O
long ADJ - O
term NOUN - O
( PUNCT - O
up IN - B-DATE
to TO - I-DATE
4 CD - I-DATE
weeks NNS - I-DATE
) PUNCT - O
treatment NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
chronic ADJ - O
or CCONJ - O
transient ADJ - O
insomnia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
is VERB - O
a DET - O
new ADJ - O
benzodiazepine NOUN - O
that ADJ - O
may VERB - O
provide VERB - O
good ADJ - O
hypnotic ADJ - O
action NOUN - O
with ADP - O
negligible ADJ - O
effect NOUN - O
on ADP - O
motor NOUN - O
coordination NOUN - O
or CCONJ - O
respiration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
was VERB - O
well ADV - O
absorbed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam JJ - B-MEDICINE
kinetics NOUN - O
in ADP - O
the DET - O
elderly ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Quazepam NNP - B-MEDICINE
, PUNCT - O
a DET - O
benzodiazepine NOUN - O
hypnotic ADJ - O
, PUNCT - O
was VERB - O
studied VERB - O
in ADP - O
normal ADJ - O
subjects NOUN - O
to PART - O
evaluate VERB - O
steady ADJ - O
- PUNCT - O
state NOUN - O
kinetics NOUN - O
of ADP - O
quazepam NN - B-MEDICINE
and CCONJ - O
of ADP - O
its ADJ - O
major ADJ - O
active ADJ - O
plasma NOUN - O
metabolites NOUN - O
, PUNCT - O
2-oxoquazepam CD - B-GPE
and CCONJ - O
N NNP - B-ORG
- HYPH - I-ORG
desalkyl-2-oxoquazepam NNP - I-ORG
, PUNCT - O
after ADP - O
15 CD - B-CARDINAL
mg NOUN - O
once ADV - O
daily ADV - O
by ADP - O
mouth NOUN - O
for ADP - O
14 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

Quazepam NNP - B-MEDICINE
was VERB - O
rapidly ADV - O
absorbed VERB - O
and CCONJ - O
its ADJ - O
two CD - B-CARDINAL
major ADJ - O
plasma NOUN - O
metabolites NOUN - O
appeared VERB - O
very ADV - O
quickly ADV - O
in ADP - O
systemic ADJ - O
circulation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Long ADJ - O
- PUNCT - O
term NOUN - O
Outcome NNP - B-ORG
of ADP - O
Irish PROPN - O
Wolfhound PROPN - O
Dogs PROPN - O
with ADP - O
Preclinical NNP - B-GPE
Cardiomyopathy NNP - I-GPE
, PUNCT - O
Atrial NNP - B-ORG
Fibrillation NNP - I-ORG
, PUNCT - O
or CCONJ - O
Both DET - O
Treated VBN - B-ORG
with ADP - O
Pimobendan PROPN - O
, PUNCT - O
Benazepril NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
or CCONJ - O
Methyldigoxin NNP - B-PERSON
Monotherapy NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Angiography ADJ - O
with ADP - O
Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
and CCONJ - O
Acetylcysteine NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-WORK_OF_ART
Role NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Saline NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Sodium NNP - I-WORK_OF_ART
Bicarbonate NNP - I-WORK_OF_ART
Preprocedural NNP - I-WORK_OF_ART
Hydration NNP - I-WORK_OF_ART
to IN - I-WORK_OF_ART
Prevent NNP - I-WORK_OF_ART
Mid NNP - I-WORK_OF_ART
- HYPH - I-WORK_OF_ART
term NN - I-WORK_OF_ART
Renal NNP - B-ORG
Insufficiency NNP - I-ORG
in ADP - O
Patients NNPS - B-GPE
with ADP - O
Chronic PROPN - O
Kidney NNP - B-ORG
Disease NNP - I-ORG
Undergoing VBG - I-ORG
Percutaneous JJ - I-ORG
Coronary NNP - I-ORG
Intervention NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effect PROPN - O
of ADP - O
Aspartate PROPN - O
and CCONJ - O
Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
Supplementation PROPN - O
on ADP - O
Muscle PROPN - O
Contractile PROPN - O
Properties PROPN - O

-DOCSTART- -X- - O

Six CD - B-DATE
- HYPH - I-DATE
Month NN - I-DATE
Evaluation NOUN - O
of ADP - O
a DET - O
Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
- PUNCT - O
Containing PROPN - O
Toothpaste PROPN - O
for ADP - O
Reduction NOUN - O
of ADP - O
Established PROPN - O
Gingivitis PROPN - O
: PUNCT - O
A DET - O
Randomized ADJ - O
USA PROPN - O
- PUNCT - O
Based VERB - O
Clinical PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
Hydration PROPN - O
Fluids PROPN - O
Commonly ADV - O
Used VERB - O
With ADP - O
High PROPN - O
- PUNCT - O
Dose PROPN - O
Methotrexate PROPN - O
Chemotherapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Usefulness NNP - B-ORG
of IN - I-ORG
Sodium NNP - I-ORG
Bicarbonate NNP - I-ORG
for IN - I-ORG
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Contrast NNP - I-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Nephropathy NNP - I-ORG
in IN - I-ORG
Patients NNS - I-ORG
Undergoing VBG - I-ORG
Cardiac NNP - I-ORG
Resynchronization NNP - I-ORG
Therapy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Single ADJ - O
and CCONJ - O
Combined PROPN - O
Effects PROPN - O
of ADP - O
Beetroot PROPN - O
Crystals PROPN - O
and CCONJ - O
Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
on ADP - O
4-km CD - B-ORG
Cycling NNP - I-ORG
Time NNP - I-ORG
Trial NNP - I-ORG
Performance NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Dose NNP - B-ORG
- HYPH - I-ORG
Response NN - I-ORG
of IN - I-ORG
Sodium NNP - I-ORG
Bicarbonate NNP - I-ORG
Ingestion NNP - I-ORG
Highlights NNPS - I-ORG
Individuality NNP - I-ORG
in ADP - O
Time PROPN - O
Course PROPN - O
of ADP - O
Blood PROPN - O
Analyte PROPN - O
Responses PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sodium NNP - B-MEDICINE
Bicarbonate NNP - I-MEDICINE
Facilitates PROPN - O
Hemostasis PROPN - O
in ADP - O
the DET - O
Presence PROPN - O
of ADP - O
Cerebrospinal PROPN - O
Fluid PROPN - O
Through ADP - O
Amplification NOUN - O
of ADP - O
Platelet PROPN - O
Aggregation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
characterize VERB - O
pharmacy NOUN - O
- PUNCT - O
related VERB - O
theft NOUN - O
data NOUN - O
reported VERB - O
to ADP - O
the DT - B-ORG
Rx NNP - I-ORG
Pattern NNP - I-ORG
Analysis NNP - I-ORG
Tracking NNP - I-ORG
Robberies NNPS - I-ORG
and CC - I-ORG
Other NNP - I-ORG
Losses NNPS - I-ORG
( PUNCT - O
RxPATROL NNP - B-PERSON
® NN - I-PERSON
) PUNCT - O
database NOUN - O
during ADP - O
the DET - O
time NOUN - O
periods NOUN - O
before ADV - O
( PUNCT - O
2007 CD - B-DATE
- SYM - I-DATE
2010 CD - I-DATE
) PUNCT - O
and CCONJ - O
after ADP - O
( PUNCT - O
2011 CD - B-DATE
- SYM - I-DATE
2016 CD - I-DATE
) PUNCT - O
the DET - O
August NNP - B-DATE
2010 CD - I-DATE
switch VERB - O
to ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
® . - I-FAC

Variables NOUN - O
analyzed VERB - O
included VERB - O
incident NOUN - O
counts NOUN - O
, PUNCT - O
drugs NOUN - O
involved VERB - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
or CCONJ - O
other ADJ - O
oxycodone NOUN - O
products NOUN - O
) PUNCT - O
, PUNCT - O
pharmacy NOUN - O
- PUNCT - O
security NOUN - O
features NOUN - O
, PUNCT - O
and CCONJ - O
other ADJ - O
incident NOUN - O
- PUNCT - O
related VERB - O
information NOUN - O
. PUNCT - O

Incidents NNS - B-ORG
reported VERB - O
as ADP - O
robberies NOUN - O
that ADJ - O
involved VERB - O
OxyContin NNP - B-MEDICINE
initially ADV - O
increased VERB - O
from ADP - O
2007 CD - B-DATE
to ADP - O
2010 CD - B-DATE
and CCONJ - O
then ADV - O
steadily ADV - O
decreased VERB - O
from ADP - O
296 CD - B-CARDINAL
in ADP - O
2010 CD - B-DATE
to ADP - O
13 CD - B-CARDINAL
in ADP - O
2016 CD - B-DATE
. PUNCT - O

Total ADJ - O
burglary NOUN - O
reports NOUN - O
that ADJ - O
involved VERB - O
OxyContin NNP - B-MEDICINE
decreased VERB - O
after ADP - O
2009 CD - B-DATE
. PUNCT - O

Following VERB - O
replacement NOUN - O
of ADP - O
the DET - O
original ADJ - O
formulation NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
with ADP - O
a DET - O
new ADJ - O
formulation NOUN - O
that ADJ - O
has VERB - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
properties NOUN - O
in ADP - O
2010 CD - B-DATE
, PUNCT - O
pharmacy NOUN - O
thefts NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
reported VERB - O
to ADP - O
the DET - O
RxPATROL NNP - B-GPE
® NOUN - O
database NOUN - O
decreased VERB - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
open ADJ - O
label NOUN - O
extension NOUN - O
examined VERB - O
pharmacokinetics NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
® . - I-ORG

OxyContin NNP - B-MEDICINE
ER NNP - I-ORG
. PUNCT - O

Again ADV - O
scores NOUN - O
compared VERB - O
to ADP - O
both DET - O
OxyContin NNP - B-MEDICINE
ER NNP - I-ORG
and CCONJ - O
oxycodone NOUN - O
IR PROPN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
REMOXY NNP - B-ORG
ER NNP - I-ORG
demonstrated VERB - O
significantly ADV - O
lower ADJ - O
nasal NOUN - O
abuse NOUN - O
potential NOUN - O
compared VERB - O
to ADP - O
oxycodone NOUN - O
IR NNP - B-ORG
or CCONJ - O
OxyContin NNP - B-MEDICINE
ER NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Family NOUN - O
behind ADP - O
OxyContin NNP - B-MEDICINE
named VERB - O
in ADP - O
lawsuit NOUN - O
for ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aim PROPN - O
: PUNCT - O
This DET - O
study NOUN - O
aims VERB - O
to PART - O
explore VERB - O
the DET - O
standardized VERB - O
nursing NOUN - O
and CCONJ - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
on ADP - O
oral ADJ - O
mucosal NOUN - O
pain NOUN - O
in ADP - O
nasopharyngeal ADJ - O
carcinoma NOUN - O
( PUNCT - O
NPC NN - B-ORG
) PUNCT - O
patients NOUN - O
with ADP - O
concurrent ADJ - O
chemoradiotherapy NOUN - O
. PUNCT - O

Patients NOUN - O
consuming VERB - O
OxyContin NNP - B-MEDICINE
for ADP - O
moderate ADJ - O
and CCONJ - O
severe ADJ - O
pain NOUN - O
were VERB - O
divided VERB - O
into ADP - O
the DET - O
experimental ADJ - O
group NOUN - O
and CCONJ - O
control NOUN - O
group NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

All ADJ - O
the DET - O
patients NOUN - O
were VERB - O
given VERB - O
OxyContin NNP - B-MEDICINE
10 CD - I-PRODUCT
mg NOUN - O
orally ADV - O
, PUNCT - O
and CCONJ - O
the DET - O
dose NOUN - O
was VERB - O
adjusted VERB - O
according VERB - O
to ADP - O
the DET - O
degree NOUN - O
of ADP - O
pain NOUN - O
relief NOUN - O
until ADP - O
it PRON - O
was VERB - O
significantly ADV - O
relieved VERB - O
. PUNCT - O

Results NOUN - O
: PUNCT - O
There ADV - O
was VERB - O
no DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
the DET - O
total ADJ - O
dose NOUN - O
of ADP - O
radiotherapy NOUN - O
and CCONJ - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

OxyContin NNP - B-MEDICINE
could VERB - O
significantly ADV - O
improve VERB - O
the DET - O
quality NOUN - O
of ADP - O
life NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
moderate ADJ - O
pain NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
while ADP - O
the DET - O
effect NOUN - O
was VERB - O
not ADV - O
significant ADJ - O
in ADP - O
patients NOUN - O
with ADP - O
severe ADJ - O
pain NOUN - O
. PUNCT - O

The DET - O
application NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
and CCONJ - O
cancer NOUN - O
pain NOUN - O
standardized VERB - O
nursing NOUN - O
care NOUN - O
can VERB - O
improve VERB - O
the DET - O
analgesic ADJ - O
efficacy NOUN - O
, PUNCT - O
reduce VERB - O
drug NOUN - O
adverse ADJ - O
effects NOUN - O
, PUNCT - O
and CCONJ - O
improve VERB - O
the DET - O
patient NOUN - O
's PART - O
quality NOUN - O
of ADP - O
life NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Long ADV - O
- PUNCT - O
acting VERB - O
opioids NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
OxyContin NNP - B-MEDICINE
were VERB - O
used VERB - O
commonly ADV - O
. PUNCT - O

-DOCSTART- -X- - O

' PUNCT - O
Delisting PROPN - O
' PUNCT - O
OxyContin NNP - B-MEDICINE
® NOUN - O
to PART - O
reduce VERB - O
prescription NOUN - O
opioid ADV - O
- PUNCT - O
related VERB - O
harms NOUN - O
in ADP - O
Ontario NNP - B-GPE
( PUNCT - O
Canada)-gauging NOUN - O
effects NOUN - O
5 CD - B-CARDINAL
  SPACE - O
years NOUN - O
later ADV - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
putative ADJ - O
abuse NOUN - O
deterrent NOUN - O
formulation NOUN - O
of ADP - O
oxycodone NOUN - O
extended VERB - O
release NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
® NN - I-ORG
) PUNCT - O
was VERB - O
introduced VERB - O
in ADP - O
2010 CD - B-DATE
. PUNCT - O

We PRON - O
measured VERB - O
trends NOUN - O
of ADP - O
diversion NOUN - O
, PUNCT - O
abuse NOUN - O
and CCONJ - O
street NOUN - O
price NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
to PART - O
assess VERB - O
the DET - O
durability NOUN - O
of ADP - O
the DET - O
initial ADJ - O
reduction NOUN - O
in ADP - O
abuse NOUN - O
. PUNCT - O

The DET - O
average ADJ - O
quarterly JJ - B-DATE
rates NOUN - O
of ADP - O
abuse NOUN - O
and CCONJ - O
diversion NOUN - O
for ADP - O
OxyContin NNP - B-MEDICINE
were VERB - O
compared VERB - O
from ADP - O
before ADP - O
reformulation NOUN - O
to ADP - O
the DET - O
rate NOUN - O
in ADP - O
second JJ - B-DATE
quarter NN - I-DATE
2015 CD - I-DATE
. PUNCT - O

OxyContin JJ - B-MEDICINE
abuse NOUN - O
and CCONJ - O
diversion NOUN - O
declined VERB - O
significantly ADV - O
each DT - B-DATE
quarter NN - I-DATE
after ADP - O
reformulation NOUN - O
and CCONJ - O
persisted VERB - O
for ADP - O
5 CD - B-DATE
years NNS - I-DATE
. PUNCT - O

The DET - O
rate NOUN - O
of ADP - O
abuse NOUN - O
of ADP - O
other ADJ - O
opioid ADJ - O
analgesics NOUN - O
increased VERB - O
initially ADV - O
and CCONJ - O
then ADV - O
decreased VERB - O
, PUNCT - O
but CCONJ - O
to ADP - O
lesser ADJ - O
extent NOUN - O
than ADP - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

The DET - O
geometric ADJ - O
mean ADJ - O
difference NOUN - O
in ADP - O
the DET - O
street NOUN - O
price NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
was VERB - O
36 CD - B-PERCENT
% NN - I-PERCENT
lower ADJ - O
than ADP - O
the DET - O
reformulated VERB - O
product NOUN - O
in ADP - O
the DT - B-DATE
year NN - I-DATE
after ADP - O
reformulation NOUN - O
. PUNCT - O

Despite ADP - O
methods NOUN - O
to PART - O
circumvent VERB - O
the DET - O
abuse NOUN - O
deterrent NOUN - O
mechanism NOUN - O
, PUNCT - O
abuse NOUN - O
and CCONJ - O
diversion NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
decreased VERB - O
promptly ADV - O
following VERB - O
the DET - O
introduction NOUN - O
of ADP - O
a DET - O
crush- NOUN - O
and CCONJ - O
solubility- ADJ - O
resistant ADJ - O
formulation NOUN - O
and CCONJ - O
continued VERB - O
to PART - O
decrease VERB - O
over ADP - O
the DET - O
subsequent ADJ - O
5 CD - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
open ADJ - O
cohort NOUN - O
study NOUN - O
assessed VERB - O
changes NOUN - O
in ADP - O
doctor NOUN - O
- PUNCT - O
shopping NOUN - O
in ADP - O
the DET - O
U.S. NNP - B-GPE
for ADP - O
a DET - O
brand NOUN - O
extended VERB - O
release NOUN - O
( PUNCT - O
ER PROPN - O
) PUNCT - O
oxycodone NOUN - O
product NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
) PUNCT - O
and CCONJ - O
comparator NOUN - O
opioids NOUN - O
before ADP - O
( PUNCT - O
July NNP - B-DATE
, , - I-DATE
2009 CD - I-DATE
to ADP - O
June NNP - B-DATE
, , - I-DATE
2010 CD - I-DATE
) PUNCT - O
versus X - O
after ADP - O
( PUNCT - O
January NNP - B-DATE
, PUNCT - O
2011 CD - B-DATE
to ADP - O
June NNP - B-DATE
, PUNCT - O
2013 CD - B-DATE
) PUNCT - O
introduction NOUN - O
of ADP - O
reformulated VERB - O
brand NOUN - O
ER PROPN - O
oxycodone NOUN - O
with ADP - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
properties NOUN - O
, PUNCT - O
using VERB - O
IMS NNP - B-ORG
LRx NOUN - O
longitudinal ADJ - O
data NOUN - O
covering VERB - O
> X - O
150 CD - B-CARDINAL
million CD - I-CARDINAL
patients NOUN - O
and CCONJ - O
65 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
retail ADJ - O
U.S. NNP - B-GPE
prescriptions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Drawing VERB - O
on ADP - O
sources NOUN - O
ranging VERB - O
from ADP - O
postwar ADJ - O
Congressional JJ - B-ORG
hearings NOUN - O
concerning VERB - O
the DET - O
veteran NOUN - O
welfare NOUN - O
state NOUN - O
to ADP - O
debates NOUN - O
surrounding VERB - O
Rush NNP - B-PERSON
Limbaugh NNP - I-PERSON
's POS - I-PERSON
OxyContin NNP - B-MEDICINE
addiction NOUN - O
, PUNCT - O
Wailoo NNP - B-GPE
offers VERB - O
a DET - O
fresh ADJ - O
analysis NOUN - O
of ADP - O
both DET - O
U.S. NNP - B-GPE
political ADJ - O
history NOUN - O
and CCONJ - O
medical ADJ - O
history NOUN - O
, PUNCT - O
showing VERB - O
how ADV - O
today NN - B-DATE
's PART - O
highly ADV - O
polarized ADJ - O
party NOUN - O
system NOUN - O
emerged VERB - O
in ADP - O
part NOUN - O
from ADP - O
debates NOUN - O
surrounding VERB - O
the DET - O
existence NOUN - O
and CCONJ - O
worth NOUN - O
of ADP - O
pain NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
its ADJ - O
management NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

OxyContin NNP - B-MEDICINE
was VERB - O
submitted VERB - O
and CCONJ - O
justifiably ADV - O
approved VERB - O
by ADP - O
the DET - O
agency NOUN - O
as ADP - O
a DET - O
12-hour CD - B-CARDINAL
dosage NOUN - O
form NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
extended ADJ - O
- PUNCT - O
release NOUN - O
opioid ADJ - O
analgesic NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
, PUNCT - O
OC PROPN - O
) PUNCT - O
was VERB - O
reformulated VERB - O
with ADP - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
properties NOUN - O
to PART - O
deter VERB - O
abuse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lessons NOUN - O
Learned PROPN - O
From ADP - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
reformulated VERB - O
version NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
extended VERB - O
- PUNCT - O
release NOUN - O
oxycodone NOUN - O
) PUNCT - O
with ADP - O
physicochemical ADJ - O
properties NOUN - O
to PART - O
deter VERB - O
abuse NOUN - O
presented VERB - O
an DET - O
opportunity NOUN - O
to PART - O
evaluate VERB - O
posts NOUN - O
about ADP - O
the DET - O
reformulation NOUN - O
in ADP - O
online ADJ - O
discussions NOUN - O
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
use VERB - O
messages NOUN - O
on ADP - O
Internet NOUN - O
forums NOUN - O
to PART - O
evaluate VERB - O
reactions NOUN - O
to ADP - O
the DET - O
introduction NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
and CCONJ - O
to PART - O
identify VERB - O
methods NOUN - O
aimed VERB - O
to PART - O
defeat VERB - O
the DET - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
properties NOUN - O
of ADP - O
the DET - O
product NOUN - O
. PUNCT - O

Posts NOUN - O
collected VERB - O
from ADP - O
7 CD - B-CARDINAL
forums NOUN - O
between IN - B-DATE
January NNP - I-DATE
1 CD - I-DATE
, , - I-DATE
2008 CD - I-DATE
and CCONJ - O
September NNP - B-DATE
30 CD - I-DATE
, , - I-DATE
2013 CD - I-DATE
were VERB - O
evaluated VERB - O
before ADP - O
and CCONJ - O
after ADP - O
the DET - O
introduction NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
on ADP - O
August NNP - B-DATE
9 CD - I-DATE
, , - I-DATE
2010 CD - I-DATE
. PUNCT - O

A DET - O
quantitative ADJ - O
evaluation NOUN - O
of ADP - O
discussion NOUN - O
levels NOUN - O
across ADP - O
the DET - O
study NOUN - O
period NOUN - O
and CCONJ - O
a DET - O
qualitative ADJ - O
coding NOUN - O
of ADP - O
post ADJ - O
content NOUN - O
for ADP - O
OxyContin NNP - B-MEDICINE
and CCONJ - O
2 CD - B-CARDINAL
comparators NOUN - O
for ADP - O
the DT - B-DATE
26 CD - I-DATE
month NN - I-DATE
period NOUN - O
before ADP - O
and CCONJ - O
after ADP - O
OxyContin NNP - B-MEDICINE
reformulation NOUN - O
were VERB - O
conducted VERB - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
post NOUN - O
content NOUN - O
related VERB - O
to ADP - O
recipes NOUN - O
for ADP - O
defeating NOUN - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
were VERB - O
evaluated VERB - O
from ADP - O
August NNP - B-DATE
9 CD - I-DATE
, , - I-DATE
2010 CD - I-DATE
through ADP - O
September NNP - B-DATE
2013.Over NUM - O
the DET - O
study NOUN - O
period NOUN - O
, PUNCT - O
45,936 CD - B-CARDINAL
posts NOUN - O
related VERB - O
to ADP - O
OxyContin NNP - B-MEDICINE
, PUNCT - O
18,685 CD - B-CARDINAL
to ADP - O
Vicodin NNP - B-ORG
( PUNCT - O
hydrocodone NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
23,863 CD - B-CARDINAL
to ADP - O
Dilaudid NNP - B-ORG
( PUNCT - O
hydromorphone NOUN - O
) PUNCT - O
were VERB - O
identified VERB - O
. PUNCT - O

The DET - O
proportion NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
- PUNCT - O
related VERB - O
posts NOUN - O
fluctuated VERB - O
between ADP - O
6.35 CD - B-CARDINAL
and CCONJ - O
8.25 CD - B-CARDINAL
posts NOUN - O
per ADP - O
1000 CD - B-CARDINAL
posts NOUN - O
before ADP - O
the DET - O
reformulation NOUN - O
, PUNCT - O
increased VERB - O
to ADP - O
10.76 CD - B-CARDINAL
in ADP - O
Q3 NNP - B-DATE
2010 CD - I-DATE
when ADV - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
was VERB - O
introduced VERB - O
, PUNCT - O
and CCONJ - O
decreased VERB - O
from ADP - O
9.14 CD - B-CARDINAL
in ADP - O
Q4 NNP - B-DATE
2010 CD - I-DATE
to ADP - O
3.46 CD - B-CARDINAL
in ADP - O
Q3 PROPN - O
2013 CD - B-DATE
in ADP - O
the DET - O
period NOUN - O
following VERB - O
the DET - O
reformulation NOUN - O
. PUNCT - O

The DET - O
sentiment NOUN - O
profile NOUN - O
for ADP - O
OxyContin NNP - B-MEDICINE
changed VERB - O
following VERB - O
reformulation NOUN - O
; PUNCT - O
the DET - O
post NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
preintroduction NOUN - O
change NOUN - O
in ADP - O
the DET - O
ERo NOUN - O
indicated VERB - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
was VERB - O
discouraged VERB - O
significantly ADV - O
more ADV - O
than ADP - O
the DET - O
original ADJ - O
formulation NOUN - O
( PUNCT - O
ratio NOUN - O
of ADP - O
ERos=0.43 NNP - B-ORG
, PUNCT - O
P<.001 NNP - B-GPE
) PUNCT - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
37 CD - B-CARDINAL
recipes NOUN - O
for ADP - O
circumventing VERB - O
the DET - O
abuse NOUN - O
- PUNCT - O
deterrent ADJ - O
characteristics NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
were VERB - O
observed VERB - O
; PUNCT - O
32 CD - B-CARDINAL
were VERB - O
deemed VERB - O
feasible ADJ - O
( PUNCT - O
ie X - O
, PUNCT - O
able ADJ - O
to PART - O
abuse VERB - O
) PUNCT - O
. PUNCT - O

The DET - O
frequency NOUN - O
of ADP - O
posts NOUN - O
reporting VERB - O
abuse NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
via ADP - O
these DET - O
recipes NOUN - O
was VERB - O
low ADJ - O
and CCONJ - O
decreased VERB - O
over ADP - O
time NOUN - O
. PUNCT - O

Among ADP - O
the DET - O
5677 CD - B-CARDINAL
posts NOUN - O
mentioning VERB - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
, PUNCT - O
825 CD - B-CARDINAL
posts NOUN - O
discussed VERB - O
recipes NOUN - O
and CCONJ - O
498 CD - B-CARDINAL
reported VERB - O
abuse NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
by ADP - O
such ADJ - O
recipes NOUN - O
( PUNCT - O
41 CD - B-CARDINAL
reported VERB - O
injecting VERB - O
and CCONJ - O
128 CD - B-CARDINAL
reported VERB - O
snorting).After PUNCT - O
introduction NOUN - O
of ADP - O
physicochemical ADJ - O
properties NOUN - O
to PART - O
deter VERB - O
abuse NOUN - O
, PUNCT - O
changes NOUN - O
in ADP - O
discussion NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
on ADP - O
forums NOUN - O
occurred VERB - O
reflected VERB - O
by ADP - O
a DET - O
reduction NOUN - O
in ADP - O
discussion NOUN - O
levels NOUN - O
and CCONJ - O
endorsing VERB - O
content NOUN - O
. PUNCT - O

Despite ADP - O
discussion NOUN - O
of ADP - O
recipes NOUN - O
, PUNCT - O
there ADV - O
is VERB - O
a DET - O
relatively ADV - O
small ADJ - O
proportion NOUN - O
of ADP - O
reported VERB - O
abuse NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
via ADP - O
recipes NOUN - O
, PUNCT - O
particularly ADV - O
by ADP - O
injecting VERB - O
or CCONJ - O
snorting VERB - O
routes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DT - B-DATE
past NN - I-DATE
decade NN - I-DATE
, PUNCT - O
OxyContin NNP - B-MEDICINE
diversion NOUN - O
and CCONJ - O
misusehave NOUN - O
been VERB - O
firmly ADV - O
established VERB - O
in ADP - O
Ontarian JJ - B-GPE
public ADJ - O
discourse NOUN - O
as ADP - O
serious ADJ - O
problems NOUN - O
requiring VERB - O
major ADJ - O
intervention NOUN - O
. PUNCT - O

Theanalysis NNP - B-PERSON
refuses VERB - O
the DET - O
impossible ADJ - O
choice NOUN - O
between ADP - O
the DET - O
' PUNCT - O
deserving VERB - O
pain NOUN - O
patient NOUN - O
' PUNCT - O
and CCONJ - O
the DET - O
' PUNCT - O
undeserving ADJ - O
addict NOUN - O
, PUNCT - O
' PUNCT - O
between ADP - O
the DET - O
war NOUN - O
on ADP - O
pain NOUN - O
and CCONJ - O
the DET - O
war NOUN - O
on ADP - O
drugs NOUN - O
, PUNCT - O
and CCONJ - O
between ADP - O
a DET - O
notion NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
as ADP - O
either CCONJ - O
miracle NOUN - O
panacea NOUN - O
or CCONJ - O
destructive ADJ - O
poison NOUN - O
. PUNCT - O

Rather ADV - O
than ADP - O
falling VERB - O
in ADP - O
step NOUN - O
with ADP - O
these DET - O
binaries NOUN - O
, PUNCT - O
OxyContinis NNP - B-PERSON
theorized VERB - O
across ADP - O
them PRON - O
, PUNCT - O
or CCONJ - O
multiply ADV - O
, PUNCT - O
with ADP - O
the DET - O
aim NOUN - O
of ADP - O
moving VERB - O
beyond ADP - O
established VERB - O
moral ADJ - O
and CCONJ - O
theoretical ADJ - O
registers NOUN - O
for ADP - O
exploring VERB - O
embodied VERB - O
consumption NOUN - O
. PUNCT - O

This DET - O
discursive ADJ - O
study NOUN - O
is VERB - O
based VERB - O
on ADP - O
a DET - O
broad ADJ - O
range NOUN - O
of ADP - O
texts NOUN - O
collected VERB - O
between IN - B-DATE
2009 CD - I-DATE
- SYM - I-DATE
2013 CD - I-DATE
: PUNCT - O
Hansard NOUN - O
reports VERB - O
from ADP - O
the DT - B-ORG
Legislative NNP - I-ORG
Assembly NNP - I-ORG
of IN - I-ORG
Ontario NNP - I-ORG
; PUNCT - O
newspaper NOUN - O
, PUNCT - O
magazine NOUN - O
, PUNCT - O
and CCONJ - O
internet NOUN - O
coverage NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
; PUNCT - O
and CCONJ - O
policy NOUN - O
documents NOUN - O
, PUNCT - O
research NOUN - O
reports NOUN - O
, PUNCT - O
and CCONJ - O
position NOUN - O
papers NOUN - O
and CCONJ - O
news NOUN - O
releases NOUN - O
produced VERB - O
by ADP - O
government NOUN - O
agencies NOUN - O
, PUNCT - O
advocacy NOUN - O
organizations NOUN - O
, PUNCT - O
professional ADJ - O
bodies NOUN - O
, PUNCT - O
think VERB - O
tanks NOUN - O
, PUNCT - O
tribal ADJ - O
councils NOUN - O
, PUNCT - O
and CCONJ - O
law NOUN - O
enforcement NOUN - O
agencies NOUN - O
. PUNCT - O

Pharmaceutical NOUN - O
industry NOUN - O
and CCONJ - O
state NOUN - O
actors NOUN - O
have VERB - O
attempted VERB - O
to PART - O
dualistically ADV - O
parse VERB - O
disparate ADJ - O
materializations NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
, PUNCT - O
a DET - O
tactic NOUN - O
that ADJ - O
intensified VERB - O
as ADP - O
media NOUN - O
pressure NOUN - O
helped VERB - O
produce VERB - O
the DET - O
notion NOUN - O
of ADP - O
a DET - O
public ADJ - O
health NOUN - O
crisis NOUN - O
and CCONJ - O
, PUNCT - O
implicitly ADV - O
, PUNCT - O
a DET - O
crisis NOUN - O
of ADP - O
welfare NOUN - O
dependence NOUN - O
. PUNCT - O

Attempts NOUN - O
to PART - O
contain VERB - O
the DET - O
multiplicity NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
result NOUN - O
in ADP - O
the DET - O
further ADJ - O
entrenchment NOUN - O
of ADP - O
privatized ADJ - O
and CCONJ - O
individualized ADJ - O
approaches NOUN - O
to ADP - O
pain VERB - O
and CCONJ - O
painkilling VERB - O
and CCONJ - O
serve VERB - O
to PART - O
undermine VERB - O
rather ADV - O
than ADP - O
secure ADJ - O
public ADJ - O
health NOUN - O
and CCONJ - O
safety NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

OxyContin NNP - B-MEDICINE
in ADP - O
Ontario NNP - B-GPE
: PUNCT - O
the DET - O
multiple ADJ - O
materialities NOUN - O
of ADP - O
prescription NOUN - O
painkillers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
2009 CD - B-DATE
we PRON - O
surveyed VERB - O
400 CD - B-CARDINAL
tribal ADJ - O
members NOUN - O
of ADP - O
a DET - O
midwestern ADJ - O
American JJ - B-NORP
Indian JJ - B-NORP
reservation NOUN - O
to PART - O
assess VERB - O
the DET - O
prevalence NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
use NOUN - O
. PUNCT - O

Thirty CD - B-PERCENT
percent NN - I-PERCENT
of ADP - O
tribal ADJ - O
participants NOUN - O
reported VERB - O
nonmedical ADJ - O
use NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
ever ADV - O
, PUNCT - O
18.9 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DT - B-DATE
past JJ - I-DATE
year NN - I-DATE
, PUNCT - O
and CCONJ - O
13.4 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DT - B-DATE
past JJ - I-DATE
month NN - I-DATE
. PUNCT - O

Participants NOUN - O
aged VERB - O
18 CD - B-DATE
to TO - I-DATE
25 CD - I-DATE
years NNS - I-DATE
were VERB - O
most ADV - O
likely ADJ - O
to PART - O
have VERB - O
used VERB - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

OxyContin NNP - B-MEDICINE
, PUNCT - O
the DET - O
FDA NNP - B-ORG
, PUNCT - O
and CCONJ - O
Drug NNP - B-ORG
Control NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DT - B-DATE
second JJ - I-DATE
half NN - I-DATE
of IN - I-DATE
2010 CD - I-DATE
, PUNCT - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
extended ADJ - O
- PUNCT - O
release NOUN - O
oxycodone NOUN - O
hydrochloride NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
; PUNCT - O
Purdue NNP - B-ORG
Pharma NNP - I-ORG
) PUNCT - O
was VERB - O
introduced VERB - O
and CCONJ - O
propoxyphene NOUN - O
was VERB - O
withdrawn VERB - O
from ADP - O
the DET - O
US NNP - B-GPE
market NOUN - O
. PUNCT - O

Introduction NOUN - O
of ADP - O
abuse NOUN - O
- PUNCT - O
deterrent NOUN - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
resistant ADJ - O
to ADP - O
crushing VERB - O
or CCONJ - O
dissolving VERB - O
) PUNCT - O
on ADP - O
August NNP - B-DATE
9 CD - I-DATE
, , - I-DATE
2010 CD - I-DATE
, PUNCT - O
and CCONJ - O
market NOUN - O
withdrawal NOUN - O
of ADP - O
propoxyphene NOUN - O
on ADP - O
November NNP - B-DATE
19 CD - I-DATE
, , - I-DATE
2010 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
OxyContin NNP - B-MEDICINE
crisis NOUN - O
: PUNCT - O
problematisation NOUN - O
and CCONJ - O
responsibilisation NOUN - O
strategies NOUN - O
in ADP - O
addiction NOUN - O
, PUNCT - O
pain NOUN - O
, PUNCT - O
and CCONJ - O
general ADJ - O
medicine NOUN - O
journals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
pain NOUN - O
medication NOUN - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
hereafter ADV - O
referred VERB - O
to ADP - O
as ADP - O
oxycodone NOUN - O
extended VERB - O
release NOUN - O
) PUNCT - O
has VERB - O
been VERB - O
the DET - O
subject NOUN - O
of ADP - O
sustained ADJ - O
, PUNCT - O
and CCONJ - O
largely ADV - O
negative ADJ - O
, PUNCT - O
media NOUN - O
attention NOUN - O
in ADP - O
recent JJ - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Reformulated NNP - B-PERSON
OxyContin NNP - I-MEDICINE
® . - I-PERSON

This DET - O
noninterventional ADJ - O
single ADJ - O
- PUNCT - O
session NOUN - O
study NOUN - O
asked VERB - O
participants NOUN - O
who NOUN - O
were VERB - O
medically ADV - O
- PUNCT - O
healthy ADJ - O
recreational ADJ - O
opioid ADJ - O
users NOUN - O
, PUNCT - O
aged VERB - O
18 CD - B-DATE
years NNS - I-DATE
and CCONJ - O
older ADJ - O
, PUNCT - O
to PART - O
consider VERB - O
how ADV - O
they PRON - O
would VERB - O
use VERB - O
commonly ADV - O
available ADJ - O
supplies NOUN - O
to PART - O
tamper VERB - O
with ADP - O
placebo NOUN - O
ORF NNP - B-ORG
and CCONJ - O
placebo NOUN - O
original ADJ - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
OC NOUN - O
) PUNCT - O
tablets NOUN - O
, PUNCT - O
and CCONJ - O
how ADV - O
they PRON - O
would VERB - O
assess VERB - O
the DET - O
attractiveness NOUN - O
of ADP - O
tampering VERB - O
and CCONJ - O
abusing VERB - O
ORF NNP - B-ORG
tablets NOUN - O
, PUNCT - O
as ADP - O
compared VERB - O
with ADP - O
other ADJ - O
opioid ADJ - O
formulations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Provinces NOUN - O
/ SYM - O
territories NOUN - O
join VERB - O
together ADV - O
to PART - O
ask VERB - O
the DET - O
federal ADJ - O
government NOUN - O
to PART - O
delay VERB - O
approving VERB - O
generic ADJ - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ontario PROPN - O
pharmacists NOUN - O
concerned ADJ - O
about ADP - O
the DET - O
risks NOUN - O
arising VERB - O
from ADP - O
approval NOUN - O
of ADP - O
generic ADJ - O
OxyContin NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ontario PROPN - O
police NOUN - O
chiefs NOUN - O
call VERB - O
on ADP - O
the DET - O
federal ADJ - O
government NOUN - O
to PART - O
keep VERB - O
generic ADJ - O
OxyContin NNP - B-MEDICINE
out ADP - O
of ADP - O
Canada NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
August NNP - B-DATE
2010 CD - I-DATE
, PUNCT - O
a DET - O
tamper NOUN - O
- PUNCT - O
resistant ADJ - O
formulation NOUN - O
of ADP - O
controlled VERB - O
- PUNCT - O
release NOUN - O
oxycodone NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
- HYPH - I-ORG
OP NNP - I-ORG
) PUNCT - O
was VERB - O
introduced VERB - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
but CCONJ - O
not ADV - O
in ADP - O
Canada NNP - B-GPE
. PUNCT - O

Our ADJ - O
objective NOUN - O
was VERB - O
to PART - O
determine VERB - O
whether ADP - O
introduction NOUN - O
of ADP - O
OxyContin NNP - B-MEDICINE
- HYPH - I-ORG
OP NNP - I-ORG
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
influenced VERB - O
prescription NOUN - O
volumes NOUN - O
for ADP - O
the DET - O
original ADJ - O
controlled VERB - O
- PUNCT - O
release NOUN - O
oxycodone NOUN - O
formulation NOUN - O
( PUNCT - O
OxyContin NNP - B-MEDICINE
) PUNCT - O
at ADP - O
Canadian JJ - B-NORP
pharmacies NOUN - O
near ADP - O
the DET - O
international ADJ - O
border NOUN - O
. PUNCT - O

We PRON - O
analyzed VERB - O
data NOUN - O
on ADP - O
all DET - O
outpatient NOUN - O
prescriptions NOUN - O
for ADP - O
OxyContin NNP - B-MEDICINE
dispensed VERB - O
by ADP - O
Canadian JJ - B-NORP
pharmacies NOUN - O
near ADP - O
each DET - O
border NOUN - O
crossing NOUN - O
between ADP - O
2010 CD - B-DATE
Apr. NNP - I-DATE
1 CD - I-DATE
and CC - I-DATE
2012 CD - I-DATE
Feb. NNP - I-DATE
29 CD - I-DATE
. PUNCT - O

Our ADJ - O
analyses NOUN - O
suggest VERB - O
that ADP - O
242 CD - B-CARDINAL
  SPACE - O
075 NUM - O
excess ADJ - O
OxyContin NNP - B-MEDICINE
tablets NOUN - O
were VERB - O
dispensed VERB - O
near ADP - O
the DT - B-FAC
Detroit NNP - I-FAC
- HYPH - I-FAC
Windsor NNP - I-FAC
Tunnel NNP - I-FAC
between IN - B-DATE
August NNP - I-DATE
2010 CD - I-DATE
and CC - I-DATE
October NNP - I-DATE
2011 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
, PUNCT - O
tolerability NOUN - O
, PUNCT - O
and CCONJ - O
safety NOUN - O
of ADP - O
intranasal NOUN - O
administration NOUN - O
of ADP - O
reformulated VERB - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
® NOUN - O
) PUNCT - O
tablets NOUN - O
compared VERB - O
with ADP - O
original ADJ - O
OxyContin NNP - B-MEDICINE
( PUNCT - O
® NOUN - O
) PUNCT - O
tablets NOUN - O
in ADP - O
healthy ADJ - O
adults NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
case NOUN - O
presented VERB - O
in ADP - O
this DET - O
manuscript NOUN - O
illustrates VERB - O
a DET - O
reconciliation NOUN - O
of ADP - O
an DET - O
opiate ADJ - O
positive ADJ - O
immunoassay NOUN - O
result NOUN - O
in ADP - O
a DET - O
patient NOUN - O
who NOUN - O
was VERB - O
prescribed VERB - O
only ADV - O
OxyContin NNP - B-MEDICINE
and CCONJ - O
Wellbutrin NNP - B-PERSON
after ADP - O
traumatic ADJ - O
amputations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
coagulation NOUN - O
laboratory NOUN - O
monitoring NOUN - O
of ADP - O
AFSTYLA NNP - B-MEDICINE
single ADJ - O
- PUNCT - O
chain NOUN - O
FVIII NN - B-ORG
concentrate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
in ADP - O
this DET - O
study NOUN - O
, PUNCT - O
an DET - O
extensive ADJ - O
work NOUN - O
is VERB - O
conducted VERB - O
to PART - O
investigate VERB - O
the DET - O
impact NOUN - O
of ADP - O
Cu(II)-doping NNP - B-ORG
on ADP - O
the DET - O
susceptibility NOUN - O
of ADP - O
Escherichia NNP - B-PRODUCT
coli ADJ - O
ATCC PROPN - O
10536 NUM - O
against ADP - O
Cu(II)-selective NNP - B-ORG
Cefaclor NNP - I-MEDICINE
- PUNCT - O
silver NOUN - O
nanoconjugates NOUN - O
( PUNCT - O
i.e. X - O
, PUNCT - O
Cf NNP - B-PERSON
- HYPH - I-PERSON
AgNPs NNP - I-PERSON
) PUNCT - O
and CCONJ - O
its ADJ - O
organic ADJ - O
precursor NOUN - O
( PUNCT - O
i.e. X - O
Cefaclor NNP - B-MEDICINE
) PUNCT - O
. PUNCT - O

At ADP - O
first RB - B-ORDINAL
, PUNCT - O
the DET - O
maximal ADJ - O
non ADJ - O
- ADJ - O
cytotoxic ADJ - O
dose NOUN - O
of ADP - O
Cu(II PROPN - O
) PUNCT - O
that ADJ - O
was VERB - O
sub NOUN - O
- PUNCT - O
lethal ADJ - O
for ADP - O
Escherichia NNP - B-ORG
coli ADJ - O
was VERB - O
determined VERB - O
by ADP - O
MTT NNP - B-ORG
assay NOUN - O
and CCONJ - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
100 CD - B-MONEY
  _SP - I-MONEY
μg PROPN - O
/ SYM - O
L. PROPN - O
Afterwards PROPN - O
, PUNCT - O
MICs NOUN - O
of ADP - O
Cf NNP - B-ORG
- HYPH - I-ORG
AgNPs NNP - I-ORG
and CC - I-ORG
Cefaclor NNP - I-MEDICINE
against ADP - O
controlled VERB - O
and CCONJ - O
Cu(II)-doped NNP - B-ORG
E. NNP - I-ORG
coli ADJ - O
cells NOUN - O
were VERB - O
determined VERB - O
by ADP - O
using VERB - O
Agar NNP - B-ORG
well NOUN - O
diffusion NOUN - O
method NOUN - O
. PUNCT - O

The DET - O
susceptibility NOUN - O
of ADP - O
E. PROPN - O
coli ADJ - O
cells NOUN - O
against ADP - O
Cf NNP - B-PERSON
- HYPH - I-PERSON
AgNPs NNP - I-PERSON
was VERB - O
increased VERB - O
upon ADP - O
Cu(II PROPN - O
) PUNCT - O
doping VERB - O
, PUNCT - O
whereas ADP - O
the DET - O
bactericidal ADJ - O
activity NOUN - O
of ADP - O
Cefaclor NNP - B-MEDICINE
against ADP - O
Cu(II)-doped NNP - B-ORG
E. NNP - I-ORG
coli ADJ - O
cells NOUN - O
was VERB - O
retarded VERB - O
due ADP - O
to ADP - O
hydrolysis NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
morphological ADJ - O
changes NOUN - O
induced VERB - O
in ADP - O
controlled VERB - O
and CCONJ - O
Cu(II)-doped NNP - B-PERSON
samples NOUN - O
of ADP - O
E. PROPN - O
coli ADJ - O
after ADP - O
treatment NOUN - O
with ADP - O
Cefaclor NNP - B-MEDICINE
and CCONJ - O
Cf PROPN - O
- PUNCT - O
AgNPs PROPN - O
were VERB - O
also ADV - O
monitored VERB - O
by ADP - O
Atomic NNP - B-NORP
force NOUN - O
microscopy NOUN - O
( PUNCT - O
AFM NNP - B-ORG
) PUNCT - O
. PUNCT - O

Indeed ADV - O
, PUNCT - O
further ADJ - O
clinical ADJ - O
studies NOUN - O
are VERB - O
necessary ADJ - O
to PART - O
determine VERB - O
the DET - O
relevant ADJ - O
role NOUN - O
of ADP - O
Cf NNP - B-PERSON
- HYPH - I-PERSON
AgNPs NNP - I-PERSON
compared VERB - O
with ADP - O
that DET - O
of ADP - O
the DET - O
Cefaclor NNP - B-MEDICINE
now ADV - O
available ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

HPLC VERB - O
method NOUN - O
development NOUN - O
and CCONJ - O
validation NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
Cefaclor NNP - B-MEDICINE
in ADP - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NNP - B-GPE
( PUNCT - O
19.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Azithromycin NNP - B-ORG
( PUNCT - O
14.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
the DET - O
combination NOUN - O
of ADP - O
Amoxicillin NNP - B-GPE
and CCONJ - O
Clavulanic NNP - B-ORG
acid NOUN - O
( PUNCT - O
13.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
Cefaclor NNP - B-MEDICINE
( PUNCT - O
11.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
the DET - O
most ADV - O
commonly ADV - O
prescribed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Cefaclor NNP - B-MEDICINE
reduced VERB - O
Cu2 PROPN - O
+ CCONJ - O
to ADP - O
Cu1 PROPN - O
+ CCONJ - O
that DET - O
further ADV - O
reacted VERB - O
with ADP - O
molecular ADJ - O
oxygen NOUN - O
to PART - O
produce VERB - O
hydrogen NOUN - O
peroxide NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cefaclor NNP - B-MEDICINE
is VERB - O
widely ADV - O
prescribed VERB - O
for ADP - O
various ADJ - O
infectious ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AN DET - O
ANTIFUNGAL PROPN - O
CREAM ADJ - O
COMPRISING NOUN - O
TERBINAFINE VBD - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

NAIL NNP - B-PERSON
CARE PROPN - O
PREPARATIONS NOUN - O
CONTAINING PROPN - O
TERBINAFINE NN - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

HIGH ADJ - O
CONTENT PROPN - O
TERBINAFINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
TABLET NOUN - O
AND CCONJ - O
METHOD NOUN - O
FOR ADP - O
PRODUCING VERB - O

-DOCSTART- -X- - O

: PUNCT - O
Focus NOUN - O
on ADP - O
Lorazepam NNP - B-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Cancer NNP - I-ORG
Biomarker NNP - I-ORG
Changes NNP - I-ORG
in ADP - O
Overweight PROPN - O
Individuals PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lorazepam NNP - B-MEDICINE
is VERB - O
a DET - O
benzodiazepine ADJ - O
derivative ADJ - O
that ADJ - O
is VERB - O
globally ADV - O
used VERB - O
for ADP - O
the DET - O
therapy NOUN - O
of ADP - O
anxiety NOUN - O
and CCONJ - O
insomnia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lorazepam JJ - B-MEDICINE
and CCONJ - O
electroconvulsive ADJ - O
therapy NOUN - O
( PUNCT - O
ECT NNP - B-ORG
) PUNCT - O
are VERB - O
effective ADJ - O
treatments NOUN - O
for ADP - O
catatonia NOUN - O
. PUNCT - O

Lorazepam NNP - B-MEDICINE
and/or CCONJ - O
ECT NNP - B-ORG
were VERB - O
used VERB - O
in ADP - O
the DET - O
patients NOUN - O
' PART - O
treatment NOUN - O
schedule NOUN - O
. PUNCT - O

Lorazepam NNP - B-MEDICINE
is VERB - O
a DET - O
reasonable ADJ - O
initial ADJ - O
choice NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
catatonia NOUN - O
, PUNCT - O
with ADP - O
rapid ADJ - O
consideration NOUN - O
for ADP - O
ECT NNP - B-ORG
if ADP - O
there ADV - O
is VERB - O
no DET - O
rapid ADJ - O
response NOUN - O
to ADP - O
lorazepam NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Population NOUN - O
Pharmacokinetic/ NOUN - O
Pharmacodynamic NNP - B-PERSON
Modelling NNP - I-PERSON
of ADP - O
Auditory NNP - B-PERSON
- PUNCT - O
Evoked PROPN - O
Event NOUN - O
- PUNCT - O
Related VERB - O
Potentials PROPN - O
with ADP - O
Lorazepam NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Case PROPN - O
Report PROPN - O
of ADP - O
Intramuscular PROPN - O
Lorazepam NNP - B-MEDICINE
in ADP - O
Catatonia NNP - B-GPE
of ADP - O
a DET - O
Parkinson PROPN - O
's PART - O
Disease NNP - B-ORG
Patient NNP - I-ORG
after ADP - O
Deep PROPN - O
Brain PROPN - O
Stimulation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Lorazepam NNP - B-MEDICINE
With IN - I-PERSON
Haloperidol NNP - I-PERSON
vs IN - I-PERSON
Haloperidol NNP - I-PERSON
Alone RB - I-PERSON
on ADP - O
Agitated PROPN - O
Delirium PROPN - O
in ADP - O
Patients NOUN - O
With ADP - O
Advanced PROPN - O
Cancer PROPN - O
Receiving VERB - O
Palliative PROPN - O
Care NOUN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Clinical PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetics NNPS - I-ORG
and CCONJ - O
Exploratory NNP - B-ORG
Pharmacodynamics NNPS - I-ORG
of IN - I-ORG
Lorazepam NNP - I-MEDICINE
in IN - I-ORG
Pediatric PROPN - O
Status PROPN - O
Epilepticus PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Response PROPN - O
of ADP - O
Catatonia PROPN - O
to ADP - O
Amisulpride PROPN - O
and CCONJ - O
Lorazepam NNP - B-MEDICINE
in ADP - O
an DET - O
Adolescent PROPN - O
with ADP - O
Schizophenia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Intramuscular PROPN - O
Midazolam PROPN - O
and CCONJ - O
Lorazepam NNP - B-MEDICINE
on IN - I-ORG
Acute NNP - I-ORG
Agitation NNP - I-ORG
in ADP - O
Non PROPN - O
- ADJ - O
Elderly ADJ - O
Subjects NOUN - O
- PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Implication NOUN - O
of ADP - O
UGT2B15 PROPN - O
Genotype PROPN - O
Polymorphism PROPN - O
on ADP - O
Postoperative PROPN - O
Anxiety PROPN - O
Levels PROPN - O
in ADP - O
Patients NNP - B-ORG
Receiving VBG - I-ORG
Lorazepam NNP - I-MEDICINE
Premedication NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Placebo PROPN - O
vs ADP - O
Amoxicillin NNP - B-MEDICINE
for ADP - O
Nonsevere PROPN - O
Fast PROPN - O
- PUNCT - O
Breathing PROPN - O
Pneumonia PROPN - O
in ADP - O
Malawian NNP - B-NORP
Children PROPN - O

-DOCSTART- -X- - O

Amoxicillin NN - B-MEDICINE
and CCONJ - O
tylosin NOUN - O
were VERB - O
selected VERB - O
as ADP - O
prototype NOUN - O
hydrophilic ADJ - O
and CCONJ - O
lipophilic ADJ - O
drugs NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Amoxicillin NNP - B-MEDICINE
accumulated VERB - O
more ADV - O
in ADP - O
skim VERB - O
milk NOUN - O
than ADP - O
in ADP - O
cream NOUN - O
and CCONJ - O
casein NOUN - O
, PUNCT - O
both DET - O
in ADP - O
vitro NOUN - O
( PUNCT - O
92 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
in ADP - O
vivo NOUN - O
( PUNCT - O
73 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
skim VERB - O
milk NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
whole ADJ - O
milk NOUN - O
ratio NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NN - B-MEDICINE
/ SYM - O
clavulanic ADJ - O
acid+aminoglycoside ADV - O
as ADP - O
empirical ADJ - O
antibiotic ADJ - O
treatment NOUN - O
in ADP - O
severe ADJ - O
community NOUN - O
- PUNCT - O
acquired VERB - O
infections NOUN - O
with ADP - O
diagnostic ADJ - O
uncertainty NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Azithromycin PROPN - O
, PUNCT - O
the DET - O
combination NOUN - O
of ADP - O
Amoxicillin NNP - B-MEDICINE
and CCONJ - O
Metronidazole NNP - B-GPE
, PUNCT - O
and CCONJ - O
Amoxicillin NNP - B-MEDICINE
were VERB - O
the DET - O
three CD - B-CARDINAL
most ADV - O
commonly ADV - O
prescribed VERB - O
systemic ADJ - O
antibiotics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Morphological ADJ - O
, PUNCT - O
Release PROPN - O
and CCONJ - O
Antibacterial NNP - B-ORG
Performances NNP - I-ORG
of ADP - O
Amoxicillin NNP - B-MEDICINE
- PUNCT - O
Loaded VERB - O
Cellulose PROPN - O
Aerogels PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NNP - B-MEDICINE
was VERB - O
the DET - O
commonest ADV - O
used VERB - O
index NOUN - O
drug NOUN - O
( PUNCT - O
65.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Comprising VERB - O
Low PROPN - O
- PUNCT - O
Dose PROPN - O
Rabeprazole PROPN - O
, PUNCT - O
Bismuth NNP - B-GPE
, PUNCT - O
Amoxicillin NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Tetracycline NNP - B-PERSON
Is VERB - O
an DET - O
Effective ADJ - O
and CCONJ - O
Safe ADJ - O
First PROPN - O
- PUNCT - O
Line PROPN - O
Treatment PROPN - O
for ADP - O
Helicobacter PROPN - O
pylori NOUN - O
Infection PROPN - O
in ADP - O
a DET - O
Population PROPN - O
with ADP - O
High PROPN - O
Antibiotic PROPN - O
Resistance PROPN - O
: PUNCT - O
a DET - O
Prospective NNP - B-NORP
, PUNCT - O
Multicenter PROPN - O
, PUNCT - O
Randomized VERB - O
, PUNCT - O
Parallel PROPN - O
- PUNCT - O
Controlled VERB - O
Clinical PROPN - O
Trial PROPN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NN - B-MEDICINE
- PUNCT - O
clavulanate NOUN - O
versus ADP - O
azithromycin ADJ - O
for ADP - O
respiratory ADJ - O
exacerbations NOUN - O
in ADP - O
children NOUN - O
with ADP - O
bronchiectasis NOUN - O
( PUNCT - O
BEST-2 NNP - B-ORG
) PUNCT - O
: PUNCT - O
a DET - O
multicentre ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
non ADJ - O
- ADJ - O
inferiority ADJ - O
, PUNCT - O
randomised VERB - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NNP - B-MEDICINE
is VERB - O
expected VERB - O
to PART - O
pose VERB - O
adverse ADJ - O
effects NOUN - O
for ADP - O
cyanobacteria NOUN - O
, PUNCT - O
whereas ADP - O
metformin NOUN - O
and CCONJ - O
ibuprofen VERB - O
pose VERB - O
a DET - O
small ADJ - O
potential NOUN - O
for ADP - O
adverse ADJ - O
effects NOUN - O
to ADP - O
invertebrates NOUN - O
and CCONJ - O
fish NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NNP - B-MEDICINE
or CCONJ - O
ASP NNP - B-ORG
( PUNCT - O
20 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
from ADP - O
different ADJ - O
concentrations NOUN - O
of ADP - O
sanitizers NOUN - O
was VERB - O
directly ADV - O
placed VERB - O
into ADP - O
the DET - O
chicken NOUN - O
's PART - O
crop NOUN - O
and CCONJ - O
blood NOUN - O
samples NOUN - O
were VERB - O
taken VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Amoxicillin NN - B-MEDICINE
and CCONJ - O
fosfomycin NOUN - O
may VERB - O
sensitize VERB - O
the DET - O
uterus NOUN - O
to ADP - O
oxytocin NOUN - O
via ADP - O
the DET - O
reduction NOUN - O
of ADP - O
AQP5 PROPN - O
expression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Tolerability NNP - B-ORG
of IN - I-ORG
Two CD - I-ORG
Quadruple NNPS - I-ORG
Regimens NNS - I-ORG
: : - I-ORG
Bismuth NNP - I-ORG
, PUNCT - O
Omeprazole NNP - B-ORG
, PUNCT - O
Metronidazole NNP - B-PRODUCT
with ADP - O
Amoxicillin NNP - B-MEDICINE
or CCONJ - O
Tetracycline NNP - B-GPE
as ADP - O
First PROPN - O
- PUNCT - O
Line PROPN - O
Treatment PROPN - O
for ADP - O
Eradication PROPN - O
of ADP - O
Helicobacter PROPN - O
Pylori PROPN - O
in ADP - O
Patients NNPS - B-GPE
with ADP - O
Duodenal PROPN - O
Ulcer PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Compilation NOUN - O
of ADP - O
a DET - O
Near PROPN - O
- PUNCT - O
Infrared PROPN - O
Library PROPN - O
for ADP - O
Construction PROPN - O
of ADP - O
Quantitative PROPN - O
Models PROPN - O
of ADP - O
Oral PROPN - O
Dosage PROPN - O
Forms PROPN - O
for ADP - O
Amoxicillin NNP - B-MEDICINE
and CCONJ - O
Potassium PROPN - O
Clavulanate PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Infantile PROPN - O
Acute PROPN - O
Conjunctivitis PROPN - O
Induced VERB - O
by ADP - O
β DET - O
- PUNCT - O
Lactamase PROPN - O
- PUNCT - O
Positive PROPN - O
Amoxicillin NNP - B-MEDICINE
- PUNCT - O
Clavulanate PROPN - O
- PUNCT - O
Resistant PROPN - O
Strain PROPN - O
of ADP - O
Haemophilus NNP - B-ORG
influenzae NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
Clinical PROPN - O
Practice PROPN - O
Guideline PROPN - O
for ADP - O
the DET - O
Management PROPN - O
of ADP - O
Patients PROPN - O
With ADP - O
Acute PROPN - O
Spinal PROPN - O
Cord PROPN - O
Injury PROPN - O
: PUNCT - O
Recommendations NOUN - O
on ADP - O
the DET - O
Use PROPN - O
of ADP - O
Methylprednisolone NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Succinate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
effects NOUN - O
and CCONJ - O
apoptosis NOUN - O
of ADP - O
intrathecal ADJ - O
injection NOUN - O
of ADP - O
Methylprednisolone NNP - B-FAC
Sodium NNP - I-FAC
Succinate NNP - I-FAC
( PUNCT - O
MPss NNP - B-ORG
) PUNCT - O
for ADP - O
acute ADJ - O
spinal ADJ - O
cord NOUN - O
injury NOUN - O
( PUNCT - O
SCI NNP - B-ORG
) PUNCT - O
in ADP - O
New NNP - B-GPE
Zealand NNP - I-GPE
rabbits NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
clinical ADJ - O
outcomes NOUN - O
of ADP - O
local ADJ - O
application NOUN - O
of ADP - O
corticosteroids NOUN - O
combined VERB - O
with ADP - O
surgery NOUN - O
for ADP - O
CSH.We NNP - B-ORG
retrospectively ADV - O
analysed VERB - O
the DET - O
data NOUN - O
of ADP - O
the DET - O
patients NOUN - O
undergoing VERB - O
surgery NOUN - O
and CCONJ - O
local ADJ - O
application NOUN - O
of ADP - O
Methylprednisolone NNP - B-FAC
Sodium NNP - I-FAC
Succinate NNP - I-FAC
for IN - I-FAC
Injection NNP - I-FAC
( PUNCT - O
MPSS NNP - B-ORG
) PUNCT - O
into ADP - O
the DET - O
hematoma NOUN - O
cavity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
was VERB - O
detected VERB - O
in ADP - O
all ADJ - O
the DET - O
samples NOUN - O
at ADP - O
all DET - O
times NOUN - O
in ADP - O
all ADJ - O
the DET - O
groups NOUN - O
in ADP - O
which ADJ - O
topical ADJ - O
metronidazole NN - B-MEDICINE
was VERB - O
applied VERB - O
to ADP - O
the DET - O
wounds NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
is VERB - O
a DET - O
nitroimidazole ADJ - O
antibacterial ADJ - O
agent NOUN - O
that ADJ - O
is VERB - O
highly ADV - O
effective ADJ - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
protozoal ADJ - O
and CCONJ - O
anaerobic ADJ - O
infections NOUN - O
. PUNCT - O

Metronidazole NN - B-MEDICINE
is VERB - O
known VERB - O
to PART - O
cause VERB - O
hematologic ADJ - O
adverse ADJ - O
effects NOUN - O
, PUNCT - O
including VERB - O
a DET - O
reversible ADJ - O
mild ADJ - O
neutropenia NOUN - O
; PUNCT - O
in ADP - O
rare ADJ - O
circumstances NOUN - O
, PUNCT - O
thrombocytopenia NOUN - O
has VERB - O
been VERB - O
associated VERB - O
with ADP - O
metronidazole JJ - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Case NOUN - O
of ADP - O
Aplastic PROPN - O
Anemia PROPN - O
Associated VERB - O
With ADP - O
Long PROPN - O
- PUNCT - O
Term PROPN - O
Metronidazole NNP - B-MEDICINE
Use PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NN - B-MEDICINE
may VERB - O
still ADV - O
be VERB - O
an DET - O
appropriate ADJ - O
therapeutic ADJ - O
option NOUN - O
for ADP - O
mild ADJ - O
Clostridium NNP - B-ORG
difficile ADJ - O
infection NOUN - O
( PUNCT - O
CDI PROPN - O
) PUNCT - O
in ADP - O
select ADJ - O
patients NOUN - O
, PUNCT - O
but CCONJ - O
data NOUN - O
is VERB - O
limited VERB - O
to PART - O
guide VERB - O
clinicians NOUN - O
in ADP - O
identifying VERB - O
these DET - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
, PUNCT - O
a DET - O
commonly ADV - O
used VERB - O
antibiotic ADJ - O
drug NOUN - O
, PUNCT - O
can VERB - O
cause VERB - O
adverse ADJ - O
effects NOUN - O
in ADP - O
the DET - O
central ADJ - O
nervous ADJ - O
system NOUN - O
termed VERB - O
metronidazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
encephalopathy ADJ - O
, PUNCT - O
leading VERB - O
to ADP - O
diagnostic ADJ - O
challenges NOUN - O
. PUNCT - O

Metronidazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
encephalopathy NOUN - O
should VERB - O
be VERB - O
considered VERB - O
in ADP - O
patients NOUN - O
presenting VERB - O
with ADP - O
neurological ADJ - O
symptoms NOUN - O
in ADP - O
relation NOUN - O
to ADP - O
newly ADV - O
initiated VERB - O
or CCONJ - O
prolonged VERB - O
metronidazole JJ - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
Paste PROPN - O
Containing PROPN - O
Gentamicin PROPN - O
, PUNCT - O
Amoxicillin NNP - B-GPE
and CCONJ - O
Metronidazole NNP - B-MEDICINE
in ADP - O
Endodontic NNP - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Primary NNP - I-ORG
Molars NNPS - I-ORG
in ADP - O
Vivo NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
- PUNCT - O
Resistant NOUN - O
Trichomoniasis NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Metronidazole JJ - B-MEDICINE
treatment NOUN - O
in ADP - O
the DET - O
experimental ADJ - O
model NOUN - O
showed VERB - O
an DET - O
increase NOUN - O
in ADP - O
LPO NNP - B-ORG
, PUNCT - O
TOS NNP - B-ORG
, PUNCT - O
and CCONJ - O
TOS NNP - B-ORG
/ SYM - I-ORG
TAS NNP - I-ORG
and CCONJ - O
a DET - O
decrease NOUN - O
in ADP - O
CAT NNP - B-ORG
, PUNCT - O
SOD NNP - B-ORG
, PUNCT - O
GPx NOUN - O
, PUNCT - O
and CCONJ - O
TAS NNP - B-ORG
. PUNCT - O

Metronidazole JJ - B-MEDICINE
treatment NOUN - O
in ADP - O
a DET - O
dose NOUN - O
of ADP - O
100 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Metronidazole NNP - B-MEDICINE
on ADP - O
the DET - O
Oxidoreductive PROPN - O
Processes PROPN - O
in ADP - O
the DET - O
Submandibular PROPN - O
and CCONJ - O
Parotid NNP - B-GPE
Glands NNPS - I-GPE
in ADP - O
Experimental NNP - B-ORG
Research NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole JJ - B-MEDICINE
resistance NOUN - O
and CCONJ - O
nim NOUN - O
genes NOUN - O
in ADP - O
anaerobes NOUN - O
: PUNCT - O
A DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
in ADP - O
SPF NNP - B-ORG
mice NOUN - O
also ADV - O
upregulates VERB - O
skeletal ADJ - O
muscle NOUN - O
FoxO3 PROPN - O
, PUNCT - O
described VERB - O
as ADP - O
involved VERB - O
in ADP - O
apoptosis NOUN - O
and CCONJ - O
muscle NOUN - O
regeneration NOUN - O
. PUNCT - O

Metronidazole NN - B-MEDICINE
in ADP - O
germ NOUN - O
- PUNCT - O
free ADJ - O
( PUNCT - O
GF NOUN - O
) PUNCT - O
mice NOUN - O
increases VERB - O
the DET - O
expression NOUN - O
of ADP - O
other ADJ - O
core NOUN - O
clock NOUN - O
genes NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
Bmal1 NNP - B-ORG
and CCONJ - O
Per2 NNP - B-ORG
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
metabolic NOUN - O
regulators VERB - O
FoxO1 PROPN - O
and CCONJ - O
Pdk4 NNP - B-GPE
, PUNCT - O
suggesting VERB - O
a DET - O
microbiota ADJ - O
- PUNCT - O
independent ADJ - O
pharmacologic ADJ - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
( PUNCT - O
MTZ PROPN - O
) PUNCT - O
is VERB - O
the DET - O
current ADJ - O
drug NOUN - O
of ADP - O
choice NOUN - O
for ADP - O
amebiasis NOUN - O
, PUNCT - O
giardiasis NOUN - O
, PUNCT - O
and CCONJ - O
trichomoniasis NOUN - O

-DOCSTART- -X- - O

The DT - B-ORG
Role NNP - I-ORG
of IN - I-ORG
Iron NNP - I-ORG
Status NNP - I-ORG
in ADP - O
the DT - B-LOC
Early NNP - I-LOC
Progression NNP - I-LOC
of IN - I-LOC
Metronidazole NNP - I-MEDICINE
Resistance NNP - I-LOC
in ADP - O
Trichomonas NNP - B-GPE
vaginalis NOUN - O
Under ADP - O
Microaerophilic PROPN - O
Conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Role PROPN - O
of ADP - O
Metronidazole NNP - B-MEDICINE
in ADP - O
Mild PROPN - O
Clostridium PROPN - O
difficile ADV - O
Infections PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
the DET - O
Antimicrobial PROPN - O
In ADP - O
Vitro PROPN - O
Efficacy PROPN - O
of ADP - O
Amoxicillin NNP - B-ORG
/ SYM - I-ORG
Metronidazole NNP - I-MEDICINE
against ADP - O
Azithromycin NNP - B-ORG
- HYPH - I-ORG
A NNP - I-ORG
Systematic NNP - I-ORG
Review NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Metronidazole NNP - B-MEDICINE
as ADP - O
a DET - O
monotherapy NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
granulomatous ADJ - O
cheilitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Two NNP - I-ORG
Doses NNPS - I-ORG
of IN - I-ORG
Ropivacaine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
for ADP - O
Lumbosacral PROPN - O
Epidural PROPN - O
Anaesthesia PROPN - O
in ADP - O
Goats PROPN - O

-DOCSTART- -X- - O

Argatroban NNP - B-MEDICINE
may VERB - O
have VERB - O
a DET - O
more ADV - O
significant ADJ - O
platelet NOUN - O
- PUNCT - O
preserving VERB - O
effect NOUN - O
than ADP - O
UFH PROPN - O
, PUNCT - O
regardless ADV - O
of ADP - O
whether ADP - O
HIT PROPN - O
is VERB - O
present ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Argatroban NN - B-MEDICINE
is VERB - O
a DET - O
direct ADJ - O
thrombin NOUN - O
inhibitor NOUN - O
used VERB - O
as ADP - O
an DET - O
anticoagulant NOUN - O
for ADP - O
patients NOUN - O
who NOUN - O
have VERB - O
Heparin RB - B-LOC
induced VERB - O
thrombocytopenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
chemistry NOUN - O
is VERB - O
applied VERB - O
to ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
the DET - O
hygric ADJ - O
acid NOUN - O
moiety NOUN - O
of ADP - O
lincomycin NOUN - O
and CCONJ - O
the DET - O
pipecolic NOUN - O
acid NOUN - O
moiety NOUN - O
of ADP - O
Argatroban NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Argatroban JJ - B-MEDICINE
reversal NOUN - O
was VERB - O
performed VERB - O
with ADP - O
prothrombin NOUN - O
complex ADJ - O
concentrate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Response NOUN - O
by ADP - O
Barreto NNP - B-GPE
and CCONJ - O
Grotta NNP - B-PERSON
to ADP - O
Letter PROPN - O
Regarding VERB - O
Article PROPN - O
, PUNCT - O
" PUNCT - O
Randomized VBN - B-WORK_OF_ART
, , - I-WORK_OF_ART
Multicenter NNP - I-WORK_OF_ART
Trial NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
ARTSS-2 NNP - I-WORK_OF_ART
( -LRB- - I-WORK_OF_ART
Argatroban NNP - I-MEDICINE
With IN - I-WORK_OF_ART
Recombinant NNP - I-WORK_OF_ART
Tissue NNP - I-WORK_OF_ART
Plasminogen NNP - I-WORK_OF_ART
Activator NNP - I-WORK_OF_ART
for IN - I-WORK_OF_ART
Acute NNP - I-WORK_OF_ART
Stroke NNP - I-WORK_OF_ART
) PUNCT - O
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Whilst PROPN - O
vitamin NOUN - O
K NOUN - O
antagonists NOUN - O
are VERB - O
not ADV - O
appropriate ADJ - O
, PUNCT - O
anticoagulant ADJ - O
options NOUN - O
include VERB - O
Fondaparinux NNP - B-ORG
, , - I-ORG
Sodium NNP - I-ORG
Danaparoid NNP - I-ORG
, PUNCT - O
DOACs PROPN - O
, PUNCT - O
Argatroban NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Bivalirudin NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

More ADJ - O
on ADP - O
the DT - B-ORG
Limitations NNPS - I-ORG
of IN - I-ORG
the DT - I-ORG
Activated NNP - I-ORG
Partial NNP - I-ORG
Thromboplastin NNP - I-ORG
Time NNP - I-ORG
for IN - I-ORG
Monitoring NNP - I-ORG
Argatroban NNP - I-MEDICINE
Therapy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Response NOUN - O
to ADP - O
: PUNCT - O
" PUNCT - O
More ADJ - O
on ADP - O
the DET - O
Limitations PROPN - O
of ADP - O
the DET - O
aPTT NOUN - O
for ADP - O
Monitoring NNP - B-ORG
Argatroban NNP - I-MEDICINE
Therapy NNP - I-ORG
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Argatroban NNP - B-MEDICINE
in ADP - O
Thrombocytopenic JJ - B-ORG
Patients NNPS - I-ORG
Sensitized VBD - I-ORG
to ADP - O
Circulating PROPN - O
Protamine PROPN - O
- PUNCT - O
Heparin PROPN - O
Complexes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
Anticoagulation PROPN - O
Using VERB - O
Argatroban NNP - B-MEDICINE
During ADP - O
Transcatheter NNP - B-ORG
Aortic NNP - I-ORG
Valve NNP - I-ORG
Implantation NNP - I-ORG
in ADP - O
a DET - O
Patient NOUN - O
With ADP - O
Heparin PROPN - O
- PUNCT - O
Induced PROPN - O
Thrombocytopenia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Dabigatran PROPN - O
and CCONJ - O
Argatroban NNP - B-MEDICINE
Diametrically ADV - O
Modulate ADJ - O
Thrombin NOUN - O
Exosite PROPN - O
Function PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Argatroban NNP - B-MEDICINE
( PUNCT - O
ARGA NNP - B-ORG
) PUNCT - O
, PUNCT - O
used VERB - O
as ADP - O
intravenous ADJ - O
anticoagulant ADJ - O
drug NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
photodegrade VERB - O
under ADP - O
light ADJ - O
exposure NOUN - O
, PUNCT - O
requiring VERB - O
specific ADJ - O
precautions NOUN - O
at ADP - O
handling NOUN - O
, PUNCT - O
storage NOUN - O
and CCONJ - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Argatroban JJ - B-MEDICINE
infusion NOUN - O
was VERB - O
started VERB - O
at ADP - O
0.5 CD - B-CARDINAL
µg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
minute NOUN - O
, PUNCT - O
and CCONJ - O
adjusted VERB - O
in ADP - O
0.1 CD - B-CARDINAL
- SYM - O
0.25 NUM - O
µg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
minute NOUN - O
increments NOUN - O
when ADV - O
the DET - O
activated VERB - O
partial ADJ - O
thromboplastin NOUN - O
time NOUN - O
( PUNCT - O
aPTT NOUN - O
) PUNCT - O
was VERB - O
not ADV - O
within ADP - O
the DET - O
target NOUN - O
range NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Argatroban JJ - B-MEDICINE
hydrate NOUN - O
was VERB - O
being VERB - O
used VERB - O
during ADP - O
dialysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Challenging NNP - B-ORG
Argatroban NNP - I-MEDICINE
Management NNP - I-ORG
of ADP - O
a DET - O
Child PROPN - O
on ADP - O
Extracorporeal PROPN - O
Support PROPN - O
and CCONJ - O
Subsequent PROPN - O
Heart PROPN - O
Transplant PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Minimal PROPN - O
Prolongation PROPN - O
of ADP - O
Prothrombin PROPN - O
Time PROPN - O
with ADP - O
Extended ADJ - O
Exposure NOUN - O
to ADP - O
Argatroban NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
causing VERB - O
acute ADJ - O
liver NOUN - O
failure NOUN - O
complicating VERB - O
post ADJ - O
- ADJ - O
operative ADJ - O
management NOUN - O
in ADP - O
a DET - O
neurosurgical ADJ - O
patient NOUN - O

-DOCSTART- -X- - O

BACKGROUND::Levetiracetam NN - B-ORG
is VERB - O
prescribed VERB - O
for ADP - O
a DET - O
broad ADJ - O
spectrum NOUN - O
of ADP - O
seizure NOUN - O
types NOUN - O
but CCONJ - O
does VERB - O
not ADV - O
have VERB - O
a DET - O
specific ADJ - O
indication NOUN - O
for ADP - O
absence NOUN - O
epilepsy NOUN - O
. PUNCT - O

RESULTS::Levetiracetam NN - B-CARDINAL
was VERB - O
discontinued VERB - O
in ADP - O
74 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n NOUN - O
= SYM - O
53/72 CD - B-CARDINAL
) PUNCT - O
because ADP - O
of ADP - O
incomplete ADJ - O
seizure NOUN - O
control NOUN - O
( PUNCT - O
59 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
n NOUN - O
= SYM - O
35/72 CD - B-CARDINAL
) PUNCT - O
and/or CCONJ - O
intolerable ADJ - O
side NOUN - O
effects NOUN - O
( PUNCT - O
41 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
n CCONJ - O
= SYM - O
24/72 CD - B-CARDINAL
) PUNCT - O
after ADP - O
a DET - O
median ADJ - O
8.5 CD - B-DATE
months NNS - I-DATE
( PUNCT - O
interquartile ADJ - O
range NOUN - O
2 CD - B-CARDINAL
, PUNCT - O
17 CD - B-DATE
months NNS - I-DATE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical ADJ - O
Use PROPN - O
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Levetiracetam NNP - B-MEDICINE
for ADP - O
Absence PROPN - O
Epilepsies PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
use NOUN - O
was VERB - O
not ADV - O
significantly ADV - O
associated VERB - O
with ADP - O
a DET - O
higher ADJ - O
risk NOUN - O
of ADP - O
AKI NNP - B-ORG
within ADP - O
30 CD - B-DATE
days NNS - I-DATE
( PUNCT - O
13 CD - B-CARDINAL
[ PUNCT - O
0.33 CD - B-PERCENT
% NN - I-PERCENT
] PUNCT - O
events NOUN - O
in ADP - O
levetiracetam NN - B-MEDICINE
users NOUN - O
and CCONJ - O
21 CD - B-CARDINAL
[ PUNCT - O
0.26 CD - B-PERCENT
% NN - I-PERCENT
] PUNCT - O
events NOUN - O
in ADP - O
nonusers NOUN - O
[ PUNCT - O
odds NOUN - O
ratio NOUN - O
, PUNCT - O
1.24 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
0.62 CD - B-CARDINAL
to ADP - O
2.47 CD - B-CARDINAL
] PUNCT - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Population NOUN - O
- PUNCT - O
Based VERB - O
Study PROPN - O
of ADP - O
Risk PROPN - O
of ADP - O
AKI PROPN - O
with ADP - O
Levetiracetam NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NNP - B-MEDICINE
has VERB - O
been VERB - O
introduced VERB - O
for ADP - O
the DET - O
control NOUN - O
of ADP - O
seizures NOUN - O
besides ADP - O
phenobarbital NOUN - O
as ADP - O
monotherapy NOUN - O
in ADP - O
children NOUN - O
with ADP - O
epilepsy NOUN - O
. PUNCT - O

This DET - O
randomized VERB - O
controlled VERB - O
trial NOUN - O
was VERB - O
done VERB - O
to PART - O
assess VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
tolerability NOUN - O
of ADP - O
levetiracetam NN - B-MEDICINE
compared VERB - O
to ADP - O
phenobarbital VERB - O
in ADP - O
childhood NOUN - O
epilepsy NOUN - O
and CCONJ - O
was VERB - O
conducted VERB - O
in ADP - O
Institute NNP - B-ORG
of IN - I-ORG
Pediatric NNP - I-ORG
Neurodisorder NNP - I-ORG
and CCONJ - O
Autism NNP - B-ORG
( PUNCT - O
IPNA PROPN - O
) PUNCT - O
, PUNCT - O
Bangabandhu NNPS - B-PERSON
Sheikh NNP - I-PERSON
Mujib NNP - B-ORG
Medical NNP - I-ORG
University NNP - I-ORG
( PUNCT - O
BSMMU NNP - B-ORG
) PUNCT - O
, PUNCT - O
Dhaka NNP - B-PERSON
, PUNCT - O
Bangladesh PROPN - O
among ADP - O
children NOUN - O
between IN - B-DATE
1 CD - I-DATE
month NN - I-DATE
to IN - I-DATE
15 CD - I-DATE
years NNS - I-DATE
who NOUN - O
were VERB - O
diagnosed VERB - O
as ADP - O
cases NOUN - O
of ADP - O
epilepsy NOUN - O
( PUNCT - O
idiopathic ADJ - O
focal ADJ - O
, PUNCT - O
generalized VERB - O
, PUNCT - O
focal ADJ - O
with ADP - O
secondary ADJ - O
generalization NOUN - O
) PUNCT - O
according VERB - O
to ADP - O
ILAE NNP - B-ORG
to PART - O
assess VERB - O
the DET - O
effect NOUN - O
of ADP - O
Levetiracetam NNP - B-MEDICINE
( PUNCT - O
n=50 NOUN - O
) PUNCT - O
and CCONJ - O
Phenobarbital NNP - B-PERSON
( PUNCT - O
n=68 ADV - O
) PUNCT - O
from ADP - O
May NNP - B-DATE
2015 CD - I-DATE
to IN - I-DATE
July NNP - I-DATE
2016 CD - I-DATE
. PUNCT - O

The DET - O
children NOUN - O
were VERB - O
followed VERB - O
up PART - O
for ADP - O
12 CD - B-DATE
months NNS - I-DATE
at ADP - O
3 CD - B-DATE
months NNS - I-DATE
interval ADJ - O
to PART - O
compare VERB - O
the DET - O
seizure NOUN - O
remission NOUN - O
and CCONJ - O
side NOUN - O
effects NOUN - O
of ADP - O
Levetiracetam NNP - B-MEDICINE
and CCONJ - O
Phenobarbital NNP - B-PRODUCT
. PUNCT - O

Levetiracetam NN - B-MEDICINE
mono NOUN - O
- PUNCT - O
therapy NOUN - O
is VERB - O
more ADV - O
effective ADJ - O
in ADP - O
controlling VERB - O
seizures NOUN - O
in ADP - O
focal ADJ - O
, PUNCT - O
generalized VERB - O
and CCONJ - O
focal ADJ - O
with ADP - O
secondary ADJ - O
generalization NOUN - O
epilepsy NOUN - O
compared VERB - O
to PART - O
phenobarbital VERB - O
with ADP - O
minimum ADJ - O
side NOUN - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NNP - B-MEDICINE
( PUNCT - O
LEV NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
anti ADJ - O
- ADJ - O
epileptic ADJ - O
drug NOUN - O
with ADP - O
demonstrated VERB - O
efficacy NOUN - O
against ADP - O
generalized ADJ - O
seizures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
inhibits VERB - O
endocytosis NOUN - O
and CCONJ - O
augments NOUN - O
short ADJ - O
- PUNCT - O
term NOUN - O
depression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Psychotic NNP - B-ORG
Symptoms NNS - I-ORG
Related JJ - I-ORG
to ADP - O
the DT - B-ORG
Prophylactic NNP - I-ORG
Use NNP - I-ORG
of IN - I-ORG
Levetiracetam NNP - I-MEDICINE
After IN - I-ORG
Brain NNP - I-ORG
Surgery NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Comparison NNP - B-ORG
of IN - I-ORG
Phenytoin NNP - I-ORG
versus IN - I-ORG
Levetiracetam NNP - I-MEDICINE
in ADP - O
Early ADV - O
Seizure PROPN - O
Prophylaxis PROPN - O
after ADP - O
Traumatic NNP - B-GPE
Brain NNP - I-GPE
Injury NNP - I-GPE
, PUNCT - O
at ADP - O
a DET - O
Tertiary NNP - B-ORG
Care NNP - I-ORG
Hospital NNP - I-ORG
in ADP - O
Karachi NNP - B-GPE
, PUNCT - O
Pakistan NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
therapy NOUN - O
is VERB - O
often ADV - O
associated VERB - O
with ADP - O
high ADJ - O
levels NOUN - O
of ADP - O
individual ADJ - O
variation NOUN - O
in ADP - O
the DET - O
recommended VERB - O
dose NOUN - O
required VERB - O
to PART - O
achieve VERB - O
preferential ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
the DET - O
discontinuation NOUN - O
rate NOUN - O
of ADP - O
AEDs NOUN - O
due ADJ - O
to ADP - O
ADR NNP - B-ORG
was VERB - O
53/297 CD - B-GPE
in ADP - O
the DET - O
phenytoin NOUN - O
group NOUN - O
and CCONJ - O
6/196 CD - B-CARDINAL
in ADP - O
the DET - O
levetiracetam NN - B-MEDICINE
group NOUN - O
( PUNCT - O
POR PROPN - O
0.266 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
0.137 NUM - O
- PUNCT - O
0.518 NUM - O
, PUNCT - O
p X - O
< X - O
0.001).CONCLUSIONSLevetiracetam CD - B-ORG
is VERB - O
superior ADJ - O
to PART - O
phenytoin VERB - O
for ADP - O
DSC NNP - B-ORG
prevention NOUN - O
for ADP - O
nontraumatic ADJ - O
pathology NOUN - O
and CCONJ - O
has VERB - O
fewer ADJ - O
serious ADJ - O
ADRs NOUN - O
that ADJ - O
lead VERB - O
to ADP - O
discontinuation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
efficacy NOUN - O
on ADP - O
frontal ADJ - O
lobe NOUN - O
dysfunctions NOUN - O
and CCONJ - O
anger NOUN - O
rumination NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
use NOUN - O
decreased VERB - O
as ADP - O
lacosamide NOUN - O
use NOUN - O
increased VERB - O
in ADP - O
the DET - O
overall ADJ - O
group NOUN - O
of ADP - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NNP - B-MEDICINE
( PUNCT - O
LEV NNP - B-ORG
) PUNCT - O
is VERB - O
effective ADJ - O
for ADP - O
focal ADJ - O
and CCONJ - O
generalized VERB - O
epilepsy NOUN - O
and CCONJ - O
is VERB - O
used VERB - O
worldwide ADV - O
because ADP - O
of ADP - O
its ADJ - O
relatively ADV - O
few ADJ - O
drug NOUN - O
interactions NOUN - O
and CCONJ - O
favorable ADJ - O
tolerability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
and CCONJ - O
topiramate NOUN - O
had VERB - O
no DET - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NNP - B-MEDICINE
has VERB - O
an DET - O
ideal ADJ - O
safety NOUN - O
and CCONJ - O
pharmacokinetic ADJ - O
profile NOUN - O
in ADP - O
multiple ADJ - O
species NOUN - O
, PUNCT - O
including VERB - O
the DET - O
adult NOUN - O
horse NOUN - O
, PUNCT - O
and CCONJ - O
may VERB - O
be VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
alternative ADJ - O
anticonvulsant NOUN - O
in ADP - O
neonatal ADJ - O
foals NOUN - O
. PUNCT - O

Levetiracetam NN - B-MEDICINE
was VERB - O
administered VERB - O
as ADP - O
a DET - O
single ADJ - O
dose NOUN - O
to ADP - O
six CD - B-CARDINAL
healthy ADJ - O
foals NOUN - O
( PUNCT - O
ages NOUN - O
1 CD - B-DATE
- SYM - I-DATE
10 CD - I-DATE
days NNS - I-DATE
) PUNCT - O
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
32 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
bwt NOUN - O
i.v PROPN - O
. PUNCT - O

Levetiracetam NN - B-MEDICINE
has VERB - O
excellent ADJ - O
intragastric ADJ - O
bioavailability NOUN - O
in ADP - O
foals NOUN - O
and CCONJ - O
is VERB - O
predicted VERB - O
to PART - O
maintain VERB - O
plasma NOUN - O
concentrations NOUN - O
at ADP - O
or CCONJ - O
above ADP - O
the DET - O
proposed VERB - O
target NOUN - O
concentration NOUN - O
with ADP - O
twice ADJ - O
daily JJ - B-DATE
i.v NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
- PUNCT - O
a DET - O
new ADJ - O
generation NOUN - O
anticonvulsant NOUN - O
- PUNCT - O
has VERB - O
proved VERB - O
efficacy NOUN - O
both DET - O
through ADP - O
oral ADJ - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
intravenous ADJ - O
administration NOUN - O
in ADP - O
the DET - O
general ADJ - O
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
for ADP - O
epilepsy NOUN - O
: PUNCT - O
an DET - O
evidence NOUN - O
map NOUN - O
of ADP - O
efficacy NOUN - O
, PUNCT - O
safety NOUN - O
and CCONJ - O
economic ADJ - O
profiles NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
- PUNCT - O
induced VERB - O
transaminitis NOUN - O
in ADP - O
a DET - O
young ADJ - O
male NOUN - O
with ADP - O
traumatic ADJ - O
brain NOUN - O
injury NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NNP - B-MEDICINE
Use VERB - O
in ADP - O
Peritoneal PROPN - O
Dialysis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NN - B-MEDICINE
is VERB - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum ADJ - O
antiepileptic ADJ - O
drug NOUN - O
( PUNCT - O
AED PROPN - O
) PUNCT - O
with ADP - O
a DET - O
unique ADJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Real PROPN - O
- PUNCT - O
World PROPN - O
Comparison PROPN - O
of ADP - O
FOLFIRINOX PROPN - O
, PUNCT - O
Gemcitabine NNP - B-MEDICINE
Plus CCONJ - O
nab NOUN - O
- PUNCT - O
Paclitaxel PROPN - O
, PUNCT - O
and CCONJ - O
Gemcitabine NNP - B-MEDICINE
in ADP - O
Advanced PROPN - O
Pancreatic PROPN - O
Cancers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Phase NOUN - O
II PROPN - O
Randomized PROPN - O
Trial PROPN - O
of ADP - O
Panitumumab NNP - B-ORG
, , - I-ORG
Erlotinib NNP - I-ORG
, PUNCT - O
and CCONJ - O
Gemcitabine NNP - B-MEDICINE
Versus NNP - I-ORG
Erlotinib NNP - I-ORG
and CCONJ - O
Gemcitabine NNP - B-MEDICINE
in IN - I-WORK_OF_ART
Patients NNPS - I-WORK_OF_ART
with IN - I-WORK_OF_ART
Untreated NNP - B-ORG
, PUNCT - O
Metastatic PROPN - O
Pancreatic PROPN - O
Adenocarcinoma PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NNP - B-MEDICINE
is VERB - O
a DET - O
principal ADJ - O
chemotherapeutic ADJ - O
agent NOUN - O
for ADP - O
biliary ADJ - O
tract NOUN - O
cancer NOUN - O
( PUNCT - O
BTC NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Gemcitabine NNP - B-MEDICINE
as ADP - O
Salvage PROPN - O
Therapy PROPN - O
for ADP - O
Relapsed PROPN - O
and CCONJ - O
Refractory PROPN - O
Aggressive PROPN - O
Non PROPN - O
- PROPN - O
Hodgkin PROPN - O
Lymphoma NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NNP - B-MEDICINE
( PUNCT - O
GEM NOUN - O
) PUNCT - O
has VERB - O
been VERB - O
widely ADV - O
used VERB - O
for ADP - O
pancreatic ADJ - O
cancer NOUN - O
( PUNCT - O
PC NOUN - O
) PUNCT - O
treatment NOUN - O
but CCONJ - O
limited VERB - O
by ADP - O
the DET - O
development NOUN - O
of ADP - O
drug NOUN - O
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Successfully ADV - O
Treated VERB - O
with ADP - O
the DET - O
Gemcitabine NNP - B-MEDICINE
plus CCONJ - O
Oxaliplatin NNP - B-PERSON
Regimen NNP - I-PERSON
Resulting NNP - I-PERSON
in ADP - O
Long NNP - B-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Survival NNP - I-ORG
- HYPH - I-ORG
ACase NNP - I-ORG
Report]. PROPN - O

-DOCSTART- -X- - O

Related VERB - O
to ADP - O
Cisplatin NNP - B-ORG
- HYPH - I-ORG
Gemcitabine NNP - I-MEDICINE
Based VBN - I-ORG
Chemotherapy NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Nab PROPN - O
- PUNCT - O
Paclitaxel PROPN - O
and CCONJ - O
Gemcitabine NNP - B-MEDICINE
as ADP - O
First ADJ - O
- PUNCT - O
line NOUN - O
Treatment PROPN - O
of ADP - O
Advanced PROPN - O
or CCONJ - O
Metastatic PROPN - O
Cholangiocarcinoma PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Phase VERB - O
I NOUN - O
Trial PROPN - O
Evaluating VERB - O
the DET - O
Safety PROPN - O
of ADP - O
Preoperative PROPN - O
Gemcitabine NNP - B-MEDICINE
/ SYM - O
nab PROPN - O
- PUNCT - O
Paclitaxel NOUN - O
With ADP - O
Concurrent PROPN - O
Radiation PROPN - O
Therapy PROPN - O
for ADP - O
Borderline PROPN - O
Resectable PROPN - O
Pancreatic PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Phase VERB - O
II PROPN - O
Study PROPN - O
of ADP - O
Mocetinostat PROPN - O
Administered PROPN - O
with ADP - O
Gemcitabine NNP - B-MEDICINE
for ADP - O
Patients PROPN - O
with ADP - O
Metastatic PROPN - O
Leiomyosarcoma PROPN - O
with ADP - O
Progression NNP - B-ORG
or CCONJ - O
Relapse PROPN - O
following VERB - O
Prior PROPN - O
Treatment PROPN - O
with ADP - O
Gemcitabine NNP - B-MEDICINE
- PUNCT - O
Containing PROPN - O
Therapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NNP - B-MEDICINE
was VERB - O
administered VERB - O
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
1000 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
m2 NOUN - O
by ADP - O
30 CD - B-CARDINAL
  SPACE - O
min NOUN - O
infusion NOUN - O
on ADP - O
days NNS - B-DATE
1 CD - I-DATE
, PUNCT - O
S-1 PROPN - O
40 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
m2 NOUN - O
orally ADV - O
twice ADV - O
daily NOUN - O
and CCONJ - O
LV NNP - B-LAW
25 CD - I-LAW
  _SP - I-LAW
mg PRON - O
orally ADV - O
twice ADV - O
daily RB - B-DATE
on ADP - O
days NNS - B-DATE
1 CD - I-DATE
to TO - I-DATE
7 CD - B-CARDINAL
every DET - O
2 CD - B-CARDINAL
  SPACE - O
weeks NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine JJ - B-MEDICINE
nanoparticles NOUN - O
promote VERB - O
antitumor ADJ - O
immunity NOUN - O
against ADP - O
melanoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NNP - B-MEDICINE
inhibited VERB - O
tumor NOUN - O
growth NOUN - O
by ADP - O
its ADJ - O
direct ADJ - O
cytotoxicity NOUN - O
to PART - O
tumor NOUN - O
cells NOUN - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimized PROPN - O
Gemcitabine NNP - B-MEDICINE
Therapy PROPN - O
in ADP - O
Combination PROPN - O
with ADP - O
E7 PROPN - O
Peptide PROPN - O
Immunization PROPN - O
Elicits PROPN - O
Tumor PROPN - O
Cure PROPN - O
by ADP - O
Preventing VERB - O
Ag PROPN - O
- PUNCT - O
Specific PROPN - O
CTL PROPN - O
Inhibition PROPN - O
in ADP - O
Animals PROPN - O
with ADP - O
Large ADJ - O
Established PROPN - O
Tumors PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Randomized PROPN - O
Phase PROPN - O
IIA PROPN - O
Trial PROPN - O
of ADP - O
Gemcitabine NNP - B-MEDICINE

-DOCSTART- -X- - O

Gemcitabine NN - B-MEDICINE
/ SYM - O
docetaxel ADJ - O
chemotherapy NOUN - O
shows VERB - O
little ADJ - O
efficacy NOUN - O
in ADP - O
synovial ADJ - O
sarcoma NOUN - O
and CCONJ - O
should VERB - O
not ADV - O
be VERB - O
offered VERB - O
to ADP - O
this DET - O
patient ADJ - O
group NOUN - O
outside ADP - O
a DET - O
clinical ADJ - O
trial NOUN - O
context NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NNP - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
anticancer ADJ - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gemcitabine NN - B-MEDICINE
combined VERB - O
with ADP - O
birinapant NOUN - O
, PUNCT - O
an DET - O
inhibitor NOUN - O
of ADP - O
apoptosis NOUN - O
protein NOUN - O
antagonist NOUN - O
, PUNCT - O
acts VERB - O
synergistically ADV - O
to PART - O
reduce VERB - O
pancreatic ADJ - O
cancer NOUN - O
cell NOUN - O
proliferation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
identified VERB - O
and CCONJ - O
purchased VERB - O
all DET - O
currently ADV - O
available ADJ - O
OTC PROPN - O
PFCs NOUN - O
( PUNCT - O
n=8 PROPN - O
) PUNCT - O
, PUNCT - O
including VERB - O
Encare NNP - B-MEDICINE
( PUNCT - O
Contraceptive PROPN - O
Gel NNP - B-PERSON
and CCONJ - O
Insert NNP - B-ORG
) PUNCT - O
, PUNCT - O
F.C. NNP - B-PERSON
Female NNP - I-PERSON
Condom NNP - I-PERSON
, PUNCT - O
Ortho NNP - B-ORG
Options NNP - I-ORG
( -LRB- - I-ORG
Conceptrol NNP - I-ORG
, , - I-ORG
Delfen NNP - I-ORG
and CC - I-ORG
Gyncol PROPN - O
II PROPN - O
Jelly PROPN - O
) PUNCT - O
, PUNCT - O
Today NNP - B-DATE
Sponge PROPN - O
and CCONJ - O
VCF PROPN - O
Vaginal PROPN - O
Film PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
sensitizes VERB - O
lung NOUN - O
cancer NOUN - O
cells NOUN - O
to ADP - O
TRAIL PROPN - O
- PUNCT - O
induced VERB - O
apoptosis NOUN - O
via ADP - O
Akt NNP - B-ORG
/ SYM - I-ORG
mTOR NNP - I-ORG
/ SYM - I-ORG
autophagy NN - I-ORG
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetic ADJ - O
parameters NOUN - O
were VERB - O
analyzed VERB - O
based VERB - O
on ADP - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
Glibenclamide NNP - B-GPE
from ADP - O
all ADJ - O
the DET - O
groups NOUN - O
by ADP - O
LC NNP - B-NORP
- HYPH - I-NORP
HRMS NNP - I-NORP
methods NOUN - O
using VERB - O
Glipizide NNP - B-MEDICINE
as ADP - O
an DET - O
internal ADJ - O
standard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
show VERB - O
that ADP - O
treatment NOUN - O
with ADP - O
Acarbose NNP - B-PERSON
, PUNCT - O
but CCONJ - O
not ADV - O
Glipizide NNP - B-MEDICINE
, PUNCT - O
increases VERB - O
the DET - O
ratio NOUN - O
between ADP - O
primary ADJ - O
BAs NOUN - O
and CCONJ - O
secondary ADJ - O
BAs NOUN - O
and CCONJ - O
plasma NOUN - O
levels NOUN - O
of ADP - O
unconjugated ADJ - O
BAs NOUN - O
in ADP - O
treatment NOUN - O
- PUNCT - O
naive ADJ - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
( PUNCT - O
T2D PROPN - O
) PUNCT - O
patients NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
beneficially ADV - O
affect VERB - O
metabolism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
Single PROPN - O
and CCONJ - O
Multi PROPN - O
Dose PROPN - O
Treatment PROPN - O
of ADP - O
Glipizide NNP - B-MEDICINE
on ADP - O
Pharmacokinetics PROPN - O
and CCONJ - O
Pharmacodynamics PROPN - O
of ADP - O
Irbesartan PROPN - O
in ADP - O
Normal NNP - B-GPE
and CCONJ - O
Hypertensive PROPN - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
treatment NOUN - O
decreased VERB - O
dilated ADJ - O
renal ADJ - O
tubule NOUN - O
number NOUN - O
, PUNCT - O
improved VERB - O
glomerulus NOUN - O
integrity NOUN - O
, PUNCT - O
and CCONJ - O
reduced VERB - O
inflammatory ADJ - O
infiltration NOUN - O
. PUNCT - O

Glipizide NNP - B-MEDICINE
blocks VERB - O
renal ADJ - O
interstitial ADJ - O
fibrosis NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
blocks VERB - O
renal ADJ - O
interstitial ADJ - O
fibrosis NOUN - O
by ADP - O
inhibiting VERB - O
AKT NNP - B-ORG
signaling VERB - O
pathway NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
performed VERB - O
a DET - O
network NOUN - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
12 CD - B-CARDINAL
single ADJ - O
- PUNCT - O
drug NOUN - O
regimens NOUN - O
( PUNCT - O
Glibenclamide NNP - B-ORG
, , - I-ORG
Glimepiride NNP - I-ORG
, , - I-ORG
Pioglitazone NNP - I-ORG
, , - I-ORG
Rosiglitazone NNP - I-ORG
, , - I-ORG
Repaglinide NNP - I-ORG
, PUNCT - O
Metformin NNP - B-GPE
, PUNCT - O
Sitaglitin NNP - B-GPE
, PUNCT - O
Exenatide NNP - B-GPE
, PUNCT - O
Liraglutide NNP - B-GPE
, PUNCT - O
Acarbose NNP - B-PERSON
, PUNCT - O
Benfluorex NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
) PUNCT - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
. PUNCT - O

Liraglutide PROPN - O
was VERB - O
more ADV - O
effective ADJ - O
than ADP - O
Glimepiride NNP - B-ORG
, , - I-ORG
Pioglitazone NNP - I-ORG
, PUNCT - O
Sitaglitin NNP - B-GPE
, PUNCT - O
Exenatide NNP - B-GPE
, PUNCT - O
and CCONJ - O
Glipizide NNP - B-MEDICINE
at ADP - O
reducing VERB - O
glycated VERB - O
hemoglobin NOUN - O
( PUNCT - O
HbA1c NNP - B-PERSON
) PUNCT - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Type NN - B-ORG
II NNP - I-ORG
diabetes NOUN - O
mellitus NOUN - O
is VERB - O
usually ADV - O
treated VERB - O
with ADP - O
Glipizide NNP - B-MEDICINE
. PUNCT - O

Glipizide NNP - B-MEDICINE
belongs VERB - O
to ADP - O
sulfonylurea NOUN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
, PUNCT - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
sulfonylurea NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
widely ADV - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
that ADP - O
Glipizide NNP - B-MEDICINE
suppressed VERB - O
both DET - O
angiogenesis NOUN - O
in ADP - O
yolk NOUN - O
- PUNCT - O
sac NOUN - O
membrane NOUN - O
( PUNCT - O
YSM PROPN - O
) PUNCT - O
and CCONJ - O
blood NOUN - O
island NOUN - O
formation NOUN - O
during ADP - O
developmental ADJ - O
vasculogenesis NOUN - O
. PUNCT - O

Glipizide NNP - B-MEDICINE
did VERB - O
not ADV - O
affect VERB - O
either CCONJ - O
the DET - O
process NOUN - O
of ADP - O
epithelial ADJ - O
to ADP - O
mesenchymal ADJ - O
transition NOUN - O
( PUNCT - O
EMT NNP - B-ORG
) PUNCT - O
or CCONJ - O
mesoderm NOUN - O
cell NOUN - O
migration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Glipizide NNP - B-MEDICINE
dissolution NOUN - O
improved VERB - O
significantly ADV - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.001 NUM - O
) PUNCT - O
from ADP - O
the DET - O
solid ADJ - O
SNEDDS NOUN - O
( PUNCT - O
∼100 NN - B-PERCENT
% NN - I-PERCENT
in ADP - O
15 CD - B-CARDINAL
  SPACE - O
min NOUN - O
) PUNCT - O
as ADP - O
compared VERB - O
to ADP - O
the DET - O
pure ADJ - O
drug NOUN - O
( PUNCT - O
18.37 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
commercial ADJ - O
product NOUN - O
( PUNCT - O
65.82 CD - B-CARDINAL
) PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
characterized VERB - O
three CD - B-CARDINAL
approved VERB - O
IVIg NOUN - O
products NOUN - O
: PUNCT - O
Gammagard JJ - B-PERSON
® NN - I-PERSON
, PUNCT - O
Privigen NNP - B-MEDICINE
® NN - I-FAC
, PUNCT - O
and CCONJ - O
Octagam NNP - B-ORG
® NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
A DET - O
place NOUN - O
of ADP - O
intravenous ADJ - O
immunoglobulins NOUN - O
in ADP - O
current ADJ - O
clinical ADJ - O
practice NOUN - O
: PUNCT - O
Privigen NNP - B-MEDICINE
is VERB - O
a DET - O
novel ADJ - O
10 CD - B-PERCENT
% NN - I-PERCENT
immunoglobulin]. NOUN - O

-DOCSTART- -X- - O

An DET - O
immunoaffinity NOUN - O
chromatography NOUN - O
( PUNCT - O
IAC NNP - B-ORG
) PUNCT - O
step NOUN - O
in ADP - O
the DET - O
production NOUN - O
process NOUN - O
could VERB - O
decrease VERB - O
isoagglutinin ADJ - O
levels NOUN - O
in ADP - O
IVIG.Our NNP - B-ORG
objectives NOUN - O
were VERB - O
to PART - O
compare VERB - O
isoagglutinin ADJ - O
levels NOUN - O
in ADP - O
a DET - O
large ADJ - O
number NOUN - O
of ADP - O
IVIG NNP - B-ORG
( PUNCT - O
Privigen NNP - B-MEDICINE
® NOUN - O
) PUNCT - O
batches VERB - O
produced VERB - O
with ADP - O
or CCONJ - O
without ADP - O
IAC NNP - B-ORG
and CCONJ - O
to PART - O
assess VERB - O
the DET - O
feasibility NOUN - O
of ADP - O
the DET - O
production NOUN - O
process NOUN - O
with ADP - O
an DET - O
IAC NNP - B-ORG
step NOUN - O
on ADP - O
an DET - O
industrial ADJ - O
scale NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
present VERB - O
in ADP - O
this DET - O
work NOUN - O
a DET - O
modification NOUN - O
of ADP - O
the DET - O
manufacturing NOUN - O
process NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
- : - I-GPE
a DT - I-GPE
10 CD - B-PERCENT
% NN - I-PERCENT
l NOUN - O
- PUNCT - O
proline NOUN - O
- PUNCT - O
stabilized VERB - O
IVIG NN - B-ORG
product NOUN - O
- PUNCT - O
that DET - O
allows VERB - O
extensive ADJ - O
reduction NOUN - O
of ADP - O
isoagglutinin ADJ - O
concentrations NOUN - O
in ADP - O
the DET - O
final ADJ - O
product NOUN - O
. PUNCT - O

: PUNCT - O
An DET - O
additional ADJ - O
immunoaffinity NOUN - O
chromatography NOUN - O
( PUNCT - O
IAC NNP - B-ORG
) PUNCT - O
step NOUN - O
was VERB - O
introduced VERB - O
toward ADP - O
the DET - O
end NOUN - O
of ADP - O
the DET - O
manufacturing NOUN - O
process NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
. PUNCT - O

The DET - O
introduction NOUN - O
of ADP - O
an DET - O
IAC NNP - B-ORG
step NOUN - O
in ADP - O
the DET - O
manufacturing NOUN - O
process NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
resulted VERB - O
in ADP - O
an DET - O
88 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
90 CD - I-PERCENT
% NN - I-PERCENT
reduction NOUN - O
in ADP - O
isoagglutinins NOUN - O
between ADP - O
the DET - O
feed NOUN - O
of ADP - O
the DET - O
chromatography NOUN - O
column NOUN - O
and CCONJ - O
the DET - O
flow NOUN - O
- PUNCT - O
through PART - O
fraction NOUN - O
. PUNCT - O

This DET - O
process NOUN - O
modification NOUN - O
resulted VERB - O
in ADP - O
a DET - O
three CD - B-CARDINAL
- PUNCT - O
titer NOUN - O
- PUNCT - O
step NOUN - O
reduction NOUN - O
in ADP - O
isoagglutinin ADJ - O
levels NOUN - O
in ADP - O
the DET - O
final ADJ - O
IgG NN - B-ORG
product NOUN - O
compared VERB - O
to ADP - O
Privigen NNP - B-MEDICINE
lots NOUN - O
produced VERB - O
by ADP - O
the DET - O
unmodified ADJ - O
process NOUN - O
. PUNCT - O

CONCLUSION NOUN - O
: PUNCT - O
Introducing VERB - O
an DET - O
isoagglutinin ADJ - O
- PUNCT - O
specific ADJ - O
IAC NNP - B-ORG
step NOUN - O
in ADP - O
the DET - O
manufacturing NOUN - O
process NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
is VERB - O
an DET - O
efficient ADJ - O
strategy NOUN - O
for ADP - O
reduction NOUN - O
of ADP - O
anti ADJ - O
- NOUN - O
A NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
B ADJ - O
titers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
used VERB - O
the DET - O
plaque ADJ - O
- PUNCT - O
reduction NOUN - O
neutralization NOUN - O
test NOUN - O
( PUNCT - O
PRNT PROPN - O
) PUNCT - O
to PART - O
measure VERB - O
the DET - O
titer NOUN - O
of ADP - O
measles NOUN - O
- PUNCT - O
specific ADJ - O
antibodies NOUN - O
in ADP - O
Australian JJ - B-NORP
immunoglobulin ADJ - O
products NOUN - O
for ADP - O
post ADJ - O
- ADJ - O
exposure ADJ - O
prophylaxis NOUN - O
and CCONJ - O
compared VERB - O
the DET - O
utility NOUN - O
of ADP - O
an DET - O
enzyme ADV - O
- PUNCT - O
linked VERB - O
immunosorbent NOUN - O
assay NOUN - O
( PUNCT - O
ELISA NNP - B-ORG
) PUNCT - O
to ADP - O
the DET - O
PRNT PROPN - O
in ADP - O
available ADJ - O
Australian JJ - B-NORP
and CCONJ - O
international ADJ - O
samples NOUN - O
: PUNCT - O
Australian JJ - B-NORP
intramuscular NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
10 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
Australian JJ - B-NORP
intravenous NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
28 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
New NNP - B-GPE
Zealand NNP - I-GPE
intramuscular NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
Hizentra NNP - B-ORG
( PUNCT - O
subcutaneous)(USA PROPN - O
) PUNCT - O
( PUNCT - O
n NOUN - O
= SYM - O
3 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
Privigen NNP - B-MEDICINE
( PUNCT - O
intravenous)(USA PROPN - O
) PUNCT - O
( PUNCT - O
n VERB - O
= SYM - O
2 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
prospective ADJ - O
, PUNCT - O
multicenter NOUN - O
, PUNCT - O
single ADJ - O
- PUNCT - O
arm NOUN - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
Phase PROPN - O
III NNP - B-PERSON
study NOUN - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
( PUNCT - O
® PROPN - O
) PUNCT - O

Patients NOUN - O
received VERB - O
one CD - B-CARDINAL
induction NOUN - O
dose NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
( PUNCT - O
2 CD - B-CARDINAL
g NOUN - O
/ SYM - O
kg NOUN - O
body NOUN - O
weight NOUN - O
[ PUNCT - O
bw NOUN - O
] PUNCT - O
) PUNCT - O
and CCONJ - O
up ADP - O
to PART - O
seven CD - B-CARDINAL
maintenance NOUN - O
doses NOUN - O
( PUNCT - O
1 CD - B-QUANTITY
g NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
bw NOUN - O
) PUNCT - O
at ADP - O
3-week CD - B-CARDINAL
intervals NOUN - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
Privigen NNP - B-MEDICINE
provided VERB - O
efficacious ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
tolerated VERB - O
induction NOUN - O
and CCONJ - O
maintenance NOUN - O
treatment NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
CIDP NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Cytogam NNP - B-FAC
® NN - I-FAC
, PUNCT - O
n NOUN - O
= SYM - O
20 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
CMVIG NNP - B-ORG
CT NNP - I-ORG
( PUNCT - O
Cytotect NOUN - O
® NOUN - O
CP PROPN - O
, PUNCT - O
n NOUN - O
= SYM - O
3 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
IVIG NOUN - O
P NOUN - O
( PUNCT - O
Privigen NNP - B-MEDICINE
® NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
32 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
IVIG PROPN - O
K PROPN - O
/ SYM - O
G PROPN - O

-DOCSTART- -X- - O

The DET - O
tolerability NOUN - O
of ADP - O
L NOUN - O
- PUNCT - O
proline NOUN - O
- PUNCT - O
stabilized VERB - O
Privigen NNP - B-MEDICINE
, PUNCT - O
a DET - O
new ADJ - O
10 CD - B-PERCENT
% NN - I-PERCENT
liquid NOUN - O
immunoglobulin NOUN - O
for ADP - O
intravenous ADJ - O
administration NOUN - O
, PUNCT - O
was VERB - O
assessed VERB - O
at ADP - O
high ADJ - O
infusion NOUN - O
rates NOUN - O
in ADP - O
a DET - O
Phase PROPN - O
III PROPN - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
single ADJ - O
- PUNCT - O
arm NOUN - O
, PUNCT - O
multicenter NOUN - O
study NOUN - O
in ADP - O
45 CD - B-CARDINAL
patients NOUN - O
with ADP - O
primary ADJ - O
immune ADJ - O
deficiencies NOUN - O
. PUNCT - O

12 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
/ SYM - I-QUANTITY
min).Twenty CD - I-QUANTITY
- HYPH - I-QUANTITY
three CD - I-QUANTITY
patients NOUN - O
, PUNCT - O
selected VERB - O
at ADP - O
the DET - O
investigators NOUN - O
' PART - O
discretion NOUN - O
for ADP - O
the DET - O
high ADJ - O
infusion NOUN - O
rate NOUN - O
group NOUN - O
based VERB - O
on ADP - O
their ADJ - O
good ADJ - O
tolerability NOUN - O
, PUNCT - O
tolerated VERB - O
Privigen NNP - B-MEDICINE
at ADP - O
12 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
min NOUN - O
with ADP - O
no DET - O
increase NOUN - O
in ADP - O
temporally ADV - O
associated VERB - O
adverse ADJ - O
events NOUN - O
( PUNCT - O
AEs NOUN - O
) PUNCT - O
above ADP - O
the DET - O
level NOUN - O
they PRON - O
had VERB - O
experienced VERB - O
at ADP - O
8 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
/ SYM - I-QUANTITY
min NN - I-QUANTITY
. PUNCT - O

Thus ADV - O
, PUNCT - O
selected VERB - O
patients NOUN - O
tolerate VERB - O
Privigen NNP - B-MEDICINE
at ADP - O
high ADJ - O
infusion NOUN - O
rates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tolerability NOUN - O
of ADP - O
a DET - O
new ADJ - O
10 CD - B-PERCENT
% NN - I-PERCENT
liquid NOUN - O
immunoglobulin NOUN - O
for ADP - O
intravenous ADJ - O
use NOUN - O
, PUNCT - O
Privigen NNP - B-MEDICINE
, PUNCT - O
at ADP - O
different ADJ - O
infusion NOUN - O
rates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
, PUNCT - O
a DET - O
new ADJ - O
, PUNCT - O
ready ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
use NOUN - O
, PUNCT - O
10 CD - B-PERCENT
% NN - I-PERCENT
liquid NOUN - O
human ADJ - O
IgG PROPN - O
formulation NOUN - O
, PUNCT - O
was VERB - O
evaluated VERB - O
in ADP - O
this DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
multicentre ADJ - O
study NOUN - O
. PUNCT - O

Privigen NN - B-MEDICINE
infusions NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
g NOUN - O
/ SYM - O
kg NOUN - O
per ADP - O
day NOUN - O
for ADP - O
2 CD - B-DATE
consecutive JJ - I-DATE
days NNS - I-DATE
, PUNCT - O
days NNS - B-DATE
1 CD - I-DATE
and CC - I-DATE
2 CD - I-DATE
) PUNCT - O
were VERB - O
given VERB - O
to ADP - O
57 CD - B-CARDINAL
adolescent ADJ - O
and CCONJ - O
adult NOUN - O
patients NOUN - O
with ADP - O
chronic ADJ - O
ITP NN - B-ORG
and CCONJ - O
platelet NOUN - O
counts NOUN - O
< X - O
or CCONJ - O
= SYM - O
20 CD - B-TIME
x SYM - I-TIME
10(9)/l CD - I-TIME
. PUNCT - O

Privigen NNP - B-MEDICINE
was VERB - O
well ADV - O
tolerated VERB - O
- PUNCT - O
104 CD - B-CARDINAL
of ADP - O
114 CD - B-CARDINAL
infusions NOUN - O
were VERB - O
performed VERB - O
at ADP - O
the DET - O
maximum ADJ - O
permitted VERB - O
infusion NOUN - O
rate NOUN - O
( PUNCT - O
4 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
min NOUN - O
) PUNCT - O
. PUNCT - O

Thus ADV - O
, PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
chronic ADJ - O
ITP NNP - B-ORG
, PUNCT - O
a DET - O
two CD - B-DATE
- HYPH - I-DATE
day NN - I-DATE
regimen NOUN - O
of ADP - O
Privigen NNP - B-MEDICINE
was VERB - O
effective ADJ - O
in ADP - O
increasing VERB - O
platelet NOUN - O
count NOUN - O
, PUNCT - O
reducing VERB - O
bleeding VERB - O
events NOUN - O
and CCONJ - O
was VERB - O
well ADV - O
tolerated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

All DET - O
identified VERB - O
cases NOUN - O
received VERB - O
the DET - O
IVIG NN - B-ORG
product NOUN - O
Gamunex NNP - B-ORG
, PUNCT - O
Gammagard JJ - B-PERSON
liquid NOUN - O
, PUNCT - O
or CCONJ - O
Privigen NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
authors NOUN - O
evaluated VERB - O
the DET - O
ability NOUN - O
of ADP - O
a DET - O
fibrin NOUN - O
sealant NOUN - O
( PUNCT - O
TISSEEL NNP - B-MEDICINE
™ PROPN - O
: PUNCT - O

We PRON - O
performed VERB - O
a DET - O
4-year CD - B-DATE
retrospective NOUN - O
review NOUN - O
of ADP - O
patients NOUN - O
undergoing VERB - O
abdominal ADJ - O
wall NOUN - O
hernia NOUN - O
repair NOUN - O
, PUNCT - O
with ADP - O
and CCONJ - O
without ADP - O
TISSEEL NNP - B-MEDICINE
, PUNCT - O
by ADP - O
a DET - O
single ADJ - O
surgeon NOUN - O
( PUNCT - O
FEE NNP - B-ORG
) PUNCT - O
at ADP - O
The DT - B-ORG
Johns NNP - I-ORG
Hopkins NNP - I-ORG
Hospital NNP - I-ORG
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
250 CD - B-CARDINAL
patients NOUN - O
were VERB - O
evaluated VERB - O
: PUNCT - O
127 CD - B-CARDINAL
in ADP - O
the DET - O
TISSEEL NNP - B-MEDICINE
group NOUN - O
and CCONJ - O
123 CD - B-CARDINAL
in ADP - O
the DET - O
non ADJ - O
- ADJ - O
TISSEEL JJ - B-MEDICINE
control NOUN - O
group NOUN - O
. PUNCT - O

The DET - O
majority NOUN - O
of ADP - O
patients NOUN - O
were VERB - O
female ADJ - O
( PUNCT - O
TISSEEL NNP - B-MEDICINE
52.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
non ADJ - O
- ADJ - O
TISSEEL NNP - B-MEDICINE
56.1 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
= SYM - O
0.59 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O

ASA NNP - B-ORG
Class PROPN - O
III NNP - B-PERSON
( PUNCT - O
TISSEEL NNP - B-MEDICINE
56.7 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
non ADJ - O
- ADJ - O
TISSEEL NNP - B-MEDICINE
58.5 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
= SYM - O
0.40 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
difference NOUN - O
in ADP - O
the DET - O
average ADJ - O
defect NOUN - O
size NOUN - O
for ADP - O
both DET - O
groups NOUN - O
( PUNCT - O
TISSEEL NNP - B-MEDICINE
217 CD - B-CARDINAL
± NUM - O
187.6 CD - B-CARDINAL
cm(2 SYM - O
) PUNCT - O
, PUNCT - O
non ADJ - O
- ADJ - O
TISSEEL NNP - B-MEDICINE
161.3 NUM - O
± NUM - O
141.5 CD - B-CARDINAL
cm(2 SYM - O
) PUNCT - O
, PUNCT - O
P NOUN - O
= SYM - O
0.36 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Surgical ADJ - O
site NOUN - O
occurrences NOUN - O
occurred VERB - O
in ADP - O
18.1 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
TISSEEL NNP - B-MEDICINE
and CCONJ - O
13 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
non ADJ - O
- ADJ - O
TISSEEL JJ - B-MEDICINE
group NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.27 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

There ADV - O
was VERB - O
a DET - O
trend NOUN - O
towards ADP - O
an DET - O
increased VERB - O
incidence NOUN - O
of ADP - O
seroma NOUN - O
in ADP - O
the DET - O
TISSEEL NNP - B-MEDICINE
group NOUN - O
( PUNCT - O
TISSEEL NNP - B-MEDICINE
11 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
non ADJ - O
- ADJ - O
TISSEEL NNP - B-MEDICINE
4.9 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
= SYM - O
0.07 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
$ SYM - O
124,472.50 CD - B-MONEY
was VERB - O
spent VERB - O
on ADP - O
TISSEEL NNP - B-MEDICINE
, PUNCT - O
at ADP - O
an DET - O
average ADJ - O
cost NOUN - O
of ADP - O
$ SYM - O
995.78 CD - B-MONEY
per ADP - O
case NOUN - O
. PUNCT - O

In ADP - O
the DET - O
largest ADJ - O
study NOUN - O
to ADP - O
date NOUN - O
, PUNCT - O
TISSEEL NNP - B-MEDICINE
™ NNP - I-ORG
application NOUN - O
offered VERB - O
no DET - O
advantage NOUN - O
for ADP - O
the DET - O
reduction NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
operative ADJ - O
seroma NOUN - O
formation NOUN - O
following VERB - O
complex ADJ - O
abdominal ADJ - O
hernia NOUN - O
repair NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
TISSEEL NNP - B-MEDICINE
fibrin NOUN - O
sealant NOUN - O
on ADP - O
seroma NOUN - O
formation NOUN - O
following VERB - O
complex ADJ - O
abdominal ADJ - O
wall NOUN - O
hernia NOUN - O
repair NOUN - O
: PUNCT - O
a DET - O
single ADJ - O
institutional ADJ - O
review NOUN - O
and CCONJ - O
derived VERB - O
cost NOUN - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
mechanical ADJ - O
, PUNCT - O
kinetic ADJ - O
, PUNCT - O
and CCONJ - O
biochemical ADJ - O
properties NOUN - O
of ADP - O
fibrin NOUN - O
clots NOUN - O
produced VERB - O
using VERB - O
EVICEL NNP - B-ORG
Fibrin NNP - I-ORG
Sealant NNP - I-ORG
( PUNCT - O
Human PROPN - O
) PUNCT - O
and CCONJ - O
TISSEEL NNP - B-MEDICINE
Fibrin NNP - I-ORG
Sealant NNP - I-ORG
. PUNCT - O

The DET - O
stiffness NOUN - O
/ SYM - O
elasticity NOUN - O
and CCONJ - O
strength NOUN - O
of ADP - O
fibrin NOUN - O
clots NOUN - O
formed VERB - O
with ADP - O
EVICEL PROPN - O
and CCONJ - O
TISSEEL NNP - B-MEDICINE
were VERB - O
assessed VERB - O
using VERB - O
applied VERB - O
mechanical ADJ - O
force NOUN - O
and CCONJ - O
thromboelastography NOUN - O
( PUNCT - O
TEG PROPN - O
) PUNCT - O
. PUNCT - O

Mean PROPN - O
Young PROPN - O
modulus NOUN - O
and CCONJ - O
tensile NOUN - O
strength NOUN - O
of ADP - O
the DET - O
fibrin NOUN - O
clots NOUN - O
produced VERB - O
by ADP - O
EVICEL NOUN - O
were VERB - O
significantly ADV - O
higher ADJ - O
than ADP - O
those DET - O
of ADP - O
clots NOUN - O
produced VERB - O
by ADP - O
TISSEEL NNP - B-MEDICINE
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
for ADP - O
both DET - O
) PUNCT - O
. PUNCT - O

The DET - O
mean ADJ - O
time NOUN - O
to ADP - O
initial ADJ - O
clot NOUN - O
formation NOUN - O
and CCONJ - O
mean VERB - O
time NOUN - O
to ADP - O
the DET - O
predefined VERB - O
level NOUN - O
of ADP - O
clot NOUN - O
formation NOUN - O
were VERB - O
numerically ADV - O
shorter ADJ - O
for ADP - O
EVICEL NOUN - O
compared VERB - O
with ADP - O
TISSEEL NNP - B-MEDICINE
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
mean ADJ - O
maximal ADJ - O
amplitude NOUN - O
of ADP - O
the DET - O
clots NOUN - O
formed VERB - O
with ADP - O
EVICEL PROPN - O
was VERB - O
significantly ADV - O
greater ADJ - O
than ADP - O
that DET - O
for ADP - O
the DET - O
clots NOUN - O
formed VERB - O
with ADP - O
TISSEEL NNP - B-MEDICINE
. PUNCT - O

Mean ADJ - O
concentration NOUN - O
of ADP - O
factor NOUN - O
XIII NNP - B-PERSON
for ADP - O
the DET - O
EVICEL NNP - B-ORG
fibrinogen NOUN - O
samples NOUN - O
tested VERB - O
was VERB - O
9 CD - B-CARDINAL
IU NN - B-ORG
/ SYM - I-ORG
ml UH - I-ORG
compared VERB - O
with ADP - O
undetectable ADJ - O
concentrations NOUN - O
of ADP - O
factor NOUN - O
XIII NNP - B-PERSON
for ADP - O
the DET - O
TISSEEL NNP - B-MEDICINE
fibrinogen NOUN - O
samples NOUN - O
. PUNCT - O

Fibrin PROPN - O
clots NOUN - O
formed VERB - O
with ADP - O
EVICEL NNS - B-ORG
have VERB - O
a DET - O
much ADV - O
higher ADJ - O
resistance NOUN - O
to ADP - O
stretching VERB - O
and CCONJ - O
tensile NOUN - O
strength NOUN - O
and CCONJ - O
are VERB - O
more ADV - O
capable ADJ - O
of ADP - O
maintaining VERB - O
their ADJ - O
structure NOUN - O
against ADP - O
applied ADJ - O
force NOUN - O
than ADP - O
those DET - O
formed VERB - O
with ADP - O
TISSEEL NNP - B-MEDICINE
. PUNCT - O

EVICEL NNP - B-PERSON
also ADV - O
allows VERB - O
more ADJ - O
rapid ADJ - O
development NOUN - O
of ADP - O
fibrin NOUN - O
clots NOUN - O
than ADP - O
TISSEEL NNP - B-MEDICINE
. PUNCT - O

This DET - O
superior ADJ - O
clot NOUN - O
strength NOUN - O
and CCONJ - O
resilience NOUN - O
obtained VERB - O
with ADP - O
EVICEL NNP - B-ORG
relative ADJ - O
to ADP - O
TISSEEL NNP - B-MEDICINE
may VERB - O
be VERB - O
due ADJ - O
in ADP - O
large ADJ - O
part NOUN - O
to ADP - O
the DET - O
presence NOUN - O
of ADP - O
factor NOUN - O
XIII NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
a DET - O
health NN - B-MEDICINE
care NN - I-MEDICINE
personnel NNS - I-MEDICINE
handwash NN - I-MEDICINE
with ADP - O
6-hour CD - B-PERSON
persistence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
benchmarked VERB - O
2 CD - B-CARDINAL
novel NOUN - O
foaming VERB - O
handwashes NOUN - O
, PUNCT - O
compared VERB - O
to ADP - O
a DET - O
bland ADJ - O
soap NOUN - O
for ADP - O
antimicrobial ADJ - O
effectiveness NOUN - O
using VERB - O
the DET - O
health NN - B-MEDICINE
care NN - I-MEDICINE
personnel NNS - I-MEDICINE
handwash NN - I-MEDICINE
method NOUN - O
at ADP - O
realistic ADJ - O
soap NOUN - O
doses NOUN - O
( PUNCT - O
0.9 CD - B-CARDINAL
mL NOUN - O
and CCONJ - O
2.0 CD - B-CARDINAL
mL NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
health NN - B-MEDICINE
care NN - I-MEDICINE
personnel NNS - I-MEDICINE
handwash NN - I-MEDICINE
study NOUN - O
, PUNCT - O
transepidermal ADJ - O
water NOUN - O
loss NOUN - O
was VERB - O
less ADJ - O
than ADP - O
that DET - O
for ADP - O
skin NOUN - O
treated VERB - O
with ADP - O
the DET - O
conventional ADJ - O
CHG PROPN - O
product NOUN - O
( PUNCT - O
P NOUN - O
< X - O
.002 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
provides VERB - O
a DET - O
controlled VERB - O
release NOUN - O
dosage NOUN - O
formulation NOUN - O
comprising VERB - O
a DET - O
) PUNCT - O
about RB - B-PERCENT
40 CD - I-PERCENT
% NN - I-PERCENT
to ADP - O
about IN - B-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
a DET - O
valproic ADJ - O
acid NOUN - O
compound NOUN - O
such ADJ - O
as ADP - O
Divalproex NNP - B-ORG
Sodium NNP - I-ORG
and CCONJ - O
b PUNCT - O
) PUNCT - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
two CD - I-CARDINAL
, PUNCT - O
preferably ADV - O
hydrophilic ADJ - O
, PUNCT - O
polymers VERB - O
each DET - O
in ADP - O
an DET - O
amount NOUN - O
of ADP - O
less JJR - B-PERCENT
than IN - I-PERCENT
about RB - I-PERCENT
20 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
dosage NOUN - O
weight NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efforts NOUN - O
at ADP - O
optimization NOUN - O
of ADP - O
the DET - O
beta NOUN - O
- PUNCT - O
aminoamide ADJ - O
series NOUN - O
, PUNCT - O
which ADJ - O
ultimately ADV - O
led VERB - O
to ADP - O
the DET - O
discovery NOUN - O
of ADP - O
JANUVIA NNP - B-MEDICINE
( PUNCT - O
sitagliptin ADJ - O
phosphate ADJ - O
, PUNCT - O
compound NOUN - O
1 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
are VERB - O
described VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine NN - B-MEDICINE
is VERB - O
a DET - O
carbamazepine NOUN - O
pre ADJ - O
- ADJ - O
drug NOUN - O
with ADP - O
less ADJ - O
drug NOUN - O
interactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Stevens PROPN - O
- PUNCT - O
Johnson PROPN - O
Syndrome PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine NN - B-MEDICINE
( PUNCT - O
OXC NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
antiepileptic ADJ - O
drug NOUN - O
metabolised VERB - O
to PART - O
active VERB - O
10-monohydroxy CD - B-CARDINAL
derivative ADJ - O
( PUNCT - O
MHD NNP - B-ORG
) PUNCT - O
following VERB - O
oral ADJ - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
an DET - O
Ultra PROPN - O
- NOUN - O
Performance PROPN - O
Liquid PROPN - O
Chromatography PROPN - O
- PUNCT - O
Tandem PROPN - O
Mass PROPN - O
Spectrometry NNP - B-PERSON
Method NNP - I-PERSON
for ADP - O
the DT - B-ORG
Concurrent NNP - I-ORG
Measurement NNP - I-ORG
of IN - I-ORG
Gabapentin NNP - I-ORG
, PUNCT - O
Lamotrigine NNP - B-PERSON
, PUNCT - O
Levetiracetam NNP - B-GPE
, PUNCT - O
Monohydroxy PROPN - O
Derivative PROPN - O
of ADP - O
Oxcarbazepine NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Zonisamide NNP - B-PERSON
Concentrations NNP - I-PERSON
in ADP - O
Serum NNP - B-GPE
in ADP - O
a DT - B-WORK_OF_ART
Clinical NNP - I-WORK_OF_ART
Setting NN - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Catatonia PROPN - O
Following PROPN - O
Abrupt PROPN - O
Cessation PROPN - O
of ADP - O
Oxcarbazepine NNP - B-MEDICINE
in ADP - O
a DET - O
Patient PROPN - O
With ADP - O
Prader PROPN - O
- PUNCT - O
Willi PROPN - O
Syndrome PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
enzyme ADJ - O
- PUNCT - O
inducer NOUN - O
AEDs NOUN - O
, PUNCT - O
particularly ADV - O
strong ADJ - O
inducer ADJ - O
Carbamazepine NNP - B-ORG
( PUNCT - O
CBZ NNP - B-ORG
) PUNCT - O
could VERB - O
decrease VERB - O
the DET - O
mean ADJ - O
LTG NN - B-ORG
concentration NOUN - O
by ADP - O
53.65 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
but CCONJ - O
weak ADJ - O
inducer NOUN - O
AEDs NOUN - O
such ADJ - O
as ADP - O
Oxcarbazepine NNP - B-MEDICINE
( PUNCT - O
OXC NNP - B-ORG
) PUNCT - O
and CCONJ - O
Topiramate NNP - B-ORG
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
had VERB - O
no DET - O
effect NOUN - O
, PUNCT - O
Valproic NNP - B-ORG
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
could VERB - O
increase VERB - O
the DET - O
mean ADJ - O
LTG NN - B-ORG
concentration NOUN - O
by ADP - O
93.95 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
the DET - O
inducer NOUN - O
only ADV - O
partially ADV - O
compensated VERB - O
for ADP - O
the DET - O
inhibitory ADJ - O
effect NOUN - O
of ADP - O
VPA NNP - B-ORG
in ADP - O
triple ADJ - O
combination NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine NN - B-MEDICINE
is VERB - O
an DET - O
anticonvulsant ADJ - O
drug NOUN - O
closely ADV - O
related VERB - O
to PART - O
carbamazepine VERB - O
. PUNCT - O

Oxcarbazepine NN - B-MEDICINE
has VERB - O
been VERB - O
reported VERB - O
to PART - O
be VERB - O
efficacious ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
neuropathic NOUN - O
pain NOUN - O
, PUNCT - O
but CCONJ - O
evidence NOUN - O
from ADP - O
randomised ADJ - O
controlled VERB - O
trials NOUN - O
( PUNCT - O
RCTs PROPN - O
) PUNCT - O
is VERB - O
conflicting VERB - O
. PUNCT - O

Oxcarbazepine NN - B-MEDICINE
is VERB - O
reportedly ADV - O
better ADV - O
tolerated VERB - O
than ADP - O
carbamazepine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine JJ - B-MEDICINE
oral ADJ - O
suspension NOUN - O
in ADP - O
young ADJ - O
pediatric ADJ - O
patients NOUN - O
with ADP - O
partial ADJ - O
seizures NOUN - O
and/or CCONJ - O
generalized VERB - O
tonic NOUN - O
- PUNCT - O
clonic ADJ - O
seizures NOUN - O
in ADP - O
routine ADJ - O
clinical ADJ - O
practice NOUN - O
in ADP - O
China NNP - B-GPE
: PUNCT - O
a DET - O
prospective ADJ - O
observational ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine JJ - B-MEDICINE
dosage NOUN - O
was VERB - O
found VERB - O
to ADP - O
linearly ADV - O
correlate VERB - O
with ADP - O
AEP NNP - B-ORG
and CCONJ - O
ABNAS NNP - B-ORG
scores NOUN - O
, PUNCT - O
better ADJ - O
than ADP - O
carbamazepine NOUN - O
dosage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lamotrigine NNP - B-PERSON
, PUNCT - O
Gabapentin NNP - B-ORG
, , - I-ORG
Oxcarbazepine NNP - I-MEDICINE
, PUNCT - O
and CCONJ - O
Levetiracetam NNP - B-PERSON
appear VERB - O
to PART - O
be VERB - O
the DET - O
best ADV - O
- PUNCT - O
tolerated VERB - O
AEDs NOUN - O
with ADP - O
a DET - O
  SPACE - O
≤2 PROPN - O
% NOUN - O
withdrawal NOUN - O
rate NOUN - O
, PUNCT - O
while ADP - O
Tiagabine NNP - B-PERSON
and CCONJ - O
Everolimus NNP - B-PERSON
are VERB - O
discontinued VERB - O
in ADP - O
up ADP - O
to PART - O
> X - O
20 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
patients NOUN - O
because ADP - O
of ADP - O
intolerable ADJ - O
TEAEs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine JJ - B-MEDICINE
oral ADJ - O
suspension NOUN - O
in ADP - O
pediatric ADJ - O
patients NOUN - O
with ADP - O
partial ADJ - O
seizures NOUN - O
and/or CCONJ - O
generalized VERB - O
tonic NOUN - O
- PUNCT - O
clonic ADJ - O
seizures NOUN - O
: PUNCT - O
a DET - O
multi ADJ - O
- ADJ - O
center NOUN - O
, PUNCT - O
single ADJ - O
arm NOUN - O
, PUNCT - O
observational ADJ - O
study NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Oxcarbazepine NN - B-MEDICINE
is VERB - O
used VERB - O
in ADP - O
bipolar ADJ - O
disorder NOUN - O
although ADP - O
it PRON - O
is VERB - O
not ADV - O
stated VERB - O
in ADP - O
the DET - O
data NOUN - O
sheet NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sprue PROPN - O
- PUNCT - O
Like PROPN - O
Enteropathy PROPN - O
Associated PROPN - O
With ADP - O
Oxcarbazepine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
MYB PROPN - O
transcription NOUN - O
factor NOUN - O
is VERB - O
a DET - O
candidate NOUN - O
to PART - O
control VERB - O
pungency NOUN - O
in ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capsicum NN - B-PERSON
annuum NOUN - O
produces VERB - O
a DET - O
single ADJ - O
flower NOUN - O
per ADP - O
node X - O
and CCONJ - O
has VERB - O
an DET - O
early ADJ - O
flowering VERB - O
habit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CaWRKY27 PROPN - O
Negatively PROPN - O
Regulates PROPN - O
H2O2-Mediated VERB - O
Thermotolerance PROPN - O
in ADP - O
Pepper NNP - B-GPE
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Cold ADJ - O
plasma NOUN - O
pretreatment NOUN - O
enhances VERB - O
drying VERB - O
kinetics NOUN - O
and CCONJ - O
quality NOUN - O
attributes NOUN - O
of ADP - O
chili NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Capsaicinoids NOUN - O
from ADP - O
hot ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
and CCONJ - O
their ADJ - O
phytotoxic ADJ - O
effect NOUN - O
on ADP - O
seedling NOUN - O
growth NOUN - O
of ADP - O
lettuce NOUN - O
( PUNCT - O
Lactuca NNP - B-PERSON
sativa NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
is VERB - O
one CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
important ADJ - O
crops NOUN - O
in ADP - O
Brazilian JJ - B-NORP
farming NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Parasitoids NOUN - O
diversity NOUN - O
in ADP - O
organic ADJ - O
Sweet NNP - B-PERSON
Pepper NNP - I-PERSON
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
associated VERB - O
with ADP - O
Basil NNP - B-PERSON
( PUNCT - O
Ocimum NNP - B-ORG
basilicum PROPN - O
) PUNCT - O
and CCONJ - O
Marigold NNP - B-PERSON
( PUNCT - O
Tagetes PROPN - O
erecta NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
investigated VERB - O
the DET - O
antineoplastic ADJ - O
effects NOUN - O
of ADP - O
pectic ADJ - O
polysaccharides NOUN - O
that ADJ - O
were VERB - O
extracted VERB - O
from ADP - O
green ADJ - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
[ PUNCT - O
CAP NNP - B-ORG
] PUNCT - O
) PUNCT - O
in ADP - O
the DET - O
Ehrlich NNP - B-PERSON
carcinoma NOUN - O
in ADP - O
mice NOUN - O
and CCONJ - O
in ADP - O
human ADJ - O
mammary ADJ - O
tumor NOUN - O
lineages NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
hope NOUN - O
to PART - O
provide VERB - O
other ADJ - O
eco ADJ - O
- PUNCT - O
friendly ADJ - O
alternatives NOUN - O
solutions NOUN - O
to PART - O
counter VERB - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
pest NOUN - O
, PUNCT - O
people NOUN - O
have VERB - O
identified VERB - O
a DET - O
number NOUN - O
of ADP - O
protease NOUN - O
inhibitors NOUN - O
( PUNCT - O
PIs NOUN - O
) PUNCT - O
from ADP - O
the DET - O
domesticated VERB - O
capsicum NOUN - O
species VERB - O
Capsicum NNP - B-PERSON
annuum NOUN - O
, PUNCT - O
several ADJ - O
of ADP - O
which ADJ - O
potently ADV - O
inhibited VERB - O
H. NNP - B-NORP
armigera NOUN - O
gut NOUN - O
proteases NOUN - O
and CCONJ - O
impeded ADJ - O
growth NOUN - O
of ADP - O
H. NNP - B-NORP
armigera NOUN - O
larva NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Negatively ADV - O
Regulates VERB - O
the DT - B-ORG
Defense NNP - I-ORG
Response NNP - I-ORG
against ADP - O
Phytophthora NNP - B-ORG
capsici NOUN - O
in ADP - O
Pepper NNP - B-ORG
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
antioxidative ADJ - O
interaction NOUN - O
between IN - B-CARDINAL
two CD - I-CARDINAL
fruits NOUN - O
of ADP - O
contra NOUN - O
- PUNCT - O
similar ADJ - O
characteristics NOUN - O
belonging VERB - O
to ADP - O
same ADJ - O
botanical ADJ - O
family NOUN - O
Solanacea NNP - B-PERSON
namely ADV - O
S. PROPN - O
anguivi NOUN - O
and CCONJ - O
Capsicum NNP - B-PERSON
annuum NOUN - O
was VERB - O
accomplished VERB - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antineoplastic ADJ - O
effect NOUN - O
of ADP - O
pectic ADJ - O
polysaccharides NOUN - O
from ADP - O
green ADJ - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
on ADP - O
mammary ADJ - O
tumor NOUN - O
cells NOUN - O
in ADP - O
vivo NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Red NNP - B-ORG
Pepper NNP - I-ORG
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
synthesis NOUN - O
methods NOUN - O
for ADP - O
semantic ADJ - O
segmentation NOUN - O
in ADP - O
agriculture NOUN - O
: PUNCT - O
A DET - O
Capsicum NNP - B-ORG
annuum NOUN - O
dataset NOUN - O

-DOCSTART- -X- - O

Genome ADV - O
- PUNCT - O
wide ADJ - O
identification NOUN - O
of ADP - O
the DET - O
AP2/ERF NNP - B-PERSON
transcription NOUN - O
factor NOUN - O
family NOUN - O
in ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
proteome NOUN - O
of ADP - O
peroxisomes NOUN - O
purified VERB - O
from ADP - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
fruit NOUN - O
is VERB - O
reported VERB - O
, PUNCT - O
where ADV - O
an DET - O
iron NOUN - O
- PUNCT - O
superoxide NOUN - O
dismutase NOUN - O
( PUNCT - O
Fe NNP - B-ORG
- HYPH - I-ORG
SOD NNP - I-ORG
) PUNCT - O
was VERB - O
localized VERB - O
in ADP - O
these DET - O
organelles NOUN - O
, PUNCT - O
besides ADP - O
other ADJ - O
antioxidant NOUN - O
enzymes NOUN - O
such ADJ - O
as ADP - O
catalase NOUN - O
and CCONJ - O
a DET - O
Mn NNP - B-ORG
- HYPH - I-ORG
SOD NNP - I-ORG
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
enzymes NOUN - O
involved VERB - O
in ADP - O
the DET - O
metabolism NOUN - O
of ADP - O
carbohydrates NOUN - O
, PUNCT - O
malate VERB - O
, PUNCT - O
lipids NOUN - O
and CCONJ - O
fatty ADJ - O
acids NOUN - O
, PUNCT - O
amino ADJ - O
acids NOUN - O
, PUNCT - O
the DET - O
glyoxylate ADJ - O
cycle NOUN - O
and CCONJ - O
in ADP - O
the DET - O
potential ADJ - O
organelles NOUN - O
' PART - O
movements NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORG
Report NNP - I-ORG
of IN - I-ORG
Botrytis NNP - I-ORG
cinerea NN - I-ORG
Causing PROPN - O
Gray PROPN - O
Mold PROPN - O
Disease PROPN - O
of ADP - O
Bell NNP - B-ORG
Pepper NNP - I-ORG
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

Resistance NNP - B-ORG
Response NNP - I-ORG
of IN - I-ORG
Chilli NNP - I-ORG
( PUNCT - O
Capsicum NNP - B-MEDICINE
annuum NN - I-MEDICINE
L. PROPN - O
) PUNCT - O
F1 PROPN - O
to ADP - O
Fusarium NN - B-ORG
oxysporum NOUN - O
Involves VERB - O
Expression PROPN - O
of ADP - O
the DET - O
CaChi2 PROPN - O
Gene PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

CaSK23 PROPN - O
, PUNCT - O
a DET - O
Putative ADJ - O
GSK3/SHAGGY PROPN - O
- PUNCT - O
Like PROPN - O
Kinase PROPN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
, PUNCT - O
Acts VERB - O
as ADP - O
a DET - O
Negative PROPN - O
Regulator PROPN - O
of ADP - O
Pepper NNP - B-ORG
's POS - I-ORG
Response NNP - I-ORG
to ADP - O
Ralstonia NNP - B-GPE
solanacearum PROPN - O
Attack PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Antioxidant ADJ - O
activities NOUN - O
and CCONJ - O
bioactive ADJ - O
compounds NOUN - O
of ADP - O
five CD - B-CARDINAL
Jalopeno NNP - B-ORG
peppers NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
cultivars NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capsicum NNP - B-ORG
annuum NOUN - O
Fruit PROPN - O
Extract PROPN - O
: PUNCT - O
A DET - O
Novel PROPN - O
Reducing VERB - O
Agent PROPN - O
for ADP - O
the DT - B-WORK_OF_ART
Green NNP - I-WORK_OF_ART
Synthesis NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
ZnO NNP - I-WORK_OF_ART
Nanoparticles NNPS - I-WORK_OF_ART
and CCONJ - O
Their PRP$ - B-ORG
Multifunctional NNP - I-ORG
Applications NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Genetic ADJ - O
and CCONJ - O
environmental ADJ - O
factors NOUN - O
underlying VERB - O
variation NOUN - O
in ADP - O
yield NOUN - O
performance NOUN - O
and CCONJ - O
bioactive NOUN - O
compound NOUN - O
content NOUN - O
of ADP - O
hot ADJ - O
pepper NOUN - O
varieties NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
cultivated VERB - O
in ADP - O
two CD - B-CARDINAL
contrasting ADJ - O
Italian JJ - B-NORP
locations NOUN - O

-DOCSTART- -X- - O

Diversely PROPN - O
Stained PROPN - O
Capsicum NNP - B-MEDICINE
annuum NN - I-MEDICINE
Seed NNP - B-PERSON
Specimens NNPS - I-PERSON
of ADP - O
Different PROPN - O
Cultivars PROPN - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
candidate NOUN - O
genes NOUN - O
underlying VERB - O
genic ADJ - O
male NOUN - O
- PUNCT - O
sterile ADJ - O
msc-1 NOUN - O
locus NOUN - O
via ADP - O
genome DET - O
resequencing NOUN - O
in ADP - O
Capsicum NNP - B-GPE
annuum NOUN - O
L. NNP - B-PERSON

-DOCSTART- -X- - O

Characterization NOUN - O
and CCONJ - O
classification NOUN - O
of ADP - O
Spanish JJ - B-NORP
paprika NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
by ADP - O
liquid ADJ - O
chromatography NOUN - O
coupled VERB - O
to ADP - O
electrochemical ADJ - O
detection NOUN - O
with ADP - O
screen NOUN - O
- PUNCT - O
printed VERB - O
carbon NOUN - O
- PUNCT - O
based VERB - O
nanomaterials NOUN - O
electrodes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Whole JJ - B-ORG
Genome NNP - I-ORG
Resequencing NNP - I-ORG
of IN - I-ORG
Capsicum NNP - B-ORG
baccatum NOUN - O
and CCONJ - O
Capsicum NNP - B-PERSON
annuum VERB - O
to ADP - O

-DOCSTART- -X- - O

In ADP - O
fall NN - B-DATE
2014 CD - I-DATE
, PUNCT - O
5 CD - B-CARDINAL
to PART - O
75 CD - B-PERCENT
% NN - I-PERCENT
percent NN - I-PERCENT
of ADP - O
chili NOUN - O
and CCONJ - O
bell NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
in ADP - O
commercial ADJ - O
fields NOUN - O
located VERB - O
in ADP - O
the DET - O
Mexican JJ - B-NORP
states NOUN - O
of ADP - O
Durango NNP - B-GPE
, PUNCT - O
Zacatecas NNP - B-GPE
, PUNCT - O
and CCONJ - O
Michoacán NNP - B-PERSON
had VERB - O
symptoms NOUN - O
of ADP - O
deformed VERB - O
, PUNCT - O
small ADJ - O
, PUNCT - O
mosaic ADJ - O
, PUNCT - O
curled VERB - O
, PUNCT - O
and CCONJ - O
chlorotic ADJ - O
leaves NOUN - O
; PUNCT - O
shortened VERB - O
internodes NOUN - O
; PUNCT - O
plant NOUN - O
dwarfing NOUN - O
; PUNCT - O
or CCONJ - O
phyllody NOUN - O
and CCONJ - O
rosetting ADJ - O
leaf NOUN - O
tips NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
cv PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
fruit NOUN - O
ripening NOUN - O
is VERB - O
a DET - O
complex ADJ - O
process NOUN - O
associated VERB - O
with ADP - O
the DET - O
metabolism NOUN - O
of ADP - O
reactive ADJ - O
oxygen NOUN - O
species NOUN - O
( PUNCT - O
ROS PROPN - O
) PUNCT - O
and CCONJ - O
nitrogen NOUN - O
oxygen NOUN - O
species NOUN - O
( PUNCT - O
RNS PROPN - O
) PUNCT - O
, PUNCT - O
little ADJ - O
is VERB - O
known VERB - O
about ADP - O
the DET - O
potential ADJ - O
involvement NOUN - O
of ADP - O
endogenous ADJ - O
H2S. NN - B-ORG
Using VBG - I-ORG
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
as ADP - O
a DET - O
model ADJ - O
non ADJ - O
- ADJ - O
climacteric ADJ - O
fruit NOUN - O
during ADP - O
the DET - O
green ADJ - O
and CCONJ - O
red ADJ - O
ripening NOUN - O
stages NOUN - O
, PUNCT - O
we PRON - O
studied VERB - O
endogenous ADJ - O
H2S ADJ - O
content NOUN - O
and CCONJ - O
cytosolic ADJ - O
l NOUN - O
- PUNCT - O
cysteine NOUN - O
desulfhydrase NOUN - O
( PUNCT - O
L PROPN - O
- PUNCT - O
DES PROPN - O
) PUNCT - O
activity NOUN - O
which ADJ - O
increased VERB - O
by ADP - O
14 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
28 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
, PUNCT - O
in ADP - O
red ADJ - O
pepper NOUN - O
fruits NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
this DET - O
important ADJ - O
gene NOUN - O
family NOUN - O
was VERB - O
not ADV - O
fully ADV - O
characterized VERB - O
in ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
, PUNCT - O
an DET - O
economically ADV - O
important ADJ - O
vegetable NOUN - O
crop NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Biochar PROPN - O
potential ADJ - O
in ADP - O
intensive ADJ - O
cultivation NOUN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
( PUNCT - O
sweet ADJ - O
pepper NOUN - O
) PUNCT - O
: PUNCT - O
crop NOUN - O
yield NOUN - O
and CCONJ - O
plant NOUN - O
protection NOUN - O

-DOCSTART- -X- - O

1H NNP - B-CARDINAL
NMR NNP - B-ORG
- PUNCT - O
based VERB - O
metabolomic NOUN - O
profiling NOUN - O
for ADP - O
identification NOUN - O
of ADP - O
metabolites NOUN - O
in ADP - O
Capsicum NNP - B-GPE
annuum NOUN - O
cv PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Heritability NOUN - O
of ADP - O
the DET - O
resistance NOUN - O
to PART - O
pepper VERB - O
huasteco ADJ - O
yellow ADJ - O
vein NOUN - O
virus NOUN - O
in ADP - O
wild ADJ - O
genotypes NOUN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
direct ADJ - O
impact NOUN - O
of ADP - O
salt NOUN - O
stress NOUN - O
on ADP - O
seed NOUN - O
germination NOUN - O
, PUNCT - O
the DET - O
experiment NOUN - O
was VERB - O
conducted VERB - O
using VERB - O
Capsicum NNP - B-ORG
annuum NOUN - O
seeds NOUN - O
that ADJ - O
were VERB - O
treated VERB - O
with ADP - O
different ADJ - O
molar ADJ - O
concentrations NOUN - O
of ADP - O
NaCl NNP - B-LOC
. PUNCT - O

-DOCSTART- -X- - O

Pyriforme PROPN - O
) PUNCT - O
and CCONJ - O
Serrano NNP - B-ORG
peppers NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
using VERB - O
an DET - O
MPN NNP - B-ORG
technique NOUN - O

-DOCSTART- -X- - O

An DET - O
exhaustive ADJ - O
analysis NOUN - O
of ADP - O
the DET - O
CaARF NNP - B-NORP
family NOUN - O
was VERB - O
performed VERB - O
using VERB - O
the DET - O
latest ADJ - O
publicly ADV - O
available ADJ - O
genome DET - O
for ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

Phylogenetic ADJ - O
analysis NOUN - O
of ADP - O
the DET - O
ARFs NOUN - O
from ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
, PUNCT - O
tomato NOUN - O
( PUNCT - O
Solanum NNP - B-NORP
lycopersicum VERB - O
L. NNP - B-PERSON
) PUNCT - O
, PUNCT - O
Arabidopsis NNP - B-PERSON
and CCONJ - O
rice NOUN - O

-DOCSTART- -X- - O

Complete VERB - O
genome DET - O
sequencing NOUN - O
and CCONJ - O
analysis NOUN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
varieties NOUN - O

-DOCSTART- -X- - O

Large ADJ - O
- PUNCT - O
scale NOUN - O
profiling NOUN - O
of ADP - O
carotenoids NOUN - O
by ADP - O
using VERB - O
non ADJ - O
aqueous ADJ - O
reversed ADJ - O
phase NOUN - O
liquid NOUN - O
chromatography NOUN - O
- PUNCT - O
photodiode ADJ - O
array NOUN - O
detection NOUN - O
- PUNCT - O
triple ADJ - O
quadrupole NOUN - O
linear NOUN - O
ion NOUN - O
trap NOUN - O
mass NOUN - O
spectrometry NOUN - O
: PUNCT - O
Application NOUN - O
to ADP - O
some DET - O
varieties NOUN - O
of ADP - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Proteomic ADJ - O
analysis NOUN - O
reveals VERB - O
strong ADJ - O
mitochondrial ADJ - O
involvement NOUN - O
in ADP - O
cytoplasmic ADJ - O
male ADJ - O
sterility NOUN - O
of ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Developmental ADJ - O
landmarks NOUN - O
during ADP - O
floral ADJ - O
ontogeny NOUN - O
of ADP - O
jalapeño NOUN - O
chili NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
and CCONJ - O
the DET - O
effect NOUN - O
of ADP - O
gibberellin NOUN - O
on ADP - O
ovary ADJ - O
growth NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial NNP - B-ORG
Activity NNP - I-ORG
of IN - I-ORG
Selected NNP - I-ORG
Polyphenols NNPS - I-ORG
and CC - I-ORG
Capsaicinoids NNPS - B-PERSON
Identified VBN - I-PERSON
in ADP - O
Pepper NNP - B-PERSON
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
and CCONJ - O
Their ADJ - O
Possible ADJ - O
Mode PROPN - O
of ADP - O
Interaction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
drying VERB - O
methods NOUN - O
( PUNCT - O
microwave NOUN - O
vacuum NOUN - O
, PUNCT - O
freeze NOUN - O
, PUNCT - O
hot ADJ - O
air NOUN - O
and CCONJ - O
sun NOUN - O
drying VERB - O
) PUNCT - O
on ADP - O
physical ADJ - O
, PUNCT - O
chemical NOUN - O
and CCONJ - O
nutritional ADJ - O
attributes NOUN - O
of ADP - O
five CD - B-CARDINAL
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Three CD - B-CARDINAL
gibberellin NOUN - O
receptors NOUN - O
, PUNCT - O
CaGID1b.1 NNPS - B-ORG
, PUNCT - O
CaGID1b.2 NNP - B-PERSON
and CCONJ - O
CaGID1c NNP - B-PERSON
, PUNCT - O
and CCONJ - O
a DET - O
DELLA NNP - B-ORG
protein NOUN - O
, PUNCT - O
CaGAI NNP - B-PERSON
, PUNCT - O
have VERB - O
been VERB - O
identified VERB - O
in ADP - O
Capsicum NNP - B-GPE
annuum NOUN - O
L. NNP - B-PERSON

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
experiment NOUN - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
test VERB - O
the DET - O
impact NOUN - O
of ADP - O
hydrogen NOUN - O
sulfide NOUN - O
( PUNCT - O
H2S VERB - O
) PUNCT - O
on ADP - O
growth NOUN - O
, PUNCT - O
key NOUN - O
oxidant NOUN - O
such ADJ - O
as ADP - O
hydrogen NOUN - O
peroxide NOUN - O
, PUNCT - O
mineral NOUN - O
elements NOUN - O
, PUNCT - O
and CCONJ - O
antioxidative ADJ - O
defense NOUN - O
in ADP - O
Capia NNP - B-GPE
- PUNCT - O
type NOUN - O
red ADJ - O
sweet ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
plants NOUN - O
subjected VERB - O
to ADP - O
high ADJ - O
concentration NOUN - O
of ADP - O
zinc NOUN - O
( PUNCT - O
Zn PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Risk PROPN - O
Assessment PROPN - O
Model PROPN - O
for ADP - O
Bacterial PROPN - O
Leaf PROPN - O
Spot PROPN - O
of ADP - O
Pepper PROPN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
) PUNCT - O
, PUNCT - O
Caused VERB - O
by ADP - O
Xanthomonas NNP - B-PERSON
euvesicatoria NOUN - O
, PUNCT - O

-DOCSTART- -X- - O

Hypolipidemic PROPN - O
and CCONJ - O
Antioxidant PROPN - O
Properties PROPN - O
of ADP - O
Hot PROPN - O
Pepper PROPN - O
Flower PROPN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Recent ADJ - O
results NOUN - O
from ADP - O
our ADJ - O
laboratory NOUN - O
have VERB - O
shown VERB - O
the DET - O
purification NOUN - O
of ADP - O
a DET - O
new ADJ - O
trypsin NOUN - O
inhibitor NOUN - O
, PUNCT - O
named VERB - O
CaTI NNP - B-ORG
, PUNCT - O
from ADP - O
chilli NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
seeds NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Reversed ADJ - O
- PUNCT - O
Phase PROPN - O
High PROPN - O
- PUNCT - O
Performance PROPN - O
Liquid PROPN - O
Chromatography PROPN - O
for ADP - O
the DET - O
Quantification PROPN - O
and CCONJ - O
Optimization PROPN - O
for ADP - O
Extracting VERB - O
10 NUM - O
Kinds PROPN - O
of ADP - O
Carotenoids PROPN - O
in ADP - O
Pepper PROPN - O
( PUNCT - O
Capsicum NNP - B-MEDICINE
annuum NN - I-MEDICINE
L. PROPN - O
) PUNCT - O
Leaves PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Rhizospheric PROPN - O
Microbiome PROPN - O
Profiling PROPN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
Cultivated NNP - I-PERSON
in ADP - O
Amended VBN - B-GPE
Soils NNPS - I-GPE
by ADP - O
16S NUM - O
and CCONJ - O
Internal PROPN - O
Transcribed PROPN - O
Spacer PROPN - O
2 NUM - O
rRNA PROPN - O
Amplicon PROPN - O
Metagenome PROPN - O
Sequencing PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To ADP - O
date NOUN - O
, PUNCT - O
there ADV - O
have VERB - O
been VERB - O
no DET - O
comprehensive ADJ - O
studies NOUN - O
investigating VERB - O
chromosomal ADJ - O
location NOUN - O
, PUNCT - O
gene NOUN - O
structure NOUN - O
, PUNCT - O
gene NOUN - O
phylogeny NOUN - O
, PUNCT - O
conserved VERB - O
motifs NOUN - O
, PUNCT - O
or CCONJ - O
gene NOUN - O
expression NOUN - O
of ADP - O
NAC NNP - B-ORG
in ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

The DET - O
recent ADJ - O
release NOUN - O
of ADP - O
the DET - O
complete ADJ - O
genome DET - O
sequence NOUN - O
of ADP - O
pepper NOUN - O
allowed VERB - O
us PRON - O
to PART - O
perform VERB - O
a DET - O
genome ADV - O
- PUNCT - O
wide ADJ - O
investigation NOUN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
NAC NNP - I-PERSON
( PUNCT - O
CaNAC NOUN - O
) PUNCT - O
proteins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mapping VERB - O
of ADP - O
male ADJ - O
sterility NOUN - O
gene NOUN - O
ms10 NOUN - O
in ADP - O
chilli NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Proteomic ADJ - O
analysis NOUN - O
of ADP - O
salicylic ADJ - O
acid NOUN - O
enhanced VERB - O
disease NOUN - O
resistance NOUN - O
in ADP - O
bacterial ADJ - O
wilt NOUN - O
affected VERB - O
chilli NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
crop NOUN - O

-DOCSTART- -X- - O

Process NOUN - O
optimization NOUN - O
and CCONJ - O
characterization NOUN - O
of ADP - O
fragrant ADJ - O
oil NOUN - O
from ADP - O
red ADJ - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
seed NOUN - O
extracted VERB - O
by ADP - O
subcritical ADJ - O
butane NOUN - O
extraction NOUN - O

-DOCSTART- -X- - O

Pyriforme PROPN - O
) PUNCT - O
and CCONJ - O
Serrano NNP - B-ORG
peppers NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O
using VERB - O
an DET - O
MPN NNP - B-ORG
technique NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capsicum NN - B-ORG
annuum NOUN - O
( PUNCT - O
Solanaceae PROPN - O
) PUNCT - O
, PUNCT - O
commonly ADV - O
known VERB - O
as ADP - O
chilli NOUN - O
, PUNCT - O
is VERB - O
a DET - O
medicinal ADJ - O
spice NOUN - O
used VERB - O
in ADP - O
various ADJ - O
Indian JJ - B-NORP
traditional ADJ - O
systems NOUN - O
of ADP - O
medicine NOUN - O
and CCONJ - O
it PRON - O
has VERB - O
been VERB - O
acknowledged VERB - O
to PART - O
treat VERB - O
various ADJ - O
health NOUN - O
ailments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Phytochemistry NOUN - O
and CCONJ - O
gastrointestinal ADJ - O
benefits NOUN - O
of ADP - O
the DET - O
medicinal ADJ - O
spice NOUN - O
, PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
( PUNCT - O
Chilli PROPN - O
) PUNCT - O
: PUNCT - O
a DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Deciphering VERB - O
the DET - O
role NOUN - O
of ADP - O
the DET - O
phenylpropanoid NOUN - O
metabolism NOUN - O
in ADP - O
the DET - O
tolerance NOUN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
to ADP - O
Verticillium NNP - B-ORG
dahliae VERB - O
Kleb PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Genetic ADJ - O
Diversity PROPN - O
, PUNCT - O
Population PROPN - O
Structure PROPN - O
, PUNCT - O
and CCONJ - O
Heritability NNP - B-ORG
of IN - I-ORG
Fruit NNP - I-ORG
Traits NNPS - I-ORG
in ADP - O
Capsicum NNP - B-GPE
annuum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capsicum NN - B-ORG
annuum NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

S NOUN - O
- PUNCT - O
nitrosoglutathione NOUN - O
reductase NOUN - O
( PUNCT - O
GSNOR NNP - B-ORG
) PUNCT - O
activity NOUN - O
is VERB - O
down ADV - O
- PUNCT - O
regulated VERB - O
during ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
fruit NOUN - O
ripening NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spent PROPN - O
Mushroom PROPN - O
Compost PROPN - O
( PUNCT - O
SMC NNP - B-ORG
) PUNCT - O
as ADP - O
Soil NNP - B-PERSON
Conditioner NNP - I-PERSON
on ADP - O
the DET - O
Growth PROPN - O
and CCONJ - O
Yield PROPN - O
Performance PROPN - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
and CCONJ - O
Solanum NNP - B-ORG
lycopersicon NOUN - O
L. NNP - B-PERSON
Seedlings NNP - I-PERSON
under ADP - O
Greenhouse NNP - B-ORG
Conditions NNP - I-ORG
in ADP - O
Ghana NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Genome ADV - O
- PUNCT - O
wide ADJ - O
SNP PROPN - O
discovery NOUN - O
and CCONJ - O
population NOUN - O
structure NOUN - O
analysis NOUN - O
in ADP - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
) PUNCT - O

-DOCSTART- -X- - O

Overexpression PROPN - O
of ADP - O
Pea PROPN - O
DNA PROPN - O
Helicase PROPN - O
45 NUM - O
( PUNCT - O
PDH45 NNP - B-ORG
) PUNCT - O
imparts VERB - O
tolerance NOUN - O
to ADP - O
multiple ADJ - O
abiotic ADJ - O
stresses NOUN - O
in ADP - O
chili PROPN - O
( PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial ADJ - O
activity NOUN - O
and CCONJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O
of ADP - O
a DET - O
thionin NOUN - O
- PUNCT - O
like ADJ - O
peptide NOUN - O
from ADP - O
Capsicum NNP - B-GPE
annuum NOUN - O
fruits NOUN - O
and CCONJ - O
combinatorial ADJ - O
treatment NOUN - O
with ADP - O
fluconazole NOUN - O
against ADP - O
Fusarium NN - B-ORG
solani NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Chemical NNP - B-ORG
, PUNCT - O
Organic PROPN - O
and CCONJ - O
Bio PROPN - O
- PUNCT - O
Fertilizers PROPN - O
Application PROPN - O
on ADP - O
Bell NNP - B-ORG
Pepper NNP - I-ORG
, PUNCT - O
Capsicum NNP - B-ORG
annuum NOUN - O
L. NNP - B-PERSON
and CCONJ - O
Biological NNP - B-ORG
Parameters NNPS - I-ORG
of IN - I-ORG
Myzus NNP - I-ORG
persicae NOUN - O
( PUNCT - O
Sulzer NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
work NOUN - O
was VERB - O
to PART - O
isolate VERB - O
and CCONJ - O
identify VERB - O
native ADJ - O
bacteria NOUN - O
from ADP - O
plants NOUN - O
collected VERB - O
in ADP - O
the DT - B-GPE
State NNP - I-GPE
of IN - I-GPE
Yucatán NNP - I-GPE
, PUNCT - O
México NNP - B-GPE
with ADP - O
the DET - O
ability NOUN - O
to PART - O
promote VERB - O
growth NOUN - O
of ADP - O
chili NOUN - O
pepper NOUN - O
( PUNCT - O
Capsicum NNP - B-PERSON
annuum NOUN - O
L. NNP - B-PERSON
cv NNP - I-PERSON
Jalapeño NNP - I-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Application NOUN - O
and CCONJ - O
bioactive ADJ - O
properties NOUN - O
of ADP - O
CaTI NNP - B-ORG
, PUNCT - O
a DET - O
trypsin NOUN - O
inhibitor NOUN - O
from ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
seeds NOUN - O
: PUNCT - O
membrane ADJ - O
permeabilization NOUN - O
, PUNCT - O
oxidative ADJ - O
stress NOUN - O
and CCONJ - O
intracellular ADJ - O
target NOUN - O
in ADP - O
phytopathogenic ADJ - O
fungi NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
complete ADJ - O
chloroplast NOUN - O
genome DET - O
of ADP - O
Capsicum NNP - B-ORG
annuum NOUN - O
var NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
is VERB - O
the DET - O
most ADV - O
potent ADJ - O
osteoclast ADJ - O
inhibitor NOUN - O
and CCONJ - O
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
advanced ADJ - O
cancer NOUN - O
patients NOUN - O
with ADP - O
bone NOUN - O
metastasis NOUN - O
, PUNCT - O
but CCONJ - O
its ADJ - O
role NOUN - O
on ADP - O
cancer NOUN - O
stem NOUN - O
cells NOUN - O
( PUNCT - O
CSCs PROPN - O
) PUNCT - O
remains VERB - O
unclear ADJ - O
. PUNCT - O

Zoledronic JJ - B-GPE
acid NOUN - O
inhibited VERB - O
cervical ADJ - O
cancer NOUN - O
cells NOUN - O
derived VERB - O
CSCs NOUN - O
proliferation NOUN - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

Zoledronic JJ - B-GPE
acid NOUN - O
inhibited VERB - O
phosphorylated ADJ - O
Erk1/2 NNP - B-PERSON
and CCONJ - O
Akt PROPN - O
in ADP - O
cervical ADJ - O
cancer NOUN - O
cells NOUN - O
derived VERB - O
CSCs NOUN - O
. PUNCT - O

Zoledronic JJ - B-PERSON
acid NOUN - O
inhibited VERB - O
the DET - O
growth NOUN - O
of ADP - O
cervical ADJ - O
cancer NOUN - O
cells NOUN - O
derived VERB - O
CSCs NOUN - O
through ADP - O
attenuating VERB - O
their ADJ - O
stemness NOUN - O
phenotype NOUN - O
, PUNCT - O
inducing VERB - O
apoptosis NOUN - O
, PUNCT - O
and CCONJ - O
arresting VERB - O
cell NOUN - O
cycle NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
is VERB - O
superior ADJ - O
to ADP - O
tenofovir DET - O
disoproxil VERB - O
fumarate NOUN - O
- PUNCT - O
switching NOUN - O
for ADP - O
low ADJ - O
bone NOUN - O
mineral NOUN - O
density NOUN - O
in ADP - O
adults NOUN - O
with ADP - O
HIV PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
mesothelioma NOUN - O
- PUNCT - O
a DET - O
feasibility NOUN - O
study NOUN - O
( PUNCT - O
Zol NNP - B-ORG
- HYPH - I-ORG
A NNP - I-ORG
Trial NNP - I-ORG
) PUNCT - O

-DOCSTART- -X- - O

Epigallocatechin-3-gallate PROPN - O
reduces VERB - O
damage NOUN - O
to ADP - O
osteoblast VERB - O
- PUNCT - O
like ADJ - O
cells NOUN - O
treated VERB - O
with ADP - O
Zoledronic NNP - B-GPE
acid NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
developed VERB - O
Zoledronic NNP - B-GPE
acid NOUN - O

To PART - O
solve VERB - O
these DET - O
two CD - B-CARDINAL
problems NOUN - O
, PUNCT - O
we PRON - O
prepared VERB - O
a DET - O
new ADJ - O
biomaterial NOUN - O
, PUNCT - O
the DET - O
Mg NNP - B-PERSON
- HYPH - I-PERSON
Sr NNP - I-PERSON
alloys VERB - O
that ADJ - O
were VERB - O
first ADV - O
coated VERB - O
with ADP - O
calcium NOUN - O
phosphate ADV - O
and CCONJ - O
then ADV - O
loaded VERB - O
with ADP - O
a DET - O
tumor NOUN - O
- PUNCT - O
inhibiting VERB - O
molecule NOUN - O
( PUNCT - O
Zoledronic NNP - B-NORP
acid NOUN - O
, PUNCT - O
ZA NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
induces VERB - O
cytogenetic ADJ - O
toxicity NOUN - O
in ADP - O
male ADJ - O
germline NOUN - O
cells NOUN - O
of ADP - O
Swiss JJ - B-NORP
albino NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
inhibited VERB - O
osteoclast ADJ - O
survival NOUN - O
, PUNCT - O
whereas ADP - O
an DET - O
inhibitory ADJ - O
effect NOUN - O
of ADP - O
denosumab NOUN - O
on ADP - O
osteoclast ADJ - O
survival NOUN - O
was VERB - O
not ADV - O
observed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
( PUNCT - O
Reclast PROPN - O
® NOUN - O
, PUNCT - O
Aclasta NNP - B-PERSON
® NNP - I-PERSON
) PUNCT - O
is VERB - O
an DET - O
intravenous ADJ - O
, PUNCT - O
highly ADV - O
potent ADJ - O
aminobisphosphonate NOUN - O
approved VERB - O
worldwide ADV - O
, PUNCT - O
including VERB - O
in ADP - O
the DET - O
USA NNP - B-GPE
, PUNCT - O
EU NNP - B-ORG
and CCONJ - O
Japan NNP - B-GPE
for ADP - O
use NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
primary ADJ - O
or CCONJ - O
secondary ADJ - O
osteoporosis NOUN - O
or CCONJ - O
low ADJ - O
bone NOUN - O
mass NOUN - O
( PUNCT - O
approved VERB - O
indications NOUN - O
vary VERB - O
between ADP - O
countries NOUN - O
) PUNCT - O
. PUNCT - O

Zoledronic JJ - B-PERSON
acid NOUN - O
once ADV - O
yearly ADV - O
for ADP - O
up ADP - O
to PART - O
3 NUM - O
  SPACE - O
years NOUN - O
improved VERB - O
bone NOUN - O
mineral NOUN - O
density NOUN - O
( PUNCT - O
BMD NNP - B-ORG
) PUNCT - O
at ADP - O
several ADJ - O
skeletal ADJ - O
sites NOUN - O
, PUNCT - O
reduced VERB - O
fracture NOUN - O
risk NOUN - O
and CCONJ - O
bone NOUN - O
turnover NOUN - O
, PUNCT - O
and/or CCONJ - O
preserved VERB - O
bone NOUN - O
structure NOUN - O
and CCONJ - O
mass NOUN - O
relative NOUN - O
to ADP - O
placebo NOUN - O
in ADP - O
clinical ADJ - O
studies NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
primary ADJ - O
or CCONJ - O
secondary ADJ - O
osteoporosis NOUN - O
. PUNCT - O

Zoledronic JJ - B-PERSON
acid NOUN - O
administered VERB - O
annually ADV - O
or CCONJ - O
once ADV - O
in ADP - O
2 CD - B-DATE
  _SP - I-DATE
years NNS - I-DATE
was VERB - O
also ADV - O
effective ADJ - O
in ADP - O
preventing VERB - O
bone NOUN - O
loss NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
low ADJ - O
bone NOUN - O
mass NOUN - O
. PUNCT - O

Zoledronic JJ - B-PERSON
acid NOUN - O
was VERB - O
generally ADV - O
well ADV - O
tolerated VERB - O
, PUNCT - O
with ADP - O
the DET - O
most ADV - O
common ADJ - O
adverse ADJ - O
events NOUN - O
( PUNCT - O
AEs NOUN - O
) PUNCT - O
being VERB - O
transient ADJ - O
, PUNCT - O
mild ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
moderate ADJ - O
post ADJ - O
- ADJ - O
infusion ADJ - O
symptoms NOUN - O
, PUNCT - O
which ADJ - O
decreased VERB - O
with ADP - O
subsequent ADJ - O
infusions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
, PUNCT - O
an DET - O
FPPS NNP - B-ORG
inhibitor NOUN - O
, PUNCT - O
ameliorates VERB - O
liver NOUN - O
steatosis NOUN - O
through ADP - O
inhibiting VERB - O
hepatic ADJ - O
de X - O
novo NOUN - O
lipogenesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
( PUNCT - O
ZOL NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
nitrogen NOUN - O
- PUNCT - O
containing VERB - O
bisphosphonate NOUN - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
bone NOUN - O
diseases NOUN - O
and CCONJ - O
calcium NOUN - O
metabolism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
label NOUN - O
- PUNCT - O
free ADJ - O
, PUNCT - O
sensitive ADJ - O
and CCONJ - O
selective ADJ - O
off PART - O
and CCONJ - O
on ADP - O
signaling VERB - O
fluorescence NOUN - O
platform NOUN - O
for ADP - O
assay NOUN - O
of ADP - O
trace NOUN - O
levels NOUN - O
of ADP - O
Zoledronic NNP - B-GPE
acid NOUN - O
( PUNCT - O
ZA NNP - B-PERSON
) PUNCT - O
drug NOUN - O
in ADP - O
human ADJ - O
biological ADJ - O
samples NOUN - O
based VERB - O
on ADP - O
nitrogen NOUN - O
doped VERB - O
carbon NOUN - O
dots NOUN - O
( PUNCT - O

-DOCSTART- -X- - O

P NOUN - O
  SPACE - O
> X - O
  SPACE - O
.05).Zoledronic PUNCT - O
acid NOUN - O
appears VERB - O
to PART - O
be VERB - O
more ADV - O
effective ADJ - O
in ADP - O
postmenopausal ADJ - O
osteoporosis NOUN - O
in ADP - O
Han NNP - B-NORP
than ADP - O
in ADP - O
Uighur NNP - B-NORP
subjects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
is VERB - O
an DET - O
effective ADJ - O
radiosensitizer NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
osteosarcoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zoledronic JJ - B-GPE
acid NOUN - O
( PUNCT - O
ZOL NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
clinically ADV - O
available ADJ - O
agent NOUN - O
that ADJ - O
inhibits VERB - O
bone NOUN - O
destruction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
Topical PROPN - O
Sucralfate NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
Management NNP - I-ORG
of IN - I-ORG
Pressure NNP - I-ORG
Ulcer NNP - I-ORG
in ADP - O
Hospitalized ADJ - O
Patients PROPN - O
: PUNCT - O
A DET - O
Prospective PROPN - O
, PUNCT - O
Randomized VERB - O
, PUNCT - O
Placebo PROPN - O
- PUNCT - O
Controlled PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sucralfate JJ - B-MEDICINE
, PUNCT - O
rebamipide VERB - O
, PUNCT - O
and CCONJ - O
cimetidine NOUN - O
displayed VERB - O
gastro ADV - O
- PUNCT - O
protective ADJ - O
effects NOUN - O
in ADP - O
vivo NOUN - O
( PUNCT - O
decreased ADJ - O
number NOUN - O
of ADP - O
gastric ADJ - O
ulcers NOUN - O
: PUNCT - O
-50 NOUN - O
% NOUN - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
, PUNCT - O
-22 PUNCT - O
% NOUN - O
NS PROPN - O
, PUNCT - O
and CCONJ - O
-69 NUM - O
% NOUN - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
, PUNCT - O
respectively ADV - O
, PUNCT - O
and CCONJ - O
reduced VERB - O
length NOUN - O
of ADP - O
gastric ADJ - O
lesions NOUN - O
: PUNCT - O
-62 CD - B-PERCENT
% NN - I-PERCENT
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
, PUNCT - O
-29 VERB - O
% NOUN - O
NS NOUN - O
, PUNCT - O
and CCONJ - O
-70 NOUN - O
% NOUN - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Clinical NNP - B-ORG
Drug NNP - I-ORG
- HYPH - I-ORG
Drug NNP - I-ORG
Pharmacokinetic NNP - I-ORG
Interaction NNP - I-ORG
Potential NNP - I-ORG
of IN - I-ORG
Sucralfate NNP - I-MEDICINE
with IN - I-ORG
Other JJ - I-ORG
Drugs NNS - I-ORG
: : - I-ORG
Review PROPN - O
and CCONJ - O
Perspectives PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sucralfate JJ - B-MEDICINE
impairs NOUN - O
absorption NOUN - O
of ADP - O
ciprofloxacin PROPN - O
and CCONJ - O
other ADJ - O
fluoroquinolones NOUN - O
in ADP - O
humans NOUN - O
, PUNCT - O
but CCONJ - O
no DET - O
sucralfate JJ - B-MEDICINE
- PUNCT - O
fluoroquinolone ADJ - O
interaction NOUN - O
has VERB - O
been VERB - O
reported VERB - O
in ADP - O
dogs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluating VERB - O
Sucralfate NNP - B-MEDICINE
as ADP - O
a DET - O
Phosphate PROPN - O
Binder PROPN - O
in ADP - O
Normal PROPN - O
Cats PROPN - O
and CCONJ - O
Cats NNPS - B-PERSON
with ADP - O
Chronic PROPN - O
Kidney PROPN - O
Disease PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Sucralfate NNP - B-MEDICINE
increased VERB - O
the DET - O
content NOUN - O
of ADP - O
acidic ADJ - O
mucins NOUN - O
, PUNCT - O
primarily ADV - O
at ADP - O
the DET - O
expense NOUN - O
of ADP - O
sialomucin NOUN - O
, PUNCT - O
which ADJ - O
was VERB - O
affected VERB - O
by ADP - O
the DET - O
dose NOUN - O
and CCONJ - O
time NOUN - O
of ADP - O
intervention NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sucralfate NN - B-MEDICINE
is VERB - O
known VERB - O
to PART - O
have VERB - O
multiple ADJ - O
beneficial ADJ - O
effects NOUN - O
on ADP - O
wound NOUN - O
healing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

MOISTURIZING VERB - O
HAND NNP - B-MEDICINE
SANITIZER NNP - I-MEDICINE

-DOCSTART- -X- - O

NON NNP - B-ORG
- : - I-ORG
ALCOHOLIC NN - I-ORG
HAND NNP - I-ORG
SANITIZER NNP - I-ORG

-DOCSTART- -X- - O

: PUNCT - O
Trapped VERB - O
in ADP - O
a DT - B-LOC
Sea NNP - I-LOC
of IN - I-LOC
Uncertainty NNP - I-LOC
: PUNCT - O
Limitations NOUN - O
in ADP - O
Unintentional NNP - B-ORG
Injury NNP - I-ORG
Research NNP - I-ORG
in ADP - O
the DET - O
Philippines NNP - B-GPE
and CCONJ - O
Interdisciplinary NNP - B-ORG
Solutions NNPS - I-ORG
to PART - O
Reduce VERB - O
Fatal PROPN - O
Box PROPN - O
Jellyfish PROPN - O
Stings PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Scorpion PROPN - O
Sting NNP - B-MEDICINE
Management PROPN - O
at ADP - O
Tertiary PROPN - O
and CCONJ - O
Secondary ADJ - O
Care PROPN - O
Emergency PROPN - O
Departments PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Recent ADJ - O
Trends PROPN - O
in ADP - O
Wasp PROPN - O
Nest PROPN - O
Removal PROPN - O
and CCONJ - O
Hymenoptera PROPN - O
Stings PROPN - O
in ADP - O
South NNP - B-GPE
Korea NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Smoke NN - B-WORK_OF_ART
Conditions NNS - I-WORK_OF_ART
Affect VBP - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Release NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Venom NNP - I-WORK_OF_ART
Droplet NNP - I-WORK_OF_ART
Accompanying NNP - I-WORK_OF_ART
Sting NNP - I-MEDICINE
Extension NN - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Honey NNP - I-WORK_OF_ART
Bees NNP - I-WORK_OF_ART

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
the DET - O
role NOUN - O
of ADP - O
cGas PROPN - O
- PUNCT - O
Sting VBG - B-MEDICINE
pathway NOUN - O
in ADP - O
response NOUN - O
to ADP - O
ECTV NNP - B-ORG
is VERB - O
not ADV - O
clearly ADV - O
understood VERB - O
. PUNCT - O

I PRON - O
IFN NNP - B-ORG
responses VERB - O
to ADP - O
ECTV NNP - B-ORG
that ADJ - O
are VERB - O
dependent ADJ - O
upon ADP - O
cGas NOUN - O
, PUNCT - O
Sting NN - B-MEDICINE
, PUNCT - O
TANK NNP - B-ORG
binding VERB - O
kinase NOUN - O
1 CD - B-CARDINAL
( PUNCT - O
Tbk1 NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
interferon NOUN - O
regulatory ADJ - O
factor NOUN - O
3 CD - B-CARDINAL
( PUNCT - O
Irf3 PROPN - O
) PUNCT - O
signaling VERB - O
. PUNCT - O

Disruption NOUN - O
of ADP - O
cGas PROPN - O
or CCONJ - O
Sting VBG - B-MEDICINE
expression NOUN - O
in ADP - O
mouse NOUN - O
macrophages NOUN - O
blocked VERB - O
the DET - O
type NOUN - O
I PRON - O
IFN NNP - B-ORG
production NOUN - O
and CCONJ - O
facilitated VERB - O
ECTV NNP - B-ORG
replication NOUN - O
. PUNCT - O

Consistently ADV - O
, PUNCT - O
mice NOUN - O
deficient ADJ - O
in ADP - O
cGas PROPN - O
or CCONJ - O
Sting NNP - B-MEDICINE
exhibited VERB - O
lower ADJ - O
type NOUN - O
I PRON - O
IFN NNP - B-ORG
levels NOUN - O
and CCONJ - O
higher ADJ - O
viral ADJ - O
loads NOUN - O
, PUNCT - O
and CCONJ - O
are VERB - O
more ADV - O
susceptible ADJ - O
to ADP - O
mousepox NOUN - O
. PUNCT - O

Collectively ADV - O
, PUNCT - O
our ADJ - O
study NOUN - O
indicates VERB - O
that ADP - O
the DET - O
cGas NOUN - O
- PUNCT - O
Sting NNP - B-MEDICINE
pathway NOUN - O
is VERB - O
critical ADJ - O
for ADP - O
sensing NOUN - O
of ADP - O
ECTV NNP - B-ORG
infection NOUN - O
, PUNCT - O
inducing VERB - O
the DET - O
type NOUN - O
I PRON - O
IFN NNP - B-ORG
production NOUN - O
, PUNCT - O
and CCONJ - O
controlling VERB - O
ECTV NNP - B-ORG
replication NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Millepora NNP - B-GPE
species VERB - O
( PUNCT - O
Fire NNP - B-ORG
Coral NNP - I-ORG
) -RRB- - I-ORG
Sting NN - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

ATORVASTATIN NNP - B-MEDICINE
CALCIUM NNP - I-MEDICINE
PROPYLENE VERB - O
GLYCOL NOUN - O
SOLVATES NOUN - O

-DOCSTART- -X- - O

NOVEL PROPN - O
CRYSTALLINE PROPN - O
FORM NOUN - O
OF ADP - O
ATORVASTATIN NNP - B-MEDICINE
CALCIUM NNP - I-MEDICINE
SALT NOUN - O
OR CCONJ - O
HYDRATE NOUN - O
THEREOF NOUN - O

-DOCSTART- -X- - O

AMORPHOUS PROPN - O
ATORVASTATIN NNP - B-MEDICINE
CALCIUM RB - I-MEDICINE

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
THE DET - O
PREPARATION NOUN - O
OF ADP - O
AMORPHOUS PROPN - O
ATORVASTATIN NNP - B-MEDICINE
CALCIUM NNP - I-MEDICINE
SALT NOUN - O

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
FORMS PROPN - O
OF ADP - O
ATORVASTATIN NNP - B-MEDICINE
CALCIUM NNP - I-MEDICINE
SUBSTANTIALLY VERB - O
FREE ADJ - O
OF ADP - O
IMPURITIES PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
METHOD NN - B-ORG
FOR ADP - O
THE DET - O
PREPARATION NOUN - O
OF ADP - O
ATORVASTATIN NNP - B-MEDICINE
CALCIUM NNP - I-MEDICINE
TABLETS NOUN - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Bolus PROPN - O
dosing VERB - O
versus ADP - O
continuous ADJ - O
infusion NOUN - O
of ADP - O
Piperacillin NNP - B-GPE
and CCONJ - O
Tazobactam NNP - B-GPE
on ADP - O
the DET - O
development NOUN - O
of ADP - O
antimicrobial ADJ - O
resistance NOUN - O
in ADP - O
Pseudomonas NNP - B-GPE
aeruginosa NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
group NOUN - O
previously ADV - O
reported VERB - O
the DET - O
photoinstability NOUN - O
of ADP - O
some DET - O
desonide VBP - B-MEDICINE
topical ADJ - O
commercial ADJ - O
formulations NOUN - O
under ADP - O
direct ADJ - O
exposure NOUN - O
to ADP - O
UVA PROPN - O
radiation NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
prepare VERB - O
and CCONJ - O
characterize VERB - O
a DET - O
gel NOUN - O
- PUNCT - O
cream NOUN - O
containing VERB - O
desonide NN - B-MEDICINE
, PUNCT - O
with ADP - O
greater ADJ - O
photostability NOUN - O
than ADP - O
the DET - O
commercial ADJ - O
gel NOUN - O
- PUNCT - O
cream NOUN - O
( PUNCT - O
C PROPN - O
- PUNCT - O
GC PROPN - O
) PUNCT - O
. PUNCT - O

D PROPN - O
- PUNCT - O
GC PROPN - O
showed VERB - O
a DET - O
good ADJ - O
photostability NOUN - O
profile NOUN - O
, PUNCT - O
presenting VERB - O
a DET - O
desonide NN - B-MEDICINE
content NOUN - O
of ADP - O
95.70 CD - B-PERCENT
% NN - I-PERCENT
after ADP - O
48 CD - B-CARDINAL
  SPACE - O
h DET - O
of ADP - O
exposure NOUN - O
to ADP - O
UVA PROPN - O
radiation NOUN - O
, PUNCT - O
and CCONJ - O
stability NOUN - O
under ADP - O
room NOUN - O
conditions NOUN - O
during ADP - O
60 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

The DET - O
amount NOUN - O
of ADP - O
desonide NN - B-MEDICINE
released VERB - O
from ADP - O
D NNP - B-ORG
- HYPH - I-ORG
GC NNP - I-ORG
and CCONJ - O
C PROPN - O
- PUNCT - O
GC PROPN - O
was VERB - O
57.8 CD - B-CARDINAL
and CCONJ - O
51.7 CD - B-CARDINAL
  SPACE - O

The DET - O
in X - O
vitro X - O
skin NOUN - O
permeation NOUN - O
showed VERB - O
that DET - O
desonide NN - B-MEDICINE
reached VERB - O
the DET - O
site NOUN - O
of ADP - O
action NOUN - O
of ADP - O
the DET - O
topical ADJ - O
corticosteroids NOUN - O
, PUNCT - O
from ADP - O
both DET - O
formulations NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
desonide NN - B-MEDICINE
amount NOUN - O
retained VERB - O
in ADP - O
the DET - O
dermis NOUN - O
was VERB - O
lower ADJ - O
with ADP - O
D NNP - B-ORG
- HYPH - I-ORG
GC NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
investigated VERB - O
the DET - O
ability NOUN - O
of ADP - O
the DET - O
antioxidants NOUN - O
ascorbic NOUN - O
acid NOUN - O
, PUNCT - O
butylhydroxyanisole NOUN - O
( PUNCT - O
BHA NNP - B-ORG
) PUNCT - O
, PUNCT - O
butylhydroxytoluene PROPN - O
( PUNCT - O
BHT PROPN - O
) PUNCT - O
, PUNCT - O
α NOUN - O
- PUNCT - O
tocopherol NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
UV NOUN - O
filter NOUN - O
benzophenone-3 NOUN - O
( PUNCT - O
BP-3 PROPN - O
) PUNCT - O
to PART - O
prevent VERB - O
the DET - O
photodegradation NOUN - O
of ADP - O
desonide NN - B-MEDICINE
in ADP - O
hair NOUN - O
solution NOUN - O
( PUNCT - O
desonide RB - B-MEDICINE
0.1 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
the DET - O
stability NOUN - O
of ADP - O
the DET - O
proposed VERB - O
formulation NOUN - O
under ADP - O
environmental ADJ - O
conditions NOUN - O
. PUNCT - O

The DET - O
tested VERB - O
antioxidants NOUN - O
were VERB - O
not ADV - O
able ADJ - O
to PART - O
prevent VERB - O
the DET - O
photolysis NOUN - O
of ADP - O
desonide NN - B-MEDICINE
, PUNCT - O
whereas ADP - O
the DET - O
addition NOUN - O
of ADP - O
0.3 CD - B-PERCENT
% NN - I-PERCENT
BP-3 PROPN - O
enhanced VERB - O
the DET - O
photostability NOUN - O
of ADP - O
the DET - O
drug NOUN - O
. PUNCT - O

After ADP - O
15 CD - B-CARDINAL
  SPACE - O
h NUM - O
of ADP - O
direct ADJ - O
exposure NOUN - O
to ADP - O
UVA PROPN - O
radiation NOUN - O
, PUNCT - O
the DET - O
desonide NN - B-MEDICINE
remaining VERB - O
content NOUN - O
in ADP - O
the DET - O
hair NOUN - O
solution NOUN - O
with ADP - O
BP-3 NNP - B-PRODUCT
was VERB - O
approximately RB - B-PERCENT
98 CD - I-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
effects NOUN - O
of ADP - O
TLC NNP - B-ORG
- PUNCT - O
Ag PROPN - O
dressings NOUN - O
in ADP - O
a DET - O
model NOUN - O
of ADP - O
chronic ADJ - O
skin NOUN - O
inflammation NOUN - O
induced VERB - O
by ADP - O
repeated VERB - O
application NOUN - O
of ADP - O
12-O CD - B-DATE
- : - I-DATE
tetradecanoylphorbol-13-acetate NN - I-DATE
to ADP - O
the DET - O
skin NOUN - O
of ADP - O
hairless NOUN - O
mice NOUN - O
, PUNCT - O
in ADP - O
comparison NOUN - O
with ADP - O
TLC NNP - B-ORG
dressing VERB - O
, PUNCT - O
Silcryst NN - B-PRODUCT
nanocrystalline NOUN - O
dressing NOUN - O
, PUNCT - O
desonide NN - B-MEDICINE
cream NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
a DET - O
corticoid NOUN - O
cream NOUN - O
used VERB - O
as ADP - O
positive ADJ - O
control NOUN - O
, PUNCT - O
and CCONJ - O
gauze NOUN - O
. PUNCT - O

TLC PROPN - O
- PUNCT - O
Ag PROPN - O
reduced VERB - O
significantly ADV - O
the DET - O
macroscopic ADJ - O
score NOUN - O
of ADP - O
chronic ADJ - O
skin NOUN - O
inflammation NOUN - O
from ADP - O
day NOUN - O
10 NUM - O
in ADP - O
comparison NOUN - O
with ADP - O
gauze NOUN - O
and CCONJ - O
TLC NNP - B-ORG
dressing NOUN - O
, PUNCT - O
similarly ADV - O
to ADP - O
Silcryst NN - B-ORG
nanocrystalline NOUN - O
dressing NOUN - O
and CCONJ - O
desonide NN - B-MEDICINE
cream NOUN - O
, PUNCT - O
which ADJ - O
presented VERB - O
the DET - O
best ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
effects NOUN - O
. PUNCT - O

TLC PROPN - O
- PUNCT - O
Ag PROPN - O
reduced VERB - O
significantly ADV - O
the DET - O
microscopic ADJ - O
score NOUN - O
of ADP - O
chronic ADJ - O
skin NOUN - O
inflammation NOUN - O
in ADP - O
comparison NOUN - O
with ADP - O
TLC NNP - B-ORG
dressing NOUN - O
and CCONJ - O
gauze NOUN - O
, PUNCT - O
similarly ADV - O
to ADP - O
Silcryst NN - B-ORG
nanocrystalline NOUN - O
dressing NOUN - O
but CCONJ - O
significantly ADV - O
less ADV - O
than ADP - O
desonide NN - B-MEDICINE
cream NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Previous ADJ - O
studies NOUN - O
have VERB - O
also ADV - O
demonstrated VERB - O
that ADP - O
this DET - O
hydrogel NOUN - O
formulation NOUN - O
of ADP - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
improved ADJ - O
moisturization NOUN - O
and CCONJ - O
reduced VERB - O
transepidermal ADJ - O
water NOUN - O
loss NOUN - O
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
clinical ADJ - O
noninferiority NOUN - O
study NOUN - O
was VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
desonide NN - B-MEDICINE
ointment NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
the DET - O
clinical ADJ - O
standard NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
mild NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
moderate ADJ - O
atopic ADJ - O
dermatitis NOUN - O
. PUNCT - O

Desonide NN - B-MEDICINE
hydrogel NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
was VERB - O
shown VERB - O
, PUNCT - O
through ADP - O
visual ADJ - O
grading NOUN - O
assessments NOUN - O
and CCONJ - O
noninvasive ADJ - O
instrumentation NOUN - O
measurements NOUN - O
, PUNCT - O
to PART - O
be VERB - O
as ADV - O
effective ADJ - O
as ADP - O
generic ADJ - O
desonide NN - B-MEDICINE
ointment NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
reducing VERB - O
the DET - O
signs NOUN - O
and CCONJ - O
symptoms NOUN - O
of ADP - O
mild NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
moderate ADJ - O
atopic ADJ - O
dermatitis NOUN - O
in ADP - O
patients NOUN - O
aged VERB - O
12 CD - B-DATE
to TO - I-DATE
65 CD - I-DATE
years NNS - I-DATE
during ADP - O
a DET - O
four CD - B-DATE
- HYPH - I-DATE
week NN - I-DATE
period NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
patients NOUN - O
rated VERB - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
significantly ADV - O
better ADV - O
than ADP - O
desonide JJ - B-MEDICINE
ointment NOUN - O
for ADP - O
absorbability NOUN - O
and CCONJ - O
( PUNCT - O
lack NOUN - O
of ADP - O
) PUNCT - O
greasiness NOUN - O
. PUNCT - O

Desonide NN - B-MEDICINE
hydrogel NOUN - O
, PUNCT - O
which ADJ - O
uses VERB - O
a DET - O
hydrogel NOUN - O
vehicle NOUN - O
, PUNCT - O
was VERB - O
preferred VERB - O
by ADP - O
patients NOUN - O
and CCONJ - O
shown VERB - O
to PART - O
restore VERB - O
the DET - O
skin NOUN - O
barrier NOUN - O
, PUNCT - O
thus ADV - O
offering VERB - O
an DET - O
efficacious ADJ - O
alternative NOUN - O
to ADP - O
desonide NN - B-MEDICINE
ointment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
patients NOUN - O
' PART - O
real ADJ - O
- PUNCT - O
world NOUN - O
experiences NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
mild NOUN - O
to PART - O
moderate VERB - O
atopic ADJ - O
dermatitis NOUN - O
( PUNCT - O
AD NOUN - O
) PUNCT - O
. PUNCT - O

Physicians NNS - B-NORP
who NOUN - O
participated VERB - O
in ADP - O
this DET - O
patient NOUN - O
- PUNCT - O
experience NOUN - O
program NOUN - O
identified VERB - O
eligible ADJ - O
participants NOUN - O
( PUNCT - O
age NOUN - O
range NOUN - O
, PUNCT - O
< X - O
3 CD - B-DATE
months NNS - I-DATE
to IN - I-DATE
91 CD - I-DATE
years NNS - I-DATE
) PUNCT - O
for ADP - O
treatment NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
. PUNCT - O

Patients NOUN - O
( PUNCT - O
or CCONJ - O
their ADJ - O
parents NOUN - O
/ SYM - O
guardians NOUN - O
) PUNCT - O
voluntarily ADV - O
participated VERB - O
by ADP - O
providing VERB - O
consent NOUN - O
and CCONJ - O
completing VERB - O
2 CD - B-CARDINAL
surveys NOUN - O
: PUNCT - O
one CD - B-CARDINAL
at ADP - O
baseline NOUN - O
( PUNCT - O
pretreatment ADJ - O
) PUNCT - O
and CCONJ - O
the DET - O
other ADJ - O
approximately RB - B-DATE
3 CD - I-DATE
weeks NNS - I-DATE
after ADP - O
initiation NOUN - O
of ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
treatment NOUN - O
( PUNCT - O
posttreatment NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
second JJ - B-ORDINAL
survey NOUN - O
assessed VERB - O
compliance NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
, PUNCT - O
satisfaction NOUN - O
with ADP - O
treatment NOUN - O
, PUNCT - O
characteristics NOUN - O
of ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
, PUNCT - O
intent ADJ - O
to PART - O
continue VERB - O
treatment NOUN - O
, PUNCT - O
and CCONJ - O
willingness NOUN - O
to PART - O
recommend VERB - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
to ADP - O
others NOUN - O
. PUNCT - O

Participant ADJ - O
satisfaction NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
was VERB - O
95 CD - B-PERCENT
% NN - I-PERCENT
greater ADJ - O
than ADP - O
satisfaction NOUN - O
with ADP - O
prior ADJ - O
topical ADJ - O
medications NOUN - O
for ADP - O
AD NN - B-ORG
( PUNCT - O
P NOUN - O
< X - O
.01 PUNCT - O
) PUNCT - O
. PUNCT - O

Adherence NOUN - O
to ADP - O
treatment NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
was VERB - O
more JJR - B-PERCENT
than IN - I-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
based VERB - O
on ADP - O
reports NOUN - O
from ADP - O
participants NOUN - O
. PUNCT - O

Eighty CD - B-PERCENT
- HYPH - I-PERCENT
nine CD - I-PERCENT
percent NN - I-PERCENT
of ADP - O
participants NOUN - O
reported VERB - O
that ADP - O
they PRON - O
would VERB - O
continue VERB - O
to PART - O
use VERB - O
the DET - O
medication NOUN - O
for ADP - O
their ADJ - O
condition NOUN - O
if ADP - O
needed VERB - O
and CCONJ - O
85 CD - B-PERCENT
% NN - I-PERCENT
would VERB - O
recommend VERB - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
to ADP - O
others NOUN - O
. PUNCT - O

Participants NOUN - O
reported VERB - O
favorable ADJ - O
experiences NOUN - O
after ADP - O
treatment NOUN - O
with ADP - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
compared VERB - O
with ADP - O
prior ADJ - O
topical ADJ - O
therapies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
receiving VERB - O
desonide RB - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
plus CCONJ - O
an DET - O
emollient NOUN - O
achieved VERB - O
significant ADJ - O
reductions NOUN - O
in ADP - O
severity NOUN - O
scores NOUN - O
compared VERB - O
to ADP - O
those DET - O
receiving VERB - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
as ADP - O
monotherapy NOUN - O
( PUNCT - O
80 CD - B-PERCENT
% NN - I-PERCENT
vs IN - I-PERCENT
70 CD - I-PERCENT
% NN - I-PERCENT
; PUNCT - O
p X - O
< X - O
0.01 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
one CD - B-DATE
month NN - I-DATE
of ADP - O
antibiotic ADJ - O
treatment NOUN - O
with ADP - O
josamycin NOUN - O
combined VERB - O
with ADP - O
daily JJ - B-DATE
application NOUN - O
of ADP - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
topical ADJ - O
cream NOUN - O
, PUNCT - O
all DET - O
symptoms NOUN - O
subsided VERB - O
without ADP - O
relapse NOUN - O
in ADP - O
the DT - B-DATE
ensuing VBG - I-DATE
6 CD - I-DATE
months NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
recent ADJ - O
formulation NOUN - O
advance NOUN - O
has VERB - O
enabled VERB - O
the DET - O
development NOUN - O
of ADP - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
into ADP - O
a DET - O
novel ADJ - O
moisturizing VERB - O
aqueous ADJ - O
gel NOUN - O
( PUNCT - O
hydrogel NOUN - O
) PUNCT - O
that DET - O
is VERB - O
free ADJ - O
of ADP - O
alcohol NOUN - O
and CCONJ - O
surfactants NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
validates VERB - O
the DET - O
systemic ADJ - O
safety NOUN - O
of ADP - O
a DET - O
novel ADJ - O
desonide NN - B-MEDICINE
hydrogel NOUN - O
formulation NOUN - O
in ADP - O
young ADJ - O
pediatric ADJ - O
patients NOUN - O
and CCONJ - O
confirms VERB - O
the DET - O
longstanding ADJ - O
tolerability NOUN - O
and CCONJ - O
efficacy NOUN - O
profile NOUN - O
of ADP - O
desonide NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
investigator NOUN - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
4-week CD - B-DATE
, PUNCT - O
parallel NOUN - O
- PUNCT - O
group NOUN - O
, PUNCT - O
multicenter NOUN - O
pilot NOUN - O
study NOUN - O
to PART - O
compare VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
a DET - O
nonsteroidal ADJ - O
cream NOUN - O
( PUNCT - O
Promiseb PROPN - O
Topical PROPN - O
Cream PROPN - O
) PUNCT - O
and CCONJ - O
desonide NN - B-MEDICINE
cream NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
the DET - O
twice ADV - O
- PUNCT - O
daily JJ - B-DATE
treatment NOUN - O
of ADP - O
mild NOUN - O
to PART - O
moderate ADJ - O
seborrheic ADJ - O
dermatitis NOUN - O
of ADP - O
the DET - O
face NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
photochemistry NOUN - O
of ADP - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
desonide NN - B-MEDICINE
( PUNCT - O
De NNP - B-ORG
, PUNCT - O
1 LS - B-DATE
) PUNCT - O
was VERB - O
studied VERB - O
in ADP - O
aerobic NOUN - O
as ADV - O
well ADV - O
as ADP - O
in ADP - O
anaerobic ADJ - O
condition NOUN - O
with ADP - O
different ADJ - O
irradiation NOUN - O
wavelengths NOUN - O
( PUNCT - O
254 CD - B-CARDINAL
, PUNCT - O
310 CD - B-CARDINAL
nm NUM - O
) PUNCT - O
in ADP - O
acetonitrile NOUN - O
and CCONJ - O
2-propanol NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Overview VERB - O
on ADP - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
: PUNCT - O
a DET - O
clinical ADJ - O
safety NOUN - O
profile NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
desonide NN - B-MEDICINE
0.05 CD - B-PERCENT
% NN - I-PERCENT
cream NOUN - O
and CCONJ - O
lotion NOUN - O
in ADP - O
steroid NOUN - O
- PUNCT - O
responsive ADJ - O
dermatoses NOUN - O
in ADP - O
Indian JJ - B-NORP
patients NOUN - O
: PUNCT - O
a DET - O
post ADJ - O
- ADJ - O
marketing ADJ - O
surveillance NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Stereoselective ADJ - O
process NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
of ADP - O
the DET - O
22R CD - B-CARDINAL
epimer NOUN - O
of ADP - O
budesonide NOUN - O

-DOCSTART- -X- - O

A DET - O
topical ADJ - O
composition NOUN - O
and CCONJ - O
the DET - O
method NOUN - O
using VERB - O
the DET - O
composition NOUN - O
, PUNCT - O
which ADJ - O
contains VERB - O
a DET - O
n DET - O
antifungal ADJ - O
agent NOUN - O
and CCONJ - O
a DET - O
low ADJ - O
potency NOUN - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
steroid NOUN - O
which ADJ - O
is VERB - O
safe ADJ - O
a DET - O
nd NOUN - O
effective ADJ - O
such ADJ - O
as ADP - O
desonide NN - B-MEDICINE
or CCONJ - O
its ADJ - O
derivative NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

All DET - O
patients NOUN - O
were VERB - O
instructed VERB - O
to PART - O
use VERB - O
tretinoin NOUN - O
cream NOUN - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
hydroquinone NOUN - O
5 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
desonide VBP - B-MEDICINE
0.1 CD - B-PERCENT
% NN - I-PERCENT
cream NOUN - O
nightly ADV - O
for ADP - O
2 CD - B-DATE
- SYM - I-DATE
4 CD - I-DATE
weeks NNS - I-DATE
prior ADV - O
to ADP - O
the DET - O
laser NOUN - O
treatment NOUN - O
. PUNCT - O

Hyperpigmentation NOUN - O
occurred VERB - O
, PUNCT - O
but CCONJ - O
was VERB - O
reduced VERB - O
with ADP - O
regular ADJ - O
use NOUN - O
of ADP - O
tretinoin NOUN - O
, PUNCT - O
hydroquinone NOUN - O
, PUNCT - O
and CCONJ - O
desonide VBP - B-MEDICINE
cream NOUN - O
both CCONJ - O
pre- ADJ - O
and CCONJ - O
postoperatively ADV - O
along ADP - O
with ADP - O
use NOUN - O
of ADP - O
broad ADJ - O
spectrum NOUN - O
sunscreen NOUN - O
after ADP - O
treatments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
and CCONJ - O
analysis NOUN - O
of ADP - O
a DET - O
degradation NOUN - O
product NOUN - O
of ADP - O
the DET - O
glucocorticoid ADJ - O
desonide NN - B-MEDICINE
in ADP - O
ointment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Potency NOUN - O
ranking VERB - O
of ADP - O
two CD - B-CARDINAL
new ADJ - O
topical ADJ - O
corticosteroid NOUN - O
creams NOUN - O
containing VERB - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
desonide NN - B-MEDICINE
or CCONJ - O
0.05 CD - B-PERCENT
% NN - I-PERCENT
halometasone NOUN - O
utilising VERB - O
the DET - O
human ADJ - O
skin NOUN - O
blanching VERB - O
assay NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
ratios NOUN - O
of ADP - O
antiinflammatory ADJ - O
activity NOUN - O
after ADP - O
oral ADJ - O
administration NOUN - O
( PUNCT - O
oral ADJ - O
ED50/cutaneous PROPN - O
ED50 PROPN - O
) PUNCT - O
for ADP - O
desonide NN - B-MEDICINE
( PUNCT - O
Locapred PROPN - O
) PUNCT - O
and CCONJ - O
hydrocortisone NOUN - O
( PUNCT - O
hydrocortisone NOUN - O
acetate VERB - O
) PUNCT - O
were VERB - O
compared VERB - O
in ADP - O
various ADJ - O
nonimmunological ADJ - O
and CCONJ - O
immunological ADJ - O
experimental ADJ - O
models NOUN - O
on ADP - O
mouse NOUN - O
ears NOUN - O
: PUNCT - O
edema NOUN - O
induced VERB - O
by ADP - O
croton NOUN - O
oil NOUN - O
; PUNCT - O
primary ADJ - O
irritation NOUN - O
due ADP - O
to ADP - O
picryl ADJ - O
chloride NOUN - O
; PUNCT - O
the DET - O
acute ADJ - O
phase NOUN - O
( PUNCT - O
6 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
and CCONJ - O
the DET - O
beginning NOUN - O
of ADP - O
the DET - O
chronic ADJ - O
phase NOUN - O
( PUNCT - O
24 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
of ADP - O
inflammation NOUN - O
due ADJ - O
to ADP - O
cantharidin NOUN - O
; PUNCT - O
delayed VERB - O
contact NOUN - O
hypersensitivity NOUN - O
to PART - O
picryl ADJ - O
chloride VERB - O
; PUNCT - O
and CCONJ - O
the DET - O
semi ADV - O
- PUNCT - O
delayed VERB - O
( PUNCT - O
6 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
and CCONJ - O
delayed VERB - O
( PUNCT - O
24 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
phases NOUN - O
of ADP - O
contact NOUN - O
hypersensitivity NOUN - O
to PART - O
oxazolone VERB - O
. PUNCT - O

These DET - O
investigations NOUN - O
showed VERB - O
that ADP - O
, PUNCT - O
besides ADP - O
having VERB - O
a DET - O
better ADJ - O
antiinflammatory ADJ - O
effect NOUN - O
, PUNCT - O
desonide NN - B-MEDICINE
had VERB - O
a DET - O
better ADJ - O
ratio NOUN - O
of ADP - O
local ADJ - O
activity NOUN - O
to ADP - O
systemic ADJ - O
effect NOUN - O
in ADP - O
all ADJ - O
the DET - O
models NOUN - O
. PUNCT - O

Such ADJ - O
results NOUN - O
were VERB - O
confirmed VERB - O
in ADP - O
rats NOUN - O
in ADP - O
which ADJ - O
desonide NN - B-MEDICINE
reduced VERB - O
24 CD - B-CARDINAL
h NOUN - O
carrageenin NOUN - O
abscess NOUN - O
after ADP - O
cutaneous ADJ - O
application NOUN - O
without ADP - O
any DET - O
significant ADJ - O
thymolytic ADJ - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
: PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
trial NOUN - O
is VERB - O
to PART - O
compare VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
( PUNCT - O
saffron PROPN - O
) PUNCT - O
versus ADP - O
methylphenidate NOUN - O
in ADP - O
improving VERB - O
symptoms NOUN - O
of ADP - O
children NOUN - O
with ADP - O
ADHD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
Versus NNP - I-PERSON
Methylphenidate NNP - I-PERSON
in ADP - O
Treatment PROPN - O
of ADP - O
Children PROPN - O
with ADP - O
Attention PROPN - O
- PUNCT - O
Deficit PROPN - O
/ SYM - O
Hyperactivity PROPN - O
Disorder PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
, PUNCT - O
and CCONJ - O
its ADJ - O
main ADJ - O
constituents NOUN - O
, PUNCT - O
crocin NOUN - O
, PUNCT - O
and CCONJ - O
crocetin NOUN - O
have VERB - O
shown VERB - O
promising ADJ - O
effects NOUN - O
as ADP - O
an DET - O
antileukemic ADJ - O
agent NOUN - O
in ADP - O
animal NOUN - O
models NOUN - O
and CCONJ - O
cell NOUN - O
culture NOUN - O
systems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
) PUNCT - O
petal NOUN - O
as ADP - O
a DET - O
new ADJ - O
pharmacological ADJ - O
target NOUN - O
: PUNCT - O
a DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
specific ADJ - O
PCR PROPN - O
primer NOUN - O
was VERB - O
designed VERB - O
base NOUN - O
on ADP - O
ITS2 PROPN - O
sequence NOUN - O
in ADP - O
GenBank NNP - B-ORG
, PUNCT - O
and CCONJ - O
we PRON - O
developed VERB - O
a DET - O
SYBRGreen NNP - B-CARDINAL
real ADJ - O
- PUNCT - O
time NOUN - O
fluorescence NOUN - O
quantitative ADJ - O
PCR NNP - B-ORG
system NOUN - O
for ADP - O
identification NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
and CCONJ - O
Carthamus NNP - B-ORG
tinctorius NOUN - O
source NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
A DET - O
real ADJ - O
- PUNCT - O
time NOUN - O
fluorescence NOUN - O
quantitative ADJ - O
PCR NNP - B-ORG
method NOUN - O
for ADP - O
source NOUN - O
identification NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
and CCONJ - O
Carthamus NNP - B-ORG

-DOCSTART- -X- - O

Smooth ADJ - O
muscle NOUN - O
relaxant ADJ - O
activity NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
( PUNCT - O
saffron PROPN - O
) PUNCT - O
and CCONJ - O
its ADJ - O
constituents NOUN - O
: PUNCT - O
possible ADJ - O
mechanisms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
, PUNCT - O
Iridaceae NNP - B-GPE
) PUNCT - O
is VERB - O
a DET - O
common ADJ - O
spice NOUN - O
that ADJ - O
is VERB - O
also ADV - O
valuable ADJ - O
in ADP - O
Chinese JJ - B-NORP
herbal ADJ - O
medicine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First ADJ - O
Report PROPN - O
of ADP - O
Beet PROPN - O
western ADJ - O
yellows NOUN - O
virus NOUN - O
Infecting VBG - B-ORG
Crocus NNP - I-ORG
sativus NOUN - O
in ADP - O
China NNP - B-GPE

-DOCSTART- -X- - O

Saffron NNP - B-ORG
stigmas NOUN - O
from ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
L. NNP - B-PERSON
( PUNCT - O
Iridaceae PROPN - O
) PUNCT - O
are VERB - O
used VERB - O
as ADP - O
a DET - O
drug NOUN - O
in ADP - O
folk NOUN - O
medicine NOUN - O
, PUNCT - O
as ADP - O
a DET - O
food NOUN - O
additive NOUN - O
and CCONJ - O
as ADP - O
a DET - O
dying VERB - O
agent NOUN - O
for ADP - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
3500 CD - I-CARDINAL
  SPACE - O
years NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Corm NOUN - O
, PUNCT - O
being VERB - O
a DET - O
unit NOUN - O
of ADP - O
reproduction NOUN - O
and CCONJ - O
storage NOUN - O
, PUNCT - O
plays VERB - O
an DET - O
indispensable ADJ - O
role NOUN - O
in ADP - O
the DET - O
life NOUN - O
cycle NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
( PUNCT - O
saffron PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
stigmas NOUN - O
and CCONJ - O
byproducts VERB - O
: PUNCT - O
Qualitative ADJ - O
fingerprint NOUN - O
, PUNCT - O
antioxidant NOUN - O
potentials NOUN - O
and CCONJ - O
enzyme ADJ - O
inhibitory NOUN - O
activities NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

UHPLC NNP - B-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Saffron NNP - I-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
: PUNCT - O
Optimization NOUN - O
of ADP - O
Separation PROPN - O
Using PROPN - O
Chemometrics PROPN - O
and CCONJ - O
Detection PROPN - O
of ADP - O
Minor PROPN - O
Crocetin PROPN - O
Esters PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
ultrasonic ADJ - O
waves NOUN - O
on ADP - O
crocin NOUN - O
and CCONJ - O
safranal ADJ - O
content NOUN - O
and CCONJ - O
expression NOUN - O
of ADP - O
their ADJ - O
controlling VERB - O
genes NOUN - O
in ADP - O
suspension NOUN - O
culture NOUN - O
of ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
  SPACE - O
L. PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
, PUNCT - O
commonly ADV - O
known VERB - O
as ADP - O
saffron X - O
, PUNCT - O
has VERB - O
been VERB - O
used VERB - O
in ADP - O
folk NOUN - O
medicine NOUN - O
for ADP - O
centuries NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Tumor NOUN - O
- PUNCT - O
Suppressing PROPN - O
Properties PROPN - O
of ADP - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
: PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
is VERB - O
the DET - O
only ADJ - O
plant NOUN - O
species NOUN - O
which ADJ - O
produces VERB - O
apocarotenoids NOUN - O
like ADP - O
crocin NOUN - O
, PUNCT - O
picrocrocin NOUN - O
and CCONJ - O
safranal ADJ - O
in ADP - O
significant ADJ - O
amounts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
, PUNCT - O
Serenoa PROPN - O
repens NOUN - O
and CCONJ - O
Pinus NNP - B-ORG
massoniana NOUN - O
extracts NOUN - O
modulate VERB - O
inflammatory ADJ - O
response NOUN - O
in ADP - O
isolated ADJ - O
rat NOUN - O
prostate NOUN - O
challenged VERB - O
with ADP - O
LPS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
new ADJ - O
UHPLC NNP - B-ORG
- PUNCT - O
DAD PROPN - O
- PUNCT - O
MS PROPN - O
method NOUN - O
based VERB - O
on ADP - O
a DET - O
Core NNP - B-ORG
- HYPH - I-ORG
Shell NNP - I-ORG
particles NOUN - O
column NOUN - O
was VERB - O
developed VERB - O
to PART - O
realize VERB - O
the DET - O
rapid ADJ - O
separation NOUN - O
of ADP - O
saffron ADJ - O
stigma NOUN - O
metabolites NOUN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Numerous ADJ - O
adverse ADJ - O
effects NOUN - O
of ADP - O
antidepressants NOUN - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
attitudes NOUN - O
of ADP - O
breastfeeding VERB - O
mothers NOUN - O
, PUNCT - O
who NOUN - O
prefer VERB - O
to PART - O
consume VERB - O
herbal ADJ - O
medicine NOUN - O
rather ADV - O
than ADP - O
chemical ADJ - O
drugs NOUN - O
, PUNCT - O
encouraged VERB - O
us PRON - O
to PART - O
assess VERB - O
the DET - O
effects NOUN - O
of ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
on ADP - O
mothers NOUN - O
suffering VERB - O
from ADP - O
mild NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
moderate ADJ - O
postpartum ADJ - O
depressive ADJ - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
of ADP - O
saffron ADJ - O
stigma NOUN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
in ADP - O
mothers NOUN - O
suffering VERB - O
from ADP - O
mild NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
moderate ADJ - O
postpartum NOUN - O
depression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
) PUNCT - O
intake NOUN - O
provides VERB - O
nutritional ADJ - O
preconditioning VERB - O
against ADP - O
myocardial ADJ - O
ischemia NOUN - O
- PUNCT - O
reperfusion NOUN - O
injury NOUN - O
in ADP - O
Wild NNP - B-LOC
Type NNP - I-LOC
and CCONJ - O
ApoE(-/- NOUN - O

-DOCSTART- -X- - O

Metabolic ADJ - O
effects NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
and CCONJ - O
protective ADJ - O
action NOUN - O
against ADP - O
non ADJ - O
- ADJ - O
alcoholic ADJ - O
fatty ADJ - O
liver NOUN - O
disease NOUN - O
in ADP - O
diabetic ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
( PUNCT - O
C. PROPN - O
  SPACE - O
sativus NOUN - O
) PUNCT - O
, PUNCT - O
commonly ADV - O
known VERB - O
as ADP - O
saffron NOUN - O
, PUNCT - O
is VERB - O
used VERB - O
as ADP - O
a DET - O
food NOUN - O
additive NOUN - O
, PUNCT - O
preservative ADJ - O
, PUNCT - O
and CCONJ - O
medicinal ADJ - O
herb NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Neuroprotective ADJ - O
effect NOUN - O
of ADP - O
safranal ADJ - O
, PUNCT - O
an DET - O
active ADJ - O
ingredient NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
, PUNCT - O
in ADP - O
a DET - O
rat NOUN - O
model NOUN - O
of ADP - O
transient ADJ - O
cerebral ADJ - O
ischemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
has VERB - O
a DET - O
long ADJ - O
history NOUN - O
of ADP - O
use NOUN - O
as ADP - O
a DET - O
food NOUN - O
additive NOUN - O
and CCONJ - O
a DET - O
traditional ADJ - O
medicine NOUN - O
for ADP - O
treating VERB - O
a DET - O
number NOUN - O
of ADP - O
disorders NOUN - O
. PUNCT - O

A DET - O
patent NOUN - O
search NOUN - O
strategy NOUN - O
was VERB - O
designed VERB - O
based VERB - O
on ADP - O
keywords NOUN - O
and CCONJ - O
concepts NOUN - O
related VERB - O
to ADP - O
Crocus NNP - B-NORP
sativus NOUN - O
L. NNP - B-PERSON
and CCONJ - O
its ADJ - O
bioactives- ADJ - O
safranal ADJ - O
, PUNCT - O
crocin NOUN - O
and CCONJ - O
crocetin NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
different ADJ - O
patent NOUN - O
classification NOUN - O
codes NOUN - O
relevant ADJ - O
to ADP - O
the DET - O
technology NOUN - O
areas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Razi NNP - B-ORG
's PART - O
Al NNP - B-PERSON
- HYPH - I-PERSON
Hawi NNP - I-PERSON
and CCONJ - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NNS - I-MEDICINE
) PUNCT - O
: PUNCT - O
a DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
protects VERB - O
against ADP - O
SDS‑induced NNP - B-ORG
intestinal ADJ - O
damage NOUN - O
and CCONJ - O
extends VERB - O
lifespan ADJ - O
in ADP - O
Drosophila NNP - B-ORG
melanogaster NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Introduction NOUN - O
: PUNCT - O
Saffron NNP - B-PERSON
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
has VERB - O
demonstrated VERB - O
antidepressant ADJ - O
effects NOUN - O
in ADP - O
clinical ADJ - O
studies NOUN - O
and CCONJ - O
extensive ADJ - O
anxiolytic ADJ - O
effects NOUN - O
in ADP - O
experimental ADJ - O
animal NOUN - O
models NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sudan NNP - B-GPE
dyes VERB - O
in ADP - O
adulterated VERB - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
: PUNCT - O
Identification NOUN - O
and CCONJ - O
quantification NOUN - O
by ADP - O
( PUNCT - O
1)H CD - B-ORG
NMR NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Antimicrobial ADJ - O
activity NOUN - O
, PUNCT - O
synergism NOUN - O
and CCONJ - O
inhibition NOUN - O
of ADP - O
germ NOUN - O
tube NOUN - O
formation NOUN - O
by ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
- PUNCT - O
derived VERB - O
compounds NOUN - O
against ADP - O
Candida NNP - B-GPE
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determining VERB - O
the DET - O
most ADV - O
effective ADJ - O
traits NOUN - O
to PART - O
improve VERB - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
yield NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Petals NOUN - O
of ADP - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
as ADP - O
a DET - O
potential ADJ - O
source NOUN - O
of ADP - O
the DET - O
antioxidants NOUN - O
crocin NOUN - O
and CCONJ - O
kaempferol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Broadly ADV - O
speaking VERB - O
proteomic ADJ - O
studies NOUN - O
are VERB - O
one CD - B-CARDINAL
of ADP - O
the DET - O
various ADJ - O
techniques NOUN - O
of ADP - O
utmost ADJ - O
importance NOUN - O
for ADP - O
understanding VERB - O
complex ADJ - O
biological ADJ - O
processes NOUN - O
that ADJ - O
occur VERB - O
under ADP - O
inductive ADJ - O
conditions NOUN - O
and CCONJ - O
revealing VERB - O
the DET - O
multidimensional ADJ - O
aspects NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
in ADP - O
biological ADJ - O
systems NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
safranal ADJ - O
as ADP - O
the DET - O
main ADJ - O
allelochemical NOUN - O
from ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NNS - I-MEDICINE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
is VERB - O
commonly ADV - O
known VERB - O
as ADP - O
world NOUN - O
's PART - O
most ADV - O
expensive ADJ - O
spice NOUN - O
with ADP - O
rich ADJ - O
source NOUN - O
of ADP - O
apocarotenoids NOUN - O
and CCONJ - O
possesses VERB - O
magnificent ADJ - O
medicinal ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
systematic ADJ - O
review NOUN - O
of ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
examining VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
on ADP - O
psychological ADJ - O
and CCONJ - O
behavioral ADJ - O
outcomes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
stigmas NOUN - O
form VERB - O
rich ADJ - O
source NOUN - O
of ADP - O
apocarotenoids NOUN - O
like ADP - O
crocin NOUN - O
, PUNCT - O
picrocrocin NOUN - O
and CCONJ - O
saffranal ADJ - O
which ADJ - O
besides ADP - O
imparting VERB - O
color NOUN - O
, PUNCT - O
flavour NOUN - O
and CCONJ - O
aroma NOUN - O
to PART - O
saffron VERB - O
spice NOUN - O
also ADV - O
have VERB - O
tremendous ADJ - O
pharmacological ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Native PROPN - O
Bacillus PROPN - O
amyloliquefaciens VERB - O
W2 PROPN - O
as ADP - O
a DET - O
potential ADJ - O
biocontrol NOUN - O
for ADP - O
Fusarium NNP - B-ORG
oxysporum NOUN - O
R1 NNP - B-ORG
causing VERB - O
corm NOUN - O
rot NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O

-DOCSTART- -X- - O

Smooth ADJ - O
muscle NOUN - O
relaxant ADJ - O
activity NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
( PUNCT - O
saffron PROPN - O
) PUNCT - O
and CCONJ - O
its ADJ - O
constituents NOUN - O
: PUNCT - O
possible ADJ - O
mechanisms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Volatile PROPN - O
compounds NOUN - O
in ADP - O
pressed VERB - O
ewes NOUN - O
' PART - O
milk NOUN - O
cheese NOUN - O
with ADP - O
saffron ADJ - O
spice NOUN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Flavonoid NNP - B-GPE
Determination PROPN - O
in ADP - O
the DT - B-ORG
Quality NNP - I-ORG
Control NNP - I-ORG
of IN - I-ORG
Floral NNP - I-ORG
Bioresidues NNPS - I-ORG
from ADP - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
is VERB - O
known VERB - O
in ADP - O
herbal ADJ - O
medicine NOUN - O
for ADP - O
the DET - O
various ADJ - O
pharmacological ADJ - O
effects NOUN - O
of ADP - O
its ADJ - O
components NOUN - O
, PUNCT - O
but CCONJ - O
no DET - O
data NOUN - O
are VERB - O
found VERB - O
in ADP - O
literature NOUN - O
about ADP - O
its ADJ - O
biological ADJ - O
properties NOUN - O
toward ADP - O
Helicobacter NNP - B-PERSON
pylori NOUN - O
, PUNCT - O
Plasmodium NNP - B-ORG
spp NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
is VERB - O
a DET - O
sterile ADJ - O
species NOUN - O
( PUNCT - O
3n PUNCT - O
) PUNCT - O
whose ADJ - O
origin NOUN - O
has VERB - O
not ADV - O
been VERB - O
yet ADV - O
clarified VERB - O
. PUNCT - O

Crocus NN - B-MEDICINE
sativus NN - I-MEDICINE
stigmas NOUN - O
are VERB - O
saffron ADP - O
raw ADJ - O
source NOUN - O
but CCONJ - O
, PUNCT - O
because ADP - O
of ADP - O
their ADJ - O
high ADJ - O
economic ADJ - O
value NOUN - O
, PUNCT - O
sometimes ADV - O
this DET - O
spice NOUN - O
is VERB - O
adulterated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NNP - B-ORG
sativus NOUN - O
L. NNP - B-PERSON
, PUNCT - O
commonly ADV - O
known VERB - O
as ADP - O
saffron NOUN - O
, PUNCT - O
is VERB - O
the DET - O
raw ADJ - O
material NOUN - O
for ADP - O
one CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
expensive ADJ - O
spice NOUN - O
in ADP - O
the DET - O
world NOUN - O
, PUNCT - O
and CCONJ - O
it PRON - O
has VERB - O
been VERB - O
used VERB - O
in ADP - O
folk NOUN - O
medicine NOUN - O
for ADP - O
centuries NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Plant NOUN - O
growth NOUN - O
promoting VERB - O
bacteria NOUN - O
from ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
rhizosphere NOUN - O

-DOCSTART- -X- - O

Identification NOUN - O
of ADP - O
bacteria NOUN - O
associated VERB - O
with ADP - O
underground ADJ - O
parts NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
by ADP - O
16S NUM - O
rRNA PROPN - O
gene NOUN - O
targeted VERB - O
metagenomic ADJ - O
approach NOUN - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
) PUNCT - O
for ADP - O
depression NOUN - O
: PUNCT - O
a DET - O
systematic ADJ - O
review NOUN - O
of ADP - O
clinical ADJ - O
studies NOUN - O
and CCONJ - O
examination NOUN - O
of ADP - O
underlying VERB - O
antidepressant ADJ - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Increasing VERB - O
the DET - O
applications NOUN - O
of ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
flowers NOUN - O
as ADP - O
natural ADJ - O
antioxidants NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Plant NOUN - O
growth NOUN - O
promoting VERB - O
bacteria NOUN - O
from ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
rhizosphere NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
split NOUN - O
foliar ADJ - O
fertilisation NOUN - O
on ADP - O
the DET - O
quality NOUN - O
and CCONJ - O
quantity NOUN - O
of ADP - O
active ADJ - O
constituents NOUN - O
in ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
on ADP - O
sodium NOUN - O
valporate NOUN - O
induced VERB - O
cytogenetic ADJ - O
and CCONJ - O
testicular ADJ - O
alterations NOUN - O
in ADP - O
albino NOUN - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aims VERB - O
to PART - O
investigate VERB - O
the DET - O
protective ADJ - O
effects NOUN - O
of ADP - O
hydroalcoholic ADJ - O
extract NOUN - O
, PUNCT - O
remaining VERB - O
from ADP - O
Crocus NNP - B-ORG
sativus NOUN - O
petals NOUN - O
( PUNCT - O
CSP PROPN - O
) PUNCT - O
against ADP - O
APAP NNP - B-ORG
- PUNCT - O
induced VERB - O
hepatotoxicity NOUN - O
by ADP - O
measuring VERB - O
the DET - O
blood NOUN - O
parameters NOUN - O
and CCONJ - O
studying VERB - O
the DET - O
histopathology NOUN - O
of ADP - O
liver NOUN - O
in ADP - O
male ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crocus NN - B-MEDICINE
sativus NNS - I-MEDICINE
has VERB - O
been VERB - O
used VERB - O
as ADP - O
a DET - O
traditional ADJ - O
Chinese JJ - B-NORP
medicine NOUN - O
for ADP - O
a DET - O
long ADJ - O
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Direct ADJ - O
somatic ADJ - O
embryogenesis NOUN - O
with ADP - O
high ADJ - O
frequency NOUN - O
plantlet NOUN - O
regeneration NOUN - O
and CCONJ - O
successive ADJ - O
cormlet NOUN - O
production NOUN - O
in ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Metal PROPN - O
Content PROPN - O
in ADP - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
Corms NNP - I-PERSON
in ADP - O
Dormancy NNP - B-GPE
and CCONJ - O
Waking PROPN - O
Stages PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Saffron NNP - B-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
stigma NOUN - O
) PUNCT - O
, PUNCT - O
the DET - O
most ADV - O
valuable ADJ - O
medicinal ADJ - O
food NOUN - O
product NOUN - O
, PUNCT - O
belongs VERB - O
to ADP - O
the DET - O
Iridaceae NNP - B-PERSON
family NOUN - O
which ADJ - O
has VERB - O
been VERB - O
widely ADV - O
used VERB - O
as ADP - O
a DET - O
coloring VERB - O
and CCONJ - O
flavoring VERB - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
antioxidant ADJ - O
activities NOUN - O
of ADP - O
bioactive ADJ - O
compounds NOUN - O
and CCONJ - O
various ADJ - O
extracts NOUN - O
obtained VERB - O
from ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
L. NNP - B-PERSON
) PUNCT - O
: PUNCT - O
a DET - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
search NOUN - O
terms NOUN - O
used VERB - O
were VERB - O
saffron NOUN - O
, PUNCT - O
Crocus NNP - B-ORG
sativus NOUN - O
, PUNCT - O
crocin NOUN - O
, PUNCT - O
crocetin NOUN - O
, PUNCT - O
safranal ADJ - O
, PUNCT - O
picrocrocin NOUN - O
, PUNCT - O
Avicenna NNP - B-PERSON
and CCONJ - O
' PUNCT - O
Ibn NNP - B-PERSON
Sina NNP - I-PERSON
' '' - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NN - I-ORG
of IN - I-ORG
Chronic NNP - I-ORG
Administration NNP - I-ORG
of IN - I-ORG
Saffron NNP - I-ORG
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus VBZ - I-MEDICINE
) PUNCT - O

-DOCSTART- -X- - O

UGT707B1 NNP - B-ORG
is VERB - O
a DET - O
new ADJ - O
glucosyltransferase NOUN - O
isolated VERB - O
from ADP - O
saffron PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NN - I-MEDICINE
) PUNCT - O
that ADJ - O
localizes VERB - O
to ADP - O
the DET - O
cytoplasm NOUN - O
and CCONJ - O
the DET - O
nucleus NOUN - O
of ADP - O
stigma NOUN - O
and CCONJ - O
tepal NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alleviation NOUN - O
of ADP - O
viper NOUN - O
venom NOUN - O
induced VERB - O
platelet NOUN - O
apoptosis NOUN - O
by ADP - O
crocin PROPN - O
( PUNCT - O
Crocus NNP - B-MEDICINE
sativus NNS - I-MEDICINE
) PUNCT - O
: PUNCT - O
implications NOUN - O
for ADP - O
thrombocytopenia NOUN - O
in ADP - O
viper NOUN - O
bites NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

KETOROLAC NNP - B-ORG
TROMETHAMINE NNP - I-ORG
COMPOSITIONS NN - I-ORG
FOR IN - I-ORG
TREATING NN - I-ORG
OR CC - I-ORG
PREVENTING NN - I-ORG
OCULAR NNP - I-ORG
PAIN NNP - I-ORG

-DOCSTART- -X- - O

KETOROLAC NNP - B-ORG
TROMETHAMINE NNP - I-ORG
COMPOSITIONS NN - I-ORG
FOR IN - I-ORG
TREATING NN - I-ORG
OR CC - I-ORG
PREVENTING NN - I-ORG
OCULAR NNP - I-ORG
PAIN NNP - I-ORG

-DOCSTART- -X- - O

Topical PROPN - O
Olopatadine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
versus ADP - O
Ketotifen NNP - B-ORG
Fumarate NNP - I-ORG
for IN - I-ORG
Allergic JJ - B-PERSON
Conjunctivitis NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Intestinal ADJ - O
Anisakiasis NOUN - O
Treated VERB - O
Successfully ADV - O
with ADP - O
Prednisolone PROPN - O
and CCONJ - O
Olopatadine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Novel PROPN - O
Topical PROPN - O
2 NUM - O
% NOUN - O
Povidone PROPN - O
- PUNCT - O
Iodine PROPN - O
Solution PROPN - O
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Common PROPN - O
Warts PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

We PRON - O
looked VERB - O
for ADP - O
articles NOUN - O
with ADP - O
information NOUN - O
regarding VERB - O
perineal ADJ - O
blisters NOUN - O
related VERB - O
to ADP - O
Senna NNP - B-ORG
as ADV - O
well ADV - O
as ADP - O
other ADJ - O
secondary ADJ - O
effects NOUN - O
of ADP - O
Senna NNP - B-ORG
laxatives NOUN - O
in ADP - O
children NOUN - O
when ADV - O
used VERB - O
on ADP - O
a DET - O
long ADJ - O
- PUNCT - O
term NOUN - O
basis NOUN - O
. PUNCT - O

Eight CD - B-CARDINAL
articles NOUN - O
in ADP - O
the DET - O
literature NOUN - O
reported VERB - O
perineal ADJ - O
blisters NOUN - O
after ADP - O
administration NOUN - O
of ADP - O
Senna NNP - B-ORG
laxatives NOUN - O
in ADP - O
28 CD - B-CARDINAL
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Loperamide PROPN - O
( PUNCT - O
Imodium NNP - B-MEDICINE
) PUNCT - O
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
prescription ADJ - O
opioid ADJ - O
receptor NOUN - O
agonist NOUN - O
available ADJ - O
over ADP - O
- PUNCT - O
the DET - O
- PUNCT - O
counter NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
diarrhea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Death NOUN - O
due ADJ - O
to ADP - O
anaphylactic ADJ - O
shock NOUN - O
after ADP - O
ingestion NOUN - O
of ADP - O
Imodium NNP - B-MEDICINE
instants NOUN - O
( PUNCT - O
Loperamide PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
methylcellulose NOUN - O
( PUNCT - O
Citrucel PROPN - O
) PUNCT - O
and CCONJ - O
loperamide NOUN - O
( PUNCT - O
Imodium NN - B-MEDICINE
) PUNCT - O
in ADP - O
managing VERB - O
fecal ADJ - O
incontinence NOUN - O
by ADP - O
comparing VERB - O
cure NOUN - O
rates NOUN - O
with ADP - O
expectant ADJ - O
management NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
loperamide NOUN - O
( PUNCT - O
Imodium NNP - B-MEDICINE
) PUNCT - O
on ADP - O
fecal ADJ - O
excretion NOUN - O
of ADP - O
electrolytes NOUN - O
was VERB - O
studied VERB - O
using VERB - O
a DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
protocol NOUN - O
in ADP - O
63 CD - B-CARDINAL
infants NOUN - O
aged VERB - O
1 CD - B-DATE
to IN - I-DATE
32 CD - I-DATE
months NNS - I-DATE
, PUNCT - O
presenting VERB - O
with ADP - O
acute ADJ - O
diarrhea NOUN - O
. PUNCT - O

The DET - O
therapeutic ADJ - O
protocol NOUN - O
was VERB - O
the DET - O
same ADJ - O
for ADP - O
all ADJ - O
the DET - O
infants NOUN - O
: PUNCT - O
ad NOUN - O
libitum NOUN - O
oral ADJ - O
rehydration NOUN - O
, PUNCT - O
with ADP - O
no DET - O
drug NOUN - O
being VERB - O
administered VERB - O
except ADP - O
for ADP - O
Imodium NNP - B-MEDICINE
at ADP - O
an DET - O
average ADJ - O
dose NOUN - O
of ADP - O
20 CD - B-CARDINAL
to TO - I-CARDINAL
25 CD - I-CARDINAL
drops NOUN - O
/ SYM - O
kg/24 NOUN - O
h PRON - O
( PUNCT - O
0.16 CD - B-CARDINAL
to ADP - O
0.20 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg/24 PROPN - O
h PUNCT - O
) PUNCT - O
, PUNCT - O
given VERB - O
every DT - B-TIME
8 CD - I-TIME
hours NNS - I-TIME
for ADP - O
at RB - B-TIME
least RBS - I-TIME
48 CD - I-TIME
hours NNS - I-TIME
. PUNCT - O

Comparison NOUN - O
of ADP - O
the DET - O
two CD - B-CARDINAL
groups NOUN - O
of ADP - O
infants NOUN - O
, PUNCT - O
one CD - B-CARDINAL
receiving VERB - O
Imodium NNP - B-MEDICINE
, PUNCT - O
the DET - O
other ADJ - O
a DET - O
placebo NOUN - O
, PUNCT - O
showed VERB - O
a DET - O
significant ADJ - O
difference NOUN - O
( PUNCT - O
p X - O
less JJR - B-PERCENT
than IN - I-PERCENT
1 CD - I-PERCENT
% NN - I-PERCENT
) PUNCT - O
in ADP - O
fecal ADJ - O
sodium NOUN - O
concentration NOUN - O
, PUNCT - O
due ADJ - O
rather ADV - O
to ADP - O
an DET - O
increase NOUN - O
in ADP - O
stool NOUN - O
Na+ ADJ - O
in ADP - O
the DET - O
placebo NOUN - O
group NOUN - O
than ADP - O
to ADP - O
a DET - O
decrease NOUN - O
in ADP - O
the DET - O
group NOUN - O
treated VERB - O
with ADP - O
Imodium NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Imodium NNP - B-MEDICINE
in ADP - O
neurotic ADJ - O
diarrhoeas NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Examination PROPN - O
of ADP - O
Imodium NNP - B-MEDICINE
in ADP - O
patients NOUN - O
suffering VERB - O
from ADP - O
acute ADJ - O
and CCONJ - O
chronic ADJ - O
diarrhoea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
the DET - O
currently ADV - O
marketed VERB - O
form NOUN - O
of ADP - O
loperamide NOUN - O
( PUNCT - O
Imodium NN - B-MEDICINE
capsules NOUN - O
) PUNCT - O
that ADJ - O
might VERB - O
relate VERB - O
to PART - O
abuse VERB - O
potential NOUN - O
were VERB - O
examined VERB - O
. PUNCT - O

-DOCSTART- -X- - O

63 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
23 CD - B-DATE
- HYPH - I-DATE
-78 NN - I-DATE
years NNS - I-DATE
) PUNCT - O
with ADP - O
irradiation NOUN - O
- PUNCT - O
induced VERB - O
diarrhoea NOUN - O
, PUNCT - O
the DET - O
majority NOUN - O
of ADP - O
them PRON - O
resistant ADJ - O
to ADP - O
treatment NOUN - O
with ADP - O
diphenoxylate NOUN - O
, PUNCT - O
were VERB - O
started VERB - O
on ADP - O
4-(p NUM - O
- PUNCT - O
chlorophenyl)-4-hydroxy NOUN - O
- PUNCT - O
N NOUN - O
, PUNCT - O
N'-dimethyl NOUN - O
- PUNCT - O
alpha NOUN - O
, PUNCT - O
alpha NOUN - O
- PUNCT - O
diphenyl-1-piperidine NOUN - O
butyramide NOUN - O
( PUNCT - O
loperidine NOUN - O
, PUNCT - O
Imodium NNP - B-MEDICINE
) PUNCT - O
4 CD - B-CARDINAL
mg NOUN - O
daily RB - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
( PUNCT - O
CAP NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
FDA NNP - B-ORG
- PUNCT - O
approved VERB - O
and CCONJ - O
frequently ADV - O
used VERB - O
chemotherapeutic ADJ - O
agent NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
various ADJ - O
cancers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
nanoniosomes NOUN - O
and CCONJ - O
evaluation NOUN - O
of ADP - O
anticancer NOUN - O
efficacy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nasolacrimal NNP - B-PERSON
Duct NNP - I-PERSON
Stenosis NN - I-PERSON
after ADP - O
Oral NNP - B-ORG
Capecitabine NNP - I-MEDICINE
Administration NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Addition PROPN - O
of ADP - O
Capecitabine NNP - B-MEDICINE
in ADP - O
Breast PROPN - O
Cancer PROPN - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
platinum NOUN - O
- PUNCT - O
pretreated VERB - O
advanced ADJ - O
or CCONJ - O
recurrent ADJ - O
cervical ADJ - O
carcinoma NOUN - O
: PUNCT - O
a DET - O
retrospective ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
dose VERB - O
escalation NOUN - O
after ADP - O
an DET - O
initial ADJ - O
genotype NOUN - O
- PUNCT - O
guided VERB - O
dose NOUN - O
reduction NOUN - O
is VERB - O
advocated VERB - O
when ADV - O
treatment NOUN - O
is VERB - O
well ADV - O
tolerated ADJ - O
. PUNCT - O

Capecitabine NN - B-MEDICINE
doses NOUN - O
were VERB - O
reduced VERB - O
in ADP - O
case NOUN - O
of ADP - O
a DET - O
DPYD PROPN - O
variant NOUN - O
( PUNCT - O
DPYD*2A PROPN - O
, PUNCT - O
c.2846A PROPN - O
> X - O
T PROPN - O
, PUNCT - O
DPYD*13 NNP - B-ORG
, PUNCT - O
or CCONJ - O
c.1236G VERB - O
> X - O
A NOUN - O
) PUNCT - O
and CCONJ - O
subsequently ADV - O
adjusted VERB - O
on ADP - O
the DET - O
basis NOUN - O
of ADP - O
tolerance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
monotherapy NOUN - O
in ADP - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
resistant ADJ - O
to PART - O
anthracycline VERB - O
and CCONJ - O
taxane ADJ - O
: PUNCT - O
A DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
Plus CCONJ - O
Oxaliplatin PROPN - O
Versus PROPN - O
Gemcitabine PROPN - O
Plus CCONJ - O
Oxaliplatin PROPN - O
as ADP - O
First NNP - B-ORG
- HYPH - I-ORG
Line NN - I-ORG
Therapy NNP - I-ORG
for IN - I-ORG
Advanced NNP - I-ORG
Biliary NNP - I-ORG
Tract PROPN - O
Cancers NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
is VERB - O
a DET - O
prodrug NOUN - O
and CCONJ - O
is VERB - O
selectively ADV - O
activated VERB - O
by ADP - O
tumor NOUN - O
cells NOUN - O
to ADP - O
its ADJ - O
cytotoxic ADJ - O
moiety NOUN - O
, PUNCT - O
5-fluorouracil NUM - O
, PUNCT - O
by ADP - O
thymidine NOUN - O
phosphorylase NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
generally ADV - O
expressed VERB - O
at ADP - O
high ADJ - O
levels NOUN - O
in ADP - O
tumors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
bioequivalence NOUN - O
in ADP - O
healthy ADJ - O
volunteers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
and CCONJ - O
Celecoxib NNP - B-ORG
as ADP - O
a DET - O
Promising PROPN - O
Therapy PROPN - O
for ADP - O
Thymic PROPN - O
Neoplasms PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
leukoencephalopathy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NN - I-ORG
of IN - I-ORG
Supplementary NNP - I-ORG
Omegaven NNP - I-ORG
® NOUN - O
on ADP - O
the DT - B-ORG
Clinical NNP - I-ORG
Outcome NNP - I-ORG
of IN - I-ORG
Patients NNPS - I-ORG
With IN - I-ORG
Advanced JJ - I-ORG
Esophagogastric NNP - I-ORG
Adenocarcinoma NNP - I-ORG
Receiving NNP - I-ORG
Palliative NNP - I-ORG
Epirubicin NNP - I-ORG
, PUNCT - O
Oxaliplatin NNP - B-LOC
, PUNCT - O
and CCONJ - O
Capecitabine NNP - B-MEDICINE
Chemotherapy NNP - I-PERSON
: PUNCT - O
A PROPN - O
Phase NOUN - O
II NNP - B-PRODUCT
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Real ADJ - O
- PUNCT - O
World PROPN - O
Adverse PROPN - O
Effects PROPN - O
of ADP - O
Capecitabine NNP - B-MEDICINE
Toxicity PROPN - O
in ADP - O
an DET - O
Elderly PROPN - O
Population PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
- PUNCT - O
cisplatin NOUN - O
failed VERB - O
to PART - O
demonstrate VERB - O
superior ADJ - O
efficacy NOUN - O
compared VERB - O
with ADP - O
S-1-cisplatin NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NNP - B-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Myocardial NNP - I-ORG
Infarction NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
- PUNCT - O
cisplatin NOUN - O
versus ADP - O
5-fluorouracil CD - B-CARDINAL
/ SYM - O
leucovorin NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
radiotherapy NOUN - O
for ADP - O
adjuvant ADJ - O
therapy NOUN - O
of ADP - O
lymph NOUN - O
node NOUN - O
positive ADJ - O
locally ADV - O
advanced ADJ - O
gastric ADJ - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Low PROPN - O
- PUNCT - O
Dose PROPN - O
Single PROPN - O
- PUNCT - O
Agent PROPN - O
Capecitabine NNP - B-MEDICINE
in ADP - O
Inoperable PROPN - O
Gallbladder PROPN - O
Cancer PROPN - O
with ADP - O
Jaundice NNP - B-ORG
Post NNP - I-ORG
- HYPH - I-ORG
Single NNP - I-ORG
- HYPH - I-ORG
System NNP - I-ORG
Single NNP - I-ORG
- HYPH - I-ORG
Catheter NNP - I-ORG
External NNP - I-ORG
Biliary NNP - I-ORG
Drainage NNP - I-ORG
: PUNCT - O
a DET - O
Pilot PROPN - O
Study PROPN - O
from ADP - O
a DET - O
Highly PROPN - O
Endemic PROPN - O
Area PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Neoadjuvant PROPN - O
Radiotherapy PROPN - O
with ADP - O
Capecitabine NNP - B-MEDICINE
Plus CCONJ - O
Bevacizumab PROPN - O
for ADP - O
Locally ADV - O
Advanced ADJ - O
Lower PROPN - O
Rectal PROPN - O
Cancer PROPN - O
: PUNCT - O
Results NOUN - O
of ADP - O
a DET - O
Single NNP - B-ORG
- PUNCT - O
institute NOUN - O
Phase NNP - B-PRODUCT
II NNP - I-PRODUCT
Study NNP - I-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
Between ADP - O
Serum PROPN - O
Folate PROPN - O
Level PROPN - O
and CCONJ - O
Toxicity NNP - B-ORG
of IN - I-ORG
Capecitabine NNP - I-MEDICINE
During IN - I-ORG
Treatment NNP - I-ORG
for IN - I-ORG
Colorectal NNP - I-ORG
Cancer NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
plus CCONJ - O
cisplatin ADJ - O
( PUNCT - O
XP NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
standard ADJ - O
global ADJ - O
regimen NOUN - O
, PUNCT - O
while ADP - O
S-1 NNP - B-ORG

-DOCSTART- -X- - O

A DET - O
Multicenter PROPN - O
Phase PROPN - O
II PROPN - O
Study PROPN - O
of ADP - O
Gemcitabine PROPN - O
, PUNCT - O
Capecitabine NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Bevacizumab NNP - B-ORG
for IN - I-ORG
Locally ADV - O
Advanced ADJ - O
or CCONJ - O
Metastatic PROPN - O
Biliary PROPN - O
Tract PROPN - O
Cancer PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Case PROPN - O
Report PROPN - O
- PUNCT - O
Stevens PROPN - O
- PUNCT - O
Johnson PROPN - O
Syndrome PROPN - O
as ADP - O
an DET - O
Adverse PROPN - O
Effect PROPN - O
of ADP - O
Capecitabine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Toxicity PROPN - O
, PUNCT - O
Tolerability NNP - B-ORG
, PUNCT - O
and CCONJ - O
Compliance NOUN - O
of ADP - O
Concurrent PROPN - O
Capecitabine NNP - B-MEDICINE
or CCONJ - O
5-Fluorouracil NUM - O
in ADP - O
Radical PROPN - O
Management PROPN - O
of ADP - O
Anal PROPN - O
Cancer PROPN - O

-DOCSTART- -X- - O

Capecitabine NN - B-MEDICINE
as ADP - O
a DET - O
minor ADJ - O
groove NOUN - O
binder NOUN - O
of ADP - O
DNA PROPN - O
: PUNCT - O
molecular ADJ - O
docking NOUN - O
, PUNCT - O
molecular ADJ - O
dynamics NOUN - O
, PUNCT - O
and CCONJ - O
multi ADJ - O
- ADJ - O
spectroscopic ADJ - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Corrigendum VERB - O
to ADP - O
" PUNCT - O
Neoadjuvant PROPN - O
5-FU PROPN - O
or CCONJ - O
Capecitabine NNP - B-MEDICINE
Plus CCONJ - O
Radiation PROPN - O
With ADP - O
or CCONJ - O
Without IN - B-PERSON
Oxaliplatin NNP - I-PERSON
in ADP - O
Rectal NNP - B-WORK_OF_ART
Cancer NNP - I-WORK_OF_ART
Patients NNPS - I-WORK_OF_ART
: PUNCT - O

-DOCSTART- -X- - O

Fructus NN - B-ORG
mume NN - I-ORG
Extracts NOUN - O
Alleviate PROPN - O
Diarrhea PROPN - O
in ADP - O
Breast PROPN - O
Cancer NOUN - O
Patients NOUN - O
Receiving VERB - O
the DET - O
Combination PROPN - O
Therapy PROPN - O
of ADP - O
Lapatinib NNP - B-ORG
and CCONJ - O
Capecitabine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
is VERB - O
a DET - O
Vaughan NNP - B-ORG
- HYPH - I-ORG
Williams NNP - I-ORG
Class PROPN - O
III NNP - B-PERSON
antiarrhythmic NOUN - O
medication NOUN - O
that ADJ - O
is VERB - O
commonly ADV - O
used VERB - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
both CCONJ - O
atrial ADJ - O
and CCONJ - O
ventricular ADJ - O
arrhythmias NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Compatibility PROPN - O
of ADP - O
Baclofen PROPN - O
, PUNCT - O
Carvedilol NNP - B-PERSON
, PUNCT - O
Hydrochlorothiazide PROPN - O
, PUNCT - O
Mercaptopurine NNP - B-PERSON
, PUNCT - O
Methadone NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Oseltamivir NNP - B-PERSON
Phosphate NNP - I-PERSON
, PUNCT - O
Phenobarbital JJ - B-ORG
, PUNCT - O
Propranolol NNP - B-PERSON
Hydrochloride NNP - I-PERSON
, PUNCT - O
Pyrazinamide NNP - B-GPE
, PUNCT - O
Sotalol NNP - B-MEDICINE
Hydrochloride NNP - I-PERSON
, PUNCT - O
Spironolactone PROPN - O
, PUNCT - O
Tacrolimus NNP - B-PERSON
Monohydrate NNP - I-PERSON
, PUNCT - O
Ursodeoxycholic PROPN - O
Acid PROPN - O
, PUNCT - O
and CCONJ - O
Vancomycin NNP - B-ORG
Hydrochloride NNP - I-ORG
Oral NNP - I-ORG
Suspensions NNPS - I-ORG
Compounded NNP - I-ORG
with ADP - O
SyrSpend PROPN - O
SF PROPN - O
pH4 PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
administration NOUN - O
was VERB - O
discontinued VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
selective ADJ - O
beta NOUN - O
- PUNCT - O
adrenergic NOUN - O
blocking VERB - O
agent NOUN - O
without ADP - O
intrinsic ADJ - O
sympathomimetic ADJ - O
activity NOUN - O
. PUNCT - O

Sotalol NN - B-MEDICINE
therapy NOUN - O
has VERB - O
been VERB - O
indicated VERB - O
for ADP - O
the DET - O
management NOUN - O
of ADP - O
supraventricular ADJ - O
arrhythmias NOUN - O
, PUNCT - O
refractory ADJ - O
life NOUN - O
threatening VERB - O
ventricular ADJ - O
arrhythmias NOUN - O
and CCONJ - O
atrial ADJ - O
fibrillation NOUN - O
/ SYM - O
flutter NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Digging VERB - O
into ADP - O
Lipid NNP - B-ORG
Membrane NNP - I-ORG
Permeation NNP - I-ORG
for ADP - O
Cardiac NNP - B-ORG
Ion NNP - I-ORG
Channel NNP - I-ORG
Blocker NNP - I-ORG
d NN - I-ORG
- : - I-ORG
Sotalol NNP - I-MEDICINE
with ADP - O
All NNP - B-ORG
- HYPH - I-ORG
Atom NNP - I-ORG
Simulations NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
significantly ADV - O
increased VERB - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
and CCONJ - O
ERPs NOUN - O
, PUNCT - O
but CCONJ - O
, PUNCT - O
despite ADP - O
increasing VERB - O
plasma NOUN - O
concentrations NOUN - O
, PUNCT - O
higher ADJ - O
dosages NOUN - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
a DET - O
progressive ADJ - O
increase NOUN - O
in ADP - O
QT NNP - B-ORG
interval NOUN - O
or CCONJ - O
ERPs NOUN - O
. PUNCT - O

Sotalol NNP - B-MEDICINE
at ADP - O
a DET - O
dose NOUN - O
of ADP - O
2 CD - B-CARDINAL
, PUNCT - O
3 CD - B-CARDINAL
and CCONJ - O
4 CD - B-DATE

-DOCSTART- -X- - O

The DET - O
Basis PROPN - O
for ADP - O
Low PROPN - O
- PUNCT - O
affinity NOUN - O
hERG ADJ - O
Potassium PROPN - O
Channel PROPN - O
Block PROPN - O
by ADP - O
Sotalol NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
is VERB - O
a DET - O
racemic ADJ - O
mixture NOUN - O
possessing VERB - O
beta NOUN - O
- PUNCT - O
blocker NOUN - O
and CCONJ - O
class NOUN - O
III NUM - O
anti ADJ - O
arrhythmic ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
hydrochloride NOUN - O
was VERB - O
a DET - O
safe ADJ - O
anti ADJ - O
- ADJ - O
arrhythmic ADJ - O
drug NOUN - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
this DET - O
case NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
availability NOUN - O
of ADP - O
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
Sotalol NNP - B-MEDICINE
has VERB - O
equalized VERB - O
the DET - O
treatment NOUN - O
options NOUN - O
since ADP - O
both CCONJ - O
amiodarone ADJ - O
and CCONJ - O
sotalol NN - B-MEDICINE
are VERB - O
available ADJ - O
in ADP - O
both DET - O
IV NNP - B-ORG
and CCONJ - O
oral ADJ - O
formulations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sotalol NNP - B-MEDICINE
, PUNCT - O
a DET - O
beta NOUN - O
- PUNCT - O
blocking VERB - O
agent NOUN - O
with ADP - O
antiarrhythmic ADJ - O
activity NOUN - O
, PUNCT - O
was VERB - O
also ADV - O
common ADJ - O
( PUNCT - O
15 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

During ADP - O
Dofetilide PROPN - O
or CCONJ - O
Sotalol NNP - B-MEDICINE
Initiation PROPN - O
: PUNCT - O
Utility NOUN - O
of ADP - O
a DET - O
Novel PROPN - O
T NOUN - O
Wave PROPN - O
Analysis PROPN - O
Program PROPN - O
" PUNCT - O
by ADP - O
Sugrue NNP - B-PERSON
A. NNP - I-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Wenxin NNP - B-PERSON
Keli NNP - I-PERSON
versus ADP - O
Sotalol NNP - B-MEDICINE
for ADP - O
Paroxysmal PROPN - O
Atrial PROPN - O
Fibrillation PROPN - O
Caused VERB - O
by ADP - O
Hyperthyroidism PROPN - O
: PUNCT - O
A DET - O
Prospective PROPN - O
, PUNCT - O
Open ADJ - O
Label PROPN - O
, PUNCT - O
and CCONJ - O
Randomized PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
an DET - O
HPLC NNP - B-ORG
- PUNCT - O
UV NOUN - O
method NOUN - O
for ADP - O
analysis NOUN - O
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
loxapine NOUN - O
succinate NOUN - O
in ADP - O
an DET - O
activated VERB - O
carbon NOUN - O
disposal NOUN - O
system NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
pharmaceutical NOUN - O
technology NOUN - O
, PUNCT - O
and CCONJ - O
is VERB - O
especially ADV - O
a DET - O
kind NOUN - O
of ADP - O
slow ADJ - O
control NOUN - O
released VERB - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
capsule NOUN - O
and CCONJ - O
its ADJ - O
preparation NOUN - O
process NOUN - O
. PUNCT - O

The DET - O
dosage NOUN - O
of ADP - O
the DET - O
slow ADJ - O
control NOUN - O
released VERB - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
capsule NOUN - O
is VERB - O
10 CD - B-CARDINAL
- SYM - I-CARDINAL
40 CD - I-CARDINAL
mg NOUN - O
. PUNCT - O

Test NOUN - O
shows VERB - O
that ADP - O
the DET - O
slow ADJ - O
control NOUN - O
released VERB - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
capsule NOUN - O
has VERB - O
quick ADJ - O
treating VERB - O
effect NOUN - O
and CCONJ - O
sustained ADJ - O
medicine NOUN - O
release NOUN - O
over IN - B-PERCENT
90 CD - I-PERCENT
% NN - I-PERCENT
in ADP - O
12 CD - B-CARDINAL
hr NOUN - O
. PUNCT - O

Compared VERB - O
with ADP - O
common ADJ - O
methylphenidate NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
tablet NOUN - O
, PUNCT - O
the DET - O
present ADJ - O
invention NOUN - O
has VERB - O
decreased VERB - O
medicine NOUN - O
taking VERB - O
times NOUN - O
and CCONJ - O
reduced VERB - O
toxic ADJ - O
side NOUN - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
found VERB - O
data NOUN - O
from ADP - O
trials NOUN - O
for ADP - O
the DET - O
following VERB - O
compounds NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
oral ADJ - O
suspension NOUN - O
( PUNCT - O
MEROS PROPN - O
; PUNCT - O
NWP06 NNP - B-GPE
, PUNCT - O
Quillivant PROPN - O
™ PROPN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
chewable ADJ - O
capsules NOUN - O
( PUNCT - O
NWP09 NNP - B-ORG
, PUNCT - O
QuilliChew NNP - B-ORG
ER NNP - I-ORG
™ NNP - I-ORG
) PUNCT - O
; PUNCT - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
extended VERB - O
- PUNCT - O
release NOUN - O
capsules NOUN - O
( PUNCT - O
Aptensio NNP - B-ORG
XR NNP - I-ORG
™ NNP - I-ORG
) PUNCT - O
; PUNCT - O
( PUNCT - O
4 LS - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
orally ADV - O
disintegrating VERB - O
tablets NOUN - O
( PUNCT - O
XR NNP - B-ORG
- HYPH - I-ORG
ODT NNP - I-ORG
; PUNCT - O
NT-0102 NNP - B-PRODUCT
, PUNCT - O
Cotempla PROPN - O
™ PROPN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
5 LS - B-CARDINAL
) PUNCT - O
ORADUR NNP - B-ORG
technology NOUN - O
( PUNCT - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
tamper NOUN - O
- PUNCT - O
resistant ADJ - O
formulation NOUN - O
) PUNCT - O
methylphenidate NOUN - O
sustained VERB - O
release NOUN - O
( PUNCT - O
SR PROPN - O
) PUNCT - O
; PUNCT - O
and CCONJ - O
( PUNCT - O
6 CD - B-CARDINAL
) PUNCT - O
methylphenidate NOUN - O
modified VERB - O
- PUNCT - O
release NOUN - O
( PUNCT - O
HLD-200 PROPN - O
; PUNCT - O
Bejorna NNP - B-ORG
™ NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
increasing VERB - O
use NOUN - O
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
MPH NNP - B-ORG
) PUNCT - O
in ADP - O
children NOUN - O
led VERB - O
us PRON - O
to PART - O
examine VERB - O
the DET - O
effects NOUN - O
of ADP - O
MPH NNP - B-ORG
administration NOUN - O
in ADP - O
developing VERB - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
individualized ADJ - O
dosing NOUN - O
within ADP - O
the DET - O
approved VERB - O
dose NOUN - O
range NOUN - O
for ADP - O
osmotic ADJ - O
- PUNCT - O
release NOUN - O
oral ADJ - O
system NOUN - O
( PUNCT - O
OROS PROPN - O
) PUNCT - O
methylphenidate NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
adults NOUN - O
with ADP - O
attention NOUN - O
- PUNCT - O
deficit NOUN - O
/ SYM - O
hyperactivity NOUN - O
disorder NOUN - O
( PUNCT - O
ADHD NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Experimental ADJ - O
studies NOUN - O
on ADP - O
the DET - O
long ADJ - O
- PUNCT - O
term NOUN - O
effects NOUN - O
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
asked VERB - O
whether ADP - O
we PRON - O
could VERB - O
enhance VERB - O
interest NOUN - O
in ADP - O
several ADJ - O
types NOUN - O
of ADP - O
novel ADJ - O
stimuli NOUN - O
in ADP - O
lab NOUN - O
- PUNCT - O
reared VERB - O
, PUNCT - O
female ADJ - O
Trinidadian JJ - B-NORP
guppies NOUN - O
by ADP - O
administering VERB - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
a DET - O
stimulant NOUN - O
known VERB - O
to PART - O
increase VERB - O
dopamine NOUN - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
the DET - O
effect NOUN - O
of ADP - O
baicalin NOUN - O
on ADP - O
the DET - O
behavioral ADJ - O
characteristics NOUN - O
of ADP - O
rats NOUN - O
with ADP - O
attention NOUN - O
deficit NOUN - O
hyperactivity NOUN - O
disorder NOUN - O
( PUNCT - O
ADHD NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
to PART - O
provide VERB - O
a DET - O
basis NOUN - O
for ADP - O
further ADJ - O
research NOUN - O
on ADP - O
baicalin NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
ADHD.A PROPN - O
total NOUN - O
of ADP - O
40 CD - B-CARDINAL
SHR NNP - B-ORG
rats NOUN - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
model NOUN - O
group NOUN - O
, PUNCT - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
MPH NNP - B-ORG
) PUNCT - O
group NOUN - O
, PUNCT - O
and CCONJ - O
low- ADJ - O
, PUNCT - O
medium- NOUN - O
, PUNCT - O
and CCONJ - O
high ADJ - O
- PUNCT - O
dose NOUN - O
baicalin NOUN - O
groups NOUN - O
, PUNCT - O
with ADP - O
8 CD - B-CARDINAL
rats NOUN - O
in ADP - O
each DET - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
proof NOUN - O
of ADP - O
concept NOUN - O
investigation NOUN - O
seeks VERB - O
to PART - O
examine VERB - O
the DET - O
clinical ADJ - O
effects NOUN - O
and CCONJ - O
safety NOUN - O
profile NOUN - O
of ADP - O
KPAX002 NNP - B-GPE
( PUNCT - O
a DET - O
combination NOUN - O
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
mitochondrial ADJ - O
support NOUN - O
nutrients NOUN - O
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
CFS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
examined VERB - O
the DET - O
effects NOUN - O
of ADP - O
chronic ADJ - O
and CCONJ - O
acute ADJ - O
treatment NOUN - O
with ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
Ritalin NNP - B-PERSON
) PUNCT - O
on ADP - O
isolation NOUN - O
- PUNCT - O
induced VERB - O
ultrasonic ADJ - O
vocalizations NOUN - O
, PUNCT - O
spontaneous ADJ - O
locomotor NOUN - O
activity NOUN - O
, PUNCT - O
and CCONJ - O
neuromotor NOUN - O
coordination NOUN - O
in ADP - O
3- CD - B-DATE
to IN - I-DATE
11-day CD - I-DATE
- HYPH - I-DATE
old JJ - I-DATE
CD-1 PROPN - O
mouse NOUN - O
pups NOUN - O
. PUNCT - O

In ADP - O
Experiment NNP - B-DATE
1 CD - I-DATE
, PUNCT - O
3- NUM - O
to ADP - O
11-day NUM - O
- PUNCT - O
old ADJ - O
pups NOUN - O
received VERB - O
daily JJ - B-DATE
injections NOUN - O
of ADP - O
saline NOUN - O
, PUNCT - O
5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
or CCONJ - O
20 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
or CCONJ - O
no DET - O
injection NOUN - O
and CCONJ - O
were VERB - O
tested VERB - O
on ADP - O
postnatal NOUN - O
Days NOUN - O
3 NUM - O
, PUNCT - O
5 NUM - O
, PUNCT - O
7 CD - B-DATE
, PUNCT - O
9 CD - B-DATE
, PUNCT - O
and CCONJ - O
11 CD - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
chronic ADJ - O
and CCONJ - O
acute ADJ - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
Ritalin NNP - B-PERSON
) PUNCT - O
administration NOUN - O
on ADP - O
locomotor NOUN - O
activity NOUN - O
, PUNCT - O
ultrasonic ADJ - O
vocalizations NOUN - O
, PUNCT - O
and CCONJ - O
neuromotor NOUN - O
development NOUN - O
in ADP - O
3- CD - B-GPE
to ADP - O
11-day NUM - O
- PUNCT - O
old ADJ - O
CD-1 PROPN - O
mouse NOUN - O
pups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Psychopharmacological ADJ - O
treatment NOUN - O
with ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
is VERB - O
recommended VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
for ADP - O
ADHD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
determine VERB - O
via ADP - O
a DET - O
case NOUN - O
- PUNCT - O
only ADJ - O
design NOUN - O
whether ADP - O
the DET - O
use NOUN - O
of ADP - O
methylphenidate JJ - B-MEDICINE
hydrochloride NN - I-MEDICINE
or CCONJ - O
atomoxetine NOUN - O
hydrochloride NOUN - O
reduces VERB - O
the DET - O
risk NOUN - O
of ADP - O
injuries NOUN - O
among ADP - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O
with ADP - O
ADHD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Memantine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
dementia NOUN - O
subtypes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Memantine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
is VERB - O
an DET - O
uncompetitive ADJ - O
N NOUN - O
- PUNCT - O
methyl NOUN - O
- PUNCT - O
D NOUN - O
- PUNCT - O
aspartate PROPN - O
( PUNCT - O
NMDA NNP - B-ORG
) PUNCT - O
antagonist NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
moderate ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
severe ADJ - O
Alzheimer PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
present ADJ - O
paper NOUN - O
deals VERB - O
with ADP - O
the DET - O
development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
a DET - O
stability NOUN - O
indicating VERB - O
high ADJ - O
performance NOUN - O
liquid NOUN - O
chromatographic ADJ - O
method NOUN - O
for ADP - O
the DET - O
quantitative ADJ - O
determination NOUN - O
of ADP - O
Memantine NNP - B-GPE
hydrochloride NOUN - O
. PUNCT - O

Memantine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
was VERB - O
derivatized VERB - O
with ADP - O
0.015 CD - B-CARDINAL
M NOUN - O
9-fluorenylmethyl NUM - O
chloroformate NOUN - O
( PUNCT - O
FMOC PROPN - O
) PUNCT - O
and CCONJ - O
0.5 CD - B-CARDINAL
M NOUN - O
borate VERB - O
buffer NOUN - O
solution NOUN - O
by ADP - O
keeping VERB - O
it PRON - O
at ADP - O
room NOUN - O
temperature NOUN - O
for ADP - O
about RB - B-TIME
20 CD - I-TIME
minutes NNS - I-TIME
and CCONJ - O
the DET - O
chromatographic ADJ - O
separation NOUN - O
achieved VERB - O
by ADP - O
injecting VERB - O
10 CD - B-CARDINAL
muL NOUN - O
of ADP - O
the DET - O
derivatized VERB - O
mixture NOUN - O
into ADP - O
a DET - O
Waters NNP - B-GPE
HPLC NNP - I-GPE
system NOUN - O
with ADP - O
photodiode ADJ - O
array NOUN - O
detector NOUN - O
using VERB - O
a DET - O
kromasil NOUN - O
C18 NNP - B-ORG
column NOUN - O
( PUNCT - O
150 CD - B-CARDINAL
x SYM - O
4.6 CD - B-QUANTITY
mm NN - I-QUANTITY
) PUNCT - O
, PUNCT - O
5 CD - B-QUANTITY
mu NNS - I-QUANTITY
. PUNCT - O

Forced ADJ - O
degradation NOUN - O
studies NOUN - O
were VERB - O
performed VERB - O
on ADP - O
bulk ADJ - O
sample NOUN - O
of ADP - O
Memantine NNP - B-GPE
hydrochloride NOUN - O
using VERB - O
acid NOUN - O
( PUNCT - O
5.0 CD - B-CARDINAL
Normal NNP - B-PERSON
( PUNCT - O
N NNP - B-ORG
) PUNCT - O
hydrochloric ADJ - O
acid NOUN - O
) PUNCT - O
, PUNCT - O
base NOUN - O
( PUNCT - O
1.0 CD - B-CARDINAL
N NOUN - O
sodium NOUN - O
hydroxide NOUN - O
) PUNCT - O
, PUNCT - O
oxidation NOUN - O
( PUNCT - O
30 CD - B-PERCENT
% NN - I-PERCENT
hydrogen NOUN - O
peroxide NOUN - O
) PUNCT - O
, PUNCT - O
thermal ADJ - O
( PUNCT - O
105 CD - B-QUANTITY
degrees NNS - I-QUANTITY
C PROPN - O
) PUNCT - O
, PUNCT - O
photolytic NOUN - O
and CCONJ - O
humidity NOUN - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone CD - B-MEDICINE
therapy NOUN - O
was VERB - O
associated VERB - O
with ADP - O
reduced VERB - O
all DET - O
- PUNCT - O
cause NOUN - O
mortality NOUN - O
in ADP - O
women NOUN - O
( PUNCT - O
hazard NOUN - O
ratio NOUN - O
: PUNCT - O
0.66 CD - B-CARDINAL
; PUNCT - O
p X - O
  SPACE - O
= SYM - O
0.01 CD - B-CARDINAL
) PUNCT - O
but CCONJ - O
not ADV - O
in ADP - O
men NOUN - O
( PUNCT - O
pinteraction NOUN - O
  SPACE - O
= SYM - O
0.02 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
Between ADP - O
High PROPN - O
- PUNCT - O
Dose PROPN - O
Spironolactone NNP - B-MEDICINE
and CCONJ - O
Decongestion NNP - B-ORG
in IN - I-ORG
Patients NNPS - I-ORG
with IN - I-ORG
Acute PROPN - O
Heart PROPN - O
Failure NOUN - O
: PUNCT - O
An PROPN - O
Observational PROPN - O
Retrospective PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone NNP - B-MEDICINE
and CCONJ - O
Outcomes PROPN - O
in ADP - O
Older ADJ - O
Patients NOUN - O
with ADP - O
Heart PROPN - O
Failure PROPN - O
and CCONJ - O
Reduced PROPN - O
Ejection PROPN - O
Fraction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone CD - B-MEDICINE
reduced VERB - O
sucrose NOUN - O
intake NOUN - O
in ADP - O
female ADJ - O
rats NOUN - O
only ADV - O
, PUNCT - O
and CCONJ - O
locomotion NOUN - O
in ADP - O
male ADJ - O
and CCONJ - O
female ADJ - O
rats NOUN - O
during ADP - O
sucrose ADJ - O
self NOUN - O
- PUNCT - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Frequency NOUN - O
of ADP - O
Treatment NNP - B-ORG
Switching VBG - I-ORG
for IN - I-ORG
Spironolactone NNP - I-MEDICINE

-DOCSTART- -X- - O

Spironolactone NNP - B-MEDICINE
( PUNCT - O
an DET - O
adjuvant ADJ - O
therapy NOUN - O
) PUNCT - O
in ADP - O
rheumatoid NOUN - O
arthritis NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
control NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone NNP - B-MEDICINE
was VERB - O
found VERB - O
to PART - O
function VERB - O
as ADP - O
an DET - O
inhibitor NOUN - O
of ADP - O
the DET - O
ERBB4 NNP - B-PERSON
receptor NOUN - O
. PUNCT - O

Spironolactone NN - B-MEDICINE
is VERB - O
an DET - O
antagonist NOUN - O
of ADP - O
NRG1-ERBB4 NNP - B-ORG
signaling VERB - O
and CCONJ - O
schizophrenia NOUN - O
- PUNCT - O
relevant ADJ - O
endophenotypes NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Incident NNP - B-ORG
Hyperkalemia NNP - I-ORG
, PUNCT - O
Hypokalemia NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Clinical PROPN - O
Outcomes PROPN - O
During ADP - O
Spironolactone NNP - B-MEDICINE
Treatment NOUN - O
of ADP - O
Heart PROPN - O
Failure PROPN - O
With ADP - O
Preserved PROPN - O
Ejection PROPN - O
Fraction NOUN - O
: PUNCT - O
Analysis NOUN - O
of ADP - O
the DET - O
TOPCAT PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Topical NNP - B-ORG
Administration NNP - I-ORG
of IN - I-ORG
Spironolactone NNP - I-MEDICINE
- HYPH - I-ORG
Loaded VBN - I-ORG
Nanomicelles NNPS - I-ORG
Prevents NNPS - I-ORG
Glucocorticoid NNP - I-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Delayed VBN - I-ORG
Corneal NNP - I-ORG
Wound PROPN - O
Healing PROPN - O
in ADP - O
Rabbits NNPS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone CD - B-MEDICINE
voltammetric ADJ - O
determination NOUN - O
on ADP - O
renewable ADJ - O
amalgam NOUN - O
film NOUN - O
electrode NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone NNP - B-MEDICINE
was VERB - O
increased VERB - O
to ADP - O
50 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
day NOUN - O
in ADP - O
all DET - O
patients NOUN - O
; PUNCT - O
43 CD - B-CARDINAL
( PUNCT - O
68 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
patients NOUN - O
required VERB - O
one CD - B-CARDINAL
or CCONJ - O
more ADJ - O
patiromer NOUN - O
dose NOUN - O
titration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone NN - B-MEDICINE
has VERB - O
been VERB - O
marketed VERB - O
for ADP - O
over IN - B-DATE
half PDT - I-DATE
a DT - I-DATE
century NN - I-DATE
as ADP - O
a DET - O
' PUNCT - O
potassium NOUN - O
- PUNCT - O
sparing NOUN - O
diuretic NOUN - O
' PUNCT - O
, PUNCT - O
used VERB - O
primarily ADV - O
in ADP - O
patients NOUN - O
with ADP - O
ascites NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NNP - B-ORG
of IN - I-ORG
Active NNP - I-ORG
and CC - I-ORG
Passive NNP - I-ORG
Components NNPS - I-ORG
of IN - I-ORG
LV NNP - I-ORG
Diastolic NNP - I-ORG
Filling NNP - I-ORG
With IN - I-ORG
Exercise NNP - I-ORG
Intolerance NN - I-ORG
in ADP - O
Heart PROPN - O
Failure PROPN - O
With ADP - O
Preserved PROPN - O
Ejection PROPN - O
Fraction NOUN - O
: PUNCT - O
Mechanistic ADJ - O
Insights PROPN - O
From ADP - O
Spironolactone NNP - B-MEDICINE
Response PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone CD - B-MEDICINE
treatment NOUN - O
reverted VERB - O
hyperphosphorylation NOUN - O
of ADP - O
activated VERB - O
Erbb4 NOUN - O
in ADP - O
these DET - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Response NOUN - O
by ADP - O
Good NNP - B-PERSON
et NNP - I-PERSON
al NNP - I-PERSON
to ADP - O
Letter PROPN - O
Regarding VERB - O
Article PROPN - O
, PUNCT - O
" PUNCT - O
Pannexin-1 NN - B-WORK_OF_ART
Channels NNS - I-WORK_OF_ART
as IN - I-WORK_OF_ART
an DT - I-WORK_OF_ART
Unexpected NNP - I-WORK_OF_ART
New NNP - I-WORK_OF_ART
Target NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
the DT - I-WORK_OF_ART
Antihypertensive NNP - I-WORK_OF_ART
Drug NNP - I-WORK_OF_ART
Spironolactone NNP - I-MEDICINE
" PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Spironolactone CD - B-MEDICINE
up ADP - O
- PUNCT - O
titration NOUN - O
was VERB - O
associated VERB - O
with ADP - O
lower ADJ - O
risk NOUN - O
of ADP - O
HF NNP - B-ORG
hospitalization NOUN - O
or CCONJ - O
death NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
high ADJ - O
cystatin NOUN - O
C NOUN - O
( PUNCT - O
CysC NNP - B-ORG
) PUNCT - O
( PUNCT - O
interaction NOUN - O
, PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.021 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Enhancing VERB - O
the DET - O
Catalytic PROPN - O
Activity PROPN - O
of ADP - O
Co3O4 PROPN - O
Nanosheets PROPN - O
for ADP - O
Li PROPN - O
- PUNCT - O
O2 PROPN - O
Batteries PROPN - O
by ADP - O
the DT - B-ORG
Incoporation NNP - I-ORG
of IN - I-ORG
Oxygen NNP - I-MEDICINE
Vacancy NNP - I-ORG
with ADP - O
Hydrazine PROPN - O
Hydrate PROPN - O
Reduction PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
evolution NOUN - O
is VERB - O
not ADV - O
enhanced VERB - O
after ADP - O
a DET - O
critical ADJ - O
thickness NOUN - O
, PUNCT - O
about RB - B-CARDINAL
28 CD - I-CARDINAL
nm NOUN - O
in ADP - O
our ADJ - O
study NOUN - O
, PUNCT - O
is VERB - O
reached VERB - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
High PROPN - O
- PUNCT - O
Flow NOUN - O
Oxygen NNP - B-MEDICINE
Therapy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
evolution NOUN - O
complex NOUN - O
( PUNCT - O
OEC NNP - B-ORG
) PUNCT - O
in ADP - O
photosystem NOUN - O
II NNP - B-PERSON
( PUNCT - O
PSII PROPN - O
) PUNCT - O
is VERB - O
sensitive ADJ - O
to ADP - O
environmental ADJ - O
stressors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
conducted VERB - O
a DET - O
secondary ADJ - O
analysis NOUN - O
of ADP - O
data NOUN - O
from ADP - O
359 CD - B-CARDINAL
COPD NNS - B-ORG
participants NOUN - O
assigned VERB - O
to ADP - O
oxygen NN - B-MEDICINE
in ADP - O
the DET - O
Long ADJ - O
- PUNCT - O
term NOUN - O
Oxygen NNP - B-MEDICINE
Treatment NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
evolution NOUN - O
reaction NOUN - O
( PUNCT - O
OER NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
sluggish ADJ - O
electrocatalytic ADJ - O
reaction NOUN - O
in ADP - O
solid ADJ - O
oxide NOUN - O
electrolysis NOUN - O
cell NOUN - O
( PUNCT - O
SOEC PROPN - O
) PUNCT - O
at ADP - O
high ADJ - O
temperatures NOUN - O
( PUNCT - O
600~850 NUM - O
oC NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Photo‐Electrochemical PROPN - O
Oxygen NNP - B-MEDICINE
Evolution NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
vacancies NOUN - O
are VERB - O
the DET - O
most ADV - O
common ADJ - O
among ADP - O
them PRON - O
and CCONJ - O
have VERB - O
always ADV - O
been VERB - O
the DET - O
subject NOUN - O
of ADP - O
both CCONJ - O
theoretical ADJ - O
and CCONJ - O
experimental ADJ - O
research NOUN - O
as ADP - O
they PRON - O
play VERB - O
a DET - O
crucial ADJ - O
role NOUN - O
in ADP - O
tuning VERB - O
the DET - O
inherent ADJ - O
properties NOUN - O
of ADP - O
titanium NOUN - O
oxides NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NNP - B-MEDICINE
- HYPH - I-ORG
Scavenging NNP - I-ORG
Multilayered NNP - I-ORG
Biopapers NNP - I-ORG
Containing NNP - I-ORG
Palladium NNP - I-ORG
Nanoparticles NNPS - I-ORG

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
therapy NOUN - O
- PUNCT - O
related VERB - O
discomfort NOUN - O
was VERB - O
low ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Hollow PROPN - O
Polyhedral PROPN - O
Arrays PROPN - O
Composed VERB - O
of ADP - O
a DET - O
Co3O4 PROPN - O
Nanocrystal PROPN - O
Ensemble PROPN - O
on ADP - O
a DET - O
Honeycomb NNP - B-GPE
- PUNCT - O
like PROPN - O
Carbon PROPN - O
Hybrid PROPN - O
for ADP - O
Boosting PROPN - O
Highly ADV - O
Active ADJ - O
and CCONJ - O
Stable PROPN - O
Evolution PROPN - O
Oxygen NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
is VERB - O
not ADV - O
universally ADV - O
required VERB - O
for ADP - O
all DET - O
patients NOUN - O
. PUNCT - O

Oxygen NN - B-MEDICINE
should VERB - O
be VERB - O
administered VERB - O
to PART - O
maintain VERB - O
SpO2 NNP - B-PERSON
at ADP - O
92 CD - B-PERCENT
% NN - I-PERCENT
or CCONJ - O
above ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Abnormal NNP - B-ORG
Microstructural NNP - I-ORG
Development NNP - I-ORG
of IN - I-ORG
the DT - I-ORG
Cerebral NNP - I-ORG
Cortex NNP - I-ORG
in ADP - O
Neonates PROPN - O
With ADP - O
Congenital ADJ - O
Heart NOUN - O
Disease PROPN - O
Is VERB - O
Associated VERB - O
With ADP - O
Impaired ADJ - O
Cerebral PROPN - O
Oxygen NNP - B-MEDICINE
Delivery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Review PROPN - O
of ADP - O
Oxygen NNP - B-MEDICINE
Use PROPN - O
During ADP - O
Chest PROPN - O
Compressions PROPN - O
in ADP - O
Newborns PROPN - O
- PUNCT - O
A PROPN - O
Meta PROPN - O
- PUNCT - O
Analysis PROPN - O
of ADP - O
Animal PROPN - O
Data PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Oxygen NN - B-MEDICINE
- PUNCT - O
Deficient PROPN - O
Dumbbell PROPN - O
- PUNCT - O
Shaped PROPN - O
Anatase PROPN - O
TiO2-x PROPN - O
Mesocrystals NOUN - O
with ADP - O
Nearly ADV - O
100 NUM - O
  SPACE - O
% NOUN - O

-DOCSTART- -X- - O

Study NOUN - O
on ADP - O
Drug PROPN - O
- PUNCT - O
Drug NOUN - O
Interactions NOUN - O
Between ADP - O
Chiglitazar PROPN - O
, PUNCT - O
a DET - O
Novel PROPN - O
PPAR PROPN - O
Pan PROPN - O
- PROPN - O
Agonist PROPN - O
, PUNCT - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
Healthy PROPN - O
Subjects PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Improved NNP - B-ORG
Chromatographic NNP - I-ORG
Separation NNP - I-ORG
of IN - I-ORG
Sitagliptin PROPN - O
Phosphate PROPN - O
and CCONJ - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Voltammetric NNP - B-PERSON
Assay NNP - I-PERSON
of ADP - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
Using VERB - O
Pyrogallol NN - B-PERSON
Modified VBN - I-PERSON
Carbon PROPN - O
Paste PROPN - O
Electrode PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation PROPN - O
and CCONJ - O
Evaluation NOUN - O
of ADP - O
In PROPN - O
- PUNCT - O
vitro NOUN - O
Characterization NOUN - O
of ADP - O
Gastic PROPN - O
- PUNCT - O
Mucoadhesive NOUN - O
Microparticles PROPN - O
/ SYM - O
Discs PROPN - O
Containing PROPN - O
Metformin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Water NOUN - O
- PUNCT - O
soluble ADJ - O
Fraction NNP - B-ORG
of IN - I-ORG
Abelmoschus NNP - I-ORG
esculentus NOUN - O
L PROPN - O
Interacts PROPN - O
with ADP - O
Glucose NNP - B-ORG
and CCONJ - O
Metformin NNP - B-ORG
Hydrochloride NNP - I-ORG
and CCONJ - O
Alters PROPN - O
Their ADJ - O
Absorption PROPN - O
Kinetics PROPN - O
after ADP - O
Coadministration PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Formulation NOUN - O
and CCONJ - O
In ADP - O
vitro NOUN - O
Evaluation PROPN - O
of ADP - O
Sustained PROPN - O
Release PROPN - O
Dosage PROPN - O
Form NOUN - O
with ADP - O
Taste NNP - B-PERSON
Masking NNP - I-PERSON
of ADP - O
Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Metformin NNP - B-PERSON
Hydrochloride NNP - I-PERSON
( PUNCT - O
MF NNP - B-ORG
) PUNCT - O
is VERB - O
glucose NOUN - O
lowering VERB - O
agent NOUN - O
that ADJ - O
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
management NOUN - O
for ADP - O
type NOUN - O
II CD - B-ORG
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
the DET - O
Effects NOUN - O
of ADP - O
Piroxicam NNP - B-MEDICINE
and CCONJ - O
Diclofenac PROPN - O
Sodium PROPN - O
as ADP - O
Treatments NNP - B-ORG
for IN - I-ORG
Primary NNP - I-ORG
Dysmenorrhea NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
( PUNCT - O
Px PROPN - O
) PUNCT - O
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
that ADJ - O
is VERB - O
widely ADV - O
prescribed VERB - O
in ADP - O
various ADJ - O
inflammatory ADJ - O
disorders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
is VERB - O
a DET - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
widely ADV - O
used VERB - O
in ADP - O
rheumatic ADJ - O
diseases NOUN - O
. PUNCT - O

Piroxicam NN - B-MEDICINE
- PUNCT - O
hepatotoxicity NOUN - O
has VERB - O
been VERB - O
reported VERB - O
as ADP - O
one NUM - O
of ADP - O
its ADJ - O
principal ADJ - O
side NOUN - O
effects NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
aimed VERB - O
at ADP - O
studying VERB - O
the DET - O
protective ADJ - O
effect NOUN - O
of ADP - O
Ginger NNP - B-ORG
on IN - I-ORG
Piroxicam NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
histopathological ADJ - O
changes NOUN - O
in ADP - O
livers NOUN - O
of ADP - O
male ADJ - O
mice NOUN - O
. PUNCT - O

Group PROPN - O
ІІI PROPN - O
received VERB - O
Piroxicam NNP - B-MEDICINE
intraperitoneally ADV - O
in ADP - O
a DET - O
dose NOUN - O
of ADP - O
0.3 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
per ADP - O
day NOUN - O
for ADP - O
four CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Group PROPN - O
ІV PROPN - O
received VERB - O
( PUNCT - O
Piroxicam NNP - B-MEDICINE
  _SP - I-GPE
+ CCONJ - O
  SPACE - O
Ginger PROPN - O
) PUNCT - O
. PUNCT - O

Piroxicam NNP - B-MEDICINE
has VERB - O
toxic ADJ - O
effects NOUN - O
on ADP - O
the DET - O
liver NOUN - O
as ADP - O
indicated VERB - O
by ADP - O
biochemical ADJ - O
, PUNCT - O
histological ADJ - O
and CCONJ - O
immunohistochemical ADJ - O
results NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
inspired VERB - O
by ADP - O
the DET - O
increasing VERB - O
interest NOUN - O
in ADP - O
the DET - O
field NOUN - O
of ADP - O
macromolecular ADJ - O
prodrugs NOUN - O
and CCONJ - O
Piroxicam NNP - B-MEDICINE
maleate NOUN - O
was VERB - O
used VERB - O
as ADP - O
a DET - O
model NOUN - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
( PUNCT - O
PXC PROPN - O
) PUNCT - O
was VERB - O
used VERB - O
as ADP - O
an DET - O
internal ADJ - O
standard NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Grade PROPN - O
II PROPN - O
and CCONJ - O
III NNP - B-ORG
Actinic NNP - I-ORG
Keratosis NNP - I-ORG
Lesions NNPS - I-ORG
with ADP - O
a DET - O
Film NN - B-ORG
- HYPH - I-ORG
Forming VBG - I-ORG
Medical JJ - I-ORG
Device PROPN - O
Containing PROPN - O
Sunscreen PROPN - O
/ SYM - O
Piroxicam NNP - B-MEDICINE
0.8 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
a DET - O
Retinoic PROPN - O
Acid PROPN - O
/ SYM - O
Glycolic PROPN - O
Gel PROPN - O
: PUNCT - O
A PROPN - O
Pilot PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Multiple NNP - B-ORG
Actinic NNP - I-ORG
Keratosis NNP - I-ORG
and CCONJ - O
Field NNP - B-WORK_OF_ART
of IN - I-WORK_OF_ART
Cancerization NNP - I-WORK_OF_ART
with IN - I-WORK_OF_ART
Topical NNP - I-WORK_OF_ART
Piroxicam NNP - I-MEDICINE
0.8 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
Sunscreen PROPN - O
50 NUM - O
+ CCONJ - O
in ADP - O
Organ PROPN - O
Transplant PROPN - O
Recipients PROPN - O
: PUNCT - O
A DET - O
Series NNP - B-EVENT
of ADP - O
10 NUM - O
Cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Anti JJ - B-ORG
- JJ - I-ORG
Inflammatory JJ - I-ORG
Oxicams NNPS - I-ORG
as ADP - O
Multi JJ - B-ORG
- HYPH - I-ORG
donor NN - I-ORG
Ligand NNP - B-ORG
Systems NNPS - I-ORG
: PUNCT - O
pH- NOUN - O
and CCONJ - O
Solvent NNP - B-ORG
- HYPH - I-ORG
Dependent NNP - I-ORG
Coordination NNP - I-ORG
Modes NNPS - I-ORG
of IN - I-ORG
Meloxicam NNP - I-ORG
and CCONJ - O
Piroxicam NNP - B-MEDICINE
to ADP - O
Ru PROPN - O
and CCONJ - O
Os NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
vivo NOUN - O
Piroxicam NNP - B-MEDICINE
Metabolites NNPS - I-PERSON
: PUNCT - O
Possible ADJ - O
Source NOUN - O
for ADP - O
Synthesis PROPN - O
of ADP - O
Central PROPN - O
Nervous PROPN - O
System PROPN - O
( PUNCT - O
CNS NNP - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
of ADP - O
Microcrystals PROPN - O
of ADP - O
Piroxicam NNP - B-MEDICINE
Monohydrate PROPN - O
by ADP - O
Antisolvent PROPN - O
Precipitation PROPN - O
via ADP - O
Microfabricated PROPN - O
Metallic PROPN - O
Membranes PROPN - O
with ADP - O
Ordered PROPN - O
Pore PROPN - O
Arrays PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Ex PROPN - O
vivo NOUN - O
Skin NNP - B-LAW
Permeation NNP - I-LAW
Evaluation NNP - I-LAW
of ADP - O
An DET - O
Innovative PROPN - O
Transdermal PROPN - O
Vehicle PROPN - O
Using VERB - O
Nimesulide PROPN - O
and CCONJ - O
Piroxicam NNP - B-MEDICINE
as ADP - O
Model PROPN - O
Drugs PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
has VERB - O
antitumour ADJ - O
effects NOUN - O
in ADP - O
dogs NOUN - O
with ADP - O
cancer NOUN - O
, PUNCT - O
although ADP - O
side NOUN - O
effects NOUN - O
may VERB - O
limit VERB - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
is VERB - O
among ADP - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
NSAIDs NOUN - O
and CCONJ - O
excels NOUN - O
in ADP - O
controlling VERB - O
pain NOUN - O
, PUNCT - O
swelling NOUN - O
, PUNCT - O
trismus NOUN - O
and CCONJ - O
other ADJ - O
common ADJ - O
symptoms NOUN - O
of ADP - O
inflammation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
significantly ADV - O
enhanced VERB - O
the DET - O
activity NOUN - O
of ADP - O
vinblastine NOUN - O
in ADP - O
dogs NOUN - O
with ADP - O
UC NNP - B-GPE
where ADV - O
the DET - O
cancer NOUN - O
closely ADV - O
mimics VERB - O
the DET - O
human ADJ - O
condition NOUN - O
, PUNCT - O
clearly ADV - O
justifying VERB - O
further ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Piroxicam NNP - B-MEDICINE
and CCONJ - O
doxycycline VERB - O
treatment NOUN - O
for ADP - O
an DET - O
oral ADJ - O
squamous ADJ - O
cell NOUN - O
carcinoma NOUN - O
in ADP - O
an DET - O
inshore ADJ - O
bottlenose NOUN - O
dolphin NOUN - O
( PUNCT - O
Tursiops PROPN - O
aduncus PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Based VERB - O
on ADP - O
the DET - O
obtained VERB - O
results NOUN - O
presence NOUN - O
of ADP - O
Diclofenac NNP - B-ORG
, PUNCT - O
Piroxicam NNP - B-MEDICINE
and CCONJ - O
Naproxen NNP - B-PERSON
, PUNCT - O
could VERB - O
significantly ADV - O
decrease VERB - O
the DET - O
percentage NOUN - O
of ADP - O
Sirolimus NNP - B-NORP
protein NOUN - O
binding VERB - O
. PUNCT - O

The DET - O
Binding NNP - B-NORP
reduction NOUN - O
was VERB - O
the DET - O
most ADJ - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
Piroxicam NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
( PUNCT - O
FEX NNP - B-ORG
) PUNCT - O
has VERB - O
previously ADV - O
been VERB - O
shown VERB - O
to PART - O
have VERB - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
properties NOUN - O
in ADP - O
relieving VERB - O
nasal NOUN - O
congestion NOUN - O
in ADP - O
allergic ADJ - O
rhinitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
is VERB - O
the DET - O
acid ADJ - O
metabolite NOUN - O
of ADP - O
terfenadine NOUN - O
( PUNCT - O
Seldane PROPN - O
) PUNCT - O
. PUNCT - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
doses VERB - O
up PART - O
to ADP - O
800 CD - B-CARDINAL
mg PRON - O
once ADV - O
daily RB - B-DATE
or CCONJ - O
690 CD - B-CARDINAL
mg PRON - O
twice ADV - O
daily ADV - O
for ADP - O
28 CD - B-DATE
days NNS - I-DATE
resulted VERB - O
in ADP - O
no DET - O
dose NOUN - O
- PUNCT - O
related VERB - O
increases NOUN - O
in ADP - O
QTc NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
significantly ADV - O
reduced VERB - O
pruritus ADJ - O
severity NOUN - O
, PUNCT - O
number NOUN - O
of ADP - O
wheals NOUN - O
, PUNCT - O
and CCONJ - O
interference NOUN - O
with ADP - O
sleep NOUN - O
and CCONJ - O
normal ADJ - O
daily JJ - B-DATE
activities NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
chronic ADJ - O
urticaria NOUN - O
compared VERB - O
with ADP - O
placebo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
( PUNCT - O
Allegra NNP - B-PERSON
, PUNCT - O
Telfast NNP - B-LOC
) PUNCT - O
is VERB - O
approved VERB - O
in ADP - O
the DET - O
US NNP - B-GPE
for ADP - O
twice ADV - O
- PUNCT - O
daily ADJ - O
dosing NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
seasonal ADJ - O
allergic ADJ - O
rhinitis NOUN - O
( PUNCT - O
SAR NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-GPE
HCl NNS - I-GPE
( PUNCT - O
30 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
was VERB - O
administered VERB - O
as ADP - O
a DET - O
6-mg NNP - B-CARDINAL
/ SYM - O
mL NOUN - O
suspension NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
mL NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
at ADP - O
each DET - O
dosage NOUN - O
provided VERB - O
significant ADJ - O
improvement NOUN - O
in ADP - O
total ADJ - O
symptom NOUN - O
score NOUN - O
( PUNCT - O
P NOUN - O
< X - O
or CCONJ - O
= SYM - O
.003 PUNCT - O
) PUNCT - O

Fexofenadine NN - B-PRODUCT
HCl NOUN - O
is VERB - O
both CCONJ - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
ragweed ADJ - O
seasonal ADJ - O
allergic ADJ - O
rhinitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
interaction NOUN - O
of ADP - O
racemic ADJ - O
R NOUN - O
, PUNCT - O
S PROPN - O
- PUNCT - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
rac NOUN - O
- PUNCT - O
VEN NOUN - O
) PUNCT - O
drug NOUN - O
with ADP - O
calf NOUN - O
thymus ADJ - O
deoxyribonucleic ADJ - O
acid NOUN - O
( PUNCT - O
ct NOUN - O
- PUNCT - O
DNA PROPN - O
) PUNCT - O
was VERB - O
studied VERB - O
using VERB - O
various ADJ - O
physico ADJ - O
- PUNCT - O
chemical NOUN - O
techniques NOUN - O
and CCONJ - O
molecular ADJ - O
docking NOUN - O
at ADP - O
simulated ADJ - O
physiological ADJ - O
conditions NOUN - O
( PUNCT - O
pH=7.4 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Racemic NNP - B-ORG
R NNP - I-ORG
, PUNCT - O
S PROPN - O
- PUNCT - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
- PUNCT - O
DNA NOUN - O
interaction NOUN - O
: PUNCT - O
experimental ADJ - O
and CCONJ - O
computational ADJ - O
evidence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
designed VERB - O
to PART - O
examine VERB - O
the DET - O
interaction NOUN - O
of ADP - O
racemic ADJ - O
antidepressant NOUN - O
drug NOUN - O
" PUNCT - O
S PROPN - O
, PUNCT - O
R PROPN - O
- PUNCT - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
( PUNCT - O
VEN PROPN - O
) PUNCT - O
" PUNCT - O
with ADP - O
bovine ADJ - O
serum NOUN - O
albumin NOUN - O
( PUNCT - O
BSA NNP - B-ORG
) PUNCT - O
under ADP - O
physiological ADJ - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
hydrophilic NOUN - O
, PUNCT - O
hydrophobic NOUN - O
and CCONJ - O
waxy NOUN - O
matrix NOUN - O
excipients NOUN - O
for ADP - O
sustained ADJ - O
release NOUN - O
tablets NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Transdermal ADJ - O
delivery NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
: PUNCT - O
the DET - O
effects NOUN - O
of ADP - O
enhancers NOUN - O
on ADP - O
permeation NOUN - O
across ADP - O
pig NOUN - O
ear NOUN - O
skin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
process NOUN - O
for ADP - O
preparing VERB - O
venlafaxine NOUN - O
in ADP - O
a DET - O
high ADJ - O
yield NOUN - O
as ADV - O
well ADV - O
as ADP - O
processes NOUN - O
for ADP - O
producing VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
of ADP - O
form NOUN - O
I PRON - O
having VERB - O
a DET - O
very ADV - O
hight ADJ - O
polymorphic ADJ - O
purity NOUN - O
are VERB - O
described VERB - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
process NOUN - O
for ADP - O
preparing VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
also ADV - O
a DET - O
process NOUN - O
for ADP - O
preparing VERB - O
l-[2-amino- PROPN - O
l-(4-methoxy PROPN - O
phenyl)ethyl]cyclohexanol NOUN - O
hydrochloride NOUN - O
, PUNCT - O
an DET - O
intermediate NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
are VERB - O
disclosed VERB - O
. PUNCT - O

The DET - O
venlafaxine NOUN - O
base NOUN - O
is VERB - O
further ADV - O
converted VERB - O
into ADP - O
its ADJ - O
salt NOUN - O
namely ADV - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
. PUNCT - O

; PUNCT - O
Both DET - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
l-[2-amino NOUN - O
- PUNCT - O
l-(4-methoxy NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Preparation NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
crystal NOUN - O
Form NOUN - O
I PRON - O

-DOCSTART- -X- - O

Crystalline ADJ - O
forms NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

1-[2-Amino-1-(4-methoxyphenyl)ethyl]cyclohexanol NUM - O
thus ADV - O
obtained VERB - O
was VERB - O
subjected VERB - O
to ADP - O
N CD - B-ORG
, PUNCT - O
N PROPN - O
- PUNCT - O
dimethylation NOUN - O
using VERB - O
formic ADJ - O
acid NOUN - O
- PUNCT - O
formaldehyde NOUN - O
in ADP - O
boiling VERB - O
1,4-dioxane CD - B-GPE
: PUNCT - O
water NOUN - O
mixture NOUN - O
to PART - O
obtain VERB - O
1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl NUM - O
] PUNCT - O
cyclohexanol NOUN - O
in ADP - O
high ADJ - O
purity NOUN - O
, PUNCT - O
which ADJ - O
was VERB - O
treated VERB - O
with ADP - O
isopropanol NOUN - O
saturated VERB - O
with ADP - O
HCl NOUN - O
gas NOUN - O
to PART - O
get VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
high ADJ - O
purity NOUN - O
and CCONJ - O
high ADJ - O
yield NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pellets NOUN - O
containing VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

Extended ADJ - O
release NOUN - O
formulation NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
research NOUN - O
work NOUN - O
was VERB - O
to PART - O
develop VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
- PUNCT - O
coated VERB - O
and CCONJ - O
layered VERB - O
matrix NOUN - O
tablets NOUN - O
using VERB - O
hypromellose NOUN - O
adopting VERB - O
wet ADJ - O
granulation NOUN - O
technique NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
current ADJ - O
article NOUN - O
we PRON - O
are VERB - O
reporting VERB - O
the DET - O
development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
a DET - O
fast ADJ - O
and CCONJ - O
simple ADJ - O
stability NOUN - O
indicating NOUN - O
, PUNCT - O
isocratic ADJ - O
high ADJ - O
performance NOUN - O
liquid NOUN - O
chromatographic NOUN - O
( PUNCT - O
HPLC NNP - B-ORG
) PUNCT - O
method NOUN - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
sustained VERB - O
release NOUN - O
formulations NOUN - O
. PUNCT - O

The DET - O
quantitative ADJ - O
determination NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
was VERB - O
performed VERB - O
on ADP - O
a DET - O
Kromasil PROPN - O
C18 PROPN - O
analytical ADJ - O
column NOUN - O
( PUNCT - O
250 CD - B-CARDINAL
× NOUN - O
4.6 CD - B-QUANTITY
mm NNP - I-QUANTITY
i.d PROPN - O
. PROPN - O
, PUNCT - O

-DOCSTART- -X- - O

Controlled VERB - O
release NOUN - O
pharmaceutical ADJ - O
composition NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
and CCONJ - O
process NOUN - O
for ADP - O
preparation NOUN - O
thereof ADV - O

-DOCSTART- -X- - O

Controlled VERB - O
release NOUN - O
pharmaceutical ADJ - O
composition NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
and CCONJ - O
process NOUN - O
for ADP - O
preparation NOUN - O
thereof ADV - O

-DOCSTART- -X- - O

Extended ADJ - O
release NOUN - O
coated ADJ - O
microtablets NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
an DET - O
extended ADJ - O
release NOUN - O
once ADV - O
daily ADJ - O
pharmaceutic ADJ - O
al NNP - B-ORG
formulation NOUN - O
comprising NOUN - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
pharmaceutically ADV - O
acceptable ADJ - O
excipients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
relates VERB - O
to ADP - O
pellets NOUN - O
containing VERB - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
a DET - O
process NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
. PUNCT - O

The DET - O
pellets NOUN - O
according VERB - O
to ADP - O
the DET - O
invention NOUN - O
are VERB - O
nearly ADV - O
spherical ADJ - O
in ADP - O
shape NOUN - O
and CCONJ - O
comprise VERB - O
pharmaceutically ADV - O
active ADJ - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
in ADP - O
an DET - O
amount NOUN - O
of ADP - O
at ADP - O
most RBS - B-PERCENT
80 CD - I-PERCENT
% NN - I-PERCENT
by ADP - O
weight NOUN - O
, PUNCT - O
furthermore ADV - O
10 CD - B-PERCENT
to TO - I-PERCENT
60 CD - I-PERCENT
% NN - I-PERCENT
by ADP - O
weight NOUN - O
of ADP - O
sodium NOUN - O
chloride NOUN - O
and/or CCONJ - O
potassium NOUN - O
chloride NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
an DET - O
extended ADJ - O
release NOUN - O
once ADV - O
daily JJ - B-DATE
pharmaceutical ADJ - O
formulation NOUN - O
comprising NOUN - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
and CCONJ - O
pharmaceutically ADV - O
acceptable ADJ - O
excipients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
capsule NOUN - O
comprising NOUN - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
wherein ADV - O
part NOUN - O
of ADP - O
the DET - O
drug NOUN - O
content NOUN - O
is VERB - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
delayed VERB - O
- PUNCT - O
release NOUN - O
coated VERB - O
spheroids NOUN - O
and CCONJ - O
a DET - O
second JJ - B-ORDINAL
part NOUN - O
of ADP - O
the DET - O
drug NOUN - O
content NOUN - O
is VERB - O
in ADP - O
a DET - O
prompt ADJ - O
- PUNCT - O
release NOUN - O
form NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crystalline ADJ - O
forms NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
novel NOUN - O
crystalline ADJ - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
which ADJ - O
exists VERB - O
in ADP - O
hydrated VERB - O
form NOUN - O
( PUNCT - O
e.g. ADV - O
, PUNCT - O
as ADP - O
a DET - O
monohydrate NOUN - O
) PUNCT - O
, PUNCT - O
methods NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
novel NOUN - O
crystalline ADJ - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
which ADJ - O
exists VERB - O
in ADP - O
hydrated VERB - O
form NOUN - O
( PUNCT - O
e.g. ADV - O
, PUNCT - O
as ADP - O
a DET - O
monohydrate NOUN - O
) PUNCT - O
, PUNCT - O
methods NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
novel NOUN - O
crystalline ADJ - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
which ADJ - O
exists VERB - O
in ADP - O
hydrated VERB - O
form NOUN - O
( PUNCT - O
e.g. ADV - O
, PUNCT - O
as ADP - O
a DET - O
monohydrate NOUN - O
) PUNCT - O
, PUNCT - O
methods NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
highly ADV - O
thermally ADV - O
stable ADJ - O
novel ADJ - O
anhydrous ADJ - O
crystalline NOUN - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
methods NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
highly ADV - O
thermally ADV - O
stable ADJ - O
novel ADJ - O
anhydrous ADJ - O
crystalline NOUN - O
polymorphic ADJ - O
form NOUN - O
of ADP - O
venlafaxine NN - B-MEDICINE
hydrochloride NN - I-MEDICINE
, PUNCT - O
methods NOUN - O
for ADP - O
the DET - O
preparation NOUN - O
thereof ADV - O
, PUNCT - O
and CCONJ - O
its ADJ - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Montelukast NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
Formulation NOUN - O
containing VERB - O
Green PROPN - O
Tea PROPN - O
Extract NOUN - O
to PART - O
Reduce VB - B-ORG
the DT - I-ORG
Oxidative NNP - I-ORG
Stress NNP - I-ORG
in ADP - O
Guinea NNP - B-GPE
Pig PROPN - O
model NOUN - O
of ADP - O
Chronic NNP - B-WORK_OF_ART
Allergic NNP - I-WORK_OF_ART
Asthma NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
was VERB - O
loaded VERB - O
with ADP - O
model NOUN - O
drug NOUN - O
( PUNCT - O
Montelukast NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
) PUNCT - O
during ADP - O
the DET - O
preparation NOUN - O
phase NOUN - O
and CCONJ - O
studied VERB - O
for ADP - O
drug NOUN - O
release NOUN - O
capability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Novel JJ - B-ORG
Compounds NNPS - I-ORG
and CC - I-ORG
Preparation NNP - I-ORG
for IN - I-ORG
Montelukast NNP - I-ORG
Sodium NNP - I-ORG

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Montelukast NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
and CCONJ - O
Bambuterol NNP - B-ORG
Hydrochloride NNP - I-ORG
in ADP - O
Tablets NNPS - B-ORG
using VERB - O
RP NNP - B-PERSON
HPLC NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
a DET - O
RP PROPN - O
- PUNCT - O
HPLC PROPN - O
Method PROPN - O
for ADP - O
Estimation PROPN - O
of ADP - O
Montelukast NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
in ADP - O
Bulk PROPN - O
and CCONJ - O
in ADP - O
Tablet NNP - B-ORG
Dosage NNP - I-ORG
Form NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Each DET - O
subject NOUN - O
was VERB - O
randomly ADV - O
assigned VERB - O
to PART - O
receive VERB - O
the DET - O
test NOUN - O
( PUNCT - O
Dong NNP - B-ORG
- HYPH - I-ORG
Kook NNP - I-ORG
Montelukast NN - I-ORG
Sodium NN - I-ORG
Chewable NNP - I-ORG
Tablet PROPN - O
5 CD - B-CARDINAL
mg NOUN - O
® PUNCT - O
) PUNCT - O
or CCONJ - O
reference NOUN - O

-DOCSTART- -X- - O

Iron NNP - B-ORG
Status NNP - I-ORG
of IN - I-ORG
Kenyan NNP - I-ORG
Pregnant NNP - I-ORG
Women NNPS - I-ORG
after ADP - O
Adjusting VBG - B-ORG
for IN - I-ORG
Inflammation NNP - I-MEDICINE
Using VBG - I-ORG
BRINDA NNP - I-ORG
Regression NNP - I-ORG
Analysis NNP - I-ORG
and CC - I-ORG
Other NNP - I-ORG
Correction NNP - I-ORG
Methods NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Anti ADJ - O
- ADJ - O
Inflammation NNP - B-MEDICINE
Effect PROPN - O
of ADP - O
Small PROPN - O
Molecule PROPN - O
Oligopeptides PROPN - O
Prepared PROPN - O
from ADP - O
Panax NNP - B-GPE
ginseng PROPN - O
C. NNP - B-PERSON
A. NNP - I-PERSON
Meyer NNP - I-PERSON
in ADP - O
Rats NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
Resolution NOUN - O
the DET - O
End NOUN - O
of ADP - O
Inflammation NNP - B-MEDICINE
? PUNCT - O

-DOCSTART- -X- - O

Chronic PROPN - O
Inflammation NNP - B-MEDICINE
Contributes PROPN - O
to ADP - O
Tumor PROPN - O
Growth NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

MerTK NNP - B-ORG
Downregulates VBZ - I-ORG
Lipopolysaccharide NNP - I-ORG
- HYPH - I-ORG
Induced VBN - I-ORG
Inflammation NNP - I-MEDICINE

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
is VERB - O
closely ADV - O
correlated VERB - O
with ADP - O
immunity NOUN - O
, PUNCT - O
the DET - O
same ADJ - O
immune ADJ - O
cell NOUN - O
populations NOUN - O
contributing VERB - O
to ADP - O
both CCONJ - O
inflammation NN - B-MEDICINE
and CCONJ - O
immune ADJ - O
response NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Essential ADJ - O
Roles PROPN - O
for ADP - O
the DT - B-ORG
Non NNP - I-ORG
- JJ - I-ORG
Canonical NNP - I-ORG
IκB NNP - I-ORG
Kinases NNPS - I-ORG
in IN - I-ORG
Linking NNP - I-ORG
Inflammation NNP - I-MEDICINE
to IN - I-ORG
Cancer NNP - I-ORG
, , - I-ORG
Obesity NNP - I-ORG
, PUNCT - O
and CCONJ - O
Diabetes NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Inhibits VBZ - B-ORG
Propionibacterium NNP - I-ORG
acnes VERB - O
- PUNCT - O
Induced VERB - O
Inflammation NNP - B-MEDICINE

-DOCSTART- -X- - O

Gadolinium NNP - B-ORG
Enhancement NNP - I-ORG
is VERB - O
not ADV - O
Associated VERB - O
with ADP - O
Disc PROPN - O
Inflammation NNP - B-MEDICINE
in ADP - O
Patients PROPN - O
with ADP - O
Sciatica NNP - B-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

GDF11 NNP - B-PERSON
Antagonizes NNP - I-PERSON
Psoriasis NNP - I-PERSON
- PUNCT - O
like INTJ - O
Skin PROPN - O
Inflammation NNP - B-MEDICINE
via ADP - O
Suppression PROPN - O
of ADP - O
NF PROPN - O
- PUNCT - O
κB PROPN - O
Signaling PROPN - O
Pathway PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Acupoint PROPN - O
Attenuates VERB - O
Lipopolysaccharide NOUN - O
- PUNCT - O
Induced PROPN - O
Inflammation NNP - B-MEDICINE
in ADP - O
Rats PROPN - O
by ADP - O
Inhibiting PROPN - O
Ca2 PROPN - O

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
- PUNCT - O
based VERB - O
indexes NOUN - O
such ADJ - O
as ADP - O
neutrophil NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
lymphocyte NOUN - O
ratio NOUN - O
( PUNCT - O
NLR PROPN - O
) PUNCT - O
, PUNCT - O
platelet NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
lymphocyte NOUN - O
ratio NOUN - O
( PUNCT - O
PLR NNP - B-ORG
) PUNCT - O
, PUNCT - O
lymphocyte NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
monocyte NOUN - O
ratio NOUN - O
( PUNCT - O
LMR PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
systemic ADJ - O
immune ADJ - O
- PUNCT - O
inflammation NN - B-MEDICINE
indexes NOUN - O
( PUNCT - O
SII NNP - B-ORG
) PUNCT - O
have VERB - O
been VERB - O
reported VERB - O
to PART - O
be VERB - O
associated VERB - O
with ADP - O
prognosis NOUN - O
in ADP - O
cancer NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Central JJ - B-ORG
and CC - I-ORG
Peripheral NNP - I-ORG
Inflammation NNP - I-MEDICINE
Link NNP - I-ORG
Metabolic NNP - I-ORG
Syndrome NNP - I-ORG
and CCONJ - O
Major JJ - B-ORG
Depressive JJ - I-ORG
Disorder NN - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
, PUNCT - O
necrosis NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
kinase NOUN - O
RIP3 PROPN - O
are VERB - O
key ADJ - O
mediators NOUN - O
of ADP - O
AAG NN - B-ORG
- PUNCT - O
dependent ADJ - O
alkylation NOUN - O
- PUNCT - O
induced VERB - O
retinal ADJ - O
degeneration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
and CCONJ - O
hearing NOUN - O
status NOUN - O
in ADP - O
mid NOUN - O
- NOUN - O
childhood NOUN - O
and CCONJ - O
mid ADJ - O
- NOUN - O
life NOUN - O
: PUNCT - O
a DET - O
population NOUN - O
- PUNCT - O
based VERB - O
cross ADJ - O
- ADJ - O
sectional ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
- PUNCT - O
based VERB - O
prognostic ADJ - O
scores NOUN - O
are VERB - O
associated VERB - O
with ADP - O
tumor NOUN - O
recurrence NOUN - O
and CCONJ - O
survival NOUN - O
in ADP - O
various ADJ - O
cancers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Mass NOUN - O
of ADP - O
adipose NOUN - O
tissue NOUN - O
: PUNCT - O
Inflammation NN - B-MEDICINE
, PUNCT - O
pseudo NOUN - O
- PUNCT - O
tumour NOUN - O
and CCONJ - O
tumour NOUN - O
: PUNCT - O
The DET - O
cornelian ADJ - O
fan NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Pericardial ADJ - O
fluids NOUN - O
or CCONJ - O
Cardiopulmonary NNP - B-PERSON
Bypass NNP - I-PERSON
- HYPH - I-PERSON
Is VBZ - I-PERSON
There ADV - O
a DET - O
Major PROPN - O
Culprit PROPN - O
for ADP - O
Changes PROPN - O
in ADP - O
Coagulation PROPN - O
and CCONJ - O
Inflammation NNP - B-MEDICINE
? PUNCT - O

-DOCSTART- -X- - O

MTOR PROPN - O
- PUNCT - O
Mediated PROPN - O
Autophagy PROPN - O
Is VERB - O
Involved VERB - O
in ADP - O
the DT - B-ORG
Protective NNP - I-ORG
Effect NNP - I-ORG
of IN - I-ORG
Ketamine NNP - I-ORG
on IN - I-ORG
Allergic NNP - I-ORG
Airway NNP - I-ORG
Inflammation NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Inflammation NN - B-MEDICINE
and CCONJ - O
post ADJ - O
- ADJ - O
traumatic ADJ - O
stress NOUN - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Expression NOUN - O
and CCONJ - O
Function PROPN - O
of ADP - O
Macrophage PROPN - O
- PUNCT - O
Inducible ADJ - O
C NOUN - O
- PUNCT - O
type NOUN - O
Lectin NNP - B-GPE
( PUNCT - O
Mincle NNP - B-GPE
) PUNCT - O
in ADP - O
Inflammation NNP - B-MEDICINE
Driven NNP - I-ORG
Parturition NNP - I-ORG
in ADP - O
Fetal PROPN - O
Membranes PROPN - O
and CCONJ - O
Myometrium PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Dose NN - B-ORG
- HYPH - I-ORG
Dependent JJ - I-ORG
Toxic NNP - I-ORG
Effect NNP - I-ORG
of IN - I-ORG
Cotinine NNP - I-ORG
- HYPH - I-ORG
Verified NNP - I-ORG
Tobacco NNP - I-ORG
Smoking NNP - I-ORG
on IN - I-ORG
Systemic NNP - I-ORG
Inflammation NNP - I-MEDICINE
in ADP - O
Apparently ADV - O
Healthy PROPN - O
Men PROPN - O
and CCONJ - O
Women PROPN - O
: PUNCT - O
A DET - O
Nationwide PROPN - O
Population NOUN - O
- PUNCT - O
Based VERB - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

At ADP - O
1 CD - B-CARDINAL
  SPACE - O
week NOUN - O
following VERB - O
STZ PROPN - O
injection NOUN - O
, PUNCT - O
the DET - O
diabetic ADJ - O
rats NOUN - O
were VERB - O
treated VERB - O
with ADP - O
Levemir NNP - B-MEDICINE
subcutaneously ADV - O
for ADP - O
  SPACE - O
4 NUM - O
  SPACE - O
weeks NNS - B-DATE
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
intervention NOUN - O
was VERB - O
instituted VERB - O
consisting VERB - O
of ADP - O
a DET - O
three CD - B-DATE
- HYPH - I-DATE
month NN - I-DATE
educational ADJ - O
program NOUN - O
and CCONJ - O
a DET - O
basal NOUN - O
- PUNCT - O
bolus NOUN - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
, PUNCT - O
NovoNordisk NNP - B-ORG
) PUNCT - O
and CCONJ - O
aspart ADJ - O
( PUNCT - O
Novorapid NNP - B-ORG
, PUNCT - O
NovoNordisk NNP - B-ORG
) PUNCT - O
insulin NOUN - O
regimen NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recent ADJ - O
studies NOUN - O
have VERB - O
identified VERB - O
unique ADJ - O
brain NOUN - O
effects NOUN - O
of ADP - O
insulin NOUN - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
® NNP - I-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
compare VERB - O
adherence NOUN - O
and CCONJ - O
persistence NOUN - O
of ADP - O
patients NOUN - O
initiating VERB - O
basal ADJ - O
insulin NOUN - O
therapy NOUN - O
with ADP - O
Levemir NNP - B-MEDICINE
FlexPen NNP - I-PERSON
versus ADP - O
those DET - O
initiating VERB - O
basal ADJ - O
insulin NOUN - O
therapy NOUN - O
with ADP - O
NPH PROPN - O
via ADP - O
vial NOUN - O
and CCONJ - O
syringe NOUN - O
. PUNCT - O

Data NOUN - O
were VERB - O
gathered VERB - O
from ADP - O
a DET - O
large ADJ - O
US NNP - B-GPE
retrospective ADJ - O
claims NOUN - O
database NOUN - O
, PUNCT - O
and CCONJ - O
included VERB - O
patients NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
that ADJ - O
initiated VERB - O
basal ADJ - O
insulin NOUN - O
therapy NOUN - O
with ADP - O
either CCONJ - O
Levemir NNP - B-MEDICINE
FlexPen NNP - I-PERSON
or CCONJ - O
NPH PROPN - O
in ADP - O
vials NOUN - O
. PUNCT - O

After ADP - O
controlling VERB - O
for ADP - O
confounders NOUN - O
using VERB - O
logistic ADJ - O
regression NOUN - O
, PUNCT - O
patients NOUN - O
initiating VERB - O
therapy NOUN - O
with ADP - O
Levemir NNP - B-MEDICINE
FlexPen NNP - I-PERSON
had VERB - O
39 CD - B-PERCENT
% NN - I-PERCENT
higher ADJ - O
adjusted ADJ - O
odds NOUN - O
of ADP - O
achieving VERB - O
an DET - O
MPR NNP - B-ORG
≥80 NN - I-ORG
% NN - I-ORG
versus ADP - O
patients NOUN - O
initiating VERB - O
therapy NOUN - O
with ADP - O
NPH PROPN - O
vial NOUN - O
( PUNCT - O
OR CCONJ - O
1.39 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
: PUNCT - O
1.04 CD - B-MONEY
- HYPH - I-MONEY
1.85 CD - I-MONEY
) PUNCT - O
. PUNCT - O

Analysis NOUN - O
of ADP - O
persistence NOUN - O
using VERB - O
a DET - O
Cox NNP - B-PRODUCT
proportional ADJ - O
hazards NOUN - O
model NOUN - O
indicated VERB - O
that ADP - O
patients NOUN - O
initiating VERB - O
Levemir NNP - B-MEDICINE
FlexPen NNP - I-PERSON
had VERB - O
a DET - O
38 CD - B-PERCENT
% NN - I-PERCENT
lower ADJ - O
hazard NOUN - O
of ADP - O
discontinuation NOUN - O
compared VERB - O
to ADP - O
NPH PROPN - O
vial NOUN - O
( PUNCT - O
HR PROPN - O
0.62 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
: PUNCT - O
0.55 CD - B-CARDINAL
- SYM - O
0.70 NUM - O
) PUNCT - O
. PUNCT - O

These DET - O
results NOUN - O
suggest VERB - O
that ADP - O
persistence NOUN - O
and CCONJ - O
adherence NOUN - O
with ADP - O
insulin NOUN - O
may VERB - O
be VERB - O
improved VERB - O
for ADP - O
patients NOUN - O
initiating VERB - O
basal ADJ - O
insulin NOUN - O
therapy NOUN - O
with ADP - O
Levemir NNP - B-MEDICINE
FlexPen NNP - I-PERSON
versus ADP - O
NPH PROPN - O
vial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
Once PROPN - O
Daily PROPN - O
Levemir NNP - B-MEDICINE
was VERB - O
a DET - O
24-week CD - B-CARDINAL
international ADJ - O
observational ADJ - O
study NOUN - O
involving VERB - O
10 CD - B-CARDINAL
countries NOUN - O
which ADJ - O
evaluated VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
effectiveness NOUN - O
of ADP - O
initiating VERB - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
insulin NOUN - O
detemir NOUN - O
in ADP - O
people NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
being VERB - O
treated VERB - O
with ADP - O
one CD - B-CARDINAL
or CCONJ - O
more ADJ - O
OADs NOUN - O
( PUNCT - O
clinical ADJ - O
trial NOUN - O
number NOUN - O
NCT00825643 NNP - B-CARDINAL
and CCONJ - O
NCT00740519 NNP - B-PRODUCT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
of ADP - O
Once PROPN - O
- PUNCT - O
Daily ADJ - O
Levemir NNP - B-MEDICINE
( PUNCT - O
SOLVE NNP - B-ORG
( PUNCT - O
™ PROPN - O
) PUNCT - O
) PUNCT - O
is VERB - O
an DET - O
international ADJ - O
, PUNCT - O
24-week CD - B-CARDINAL
, PUNCT - O
observational ADJ - O
study NOUN - O
of ADP - O
insulin NOUN - O
initiation NOUN - O
in ADP - O
people NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
SOLVE(TM NOUN - O
) PUNCT - O
) PUNCT - O
was VERB - O
a DET - O
24-week CD - B-CARDINAL
international ADJ - O
observational ADJ - O
study NOUN - O
to PART - O
evaluate VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
effectiveness NOUN - O
of ADP - O
initiating VERB - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
insulin NOUN - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
) PUNCT - O
as ADP - O
add VERB - O
- PUNCT - O
on PART - O
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
( PUNCT - O
T2DM NNP - B-GPE
) PUNCT - O
who NOUN - O
failed VERB - O
treatment NOUN - O
of ADP - O
oral ADJ - O
anti ADJ - O
- ADJ - O
diabetic ADJ - O
drugs NOUN - O
( PUNCT - O
OAD PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
subanalysis NOUN - O
of ADP - O
the DT - B-ORG
Study NNP - I-ORG
of IN - I-ORG
Once NNP - I-ORG
Daily NNP - I-ORG
Levemir NNP - I-MEDICINE
( PUNCT - O
SOLVE NNP - B-ORG
) PUNCT - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
insulin NOUN - O
detemir NOUN - O
as ADP - O
add NOUN - O
- PUNCT - O
on PART - O
to ADP - O
oral ADJ - O
antidiabetic ADJ - O
drugs NOUN - O
( PUNCT - O
OADs NOUN - O
) PUNCT - O
in ADP - O
Chinese JJ - B-NORP
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
patients NOUN - O
according VERB - O
to ADP - O
body NOUN - O
mass NOUN - O
index NOUN - O
in ADP - O
a DET - O
real ADJ - O
- PUNCT - O
life NOUN - O
setting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levemir NNP - B-MEDICINE
and CCONJ - O
Victoza NNP - B-ORG
( PUNCT - O
antidiabetic ADJ - O
product NOUN - O
) PUNCT - O
, PUNCT - O
Abraxane NNP - B-PERSON
( PUNCT - O
antimetastatic ADJ - O
breast NOUN - O
cancer NOUN - O
product NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Nanocoll NNP - B-PERSON
and CCONJ - O
Albures PROPN - O
( PUNCT - O
for ADP - O
lymphoscintigraphy NOUN - O
and CCONJ - O
diagnosis NOUN - O
of ADP - O
cancer NOUN - O
and CCONJ - O
rheumatoid NOUN - O
arthritis NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Use VERB - O
neutral ADJ - O
protamine NOUN - O
Hagedorn NNP - B-PERSON
( PUNCT - O
NPH PROPN - O
) PUNCT - O
insulin NOUN - O
instead ADV - O
of ADP - O
long ADV - O
- PUNCT - O
acting VERB - O
insulin NOUN - O
analogues NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
insulin NOUN - O
glargine NOUN - O
( PUNCT - O
Lantus PROPN - O
) PUNCT - O
or CCONJ - O
insulin NOUN - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
as ADP - O
insulin NOUN - O
analogues NOUN - O
do VERB - O
not ADV - O
appear VERB - O
to PART - O
provide VERB - O
clinically ADV - O
meaningful ADJ - O
benefit NOUN - O
but CCONJ - O
are VERB - O
significantly ADV - O
more ADV - O
costly ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
BOT NOUN - O
with ADP - O
insulin NOUN - O
glargine NOUN - O
versus ADP - O
BOT NOUN - O
with ADP - O
insulin NOUN - O
detemir NOUN - O
: PUNCT - O
comparison NOUN - O
of ADP - O
treatment NOUN - O
costs NOUN - O
in ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
based VERB - O
on ADP - O
the DET - O
results NOUN - O
of ADP - O
the DET - O
insulin NOUN - O
glargine NOUN - O
( PUNCT - O
Lantus NNP - B-ORG
) PUNCT - O
versus ADP - O
insulin NOUN - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
) PUNCT - O
Treat NOUN - O
- PUNCT - O
To ADP - O
- PUNCT - O
Target PROPN - O
( PUNCT - O
L2T3 NOUN - O
) PUNCT - O
study NOUN - O
from ADP - O
the DT - B-ORG
German NNP - I-ORG
Statutory NNP - I-ORG
Health NNP - I-ORG
Insurance NNP - I-ORG
perspective]. PROPN - O

-DOCSTART- -X- - O

Our ADJ - O
liquid ADJ - O
chromatography NOUN - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
procedure NOUN - O
allows VERB - O
unambiguous ADJ - O
identification NOUN - O
and CCONJ - O
quantification NOUN - O
of ADP - O
the DET - O
intact ADJ - O
human ADJ - O
insulin NOUN - O
and CCONJ - O
its ADJ - O
intact ADJ - O
synthetic NOUN - O
analogues VERB - O
Humalog NNP - B-PERSON
® NN - I-PERSON
, PUNCT - O
Novolog NNP - B-FAC
® NN - I-FAC
, PUNCT - O
Apidra NNP - B-ORG
® NN - I-ORG
, PUNCT - O
Lantus NNP - B-ORG
® NN - I-ORG
, PUNCT - O
and CCONJ - O
Levemir NNP - B-MEDICINE
® . - I-PERSON
in ADP - O
human ADJ - O
blood NOUN - O
serum NOUN - O
in ADP - O
clinical ADJ - O
and CCONJ - O
overdose ADJ - O
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Levemir NNP - B-MEDICINE
) PUNCT - O
Treat NOUN - O
- PUNCT - O
To ADP - O
- PUNCT - O
Target PROPN - O
( PUNCT - O
L2T3 NOUN - O
) PUNCT - O
study NOUN - O
: PUNCT - O
A DET - O
multinational ADJ - O
, PUNCT - O
randomized VERB - O
noninferiority NOUN - O
trial NOUN - O
of ADP - O
basal ADJ - O
insulin NOUN - O
initiation NOUN - O
in ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
the DET - O
cases NOUN - O
of ADP - O
four CD - B-CARDINAL
children NOUN - O
with ADP - O
type NOUN - O
I PRON - O
diabetes VERB - O
who NOUN - O
were VERB - O
commenced VERB - O
on ADP - O
NovoMix NNP - B-ORG
30 NUM - O
or CCONJ - O
NovoRapid NNP - B-ORG
/ SYM - I-ORG
Levemir NNP - I-MEDICINE
insulin NOUN - O
injections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
search NOUN - O
for ADP - O
target NOUN - O
analytes NOUN - O
to PART - O
uncover VERB - O
the DET - O
misuse NOUN - O
of ADP - O
long ADJ - O
acting NOUN - O
insulin NOUN - O
analogues VERB - O
( PUNCT - O
Lantus NNP - B-ORG
, , - I-ORG
Insulin NNP - I-ORG
Glargine NNP - I-ORG
; PUNCT - O
Levemir NNP - B-MEDICINE
, PUNCT - O
Insulin NNP - B-PERSON
Detemir NNP - I-PERSON
) PUNCT - O
in ADP - O
doping VERB - O
control NOUN - O
samples NOUN - O
led VERB - O
to ADP - O
the DET - O
identification NOUN - O
of ADP - O
several ADJ - O
degradation NOUN - O
products NOUN - O
of ADP - O
insulin NOUN - O
or CCONJ - O
its ADJ - O
synthetic ADJ - O
analogues NOUN - O
. PUNCT - O

For ADP - O
the DET - O
determination NOUN - O
of ADP - O
surreptitious ADJ - O
Levemir NNP - B-MEDICINE
or CCONJ - O
recombinant ADJ - O
human ADJ - O
insulin NOUN - O
applications NOUN - O
, PUNCT - O
an DET - O
unequivocal ADJ - O
argument NOUN - O
was VERB - O
not ADV - O
detected VERB - O
, PUNCT - O
but CCONJ - O
promising VERB - O
approaches NOUN - O
based VERB - O
on ADP - O
a DET - O
modified VERB - O
insulin NOUN - O
degradation NOUN - O
profile NOUN - O
with ADP - O
altered ADJ - O
relative ADJ - O
intensities NOUN - O
of ADP - O
metabolites NOUN - O
are VERB - O
presented VERB - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
the DET - O
treatment NOUN - O
costs NOUN - O
of ADP - O
insulin NOUN - O
glargine NOUN - O
( PUNCT - O
IG NNP - B-ORG
; PUNCT - O
Lantus NNP - B-ORG
) PUNCT - O
to PART - O
detemir VERB - O
( PUNCT - O
ID NNP - B-ORG
; PUNCT - O
Levemir NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
both DET - O
combined VERB - O
with ADP - O
bolus ADJ - O
insulin NOUN - O
aspart NOUN - O
( PUNCT - O
NovoRapid NNP - B-ORG
) PUNCT - O
in ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
( PUNCT - O
T2D NNP - B-GPE
) PUNCT - O
in ADP - O
Germany NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Insulin PROPN - O
detemir PROPN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
[ -LRB- - I-ORG
Novo NNP - I-ORG
Nordisk NNP - I-ORG
A NNP - I-ORG
/ SYM - I-ORG
S NNP - I-ORG
, PUNCT - O
Bagsvaerd NNP - B-GPE
, PUNCT - O
Denmark NNP - B-GPE
] PUNCT - O
) PUNCT - O
is VERB - O
a DET - O
soluble ADJ - O
, PUNCT - O
long ADV - O
- PUNCT - O
acting VERB - O
basal ADJ - O
insulin NOUN - O
analog NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Search NOUN - O
terms NOUN - O
used VERB - O
were VERB - O
: PUNCT - O
Byetta NN - B-PERSON
, PUNCT - O
exenatide INTJ - O
, PUNCT - O
insulin NOUN - O
detemir NOUN - O
, PUNCT - O
NN304 NNP - B-ORG
, PUNCT - O
Exubera NNP - B-ORG
inhaled VERB - O
insulin NOUN - O
, PUNCT - O
Levemir NNP - B-MEDICINE
, PUNCT - O
pramlintide NOUN - O
, PUNCT - O
Symlin NNP - B-PERSON
, PUNCT - O
AC137 NNP - B-PRODUCT
, PUNCT - O
AC0137 UH - B-PRODUCT
, PUNCT - O
and CCONJ - O
Tripro NNP - B-ORG
- HYPH - I-ORG
Amylin NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Recombinant PROPN - O
analogues NOUN - O
marketed VERB - O
in ADP - O
the DET - O
UK NNP - B-GPE
since ADP - O
then ADV - O
include VERB - O
another DET - O
short ADJ - O
- PUNCT - O
acting NOUN - O
analogue NOUN - O
, PUNCT - O
[ PUNCT - O
symbol NOUN - O
: PUNCT - O
see VERB - O
text]insulin NOUN - O
aspart NOUN - O
( PUNCT - O
NovoRapid NNP - B-ORG
-- PUNCT - O
Novo PROPN - O
Nordisk PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
two CD - B-CARDINAL
longer ADV - O
- PUNCT - O
acting VERB - O
analogues NOUN - O
, PUNCT - O
[ PUNCT - O
symbol NOUN - O
: PUNCT - O
see VERB - O
text]insulin NOUN - O
glargine NOUN - O
( PUNCT - O
Lantus PROPN - O
-- PUNCT - O
Aventis PROPN - O
Pharma PROPN - O
) PUNCT - O
and CCONJ - O
[ PUNCT - O
symbol NOUN - O
: PUNCT - O
see VERB - O
text]insulin X - O
detemir NOUN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
-- : - I-ORG
Novo NNP - I-ORG
Nordisk NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Insulin PROPN - O
detemir PROPN - O
( PUNCT - O
Levemir NNP - B-MEDICINE
, , - I-ORG
Novo NNP - I-ORG
Nordisk NNP - I-ORG
) PUNCT - O
is VERB - O
a DET - O
novel NOUN - O
, PUNCT - O
biologically ADV - O
engineered VERB - O
analogue NOUN - O
of ADP - O
human ADJ - O
insulin NOUN - O
that ADJ - O
has VERB - O
been VERB - O
successfully ADV - O
developed VERB - O
for ADP - O
clinical ADJ - O
use NOUN - O
in ADP - O
diabetes NOUN - O
as ADP - O
a DET - O
basal ADJ - O
insulin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Megestrol NNP - B-MEDICINE
Acetate NNP - I-MEDICINE
- PUNCT - O
Induced PROPN - O
Adrenal PROPN - O
Insufficiency PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

New PROPN - O
Biopolymer PROPN - O
Nanoparticles PROPN - O
Improve VERB - O
the DET - O
Solubility PROPN - O
of ADP - O
Lipophilic PROPN - O
Megestrol NNP - B-MEDICINE
Acetate NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Use PROPN - O
of ADP - O
Megestrol NNP - B-MEDICINE
Acetate NNP - I-MEDICINE
for ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Obstructive PROPN - O
Pulmonary PROPN - O
Diseases PROPN - O

-DOCSTART- -X- - O

Megestrol NNP - B-MEDICINE
Acetate NNP - I-MEDICINE
( PUNCT - O
MA PROPN - O
) PUNCT - O
could VERB - O
improve VERB - O
appetite NOUN - O
, PUNCT - O
and CCONJ - O
was VERB - O
associated VERB - O
with ADP - O
slight ADJ - O
weight NOUN - O
gain NOUN - O
for ADP - O
CACS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
famotidine NOUN - O
, PUNCT - O
down ADV - O
- PUNCT - O
regulated VERB - O
these DET - O
genes NOUN - O
induced VERB - O
by ADP - O
bile ADJ - O
acids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
prevents NOUN - O
CDX2 PROPN - O
and CCONJ - O
SOX9 PROPN - O
expression NOUN - O
by ADP - O
inhibiting VERB - O
hedgehog NOUN - O
signaling VERB - O
in ADP - O
Barrett NNP - B-ORG
's PART - O
esophagus ADJ - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
influenced VERB - O
the DET - O
kinetics NOUN - O
of ADP - O
itraconazole NOUN - O
through ADP - O
altering VERB - O
the DET - O
dissolution NOUN - O
and CCONJ - O
absorption NOUN - O
due ADP - O
to ADP - O
the DET - O
pH NOUN - O
- PUNCT - O
dependent ADJ - O
solubility NOUN - O
of ADP - O
itraconazole NOUN - O
, PUNCT - O
inhibition NOUN - O
of ADP - O
efflux NOUN - O
transporters NOUN - O
, PUNCT - O
and CCONJ - O
inhibiting VERB - O
the DET - O
metabolism NOUN - O
of ADP - O
itraconazole NOUN - O
and CCONJ - O
hydroxyitraconazole NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mechanistic NNP - B-ORG
Assessment NNP - I-ORG
of ADP - O
the DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Omeprazole NNP - I-MEDICINE
on ADP - O
the DET - O
In PROPN - O
Vivo PROPN - O
Pharmacokinetics PROPN - O
of ADP - O
Itraconazole PROPN - O
in ADP - O
Healthy PROPN - O
Volunteers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
20 CD - B-CARDINAL
mg NOUN - O
enteric ADJ - O
coated ADJ - O
capsule ADJ - O
daily RB - B-DATE
and CCONJ - O
alginate VERB - O
10ml JJ - B-CARDINAL
three CD - I-CARDINAL
times NOUN - O
daily ADV - O
were VERB - O
administered VERB - O
14 CD - B-DATE
days NNS - I-DATE
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative PROPN - O
Study PROPN - O
of ADP - O
Alginate PROPN - O
and CCONJ - O
Omeprazole NNP - B-MEDICINE
in ADP - O
Symptomatic PROPN - O
Treatment PROPN - O
of ADP - O
Non PROPN - O
- ADJ - O
erosive ADJ - O
Gastroesophageal NNP - B-ORG
Reflux NNP - I-ORG
Disease NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
, PUNCT - O
lansoprazole NOUN - O
, PUNCT - O
pantoprazole NOUN - O
, PUNCT - O
rabeprazole NOUN - O
and CCONJ - O
esomeprazole NOUN - O
belong VERB - O
to ADP - O
PPIs NOUN - O
category NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM PROPN - O
: PUNCT - O
To PART - O
study VERB - O
the DET - O
antiulcerogenic ADJ - O
activity NOUN - O
of ADP - O
extracts NOUN - O
of ADP - O
Orbignya NNP - B-GPE
phalerata NOUN - O
( PUNCT - O
babaçu PROPN - O
) PUNCT - O
and CCONJ - O
Euterpe NNP - B-GPE
edules NOUN - O
( PUNCT - O
juçara NOUN - O
) PUNCT - O
in ADP - O
Wistar NNP - B-ORG
rats NOUN - O
after ADP - O
induction NOUN - O
of ADP - O
peptic ADJ - O
ulcer NOUN - O
, PUNCT - O
compared VERB - O
with ADP - O
Omeprazole NNP - B-MEDICINE
. PUNCT - O

group NOUN - O
I PROPN - O
, PUNCT - O
II NNP - B-ORG
, PUNCT - O
III NNP - B-ORG
, PUNCT - O
IV NNP - B-ORG
( PUNCT - O
10 CD - B-CARDINAL
rats NOUN - O
each DET - O
) PUNCT - O
subjected VERB - O
to PART - O
extract VERB - O
of ADP - O
Orbignya NNP - B-GPE
phalerata NOUN - O
, PUNCT - O
Euterpe NNP - B-ORG
edules NOUN - O
, PUNCT - O
Omeprazole NNP - B-MEDICINE
and CCONJ - O
ethanol NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

In ADP - O
the DET - O
prophylactic ADJ - O
subgroup NOUN - O
, PUNCT - O
Omeprazole NNP - B-MEDICINE
resulted VERB - O
in ADP - O
protection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Stereoselective ADJ - O
Metabolism PROPN - O
of ADP - O
Omeprazole NNP - B-MEDICINE
by ADP - O
Cytochrome PROPN - O
P450 PROPN - O
2C19 NUM - O
and CCONJ - O
3A4 CD - B-PRODUCT
: PUNCT - O
Mechanistic ADJ - O
Insights PROPN - O
from ADP - O
DFT PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Objectives NOUN - O
: PUNCT - O
Omeprazole NNP - B-MEDICINE
was VERB - O
shown VERB - O
to PART - O
improve VERB - O
the DET - O
anti ADJ - O
- ADJ - O
cancer ADJ - O
effect NOUN - O
of ADP - O
the DET - O
nucleoside NOUN - O
- PUNCT - O
analogue NOUN - O
5-fluorouracil NUM - O
. PUNCT - O

Omeprazole JJ - B-MEDICINE
concentrations NOUN - O
up ADP - O
to PART - O
80 CD - B-QUANTITY
microg NN - I-QUANTITY
/ PUNCT - O
mL PROPN - O
did VERB - O
not ADV - O
affect VERB - O
the DET - O
antiviral ADJ - O
effects NOUN - O
of ADP - O
ribavirin NOUN - O
. PUNCT - O

Omeprazole NNP - B-MEDICINE
also ADV - O
enhanced VERB - O
the DET - O
acyclovir ADV - O
- PUNCT - O
mediated VERB - O
effects NOUN - O
on ADP - O
viral ADJ - O
antigen NOUN - O
expression NOUN - O
and CCONJ - O
virus NOUN - O
replication NOUN - O
in ADP - O
HSV-1- NNP - B-ORG
and CCONJ - O
HSV-2-infected JJ - B-PRODUCT
cells NOUN - O
. PUNCT - O

Omeprazole NNP - B-MEDICINE
increases VERB - O
the DET - O
anti ADJ - O
- ADJ - O
HSV JJ - B-ORG
activity NOUN - O
of ADP - O
acyclovir NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
work NOUN - O
was VERB - O
to PART - O
develop VERB - O
a DET - O
new ADJ - O
supergeneric ADJ - O
product NOUN - O
Meloxicam NNP - B-ORG
/ SYM - I-ORG
Omeprazole NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
the DT - B-ORG
Proton NNP - I-ORG
Pump NNP - I-ORG
Inhibitors NNPS - I-ORG
Omeprazole NNP - I-MEDICINE
and CCONJ - O
Pantoprazole NNP - B-ORG
on ADP - O
the DET - O
Cytochrome PROPN - O
P450-Mediated PROPN - O
Metabolism PROPN - O
of ADP - O
Venlafaxine PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
difference NOUN - O
was VERB - O
statistically ADV - O
significant ADJ - O
, PUNCT - O
but CCONJ - O
the DET - O
adverse ADJ - O
effects NOUN - O
did VERB - O
not ADV - O
increase VERB - O
( PUNCT - O
P>0.05).Conclusion NOUN - O
: PUNCT - O
Omeprazole NNP - B-MEDICINE
is VERB - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
laryngopharyngeal ADJ - O
reflux NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
hypertrichosis NOUN - O
in ADP - O
two CD - B-CARDINAL
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Tolerability NNP - B-ORG
of IN - I-ORG
Two CD - I-ORG
Quadruple NNPS - I-ORG
Regimens NNS - I-ORG
: : - I-ORG
Bismuth NNP - I-ORG
, PUNCT - O
Omeprazole NNP - B-MEDICINE
, PUNCT - O
Metronidazole NNP - B-PRODUCT
with ADP - O
Amoxicillin NNP - B-ORG
or CCONJ - O
Tetracycline NNP - B-GPE
as ADP - O
First PROPN - O
- PUNCT - O
Line PROPN - O
Treatment PROPN - O
for ADP - O
Eradication PROPN - O
of ADP - O
Helicobacter PROPN - O
Pylori PROPN - O
in ADP - O
Patients NNPS - B-GPE
with ADP - O
Duodenal PROPN - O
Ulcer PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

A DET - O
Phase NOUN - O
1 NUM - O
Pharmacokinetic PROPN - O
Study PROPN - O
of ADP - O
Cysteamine PROPN - O
Bitartrate PROPN - O
Delayed PROPN - O
- PUNCT - O
Release NOUN - O
Capsules PROPN - O
Following VERB - O
Oral PROPN - O
Administration PROPN - O
with ADP - O
Orange PROPN - O
Juice PROPN - O
, PUNCT - O
Water PROPN - O
, PUNCT - O
or CCONJ - O
Omeprazole NNP - B-MEDICINE
in ADP - O
Cystinosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
the DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Psyllium NNP - I-ORG
Seed NNP - I-ORG
on ADP - O
Gastroesophageal PROPN - O
Reflux PROPN - O
Disease PROPN - O
With ADP - O
Oral PROPN - O
Omeprazole NNP - B-MEDICINE
in ADP - O
Patients PROPN - O
With ADP - O
Functional PROPN - O
Constipation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To ADP - O
Flavor NNP - B-PERSON
or CCONJ - O
Not ADV - O
to ADP - O
Flavor PROPN - O
Extemporaneous PROPN - O
Omeprazole NNP - B-MEDICINE
Liquid PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
( PUNCT - O
10 CD - B-CARDINAL
- SYM - I-CARDINAL
100 CD - I-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
p.o PROPN - O
. PUNCT - O
) PUNCT - O
and CCONJ - O
vonoprazan ADJ - O
( PUNCT - O
1 CD - B-CARDINAL
- SYM - I-CARDINAL
5 CD - I-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
p.o PROPN - O
. PUNCT - O
) PUNCT - O
led VERB - O
to ADP - O
a DET - O
significant ADJ - O
and CCONJ - O
dose ADJ - O
- PUNCT - O
dependent ADJ - O
increase NOUN - O
in ADP - O
gastric ADJ - O
pH. NOUN - O
3 CD - B-CARDINAL
. PUNCT - O
  SPACE - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NNP - I-ORG
of IN - I-ORG
Food NNP - I-ORG
or CC - I-ORG
Omeprazole NNP - I-MEDICINE
on ADP - O
the DET - O
Pharmacokinetics PROPN - O
of ADP - O
Osimertinib PROPN - O
in ADP - O
Patients PROPN - O
With ADP - O
Non PROPN - O
- ADJ - O
Small ADJ - O
- PUNCT - O
Cell PROPN - O
Lung PROPN - O
Cancer PROPN - O
and CCONJ - O
in ADP - O
Healthy NNP - B-PERSON
Volunteers NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
, PUNCT - O
a DET - O
gastric ADJ - O
acid NOUN - O
secretion NOUN - O
blocker NOUN - O
, PUNCT - O
is VERB - O
commonly ADV - O
used VERB - O
for ADP - O
gastrointestinal ADJ - O
diseases NOUN - O
due ADJ - O
to ADP - O
its ADJ - O
antioxidative ADJ - O
stress NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Omeprazole NNP - B-MEDICINE
promotes VERB - O
carcinogenesis NOUN - O
of ADP - O
fore NOUN - O
- PUNCT - O
stomach NOUN - O
in ADP - O
mice NOUN - O
with ADP - O
co NOUN - O
- NOUN - O
stimulation NOUN - O
of ADP - O
nitrosamine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

VACCINE PROPN - O
AGAINST PROPN - O
VISCERAL PROPN - O
MYCOSIS NOUN - O
CAUSED PROPN - O
BY ADP - O
FUNGUS PROPN - O
OF ADP - O
GENUS ADJ - O
MUCOR NN - B-MEDICINE
RACEMOSUS NN - I-MEDICINE
IN ADP - O
AGRICULTURAL ADJ - O
ANIMALS NOUN - O

-DOCSTART- -X- - O

Accordingly ADV - O
, PUNCT - O
the DET - O
purpose NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
explore VERB - O
stability NOUN - O
behavior NOUN - O
of ADP - O
a DET - O
popular ADJ - O
antihypertensive ADJ - O
combination NOUN - O
of ADP - O
amlodipine NOUN - O
besylate NOUN - O
( PUNCT - O
AML NNP - B-ORG
) PUNCT - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
LST PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Molecular ADJ - O
insight NOUN - O
into ADP - O
atypical ADJ - O
instability NOUN - O
behavior NOUN - O
of ADP - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
containing VERB - O
amlodipine NOUN - O
besylate NOUN - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Four CD - B-CARDINAL
BE NNP - B-ORG
studies NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
reported VERB - O
in ADP - O
the DET - O
literature NOUN - O
are VERB - O
reviewed VERB - O
. PUNCT - O

In ADP - O
all ADJ - O
the DET - O
four CD - B-CARDINAL
studies NOUN - O
, PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
intervals NOUN - O
( PUNCT - O
CIs NOUN - O
) PUNCT - O
of ADP - O
geometric ADJ - O
mean VERB - O
ratios NOUN - O
of ADP - O
the DET - O
test NOUN - O
and CCONJ - O
reference NOUN - O
formulations NOUN - O
for ADP - O
maximum ADJ - O
blood NOUN - O
drug NOUN - O
concentration NOUN - O
( PUNCT - O
Cmax PROPN - O
) PUNCT - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
were VERB - O
outside ADP - O
the DET - O
acceptable ADJ - O
range NOUN - O
of ADP - O
80%-125 NNP - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
whereas ADP - O
, PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CIs NOUN - O
for ADP - O
its ADJ - O
active ADJ - O
metabolite NOUN - O
, PUNCT - O
losartan ADJ - O
carboxylic NOUN - O
acid NOUN - O
( PUNCT - O
LCA NNP - B-ORG
) PUNCT - O
, PUNCT - O
were VERB - O
within ADP - O
the DET - O
acceptance NOUN - O
criteria NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
undertaken VERB - O
with ADP - O
an DET - O
aim NOUN - O
to PART - O
systematically ADV - O
design VERB - O
a DET - O
model NOUN - O
of ADP - O
factors NOUN - O
that ADJ - O
would VERB - O
yield VERB - O
an DET - O
optimized VERB - O
sustained ADJ - O
release NOUN - O
dosage NOUN - O
form NOUN - O
of ADP - O
an DET - O
anti ADJ - O
- ADJ - O
hypertensive ADJ - O
agent NOUN - O
, PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
using VERB - O
response NOUN - O
surface NOUN - O
methodology NOUN - O
( PUNCT - O
RSM NNP - B-ORG
) PUNCT - O
by ADP - O
employing VERB - O
3(2 CD - B-CARDINAL
) PUNCT - O
full ADJ - O
factorial ADJ - O
design NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
ecotoxicity NOUN - O
of ADP - O
propranolol NOUN - O
hydrochloride NOUN - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
was VERB - O
evaluated VERB - O
, PUNCT - O
both DET - O
individually ADV - O
and CCONJ - O
combined VERB - O
in ADP - O
a DET - O
binary ADJ - O
mixture NOUN - O
, PUNCT - O
by ADP - O
using VERB - O
the DET - O
Lemna NNP - B-PERSON
minor ADJ - O
growth NOUN - O
inhibition NOUN - O
test NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
observe VERB - O
the DET - O
effects NOUN - O
of ADP - O
Jinshuibao NNP - B-PERSON
Capsule NNP - I-PERSON
( PUNCT - O
JC PROPN - O
) PUNCT - O
combined VERB - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
on ADP - O
some DET - O
indices NOUN - O
of ADP - O
early ADJ - O
renal ADJ - O
damage NOUN - O
of ADP - O
hypertension NOUN - O
patients NOUN - O
of ADP - O
yin NOUN - O
and CCONJ - O
yang ADJ - O
deficiency NOUN - O
syndrome NOUN - O
( PUNCT - O
YYDS PROPN - O
) PUNCT - O
, PUNCT - O
such ADJ - O
as ADP - O
levels NOUN - O
of ADP - O
serum NOUN - O
cystatin NOUN - O
C NOUN - O
( PUNCT - O
Cys NNP - B-PERSON
C NNP - I-PERSON
) PUNCT - O
, PUNCT - O
beta2-microglobulin NOUN - O
( PUNCT - O
beta2-MG PROPN - O
) PUNCT - O
, PUNCT - O
hypersensitive ADJ - O
C NOUN - O
- PUNCT - O
reactive ADJ - O
protein NOUN - O
( PUNCT - O
hs NOUN - O
- PUNCT - O
CRP PROPN - O
) PUNCT - O
, PUNCT - O
uric ADJ - O
acid NOUN - O
( PUNCT - O
UA NNP - B-GPE
) PUNCT - O
, PUNCT - O
blood NOUN - O
pressure NOUN - O
, PUNCT - O
blood NOUN - O
lipids NOUN - O
, PUNCT - O
and CCONJ - O
fasting VERB - O
blood NOUN - O
glucose NOUN - O
( PUNCT - O
FBG NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
to PART - O
explore VERB - O
their ADJ - O
protective ADJ - O
effects NOUN - O
on ADP - O
early ADJ - O
renal ADJ - O
damage NOUN - O
of ADP - O
hypertension NOUN - O
patients NOUN - O
and CCONJ - O
on ADP - O
the DET - O
metabolisms NOUN - O
of ADP - O
blood NOUN - O
lipids NOUN - O
and CCONJ - O
blood NOUN - O
glucose NOUN - O
. PUNCT - O

Totally ADV - O
106 CD - B-CARDINAL
hypertension NOUN - O
patients NOUN - O
of ADP - O
YYDS NNP - B-ORG
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
two CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
53 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
control NOUN - O
group NOUN - O
( PUNCT - O
treated VERB - O
by ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
) PUNCT - O
and CCONJ - O
53 CD - B-CARDINAL
patients NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
group NOUN - O
( PUNCT - O
treated VERB - O
by ADP - O
JC PROPN - O
+ CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
) PUNCT - O
. PUNCT - O

Compared VERB - O
with ADP - O
the DET - O
control NOUN - O
group NOUN - O
after ADP - O
treatment NOUN - O
, PUNCT - O
the DET - O
levels NOUN - O
of ADP - O
Cys NNP - B-PERSON
C NNP - I-PERSON
, PUNCT - O
beta2-MG PROPN - O
, PUNCT - O
and CCONJ - O
hs ADV - O
- PUNCT - O
CRP PROPN - O
decreased VERB - O
more ADV - O
obviously ADV - O
after ADP - O
treatment NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
group NOUN - O
, PUNCT - O
showing VERB - O
statistical ADJ - O
difference NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05).JC CD - B-ORDINAL
combined VERB - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
showed VERB - O
better ADJ - O
effects NOUN - O
in ADP - O
treating VERB - O
early ADJ - O
renal ADJ - O
damage NOUN - O
of ADP - O
hypertension NOUN - O
patients NOUN - O
of ADP - O
YYDS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Jinshuibao PROPN - O
capsule NOUN - O
combined VERB - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
intervened VERB - O
early ADJ - O
renal ADJ - O
damage NOUN - O
of ADP - O
hypertension NOUN - O
patients NOUN - O
of ADP - O
yin NOUN - O
and CCONJ - O
yang ADJ - O
deficiency NOUN - O
: PUNCT - O
a DET - O
clinical ADJ - O
research]. NOUN - O

-DOCSTART- -X- - O

A DET - O
predefined ADJ - O
exploratory ADJ - O
analysis NOUN - O
of ADP - O
a DET - O
prospective ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
forced VERB - O
- PUNCT - O
titration NOUN - O
study NOUN - O
of ADP - O
olmesartan NOUN - O
medoxomil NOUN - O
( PUNCT - O
OM PROPN - O
) PUNCT - O
versus ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
LOS PROPN - O
) PUNCT - O
in ADP - O
subjects NOUN - O
with ADP - O
hypertension NOUN - O
not ADV - O
previously ADV - O
or CCONJ - O
previously ADV - O
treated VERB - O
with ADP - O
antihypertensive ADJ - O
medication NOUN - O
is VERB - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Novel ADJ - O
preparation NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE

-DOCSTART- -X- - O

A DET - O
stability NOUN - O
- PUNCT - O
indicating VERB - O
reversed VERB - O
- PUNCT - O
phase NOUN - O
liquid ADJ - O
chromatographic ADJ - O
method NOUN - O
has VERB - O
been VERB - O
developed VERB - O
and CCONJ - O
validated VERB - O
for ADP - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
ramipril NOUN - O
. PUNCT - O

The DET - O
method NOUN - O
demonstrated VERB - O
excellent ADJ - O
linearity NOUN - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
ramipril VERB - O
with ADP - O
regression NOUN - O
coefficients NOUN - O
of ADP - O
0.9999 CD - B-CARDINAL
and CCONJ - O
0.9998 CD - B-CARDINAL
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
linearity NOUN - O
range NOUN - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
62.5 CD - B-CARDINAL
- SYM - I-CARDINAL
5000 CD - I-CARDINAL
ng NOUN - O
/ SYM - O
ml NOUN - O
and CCONJ - O
125 CD - B-CARDINAL
- SYM - I-CARDINAL
10,000 CD - I-CARDINAL
ng PROPN - O
/ SYM - O
ml PROPN - O
with ADP - O
the DET - O
mean ADJ - O
percentage NOUN - O
recoveries NOUN - O
of ADP - O
100.36 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
±2.27 NOUN - O
) PUNCT - O
and CCONJ - O
100.16 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
±3.33 NNP - B-ORG
) PUNCT - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
ramipril NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
method NOUN - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
sensitive ADJ - O
with ADP - O
quantification NOUN - O
limits NOUN - O
of ADP - O
44.30 CD - B-CARDINAL
and CCONJ - O
79.93 CD - B-QUANTITY
ng NNS - I-QUANTITY
/ SYM - I-QUANTITY
ml NNP - I-QUANTITY
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
ramipril NOUN - O
. PUNCT - O

The DET - O
method NOUN - O
was VERB - O
successfully ADV - O
employed VERB - O
for ADP - O
the DET - O
determination NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
ramipril NOUN - O
in ADP - O
commercially ADV - O
available ADJ - O
and CCONJ - O
in ADP - O
- PUNCT - O
house NOUN - O
prepared VERB - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
exploratory ADJ - O
subgroup NOUN - O
analysis NOUN - O
of ADP - O
a DET - O
prospective ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
forced VERB - O
- PUNCT - O
titration NOUN - O
study NOUN - O
comparing VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
olmesartan NOUN - O
medoxomil NOUN - O
( PUNCT - O
OM PROPN - O
) PUNCT - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
LOS PROPN - O
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
stage NOUN - O
1 CD - B-CARDINAL
or CCONJ - O
stage VERB - O

-DOCSTART- -X- - O

Efficacy NOUN - O
/ SYM - O
safety NOUN - O
of ADP - O
olmesartan NOUN - O
medoxomil X - O
versus ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
patients NOUN - O
by ADP - O
stage NOUN - O
1 CD - B-CARDINAL
or CCONJ - O
2 NUM - O
hypertension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
simple ADJ - O
, PUNCT - O
accurate ADJ - O
, PUNCT - O
rapid ADJ - O
, PUNCT - O
specific ADJ - O
and CCONJ - O
reproducible ADJ - O
UV NOUN - O
spectrophotometric ADJ - O
method NOUN - O
was VERB - O
developed VERB - O
for ADP - O
estimation NOUN - O
of ADP - O
content NOUN - O
uniformity NOUN - O
of ADP - O
atenolol NOUN - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
its ADJ - O
combined ADJ - O
tablet NOUN - O
dosage NOUN - O
form NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
hydrochlorothiazide NOUN - O
tablet NOUN - O
and CCONJ - O
a DET - O
preparation NOUN - O
method NOUN - O
thereof ADV - O
. PUNCT - O

The DET - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
hydrochlorothiazide NOUN - O
tablet NOUN - O
comprises VERB - O
a DET - O
core NOUN - O
and CCONJ - O
a DET - O
film NOUN - O
coat NOUN - O
layer NOUN - O
and CCONJ - O
is VERB - O
characterized VERB - O
in ADP - O
that ADP - O
the DET - O
core NOUN - O
is VERB - O
composed VERB - O
of ADP - O
the DET - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
the DET - O
hydrochlorothiazide NOUN - O
which ADJ - O
serve VERB - O
as ADP - O
the DET - O
medicinal ADJ - O
active ADJ - O
components NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
medicinally ADV - O
available ADJ - O
accessory NOUN - O
. PUNCT - O

The DET - O
preparation NOUN - O
method NOUN - O
of ADP - O
the DET - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
hydrochlorothiazide NOUN - O
tablet NOUN - O
is VERB - O
as ADP - O
the DET - O
following VERB - O
: PUNCT - O
the DET - O
hydrochlorothiazide NOUN - O
is VERB - O
mixed VERB - O
with ADP - O
the DET - O
easily ADV - O
- PUNCT - O
dissolvable ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
lactose NOUN - O
monohydrate NOUN - O
, PUNCT - O
and CCONJ - O
then ADV - O
the DET - O
mixture NOUN - O
is VERB - O
made VERB - O
into ADP - O
grains NOUN - O
the DET - O
hydrochlorothiazide NOUN - O
is VERB - O
dispersed VERB - O
in ADP - O
the DET - O
easily ADV - O
- PUNCT - O
dissolvable ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
lactose NOUN - O
monohydrate NOUN - O
, PUNCT - O
and CCONJ - O
then ADV - O
mixed VERB - O
with ADP - O
the DET - O
microcrystalline NOUN - O
cellulose NOUN - O
, PUNCT - O
the DET - O
pregelatinized VERB - O
starch NOUN - O
and CCONJ - O
magnesium NOUN - O
stearate NOUN - O
then ADV - O
tablets NOUN - O
are VERB - O
made VERB - O
and CCONJ - O
coated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
the DET - O
current ADJ - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
feasibility NOUN - O
of ADP - O
proniosomes NOUN - O
as ADP - O
transdermal ADJ - O
drug NOUN - O
delivery NOUN - O
system NOUN - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
. PUNCT - O

In ADP - O
vivo NOUN - O
pharmacokinetic ADJ - O
study NOUN - O
of ADP - O
PNP PROPN - O
- PUNCT - O
H PROPN - O
showed VERB - O
a DET - O
significant ADJ - O
increase NOUN - O
in ADP - O
bioavailability NOUN - O
( PUNCT - O
1.93 CD - B-CARDINAL
times NOUN - O
) PUNCT - O
compared VERB - O
with ADP - O
oral ADJ - O
formulation NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Proniosomal ADJ - O
transdermal ADJ - O
therapeutic ADJ - O
system NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
: PUNCT - O
development NOUN - O
and CCONJ - O
pharmacokinetic ADJ - O
evaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM NNP - B-ORG
: PUNCT - O
To PART - O
develop VERB - O
a DET - O
simple ADJ - O
, PUNCT - O
accurate ADJ - O
, PUNCT - O
rapid ADJ - O
and CCONJ - O
precise ADJ - O
UV NOUN - O
spectrophotometric ADJ - O
method NOUN - O
for ADP - O
the DET - O
estimation NOUN - O
of ADP - O
atenolol NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
hydrochlorothiazide NOUN - O
. PUNCT - O

: PUNCT - O
The DET - O
method NOUN - O
employs VERB - O
formation NOUN - O
and CCONJ - O
solving VERB - O
simultaneous ADJ - O
equation NOUN - O
using VERB - O
251.60 CD - B-CARDINAL
nm NOUN - O
and CCONJ - O
224.20 CD - B-CARDINAL
nm NOUN - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
and CCONJ - O
atenolol NOUN - O
, PUNCT - O
224.20 CD - B-CARDINAL
and CCONJ - O
271.60 CD - B-CARDINAL
for ADP - O
atenolol NOUN - O
and CCONJ - O
hydrochlorothiazide NOUN - O
as ADP - O
two CD - B-CARDINAL
analytical ADJ - O
wavelengths NOUN - O
, PUNCT - O
using VERB - O
methanol NOUN - O
water NOUN - O
as ADP - O
a DET - O
solvent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
present ADJ - O
work NOUN - O
, PUNCT - O
four CD - B-CARDINAL
different ADJ - O
spectrophotometric ADJ - O
methods NOUN - O
for ADP - O
simultaneous ADJ - O
estimation NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
amlodipine ADJ - O
besilate NOUN - O
and CCONJ - O
hydrochlorothiazide ADJ - O
in ADP - O
raw ADJ - O
materials NOUN - O
and CCONJ - O
in ADP - O
formulations NOUN - O
are VERB - O
described VERB - O
. PUNCT - O

The DET - O
linearity NOUN - O
range NOUN - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
8 CD - B-CARDINAL
- SYM - I-CARDINAL
40 CD - I-CARDINAL
, PUNCT - O
1 CD - B-CARDINAL
- SYM - O
5 NUM - O
and CCONJ - O
3 CD - B-CARDINAL
- SYM - O
15 NUM - O
μg PROPN - O
mL-1 NOUN - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
amlodipine ADJ - O
besilate NOUN - O
and CCONJ - O
hydrochlorothiazide NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
crystalline NOUN - O
Form PROPN - O
+ CCONJ - O
- PUNCT - O
, PUNCT - O
a DET - O
process NOUN - O
for ADP - O
its ADJ - O
preparation NOUN - O
, PUNCT - O
a DET - O
pharmaceutical ADJ - O
composition NOUN - O
therefrom ADP - O
, PUNCT - O
its ADJ - O
use NOUN - O
in ADP - O
therapy NOUN - O
and CCONJ - O
in ADP - O
a DET - O
purification NOUN - O
process NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Process NOUN - O
for ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE

-DOCSTART- -X- - O

Process NOUN - O
for ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE

-DOCSTART- -X- - O

A DET - O
randomized ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
forced VERB - O
- PUNCT - O
titration NOUN - O
study NOUN - O
to PART - O
compare VERB - O
olmesartan ADJ - O
medoxomil NOUN - O
versus ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
stage NOUN - O
1 CD - B-CARDINAL
and CCONJ - O
2 NUM - O
hypertension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effects NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
an DET - O
angiotensin NOUN - O
AT(1 NUM - O
) PUNCT - O
receptor NOUN - O
blocker NOUN - O
on ADP - O
immobility NOUN - O
in ADP - O
forced VERB - O
swim NOUN - O
test NOUN - O
have VERB - O
been VERB - O
studied VERB - O
. PUNCT - O

Effect NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
nortriptyline ADJ - O
HCl NOUN - O
, PUNCT - O
fluoxetine NOUN - O
HCl NOUN - O
and CCONJ - O
reserpine NOUN - O
per ADP - O
se X - O
and CCONJ - O
in ADP - O
combination NOUN - O
on ADP - O
forced VERB - O
swimming NOUN - O
- PUNCT - O
induced VERB - O
immobility NOUN - O
in ADP - O
mice NOUN - O
have VERB - O
also ADV - O
been VERB - O
studied VERB - O
. PUNCT - O

In ADP - O
mice NOUN - O
, PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
elicits NOUN - O
biphasic ADJ - O
responses NOUN - O
i.e. X - O
positive ADJ - O
responses NOUN - O
at ADP - O
lower ADJ - O
doses NOUN - O
( PUNCT - O
0.1 CD - B-CARDINAL
, PUNCT - O
1.0 CD - B-CARDINAL
and CC - I-CARDINAL
5 NUM - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
i.p PROPN - O
. PUNCT - O
) PUNCT - O
in ADP - O
the DET - O
forced VERB - O
swim NOUN - O
test NOUN - O
, PUNCT - O
a DET - O
test NOUN - O
of ADP - O
potential ADJ - O
antidepressant ADJ - O
activity NOUN - O
and CCONJ - O
vice NOUN - O
versa ADV - O
at ADP - O
higher ADJ - O
dose NOUN - O
( PUNCT - O
20 CD - B-CARDINAL
and CC - I-CARDINAL
100 CD - I-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
i.p PROPN - O
. PUNCT - O
) PUNCT - O
. PUNCT - O

In ADP - O
chronic ADJ - O
studies NOUN - O
, PUNCT - O
enhancement NOUN - O
in ADP - O
immobility NOUN - O
was VERB - O
observed VERB - O
for ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
3 CD - B-CARDINAL
and CCONJ - O
30 NUM - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
p.o PROPN - O
. PROPN - O
, PUNCT - O
21 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
. PUNCT - O

In ADP - O
acute ADJ - O
combination NOUN - O
studies NOUN - O
, PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
1 CD - B-CARDINAL
and CCONJ - O
5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
significantly ADV - O
reversed VERB - O
the DET - O
reserpine NOUN - O
- PUNCT - O
induced VERB - O
immobility NOUN - O
, PUNCT - O
but CCONJ - O
vice NOUN - O
versa NOUN - O
at ADP - O
100 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
. PUNCT - O

The DET - O
obtained VERB - O
biphasic ADJ - O
effect NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
on ADP - O
immobility NOUN - O
in ADP - O
mice NOUN - O
might VERB - O
be VERB - O
due ADP - O
to ADP - O
inhibitory ADJ - O
effect NOUN - O
on ADP - O
AT(1 NNP - B-CARDINAL
) PUNCT - O
receptor NOUN - O
at ADP - O
lower ADJ - O
dose NOUN - O
and CCONJ - O
pronounced VERB - O
effect NOUN - O
on ADP - O
AT(2 PROPN - O
) PUNCT - O
receptor NOUN - O
at ADP - O
higher ADJ - O
dose NOUN - O
( PUNCT - O
large ADJ - O
concentrations NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
can VERB - O
displace VERB - O
Angiotensin NNP - B-PERSON
II NNP - I-PERSON
( PUNCT - O
Ang NNP - B-PERSON
II NNP - I-PERSON
) PUNCT - O
from ADP - O
its ADJ - O
AT(1 NNP - B-CARDINAL
) PUNCT - O
receptor NOUN - O
to ADP - O
AT(2 PROPN - O
) PUNCT - O
receptor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Crystalline ADJ - O
form NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE

-DOCSTART- -X- - O

12-week NUM - O
- PUNCT - O
old ADJ - O
salt NOUN - O
- PUNCT - O
loaded VERB - O
spontaneous ADJ - O
hypertensive ADJ - O
rats NOUN - O
( PUNCT - O
SHRs NOUN - O
) PUNCT - O
were VERB - O
divided VERB - O
into ADP - O
four CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
atorvastatin PROPN - O
( PUNCT - O
AVT NNP - B-ORG
) PUNCT - O
, PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
( PUNCT - O
LP NNP - B-ORG
) PUNCT - O
, PUNCT - O
atorvastatin NOUN - O
combined VERB - O
with ADP - O
peroxisome ADJ - O
proliferators NOUN - O
- PUNCT - O
activated VERB - O
receptor NOUN - O
γ PROPN - O
( PUNCT - O
PPAR NNP - B-ORG
- HYPH - I-ORG
γ NNP - I-ORG
) PUNCT - O
inhibitor NOUN - O
( PUNCT - O
AVT NNP - B-ORG
  SPACE - O
+ CCONJ - O
  SPACE - O
GW9662 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
saline VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Provided VERB - O
is VERB - O
a DET - O
method NOUN - O
of ADP - O
improving VERB - O
the DET - O
flowability NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
powder NOUN - O
having VERB - O
an DET - O
initial ADJ - O
Hausner NNP - B-NORP
ratio NOUN - O
of ADP - O
1.45 CD - B-CARDINAL
or CCONJ - O
more ADJ - O
, PUNCT - O
which ADJ - O
method NOUN - O
includes VERB - O
reslurrying VERB - O
the DET - O
losatrtan NOUN - O
potassium NOUN - O
in ADP - O
a DET - O
reslurry ADJ - O
solvent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
a DET - O
4-week CD - B-CARDINAL
run NOUN - O
- PUNCT - O
in PART - O
period NOUN - O
with ADP - O
therapeutic ADJ - O
lifestyle NOUN - O
changes NOUN - O
and CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
100 CD - B-CARDINAL
mg NOUN - O
once ADV - O
daily ADV - O
, PUNCT - O
patients NOUN - O
who NOUN - O
met VERB - O
both DET - O
blood NOUN - O
pressure NOUN - O
criteria NOUN - O
( PUNCT - O
80 CD - B-QUANTITY
mm NN - I-QUANTITY
Hg NN - I-QUANTITY
≤ NOUN - O

< X - O
110 CD - B-QUANTITY
mm NNP - I-QUANTITY
Hg NNP - I-QUANTITY
) PUNCT - O
and CCONJ - O
the DET - O
LDL NNP - B-ORG
- PUNCT - O
C PROPN - O
level NOUN - O
criteria NOUN - O
( PUNCT - O
defined VERB - O
in ADP - O
the DT - B-ORG
National NNP - I-ORG
Cholesterol NNP - I-ORG
Education NNP - I-ORG
Program NNP - I-ORG
Adult NNP - I-ORG
Treatment NNP - I-ORG
Panel NNP - I-ORG
III NNP - I-ORG
cardiovascular ADJ - O
risk NOUN - O
categories NOUN - O
) PUNCT - O
were VERB - O
randomized VERB - O
to ADP - O
1 CD - B-CARDINAL
of ADP - O
3 CD - B-CARDINAL
groups NOUN - O
and CCONJ - O
treated VERB - O
once ADV - O
daily ADV - O
for ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
: PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
100 CD - B-CARDINAL
mg NOUN - O
+ CCONJ - O
rosuvastatin ADJ - O
20 CD - B-CARDINAL
mg NOUN - O
treatment NOUN - O
( PUNCT - O
L NNP - B-ORG
/ SYM - I-ORG
R NNP - I-ORG
100/20 NUM - O
) PUNCT - O
group NOUN - O
, PUNCT - O
amlodipine NOUN - O
camsylate NOUN - O
5 CD - B-CARDINAL
mg PRON - O
+ CCONJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
100 CD - B-CARDINAL
mg NOUN - O
treatment NOUN - O
( PUNCT - O
A PROPN - O
/ SYM - O
L PROPN - O
5/100 CD - B-CARDINAL
) PUNCT - O
group NOUN - O
, PUNCT - O
and CCONJ - O
amlodipine VERB - O
5mg+ CD - B-CARDINAL
losartan NN - B-MEDICINE
potassium NN - I-MEDICINE
100 CD - B-CARDINAL
mg NOUN - O
+ CCONJ - O
rosuvastatin ADJ - O
20 CD - B-QUANTITY
mg NNS - I-QUANTITY
( PUNCT - O
A NNP - B-ORG
/ SYM - I-ORG
L NN - I-ORG
/ SYM - I-ORG
R NNP - I-ORG
5/100/20 NUM - O
) PUNCT - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
novel VERB - O
amorphous ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
novel ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
a DET - O
crystalline ADJ - O
form NOUN - O
that ADJ - O
is VERB - O
a DET - O
hydrate ADJ - O
, PUNCT - O
novel ADJ - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
IV PROPN - O
and CCONJ - O
solvates NOUN - O
thereof ADV - O
, PUNCT - O
novel ADJ - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
V NOUN - O
and CCONJ - O
solvates NOUN - O
thereof ADV - O
, PUNCT - O
to ADP - O
processes NOUN - O
for ADP - O
their ADJ - O
preparation NOUN - O
, PUNCT - O
to ADP - O
compositions NOUN - O
containing VERB - O
them PRON - O
and CCONJ - O
to ADP - O
their ADJ - O
use NOUN - O
in ADP - O
medicine NOUN - O
. PUNCT - O

This DET - O
invention NOUN - O
further ADV - O
relates VERB - O
to ADP - O
a DET - O
novel ADJ - O
process NOUN - O
for ADP - O
preparing VERB - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
I PROPN - O
and CCONJ - O
Form PROPN - O
II PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
invention NOUN - O
relates VERB - O
to ADP - O
novel VERB - O
amorphous ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
novel ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
a DET - O
crystalline ADJ - O
form NOUN - O
that ADJ - O
is VERB - O
a DET - O
hydrate ADJ - O
, PUNCT - O
novel ADJ - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
IV PROPN - O
and CCONJ - O
solvates NOUN - O
thereof ADV - O
, PUNCT - O
novel ADJ - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
V NOUN - O
and CCONJ - O
solvates NOUN - O
thereof ADV - O
, PUNCT - O
to ADP - O
processes NOUN - O
for ADP - O
their ADJ - O
preparation NOUN - O
, PUNCT - O
to ADP - O
compositions NOUN - O
containing VERB - O
them PRON - O
and CCONJ - O
to ADP - O
their ADJ - O
use NOUN - O
in ADP - O
medicine NOUN - O
. PUNCT - O

This DET - O
invention NOUN - O
further ADV - O
relates VERB - O
to ADP - O
a DET - O
novel ADJ - O
process NOUN - O
for ADP - O
preparing VERB - O
crystalline ADJ - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
Form NOUN - O
I PROPN - O
and CCONJ - O
Form PROPN - O
II PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
comparative ADJ - O
study NOUN - O
of ADP - O
first JJ - B-ORDINAL
- PUNCT - O
derivative ADJ - O
spectrophotometry NOUN - O
and CCONJ - O
high ADJ - O
- PUNCT - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
applied VERB - O
to ADP - O
the DET - O
determination NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
pharmacokinetic ADJ - O
( PUNCT - O
PK NNP - B-ORG
) PUNCT - O
characteristics NOUN - O
and CCONJ - O
tolerability NOUN - O
of ADP - O
an DET - O
FDC NNP - B-ORG
of ADP - O
6.94 CD - B-CARDINAL
mg PRON - O
amlodipine NOUN - O
besylate NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
mg PRON - O
as ADP - O
amlodipine)/50 X - O
mg PRON - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
compared VERB - O
to ADP - O
an DET - O
FDC NNP - B-ORG
of ADP - O
5 CD - B-CARDINAL
mg PRON - O
amlodipine NOUN - O
camsylate/50 NOUN - O
mg NOUN - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
healthy ADJ - O
subjects NOUN - O
. PUNCT - O

An DET - O
FDC NNP - B-ORG
of ADP - O
6.94 CD - B-CARDINAL
mg PRON - O
amlodipine NOUN - O
besylate NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
mg PRON - O
as ADP - O
amlodipine)/50 X - O
mg PRON - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
produced VERB - O
similar ADJ - O
results NOUN - O
to ADP - O
an DET - O
FDC NNP - B-ORG
of ADP - O
5 CD - B-CARDINAL
mg PRON - O
amlodipine NOUN - O
camsylate/50 NOUN - O
mg NOUN - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
treatment NOUN - O
with ADP - O
respect NOUN - O
to ADP - O
the DET - O
PK NNP - B-ORG
parameters NOUN - O
of ADP - O
amlodipine NOUN - O
and CCONJ - O
losartan NOUN - O
based VERB - O
on ADP - O
Cmax NNP - B-ORG
and CCONJ - O
AUC0-t NNP - B-ORG
values NOUN - O
. PUNCT - O

The DET - O
amlodipine NOUN - O
besylate NOUN - O
/ SYM - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
combination NOUN - O
was VERB - O
well ADV - O
tolerated VERB - O
by ADP - O
healthy ADJ - O
male ADJ - O
subjects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

E-3174 PROPN - O
is VERB - O
responsible ADJ - O
for ADP - O
most ADJ - O
of ADP - O
the DET - O
pharmacological ADJ - O
effects NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
, PUNCT - O
and CCONJ - O
its ADJ - O
long ADJ - O
half ADJ - O
- PUNCT - O
life NOUN - O
contributes VERB - O
to ADP - O
the DET - O
extended ADJ - O
duration NOUN - O
of ADP - O
action NOUN - O
of ADP - O
the DET - O
drug NOUN - O
. PUNCT - O

In ADP - O
mild ADJ - O
to PART - O
moderate VERB - O
hypertension NOUN - O
, PUNCT - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
has VERB - O
similar ADJ - O
efficacy NOUN - O
to PART - O
enalapril VERB - O
, PUNCT - O
atenolol NOUN - O
and CCONJ - O
felodipine NOUN - O
extended VERB - O
release NOUN - O
. PUNCT - O

When ADV - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
is VERB - O
combined VERB - O
with ADP - O
hydrochlorothiazide NOUN - O
there ADV - O
is VERB - O
a DET - O
further ADJ - O
reduction NOUN - O
in ADP - O
blood NOUN - O
pressure NOUN - O
. PUNCT - O

The DET - O
overall ADJ - O
rate NOUN - O
of ADP - O
patient ADJ - O
withdrawal NOUN - O
from ADP - O
therapy NOUN - O
due ADP - O
to PART - O
adverse ADJ - O
experiences NOUN - O
with ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
is VERB - O
lower ADJ - O
( PUNCT - O
2.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
than ADP - O
that DET - O
of ADP - O
placebo NOUN - O
( PUNCT - O
3.7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

A DET - O
number NOUN - O
of ADP - O
areas NOUN - O
concerning VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
remain VERB - O
to PART - O
be VERB - O
clarified VERB - O
. PUNCT - O

Postmarketing NOUN - O
surveillance NOUN - O
has VERB - O
shown VERB - O
that ADP - O
angioedema NOUN - O
, PUNCT - O
a DET - O
rare ADJ - O
but CCONJ - O
life NOUN - O
- PUNCT - O
threatening VERB - O
adverse ADJ - O
effect NOUN - O
of ADP - O
ACE NNP - B-ORG
inhibitors NOUN - O
, PUNCT - O
also ADV - O
occurs VERB - O
with ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
. PUNCT - O

Further ADJ - O
data NOUN - O
are VERB - O
needed VERB - O
on ADP - O
the DET - O
use NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
renal ADJ - O
impairment NOUN - O
before ADP - O
accepting VERB - O
the DET - O
recommendation NOUN - O
that ADJ - O
dosage NOUN - O
adjustment NOUN - O
is VERB - O
not ADV - O
necessary ADJ - O
. PUNCT - O

The DET - O
pharmacokinetics NOUN - O
and CCONJ - O
pharmacodynamics NOUN - O
of ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
hepatic ADJ - O
disease NOUN - O
also ADV - O
require VERB - O
further ADJ - O
investigation NOUN - O
. PUNCT - O

Losartan JJ - B-ORG
potassium NOUN - O
increases VERB - O
uric ADJ - O
acid NOUN - O
secretion NOUN - O
and CCONJ - O
lowers NOUN - O
plasma VERB - O
uric ADJ - O
acid NOUN - O
levels NOUN - O
, PUNCT - O
which ADJ - O
may VERB - O
be VERB - O
of ADP - O
benefit NOUN - O
when ADV - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
is VERB - O
combined VERB - O
with ADP - O
a DET - O
thiazide NOUN - O
diuretic ADJ - O
, PUNCT - O
but CCONJ - O
which ADJ - O
may VERB - O
otherwise ADV - O
lead VERB - O
to ADP - O
uric ADJ - O
acid NOUN - O
stone NOUN - O
formation NOUN - O
and CCONJ - O
possibly ADV - O
to ADP - O
nephropathy ADJ - O
. PUNCT - O

Such ADJ - O
data NOUN - O
on ADP - O
losartan JJ - B-MEDICINE
potassium NN - I-MEDICINE
are VERB - O
not ADV - O
currently ADV - O
available ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Ingestion NOUN - O
of ADP - O
Exopolymers PROPN - O
from ADP - O
Aureobasidium PROPN - O
pullulans NOUN - O
Reduces PROPN - O
the DET - O
Duration PROPN - O
of ADP - O
Cold NNP - B-MEDICINE
and CC - I-MEDICINE
Flu NNP - I-MEDICINE
Symptoms PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

OTC PROPN - O
product NOUN - O
: PUNCT - O
Zicam NNP - B-ORG
Cold NNP - I-ORG
and CCONJ - O
Flu NNP - B-ORG
Medicated NNP - I-ORG
Spoons NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Casein NNP - B-MEDICINE
is VERB - O
sensitive ADJ - O
to ADP - O
thermal ADJ - O
exposure NOUN - O
( PUNCT - O
DSC NNP - B-PERSON
) PUNCT - O
, PUNCT - O
and CCONJ - O
no DET - O
significant ADJ - O
change NOUN - O
in ADP - O
the DET - O
casein NN - B-MEDICINE
was VERB - O
observed VERB - O
during ADP - O
acidification NOUN - O
( PUNCT - O
FTIR NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Casein NNP - B-MEDICINE
protein NOUN - O
had VERB - O
a DET - O
most ADV - O
likely ADJ - O
and CCONJ - O
likely ADJ - O
beneficial ADJ - O
effect NOUN - O
on ADP - O
countermovement NOUN - O
- PUNCT - O
jump NOUN - O
recovery NOUN - O
at ADP - O
12 CD - B-CARDINAL
and CCONJ - O
36 CD - B-CARDINAL
  SPACE - O
h DET - O
postmatch NOUN - O
( PUNCT - O
CP PROPN - O
-1.6 PROPN - O
; PUNCT - O
±1.2 PUNCT - O
% NOUN - O
vs ADP - O
CON PROPN - O
-6.6 PROPN - O
; PUNCT - O
±1.7 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
-4.1 NOUN - O
; PUNCT - O
±2.3 ADP - O
% NOUN - O
vs ADP - O
-0.4 PROPN - O
; PUNCT - O
±1.1 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

High PROPN - O
Internal PROPN - O
Phase PROPN - O
Emulsion PROPN - O
Gels NOUN - O
Stabilized VERB - O
by ADP - O
Natural PROPN - O
Casein NNP - B-MEDICINE
peptides NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Reassembling VERB - O
of ADP - O
Alkali PROPN - O
- PUNCT - O
Treated PROPN - O
Casein NNP - B-MEDICINE
Micelles PROPN - O
by ADP - O
Microbial NNP - B-ORG
Transglutaminase NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Casein NN - B-MEDICINE
kinase PROPN - O
II CD - B-ORG
- PUNCT - O
dependent ADJ - O
phosphorylation NOUN - O
of ADP - O
DNA NOUN - O
topoisomerase NOUN - O
II NNP - B-ORG
suppresses VERB - O
the DET - O
effect NOUN - O
of ADP - O
a DET - O
catalytic ADJ - O
topo NOUN - O
II CD - B-ORG
inhibitor NOUN - O
, PUNCT - O
ICRF-193 PROPN - O
, PUNCT - O
in ADP - O
fission NOUN - O
yeast NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Protein NOUN - O
14 NUM - O
- PUNCT - O
3 NUM - O
- PUNCT - O
3ε NOUN - O
Regulates PROPN - O
Cell PROPN - O
Proliferation PROPN - O
and CCONJ - O
Casein NNP - B-MEDICINE
Synthesis PROPN - O
via ADP - O
PI3K NNP - B-ORG
- PUNCT - O
mTOR PROPN - O
Pathway PROPN - O
in ADP - O
Dairy PROPN - O
Cow PROPN - O
Mammary PROPN - O
Epithelial PROPN - O
Cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Casein NN - B-MEDICINE
mixture NOUN - O
preparation NOUN - O
( PUNCT - O
CMP PROPN - O
) PUNCT - O
, PUNCT - O
one CD - B-CARDINAL
of ADP - O
the DET - O
permissible ADJ - O
substances NOUN - O
specified VERB - O
in ADP - O
the DET - O
regulations NOUN - O
, PUNCT - O
was VERB - O
isolated VERB - O
from ADP - O
organic ADJ - O
milk NOUN - O
using VERB - O
citric ADJ - O
acid NOUN - O
and CCONJ - O
dibasic ADJ - O
potassium NOUN - O
phosphate ADJ - O
for ADP - O
organic ADJ - O
processed VERB - O
foods NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Casein NN - B-MEDICINE
kinase PROPN - O
II NNP - B-ORG
- PUNCT - O
mediated VERB - O
phosphorylation NOUN - O
of ADP - O
lipin NOUN - O
1β NUM - O
phosphatidate ADJ - O
phosphatase NOUN - O
at ADP - O
Ser-285 NNP - B-GPE
and CCONJ - O
Ser-287 NNP - B-GPE
regulates VERB - O
its ADJ - O
interaction NOUN - O
with ADP - O
14 CD - B-CARDINAL
- HYPH - I-CARDINAL
3 CD - I-CARDINAL
- HYPH - I-CARDINAL
3β CD - I-CARDINAL
protein NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Inhibition NOUN - O
of ADP - O
Casein NNP - B-MEDICINE
Kinase NNP - I-FAC
1 CD - I-FAC
Alpha NNP - I-FAC
in ADP - O
Acute NNP - B-GPE
Myeloid NNP - I-GPE
Leukemia NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Casein NNP - B-MEDICINE
Hydrolysate PROPN - O
Does VERB - O
Not ADV - O
Enhance VERB - O

Compared VERB - O
With ADP - O
the DET - O
Parent PROPN - O
Intact PROPN - O
Casein NNP - B-MEDICINE
When ADV - O
Fed NNP - B-ORG
to ADP - O
Growing VBG - B-PERSON
Pigs NNPS - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Casein NN - B-MEDICINE
micelles NOUN - O
are VERB - O
~200 NUM - O
  SPACE - O
nm NUM - O
electronegative ADJ - O
particles NOUN - O
that ADJ - O
constitute VERB - O
80 CD - B-CARDINAL
  SPACE - O
wt% NUM - O
of ADP - O
the DET - O
milk NOUN - O
proteins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Human PROPN - O
Milk PROPN - O
Casein NNP - B-MEDICINE
and CCONJ - O
Whey PROPN - O
Protein PROPN - O
and CCONJ - O
Infant NNP - B-ORG
Body NNP - I-ORG
Composition NNP - I-ORG
over ADP - O
the DT - B-DATE
First JJ - I-DATE
12 CD - I-DATE
Months NNS - I-DATE
of ADP - O
Lactation NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Compared VERB - O
to ADP - O
Casein NNP - B-MEDICINE
and CCONJ - O
Soy NNP - B-PERSON
Protein NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Casein NN - B-MEDICINE
micelles NOUN - O
are VERB - O
present ADJ - O
in ADP - O
bovine ADJ - O
milk NOUN - O
as ADP - O
colloidal ADJ - O
particles NOUN - O
with ADP - O
diameters NOUN - O
of ADP - O
20 CD - B-CARDINAL
- SYM - I-CARDINAL
600 CD - I-CARDINAL
nm NOUN - O
, PUNCT - O
which ADJ - O
are VERB - O
complex ADJ - O
macromolecular ADJ - O
assemblies NOUN - O
composed VERB - O
of ADP - O
four CD - B-CARDINAL
distinct ADJ - O
types NOUN - O
of ADP - O
casein NN - B-MEDICINE
and CCONJ - O
colloidal ADJ - O
calcium NOUN - O
phosphate NOUN - O
( PUNCT - O
CCP NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Storage NOUN - O
of ADP - O
Micellar NNP - B-ORG
Casein NNP - I-MEDICINE
Powders NNPS - I-ORG
with ADP - O
and CCONJ - O
without ADP - O
Lactose PROPN - O
: PUNCT - O
Consequences NOUN - O
on ADP - O
Color NOUN - O
, PUNCT - O
Solubility PROPN - O
, PUNCT - O
and CCONJ - O
Chemical NNP - B-ORG
Modifications NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Casein NNP - B-MEDICINE
Phosphopeptide PROPN - O
- PUNCT - O
Amorphous PROPN - O
Calcium PROPN - O
Phosphate PROPN - O
and CCONJ - O
Calcium PROPN - O
Sodium PROPN - O
Phosphosilicate PROPN - O
on ADP - O
Demineralized PROPN - O
Enamel PROPN - O
Lesions PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
for ADP - O
juvenile ADJ - O
myoclonic ADJ - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
was VERB - O
stopped VERB - O
and CCONJ - O
ocular ADJ - O
hypotensive NOUN - O
therapy NOUN - O
with ADP - O
a DET - O
topical ADJ - O
cycloplegic NOUN - O
and CCONJ - O
corticosteroids NOUN - O
were VERB - O
started VERB - O
, PUNCT - O
resolving VERB - O
ciliochoroidal ADJ - O
effusion NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
is VERB - O
an DET - O
anticonvulsant ADJ - O
drug NOUN - O
also ADV - O
prescribed VERB - O
for ADP - O
migraine NOUN - O
prophylaxis NOUN - O
that ADJ - O
acts VERB - O
through ADP - O
several ADJ - O
mechanisms NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

Topiramate NN - B-MEDICINE
did VERB - O
not ADV - O
affect VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
food NOUN - O
intake NOUN - O
. PUNCT - O

Topiramate NN - B-MEDICINE
did VERB - O
not ADV - O
modify VERB - O
liver NOUN - O
and CCONJ - O
adipose VERB - O
tissue NOUN - O
histology NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacometric NNP - B-ORG
Bridging NNP - I-ORG
Approach NNP - I-ORG
for ADP - O
U.S. NNP - B-ORG
Food NNP - I-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
Approval NNP - I-ORG
and CC - I-ORG
Identification NNP - I-ORG
of IN - I-ORG
Topiramate NNP - I-MEDICINE
Dosing NNP - I-ORG
Regimen NNPS - I-ORG
for IN - I-ORG
Pediatric NNP - I-ORG
Patients NNPS - I-ORG
2 CD - B-DATE
- SYM - I-DATE
9 CD - I-DATE
Years NNS - I-DATE
of ADP - O
Age PROPN - O
With ADP - O
Epilepsy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
for ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Dually RB - I-ORG
Dependent NNP - I-ORG
on IN - I-ORG
Opiates NNP - I-ORG
and CC - I-ORG
Cocaine NNP - I-ORG
: PUNCT - O
A DET - O
Single PROPN - O
- PUNCT - O
center NOUN - O
Placebo NNP - B-GPE
- PUNCT - O
controlled VERB - O
Trial NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NNP - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
and CCONJ - O
lorazepam PROPN - O
( PUNCT - O
LZP NNP - B-ORG
) PUNCT - O
are VERB - O
two CD - B-CARDINAL
examples NOUN - O
of ADP - O
frequently ADV - O
prescribed VERB - O
medications NOUN - O
that ADJ - O
are VERB - O
associated VERB - O
with ADP - O
a DET - O
high ADJ - O
incidence NOUN - O
of ADP - O
cognitive ADJ - O
impairment NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
factors NOUN - O
that ADJ - O
underlie VERB - O
interindividual ADJ - O
differences NOUN - O
in ADP - O
side NOUN - O
effect NOUN - O
profiles NOUN - O
have VERB - O
not ADV - O
been VERB - O
fully ADV - O
characterized VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
- PUNCT - O
Associated VERB - O
Renal PROPN - O
Tubular PROPN - O
Acidosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
and CCONJ - O
flunarizine NOUN - O
administered VERB - O
orally ADV - O
for ADP - O
a DET - O
short ADJ - O
duration NOUN - O
can VERB - O
effectively ADV - O
improve VERB - O
the DET - O
pain NOUN - O
threshold NOUN - O
and CCONJ - O
CS NNP - B-ORG
of ADP - O
patients NOUN - O
with ADP - O
migraine NOUN - O
, PUNCT - O
and CCONJ - O
efficiently ADV - O
relieve VERB - O
allodynia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Microseizures NOUN - O
Induced VERB - O
by ADP - O
Topiramate NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
is VERB - O
more ADV - O
effective ADJ - O
than ADP - O
acetazolamide ADV - O
at ADP - O
lowering VERB - O
intracranial ADJ - O
pressure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Re ADP - O
: PUNCT - O
Nephrolithiasis NOUN - O
and CCONJ - O
Nephrocalcinosis PROPN - O
from ADP - O
Topiramate NNP - B-MEDICINE
Therapy PROPN - O
in ADP - O
Children PROPN - O
with ADP - O
Epilepsy NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
inhibits VERB - O
renal ADJ - O
carbonic ADJ - O
anhydrase NOUN - O
, PUNCT - O
which ADJ - O
can VERB - O
lead VERB - O
to ADP - O
renal ADJ - O
tubular ADJ - O
acidosis NOUN - O
and CCONJ - O
hypercalciuria NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
induced VERB - O
renal ADJ - O
tubular ADJ - O
acidosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
- PUNCT - O
induced VERB - O
Neuropathy NNP - B-ORG
Mimicking NNP - I-ORG
Carpal NNP - I-ORG
Tunnel NNP - I-ORG
Syndrome NNP - I-ORG
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NNP - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
is VERB - O
the DET - O
main ADJ - O
antiepileptic ADJ - O
drug NOUN - O
used VERB - O
for ADP - O
the DET - O
control NOUN - O
of ADP - O
partial ADJ - O
and CCONJ - O
generalized VERB - O
seizures NOUN - O
in ADP - O
both DET - O
adults NOUN - O
and CCONJ - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recurrent NNP - B-ORG
Admissions NNP - I-ORG
for ADP - O
Hypothermia NNP - B-ORG
From IN - I-ORG
Concomitant NNP - I-ORG
Topiramate NNP - I-MEDICINE
and CCONJ - O
Phenobarbital PROPN - O
: PUNCT - O
A DET - O
Case PROPN - O
Report PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
modulates NOUN - O
trigeminal ADJ - O
pain NOUN - O
processing NOUN - O
in ADP - O
thalamo NOUN - O
- PUNCT - O
cortical ADJ - O
networks NOUN - O
in ADP - O
humans NOUN - O
after ADP - O
single ADJ - O
dose NOUN - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NNP - B-MEDICINE
Reduces PROPN - O
Aortic PROPN - O
Cross PROPN - O
- PUNCT - O
Clamping PROPN - O
- PUNCT - O
Induced VERB - O
Lung PROPN - O
Injury PROPN - O
in ADP - O
Male NNP - B-ORG
Rats NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Topiramate NN - B-MEDICINE
's PART - O
effectiveness NOUN - O
on ADP - O
weight NOUN - O
reduction NOUN - O
in ADP - O
overweight ADJ - O
/ SYM - O
obese ADJ - O
persons NOUN - O
with ADP - O
schizophrenia NOUN - O
: PUNCT - O
study NOUN - O
protocol NOUN - O
for ADP - O
a DET - O
randomized ADJ - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Topiramate JJ - B-MEDICINE
add VERB - O
- PUNCT - O
on PART - O
treatment NOUN - O
associated VERB - O
with ADP - O
normalization NOUN - O
of ADP - O
prolactin ADJ - O
levels NOUN - O
in ADP - O
a DET - O
patient NOUN - O
with ADP - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Healthcare NNP - B-ORG
Provider PROPN - O
Discrimination PROPN - O
toward ADP - O
Pregnant PROPN - O
Women PROPN - O
with ADP - O
Rifampin NNP - B-MEDICINE
- HYPH - I-ORG
Resistant NNP - I-ORG
Tuberculosis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Role PROPN - O
of ADP - O
Rifampin NNP - B-MEDICINE
against ADP - O
Staphylococcal NNP - B-ORG
Biofilm NNP - I-ORG
Infections NNP - I-ORG

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
resistance NOUN - O
is VERB - O
a DET - O
critical ADJ - O
concern NOUN - O
for ADP - O
tuberculosis NOUN - O
treatment NOUN - O
. PUNCT - O

Rifampin NNP - B-MEDICINE
quinone NOUN - O
- PUNCT - O
treated VERB - O
mycobacteria NOUN - O
also ADV - O
had VERB - O
cross ADJ - O
- ADJ - O
resistance NOUN - O
to ADP - O
other ADJ - O
rifamycin NOUN - O
class NOUN - O
drugs NOUN - O
, PUNCT - O
including VERB - O
rifabutin NOUN - O
and CCONJ - O
rifapentine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Synergistic ADJ - O
Antimicrobial PROPN - O
Activity PROPN - O
of ADP - O
Colistin PROPN - O
in ADP - O
Combination PROPN - O
with ADP - O
Rifampin NNP - B-MEDICINE
and CCONJ - O
Azithromycin NNP - B-ORG
against ADP - O
Escherichia NNP - B-ORG
coli ADJ - O
Producing VERB - O
MCR-1 PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Dose NNP - B-ORG
- HYPH - I-ORG
Dependent NNP - I-ORG
Synergistic NNP - I-ORG
Interactions NNPS - I-ORG
of ADP - O
Colistin NNP - B-GPE
with ADP - O
Rifampin NNP - B-MEDICINE
, PUNCT - O
Meropenem NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Tigecycline NN - B-PERSON
against ADP - O
Carbapenem NNP - B-ORG
- HYPH - I-ORG
Resistant NNP - I-ORG
Klebsiella NNP - I-ORG
pneumoniae VBD - I-ORG
Biofilms NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Topical ADJ - O
rifampin NN - B-MEDICINE
powder NOUN - O
for ADP - O
orthopedic ADJ - O
trauma NOUN - O
part NOUN - O
I PRON - O
: PUNCT - O
Rifampin NN - B-MEDICINE
powder NOUN - O
reduces VERB - O
recalcitrant ADJ - O
infection NOUN - O
in ADP - O
a DET - O
delayed VERB - O
treatment NOUN - O
musculoskeletal NOUN - O
trauma NOUN - O
model NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Colistin NNP - B-PERSON
Monotherapy NNP - I-PERSON
Versus NNP - I-PERSON
Colistin NNP - I-PERSON
and CCONJ - O
Rifampin NNP - B-MEDICINE
Combination NNP - I-ORG
Therapy NNP - I-ORG
in ADP - O
Pneumonia NNP - B-GPE

-DOCSTART- -X- - O

Adjuvant ADJ - O
Use PROPN - O
of ADP - O
Rifampin NNP - B-MEDICINE
for ADP - O
Refractory PROPN - O
Intrahepatic PROPN - O
Cholestasis PROPN - O
of ADP - O
Pregnancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Diverse NNP - B-ORG
Clinical NNP - I-ORG
Isolates NNPS - I-ORG
of IN - I-ORG
Mycobacterium NNP - I-ORG
tuberculosis NOUN - O
Develop NNP - B-ORG
Macrophage NNP - I-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Rifampin NNP - I-MEDICINE
Tolerance NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
Oritavancin PROPN - O
Combinations PROPN - O
with ADP - O
Rifampin NNP - B-MEDICINE
, PUNCT - O
Gentamicin NNP - B-GPE
, PUNCT - O
or CCONJ - O
Linezolid NNP - B-ORG
against ADP - O
Prosthetic JJ - B-ORG
Joint NNP - I-ORG
Infection NNP - I-ORG
- HYPH - I-ORG
Associated NNP - I-ORG

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
is VERB - O
a DET - O
powerful ADJ - O
antibiotic NOUN - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
biofilm NOUN - O
- PUNCT - O
forming VERB - O
bacteria NOUN - O
with ADP - O
studies NOUN - O
supporting VERB - O
its ADJ - O
use NOUN - O
in ADP - O
PMMA PROPN - O
cement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
and CCONJ - O
tobramycin ADJ - O
combination NOUN - O
with ADP - O
PMMA NNP - B-ORG
antibiotic ADJ - O
cement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
co NOUN - O
- NOUN - O
administration NOUN - O
increased VERB - O
M3 NNP - B-ORG
Cmax NNP - I-ORG
, PUNCT - O
ss PROPN - O
by ADP - O
53 CD - B-PERCENT
% NN - I-PERCENT
while ADP - O
M5 NNP - B-ORG
Cmax NNP - I-ORG
, PUNCT - O
ss PROPN - O
remained VERB - O
unchanged ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
pretreatment NOUN - O
was VERB - O
employed VERB - O
to PART - O
increase VERB - O
persister ADJ - O
formation NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
resulting VERB - O
cells NOUN - O
were VERB - O
exposed VERB - O
to ADP - O
a DET - O
high ADJ - O
concentration NOUN - O
of ADP - O
ampicillin NOUN - O
( PUNCT - O
10× NUM - O
MIC NNP - B-ORG
) PUNCT - O
to PART - O
remove VERB - O
nonpersisters NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Characterization NOUN - O
of ADP - O
Mutations PROPN - O
Conferring PROPN - O
Resistance PROPN - O
to ADP - O
Rifampin NNP - B-MEDICINE
in ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
Clinical NNP - B-PERSON
Strains NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Debridement PROPN - O
and CCONJ - O
Implant PROPN - O
Retention PROPN - O
) PUNCT - O
and CCONJ - O
Impact NNP - B-ORG
of IN - I-ORG
Rifampin NNP - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Four CD - B-DATE
Months NNPS - I-DATE
of ADP - O
Rifampin NNP - B-MEDICINE
or CCONJ - O
Nine NNP - B-ORG
Months NNPS - I-ORG
of ADP - O
Isoniazid PROPN - O
for ADP - O
Latent PROPN - O
Tuberculosis PROPN - O
in ADP - O
Adults NNPS - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NNP - B-MEDICINE
PB NNP - I-PERSON
was VERB - O
positively ADV - O
correlated VERB - O
with ADP - O
its ADJ - O
plasma NOUN - O
concentration NOUN - O
( PUNCT - O
P NOUN - O
value NOUN - O
= SYM - O
0.0051 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Side PROPN - O
Effects PROPN - O
of ADP - O
Rifampin NNP - B-MEDICINE
versus ADP - O
Isoniazid PROPN - O
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Mutations NOUN - O
of ADP - O
rpob VERB - O
Gene NNP - B-PERSON
Associated NNP - I-PERSON
with ADP - O
Rifampin NNP - B-MEDICINE
Resistance NNP - I-ORG
among IN - I-ORG
Mycobacterium NNP - I-ORG
Tuberculosis NNP - I-ORG
Isolated VBN - I-ORG
in ADP - O
Tuberculosis NNP - B-ORG
Regional NNP - I-ORG
Reference NNP - I-ORG
Laboratory NNP - I-ORG
in ADP - O
Northeast NNP - B-LOC
of ADP - O
Iran NNP - B-GPE
during ADP - O
2015 CD - B-DATE
- SYM - I-DATE
2016 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Rifampin NNP - B-MEDICINE
- PUNCT - O
Isoniazid PROPN - O
- PUNCT - O
Containing PROPN - O
Antituberculosis PROPN - O
Therapy PROPN - O
on ADP - O
Efavirenz PROPN - O
Pharmacokinetics PROPN - O
in ADP - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Children NOUN - O
3 NUM - O
to ADP - O
14 NUM - O
Years NOUN - O
Old PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
elution NOUN - O
from ADP - O
the DET - O
grafts NOUN - O
was VERB - O
studied VERB - O
by ADP - O
spectroscopic ADJ - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Validation NOUN - O
of ADP - O
the DT - B-ORG
FluoroType NNP - I-ORG
MTBDR NNP - I-ORG
Assay NNP - I-ORG
for IN - I-ORG
Detection NNP - I-ORG
of IN - I-ORG
Rifampin NNP - I-MEDICINE
and CCONJ - O
Isoniazid PROPN - O
Resistance PROPN - O
in ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
Complex NNP - B-ORG
Isolates NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Rifampin NN - B-MEDICINE
resistance NOUN - O
has VERB - O
dampened VERB - O
the DET - O
existing VERB - O
efforts NOUN - O
being VERB - O
made VERB - O
to PART - O
control VERB - O
the DET - O
global ADJ - O
crisis NOUN - O
of ADP - O
Tuberculosis NNP - B-ORG
and CCONJ - O
antimicrobial ADJ - O
resistance NOUN - O
in ADP - O
general ADJ - O
. PUNCT - O

Previous ADJ - O
studies NOUN - O
that ADJ - O
attempted VERB - O
to PART - O
provide VERB - O
insights NOUN - O
into ADP - O
the DET - O
structural ADJ - O
mechanism NOUN - O
of ADP - O
Rifampin NNP - B-MEDICINE
resistance NOUN - O
did VERB - O
not ADV - O
utilize VERB - O
the DET - O
X NOUN - O
- NOUN - O
ray NOUN - O
crystal NOUN - O
structure NOUN - O
of ADP - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
RNA NNP - B-ORG
polymerase VERB - O
due ADP - O
to ADP - O
its ADJ - O
unavailability NOUN - O
. PUNCT - O

We PRON - O
provide VERB - O
an DET - O
atomistic ADJ - O
mechanism NOUN - O
of ADP - O
Rifampin NNP - B-MEDICINE
resistance NOUN - O
in ADP - O
a DET - O
single ADJ - O
active ADJ - O
site NOUN - O
mutating NOUN - O
Mycobacterium PROPN - O
tuberculosis NOUN - O
RNA NNP - B-ORG
polymerase NOUN - O
, PUNCT - O
using VERB - O
a DET - O
recently ADV - O
resolved VERB - O
crystal NOUN - O
structure NOUN - O
. PUNCT - O

We PRON - O
also ADV - O
unravel VERB - O
the DET - O
structural ADJ - O
interplay NOUN - O
of ADP - O
this DET - O
mutation NOUN - O
upon ADP - O
co ADJ - O
- ADJ - O
binding ADJ - O
of ADP - O
Rifampin NNP - B-MEDICINE
with ADP - O
a DET - O
novel ADJ - O
inhibitor NOUN - O
, PUNCT - O
D NNP - B-ORG
- HYPH - I-ORG
AAP1 NNP - I-ORG
. PUNCT - O

Mutation NOUN - O
distorted VERB - O
the DET - O
overall ADJ - O
conformational ADJ - O
landscape NOUN - O
of ADP - O
Mycobacterium NNP - B-ORG
tuberculosis NOUN - O
RNA NNP - B-ORG
polymerase NOUN - O
, PUNCT - O
reduced VERB - O
binding VERB - O
affinity NOUN - O
of ADP - O
Rifampin NNP - B-MEDICINE
and CCONJ - O
shifted VERB - O
the DET - O
overall ADJ - O
residue NOUN - O
interaction NOUN - O
network NOUN - O
of ADP - O
the DET - O
enzyme ADJ - O
upon ADP - O
binding VERB - O
of ADP - O
only ADV - O
Rifampin NNP - B-MEDICINE
. PUNCT - O

Interestingly ADV - O
, PUNCT - O
co VERB - O
- ADJ - O
binding ADJ - O
with ADP - O
DAAP1 NNP - B-GPE
, PUNCT - O
though ADP - O
impacted VERB - O
by ADP - O
the DET - O
mutation NOUN - O
, PUNCT - O
exhibited VERB - O
improved VERB - O
Rifampin NNP - B-MEDICINE
binding VERB - O
interactions NOUN - O
amidst ADP - O
a DET - O
distorted VERB - O
residue NOUN - O
interaction NOUN - O
network NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
cases NOUN - O
of ADP - O
difficult ADJ - O
airway NOUN - O
are VERB - O
illustrated VERB - O
where ADV - O
anaesthetising VERB - O
upper ADJ - O
airway NOUN - O
with ADP - O
nebulisation NOUN - O
with ADP - O
4 CD - B-PERCENT
% NN - I-PERCENT
lignocaine NOUN - O
( PUNCT - O
Xylocaine NNP - B-MEDICINE
™ NNP - I-ORG
) PUNCT - O
or CCONJ - O
2 CD - B-PERCENT
% NN - I-PERCENT
lignocaine NOUN - O
( PUNCT - O
Xylocaine NNP - B-MEDICINE
™ NNP - I-ORG
) PUNCT - O
jelly ADV - O
resulted VERB - O
in ADP - O
stridor NOUN - O
and CCONJ - O
upper ADJ - O
airway NOUN - O
obstruction NOUN - O
. PUNCT - O

This DET - O
is VERB - O
the DET - O
first JJ - B-ORDINAL
reported VERB - O
case NOUN - O
of ADP - O
airway NOUN - O
obstruction NOUN - O
after ADP - O
lignocaine NOUN - O
( PUNCT - O
Xylocaine NNP - B-MEDICINE
™ NNP - I-ORG
) PUNCT - O
jelly ADV - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
compare VERB - O
preprocedure ADJ - O
Diclofenac NNP - B-ORG
suppository NOUN - O
and CCONJ - O
Xylocaine NNP - B-MEDICINE
gel NOUN - O
with ADP - O
Xylocaine NNP - B-MEDICINE
gel NOUN - O
only ADV - O
in ADP - O
patients NOUN - O
undergoing VERB - O
transrectal ADJ - O
ultrasound NOUN - O
( PUNCT - O
TRUS)-guided VERB - O
biopsy NOUN - O
of ADP - O
prostate NOUN - O
for ADP - O
pain NOUN - O
. PUNCT - O

Group PROPN - O
A PROPN - O
included VERB - O
those DET - O
patients NOUN - O
who NOUN - O
received VERB - O
Diclofenac NNP - B-ORG
suppository NOUN - O
2 CD - B-TIME
hours NNS - I-TIME
before ADV - O
in ADP - O
combination NOUN - O
with ADP - O
10 CD - B-CARDINAL
mL NOUN - O
of ADP - O
2 CD - B-PERCENT
% NN - I-PERCENT
Xylocaine NN - B-MEDICINE
gel NOUN - O
5 CD - B-TIME
minutes NNS - I-TIME
before ADP - O
biopsy NOUN - O
. PUNCT - O

Group PROPN - O
B PROPN - O
received VERB - O
Xylocaine NNP - B-MEDICINE
gel NOUN - O
only ADV - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
trigonal ADJ - O
block NOUN - O
consists VERB - O
of ADP - O
injecting VERB - O
0.25 CD - B-PERCENT
% NN - I-PERCENT
bupivacaine NOUN - O
with ADP - O
1.0 CD - B-PERCENT
% NN - I-PERCENT
Xylocaine NNP - B-MEDICINE
into ADP - O
the DET - O
anterior NOUN - O
vagina NOUN - O
under ADP - O
the DET - O
trigone NOUN - O
under ADP - O
cystoscopic NOUN - O
guidance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NN - B-MEDICINE
alone ADV - O
and CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
oclacitinib NOUN - O
increased VERB - O
mean PROPN - O
STT-1 PROPN - O
values NOUN - O
by ADP - O
11.84 CD - B-CARDINAL
  SPACE - O
± PUNCT - O
  SPACE - O
5.2 NUM - O
and CCONJ - O
12.46 CD - B-CARDINAL
  SPACE - O
± PUNCT - O
  SPACE - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
combined VERB - O
with ADP - O
corticosteroids NOUN - O
effectively ADV - O
improved VERB - O
the DET - O
outcome NOUN - O
of ADP - O
a DET - O
cohort NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
immune ADV - O
- PUNCT - O
mediated VERB - O
necrotising ADJ - O
myopathy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
, PUNCT - O
a DET - O
major ADJ - O
immunosuppressant NOUN - O
used VERB - O
after ADP - O
transplantation NOUN - O
, PUNCT - O
is VERB - O
associated VERB - O
with ADP - O
large ADJ - O
interindividual ADJ - O
variation NOUN - O
involving VERB - O
genetic ADJ - O
polymorphisms NOUN - O
in ADP - O
metabolic NOUN - O
processes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Immunomics NOUN - O
of ADP - O
Renal NNP - B-ORG
Allograft NNP - I-ORG
Acute NNP - I-ORG
T PROPN - O
Cell NNP - B-ORG
- HYPH - I-ORG
Mediated NNP - I-ORG
Rejection NNP - I-ORG
Biopsies NNPS - I-ORG
of IN - I-ORG
Tacrolimus- NNP - I-ORG
and CC - I-ORG
Belatacept PROPN - O
- PUNCT - O
Treated VERB - O
Patients PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
, PUNCT - O
an DET - O
immunosuppressant NOUN - O
used VERB - O
in ADP - O
AChR NNP - B-ORG
- HYPH - I-ORG
MG NNP - I-ORG
and CCONJ - O
transplantation NOUN - O
patients NOUN - O
, PUNCT - O
inhibits VERB - O
T PROPN - O
cell NOUN - O
responses NOUN - O
through ADP - O
interference NOUN - O
with ADP - O
IL-2 PROPN - O
transcription NOUN - O
. PUNCT - O

Tacrolimus NNP - B-MEDICINE
also ADV - O
inhibits VERB - O
pathogenic ADJ - O
Th17 NOUN - O
cells NOUN - O
coproducing VERB - O
IL-17 NNP - B-ORG
and CCONJ - O
IFN NNP - B-ORG
- HYPH - I-ORG
γ NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NN - B-MEDICINE
is VERB - O
the DET - O
mainstay NOUN - O
of ADP - O
immunosuppression NOUN - O
in ADP - O
renal ADJ - O
transplantation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Conversion NOUN - O
from ADP - O
Twice NNP - B-ORG
- HYPH - I-ORG
Daily NNP - I-ORG
Prograf PROPN - O
® NOUN - O
to ADP - O
Once ADV - O
- PUNCT - O
Daily PROPN - O
Advagraf PROPN - O
® NOUN - O
in ADP - O
Multi NNP - B-ORG
- PUNCT - O
ethnic ADJ - O
Asian NNP - B-NORP
Adult PROPN - O
Renal ADJ - O
Transplant NOUN - O
Recipients PROPN - O
With ADP - O
or CCONJ - O
Without ADP - O
Concomitant PROPN - O
Use PROPN - O
of ADP - O
Diltiazem NNP - B-PERSON
: PUNCT - O
Impact NOUN - O
of ADP - O
CYP3A5 PROPN - O
and CCONJ - O
MDR1 PROPN - O
Genetic NNP - B-PERSON
Polymorphisms NNPS - I-PERSON
on ADP - O
Tacrolimus NNP - B-MEDICINE
Exposure NN - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetics NNPS - I-ORG
of IN - I-ORG
Tacrolimus NNP - I-MEDICINE
in ADP - O
Transplant PROPN - O
Recipients PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NN - B-MEDICINE
and CCONJ - O
mycophenolic ADJ - O
acid NOUN - O
dosing NOUN - O
after ADP - O
renal ADJ - O
transplantation NOUN - O
is VERB - O
individualized VERB - O
through ADP - O
therapeutic ADJ - O
drug NOUN - O
monitoring NOUN - O
( PUNCT - O
TDM NNP - B-ORG
) PUNCT - O
. PUNCT - O

Tacrolimus NN - B-MEDICINE
and CCONJ - O
mycophenolic ADJ - O
acid NOUN - O
dosing VERB - O
recommendation NOUN - O
differences NOUN - O
occurred VERB - O
on ADP - O
44.4 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
4.7 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
occasions NOUN - O
. PUNCT - O

Tacrolimus NNP - B-MEDICINE
DBS JJ - B-ORG
dosing ADJ - O
recommendations NOUN - O
were VERB - O
0.35 CD - B-CARDINAL
± NUM - O
0.14 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
higher ADJ - O
than ADP - O
for ADP - O
WB NNP - B-ORG
and CCONJ - O
8 CD - B-PERCENT
± CD - I-PERCENT
3 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
initial ADJ - O
dose NOUN - O
. PUNCT - O

Tacrolimus NN - B-MEDICINE
and CCONJ - O
mycophenolic ADJ - O
acid NOUN - O
TDM NNP - B-ORG
for ADP - O
outpatient NOUN - O
renal ADJ - O
transplant NOUN - O
recipients NOUN - O
, PUNCT - O
based VERB - O
on ADP - O
abbreviated ADJ - O
AUC NNP - B-ORG
collected VERB - O
with ADP - O
a DET - O
DBS NNP - B-ORG
sampling NOUN - O
device NOUN - O
, PUNCT - O
is VERB - O
comparable ADJ - O
to ADP - O
conventional ADJ - O
TDM NNP - B-ORG
based VERB - O
on ADP - O
WB NNP - B-ORG
sampling NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus JJ - B-MEDICINE
distribution NOUN - O
into ADP - O
oral ADJ - O
fluids NOUN - O
exhibited VERB - O
a DET - O
delay NOUN - O
with ADP - O
a DET - O
pronounced VERB - O
counter ADJ - O
- NOUN - O
clockwise NOUN - O
hysteresis NOUN - O
with ADP - O
respect NOUN - O
to ADP - O
the DET - O
time NOUN - O
after ADP - O
dose NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
and CCONJ - O
Beni NNP - B-PERSON
- HYPH - I-PERSON
Madonna NNP - I-PERSON
( PUNCT - O
a DET - O
new ADJ - O
cultivar NOUN - O
citrus NOUN - O
categorized VERB - O
as ADP - O
' PUNCT - O
Tangor PROPN - O
' PUNCT - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
, PUNCT - O
not ADV - O
triamcinolone VERB - O
acetonide NOUN - O
, PUNCT - O
interacts NOUN - O
synergistically ADV - O
with ADP - O
itraconazole NOUN - O
, PUNCT - O
terbinafine NOUN - O
, PUNCT - O
bifonazole NOUN - O
, PUNCT - O
and CCONJ - O
amorolfine ADJ - O
against ADP - O
clinical ADJ - O
dermatophyte NOUN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
and CCONJ - O
Nerve NNP - B-ORG
Growth NNP - I-ORG
factor NOUN - O
Treated VBD - B-ORG
Allografts NNP - I-ORG
for IN - I-ORG
Neural NNP - I-ORG
Tissue NNP - I-ORG
Regeneration NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
and CCONJ - O
Single PROPN - O
Intraoperative PROPN - O
High PROPN - O
- PUNCT - O
dose NOUN - O
of ADP - O
Anti ADJ - O
- PUNCT - O
T NOUN - O
- PUNCT - O
lymphocyte NOUN - O
Globulins VBZ - B-FAC
Versus NNP - I-FAC
Tacrolimus NNP - I-MEDICINE
Monotherapy NNP - I-FAC
in ADP - O
Adult NNP - B-ORG
Liver NNP - I-ORG
Transplantation NN - I-ORG
: PUNCT - O
One CD - B-DATE
- HYPH - I-DATE
year NN - I-DATE
Results NOUN - O
of ADP - O
an DET - O
Investigator NOUN - O
- PUNCT - O
driven VERB - O
Randomized NNP - B-ORG
Controlled NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NN - B-MEDICINE
0.03 CD - B-PERCENT
% NN - I-PERCENT
ointment NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
paediatric ADJ - O
lichen NOUN - O
sclerosus NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
series NOUN - O
and CCONJ - O
literature NOUN - O
review NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Large ADJ - O
- PUNCT - O
Scale NOUN - O
Variability PROPN - O
of ADP - O
Inpatient PROPN - O
Tacrolimus NNP - B-MEDICINE
Therapeutic ADJ - O
Drug PROPN - O
Monitoring PROPN - O
at ADP - O
an DET - O
Academic PROPN - O
Transplant PROPN - O
Center PROPN - O
: PUNCT - O
A DET - O
Retrospective PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
- PUNCT - O
Induced VERB - O
Pain PROPN - O
Syndrome PROPN - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
- HYPH - I-PERSON
Associated NNP - I-PERSON
Jaundice NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Survival NNP - B-ORG
Time NN - I-ORG
to ADP - O
Biopsy NNP - B-ORG
- HYPH - I-ORG
Proven NNP - I-ORG
Acute PROPN - O
Rejection PROPN - O
and CCONJ - O
Tacrolimus NNP - B-MEDICINE
Adverse NNP - I-ORG
Drug NNP - I-ORG
Reactions NNPS - I-ORG
in ADP - O
Pediatric NNP - B-ORG
Liver NNP - I-ORG
Transplantation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Tacrolimus NNP - B-MEDICINE
( PUNCT - O
0.2 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
daily RB - B-DATE
) PUNCT - O
was VERB - O
administered VERB - O
from ADP - O
day NN - B-DATE
1 CD - I-DATE
to IN - I-DATE
day NN - I-DATE
30 CD - I-DATE
( PUNCT - O
TAC1 PROPN - O
) PUNCT - O
or CCONJ - O
from ADP - O
day NOUN - O
7 CD - B-DATE
to IN - I-DATE
day NN - I-DATE
30 NUM - O
( PUNCT - O
TAC7 PROPN - O
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
feasibility NOUN - O
, PUNCT - O
acceptability NOUN - O
and CCONJ - O
tolerability NOUN - O
of ADP - O
RGN107 NNP - B-GPE
use NOUN - O
, PUNCT - O
a DET - O
natural ADJ - O
powder NOUN - O
blend NOUN - O
of ADP - O
Arnica NNP - B-GPE
Montana NNP - I-GPE
, PUNCT - O
Calendula NNP - B-PERSON
Officinalis NNP - I-PERSON
, PUNCT - O
Mentha NNP - B-ORG
Arvensis NNP - I-ORG
and CCONJ - O
Santalum NNP - B-PERSON
Album NNP - I-PERSON
, PUNCT - O
among ADP - O
hospice NOUN - O
patients NOUN - O
and CCONJ - O
their ADJ - O
wound NOUN - O
caregivers NOUN - O
in ADP - O
the DET - O
palliative ADJ - O
wound NOUN - O
care NOUN - O
management NOUN - O
of ADP - O
chronic ADJ - O
wound NOUN - O
symptoms NOUN - O
at ADP - O
end NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
life NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
double ADJ - O
blind ADJ - O
trial NOUN - O
, PUNCT - O
was VERB - O
designed VERB - O
, PUNCT - O
in ADP - O
which ADJ - O
118 CD - B-CARDINAL
patients NOUN - O
undergoing VERB - O
the DET - O
removal NOUN - O
of ADP - O
impacted VERB - O
wisdom NOUN - O
teeth NOUN - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
the DET - O
following VERB - O
groups NOUN - O
; PUNCT - O
41 CD - B-CARDINAL
patients NOUN - O
received VERB - O
Metronidazole NNP - B-LOC
, PUNCT - O
39 CD - B-CARDINAL
patients NOUN - O
received VERB - O
Arnica NNP - B-GPE
Montana NNP - I-GPE
, PUNCT - O
38 CD - B-CARDINAL
patients NOUN - O
received VERB - O
the DET - O
placebo NOUN - O
. PUNCT - O

Arnica NNP - B-GPE
Montana NNP - I-GPE
appeared VERB - O
to PART - O
give VERB - O
rise NOUN - O
to ADP - O
greater ADJ - O
pain NOUN - O
than ADP - O
placebo NOUN - O
( PUNCT - O
p X - O
less ADJ - O
than ADP - O
0.05 NUM - O
) PUNCT - O
and CCONJ - O
caused VERB - O
more ADJ - O
swelling NOUN - O
than ADP - O
the DET - O
placebo NOUN - O
( PUNCT - O
p X - O
less ADJ - O
than ADP - O
0.01 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

an DET - O
effective ADJ - O
amount NOUN - O
of ADP - O
a DET - O
plant NOUN - O
extract NOUN - O
containing VERB - O
saponins NOUN - O
, PUNCT - O
said VERB - O
extract NOUN - O
being VERB - O
selected VERB - O
from ADP - O
the DET - O
group NOUN - O
consisting VERB - O
of ADP - O
Hedera NNP - B-ORG
haelix PROPN - O
L PROPN - O
extract NOUN - O
, PUNCT - O
Ruscus NNP - B-ORG
aculeatus NOUN - O
L PROPN - O
extract NOUN - O
and CCONJ - O
Aesculus NNP - B-ORG
hipocastanus PROPN - O
L PROPN - O
extract NOUN - O
, PUNCT - O
said VERB - O
extract NOUN - O
containing VERB - O
30 CD - B-PERCENT
to TO - I-PERCENT
100 CD - I-PERCENT
percent NN - I-PERCENT
saponins NOUN - O
, PUNCT - O
( PUNCT - O
ii PUNCT - O
) PUNCT - O
an DET - O
effective ADJ - O
amount NOUN - O
of ADP - O
an DET - O
extract NOUN - O
of ADP - O
Arnica NNP - B-ORG
Montana NNP - I-ORG
L NNP - I-ORG
, PUNCT - O
said VERB - O
extract NOUN - O
being VERB - O
provided VERB - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
a DET - O
tincture NOUN - O
or CCONJ - O
a DET - O
glycol ADJ - O
extract NOUN - O
, PUNCT - O
and CCONJ - O
( PUNCT - O
iii PUNCT - O
) PUNCT - O
an DET - O
effective ADJ - O
amount NOUN - O
of ADP - O
kola NOUN - O
nut NOUN - O
extract NOUN - O
, PUNCT - O
said VERB - O
extract VERB - O
containing VERB - O
caffeine NOUN - O
in ADP - O
an DET - O
amount NOUN - O
ranging VERB - O
from ADP - O
1.25 CD - B-CARDINAL
to ADP - O
10 NUM - O
weight NOUN - O
percent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Slenderizing NOUN - O
and CCONJ - O
anti ADJ - O
- ADJ - O
cellulitis ADJ - O
cosmetic ADJ - O
composition NOUN - O
based VERB - O
on ADP - O
an DET - O
extract NOUN - O
of ADP - O
a DET - O
plant NOUN - O
containing VERB - O
saponins NOUN - O
, PUNCT - O
an DET - O
extract NOUN - O
of ADP - O
Arnica NNP - B-ORG
Montana NNP - I-ORG
L NNP - I-ORG
and CCONJ - O
a DET - O
kola NOUN - O
nut NOUN - O
extract NOUN - O
, PUNCT - O
and CCONJ - O
to ADP - O
a DET - O
process NOUN - O
for ADP - O
using VERB - O
the DET - O
same ADJ - O

-DOCSTART- -X- - O

Dacomitinib PROPN - O
( PUNCT - O
Vizimpro NNP - B-MEDICINE
® NOUN - O
) PUNCT - O
is VERB - O
an DET - O
orally ADV - O
administered VERB - O
, PUNCT - O
small ADJ - O
- PUNCT - O
molecule NOUN - O
irreversible ADJ - O
inhibitor NOUN - O
of ADP - O
HER1 NNP - B-GPE
( PUNCT - O
EGFR PROPN - O
) PUNCT - O
, PUNCT - O
HER2 PROPN - O
and CCONJ - O
HER4 PROPN - O
that ADJ - O
was VERB - O
developed VERB - O
by ADP - O
Pfizer NNP - B-ORG
Inc. NNP - I-ORG
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
solid ADJ - O
tumours NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
condition NOUN - O
occurred VERB - O
due ADP - O
to ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
excessive ADJ - O
self NOUN - O
- PUNCT - O
administration NOUN - O
of ADP - O
calcium NOUN - O
- PUNCT - O
rich ADJ - O
antacid JJ - B-MEDICINE
tablets NOUN - O
. PUNCT - O

Acute ADJ - O
pancreatitis NOUN - O
secondary ADJ - O
to ADP - O
antacid RB - B-MEDICINE
- PUNCT - O
induced VERB - O
milk NOUN - O
- PUNCT - O
alkali ADJ - O
syndrome NOUN - O
has VERB - O
been VERB - O
minimally ADV - O
reported VERB - O
in ADP - O
the DET - O
literature NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
antacid JJ - B-MEDICINE
medication NOUN - O
and CCONJ - O
achlorhydria NOUN - O
can VERB - O
cause VERB - O
false ADJ - O
negative ADJ - O
pH PROPN - O
tests NOUN - O
that ADJ - O
may VERB - O
delay VERB - O
feeding NOUN - O
and CCONJ - O
increase VERB - O
resource NOUN - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Designing VERB - O
a DET - O
novel ADJ - O
antacid NN - B-MEDICINE
for ADP - O
sensitive ADJ - O
populations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
clinical ADJ - O
studies NOUN - O
were VERB - O
performed VERB - O
in ADP - O
healthy ADJ - O
volunteers NOUN - O
to PART - O
investigate VERB - O
food NOUN - O
and CCONJ - O
antacid JJ - B-MEDICINE
effects NOUN - O
on ADP - O
lesinurad NOUN - O
, PUNCT - O
a DET - O
novel NOUN - O
selective ADJ - O
uric ADJ - O
acid NOUN - O
reabsorption NOUN - O
inhibitor NOUN - O
approved VERB - O
for ADP - O
treatment NOUN - O
of ADP - O
hyperuricemia NOUN - O
associated VERB - O
with ADP - O
gout NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
xanthine NOUN - O
oxidase NOUN - O
inhibitors NOUN - O
. PUNCT - O

Study NOUN - O
1 CD - B-CARDINAL
evaluated VERB - O
a DET - O
high ADJ - O
- PUNCT - O
fat NOUN - O
, PUNCT - O
high ADJ - O
- PUNCT - O
calorie NOUN - O
meal NOUN - O
or CCONJ - O
high ADJ - O
doses NOUN - O
of ADP - O
antacids NOUN - O
( PUNCT - O
3000 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
calcium NOUN - O
carbonate NOUN - O
or CCONJ - O
1600 CD - B-CARDINAL
  SPACE - O
mg X - O
magnesium NOUN - O

Study NOUN - O
2 CD - B-CARDINAL
evaluated VERB - O
low ADJ - O
doses NOUN - O
of ADP - O
antacids NOUN - O
( PUNCT - O
1250 CD - B-DATE
  SPACE - O
mg X - O
calcium NOUN - O
carbonate NOUN - O
or CCONJ - O
800 CD - B-CARDINAL
  SPACE - O
mg PRON - O
magnesium NOUN - O

High ADJ - O
doses NOUN - O
of ADP - O
antacids NOUN - O
reduced VERB - O
lesinurad NOUN - O
AUC NNP - B-ORG
up IN - B-PERCENT
to IN - I-PERCENT
40 CD - I-PERCENT
% NN - I-PERCENT
and CCONJ - O
reduced VERB - O
the DET - O
lesinurad NOUN - O
uric ADJ - O
acid NOUN - O
- PUNCT - O
lowering VERB - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Controlled VERB - O
- PUNCT - O
release NOUN - O
of ADP - O
antacids NOUN - O
from ADP - O
biopolymer ADJ - O
microgels NOUN - O
under ADP - O
simulated VERB - O
gastric ADJ - O
conditions NOUN - O
: PUNCT - O
Impact NOUN - O
of ADP - O
bead NOUN - O
dimensions NOUN - O
, PUNCT - O
pore NOUN - O
size NOUN - O
, PUNCT - O
and CCONJ - O
alginate NOUN - O
/ SYM - O
pectin NOUN - O
ratio NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
evaluates VERB - O
and CCONJ - O
compares VERB - O
the DET - O
antacid JJ - B-MEDICINE
effect NOUN - O
of ADP - O
broccoli ADJ - O
, PUNCT - O
kale NOUN - O
, PUNCT - O
radish NOUN - O
, PUNCT - O
cucumber NOUN - O
, PUNCT - O
lemon NOUN - O
juice NOUN - O
, PUNCT - O
cold ADJ - O
milk NOUN - O
and CCONJ - O
curd NOUN - O
in ADP - O
an DET - O
artificial ADJ - O
stomach NOUN - O
model NOUN - O
. PUNCT - O

The DET - O
pH NOUN - O
of ADP - O
the DET - O
test NOUN - O
samples NOUN - O
and CCONJ - O
their ADJ - O
neutralizing VERB - O
effect NOUN - O
on ADP - O
artificial ADJ - O
gastric ADJ - O
acid NOUN - O
was VERB - O
determined VERB - O
and CCONJ - O
compared VERB - O
with ADP - O
that DET - O
of ADP - O
water NOUN - O
, PUNCT - O
the DET - O
active ADJ - O
control NOUN - O
sodium NOUN - O
bicarbonate NOUN - O
and CCONJ - O
a DET - O
marketed ADJ - O
antacid JJ - B-MEDICINE
preparation NOUN - O
ENO NNP - B-ORG
. PUNCT - O

All DET - O
test NOUN - O
samples NOUN - O
also ADV - O
exhibited VERB - O
a DET - O
significantly ADV - O
( PUNCT - O
p<0.001 NOUN - O
) PUNCT - O
higher ADJ - O
duration NOUN - O
of ADP - O
consistent ADJ - O
neutralization NOUN - O
and CCONJ - O
higher ADJ - O
antacid JJ - B-MEDICINE
capacity NOUN - O
than ADP - O
water NOUN - O
. PUNCT - O

Highest JJS - B-PERSON
antacid JJ - B-MEDICINE
activity NOUN - O
was VERB - O
demonstrated VERB - O
by ADP - O
cold ADJ - O
milk NOUN - O
and CCONJ - O
broccoli NOUN - O
which ADJ - O
was VERB - O
comparable ADJ - O
with ADP - O
ENO NNP - B-ORG
and CCONJ - O
sodium NOUN - O
bicarbonate NOUN - O
. PUNCT - O

It PRON - O
may VERB - O
be VERB - O
concluded VERB - O
that ADP - O
the DET - O
natural ADJ - O
food NOUN - O
ingredients NOUN - O
used VERB - O
in ADP - O
this DET - O
study NOUN - O
exhibited VERB - O
significant ADJ - O
antacid JJ - B-MEDICINE
activity NOUN - O
, PUNCT - O
justifying VERB - O
their ADJ - O
use NOUN - O
as ADP - O
essential ADJ - O
dietary ADJ - O
components NOUN - O
to PART - O
counter VERB - O
hyperacidity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Group PROPN - O
I PRON - O
underwent VERB - O
routine ADJ - O
periodontal ADJ - O
treatment NOUN - O
methods NOUN - O
for ADP - O
streptococcal ADJ - O
gingivitis NOUN - O
, PUNCT - O
while ADP - O
a DET - O
supportive ADJ - O
treatment NOUN - O
that ADJ - O
involved VERB - O
an DET - O
antacid JJ - B-MEDICINE
chewing VERB - O
tablet NOUN - O
two CD - B-CARDINAL
times NOUN - O
a DET - O
day NOUN - O
for ADP - O
a DT - B-DATE
week NN - I-DATE
based VERB - O
on ADP - O
the DET - O
microorganism NOUN - O
's PART - O
growth NOUN - O
characteristics NOUN - O
was VERB - O
used VERB - O
on ADP - O
patients NOUN - O
in ADP - O
Group PROPN - O
II PROPN - O
. PUNCT - O

The DET - O
decrease NOUN - O
in ADP - O
the DET - O
oral ADJ - O
pH PROPN - O
was VERB - O
statistically ADV - O
significant ADJ - O
after ADP - O
the DET - O
periodontal ADJ - O
treatment NOUN - O
procedures NOUN - O
with ADP - O
supportive ADJ - O
method NOUN - O
( PUNCT - O
p<0.001).The DET - O
use NOUN - O
of ADP - O
antacids NOUN - O
in ADP - O
addition NOUN - O
to ADP - O
conventional ADJ - O
periodontal ADJ - O
treatment NOUN - O
may VERB - O
be VERB - O
effective ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
oral ADJ - O
streptococcal ADJ - O
infections NOUN - O
.. PUNCT - O

-DOCSTART- -X- - O

PubMed NNP - B-ORG
/ SYM - I-ORG
MEDLINE NNP - I-ORG
, PUNCT - O
Embase NNP - B-ORG
, PUNCT - O
and CCONJ - O
the DET - O
Cochrane NNP - B-PERSON
library NOUN - O
electronic ADJ - O
databases NOUN - O
were VERB - O
searched VERB - O
through ADP - O
October NNP - B-DATE
2015 CD - I-DATE
for ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
comparing VERB - O
alginate ADJ - O
- PUNCT - O
containing VERB - O
compounds NOUN - O
to ADP - O
placebo NOUN - O
, PUNCT - O
antacids NOUN - O
, PUNCT - O
histamine-2 ADJ - O
receptor NOUN - O
antagonists NOUN - O
( PUNCT - O
H2RAs PROPN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
PPIs NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
GERD NNP - B-PERSON
symptoms NOUN - O
. PUNCT - O

Alginate PROPN - O
- PUNCT - O
based VERB - O
therapies NOUN - O
increased VERB - O
the DET - O
odds NOUN - O
of ADP - O
resolution NOUN - O
of ADP - O
GERD NNP - B-PERSON
symptoms NOUN - O
when ADV - O
compared VERB - O
to PART - O
placebo NOUN - O
or CCONJ - O
antacids NOUN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
4.42 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
2.45 NUM - O
- SYM - O
7.97 NUM - O
) PUNCT - O
with ADP - O
a DET - O
moderate ADJ - O
degree NOUN - O
of ADP - O
heterogeneity NOUN - O
between ADP - O
studies NOUN - O
( PUNCT - O
I2 PROPN - O
= SYM - O
71 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
P NOUN - O
= SYM - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

Alginates NOUN - O
are VERB - O
more ADV - O
effective ADJ - O
than ADP - O
placebo NOUN - O
or CCONJ - O
antacids NOUN - O
for ADP - O
treating VERB - O
GERD NNP - B-PERSON
symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Famotidine PROPN - O
( PUNCT - O
FMT PROPN - O
) PUNCT - O
and CCONJ - O
ibuprofen PROPN - O
( PUNCT - O
IBU PROPN - O
) PUNCT - O
were VERB - O
used VERB - O
as ADP - O
model NOUN - O
drugs NOUN - O
to PART - O
obtain VERB - O
coamorphous ADJ - O
systems NOUN - O
, PUNCT - O
where ADV - O
the DET - O
guanidine NOUN - O
moiety NOUN - O
of ADP - O
the DET - O
antacid NN - B-MEDICINE
and CCONJ - O
the DET - O
carboxylic ADJ - O
group NOUN - O
of ADP - O
the DET - O
nonsteroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drug NOUN - O
could VERB - O
potentially ADV - O
participate VERB - O
in ADP - O
H NOUN - O
- PUNCT - O
bonds NOUN - O
leading VERB - O
to ADP - O
a DET - O
given VERB - O
structural ADJ - O
motif NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Possible ADJ - O
risk NOUN - O
factors NOUN - O
include VERB - O
age NOUN - O
, PUNCT - O
being VERB - O
immunocompromised VERB - O
, PUNCT - O
prior ADJ - O
antibiotic ADJ - O
exposure NOUN - O
, PUNCT - O
the DET - O
use NOUN - O
of ADP - O
antacids NOUN - O
, PUNCT - O
and CCONJ - O
diseases NOUN - O
that ADJ - O
alter VERB - O
intestinal ADJ - O
microbiota NOUN - O
. PUNCT - O

Cases NOUN - O
having VERB - O
≥1 NNS - B-CARDINAL
comorbidities NOUN - O
were VERB - O
found VERB - O
to PART - O
be VERB - O
associated VERB - O
with ADP - O
previous ADJ - O
antacid NN - B-MEDICINE
exposure NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.0005 CD - B-CARDINAL
) PUNCT - O
while ADP - O
antimicrobial(s NOUN - O
) PUNCT - O
use NOUN - O
was VERB - O
associated VERB - O
with ADP - O
CDI PROPN - O
hospitalization NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Similarly ADV - O
, PUNCT - O
exposure NOUN - O
to ADP - O
either CCONJ - O
antacid JJ - B-MEDICINE
suppression NOUN - O
or CCONJ - O
antimicrobials NOUN - O
or CCONJ - O
both DET - O
with ADP - O
comorbidities NOUN - O
were VERB - O
found VERB - O
to PART - O
have VERB - O
a DET - O
significant ADJ - O
association NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.0005 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
associated VERB - O
with ADP - O
CDI PROPN - O
hospitalization NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
alginate NOUN - O
- PUNCT - O
based VERB - O
reflux NOUN - O
suppressant NOUN - O
and CCONJ - O
magnesium NOUN - O
- PUNCT - O
aluminium NOUN - O
antacid JJ - B-MEDICINE
gel NOUN - O
for ADP - O
treatment NOUN - O
of ADP - O
heartburn NOUN - O
in ADP - O
pregnancy NOUN - O
: PUNCT - O
a DET - O
randomized VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
compares VERB - O
the DET - O
antacid JJ - B-MEDICINE
effect NOUN - O
of ADP - O
raw ADJ - O
spinach NOUN - O
juice NOUN - O
with ADP - O
an DET - O
antioxidant ADJ - O
- PUNCT - O
rich ADJ - O
methanolic ADJ - O
extract NOUN - O
of ADP - O
spinach NOUN - O
( PUNCT - O
NAOE NNP - B-ORG
) PUNCT - O
in ADP - O
an DET - O
artificial ADJ - O
stomach NOUN - O
model NOUN - O
. PUNCT - O

MethodsThe PROPN - O
pH PROPN - O
of ADP - O
NAOE NNP - B-ORG
at ADP - O
various ADJ - O
concentrations NOUN - O
( PUNCT - O
50 CD - B-CARDINAL
, PUNCT - O
100 CD - B-CARDINAL
and CCONJ - O
200 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
) PUNCT - O
and CCONJ - O
its ADJ - O
neutralizing VERB - O
effect NOUN - O
on ADP - O
artificial ADJ - O
gastric ADJ - O
acid NOUN - O
was VERB - O
determined VERB - O
and CCONJ - O
compared VERB - O
with ADP - O
that DET - O
of ADP - O
raw ADJ - O
spinach NOUN - O
juice NOUN - O
, PUNCT - O
water NOUN - O
, PUNCT - O
the DET - O
active ADJ - O
control NOUN - O
sodium NOUN - O
bicarbonate NOUN - O
( PUNCT - O
SB NNP - B-ORG
) PUNCT - O
and CCONJ - O
a DET - O
marketed ADJ - O
antacid JJ - B-MEDICINE
preparation NOUN - O
ENO NNP - B-ORG
. PUNCT - O

Results NOUN - O
NAOE PROPN - O
( PUNCT - O
50 CD - B-CARDINAL
, PUNCT - O
100 CD - B-CARDINAL
and CCONJ - O
200 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
) PUNCT - O
, PUNCT - O
spinach NOUN - O
juice NOUN - O
, PUNCT - O
SB NNP - B-ORG
and CCONJ - O
ENO NNP - B-ORG
showed VERB - O
significantly ADV - O
better ADV - O
acid NOUN - O
- PUNCT - O
neutralizing VERB - O
effect NOUN - O
, PUNCT - O
consistent ADJ - O
duration NOUN - O
of ADP - O
neutralization NOUN - O
and CCONJ - O
higher ADJ - O
antacid JJ - B-MEDICINE
capacity NOUN - O
when ADV - O
compared VERB - O
with ADP - O
water NOUN - O
. PUNCT - O

Highest ADJ - O
antacid JJ - B-MEDICINE
activity NOUN - O
was VERB - O
demonstrated VERB - O
by ADP - O
ENO NNP - B-ORG
and CCONJ - O
SB NNP - B-ORG
followed VERB - O
by ADP - O
spinach NOUN - O
juice NOUN - O
and CCONJ - O
NAOE200 PROPN - O
. PUNCT - O

ConclusionsThus NNP - B-ORG
, PUNCT - O
it PRON - O
may VERB - O
be VERB - O
concluded VERB - O
that ADP - O
spinach NOUN - O
displays NOUN - O
significant ADJ - O
antacid JJ - B-MEDICINE
activity NOUN - O
be VERB - O
it PRON - O
in ADP - O
the DET - O
raw ADJ - O
juice NOUN - O
form NOUN - O
or CCONJ - O
as ADP - O
an DET - O
extract NOUN - O
in ADP - O
methanol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
use NOUN - O
of ADP - O
concurrent ADJ - O
analgesia NOUN - O
, PUNCT - O
sedation NOUN - O
/ SYM - O
anxiolytic ADJ - O
medications NOUN - O
and CCONJ - O
antacid JJ - B-MEDICINE
/ SYM - O
antiemetic ADJ - O
medications NOUN - O
was VERB - O
not ADV - O
different ADJ - O
between ADP - O
groups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
were VERB - O
the DET - O
most ADV - O
common ADJ - O
complaints NOUN - O
, PUNCT - O
accounting VERB - O
for ADP - O
69.57 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
gastrointestinal ADJ - O
symptoms NOUN - O
in ADP - O
Group NNP - B-PERSON
G. NNP - I-PERSON
Hyponatremia NNP - I-PERSON
was VERB - O
the DET - O
most ADV - O
common ADJ - O
electrolyte NOUN - O
disorder NOUN - O
, PUNCT - O
occurring VERB - O
in ADP - O
72.86 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n PROPN - O
  SPACE - O
= SYM - O
  SPACE - O
18 NUM - O
) PUNCT - O
of ADP - O
patients NOUN - O
in ADP - O
Group NNP - B-PERSON
G. NNP - I-PERSON
Hypoadrenalism NNP - I-PERSON
and CCONJ - O
hypothyroidism NOUN - O
were VERB - O
reported VERB - O
by ADP - O
69.57 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
60.78 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
patients NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
in ADP - O
Group NNP - B-PERSON
G. NNP - I-PERSON
None NNP - I-PERSON
of ADP - O
the DET - O
gastrointestinal ADJ - O
symptoms NOUN - O
were VERB - O
relieved VERB - O
by ADP - O
4 CD - B-CARDINAL
  SPACE - O
weeks NNS - B-DATE
of ADP - O
treatment NOUN - O
with ADP - O
antacid NN - B-MEDICINE
and CCONJ - O
motility NOUN - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
calcium NOUN - O
carbonate NOUN - O
and CCONJ - O
magnesium NOUN - O
/ SYM - O
aluminium NOUN - O
hydroxide ADJ - O
antacids NOUN - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
a DET - O
1200 CD - B-CARDINAL
mg NOUN - O
dose NOUN - O
of ADP - O
raltegravir NOUN - O
was VERB - O
assessed VERB - O
in ADP - O
this DET - O
study NOUN - O
. PUNCT - O

Patients NOUN - O
needed VERB - O
to PART - O
be VERB - O
on ADP - O
raltegravir NOUN - O
as ADP - O
part NOUN - O
of ADP - O
a DET - O
stable ADJ - O
treatment NOUN - O
regimen NOUN - O
for ADP - O
HIV PROPN - O
, PUNCT - O
and CCONJ - O
upon ADP - O
entry NOUN - O
into ADP - O
the DET - O
trial NOUN - O
received VERB - O
5 CD - B-DATE
days NNS - I-DATE
of ADP - O
1200 CD - B-DATE
mg NOUN - O
raltegravir VERB - O
as ADP - O
pretreatment NOUN - O
, PUNCT - O
before ADP - O
they PRON - O
entered VERB - O
the DET - O
four CD - B-CARDINAL
- PUNCT - O
period NOUN - O
study NOUN - O
: PUNCT - O
1200 CD - B-CARDINAL
mg NOUN - O
of ADP - O
raltegravir NOUN - O
alone ADV - O
( PUNCT - O
period NOUN - O
1 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
calcium NOUN - O
carbonate NOUN - O
antacid JJ - B-MEDICINE
as ADP - O
TUMS NOUN - O
® PUNCT - O

1000 NUM - O
and CCONJ - O
1200 CD - B-CARDINAL
mg NOUN - O
raltegravir NOUN - O
given VERB - O
concomitantly ADV - O
( PUNCT - O
Period PROPN - O
2 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
magnesium NOUN - O
/ SYM - O
aluminium NOUN - O
hydroxide NOUN - O
antacid JJ - B-MEDICINE
as ADP - O
20 CD - B-QUANTITY
ml NNP - I-QUANTITY
MAALOX NNP - I-QUANTITY
® NN - I-QUANTITY

Maximum PROPN - O
Strength PROPN - O
substitute NOUN - O
MS NNP - B-PERSON
given VERB - O
12 CD - B-CARDINAL
h NOUN - O
after ADP - O
administration NOUN - O
of ADP - O
1200 CD - B-CARDINAL
mg X - O
raltegravir PROPN - O
( PUNCT - O
period NOUN - O
3 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
calcium NOUN - O
carbonate NOUN - O
antacid JJ - B-MEDICINE
as ADP - O
TUMS NOUN - O
® NOUN - O

AUC0 PROPN - O
- PUNCT - O
24 PROPN - O
, PUNCT - O
C24 PROPN - O
, PUNCT - O
Cmax PROPN - O
and CCONJ - O
Tmax PROPN - O
were VERB - O
calculated VERB - O
from ADP - O
the DET - O
individual ADJ - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
1200 CD - B-DATE
mg SYM - O
QD PROPN - O
raltegravir NOUN - O
after ADP - O
administration NOUN - O
alone ADV - O
or CCONJ - O
with ADP - O
a DET - O
calcium NOUN - O
carbonate NOUN - O
antacid JJ - B-MEDICINE
or CCONJ - O
with ADP - O
a DET - O
staggered ADJ - O
dose NOUN - O
of ADP - O
a DET - O
calcium NOUN - O
carbonate NOUN - O
antacid NN - B-MEDICINE
or CCONJ - O
magnesium NOUN - O
/ SYM - O
aluminium NOUN - O
hydroxide NOUN - O
antacid VB - B-MEDICINE
. PUNCT - O

Metal NOUN - O
- PUNCT - O
cation NOUN - O
antacids NOUN - O
variably ADV - O
affected VERB - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
1200 CD - B-CARDINAL
mg SYM - O
QD PROPN - O
raltegravir NOUN - O
. PUNCT - O

When ADV - O
calcium NOUN - O
carbonate NOUN - O
antacid NN - B-MEDICINE
was VERB - O
given VERB - O
with ADP - O
1200 CD - B-CARDINAL
mg NOUN - O
raltegravir VERB - O
concomitantly ADV - O
, PUNCT - O
the DET - O
geometric ADJ - O
mean ADJ - O
ratio NOUN - O
( PUNCT - O
GMR PROPN - O
) PUNCT - O
and CCONJ - O
its ADJ - O
associated VERB - O
90 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
) PUNCT - O
for ADP - O
AUC0 PROPN - O
- PUNCT - O
24 PROPN - O
, PUNCT - O
Cmax NNP - B-ORG
and CCONJ - O
C24 NNP - B-PRODUCT
h NOUN - O
were VERB - O
0.28 CD - B-CARDINAL
( PUNCT - O
0.24 CD - B-CARDINAL
, PUNCT - O
0.32 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
0.26 CD - B-CARDINAL
( PUNCT - O
0.21 CD - B-CARDINAL
, PUNCT - O
0.32 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
0.52 CD - B-CARDINAL
( PUNCT - O
0.45 CD - B-CARDINAL
, PUNCT - O
0.61 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

When ADV - O
calcium NOUN - O
carbonate NOUN - O
antacid NN - B-MEDICINE
and CCONJ - O
magnesium NOUN - O
/ SYM - O
aluminium NOUN - O
hydroxide NOUN - O
were VERB - O
given VERB - O
12 CD - B-CARDINAL
h NOUN - O
after ADP - O
raltegravir NOUN - O
1200 CD - B-CARDINAL
mg NOUN - O
QD PROPN - O
dosing VERB - O
, PUNCT - O
the DET - O
GMR PROPN - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
) PUNCT - O
values NOUN - O
for ADP - O
AUC0 NNP - B-PRODUCT
- HYPH - I-PRODUCT
24 NNP - I-PRODUCT
and CCONJ - O
Cmax NNP - B-ORG
were VERB - O
0.90 CD - B-CARDINAL
( PUNCT - O
0.80 CD - B-CARDINAL
, PUNCT - O
1.03 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
0.98 CD - B-CARDINAL
( PUNCT - O
0.81 CD - B-CARDINAL
, PUNCT - O
1.17 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
0.86 CD - B-CARDINAL
( PUNCT - O
0.73 CD - B-CARDINAL
, PUNCT - O
1.03 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
0.86 CD - B-CARDINAL
( PUNCT - O
0.65 CD - B-CARDINAL
, PUNCT - O
1.15 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

However ADV - O
, PUNCT - O
significant ADJ - O
reduction NOUN - O
in ADP - O
the DET - O
trough ADJ - O
concentrations NOUN - O
of ADP - O
raltegravir NOUN - O
was VERB - O
observed VERB - O
: PUNCT - O
C24 VERB - O
h NOUN - O
0.43 CD - B-CARDINAL
( PUNCT - O
0.36 CD - B-CARDINAL
, PUNCT - O
0.51 CD - B-CARDINAL
) PUNCT - O
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
calcium NOUN - O
carbonate NOUN - O
antacids NOUN - O
and CCONJ - O
0.42 CD - B-CARDINAL
( PUNCT - O
0.34 CD - B-CARDINAL
, PUNCT - O
0.52 CD - B-CARDINAL
) PUNCT - O
in ADP - O
presence NOUN - O
of ADP - O
magnesium NOUN - O
/ SYM - O
aluminium NOUN - O
hydroxide NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Overall ADV - O
, PUNCT - O
the DET - O
use NOUN - O
of ADP - O
metal NOUN - O
- PUNCT - O
cation NOUN - O
antacids NOUN - O
with ADP - O
1200 CD - B-CARDINAL
mg NOUN - O
QD PROPN - O
raltegravir NOUN - O
is VERB - O
not ADV - O
recommended VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
dog NOUN - O
had VERB - O
received VERB - O
antiemetic ADJ - O
and CCONJ - O
antacid JJ - B-MEDICINE
treatment NOUN - O
, PUNCT - O
without ADP - O
improvement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluated VERB - O
associations NOUN - O
between ADP - O
cardiovascular ADJ - O
and CCONJ - O
antacid JJ - B-MEDICINE
medications NOUN - O
, PUNCT - O
and CCONJ - O
mortality NOUN - O
, PUNCT - O
in ADP - O
oxygen NOUN - O
- PUNCT - O
dependent ADJ - O
pulmonary ADJ - O
fibrosis NOUN - O
( PUNCT - O
PF PROPN - O
) PUNCT - O
of ADP - O
unknown ADJ - O
cause NOUN - O
. PUNCT - O

There ADV - O
were VERB - O
no DET - O
associations NOUN - O
with ADP - O
mortality NOUN - O
for ADP - O
antacid JJ - B-MEDICINE
treatments NOUN - O
, PUNCT - O
β NOUN - O
- PUNCT - O
blockers NOUN - O
, PUNCT - O
diuretics NOUN - O
or CCONJ - O
statins NOUN - O
. PUNCT - O

In ADP - O
oxygen NOUN - O
- PUNCT - O
dependent ADJ - O
PF PROPN - O
, PUNCT - O
treatment NOUN - O
with ADP - O
ACEI PROPN - O
/ SYM - O
ARB PROPN - O
was VERB - O
associated VERB - O
with ADP - O
improved VERB - O
survival NOUN - O
, PUNCT - O
antiplatelet ADJ - O
drugs NOUN - O
with ADP - O
decreased VERB - O
survival NOUN - O
, PUNCT - O
whereas ADP - O
there ADV - O
was VERB - O
no DET - O
association NOUN - O
between ADP - O
antacid NN - B-MEDICINE
, PUNCT - O
β NOUN - O
- PUNCT - O
blocker NOUN - O
, PUNCT - O
diuretic ADJ - O
or CCONJ - O
statin ADJ - O
treatment NOUN - O
and CCONJ - O
survival NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carbonated VERB - O
hydrocalumite NOUN - O
synthesized VERB - O
by ADP - O
the DET - O
microwave NOUN - O
method NOUN - O
as ADP - O
a DET - O
possible ADJ - O
antacid NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
ranitidine NOUN - O
( PUNCT - O
antacid NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
food NOUN - O
, PUNCT - O
and CCONJ - O
formulation NOUN - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
fostamatinib NOUN - O
: PUNCT - O
results NOUN - O
from ADP - O
five CD - B-CARDINAL
phase NOUN - O
I PRON - O
clinical ADJ - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rinsing VERB - O
with ADP - O
antacid JJ - B-MEDICINE
suspension NOUN - O
reduces VERB - O
hydrochloric ADJ - O
acid NOUN - O
- PUNCT - O
induced VERB - O
erosion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Secondary ADJ - O
objectives NOUN - O
included VERB - O
the DET - O
identification NOUN - O
of ADP - O
risk NOUN - O
factors NOUN - O
for ADP - O
intolerance NOUN - O
of ADP - O
PPI PROPN - O
discontinuation NOUN - O
, PUNCT - O
the DET - O
occurrence NOUN - O
of ADP - O
gastrointestinal ADJ - O
( PUNCT - O
GI NNP - B-ORG
) PUNCT - O
complications NOUN - O
after ADP - O
PPI PROPN - O
discontinuation NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
percentage NOUN - O
of ADP - O
patients NOUN - O
who NOUN - O
required VERB - O
" PUNCT - O
as ADP - O
needed VERB - O
" PUNCT - O
acid ADJ - O
suppressive ADJ - O
therapy NOUN - O
( PUNCT - O
AST PROPN - O
) PUNCT - O
with ADP - O
an DET - O
antacid JJ - B-MEDICINE
or CCONJ - O
histamine-2 ADJ - O
receptor NOUN - O
antagonist NOUN - O
( PUNCT - O
H2RA NNP - B-ORG
) PUNCT - O
to PART - O
control VERB - O
their ADJ - O
symptoms NOUN - O
while ADP - O
hospitalized VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Future ADJ - O
studies NOUN - O
should VERB - O
be VERB - O
done VERB - O
in ADP - O
vulnerable ADJ - O
subgroups NOUN - O
of ADP - O
population NOUN - O
including VERB - O
children NOUN - O
, PUNCT - O
patients NOUN - O
receiving VERB - O
antacid JJ - B-MEDICINE
or CCONJ - O
Al NNP - B-ORG
- HYPH - I-ORG
containing VBG - I-ORG
pharmeteucials NOUN - O
on ADP - O
a DET - O
daily ADJ - O
basis NOUN - O
, PUNCT - O
patients NOUN - O
with ADP - O
reduced VERB - O
renal ADJ - O
function NOUN - O
, PUNCT - O
and CCONJ - O
patients NOUN - O
on ADP - O
parenteral ADJ - O
nutrition NOUN - O
regimens NOUN - O
that ADJ - O
are VERB - O
likely ADJ - O
to PART - O
be VERB - O
affected VERB - O
by ADP - O
possible ADJ - O
adverse ADJ - O
health NOUN - O
effects NOUN - O
of ADP - O
Al NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
an DET - O
anti ADJ - O
- ADJ - O
reflux ADJ - O
medical ADJ - O
device NOUN - O
in ADP - O
the DET - O
control NOUN - O
of ADP - O
deflation NOUN - O
cough NOUN - O
: PUNCT - O
A DET - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
comparative ADJ - O
study NOUN - O
with ADP - O
an DET - O
antacid JJ - B-MEDICINE
drug NOUN - O
in ADP - O
chronic ADJ - O
coughers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
reported VERB - O
earlier ADV - O
that ADP - O
the DET - O
laxative ADJ - O
action NOUN - O
of ADP - O
magnesium NOUN - O
oxide NOUN - O
is VERB - O
reversed VERB - O
by ADP - O
the DET - O
concomitant ADJ - O
use NOUN - O
of ADP - O
antacids NOUN - O
in ADP - O
cancer NOUN - O
patients NOUN - O
receiving VERB - O
opioid ADJ - O
analgesics NOUN - O
. PUNCT - O

Therefore ADV - O
, PUNCT - O
it PRON - O
is VERB - O
important ADJ - O
to PART - O
avoid VERB - O
negative ADJ - O
drug NOUN - O
interaction NOUN - O
between ADP - O
magnesium NOUN - O
oxide NOUN - O
and CCONJ - O
antacids NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
CHOP NNP - B-ORG
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Only RB - B-PERCENT
43 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
respondents NOUN - O
would VERB - O
use VERB - O
antacid JJ - B-MEDICINE
drugs NOUN - O
in ADP - O
case NOUN - O
of ADP - O
symptomatic ADJ - O
gastro PUNCT - O
- PUNCT - O
oesophageal ADJ - O
reflux NOUN - O
disease NOUN - O
( PUNCT - O
GERD NNP - B-PERSON
) PUNCT - O
, PUNCT - O
and CCONJ - O
only RB - B-PERCENT
11 CD - I-PERCENT
% NN - I-PERCENT
would VERB - O
prescribe VERB - O
these DET - O
drugs NOUN - O
regardless ADV - O
of ADP - O
GERD NN - B-PERSON
diagnosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recent ADJ - O
studies NOUN - O
have VERB - O
shown VERB - O
that ADP - O
Gaviscon NNP - B-ORG
Double NNP - I-ORG
Action NNP - I-ORG
Liquid NNP - I-ORG
( PUNCT - O
a DET - O
combination NOUN - O
alginate VERB - O
- PUNCT - O
antacid JJ - B-MEDICINE
) PUNCT - O
administered VERB - O
post ADJ - O
- ADJ - O
prandially ADV - O
co NOUN - O
- NOUN - O
localises NOUN - O
with ADP - O
the DET - O
acid NOUN - O
pocket NOUN - O
, PUNCT - O
the DET - O
' PUNCT - O
reservoir NOUN - O
' PUNCT - O
for ADP - O
post ADJ - O
- ADJ - O
prandial ADJ - O
acid NOUN - O
reflux NOUN - O
. PUNCT - O

To PART - O
compare VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
Gaviscon NNP - B-ORG
Double NNP - I-ORG
Action NNP - I-ORG
Liquid NNP - I-ORG
to ADP - O
an DET - O
equivalent ADJ - O
strength NOUN - O
antacid JJ - B-MEDICINE
without ADP - O
alginate ADJ - O
in ADP - O
controlling VERB - O
post ADJ - O
- ADJ - O
prandial ADJ - O
acid NOUN - O
reflux NOUN - O
in ADP - O
GERD NNP - B-ORG
patients NOUN - O
. PUNCT - O

In ADP - O
a DET - O
double ADJ - O
- PUNCT - O
blinded NOUN - O
randomised ADJ - O
crossover NOUN - O
design NOUN - O
they PRON - O
then ADV - O
took VERB - O
Gaviscon NNP - B-ORG
or CCONJ - O
CVS NNP - B-ORG
brand NOUN - O
antacid NN - B-MEDICINE
, PUNCT - O
each DET - O
with ADP - O
~18 NOUN - O
  SPACE - O
mmol NOUN - O
/ SYM - O
L NOUN - O
acid NOUN - O
neutralising NOUN - O
capacity NOUN - O
. PUNCT - O

Gaviscon PROPN - O
studies NOUN - O
had VERB - O
significantly ADV - O
less ADJ - O
distal ADJ - O
oesophageal ADJ - O
acid NOUN - O
exposure NOUN - O
and CCONJ - O
greater ADJ - O
nadir NOUN - O
refluxate VERB - O
pH NOUN - O
in ADP - O
the DET - O
30 CD - B-CARDINAL
- SYM - I-CARDINAL
150 CD - I-CARDINAL
  SPACE - O
min NOUN - O
post ADJ - O
- ADJ - O
prandial ADJ - O
period NOUN - O
than ADP - O
antacid JJ - B-MEDICINE
studies NOUN - O
. PUNCT - O

Gaviscon NNP - B-ORG
Double NNP - I-ORG
Action NNP - I-ORG
Liquid NNP - I-ORG
is VERB - O
more ADV - O
effective ADJ - O
than ADP - O
an DET - O
antacid NN - B-MEDICINE
without ADP - O
alginate NOUN - O
in ADP - O
controlling VERB - O
post ADJ - O
- ADJ - O
prandial ADJ - O
oesophageal ADJ - O
acid NOUN - O
exposure NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Gaviscon PROPN - O
Double PROPN - O
Action NOUN - O
Liquid PROPN - O
( PUNCT - O
antacid JJ - B-MEDICINE
& CCONJ - O
alginate NOUN - O
) PUNCT - O
is VERB - O
more ADV - O
effective ADJ - O
than ADP - O
antacid JJ - B-MEDICINE
in ADP - O
controlling VERB - O
post ADJ - O
- ADJ - O
prandial ADJ - O
oesophageal ADJ - O
acid NOUN - O
exposure NOUN - O
in ADP - O
GERD NNP - B-PERSON
patients NOUN - O
: PUNCT - O
a DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
crossover NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Barrett NNP - B-PERSON
's PART - O
esophagus NOUN - O
, PUNCT - O
and CCONJ - O
( PUNCT - O
4 LS - B-CARDINAL
) PUNCT - O
prescription NOUN - O
antacid NN - B-MEDICINE
initiation NOUN - O
among ADP - O
Medicare NNP - B-ORG
beneficiaries NOUN - O
. PUNCT - O

Secondary ADJ - O
analyses NOUN - O
of ADP - O
sub NOUN - O
- PUNCT - O
cohorts NOUN - O
without ADP - O
past ADJ - O
bisphosphonates NOUN - O
or CCONJ - O
upper ADJ - O
endoscopy ADJ - O
assessed ADJ - O
bisphosphonate NOUN - O
initiation NOUN - O
and CCONJ - O
risk NOUN - O
of ADP - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
upper ADJ - O
endoscopy NOUN - O
, PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
incident NOUN - O
Barrett NNP - B-PERSON
's PART - O
esophagus NOUN - O
, PUNCT - O
and CCONJ - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
prescription NOUN - O
antacid NN - B-MEDICINE
initiation NOUN - O
. PUNCT - O

In ADP - O
sub NOUN - O
- PUNCT - O
cohorts NOUN - O
, PUNCT - O
compared VERB - O
to ADP - O
none NOUN - O
, PUNCT - O
lowest ADJ - O
cumulative ADJ - O
bisphosphonate NOUN - O
use NOUN - O
( PUNCT - O
one CD - B-CARDINAL
to PART - O
nine CD - B-CARDINAL
pills NOUN - O
) PUNCT - O
was VERB - O
associated VERB - O
with ADP - O
higher ADJ - O
risk NOUN - O
of ADP - O
endoscopy NOUN - O
( PUNCT - O
OR CCONJ - O
1.11 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
1.08 NUM - O
- SYM - O
1.14 NUM - O
) PUNCT - O
and CCONJ - O
antacid JJ - B-MEDICINE
initiation NOUN - O
( PUNCT - O
OR CCONJ - O
1.13 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.10 CD - B-CARDINAL
- SYM - O
1.16 NUM - O
) PUNCT - O
; PUNCT - O
higher ADJ - O
intensity NOUN - O
conferred VERB - O
no DET - O
increased VERB - O
risk NOUN - O
. PUNCT - O

Bisphosphonate VERB - O
initiation NOUN - O
appears VERB - O
to PART - O
identify VERB - O
patients NOUN - O
susceptible ADJ - O
to ADP - O
early ADJ - O
irritating NOUN - O
effects NOUN - O
; PUNCT - O
clinicians NOUN - O
might VERB - O
offer VERB - O
alternatives NOUN - O
and CCONJ - O
delay VERB - O
endoscopy NOUN - O
or CCONJ - O
antacids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
health NOUN - O
: PUNCT - O
antacid JJ - B-MEDICINE
toothpaste NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
contribution NOUN - O
we PRON - O
present VERB - O
physicochemical ADJ - O
aspects NOUN - O
of ADP - O
the DET - O
composition NOUN - O
of ADP - O
the DET - O
Chaco NNP - B-ORG
, PUNCT - O
experimental ADJ - O
animal NOUN - O
studies NOUN - O
that ADJ - O
evaluate VERB - O
its ADJ - O
antiulcer NOUN - O
effect NOUN - O
and CCONJ - O
in ADP - O
vitro NOUN - O
test NOUN - O
that ADJ - O
studies VERB - O
the DET - O
antacid JJ - B-MEDICINE
property NOUN - O
. PUNCT - O

The DET - O
proposed VERB - O
mechanism NOUN - O
of ADP - O
therapeutic ADJ - O
action NOUN - O
is VERB - O
due ADJ - O
to ADP - O
a DET - O
cytoprotective ADJ - O
effect NOUN - O
on ADP - O
the DET - O
gastric ADJ - O
mucosa NOUN - O
by ADP - O
independent ADJ - O
mechanisms NOUN - O
of ADP - O
acid NOUN - O
secretion NOUN - O
inhibition NOUN - O
, PUNCT - O
as ADP - O
it PRON - O
has VERB - O
no DET - O
antacid JJ - B-MEDICINE
property NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
on ADP - O
heartburn NOUN - O
, PUNCT - O
assumption NOUN - O
of ADP - O
antacid JJ - B-MEDICINE
medication NOUN - O
, PUNCT - O
weight NOUN - O
loss NOUN - O
, PUNCT - O
and CCONJ - O
rate NOUN - O
of ADP - O
complications NOUN - O
in ADP - O
both DET - O
patients NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
GERD NNP - B-PERSON
or CCONJ - O
HH PROPN - O
were VERB - O
collected VERB - O
. PUNCT - O

The DET - O
number NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
preoperative ADJ - O
heartburn NOUN - O
( PUNCT - O
40 CD - B-CARDINAL
to TO - I-CARDINAL
10 CD - I-CARDINAL
) PUNCT - O
and/or CCONJ - O
assumption NOUN - O
of ADP - O
antacid JJ - B-MEDICINE
drugs NOUN - O
( PUNCT - O
38 CD - B-CARDINAL
to PART - O
7 CD - B-CARDINAL
) PUNCT - O
significantly ADV - O
decreased VERB - O
after ADP - O
LAGB NNP - B-ORG
CONCLUSIONS NOUN - O
: PUNCT - O
LAGB NNP - B-ORG
is VERB - O
an DET - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
surgical ADJ - O
treatment NOUN - O
for ADP - O
morbidly ADJ - O
obesity NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
GERD NNP - B-PERSON
or CCONJ - O
HH NNP - B-ORG
, PUNCT - O
since ADP - O
it PRON - O
induces VERB - O
both CCONJ - O
a DET - O
significant ADJ - O
weight NOUN - O
loss NOUN - O
and CCONJ - O
an DET - O
improvement NOUN - O
of ADP - O
reflux NOUN - O
symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

On ADP - O
multivariate ADJ - O
logistic ADJ - O
regression NOUN - O
, PUNCT - O
the DET - O
use NOUN - O
of ADP - O
chronic ADJ - O
antacid NN - B-MEDICINE
therapy NOUN - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
= SYM - O
1.9 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
: PUNCT - O
1.02 CD - B-CARDINAL
- SYM - O
3.68 NUM - O
, PUNCT - O
P NOUN - O
= SYM - O
0.04 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
antibiotic ADJ - O
exposure NOUN - O
greater JJR - B-DATE
than IN - I-DATE
7 CD - I-DATE
days NNS - I-DATE
( PUNCT - O
odds NOUN - O
ratio NOUN - O
= SYM - O
2.2 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
: PUNCT - O
1.11 CD - B-CARDINAL
- SYM - O
4.44 NUM - O
, PUNCT - O
P NOUN - O
= SYM - O
0.02 CD - B-CARDINAL
) PUNCT - O
were VERB - O
independently ADV - O
associated VERB - O
with ADP - O
developing VERB - O
CDI PROPN - O
. PUNCT - O

Our ADJ - O
study NOUN - O
demonstrates VERB - O
that ADJ - O
use NOUN - O
of ADP - O
chronic ADJ - O
antacid JJ - B-MEDICINE
therapy NOUN - O
and CCONJ - O
long ADJ - O
duration NOUN - O
of ADP - O
antimicrobial ADJ - O
exposure NOUN - O
are VERB - O
associated VERB - O
with ADP - O
development NOUN - O
of ADP - O
CDI PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
evaluated VERB - O
the DET - O
effects NOUN - O
of ADP - O
concomitant ADJ - O
medications NOUN - O
altering VERB - O
gastric ADJ - O
pH PROPN - O
( PUNCT - O
antacid NNP - B-MEDICINE
, PUNCT - O
ranitidine NOUN - O
, PUNCT - O
and CCONJ - O
esomeprazole NOUN - O
) PUNCT - O
and CCONJ - O
gastric ADJ - O
motility NOUN - O
( PUNCT - O
metoclopramide NOUN - O
) PUNCT - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
posaconazole NOUN - O
tablets NOUN - O
. PUNCT - O

In ADP - O
each DET - O
treatment NOUN - O
period NOUN - O
, PUNCT - O
a DET - O
single ADJ - O
400-mg NOUN - O
dose NOUN - O
( PUNCT - O
4 CD - B-QUANTITY
100-mg CD - I-QUANTITY
tablets NOUN - O
) PUNCT - O
of ADP - O
posaconazole NOUN - O
was VERB - O
administered VERB - O
alone ADV - O
or CCONJ - O
with ADP - O
20 CD - B-QUANTITY
ml NN - I-QUANTITY
antacid NNP - B-MEDICINE
( PUNCT - O
2 CD - B-CARDINAL
g NOUN - O
of ADP - O
aluminum NOUN - O
hydroxide NOUN - O
and CCONJ - O
2 CD - B-CARDINAL
g NOUN - O
of ADP - O
magnesium NOUN - O
hydroxide NOUN - O
) PUNCT - O
, PUNCT - O
ranitidine NOUN - O
( PUNCT - O
150 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
, PUNCT - O
esomeprazole NOUN - O
( PUNCT - O
40 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
metoclopramide NOUN - O
( PUNCT - O
15 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
. PUNCT - O

Geometric ADJ - O
mean VERB - O
ratios NOUN - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
intervals NOUN - O
[ PUNCT - O
CIs NOUN - O
] PUNCT - O
) PUNCT - O
of ADP - O
the DET - O
area NOUN - O
under ADP - O
the DET - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
curve NOUN - O
from ADP - O
time NOUN - O
zero NUM - O
to ADP - O
infinity NOUN - O
( PUNCT - O
AUC0-inf PROPN - O
) PUNCT - O
( PUNCT - O
posaconazole NOUN - O
with ADP - O
medications NOUN - O
affecting VERB - O
gastric ADJ - O
pH NOUN - O
and CCONJ - O
gastric ADJ - O
motility NOUN - O
versus ADP - O
posaconazole NOUN - O
alone ADV - O
) PUNCT - O
were VERB - O
1.03 CD - B-CARDINAL
( PUNCT - O
0.88 CD - B-CARDINAL
- SYM - O
1.20 NUM - O
) PUNCT - O
with ADP - O
antacid NN - B-MEDICINE
, PUNCT - O
0.97 CD - B-CARDINAL
( PUNCT - O
0.84 CD - B-CARDINAL
- SYM - O
1.12 NUM - O
) PUNCT - O
with ADP - O
ranitidine NOUN - O
, PUNCT - O
1.01 CD - B-CARDINAL
( PUNCT - O
0.87 CD - B-CARDINAL
- SYM - O
1.17 NUM - O
) PUNCT - O
with ADP - O
esomeprazole NOUN - O
, PUNCT - O
and CCONJ - O
0.93 CD - B-CARDINAL
( PUNCT - O
0.79 CD - B-CARDINAL
- SYM - O
1.09 NUM - O
) PUNCT - O
with ADP - O
metoclopramide NOUN - O
. PUNCT - O

Geometric ADJ - O
mean VERB - O
ratios NOUN - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CIs NOUN - O
) PUNCT - O
of ADP - O
the DET - O
maximum ADJ - O
concentration NOUN - O
of ADP - O
drug NOUN - O
in ADP - O
serum PROPN - O
( PUNCT - O
Cmax PROPN - O
) PUNCT - O
were VERB - O
1.06 CD - B-CARDINAL
( PUNCT - O
0.90 CD - B-CARDINAL
- SYM - O
1.26 NUM - O
) PUNCT - O
with ADP - O
antacid NN - B-MEDICINE
, PUNCT - O
1.04 CD - B-CARDINAL
( PUNCT - O
0.88 CD - B-CARDINAL
- SYM - O
1.23 NUM - O
) PUNCT - O
with ADP - O
ranitidine NOUN - O
, PUNCT - O
1.05 CD - B-CARDINAL
( PUNCT - O
0.89 CD - B-CARDINAL
- SYM - O
1.24 NUM - O
) PUNCT - O
with ADP - O
esomeprazole NOUN - O
, PUNCT - O
and CCONJ - O
0.86 CD - B-CARDINAL
( PUNCT - O
0.73 CD - B-CARDINAL
- SYM - O
1.02 NUM - O
) PUNCT - O
with ADP - O
metoclopramide NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

WHAT NOUN - O
IS VERB - O
KNOWN VERB - O
AND CCONJ - O
OBJECTIVE NOUN - O
: PUNCT - O
Baking VERB - O
soda NOUN - O
is VERB - O
a DET - O
common ADJ - O
household NOUN - O
product NOUN - O
promoted VERB - O
by ADP - O
the DET - O
manufacturer NOUN - O
as ADP - O
an DET - O
antacid NN - B-MEDICINE
. PUNCT - O

Of ADP - O
the DET - O
192 CD - B-CARDINAL
cases NOUN - O
we PRON - O
identified VERB - O
, PUNCT - O
55·8 CD - B-PERCENT
% NN - I-PERCENT
were VERB - O
female ADJ - O
, PUNCT - O
ages NOUN - O
ranged VERB - O
2 CD - B-DATE
  _SP - I-DATE
months NNS - I-DATE
to ADP - O
79 CD - B-CARDINAL
  SPACE - O
years NNS - B-DATE
, PUNCT - O
and CCONJ - O
the DET - O
most ADV - O
common ADJ - O
reasons NOUN - O
for ADP - O
misuse NOUN - O
included VERB - O
antacid NN - B-MEDICINE
( PUNCT - O
60·4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
' PUNCT - O
beat VERB - O
a DET - O
urine NOUN - O
drug NOUN - O
test NOUN - O
' PUNCT - O
( PUNCT - O
11·5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
treat VERB - O
a DET - O
UTI NNP - B-ORG
( PUNCT - O
4·7 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Patients NOUN - O
at ADP - O
highest ADJ - O
risk NOUN - O
of ADP - O
toxicity NOUN - O
may VERB - O
include VERB - O
those DET - O
who NOUN - O
chronically ADV - O
use VERB - O
an DET - O
antacid NN - B-MEDICINE
, PUNCT - O
those DET - O
who NOUN - O
use VERB - O
the DET - O
method NOUN - O
to PART - O
' PUNCT - O
beat VERB - O
' PUNCT - O
urine NOUN - O
drug NOUN - O
screens NOUN - O
, PUNCT - O
pregnant ADJ - O
women NOUN - O
and CCONJ - O
young ADJ - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
alginate ADJ - O
- PUNCT - O
antacid JJ - B-MEDICINE
formulation NOUN - O
localizes NOUN - O
to ADP - O
the DET - O
acid NOUN - O
pocket NOUN - O
to PART - O
reduce VERB - O
acid NOUN - O
reflux NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
gastroesophageal ADJ - O
reflux NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
systematically ADV - O
review VERB - O
the DET - O
effect NOUN - O
of ADP - O
antacid JJ - B-MEDICINE
medication NOUN - O
on ADP - O
stress NOUN - O
- PUNCT - O
related VERB - O
mucosal NOUN - O
disease NOUN - O
( PUNCT - O
SRMD NNP - B-ORG
) PUNCT - O
bleeding NOUN - O
, PUNCT - O
hospital NOUN - O
acquired VERB - O
pneumonia NOUN - O
( PUNCT - O
HAP NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
hospital NOUN - O
mortality NOUN - O
in ADP - O
critically ADV - O
ill ADJ - O
patients NOUN - O
admitted VERB - O
to ADP - O
intensive ADJ - O
care NOUN - O
unit NOUN - O
( PUNCT - O
ICU NNP - B-ORG
) PUNCT - O
. PUNCT - O

Randomized VERB - O
control NOUN - O
trials NOUN - O
( PUNCT - O
RCTs PROPN - O
) PUNCT - O
focused VERB - O
on ADP - O
comparison NOUN - O
between ADP - O
antacid NN - B-MEDICINE
and CCONJ - O
sucralfate ADJ - O
were VERB - O
collected VERB - O
, PUNCT - O
and CCONJ - O
then ADV - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
was VERB - O
performed VERB - O
. PUNCT - O

Antacid JJ - B-MEDICINE
medication NOUN - O
significantly ADV - O
increased VERB - O
the DET - O
incidence NOUN - O
of ADP - O
HAP NNP - B-ORG
when ADV - O
compared VERB - O
with ADP - O
sucralfate NOUN - O
in ADP - O
11 CD - B-CARDINAL
trials NOUN - O
[ PUNCT - O
19.36 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
249/1286 NNP - B-ORG
) PUNCT - O
vs. ADP - O
15.23 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
184/1208 PROPN - O
) PUNCT - O
, PUNCT - O
odds NOUN - O
ratio NOUN - O
( PUNCT - O
OR)=1.27 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
95%CI NUM - O
) PUNCT - O
: PUNCT - O
1.03 CD - B-CARDINAL
- SYM - O
1.57 NUM - O
, PUNCT - O
P=0.02]. NNP - B-CARDINAL
Subgroup NNP - B-ORG
analyses NOUN - O
showed VERB - O
that ADP - O
antacid JJ - B-MEDICINE
therapy NOUN - O
significantly ADV - O
reduce VERB - O
the DET - O
incidence NOUN - O
of ADP - O
clinically ADV - O
significant ADJ - O
bleeding NOUN - O
compared VERB - O
with ADP - O
sucralfate ADJ - O
[ PUNCT - O
1.80 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
12/667 PROPN - O
) PUNCT - O
vs. ADP - O
3.86 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
26/673 NUM - O
) PUNCT - O
, PUNCT - O
OR=0.46 PROPN - O
, PUNCT - O
95%CI NUM - O
: PUNCT - O
0.23 CD - B-CARDINAL
- PUNCT - O
0.91 NUM - O
, PUNCT - O
P=0.03 PROPN - O
] PUNCT - O
, PUNCT - O
however ADV - O
, PUNCT - O
it PRON - O
did VERB - O
not ADV - O
lower VERB - O
the DET - O
incidence NOUN - O
of ADP - O
overt ADJ - O
bleeding VERB - O
[ PUNCT - O
7.09 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
40/564 PROPN - O
) PUNCT - O
vs. ADP - O
7.35 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
36/490 PROPN - O
) PUNCT - O
, PUNCT - O
OR=1.00 NNP - B-ORG
, PUNCT - O
95%CI NUM - O
: PUNCT - O
0.62 CD - B-CARDINAL
- SYM - I-CARDINAL
1.62 CD - I-CARDINAL
, PUNCT - O

There ADV - O
was VERB - O
no DET - O
significant ADJ - O
difference NOUN - O
between ADP - O
antacid JJ - B-MEDICINE
group NOUN - O
and CCONJ - O
sucralfate VERB - O
group NOUN - O
on ADP - O
neither CCONJ - O
ICU NNP - B-ORG
mortality NOUN - O
nor CCONJ - O
hospitalization NOUN - O
mortality NOUN - O
in ADP - O
11 CD - B-CARDINAL
studies NOUN - O
[ PUNCT - O
25.58 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
288/1126 LS - B-CARDINAL
) PUNCT - O
vs. ADP - O
23.65 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
268/1133 PROPN - O
) PUNCT - O
, PUNCT - O
OR=1.11 NNP - B-ORG
, PUNCT - O
95%CI NUM - O
: PUNCT - O
0.92 CD - B-CARDINAL
- PUNCT - O
1.35 NUM - O
, PUNCT - O
P=0.28]. ADJ - O
CONCLUSIONS NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Relationship NOUN - O
between ADP - O
antacid JJ - B-MEDICINE
therapy NOUN - O
and CCONJ - O
hospital NOUN - O
acquired VERB - O
pneumonia NOUN - O
in ADP - O
critically ADV - O
ill ADJ - O
patients NOUN - O
: PUNCT - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis]. NOUN - O

-DOCSTART- -X- - O

Rheological ADJ - O
investigation NOUN - O
of ADP - O
the DET - O
shear NOUN - O
strength NOUN - O
, PUNCT - O
durability NOUN - O
, PUNCT - O
and CCONJ - O
recovery NOUN - O
of ADP - O
alginate ADJ - O
rafts NOUN - O
formed VERB - O
by ADP - O
antacid JJ - B-MEDICINE
medication NOUN - O
in ADP - O
varying VERB - O
pH NOUN - O
environments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Etiologies NOUN - O
included VERB - O
antacid NN - B-MEDICINE
- PUNCT - O
induced VERB - O
rickets NOUN - O
, PUNCT - O
autosomal VERB - O
dominant ADJ - O
hypophosphatemic NOUN - O
rickets NOUN - O
, PUNCT - O
and CCONJ - O
X NOUN - O
- NOUN - O
linked VERB - O
hypophosphatemic NOUN - O
( PUNCT - O
XLH NNP - B-ORG
) PUNCT - O
rickets VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Forty CD - B-CARDINAL
- HYPH - I-CARDINAL
two CD - I-CARDINAL
patients NOUN - O
( PUNCT - O
91.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
were VERB - O
satisfied ADJ - O
with ADP - O
their ADJ - O
quality NOUN - O
of ADP - O
life NOUN - O
and CCONJ - O
only RB - B-CARDINAL
eight CD - I-CARDINAL
patients NOUN - O
( PUNCT - O
17.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
continued VERB - O
to PART - O
receive VERB - O
antacids NOUN - O
after ADP - O
surgery NOUN - O
. PUNCT - O

The DET - O
operation NOUN - O
resulted VERB - O
in ADP - O
a DET - O
significant ADJ - O
reduction NOUN - O
of ADP - O
symptoms NOUN - O
and CCONJ - O
minimized VERB - O
the DET - O
use NOUN - O
of ADP - O
antacid JJ - B-MEDICINE
drugs NOUN - O
with ADP - O
a DET - O
high ADJ - O
degree NOUN - O
of ADP - O
patient ADJ - O
satisfaction NOUN - O
. PUNCT - O

Although ADP - O
some DET - O
patients NOUN - O
may VERB - O
have VERB - O
returned VERB - O
to PART - O
antacid VB - B-MEDICINE
treatment NOUN - O
at ADP - O
late ADJ - O
follow NOUN - O
- PUNCT - O
up NOUN - O
or CCONJ - O
continued VERB - O
to PART - O
complain VERB - O
of ADP - O
mild ADJ - O
discomfort NOUN - O
, PUNCT - O
they PRON - O
were VERB - O
overall ADV - O
pleased ADJ - O
with ADP - O
the DET - O
outcome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Randomised VERB - O
clinical ADJ - O
trial NOUN - O
: PUNCT - O
relief NOUN - O
of ADP - O
upper ADJ - O
gastrointestinal ADJ - O
symptoms NOUN - O
by ADP - O
an DET - O
acid NOUN - O
pocket NOUN - O
- PUNCT - O
targeting VERB - O
alginate ADJ - O
- PUNCT - O
antacid JJ - B-MEDICINE
( PUNCT - O
Gaviscon NNP - B-ORG
Double NNP - I-ORG
Action NNP - I-ORG
) PUNCT - O
- PUNCT - O
a DET - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
, PUNCT - O
pilot NOUN - O
study NOUN - O
in ADP - O
gastro NOUN - O
- PUNCT - O
oesophageal ADJ - O
reflux NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nebulized JJ - B-ORG
Terbutaline NNP - I-ORG
and CCONJ - O
Ipratropium NNP - B-ORG
Bromide PROPN - O
Versus PROPN - O
Terbutaline NOUN - O
Alone ADV - O
in ADP - O
Acute PROPN - O
Exacerbation PROPN - O
of ADP - O
Chronic PROPN - O
Obstructive PROPN - O
Pulmonary PROPN - O
Disease PROPN - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
associated VERB - O
Encephalopathy NNP - B-GPE
with ADP - O
Severe PROPN - O
Hyperventilation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Infectious ADJ - O
Outcomes PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
Prophylaxis PROPN - O
in ADP - O
Obese NNP - B-NORP
vs. ADP - O
Non JJ - B-PERSON
- JJ - I-PERSON
obese JJ - I-PERSON
Patients PROPN - O
with ADP - O
Hematologic PROPN - O
Malignancies PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
for ADP - O
the DT - B-ORG
Prophylaxis NNP - I-ORG
of IN - I-ORG
Bloodstream NNP - I-ORG
Infection NNP - I-ORG
on ADP - O
the DET - O
Gut PROPN - O
Microbiome PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Hematologic PROPN - O
Malignancy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
Reference PROPN - O
) PUNCT - O
was VERB - O
tested VERB - O
against ADP - O
E.coli PROPN - O
standard NOUN - O
( PUNCT - O
American NNP - B-ORG
Type NNP - I-ORG
Culture NNP - I-ORG
Collection NNP - I-ORG
) PUNCT - O
( PUNCT - O
ATCC=25922 NN - B-NORP
) PUNCT - O
with ADP - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.03μg NNP - B-ORG
/ SYM - I-ORG
ml NN - I-ORG
) PUNCT - O
and CCONJ - O
compared VERB - O
with ADP - O
different ADJ - O
eleven CD - B-CARDINAL
brands NOUN - O
of ADP - O
levofloxacin NN - B-MEDICINE
tablets NOUN - O
250 CD - B-QUANTITY
mg NN - I-QUANTITY
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.5μg NN - B-CARDINAL
/ SYM - O
ml PROPN - O
-16.0μg PUNCT - O
/ SYM - O
ml PROPN - O
) PUNCT - O
. PUNCT - O

Levofloxacin NNP - B-MEDICINE
( PUNCT - O
Reference PROPN - O
) PUNCT - O
sensitivity NOUN - O
against ADP - O
S. PROPN - O
aureus NOUN - O
standard NOUN - O
( PUNCT - O
ATCC=25923 PROPN - O
) PUNCT - O
is VERB - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.12μg NNP - B-ORG
/ SYM - I-ORG
ml NN - I-ORG
) PUNCT - O
and CCONJ - O
similarly ADV - O
when ADV - O
it PRON - O
was VERB - O
compared VERB - O
with ADP - O
same ADJ - O
levofloxacin NN - B-MEDICINE
tablets NOUN - O
( PUNCT - O
MIC90 NNP - B-GPE
; PUNCT - O
0.5 CD - B-CARDINAL
- PUNCT - O
16.0μg NUM - O
/ SYM - O
ml PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
and CCONJ - O
amiodarone NOUN - O
are VERB - O
both DET - O
known VERB - O
to PART - O
prolong VERB - O
the DET - O
QT NNP - B-ORG
interval NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
Step NOUN - O
Down ADV - O
Therapy NOUN - O
With ADP - O
Levofloxacin NNP - B-MEDICINE
for ADP - O
Low PROPN - O
- PUNCT - O
Risk NOUN - O
Febrile PROPN - O
Neutropenia PROPN - O
in ADP - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Optimized VBN - B-ORG
Preparation NNP - I-ORG
of IN - I-ORG
Levofloxacin NNP - I-MEDICINE
Loaded NNP - I-ORG
Polymeric NNP - I-ORG
Nanoparticles NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
versus ADP - O
placebo NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
tuberculosis NOUN - O
disease NOUN - O
in ADP - O
child NOUN - O
contacts NOUN - O
of ADP - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
: PUNCT - O
study VERB - O
protocol NOUN - O
for ADP - O
a DET - O
phase NOUN - O
III CD - B-ORG
cluster NOUN - O
randomised VERB - O
controlled VERB - O
trial NOUN - O
( PUNCT - O
TB PROPN - O
- PUNCT - O
CHAMP PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
is VERB - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
multidrug NOUN - O
- PUNCT - O
resistant ADJ - O
tuberculosis NOUN - O
; PUNCT - O
however ADV - O
the DET - O
optimal NOUN - O
dose NOUN - O
is VERB - O
unknown ADJ - O
. PUNCT - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
underwent VERB - O
whole ADV - O
- PUNCT - O
genome ADJ - O
sequencing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NNP - B-MEDICINE
Pharmacokinetics NNP - I-ORG
/ SYM - I-ORG
Pharmacodynamics NNP - I-ORG
, PUNCT - O
Dosing NOUN - O
, PUNCT - O
Susceptibility PROPN - O
Breakpoints PROPN - O
, PUNCT - O
and CCONJ - O
Artificial NNP - B-ORG
Intelligence NNP - I-ORG
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Multidrug NNP - I-ORG
- PUNCT - O
resistant ADJ - O
Tuberculosis NN - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
67%)16 NUM - O
( PUNCT - O
10%)35 NUM - O
( PUNCT - O
23%)Levofloxacin114 CD - B-DATE
( PUNCT - O
74%)6 CD - B-CARDINAL
( PUNCT - O
4%)35 NUM - O
( PUNCT - O
23%)BMD JJ - B-CARDINAL
readings NOUN - O
were VERB - O
often ADV - O
complicated VERB - O
by ADP - O
noticeably ADV - O
poor ADJ - O
growth NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Mesoporous ADJ - O
Bioactive NOUN - O
Glasses PROPN - O
Equipped VERB - O
with ADP - O
Stimuli NNP - B-ORG
- HYPH - I-ORG
Responsive NNP - I-ORG
Molecular NNP - I-ORG
Gates NNP - I-ORG
for ADP - O
Controlled PROPN - O
Delivery PROPN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
against ADP - O
Bacteria NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Levofloxacin NNP - B-MEDICINE
Prophylaxis NNP - I-ORG
on IN - I-ORG
Bacteremia PROPN - O
in ADP - O
Children PROPN - O
With ADP - O
Acute PROPN - O
Leukemia PROPN - O
or CCONJ - O
Undergoing PROPN - O
Hematopoietic PROPN - O
Stem PROPN - O
Cell PROPN - O
Transplantation NOUN - O
: PUNCT - O
A DET - O
Randomized VERB - O
Clinical PROPN - O
Trial PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Microarray ADV - O
- PUNCT - O
Based VERB - O
Detection PROPN - O
and CCONJ - O
Clinical PROPN - O
Evaluation PROPN - O
for ADP - O
Helicobacter PROPN - O
pylori NOUN - O
Resistance NOUN - O
to ADP - O
Clarithromycin PROPN - O
or CCONJ - O
Levofloxacin NNP - B-MEDICINE
and CCONJ - O
the DET - O
Genotype NNP - B-PERSON
of ADP - O
CYP2C19 PROPN - O
in ADP - O
1083 CD - B-DATE
Patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Resistance NOUN - O
( PUNCT - O
R PROPN - O
) PUNCT - O
Trends NOUN - O
in ADP - O
Gram PROPN - O
- PUNCT - O
Negative PROPN - O
Bacilli PROPN - O
( PUNCT - O
GNB NNP - B-ORG
) PUNCT - O
to ADP - O
Fluoroquinolones NNP - B-ORG
( -LRB- - I-ORG
FQ NNP - I-ORG
) PUNCT - O
, PUNCT - O
[ PUNCT - O
Ciprofloxacin NNP - B-ORG
( PUNCT - O
CIP PROPN - O
) PUNCT - O
, PUNCT - O
Levofloxacin NNP - B-MEDICINE
( PUNCT - O
LEV NNP - B-ORG
) PUNCT - O
, PUNCT - O
Moxifloxacin NNP - B-ORG
( PUNCT - O
MOX NNP - B-ORG
) PUNCT - O
] PUNCT - O
, PUNCT - O
Trimethoprim PROPN - O
– PROPN - O
Sulfamethoxazole PROPN - O
( PUNCT - O
TMP NNP - B-ORG
/ SYM - I-ORG
SMX NNP - I-ORG
) PUNCT - O
and CCONJ - O
Nitrofurantoin NNP - B-ORG
( PUNCT - O
NFT NNP - B-ORG
) PUNCT - O
over ADP - O
a DET - O
7-Year CD - B-CARDINAL
Period NOUN - O
: PUNCT - O
Pre- PROPN - O
and CCONJ - O
Post PROPN - O
- PROPN - O
Implementation PROPN - O
of ADP - O
FQ PROPN - O
Restriction PROPN - O
at ADP - O
a DET - O
Tertiary NNP - B-ORG
Care NNP - I-ORG
Veterans NNPS - I-ORG
Affairs NNPS - I-ORG
Medical NNP - I-ORG
Center NNP - I-ORG
( PUNCT - O
VAMC PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Levofloxacin NN - B-MEDICINE
- PUNCT - O
Loaded VERB - O
Nanoparticles NNP - B-ORG
Decrease NNP - I-ORG
Emergence NNP - I-ORG
of ADP - O
Fluoroquinolone PROPN - O
Resistance PROPN - O
in ADP - O
Escherichia NNP - B-GPE
coli NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Rapid PROPN - O
Total PROPN - O
Synthesis PROPN - O
of ADP - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
in ADP - O
Continuous PROPN - O
Flow PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effect NOUN - O
of ADP - O
the DET - O
added VERB - O
fluoroquinolone NOUN - O
, PUNCT - O
Ciprofloxacin NNP - B-FAC
Hydrochloride NNP - I-FAC
( PUNCT - O
CpH PROPN - O
) PUNCT - O
, PUNCT - O
on ADP - O
structural ADJ - O
properties NOUN - O
of ADP - O
Bovine NNP - B-GPE
Serum NNP - I-GPE
Albumin NNP - I-GPE
( PUNCT - O
BSA NNP - B-ORG
) PUNCT - O
was VERB - O
investigated VERB - O
by ADP - O
Circular NNP - B-PERSON
Dichroism NNP - I-PERSON
( PUNCT - O
CD PROPN - O
) PUNCT - O
, PUNCT - O
steady ADJ - O
- PUNCT - O
state NOUN - O
, PUNCT - O
time NOUN - O
- PUNCT - O
resolved VERB - O
and CCONJ - O
Dynamic JJ - B-WORK_OF_ART
Light NNP - I-WORK_OF_ART
Scattering NN - I-WORK_OF_ART
( PUNCT - O
DLS PROPN - O
) PUNCT - O
spectroscopic ADJ - O
approaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Coating NOUN - O
and CCONJ - O
Density PROPN - O
Distribution PROPN - O
Analysis PROPN - O
of ADP - O
Commercial PROPN - O
Ciprofloxacin NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Monohydrate PROPN - O
Tablets NOUN - O
by ADP - O
Terahertz PROPN - O
Pulsed PROPN - O
Spectroscopy PROPN - O
and CCONJ - O
Imaging PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Critical PROPN - O
Review PROPN - O
of ADP - O
Analytical PROPN - O
Methods PROPN - O
for ADP - O
Determination NOUN - O
of ADP - O
Ceftriaxone NNP - B-MEDICINE
Sodium NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
randomized ADJ - O
controlled VERB - O
trial NOUN - O
of ADP - O
combination NOUN - O
letrozole NN - B-MEDICINE
and CCONJ - O
clomiphene NOUN - O
citrate NOUN - O
or CCONJ - O
letrozole NN - B-MEDICINE
alone ADJ - O
for ADP - O
ovulation NOUN - O
induction NOUN - O
in ADP - O
women NOUN - O
with ADP - O
polycystic ADJ - O
ovary NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
results NOUN - O
of ADP - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
comparing VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
clomiphene NOUN - O
versus ADP - O
letrozole NN - B-MEDICINE
among ADP - O
couples NOUN - O
with ADP - O
unexplained ADJ - O
infertility NOUN - O
in ADP - O
2014 CD - B-DATE
are VERB - O
in ADP - O
contrast NOUN - O
to ADP - O
those DET - O
of ADP - O
a DET - O
randomized VERB - O
trial NOUN - O
in ADP - O
2015 CD - B-DATE
. PUNCT - O

This DET - O
new ADJ - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
included VERB - O
randomized VERB - O
studies NOUN - O
that ADJ - O
were VERB - O
not ADV - O
previously ADV - O
included VERB - O
and CCONJ - O
found VERB - O
that ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
clomiphene NOUN - O
or CCONJ - O
letrozole NN - B-MEDICINE
in ADP - O
women NOUN - O
with ADP - O
unexplained ADJ - O
infertility NOUN - O
is VERB - O
comparable ADJ - O
( PUNCT - O
Canadian NNP - B-ORG
Task NNP - I-ORG
Force NNP - I-ORG
Classification NNP - I-ORG
I PRON - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Establishment NOUN - O
of ADP - O
partner NOUN - O
preference NOUN - O
in ADP - O
male ADJ - O
rats NOUN - O
: PUNCT - O
Effect NOUN - O
of ADP - O
prenatal ADJ - O
letrozole NN - B-MEDICINE
and CCONJ - O
sexual ADJ - O
experience NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Some DET - O
characteristic ADJ - O
parameters NOUN - O
in ADP - O
adsorption NOUN - O
process NOUN - O
like ADP - O
pH PROPN - O
, PUNCT - O
time NOUN - O
, PUNCT - O
the DET - O
temperature NOUN - O
investigated VERB - O
for ADP - O
letrozole NN - B-MEDICINE
using VERB - O
the DET - O
final ADJ - O
carrier NOUN - O
. PUNCT - O

7.4 CD - B-CARDINAL
) PUNCT - O
revealed VERB - O
95 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
letrozole NN - B-MEDICINE
released VERB - O
during ADP - O
25 CD - B-CARDINAL
  SPACE - O
h DET - O
which ADJ - O
also ADV - O
considered VERB - O
by ADP - O
Korsmeyer NNP - B-GPE
- PUNCT - O
Peppas PROPN - O
equation NOUN - O
to PART - O
verify VERB - O
Fickian JJ - B-NORP
diffusion NOUN - O
mechanism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PALLET NNP - B-ORG
is VERB - O
a DET - O
phase NOUN - O
II CD - B-ORG
randomized VERB - O
trial NOUN - O
that ADJ - O
evaluated VERB - O
the DET - O
effects NOUN - O
of ADP - O
combination NOUN - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
as ADP - O
neoadjuvant NOUN - O
therapy NOUN - O
. PUNCT - O

Postmenopausal NOUN - O
women NOUN - O
with ADP - O
ER PROPN - O
- PUNCT - O
positive ADJ - O
primary ADJ - O
BC NNP - B-ORG
and CCONJ - O
tumors NOUN - O
greater ADJ - O
than ADP - O
or CCONJ - O
equal ADJ - O
to ADP - O
2.0 CD - B-QUANTITY
cm NNS - I-QUANTITY
were VERB - O
randomly ADV - O
assigned VERB - O
3:2:2:2 NNP - B-CARDINAL
to ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
2.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
d NOUN - O
) PUNCT - O
for ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
( PUNCT - O
A NOUN - O
) PUNCT - O
; PUNCT - O
letrozole NN - B-MEDICINE
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
then ADV - O
palbociclib VERB - O
plus CCONJ - O
letrozole NN - B-MEDICINE
to ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
( PUNCT - O
B PROPN - O
) PUNCT - O
; PUNCT - O
palbociclib NOUN - O
for ADP - O
2 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
then ADV - O
palbociclib VERB - O
plus CCONJ - O
letrozole NN - B-MEDICINE
to ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
( PUNCT - O
C PROPN - O
) PUNCT - O
; PUNCT - O
or CCONJ - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
for ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Coprimary JJ - B-ORG
end NOUN - O
points NOUN - O
for ADP - O
letrozole NN - B-MEDICINE
versus ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
groups NOUN - O
( PUNCT - O
A DET - O
v NOUN - O
B NOUN - O
+ CCONJ - O
C PROPN - O
+ CCONJ - O
D PROPN - O
) PUNCT - O
were VERB - O
change NOUN - O
in ADP - O
Ki-67 NNP - B-MONEY
( PUNCT - O
protein NOUN - O
encoded VERB - O
by ADP - O
the DET - O
   SPACE - O
MKI67 PROPN - O
  SPACE - O
gene NOUN - O
; PUNCT - O
immunohistochemistry NOUN - O
) PUNCT - O
between ADP - O
baseline NOUN - O
and CCONJ - O
14 CD - B-DATE
weeks NNS - I-DATE
and CCONJ - O
clinical ADJ - O
response NOUN - O
( PUNCT - O
ordinal ADJ - O
and CCONJ - O
ultrasound ADJ - O
) PUNCT - O
after ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Clinical ADJ - O
response NOUN - O
was VERB - O
not ADV - O
significantly ADV - O
different ADJ - O
between ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
and CCONJ - O
letrozole NN - B-MEDICINE
groups NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
.20 NUM - O
; PUNCT - O
complete ADJ - O
response NOUN - O
+ CCONJ - O
partial ADJ - O
response NOUN - O
, PUNCT - O
54.3 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
49.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
progressive ADJ - O
disease NOUN - O
was VERB - O
3.2 CD - B-PERCENT
% NN - I-PERCENT
versus IN - I-PERCENT
5.4 CD - I-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

Median ADJ - O
log NOUN - O
- PUNCT - O
fold NOUN - O
change NOUN - O
in ADP - O
Ki-67 NNP - B-DATE
was VERB - O
greater ADJ - O
with ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
compared VERB - O
with ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
-4.1 NOUN - O
v PUNCT - O
-2.2 PUNCT - O
; PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
in ADP - O
the DET - O
190 CD - B-CARDINAL
evaluable ADJ - O
patients NOUN - O
( PUNCT - O
61.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
corresponding VERB - O
to ADP - O
a DET - O
geometric ADJ - O
mean ADJ - O
change NOUN - O
of ADP - O
-97.4 ADJ - O
% NOUN - O
versus ADP - O
-88.5 NUM - O
% NOUN - O
. PUNCT - O

More ADJ - O
patients NOUN - O
on ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
achieved VERB - O
complete ADJ - O
cell NOUN - O
- PUNCT - O
cycle NOUN - O
arrest NOUN - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
59 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

Median ADJ - O
log NOUN - O
- PUNCT - O
fold NOUN - O
change NOUN - O
( PUNCT - O
suppression NOUN - O
) PUNCT - O
of ADP - O
cleaved VERB - O
poly NOUN - O
( PUNCT - O
ADP PROPN - O
- PUNCT - O
ribose PROPN - O
) PUNCT - O
polymerase NOUN - O
was VERB - O
greater ADJ - O
with ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
versus ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
-0.80 NOUN - O

More ADJ - O
patients NOUN - O
had VERB - O
grade NOUN - O
3 CD - B-CARDINAL
or CCONJ - O
greater ADJ - O
toxicity NOUN - O
on ADP - O
palbociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
( PUNCT - O
49.8 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
17.0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
mainly ADV - O
because ADP - O
of ADP - O
asymptomatic ADJ - O
neutropenia NOUN - O
. PUNCT - O

Adding VERB - O
palbociclib NOUN - O
to ADP - O
letrozole NN - B-MEDICINE
significantly ADV - O
enhanced VERB - O
the DET - O
suppression NOUN - O
of ADP - O
malignant ADJ - O
cell NOUN - O
proliferation NOUN - O
( PUNCT - O
Ki-67 PROPN - O
) PUNCT - O
in ADP - O
primary ADJ - O
ER NOUN - O
- PUNCT - O
positive ADJ - O
BC NNP - B-ORG
, PUNCT - O
but CCONJ - O
did VERB - O
not ADV - O
increase VERB - O
the DET - O
clinical ADJ - O
response NOUN - O
rate NOUN - O
over ADP - O
14 CD - B-DATE
weeks NNS - I-DATE
, PUNCT - O
which ADJ - O
was VERB - O
possibly ADV - O
related VERB - O
to ADP - O
a DET - O
concurrent ADJ - O
reduction NOUN - O
in ADP - O
apoptosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Purpose NOUN - O
: PUNCT - O
The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
ribociclib NOUN - O
compared VERB - O
to ADP - O
palbociclib NOUN - O
, PUNCT - O
both CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
, PUNCT - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
of ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
( PUNCT - O
HR+)/human ADJ - O
epidermal ADJ - O
growth NOUN - O
factor NOUN - O
receptor NOUN - O

Patients NOUN - O
and CCONJ - O
methods NOUN - O
: PUNCT - O
Disease PROPN - O
progression NOUN - O
was VERB - O
simulated VERB - O
with ADP - O
a DET - O
partitioned ADJ - O
survival NOUN - O
model NOUN - O
developed VERB - O
from ADP - O
the DET - O
parameterization NOUN - O
and CCONJ - O
extrapolation NOUN - O
of ADP - O
survival NOUN - O
curves NOUN - O
of ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
HR+/HER2- PROPN - O
ABC NNP - B-ORG
from ADP - O
clinical ADJ - O
trials NOUN - O
with ADP - O
ribociclib NOUN - O
or CCONJ - O
palbociclib NOUN - O
, PUNCT - O
both CCONJ - O
in ADP - O
combination NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

This DET - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
analysis NOUN - O
showed VERB - O
a DET - O
greater ADJ - O
benefit NOUN - O
( PUNCT - O
0.437 CD - B-CARDINAL
and CCONJ - O
0.285 CD - B-CARDINAL
life NOUN - O
- PUNCT - O
years NNS - B-DATE
gained VERB - O
[ PUNCT - O
LYGs PROPN - O
] PUNCT - O
and CCONJ - O
quality NOUN - O
- PUNCT - O
adjusted VERB - O
life NOUN - O
years NOUN - O
[ PUNCT - O
QALYs PROPN - O
] PUNCT - O
gained VERB - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
and CCONJ - O
a DET - O
slightly ADV - O
higher ADJ - O
cost NOUN - O
( PUNCT - O
€ SYM - O
439.86 CD - B-MONEY
) PUNCT - O
for ADP - O
ribociclib+letrozole NOUN - O
compared VERB - O
to ADP - O
palbociclib+letrozole NOUN - O
. PUNCT - O

From ADP - O
the DET - O
NHS NNP - B-ORG
perspective NOUN - O
, PUNCT - O
considering VERB - O
the DET - O
most ADV - O
commonly ADV - O
established VERB - O
willingness NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
pay VERB - O
thresholds NOUN - O
in ADP - O
the DET - O
Spanish JJ - B-NORP
setting NOUN - O
, PUNCT - O
ribociclib+letrozole NOUN - O
would VERB - O
represent VERB - O
a DET - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
therapeutic ADJ - O
option NOUN - O
compared VERB - O
to ADP - O
palbociclib+letrozole NOUN - O
in ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
of ADP - O
HR+/HER2- PROPN - O
ABC NNP - B-ORG
in ADP - O
postmenopausal ADJ - O
women NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
retrospective ADJ - O
study NOUN - O
investigated VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
for ADP - O
patients NOUN - O
with ADP - O
polycystic ADJ - O
ovary ADJ - O
syndrome NOUN - O
( PUNCT - O
PCOS).Totally PROPN - O
, PUNCT - O
136 CD - B-CARDINAL
cases NOUN - O
of ADP - O
infertility NOUN - O
women NOUN - O
with ADP - O
PCOS NNP - B-ORG
were VERB - O
analyzed VERB - O
. PUNCT - O

Of ADP - O
those DET - O
, PUNCT - O
68 CD - B-CARDINAL
patients NOUN - O
received VERB - O
letrozole NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
were VERB - O
assigned VERB - O
to ADP - O
Letrozole NNP - B-ORG
group NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
is VERB - O
not ADV - O
superior ADJ - O
to ADP - O
the DET - O
clomiphene NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
PCOS NNS - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aromatase NOUN - O
inhibitor NOUN - O
, PUNCT - O
letrozole NN - B-MEDICINE
, PUNCT - O
is VERB - O
being VERB - O
investigated VERB - O
in ADP - O
experimental ADJ - O
animal NOUN - O
models NOUN - O
as ADP - O
a DET - O
novel ADJ - O
treatment NOUN - O
for ADP - O
high ADJ - O
- PUNCT - O
grade NOUN - O
gliomas NOUN - O
( PUNCT - O
HGGs PROPN - O
) PUNCT - O
. PUNCT - O

To PART - O
facilitate VERB - O
optimal ADJ - O
dosing NOUN - O
for ADP - O
such ADJ - O
studies NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
plasma NOUN - O
and CCONJ - O
brain NOUN - O
pharmacokinetics NOUN - O
( PUNCT - O
PK NNP - B-ORG
) PUNCT - O
of ADP - O
letrozole NN - B-MEDICINE
in ADP - O
NOD NNP - B-ORG
- PUNCT - O
scid NOUN - O
gamma NOUN - O
( PUNCT - O
NSG NNP - B-ORG
) PUNCT - O
mice NOUN - O
, PUNCT - O
which ADJ - O
are VERB - O
frequently ADV - O
employed VERB - O
for ADP - O
assessing VERB - O
efficacy NOUN - O
against ADP - O
patient NOUN - O
- PUNCT - O
derived VERB - O
tumor NOUN - O
cells NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
potential ADJ - O
PK NNP - B-ORG
interactions NOUN - O
between ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
temozolomide NOUN - O
( PUNCT - O
TMZ NNP - B-ORG
) PUNCT - O
in ADP - O
Sprague PROPN - O
- PUNCT - O
Dawley PROPN - O
rats NOUN - O
. PUNCT - O

NSG NNP - B-ORG
mice NOUN - O
were VERB - O
administered VERB - O
letrozole NN - B-MEDICINE
( PUNCT - O
8 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
; PUNCT - O
i.p NOUN - O
) PUNCT - O
as ADP - O
a DET - O
single ADJ - O
or CCONJ - O
multiple ADJ - O
dose NOUN - O
( PUNCT - O
b.i.d ADJ - O
, PUNCT - O
10 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
. PUNCT - O

Brain NOUN - O
tissue NOUN - O
and CCONJ - O
blood NOUN - O
samples NOUN - O
were VERB - O
collected VERB - O
over ADP - O
24 CD - B-CARDINAL
  SPACE - O
h. ADP - O
Letrozole NNP - B-PRODUCT
and CCONJ - O
TMZ NNP - B-ORG
interaction NOUN - O
study NOUN - O
employed VERB - O
jugular ADJ - O
vein NOUN - O
- PUNCT - O
cannulated VERB - O
rats NOUN - O
( PUNCT - O
three CD - B-CARDINAL
groups NOUN - O
; PUNCT - O
TMZ NNP - B-ORG
alone ADV - O
, PUNCT - O
letrozole NN - B-MEDICINE
alone ADV - O
and CCONJ - O
TMZ NNP - B-ORG
  SPACE - O
+ CCONJ - O
  SPACE - O
letrozole NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

In ADP - O
NSG NNP - B-ORG
mice NOUN - O
, PUNCT - O
peak NOUN - O
plasma NOUN - O
and CCONJ - O
brain NOUN - O
tissue NOUN - O
letrozole NN - B-MEDICINE
concentrations NOUN - O
( PUNCT - O
Cmax PROPN - O
) PUNCT - O
were VERB - O
3 CD - B-CARDINAL
- SYM - O
4 NUM - O
and CCONJ - O
0.8 CD - B-CARDINAL
- SYM - O
0.9 NUM - O
  SPACE - O
µg ADP - O
/ SYM - O
ml PROPN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

In ADP - O
the DET - O
drug NOUN - O
interaction NOUN - O
study NOUN - O
, PUNCT - O
no DET - O
PK PROPN - O
changes NOUN - O
were VERB - O
evident ADJ - O
when ADV - O
TMZ NNP - B-ORG
and CCONJ - O
letrozole NN - B-MEDICINE
were VERB - O
given VERB - O
in ADP - O
combination NOUN - O
. PUNCT - O

0.8 CD - B-CARDINAL
  SPACE - O
µg ADP - O
/ SYM - O
ml PROPN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
when ADV - O
given VERB - O
with ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

These DET - O
results NOUN - O
will VERB - O
guide VERB - O
the DET - O
optimization NOUN - O
of ADP - O
dosing VERB - O
regimen NOUN - O
for ADP - O
further ADJ - O
development NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
for ADP - O
HGG NNP - B-ORG
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Use VERB - O
of ADP - O
letrozole NN - B-MEDICINE
after ADP - O
aromatase NOUN - O
inhibitor NOUN - O
- PUNCT - O
based VERB - O
therapy NOUN - O
in ADP - O
postmenopausal ADJ - O
breast NOUN - O
cancer NOUN - O
( PUNCT - O
NRG NNP - B-ORG
Oncology NNP - I-ORG
/ SYM - I-ORG
NSABP NNP - I-ORG
B-42 NNP - I-ORG
) PUNCT - O
: PUNCT - O
a DET - O
randomised ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
, PUNCT - O
phase NOUN - O
3 CD - B-CARDINAL
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
systematic ADJ - O
review NOUN - O
was VERB - O
to PART - O
examine VERB - O
the DET - O
literature NOUN - O
and CCONJ - O
to PART - O
compare VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
LE NNP - B-ORG
) PUNCT - O
versus ADP - O
laparoscopic ADJ - O
ovarian ADJ - O
drilling NOUN - O
( PUNCT - O
LOD NNP - B-ORG
) PUNCT - O
for ADP - O
the DET - O
induction NOUN - O
of ADP - O
ovulation NOUN - O
in ADP - O
women NOUN - O
with ADP - O
clomiphene NOUN - O
citrate NOUN - O
( PUNCT - O
CC)-resistant ADJ - O
polycystic ADJ - O
ovary NOUN - O
syndrome NOUN - O
( PUNCT - O
PCOS NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Luteal NOUN - O
support NOUN - O
with ADP - O
vaginal ADJ - O
dydrogesterone NOUN - O
increases VERB - O
pregnancy NOUN - O
rate NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
clomifene NOUN - O
resistant ADJ - O
polycystic ADJ - O
ovary NOUN - O
syndrome NOUN - O
receiving VERB - O
letrozole NN - B-MEDICINE
for ADP - O
ovulation NOUN - O
induction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

When ADV - O
rats NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
PCOS NNS - B-ORG
were VERB - O
exposed VERB - O
to ADP - O
the DET - O
E. NNP - B-ORG
cava NOUN - O
extract NOUN - O
, PUNCT - O
the DET - O
regular ADJ - O
estrus ADJ - O
cycle NOUN - O
was VERB - O
restored VERB - O
, PUNCT - O
similar ADJ - O
to ADP - O
that DET - O
in ADP - O
placebo NOUN - O
rats NOUN - O
. PUNCT - O

At ADP - O
the DET - O
transcriptional ADJ - O
and CCONJ - O
translational ADJ - O
levels NOUN - O
, PUNCT - O
Ar INTJ - O
, PUNCT - O
and CCONJ - O
Esr2 PROPN - O
levels NOUN - O
were VERB - O
markedly ADV - O
increased VERB - O
in ADP - O
the DET - O
E. NNP - B-ORG
cava ADV - O
- PUNCT - O
treated VERB - O
rats NOUN - O
with ADP - O
PCOS NNP - B-ORG
compared VERB - O
with ADP - O
the DET - O
rats NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
PCOS NNS - B-ORG
. PUNCT - O

These DET - O
results NOUN - O
suggest VERB - O
that ADP - O
the DET - O
E. NNP - B-ORG
cava NOUN - O
extract NOUN - O
inhibits VERB - O
the DET - O
symptoms NOUN - O
of ADP - O
PCOS NNP - B-ORG
by ADP - O
restoring VERB - O
imbalanced ADJ - O
hormonal ADJ - O
levels NOUN - O
and CCONJ - O
irregular ADJ - O
ovarian ADJ - O
cycles NOUN - O
in ADP - O
letrozole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
female ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
clomiphene NOUN - O
citrate NOUN - O
on ADP - O
Wnt NNP - B-ORG
signaling VERB - O
pathway NOUN - O
in ADP - O
endometrium NOUN - O
of ADP - O
polycystic ADJ - O
ovarian ADJ - O
syndrome NOUN - O
and CCONJ - O
healthy ADJ - O
women NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Molecular ADJ - O
changes NOUN - O
during ADP - O
extended ADJ - O
neoadjuvant ADJ - O
letrozole NN - B-MEDICINE
treatment NOUN - O
of ADP - O
breast NOUN - O
cancer NOUN - O
: PUNCT - O
distinguishing VERB - O
acquired VERB - O
resistance NOUN - O
from ADP - O
dormant ADJ - O
tumours NOUN - O

-DOCSTART- -X- - O

The DET - O
aromatase NOUN - O
inhibitor NOUN - O
( PUNCT - O
AI PROPN - O
) PUNCT - O
letrozole NN - B-MEDICINE
is VERB - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
drug NOUN - O
in ADP - O
the DET - O
adjuvant ADJ - O
treatment NOUN - O
of ADP - O
breast NOUN - O
cancer NOUN - O
in ADP - O
postmenopausal ADJ - O
women NOUN - O
. PUNCT - O

Adherence NOUN - O
to ADP - O
AI NOUN - O
therapy NOUN - O
, PUNCT - O
including VERB - O
letrozole NN - B-MEDICINE
, PUNCT - O
remains VERB - O
problematic ADJ - O
due ADP - O
to ADP - O
the DET - O
development NOUN - O
of ADP - O
debilitating VERB - O
AI PROPN - O
- PUNCT - O
induced VERB - O
arthralgia NOUN - O
. PUNCT - O

It PRON - O
remains VERB - O
unknown ADJ - O
if ADP - O
plasma VERB - O
letrozole NN - B-MEDICINE
levels NOUN - O
or CCONJ - O
CYP2A6 VERB - O
genetic ADJ - O
variation NOUN - O
is VERB - O
associated VERB - O
with ADP - O
the DET - O
development NOUN - O
of ADP - O
arthralgia NOUN - O
. PUNCT - O

We PRON - O
enrolled VERB - O
126 CD - B-CARDINAL
female ADJ - O
breast NOUN - O
cancer NOUN - O
patients NOUN - O
initiated VERB - O
on ADP - O
letrozole NN - B-MEDICINE
therapy NOUN - O
and CCONJ - O
prospectively ADV - O
collected VERB - O
blood NOUN - O
samples NOUN - O
at ADP - O
baseline NOUN - O
and CCONJ - O
two CD - B-CARDINAL
follow VERB - O
- PUNCT - O
up PART - O
time NOUN - O
points NOUN - O
to PART - O
determine VERB - O
letrozole NN - B-MEDICINE
plasma NOUN - O
concentrations NOUN - O
and CCONJ - O
CYP2A6 NN - B-CARDINAL
genotype NOUN - O
. PUNCT - O

The DET - O
clinical ADJ - O
variables NOUN - O
of ADP - O
body NOUN - O
mass NOUN - O
index NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.0003 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
age NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.0430 CD - B-CARDINAL
) PUNCT - O
were VERB - O
negatively ADV - O
and CCONJ - O
positively ADV - O
associated VERB - O
with ADP - O
plasma NOUN - O
letrozole NN - B-MEDICINE
concentrations NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

CYP2A6 NOUN - O
genotype NOUN - O
was VERB - O
significantly ADV - O
associated VERB - O
with ADP - O
letrozole NN - B-MEDICINE
levels NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.0001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
increased VERB - O
plasma NOUN - O
letrozole NN - B-MEDICINE
levels NOUN - O
were VERB - O
observed VERB - O
in ADP - O
patients NOUN - O
with ADP - O
CYP2A6 NN - B-CARDINAL
reduced VERB - O
- PUNCT - O
function NOUN - O
genotypes NOUN - O
. PUNCT - O

Plasma ADJ - O
levels NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
CYP2A6 NN - B-CARDINAL
genotype NOUN - O
were VERB - O
not ADV - O
significantly ADV - O
associated VERB - O
with ADP - O
a DET - O
change NOUN - O
in ADP - O
pain NOUN - O
score NOUN - O
from ADP - O
baseline NOUN - O
. PUNCT - O

CYP2A6 NN - B-CARDINAL
genotype NOUN - O
was VERB - O
a DET - O
significant ADJ - O
predictor NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
plasma NOUN - O
levels NOUN - O
, PUNCT - O
but CCONJ - O
was VERB - O
not ADV - O
associated VERB - O
with ADP - O
the DET - O
development NOUN - O
of ADP - O
arthralgia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Consecutive ADJ - O
tumour NOUN - O
samples NOUN - O
from ADP - O
62 CD - B-CARDINAL
patients NOUN - O
undergoing VERB - O
extended VERB - O
( PUNCT - O
4 CD - B-DATE
- SYM - I-DATE
45 CD - I-DATE
  SPACE - O
months NOUN - O
) PUNCT - O
neoadjuvant NOUN - O
aromatase NOUN - O
inhibitor NOUN - O
therapy NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
were VERB - O
subjected VERB - O
to ADP - O
transcriptomic ADJ - O
and CCONJ - O
proteomic ADJ - O
analysis NOUN - O
, PUNCT - O
representing VERB - O
before ADV - O
( PUNCT - O
≤ PROPN - O
  SPACE - O
0 NUM - O
) PUNCT - O
, PUNCT - O
early ADJ - O
( PUNCT - O
13 CD - B-CARDINAL
- SYM - O
120 NUM - O
  SPACE - O
days NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
( PUNCT - O
> X - O
  SPACE - O
120 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
) PUNCT - O
neoadjuvant NOUN - O
aromatase NOUN - O
inhibitor NOUN - O
therapy NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

The DET - O
DNA NOUN - O
methylation NOUN - O
marks VERB - O
5-methylcytosine NUM - O
and CCONJ - O
5-hydroxymethylcytosine CD - B-CARDINAL
were VERB - O
significantly ADV - O
reduced VERB - O
in ADP - O
resistant ADJ - O
tumours NOUN - O
compared VERB - O
with ADP - O
dormant ADJ - O
tissues NOUN - O
after ADP - O
extended ADJ - O
letrozole NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
results NOUN - O
of ADP - O
the DET - O
first JJ - B-ORDINAL
phase NOUN - O
II CD - B-PERSON
trial NOUN - O
evaluating VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
the DET - O
novel ADJ - O
combination NOUN - O
of ADP - O
imatinib NOUN - O
mesylate NOUN - O
and CCONJ - O
letrozole NN - B-MEDICINE
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
metastatic ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

Patients PROPN - O
and CCONJ - O
Methods NNS - B-PRODUCT
45 CD - I-PRODUCT
postmenopausal VERB - O
women NOUN - O
with ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
metastatic ADJ - O
breast NOUN - O
cancer NOUN - O
whose ADJ - O
tumors NOUN - O
demonstrated VERB - O
c NOUN - O
- PUNCT - O
kit NOUN - O
and/or CC - B-PRODUCT
PDGFR NNP - I-PRODUCT
- HYPH - I-PRODUCT
β NNP - I-PRODUCT
positivity NOUN - O
were VERB - O
treated VERB - O
with ADP - O
imatinib NOUN - O
mesylate VERB - O
400 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
PO NNP - B-ORG
twice ADV - O
daily ADV - O
and CCONJ - O
letrozole NN - B-MEDICINE
2.5 CD - B-CARDINAL
  SPACE - O
mg ADP - O
PO NNP - B-ORG
once ADV - O
daily ADV - O
until ADP - O
disease NOUN - O
progression NOUN - O
or CCONJ - O
unacceptable ADJ - O
toxicity NOUN - O
. PUNCT - O

The DET - O
combination NOUN - O
of ADP - O
imatinib NOUN - O
mesylate NOUN - O
and CCONJ - O
letrozole NN - B-MEDICINE
is VERB - O
well ADV - O
tolerated VERB - O
but CCONJ - O
appears VERB - O
to PART - O
have VERB - O
limited VERB - O
efficacy NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
metastatic ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
influence NOUN - O
of ADP - O
oral ADJ - O
N PROPN - O
- PUNCT - O
acetylcysteine PROPN - O
( PUNCT - O
NAC NNP - B-ORG
) PUNCT - O
application NOUN - O
as ADP - O
an DET - O
adjuvant NOUN - O
to ADP - O
letrozole NN - B-MEDICINE
on ADP - O
induced VERB - O
ovulation NOUN - O
outcomes NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
polycystic ADJ - O
ovary ADJ - O
syndrome NOUN - O
( PUNCT - O
PCOS).This PROPN - O
was VERB - O
a DET - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
double ADJ - O
- PUNCT - O
blind ADJ - O
randomized VERB - O
clinical ADJ - O
trial NOUN - O
with ADP - O
130 CD - B-CARDINAL
PCOS NN - B-ORG
patients NOUN - O
who NOUN - O
were VERB - O
infertile ADJ - O
. PUNCT - O

Patients NOUN - O
in ADP - O
Group PROPN - O
1 NUM - O
were VERB - O
administered VERB - O
letrozole NN - B-MEDICINE
5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
d NOUN - O
plus CCONJ - O
NAC NNP - B-ORG
1.2 NUM - O
g NOUN - O
/ SYM - O
d NOUN - O
and CCONJ - O
patients NOUN - O
in ADP - O
Group NNP - B-ORG
2 CD - I-ORG
were VERB - O
administered VERB - O
letrozole NN - B-MEDICINE
plus CCONJ - O
placebo NOUN - O
for ADP - O
5 CD - B-DATE
days NNS - I-DATE
starting VERB - O
at ADP - O
the DT - B-DATE
3rd JJ - I-DATE
day NN - I-DATE
of ADP - O
the DET - O
menstruation NOUN - O
period NOUN - O
. PUNCT - O

The DET - O
number NOUN - O
of ADP - O
follicles NOUN - O
> X - O
18 CD - B-QUANTITY
mm NN - I-QUANTITY
was VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
the DET - O
letrozole NN - B-MEDICINE
+ CCONJ - O
NAC NNP - B-ORG
group NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.007 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
ovulation NOUN - O
and CCONJ - O
pregnancy NOUN - O
rates NOUN - O
were VERB - O
also ADV - O
significantly ADV - O
higher ADJ - O
in ADP - O
the DET - O
letrozole NN - B-MEDICINE
+ CCONJ - O
NAC NNP - B-ORG
group NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.045 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

NAC NNP - B-ORG
is VERB - O
demonstrated VERB - O
to PART - O
be VERB - O
a DET - O
safe ADJ - O
and CCONJ - O
well ADV - O
- PUNCT - O
tolerated VERB - O
adjuvant ADJ - O
to ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
can VERB - O
increase VERB - O
the DET - O
pregnancy NOUN - O
rates NOUN - O
in ADP - O
PCOS NNP - B-ORG
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Studies NOUN - O
also ADV - O
demonstrated VERB - O
that ADP - O
the DET - O
differences NOUN - O
between ADP - O
serum NOUN - O
and CCONJ - O
brain NOUN - O
levels NOUN - O
of ADP - O
E2 PROPN - O
can VERB - O
be VERB - O
eliminated VERB - O
by ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
ARO PROPN - O
inhibitor NOUN - O
) PUNCT - O
treatment NOUN - O
, PUNCT - O
which ADJ - O
indicates VERB - O
that ADP - O
the DET - O
differences NOUN - O
are VERB - O
due ADJ - O
to ADP - O
local ADJ - O
ARO PROPN - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
about RB - B-DATE
2001 CD - I-DATE
clinical ADJ - O
trials NOUN - O
have VERB - O
reached VERB - O
differing VERB - O
conclusions NOUN - O
as ADP - O
to ADP - O
whether ADP - O
the DET - O
AI NNP - B-ORG
letrozole NN - B-MEDICINE
is VERB - O
at ADP - O
least ADV - O
as ADV - O
effective ADJ - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
clomiphene NOUN - O
citrate NOUN - O
( PUNCT - O
CC NNP - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
aromatase NOUN - O
inhibitor NOUN - O
letrozole NN - B-MEDICINE
was VERB - O
used VERB - O
in ADP - O
all DET - O
studies NOUN - O
. PUNCT - O

Letrozole NN - B-MEDICINE
compared VERB - O
to PART - O
clomiphene VERB - O
citrate NOUN - O
( PUNCT - O
CC NNP - B-ORG
) PUNCT - O
with ADP - O
or CCONJ - O
without ADP - O
adjuncts NOUN - O
followed VERB - O
by ADP - O
timed VERB - O
intercourseLive ADJ - O
birth NOUN - O
rates NOUN - O
were VERB - O
higher ADJ - O
with ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
with ADP - O
or CCONJ - O
without ADP - O
adjuncts NOUN - O
) PUNCT - O
compared VERB - O
to PART - O
clomiphene VERB - O
citrate NOUN - O
( PUNCT - O
with ADP - O
our ADJ - O
without ADP - O
adjuncts NOUN - O
) PUNCT - O
followed VERB - O
by ADP - O
timed ADJ - O
intercourse NOUN - O
( PUNCT - O
OR PROPN - O
1.68 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
1.42 CD - B-CARDINAL
to ADP - O
1.99 CD - B-CARDINAL
; PUNCT - O
2954 CD - B-DATE
participants NOUN - O
; PUNCT - O
13 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
number NOUN - O
needed VERB - O
to PART - O
treat VERB - O
for ADP - O
an DET - O
additional ADJ - O
beneficial ADJ - O
outcome NOUN - O
( PUNCT - O
NNTB PROPN - O
) PUNCT - O
= SYM - O
10 CD - B-CARDINAL
; PUNCT - O
moderate ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
is VERB - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
that ADP - O
OHSS NNP - B-ORG
rates NOUN - O
are VERB - O
similar ADJ - O
with ADP - O
letrozole NN - B-MEDICINE
or CCONJ - O
clomiphene NOUN - O
citrate NOUN - O
( PUNCT - O
0.5 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
both DET - O
arms NOUN - O
: PUNCT - O
risk NOUN - O
difference NOUN - O
( PUNCT - O
RD PROPN - O
) PUNCT - O
-0.00 PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
-0.01 NOUN - O
to ADP - O
0.00 CD - B-CARDINAL
; PUNCT - O
2536 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
12 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
is VERB - O
evidence NOUN - O
for ADP - O
a DET - O
higher ADJ - O
pregnancy NOUN - O
rate NOUN - O
in ADP - O
favour NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
OR PROPN - O
1.56 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
1.37 NUM - O
to ADP - O
1.78 CD - B-CARDINAL
; PUNCT - O
4629 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
25 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
1 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
NNTB NOUN - O
= SYM - O
10 CD - B-CARDINAL
; PUNCT - O
moderate ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
is VERB - O
little ADJ - O
or CCONJ - O
no DET - O
difference NOUN - O
between ADP - O
treatment NOUN - O
groups NOUN - O
in ADP - O
the DET - O
rate NOUN - O
of ADP - O
miscarriage NOUN - O
by ADP - O
pregnancy PROPN - O
( PUNCT - O
20 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
CC NNP - B-ORG
versus ADP - O
19 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
letrozole NN - B-MEDICINE
; PUNCT - O
OR CCONJ - O
0.94 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.70 NUM - O
to ADP - O
1.26 CD - B-CARDINAL
; PUNCT - O
1210 CD - B-DATE
participants NOUN - O
; PUNCT - O
18 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O

I2 PROPN - O
= SYM - O
0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
and CCONJ - O
multiple ADJ - O
pregnancy NOUN - O
rate NOUN - O
( PUNCT - O
1.7 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
CC NNP - B-ORG
versus ADP - O
1.3 CD - B-PERCENT
% NN - I-PERCENT
with ADP - O
letrozole NN - B-MEDICINE
; PUNCT - O
OR CCONJ - O
0.69 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
0.41 CD - B-CARDINAL
to ADP - O
1.16 CD - B-CARDINAL
; PUNCT - O
3579 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
17 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
0 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

Letrozole NN - B-MEDICINE
compared VERB - O
to ADP - O
laparoscopic ADJ - O
ovarian ADJ - O
drillingThere VERB - O
is VERB - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
that ADJ - O
live VERB - O
birth NOUN - O
rates NOUN - O
are VERB - O
similar ADJ - O
with ADP - O
letrozole NN - B-MEDICINE
or CCONJ - O
laparoscopic NOUN - O
ovarian ADJ - O
drilling NOUN - O
( PUNCT - O
OR CCONJ - O
1.38 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
0.95 NUM - O
to ADP - O
2.02 CD - B-CARDINAL
; PUNCT - O
548 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
3 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
I2 PROPN - O
= SYM - O
23 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

There ADV - O
is VERB - O
high ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
that ADP - O
OHSS NNP - B-ORG
rates NOUN - O
are VERB - O
similar ADJ - O
with ADP - O
letrozole NN - B-MEDICINE
or CCONJ - O
clomiphene NOUN - O
citrate NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
of ADP - O
no DET - O
difference NOUN - O
in ADP - O
live ADJ - O
birth NOUN - O
and CCONJ - O
pregnancy NOUN - O
rates NOUN - O
between ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
laparoscopic NOUN - O
ovarian ADJ - O
drilling NOUN - O
, PUNCT - O
although ADP - O
there ADV - O
were VERB - O
few ADJ - O
relevant ADJ - O
studies NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
observational ADJ - O
study NOUN - O
aimed VERB - O
to PART - O
evaluate VERB - O
the DET - O
long ADJ - O
- PUNCT - O
term NOUN - O
effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
in ADP - O
postmenopausal ADJ - O
Korean JJ - B-NORP
women NOUN - O
with ADP - O
operable ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

Self NOUN - O
- PUNCT - O
reported VERB - O
quality NOUN - O
of ADP - O
life NOUN - O
( PUNCT - O
QoL NNP - B-ORG
) PUNCT - O
scores NOUN - O
were VERB - O
serially ADV - O
assessed VERB - O
for ADP - O
3 CD - B-DATE
years NNS - I-DATE
during ADP - O
adjuvant ADJ - O
letrozole NN - B-MEDICINE
treatment NOUN - O
using VERB - O
the DET - O
Korean JJ - B-NORP
version NOUN - O
of ADP - O
the DT - B-ORG
Functional NNP - I-ORG
Assessment NNP - I-ORG
of IN - I-ORG
Cancer NNP - I-ORG
Therapy NNP - I-ORG
- HYPH - I-ORG
Breast NNP - I-ORG
questionnaires NOUN - O
( PUNCT - O
version NOUN - O
3 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
serial ADJ - O
trial NOUN - O
outcome NOUN - O
index NOUN - O
, PUNCT - O
the DET - O
sum NOUN - O
of ADP - O
the DET - O
physical ADJ - O
and CCONJ - O
functional ADJ - O
well NOUN - O
- PUNCT - O
being VERB - O
subscales NOUN - O
, PUNCT - O
increased VERB - O
gradually ADV - O
and CCONJ - O
significantly ADV - O
from ADP - O
baseline NOUN - O
during ADP - O
letrozole NN - B-MEDICINE
treatment NOUN - O
( PUNCT - O
p<0.001 PROPN - O
) PUNCT - O
. PUNCT - O

The DET - O
mean VERB - O
BMD NNP - B-ORG
significantly ADV - O
decreased VERB - O
from ADP - O
-0.39 PUNCT - O
at ADP - O
baseline NOUN - O
to ADP - O
-0.87 NOUN - O
after ADP - O
36 CD - B-DATE
months NNS - I-DATE
( PUNCT - O
p<0.001).QoL NOUN - O
gradually ADV - O
improved VERB - O
during ADP - O
letrozole NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

BMD VBN - B-ORG
and CCONJ - O
serum PROPN - O
cholesterol NOUN - O
level NOUN - O
changes NOUN - O
were VERB - O
similar ADJ - O
to ADP - O
those DET - O
in ADP - O
Western ADJ - O
countries NOUN - O
, PUNCT - O
indicating VERB - O
that ADP - O
adjuvant ADJ - O
letrozole NN - B-MEDICINE
treatment NOUN - O
is VERB - O
well ADV - O
tolerated VERB - O
in ADP - O
Korean JJ - B-NORP
women NOUN - O
, PUNCT - O
with ADP - O
minimal ADJ - O
ethnic ADJ - O
variation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
molecular ADJ - O
mechanism NOUN - O
of ADP - O
the DET - O
aromatase NOUN - O
inhibitor NOUN - O
letrozole NN - B-MEDICINE
was VERB - O
investigated VERB - O
. PUNCT - O

Six CD - B-CARDINAL
different ADJ - O
concentrations NOUN - O
were VERB - O
selected VERB - O
for ADP - O
letrozole NN - B-MEDICINE
in ADP - O
order NOUN - O
to PART - O
incubate VERB - O
mouse NOUN - O
spermatogonia NOUN - O
[ PUNCT - O
GC-1 PROPN - O
spermatogonia NOUN - O
( PUNCT - O
spg NOUN - O
) PUNCT - O
] PUNCT - O
for ADP - O
24 CD - B-DATE
, PUNCT - O
48 CD - B-DATE
and CCONJ - O
72 CD - B-DATE
h NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

Cell PROPN - O
Counting PROPN - O
Kit-8 PROPN - O
( PUNCT - O
CCK-8 PROPN - O
) PUNCT - O
was VERB - O
used VERB - O
to PART - O
observe VERB - O
the DET - O
effect NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
on ADP - O
the DET - O
proliferation NOUN - O
of ADP - O
GC-1 PROPN - O
spg NOUN - O
cells NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
effect NOUN - O
was VERB - O
further ADV - O
verified VERB - O
by ADP - O
cell NOUN - O
plate NOUN - O
clone NOUN - O
formation NOUN - O
assay VERB - O
. PUNCT - O

Reverse ADJ - O
transcription NOUN - O
- PUNCT - O
polymerase NOUN - O
chain NOUN - O
reaction NOUN - O
( PUNCT - O
RT PROPN - O
- PUNCT - O
PCR PROPN - O
) PUNCT - O
and CCONJ - O
western ADJ - O
blot NOUN - O
analysis NOUN - O
were VERB - O
used VERB - O
to PART - O
detect VERB - O
the DET - O
effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
on ADP - O
MAPK NNP - B-ORG
signaling NOUN - O
pathways NOUN - O
[ PUNCT - O
Ras PROPN - O
/ SYM - O
extracellular ADJ - O
signal NOUN - O
- PUNCT - O
regulated VERB - O
kinase NOUN - O
1 CD - B-CARDINAL
( PUNCT - O
ERK1)/c PROPN - O
- PUNCT - O
Myc PROPN - O
] PUNCT - O
, PUNCT - O
proliferation NOUN - O
indexes NOUN - O
[ PUNCT - O
Ki-67 NNP - B-ORG
and CCONJ - O
proliferating VERB - O
cell NOUN - O
nuclear ADJ - O
antigen NOUN - O
( PUNCT - O
PCNA)]. PROPN - O
Bromodeoxyuridine NNP - B-PERSON
( PUNCT - O
BrdU PROPN - O
) PUNCT - O
staining NOUN - O
was VERB - O
used VERB - O
to PART - O
study VERB - O
the DET - O
effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
MAPK NNP - B-ORG
signaling VERB - O
pathways NOUN - O
on ADP - O
cell NOUN - O
proliferation NOUN - O
. PUNCT - O

Study NOUN - O
results NOUN - O
also ADV - O
revealed VERB - O
a DET - O
significant ADJ - O
increase NOUN - O
in ADP - O
letrozole NN - B-MEDICINE
concentration NOUN - O
along ADP - O
with ADP - O
the DET - O
time NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
of ADP - O
plate NOUN - O
clone NOUN - O
formation NOUN - O
assay VERB - O
further ADV - O
indicated VERB - O
that ADP - O
letrozole NN - B-MEDICINE
could VERB - O
significantly ADV - O
promote VERB - O
the DET - O
proliferation NOUN - O
capacity NOUN - O
of ADP - O
GC-1 PROPN - O
spg NOUN - O
cells NOUN - O
( PUNCT - O
p<0.05 NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
results NOUN - O
of ADP - O
RT PROPN - O
- PUNCT - O
PCR PROPN - O
and CCONJ - O
western ADJ - O
blot NOUN - O
analysis NOUN - O
confirmed VERB - O
letrozole NN - B-MEDICINE
significantly ADV - O
activated VERB - O
the DET - O
expression NOUN - O
of ADP - O
Ras NNP - B-ORG
/ SYM - I-ORG
ERK1/c NNP - I-ORG
- HYPH - I-ORG
Myc NNP - I-ORG
in ADP - O
the DET - O
classical ADJ - O
MAPK NNP - B-ORG
pathway NOUN - O
. PUNCT - O

The DET - O
number NOUN - O
of ADP - O
BrdU PROPN - O
cells NOUN - O
in ADP - O
the DET - O
letrozole NN - B-MEDICINE
group NOUN - O
was VERB - O
also ADV - O
higher ADJ - O
than ADP - O
that DET - O
of ADP - O
the DET - O
control NOUN - O
group NOUN - O
, PUNCT - O
while ADP - O
the DET - O
number NOUN - O
of ADP - O
BrdU PROPN - O
- PUNCT - O
stained VERB - O
cells NOUN - O
in ADP - O
the DET - O
letrozole NN - B-MEDICINE
+ CCONJ - O
MAPK PROPN - O
inhibition NOUN - O
group NOUN - O
showed VERB - O
a DET - O
significant ADJ - O
decrease NOUN - O
in ADP - O
comparison NOUN - O
to ADP - O
the DET - O
letrozole NN - B-MEDICINE
group NOUN - O
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
letrozole NN - B-MEDICINE
activated VERB - O
the DET - O
MAPK NNP - B-ORG
signaling VERB - O
pathway NOUN - O
and CCONJ - O
promoted VERB - O
the DET - O
proliferation NOUN - O
of ADP - O
mouse NOUN - O
spermatogonia NOUN - O
GC-1 PROPN - O
spg NOUN - O
cells NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
provides VERB - O
a DET - O
theoretical ADJ - O
basis NOUN - O
for ADP - O
the DET - O
clinical ADJ - O
application NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
evaluated VERB - O
whether ADP - O
inhibition NOUN - O
of ADP - O
aromatase NOUN - O
inhibitor NOUN - O
letrozole NN - B-MEDICINE
protects NOUN - O
against ADP - O
seizures NOUN - O
and CCONJ - O
neuronal ADJ - O
degeneration NOUN - O
induced VERB - O
by ADP - O
kainic ADJ - O
acid NOUN - O
( PUNCT - O
KA NNP - B-ORG
) PUNCT - O
( PUNCT - O
10 CD - B-MONEY
  _SP - I-MONEY
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
i.p PROPN - O
. PUNCT - O
) PUNCT - O
in ADP - O
Swiss JJ - B-NORP
albino NOUN - O
mice NOUN - O
. PUNCT - O

Pretreatment NOUN - O
with ADP - O
finasteride NOUN - O
, PUNCT - O
a DET - O
selective ADJ - O
inhibitor NOUN - O
of ADP - O
5α NOUN - O
- PUNCT - O
reductase NOUN - O
and CCONJ - O
indomethacin NOUN - O
, PUNCT - O
a DET - O
selective ADJ - O
inhibitor NOUN - O
of ADP - O
3α NN - B-CARDINAL
- PUNCT - O
hydroxysteroid NOUN - O
oxidoreductase NOUN - O
enzyme ADJ - O
( PUNCT - O
3α PROPN - O
- PUNCT - O
HSOR PROPN - O
) PUNCT - O
, PUNCT - O
reversed VERB - O
the DET - O
protective ADJ - O
effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
in ADP - O
KA NNP - B-GPE
- PUNCT - O
induced VERB - O
seizures NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

Microscopic ADJ - O
examination NOUN - O
using VERB - O
cresyl NOUN - O
violet NOUN - O
staining NOUN - O
revealed VERB - O
that ADP - O
letrozole NN - B-MEDICINE
did VERB - O
not ADV - O
modify VERB - O
KA NNP - B-ORG
- PUNCT - O
induced VERB - O
neurotoxicity NOUN - O
in ADP - O
the DET - O
CA1 NNPS - B-PRODUCT
, PUNCT - O
CA3 NNP - B-PRODUCT
and CCONJ - O
DG NNP - B-ORG
region NOUN - O
of ADP - O
the DET - O
hippocampus NOUN - O
. PUNCT - O

Finasteride ADJ - O
and CCONJ - O
indomethacin VERB - O
attenuated ADJ - O
letrozole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
elevations NOUN - O
of ADP - O
5α NNP - B-PERSON
- HYPH - I-PERSON
DHT NN - I-PERSON
and CCONJ - O
3α NNP - B-PRODUCT
- HYPH - I-PRODUCT
Diol NNS - I-PRODUCT
. PUNCT - O

Our ADJ - O
results NOUN - O
indicate VERB - O
the DET - O
potential ADJ - O
anticonvulsant ADJ - O
effects NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
against ADP - O
KA NNP - B-ORG
- PUNCT - O
induced VERB - O
seizures NOUN - O
in ADP - O
mice NOUN - O
that ADJ - O
might VERB - O
be VERB - O
mediated VERB - O
by ADP - O
inhibiting VERB - O
aromatization NOUN - O
of ADP - O
testosterone NOUN - O
to ADP - O
17β NNS - B-DATE
- : - I-DATE
estradiol NNS - I-DATE
, PUNCT - O
a DET - O
proconvulsant ADJ - O
hormone NOUN - O
and CCONJ - O
by ADP - O
redirecting VERB - O
the DET - O
synthesis NOUN - O
to PART - O
anticonvulsant VERB - O
metabolites NOUN - O
, PUNCT - O
5α NNP - B-PERSON
- : - I-PERSON
DHT NN - I-PERSON
and CCONJ - O
3α NNP - B-PRODUCT
- HYPH - I-PRODUCT
Diol NNS - I-PRODUCT
. PUNCT - O

-DOCSTART- -X- - O

Health NOUN - O
- PUNCT - O
related VERB - O
quality NOUN - O
of ADP - O
life NOUN - O
of ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
, PUNCT - O
human ADJ - O
epidermal ADJ - O
growth NOUN - O
factor NOUN - O
receptor NOUN - O
2-negative CD - B-ORG
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
treated VERB - O
with ADP - O
ribociclib NOUN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
letrozole NN - B-MEDICINE
: PUNCT - O
results NOUN - O
from ADP - O
MONALEESA-2 NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
three CD - B-CARDINAL
cases NOUN - O
of ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
breast NOUN - O
cancer NOUN - O
, PUNCT - O
who NOUN - O
experienced VERB - O
tendinopathy NOUN - O
or CCONJ - O
muscle NOUN - O
tendon NOUN - O
rupture NOUN - O
under ADP - O
antihormonal ADJ - O
treatment NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
in ADP - O
our ADJ - O
cases NOUN - O
, PUNCT - O
there ADV - O
were VERB - O
no DET - O
signs NOUN - O
of ADP - O
underlying VERB - O
systemic ADJ - O
disease NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
abnormal ADJ - O
physical ADJ - O
activity NOUN - O
preceding VERB - O
the DET - O
complaints NOUN - O
, PUNCT - O
and CCONJ - O
there ADV - O
was VERB - O
no DET - O
use NOUN - O
of ADP - O
other ADJ - O
drugs NOUN - O
beside ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Obesity NOUN - O
and CCONJ - O
outcome NOUN - O
of ADP - O
post ADJ - O
- ADJ - O
menopausal ADJ - O
women NOUN - O
receiving VERB - O
adjuvant ADJ - O
letrozole NN - B-MEDICINE
for ADP - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
compare VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
with ADP - O
placebo NOUN - O
pretreatment NOUN - O
in ADP - O
the DET - O
medical ADJ - O
management NOUN - O
of ADP - O
first JJ - B-ORDINAL
trimester NOUN - O
missed VERB - O
miscarriage NOUN - O
. PUNCT - O

Four CD - B-CARDINAL
hundred CD - I-CARDINAL
and CC - I-CARDINAL
thirty CD - I-CARDINAL
- HYPH - I-CARDINAL
eight CD - I-CARDINAL
women NOUN - O
were VERB - O
randomly ADV - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
of ADP - O
219 CD - B-CARDINAL
; PUNCT - O
the DET - O
placebo NOUN - O
group NOUN - O
received VERB - O
placebo NOUN - O
tablets NOUN - O
twice ADV - O
daily ADV - O
for ADP - O
3 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
followed VERB - O
by ADP - O
800 CD - B-QUANTITY
micrograms NNS - I-QUANTITY
of ADP - O
misoprostol NOUN - O
vaginally ADV - O
on ADP - O
the DT - B-DATE
fourth JJ - I-DATE
day NN - I-DATE
of ADP - O
enrolment NOUN - O
, PUNCT - O
while ADP - O
the DET - O
letrozole NN - B-MEDICINE
group NOUN - O
received VERB - O
letrozole NN - B-MEDICINE
10 CD - B-CARDINAL
  SPACE - O
mg PRON - O
twice ADV - O
daily RB - B-DATE
for ADP - O
three CD - B-DATE
days NNS - I-DATE
followed VERB - O
by ADP - O
800 CD - B-QUANTITY
micrograms NNS - I-QUANTITY
misoprostol NOUN - O
administered VERB - O
vaginally ADV - O
. PUNCT - O

There ADV - O
were VERB - O
significant ADJ - O
differences NOUN - O
between ADP - O
the DET - O
two CD - B-CARDINAL
groups NOUN - O
, PUNCT - O
with ADP - O
better ADJ - O
outcomes NOUN - O
found VERB - O
for ADP - O
the DET - O
letrozole NN - B-MEDICINE
group NOUN - O
in ADP - O
terms NOUN - O
of ADP - O
rates NOUN - O
of ADP - O
complete ADJ - O
miscarriage NOUN - O
, PUNCT - O
onset NOUN - O
of ADP - O
vaginal ADJ - O
bleeding NOUN - O
, PUNCT - O
and CCONJ - O
interval NOUN - O
between ADP - O
induction NOUN - O
and CCONJ - O
onset NOUN - O
of ADP - O
expulsion NOUN - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

A DET - O
higher ADJ - O
rate NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
was VERB - O
reported VERB - O
for ADP - O
the DET - O
letrozole NN - B-MEDICINE
group NOUN - O
( PUNCT - O
p VERB - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.002 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Adding VERB - O
letrozole NN - B-MEDICINE
to PART - O
misoprostol NOUN - O
improves VERB - O
the DET - O
success NOUN - O
rate NOUN - O
and CCONJ - O
decreases VERB - O
the DET - O
interval NOUN - O
between ADP - O
induction NOUN - O
and CCONJ - O
expulsion NOUN - O
in ADP - O
cases NOUN - O
of ADP - O
first JJ - B-ORDINAL
trimester NOUN - O
miscarriage NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
is VERB - O
higher ADJ - O
with ADP - O
letrozole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
recently ADV - O
showed VERB - O
that ADP - O
a DET - O
subpopulation NOUN - O
of ADP - O
male ADJ - O
rats NOUN - O
prenatally ADV - O
treated VERB - O
with ADP - O
letrozole NN - B-MEDICINE
( PUNCT - O
0.56 CD - B-CARDINAL
  SPACE - O
μg PROPN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
G10-G22 NNP - B-PERSON
) PUNCT - O
, PUNCT - O
a DET - O
non ADJ - O
- ADJ - O
steroidal ADJ - O
third JJ - B-ORDINAL
generation NOUN - O
aromatase NOUN - O
inhibitor NOUN - O
, PUNCT - O
had VERB - O
same ADJ - O
- PUNCT - O
sex NOUN - O
preference NOUN - O
, PUNCT - O
female ADJ - O
sexual ADJ - O
behavior NOUN - O
( PUNCT - O
including VERB - O
lordosis NOUN - O
and CCONJ - O
proceptivity NOUN - O
) PUNCT - O
and CCONJ - O
penile ADJ - O
erections NOUN - O
when ADV - O
exposed VERB - O
to ADP - O
other ADJ - O
males NOUN - O
. PUNCT - O

Males NOUN - O
treated VERB - O
prenatally ADV - O
with ADP - O
letrozole NN - B-MEDICINE
with ADP - O
same ADJ - O
- PUNCT - O
sex NOUN - O
preference NOUN - O
showed VERB - O
more ADJ - O
immobility NOUN - O
and CCONJ - O
less ADV - O
active ADJ - O
behaviors NOUN - O
( PUNCT - O
swimming VERB - O
and CCONJ - O
climbing NOUN - O
) PUNCT - O
in ADP - O
the DET - O
FST NNP - B-ORG
than ADP - O
males NOUN - O
with ADP - O
female ADJ - O
preference NOUN - O
. PUNCT - O

These DET - O
results NOUN - O
indicate VERB - O
that ADP - O
an DET - O
association NOUN - O
exists VERB - O
between ADP - O
prenatal ADJ - O
letrozole NN - B-MEDICINE
treatment NOUN - O
, PUNCT - O
same ADJ - O
- PUNCT - O
sex NOUN - O
preference NOUN - O
and CCONJ - O
immobility NOUN - O
in ADP - O
the DET - O
FST NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Erratum NN - B-ORG
to ADP - O
" PUNCT - O
First JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
ribociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
for ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
HR+ NNP - B-PERSON
, PUNCT - O

-DOCSTART- -X- - O

Our ADJ - O
patient NOUN - O
had VERB - O
received VERB - O
chemotherapy NOUN - O
and CCONJ - O
hormonal ADJ - O
therapy NOUN - O
( PUNCT - O
tamoxifen NOUN - O
for ADP - O
3 CD - B-DATE
  _SP - I-DATE
years NNS - I-DATE
and CCONJ - O
letrozole NN - B-MEDICINE
in ADP - O
the DET - O
following VERB - O
3 CD - B-CARDINAL
  SPACE - O
years NNS - B-DATE
) PUNCT - O
for ADP - O
her ADJ - O
primary ADJ - O
cancer NOUN - O
and CCONJ - O
developed VERB - O
an DET - O
orbital ADJ - O
metastasis NOUN - O
while ADP - O
she PRON - O
was VERB - O
under ADP - O
aromatase NOUN - O
inhibitor NOUN - O
- PUNCT - O
based VERB - O
therapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
, PUNCT - O
a DET - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
benefit NOUN - O
was VERB - O
reported VERB - O
with ADP - O
addition NOUN - O
of ADP - O
bevacizumab NOUN - O
to ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
letrozole NN - B-MEDICINE
. PUNCT - O

We PRON - O
hypothesized VERB - O
that ADP - O
functional ADJ - O
age NOUN - O
measures NOUN - O
could VERB - O
be VERB - O
used VERB - O
to PART - O
identify VERB - O
patients NOUN - O
at ADP - O
risk NOUN - O
for ADP - O
toxicity NOUN - O
while ADP - O
receiving VERB - O
letrozole NN - B-MEDICINE
plus CCONJ - O
bevacizumab NOUN - O
for ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

METHODS NOUN - O
: PUNCT - O
CALGB NNP - B-PRODUCT
40503 CD - I-PRODUCT
was VERB - O
a DET - O
phase NOUN - O
III CD - B-PERSON
trial NOUN - O
that ADJ - O
enrolled VERB - O
patients NOUN - O
with ADP - O
hormone NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
randomized VERB - O
to ADP - O
letrozole NN - B-MEDICINE
with ADP - O
or CCONJ - O
without ADP - O
bevacizumab NOUN - O
. PUNCT - O

One CD - B-CARDINAL
hundred CD - I-CARDINAL
thirteen NUM - O
( PUNCT - O
58 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
of ADP - O
195 CD - B-CARDINAL
patients NOUN - O
treated VERB - O
with ADP - O
letrozole NN - B-MEDICINE
plus CCONJ - O
bevacizumab NOUN - O
completed VERB - O
the DET - O
pretreatment NOUN - O
assessment NOUN - O
questionnaire NOUN - O
. PUNCT - O

Age PROPN - O
( PUNCT - O
≥ NN - B-PERSON
  SPACE - O
65 CD - B-CARDINAL
  SPACE - O
years NOUN - O
) PUNCT - O
, PUNCT - O
decreased VERB - O
vision NOUN - O
, PUNCT - O
and CCONJ - O
impairments NOUN - O
in ADP - O
physical ADJ - O
function NOUN - O
correlated VERB - O
with ADP - O
increased VERB - O
incidence NOUN - O
of ADP - O
toxicity NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
letrozole NN - B-MEDICINE
plus CCONJ - O
bevacizumab NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determine VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
ribociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
de PROPN - O
novo ADJ - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
ribociclib VERB - O
( PUNCT - O
600 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
day NOUN - O
; PUNCT - O
3 CD - B-CARDINAL
  SPACE - O
weeks NNS - B-DATE
- : - I-DATE
on/1 CD - I-DATE
  SPACE - O
week NOUN - O
- PUNCT - O
off NOUN - O
) PUNCT - O
plus CCONJ - O
letrozole NN - B-MEDICINE
( PUNCT - O
2.5 CD - B-CARDINAL
  SPACE - O
mg NN - B-DATE
/ SYM - I-DATE
day NN - I-DATE
; PUNCT - O
continuous ADJ - O
) PUNCT - O
or CCONJ - O
placebo NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
until ADP - O
disease NOUN - O
progression NOUN - O
, PUNCT - O
unacceptable ADJ - O
toxicity NOUN - O
, PUNCT - O
death NOUN - O
, PUNCT - O
or CCONJ - O
treatment NOUN - O
discontinuation NOUN - O
. PUNCT - O

Six CD - B-CARDINAL
hundred CD - I-CARDINAL
and CC - I-CARDINAL
sixty CD - I-CARDINAL
- HYPH - I-CARDINAL
eight CD - I-CARDINAL
patients NOUN - O
were VERB - O
enrolled VERB - O
, PUNCT - O
of ADP - O
whom NOUN - O
227 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
34 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
ribociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
vs ADP - O
placebo NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
arm NOUN - O
: PUNCT - O
n PUNCT - O
  SPACE - O
= SYM - O
  SPACE - O
114 NUM - O
vs. NOUN - O

Median ADJ - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
was VERB - O
not ADV - O
reached VERB - O
in ADP - O
the DET - O
ribociclib NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
arm NOUN - O
versus ADP - O
16.4 CD - B-CARDINAL
  SPACE - O
months NNS - B-DATE
in ADP - O
the DET - O
placebo NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
arm NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
de PROPN - O
novo ADJ - O
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
( PUNCT - O
hazard VERB - O
ratio NOUN - O
0.45 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
0.27 CD - B-CARDINAL
- SYM - O
0.75 NUM - O
) PUNCT - O
. PUNCT - O

Ribociclib NN - B-PERSON
plus CCONJ - O
letrozole NN - B-MEDICINE
improved VERB - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
vs ADP - O
placebo NOUN - O
plus CCONJ - O
letrozole NN - B-MEDICINE
and CCONJ - O
was VERB - O
well ADV - O
tolerated VERB - O
in ADP - O
postmenopausal ADJ - O
women NOUN - O
with ADP - O
HR+ NNP - B-PERSON
, PUNCT - O
HER2- NNP - B-ORG
de FW - I-ORG
novo JJ - I-ORG
advanced ADJ - O
breast NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

She PRON - O
received VERB - O
letrozole NN - B-MEDICINE
as ADP - O
second JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
therapy NOUN - O
. PUNCT - O

After ADP - O
commencing VERB - O
letrozole NN - B-MEDICINE
, PUNCT - O
the DET - O
tumor NOUN - O
reduced VERB - O
further ADV - O
, PUNCT - O
and CCONJ - O
the DET - O
local ADJ - O
ulcer NOUN - O
disappeared VERB - O
showing VERB - O
only ADJ - O
induration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Additionally ADV - O
, PUNCT - O
letrozole NN - B-MEDICINE
, PUNCT - O
a DET - O
potent ADJ - O
aromatase NOUN - O
inhibitor NOUN - O
, PUNCT - O
exhibited VERB - O
marked ADJ - O
activity NOUN - O
against ADP - O
C6 NNP - B-ORG
glioma NOUN - O
in ADP - O
Sprague NNP - B-LOC
- HYPH - I-LOC
Dawley NNP - I-LOC
rats NOUN - O
. PUNCT - O

Here ADV - O
, PUNCT - O
we PRON - O
conducted VERB - O
extensive ADJ - O
single ADJ - O
dose NOUN - O
and CCONJ - O
steady ADJ - O
state NOUN - O
plasma NOUN - O
and CCONJ - O
brain NOUN - O
extracellular NOUN - O
fluid NOUN - O
( PUNCT - O
ECF PROPN - O
) PUNCT - O
pharmacokinetics PROPN - O
( PUNCT - O
PK NNP - B-ORG
) PUNCT - O
of ADP - O
letrozole NN - B-MEDICINE
in ADP - O
both CCONJ - O
female ADJ - O
and CCONJ - O
male ADJ - O
rats NOUN - O
to PART - O
facilitate VERB - O
further ADJ - O
evaluation NOUN - O
of ADP - O
its ADJ - O
anti ADJ - O
- ADJ - O
HGG ADJ - O
efficacy NOUN - O
. PUNCT - O

Serial ADJ - O
blood NOUN - O
and CCONJ - O
ECF PROPN - O
samples NOUN - O
( PUNCT - O
using VERB - O
intracerebral ADJ - O
microdialysis NOUN - O
) PUNCT - O
were VERB - O
collected VERB - O
and CCONJ - O
letrozole NN - B-MEDICINE
was VERB - O
quantitated VERB - O
employing VERB - O
an DET - O
HPLC NNP - B-NORP
method NOUN - O
. PUNCT - O

Marked VERB - O
gender NOUN - O
- PUNCT - O
dependent ADJ - O
difference NOUN - O
in ADP - O
letrozole NN - B-MEDICINE
PK NNP - B-ORG
were VERB - O
observed VERB - O
with ADP - O
both DET - O
plasma NOUN - O
and CCONJ - O
brain NOUN - O
ECF NNP - B-ORG
levels NOUN - O
being VERB - O
markedly ADV - O
higher ADJ - O
in ADP - O
female ADJ - O
rats NOUN - O
relative ADJ - O
to ADP - O
those DET - O
in ADP - O
male ADJ - O
rats NOUN - O
. PUNCT - O

For ADP - O
instance NOUN - O
, PUNCT - O
the DET - O
steady ADJ - O
state NOUN - O
peak NOUN - O
plasma NOUN - O
and CCONJ - O
ECF ADJ - O
letrozole NN - B-MEDICINE
levels NOUN - O
in ADP - O
female ADJ - O
rats NOUN - O
were VERB - O
4.8 NUM - O
  SPACE - O
µg ADP - O
/ SYM - O
ml NOUN - O
and CCONJ - O
2.3 NUM - O
  SPACE - O
µg NOUN - O
/ SYM - O
ml PROPN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

A DET - O
  SPACE - O
preliminary ADJ - O
assessment NOUN - O
of ADP - O
the DET - O
letrozole NN - B-MEDICINE
levels NOUN - O
in ADP - O
C6 NNP - B-CARDINAL
tumors NOUN - O
excised VERB - O
25 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
post NOUN - O
implantation NOUN - O
indicated VERB - O
that ADP - O
the DET - O
steady ADJ - O
state NOUN - O
tumor NOUN - O
levels NOUN - O
were VERB - O
in ADP - O
the DET - O
range NOUN - O
of ADP - O
4–10 NOUN - O
  SPACE - O
µg NOUN - O
/ SYM - O
g NOUN - O
of ADP - O
tumor NOUN - O
tissue NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
serum NOUN - O
estradiol NOUN - O
/ SYM - O
oocyte ADJ - O
ratio NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
breast NOUN - O
cancer NOUN - O
undergoing VERB - O
ovarian ADJ - O
stimulation NOUN - O
with ADP - O
letrozole NN - B-MEDICINE
and CCONJ - O
gonadotropins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
case NOUN - O
of ADP - O
anastrozole NOUN - O
- PUNCT - O
related VERB - O
hallucinations NOUN - O
, PUNCT - O
can VERB - O
switching VERB - O
to ADP - O
letrozole NN - B-MEDICINE
be VERB - O
a DET - O
treatment NOUN - O
option NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
report VERB - O
that ADP - O
miR-1271 NOUN - O
was VERB - O
significantly ADV - O
down ADV - O
- PUNCT - O
regulated VERB - O
in ADP - O
letrozole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
BCa NOUN - O
tissues NOUN - O
and CCONJ - O
in ADP - O
letrozole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
BCa NOUN - O
cells NOUN - O
. PUNCT - O

Form VERB - O
a DET - O
mechanistic ADJ - O
standpoint NOUN - O
, PUNCT - O
reintroduction NOUN - O
of ADP - O
exogenous ADJ - O
miR-1271 NOUN - O
could VERB - O
effectively ADV - O
restore VERB - O
ERα NOUN - O
level NOUN - O
via ADP - O
inhibiting VERB - O
DDIT3 NNP - B-PRODUCT
expression NOUN - O
, PUNCT - O
thereby ADV - O
potentiating VERB - O
letrozole NN - B-MEDICINE
sensitivity NOUN - O
in ADP - O
BCa NOUN - O
cells NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
DDIT3 NNP - B-ORG
deregulation NOUN - O
promoted VERB - O
letrozole NN - B-MEDICINE
- PUNCT - O
resistance NOUN - O
by ADP - O
acting VERB - O
as ADP - O
a DET - O
potent ADJ - O
corepressor NOUN - O
of ADP - O
ESR1 PROPN - O
transcription NOUN - O
. PUNCT - O

Taken VERB - O
together ADV - O
, PUNCT - O
we PRON - O
have VERB - O
identified VERB - O
that ADP - O
disruption NOUN - O
of ADP - O
the DET - O
miR-1271/DDIT3/ERα PUNCT - O
cascade NOUN - O
plays VERB - O
a DET - O
causative ADJ - O
role NOUN - O
in ADP - O
the DET - O
pathogenesis NOUN - O
of ADP - O
letrozole NN - B-MEDICINE
resistance NOUN - O
in ADP - O
BCa NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
the DET - O
letrozole NN - B-MEDICINE
study NOUN - O
, PUNCT - O
adult VERB - O
female ADJ - O
rats NOUN - O
were VERB - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
group NOUN - O
I PRON - O
received VERB - O
1 CD - B-PERCENT
% NN - I-PERCENT
carboxy NOUN - O
methyl NOUN - O
cellulose NOUN - O
and CCONJ - O
group NOUN - O
II NNP - B-ORG
received VERB - O
1 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg VERB - O
letrozole NN - B-MEDICINE
orally ADV - O
. PUNCT - O

Triglyceride NOUN - O
level NOUN - O
was VERB - O
higher ADJ - O
in ADP - O
HFD NN - B-ORG
study NOUN - O
while ADP - O
total ADJ - O
cholesterol NOUN - O
level NOUN - O
was VERB - O
higher ADJ - O
in ADP - O
the DET - O
letrozole NN - B-MEDICINE
study NOUN - O
. PUNCT - O

Histopathological ADJ - O
changes VERB - O
like ADP - O
increase VERB - O
cystic ADJ - O
follicle NOUN - O
, PUNCT - O
diminished ADJ - O
granulosa NOUN - O
cell NOUN - O
layer NOUN - O
and CCONJ - O
thickened VERB - O
theca ADJ - O
cell NOUN - O
layer NOUN - O
were VERB - O
observed VERB - O
in ADP - O
letrozole NN - B-MEDICINE
as ADV - O
well ADV - O
as ADP - O
HFD NN - B-ORG
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

There ADV - O
were VERB - O
five CD - B-CARDINAL
patients NOUN - O
with ADP - O
advanced ADJ - O
or CCONJ - O
unresectable ADJ - O
recurrent NOUN - O
estrogen NOUN - O
, PUNCT - O
progesterone NOUN - O
and CCONJ - O
androgen NOUN - O
receptor NOUN - O
- PUNCT - O
positive ADJ - O
ESS NN - B-ORG
, PUNCT - O
treated VERB - O
with ADP - O
aromatase NOUN - O
inhibitors NOUN - O
: PUNCT - O
letrozole NN - B-MEDICINE
or CCONJ - O
anastrozole NOUN - O
( PUNCT - O
at ADP - O
a DET - O
daily JJ - B-DATE
dose NOUN - O
of ADP - O
2.5 CD - B-CARDINAL
mg NOUN - O
and CCONJ - O
1 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
, PUNCT - O
as ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
endocrine NOUN - O
therapy NOUN - O
in ADP - O
all DET - O
but ADP - O
one CD - B-CARDINAL
case NOUN - O
treated VERB - O
following VERB - O
progression NOUN - O
with ADP - O
megestrol NOUN - O
acetate NOUN - O
. PUNCT - O

Disease PROPN - O
stabilization NOUN - O
was VERB - O
achieved VERB - O
in ADP - O
four CD - B-CARDINAL
cases NOUN - O
( PUNCT - O
80 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
including VERB - O
two CD - B-CARDINAL
with ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
progression NOUN - O
- PUNCT - O
free ADJ - O
survival NOUN - O
for ADP - O
up IN - B-DATE
to TO - I-DATE
10 CD - I-DATE
years NNS - I-DATE
attained VERB - O
under ADP - O
letrozole NN - B-MEDICINE
treatment NOUN - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
case NOUN - O
after ADP - O
prior ADJ - O
progestin ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Sanofi NNP - B-PERSON
Pasteur NNP - I-PERSON
, PUNCT - O
the DET - O
manufacturer NOUN - O
of ADP - O
the DET - O
only ADJ - O
yellow ADJ - O
fever NOUN - O
vaccine NOUN - O
( PUNCT - O
YF PROPN - O
- PUNCT - O
VAX NNP - B-MEDICINE
) PUNCT - O
licensed VERB - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
, PUNCT - O
has VERB - O
announced VERB - O
that ADP - O
their ADJ - O
stock NOUN - O
of ADP - O
YF NNP - B-PRODUCT
- HYPH - I-PRODUCT
VAX NNP - I-MEDICINE
is VERB - O
totally ADV - O
depleted VERB - O
as ADP - O
of ADP - O
July NNP - B-DATE
24 CD - I-DATE
, , - I-DATE
2017 CD - I-DATE
. PUNCT - O

YF PROPN - O
- PUNCT - O
VAX NNP - B-MEDICINE
for ADP - O
civilian ADJ - O
use NOUN - O
will VERB - O
be VERB - O
unavailable ADJ - O
for ADP - O
ordering VERB - O
from ADP - O
Sanofi NNP - B-GPE
Pasteur NNP - B-NORP
until ADP - O
mid-2018 NN - B-DATE
, PUNCT - O
when ADV - O
their ADJ - O
new ADJ - O
manufacturing NOUN - O
facility NOUN - O
is VERB - O
expected VERB - O
to PART - O
be VERB - O
completed VERB - O
. PUNCT - O

However ADV - O
, PUNCT - O
YF NNP - B-PERSON
- HYPH - I-PERSON
VAX NNP - I-MEDICINE
might VERB - O
be VERB - O
available ADJ - O
at ADP - O
some DET - O
clinics NOUN - O
for ADP - O
several JJ - B-DATE
months NNS - I-DATE
, PUNCT - O
until ADP - O
remaining VERB - O
supplies NOUN - O
at ADP - O
those DET - O
sites NOUN - O
are VERB - O
exhausted ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
total ADJ - O
, PUNCT - O
360 CD - B-CARDINAL
fish NOUN - O
were VERB - O
vaccinated VERB - O
with ADP - O
either CCONJ - O
50 CD - B-CARDINAL
  SPACE - O
μl NOUN - O
of ADP - O
an DET - O
oil NOUN - O
- PUNCT - O
based VERB - O
injection NOUN - O
vaccine NOUN - O
( PUNCT - O
VAX NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
with ADP - O
Aeromonas NNP - B-GPE
salmonicida NOUN - O
and CCONJ - O
Vibrio NNP - B-ORG
salmonicida VERB - O
antigens NOUN - O
, PUNCT - O
or CCONJ - O
PBS NNP - B-ORG
. PUNCT - O

Immunoblotting PROPN - O
demonstrated VERB - O
specific ADJ - O
response NOUN - O
against ADP - O
the DET - O
LPS NNP - B-ORG
antigen NOUN - O
of ADP - O
A. NN - B-PERSON
  _SP - I-PERSON
salmonicida VERB - O
in ADP - O
the DET - O
10 CD - B-CARDINAL
° NNP - B-ORG
C NNP - I-ORG
and CCONJ - O
15 CD - B-CARDINAL
° NNP - B-ORG
C NNP - I-ORG
VAX NNP - I-MEDICINE
groups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
RV144 CC - B-PRODUCT
prime ADJ - O
- PUNCT - O
boost NOUN - O
regimen NOUN - O
demonstrated VERB - O
efficacy NOUN - O
against ADP - O
HIV PROPN - O
acquisition NOUN - O
while ADP - O
VAX003 NNP - B-ORG
and CCONJ - O
VAX004 PROPN - O
did VERB - O
not ADV - O
. PUNCT - O

After ADP - O
two CD - B-CARDINAL
protein NOUN - O
immunizations NOUN - O
, PUNCT - O
IgG NNP - B-ORG
responses NOUN - O
to ADP - O
92TH023 ADJ - O
gp120 ADJ - O
( PUNCT - O
contained VERB - O
in ADP - O
ALVAC PROPN - O
- PUNCT - O
HIV PROPN - O
vaccine NOUN - O
) PUNCT - O
were VERB - O
significantly ADV - O
higher ADJ - O
in ADP - O
RV144 NNP - B-PRODUCT
but CCONJ - O
responses VERB - O
to ADP - O
other ADJ - O
Env NNP - B-DATE
were VERB - O
higher ADJ - O
in ADP - O
the DET - O
VAX NNP - B-MEDICINE
trials NOUN - O
lacking VERB - O
ALVAC PROPN - O
- PUNCT - O
HIV PROPN - O
. PUNCT - O

All DET - O
trials NOUN - O
induced VERB - O
antibodies NOUN - O
to ADP - O
gp70 NOUN - O
V1 PROPN - O
V2 PROPN - O
but CCONJ - O
VAX004 PROPN - O
responses VERB - O
to ADP - O
92TH023 PROPN - O
gp70 NOUN - O
V1 PROPN - O
V2 PROPN - O
were VERB - O
weak ADJ - O
. PUNCT - O

All DET - O
CycV2 PROPN - O
responses NOUN - O
were VERB - O
undetectable ADJ - O
in ADP - O
VAX004 PROPN - O
while ADP - O
92TH023 NOUN - O
gp70 NOUN - O
V1 PROPN - O
V2 PROPN - O
was VERB - O
detected VERB - O
in ADP - O
both CCONJ - O
RV144 NNP - B-PRODUCT
and CCONJ - O
VAX003 NNP - B-PRODUCT
but CCONJ - O
MN NNP - B-GPE
CycV2 PROPN - O
was VERB - O
detected VERB - O
only ADV - O
in ADP - O
VAX003 NNP - B-GPE
. PUNCT - O

Multiple ADJ - O
protein NOUN - O
vaccinations NOUN - O
in ADP - O
VAX NNP - B-MEDICINE
trials NOUN - O
did VERB - O
not ADV - O
improve VERB - O
magnitude NOUN - O
or CCONJ - O
durability NOUN - O
of ADP - O
V1 NNP - B-PRODUCT
V2 NNP - I-PRODUCT
and CCONJ - O
CycV2 PROPN - O
antibodies NOUN - O
. PUNCT - O

peptide NOUN - O
at ADP - O
the DET - O
N NN - B-ORG
terminus NOUN - O
of ADP - O
AIDSVAX ADJ - O
® PUNCT - O

B NOUN - O
/ SYM - O
E NOUN - O
and CCONJ - O
B PROPN - O
/ SYM - O
B PROPN - O
gp120 ADJ - O
proteins NOUN - O
induced VERB - O
antibodies NOUN - O
in ADP - O
all DET - O
trials NOUN - O
, PUNCT - O
although ADP - O
significantly ADV - O
higher ADV - O
in ADP - O
VAX NNP - B-MEDICINE
trials NOUN - O
. PUNCT - O

Although ADP - O
confounded VERB - O
by ADP - O
different ADJ - O
modes NOUN - O
of ADP - O
HIV PROPN - O
transmission NOUN - O
, PUNCT - O
higher ADJ - O
Env PROPN - O
- PUNCT - O
specific ADJ - O
IgA NNP - B-ORG
and CCONJ - O
IgG4 JJ - B-ORG
binding ADJ - O
antibodies NOUN - O
induced VERB - O
in ADP - O
the DET - O
VAX NNP - B-MEDICINE
trials NOUN - O
compared VERB - O
to ADP - O
RV144 NNP - B-ORG
raises VERB - O
the DET - O
hypothesis NOUN - O
that ADJ - O
these DET - O
differences NOUN - O
may VERB - O
have VERB - O
contributed VERB - O
to ADP - O
different ADJ - O
vaccine NOUN - O
efficacy NOUN - O
results VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
efficacy NOUN - O
of ADP - O
inactivated VERB - O
West NNP - B-LOC
Nile NNP - I-LOC
vaccine NOUN - O
( PUNCT - O
WN NNP - B-PRODUCT
- HYPH - I-PRODUCT
VAX NNP - I-MEDICINE
) PUNCT - O
in ADP - O
mice NOUN - O
and CCONJ - O
monkeys NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

But CCONJ - O
, PUNCT - O
Middle JJ - B-NORP
American JJ - I-NORP
VAX NNP - B-MEDICINE
3 CD - I-PRODUCT
, PUNCT - O
VAX NNP - B-MEDICINE
4 CD - I-PRODUCT
, PUNCT - O
and CCONJ - O
VAX NNP - B-MEDICINE
6 CD - I-PRODUCT
with ADP - O
SAP6 NNP - B-ORG
and CCONJ - O
SU91 PROPN - O
QTL PROPN - O
were VERB - O
resistant ADJ - O
( PUNCT - O
2.3–2.5 PUNCT - O
) PUNCT - O
to PART - O
ARX8AC VB - B-PERSON
and CCONJ - O
intermediate ADJ - O
to ADP - O
Xcp25 NNP - B-PERSON
( PUNCT - O
3.4–6.5 NUM - O
) PUNCT - O
in ADP - O
the DET - O
trifoliolate ADJ - O
leaf NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
bacterial ADJ - O
ghosts NOUN - O
( PUNCT - O
BG NNP - B-ORG
) PUNCT - O
were VERB - O
collected VERB - O
after ADP - O
wash NOUN - O
and CCONJ - O
loaded VERB - O
with ADP - O
anti ADJ - O
- ADJ - O
caries NOUN - O
DNA NOUN - O
vaccine NOUN - O
pGJGLU NOUN - O
/ SYM - O
VAX NNP - B-MEDICINE
. PUNCT - O

Mice NOUN - O
were VERB - O
divided VERB - O
into ADP - O
four CD - B-CARDINAL
groups NOUN - O
and CCONJ - O
immunized VERB - O
through ADP - O
the DET - O
nasal NOUN - O
route NOUN - O
with ADP - O
pGJGLU PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
- PUNCT - O
loaded VERB - O
BG PROPN - O
( PUNCT - O
Group PROPN - O
Ghost+pGJGLU PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
) PUNCT - O
, PUNCT - O
pVAX1-loaded VERB - O
BG PROPN - O
( PUNCT - O
Group PROPN - O
Ghost+pVAX1 PROPN - O
) PUNCT - O
, PUNCT - O
pGJGLU PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
- HYPH - I-PRODUCT
Bupivacaine JJ - I-PRODUCT
complex NOUN - O
( PUNCT - O
Group PROPN - O
pGJGLU PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
) PUNCT - O
and CCONJ - O
pVAX1-Bupivacaine ADJ - O
complex NOUN - O
( PUNCT - O
Group PROPN - O
pVAX1 PROPN - O
) PUNCT - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

RESULTS NOUN - O
: PUNCT - O
ELISA NN - B-ORG
results NOUN - O
showed VERB - O
that ADP - O
group NOUN - O
Ghost+pGJGLU NNP - B-ORG
/ SYM - I-ORG
VAX NNP - I-MEDICINE
had VERB - O
significantly ADV - O
higher ADJ - O
level NOUN - O
of ADP - O
specific ADJ - O
anti ADJ - O
- ADJ - O
GLU PROPN - O
SIgA NOUN - O
antibody NOUN - O
[ PUNCT - O
( PUNCT - O
0.367 CD - B-CARDINAL
± PUNCT - O
0.086 NUM - O
) PUNCT - O
A/µg NOUN - O
] PUNCT - O
compared VERB - O
with ADP - O
group NOUN - O
Ghost+pVAX1 NNP - B-LAW
[ -LRB- - I-LAW
( PUNCT - O
0.122 CD - B-CARDINAL
± PROPN - O
0.077 CD - B-CARDINAL
) PUNCT - O
A/µg PROPN - O
] PUNCT - O
, PUNCT - O

Group PROPN - O
pGJGLU PROPN - O
/ SYM - O
VAX[(0.068 PROPN - O
± PROPN - O
0.068 CD - B-CARDINAL
) PUNCT - O
A/µg NOUN - O
] PUNCT - O
or CCONJ - O

Group PROPN - O
pVAX1[(0.089 VERB - O
± PROPN - O
0.089 CD - B-CARDINAL
) PUNCT - O
A/µg NOUN - O
] PUNCT - O

St PROPN - O
ghost NOUN - O
was VERB - O
developed VERB - O
successfully ADV - O
, PUNCT - O
which ADJ - O
enhanced VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
immune ADJ - O
responses NOUN - O
induced VERB - O
by ADP - O
anti ADJ - O
- ADJ - O
caries NOUN - O
DNA NOUN - O
vaccine NOUN - O
pGJGLU NOUN - O
/ SYM - O
VAX NNP - B-MEDICINE
via ADP - O
the DET - O
nasal NOUN - O
route NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
construct VERB - O
a DET - O
new ADJ - O
fusion NOUN - O
anti ADJ - O
- ADJ - O
caries NOUN - O
DNA NOUN - O
vaccine NOUN - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
encoding VERB - O
antigens NOUN - O
of ADP - O
both DET - O
S. NNP - B-NORP
mutans NNS - I-NORP
and CCONJ - O
S. PROPN - O
sobrinus NOUN - O
so ADP - O
as ADP - O
to PART - O
enhance VERB - O
the DET - O
protective ADJ - O
effect NOUN - O
of ADP - O
DNA NOUN - O
vaccine NOUN - O
against ADP - O
S. PROPN - O
sobrinus NOUN - O
infection NOUN - O
. PUNCT - O

- PUNCT - O
I PRON - O
was VERB - O
amplified VERB - O
by ADP - O
semi ADJ - O
- PUNCT - O
nest NOUN - O
PCR NNP - B-ORG
and CCONJ - O
then ADV - O
inserted VERB - O
into ADP - O
the DET - O
plasmid ADJ - O
pGJA ADJ - O
- PUNCT - O
P NOUN - O
/ SYM - O
VAX NNP - B-MEDICINE
to PART - O
construct VERB - O
the DET - O
recombinant ADJ - O
plasmid NOUN - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
. PUNCT - O

Mice NOUN - O
were VERB - O
immunized ADJ - O
with ADP - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
and CCONJ - O
control NOUN - O
plasmids NOUN - O
via ADP - O
the DET - O
intramuscular ADJ - O
( PUNCT - O
i.m PROPN - O
) PUNCT - O
or CCONJ - O
intranasal NOUN - O
( PUNCT - O
i.n PROPN - O
) PUNCT - O
routes NOUN - O
. PUNCT - O

Rats NOUN - O
were VERB - O
orally ADV - O
challenged VERB - O
with ADP - O
S. PROPN - O
mutans NOUN - O
Ingbritt NNP - B-PERSON
or CCONJ - O
S. PROPN - O
sobrinus VERB - O
6715 NUM - O
and CCONJ - O
then ADV - O
immunized VERB - O
i.n PROPN - O
with ADP - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
, PUNCT - O
pGJA PROPN - O
- PUNCT - O
P NOUN - O
/ SYM - O
VAX NNP - B-MEDICINE
or CCONJ - O
pVAX1 NOUN - O
. PUNCT - O

The DET - O
recombinant ADJ - O
plasmid NOUN - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
encoded VERB - O
the DET - O
genes NOUN - O
of ADP - O
antigens NOUN - O
of ADP - O
both DET - O
S. PROPN - O
mutans NOUN - O
and CCONJ - O
S. PROPN - O
sobrinus NOUN - O
. PUNCT - O

As ADP - O
for ADP - O
antibody NOUN - O
reactions NOUN - O
, PUNCT - O
mice NOUN - O
in ADP - O
the DET - O
experiment NOUN - O
group NOUN - O
had VERB - O
significantly ADV - O
higher ADJ - O
levels NOUN - O
of ADP - O
anti ADJ - O
- NOUN - O
PAc ADJ - O
, PUNCT - O
anti ADJ - O
- ADJ - O
GLU ADJ - O
and CCONJ - O
anti ADJ - O
- ADJ - O
CAT ADJ - O
IgG PROPN - O
antibodies NOUN - O
than ADP - O
those DET - O
in ADP - O
the DET - O
pVAX1 NOUN - O
group NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.01 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

In ADP - O
the DET - O
group NOUN - O
infected VERB - O
with ADP - O
S. PROPN - O
mutans NOUN - O
or CCONJ - O
S. PROPN - O
sobrinus NOUN - O
, PUNCT - O
the DET - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
- PUNCT - O
immunized ADJ - O
rats NOUN - O
showed VERB - O
significantly ADV - O
fewer ADJ - O
E NOUN - O
, PUNCT - O
Ds NNP - B-PERSON
and CCONJ - O
Dm NNP - B-PERSON
lesions NOUN - O
than ADP - O
pVAX1-immunized VERB - O
rats NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
decreased VERB - O
Ds NNP - B-PERSON
and CCONJ - O
Dm NNP - B-PERSON
levels NOUN - O
than ADP - O
pGJA PROPN - O
- PUNCT - O
P NOUN - O
/ SYM - O
VAX NNP - B-MEDICINE
- PUNCT - O
immunized ADJ - O
rats NOUN - O
( PUNCT - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
while ADP - O
there ADV - O
was VERB - O
no DET - O
obvious ADJ - O
difference NOUN - O
in ADP - O
E NOUN - O
lesions NOUN - O
between ADP - O
the DET - O
two CD - B-CARDINAL
groups NOUN - O
( PUNCT - O
P NOUN - O
> X - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

A DET - O
new ADJ - O
fusion NOUN - O
anti ADJ - O
- ADJ - O
caries NOUN - O
DNA NOUN - O
vaccine NOUN - O
pGJGAC PROPN - O
/ SYM - O
VAX NNP - B-MEDICINE
encoding VERB - O
antigens NOUN - O
of ADP - O
both DET - O
S. NNP - B-NORP
mutans NNS - I-NORP
and CCONJ - O
S. PROPN - O
sobrinus NOUN - O
is VERB - O
constructed VERB - O
successfully ADV - O
and CCONJ - O
expressed VERB - O
correctly ADV - O
in ADP - O
eukaryotic ADJ - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
OXYCODONE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
OXYCODONE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
OXYCODONE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

In ADP - O
the DET - O
Phase PROPN - O
IA PROPN - O
trial NOUN - O
, PUNCT - O
6 CD - B-CARDINAL
JRC NNP - B-ORG
non ADJ - O
- ADJ - O
sensitive ADJ - O
subjects NOUN - O
and CCONJ - O
9 CD - B-CARDINAL
JRC PROPN - O
and/or CCONJ - O
Mountain NNP - B-LOC
Cedar NNP - I-LOC

-DOCSTART- -X- - O

4.5 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
Sicilian JJ - B-NORP
population NOUN - O
suspected VERB - O
of ADP - O
Peach NNP - B-MEDICINE
sensitization NOUN - O
were VERB - O
positive ADJ - O
to ADP - O
Peach NNP - B-MEDICINE
whole ADJ - O
extract NOUN - O
and CCONJ - O
negative ADJ - O
to ADP - O
all ADJ - O
the DET - O
molecules NOUN - O
available ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Novel PROPN - O
Primers PROPN - O
and CCONJ - O
Sampling VERB - O
for ADP - O
PCR PROPN - O
Detection PROPN - O
of ADP - O
Xylella PROPN - O
fastidiosa NOUN - O
in ADP - O
Peach NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Peach NNP - B-MEDICINE
( PUNCT - O
Prunus PROPN - O
persica PROPN - O
) PUNCT - O
has VERB - O
undergone VERB - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
5000 CD - I-CARDINAL
  SPACE - O
years NOUN - O
of ADP - O
domestication NOUN - O
that ADJ - O
led VERB - O
to ADP - O
remarkable ADJ - O
changes NOUN - O
in ADP - O
a DET - O
series NOUN - O
of ADP - O
agronomically ADV - O
important ADJ - O
traits NOUN - O
, PUNCT - O
but CCONJ - O
genetic ADJ - O
bases NOUN - O
underlying VERB - O
these DET - O
changes NOUN - O
and CCONJ - O
the DET - O
effects NOUN - O
of ADP - O
artificial ADJ - O
selection NOUN - O
on ADP - O
genomic ADJ - O
diversity NOUN - O
are VERB - O
not ADV - O
well ADV - O
understood VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Peach NN - B-MEDICINE
is VERB - O
rich ADJ - O
in ADP - O
polyphenols NOUN - O
with ADP - O
flavonols NOUN - O
as ADP - O
the DET - O
main ADJ - O
flavonoids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Genetic NNP - B-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Populations NNPS - I-ORG
of IN - I-ORG
the DT - I-ORG
Peach NNP - I-MEDICINE
Fruit NNP - I-ORG
Fly NNP - I-ORG
, PUNCT - O
Bactrocera NNP - B-PERSON
zonata NOUN - O
( PUNCT - O
Diptera NOUN - O
: PUNCT - O
Tephritidae PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
Iran NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Peach NN - B-MEDICINE
is VERB - O
a DET - O
perishable ADJ - O
fruit NOUN - O
of ADP - O
great ADJ - O
importance NOUN - O
for ADP - O
the DET - O
Greek JJ - B-NORP
food NOUN - O
export NOUN - O
market NOUN - O
which ADJ - O
is VERB - O
prone ADJ - O
to ADP - O
rapid ADJ - O
deterioration NOUN - O
after ADP - O
harvesting NOUN - O
. PUNCT - O

Peach NN - B-MEDICINE
pieces NOUN - O
were VERB - O
immersed VERB - O
in ADP - O
tertiary ADJ - O
solutions NOUN - O
of ADP - O
glycerol NOUN - O
, PUNCT - O
erythritol NOUN - O
, PUNCT - O
steviol VERB - O
glucosides NOUN - O
and CCONJ - O
mineral NOUN - O
salts NOUN - O
at ADP - O
pre ADJ - O
- ADJ - O
selected ADJ - O
OD NNP - B-ORG
conditions NOUN - O
( PUNCT - O
25 CD - B-CARDINAL
- SYM - I-CARDINAL
45 CD - I-CARDINAL
° NOUN - O
C NOUN - O
for ADP - O
3 CD - B-CARDINAL
- SYM - O
240 NUM - O
min NOUN - O
, PUNCT - O
wfruit VERB - O
/wsolution NOUN - O
= SYM - O
1:5 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Peach VB - B-MEDICINE
brachytic ADJ - O
dwarfism NOUN - O
determined VERB - O
by ADP - O
Dwarf NNP - B-ORG
gene NOUN - O
( PUNCT - O
Dw PROPN - O
) PUNCT - O
is VERB - O
an DET - O
undesired ADJ - O
trait NOUN - O
segregating VERB - O
in ADP - O
some DET - O
peach NN - B-MEDICINE
breeding NOUN - O
programs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

E PROPN - O
- PUNCT - O
Nose PROPN - O
and CCONJ - O
GC PROPN - O
- PUNCT - O
MS PROPN - O
Reveal VERB - O
a DET - O
Difference NOUN - O
in ADP - O
the DET - O
Volatile PROPN - O
Profiles PROPN - O
of ADP - O
White- PROPN - O
and CCONJ - O
Red NNP - B-ORG
- HYPH - I-ORG
Fleshed NNP - I-ORG
Peach NNP - I-MEDICINE
Fruit NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

β PUNCT - O
- PUNCT - O
Fructofuranosidase PROPN - O
and CCONJ - O
β DET - O
-D NOUN - O
- PUNCT - O
Fructosyltransferase NOUN - O
from ADP - O
New NNP - B-GPE
Aspergillus NNP - I-GPE
carbonarius NOUN - O
PC-4 PROPN - O
Strain NNP - B-PERSON
Isolated VBN - I-PERSON
from ADP - O
Canned PROPN - O
Peach NNP - B-MEDICINE
Syrup PROPN - O
: PUNCT - O
Effect NOUN - O
of ADP - O
Carbon PROPN - O
and CCONJ - O
Nitrogen PROPN - O
Sources PROPN - O
on ADP - O
Enzyme NNP - B-ORG
Production NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

SLFL PROPN - O
Genes VERB - O
Participate PROPN - O
in ADP - O
the DT - B-ORG
Ubiquitination NNP - I-ORG
and CC - I-ORG
Degradation NNP - I-ORG
Reaction NNP - I-ORG
of IN - I-ORG
S NNP - I-ORG
- HYPH - I-ORG
RNase NNP - I-ORG
in ADP - O
Self PROPN - O
- PUNCT - O
compatible ADJ - O
Peach NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Peach NNP - B-MEDICINE
is VERB - O
a DET - O
genetic ADJ - O
and CCONJ - O
genomic ADJ - O
model NOUN - O
within ADP - O
the DET - O
Rosaceae NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Microneedle NNP - B-ORG
Type NNP - I-ORG
on IN - I-ORG
Transdermal NNP - I-ORG
Permeation NNP - I-ORG
of IN - I-ORG
Rizatriptan NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Bioequivalence NOUN - O
Study PROPN - O
of ADP - O
Two PROPN - O
Orodispersible PROPN - O
Rizatriptan NNP - B-MEDICINE
Formulations PROPN - O
of ADP - O
10 CD - B-CARDINAL
mg NOUN - O
in ADP - O
Healthy PROPN - O
Volunteers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Bioavailability NNP - B-ORG
Enhancement NNP - I-ORG
of IN - I-ORG
Rizatriptan NNP - I-MEDICINE
Benzoate NNP - I-ORG
by ADP - O
Oral NNP - B-ORG
Disintegrating NNP - I-ORG
Strip NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Rizatriptan NNP - B-MEDICINE
was VERB - O
found VERB - O
more ADV - O
efficacious ADJ - O
than ADP - O
conventional ADJ - O
therapy NOUN - O
in ADP - O
terminating VERB - O
an DET - O
attack NOUN - O
of ADP - O
migraine NOUN - O
and CCONJ - O
its ADJ - O
' PUNCT - O
associated ADJ - O
symptoms NOUN - O
but CCONJ - O
looking VERB - O
into ADP - O
the DET - O
contra NOUN - O
- PUNCT - O
indications NOUN - O
, PUNCT - O
side NOUN - O
- PUNCT - O
effects NOUN - O
and CCONJ - O
cost NOUN - O
of ADP - O
the DET - O
former ADJ - O
there ADV - O
has VERB - O
been VERB - O
limitation NOUN - O
in ADP - O
its ADJ - O
prescription NOUN - O
as ADV - O
well ADV - O
as ADP - O
the DET - O
use NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Rizatriptan NNP - B-MEDICINE
10-mg PROPN - O
ODT NNP - B-ORG
was VERB - O
superior ADJ - O
to PART - O
placebo VERB - O
at ADP - O
providing VERB - O
two CD - B-TIME
- HYPH - I-TIME
hour NN - I-TIME
pain NOUN - O
relief NOUN - O
and CCONJ - O
two CD - B-TIME
- HYPH - I-TIME
hour NN - I-TIME
pain NOUN - O
freedom NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
acute ADJ - O
migraine NOUN - O
in ADP - O
those DET - O
who NOUN - O
do VERB - O
not ADV - O
respond VERB - O
to ADP - O
sumatriptan NOUN - O
100 CD - B-CARDINAL
  SPACE - O
mg PRON - O
. PUNCT - O

Rizatriptan NNP - B-MEDICINE
was VERB - O
generally ADV - O
well ADV - O
tolerated VERB - O
in ADP - O
this DET - O
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transdermal JJ - B-ORG
Methods NNPS - I-ORG
And CC - I-ORG
Systems NNPS - I-ORG
For ADP - O
The DET - O
Delivery NOUN - O
Of ADP - O
Rizatriptan NNP - B-MEDICINE

-DOCSTART- -X- - O

Rizatriptan NNP - B-MEDICINE
was VERB - O
generally ADV - O
well ADV - O
tolerated VERB - O
by ADP - O
both DET - O
groups NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Incubation NOUN - O
of ADP - O
isolated ADJ - O
primary ADJ - O
oligodendrocyte ADP - O
precursor NOUN - O
cells NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
in ADP - O
vitro NOUN - O
significantly ADV - O
promoted VERB - O
the DET - O
differentiation NOUN - O
and CCONJ - O
maturation NOUN - O
of ADP - O
oligodendrocyte ADJ - O
precursor NOUN - O
cells NOUN - O
. PUNCT - O

Employing VERB - O
different ADJ - O
inhibitors NOUN - O
of ADP - O
the DET - O
MAPK NNP - B-ORG
pathway NOUN - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
the DET - O
phosphorylation NOUN - O
of ADP - O
ERK1/2 NNP - B-ORG
and CCONJ - O
p38 NOUN - O
MAPK NNP - B-ORG
is VERB - O
required VERB - O
for ADP - O
this DET - O
effect NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

The DET - O
cuprizone NOUN - O
- PUNCT - O
induced VERB - O
demyelination NOUN - O
mouse NOUN - O
model NOUN - O
was VERB - O
applied VERB - O
to PART - O
examine VERB - O
the DET - O
pro ADJ - O
- ADJ - O
remyelinating ADJ - O
effect NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
in ADP - O
vivo NOUN - O
. PUNCT - O

The DET - O
proportion NOUN - O
of ADP - O
myelinated VERB - O
axons NOUN - O
was VERB - O
also ADV - O
increased VERB - O
after ADP - O
omeprazole JJ - B-MEDICINE
treatment NOUN - O
as ADP - O
revealed VERB - O
by ADP - O
transmission NOUN - O
electron NOUN - O
microscopy NOUN - O
. PUNCT - O

Our ADJ - O
data NOUN - O
demonstrate VERB - O
that ADP - O
omeprazole NN - B-MEDICINE
is VERB - O
a DET - O
promising ADJ - O
drug NOUN - O
candidate NOUN - O
for ADP - O
remyelination NOUN - O
in ADP - O
MS NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
conducted VERB - O
to PART - O
determine VERB - O
the DET - O
effect NOUN - O
of ADP - O
magnesium NOUN - O
and CCONJ - O
aluminum NOUN - O
hydroxides NOUN - O
plus CCONJ - O
simethicone NOUN - O
, PUNCT - O
famotidine NOUN - O
, PUNCT - O
and CCONJ - O
omeprazole NN - B-MEDICINE
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
saxagliptin NOUN - O
and CCONJ - O
its ADJ - O
active ADJ - O
metabolite NOUN - O
, PUNCT - O
5-hydroxy CD - B-CARDINAL
saxagliptin NOUN - O
. PUNCT - O

Coadministration NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
did VERB - O
not ADV - O
affect VERB - O
saxagliptin ADJ - O
Cmax PROPN - O
or CCONJ - O
AUC NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
prospective ADJ - O
, PUNCT - O
open ADJ - O
label NOUN - O
, PUNCT - O
non ADJ - O
random ADJ - O
( PUNCT - O
consecutive ADJ - O
) PUNCT - O
, PUNCT - O
experimental ADJ - O
study NOUN - O
was VERB - O
performed VERB - O
due ADP - O
to PART - O
compare VERB - O
the DET - O
therapeutic ADJ - O
efficacy NOUN - O
of ADP - O
alginate NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
in ADP - O
relieving VERB - O
symptoms NOUN - O
of ADP - O
non ADJ - O
erosive ADJ - O
reflux NOUN - O
disease NOUN - O
( PUNCT - O
NERD PROPN - O
) PUNCT - O
and CCONJ - O
was VERB - O
carried VERB - O
out PART - O
in ADP - O
the DT - B-ORG
Outpatient NNP - I-ORG
Department NNP - I-ORG
of IN - I-ORG
Gastroenterology NNP - I-ORG
, PUNCT - O
Dhaka NNP - B-ORG
Medical NNP - I-ORG
College NNP - I-ORG
Hospital NNP - I-ORG
, PUNCT - O
Dhaka NNP - B-GPE
, PUNCT - O
Bangladesh PROPN - O
from ADP - O
December NNP - B-DATE
2013 CD - I-DATE
to ADP - O
May NNP - B-DATE
2014 CD - I-DATE
. PUNCT - O

Among ADP - O
them PRON - O
, PUNCT - O
30 CD - B-CARDINAL
subjects NOUN - O
were VERB - O
assigned VERB - O
to ADP - O
the DET - O
omeprazole JJ - B-MEDICINE
group NOUN - O
( PUNCT - O
Group PROPN - O
I PROPN - O
) PUNCT - O
and CCONJ - O
30 CD - B-CARDINAL
subjects NOUN - O
to ADP - O
the DET - O
alginate ADJ - O
group NOUN - O
( PUNCT - O
Group PROPN - O
II PROPN - O
) PUNCT - O
. PUNCT - O

In ADP - O
ITT PROPN - O
analysis NOUN - O
, PUNCT - O
achieving VERB - O
complete ADJ - O
symptom NOUN - O
relief NOUN - O
( PUNCT - O
heart NOUN - O
burn NOUN - O
) PUNCT - O
was VERB - O
56.7 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
alginate NOUN - O
group NOUN - O
& CCONJ - O
60 CD - B-PERCENT
% NN - I-PERCENT
in ADP - O
omeprazole JJ - B-MEDICINE
group NOUN - O
. PUNCT - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
overall ADJ - O
satisfaction NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
& CCONJ - O
alginate VERB - O
was VERB - O
more JJR - B-PERCENT
than IN - I-PERCENT
86 CD - I-PERCENT
% NN - I-PERCENT
and CCONJ - O
the DET - O
mean ADJ - O
duration NOUN - O
of ADP - O
heart NOUN - O
burn VERB - O
free ADJ - O
was VERB - O
found VERB - O
5.0±4.0 CD - B-DATE
days NNS - I-DATE
in ADP - O
Group NNP - B-ORG
I PROPN - O
and CCONJ - O
3.65±2.8 NNP - B-DATE
days NNS - I-DATE
in ADP - O
Group NNP - B-EVENT
II NNP - I-EVENT
. PUNCT - O

Therapeutic ADJ - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
profiles NOUN - O
of ADP - O
alginate ADJ - O
were VERB - O
comparable ADJ - O
to PART - O
omeprazole VB - B-MEDICINE
after ADP - O
two CD - B-DATE
weeks NNS - I-DATE
treatment NOUN - O
in ADP - O
NERD NNP - B-ORG
subjects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Female JJ - B-PERSON
Sprague NNP - I-PERSON
Dawley NN - I-PERSON
albino NOUN - O
rats NOUN - O
were VERB - O
divided VERB - O
into ADP - O
five CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
control NOUN - O
( PUNCT - O
saline NOUN - O
group NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
, PUNCT - O
negative ADJ - O
control NOUN - O
( PUNCT - O
indomethacin ADJ - O
group NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
, PUNCT - O
positive ADJ - O
control NOUN - O
( PUNCT - O
omeprazole JJ - B-MEDICINE
group NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
, PUNCT - O
low ADJ - O
dose NOUN - O
therapy NOUN - O
( PUNCT - O
caftaric ADJ - O
acid NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
, PUNCT - O
and CCONJ - O
high ADJ - O
dose NOUN - O
therapy NOUN - O
( PUNCT - O
caftaric ADJ - O
acid NOUN - O
, PUNCT - O
n NOUN - O
= SYM - O
8) NUM - O
. PUNCT - O

But CCONJ - O
another DET - O
important ADJ - O
point NOUN - O
to PART - O
note VERB - O
is VERB - O
that ADP - O
high ADJ - O
dose NOUN - O
caftaric ADJ - O
acid NOUN - O
therapy NOUN - O
performed VERB - O
gastroprotective ADJ - O
effect NOUN - O
as ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
assessed VERB - O
the DET - O
therapeutic ADJ - O
potential NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
( PUNCT - O
OME PROPN - O
) PUNCT - O
, PUNCT - O
the DET - O
most ADV - O
commonly ADV - O
prescribed ADJ - O
proton NOUN - O
pump NOUN - O
inhibitor NOUN - O
( PUNCT - O
PPI PROPN - O
) PUNCT - O
used VERB - O
to PART - O
treat VERB - O
gastroesophageal NOUN - O
hyperacidity NOUN - O
, PUNCT - O
against ADP - O
cisplatin ADJ - O
( PUNCT - O
CP)-induced VERB - O
toxicity NOUN - O
in ADP - O
human ADJ - O
renal ADJ - O
tubular NOUN - O
HK-2 PROPN - O
  SPACE - O
cells NOUN - O
and CCONJ - O
rat NOUN - O
kidneys NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Second RB - B-ORDINAL
, PUNCT - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
two CD - B-CARDINAL
- PUNCT - O
treatment NOUN - O
, PUNCT - O
fixed VERB - O
- PUNCT - O
sequence NOUN - O
comparative ADJ - O
bioavailability NOUN - O
study NOUN - O
in ADP - O
healthy ADJ - O
adults NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
28 CD - B-CARDINAL
) PUNCT - O
under ADP - O
fasted VERB - O
conditions NOUN - O
compared VERB - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
a DET - O
single ADJ - O
oral ADJ - O
dose NOUN - O
of ADP - O
SUBA PROPN - O
itraconazole ADJ - O
capsules NOUN - O
( PUNCT - O
2 CD - B-CARDINAL
65-mg NUM - O
capsules NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
with ADP - O
and CCONJ - O
without ADP - O
coadministration NOUN - O
of ADP - O
daily ADJ - O
omeprazole JJ - B-MEDICINE
delayed VERB - O
- PUNCT - O
release NOUN - O
capsules NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
40-mg NUM - O
capsule NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
under ADP - O
steady ADJ - O
- PUNCT - O
state NOUN - O
conditions NOUN - O
. PUNCT - O

When ADV - O
dosed VERB - O
concomitantly ADV - O
with ADP - O
omeprazole NN - B-MEDICINE
, PUNCT - O
there ADV - O
was VERB - O
a DET - O
22 CD - B-PERCENT
% NN - I-PERCENT
increase NOUN - O
in ADP - O
the DET - O
total ADJ - O
plasma NOUN - O
exposure NOUN - O
of ADP - O
ITZ NNP - B-ORG
, PUNCT - O
as ADP - O
measured VERB - O
by ADP - O
the DET - O
area NOUN - O
under ADP - O
the DET - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
curve NOUN - O
from ADP - O
time NOUN - O
zero NUM - O
to ADP - O
infinity NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.0069 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
a DET - O
31 CD - B-PERCENT
% NN - I-PERCENT
increase NOUN - O
in ADP - O
the DET - O
peak NOUN - O
plasma NOUN - O
exposure NOUN - O
of ADP - O
ITZ NNP - B-ORG
, PUNCT - O
as ADP - O
measured VERB - O
by ADP - O
the DET - O
maximum ADJ - O
concentration NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
  SPACE - O
0.0083 NUM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
we PRON - O
established VERB - O
a DET - O
UHPLC NNP - B-ORG
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
method VERB - O
for ADP - O
simultaneous ADJ - O
quantitation NOUN - O
of ADP - O
four CD - B-CARDINAL
CYP450 NNP - B-ORG
probe NOUN - O
drugs NOUN - O
( PUNCT - O
phenacetin ADJ - O
, PUNCT - O
omeprazole JJ - B-MEDICINE
, PUNCT - O
metoprolol NOUN - O
and CCONJ - O
midazolam NOUN - O
) PUNCT - O
and CCONJ - O
their ADJ - O
metabolites NOUN - O
( PUNCT - O
acetaminophen ADV - O
, PUNCT - O
5'-hydroxy CD - B-CARDINAL
omeprazole NN - B-MEDICINE
, PUNCT - O
α PUNCT - O
- PUNCT - O
hydroxy NOUN - O
metoprolol NOUN - O
and CCONJ - O
1'-hydroxy CD - B-CARDINAL
midazolam NOUN - O
) PUNCT - O
in ADP - O
rat NOUN - O
plasma NOUN - O
. PUNCT - O

The DET - O
calibration NOUN - O
curves NOUN - O
were VERB - O
linear ADJ - O
over ADP - O
the DET - O
concentration NOUN - O
range VERB - O
10 CD - B-CARDINAL
- SYM - I-CARDINAL
5000 CD - I-CARDINAL
  SPACE - O
ng PROPN - O
/ SYM - O
mL PROPN - O
for ADP - O
phenacetin ADJ - O
, PUNCT - O
omeprazole JJ - B-MEDICINE
, PUNCT - O
metoprolol NOUN - O
and CCONJ - O
midazolam NOUN - O
, PUNCT - O
and CCONJ - O
1 CD - B-CARDINAL
- SYM - I-CARDINAL
500 CD - I-CARDINAL
  SPACE - O
ng PROPN - O
/ SYM - O
mL PROPN - O
for ADP - O
their ADJ - O
metabolites NOUN - O
. PUNCT - O

The DET - O
method NOUN - O
was VERB - O
successfully ADV - O
applied VERB - O
to ADP - O
the DET - O
pharmacokinetic ADJ - O
study NOUN - O
of ADP - O
probe NOUN - O
drugs NOUN - O
/ SYM - O
metabolites NOUN - O
and CCONJ - O
DDIs NOUN - O
with ADP - O
3-n CD - B-CARDINAL
- PUNCT - O
butylphthalide NOUN - O
( PUNCT - O
NBP NNP - B-ORG
) PUNCT - O
after ADP - O
administration NOUN - O
of ADP - O
a DET - O
single ADJ - O
oral ADJ - O
dose NOUN - O
of ADP - O
phenacetin ADJ - O
, PUNCT - O
omeprazole JJ - B-MEDICINE
, PUNCT - O
metoprolol NOUN - O
and CCONJ - O
midazolam NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Twelve CD - B-DATE
- HYPH - I-DATE
month NN - I-DATE
- HYPH - I-DATE
old JJ - I-DATE
male ADJ - O
C57BL/6 NN - B-PRODUCT
mice NOUN - O
received VERB - O
control NOUN - O
feed NOUN - O
or CCONJ - O
feeds VERB - O
/ SYM - O
water NOUN - O
containing VERB - O
therapeutic ADJ - O
doses NOUN - O
of ADP - O
drugs NOUN - O
in ADP - O
regimens NOUN - O
of ADP - O
polypharmacy NOUN - O
with ADP - O
Zero NNP - B-CARDINAL
DBI PROPN - O
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
irbesartan NOUN - O
) PUNCT - O
, PUNCT - O
Low PROPN - O
DBI PROPN - O
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
citalopram NOUN - O
) PUNCT - O
, PUNCT - O
High PROPN - O
DBI PROPN - O
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
oxybutynin NOUN - O
, PUNCT - O
oxycodone NOUN - O
, PUNCT - O
citalopram NOUN - O
) PUNCT - O
or CCONJ - O
monotherapy NOUN - O
with ADP - O
each DET - O
of ADP - O
the DET - O
five CD - B-CARDINAL
drugs NOUN - O
from ADP - O
the DET - O
High PROPN - O
DBI PROPN - O
diet NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

From ADP - O
12 CD - B-DATE
to TO - I-DATE
21 CD - I-DATE
months NNS - I-DATE
of IN - I-DATE
age NN - I-DATE
male NN - I-DATE
C57BL/6 NN - I-DATE
mice NOUN - O
were VERB - O
fed VERB - O
control NOUN - O
or CCONJ - O
treatment NOUN - O
containing VERB - O
therapeutic ADJ - O
doses NOUN - O
of ADP - O
five CD - B-CARDINAL
drugs NOUN - O
with ADP - O
Zero NNP - B-CARDINAL
DBI PROPN - O
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
irbesartan NOUN - O
) PUNCT - O
, PUNCT - O
Low PROPN - O
DBI PROPN - O
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
paracetamol NOUN - O
, PUNCT - O
citalopram NOUN - O
) PUNCT - O
, PUNCT - O
High PROPN - O
DBI NNP - B-ORG
( PUNCT - O
simvastatin ADV - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
oxybutynin NOUN - O
, PUNCT - O
oxycodone NOUN - O
, PUNCT - O
citalopram NOUN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
single ADJ - O
drug NOUN - O
( PUNCT - O
simvastatin ADJ - O
, PUNCT - O
metoprolol NOUN - O
, PUNCT - O
oxybutynin NOUN - O
, PUNCT - O
oxycodone NOUN - O
or CCONJ - O
citalopram NOUN - O
) PUNCT - O
( PUNCT - O
n=40/ NOUN - O
group NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
single ADJ - O
- PUNCT - O
center NOUN - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
parallel ADJ - O
- PUNCT - O
group NOUN - O
trial NOUN - O
investigated VERB - O
pharmacokinetic ADJ - O
interactions NOUN - O
of ADP - O
oral ADJ - O
semaglutide NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
( PUNCT - O
40 CD - B-CARDINAL
  SPACE - O
mg PRON - O
once ADV - O
- PUNCT - O
daily RB - B-DATE
) PUNCT - O
in ADP - O
54 CD - B-CARDINAL
healthy ADJ - O
subjects NOUN - O
. PUNCT - O

( PUNCT - O
Cmax PROPN - O
, PUNCT - O
semaglutide ADV - O
, PUNCT - O
Day10 NNP - B-PERSON
) PUNCT - O
at ADP - O
day NOUN - O
10.Exposure NUM - O
of ADP - O
semaglutide NOUN - O
appeared VERB - O
to PART - O
be VERB - O
slightly ADV - O
increased VERB - O
, PUNCT - O
although ADP - O
not ADV - O
statistically ADV - O
significantly ADV - O
, PUNCT - O
with ADP - O
oral ADJ - O
semaglutide NOUN - O
plus CCONJ - O
omeprazole NN - B-MEDICINE
versus ADP - O
oral ADJ - O
semaglutide NOUN - O
alone ADV - O
( PUNCT - O
AUC0 NNP - B-ORG
- HYPH - I-ORG
24h NNS - I-ORG
, PUNCT - O
semaglutide ADV - O
, PUNCT - O
Day10 NNP - B-ORG
[ PUNCT - O
estimated VERB - O
treatment NOUN - O
ratio NOUN - O
1.13 CD - B-CARDINAL
; PUNCT - O
90%CI CD - B-CARDINAL
0.88 CD - I-CARDINAL
, PUNCT - O
1.45 CD - B-CARDINAL
] PUNCT - O
and CCONJ - O
Cmax NNP - B-ORG
, PUNCT - O
semaglutide ADV - O
, PUNCT - O
Day10 NNP - B-ORG
[ PUNCT - O
estimated VERB - O
treatment NOUN - O
ratio NOUN - O
1.16 CD - B-CARDINAL
; PUNCT - O
90%CI CD - B-CARDINAL
0.90 CD - I-CARDINAL
, PUNCT - O
1.49 CD - B-CARDINAL
] PUNCT - O
) PUNCT - O
. PUNCT - O

Gastric PROPN - O
pH PROPN - O
was VERB - O
higher ADJ - O
with ADP - O
oral ADJ - O
semaglutide NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
versus ADP - O
oral ADJ - O
semaglutide NOUN - O
alone ADV - O
. PUNCT - O

There ADV - O
was VERB - O
a DET - O
slight ADJ - O
non ADJ - O
- ADJ - O
statistically ADV - O
significant ADJ - O
increase NOUN - O
in ADP - O
semaglutide NOUN - O
exposure NOUN - O
when ADV - O
oral ADJ - O
semaglutide NOUN - O
was VERB - O
administered VERB - O
with ADP - O
omeprazole NN - B-MEDICINE
, PUNCT - O
but CCONJ - O
this DET - O
is VERB - O
not ADV - O
considered VERB - O
clinically ADV - O
relevant ADJ - O
and CCONJ - O
no DET - O
dose NOUN - O
adjustment NOUN - O
is VERB - O
likely ADJ - O
to PART - O
be VERB - O
required VERB - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
drug NOUN - O
- PUNCT - O
interaction NOUN - O
study NOUN - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
, PUNCT - O
a DET - O
proton NOUN - O
- PUNCT - O
pump NOUN - O
inhibitor NOUN - O
, PUNCT - O
on ADP - O
ibrutinib X - O
's PART - O
pharmacokinetics NOUN - O
( PUNCT - O
PK NNP - B-ORG
) PUNCT - O
in ADP - O
healthy ADJ - O
participants NOUN - O
. PUNCT - O

Ibrutinib PROPN - O
( PUNCT - O
560 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
, PUNCT - O
single ADJ - O
dose NOUN - O
) PUNCT - O
was VERB - O
administered VERB - O
after ADP - O
an DET - O
overnight ADJ - O
fast ADV - O
alone ADV - O
on ADP - O
day NN - B-DATE
1 CD - I-DATE
and CCONJ - O
with ADP - O
omeprazole NN - B-MEDICINE
on ADP - O
day NN - B-DATE
7 CD - I-DATE
. PUNCT - O

The DET - O
effect NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
on ADP - O
ibrutinib X - O
's PART - O
PK NNP - B-ORG
was VERB - O
determined VERB - O
by ADP - O
assessing VERB - O
geometric ADJ - O
mean NOUN - O
ratios NOUN - O
( PUNCT - O
GMRs PROPN - O
) PUNCT - O
and CCONJ - O
90 CD - B-PERCENT
% NN - I-PERCENT
CIs NOUN - O
. PUNCT - O

AUC48h PROPN - O
and CCONJ - O
AUClast NOUN - O
of ADP - O
ibrutinib NOUN - O
plus CCONJ - O
omeprazole JJ - B-MEDICINE
versus X - O
ibrutinib X - O
alone ADV - O
showed VERB - O
a DET - O
modest ADJ - O
decrease NOUN - O
( PUNCT - O
GMR PROPN - O
[ PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
] PUNCT - O
98.3 CD - B-PERCENT
% NN - I-PERCENT
[ PUNCT - O
83.1 CD - B-CARDINAL
- SYM - O
116.3 NUM - O
] PUNCT - O
and CCONJ - O
92.5 CD - B-PERCENT
% NN - I-PERCENT
[ PUNCT - O
77.8 CD - B-CARDINAL
- HYPH - I-CARDINAL
109.9 CD - I-CARDINAL
] PUNCT - O
, PUNCT - O
respectively ADV - O
) PUNCT - O
; PUNCT - O
Cmax NNP - B-ORG
decreased VERB - O
by ADP - O
62.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
GMR PROPN - O
[ PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
] PUNCT - O
37.5 CD - B-PERCENT
% NN - I-PERCENT
[ PUNCT - O
26.4 CD - B-CARDINAL
- PUNCT - O
53.4 NUM - O
] PUNCT - O
) PUNCT - O
, PUNCT - O
with ADP - O
delayed VERB - O
tmax ADJ - O
( PUNCT - O
1 CD - B-CARDINAL
- SYM - O
2 NUM - O
  SPACE - O
h NOUN - O
) PUNCT - O
and CCONJ - O
terminal ADJ - O
half JJ - B-CARDINAL
- PUNCT - O
life NOUN - O
unaffected ADJ - O
. PUNCT - O

Mean PROPN - O
AUC NNP - B-ORG
for ADP - O
PCI-45227 NNP - B-ORG
( PUNCT - O
primary ADJ - O
metabolite NOUN - O
) PUNCT - O
was VERB - O
~ SYM - O
  SPACE - O
20 CD - B-PERCENT
% NN - I-PERCENT
lower ADJ - O
with ADP - O
ibrutinib X - O
plus CCONJ - O
omeprazole JJ - B-MEDICINE
versus X - O
ibrutinib X - O
alone ADV - O
. PUNCT - O

The DET - O
decrease NOUN - O
in ADP - O
Cmax NNP - B-ORG
without ADP - O
a DET - O
corresponding ADJ - O
decrease NOUN - O
in ADP - O
AUC NNP - B-ORG
by ADP - O
omeprazole NN - B-MEDICINE
was VERB - O
not ADV - O
clinically ADV - O
relevant ADJ - O
for ADP - O
ibrutinib X - O
's PART - O
bioavailability NOUN - O
. PUNCT - O

No DET - O
dose NOUN - O
adjustments NOUN - O
are VERB - O
recommended VERB - O
during ADP - O
ibrutinib X - O
's PART - O
co NOUN - O
- NOUN - O
administration NOUN - O
with ADP - O
omeprazole JJ - B-MEDICINE
or CCONJ - O
other ADJ - O
pH NOUN - O
- PUNCT - O
altering VERB - O
agents NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
results NOUN - O
obtained VERB - O
from ADP - O
enzymic ADJ - O
analyses NOUN - O
showed VERB - O
that ADP - O
the DET - O
omeprazole NN - B-MEDICINE
inhibited VERB - O
tyrosinase NOUN - O
activity NOUN - O
( PUNCT - O
IC50 PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
40 NUM - O
  SPACE - O
± PUNCT - O
  SPACE - O
1.2 CD - B-CARDINAL
  SPACE - O
μM NNP - B-ORG
) PUNCT - O
with ADP - O
a DET - O
reversible ADJ - O
and CCONJ - O
competitive ADJ - O
mechanism NOUN - O
. PUNCT - O

Fluorescence NOUN - O
quenching NOUN - O
assays NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
interaction NOUN - O
between ADP - O
omeprazole NN - B-MEDICINE
and CCONJ - O
tyrosinase NOUN - O
was VERB - O
driven VERB - O
by ADP - O
hydrophobic ADJ - O
forces NOUN - O
and CCONJ - O
hydrogen NOUN - O
bonds NOUN - O
in ADP - O
a DET - O
static ADJ - O
procedure NOUN - O
. PUNCT - O

Molecular ADJ - O
docking NOUN - O
further ADV - O
revealed VERB - O
that ADP - O
hydrogen NOUN - O
bonds NOUN - O
and CCONJ - O
hydrophobic NOUN - O
forces NOUN - O
were VERB - O
generated VERB - O
by ADP - O
omeprazole NN - B-MEDICINE
with ADP - O
the DET - O
amino NOUN - O
acid NOUN - O
residues NOUN - O
located VERB - O
in ADP - O
the DET - O
A DET - O
chain NOUN - O
of ADP - O
tyrosinase NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
the DET - O
results NOUN - O
from ADP - O
preservation NOUN - O
assays NOUN - O
showed VERB - O
that ADP - O
omeprazole NN - B-MEDICINE
could VERB - O
inhibit VERB - O
the DET - O
activities NOUN - O
of ADP - O
polyphenol NOUN - O
oxidase NOUN - O
( PUNCT - O
PPO PROPN - O
) PUNCT - O
and CCONJ - O
peroxidase PROPN - O
( PUNCT - O
POD NNP - B-ORG
) PUNCT - O
, PUNCT - O
prevent VERB - O
the DET - O
oxidation NOUN - O
of ADP - O
total ADJ - O
phenolics NOUN - O
and CCONJ - O
flavonoid NOUN - O
, PUNCT - O
thereby ADV - O
delay VERB - O
the DET - O
browning NOUN - O
of ADP - O
fresh ADV - O
- PUNCT - O
cut VERB - O
apples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
rolapitant NOUN - O
administered VERB - O
orally ADV - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
dextromethorphan NOUN - O
( PUNCT - O
CYP2D6 PROPN - O
) PUNCT - O
, PUNCT - O
tolbutamide NOUN - O
( PUNCT - O
CYP2C9 PROPN - O
) PUNCT - O
, PUNCT - O
omeprazole NN - B-MEDICINE
( PUNCT - O
CYP2C19 NNP - B-ORG
) PUNCT - O
, PUNCT - O
efavirenz NOUN - O
( PUNCT - O
CYP2B6 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
repaglinide NOUN - O
( PUNCT - O
CYP2C8 PROPN - O
) PUNCT - O
in ADP - O
healthy ADJ - O
subjects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
observe VERB - O
the DET - O
therapeutic ADJ - O
effect NOUN - O
of ADP - O
combined VERB - O
acupuncture NOUN - O
combined VERB - O
with ADP - O
omeprazole NN - B-MEDICINE
on ADP - O
patients NOUN - O
with ADP - O
craniocerebral ADJ - O
trauma NOUN - O
complicated VERB - O
with ADP - O
stress NOUN - O
gastric ADJ - O
mucosal NOUN - O
injury NOUN - O
. PUNCT - O

Patients NOUN - O
were VERB - O
divided VERB - O
into ADP - O
omeprazole JJ - B-MEDICINE
group NOUN - O
, PUNCT - O
acupuncture ADJ - O
group NOUN - O
and CCONJ - O
acupuncture VERB - O
plus CCONJ - O
omeprazole JJ - B-MEDICINE
combined VERB - O
treatment NOUN - O
group NOUN - O
according VERB - O
to ADP - O
random ADJ - O
number NOUN - O
table NOUN - O
method NOUN - O
. PUNCT - O

After ADP - O
diagnosis NOUN - O
, PUNCT - O
omeprazole JJ - B-MEDICINE
group NOUN - O
was VERB - O
injected VERB - O
intravenously ADV - O
omeprazole JJ - B-MEDICINE
, PUNCT - O
40 CD - B-CARDINAL
mg NOUN - O
each DET - O
time NOUN - O
, PUNCT - O
one CD - B-CARDINAL
dose NOUN - O
in ADP - O
12 CD - B-TIME
hours NNS - I-TIME
for ADP - O
7 CD - B-DATE
days NNS - I-DATE
; PUNCT - O
acupuncture ADJ - O
group NOUN - O
was VERB - O
acupunctured VERB - O
at ADP - O
bilateral ADJ - O
Zusanli JJ - B-NORP
point NOUN - O
and CCONJ - O
Zhongwan NNP - B-GPE
point NOUN - O
, PUNCT - O
20 CD - B-TIME
minutes NNS - I-TIME
for ADP - O
needle NOUN - O
retention NOUN - O
, PUNCT - O
once ADV - O
a DET - O
day NOUN - O
for ADP - O
7 CD - B-DATE
days NNS - I-DATE
; PUNCT - O
combined VERB - O
treatment NOUN - O
group NOUN - O
was VERB - O
given VERB - O
acupuncture ADJ - O
and CCONJ - O
omeprazole NN - B-MEDICINE
at ADP - O
the DET - O
same ADJ - O
time NOUN - O
. PUNCT - O

GCS PROPN - O
score NOUN - O
at ADP - O
7 CD - B-DATE
days NNS - I-DATE
after ADP - O
treatment NOUN - O
in ADP - O
omeprazole JJ - B-MEDICINE
group NOUN - O
, PUNCT - O
acupuncture ADJ - O
group NOUN - O
and CCONJ - O
combined VERB - O
treatment NOUN - O
group NOUN - O
were VERB - O
significantly ADV - O
higher ADJ - O
than ADP - O
those DET - O
at ADP - O
admission NOUN - O
, PUNCT - O
but CCONJ - O
there ADV - O
was VERB - O
no DET - O
statistical ADJ - O
difference NOUN - O
among ADP - O
the DET - O
groups NOUN - O
( PUNCT - O
9.46±2.81 NUM - O
, PUNCT - O
10.26±2.24 NUM - O
, PUNCT - O
10.52±2.50 NUM - O
, PUNCT - O
F PROPN - O
= SYM - O
2.010 CD - B-CARDINAL
, PUNCT - O
P NOUN - O
= SYM - O
0.141 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

For ADP - O
treatment NOUN - O
of ADP - O
7 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
the DET - O
incidence NOUN - O
of ADP - O
occult ADJ - O
stool NOUN - O
in ADP - O
the DET - O
combined VERB - O
treatment NOUN - O
group NOUN - O
was VERB - O
significantly ADV - O
lower ADJ - O
than ADP - O
that DET - O
in ADP - O
the DET - O
omeprazole JJ - B-MEDICINE
group NOUN - O
and CCONJ - O
acupuncture NOUN - O
group NOUN - O
( PUNCT - O
13.3 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
36.7 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
40.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
both CCONJ - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
pH PROPN - O
value NOUN - O
of ADP - O
gastric ADJ - O
excretion NOUN - O
in ADP - O
the DET - O
combined VERB - O
treatment NOUN - O
group NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
than ADP - O
that DET - O
in ADP - O
the DET - O
omeprazole JJ - B-MEDICINE
group NOUN - O
and CCONJ - O
acupuncture VERB - O
group NOUN - O
at ADP - O
5 CD - B-DATE
days NNS - I-DATE
of ADP - O
treatment NOUN - O
( PUNCT - O
4.58±0.53 NUM - O
vs. ADP - O
4.20±0.52 NUM - O
, PUNCT - O
4.28±0.43 NUM - O
, PUNCT - O
both CCONJ - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

The DET - O
level NOUN - O
of ADP - O
NT PROPN - O
at ADP - O
treatment NN - B-DATE
5 CD - I-DATE
days NNS - I-DATE
in ADP - O
the DET - O
combined VERB - O
treatment NOUN - O
group NOUN - O
was VERB - O
significantly ADV - O
higher ADJ - O
than ADP - O
that DET - O
of ADP - O
the DET - O
omeprazole JJ - B-MEDICINE
group NOUN - O
and CCONJ - O
the DET - O
acupuncture ADJ - O
group NOUN - O
( PUNCT - O
ng PROPN - O
/ SYM - O
L NOUN - O
: PUNCT - O
45.88±8.03 NUM - O
vs. ADP - O
36.15±11.54 CD - B-CARDINAL
, PUNCT - O
37.32±7.79 NUM - O
, PUNCT - O
both CCONJ - O
P NOUN - O
< X - O
0.05 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
had VERB - O
returned VERB - O
to ADP - O
normal ADJ - O
level NOUN - O
on ADP - O
the DT - B-DATE
7th JJ - I-DATE
day NN - I-DATE
after ADP - O
treatment NOUN - O
( PUNCT - O
ng PROPN - O
/ SYM - O
L NOUN - O
: PUNCT - O
56.88 CD - B-CARDINAL
±12.54 NOUN - O
) PUNCT - O
. PUNCT - O

The DET - O
level NOUN - O
of ADP - O
ET-1 NNP - B-ORG
at ADP - O
treatment NOUN - O
of ADP - O
7 CD - B-DATE
days NNS - I-DATE
in ADP - O
the DET - O
combined VERB - O
treatment NOUN - O
group NOUN - O
was VERB - O
significantly ADV - O
lower ADJ - O
than ADP - O
that DET - O
of ADP - O
the DET - O
omeprazole JJ - B-MEDICINE
group NOUN - O
and CCONJ - O
acupuncture NOUN - O
group NOUN - O

Combined VERB - O
acupuncture NOUN - O
at ADP - O
points NOUN - O
of ADP - O
Zusanli NNP - B-GPE
and CCONJ - O
Zhongwan NNP - B-GPE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
stress NOUN - O
gastric ADJ - O
mucosal NOUN - O
injury NOUN - O
after ADP - O
traumatic ADJ - O
brain NOUN - O
injury NOUN - O
, PUNCT - O
can VERB - O
reduce VERB - O
gastric ADJ - O
acid NOUN - O
secretion NOUN - O
, PUNCT - O
promote VERB - O
the DET - O
level NOUN - O
of ADP - O
NT PROPN - O
in ADP - O
serum NOUN - O
, PUNCT - O
reduce VERB - O
the DET - O
secretion NOUN - O
of ADP - O
ET-1 PROPN - O
level NOUN - O
, PUNCT - O
help VERB - O
to PART - O
repair VERB - O
the DET - O
gastric ADJ - O
mucosa NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
effect NOUN - O
of ADP - O
combined VERB - O
with ADP - O
omeprazole NN - B-MEDICINE
is VERB - O
more ADV - O
significant ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
assess VERB - O
whether ADP - O
prophylaxis NOUN - O
for ADP - O
digestive ADJ - O
disorders NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
is VERB - O
a DET - O
risk NOUN - O
factor NOUN - O
for ADP - O
adverse ADJ - O
drug NOUN - O
events NOUN - O
( PUNCT - O
ADEs PROPN - O
) PUNCT - O
and CCONJ - O
kidney NOUN - O
impairment NOUN - O
. PUNCT - O

The DET - O
first JJ - B-ORDINAL
group NOUN - O
comprised VERB - O
200 CD - B-CARDINAL
patients NOUN - O
receiving VERB - O
prophylaxis NOUN - O
for ADP - O
digestive ADJ - O
disorders NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
54 CD - B-CARDINAL
inpatients NOUN - O
who NOUN - O
received VERB - O
treatment NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
and CCONJ - O
whose ADJ - O
indication NOUN - O
was VERB - O
not ADV - O
approved VERB - O
by ADP - O
the DT - B-ORG
Brazilian NNP - I-ORG
Sanitary NNP - I-ORG
Agency NNP - I-ORG
and CCONJ - O
the DT - B-ORG
US NNP - I-ORG
Food NNP - I-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
were VERB - O
excluded VERB - O
. PUNCT - O

The DET - O
second JJ - B-ORDINAL
group NOUN - O
comprised VERB - O
219 CD - B-CARDINAL
inpatients NOUN - O
without ADP - O
a DET - O
prescription NOUN - O
for ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

Prophylaxis NOUN - O
for ADP - O
digestive ADJ - O
disorders NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
( PUNCT - O
P NOUN - O
= SYM - O
0.019 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
sex NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.010 CD - B-CARDINAL
) PUNCT - O
were VERB - O
considered VERB - O
risk NOUN - O
factors NOUN - O
for ADP - O
increased VERB - O
serum PRON - O
creatinine NOUN - O
level NOUN - O
via ADP - O
multivariate ADJ - O
logistic ADJ - O
regression NOUN - O
even ADV - O
with ADP - O
concomitant ADJ - O
use NOUN - O
of ADP - O
nephrotoxic ADJ - O
drugs NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
0.252 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Six CD - B-CARDINAL
ADEs NOUN - O
related VERB - O
to ADP - O
omeprazole NN - B-MEDICINE
were VERB - O
identified VERB - O
: PUNCT - O
2 LS - B-CARDINAL
ADRs NOUN - O
( PUNCT - O
1 CD - B-CARDINAL
possible ADJ - O
and CCONJ - O
1 CD - B-CARDINAL
definite ADJ - O
) PUNCT - O
, PUNCT - O
2 CD - B-CARDINAL
medication NOUN - O
errors NOUN - O
( PUNCT - O
nonserious ADJ - O
) PUNCT - O
, PUNCT - O
1 CD - B-CARDINAL
therapeutic ADJ - O
failure NOUN - O
, PUNCT - O
and CCONJ - O
1 CD - B-CARDINAL
drug NOUN - O
- PUNCT - O
drug NOUN - O
interaction NOUN - O
. PUNCT - O

Prophylaxis PROPN - O
for ADP - O
digestive ADJ - O
disorders NOUN - O
with ADP - O
omeprazole JJ - B-MEDICINE
and CCONJ - O
male ADJ - O
sex NOUN - O
may VERB - O
contribute VERB - O
to ADP - O
the DET - O
development NOUN - O
of ADP - O
kidney NOUN - O
impairment NOUN - O
because ADP - O
both DET - O
result VERB - O
in ADP - O
increased VERB - O
serum ADJ - O
creatinine NOUN - O
levels NOUN - O
. PUNCT - O

This DET - O
follow NOUN - O
- PUNCT - O
up NOUN - O
can VERB - O
prevent VERB - O
worsening VERB - O
clinical ADJ - O
conditions NOUN - O
and/or CCONJ - O
contraindicate VERB - O
prophylactic ADJ - O
use NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Prophylactic ADJ - O
therapy NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
for ADP - O
prevention NOUN - O
of ADP - O
equine ADJ - O
gastric ADJ - O
ulcer NOUN - O
syndrome NOUN - O
( PUNCT - O
EGUS NNP - B-ORG
) PUNCT - O
in ADP - O
horses NOUN - O
in ADP - O
active ADJ - O
training NOUN - O
: PUNCT - O
A DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
phase NOUN - O
I PRON - O
study VERB - O
( PUNCT - O
CO-338 PROPN - O
- PUNCT - O
044 NUM - O
; PUNCT - O
NCT02740712 NNP - B-CARDINAL
) PUNCT - O
, PUNCT - O
conducted VERB - O
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
solid ADJ - O
tumors NOUN - O
, PUNCT - O
evaluated VERB - O
the DET - O
effect NOUN - O
of ADP - O
the DET - O
poly(ADP PROPN - O
- PUNCT - O
ribose ADJ - O
) PUNCT - O
polymerase NOUN - O
( PUNCT - O
PARP PROPN - O
) PUNCT - O
inhibitor NOUN - O
rucaparib NOUN - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
( PUNCT - O
PK NNP - B-ORG
) PUNCT - O
of ADP - O
caffeine NOUN - O
200 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
, PUNCT - O
warfarin NOUN - O
10 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
, PUNCT - O
omeprazole VBP - B-MEDICINE
40 CD - B-CARDINAL
  SPACE - O
mg PRON - O
, PUNCT - O
and CCONJ - O
midazolam NOUN - O
2 CD - B-CARDINAL
  SPACE - O
mg X - O

Geometric PROPN - O
mean VERB - O
( PUNCT - O
GM NNP - B-ORG
) PUNCT - O
ratios VERB - O
( PUNCT - O
90 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
( PUNCT - O
CI NNP - B-ORG
) PUNCT - O
) PUNCT - O
of ADP - O
area NOUN - O
under ADP - O
the DET - O
concentration NOUN - O
- PUNCT - O
time NOUN - O
curve NOUN - O
( PUNCT - O
AUC NNP - B-ORG
) PUNCT - O
from ADP - O
time NOUN - O
zero NUM - O
to ADP - O
last ADJ - O
quantifiable ADJ - O
measurement NOUN - O
with ADP - O
and CCONJ - O
without ADP - O
rucaparib NOUN - O
were VERB - O
: PUNCT - O
caffeine NOUN - O
, PUNCT - O
2.26 CD - B-CARDINAL
( PUNCT - O
1.93 CD - B-CARDINAL
- SYM - O
2.65 NUM - O
) PUNCT - O
; PUNCT - O
S NOUN - O
- PUNCT - O
warfarin PROPN - O
, PUNCT - O
1.49 CD - B-CARDINAL
( PUNCT - O
1.40 CD - B-CARDINAL
- SYM - O
1.58 NUM - O
) PUNCT - O
; PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
1.55 CD - B-CARDINAL
( PUNCT - O
1.32 CD - B-CARDINAL
- SYM - O
1.83 NUM - O
) PUNCT - O
; PUNCT - O
midazolam NOUN - O
, PUNCT - O
1.39 CD - B-CARDINAL
( PUNCT - O
1.14 CD - B-CARDINAL
- SYM - I-CARDINAL
1.68 CD - I-CARDINAL
) PUNCT - O
; PUNCT - O
and CCONJ - O
digoxin NOUN - O
, PUNCT - O
1.20 CD - B-CARDINAL
( PUNCT - O
1.12 CD - B-CARDINAL
- SYM - I-CARDINAL
1.29 CD - I-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
new ADJ - O
combination NOUN - O
is VERB - O
composed VERB - O
of ADP - O
a DET - O
meloxicam NOUN - O
powder NOUN - O
blend NOUN - O
( PUNCT - O
MPB NNP - B-ORG
) PUNCT - O
and CCONJ - O
omeprazole JJ - B-MEDICINE
gastro NOUN - O
- PUNCT - O
resistant ADJ - O
pellets NOUN - O
( PUNCT - O
OAP NNP - B-ORG
) PUNCT - O
in ADP - O
hard ADJ - O
gelatin ADJ - O
capsules NOUN - O
. PUNCT - O

The DET - O
main ADJ - O
tasks NOUN - O
were VERB - O
to PART - O
select VERB - O
the DET - O
excipients NOUN - O
to PART - O
keep VERB - O
the DET - O
functional ADJ - O
layer NOUN - O
of ADP - O
OAP NNP - B-ORG
active ADJ - O
and CCONJ - O
to PART - O
prove VERB - O
the DET - O
bioequivalence NOUN - O
to ADP - O
the DET - O
original ADJ - O
products NOUN - O
of ADP - O
meloxicam NOUN - O
tablets NOUN - O
together ADV - O
with ADP - O
omeprazole JJ - B-MEDICINE
capsules NOUN - O
. PUNCT - O

Although ADP - O
dissolution NOUN - O
profiles NOUN - O
similar ADJ - O
to ADP - O
the DET - O
original ADJ - O
product NOUN - O
were VERB - O
obtained VERB - O
, PUNCT - O
the DET - O
unexpected ADJ - O
results NOUN - O
of ADP - O
omeprazole JJ - B-MEDICINE
low ADJ - O
bioavailability NOUN - O
in ADP - O
the DET - O
fed VERB - O
bioequivalence NOUN - O
study NOUN - O
( PUNCT - O
BES NNP - B-ORG
I PRON - O
) PUNCT - O
showed VERB - O
the DET - O
necessity NOUN - O
to PART - O
investigate VERB - O
the DET - O
formulation NOUN - O
in ADP - O
greater ADJ - O
depth NOUN - O
. PUNCT - O

A DET - O
modified ADJ - O
more ADV - O
complex ADJ - O
dissolution NOUN - O
method NOUN - O
was VERB - O
developed VERB - O
in ADP - O
order NOUN - O
to PART - O
understand VERB - O
the DET - O
release NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
under ADP - O
gastric ADJ - O
conditions NOUN - O
. PUNCT - O

This DET - O
method NOUN - O
revealed VERB - O
the DET - O
degradation NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
in ADP - O
the DET - O
formulation NOUN - O
when ADV - O
exposed VERB - O
to ADP - O
the DET - O
fed ADJ - O
conditions NOUN - O
because ADP - O
of ADP - O
the DET - O
increase NOUN - O
in ADP - O
microenvironmental ADJ - O
pH NOUN - O
in ADP - O
the DET - O
capsule NOUN - O
caused VERB - O
by ADP - O
trisodium NOUN - O
citrate NOUN - O
, PUNCT - O
commonly ADV - O
used VERB - O
for ADP - O
improving VERB - O
solubility NOUN - O
of ADP - O
meloxicam NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
assess VERB - O
the DET - O
available ADJ - O
literature NOUN - O
regarding VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate VERB - O
in ADP - O
gastroesophageal ADJ - O
reflux NOUN - O
patients NOUN - O
. PUNCT - O

Reviewed VERB - O
manuscripts NOUN - O
concerning VERB - O
the DET - O
effectiveness NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate ADJ - O
treatment NOUN - O
in ADP - O
gastroesophageal ADJ - O
reflux NOUN - O
disease NOUN - O
were VERB - O
reviewed VERB - O
and CCONJ - O
the DET - O
data NOUN - O
were VERB - O
extracted VERB - O
. PUNCT - O

Two CD - B-CARDINAL
trials NOUN - O
compared VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate VERB - O
versus ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

And CCONJ - O
another DET - O
study NOUN - O
compared VERB - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate NOUN - O
/ SYM - O
alginate VERB - O
versus ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

In ADP - O
total NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
difference NOUN - O
between ADP - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate VERB - O
and CCONJ - O
omeprazole JJ - B-MEDICINE
. PUNCT - O

However ADV - O
, PUNCT - O
there ADV - O
is VERB - O
a DET - O
trend NOUN - O
towards ADP - O
more ADV - O
sustained ADJ - O
response NOUN - O
and CCONJ - O
a DET - O
greater ADJ - O
proportion NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
sustained ADJ - O
total ADJ - O
relief NOUN - O
by ADP - O
30 CD - B-TIME
minutes NNS - I-TIME
with ADP - O
omeprazole NN - B-MEDICINE
/ SYM - O
sodium NOUN - O
bicarbonate VERB - O
. PUNCT - O

Omeprazole NNP - B-ORG
/ SYM - O
sodium NOUN - O
bicarbonate NOUN - O
therapy NOUN - O
is VERB - O
not ADV - O
more ADV - O
effective ADJ - O
than ADP - O
omeprazole JJ - B-MEDICINE
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
gastroesophageal ADJ - O
reflux NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
use NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
can VERB - O
cause VERB - O
acquired VERB - O
generalized VERB - O
hypertrichosis NOUN - O
by ADP - O
increasing VERB - O
prostaglandin NOUN - O
E2 PROPN - O
levels NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficient ADJ - O
catalysis NOUN - O
of ADP - O
omeprazole JJ - B-MEDICINE
oxidation NOUN - O
by ADP - O
BoBVMO NNP - B-ORG
was VERB - O
developed VERB - O
, PUNCT - O
indicating VERB - O
that ADP - O
this DET - O
enzyme NOUN - O
is VERB - O
a DET - O
promising ADJ - O
biocatalyst NOUN - O
for ADP - O
the DET - O
synthesis NOUN - O
of ADP - O
bulky ADJ - O
and CCONJ - O
pharmaceutically ADV - O
relevant ADJ - O
chiral ADJ - O
sulfoxide NOUN - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
we PRON - O
aimed VERB - O
to PART - O
complete VERB - O
a DET - O
formal ADJ - O
evaluation NOUN - O
of ADP - O
the DET - O
diagnostic ADJ - O
value NOUN - O
of ADP - O
CYP2C19 NNP - B-ORG
and CCONJ - O
CYP3A4 NN - B-ORG
genes NOUN - O
for ADP - O
predicting VERB - O
metabolizer NOUN - O
phenotypes NOUN - O
established VERB - O
by ADP - O
omeprazole NN - B-MEDICINE
( PUNCT - O
OME NOUN - O
) PUNCT - O
administration NOUN - O
in ADP - O
118 CD - B-CARDINAL
healthy ADJ - O
children NOUN - O
from ADP - O
Jalisco NNP - B-ORG
( PUNCT - O
western ADJ - O
Mexico NNP - B-GPE
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Correspondence NOUN - O
between ADP - O
the DET - O
CYP2C19 NNP - B-ORG
and CCONJ - O
CYP3A4 NN - B-ORG
genotypes NOUN - O
with ADP - O
the DET - O
inferred VERB - O
metabolizer NOUN - O
phenotype NOUN - O
by ADP - O
omeprazole JJ - B-MEDICINE
administration NOUN - O
in ADP - O
Mexican JJ - B-NORP
healthy ADJ - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Esomeprazole NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
and CCONJ - O
rabeprazole NOUN - O
were VERB - O
classified VERB - O
as ADP - O
having VERB - O
' PUNCT - O
no DET - O
additional ADJ - O
risks NOUN - O
known VERB - O
' PUNCT - O
. PUNCT - O

A DET - O
reduction NOUN - O
in ADP - O
maximum ADJ - O
dose NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
and CCONJ - O
rabeprazole NOUN - O
is VERB - O
recommended VERB - O
for ADP - O
CTP NNP - B-PERSON
A NN - I-PERSON
and CCONJ - O
B NOUN - O
patients NOUN - O
. PUNCT - O

For ADP - O
patients NOUN - O
with ADP - O
CTP NNP - B-ORG
C NOUN - O
cirrhosis NOUN - O
, PUNCT - O
the DET - O
only ADJ - O
PPI PROPN - O
advised VERB - O
is VERB - O
esomeprazole NOUN - O
at ADP - O
a DET - O
maximum ADJ - O
dosage NOUN - O
of ADP - O
20 CD - B-CARDINAL
  SPACE - O
mg ADV - O
per ADP - O
day NOUN - O
. PUNCT - O

We PRON - O
suggest VERB - O
using VERB - O
esomeprazole NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
or CCONJ - O
rabeprazole NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
CTP NNP - B-ORG
A NOUN - O
or CCONJ - O
B NOUN - O
cirrhosis NOUN - O
and CCONJ - O
only ADJ - O
esomeprazole NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
CTP NNP - B-PERSON
C. NNP - I-PERSON
Pharmacokinetic JJ - I-PERSON
changes NOUN - O
are VERB - O
also ADV - O
important ADJ - O
to PART - O
consider VERB - O
when ADV - O
prescribing VERB - O
PPIs NOUN - O
to PART - O
vulnerable ADJ - O
, PUNCT - O
cirrhotic ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
amoxicillin NOUN - O
group NOUN - O
received VERB - O
metronidazole NOUN - O
500 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
bismuth NOUN - O
subcitrate NOUN - O
240 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
and CCONJ - O
amoxicillin NOUN - O
1000 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
all DET - O
three CD - B-CARDINAL
times NOUN - O
a DET - O
day NOUN - O
, PUNCT - O
plus CCONJ - O
omeprazole VBP - B-MEDICINE
20 CD - B-CARDINAL
mg NOUN - O
twice ADJ - O
a DET - O
day NOUN - O
, PUNCT - O
for ADP - O
14 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

The DET - O
tetracycline NOUN - O
group NOUN - O
received VERB - O
metronidazole NOUN - O
500 CD - B-CARDINAL
mg NN - I-CARDINAL
three CD - I-CARDINAL
times NOUN - O
a DET - O
day NOUN - O
; PUNCT - O
bismuth NOUN - O
subcitrate240 ADJ - O
mg PRON - O
and CCONJ - O
tetracycline ADJ - O
HCl NOUN - O
500 CD - B-CARDINAL
mg NOUN - O
, PUNCT - O
both DET - O
four CD - B-CARDINAL
times NOUN - O
a DET - O
day NOUN - O
; PUNCT - O
and CCONJ - O
omeprazole VBP - B-MEDICINE
20 CD - B-CARDINAL
mg NOUN - O
twice ADJ - O
a DET - O
day NOUN - O
, PUNCT - O
for ADP - O
14 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
contrast NOUN - O
, PUNCT - O
in ADP - O
inpatient NOUN - O
settings NOUN - O
, PUNCT - O
the DET - O
rate NOUN - O
of ADP - O
PPI PROPN - O
prescribing NOUN - O
( PUNCT - O
from ADP - O
20.41 CD - B-CARDINAL
to ADP - O
37.21 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
utilization NOUN - O
( PUNCT - O
from ADP - O
132,329 CD - B-MONEY
DDDs NNS - I-MONEY
to ADP - O
827,747 CD - B-CARDINAL
DDDs NOUN - O
) PUNCT - O
and CCONJ - O
expenditure NOUN - O
( PUNCT - O
from ADP - O
3.15 CD - B-MONEY
million CD - I-MONEY
CNY NNP - I-MONEY
to ADP - O
25.29 CD - B-MONEY
million CD - I-MONEY
CNY NNP - I-MONEY
) PUNCT - O
increased VERB - O
from ADP - O
2007 CD - B-DATE
to ADP - O
2015 CD - B-DATE
and CCONJ - O
then ADV - O
decreased VERB - O
, PUNCT - O
dominated VERB - O
by ADP - O
injection NOUN - O
formulations NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Therefore ADV - O
, PUNCT - O
we PRON - O
studied VERB - O
the DET - O
effect NOUN - O
of ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
fasting VERB - O
on ADP - O
protein NOUN - O
binding VERB - O
of ADP - O
five CD - B-CARDINAL
commonly ADV - O
used VERB - O
probe NOUN - O
drugs NOUN - O
[ PUNCT - O
caffeine NOUN - O
( PUNCT - O
CYP1A2 NOUN - O
) PUNCT - O
, PUNCT - O
metoprolol NOUN - O
( PUNCT - O
CYP2D6 PROPN - O
) PUNCT - O
, PUNCT - O
midazolam PROPN - O
( PUNCT - O
CYP3A4 PROPN - O
) PUNCT - O
, PUNCT - O
omeprazole NN - B-MEDICINE
( PUNCT - O
CYP2C19 PROPN - O
) PUNCT - O
and CCONJ - O
S PROPN - O
- PUNCT - O
warfarin PROPN - O
( PUNCT - O
CYP2C9)].The VERB - O
free ADJ - O
and CCONJ - O
total ADJ - O
plasma NOUN - O
concentrations NOUN - O
of ADP - O
the DET - O
five CD - B-CARDINAL
probe NOUN - O
drugs NOUN - O
were VERB - O
analyzed VERB - O
by ADP - O
LC NNP - B-ORG
- HYPH - I-ORG
MS NNP - I-ORG
/ SYM - I-ORG
MS NNP - I-ORG
in ADP - O
samples NOUN - O
retrieved VERB - O
in ADP - O
a DET - O
cross ADJ - O
- PUNCT - O
over ADJ - O
study NOUN - O
in ADP - O
which ADJ - O
nine CD - B-CARDINAL
healthy ADJ - O
subjects NOUN - O
received VERB - O
an DET - O
intravenous ADJ - O
administration NOUN - O
of ADP - O
the DET - O
cocktail NOUN - O
after ADP - O
an DET - O
overnight ADJ - O
fast ADV - O
( PUNCT - O
control NOUN - O
) PUNCT - O
and CCONJ - O
after ADP - O
36 CD - B-CARDINAL
  SPACE - O
h DET - O
of ADP - O
fasting NOUN - O
. PUNCT - O

Short ADJ - O
- PUNCT - O
term NOUN - O
fasting NOUN - O
did VERB - O
not ADV - O
alter VERB - O
the DET - O
free ADJ - O
fractions NOUN - O
of ADP - O
caffeine NOUN - O
, PUNCT - O
metoprolol NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
compared VERB - O
to ADP - O
the DET - O
control NOUN - O
intervention NOUN - O
( PUNCT - O
p VERB - O
  SPACE - O
> X - O
  SPACE - O
0.05 NUM - O
) PUNCT - O
. PUNCT - O

This DET - O
study NOUN - O
demonstrates VERB - O
that ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
fasting NOUN - O
does VERB - O
not ADV - O
alter VERB - O
protein NOUN - O
binding VERB - O
of ADP - O
the DET - O
probe NOUN - O
drugs NOUN - O
caffeine NOUN - O
, PUNCT - O
metoprolol NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Moreover ADV - O
, PUNCT - O
gamma NOUN - O
oryzanol NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
protected VERB - O
the DET - O
gastric ADJ - O
mucosa NOUN - O
from ADP - O
ethanol NOUN - O
- PUNCT - O
induced VERB - O
gastric ADJ - O
lesions NOUN - O
by ADP - O
increasing VERB - O
the DET - O
level NOUN - O
of ADP - O
gastric ADJ - O
mucus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
study NOUN - O
aimed VERB - O
to PART - O
compare VERB - O
the DET - O
effect NOUN - O
of ADP - O
Psyllium PROPN - O
seed NOUN - O
and CCONJ - O
oral ADJ - O
omeprazole NN - B-MEDICINE
on ADP - O
GERD NNP - B-PERSON
in ADP - O
patients NOUN - O
with ADP - O
functional ADJ - O
constipation NOUN - O
. PUNCT - O

The DET - O
impact NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
and CCONJ - O
Psyllium NOUN - O
seed NOUN - O
on ADP - O
the DET - O
treatment NOUN - O
and CCONJ - O
recurrence NOUN - O
of ADP - O
GERD NNP - B-PERSON
was VERB - O
studied VERB - O
. PUNCT - O

Among ADP - O
the DET - O
patients NOUN - O
, PUNCT - O
the DET - O
rate NOUN - O
of ADP - O
response NOUN - O
to ADP - O
treatment NOUN - O
was VERB - O
89.2 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n NOUN - O
= SYM - O
58 CD - B-CARDINAL
) PUNCT - O
in ADP - O
the DET - O
Psyllium NNP - B-GPE
seed NOUN - O
group NOUN - O
, PUNCT - O
while ADP - O
in ADP - O
omeprazole JJ - B-MEDICINE
group NOUN - O
, PUNCT - O
it PRON - O
was VERB - O
94 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n NOUN - O
= SYM - O
63 NUM - O
; PUNCT - O

The DET - O
recurrence NOUN - O
rates NOUN - O
of ADP - O
Psyllium NOUN - O
seed NOUN - O
and CCONJ - O
omeprazole JJ - B-MEDICINE
groups NOUN - O
were VERB - O
24.1 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n NOUN - O
= SYM - O
14 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
69.8 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
n NOUN - O
= SYM - O
44 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
respectively ADV - O
( PUNCT - O
P NOUN - O
< X - O
.001 NUM - O
) PUNCT - O
. PUNCT - O

The DET - O
results NOUN - O
showed VERB - O
that ADP - O
treatment NOUN - O
of ADP - O
functional ADJ - O
constipation NOUN - O
by ADP - O
Psyllium PROPN - O
seed NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
GERD NNP - B-PERSON
leads VERB - O
to ADP - O
improvement NOUN - O
of ADP - O
GERD NNP - B-PERSON
and CCONJ - O
its ADJ - O
recurrences NOUN - O
in ADP - O
comparison NOUN - O
with ADP - O
omeprazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Antibiotics PROPN - O
and CCONJ - O
omeprazole]. PROPN - O

-DOCSTART- -X- - O

Influences NOUN - O
of ADP - O
oldenlandia NOUN - O
diffusa NOUN - O
on ADP - O
the DET - O
activities NOUN - O
of ADP - O
five CD - B-CARDINAL
CYP450 PROPN - O
subtypes NOUN - O
in ADP - O
rats NOUN - O
were VERB - O
evaluated VERB - O
by ADP - O
five CD - B-CARDINAL
specific ADJ - O
probe NOUN - O
drugs NOUN - O
( PUNCT - O
phenacetin ADJ - O
for ADP - O
CYP1A2 NOUN - O
, PUNCT - O
omeprazole NN - B-MEDICINE
for ADP - O
CYP2C19 NNP - B-ORG
, PUNCT - O
tolbutamide NOUN - O
for ADP - O
CYP2C9 NN - B-DATE
, PUNCT - O
metoprolol NOUN - O
for ADP - O
CYP2D6 NN - B-PERSON
, PUNCT - O
and CCONJ - O
midazolam NOUN - O
for ADP - O
CYP3A4 NN - B-PERSON
) PUNCT - O
according VERB - O
to ADP - O
the DET - O
pharmacokinetic ADJ - O
parameters NOUN - O
changes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
aimed VERB - O
to PART - O
clarify VERB - O
the DET - O
changes NOUN - O
in ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
the DET - O
EGFR PROPN - O
- PUNCT - O
TKIs NOUN - O
, PUNCT - O
gefitinib NOUN - O
, PUNCT - O
erlotinib NOUN - O
and CCONJ - O
osimertinib NOUN - O
, PUNCT - O
due ADP - O
to ADP - O
the DET - O
changes NOUN - O
in ADP - O
gastric ADJ - O
pH NOUN - O
after ADP - O
administration NOUN - O
of ADP - O
omeprazole JJ - B-MEDICINE
or CCONJ - O
vonoprazan ADJ - O
. PUNCT - O

AUC0 NNP - B-CARDINAL
- HYPH - I-CARDINAL
3 CD - I-CARDINAL
of ADP - O
osimertinib NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
p.o PROPN - O
. PUNCT - O
) PUNCT - O
was VERB - O
not ADV - O
significantly ADV - O
changed VERB - O
by ADP - O
omeprazole JJ - B-MEDICINE
and CCONJ - O
vonoprazan ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Changes NOUN - O
in ADP - O
gefitinib NOUN - O
, PUNCT - O
erlotinib NOUN - O
and CCONJ - O
osimertinib NOUN - O
pharmacokinetics NOUN - O
under ADP - O
various ADJ - O
gastric ADJ - O
pH NOUN - O
levels NOUN - O
following VERB - O
oral ADJ - O
administration NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
and CCONJ - O
vonoprazan VERB - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eight CD - B-DATE
weeks NNS - I-DATE
of ADP - O
omeprazole JJ - B-MEDICINE
20 CD - B-CARDINAL
mg NOUN - O
significantly ADV - O
reduces VERB - O
both DET - O
laryngopharyngeal ADJ - O
reflux NOUN - O
and CCONJ - O
comorbid VERB - O
chronic ADJ - O
rhinosinusitis NOUN - O
signs NOUN - O
and CCONJ - O
symptoms NOUN - O
: PUNCT - O
Randomised VERB - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Groups NOUN - O
2 CD - B-CARDINAL
to PART - O
5 CD - B-CARDINAL
were VERB - O
pretreated VERB - O
with ADP - O
3 CD - B-PERCENT
% NN - I-PERCENT
Tween NNP - B-DATE
80 CD - I-DATE
( PUNCT - O
ulcer NOUN - O
group NOUN - O
) PUNCT - O
, PUNCT - O
20 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
of ADP - O
omeprazole JJ - B-MEDICINE
( PUNCT - O
positive ADJ - O
group NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
200 CD - B-CARDINAL
and CC - I-CARDINAL
400 CD - I-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
of ADP - O
EEVS PROPN - O
( PUNCT - O
experimental ADJ - O
groups NOUN - O
) PUNCT - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
once ADV - O
daily ADV - O
for ADP - O
21 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
before ADP - O
ulcer NOUN - O
induction NOUN - O
. PUNCT - O

Significant ADJ - O
severe ADJ - O
gastric ADJ - O
mucosal NOUN - O
injury NOUN - O
was VERB - O
exhibited VERB - O
in ADP - O
the DET - O
ulcer NOUN - O
group NOUN - O
and CCONJ - O
EEVS NOUN - O
or CCONJ - O
omeprazole NN - B-MEDICINE
offered VERB - O
significant ADJ - O
( PUNCT - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
protection NOUN - O
against ADP - O
mucosal ADJ - O
ulceration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

0.015).The NUM - O
height NOUN - O
of ADP - O
patients NOUN - O
may VERB - O
help VERB - O
to PART - O
predict VERB - O
the DET - O
risks NOUN - O
and CCONJ - O
the DET - O
prescription NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
may VERB - O
help VERB - O
to PART - O
minimize VERB - O
the DET - O
risks NOUN - O
of ADP - O
2b CD - B-CARDINAL
and CCONJ - O
3a CD - B-CARDINAL
post ADJ - O
- ADJ - O
corrosive ADJ - O
esophageal ADJ - O
stricture NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
drug NOUN - O
other ADJ - O
than ADP - O
omeprazole NN - B-MEDICINE
was VERB - O
used VERB - O
in ADP - O
25 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
cases NOUN - O
; PUNCT - O
30.47 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
patients NOUN - O
were VERB - O
discharged VERB - O
with ADP - O
a DET - O
PPI PROPN - O
and CCONJ - O
only RB - B-PERCENT
28.2 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
them PRON - O
had VERB - O
the DET - O
correct ADJ - O
indication NOUN - O
and CCONJ - O
dosage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
the DET - O
relative ADJ - O
bioavailability NOUN - O
of ADP - O
the DET - O
tablet NOUN - O
formulation NOUN - O
versus ADP - O
the DET - O
initial ADJ - O
capsule NOUN - O
formulation NOUN - O
and CCONJ - O
the DET - O
effect NOUN - O
of ADP - O
food NOUN - O
and CCONJ - O
omeprazole NN - B-MEDICINE
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
a DET - O
single ADJ - O
- PUNCT - O
dose NOUN - O
momelotinib NOUN - O
tablet NOUN - O
were VERB - O
evaluated VERB - O
in ADP - O
healthy ADJ - O
subjects NOUN - O
. PUNCT - O

Neither CCONJ - O
the DET - O
food NOUN - O
effect NOUN - O
nor CCONJ - O
the DET - O
omeprazole JJ - B-MEDICINE
effect NOUN - O
on ADP - O
momelotinib NOUN - O
exposure NOUN - O
was VERB - O
considered VERB - O
clinically ADV - O
meaningful ADJ - O
because ADP - O
of ADP - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
profile NOUN - O
of ADP - O
momelotinib NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
however ADV - O
, PUNCT - O
after ADP - O
3 CD - B-DATE
- SYM - I-DATE
4 CD - I-DATE
weeks NNS - I-DATE
of ADP - O
culture NOUN - O
according VERB - O
to ADP - O
the DET - O
manufacturer NOUN - O
's PART - O
instructions NOUN - O
, PUNCT - O
human ADJ - O
cytochrome NOUN - O
P450 PROPN - O
( PUNCT - O
P450 PROPN - O
) PUNCT - O
2C9- NUM - O
and CCONJ - O
2C19-dependent CD - B-CARDINAL
diclofenac NOUN - O
4'-hydroxylation NUM - O
and CCONJ - O
omeprazole JJ - B-MEDICINE
5-hydroxylation NUM - O
activities NOUN - O
of ADP - O
the DET - O
iPS ADV - O
- PUNCT - O
derived VERB - O
hepatocytes NOUN - O
had VERB - O
significantly ADV - O
increased VERB - O
above ADP - O
the DET - O
activities NOUN - O
at ADP - O
1 CD - B-DATE
week NN - I-DATE
and CCONJ - O
had VERB - O
reached VERB - O
levels NOUN - O
similar ADJ - O
to ADP - O
those DET - O
in ADP - O
HepaRG NOUN - O
cells NOUN - O
, PUNCT - O
a DET - O
human ADJ - O
hepatocyte NOUN - O
- PUNCT - O
like ADJ - O
cell NOUN - O
line NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

For ADP - O
the DET - O
six CD - B-CARDINAL
experimental ADJ - O
procedures NOUN - O
( PUNCT - O
continuous ADJ - O
infusion NOUN - O
of ADP - O
norepinephrine NOUN - O
, PUNCT - O
midazolam NOUN - O
, PUNCT - O
sufentanil NOUN - O
, PUNCT - O
heparin ADV - O
, PUNCT - O
5 CD - B-PERCENT
% NN - I-PERCENT
glucose NOUN - O
, PUNCT - O
binary ADJ - O
parenteral ADJ - O
nutrition NOUN - O
and CCONJ - O
discontinuous ADJ - O
administrations NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
, PUNCT - O
piperacillin NOUN - O
/ SYM - O
tazobactam NOUN - O
and CCONJ - O
fluconazole NOUN - O
) PUNCT - O
, PUNCT - O
the DET - O
overall ADJ - O
number NOUN - O
of ADP - O
particles NOUN - O
over ADP - O
the DET - O
6-h NUM - O
infusion NOUN - O
period NOUN - O
was VERB - O
8256 CD - B-CARDINAL

-DOCSTART- -X- - O

1 CD - B-CARDINAL
dose NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
in ADP - O
rats NOUN - O
with ADP - O
IND NNP - B-ORG
- PUNCT - O
induced VERB - O
gastric ADJ - O
mucosal NOUN - O
damage NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
between ADP - O
omeprazole JJ - B-MEDICINE
use NOUN - O
and CCONJ - O
Clostridium NNP - B-ORG
difficile ADJ - O
infection NOUN - O
among ADP - O
hospitalized ADJ - O
patients NOUN - O
: PUNCT - O
A DET - O
case NOUN - O
- PUNCT - O
control NOUN - O
study NOUN - O
of ADP - O
the DET - O
Saudi JJ - B-NORP
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM NNP - B-ORG
: PUNCT - O
To PART - O
develop VERB - O
an DET - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
assay VERB - O
to PART - O
quantitate VERB - O
well ADV - O
- PUNCT - O
tolerated VERB - O
substrates NOUN - O
; PUNCT - O
midazolam PROPN - O
( PUNCT - O
CYP3A PROPN - O
) PUNCT - O
, PUNCT - O
omeprazole NN - B-MEDICINE
( PUNCT - O
CYP2C19 PROPN - O
) PUNCT - O
, PUNCT - O
dextromethorphan PROPN - O
( PUNCT - O
CYP2D6 PROPN - O
) PUNCT - O
, PUNCT - O
losartan PROPN - O
( PUNCT - O
CYP2C9 NOUN - O
) PUNCT - O
and CCONJ - O
their ADJ - O
respective ADJ - O
metabolites NOUN - O
' PART - O
concentrations NOUN - O
in ADP - O
plasma NOUN - O
samples NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
metabolism NOUN - O
of ADP - O
midazolam NOUN - O
, PUNCT - O
phenacetin ADJ - O
, PUNCT - O
omeprazole NN - B-MEDICINE
, PUNCT - O
dextromethorphan NOUN - O
, PUNCT - O
repaglinide NOUN - O
, PUNCT - O
rosuvastatin NOUN - O
, PUNCT - O
tolbutamide NOUN - O
and CCONJ - O
caffeine NOUN - O
was VERB - O
investigated VERB - O
. PUNCT - O

We PRON - O
monitored VERB - O
the DET - O
apparition NOUN - O
of ADP - O
omeprazole NN - B-MEDICINE
sulfone NOUN - O
, PUNCT - O
hydroxy ADJ - O
omeprazole NN - B-MEDICINE
, PUNCT - O
repaglinide NOUN - O
glucuronide NOUN - O
, PUNCT - O
rosuvastatin NOUN - O
lactone NOUN - O
, PUNCT - O
dextrorphan NOUN - O
, PUNCT - O
1-hydroxy CD - B-CARDINAL
midazolam NOUN - O
, PUNCT - O
4-hydroxy CD - B-CARDINAL
midazolam NOUN - O
, PUNCT - O
1,4-hydroxy CD - B-CARDINAL
midazolam NOUN - O
, PUNCT - O
paracetamol NOUN - O
and CCONJ - O
1,3-methylxanthine CD - B-GPE
. PUNCT - O

Rosuvastatin NN - B-PERSON
, PUNCT - O
omeprazole JJ - B-MEDICINE
and CCONJ - O
repaglinide ADJ - O
prediction NOUN - O
underestimated VERB - O
the DET - O
in ADP - O
vivo NOUN - O
data NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
compared VERB - O
the DET - O
effectiveness NOUN - O
and CCONJ - O
acceptability NOUN - O
of ADP - O
all DT - B-ORG
Food NNP - I-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
( PUNCT - O
FDA)-recommended PUNCT - O
dose VERB - O
proton NOUN - O
pump NOUN - O
inhibitors NOUN - O
( PUNCT - O
PPIs PROPN - O
) PUNCT - O
in ADP - O
erosive ADJ - O
esophagitis NOUN - O
( PUNCT - O
EE PROPN - O
) PUNCT - O
: PUNCT - O
Dexlansoprazole NNP - B-MONEY
60 CD - I-MONEY
  _SP - I-MONEY
mg NOUN - O
, PUNCT - O
Esomeprazole NNP - B-ORG
40 NUM - O
  SPACE - O
mg NOUN - O
, PUNCT - O
Esomeprazole NNP - B-PRODUCT
20 NUM - O
  SPACE - O
mg PRON - O
, PUNCT - O
Pantoprazole NNP - B-ORG
40 NUM - O
  SPACE - O
mg NOUN - O
, PUNCT - O
Lansoprazole NNP - B-LAW
30 CD - I-LAW
  _SP - I-LAW
mg NN - I-LAW
, , - I-LAW
Rabeprazole NNP - I-LAW
20 NUM - O
  SPACE - O
mg PRON - O
, PUNCT - O
Omeprazole NNP - B-ORG
20 NUM - O
  SPACE - O
mg NOUN - O
. PUNCT - O

In ADP - O
comparison NOUN - O
to ADP - O
the DET - O
common ADJ - O
comparator NOUN - O
omeprazole NN - B-MEDICINE
20 CD - B-DATE
  _SP - I-DATE
mg NOUN - O
, PUNCT - O
esomeprazole ADJ - O
40 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
provided VERB - O
significantly ADV - O
healing VERB - O
rates NOUN - O
at ADP - O
4 CD - B-DATE
weeks NNS - I-DATE
[ PUNCT - O
odds NOUN - O
ratio NOUN - O
( PUNCT - O
OR CCONJ - O
) PUNCT - O
, PUNCT - O
1.46 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
, PUNCT - O
1.24 CD - B-CARDINAL
- SYM - O
1.71 NUM - O
) PUNCT - O
] PUNCT - O
and CCONJ - O
8 CD - B-DATE
weeks NNS - I-DATE
[ PUNCT - O
1.58 CD - B-CARDINAL
( PUNCT - O
1.29 CD - B-CARDINAL
- SYM - O
1.92 NUM - O
) PUNCT - O
] PUNCT - O
, PUNCT - O
and CCONJ - O
improved VERB - O
the DET - O
heartburn NOUN - O
relief NOUN - O
rates NOUN - O
[ PUNCT - O
1.29 CD - B-CARDINAL
( PUNCT - O
1.07 CD - B-CARDINAL
- HYPH - I-CARDINAL
1.56)]. NN - I-CARDINAL

In ADP - O
comparison NOUN - O
to ADP - O
lansoprazole NOUN - O
30 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
, PUNCT - O
esomeprazole ADJ - O
40 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
provided VERB - O
significantly ADV - O
healing VERB - O
rates NOUN - O
at ADP - O
4 CD - B-DATE
weeks NNS - I-DATE
[ PUNCT - O
1.30 CD - B-CARDINAL
( PUNCT - O
1.10 CD - B-CARDINAL
- SYM - O
1.53 NUM - O
) PUNCT - O
] PUNCT - O
and CCONJ - O
8 CD - B-DATE
weeks NNS - I-DATE
[ PUNCT - O
1.37 CD - B-CARDINAL
( PUNCT - O
1.13 CD - B-CARDINAL
- SYM - O
1.67 NUM - O
) PUNCT - O
] PUNCT - O
, PUNCT - O
and CCONJ - O
improved VERB - O
the DET - O
heartburn NOUN - O
relief NOUN - O
rates NOUN - O
[ PUNCT - O
1.29 CD - B-CARDINAL
( PUNCT - O
1.03 CD - B-CARDINAL
- HYPH - I-CARDINAL
1.62)]. NN - I-CARDINAL

had VERB - O
significantly ADV - O
more ADJ - O
all DET - O
- PUNCT - O
cause NOUN - O
discontinuation NOUN - O
than ADP - O
omeprazole JJ - B-MEDICINE
20 NUM - O
  SPACE - O
mg ADP - O
[ PUNCT - O
1.54 CD - B-CARDINAL
( PUNCT - O
1.03 CD - B-CARDINAL
- SYM - I-CARDINAL
2.29 CD - I-CARDINAL
) PUNCT - O
] PUNCT - O
, PUNCT - O
pantoprazole NOUN - O
40 CD - B-MONEY
  _SP - I-MONEY
mg ADP - O
[ PUNCT - O
1.68 CD - B-CARDINAL
( PUNCT - O
1.08 CD - B-CARDINAL
- SYM - O
2.63 NUM - O
) PUNCT - O
] PUNCT - O
, PUNCT - O
and CCONJ - O
lansoprazole NOUN - O
30 CD - B-CARDINAL
  SPACE - O
mg ADP - O

[ PUNCT - O
1.38 CD - B-CARDINAL
( PUNCT - O
1.02 CD - B-CARDINAL
- SYM - I-CARDINAL
1.88)].The CD - I-CARDINAL
standard ADJ - O
- PUNCT - O
dose NOUN - O
esomeprazole NOUN - O
40 CD - B-MONEY
  _SP - I-MONEY
mg PRON - O
had VERB - O
more ADJ - O
superiority NOUN - O
in ADP - O
mucosal ADJ - O
erosion NOUN - O
healing NOUN - O
and CCONJ - O
heartburn VERB - O
relief NOUN - O
. PUNCT - O

Esomeprazole NOUN - O
40 NUM - O
  SPACE - O
mg NOUN - O
, PUNCT - O
pantoprazole VERB - O
40 CD - B-CARDINAL
  _SP - I-CARDINAL
mg NOUN - O
, PUNCT - O
esomeprazole ADJ - O
20 CD - B-CARDINAL
  _SP - I-CARDINAL
mg PRON - O
, PUNCT - O
and CCONJ - O
lansoprazole NOUN - O
30 NUM - O
  SPACE - O
mg PRON - O
showed VERB - O
more ADJ - O
benefits NOUN - O
in ADP - O
effectiveness NOUN - O
and CCONJ - O
acceptability NOUN - O
than ADP - O
other ADJ - O
interventions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
main ADJ - O
objective NOUN - O
of ADP - O
this DET - O
research NOUN - O
is VERB - O
to PART - O
formulate VERB - O
, PUNCT - O
optimize VERB - O
, PUNCT - O
and CCONJ - O
evaluate VERB - O
raft NOUN - O
- PUNCT - O
forming VERB - O
chewable ADJ - O
tablets NOUN - O
of ADP - O
Nizatidine NNP - B-MEDICINE
. PUNCT - O

Raft NOUN - O
forming VERB - O
chewable ADJ - O
tablets NOUN - O
containing VERB - O
Nizatidine NNP - B-MEDICINE
were VERB - O
prepared VERB - O
by ADP - O
direct ADJ - O
compression NOUN - O
and CCONJ - O
wet ADJ - O
granulation NOUN - O
methods NOUN - O
, PUNCT - O
and CCONJ - O
evaluated VERB - O
for ADP - O
drug NOUN - O
content NOUN - O
, PUNCT - O
acid ADJ - O
neutralization NOUN - O
capacity NOUN - O
, PUNCT - O
raft NOUN - O
strength NOUN - O
, PUNCT - O
and CCONJ - O
in ADV - O
- PUNCT - O
vitro X - O
drug NOUN - O
release NOUN - O
in ADP - O
0.1 CD - B-CARDINAL
  SPACE - O
N NUM - O
HCl NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nizatidine NNP - B-MEDICINE
was VERB - O
suggested VERB - O
as ADP - O
the DET - O
causal ADJ - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nizatidine NNP - B-MEDICINE
, PUNCT - O
a DET - O
histamine NOUN - O
H-2 PROPN - O
receptor NOUN - O
antagonist NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
proposed VERB - O
to PART - O
have VERB - O
weight NOUN - O
- PUNCT - O
reducing VERB - O
effects NOUN - O
. PUNCT - O

Nizatidine NNP - B-MEDICINE
was VERB - O
well ADV - O
- PUNCT - O
tolerated VERB - O
and CCONJ - O
did VERB - O
not ADV - O
adversely ADV - O
affect VERB - O
clinical ADJ - O
outcomes NOUN - O
. PUNCT - O

Nizatidine NN - B-MEDICINE
300 CD - B-CARDINAL
mg NOUN - O
b.i.d PROPN - O
. PUNCT - O
may VERB - O
have VERB - O
an DET - O
early ADJ - O
transient ADJ - O
effect NOUN - O
in ADP - O
limiting VERB - O
the DET - O
weight NOUN - O
gain NOUN - O
, PUNCT - O
but CCONJ - O
this DET - O
potential ADJ - O
early ADJ - O
effect NOUN - O
appeared VERB - O
to PART - O
be VERB - O
diminished VERB - O
or CCONJ - O
eliminated VERB - O
by ADP - O
16 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Haloperidol NN - B-MEDICINE
for ADP - O
the DET - O
management NOUN - O
of ADP - O
delirium NOUN - O
in ADP - O
adult NOUN - O
intensive ADJ - O
care NOUN - O
unit NOUN - O
patients NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Enhancement PROPN - O
of ADP - O
Transdermal PROPN - O
Delivery PROPN - O
of ADP - O
Haloperidol NNP - B-MEDICINE
via ADP - O
Spanlastic PROPN - O
Dispersions NOUN - O
: PUNCT - O
Entrapment PROPN - O
Efficiency PROPN - O
vs. ADP - O
Particle NNP - B-ORG
Size NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Prophylactic PROPN - O
Haloperidol NNP - B-MEDICINE
for ADP - O
Critically ADV - O
Ill PROPN - O
Adults PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Haloperidol NNP - B-MEDICINE
Abrogates PROPN - O
Matrix NOUN - O
Metalloproteinase-9 PROPN - O
Expression NOUN - O
by ADP - O
Inhibition PROPN - O
of ADP - O
NF PROPN - O
- PUNCT - O
κB PROPN - O
Activation NOUN - O
in ADP - O
Stimulated PROPN - O
Human PROPN - O
Monocytic PROPN - O
Cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Haloperidol NN - B-MEDICINE
treatment NOUN - O
for ADP - O
28 CD - B-DATE
days NNS - I-DATE
replicating VERB - O
clinically ADV - O
comparable ADJ - O
dosing NOUN - O
and CCONJ - O
pharmacokinetics NOUN - O
did VERB - O
not ADV - O
affect VERB - O
microglia ADJ - O
density NOUN - O
in ADP - O
saline NOUN - O
- PUNCT - O
exposed VERB - O
offspring NOUN - O
, PUNCT - O
but CCONJ - O
increased VERB - O
Iba1 NNPS - B-ORG
+ CCONJ - O
soma NOUN - O
size NOUN - O
in ADP - O
both CCONJ - O
CS NNP - B-ORG
and CCONJ - O
ACC NNP - B-ORG
, PUNCT - O
also ADV - O
suggestive VERB - O
of ADP - O
microglial ADJ - O
activation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Haloperidol NNP - B-MEDICINE
on IN - I-ORG
Delirium NNP - I-ORG
in ADP - O
Adult PROPN - O
Patients PROPN - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta NNP - B-ORG
- HYPH - I-ORG
Analysis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
total NOUN - O
of ADP - O
266 CD - B-CARDINAL
advanced ADJ - O
cancer NOUN - O
patients NOUN - O
with ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
to ADP - O
Metoclopramide NNP - B-ORG
group NOUN - O
( PUNCT - O
M PROPN - O
group NOUN - O
, PUNCT - O
n＝70 PROPN - O
) PUNCT - O
, PUNCT - O
Metoclopramide NNP - B-ORG
plus CCONJ - O
Haloperidol NNP - B-MEDICINE
group NOUN - O
( PUNCT - O
MH NNP - B-ORG
group NOUN - O
, PUNCT - O
n＝65 NOUN - O
) PUNCT - O
, PUNCT - O
moxibustion NOUN - O
＋ FW - B-ORG
M NNP - I-ORG
group NOUN - O
( PUNCT - O
n＝63 NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
moxibustion NOUN - O
＋ NOUN - O
MH NNP - B-ORG
group NOUN - O
( PUNCT - O
n＝68 PROPN - O
) PUNCT - O
. PUNCT - O

No DET - O
significant ADJ - O
differences NOUN - O
were VERB - O
found VERB - O
between ADP - O
the DET - O
MH NNP - B-ORG
and CCONJ - O
moxibustion＋M NNP - B-ORG
groups NOUN - O
in ADP - O
the DET - O
INVR NNP - B-ORG
and CCONJ - O
HAMD NNP - B-ORG
scores NOUN - O
, PUNCT - O
and CCONJ - O
in ADP - O
the DET - O
scores NOUN - O
of ADP - O
physical ADJ - O
well NOUN - O
- PUNCT - O
being NOUN - O
, PUNCT - O
emotional ADJ - O
well NOUN - O
- PUNCT - O
being NOUN - O
and CCONJ - O
total ADJ - O
score NOUN - O
of ADP - O
QOL NNP - B-ORG
( PUNCT - O
P>0.05)．. PROPN - O
CONCLUSION PROPN - O
: PUNCT - O
Moxibustion PROPN - O
plus CCONJ - O
Metoclopramide NNP - B-ORG
and CCONJ - O
Haloperidol NNP - B-MEDICINE
can VERB - O
relieve VERB - O
refractory ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
, PUNCT - O
and CCONJ - O
better ADJ - O
depression NOUN - O
and CCONJ - O
QOL NNP - B-ORG
in ADP - O
advanced ADJ - O
cancer NOUN - O
patients NOUN - O
, PUNCT - O
being VERB - O
worthy ADJ - O
of ADP - O
popularization NOUN - O
in ADP - O
clinical ADJ - O
practice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Haloperidol NNP - B-MEDICINE
serum NOUN - O
concentrations NOUN - O
in ADP - O
critically ADV - O
ill ADJ - O
patients NOUN - O
included VERB - O
in ADP - O
the DET - O
REDUCE NNP - B-ORG
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Products NOUN - O
obtained VERB - O
from ADP - O
G. PROPN - O
glauca NOUN - O
were VERB - O
evaluated VERB - O
in ADP - O
the DET - O
Haloperidol NNP - B-MEDICINE
- PUNCT - O
induced VERB - O
catalepsy NOUN - O
test NOUN - O
and CCONJ - O
in ADP - O
the DET - O
acute ADJ - O
schizophrenia NOUN - O
- PUNCT - O
like ADJ - O
symptoms NOUN - O
- PUNCT - O
induced VERB - O
with ADP - O
Ketamine NNP - B-GPE
( PUNCT - O
KET PROPN - O
) PUNCT - O
in ADP - O
mice NOUN - O
. PUNCT - O

The DET - O
methanolic ADJ - O
extract NOUN - O
from ADP - O
G. PROPN - O
glauca NOUN - O
, PUNCT - O
GRF NNP - B-ORG
, PUNCT - O
and CCONJ - O
the DET - O
pure ADJ - O
galphimines NOUN - O
were VERB - O
able ADJ - O
to PART - O
interact VERB - O
with ADP - O
the DET - O
dopaminergic ADJ - O
pathway NOUN - O
and CCONJ - O
modify VERB - O
the DET - O
behavioral ADJ - O
response NOUN - O
such ADJ - O
as ADP - O
to PART - O
potentiate VERB - O
the DET - O
cataleptic ADJ - O
effect NOUN - O
induced VERB - O
with ADP - O
Haloperidol NNP - B-MEDICINE
and CCONJ - O
to PART - O
inhibit VERB - O
the DET - O
behavior NOUN - O
induced VERB - O
by ADP - O
KET PROPN - O
in ADP - O
mice NOUN - O
exposed VERB - O
to ADP - O
OFT NNP - B-ORG
, PUNCT - O
and CCONJ - O
FST NNP - B-ORG
. PUNCT - O

It PRON - O
can VERB - O
be VERB - O
concluded VERB - O
that ADP - O
the DET - O
products NOUN - O
obtained VERB - O
from ADP - O
G. PROPN - O
glauca NOUN - O
potentiate VERB - O
the DET - O
cataleptic ADJ - O
effect NOUN - O
induced VERB - O
with ADP - O
Haloperidol NNP - B-MEDICINE
and CCONJ - O
show VERB - O
a DET - O
protector NOUN - O
effect NOUN - O
on ADP - O
some DET - O
of ADP - O
the DET - O
symptoms NOUN - O
generated VERB - O
by ADP - O
KET PROPN - O
in ADP - O
mice NOUN - O
( PUNCT - O
KET NNP - B-ORG
is VERB - O
capable ADJ - O
of ADP - O
provoking VERB - O
halucinations NOUN - O
in ADP - O
humans NOUN - O
and CCONJ - O
psychosis NOUN - O
- PUNCT - O
like ADJ - O
behaviour NOUN - O
in ADP - O
mice NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Haloperidol NN - B-MEDICINE
and CCONJ - O
chlorpromazine NOUN - O
induced VERB - O
a DET - O
change NOUN - O
in ADP - O
the DET - O
expression NOUN - O
of ADP - O
all DET - O
neuropeptides NOUN - O
analyzed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Monitoring PROPN - O
Haloperidol NNP - B-MEDICINE
Plasma PROPN - O
Concentration PROPN - O
and CCONJ - O
Associated PROPN - O
Adverse PROPN - O
Events PROPN - O
in ADP - O
Critically ADV - O
Ill PROPN - O
Children NOUN - O
With ADP - O
Delirium NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Haloperidol NN - B-MEDICINE
versus ADP - O
placebo NOUN - O
for ADP - O
delirium NOUN - O
prevention NOUN - O
in ADP - O
acutely ADV - O
hospitalised VERB - O
older ADJ - O
at ADP - O
risk NOUN - O
patients NOUN - O
: PUNCT - O
a DET - O
multi ADJ - O
- ADJ - O
centre ADJ - O
double ADJ - O
- PUNCT - O
blind ADJ - O
randomised VERB - O
controlled VERB - O
clinical ADJ - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
we PRON - O
report VERB - O
novel ADJ - O
bioluminescence NOUN - O
resonance NOUN - O
energy NOUN - O
transfer NOUN - O
( PUNCT - O
BRET NNP - B-ORG
) PUNCT - O
assays NOUN - O
that ADJ - O
enable VERB - O
analyses NOUN - O
of ADP - O
ligand NOUN - O
- PUNCT - O
induced VERB - O
multimerization NOUN - O
of ADP - O
σ1R NOUN - O
and CCONJ - O
its ADJ - O
interaction NOUN - O
with ADP - O
BiP. PROPN - O
Haloperidol NNP - B-MEDICINE
, PUNCT - O
PD144418 NNPS - B-GPE
, PUNCT - O
and CCONJ - O
4-PPBP CD - B-CARDINAL
enhanced VERB - O
σ1R NOUN - O
homomer NOUN - O
BRET NNP - B-ORG
signals NOUN - O
in ADP - O
a DET - O
dose NOUN - O
dependent ADJ - O
manner NOUN - O
, PUNCT - O
suggesting VERB - O
their ADJ - O
significant ADJ - O
effects NOUN - O
in ADP - O
stabilizing VERB - O
σ1R ADJ - O
multimerization NOUN - O
, PUNCT - O
whereas ADP - O
( PUNCT - O
+ CCONJ - O
) PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
has VERB - O
potent ADJ - O
and CCONJ - O
broad ADJ - O
antibacterial ADJ - O
activity NOUN - O
against ADP - O
gram NOUN - O
- PUNCT - O
positive ADJ - O
and CCONJ - O
gram ADJ - O
- PUNCT - O
negative ADJ - O
bacteria NOUN - O
, PUNCT - O
and CCONJ - O
is VERB - O
recommended VERB - O
as ADP - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
empiric ADJ - O
therapy NOUN - O
for ADP - O
febrile ADJ - O
neutropenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
plasma VERB - O
concentration NOUN - O
above ADP - O
a DET - O
pathogen NOUN - O
's PART - O
MIC NNP - B-ORG
over ADP - O
the DET - O
whole ADJ - O
dosing NOUN - O
interval NOUN - O
( PUNCT - O
100 CD - B-PERCENT
% NN - I-PERCENT
ƒT VERB - O
> X - O
MIC NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
determinant NOUN - O
of ADP - O
outcome NOUN - O
in ADP - O
severe ADJ - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacokinetics NOUN - O
of ADP - O
the DT - B-ORG
Meropenem NNP - I-MEDICINE
Component NNP - I-ORG
of IN - I-ORG
Meropenem NNP - I-MEDICINE
- HYPH - I-ORG
Vaborbactam NNP - I-ORG
in ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
KPC PROPN - O
- PUNCT - O
Producing PROPN - O
Klebsiella PROPN - O
pneumoniae VERB - O
Bloodstream PROPN - O
Infection PROPN - O
in ADP - O
a DET - O
Pediatric PROPN - O
Patient PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

PROCEDURES NNP - B-ORG
Meropenem NNP - I-MEDICINE
- PUNCT - O
free ADJ - O
polymethyl NOUN - O
methacrylate NOUN - O
and CCONJ - O
M PROPN - O
- PUNCT - O
PMMA PROPN - O
beads NOUN - O
were VERB - O
sterilized VERB - O
by ADP - O
use NOUN - O
of ADP - O
an DET - O
autoclave NOUN - O
or CCONJ - O
VHP NNP - B-ORG
or CCONJ - O
remained VERB - O
unsterilized ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Results NOUN - O
of ADP - O
a DET - O
Phase NOUN - O
3 NUM - O
, PUNCT - O
Randomized VBN - B-ORG
, PUNCT - O
Multicenter PROPN - O
, PUNCT - O
Prospective PROPN - O
Trial NOUN - O
of ADP - O
Eravacycline PROPN - O
vs. X - O
Meropenem NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
Treatment NNP - I-ORG
of IN - I-ORG
Complicated NNP - I-ORG
Intra NNP - I-ORG
- HYPH - I-ORG
Abdominal NNP - I-ORG
Infections NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ceftazidime NN - B-ORG
/ SYM - I-ORG
Avibactam NNP - I-ORG
, PUNCT - O
Meropenem NNP - B-MEDICINE
/ SYM - I-ORG
Vaborbactam NNP - I-ORG
, PUNCT - O
or CCONJ - O
Both DET - O
? PUNCT - O

-DOCSTART- -X- - O

Fatal NNP - B-ORG
Carbapenem NNP - I-ORG
Resistance NNP - I-ORG
Development NNP - I-ORG
in ADP - O
Pseudomonas NNP - B-GPE
Aeruginosa PROPN - O
Under ADP - O
Meropenem NNP - B-MEDICINE
Monotherapy NNP - I-PERSON
, PUNCT - O
Caused VERB - O
by ADP - O
Mutations NOUN - O
in ADP - O
the DT - B-FAC
Oprd NNP - I-FAC
Outer NNP - I-FAC
Membrane NNP - I-FAC
Porin NNP - I-FAC
. PUNCT - O

-DOCSTART- -X- - O

AbstractBackgroundMeropenem NOUN - O
- PUNCT - O
vaborbactam PROPN - O
( PUNCT - O
M PROPN - O
- PUNCT - O
V PROPN - O
) PUNCT - O
is VERB - O
a DET - O
novel NOUN - O
antibiotic ADJ - O
for ADP - O
treatment NOUN - O
of ADP - O
carbapenem NOUN - O
- PUNCT - O
resistant ADJ - O
Enterobacteriaceae NNP - B-PERSON
( PUNCT - O
CRE NNP - B-ORG
) PUNCT - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
- PUNCT - O
nacubactam PROPN - O
demonstrated VERB - O
the DET - O
greatest ADJ - O
in ADP - O
vivo NOUN - O
efficacy NOUN - O
against ADP - O
9 CD - B-CARDINAL
of ADP - O
10 CD - B-CARDINAL
isolates NOUN - O
, PUNCT - O
achieving VERB - O
a DET - O
≥3 NN - B-GPE
log NOUN - O
reduction NOUN - O
from ADP - O
the DET - O
48-h CD - B-PERSON
control NOUN - O
in ADP - O
all DET - O
isolates NOUN - O
tested VERB - O
, PUNCT - O
including VERB - O
isolates NOUN - O
prepared VERB - O
as ADP - O
high ADJ - O
inoculums NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NN - B-MEDICINE
- PUNCT - O
vaborbactam NOUN - O
is VERB - O
a DET - O
new ADJ - O
beta NOUN - O
- PUNCT - O
lactam NOUN - O
/ SYM - O
beta NOUN - O
- PUNCT - O
lactamase NOUN - O
inhibitor NOUN - O
combination NOUN - O
that ADJ - O
combines VERB - O
a DET - O
carbapenem ADV - O
antibiotic ADJ - O
with ADP - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
in ADP - O
- PUNCT - O
class NOUN - O
, PUNCT - O
boronic NOUN - O
acid NOUN - O
pharmacophore ADJ - O
, PUNCT - O
serine ADJ - O
beta ADJ - O
- PUNCT - O
lactamase NOUN - O
inhibitor NOUN - O
which ADJ - O
has VERB - O
potent ADJ - O
inhibitory ADJ - O
activity NOUN - O
against ADP - O
class NOUN - O
A NOUN - O
carbapenemases NOUN - O
, PUNCT - O
especially ADV - O
Klebsiella NNP - B-PERSON
pneumoniae VERB - O
carbapenemases NOUN - O
( PUNCT - O
KPC NNP - B-ORG
) PUNCT - O
, PUNCT - O
in ADP - O
addition NOUN - O
to ADP - O
other ADJ - O
class NOUN - O
A NOUN - O
and CCONJ - O
class NOUN - O
C NOUN - O
beta NOUN - O
- PUNCT - O
lactamases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Meropenem NNP - B-MEDICINE
- PUNCT - O
Vaborbactam PROPN - O
versus ADP - O
Best PROPN - O
- PUNCT - O
Available ADJ - O
Therapy PROPN - O
in ADP - O
Patients PROPN - O
with ADP - O
Carbapenem NNP - B-ORG
- HYPH - I-ORG
Resistant NNP - I-ORG
Enterobacteriaceae NNP - I-ORG
Infections NNPS - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

WardPiperacillin– PROPN - O
TazobactamCefepimeMeropenemTotalPoCCHematology NNP - B-ORG
/ SYM - I-ORG
oncology105.1134.476.6316.10.24Bone NNP - I-ORG
marrow NN - I-ORG
transplant34.3201.0127.4362.70.35National ADJ - O
meansa76.260.230.7b0.18 NOUN - O

-DOCSTART- -X- - O

Incidence PROPN - O
of ADP - O
Acute NNP - B-PERSON
Kidney NNP - I-PERSON
Injury NNP - I-PERSON
Among ADP - O
Patients PROPN - O
Receiving VERB - O
the DET - O
Combination PROPN - O
of ADP - O
Vancomycin PROPN - O
with ADP - O
Piperacillin NNP - B-PERSON
- HYPH - I-PERSON
Tazobactam NNP - I-PERSON
or CCONJ - O
Meropenem NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
and CCONJ - O
piperacillin NOUN - O
/ SYM - O
tazobactam NOUN - O
( PUNCT - O
PIP NNP - B-ORG
/ SYM - I-ORG
TZB NNP - I-ORG
) PUNCT - O
are VERB - O
recommended VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
peritoneal ADJ - O
dialysis NOUN - O
- PUNCT - O
associated VERB - O
peritonitis NOUN - O
( PUNCT - O
PDAP PROPN - O
) PUNCT - O
caused VERB - O
by ADP - O
ceftazidime NOUN - O
- PUNCT - O
resistant ADJ - O
Pseudomonas NNP - B-GPE
and CCONJ - O
other ADJ - O
resistant ADJ - O
gram NOUN - O
- PUNCT - O
negative ADJ - O
bacteria NOUN - O
. PUNCT - O

Meropenem NNP - B-MEDICINE
and CCONJ - O
heparin ADV - O
retained VERB - O
more JJR - B-PERCENT
than IN - I-PERCENT
90 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
their ADJ - O
initial ADJ - O
concentration NOUN - O
in ADP - O
4 CD - B-CARDINAL
out ADP - O
of ADP - O
5 CD - B-CARDINAL
types NOUN - O
of ADP - O
PD PROPN - O
solutions NOUN - O
when ADV - O
stored VERB - O
at ADP - O
4 CD - B-CARDINAL
° PROPN - O
C NOUN - O
for ADP - O
168 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
followed VERB - O
by ADP - O
storage NOUN - O
at ADP - O
25 CD - B-CARDINAL
° PROPN - O
C NOUN - O
for ADP - O
3 CD - B-TIME
hours NNS - I-TIME
and CCONJ - O
then ADV - O
at ADP - O
37 CD - B-CARDINAL
° NOUN - O
C PROPN - O
for ADP - O
10 CD - B-TIME
hours NNS - I-TIME
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
markedly ADV - O
prolonged VERB - O
the DET - O
PAE NN - B-ORG
in ADP - O
two CD - B-CARDINAL
isolates NOUN - O
in ADP - O
contrast NOUN - O
to ADP - O
vancomycin PROPN - O
which ADJ - O
did VERB - O
not ADV - O
demonstrate VERB - O
significant ADJ - O
effect NOUN - O
on ADP - O
the DET - O
duration NOUN - O
of ADP - O
PAE NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ceftriaxone NN - B-ORG
- HYPH - I-ORG
Sulbactam NNP - I-ORG
- HYPH - I-ORG
EDTA NNP - I-ORG
vs. ADP - O
Meropenem NNP - B-MEDICINE
in ADP - O
PLEA NNP - B-PERSON
( PUNCT - O
a DET - O
Phase NOUN - O
3 NUM - O
, PUNCT - O
Randomized VBN - B-ORG
, , - I-ORG
Double JJ - I-ORG
- HYPH - I-ORG
Blind JJ - I-ORG
Trial NN - I-ORG
) PUNCT - O
: PUNCT - O

-DOCSTART- -X- - O

Activity NOUN - O
of ADP - O
Meropenem NNP - B-MEDICINE
/ SYM - I-ORG
Nacubactam NNP - I-ORG
Combination NNP - I-ORG
Against ADP - O
Gram PROPN - O
- PUNCT - O
Negative PROPN - O
Clinical PROPN - O
Isolates PROPN - O
: PUNCT - O
ROSCO PROPN - O
Global PROPN - O
Surveillance PROPN - O
2017 NUM - O
. PUNCT - O

-DOCSTART- -X- - O

Raising VERB - O
the DET - O
Stakes NNPS - B-ORG
: PUNCT - O
Loss NOUN - O
of ADP - O
Efflux PROPN - O
Pump PROPN - O
Regulation NOUN - O
Decreases VERB - O
Meropenem NNP - B-MEDICINE
Susceptibility PROPN - O
in ADP - O
Burkholderia NNP - B-GPE
pseudomallei VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
, PUNCT - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum NOUN - O
antibiotic NOUN - O
, PUNCT - O
is VERB - O
not ADV - O
licensed VERB - O
for ADP - O
use NOUN - O
in ADP - O
neonates NOUN - O
and CCONJ - O
infants NOUN - O
below ADP - O
3 CD - B-CARDINAL
  SPACE - O
months NOUN - O
of ADP - O
age NOUN - O
and CCONJ - O
sufficient ADJ - O
information NOUN - O
on ADP - O
its ADJ - O
plasma NOUN - O
and CCONJ - O
CSF NN - B-ORG
disposition NOUN - O
and CCONJ - O
dosing VERB - O
in ADP - O
neonates NOUN - O
and CCONJ - O
infants NOUN - O
is VERB - O
lacking VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Meropenem NNP - B-MEDICINE
potentiation NOUN - O
of ADP - O
AG NNP - B-ORG
activity NOUN - O
was VERB - O
largely ADV - O
lost VERB - O
in ADP - O
a DET - O
mutant NOUN - O
lacking VERB - O
the DET - O
MexXY NNP - B-PERSON
- HYPH - I-PERSON
OprM NNP - I-PERSON
multidrug ADJ - O
efflux NOUN - O
system NOUN - O
, PUNCT - O
an DET - O
indication NOUN - O
that ADP - O
it PRON - O
was VERB - O
targeting VERB - O
this DET - O
efflux NOUN - O
system NOUN - O
in ADP - O
enhancing VERB - O
P. NNP - B-PERSON
aeruginosa NOUN - O
susceptibility NOUN - O
to ADP - O
AGs NOUN - O
. PUNCT - O

Meropenem NNP - B-MEDICINE
failed VERB - O
to PART - O
block VERB - O
AG NNP - B-ORG
induction NOUN - O
of ADP - O
mexXY NUM - O
expression NOUN - O
or CCONJ - O
MexXY PROPN - O
- PUNCT - O
OprM PROPN - O
efflux NOUN - O
activity NOUN - O
, PUNCT - O
suggesting VERB - O
that ADP - O
it PRON - O
may VERB - O
be VERB - O
interfering VERB - O
with ADP - O
some DET - O
MexXY ADJ - O
- PUNCT - O
dependent ADJ - O
process NOUN - O
linked VERB - O
to ADP - O
AG NNP - B-ORG
susceptibility NOUN - O
. PUNCT - O

Meropenem NNP - B-MEDICINE
potentiated VERB - O
AG NNP - B-ORG
activity NOUN - O
versus ADP - O
AG NNP - B-ORG
- PUNCT - O
resistant ADJ - O
CF NOUN - O
isolates NOUN - O
, PUNCT - O
enhancing VERB - O
susceptibility NOUN - O
to ADP - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
AG NNP - B-ORG
in ADP - O
all DET - O
isolates NOUN - O
and CCONJ - O
susceptibility NOUN - O
to ADP - O
all DET - O
tested VERB - O
AGs NOUN - O
in ADP - O
50 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
the DET - O
isolates NOUN - O
. PUNCT - O

Meropenem NNP - B-MEDICINE
potentiates VERB - O
AG NNP - B-ORG
activity NOUN - O
against ADP - O
laboratory NOUN - O
and CCONJ - O
CF NOUN - O
strains NOUN - O
of ADP - O
P. NNP - B-ORG
aeruginosa NOUN - O
, PUNCT - O
both DET - O
dependent ADJ - O
on ADP - O
and CCONJ - O
independent ADJ - O
of ADP - O
MexXY NNP - B-ORG
, PUNCT - O
highlighting VERB - O
the DET - O
complexity NOUN - O
of ADP - O
AG NNP - B-ORG
resistance NOUN - O
in ADP - O
this DET - O
organism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ferrum NN - B-GPE
phosphoricum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Single PROPN - O
Amino PROPN - O
Acid PROPN - O
Residue PROPN - O
at ADP - O
Transmembrane PROPN - O
Domain PROPN - O
4 NUM - O
of ADP - O
the DET - O
α X - O
Subunit PROPN - O
Influences PROPN - O
Carisoprodol NNP - B-MEDICINE
Direct PROPN - O
Gating PROPN - O
Efficacy PROPN - O
at ADP - O
GABAA PROPN - O
Receptors PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Expanding VERB - O
ELISA PROPN - O
Screening VERB - O
in ADP - O
DUID PROPN - O
Investigations NOUN - O
to ADP - O
Include NNP - B-ORG
Carisoprodol NNP - I-MEDICINE
/ SYM - I-ORG
Meprobamate NNP - I-ORG
and CCONJ - O
Zolpidem NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
prescribed ADJ - O
muscle NOUN - O
relaxant NOUN - O
, PUNCT - O
abuse NOUN - O
of ADP - O
which ADJ - O
has VERB - O
grown VERB - O
considerably ADV - O
in ADP - O
recent JJ - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

± X - O
  SPACE - O
0.5 CD - B-CARDINAL
per ADP - O
day NOUN - O
) PUNCT - O
, PUNCT - O
Procyclidin NNP - B-PERSON
( PUNCT - O
6.1 CD - B-CARDINAL
tablets NOUN - O
  SPACE - O
+ CCONJ - O
  SPACE - O
0.6 CD - B-DATE
per IN - I-DATE
day NN - I-DATE
) PUNCT - O
and CCONJ - O
Carisoprodol NNP - B-MEDICINE
( PUNCT - O
4.2 CD - B-CARDINAL
tablets NOUN - O
  SPACE - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
: PUNCT - O
an DET - O
underrecognized ADJ - O
drug NOUN - O
of ADP - O
abuse NOUN - O
in ADP - O
north NOUN - O
India NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
is VERB - O
not ADV - O
federally ADV - O
scheduled VERB - O
under ADP - O
the DT - B-LAW
Controlled NNP - I-LAW
Substances NNPS - I-LAW
Act NNP - I-LAW
( PUNCT - O
CSA NNP - B-ORG
) PUNCT - O
. PUNCT - O

Carisoprodol NN - B-MEDICINE
should VERB - O
be VERB - O
placed VERB - O
in ADP - O
schedule NOUN - O
IV NNP - B-ORG
of ADP - O
the DET - O
CSA NNP - B-ORG
based VERB - O
on ADP - O
its ADJ - O
abuse NOUN - O
potential NOUN - O
and CCONJ - O
current ADJ - O
state NOUN - O
laws NOUN - O
and CCONJ - O
regulations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
is VERB - O
a DET - O
frequently ADV - O
prescribed VERB - O
muscle NOUN - O
relaxant NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
is VERB - O
a DET - O
centrally ADV - O
- PUNCT - O
acting VERB - O
prescription NOUN - O
drug NOUN - O
of ADP - O
known VERB - O
abuse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
- PUNCT - O
induced VERB - O
amnestic ADJ - O
state NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
and CCONJ - O
meprobamate NOUN - O
are VERB - O
excreted VERB - O
into ADP - O
breast NOUN - O
milk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
withdrawal NOUN - O
syndrome NOUN - O
misdiagnosed VERB - O
as ADP - O
a DET - O
psychotic ADJ - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Compositions NOUN - O
Comprising PROPN - O
Carisoprodol NNP - B-MEDICINE
and CCONJ - O
Methods PROPN - O
of ADP - O
Use PROPN - O
Thereof PROPN - O

-DOCSTART- -X- - O

Carisoprodol NNP - B-MEDICINE
, PUNCT - O
Phenytoin NNP - B-ORG
and CCONJ - O
Fosphenytoin NNP - B-ORG
Articles NNPS - I-ORG
and CCONJ - O
Methods PROPN - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
is VERB - O
commonly ADV - O
prescribed VERB - O
as ADP - O
a DET - O
centrally ADV - O
acting VERB - O
muscle NOUN - O
relaxant NOUN - O
, PUNCT - O
but CCONJ - O
it PRON - O
is VERB - O
also ADV - O
subject ADJ - O
to ADP - O
abuse NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
abuse NOUN - O
in ADP - O
Texas NNP - B-GPE
, PUNCT - O
1998 CD - B-DATE
- SYM - I-DATE
2003 CD - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
withdrawal NOUN - O
syndrome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Carisoprodol NN - B-MEDICINE
intoxications NOUN - O
and CCONJ - O
serotonergic NOUN - O
features NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Thermodynamic ADJ - O
study NOUN - O
of ADP - O
binary ADJ - O
system NOUN - O
Propafenone NNP - B-GPE
Hydrocloride NNP - I-GPE
with ADP - O
Metoprolol NNP - B-PERSON
Tartrate NNP - I-PERSON
: PUNCT - O
solid ADJ - O
- PUNCT - O
liquid ADJ - O
equilibrium NOUN - O
and CCONJ - O
compatibility NOUN - O
with ADP - O
α NOUN - O
- PUNCT - O
lactose NOUN - O
monohydrate NOUN - O
and CCONJ - O
corn NOUN - O
starch NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Western NNP - B-ORG
Ragweed NNP - I-ORG
( PUNCT - O
Ambrosia NNP - B-PERSON
psilostachya NOUN - O
) PUNCT - O
Control PROPN - O
and CCONJ - O
Bermudagrass NNP - B-ORG
Response NNP - I-ORG
to ADP - O
Diflufenzopyr PROPN - O
Tank PROPN - O
- PUNCT - O
Mix PROPN - O
Combinations NOUN - O

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
downregulates VERB - O
expression NOUN - O
of ADP - O
several ADJ - O
genes NOUN - O
encoding VERB - O
orphan NOUN - O
nuclear ADJ - O
receptors NOUN - O
that ADJ - O
are VERB - O
important ADJ - O
to PART - O
steroidogenesis VERB - O
in ADP - O
stallion NOUN - O
testes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
added VERB - O
to ADP - O
local ADJ - O
anesthetics NOUN - O
in ADP - O
ultrasound NOUN - O
- PUNCT - O
guided VERB - O
transversus NOUN - O
abdominis NOUN - O
plain ADJ - O
( PUNCT - O
TAP PROPN - O
) PUNCT - O
block NOUN - O
for ADP - O
analgesia NOUN - O
after ADP - O
abdominal ADJ - O
surgery NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

The DT - B-ORG
Effect NN - I-ORG
of IN - I-ORG
Dexamethasone NNP - I-MEDICINE
, PUNCT - O
Adrenergic PROPN - O
and CCONJ - O
Cholinergic PROPN - O
Receptor PROPN - O
Agonists VERB - O
on ADP - O
Phospholipid PROPN - O
Metabolism PROPN - O
in ADP - O
Human PROPN - O
Osteoarthritic PROPN - O
Synoviocytes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
treatment NOUN - O
gradually ADV - O
reduced VERB - O
hindlimb NOUN - O
grip NOUN - O
strength NOUN - O
that ADJ - O
also ADV - O
stayed VERB - O
decreased VERB - O
during ADP - O
the DET - O
20-day CD - B-DATE
recovery NOUN - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Suppression NOUN - O
of ADP - O
IgE PROPN - O
- PUNCT - O
Independent PROPN - O
Degranulation PROPN - O
of ADP - O
Murine PROPN - O
Connective PROPN - O
Tissue PROPN - O
- PUNCT - O
Type NOUN - O
Mast NOUN - O
Cells NOUN - O
by ADP - O
Dexamethasone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Melatonin NNP - B-ORG
and CC - I-ORG
Dexamethasone NNP - I-MEDICINE
on ADP - O
Facial PROPN - O
Nerve PROPN - O
Neurorrhaphy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparison NOUN - O
of ADP - O
Nebulized NNP - B-ORG
Budesonide NNP - I-ORG
and CCONJ - O
Intravenous PROPN - O
Dexamethasone NNP - B-MEDICINE
Efficacy PROPN - O
on ADP - O

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
in ADP - O
current ADJ - O
practice NOUN - O
for ADP - O
the DET - O
prevention NOUN - O
of ADP - O
postoperative ADJ - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ranibizumab VERB - O
versus ADP - O
Dexamethasone NNP - B-MEDICINE
Implant NNP - I-ORG
in ADP - O
Macular NNP - B-FAC
Edema NNP - I-FAC
Secondary JJ - I-FAC
to ADP - O
Branch PROPN - O

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
, PUNCT - O
doxorubicin NOUN - O
, PUNCT - O
or CCONJ - O
docetaxel NOUN - O
administered VERB - O
separately ADV - O
in ADP - O
their ADJ - O
effective ADJ - O
concentration NOUN - O
suppressed VERB - O
cell NOUN - O
motility NOUN - O
( PUNCT - O
in ADP - O
16 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
and CCONJ - O
caused VERB - O
cell NOUN - O
death NOUN - O
( PUNCT - O
in ADP - O
48 CD - B-CARDINAL
h NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Carnosic NOUN - O
acid NOUN - O
, PUNCT - O
Tangeretin NNP - B-PERSON
, PUNCT - O
and CCONJ - O
Ginkgolide PROPN - O
- PUNCT - O
B PROPN - O
Anti ADJ - O
- ADJ - O
Neoplastic ADJ - O
Cytotoxicity PROPN - O
in ADP - O
Dual PROPN - O
Combination PROPN - O
with ADP - O
Dexamethasone-[anti NNP - B-ORG
- HYPH - I-ORG
EGFR NNP - I-ORG
] PUNCT - O
in ADP - O
Pulmonary NNP - B-GPE
Adenocarcinoma NNP - B-PERSON
( PUNCT - O
A549 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Real ADJ - O
World PROPN - O
Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
Results PROPN - O
of ADP - O
Ixazomib PROPN - O
Lenalidomide PROPN - O
and CCONJ - O
Dexamethasone NNP - B-MEDICINE
Combination PROPN - O
in ADP - O
Relapsed PROPN - O
/ SYM - O
Refractory PROPN - O
Multiple PROPN - O
Myeloma PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Dexamethasone NNP - B-MEDICINE
( PUNCT - O
DEXA NOUN - O
) PUNCT - O
has VERB - O
been VERB - O
widely ADV - O
used VERB - O
in ADP - O
the DET - O
management NOUN - O
of ADP - O
peritumoral ADJ - O
brain NOUN - O
edema NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Effects NOUN - O
of ADP - O
Intravitreal PROPN - O
Ranibizumab PROPN - O
, PUNCT - O
Aflibercept PROPN - O
or CCONJ - O
Dexamethasone NNP - B-MEDICINE
Implant NNP - I-ORG
Injections NNPS - I-ORG
on ADP - O
Intraocular PROPN - O
Pressure PROPN - O
Changes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Co NN - B-ORG
- NN - I-ORG
Delivery NN - I-ORG
of IN - I-ORG
RUNX2-Targeting NNP - I-ORG
miRNAs NOUN - O
and CCONJ - O
shRNAs NOUN - O
Using PROPN - O
Nanoparticles NNPS - B-ORG
Composed VBN - I-ORG
of IN - I-ORG
Dexamethasone NNP - I-MEDICINE
and CCONJ - O
PEI NNP - B-ORG

-DOCSTART- -X- - O

Dexamethasone NN - B-MEDICINE
may VERB - O
produce VERB - O
a DET - O
mild ADJ - O
increase NOUN - O
in ADP - O
glucose NOUN - O
levels NOUN - O
among ADP - O
participants NOUN - O
without ADP - O
diabetes NOUN - O
during ADP - O
the DT - B-TIME
first JJ - I-TIME
12 CD - I-TIME
hours NNS - I-TIME
after ADP - O
surgery NOUN - O
( PUNCT - O
MD PROPN - O
13 NUM - O
mg NOUN - O
/ SYM - O
dL PROPN - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
6 NUM - O
to ADP - O
21 CD - B-CARDINAL
; PUNCT - O
10 CD - B-CARDINAL
studies NOUN - O
; PUNCT - O
595 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
I² PROPN - O
= SYM - O
50 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
low ADJ - O
- PUNCT - O
quality NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Intravitreal VERB - O
Therapy NOUN - O
Combining VERB - O
Dexamethasone NNP - B-MEDICINE
and CCONJ - O
Bevacizumab NNP - B-ORG
in ADP - O
Treating NNP - B-GPE
Radiation NNP - I-GPE
Retinopathy NNP - I-GPE
and CCONJ - O
Opticopathy]. PROPN - O

-DOCSTART- -X- - O

Dexamethasone NNP - B-MEDICINE
was VERB - O
assumed VERB - O
to PART - O
be VERB - O
used VERB - O
annually RB - B-DATE
in ADP - O
20 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
30 CD - B-PERCENT
% NN - I-PERCENT
  SPACE - O
and CCONJ - O
40 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
   SPACE - O
patients NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
suicide NOUN - O
attempt NOUN - O
with ADP - O
the DET - O
camphorated ADJ - O
phenol NOUN - O
preparation NOUN - O
Campho NNP - B-ORG
- HYPH - I-ORG
Phenique NNP - I-ORG
. PUNCT - O

Although ADP - O
Campho NNP - B-ORG
- HYPH - I-ORG
Phenique NNP - I-ORG
has VERB - O
been VERB - O
discussed VERB - O
extensively ADV - O
in ADP - O
the DET - O
pediatric ADJ - O
literature NOUN - O
and CCONJ - O
its ADJ - O
accidental ADJ - O
ingestion NOUN - O
by ADP - O
adults NOUN - O
has VERB - O
occasionally ADV - O
been VERB - O
reported VERB - O
, PUNCT - O
intentional ADJ - O
ingestion NOUN - O
of ADP - O
the DET - O
preparation NOUN - O
has VERB - O
not ADV - O
been VERB - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Long PROPN - O
- PUNCT - O
Term PROPN - O
Effects PROPN - O
of ADP - O
Finasteride NNP - B-MEDICINE
on ADP - O
Prostate PROPN - O
Cancer PROPN - O
Mortality PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Finasteride RB - B-MEDICINE
, PUNCT - O
a DET - O
5-alpha CD - B-CARDINAL
reductase NOUN - O
inhibitor NOUN - O
may VERB - O
have VERB - O
effects NOUN - O
on ADP - O
biomarkers NOUN - O
such ADJ - O
as ADP - O
prostate NOUN - O
- PUNCT - O
specific ADJ - O
antigen NOUN - O
( PUNCT - O
PSA NNP - B-ORG
) PUNCT - O
that ADJ - O
could VERB - O
be VERB - O
leveraged VERB - O
to PART - O
improve VERB - O
screening VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Does VERB - O
Tadalafil PROPN - O
Increase VERB - O
The DET - O
Uptake PROPN - O
of ADP - O
Finasteride NNP - B-MEDICINE
into ADP - O
Prostate PROPN - O
Tissue PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Finasteride NN - B-MEDICINE
and CCONJ - O
dutasteride NOUN - O
are VERB - O
5α NUM - O
- PUNCT - O
reductase NOUN - O
inhibitor NOUN - O
drugs NOUN - O
that ADJ - O
are VERB - O
used VERB - O
to PART - O
treat VERB - O
benign ADJ - O
prostatic ADJ - O
hyperplasia NOUN - O
( PUNCT - O
BPH PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Finasteride NN - B-MEDICINE
is VERB - O
primarily ADV - O
used VERB - O
to PART - O
treat VERB - O
benign ADJ - O
prostatic ADJ - O
hyperplasia NOUN - O
( PUNCT - O
BPH PROPN - O
) PUNCT - O
and CCONJ - O
male ADJ - O
androgenetic ADJ - O
alopecia NOUN - O
( PUNCT - O
MAA NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Stability PROPN - O
Study PROPN - O
of ADP - O
Finasteride NNP - B-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

Finasteride NN - B-MEDICINE
does VERB - O
not ADV - O
prevent VERB - O
bladder NOUN - O
cancer NOUN - O
: PUNCT - O
A DET - O
secondary ADJ - O
analysis NOUN - O
of ADP - O
the DT - B-ORG
Medical NNP - I-ORG
Therapy NNP - I-ORG
for IN - I-ORG
Prostatic JJ - I-ORG
Symptoms NNPS - I-ORG
Study NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Finasteride NN - B-MEDICINE
- PUNCT - O
Nemesis NOUN - O
of ADP - O
More ADJ - O
Than ADP - O
1 NUM - O
Urological PROPN - O
Cancer PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Adverse NNP - B-ORG
Effects NNS - I-ORG
with ADP - O
Finasteride NNP - B-MEDICINE
5 NUM - O
mg NOUN - O
/ SYM - O
day NOUN - O
for ADP - O
Patterned NNP - B-WORK_OF_ART
Hair NNP - I-WORK_OF_ART
Loss NNP - I-WORK_OF_ART
in ADP - O
Premenopausal NNP - B-PERSON
Women NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Finasteride JJ - B-MEDICINE
inhibited ADJ - O
brain NOUN - O
dopaminergic NOUN - O
system NOUN - O
and CCONJ - O
open ADJ - O
- PUNCT - O
field NOUN - O
behaviors NOUN - O
in ADP - O
adolescent ADJ - O
male ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Finasteride NN - B-MEDICINE
accelerates NOUN - O
prostate VERB - O
wound VERB - O
healing NOUN - O
after ADP - O
thulium NOUN - O
laser NOUN - O
resection NOUN - O
through ADP - O
DHT PROPN - O
and CCONJ - O
AR PROPN - O
signalling VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Finasteride NNP - B-MEDICINE
is VERB - O
used VERB - O
to PART - O
treat VERB - O
male ADJ - O
pattern NOUN - O
baldness NOUN - O
and CCONJ - O
benign ADJ - O
prostatic ADJ - O
hyperplasia NOUN - O
. PUNCT - O

Finasteride NNP - B-MEDICINE
resulted VERB - O
in ADP - O
reduced ADJ - O
fertility NOUN - O
and CCONJ - O
increased VERB - O
ER NOUN - O
stress NOUN - O
and CCONJ - O
apoptotic ADJ - O
markers NOUN - O
, PUNCT - O
which ADJ - O
were VERB - O
recovered VERB - O
by ADP - O
administration NOUN - O
of ADP - O
DA-9401 NNP - B-ORG
in ADP - O
the DET - O
SD NN - B-ORG
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Finasteride NNP - B-MEDICINE
( PUNCT - O
FIN NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
potent ADJ - O
5α NUM - O
- PUNCT - O
reductase NOUN - O
inhibitor NOUN - O
capable ADJ - O
of ADP - O
preventing VERB - O
the DET - O
conversion NOUN - O
of ADP - O
testosterone NOUN - O
to ADP - O
DHT PROPN - O
. PUNCT - O

Finasteride JJ - B-MEDICINE
loaded VERB - O
ethosomes NOUN - O
( PUNCT - O
FES NNP - B-ORG
) PUNCT - O
were VERB - O
prepared VERB - O
using VERB - O
an DET - O
ultra ADJ - O
- ADJ - O
probe ADJ - O
sonicator NOUN - O
and CCONJ - O
characterized VERB - O
for ADP - O
its ADJ - O
size NOUN - O
, PUNCT - O
morphology NOUN - O
, PUNCT - O
surface NOUN - O
charge NOUN - O
and CCONJ - O
entrapment NOUN - O
efficiency NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Less ADJ - O
than ADP - O
2.5 NUM - O
ng NOUN - O
/ SYM - O
ml NOUN - O
Taking VERB - O
Low ADJ - O
Dose PROPN - O
Finasteride NNP - B-MEDICINE
or CCONJ - O
Dutasteride PROPN - O
for ADP - O
Male PROPN - O
Androgenetic PROPN - O
Alopecia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Post NNP - B-ORG
- HYPH - I-ORG
Finasteride JJ - I-MEDICINE
Adverse NNP - I-ORG
Effects NNPS - I-ORG
in ADP - O
Male PROPN - O
Androgenic PROPN - O

-DOCSTART- -X- - O

Lens NOUN - O
deposits NOUN - O
associated VERB - O
with ADP - O
RIMSO-50 NNP - B-MEDICINE
( PUNCT - O
dimethylsulphoxide NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
instituted VERB - O
to PART - O
investigate VERB - O
in ADP - O
a DET - O
rat NOUN - O
model NOUN - O
the DET - O
effect NOUN - O
of ADP - O
topical ADJ - O
coadministration NOUN - O
of ADP - O
the DET - O
penetration NOUN - O
enhancer NOUN - O
oleic NOUN - O
acid NOUN - O
( PUNCT - O
10 CD - B-PERCENT
% NN - I-PERCENT
by ADP - O
volume NOUN - O
) PUNCT - O
and CCONJ - O
RIMSO-50 NNP - B-MEDICINE
( PUNCT - O
medical ADJ - O
grade NOUN - O
dimethyl NOUN - O
sulfoxide NOUN - O
, PUNCT - O
50 CD - B-PERCENT
% NN - I-PERCENT
by ADP - O
volume NOUN - O
) PUNCT - O
on ADP - O
rat NOUN - O
skin NOUN - O
flap NOUN - O
survival NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
P NOUN - O
- PUNCT - O
glycoprotein NOUN - O
Function PROPN - O
on ADP - O
the DT - B-GPE
Brain NNP - I-GPE
Kinetics NNPS - I-GPE
of ADP - O
the DET - O
Weak PROPN - O
Substrate PROPN - O
11C PROPN - O
- PUNCT - O
Metoclopramide NNP - B-MEDICINE
Assessed PROPN - O
with ADP - O
PET PROPN - O
Imaging PROPN - O
in ADP - O
Humans NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Transient PROPN - O
Hypersomnolence PROPN - O
Provoked VERB - O
by ADP - O
Metoclopramide NNP - B-MEDICINE
in ADP - O
a DET - O
Patient PROPN - O
with ADP - O
Degenerative PROPN - O
Parkinsonism PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Comparison NNP - B-ORG
of IN - I-ORG
Metoclopramide NNP - I-MEDICINE
and CCONJ - O
Ondansetron NNP - B-PERSON
Efficacy NNP - I-PERSON
for ADP - O
the DT - B-ORG
Prevention NNP - I-ORG
of IN - I-ORG
Nausea NNP - I-ORG
and CC - I-ORG
Vomiting NN - I-ORG

-DOCSTART- -X- - O

Metoclopramide NN - B-MEDICINE
: PUNCT - O
A DET - O
Safe ADJ - O
Alternative NOUN - O
to ADP - O
Domperidone NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Imaging PROPN - O
Reveals VERB - O
an DET - O
Importance NOUN - O
of ADP - O
Saturable PROPN - O
Liver PROPN - O
Uptake PROPN - O
Transport PROPN - O
for ADP - O
the DET - O
Pharmacokinetics PROPN - O
of ADP - O
Metoclopramide NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DT - B-LAW
Comparative NNP - I-LAW
Study NNP - I-LAW
of IN - I-LAW
Ondansetron NNP - I-LAW
and CC - I-LAW
Metoclopramide NNP - I-MEDICINE
Effects NNPS - I-LAW
in IN - I-LAW
Reducing VBG - I-LAW
Nausea NNP - I-LAW
and CC - I-LAW
Vomiting NNP - I-LAW
After IN - I-LAW
Laparoscopic NNP - I-LAW
Cholecystectomy NNP - I-LAW
. PUNCT - O

-DOCSTART- -X- - O

Metoclopramide NNP - B-MEDICINE
showed VERB - O
the DET - O
best ADJ - O
surface NOUN - O
under ADP - O
the DET - O
cumulative ADJ - O
ranking VERB - O
curve NOUN - O
( PUNCT - O
SUCRA PROPN - O
) PUNCT - O
probability NOUN - O
( PUNCT - O
92.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
followed VERB - O
by ADP - O
trimebutine NOUN - O
( PUNCT - O
74.5 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
and CCONJ - O
mosapride NOUN - O
( PUNCT - O
63.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

Metoclopramide NNP - B-MEDICINE
showed VERB - O
better ADV - O
efficacy NOUN - O
than ADP - O
itopride PROPN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
2.79 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
credible ADJ - O
interval NOUN - O
: PUNCT - O
1.29 CD - B-CARDINAL
- SYM - O
6.21 NUM - O
) PUNCT - O
and CCONJ - O
acotiamide PROPN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
3.07 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
credible ADJ - O
interval NOUN - O
: PUNCT - O
1.43 CD - B-CARDINAL
- SYM - O
6.75 NUM - O
) PUNCT - O
. PUNCT - O

Domperidone NN - B-PERSON
( PUNCT - O
SUCRA PROPN - O
probability NOUN - O
62.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
showed VERB - O
better ADV - O
efficacy NOUN - O
than ADP - O
itopride PROPN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
1.37 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
credible ADJ - O
interval NOUN - O
: PUNCT - O
1.07 CD - B-CARDINAL
- SYM - O
1.77 NUM - O
) PUNCT - O
and CCONJ - O
acotiamide PROPN - O
( PUNCT - O
OR CCONJ - O
: PUNCT - O
1.51 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
credible ADJ - O
interval NOUN - O
: PUNCT - O
1.04 CD - B-CARDINAL
- SYM - O
2.18).Metoclopramide NUM - O
, PUNCT - O
trimebutine NOUN - O
, PUNCT - O
mosapride NOUN - O
, PUNCT - O
and CCONJ - O
domperidone NOUN - O
showed VERB - O
better ADJ - O
efficacy NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
FD PROPN - O
than ADP - O
itopride NOUN - O
or CCONJ - O
acotiamide ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Metoclopramide NNP - B-MEDICINE
is VERB - O
a DET - O
commonly ADV - O
used VERB - O
anti ADJ - O
- ADJ - O
emetic ADJ - O
drug NOUN - O
known VERB - O
to PART - O
cause VERB - O
extrapyramidal ADJ - O
symptoms NOUN - O
as ADP - O
adverse ADJ - O
effects NOUN - O
, PUNCT - O
amongst ADP - O
which ADJ - O
are VERB - O
dystonic ADJ - O
reactions NOUN - O
. PUNCT - O

Metoclopramide NNP - B-MEDICINE
causes VERB - O
dystonic ADJ - O
reactions NOUN - O
which ADJ - O
are VERB - O
often ADV - O
unpredictable ADJ - O
and CCONJ - O
is VERB - O
frequently ADV - O
prescribed VERB - O
by ADP - O
health NOUN - O
providers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Metoclopramide NNP - B-MEDICINE
is VERB - O
frequently ADV - O
used VERB - O
to ADP - O
various ADJ - O
gastric ADJ - O
symptom NOUN - O
. PUNCT - O

Metoclopramide NNP - B-MEDICINE
is VERB - O
not ADV - O
widely ADV - O
known VERB - O
to PART - O
induce VERB - O
SS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Metoclopramide NN - B-MEDICINE
- PUNCT - O
induced VERB - O
Serotonin NNP - B-ORG
Syndrome NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Double PROPN - O
- PUNCT - O
Blind PROPN - O
Randomized VERB - O
Clinical PROPN - O
Trial PROPN - O
Comparing VERB - O
the DET - O
Effect PROPN - O
of ADP - O
Neostigmine PROPN - O
and CCONJ - O
Metoclopramide NNP - B-MEDICINE
on ADP - O
Gastric PROPN - O
Residual PROPN - O
Volume PROPN - O
of ADP - O
Mechanically RB - B-ORG
Ventilated NNP - I-ORG
ICU NNP - I-ORG
Patients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Metoclopramide NNP - B-MEDICINE
and CCONJ - O
haloperidol NOUN - O
were VERB - O
administered VERB - O
for ADP - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Labetalol NNP - B-PERSON
hydrochloride NOUN - O
( PUNCT - O
LBT PROPN - O
) PUNCT - O
, PUNCT - O
2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl CD - B-CARDINAL
) PUNCT - O
amino NOUN - O
] PUNCT - O

-DOCSTART- -X- - O

Labetalol NNP - B-PERSON
hydrochloride VERB - O
1.0 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
was VERB - O
combined VERB - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose VERB - O
injection NOUN - O
with ADP - O
equal ADJ - O
volumes NOUN - O
of ADP - O
each DET - O
of ADP - O
the DET - O
following VERB - O
drugs NOUN - O
: PUNCT - O

Labetalol NNP - B-PERSON
hydrochloride NOUN - O
1.0 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
and CCONJ - O
dobutamine VERB - O
2.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
( PUNCT - O
as ADP - O
the DET - O
hydrochloride NOUN - O
salt NOUN - O
) PUNCT - O
, PUNCT - O
dopamine NOUN - O
hydrochloride NOUN - O
1.6 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
, PUNCT - O
morphine NOUN - O
sulfate NOUN - O
0.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
mL PROPN - O
, PUNCT - O
nitroglycerin ADV - O
0.2 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
mL NNP - I-QUANTITY
, PUNCT - O
or CCONJ - O
ranitidine VERB - O
0.6 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
mL NNP - I-QUANTITY
( PUNCT - O
as ADP - O
the DET - O
hydrochloride NOUN - O
salt NOUN - O
) PUNCT - O
in ADP - O
5 CD - B-PERCENT
% NN - I-PERCENT
dextrose NOUN - O
injection NOUN - O
were VERB - O
stable ADJ - O
and CCONJ - O
compatible ADJ - O
for ADP - O
up IN - B-TIME
to TO - I-TIME
four CD - I-TIME
hours NNS - I-TIME
at ADP - O
20 CD - B-QUANTITY
- SYM - I-QUANTITY
25 CD - I-QUANTITY
degrees NNS - I-QUANTITY
C NOUN - O
during ADP - O
simulated ADJ - O
Y NOUN - O
- PUNCT - O
site NOUN - O
injection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Labetalol NNP - B-PERSON
hydrochloride NOUN - O
injection NOUN - O
was VERB - O
added VERB - O
to ADP - O
11 CD - B-CARDINAL
LVPs NOUN - O
at ADP - O
concentrations NOUN - O
of ADP - O
1.25 CD - B-CARDINAL
, PUNCT - O
2.50 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
3.75 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
ml UH - I-QUANTITY
. PUNCT - O

Labetalol NNP - B-PERSON
hydrochloride NOUN - O
was VERB - O
stable ADJ - O
for ADP - O
72 CD - B-TIME
hours NNS - I-TIME
at ADP - O
4 CD - B-QUANTITY
degrees NNS - I-QUANTITY
C NN - I-QUANTITY
and CC - I-QUANTITY
25 CD - B-QUANTITY
degrees NNS - I-QUANTITY
C NOUN - O
in ADP - O
all DET - O
i.v PRON - O
. PUNCT - O

-DOCSTART- -X- - O

Specifically ADV - O
, PUNCT - O
the DET - O
method NOUN - O
involves VERB - O
administering VERB - O
to ADP - O
a DET - O
patient NOUN - O
a DET - O
composition NOUN - O
comprising VERB - O
butalbital NOUN - O
, PUNCT - O
acetaminophen NOUN - O
and CCONJ - O
caffeine NOUN - O
in ADP - O
the DET - O
gelcap NOUN - O
dosage NOUN - O
form NOUN - O
, PUNCT - O
to PART - O
treat VERB - O
and/or CC - B-NORP
alleviate VERB - O
the DET - O
occurrence NOUN - O
or CCONJ - O
negative ADJ - O
effects NOUN - O
of ADP - O
various ADJ - O
forms NOUN - O
of ADP - O
headaches NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CRYSTALLINE NNP - B-ORG
FORMS NNP - I-ORG
OF IN - I-ORG
FEXOFENADINE NNP - I-ORG
HYDROCHLORIDE NNP - I-ORG
AND CC - I-ORG
PROCESSES NOUN - O
FOR ADP - O
THEIR ADJ - O
PREPARATION NOUN - O

-DOCSTART- -X- - O

POLYMORPHS NOUN - O
OF ADP - O
FEXOFENADINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
AND CCONJ - O
PROCESS NOUN - O
FOR ADP - O
THEIR ADJ - O
PREPARATION NOUN - O

-DOCSTART- -X- - O

CRYSTALLINE NNP - B-ORG
FORMS NNP - I-ORG
OF IN - I-ORG
FEXOFENADINE NNP - I-ORG
HYDROCHLORIDE NNP - I-ORG
AND CC - I-ORG
PROCESSES NOUN - O
FOR ADP - O
THEIR ADJ - O
PREPARATION NOUN - O

-DOCSTART- -X- - O

POLYMORPHS NOUN - O
OF ADP - O
FEXOFENADINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

INDUSTRIAL PROPN - O
PROCESS NOUN - O
OF ADP - O
FEXOFENADINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

POLYMORPHS NOUN - O
OF ADP - O
FEXOFENADINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE

-DOCSTART- -X- - O

METHOD NOUN - O
FOR ADP - O
PRODUCING VERB - O
NON PROPN - O
- PUNCT - O
HYDRATED PROPN - O
FEXOFENADINE NNP - B-MEDICINE
HYDROCHLORIDE NNP - I-MEDICINE
AND CCONJ - O
A DET - O
NOVEL ADJ - O
CRYSTALLINE NOUN - O
FORM NOUN - O
OBTAINED NOUN - O
THEREBY PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
acyclovir JJ - B-MEDICINE
prophylaxis NOUN - O
against ADP - O
varicella NOUN - O
zoster NOUN - O
virus NOUN - O
disease NOUN - O
after ADP - O
allogeneic ADJ - O
hematopoietic ADJ - O
cell NOUN - O
transplantation NOUN - O
: PUNCT - O
A DET - O
systematic ADJ - O
review NOUN - O
and CCONJ - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AbstractIntravenous NNP - B-ORG
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
acyclovir NN - B-MEDICINE
is VERB - O
commonly ADV - O
administered VERB - O
medication NOUN - O
for ADP - O
viral ADJ - O
infection NOUN - O
but CCONJ - O
is VERB - O
well ADV - O
known ADJ - O
for ADP - O
its ADJ - O
nephrotoxicity NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
there ADV - O
was VERB - O
no DET - O
study NOUN - O
for ADP - O
incidence NOUN - O
, PUNCT - O
risk NOUN - O
factors NOUN - O
, PUNCT - O
and CCONJ - O
clinical ADJ - O
outcomes NOUN - O
of ADP - O
acute ADJ - O
kidney NOUN - O
injury NOUN - O
( PUNCT - O
AKI NNP - B-ORG
) PUNCT - O
associated VERB - O
with ADP - O
IV NNP - B-ORG
acyclovir NN - B-MEDICINE
administration NOUN - O
. PUNCT - O

We PRON - O
retrospectively ADV - O
reviewed VERB - O
the DET - O
medical ADJ - O
records NOUN - O
of ADP - O
287 CD - B-CARDINAL
patients NOUN - O
who NOUN - O
were VERB - O
medicated VERB - O
IV NNP - B-ORG
acyclovir RB - B-MEDICINE
from ADP - O
January NNP - B-DATE
2008 CD - I-DATE
to ADP - O
May NNP - B-DATE
2013 CD - I-DATE
in ADP - O
Gyeongsang NNP - B-ORG
National NNP - I-ORG
University NNP - I-ORG
Hospital NNP - I-ORG
. PUNCT - O

Multivariate ADJ - O
analysis NOUN - O
also ADV - O
presented VERB - O
that ADP - O
presence NOUN - O
of ADP - O
diabetes NOUN - O
, PUNCT - O
concomitant NOUN - O
NSAIDs PROPN - O
, PUNCT - O
and CCONJ - O
vancomycin ADJ - O
use NOUN - O
was VERB - O
independent ADJ - O
risk NOUN - O
factor NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
associated VERB - O
with ADP - O
AKI NNP - B-ORG
( PUNCT - O

AKI NNP - B-ORG
is VERB - O
relatively ADV - O
common ADJ - O
in ADP - O
patients NOUN - O
administrating VERB - O
acyclovir JJ - B-MEDICINE
injection NOUN - O
. PUNCT - O

Physicians NNS - B-NORP
should VERB - O
attempt VERB - O
to PART - O
prevent VERB - O
, PUNCT - O
detect VERB - O
, PUNCT - O
and CCONJ - O
manage VERB - O
acyclovir DT - B-MEDICINE
associated VERB - O
AKI NNP - B-ORG
in ADP - O
patients NOUN - O
prescribing VERB - O
acyclovir RB - B-MEDICINE
due ADP - O
to ADP - O
possible ADJ - O
association NOUN - O
of ADP - O
poor ADJ - O
prognosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CASE NNP - B-ORG
PRESENTATION::We NNP - I-ORG
report VERB - O
a DET - O
case NOUN - O
of ADP - O
bulky ADJ - O
, PUNCT - O
obstructive ADJ - O
supraglottic ADJ - O
and CCONJ - O
glottic ADJ - O
herpes NOUN - O
virus NOUN - O
laryngitis NOUN - O
that ADJ - O
presented VERB - O
with ADP - O
dysphonia NOUN - O
, PUNCT - O
dysphagia NOUN - O
, PUNCT - O
and CCONJ - O
airway NOUN - O
complaints NOUN - O
resistant ADJ - O
to PART - O
acyclovir VB - B-MEDICINE
analogues NOUN - O
that ADJ - O
was VERB - O
treated VERB - O
effectively ADV - O
with ADP - O
intralesional ADJ - O
cidofovir NOUN - O
injection NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Twenty CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
37.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
received VERB - O
acyclovir NN - B-MEDICINE
for ADP - O
the DET - O
entire ADJ - O
postoperative ADJ - O
period NOUN - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
significant ADJ - O
benefit NOUN - O
of ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
acyclovir NN - B-MEDICINE
on ADP - O
visual ADJ - O
acuity NOUN - O
( PUNCT - O
p=0.2132 NOUN - O
) PUNCT - O
or CCONJ - O
graft NOUN - O
survival NOUN - O
( PUNCT - O
p=0.241 PROPN - O
) PUNCT - O
. PUNCT - O

Prophylactic ADJ - O
postoperative NOUN - O
oral ADJ - O
acyclovir NN - B-MEDICINE
did VERB - O
not ADV - O
improve VERB - O
outcomes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acyclovir NNP - B-ORG
has VERB - O
been VERB - O
reported VERB - O
as ADP - O
a DET - O
potential ADJ - O
therapy NOUN - O
for ADP - O
pityriasis ADJ - O
rosea NOUN - O
( PUNCT - O
PR NOUN - O
) PUNCT - O
in ADP - O
several ADJ - O
clinical ADJ - O
trials NOUN - O
on ADP - O
the DET - O
basis NOUN - O
of ADP - O
evidence NOUN - O
of ADP - O
the DET - O
involvement NOUN - O
of ADP - O
human ADJ - O
herpes NOUN - O
viruses NOUN - O
6 CD - B-CARDINAL
and CCONJ - O
7.We CD - B-ORDINAL
evaluated VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
for ADP - O
abating VERB - O
PR NOUN - O
skin NOUN - O
lesions NOUN - O
within ADP - O
a DET - O
fixed VERB - O
period NOUN - O
. PUNCT - O

We PRON - O
searched VERB - O
4 CD - B-CARDINAL
databases NOUN - O
for ADP - O
clinical ADJ - O
trials NOUN - O
that ADJ - O
used VERB - O
oral ADJ - O
acyclovir NN - B-MEDICINE
to PART - O
treat VERB - O
PR NN - B-ORG
and CCONJ - O
performed VERB - O
systematic ADJ - O
review NOUN - O
and CCONJ - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
to PART - O
determine VERB - O
oral ADJ - O
acyclovir NN - B-MEDICINE
's PART - O
effect NOUN - O
on ADP - O
skin NOUN - O
lesions NOUN - O
on ADP - O
the DT - B-DATE
14th JJ - I-DATE
day NN - I-DATE
after ADP - O
commencing VERB - O
treatment NOUN - O
. PUNCT - O

Five CD - B-CARDINAL
clinical ADJ - O
trials NOUN - O
including VERB - O
four CD - B-CARDINAL
randomized VERB - O
controlled VERB - O
trials NOUN - O
were VERB - O
identified VERB - O
that ADP - O
compared VERB - O
the DET - O
effects NOUN - O
of ADP - O
oral ADJ - O
acyclovir NN - B-MEDICINE
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
133 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
nonacyclovir PROPN - O
( PUNCT - O
n CCONJ - O
  SPACE - O
= PUNCT - O
  SPACE - O
140 CD - B-CARDINAL
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
PR PROPN - O
. PUNCT - O

Oral ADJ - O
acyclovir NN - B-MEDICINE
significantly ADV - O
reduced VERB - O
erythema NOUN - O
( PUNCT - O
odds NOUN - O
ratio NOUN - O
[ PUNCT - O
OR CCONJ - O
] PUNCT - O
11.30 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
  SPACE - O
= SYM - O
  SPACE - O
5.70 CD - B-CARDINAL
- SYM - O
22.41 NUM - O
; PUNCT - O
p DET - O
  SPACE - O
< X - O
  SPACE - O
.01 PUNCT - O
) PUNCT - O
and CCONJ - O
limited ADJ - O
lesion NOUN - O
formation NOUN - O
( PUNCT - O
OR CCONJ - O
8.67 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
  SPACE - O
= SYM - O
  SPACE - O
3.29 CD - B-CARDINAL
- SYM - O
22.81 NUM - O
; PUNCT - O
p DET - O
  SPACE - O
< X - O
  SPACE - O
.01 PUNCT - O
) PUNCT - O
compared VERB - O
with ADP - O
nonacyclovir ADJ - O
treatment NOUN - O
on ADP - O
the DT - B-DATE
14th JJ - I-DATE
day NN - I-DATE
. PUNCT - O

These DET - O
results NOUN - O
were VERB - O
in ADP - O
agreement NOUN - O
with ADP - O
the DET - O
results NOUN - O
of ADP - O
subgroup NOUN - O
analysis NOUN - O
of ADP - O
only ADJ - O
high ADJ - O
- PUNCT - O
dose NOUN - O
oral ADJ - O
acyclovir NN - B-MEDICINE
treatment NOUN - O
and CCONJ - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
. PUNCT - O

Oral ADJ - O
acyclovir NN - B-MEDICINE
may VERB - O
be VERB - O
a DET - O
relatively ADV - O
safe ADJ - O
and CCONJ - O
effective ADJ - O
treatment NOUN - O
in ADP - O
the DET - O
early ADJ - O
course NOUN - O
of ADP - O
PR NOUN - O
, PUNCT - O
and CCONJ - O
patients NOUN - O
with ADP - O
PR PROPN - O
may VERB - O
achieve VERB - O
faster ADJ - O
symptoms NOUN - O
control NOUN - O
with ADP - O
acyclovir NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
literature NOUN - O
search NOUN - O
was VERB - O
performed VERB - O
( PUNCT - O
PubMed NNP - B-ORG
and CCONJ - O
the DT - B-ORG
WoS NNP - I-ORG
Core NNP - I-ORG
Collection NNP - I-ORG
) PUNCT - O
using VERB - O
keywords NOUN - O
related VERB - O
to ADP - O
: PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
targeted VERB - O
approved VERB - O
/ SYM - O
developmental ADJ - O
antivirals NOUN - O
( PUNCT - O
acyclovir RB - B-MEDICINE
, PUNCT - O
artesunate VERB - O
, PUNCT - O
brincidofovir NOUN - O
, PUNCT - O
cidofovir NOUN - O
, PUNCT - O
cyclopropavir PROPN - O
( PUNCT - O
filociclovir NOUN - O
) PUNCT - O
, PUNCT - O
foscarnet NOUN - O
, PUNCT - O
ganciclovir NOUN - O
, PUNCT - O
letermovir ADJ - O
, PUNCT - O
and CCONJ - O
maribavir NOUN - O
) PUNCT - O
; PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
pathogenic ADJ - O
dsDNA ADJ - O
viruses NOUN - O
; PUNCT - O

Activity NOUN - O
against ADP - O
≤3 PROPN - O
viruses NOUN - O
was VERB - O
documented VERB - O
for ADP - O
maribavir NOUN - O
( PUNCT - O
cytomegalovirus NOUN - O
, PUNCT - O
Epstein NNP - B-PERSON
- HYPH - I-PERSON
Barr NNP - I-PERSON
virus NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
letermovir ADJ - O
, PUNCT - O
while ADP - O
activity NOUN - O
against ADP - O
  SPACE - O
> X - O
  SPACE - O
3 CD - B-CARDINAL
viruses NOUN - O
was VERB - O
shown VERB - O
for ADP - O
ganciclovir NOUN - O
, PUNCT - O
cidofovir NOUN - O
, PUNCT - O
acyclovir NN - B-MEDICINE
, PUNCT - O
foscarnet NOUN - O
, PUNCT - O
cyclopropavir NOUN - O
, PUNCT - O
artesunate VERB - O
, PUNCT - O
and CCONJ - O
brincidofovir NOUN - O
. PUNCT - O

The DET - O
next ADJ - O
most ADV - O
potent ADJ - O
agents NOUN - O
included VERB - O
cidofovir NOUN - O
, PUNCT - O
ganciclovir NOUN - O
, PUNCT - O
foscarnet NOUN - O
, PUNCT - O
and CCONJ - O
acyclovir VBP - B-MEDICINE
with ADP - O
EC50 PROPN - O
values NOUN - O
between ADP - O
0.1 NUM - O
  SPACE - O
μM NNP - B-ORG
and CCONJ - O
> X - O
10 CD - B-CARDINAL
  SPACE - O
μM NOUN - O
for ADP - O
cytomegalovirus NOUN - O
, PUNCT - O
herpes VERB - O
simplex ADJ - O
virus NOUN - O
, PUNCT - O
and CCONJ - O
adenovirus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Soluplus NOUN - O
micelles NOUN - O
for ADP - O
acyclovir DT - B-MEDICINE
ocular ADJ - O
delivery NOUN - O
: PUNCT - O
Formulation NOUN - O
and CCONJ - O
cornea NOUN - O
and CCONJ - O
sclera ADJ - O
permeability NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aims VERB - O
to PART - O
examine VERB - O
the DET - O
combined ADJ - O
efficacy NOUN - O
of ADP - O
honey NOUN - O
with ADP - O
acyclovir JJ - B-MEDICINE
suspension NOUN - O
compared VERB - O
to PART - O
acyclovir VB - B-MEDICINE
alone ADV - O
for ADP - O
treating VERB - O
HSGS NOUN - O
in ADP - O
young ADJ - O
children NOUN - O
. PUNCT - O

One CD - B-CARDINAL
hundred CD - I-CARDINAL
children NOUN - O
aged VERB - O
2 CD - B-DATE
- SYM - I-DATE
8 CD - I-DATE
  _SP - I-DATE
years NNS - I-DATE
with ADP - O
HSGS NNS - B-ORG
were VERB - O
randomly ADV - O
classified VERB - O
into ADP - O
2 CD - B-CARDINAL
groups NOUN - O
; PUNCT - O
study NOUN - O
group NOUN - O
: PUNCT - O
treated VERB - O
with ADP - O
honey NOUN - O
plus CCONJ - O
oral ADJ - O
acyclovir NN - B-MEDICINE
and CCONJ - O
control NOUN - O
group NOUN - O
: PUNCT - O
treated VERB - O
with ADP - O
oral ADJ - O
acyclovir NN - B-MEDICINE
alone ADJ - O
. PUNCT - O

Children NOUN - O
receiving VERB - O
honey NOUN - O
plus CCONJ - O
acyclovir NN - B-MEDICINE
( PUNCT - O
i.e. X - O
study NOUN - O
group NOUN - O
) PUNCT - O
had VERB - O
significantly ADV - O
earlier ADJ - O
disappearance NOUN - O
of ADP - O
herpetic ADJ - O
oral ADJ - O
lesions NOUN - O
; PUNCT - O
median NOUN - O
3 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
vs. CCONJ - O
6 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
in ADP - O
control NOUN - O
group NOUN - O
( PUNCT - O
P NOUN - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.022 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
drooling VERB - O
; PUNCT - O
2 LS - B-DATE
  _SP - I-DATE
days NNS - I-DATE
vs. CCONJ - O
4 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE

The DET - O
combined ADJ - O
use NOUN - O
of ADP - O
honey NOUN - O
with ADP - O
oral ADJ - O
acyclovir NN - B-MEDICINE
can VERB - O
produce VERB - O
favorable ADJ - O
outcome NOUN - O
than ADP - O
acyclovir VB - B-MEDICINE
alone ADV - O
in ADP - O
children NOUN - O
with ADP - O
Primary ADJ - O
herpetic ADJ - O
gingivostomatitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
acyclovir JJ - B-MEDICINE
effective ADJ - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
varicella NOUN - O
in ADP - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Quantitative ADJ - O
detection NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
by ADP - O
surface NOUN - O
enhanced VERB - O
Raman NNP - B-GPE
spectroscopy NOUN - O
using VERB - O
a DET - O
portable ADJ - O
Raman JJ - B-ORG
spectrometer NOUN - O
coupled VERB - O
with ADP - O
multivariate ADJ - O
data NOUN - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Report NOUN - O
of ADP - O
an DET - O
atypical ADJ - O
case NOUN - O
in ADP - O
an DET - O
immunocompetent ADJ - O
patient NOUN - O
treated VERB - O
with ADP - O
oral ADJ - O
valacyclovir NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
acyclovir NN - B-MEDICINE
, PUNCT - O
valacyclovir NOUN - O
, PUNCT - O
and CCONJ - O
famciclovir NOUN - O
are VERB - O
the DET - O
mainstay NOUN - O
of ADP - O
treatment NOUN - O
for ADP - O
HSV- NNP - B-ORG
and CCONJ - O
VZV PROPN - O
- PUNCT - O
induced VERB - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Empirical ADJ - O
antibiotic ADJ - O
and CCONJ - O
acyclovir JJ - B-MEDICINE

-DOCSTART- -X- - O

Drug NOUN - O
repurposing NOUN - O
: PUNCT - O
omeprazole NOUN - O
increases VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
against ADP - O
herpes NOUN - O
simplex ADJ - O
virus NOUN - O
type NOUN - O
1 CD - B-CARDINAL
and CCONJ - O
2 CD - B-CARDINAL

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
developed VERB - O
and CCONJ - O
validated VERB - O
a DET - O
simple ADJ - O
, PUNCT - O
sensitive ADJ - O
and CCONJ - O
robust ADJ - O
LC NNP - B-ORG
- HYPH - I-ORG
MS NNP - I-ORG
/ SYM - I-ORG
MS NNP - I-ORG
method NOUN - O
for ADP - O
measuring VERB - O
the DET - O
prodrug VERB - O
valacyclovir X - O
( PUNCT - O
VACV PROPN - O
) PUNCT - O
and CCONJ - O
its ADJ - O
metabolite NOUN - O
acyclovir NN - B-MEDICINE
( PUNCT - O
ACV NNP - B-ORG
) PUNCT - O
in ADP - O
mouse NOUN - O
and CCONJ - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
sensitive ADJ - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
method NOUN - O
for ADP - O
the DET - O
quantification NOUN - O
of ADP - O
valacyclovir NOUN - O
and CCONJ - O
its ADJ - O
metabolite NOUN - O
acyclovir NN - B-MEDICINE
in ADP - O
mouse NOUN - O
and CCONJ - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
methodology NOUN - O
is VERB - O
applied VERB - O
to ADP - O
MP PROPN - O
of ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
a DET - O
successful ADJ - O
drug NOUN - O
against ADP - O
herpes NOUN - O
simplex ADJ - O
virus NOUN - O
infection NOUN - O
but CCONJ - O
with ADP - O
poor ADJ - O
pharmacokinetics NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
a DET - O
result NOUN - O
of ADP - O
combined ADJ - O
therapies NOUN - O
with ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
steroid NOUN - O
, PUNCT - O
and CCONJ - O
antithrombotic ADJ - O
agents NOUN - O
, PUNCT - O
neurological ADJ - O
symptoms NOUN - O
markedly ADV - O
improved VERB - O
in ADP - O
3 CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
whereas ADP - O
1 CD - B-CARDINAL
patient NOUN - O
was VERB - O
left VERB - O
with ADP - O
moderate ADJ - O
hemiplegia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antiviral ADJ - O
treatment NOUN - O
with ADP - O
intravenous ADJ - O
acyclovir NN - B-MEDICINE
can VERB - O
be VERB - O
effective ADJ - O
if ADP - O
initiated VERB - O
in ADP - O
a DET - O
timely ADJ - O
manner NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
comorbidities NOUN - O
and CCONJ - O
complications NOUN - O
frequently ADV - O
result VERB - O
in ADP - O
high ADJ - O
mortality NOUN - O
, PUNCT - O
especially ADV - O
in ADP - O
immunocompromised ADJ - O
hosts NOUN - O
as ADP - O
exemplified VERB - O
in ADP - O
this DET - O
case NOUN - O
presentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valacyclovir NNP - B-ORG
Neurotoxicity NNP - I-ORG
and CC - I-ORG
Nephrotoxicity NNP - I-ORG
in ADP - O
an DET - O
Elderly ADJ - O
Patient NOUN - O
Complicated VERB - O
by ADP - O
Hyponatremia NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
work NOUN - O
aims VERB - O
to PART - O
develop VERB - O
a DET - O
new ADJ - O
topical ADJ - O
formulation NOUN - O
for ADP - O
the DET - O
acyclovir JJ - B-MEDICINE
delivery NOUN - O
. PUNCT - O

The DET - O
acyclovir NNS - B-MEDICINE
loaded VERB - O
chitosan ADJ - O
NS PROPN - O
appeared VERB - O
with ADP - O
a DET - O
spherical ADJ - O
shape NOUN - O
, PUNCT - O
a DET - O
size NOUN - O
of ADP - O
about RB - B-CARDINAL
200 CD - I-CARDINAL
nm NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
negative ADJ - O
zeta NOUN - O
potential NOUN - O
of ADP - O
about RB - B-CARDINAL
40.0 CD - I-CARDINAL
mV. NOUN - O
The DET - O
loading NOUN - O
capacity NOUN - O
of ADP - O
the DET - O
drug NOUN - O
was VERB - O
about RB - B-PERCENT
8.5 CD - I-PERCENT
% NN - I-PERCENT
. PUNCT - O

In ADP - O
vitro NOUN - O
release NOUN - O
demonstrated VERB - O
that ADP - O
the DET - O
percentage NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
delivered VERB - O
from ADP - O
the DET - O
nanospheres NOUN - O
was VERB - O
approximately RB - B-PERCENT
30 CD - I-PERCENT
% NN - I-PERCENT
after ADP - O
six CD - B-TIME
hours NNS - I-TIME
. PUNCT - O

The DET - O
in X - O
vitro X - O
skin NOUN - O
permeation NOUN - O
studies NOUN - O
confirmed VERB - O
an DET - O
improved VERB - O
amount NOUN - O
of ADP - O
permeated ADJ - O
acyclovir NN - B-MEDICINE
. PUNCT - O

The DET - O
acyclovir JJ - B-MEDICINE
- ADJ - O
NS NOUN - O
complex NOUN - O
displayed VERB - O
a DET - O
higher ADJ - O
antiviral ADJ - O
activity NOUN - O
than ADP - O
that DET - O
of ADP - O
free ADJ - O
acyclovir NN - B-MEDICINE
against ADP - O
both CCONJ - O
the DET - O
HSV-1 NNP - B-PRODUCT
and CCONJ - O
the DET - O
HSV-2 PROPN - O
strain NOUN - O
. PUNCT - O

The DET - O
acyclovir RB - B-MEDICINE
- PUNCT - O
loaded VERB - O
NS NNP - B-ORG
showed VERB - O
no DET - O
anti ADJ - O
- ADJ - O
proliferative ADJ - O
activity NOUN - O
and CCONJ - O
no DET - O
signs NOUN - O
of ADP - O
cytotoxicity NOUN - O
induced VERB - O
by ADP - O
NS NNP - B-ORG
was VERB - O
detected VERB - O
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
also ADV - O
inhibited VERB - O
HSV-2 PROPN - O
attachment NOUN - O
and CCONJ - O
penetration NOUN - O
to ADP - O
the DET - O
Vero PROPN - O
cells NOUN - O
with ADP - O
an DET - O
IC50 PROPN - O
= SYM - O
46.55 CD - B-CARDINAL
± NUM - O
1.25 NUM - O
µg NOUN - O
/ SYM - O
mL PROPN - O
and CCONJ - O
54.94 CD - B-CARDINAL
± NUM - O
2.52 CD - B-CARDINAL
µg ADP - O
/ SYM - O
mL PROPN - O
respectively ADV - O
, PUNCT - O
which ADJ - O
were VERB - O
significantly ADV - O
lower ADJ - O
than ADP - O
acyclovir VB - B-MEDICINE
. PUNCT - O

However ADV - O
, PUNCT - O
acyclovir NN - B-MEDICINE
is VERB - O
more ADV - O
potent ADJ - O
in ADP - O
post ADJ - O
- ADJ - O
infection ADJ - O
assay NOUN - O
with ADP - O
an DET - O
IC50 PROPN - O
= SYM - O
0.065 CD - B-CARDINAL
± PUNCT - O
0.01 CD - B-CARDINAL
µg NOUN - O
/ SYM - O
mL PROPN - O
whereas ADP - O
gel NOUN - O
formulation NOUN - O
showed VERB - O
an DET - O
IC50 PROPN - O
= SYM - O
469.05 CD - B-CARDINAL
± NUM - O
16.65 CD - B-CARDINAL
µg ADP - O
/ SYM - O
mL PROPN - O
under ADP - O
similar ADJ - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
diagnosis NOUN - O
of ADP - O
herpes NOUN - O
zoster NOUN - O
was VERB - O
made VERB - O
, PUNCT - O
and CCONJ - O
she PRON - O
was VERB - O
treated VERB - O
with ADP - O
acyclovir NN - B-MEDICINE
with ADP - O
complete ADJ - O
skin NOUN - O
recovery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Her ADJ - O
respiratory ADJ - O
condition NOUN - O
improved VERB - O
immediately ADV - O
after ADP - O
initiation NOUN - O
of ADP - O
acyclovir JJ - B-MEDICINE
monotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

All DET - O
patients NOUN - O
were VERB - O
successfully ADV - O
treated VERB - O
with ADP - O
oral ADJ - O
acyclovir NN - B-MEDICINE
and CCONJ - O
topical ADJ - O
steroids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Charts NOUN - O
of ADP - O
subjects NOUN - O
with ADP - O
ICD9/10 NNP - B-ORG
codes NOUN - O
related VERB - O
to ADP - O
VZV NNP - B-ORG
/ SYM - I-ORG
Herpes NNP - I-ORG
infections NOUN - O
; PUNCT - O
positive ADJ - O
VZV NNP - B-ORG
PCR NNP - I-ORG
, PUNCT - O
DFA PROPN - O
or CCONJ - O
cultures NOUN - O
; PUNCT - O
and CCONJ - O
recipients NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
valacyclovir ADJ - O
or CCONJ - O
famciclovir NOUN - O
were VERB - O
manually ADV - O
reviewed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Prophylactic ADJ - O
strategies NOUN - O
included VERB - O
use NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
valacyclovir NOUN - O
, PUNCT - O
ganciclovir NOUN - O
, PUNCT - O
maribavir NOUN - O
, PUNCT - O
brincidofovir NOUN - O
, PUNCT - O
and CCONJ - O
letermovir ADJ - O
compared VERB - O
with ADP - O
placebo NOUN - O
or CCONJ - O
a DET - O
comparator NOUN - O
antiviral ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Acyclovir NNP - B-MEDICINE
is VERB - O
commonly ADV - O
used VERB - O
to PART - O
prevent VERB - O
and CCONJ - O
treat VERB - O
herpes NOUN - O
simplex ADJ - O
virus NOUN - O
( PUNCT - O
HSV NNP - B-ORG
) PUNCT - O
reactivation NOUN - O
after ADP - O
hematopoietic ADJ - O
cell NOUN - O
transplant NOUN - O
( PUNCT - O
HCT NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
only ADV - O
few ADJ - O
reports NOUN - O
have VERB - O
been VERB - O
published VERB - O
on ADP - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV NNP - B-ORG
in ADP - O
HCT NNP - B-ORG
recipients NOUN - O
. PUNCT - O

We PRON - O
reviewed VERB - O
the DET - O
medical ADJ - O
records NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
a DET - O
microbiologic ADJ - O
diagnosis NOUN - O
of ADP - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV NN - B-ORG
by ADP - O
plaque NOUN - O
reduction NOUN - O
test NOUN - O
who NOUN - O
received VERB - O
an DET - O
HCT NN - B-ORG
from ADP - O
2002 CD - B-DATE
through ADP - O
2014 CD - B-DATE
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
4 CD - B-CARDINAL
028 CD - I-CARDINAL
HCTs NOUN - O
were VERB - O
performed VERB - O
during ADP - O
the DET - O
study NOUN - O
period NOUN - O
, PUNCT - O
and CCONJ - O
18 CD - B-CARDINAL
of ADP - O
the DET - O
recipients NOUN - O
met VERB - O
the DET - O
diagnostic ADJ - O
criteria NOUN - O
for ADP - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV NNP - B-ORG
. PUNCT - O

In ADP - O
conclusion NOUN - O
, PUNCT - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV NNP - B-ORG
infection NOUN - O
is VERB - O
more ADV - O
likely ADJ - O
during ADP - O
the DET - O
period NOUN - O
of ADP - O
profound ADJ - O
deficit NOUN - O
in ADP - O
T PROPN - O
- PUNCT - O
cell NOUN - O
- PUNCT - O
mediated VERB - O
immunity NOUN - O
and CCONJ - O
is VERB - O
associated VERB - O
with ADP - O
significant ADJ - O
morbidities NOUN - O
. PUNCT - O

Higher JJR - B-ORG
doses NOUN - O
of ADP - O
acyclovir JJ - B-MEDICINE
prophylaxis NOUN - O
might VERB - O
be VERB - O
needed VERB - O
for ADP - O
patients NOUN - O
with ADP - O
history NOUN - O
of ADP - O
HSV NNP - B-ORG
during ADP - O
pre ADJ - O
- ADJ - O
engraftment ADJ - O
or CCONJ - O
GVHD ADJ - O
treatment NOUN - O
. PUNCT - O

In ADP - O
patients NOUN - O
who NOUN - O
do VERB - O
not ADV - O
respond VERB - O
or CCONJ - O
progress NOUN - O
after ADP - O
1 CD - B-DATE
week NN - I-DATE
of ADP - O
acyclovir NN - B-MEDICINE
therapy NOUN - O
, PUNCT - O
testing VERB - O
for ADP - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
HSV NNP - B-ORG
, PUNCT - O
and CCONJ - O
early ADJ - O
switch NOUN - O
to ADP - O
an DET - O
alternative ADJ - O
antiviral NOUN - O
should VERB - O
be VERB - O
considered VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Early ADJ - O
treatment NOUN - O
with ADP - O
the DET - O
anti ADJ - O
- ADJ - O
viral ADJ - O
drug NOUN - O
, PUNCT - O
acyclovir NN - B-MEDICINE
, PUNCT - O
is VERB - O
life NOUN - O
- PUNCT - O
saving NOUN - O
. PUNCT - O

There ADV - O
is VERB - O
thus ADV - O
a DET - O
growing VERB - O
consensus NOUN - O
in ADP - O
the DET - O
field NOUN - O
to PART - O
initiate VERB - O
empirical ADJ - O
treatment NOUN - O
with ADP - O
acyclovir DT - B-MEDICINE
once ADV - O
suspicion NOUN - O
of ADP - O
HSV NNP - B-ORG
hepatitis NOUN - O
is VERB - O
raised VERB - O
even ADV - O
before ADP - O
reaching VERB - O
a DET - O
conclusive ADJ - O
diagnosis NOUN - O
. PUNCT - O

Presentation NOUN - O
of ADP - O
case NOUN - O
: PUNCT - O
We PRON - O
present VERB - O
clinical ADJ - O
evidence NOUN - O
on ADP - O
the DET - O
benefit NOUN - O
of ADP - O
starting VERB - O
empirical ADJ - O
acyclovir JJ - B-MEDICINE
treatment NOUN - O
on ADP - O
the DET - O
outcome NOUN - O
of ADP - O
patients NOUN - O
suffering VERB - O
from ADP - O
HSV NNP - B-ORG
hepatitis NOUN - O
. PUNCT - O

In ADP - O
the DET - O
second JJ - B-ORDINAL
case NOUN - O
, PUNCT - O
there ADV - O
was VERB - O
enough ADJ - O
suspicion NOUN - O
of ADP - O
HSV NNP - B-ORG
hepatitis NOUN - O
to PART - O
start VERB - O
early ADJ - O
empirical ADJ - O
acyclovir NN - B-MEDICINE
therapy NOUN - O
. PUNCT - O

Due ADP - O
to ADP - O
the DET - O
frequent ADJ - O
delay NOUN - O
in ADP - O
HSV NNP - B-ORG
diagnosis NOUN - O
and CCONJ - O
the DET - O
safety NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
we PRON - O
recommend VERB - O
empirically ADV - O
administering ADJ - O
acyclovir NN - B-MEDICINE
in ADP - O
patients NOUN - O
suspected VERB - O
of ADP - O
HSV NNP - B-ORG
hepatitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Routine NOUN - O
prophylaxis NOUN - O
with ADP - O
acyclovir NN - B-MEDICINE
is VERB - O
recommended VERB - O
during ADP - O
periods NOUN - O
of ADP - O
immunosuppression NOUN - O
. PUNCT - O

This DET - O
was VERB - O
a DET - O
retrospective ADJ - O
review NOUN - O
of ADP - O
30 CD - B-CARDINAL
hematopoietic ADJ - O
cell NOUN - O
transplant NOUN - O
( PUNCT - O
HCT NNP - B-ORG
) PUNCT - O
recipients NOUN - O
between ADP - O
8/2010 NNPS - B-PERSON
and CCONJ - O
8/2015 NUM - O
who NOUN - O
received VERB - O
BCV NNP - B-ORG
doses VERB - O
not ADV - O
exceeding VERB - O
200 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
week NOUN - O
for ADP - O
adults NOUN - O
/ SYM - O
adolescents NOUN - O
and CCONJ - O
4 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
week NOUN - O
for ADP - O
pediatric NOUN - O
( PUNCT - O
< X - O
12 CD - B-CARDINAL
  SPACE - O
years NOUN - O
) PUNCT - O
patients NOUN - O
, PUNCT - O
for ADP - O
≥14 NOUN - O
  SPACE - O
days NOUN - O
BCV PROPN - O
without ADP - O
concomitant ADJ - O
acyclovir NN - B-MEDICINE
under ADP - O
clinical ADJ - O
trials NOUN - O
or CCONJ - O
single ADJ - O
patient ADJ - O
use NOUN - O
. PUNCT - O

One CD - B-CARDINAL
patient NOUN - O
was VERB - O
treated VERB - O
for ADP - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV NNP - B-ORG
and CCONJ - O
one CD - B-CARDINAL
for ADP - O
disseminated ADJ - O
VZV PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
diagnosis NOUN - O
was VERB - O
confirmed VERB - O
with ADP - O
PCR PROPN - O
and CCONJ - O
he PRON - O
had VERB - O
remarkable ADJ - O
clinical ADJ - O
improvement NOUN - O
with ADP - O
acyclovir JJ - B-MEDICINE
and CCONJ - O
supportive ADJ - O
medical ADJ - O
management NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Continuous ADJ - O
renal ADJ - O
replacement NOUN - O
therapy NOUN - O
was VERB - O
applied VERB - O
, PUNCT - O
and CCONJ - O
the DET - O
patient NOUN - O
was VERB - O
treated VERB - O
with ADP - O
acyclovir NN - B-MEDICINE
in ADP - O
adjusted VERB - O
doses NOUN - O
; PUNCT - O
renal ADJ - O
biopsy NOUN - O
revealed VERB - O
acute ADJ - O
tubular ADJ - O
necrosis NOUN - O
. PUNCT - O

The DET - O
administration NOUN - O
of ADP - O
continuous ADJ - O
renal ADJ - O
replacement NOUN - O
therapy NOUN - O
and CCONJ - O
adjusted VERB - O
doses NOUN - O
of ADP - O
acyclovir NN - B-MEDICINE
has VERB - O
a DET - O
favorable ADJ - O
effect NOUN - O
on ADP - O
the DET - O
course NOUN - O
of ADP - O
the DET - O
infection NOUN - O
, PUNCT - O
with ADP - O
complete ADJ - O
recovery NOUN - O
of ADP - O
kidney NOUN - O
function NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Intravenous ADJ - O
acyclovir NN - B-MEDICINE
was VERB - O
continued VERB - O
for ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
48h NNS - I-CARDINAL
in ADP - O
patients NOUN - O
with ADP - O
confirmed VERB - O
negative ADJ - O
viral ADJ - O
etiology NOUN - O

Antibiotics NOUN - O
and CCONJ - O
acyclovir NNS - B-MEDICINE
are VERB - O
overly ADV - O
used VERB - O
even ADV - O
when ADV - O
a DET - O
viral ADJ - O
etiology NOUN - O
is VERB - O
confirmed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
prevent VERB - O
the DET - O
abuse NOUN - O
of ADP - O
nucleoside NOUN - O
- PUNCT - O
based VERB - O
antiviral ADJ - O
drugs NOUN - O
in ADP - O
disinfectant NOUN - O
and CCONJ - O
anti ADJ - O
/ ADJ - O
bacteriostatic ADJ - O
products NOUN - O
, PUNCT - O
a DET - O
new ADJ - O
micellar ADJ - O
electrokinetic ADJ - O
chromatographic NOUN - O
( PUNCT - O
MEKC NNP - B-ORG
) PUNCT - O
method NOUN - O
for ADP - O
the DET - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
three CD - B-CARDINAL
nucleoside ADJ - O
antiviral ADJ - O
drugs NOUN - O
( PUNCT - O
ganciclovir NOUN - O
, PUNCT - O
acyclovir NN - B-MEDICINE
and CCONJ - O
penciclovir NOUN - O
) PUNCT - O
was VERB - O
established VERB - O
. PUNCT - O

It PRON - O
showed VERB - O
that ADP - O
the DET - O
method NOUN - O
was VERB - O
suitable ADJ - O
for ADP - O
the DET - O
detection NOUN - O
of ADP - O
ganciclovir NOUN - O
, PUNCT - O
acyclovir NN - B-MEDICINE
and CCONJ - O
penciclovir NOUN - O
in ADP - O
disinfectant NOUN - O
and CCONJ - O
anti ADJ - O
/ SYM - O
bacteriostat ADJ - O
products NOUN - O
with ADP - O
simplicity NOUN - O
and CCONJ - O
rapidity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
62 CD - B-DATE
year NN - I-DATE
- HYPH - I-DATE
old JJ - I-DATE
man NOUN - O
, PUNCT - O
who NOUN - O
was VERB - O
taking VERB - O
prednisolone NOUN - O
for ADP - O
nephrotic ADJ - O
syndrome NOUN - O
, PUNCT - O
was VERB - O
diagnosed VERB - O
with ADP - O
herpes NOUN - O
zoster NOUN - O
of ADP - O
the DET - O
trigeminal ADJ - O
nerve NOUN - O
and CCONJ - O
treated VERB - O
with ADP - O
oral ADJ - O
valacyclovir NOUN - O
. PUNCT - O

In ADP - O
consideration NOUN - O
of ADP - O
the DET - O
preceding VERB - O
condition NOUN - O
of ADP - O
varicella NOUN - O
zoster NOUN - O
virus NOUN - O
infection NOUN - O
, PUNCT - O
acyclovir NN - B-MEDICINE
was VERB - O
administered VERB - O
in ADP - O
addition NOUN - O
to ADP - O
unfractionated ADJ - O
heparin ADV - O
, PUNCT - O
but CCONJ - O
an DET - O
intramural ADJ - O
hematoma NOUN - O
emerged VERB - O
in ADP - O
the DET - O
left ADJ - O
internal ADJ - O
carotid NOUN - O
artery NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparing VERB - O
Treatment PROPN - O
of ADP - O
Acute PROPN - O
Retinal PROPN - O
Necrosis PROPN - O
With ADP - O
Either PROPN - O
Oral PROPN - O
Valacyclovir PROPN - O
or CCONJ - O
Intravenous PROPN - O
Acyclovir NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
proposed VERB - O
method NOUN - O
is VERB - O
applied VERB - O
to PART - O
analyze VERB - O
a DET - O
data NOUN - O
set VERB - O
from ADP - O
an DET - O
acyclovir JJ - B-MEDICINE
study NOUN - O
and CCONJ - O
investigate VERB - O
whether ADP - O
acyclovir JJ - B-MEDICINE
treatment NOUN - O
reduces VERB - O
the DET - O
mean NOUN - O
relapse NOUN - O
recurrences NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
between ADP - O
Concomitant PROPN - O
Use PROPN - O
of ADP - O
Acyclovir NNP - B-PERSON
or CCONJ - O
Valacyclovir NNP - B-LOC
with ADP - O
NSAIDs PROPN - O
and CCONJ - O
an DET - O
Increased PROPN - O
Risk PROPN - O
of ADP - O
Acute PROPN - O
Kidney PROPN - O
Injury PROPN - O
: PUNCT - O
Data NNP - B-ORG
Mining NNP - I-ORG
of IN - I-ORG
FDA PROPN - O
Adverse PROPN - O
Event PROPN - O
Reporting PROPN - O
System PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
case NOUN - O
in ADP - O
which ADJ - O
a DET - O
45 CD - B-DATE
year NN - I-DATE
old JJ - I-DATE
male NOUN - O
with ADP - O
acyclovir JJ - B-MEDICINE
- ADJ - O
resistant ADJ - O
HSV-2 PROPN - O
and CCONJ - O
positive ADJ - O
HIV-1 PROPN - O
serology NOUN - O
underwent VERB - O
surgical ADJ - O
excision NOUN - O
of ADP - O
a DET - O
verrucous ADJ - O
mass NOUN - O
on ADP - O
his ADJ - O
left ADJ - O
hemiscrotum NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
elementary ADJ - O
and CCONJ - O
exemplary ADJ - O
approach NOUN - O
is VERB - O
proposed VERB - O
for ADP - O
the DET - O
accurate ADJ - O
monitoring NOUN - O
of ADP - O
antiviral ADJ - O
drug NOUN - O
acyclovir NN - B-MEDICINE
( PUNCT - O
ACV NNP - B-ORG
) PUNCT - O
utilizing VERB - O
glassy NOUN - O
carbon NOUN - O
electrode NOUN - O
( PUNCT - O
GCE NNP - B-ORG
) PUNCT - O
fabricated VERB - O
with ADP - O
single ADJ - O
- PUNCT - O
walled ADJ - O
carbon NOUN - O
nanotubes NOUN - O
and CCONJ - O
nafion NOUN - O
composite ADJ - O
film NOUN - O
employing VERB - O
square ADJ - O
wave NOUN - O
voltammetry NOUN - O
for ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
included VERB - O
injectable ADJ - O
acyclovir NN - B-MEDICINE
( PUNCT - O
12 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NN - I-QUANTITY
iv NOUN - O
, PUNCT - O
bid NOUN - O
) PUNCT - O
, PUNCT - O
antibiotic ADJ - O
, PUNCT - O
vitamin NOUN - O
, PUNCT - O
and CCONJ - O
fluids NOUN - O
. PUNCT - O

Quantitative ADJ - O
polymerase NOUN - O
chain NOUN - O
reaction NOUN - O
was VERB - O
used VERB - O
to PART - O
measure VERB - O
the DET - O
viral ADJ - O
levels NOUN - O
in ADP - O
blood NOUN - O
, PUNCT - O
which ADJ - O
decreased VERB - O
continuously ADV - O
after ADP - O
initiation NOUN - O
of ADP - O
intravenous ADJ - O
acyclovir NN - B-MEDICINE
. PUNCT - O

This DET - O
case NOUN - O
report NOUN - O
suggests VERB - O
that ADP - O
acyclovir NN - B-MEDICINE
, PUNCT - O
given VERB - O
parenterally ADV - O
, PUNCT - O
could VERB - O
potentially ADV - O
enhance VERB - O
survival NOUN - O
of ADP - O
clinical ADJ - O
EEHV NNP - B-ORG
- PUNCT - O
infected VERB - O
individuals NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
address VERB - O
this DET - O
gap NOUN - O
, PUNCT - O
we PRON - O
fabricated VERB - O
coaxial ADJ - O
fibers NOUN - O
for ADP - O
controlled VERB - O
co NOUN - O
- NOUN - O
delivery NOUN - O
of ADP - O
two CD - B-CARDINAL
different ADJ - O
drugs NOUN - O
: PUNCT - O
bovine VERB - O
serum NOUN - O
albumin NOUN - O
as ADP - O
a DET - O
model NOUN - O
protein NOUN - O
and CCONJ - O
acyclovir NN - B-MEDICINE
as ADP - O
a DET - O
small ADJ - O
molecule NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Within ADP - O
48 CD - B-TIME
hours NNS - I-TIME
, PUNCT - O
the DET - O
patient NOUN - O
was VERB - O
treated VERB - O
with ADP - O
acyclovir JJ - B-MEDICINE
tablets NOUN - O
in ADP - O
a DET - O
dose NOUN - O
of ADP - O
800 CD - B-QUANTITY
mg TO - I-QUANTITY
three CD - I-QUANTITY
times NOUN - O
a DET - O
day NOUN - O
and CCONJ - O
an DET - O
antipyretic NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nanoparticles NOUN - O
cytotoxicity NOUN - O
( PUNCT - O
CC50 NNP - B-MONEY
972.4 CD - I-MONEY
  _SP - I-MONEY
μM NNP - I-MONEY
) PUNCT - O
in ADP - O
Vero NNP - B-PERSON
cells NOUN - O
was VERB - O
significantly ADV - O
lower ADJ - O
than ADP - O
acyclovir NNP - B-MEDICINE
( PUNCT - O
CC50 NNP - B-MONEY
561.7 CD - I-MONEY
  _SP - I-MONEY
μM NNP - I-MONEY
) PUNCT - O
indicating VERB - O
its ADJ - O
safety NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
present ADJ - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
acyclovir NN - B-MEDICINE
( PUNCT - O
ACV NNP - B-ORG
) PUNCT - O
ocular ADJ - O
drug NOUN - O
delivery NOUN - O
systems NOUN - O
of ADP - O
bovine NOUN - O
serum NOUN - O
albumin NOUN - O
( PUNCT - O
BSA NNP - B-ORG
) PUNCT - O
nanoparticles NOUN - O
as ADV - O
well ADV - O
as ADP - O
to PART - O
assess VERB - O
their ADJ - O
in ADP - O
vitro X - O
transcorneal ADJ - O
permeation NOUN - O
across ADP - O
human ADJ - O
corneal ADJ - O
epithelial NOUN - O
( PUNCT - O
HCE PROPN - O
- PUNCT - O
T PROPN - O
) PUNCT - O
cell NOUN - O
multilayers NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Previous ADJ - O
studies NOUN - O
mention VERB - O
the DET - O
use NOUN - O
of ADP - O
topical ADJ - O
acyclovir NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
equine NOUN - O
sarcoids NOUN - O
. PUNCT - O

Success NOUN - O
rates NOUN - O
vary VERB - O
and CCONJ - O
since ADP - O
the DET - O
bovine ADJ - O
papillomavirus NOUN - O
( PUNCT - O
BPV PROPN - O
) PUNCT - O
lacks VERB - O
the DET - O
presence NOUN - O
of ADP - O
a DET - O
kinase NOUN - O
necessary ADJ - O
to PART - O
activate VERB - O
acyclovir NN - B-MEDICINE
, PUNCT - O
there ADV - O
is VERB - O
no DET - O
proof NOUN - O
of ADP - O
its ADJ - O
activity NOUN - O
against ADP - O
equine ADJ - O
sarcoids NOUN - O
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
four CD - I-CARDINAL
equine NOUN - O
sarcoids NOUN - O
were VERB - O
topically ADV - O
treated VERB - O
with ADP - O
acyclovir JJ - B-MEDICINE
cream NOUN - O
and CCONJ - O
25 CD - B-CARDINAL
with ADP - O
a DET - O
placebo NOUN - O
. PUNCT - O

For ADP - O
the DET - O
swabs NOUN - O
, PUNCT - O
a DET - O
significantly ADV - O
higher ADJ - O
BPV NUM - O
positivity NOUN - O
rate NOUN - O
was VERB - O
found VERB - O
for ADP - O
acyclovir RB - B-MEDICINE
treated VERB - O
tumours NOUN - O
compared VERB - O
to ADP - O
placebo NOUN - O
treated VERB - O
sarcoids NOUN - O
only ADV - O
after ADP - O
1 CD - B-DATE
month NN - I-DATE
of ADP - O
treatment NOUN - O
and CCONJ - O
not ADV - O
at ADP - O
other ADJ - O
time NOUN - O
points NOUN - O
. PUNCT - O

None NOUN - O
of ADP - O
the DET - O
results NOUN - O
indicate VERB - O
that ADP - O
treatment NOUN - O
with ADP - O
acyclovir NN - B-MEDICINE
yields NOUN - O
any DET - O
better ADJ - O
results NOUN - O
compared VERB - O
to ADP - O
placebo NOUN - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
prospective ADJ - O
, PUNCT - O
randomized VERB - O
, PUNCT - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
single ADJ - O
- PUNCT - O
dose NOUN - O
study NOUN - O
was VERB - O
conducted VERB - O
in ADP - O
an DET - O
emergency NOUN - O
department NOUN - O
( PUNCT - O
ED NNP - B-ORG
) PUNCT - O
of ADP - O
a DET - O
tertiary ADJ - O
care NOUN - O
teaching VERB - O
hospital NOUN - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
as ADP - O
compared VERB - O
to PART - O
ketorolac VERB - O
tromethamine NOUN - O
for ADP - O
the DET - O
reduction NOUN - O
of ADP - O
pain NOUN - O
from ADP - O
ureteral ADJ - O
colic NOUN - O
in ADP - O
the DET - O
ED NNP - B-ORG
. PUNCT - O

Consecutive ADJ - O
patients NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
either CCONJ - O
a DET - O
single ADJ - O
sublingual ADJ - O
dose NOUN - O
of ADP - O
0.125 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
or CCONJ - O
a DET - O
single ADJ - O
intravenous ADJ - O
dose NOUN - O
of ADP - O
30 CD - B-CARDINAL
mg NOUN - O
of ADP - O
ketorolac NOUN - O
tromethamine NOUN - O
given VERB - O
over ADP - O
1 CD - B-TIME
minute NN - I-TIME
. PUNCT - O

Decreasing VERB - O
trends NOUN - O
in ADP - O
pain NOUN - O
over ADP - O
time NOUN - O
were VERB - O
observed VERB - O
for ADP - O
both DET - O
treatment NOUN - O
groups NOUN - O
, PUNCT - O
with ADP - O
significantly ADV - O
greater ADJ - O
pain NOUN - O
reduction NOUN - O
observed VERB - O
with ADP - O
ketorolac NOUN - O
tromethamine NOUN - O
as ADP - O
compared VERB - O
to ADP - O
hyoscyamine JJ - B-MEDICINE
sulfate NN - I-MEDICINE
. PUNCT - O

Global ADJ - O
evaluations NOUN - O
of ADP - O
pain NOUN - O
relief NOUN - O
revealed VERB - O
better ADJ - O
results NOUN - O
in ADP - O
the DET - O
ketorolac NOUN - O
tromethamine NOUN - O
group NOUN - O
than ADP - O
in ADP - O
the DET - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
group NOUN - O
, PUNCT - O
although ADP - O
this DET - O
result NOUN - O
was VERB - O
not ADV - O
statistically ADV - O
significant ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
evaluate VERB - O
the DET - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
hyoscyamine JJ - B-MEDICINE
sulfate NN - I-MEDICINE
in ADP - O
combination NOUN - O
with ADP - O
ketorolac NOUN - O
tromethamine NOUN - O
for ADP - O
the DET - O
reduction NOUN - O
of ADP - O
pain NOUN - O
in ADP - O
emergency NOUN - O
department NOUN - O
patients NOUN - O
with ADP - O
ureteral ADJ - O
colic NOUN - O
. PUNCT - O

Patients NOUN - O
received VERB - O
a DET - O
single ADJ - O
intravenous ADJ - O
dose NOUN - O
of ADP - O
30 CD - B-CARDINAL
mg NOUN - O
of ADP - O
ketorolac NOUN - O
tromethamine NOUN - O
given VERB - O
over ADP - O
a DET - O
1-minute NUM - O
period NOUN - O
with ADP - O
either CCONJ - O
a DET - O
single ADJ - O
sublingual ADJ - O
dose NOUN - O
of ADP - O
0.125 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
or CCONJ - O
a DET - O
placebo NOUN - O
. PUNCT - O

There ADV - O
was VERB - O
no DET - O
clinically ADV - O
important ADJ - O
difference NOUN - O
in ADP - O
change NOUN - O
of ADP - O
pain NOUN - O
scores NOUN - O
at ADP - O
30 CD - B-TIME
minutes NNS - I-TIME
in ADP - O
patients NOUN - O
with ADP - O
ureteral ADJ - O
colic NOUN - O
receiving VERB - O
supplemental ADJ - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Determination NOUN - O
of ADP - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
in ADP - O
technical ADJ - O
hyoscyamine]. NOUN - O

-DOCSTART- -X- - O

Because ADP - O
glucagon NOUN - O
is VERB - O
expensive ADJ - O
and CCONJ - O
frequently ADV - O
causes VERB - O
nausea NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
the DET - O
use NOUN - O
of ADP - O
oral ADJ - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
as ADP - O
an DET - O
alternate ADJ - O
agent NOUN - O
and CCONJ - O
compared VERB - O
it PRON - O
with ADP - O
IV NNP - B-ORG
glucagon NOUN - O
and CCONJ - O
no DET - O
medication NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
349 CD - B-CARDINAL
adult NOUN - O
patients NOUN - O
undergoing VERB - O
barium NOUN - O
enema NOUN - O
examinations NOUN - O
were VERB - O
randomly ADV - O
assigned VERB - O
in ADP - O
a DET - O
prospective ADJ - O
fashion NOUN - O
to ADP - O
one CD - B-CARDINAL
of ADP - O
four CD - B-CARDINAL
groups NOUN - O
: PUNCT - O
( PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
no DET - O
medication NOUN - O
( PUNCT - O
87 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
2 LS - B-CARDINAL
) PUNCT - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
IV NNP - B-ORG
glucagon NOUN - O
( PUNCT - O
88 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
; PUNCT - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
0.125 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
oral ADJ - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
( PUNCT - O
87 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
; PUNCT - O
and CCONJ - O
( PUNCT - O
4 LS - B-CARDINAL
) PUNCT - O
0.25 CD - B-QUANTITY
mg NN - I-QUANTITY
of ADP - O
oral ADJ - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
( PUNCT - O
87 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
course NOUN - O
of ADP - O
diphenhydramine ADJ - O
hydrochloride NOUN - O
and CCONJ - O
Donnatal JJ - B-PERSON
( PUNCT - O
phenobarbital ADJ - O
, PUNCT - O
hyoscyamine NN - B-MEDICINE
sulfate NN - I-MEDICINE
, PUNCT - O
atropine NOUN - O
sulfate NOUN - O
, PUNCT - O
and CCONJ - O
scopolamine NOUN - O
hydrobromide NOUN - O
) PUNCT - O
significantly ADV - O
alleviated VERB - O
the DET - O
symptoms NOUN - O
of ADP - O
vestibular ADJ - O
dysfunction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
stock NOUN - O
solution NOUN - O
of ADP - O
the DET - O
fungus NOUN - O
was VERB - O
prepared VERB - O
and CCONJ - O
aliquots NOUN - O
were VERB - O
added VERB - O
to ADP - O
each DET - O
of ADP - O
the DET - O
following VERB - O
disinfection NOUN - O
solutions NOUN - O
: PUNCT - O
ReNu NNP - B-ORG
Multi NNP - I-ORG
- HYPH - I-ORG
Purpose NNP - I-ORG
Disinfecting NNP - I-ORG
Solution NNP - I-ORG
, PUNCT - O
Opti PROPN - O
- PUNCT - O
Free PROPN - O
, PUNCT - O
AOSEPT NNP - B-ORG
Disinfection NNP - I-ORG
/ SYM - I-ORG
Neutralization NNP - I-ORG
Solution NNP - I-ORG
, PUNCT - O
Lens PROPN - O
Plus PROPN - O
Oxysept PROPN - O
1 NUM - O
, PUNCT - O
UltraCare NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
a DET - O
Softmate NNP - B-ORG
Thermal PROPN - O
Disinfecting PROPN - O
Unit PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
- PUNCT - O
non ADJ - O
- ADJ - O
susceptible ADJ - O
C. PROPN - O
parapsilosis NOUN - O
isolates NOUN - O
carrying VERB - O
the DET - O
novel ADJ - O
K143R NNP - B-PRODUCT
amino NOUN - O
acid NOUN - O
substitution NOUN - O
should VERB - O
be VERB - O
identified VERB - O
in ADP - O
clinical ADJ - O
microbiology NOUN - O
laboratories NOUN - O
to PART - O
prevent VERB - O
further ADJ - O
clonal ADJ - O
transmission NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evolution NOUN - O
of ADP - O
Fluconazole NNP - B-MEDICINE
- PUNCT - O
Resistant ADJ - O
Candida PROPN - O
albicans NOUN - O
Strains NNP - B-ORG
by IN - I-ORG
Drug NN - I-ORG
- HYPH - I-ORG
Induced NNP - I-ORG
Mating NNP - I-ORG
Competence NNP - I-ORG
and CC - I-ORG
Parasexual NNP - I-ORG
Recombination NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
loaded VERB - O
proniosomal ADJ - O
gels NOUN - O
were VERB - O
prepared VERB - O
by ADP - O
the DET - O
coacervation NOUN - O
phase NOUN - O
separation NOUN - O
method NOUN - O
using VERB - O
different ADJ - O
nonionic ADJ - O
surfactants NOUN - O
( PUNCT - O
spans NOUN - O
and CCONJ - O
tweens NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Impact NOUN - O
of ADP - O
Routine NNP - B-ORG
Cryptococcal NNP - I-ORG
Antigen NNP - I-ORG
Screening VBG - I-ORG
and CC - I-ORG
Targeted NNP - I-ORG
Preemptive NNP - I-ORG
Fluconazole NNP - I-MEDICINE
Therapy NNP - I-ORG
in ADP - O
Antiretroviral JJ - B-ORG
- HYPH - I-ORG
naive JJ - I-ORG
Human PROPN - O
Immunodeficiency PROPN - O
Virus PROPN - O
- PUNCT - O
infected VERB - O
Adults PROPN - O
With ADP - O
CD4 PROPN - O
Cell PROPN - O
Counts PROPN - O
< X - O
100/μL NUM - O
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta PROPN - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
efficacy NOUN - O
against ADP - O
two CD - B-CARDINAL
weakly ADV - O
( PUNCT - O
≤25 NN - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
, PUNCT - O
two CD - B-CARDINAL
moderately ADV - O
( PUNCT - O
26 CD - B-PERCENT
% NN - I-PERCENT
to TO - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
heavily ADV - O
( PUNCT - O
> X - O
70 CD - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
trailing VERB - O
resistant ADJ - O
isolate NOUN - O
and CCONJ - O
one CD - B-CARDINAL
resistant ADJ - O
( PUNCT - O
100 CD - B-PERCENT
% NN - I-PERCENT
growth NOUN - O
) PUNCT - O
isolate NOUN - O
were VERB - O
investigated VERB - O
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
( PUNCT - O
in ADP - O
a DET - O
Galleria NNP - B-ORG
mellonella NOUN - O
survival NOUN - O
model NOUN - O
and CCONJ - O
two CD - B-CARDINAL
nonlethal ADJ - O
murine NOUN - O
models NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Predictive ADJ - O
Model PROPN - O
for ADP - O
Fluconazole NNP - B-MEDICINE
Resistance PROPN - O
in ADP - O
Patient PROPN - O
With ADP - O
Candida PROPN - O
Bloodstream PROPN - O
Infection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Cytotoxic NNP - B-ORG
and CCONJ - O
Genotoxic NNP - B-ORG
Effects NNS - I-ORG
of IN - I-ORG
Fluconazole NNP - I-MEDICINE
on ADP - O
African NNP - B-NORP
Green PROPN - O
Monkey PROPN - O
Kidney PROPN - O
( PUNCT - O
Vero PROPN - O
) PUNCT - O
Cell PROPN - O
Line PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
and CCONJ - O
amphotericin ADJ - O
B NOUN - O
are VERB - O
used VERB - O
as ADP - O
the DET - O
first JJ - B-ORDINAL
choice NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
invasive ADJ - O
fungal ADJ - O
infections NOUN - O
of ADP - O
the DET - O
newborns NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
susceptibility NOUN - O
testing NOUN - O
indicated VERB - O
that ADP - O
strains NOUN - O
overexpressing VERB - O
ECM22 NNP - B-NORP
could VERB - O
grow VERB - O
at ADP - O
20 CD - B-CARDINAL
  SPACE - O
μg(fluconazole PROPN - O
) PUNCT - O
  SPACE - O
ml-1 NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
susceptibility NOUN - O
and CCONJ - O
resistant ADJ - O
rates NOUN - O
were VERB - O
74.1 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
9.7 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
C. PROPN - O
neoformans NOUN - O
and CCONJ - O
81.0 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
5.2 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
T. NNP - B-ORG
asahii NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
prophylaxis NOUN - O
may VERB - O
make VERB - O
no DET - O
clear ADJ - O
difference NOUN - O
to ADP - O
the DET - O
risk NOUN - O
of ADP - O
developing VERB - O
clinically ADV - O
resistant ADJ - O
Candida PROPN - O
disease NOUN - O
( PUNCT - O
RR PROPN - O
0.93 NUM - O
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
0.56 NUM - O
to ADP - O
1.56 CD - B-CARDINAL
; PUNCT - O
3 CD - B-CARDINAL
trials NOUN - O
, PUNCT - O
1198 CD - B-DATE
participants NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
certainty NOUN - O
evidence NOUN - O
) PUNCT - O
; PUNCT - O
however ADV - O
, PUNCT - O
there ADV - O
may VERB - O
be VERB - O
an DET - O
increased VERB - O
detection NOUN - O
of ADP - O
fluconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
Candida PROPN - O
isolates VERB - O
from ADP - O
surveillance NOUN - O
cultures NOUN - O
( PUNCT - O
RR NOUN - O
1.25 CD - B-MONEY
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
1.00 CD - B-CARDINAL
to ADP - O
1.55 CD - B-CARDINAL
; PUNCT - O
3 CD - B-CARDINAL
trials NOUN - O
, PUNCT - O
539 CD - B-CARDINAL
participants NOUN - O
; PUNCT - O
low ADJ - O
- PUNCT - O
certainty NOUN - O
evidence NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
400 CD - B-CARDINAL
mg NOUN - O
daily ADV - O
was VERB - O
later ADV - O
added VERB - O
to PART - O
control VERB - O
the DET - O
persistent ADJ - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole JJ - B-MEDICINE
induces VERB - O
ROS PROPN - O
in ADP - O
Cryptococcus NNP - B-ORG
neoformans NOUN - O
and CCONJ - O
contributes VERB - O
to ADP - O
DNA NOUN - O
damage NOUN - O
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NNP - B-MEDICINE
, PUNCT - O
an DET - O
azole ADJ - O
antifungal ADJ - O
agent NOUN - O
, PUNCT - O
affects VERB - O
blood NOUN - O
concentration NOUN - O
of ADP - O
tacrolimus NOUN - O
by ADP - O
inhibiting VERB - O
the DET - O
cytochromes NOUN - O
P450 PROPN - O
( PUNCT - O
CYP NNP - B-ORG
) PUNCT - O
3A4 NUM - O
and CCONJ - O
3A5 CD - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Fluconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
isolates NOUN - O
were VERB - O
unrelated ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Stability PROPN - O
of ADP - O
Compounded NNP - B-ORG
Ursodiol NNP - I-MEDICINE
Suspensions NNPS - I-ORG
in ADP - O
PCCA NNP - B-ORG
Base NNP - I-ORG
, PUNCT - O
SuspendIt NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Ursodiol NNP - B-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Paroxysmal NNP - I-ORG
Atrial NNP - I-ORG
Fibrillation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
composition NOUN - O
comprises VERB - O
a DET - O
therapeutically ADV - O
effective ADJ - O
amount NOUN - O
of ADP - O
active ADJ - O
pharmaceutical ADJ - O
ingredient NOUN - O
that ADJ - O
is VERB - O
Ursodiol NNP - B-MEDICINE
or CCONJ - O
its ADJ - O
pharmaceutically ADV - O
acceptable ADJ - O
salts NOUN - O
thereof ADV - O
with ADP - O
one NUM - O
or CCONJ - O
more ADV - O
pharmaceutically ADV - O
acceptable ADJ - O
excipients NOUN - O
, PUNCT - O
wherein ADV - O
said VERB - O
active ADJ - O
pharmaceutical NOUN - O
ingredient NOUN - O
present ADJ - O
in ADP - O
the DET - O
form NOUN - O
of ADP - O
micronized ADJ - O
and CCONJ - O
unmicronized ADJ - O
particles NOUN - O
in ADP - O
the DET - O
ratio NOUN - O
about ADV - O
5:95 NUM - O
to ADP - O
about IN - B-CARDINAL
95:5 CD - I-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
has VERB - O
been VERB - O
reported VERB - O
that ADP - O
voriconazole NN - B-MEDICINE
is VERB - O
used VERB - O
to PART - O
treat VERB - O
infections NOUN - O
caused VERB - O
by ADP - O
invasive ADJ - O
aspergillosis NOUN - O
, PUNCT - O
fluconazole NOUN - O
- PUNCT - O
resistant ADJ - O
Candida PROPN - O
, PUNCT - O
Actinoplanes PROPN - O
and CCONJ - O
Fusarium NNP - B-GPE
. PUNCT - O

This DET - O
study NOUN - O
was VERB - O
performed VERB - O
to PART - O
investigate VERB - O
the DET - O
safety NOUN - O
of ADP - O
prodrug NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
( PUNCT - O
POV NNP - B-ORG
) PUNCT - O
and CCONJ - O
explore VERB - O
the DET - O
distribution NOUN - O
and CCONJ - O
metabolism NOUN - O
of ADP - O
POV NNP - B-ORG
in ADP - O
vivo NOUN - O
. PUNCT - O

The DET - O
results NOUN - O
of ADP - O
toxicokinetics NOUN - O
showed VERB - O
that ADP - O
POV NNP - B-ORG
can VERB - O
rapidly ADV - O
converts VERB - O
to ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
SD NN - B-ORG
rats NOUN - O
after ADP - O
administration NOUN - O
. PUNCT - O

The DET - O
exposure NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
each DET - O
group NOUN - O
was VERB - O
significantly ADV - O
different ADJ - O
between ADP - O
male ADJ - O
and CCONJ - O
female ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Porous ADJ - O
and CCONJ - O
highly ADV - O
dispersible ADJ - O
voriconazole NN - B-MEDICINE
dry ADJ - O
powders NOUN - O
produced VERB - O
by ADP - O
spray NOUN - O
freeze NOUN - O
drying VERB - O
for ADP - O
pulmonary ADJ - O
delivery NOUN - O
with ADP - O
efficient ADJ - O
lung NOUN - O
deposition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
ketoconazole NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
itraconazole NOUN - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
apatinib NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Isavuconazole NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
chronic ADJ - O
pulmonary ADJ - O
aspergillosis NOUN - O
: PUNCT - O
A DET - O
retrospective ADJ - O
comparison NOUN - O
of ADP - O
rates NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
control NOUN - O
of ADP - O
exacerbation NOUN - O
of ADP - O
Allergic ADJ - O
Bronchopulmonary PROPN - O
Aspergillosis PROPN - O
due ADP - O
to ADP - O
Aspergillus PROPN - O
terreus VERB - O
in ADP - O
a DET - O
cystic ADJ - O
fibrosis NOUN - O
patient NOUN - O
with ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
adjunctive ADJ - O
therapy NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
: PUNCT - O
A DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
and CCONJ - O
validation NOUN - O
of ADP - O
a DET - O
volumetric ADJ - O
absorptive ADJ - O
microsampling ADJ - O
assay NOUN - O
for ADP - O
analysis NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
voriconazole NN - B-MEDICINE
N NOUN - O
- PUNCT - O
oxide NOUN - O
in ADP - O
human ADJ - O
whole ADJ - O
blood NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
determine VERB - O
the DET - O
interaction NOUN - O
activity NOUN - O
of ADP - O
carvacrol NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
against ADP - O
Candida NNP - B-GPE
albicans NOUN - O
( PUNCT - O
C. NNP - B-GPE
  _SP - I-GPE
albicans NOUN - O
) PUNCT - O
, PUNCT - O
C. NNP - B-PERSON
  _SP - I-PERSON
glabrata NOUN - O
and CCONJ - O
C. NNP - B-ORG
  _SP - I-ORG
krusei NOUN - O
isolates NOUN - O
. PUNCT - O

The DET - O
minimum ADJ - O
inhibitory NOUN - O
and CCONJ - O
fungicidal ADJ - O
concentrations NOUN - O
( PUNCT - O
MICs NOUN - O
and CCONJ - O
MFCs NOUN - O
) PUNCT - O
of ADP - O
carvacrol NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
were VERB - O
determined VERB - O
against ADP - O
various ADJ - O
Candida NNP - B-NORP
species NOUN - O
isolated VERB - O
from ADP - O
patients NOUN - O
with ADP - O
candidiasis NOUN - O
using VERB - O
the DT - B-ORG
Clinical NNP - I-ORG
Laboratory NNP - I-ORG
Standards NNPS - I-ORG
Institute NNP - I-ORG
( PUNCT - O
CLSI NNP - B-ORG
) PUNCT - O
M27-A2 NOUN - O
broth NOUN - O
microdilution NOUN - O
method NOUN - O
. PUNCT - O

The DET - O
nature NOUN - O
of ADP - O
the DET - O
interaction NOUN - O
was VERB - O
studied VERB - O
from ADP - O
fractional ADJ - O
inhibitory ADJ - O
concentration NOUN - O
indices NOUN - O
( PUNCT - O
FICIs PROPN - O
) PUNCT - O
for ADP - O
carvacrol NOUN - O
plus CCONJ - O
voriconazole NN - B-MEDICINE
combination NOUN - O
calculated VERB - O
from ADP - O
checkerboard NOUN - O
microdilution NOUN - O
assay NOUN - O
. PUNCT - O

The DET - O
mean ADJ - O
MICs PROPN - O
of ADP - O
voriconazole NN - B-MEDICINE
against ADP - O
C. NNP - B-GPE
  _SP - I-GPE
albicans NOUN - O
, PUNCT - O
C. NNP - B-GPE
  _SP - I-GPE
glabrata NOUN - O
and CCONJ - O
C. NNP - B-ORG
  _SP - I-ORG
krusei NOUN - O
isolates NOUN - O
were VERB - O
0.087 CD - B-CARDINAL
, PUNCT - O
1.25 CD - B-CARDINAL
and CCONJ - O
0.35μg CD - B-ORG
/ SYM - I-ORG
mL NNP - I-ORG
, PUNCT - O
respectively ADV - O
. PUNCT - O

Carvacrol NOUN - O
in ADP - O
combination NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
exhibited VERB - O
the DET - O
synergistic ADJ - O
anti ADJ - O
- ADJ - O
Candida ADJ - O
effects NOUN - O
against ADP - O
all DET - O
species NOUN - O
of ADP - O
Candida NNP - B-GPE
tested VERB - O
. PUNCT - O

FICI NN - B-ORG
values NOUN - O
for ADP - O
carvacrol NOUN - O
plus CCONJ - O
voriconazole NN - B-MEDICINE
combination NOUN - O
ranged VERB - O
from ADP - O
0.370 CD - B-CARDINAL
to ADP - O
0.853 CD - B-CARDINAL
for ADP - O
C. NNP - B-ORG
  _SP - I-ORG
albicans NOUN - O
isolates VERB - O
, PUNCT - O
0.412 CD - B-CARDINAL
to ADP - O
0.625 CD - B-CARDINAL
for ADP - O
C. NNP - B-ORG
  _SP - I-ORG
glabrata NOUN - O
isolates NOUN - O
, PUNCT - O
and CCONJ - O
0.474 CD - B-CARDINAL
to ADP - O
0.748 CD - B-CARDINAL
for ADP - O
C. NNP - B-ORG
  _SP - I-ORG
krusei NOUN - O
isolates NOUN - O
. PUNCT - O

From ADP - O
these DET - O
results NOUN - O
we PRON - O
suggest VERB - O
that ADP - O
carvacrol NOUN - O
has VERB - O
great ADJ - O
potential NOUN - O
as ADP - O
antifungal NOUN - O
, PUNCT - O
and CCONJ - O
that ADP - O
voriconazole NN - B-MEDICINE
can VERB - O
be VERB - O
supplemented VERB - O
with ADP - O
carvacrol NOUN - O
to PART - O
inhibit VERB - O
clinical ADJ - O
Candida PROPN - O
isolates NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
the DET - O
in X - O
vitro X - O
activity NOUN - O
of ADP - O
two CD - B-CARDINAL
of ADP - O
these DET - O
agents NOUN - O
, PUNCT - O
i.e. X - O
, PUNCT - O
amphotericin ADP - O
B PROPN - O
( PUNCT - O
AmB NN - B-ORG
) PUNCT - O
and CCONJ - O
voriconazole NN - B-MEDICINE
( PUNCT - O
VOR PROPN - O
) PUNCT - O
, PUNCT - O
against ADP - O
three CD - B-CARDINAL
different ADJ - O
fungi NOUN - O
in ADP - O
CSF NNP - B-ORG
in ADP - O
comparison NOUN - O
to PART - O
sabouraud VERB - O
- PUNCT - O
dextrose ADJ - O
broth NOUN - O
( PUNCT - O
SDB NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Real ADJ - O
- PUNCT - O
world NOUN - O
implications NOUN - O
of ADP - O
QT NNP - B-ORG
prolongation NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
voriconazole NN - B-MEDICINE
and CCONJ - O
amiodarone ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
trial NOUN - O
of ADP - O
the DET - O
prophylactic ADJ - O
administration NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
patients NOUN - O
who NOUN - O
undergo VERB - O
allogeneic ADJ - O
hematopoietic ADJ - O
stem NOUN - O
cell NOUN - O
transplantation NOUN - O
: PUNCT - O
study NOUN - O
protocol NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Correlation NOUN - O
of ADP - O
CYP2C19 NNP - B-ORG
genotype VERB - O
with ADP - O
plasma ADJ - O
voriconazole NN - B-MEDICINE
exposure NOUN - O
in ADP - O
South NNP - B-LOC
- PUNCT - O
western ADJ - O
Chinese JJ - B-NORP
Han NNP - B-NORP
patients NOUN - O
with ADP - O
invasive ADJ - O
fungal ADJ - O
infections NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
effects NOUN - O
of ADP - O
cytochrome ADJ - O
P450 PROPN - O
2C19 CD - B-PERSON
polymorphism NOUN - O
on ADP - O
the DET - O
metabolism NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
vitro NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
addition NOUN - O
to ADP - O
the DET - O
biological ADJ - O
characterization NOUN - O
, PUNCT - O
in ADP - O
vitro X - O
drug NOUN - O
sensitivity NOUN - O
tests NOUN - O
were VERB - O
performed VERB - O
using VERB - O
chlorhexidine NOUN - O
, PUNCT - O
itraconazole NOUN - O
, PUNCT - O
netilmicin NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
. PUNCT - O

Results NOUN - O
revealed VERB - O
that ADP - O
voriconazole NN - B-MEDICINE
was VERB - O
the DET - O
most ADV - O
effective ADJ - O
compound NOUN - O
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
chlorhexidine NOUN - O
may VERB - O
be VERB - O
an DET - O
alternative ADJ - O
treatment NOUN - O
of ADP - O
future ADJ - O
AK PROPN - O
cases NOUN - O
in ADP - O
Mexico NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

It PRON - O
can VERB - O
be VERB - O
treated VERB - O
with ADP - O
antifungal ADJ - O
drugs NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

However ADV - O
, PUNCT - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
are VERB - O
variable ADJ - O
between ADP - O
different ADJ - O
animal NOUN - O
and CCONJ - O
bird NOUN - O
species NOUN - O
. PUNCT - O

Therefore ADV - O
, PUNCT - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
were VERB - O
investigated VERB - O
in ADP - O
this DET - O
study NOUN - O
in ADP - O
Magellanic NNP - B-GPE
penguins NOUN - O
. PUNCT - O

Pharmacokinetic ADJ - O
models NOUN - O
were VERB - O
constructed VERB - O
and CCONJ - O
applied VERB - O
to PART - O
predict VERB - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
during ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
in ADP - O
Magellanic NNP - B-GPE
penguins NOUN - O
, PUNCT - O
since ADP - O
the DET - O
voriconazole NN - B-MEDICINE
treatment NOUN - O
duration NOUN - O
in ADP - O
chronic ADJ - O
aspergillosis NOUN - O
cases NOUN - O
can VERB - O
last VERB - O
up RB - B-DATE
to IN - I-DATE
several JJ - I-DATE
months NNS - I-DATE
. PUNCT - O

Plasma ADJ - O
voriconazole NN - B-MEDICINE
concentration NOUN - O
- PUNCT - O
time NOUN - O
data NOUN - O
from ADP - O
adult NOUN - O
Magellanic NNP - B-PERSON
penguins NOUN - O
( PUNCT - O
Spheniscus PROPN - O
magellanicus NOUN - O
; PUNCT - O
n PUNCT - O
  SPACE - O
= SYM - O
  SPACE - O
15 NUM - O
) PUNCT - O
following VERB - O
a DET - O
single ADJ - O
oral ADJ - O
( PUNCT - O
PO NNP - B-ORG
) PUNCT - O
dose NOUN - O
of ADP - O
either CCONJ - O
2.5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
or CCONJ - O
5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
in ADP - O
a DET - O
herring NOUN - O
in ADP - O
three CD - B-CARDINAL
separate ADJ - O
study NOUN - O
periods NOUN - O
7 CD - B-DATE
- SYM - I-DATE
12 CD - I-DATE
  SPACE - O
months NNS - B-DATE
apart ADV - O
were VERB - O
collected VERB - O
. PUNCT - O

Mean PROPN - O
plasma VERB - O
voriconazole NN - B-MEDICINE
concentrations NOUN - O
were VERB - O
above ADP - O
the DET - O
targeted ADJ - O
MIC PROPN - O
for ADP - O
Aspergillus NNP - B-PRODUCT
fumigatus NOUN - O
for ADP - O
2 CD - B-CARDINAL
  SPACE - O
hr CCONJ - O
following VERB - O
a DET - O
single ADJ - O
2.5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg VERB - O
voriconazole NN - B-MEDICINE
dose ADV - O
while ADP - O
the DET - O
plasma NOUN - O
concentrations NOUN - O
exceeded VERB - O
the DET - O
MIC NNP - B-ORG
for ADP - O
least ADJ - O
24 NUM - O
  SPACE - O
hr CCONJ - O
following VERB - O
a DET - O
5 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
dose VERB - O
. PUNCT - O

Although ADP - O
the DET - O
single ADJ - O
- PUNCT - O
dose NOUN - O
data NOUN - O
suggested VERB - O
saturated ADJ - O
elimination NOUN - O
at ADP - O
higher ADJ - O
concentrations NOUN - O
, PUNCT - O
the DET - O
model NOUN - O
with ADP - O
saturable ADJ - O
elimination NOUN - O
did VERB - O
not ADV - O
predict VERB - O
plasma NOUN - O
voriconazole NN - B-MEDICINE
concentrations NOUN - O
well ADV - O
for ADP - O
a DET - O
clinical ADJ - O
aspergillosis NOUN - O
case NOUN - O
receiving VERB - O
long ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
, PUNCT - O
possibly ADV - O
because ADP - O
of ADP - O
induction NOUN - O
of ADP - O
metabolizing VERB - O
enzymes NOUN - O
with ADP - O
chronic ADJ - O
exposure NOUN - O
. PUNCT - O

Future ADJ - O
studies NOUN - O
should VERB - O
focus VERB - O
on ADP - O
determining VERB - O
clearance NOUN - O
at ADP - O
steady ADJ - O
- PUNCT - O
state NOUN - O
to PART - O
be VERB - O
able ADJ - O
to PART - O
refine VERB - O
the DET - O
pharmacokinetic ADJ - O
models NOUN - O
presented VERB - O
here ADV - O
and CCONJ - O
improve VERB - O
model NOUN - O
performance NOUN - O
for ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
oral ADJ - O
voriconazole NN - B-MEDICINE
administration NOUN - O
in ADP - O
Magellanic NNP - B-GPE
penguins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Application NOUN - O
of ADP - O
different ADJ - O
pharmacokinetic ADJ - O
models NOUN - O
to PART - O
describe VERB - O
and CCONJ - O
predict VERB - O
pharmacokinetics NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
magellanic ADJ - O
penguins NOUN - O
following VERB - O
oral ADJ - O
administration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Visual ADJ - O
acuity NOUN - O
was VERB - O
20/30 CD - B-CARDINAL
in ADP - O
both DET - O
eyes NOUN - O
at ADP - O
presentation NOUN - O
but CCONJ - O
dropped VERB - O
to ADP - O
20/400 CD - B-CARDINAL
in ADP - O
the DET - O
right ADJ - O
eye NOUN - O
and CCONJ - O
counting VERB - O
fingers NOUN - O
at ADP - O
3 CD - B-QUANTITY
feet NNS - I-QUANTITY
in ADP - O
the DET - O
left ADJ - O
eye NOUN - O
over ADP - O
the DET - O
hospital NOUN - O
course NOUN - O
despite ADP - O
receiving VERB - O
an DET - O
intravitreal ADJ - O
injection NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
the DET - O
left ADJ - O
eye NOUN - O
and CCONJ - O
concurrent ADJ - O
IV NN - B-ORG
amphotericin ADP - O
B NOUN - O
, PUNCT - O
posaconazole NOUN - O
, PUNCT - O
and CCONJ - O
micafungin NOUN - O
. PUNCT - O

The DET - O
patient NOUN - O
was VERB - O
then ADV - O
treated VERB - O
with ADP - O
multiple ADJ - O
simultaneous ADJ - O
intravitreal NOUN - O
amphotericin NOUN - O
B NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
injections NOUN - O
bilaterally ADV - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
IV NNP - B-ORG
posaconazole NOUN - O
, PUNCT - O
which ADJ - O
was VERB - O
switched VERB - O
to ADP - O
IV NNP - B-ORG
voriconazole NN - B-MEDICINE
for ADP - O
improved VERB - O
intraocular ADJ - O
penetration NOUN - O
. PUNCT - O

The DET - O
patient NOUN - O
completed VERB - O
a DET - O
1-year CD - B-DATE
course NOUN - O
of ADP - O
oral ADJ - O
voriconazole NN - B-MEDICINE
as ADP - O
an DET - O
outpatient NOUN - O
without ADP - O
signs NOUN - O
of ADP - O
recurrent NOUN - O
activity NOUN - O
. PUNCT - O

This DET - O
report NOUN - O
describes VERB - O
the DET - O
first JJ - B-ORDINAL
successful ADJ - O
treatment NOUN - O
regimen NOUN - O
against ADP - O
O. NNP - B-ORG
gallopava PROPN - O
endophthalmitis NOUN - O
using VERB - O
a DET - O
combination NOUN - O
of ADP - O
intravitreal NOUN - O
amphotericin NOUN - O
B NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
injections NOUN - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
IV NNP - B-ORG
posaconazole NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
, PUNCT - O
which ADJ - O
resulted VERB - O
in ADP - O
an DET - O
excellent ADJ - O
visual ADJ - O
outcome NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
study NOUN - O
, PUNCT - O
a DET - O
novel ADJ - O
and CCONJ - O
high ADJ - O
- PUNCT - O
throughput NOUN - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
tandem NOUN - O
mass NOUN - O
spectrometric NOUN - O
( PUNCT - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
- PUNCT - O
MS PROPN - O
) PUNCT - O
assay NOUN - O
was VERB - O
developed VERB - O
and CCONJ - O
validated VERB - O
for ADP - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
two CD - B-CARDINAL
glycopeptides NOUN - O
( PUNCT - O
vancomycin ADJ - O
, PUNCT - O
teicoplanin NOUN - O
) PUNCT - O
and CCONJ - O
two CD - B-CARDINAL
small ADJ - O
molecule NOUN - O
compounds NOUN - O
( PUNCT - O
meropenem NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
) PUNCT - O
in ADP - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

0.3 CD - B-CARDINAL
- SYM - I-CARDINAL
30 CD - I-CARDINAL
μg PROPN - O
/ SYM - O
mL NOUN - O
for ADP - O
meropenem NOUN - O
; PUNCT - O
1 CD - B-CARDINAL
- SYM - I-CARDINAL
100 CD - I-CARDINAL
μg PROPN - O
/ SYM - O
mL PROPN - O
for ADP - O
teicoplanin NOUN - O
and CCONJ - O
vancomycin PROPN - O
; PUNCT - O
0.3 CD - B-CARDINAL
- SYM - O
10 NUM - O
μg PROPN - O
/ SYM - O
mL PROPN - O
for ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

The DET - O
lower ADJ - O
limit NOUN - O
of ADP - O
quantitation NOUN - O
( PUNCT - O
LLOQ PROPN - O
) PUNCT - O
of ADP - O
meropenem NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
were VERB - O
0.30 CD - B-CARDINAL
μg PROPN - O
/ PUNCT - O
mL INTJ - O
; PUNCT - O
and CCONJ - O
the DET - O
LLOQ PROPN - O
of ADP - O
teicoplanin NOUN - O
and CCONJ - O
vancomycin PROPN - O
were VERB - O
1.0 CD - B-CARDINAL
μg PROPN - O
/ SYM - O
mL. PUNCT - O

-DOCSTART- -X- - O

Antifungal ADJ - O
susceptibilities NOUN - O
of ADP - O
isolates NOUN - O
were VERB - O
performed VERB - O
against ADP - O
( PUNCT - O
amphotericin ADP - O
B PROPN - O
, PUNCT - O
nystatin NOUN - O
, PUNCT - O
clotrimazole NOUN - O
, PUNCT - O
fluconazole NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
micafungin NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
their ADJ - O
minimum ADJ - O
inhibitory NOUN - O
concentrations NOUN - O
( PUNCT - O
MICs PROPN - O
) PUNCT - O
were VERB - O
determined VERB - O
according VERB - O
to ADP - O
Clinical NNP - B-ORG
and CC - I-ORG
Laboratory NNP - I-ORG
Standards NNPS - I-ORG
Institute NNP - I-ORG
( PUNCT - O
CLSI NNP - B-ORG
) PUNCT - O
guidelines NOUN - O
. PUNCT - O

However ADV - O
, PUNCT - O
significant ADJ - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
negative ADJ - O
correlations NOUN - O
are VERB - O
found VERB - O
between ADP - O
fluconazole NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
MICs NOUN - O
and CCONJ - O
cell NOUN - O
surface NOUN - O
hydrophobicity NOUN - O
as ADV - O
well ADV - O
as ADP - O
biofilm ADJ - O
production NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
significant ADJ - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
negative ADJ - O
correlations NOUN - O
are VERB - O
detected VERB - O
between ADP - O
voriconazole NN - B-MEDICINE
MICs NOUN - O
and CCONJ - O
aspartyl NOUN - O
protease NOUN - O
production NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Six CD - B-CARDINAL
clinical ADJ - O
strategies NOUN - O
were VERB - O
compared VERB - O
that DET - O
differ VERB - O
in ADP - O
use NOUN - O
of ADP - O
PCR PROPN - O
diagnostics NOUN - O
( PUNCT - O
used VERB - O
vs ADP - O
not ADV - O
used VERB - O
) PUNCT - O
and CCONJ - O
in ADP - O
empiric ADJ - O
therapeutic ADJ - O
choice NOUN - O
in ADP - O
case NOUN - O
of ADP - O
unknown ADJ - O
triazole ADJ - O
susceptibility NOUN - O
: PUNCT - O
voriconazole NN - B-MEDICINE
, PUNCT - O
liposomal NOUN - O
amphotericin ADP - O
B PROPN - O
( PUNCT - O
LAmB NNP - B-ORG
) PUNCT - O
or CCONJ - O
both DET - O
. PUNCT - O

Implementing VERB - O
aspergillus CCONJ - O
PCR NNP - B-ORG
tests NOUN - O
was VERB - O
projected VERB - O
to PART - O
result VERB - O
in ADP - O
residual ADJ - O
treatment NOUN - O
- PUNCT - O
susceptibility NOUN - O
mismatches NOUN - O
of ADP - O
< NOUN - O
5 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
a DET - O
triazole ADJ - O
resistance NOUN - O
rate NOUN - O
up ADP - O
to PART - O
20 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
using VERB - O
voriconazole NN - B-MEDICINE
) PUNCT - O
. PUNCT - O

Empiric JJ - B-PERSON
LAmB NNP - I-PERSON
outperformed VERB - O
voriconazole NN - B-MEDICINE
at ADP - O
resistance NOUN - O
rates NOUN - O
> X - O
5 CD - B-PERCENT
- SYM - I-PERCENT
20 CD - I-PERCENT
% NN - I-PERCENT
, PUNCT - O
depending VERB - O
on ADP - O
PCR PROPN - O
use NOUN - O
and CCONJ - O
estimated VERB - O
survival NOUN - O
benefits NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
over ADP - O
LAmB. NNP - B-ORG
Combination NNP - I-ORG
therapy NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
LAmB NNP - B-ORG
performed VERB - O
best ADV - O
at ADP - O
all DET - O
resistance NOUN - O
rates NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
advantage NOUN - O
over ADP - O
the DET - O
other ADJ - O
strategies NOUN - O
should VERB - O
be VERB - O
weighed VERB - O
against ADP - O
the DET - O
expected VERB - O
increased VERB - O
number NOUN - O
of ADP - O
drug NOUN - O
- PUNCT - O
related VERB - O
serious ADJ - O
adverse ADJ - O
events NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

If ADP - O
BAL NNP - B-ORG
GM NNP - I-ORG
≥1.0 NNP - I-ORG
, PUNCT - O
the DET - O
patient NOUN - O
was VERB - O
switched VERB - O
to ADP - O
voriconazole NN - B-MEDICINE
for ADP - O
further ADJ - O
treatment NOUN - O
. PUNCT - O

All DET - O
nine CD - B-CARDINAL
patients NOUN - O
with ADP - O
GM NNP - B-ORG
> CCONJ - O
1 CD - B-CARDINAL
were VERB - O
switched VERB - O
to ADP - O
voriconazole NN - B-MEDICINE
from ADP - O
itraconazole NOUN - O
which ADJ - O
resulted VERB - O
in ADP - O
negative ADJ - O
GM NNP - B-ORG
levels NOUN - O
on ADP - O
follow NOUN - O
- PUNCT - O
up NOUN - O
bronchoscopy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
goal NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
determine VERB - O
the DET - O
role NOUN - O
of ADP - O
targeted VERB - O
voriconazole NN - B-MEDICINE
prophylaxis NOUN - O
( PUNCT - O
VORI PROPN - O
) PUNCT - O
in ADP - O
prevention NOUN - O
of ADP - O
invasive ADJ - O
fungal ADJ - O
infections NOUN - O
( PUNCT - O
IFI NNP - B-ORG
) PUNCT - O
after ADP - O
heart NOUN - O
transplantation NOUN - O
( PUNCT - O
HT).MethodsWe PROPN - O
conducted VERB - O
a DET - O
single ADJ - O
- PUNCT - O
center NOUN - O
, PUNCT - O
prospective ADJ - O
, PUNCT - O
observational ADJ - O
cohort NOUN - O
study NOUN - O
of ADP - O
276 CD - B-CARDINAL
HT PROPN - O
recipients NOUN - O
from ADP - O
June NNP - B-DATE
2005 CD - I-DATE
to ADP - O
April NNP - B-DATE
2017 CD - I-DATE
to PART - O
characterize VERB - O
the DET - O
incidence NOUN - O
and CCONJ - O
outcome NOUN - O
of ADP - O
IFI NNP - B-ORG
following VERB - O
targeted VERB - O
VORI PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
this DET - O
problem NOUN - O
, PUNCT - O
we PRON - O
used VERB - O
a DET - O
murine NOUN - O
model NOUN - O
of ADP - O
pulmonary ADJ - O
aspergillosis NOUN - O
caused VERB - O
by ADP - O
azole NOUN - O
- PUNCT - O
resistant ADJ - O
Aspergillus NNP - B-ORG
fumigatus NOUN - O
strains VERB - O
V29 NNP - B-ORG
and CCONJ - O
V45 NNP - B-ORG
, PUNCT - O
and CCONJ - O
compared VERB - O
treatment NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
( PUNCT - O
Vr PROPN - O
, PUNCT - O
oral ADJ - O
40 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
, PUNCT - O
bid NOUN - O
) PUNCT - O
or CCONJ - O
liposomal ADJ - O
amphotericin ADP - O
B PROPN - O
( PUNCT - O
L NNP - B-ORG
- HYPH - I-ORG
AmB NNP - I-ORG
, PUNCT - O
5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
IV NNP - B-ORG
) PUNCT - O
used VERB - O
alone ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
- PUNCT - O
speed NOUN - O
electrospinning VERB - O
with ADP - O
a DET - O
novel ADJ - O
continuous ADJ - O
cyclone NOUN - O
collection NOUN - O
was VERB - O
used VERB - O
to PART - O
manufacture VERB - O
a DET - O
formulation NOUN - O
of ADP - O
the DET - O
poorly ADJ - O
water NOUN - O
- PUNCT - O
soluble ADJ - O
antifungal ADJ - O
voriconazole NN - B-MEDICINE
( PUNCT - O
VOR PROPN - O
) PUNCT - O
with ADP - O
sulfobutylether NOUN - O
- PUNCT - O
β VERB - O
- PUNCT - O
cyclodextrin PROPN - O
( PUNCT - O
SBE PROPN - O
- PUNCT - O
β PROPN - O
- PUNCT - O
CD PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
two CD - B-CARDINAL
cases NOUN - O
of ADP - O
central ADJ - O
nervous ADJ - O
system NOUN - O
aspergillosis NOUN - O
treated VERB - O
with ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

Because ADP - O
of ADP - O
low ADJ - O
trough NOUN - O
plasma NOUN - O
concentrations NOUN - O
, PUNCT - O
we PRON - O
identified VERB - O
gain NOUN - O
- PUNCT - O
of ADP - O
- PUNCT - O
function NOUN - O
mutations NOUN - O
in ADP - O
CYP2C19 NNP - B-GPE
that ADJ - O
were VERB - O
partially ADV - O
responsible ADJ - O
for ADP - O
the DET - O
therapeutic ADJ - O
failure NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

We PRON - O
suggest VERB - O
that ADP - O
systematic ADJ - O
voriconazole JJ - B-MEDICINE
pharmacogenomic ADJ - O
investigation NOUN - O
of ADP - O
cerebral ADJ - O
aspergillosis NOUN - O
be VERB - O
performed VERB - O
to PART - O
avoid VERB - O
effective ADJ - O
therapy NOUN - O
delay NOUN - O
in ADP - O
this DET - O
life NOUN - O
- PUNCT - O
threatening VERB - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
was VERB - O
successfully ADV - O
treated VERB - O
with ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Additionally ADV - O
, PUNCT - O
the DET - O
selected VERB - O
20 CD - B-CARDINAL
isolates NOUN - O
were VERB - O
tested VERB - O
with ADP - O
eleven CD - B-CARDINAL
concentrations NOUN - O
ranging VERB - O
0.015 CD - B-CARDINAL
- HYPH - I-CARDINAL
16mg NN - I-CARDINAL
/ SYM - I-CARDINAL
L NN - I-CARDINAL
of IN - I-CARDINAL
ITR NNP - I-CARDINAL
, PUNCT - O
voriconazole NN - B-MEDICINE
, PUNCT - O
posaconazole NOUN - O
and CCONJ - O
isavuconazole NOUN - O
. PUNCT - O

One CD - B-CARDINAL
isolate NOUN - O
showed VERB - O
elevated ADJ - O
MIC NNP - B-ORG
for ADP - O
ITR NNP - B-ORG
( PUNCT - O
16mg NN - B-ORG
/ SYM - I-ORG
L NN - I-ORG
) PUNCT - O
, PUNCT - O
as ADV - O
well ADV - O
as ADP - O
voriconazole NN - B-MEDICINE
( PUNCT - O
4mg NN - B-ORDINAL
/ SYM - O
L NOUN - O
) PUNCT - O
, PUNCT - O
izavuconazole ADJ - O
( PUNCT - O
4mg NOUN - O
/ SYM - O
L NOUN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
posaconazole NOUN - O
( PUNCT - O
0.5mg NNP - B-ORG
/ SYM - I-ORG
L NN - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Chronic ADJ - O
inflammation NOUN - O
increased VERB - O
the DET - O
plasma ADJ - O
voriconazole NN - B-MEDICINE
concentration NOUN - O
via ADP - O
its ADJ - O
poor ADJ - O
metabolism NOUN - O
, PUNCT - O
whereas ADP - O
it PRON - O
did VERB - O
not ADV - O
alter VERB - O
the DET - O
plasma NOUN - O
itraconazole ADJ - O
concentration NOUN - O
. PUNCT - O

Although ADP - O
co NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
prednisolone NOUN - O
did VERB - O
not ADV - O
affect VERB - O
the DET - O
plasma NOUN - O
concentration NOUN - O
of ADP - O
triazole ADJ - O
antifungals NOUN - O
, PUNCT - O
it PRON - O
weakly ADV - O
increased VERB - O
voriconazole NN - B-MEDICINE
metabolism NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

WHAT NOUN - O
IS VERB - O
KNOWN VERB - O
AND CCONJ - O
OBJECTIVE NOUN - O
: PUNCT - O
Voriconazole NN - B-ORG
is VERB - O
a DET - O
broad ADJ - O
- PUNCT - O
spectrum ADJ - O
antifungal ADJ - O
agent NOUN - O
and CCONJ - O
is VERB - O
mainly ADV - O
metabolized VERB - O
by ADP - O
the DET - O
liver NOUN - O
, PUNCT - O
yet CCONJ - O
there ADV - O
have VERB - O
been VERB - O
no DET - O
reports NOUN - O
about ADP - O
voriconazole NN - B-MEDICINE
treatment NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
Child NNP - B-ORG
- HYPH - I-ORG
Pugh NN - I-ORG
class NOUN - O
C NOUN - O
cirrhosis NOUN - O
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
investigate VERB - O
the DET - O
pharmacokinetic ADJ - O
profile NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
voriconazole JJ - B-MEDICINE
treatment NOUN - O
in ADP - O
this DET - O
cohort NOUN - O
of ADP - O
patients NOUN - O
. PUNCT - O

A DET - O
retrospective ADJ - O
, PUNCT - O
multicenter ADJ - O
study NOUN - O
was VERB - O
performed VERB - O
in ADP - O
patients NOUN - O
with ADP - O
Child NNP - B-ORG
- HYPH - I-ORG
Pugh NN - I-ORG
class NOUN - O
C NOUN - O
cirrhosis NOUN - O
who NOUN - O
received VERB - O
a DET - O
voriconazole NN - B-MEDICINE
maintenance NOUN - O
dose NOUN - O
of ADP - O
100 CD - B-CARDINAL
  SPACE - O
mg PRON - O
twice ADV - O
daily ADV - O
( PUNCT - O
group NOUN - O
A NOUN - O
) PUNCT - O
or CCONJ - O
200 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
daily RB - B-DATE
( PUNCT - O
group NOUN - O
B PROPN - O
) PUNCT - O
orally ADV - O
or CCONJ - O
intravenously ADV - O
. PUNCT - O

All DET - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
were VERB - O
measured VERB - O
by ADP - O
high ADJ - O
- PUNCT - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
, PUNCT - O
and CCONJ - O
voriconazole NN - B-MEDICINE
- PUNCT - O
related VERB - O
adverse ADJ - O
events NOUN - O
were VERB - O
defined VERB - O
according VERB - O
to ADP - O
Common NNP - B-ORG
Terminology NNP - I-ORG
Criteria NNP - I-ORG
for ADP - O
Adverse NNP - B-ORG
Events NNPS - I-ORG
. PUNCT - O

The DET - O
relationship NOUN - O
between ADP - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
and CCONJ - O
adverse ADJ - O
events NOUN - O
was VERB - O
explored VERB - O
using VERB - O
logistic ADJ - O
regression NOUN - O
model NOUN - O
. PUNCT - O

A DET - O
total NOUN - O
of ADP - O
51 CD - B-CARDINAL
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
were VERB - O
monitored VERB - O
from ADP - O
34 CD - B-CARDINAL
patients NOUN - O
. PUNCT - O

The DET - O
Cmin PROPN - O
of ADP - O
voriconazole NN - B-MEDICINE
was VERB - O
4.42 CD - B-CARDINAL
  SPACE - O
± NUM - O
  SPACE - O
2.08 NUM - O
and CCONJ - O
5.42 CD - B-CARDINAL
  SPACE - O
± NUM - O
  SPACE - O

The DET - O
proportion NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
over ADP - O
the DET - O
upper ADJ - O
limit NOUN - O
of ADP - O
therapeutic ADJ - O
level NOUN - O
( PUNCT - O
5 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
) PUNCT - O
in ADP - O
groups NOUN - O
A NOUN - O
and CCONJ - O
B NOUN - O
was VERB - O
34.48 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
47.62 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
respectively ADV - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
23.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
8/34 CD - B-CARDINAL
) PUNCT - O
of ADP - O
patients NOUN - O
exhibited VERB - O
signs NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
- PUNCT - O
related VERB - O
adverse ADJ - O
events NOUN - O
, PUNCT - O
and CCONJ - O
87.5 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
7/8 CD - B-CARDINAL
) PUNCT - O
of ADP - O
adverse ADJ - O
events NOUN - O
occurred VERB - O
within ADP - O
the DT - B-DATE
first JJ - I-DATE
week NN - I-DATE
after ADP - O
voriconazole JJ - B-MEDICINE
treatment NOUN - O
. PUNCT - O

Logistic ADJ - O
regression NOUN - O
model NOUN - O
showed VERB - O
that ADP - O
there ADV - O
was VERB - O
a DET - O
positive ADJ - O
correlation NOUN - O
between ADP - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
and CCONJ - O
the DET - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
reactions NOUN - O
. PUNCT - O

The DET - O
voriconazole NN - B-MEDICINE
maintenance NOUN - O
dose NOUN - O
of ADP - O
100 CD - B-CARDINAL
  SPACE - O
mg PRON - O
twice ADV - O
daily RB - B-DATE
or CCONJ - O
200 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
daily RB - B-DATE
orally ADV - O
or CCONJ - O
intravenously ADV - O
may VERB - O
be VERB - O
inappropriate ADJ - O
in ADP - O
patients NOUN - O
with ADP - O
Child NNP - B-ORG
- HYPH - I-ORG
Pugh NN - I-ORG
class NOUN - O
C NOUN - O
cirrhosis NOUN - O
because ADP - O
of ADP - O
the DET - O
higher ADJ - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
and CCONJ - O
higher ADJ - O
incidence NOUN - O
of ADP - O
adverse ADJ - O
events NOUN - O
. PUNCT - O

Monitoring VERB - O
voriconazole NN - B-MEDICINE
Cmin NNP - B-PERSON
earlier ADV - O
is VERB - O
extremely ADV - O
important ADJ - O
to PART - O
prevent VERB - O
the DET - O
occurrence NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
- PUNCT - O
related VERB - O
adverse ADJ - O
reactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Eighty CD - B-CARDINAL
- HYPH - I-CARDINAL
six CD - I-CARDINAL
of ADP - O
89 NUM - O
( PUNCT - O
97 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
isolates VERB - O
with ADP - O
the DET - O
TR34/L98H NNP - B-ORG
mutation NOUN - O
had VERB - O
voriconazole NN - B-MEDICINE
and CCONJ - O
posaconazole NOUN - O
MICs NOUN - O
above ADP - O
the DET - O
CLSI NNP - B-ORG
ECV PROPN - O
, PUNCT - O
i.e. X - O
, PUNCT - O
MICs PROPN - O
of ADP - O
1 CD - B-CARDINAL
and CCONJ - O
0.25 CD - B-CARDINAL
mg NN - B-ORG
/ SYM - I-ORG
L NNP - I-ORG
, PUNCT - O
respectively ADV - O
. PUNCT - O

All DET - O
37 CD - B-CARDINAL
isolates VERB - O
with ADP - O
a DET - O
TR46/Y121F NNP - B-ORG
/ SYM - I-ORG
T289A NNP - I-ORG
mutation NOUN - O
had VERB - O
a DET - O
voriconazole NN - B-MEDICINE
MIC NNP - B-ORG
above ADP - O
the DET - O
CLSI NNP - B-ORG
ECV PROPN - O
, PUNCT - O
while ADP - O
28/37 CD - B-CARDINAL
( PUNCT - O
76 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
isolates NOUN - O
had VERB - O
an DET - O
itraconazole ADJ - O
MIC NNP - B-ORG
> X - O
1 CD - B-QUANTITY
mg NN - I-QUANTITY
/ SYM - I-QUANTITY
L. PROPN - O
Interestingly PROPN - O
, PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
voriconazole NN - B-MEDICINE
, PUNCT - O
a DET - O
monotriazole NOUN - O
with ADP - O
noted VERB - O
in ADP - O
vitro ADJ - O
activity NOUN - O
against ADP - O
a DET - O
large ADJ - O
variety NOUN - O
of ADP - O
fungi NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
successfully ADV - O
used VERB - O
both CCONJ - O
topically ADV - O
and CCONJ - O
systemically ADV - O
to PART - O
treat VERB - O
human ADJ - O
AK PROPN - O
cases NOUN - O
. PUNCT - O

To PART - O
measure VERB - O
anti ADJ - O
- ADJ - O
Acanthamoeba ADJ - O
polyphaga NOUN - O
in ADP - O
vitro NOUN - O
activity NOUN - O
, PUNCT - O
anti ADJ - O
- ADJ - O
rat ADJ - O
AK PROPN - O
efficiency NOUN - O
and CCONJ - O
rat NOUN - O
cornea ADJ - O
penetration NOUN - O
of ADP - O
eye NOUN - O
- PUNCT - O
drop NOUN - O
and CCONJ - O
oral ADJ - O
voriconazole NN - B-MEDICINE
. PUNCT - O

In ADP - O
vitro NOUN - O
, PUNCT - O
amoebicidal ADJ - O
and CCONJ - O
cysticidal ADJ - O
activities NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
were VERB - O
measured VERB - O
using VERB - O
an DET - O
XTT NNP - B-ORG
assay NOUN - O
. PUNCT - O

For ADP - O
21 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
, PUNCT - O
from ADP - O
day NN - B-DATE
7 CD - I-DATE
post ADJ - O
- ADJ - O
infection ADJ - O
, PUNCT - O
voriconazole NN - B-MEDICINE
( PUNCT - O
1 CD - B-PERCENT
% NN - I-PERCENT
solution NOUN - O
) PUNCT - O
eye NOUN - O
drops NOUN - O
were VERB - O
instilled VERB - O
or CCONJ - O
voriconazole NN - B-MEDICINE
was VERB - O
administered VERB - O
by ADP - O
gavage NOUN - O
( PUNCT - O
60 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
kg NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
. PUNCT - O

In ADP - O
vitro NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
inhibited VERB - O
trophozoite NOUN - O
proliferation NOUN - O
with ADP - O
an DET - O
IC50 PROPN - O
value NOUN - O
of ADP - O
0.02 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
and CCONJ - O
an DET - O
IC90 PROPN - O
value NOUN - O
of ADP - O
2.86 CD - B-CARDINAL
  SPACE - O
mg PROPN - O
/ SYM - O
L PROPN - O
; PUNCT - O
no DET - O
cysticidal ADJ - O
effect NOUN - O
was VERB - O
found VERB - O
. PUNCT - O

In ADP - O
AK PROPN - O
rats NOUN - O
, PUNCT - O
eye NOUN - O
drops NOUN - O
reduced VERB - O
clinical ADJ - O
worsening NOUN - O
from ADP - O
day NN - B-DATE
7 CD - I-DATE
to IN - I-DATE
day NN - I-DATE
14 NUM - O
post ADJ - O
- ADJ - O
infection ADJ - O
and CCONJ - O
oral ADJ - O
voriconazole NN - B-MEDICINE
was VERB - O
not ADV - O
effective ADJ - O
. PUNCT - O

Voriconazole NN - B-MEDICINE
cornea NOUN - O
concentrations NOUN - O
were VERB - O
directly ADV - O
dependent ADJ - O
on ADP - O
the DET - O
frequency NOUN - O
of ADP - O
eye NOUN - O
- PUNCT - O
drop NOUN - O
instillations NOUN - O
, PUNCT - O
which ADJ - O
resulted VERB - O
in ADP - O
lower ADJ - O
plasma NOUN - O
concentrations NOUN - O
, PUNCT - O
whilst ADP - O
oral ADJ - O
voriconazole NN - B-MEDICINE
resulted VERB - O
in ADP - O
lower ADJ - O
cornea NOUN - O
concentrations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
voriconazole JJ - B-MEDICINE
anti ADJ - O
- ADJ - O
Acanthamoeba ADJ - O
polyphaga NOUN - O
in ADP - O
vitro NOUN - O
activity NOUN - O
, PUNCT - O
rat NOUN - O
cornea ADJ - O
penetration NOUN - O
and CCONJ - O
efficacy NOUN - O
against ADP - O
experimental ADJ - O
rat NOUN - O
Acanthamoeba ADJ - O
keratitis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

These DET - O
agents NOUN - O
include VERB - O
voriconazole NN - B-MEDICINE
, PUNCT - O
posaconazole NOUN - O
, PUNCT - O
isavuconazole NOUN - O
, PUNCT - O
and CCONJ - O
ravuconazole NOUN - O
. PUNCT - O

The DET - O
intravenous ADJ - O
administration NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
, PUNCT - O
posaconazole NOUN - O
, PUNCT - O
and CCONJ - O
isavuconazole NOUN - O
results NOUN - O
in ADP - O
stable ADJ - O
pharmacokinetics NOUN - O
of ADP - O
these DET - O
drugs NOUN - O
, PUNCT - O
with ADP - O
mostly ADV - O
predictable ADJ - O
variations NOUN - O
influenced VERB - O
by ADP - O
common ADJ - O
and CCONJ - O
usually ADV - O
known VERB - O
factors NOUN - O
in ADP - O
routine ADJ - O
clinical ADJ - O
settings NOUN - O
. PUNCT - O

The DET - O
high ADJ - O
oral ADJ - O
bioavailability NOUN - O
of ADP - O
isavuconazole NOUN - O
and CCONJ - O
, PUNCT - O
to ADP - O
some DET - O
extent NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
makes VERB - O
them PRON - O
suitable ADJ - O
for ADP - O
intravenous ADJ - O
- PUNCT - O
to ADP - O
- PUNCT - O
oral ADJ - O
switch NOUN - O
strategies NOUN - O
. PUNCT - O

Except ADP - O
for ADP - O
intravenous ADJ - O
voriconazole NN - B-MEDICINE
( PUNCT - O
due ADP - O
to ADP - O
the DET - O
accumulation NOUN - O
of ADP - O
the DET - O
toxic ADJ - O
vehicle NOUN - O
hydroxypropyl ADJ - O
betadex NOUN - O
) PUNCT - O
, PUNCT - O
dose VERB - O
reduction NOUN - O
of ADP - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
triazoles NOUN - O
is VERB - O
not ADV - O
needed VERB - O
in ADP - O
patients NOUN - O
with ADP - O
renal ADJ - O
failure NOUN - O
; PUNCT - O
patients NOUN - O
with ADP - O
hepatic ADJ - O
insufficiency NOUN - O
require VERB - O
dose NOUN - O
reduction NOUN - O
only ADV - O
in ADP - O
advanced ADJ - O
disease NOUN - O
stages NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
the DET - O
active ADJ - O
sulfa NOUN - O
drugs NOUN - O
, PUNCT - O
sulfamethoxazole VERB - O
exhibited VERB - O
the DET - O
most ADV - O
potent ADJ - O
in ADP - O
vitro X - O
synergistic ADJ - O
interactions NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
itraconazole NOUN - O
. PUNCT - O

The DET - O
sulfamethoxazole NOUN - O
- PUNCT - O
voriconazole NN - B-MEDICINE
combination NOUN - O
restored VERB - O
voriconazole NN - B-MEDICINE
's PART - O
fungistatic ADJ - O
activity NOUN - O
against ADP - O
three CD - B-CARDINAL
of ADP - O
eight CD - B-CARDINAL
voriconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
clinical ADJ - O
isolates NOUN - O
. PUNCT - O

The DET - O
sulfamethoxazole NOUN - O
- PUNCT - O
voriconazole NN - B-MEDICINE
combination NOUN - O
enhanced VERB - O
survival NOUN - O
of ADP - O
nematodes NOUN - O
infected VERB - O
with ADP - O
C. NNP - B-PERSON
auris ADV - O
by ADP - O
nearly RB - B-PERCENT
70 CD - I-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

However ADV - O
, PUNCT - O
we PRON - O
found VERB - O
that ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
was VERB - O
promising VERB - O
for ADP - O
treating VERB - O
Phialophora NNP - B-PERSON
verrucosa NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
corneal ADJ - O
cross NOUN - O
- ADJ - O
linking VERB - O
on ADP - O
Phialophora NNP - B-GPE
verrucosa NOUN - O
keratitis NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
patient NOUN - O
received VERB - O
treatment NOUN - O
with ADP - O
oral ADJ - O
voriconazole NN - B-MEDICINE
for ADP - O
five CD - B-DATE
months NNS - I-DATE
with ADP - O
good ADJ - O
response NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aspergillus PROPN - O
isolates NOUN - O
were VERB - O
tested VERB - O
for ADP - O
resistance NOUN - O
to ADP - O
itraconazole ADJ - O
, PUNCT - O
posaconazole NOUN - O
, PUNCT - O
and CCONJ - O
voriconazole NN - B-MEDICINE
by ADP - O
the DET - O
EUCAST NN - B-NORP
method NOUN - O
. PUNCT - O

Five CD - B-CARDINAL
out ADP - O
of ADP - O
84 CD - B-CARDINAL
samples NOUN - O
yielded VERB - O
A. NN - B-ORG
fumigatus NOUN - O
isolates VERB - O
: PUNCT - O
four CD - B-CARDINAL
of ADP - O
them PRON - O
were VERB - O
itraconazole ADJ - O
- PUNCT - O
resistant ADJ - O
and CCONJ - O
were VERB - O
identified VERB - O
as ADP - O
A. NN - B-ORG
fumigatus NOUN - O
sensu NOUN - O
stricto NOUN - O
, PUNCT - O
three CD - B-CARDINAL
of ADP - O
them PRON - O
were VERB - O
posaconazole NOUN - O
- PUNCT - O
resistant ADJ - O
, PUNCT - O
and CCONJ - O
two CD - B-CARDINAL
were VERB - O
also ADV - O
voriconazole NN - B-MEDICINE
- PUNCT - O
resistant ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
radiological ADJ - O
documentation NOUN - O
for ADP - O
the DET - O
brain NOUN - O
aspergilloma NOUN - O
shows VERB - O
a DET - O
positive ADJ - O
response NOUN - O
to ADP - O
a DET - O
combination NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
and CCONJ - O
Keppra NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
object NOUN - O
of ADP - O
our ADJ - O
study NOUN - O
was VERB - O
focused VERB - O
on ADP - O
the DET - O
determination NOUN - O
of ADP - O
the DET - O
susceptibility NOUN - O
to ADP - O
amphotericin PROPN - O
B NOUN - O
, PUNCT - O
caspofungin NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
and CCONJ - O
two CD - B-CARDINAL
antifungal ADJ - O
combinations NOUN - O
( PUNCT - O
amphotericin ADP - O
B PROPN - O
/ SYM - O
caspofungin NOUN - O
and CCONJ - O
amphotericin PROPN - O
B PROPN - O
/ SYM - O
voriconazole NN - B-MEDICINE
) PUNCT - O
of ADP - O
both CCONJ - O
planktonic ADJ - O
and CCONJ - O
sessile ADJ - O
cells NOUN - O
of ADP - O
C. NNP - B-GPE
  _SP - I-GPE
albicans NOUN - O
, PUNCT - O
which ADJ - O
were VERB - O
isolated VERB - O
from ADP - O
catheters NOUN - O
. PUNCT - O

They PRON - O
went VERB - O
from ADP - O
2 CD - B-CARDINAL
to ADP - O
64μg NOUN - O
/ SYM - O
mL PROPN - O
for ADP - O
amphotericin NOUN - O
B NOUN - O
, PUNCT - O
from ADP - O
1 CD - B-CARDINAL
to ADP - O
64μg NOUN - O
/ SYM - O
mL NOUN - O
for ADP - O
caspofungin NOUN - O
and CCONJ - O
from ADP - O
2 CD - B-CARDINAL
to ADP - O
128μg NN - B-ORG
/ SYM - O
mL PROPN - O
for ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

The DET - O
combination NOUN - O
of ADP - O
amphotericin NOUN - O
B NOUN - O
to ADP - O
caspofungin NOUN - O
or CCONJ - O
to PART - O
voriconazole NN - B-MEDICINE
decreased VERB - O
significantly ADV - O
the DET - O
MIC NNP - B-ORG
values NOUN - O
for ADP - O
planctonic ADJ - O
( PUNCT - O
P<0.0001 NNP - B-GPE
) PUNCT - O
and CCONJ - O
sessile NOUN - O
cells NOUN - O
( PUNCT - O
P=0.0016 NN - B-ORG
) PUNCT - O
. PUNCT - O

The DET - O
obtained VERB - O
results NOUN - O
showed VERB - O
that ADP - O
the DET - O
combination NOUN - O
of ADP - O
amphotericin NOUN - O
B NOUN - O
with ADP - O
either DET - O
caspofungin NOUN - O
or CCONJ - O
voriconazole NN - B-MEDICINE
can VERB - O
be VERB - O
used VERB - O
as ADP - O
a DET - O
new ADJ - O
strategy NOUN - O
for ADP - O
management NOUN - O
of ADP - O
systemic ADJ - O
mycoses NOUN - O
associated VERB - O
to ADP - O
medical ADJ - O
devices NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

to ADP - O
fluconazole NOUN - O
, PUNCT - O
itraconazole ADJ - O
and CCONJ - O
voriconazole NN - B-MEDICINE
and CCONJ - O
the DET - O
correlation NOUN - O
between ADP - O
triazoles NOUN - O
susceptibility NOUN - O
: PUNCT - O
Results NOUN - O
from ADP - O
a DET - O
five CD - B-DATE
- HYPH - I-DATE
year NN - I-DATE
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
rapid ADJ - O
ultra ADJ - O
- ADJ - O
performance NOUN - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
assay VERB - O
for ADP - O
determination NOUN - O
of ADP - O
serum NOUN - O
unbound NOUN - O
fraction NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
cancer NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

First JJ - B-ORDINAL
report NOUN - O
of ADP - O
invasive ADJ - O
pulmonary ADJ - O
infection NOUN - O
by ADP - O
Didymella NNP - B-ORG
microchlamydospora NOUN - O
and CCONJ - O
successful ADJ - O
treatment NOUN - O
with ADP - O
voriconazole NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Therapeutic ADJ - O
drug NOUN - O
monitoring NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
therapy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
Child NNP - B-ORG
- HYPH - I-ORG
Pugh NN - I-ORG
class NN - I-ORG
B NOUN - O
and CCONJ - O
C NOUN - O
cirrhosis NOUN - O
: PUNCT - O
A DET - O
multicenter ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Factors NNS - B-ORG
associated VERB - O
with ADP - O
supratherapeutic ADJ - O
and CCONJ - O
subtherapeutic ADJ - O
voriconazole NN - B-MEDICINE
concentrations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
  SPACE - O
good ADJ - O
sensitivity NOUN - O
for ADP - O
amphotericin ADV - O
  SPACE - O
B NOUN - O
and CCONJ - O
voriconazole NN - B-MEDICINE
was VERB - O
demonstrated VERB - O
in ADP - O
the DET - O
resistogram NOUN - O
for ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
and CCONJ - O
the DET - O
successful ADJ - O
clinical ADJ - O
course NOUN - O
was VERB - O
confirmed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Photosensitisation NOUN - O
by ADP - O
voriconazole NN - B-MEDICINE
- PUNCT - O
N NOUN - O
- PUNCT - O
oxide NOUN - O
results NOUN - O
from ADP - O
a DET - O
sequence NOUN - O
of ADP - O
solvent NOUN - O
and CCONJ - O
pH NOUN - O
- PUNCT - O
dependent ADJ - O
photochemical ADJ - O
and CCONJ - O
thermal ADJ - O
reactions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PURPOSE PROPN - O
: PUNCT - O
To PART - O
identify VERB - O
the DET - O
risk NOUN - O
of ADP - O
inducing VERB - O
ocular NOUN - O
surface NOUN - O
dysplasia NOUN - O
following VERB - O
topical ADJ - O
administration NOUN - O
of ADP - O
1 CD - B-PERCENT
% NN - I-PERCENT
voriconazole NN - B-MEDICINE
eye NOUN - O
drop NOUN - O
. PUNCT - O

Group NOUN - O
1 CD - B-CARDINAL
received VERB - O
topical ADJ - O
1 CD - B-PERCENT
% NN - I-PERCENT
voriconazole NN - B-MEDICINE
and CCONJ - O
Group NNP - B-ORG
2 CD - I-ORG
received VERB - O
topical ADJ - O
saline NOUN - O
as ADP - O
the DET - O
control NOUN - O
group NOUN - O
. PUNCT - O

In ADP - O
Group NNP - B-ORG
1 CD - I-ORG
( -LRB- - I-ORG
Voriconazole NNP - B-ORG
Group NNP - I-ORG
) PUNCT - O
, PUNCT - O
single ADJ - O
drop NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
was VERB - O
instilled VERB - O
every DET - O
10 CD - B-CARDINAL
  SPACE - O
min NOUN - O
consecutively ADV - O
for ADP - O
17 CD - B-CARDINAL
times NOUN - O
a DET - O
day NOUN - O
for ADP - O
60 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
. PUNCT - O

This DET - O
animal NOUN - O
study NOUN - O
provides VERB - O
a DET - O
possible ADJ - O
relationship NOUN - O
between ADP - O
topically ADV - O
administered VERB - O
1 CD - B-PERCENT
% NN - I-PERCENT
voriconazole NN - B-MEDICINE
and CCONJ - O
ocular ADJ - O
surface NOUN - O
dysplasia NOUN - O
. PUNCT - O

We PRON - O
recommend VERB - O
ophthalmologists NOUN - O
to PART - O
be VERB - O
aware ADJ - O
of ADP - O
the DET - O
risk NOUN - O
of ADP - O
ocular ADJ - O
surface NOUN - O
dysplasia NOUN - O
in ADP - O
patients NOUN - O
received VERB - O
voriconazole JJ - B-MEDICINE
eye NOUN - O
drop NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Failure NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
therapy NOUN - O
due ADJ - O
to ADP - O
acquired VERB - O
azole NOUN - O
resistance NOUN - O
in ADP - O
Aspergillus NNP - B-LOC
fumigatus NOUN - O
in ADP - O
a DET - O
kidney NOUN - O
transplant NOUN - O
recipient NOUN - O
with ADP - O
chronic ADJ - O
necrotizing NOUN - O
aspergillosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pharmacogenetic ADJ - O
of ADP - O
voriconazole JJ - B-MEDICINE
antifungal ADJ - O
agent NOUN - O
in ADP - O
pediatric ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
impact NOUN - O
of ADP - O
proton NOUN - O
pump VERB - O
inhibitors NOUN - O
on ADP - O
the DET - O
pharmacokinetics NOUN - O
of ADP - O
voriconazole NN - B-MEDICINE
in ADP - O
vitro NOUN - O
and CCONJ - O
in ADP - O
vivo NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
protocol NOUN - O
describes VERB - O
a DET - O
sample NOUN - O
preparation NOUN - O
procedure NOUN - O
and CCONJ - O
a DET - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
assay VERB - O
for ADP - O
quantifying VERB - O
serum ADJ - O
voriconazole NN - B-MEDICINE
, PUNCT - O
isavuconazole NOUN - O
, PUNCT - O
and CCONJ - O
posaconazole NOUN - O
in ADP - O
a DET - O
single ADJ - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
case NOUN - O
report NOUN - O
we PRON - O
present VERB - O
an DET - O
immunocompetent ADJ - O
64-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
patient NOUN - O
presenting VERB - O
with ADP - O
an DET - O
orbitofrontal ADJ - O
invasive ADJ - O
aspergillosis NOUN - O
treated VERB - O
successfully ADV - O
with ADP - O
voriconazole JJ - B-MEDICINE
monotherapy NOUN - O
following VERB - O
biopsy NOUN - O
and CCONJ - O
orbital ADJ - O
decompression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
investigate VERB - O
enhanced VERB - O
drought NOUN - O
- PUNCT - O
stress NOUN - O
tolerance NOUN - O
, PUNCT - O
peach NOUN - O
was VERB - O
treated VERB - O
with ADP - O
water NOUN - O
, PUNCT - O
100 CD - B-CARDINAL
  SPACE - O
nM NUM - O
24-epibrassinolide CD - B-CARDINAL
( PUNCT - O
EBR NNP - B-ORG
) PUNCT - O
, PUNCT - O
1 CD - B-CARDINAL
  SPACE - O
μM NNP - B-PRODUCT
EBR NNP - I-PRODUCT
, PUNCT - O
10 CD - B-CARDINAL
  SPACE - O
μM NNP - B-PRODUCT
EBR NNP - I-PRODUCT
and CCONJ - O
1 CD - B-CARDINAL
  SPACE - O
μM POS - B-ORG
voriconazole NN - B-MEDICINE
. PUNCT - O

Exogenous ADJ - O
EBR NNP - B-ORG
at ADP - O
1 CD - B-MONEY
  _SP - I-MONEY
μM NNP - I-MONEY
decreased VERB - O
the DET - O
malondialdehyde NOUN - O
( PUNCT - O
MDA NNP - B-ORG
) PUNCT - O
content NOUN - O
under ADP - O
drought NOUN - O
stress NOUN - O
when ADV - O
compared VERB - O
with ADP - O
water- NOUN - O
, PUNCT - O
1 CD - B-CARDINAL
  SPACE - O
μM FW - B-PRODUCT
voriconazole- NOUN - O

-DOCSTART- -X- - O

We PRON - O
successfully ADV - O
treated VERB - O
her PRON - O
with ADP - O
intravenous ADJ - O
voriconazole NN - B-MEDICINE
for ADP - O
more JJR - B-DATE
than IN - I-DATE
a DT - I-DATE
month NN - I-DATE
without ADP - O
any DET - O
complications NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
voriconazole NN - B-MEDICINE
can VERB - O
be VERB - O
a DET - O
good ADJ - O
treatment NOUN - O
choice NOUN - O
for ADP - O
achieving VERB - O
better ADJ - O
treatment NOUN - O
results NOUN - O
and CCONJ - O
prognosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
14 CD - B-CARDINAL
mg NOUN - O
also ADV - O
tended VERB - O
to PART - O
reduce VERB - O
12-week CD - B-CARDINAL
confirmed VERB - O
disability NOUN - O
worsening VERB - O
by ADP - O
68.1 CD - B-PERCENT
% NN - I-PERCENT
compared VERB - O
with ADP - O
placebo NOUN - O
( PUNCT - O
hazard NOUN - O
ratio NOUN - O
: PUNCT - O
0.319 CD - B-CARDINAL
, PUNCT - O
P NOUN - O
= SYM - O
0.1194 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Teriflunomide NNP - B-MEDICINE
was VERB - O
as ADV - O
effective ADJ - O
and CCONJ - O
safe ADJ - O
in ADP - O
the DET - O
Chinese JJ - B-NORP
subpopulation NOUN - O
as ADP - O
it PRON - O
was VERB - O
in ADP - O
the DET - O
overall ADJ - O
population NOUN - O
of ADP - O
patients NOUN - O
in ADP - O
the DET - O
TOWER PROPN - O
trial NOUN - O
. PUNCT - O

Teriflunomide NNP - B-MEDICINE
has VERB - O
the DET - O
potential NOUN - O
to PART - O
meet VERB - O
unmet ADJ - O
medical ADJ - O
needs NOUN - O
for ADP - O
MS NNP - B-ORG
patients NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Efficacy PROPN - O
and CCONJ - O
Safety PROPN - O
of ADP - O
Teriflunomide NNP - B-MEDICINE
in ADP - O
Chinese ADJ - O
Patients NOUN - O
with ADP - O
Relapsing PROPN - O
Forms PROPN - O
of ADP - O
Multiple PROPN - O
Sclerosis PROPN - O
: PUNCT - O

-DOCSTART- -X- - O

Teriflunomide NNP - B-MEDICINE
Modulates NNP - B-ORG
Vascular NNP - I-ORG
Permeability NNP - I-ORG
and CC - I-ORG
Microglial NNP - I-ORG
Activation NNP - I-ORG
after ADP - O
Experimental ADJ - O
Traumatic PROPN - O
Brain PROPN - O
Injury PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
, PUNCT - O
a DET - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
, PUNCT - O
oral ADJ - O
immunomodulatory NOUN - O
therapy NOUN - O
, PUNCT - O
has VERB - O
demonstrated VERB - O
efficacy NOUN - O
across ADP - O
multiple ADJ - O
measures NOUN - O
of ADP - O
disease NOUN - O
activity NOUN - O
and CCONJ - O
worsening VERB - O
in ADP - O
patients NOUN - O
with ADP - O
relapsing VERB - O
forms NOUN - O
of ADP - O
MS NNP - B-ORG
and CCONJ - O
in ADP - O
those DET - O
with ADP - O
a DET - O
first JJ - B-ORDINAL
clinical ADJ - O
episode NOUN - O
suggestive NOUN - O
of ADP - O
MS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
, PUNCT - O
a DET - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
, PUNCT - O
oral ADJ - O
disease NOUN - O
- PUNCT - O
modifying VERB - O
therapy NOUN - O
, PUNCT - O
has VERB - O
demonstrated VERB - O
efficacy NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
relapsing VERB - O
forms NOUN - O
of ADP - O
multiple ADJ - O
sclerosis NOUN - O
( PUNCT - O
MS NNP - B-ORG
) PUNCT - O
and CCONJ - O
patients NOUN - O
with ADP - O
a DET - O
first JJ - B-ORDINAL
clinical ADJ - O
episode NOUN - O
suggestive NOUN - O
of ADP - O
MS NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide NNP - B-MEDICINE
7 CD - B-CARDINAL
mg NOUN - O
has VERB - O
a DET - O
higher ADJ - O
incidence NOUN - O
of ADP - O
diarrhea NOUN - O
( PUNCT - O
RR=1.73 NNP - B-ORG
, PUNCT - O

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
in ADP - O
Patients PROPN - O
with ADP - O
Relapsing PROPN - O
- PUNCT - O
Remitting NOUN - O
Forms PROPN - O
of ADP - O
Multiple PROPN - O
Sclerosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide NN - B-MEDICINE
and CCONJ - O
monomethylfumarate NOUN - O
target NOUN - O
HIV PROPN - O
- PUNCT - O
induced VERB - O
neuroinflammation NOUN - O
and CCONJ - O
neurotoxicity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
, PUNCT - O
a DET - O
once ADV - O
- PUNCT - O
daily JJ - B-DATE
oral ADJ - O
immunomodulator NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
relapsing VERB - O
- PUNCT - O
remitting VERB - O
multiple ADJ - O
sclerosis NOUN - O
, PUNCT - O
has VERB - O
demonstrated VERB - O
consistent ADJ - O
efficacy NOUN - O
on ADP - O
clinical ADJ - O
and CCONJ - O
MRI PROPN - O
parameters NOUN - O
in ADP - O
clinical ADJ - O
trials NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Physiologically ADV - O
Based VERB - O
Pharmacokinetic PROPN - O
Model PROPN - O
for ADP - O
Prediction PROPN - O
of ADP - O
Leflunomide PROPN - O
and CCONJ - O
Teriflunomide NNP - B-MEDICINE

-DOCSTART- -X- - O

Teriflunomide RB - B-MEDICINE
, PUNCT - O
the DET - O
main ADJ - O
active ADJ - O
metabolite NOUN - O
of ADP - O
leflunomide NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
approved VERB - O
as ADP - O
an DET - O
oral ADJ - O
treatment NOUN - O
in ADP - O
this DET - O
setting NOUN - O
. PUNCT - O

Teriflunomide NNP - B-MEDICINE
is VERB - O
teratogenic ADJ - O
in ADP - O
animals NOUN - O
and CCONJ - O
should VERB - O
not ADV - O
be VERB - O
used VERB - O
by ADP - O
pregnant ADJ - O
women NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Teriflunomide NNP - B-MEDICINE
( PUNCT - O
AUBAGIO NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Switching VERB - O
to ADP - O
Imipramine PROPN - O
Versus PROPN - O
Add PROPN - O
- PUNCT - O
on ADP - O
Mirtazapine PROPN - O
in ADP - O
Venlafaxine NNP - B-MEDICINE
- PUNCT - O
Resistant PROPN - O
Major PROPN - O
Depression NOUN - O
: PUNCT - O
A DET - O
10-Week NUM - O
Randomized VERB - O
Open PROPN - O
Study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Associations NNS - B-ORG
Between IN - I-ORG
CYP2D6 NNP - I-ORG
Metabolizer NNP - I-ORG
Status NNP - I-ORG
and CC - I-ORG
Pharmacokinetics NNP - I-ORG
and CCONJ - O
Clinical PROPN - O
Outcomes PROPN - O
of ADP - O
Venlafaxine NNP - B-MEDICINE
: PUNCT - O
A PROPN - O
Systematic PROPN - O
Review PROPN - O
and CCONJ - O
Meta NNP - B-ORG
- HYPH - I-ORG
Analysis NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
is VERB - O
an DET - O
antidepressant ADJ - O
and CCONJ - O
anxiolytic ADJ - O
agent NOUN - O
that ADJ - O
functions NOUN - O
by ADP - O
inhibiting VERB - O
central ADJ - O
serotonin NOUN - O
and CCONJ - O
norepinephrine NOUN - O
reuptake NOUN - O
, PUNCT - O
and CCONJ - O
it PRON - O
is VERB - O
a DET - O
relatively ADV - O
recently ADV - O
introduced VERB - O
drug NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Bupropion NN - B-ORG
Switch NNP - I-ORG
for ADP - O
a DT - B-ORG
Depressed JJ - I-ORG
Patient NNP - I-ORG
With IN - I-ORG
Venlafaxine NNP - I-MEDICINE
- HYPH - I-ORG
Associated NNP - I-ORG
Night NNP - I-ORG
Sweats NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
stimulates VERB - O
PNN NNP - B-ORG
proteolysis NOUN - O
and CCONJ - O
MMP-9 PROPN - O
dependent ADJ - O
enhancement NOUN - O
of ADP - O
gamma NOUN - O
power NOUN - O
; PUNCT - O
relevance VERB - O
to ADP - O
antidepressant NOUN - O
efficacy NOUN - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
the DT - B-ORG
Proton NNP - I-ORG
Pump NNP - I-ORG
Inhibitors NNPS - I-ORG
Omeprazole NNP - I-ORG
and CCONJ - O
Pantoprazole NNP - B-ORG
on ADP - O
the DET - O
Cytochrome PROPN - O
P450-Mediated PROPN - O
Metabolism PROPN - O
of ADP - O
Venlafaxine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
and CCONJ - O
the DET - O
atypical ADJ - O
antipsychotic ADJ - O
quetiapine NOUN - O
are VERB - O
often ADV - O
administered VERB - O
concomitantly ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
, PUNCT - O
a DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
medication NOUN - O
for ADP - O
depression NOUN - O
, PUNCT - O
inhibits VERB - O
the DET - O
reuptake NOUN - O
of ADP - O
both CCONJ - O
serotonin ADJ - O
and CCONJ - O
norepinephrine NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Toxicological NNP - B-ORG
Assessment NNP - I-ORG
of ADP - O
Venlafaxine NNP - B-MEDICINE
: PUNCT - O
Acute JJ - B-PERSON
and CCONJ - O
Subchronic PROPN - O
Toxicity PROPN - O
Study PROPN - O
in ADP - O
Rats PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
also ADV - O
showed VERB - O
decreased ADJ - O
functional ADJ - O
connectivity NOUN - O
between ADP - O
limbic ADJ - O
structures NOUN - O
and CCONJ - O
to PART - O
supralimbic VERB - O
areas NOUN - O
, PUNCT - O
but CCONJ - O
increased VERB - O
functional ADJ - O
connectivity NOUN - O
to ADP - O
structures NOUN - O
in ADP - O
the DET - O
midbrain NOUN - O
and CCONJ - O
brain NOUN - O
stem NOUN - O
was VERB - O
also ADV - O
found VERB - O
( PUNCT - O
all DET - O
P NOUN - O
  SPACE - O
< X - O
  SPACE - O
0.05 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
is VERB - O
an DET - O
antidepressant ADJ - O
and CCONJ - O
anti ADJ - O
- ADJ - O
anxiety ADJ - O
drug NOUN - O
that ADJ - O
has VERB - O
been VERB - O
detected VERB - O
in ADP - O
municipal ADJ - O
wastewater NOUN - O
at ADP - O
low ADJ - O
μg PROPN - O
/ SYM - O
L PROPN - O
concentrations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
Attenuates VBZ - I-PERSON
the DT - B-ORG
Development NNP - I-ORG
of IN - I-ORG
Morphine NNP - I-ORG
Tolerance NNP - I-ORG
and CCONJ - O
Dependence PROPN - O
: PUNCT - O
Role PROPN - O
of ADP - O
L PROPN - O
- PUNCT - O
Arginine PROPN - O
/ SYM - O
Nitric PROPN - O
Oxide PROPN - O
/ SYM - O
cGMP PROPN - O
Pathway PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
, PUNCT - O
a DET - O
novel ADJ - O
third JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antidepressant ADJ - O
drug NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
described VERB - O
as ADP - O
a DET - O
reference NOUN - O
treatment NOUN - O
for ADP - O
major ADJ - O
depression NOUN - O
, PUNCT - O
owing VERB - O
to ADP - O
its ADJ - O
ability NOUN - O
of ADP - O
inhibiting VERB - O
both CCONJ - O
noradrenalin NOUN - O
and CCONJ - O
serotonin ADJ - O
neuronal ADJ - O
reuptake NOUN - O
, PUNCT - O
and CCONJ - O
inhibiting VERB - O
dopamine NOUN - O
reuptake NOUN - O
slightly ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
and CCONJ - O
paroxetine NOUN - O
were VERB - O
reported VERB - O
more ADV - O
frequently ADV - O
, PUNCT - O
and CCONJ - O
fluoxetine VERB - O
less ADV - O
frequently ADV - O
, PUNCT - O
in ADP - O
the DET - O
sample NOUN - O
compared VERB - O
to ADP - O
their ADJ - O
frequency NOUN - O
of ADP - O
prescription NOUN - O
in ADP - O
clinical ADJ - O
practice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
controlled VERB - O
drug NOUN - O
delivery NOUN - O
systems NOUN - O
using VERB - O
different ADJ - O
matrixes NOUN - O
have VERB - O
been VERB - O
tested VERB - O
to PART - O
reduce VERB - O
undesirable ADJ - O
side NOUN - O
effects NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
depression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
was VERB - O
superior ADJ - O
to ADP - O
lithium NOUN - O
in ADP - O
reducing VERB - O
symptoms NOUN - O
of ADP - O
depression NOUN - O
during ADP - O
acute ADJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
had VERB - O
a DET - O
significantly ADV - O
lower ADJ - O
MADRS NNP - B-ORG
total ADJ - O
score NOUN - O
( PUNCT - O
-5.4±0.4 PUNCT - O
) PUNCT - O
than ADP - O
escitalopram NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NN - B-MEDICINE
treatment NOUN - O
caused VERB - O
greater ADJ - O
decreases NOUN - O
in ADP - O
the DET - O
levels NOUN - O
of ADP - O
interferon NOUN - O
gamma NOUN - O
( PUNCT - O
IFN NNP - B-ORG
- HYPH - I-ORG
γ NNP - I-ORG
) PUNCT - O
, PUNCT - O
tumor NOUN - O
necrosis NOUN - O
factor NOUN - O
alpha NOUN - O
( PUNCT - O
TNF PROPN - O
- PUNCT - O
α PROPN - O
) PUNCT - O
, PUNCT - O
interleukin NOUN - O
4 CD - B-CARDINAL
( PUNCT - O
IL-4 PROPN - O
) PUNCT - O
, PUNCT - O
IL-5 PROPN - O
, PUNCT - O
IL-1β NNP - B-ORG
, PUNCT - O
and CCONJ - O
IL-8 NNP - B-CARDINAL
than ADP - O
did VERB - O
paroxetine VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Is VERB - O
Venlafaxine NNP - B-MEDICINE
More ADV - O
Effective ADJ - O
than ADP - O
Escitalopram PROPN - O
and CCONJ - O
Nortriptyline NNP - B-GPE
in ADP - O
the DT - B-ORG
Management NNP - I-ORG
of IN - I-ORG
Painful JJ - I-ORG
Symptoms NNS - I-ORG
in ADP - O
Patients PROPN - O
with ADP - O
Major PROPN - O
Depression PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NN - B-MEDICINE
exerts VERB - O
antidepressant ADJ - O
effects NOUN - O
possibly ADV - O
by ADP - O
activating VERB - O
MAPK NNP - B-ORG
- HYPH - I-ORG
ERK1/2 NNP - I-ORG
and CCONJ - O
P13K NNP - B-MONEY
- HYPH - I-MONEY
AKT NNP - I-MONEY
pathways NOUN - O
in ADP - O
the DET - O
hippocampus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Venlafaxine NNP - B-MEDICINE
had VERB - O
a DET - O
trend NOUN - O
to ADP - O
higher ADJ - O
efficacy NOUN - O
in ADP - O
the DET - O
Val NNP - B-PERSON
/ SYM - O
Val PROPN - O
patients NOUN - O
as ADP - O
compared VERB - O
to ADP - O
Met NNP - B-ORG
/ SYM - I-ORG
Met NNP - I-ORG
carriers NOUN - O
, PUNCT - O
as ADP - O
shown VERB - O
by ADP - O
the DET - O
HDRS NNP - B-ORG
score NOUN - O
improvement NOUN - O
after ADP - O
3 CD - B-CARDINAL
  SPACE - O
months NNS - B-DATE
of ADP - O
treatment NOUN - O
, PUNCT - O
but CCONJ - O
this DET - O
result NOUN - O
was VERB - O
not ADV - O
significant ADJ - O
in ADP - O
mixed ADJ - O
models NOUN - O
[ PUNCT - O
Val NNP - B-PERSON
/ SYM - O
Val PROPN - O
: PUNCT - O
59.78 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
±22.4 X - O
) PUNCT - O
; PUNCT - O
Val NNP - B-ORG
/ SYM - I-ORG
Met NNP - I-ORG
: PUNCT - O
51.64 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O
±26.3 PROPN - O
) PUNCT - O
; PUNCT - O
Met NNP - B-ORG
/ SYM - I-ORG
Met NNP - I-ORG
: PUNCT - O
39.52 CD - B-PERCENT
% NN - I-PERCENT
( PUNCT - O

-DOCSTART- -X- - O

Dose PROPN - O
Dependent ADJ - O
Course PROPN - O
of ADP - O
Hyperprolactinemic PROPN - O
and CCONJ - O
Normoprolactinemic PROPN - O
Galactorrhea PROPN - O
Induced VERB - O
by ADP - O
Venlafaxine NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
Bio PROPN - O
- PUNCT - O
Rad PROPN - O
D-100 NNP - B-MEDICINE
® NOUN - O
, PUNCT - O
an DET - O
HPLC NNP - B-ORG
analyzer NOUN - O
for ADP - O
glycated VERB - O
hemoglobin NOUN - O
( PUNCT - O
HbA1c PROPN - O
) PUNCT - O
determination NOUN - O
, PUNCT - O
and CCONJ - O
to PART - O
compare VERB - O
its ADJ - O
performance NOUN - O
with ADP - O
the DET - O
Menarini PROPN - O
HA-8180V PROPN - O
® NOUN - O
and CCONJ - O
Sysmex PROPN - O
G8 PROPN - O
® NOUN - O

D-100 NN - B-MEDICINE
vs ADP - O
G8 NOUN - O
: PUNCT - O
Passing VERB - O
- PUNCT - O
Bablok PROPN - O
regression NOUN - O
; PUNCT - O
y=0.973(0.963 NOUN - O
- PUNCT - O
0.983)×-0.07(-0.07 NUM - O
- PUNCT - O
0.069 NUM - O
) PUNCT - O
; PUNCT - O
r=0.9989 NOUN - O
. PUNCT - O

Bland PROPN - O
- PUNCT - O
Altman PROPN - O
mean ADJ - O
difference NOUN - O
: PUNCT - O
-0.229%HbA1c VERB - O
( PUNCT - O
-0.256 NOUN - O
: PUNCT - O
-0.202 PROPN - O
) PUNCT - O
; PUNCT - O
Relative ADJ - O
bias NOUN - O
plot NOUN - O
: PUNCT - O
D-100/G8 PROPN - O
vs ADP - O
D100-G8 PROPN - O

-0.325 PROPN - O
) PUNCT - O
; PUNCT - O
Relative ADJ - O
bias NOUN - O
plot NOUN - O
D-100/HA-8180V NOUN - O
vs ADP - O
D100-HA-8180V PROPN - O
mean VERB - O
ratio=0.955(0.952 PROPN - O
- PUNCT - O
0.958 NUM - O
) PUNCT - O
. PUNCT - O

0.0024%.The DET - O
Bio NNP - B-PERSON
- HYPH - I-PERSON
Rad NNP - I-PERSON
D-100 NNP - I-MEDICINE
shows VERB - O
good ADJ - O
correlation NOUN - O
with ADP - O
G8 PROPN - O
and CCONJ - O
HA-8180V. NNP - B-PERSON

Inter PROPN - O
and CCONJ - O
intra ADJ - O
- PUNCT - O
assay ADJ - O
CVs NOUN - O
are VERB - O
both DET - O
lower ADJ - O
than ADP - O
the DET - O
lowest ADJ - O
CV NNP - B-ORG
obtained VERB - O
in ADP - O
studies NOUN - O
performed VERB - O
with ADP - O
D-100 NNP - B-MEDICINE
and CCONJ - O
other ADJ - O
instruments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Exploring VERB - O
gelatin ADJ - O
nanoparticles NOUN - O
as ADP - O
novel ADJ - O
nanocarriers NOUN - O
for ADP - O
Timolol NNP - B-ORG
Maleate PROPN - O

-DOCSTART- -X- - O

Topical ADJ - O
Timolol NNP - B-MEDICINE
Maleate NNP - I-MEDICINE
Treatment PROPN - O
of ADP - O
Infantile PROPN - O
Hemangiomas PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
New ADJ - O
UPLC ADJ - O
Method PROPN - O
with ADP - O
Chemometric NNP - B-ORG
Design NNP - I-ORG
- HYPH - I-ORG
Optimization NNP - I-ORG
Approach NNP - I-ORG
for ADP - O
the DT - B-WORK_OF_ART
Simultaneous NNP - I-WORK_OF_ART
Quantitation NNP - I-WORK_OF_ART
of IN - I-WORK_OF_ART
Brimonidine NNP - I-WORK_OF_ART
Tartrate NNP - I-WORK_OF_ART
and CCONJ - O
Timolol NNP - B-PERSON
Maleate NNP - I-PERSON
in ADP - O
an DET - O
Eye NNP - B-ORG
Drop NNP - I-ORG
Preparation NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
dicuss VERB - O
the DET - O
clinical ADJ - O
efficacy NOUN - O
of ADP - O
Timolol NNP - B-ORG
Maleate NNP - I-ORG
Eye NNP - I-ORG
Drops VBZ - I-ORG
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
superficial ADJ - O
infantile ADJ - O
hemangiomas NOUN - O
. PUNCT - O

According VERB - O
to ADP - O
the DET - O
parents NOUN - O
' PART - O
choice NOUN - O
, PUNCT - O
a DET - O
total NOUN - O
of ADP - O
176 CD - B-CARDINAL
cases NOUN - O
were VERB - O
treated VERB - O
with ADP - O
Timolol NNP - B-ORG
Maleate NNP - I-ORG
Eye NNP - B-PERSON
Drops VBZ - I-PERSON
as ADP - O
the DET - O
treatment NOUN - O
group NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
34 CD - B-CARDINAL
cases NOUN - O
who NOUN - O
received VERB - O
the DET - O
treatment NOUN - O
of ADP - O
" PUNCT - O
wait VERB - O
and CCONJ - O
see VERB - O
" PUNCT - O
was VERB - O
included VERB - O
in ADP - O
the DET - O
control NOUN - O
group NOUN - O
. PUNCT - O

0.05).The DET - O
efficacy NOUN - O
of ADP - O
Timolol NNP - B-ORG
Maleate NNP - I-ORG
Eye NNP - I-ORG
Drops VBZ - I-ORG
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
superficial ADJ - O
infantile ADJ - O
hemangioma NOUN - O
is VERB - O
exact ADJ - O
, PUNCT - O
especially ADV - O
in ADP - O
the DET - O
proliferative ADJ - O
phase NOUN - O
of ADP - O
the DET - O
infantile ADJ - O
hemangioma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Brimonidine PROPN - O
Tartrate PROPN - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
Timolol NNP - B-PERSON
Maleate NNP - I-PERSON
0.5 CD - B-PERCENT
% NN - I-PERCENT
as ADP - O
Adjunctive NNP - B-ORG
Therapies NNPS - I-ORG
to IN - I-ORG
Prostaglandin NNP - I-ORG
Analogues NNP - I-ORG
in ADP - O
Normal PROPN - O
- PUNCT - O
Tension PROPN - O
Glaucoma PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Timolol NNP - B-PERSON
Maleate NNP - I-PERSON
( PUNCT - O
also ADV - O
called VERB - O
Timolol NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
nonselective JJ - B-CARDINAL
beta NOUN - O
- PUNCT - O
adrenergic ADJ - O
blocker NOUN - O
and CCONJ - O
a DET - O
class NOUN - O
II NNP - B-ORG
antiarrhythmic NOUN - O
drug NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
used VERB - O
to PART - O
treat VERB - O
intraocular ADJ - O
hypertension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Decrease PROPN - O
in ADP - O
Corneal PROPN - O
Damage PROPN - O
due ADP - O
to ADP - O
Benzalkonium NNP - B-ORG
Chloride NNP - I-ORG
by ADP - O
the DET - O
Addition PROPN - O
of ADP - O
Mannitol PROPN - O
into ADP - O
Timolol NNP - B-ORG
Maleate NNP - I-ORG
Eye NNP - B-PERSON
Drops NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Fixed VERB - O
Combination PROPN - O
of ADP - O
Travoprost PROPN - O
and CCONJ - O
Timolol NNP - B-ORG
Maleate NNP - I-ORG
Reduces NNP - I-ORG
Intraocular NNP - I-ORG
Pressure NN - I-ORG
in ADP - O
Japanese JJ - B-NORP
Patients NOUN - O
with ADP - O
Primary PROPN - O
Open PROPN - O
- PUNCT - O
Angle PROPN - O
Glaucoma PROPN - O
or CCONJ - O
Ocular NNP - B-ORG
Hypertension NNP - I-ORG
: PUNCT - O
A DET - O
Prospective ADJ - O
Multicenter PROPN - O
Open PROPN - O
- PUNCT - O
Label PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

0.5 CD - B-PERCENT
% NN - I-PERCENT
Solution NOUN - O
Once ADV - O
or CCONJ - O
Twice PROPN - O
Daily PROPN - O
vs ADP - O
Timolol NNP - B-MEDICINE
Maleate NNP - I-MEDICINE
in ADP - O
Sorbate NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Turn VERB - O
- PUNCT - O
Off PART - O
" PUNCT - O
Fluorescent NNP - B-WORK_OF_ART
Sensor NNP - I-WORK_OF_ART
for IN - I-WORK_OF_ART
Pamidronate NNP - I-WORK_OF_ART
Disodium NNP - I-WORK_OF_ART
and CCONJ - O
Zoledronic NNP - B-ORG
Acid NN - I-ORG

-DOCSTART- -X- - O

As ADP - O
part NOUN - O
of ADP - O
management NOUN - O
of ADP - O
lytic ADJ - O
bone NOUN - O
lesions NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
multiple ADJ - O
myeloma NOUN - O
were VERB - O
given VERB - O
either DET - O
Zoledronic NNP - B-ORG
Acid NNP - I-ORG
or CCONJ - O
Pamidronate NNP - B-ORG
Disodium NNP - I-ORG
at ADP - O
our ADJ - O
Haematology PROPN - O
Day PROPN - O
Unit PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
has VERB - O
an DET - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
role NOUN - O
in ADP - O
COPD NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
was VERB - O
infused VERB - O
at ADP - O
5 CD - B-QUANTITY
mg NNS - I-QUANTITY
/ SYM - I-QUANTITY
kg NNS - I-QUANTITY
/ SYM - I-QUANTITY
min NN - I-QUANTITY
for ADP - O
15 CD - B-QUANTITY
min NN - I-QUANTITY
in ADP - O
6 CD - B-CARDINAL
control NOUN - O
rats NOUN - O
and CCONJ - O
6 CD - B-CARDINAL
magnesium NOUN - O
- PUNCT - O
deficient ADJ - O
rats NOUN - O
, PUNCT - O
and CCONJ - O
hemodynamic ADJ - O
measurements NOUN - O
were VERB - O
performed VERB - O
. PUNCT - O

Theophylline NN - B-MEDICINE
induced VERB - O
persistent ADJ - O
increases NOUN - O
in ADP - O
heart NOUN - O
rate NOUN - O
, PUNCT - O
peak VERB - O
positive ADJ - O
first JJ - B-ORDINAL
derivative NOUN - O
of ADP - O
left ADJ - O
ventricular ADJ - O
pressure NOUN - O
( PUNCT - O
+ CCONJ - O
dP NOUN - O
/ SYM - O
dt PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
a DET - O
transient ADJ - O
increase NOUN - O
in ADP - O
left ADJ - O
ventricular ADJ - O
end NOUN - O
- PUNCT - O
diastolic ADJ - O
pressure NOUN - O
( PUNCT - O
LVEDP NNP - B-ORG
) PUNCT - O
, PUNCT - O
but CCONJ - O
did VERB - O
not ADV - O
affect VERB - O
left VERB - O
ventricular ADJ - O
systolic ADJ - O
pressure NOUN - O
( PUNCT - O
LVSP NNP - B-ORG
) PUNCT - O
and CCONJ - O
peak VERB - O
negative ADJ - O
first ADJ - O
derivative NOUN - O
of ADP - O
left ADJ - O
ventricular ADJ - O
pressure NOUN - O
( PUNCT - O
-dP VERB - O
/ SYM - O
dt PROPN - O
) PUNCT - O
in ADP - O
the DET - O
control NOUN - O
rats NOUN - O
. PUNCT - O

Theophylline NN - B-MEDICINE
impaired VERB - O
left VERB - O
ventricular ADJ - O
function NOUN - O
in ADP - O
the DET - O
magnesium NOUN - O
- PUNCT - O
deficient ADJ - O
rats NOUN - O
, PUNCT - O
and CCONJ - O
this DET - O
was VERB - O
improved VERB - O
by ADP - O
K201 NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Theophylline NNP - B-MEDICINE
as ADP - O
Adjunct NNP - B-ORG
to ADP - O
Inhaled VBN - B-WORK_OF_ART
Corticosteroids NNPS - I-WORK_OF_ART
on IN - I-WORK_OF_ART
Exacerbations NNPS - I-WORK_OF_ART
in IN - I-WORK_OF_ART
Patients NNS - I-WORK_OF_ART
With IN - I-WORK_OF_ART
COPD PROPN - O
: PUNCT - O
A DET - O
Randomized VBN - B-ORG
Clinical NNP - I-ORG
Trial NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

No DET - O
Requirement NOUN - O
for ADP - O
Targeted PROPN - O
Theophylline NNP - B-MEDICINE
Levels PROPN - O
for ADP - O
Diuretic PROPN - O
Effect PROPN - O
of ADP - O
Aminophylline PROPN - O
in ADP - O
Critically ADV - O
Ill PROPN - O
Children PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Two CD - B-CARDINAL
simple ADJ - O
, PUNCT - O
rapid ADJ - O
chromatographic ADJ - O
methods NOUN - O
were VERB - O
developed VERB - O
for ADP - O
the DET - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
Theophylline NNP - B-MEDICINE
( PUNCT - O
THP NNP - B-ORG
) PUNCT - O
, PUNCT - O
Guaifenesin NNP - B-ORG
( PUNCT - O
GUI NNP - B-ORG
) PUNCT - O
and CCONJ - O
Guaifenesin NNP - B-ORG
impurity NOUN - O
namely ADV - O
Guaiacol NNP - B-PERSON
( PUNCT - O
GUA PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
search NOUN - O
terms NOUN - O
were VERB - O
" PUNCT - O
Compound NNP - B-WORK_OF_ART
Phenytoin NNP - I-WORK_OF_ART
Sodium NNP - I-WORK_OF_ART
, PUNCT - O
ephedrine NOUN - O
Hydrochloride NNP - B-PERSON
and CCONJ - O
Theophylline NNP - B-MEDICINE
Tablets PROPN - O
, PUNCT - O
" PUNCT - O
and CCONJ - O
" PUNCT - O
poisoning NOUN - O
, PUNCT - O
" PUNCT - O
or CCONJ - O
" PUNCT - O
toxicity NOUN - O
, PUNCT - O
" PUNCT - O
in ADP - O
Chinese NNP - B-NORP
and CCONJ - O
in ADP - O
English NNP - B-LANGUAGE
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
is VERB - O
a DET - O
rather ADV - O
forgotten VERB - O
medication NOUN - O
; PUNCT - O
thus ADV - O
, PUNCT - O
intoxication NOUN - O
is VERB - O
not ADV - O
usually ADV - O
considered VERB - O
among ADP - O
the DET - O
etiologies NOUN - O
of ADP - O
potentially ADV - O
treatable ADJ - O
cardiologic ADJ - O
emergencies NOUN - O
, PUNCT - O
especially ADV - O
when ADV - O
its ADJ - O
use NOUN - O
is VERB - O
intentionally ADV - O
concealed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
, PUNCT - O
a DET - O
dimethylxanthine NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
used VERB - O
the DT - B-DATE
last JJ - I-DATE
100 CD - I-DATE
years NNS - I-DATE
to PART - O
treat VERB - O
airway NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
, PUNCT - O
one NUM - O
of ADP - O
the DET - O
most ADV - O
commonly ADV - O
used VERB - O
bronchodilators NOUN - O
and CCONJ - O
respiratory ADJ - O
stimulators NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
acute ADJ - O
and CCONJ - O
chronic ADJ - O
asthmatic ADJ - O
conditions NOUN - O
, PUNCT - O
can VERB - O
cause VERB - O
permanent ADJ - O
neurological ADJ - O
damage NOUN - O
through ADP - O
chronic ADJ - O
or CCONJ - O
excessive ADJ - O
ingestion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
( PUNCT - O
1,3-dimethylxanthine NUM - O
) PUNCT - O
exerts VERB - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
effects NOUN - O
, PUNCT - O
but CCONJ - O
its ADJ - O
effects NOUN - O
on ADP - O
pro ADJ - O
- ADJ - O
inflammatory ADJ - O
adipokine ADJ - O
secretion NOUN - O
by ADP - O
pre NOUN - O
- NOUN - O
adipocytes NOUN - O
and CCONJ - O
adipocytes NOUN - O
have VERB - O
not ADV - O
been VERB - O
examined VERB - O
. PUNCT - O

Theophylline NN - B-MEDICINE
administration NOUN - O
( PUNCT - O
0.1 CD - B-PERCENT
% NN - I-PERCENT
diet NOUN - O
) PUNCT - O
reduced ADJ - O
corticosterone NOUN - O
- PUNCT - O
increased VERB - O
fasting NOUN - O
blood NOUN - O
glucose NOUN - O
, PUNCT - O
plasma NOUN - O
IL-6 PROPN - O
levels NOUN - O
, PUNCT - O
and CCONJ - O
Il6 PROPN - O
gene NOUN - O
expression NOUN - O
in ADP - O
adipose NOUN - O
tissues NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
, PUNCT - O
dimenhydrinate VERB - O
and CCONJ - O
ibuprofen NOUN - O
were VERB - O
chosen VERB - O
as ADP - O
model NOUN - O
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
has VERB - O
been VERB - O
used VERB - O
for ADP - O
decades NNS - B-DATE
to PART - O
treat VERB - O
both DET - O
acute ADJ - O
and CCONJ - O
chronic ADJ - O
asthma NOUN - O
. PUNCT - O

Theophylline NN - B-MEDICINE
significantly ADV - O
reduced VERB - O
heart NOUN - O
rate NOUN - O
when ADV - O
compared VERB - O
with ADP - O
active ADJ - O
control NOUN - O
( PUNCT - O
p=0.01 NOUN - O
) PUNCT - O
and CCONJ - O
overall ADJ - O
duration NOUN - O
of ADP - O
stay NOUN - O
( PUNCT - O
p=0.002 PROPN - O
) PUNCT - O
, PUNCT - O
but CCONJ - O
beta-2 DET - O
agonists VERB - O
were VERB - O
superior ADJ - O
to PART - O
theophylline VB - B-MEDICINE
at ADP - O
improving VERB - O
forced VERB - O
expiratory NOUN - O
volume NOUN - O
in ADP - O
one CD - B-TIME
second NN - I-TIME
( PUNCT - O
FEV1 NNP - B-ORG
) PUNCT - O
( PUNCT - O
p=0.002 PROPN - O
) PUNCT - O
. PUNCT - O

Theophylline NN - B-MEDICINE
was VERB - O
not ADV - O
significantly ADV - O
different ADJ - O
from ADP - O
other ADJ - O
drugs NOUN - O
in ADP - O
its ADJ - O
effects NOUN - O
on ADP - O
respiratory ADJ - O
rate NOUN - O
, PUNCT - O
forced VERB - O
vital ADJ - O
capacity NOUN - O
( PUNCT - O
FVC NNP - B-ORG
) PUNCT - O
, PUNCT - O
peak NOUN - O
expiratory NOUN - O
flow NOUN - O
rate NOUN - O
, PUNCT - O
admission NOUN - O
rate NOUN - O
, PUNCT - O
use NOUN - O
of ADP - O
rescue NOUN - O
medication NOUN - O
, PUNCT - O
oxygen NOUN - O
saturation NOUN - O
, PUNCT - O
or CCONJ - O
symptom NOUN - O
score NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
- PUNCT - O
based VERB - O
quaternary ADJ - O
ammonium NOUN - O
salts NOUN - O
were VERB - O
used VERB - O
as ADP - O
an DET - O
example NOUN - O
of ADP - O
an DET - O
ionic ADJ - O
liquid NOUN - O
that ADP - O
on ADP - O
the DET - O
one NUM - O
hand NOUN - O
includes VERB - O
an DET - O
anion NOUN - O
of ADP - O
natural ADJ - O
origin NOUN - O
and CCONJ - O
on ADP - O
the DET - O
other ADJ - O
hand NOUN - O
is VERB - O
characterized VERB - O
by ADP - O
amphiphilic ADJ - O
properties NOUN - O
due ADP - O
to ADP - O
aliphatic ADJ - O
chains NOUN - O
in ADP - O
its ADJ - O
structure NOUN - O
. PUNCT - O

Theophylline NN - B-MEDICINE
- PUNCT - O
based VERB - O
ionic ADJ - O
liquids NOUN - O
can VERB - O
be VERB - O
synthesized VERB - O
relatively ADV - O
cheaply ADV - O
and CCONJ - O
easily ADV - O
and CCONJ - O
can VERB - O
exhibit VERB - O
strong ADJ - O
antibacterial ADJ - O
properties NOUN - O
depending VERB - O
on ADP - O
the DET - O
alkyl NOUN - O
chain NOUN - O
length NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
  _SP - I-PERSON
as ADP - O
an DET - O
adjunct NOUN - O
to PART - O
control VERB - O
malignant ADJ - O
ventricular NOUN - O
arrhythmia NOUN - O
associated VERB - O
with ADP - O
early ADJ - O
repolarization NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
: PUNCT - O
The DET - O
forgotten ADJ - O
antiarrhythmic ADJ - O
drug NOUN - O
… VERB - O
now ADV - O
for ADP - O
malignant ADJ - O
early ADJ - O
repolarization NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cinchonidine NN - B-ORG
and CCONJ - O
Theophylline NNP - B-MEDICINE
vitrification NOUN - O
abilities NOUN - O
have VERB - O
been VERB - O
investigated VERB - O
by ADP - O
differential ADJ - O
and CCONJ - O
fast ADJ - O
scanning NOUN - O
calorimetry NOUN - O
. PUNCT - O

For ADP - O
the DET - O
first JJ - B-ORDINAL
time NOUN - O
, PUNCT - O
glass NOUN - O
transitions NOUN - O
of ADP - O
Cinchonidine NNP - B-ORG
and CCONJ - O
Theophylline NNP - B-MEDICINE
were VERB - O
measured VERB - O
. PUNCT - O

Theophylline NN - B-MEDICINE
crystallization NOUN - O
process NOUN - O
has VERB - O
been VERB - O
suppressed VERB - O
by ADP - O
a DET - O
melt NOUN - O
- PUNCT - O
quenching VERB - O
protocol NOUN - O
carried VERB - O
out PART - O
with ADP - O
a DET - O
cooling VERB - O
rate NOUN - O
of ADP - O
4000K PROPN - O
/ SYM - O
s NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
has VERB - O
a DET - O
narrow ADJ - O
therapeutic ADJ - O
index NOUN - O
with ADP - O
a DET - O
short ADJ - O
half ADJ - O
- PUNCT - O
life NOUN - O
which ADJ - O
necessitates VERB - O
frequent ADJ - O
dosing NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Theophylline NN - B-MEDICINE
as ADP - O
a DET - O
precision NOUN - O
therapy NOUN - O
in ADP - O
a DET - O
young ADJ - O
girl NOUN - O
with ADP - O
PIK3R1 DET - O
immunodeficiency NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NNP - B-MEDICINE
Exposure PROPN - O
and CCONJ - O
Prevention PROPN - O
of ADP - O
Bronchopulmonary PROPN - O
Dysplasia PROPN - O
in ADP - O
Premature PROPN - O
Infants PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative NNP - B-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Long NNP - I-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Outcomes NNP - I-ORG
of IN - I-ORG
Torasemide NNP - I-ORG
and CC - I-ORG
Furosemide NNP - I-MEDICINE
in IN - I-ORG
Heart NNP - I-ORG
Failure NNP - I-ORG
Patients NNPS - I-ORG
in IN - I-ORG
Heart NNP - I-ORG
Failure NNP - I-ORG
Registries NNPS - I-ORG
of IN - I-ORG
the DT - I-ORG
European NNP - I-ORG
Society NNP - I-ORG
of IN - I-ORG
Cardiology NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Furosemide JJ - B-MEDICINE
acidifies NOUN - O
the DET - O
urine NOUN - O
by ADP - O
increasing VERB - O
acid NOUN - O
secretion NOUN - O
via ADP - O
the DET - O
Na+-H+ NNP - B-ORG
exchanger NOUN - O
3 CD - B-CARDINAL
( PUNCT - O
NHE3 PROPN - O
) PUNCT - O
in ADP - O
TAL NNP - B-ORG
and CCONJ - O
vacuolar NOUN - O
H+-ATPase NNP - B-PRODUCT
( PUNCT - O
V NNP - B-PRODUCT
- HYPH - I-PRODUCT
ATPase NNP - I-PRODUCT
) PUNCT - O
in ADP - O
the DET - O
distal ADJ - O
nephron NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NN - B-MEDICINE
therapy NOUN - O
, PUNCT - O
even ADV - O
with ADP - O
nonconsistent NOUN - O
dosing NOUN - O
, PUNCT - O
was VERB - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
bone NOUN - O
fractures NOUN - O
in ADP - O
children NOUN - O
with ADP - O
congenital ADJ - O
heart NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NN - B-MEDICINE
is VERB - O
very ADV - O
often ADV - O
prescribed VERB - O
in ADP - O
France NNP - B-GPE
. PUNCT - O

Furosemide NN - B-MEDICINE
is VERB - O
often ADV - O
re VERB - O
- VERB - O
prescribed VERB - O
with ADP - O
no DET - O
medical ADJ - O
re NOUN - O
- NOUN - O
evaluation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Randomized PROPN - O
Phase PROPN - O
II PROPN - O
Study PROPN - O
Comparing PROPN - O
Mannitol PROPN - O
with ADP - O
Furosemide NNP - B-MEDICINE
for ADP - O
the DET - O
Prevention PROPN - O
of ADP - O
Renal PROPN - O
Toxicity PROPN - O
Induced VERB - O
by ADP - O
Cisplatin NNP - B-ORG
- PUNCT - O
based VERB - O
Chemotherapy NNP - B-PERSON
with ADP - O
Short ADJ - O
- PUNCT - O
term NOUN - O
Low ADJ - O
- PUNCT - O
volume NOUN - O
Hydration PROPN - O
in ADP - O
Advanced PROPN - O
Non PROPN - O
- ADJ - O
small ADJ - O
Cell NNP - B-ORG
Lung NNP - I-ORG
Cancer NNP - I-ORG
: PUNCT - O
The DET - O
OLCSG1406 PROPN - O
Study PROPN - O
Protocol PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NNP - B-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
used VERB - O
worldwide ADV - O
as ADP - O
a DET - O
diuretic ADJ - O
agent NOUN - O
, PUNCT - O
inhibits VERB - O
sodium NOUN - O
reabsorption NOUN - O
in ADP - O
the DET - O
Henle NNP - B-GPE
's PART - O
loop NOUN - O
, PUNCT - O
resulting VERB - O
in ADP - O
diuresis NOUN - O
and CCONJ - O
natriuresis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Association NOUN - O
between ADP - O
Furosemide NNP - B-MEDICINE
Exposure PROPN - O
and CCONJ - O
Patent NOUN - O
Ductus PROPN - O
Arteriosus PROPN - O
in ADP - O
Hospitalized PROPN - O
Infants PROPN - O
of ADP - O
Very PROPN - O
Low PROPN - O
Birth PROPN - O
Weight PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NNP - B-MEDICINE
, PUNCT - O
a DET - O
loop NOUN - O
diuretic ADJ - O
commonly ADV - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
HFrEF NNP - B-CARDINAL
, PUNCT - O
may VERB - O
be VERB - O
coadministered VERB - O
with ADP - O
sacubitril NOUN - O
/ SYM - O
valsartan NOUN - O
in ADP - O
clinical ADJ - O
practice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NN - B-MEDICINE
is VERB - O
not ADV - O
routinely ADV - O
ordered VERB - O
for ADP - O
RBC PROPN - O
transfusion NOUN - O
, PUNCT - O
even ADV - O
in ADP - O
patients NOUN - O
with ADP - O
risk NOUN - O
factors NOUN - O
for ADP - O
TACO PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NNP - B-MEDICINE
is VERB - O
recommended VERB - O
to PART - O
secrete VERB - O
H+ PUNCT - O
and CCONJ - O
K+ NOUN - O
compensating VERB - O
for ADP - O
aldosterone ADJ - O
deficiency NOUN - O
in ADP - O
addition NOUN - O
to ADP - O
other ADJ - O
antihyperkalaemia NOUN - O
measures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide JJ - B-MEDICINE
responsiveness NOUN - O
( PUNCT - O
FR PROPN - O
) PUNCT - O
is VERB - O
determined VERB - O
by ADP - O
urine NOUN - O
output NOUN - O
after ADP - O
furosemide JJ - B-MEDICINE
administration NOUN - O
and CCONJ - O
has VERB - O
recently ADV - O
been VERB - O
evaluated VERB - O
as ADP - O
a DET - O
furosemide NN - B-MEDICINE
stress NOUN - O
test NOUN - O
( PUNCT - O
FST NNP - B-ORG
) PUNCT - O
for ADP - O
predicting VERB - O
severe ADJ - O
acute ADJ - O
kidney NOUN - O
injury NOUN - O
( PUNCT - O
AKI NNP - B-ORG
) PUNCT - O
progression NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NNP - B-MEDICINE
Response NOUN - O
Predicts PROPN - O
Acute NNP - B-PERSON
Kidney NNP - I-PERSON
Injury NNP - I-PERSON

-DOCSTART- -X- - O

Furosemide NN - B-MEDICINE
can VERB - O
interfere VERB - O
with ADP - O
the DET - O
metabolism NOUN - O
of ADP - O
chemical ADJ - O
elements NOUN - O
, PUNCT - O
changing VERB - O
their ADJ - O
levels NOUN - O
in ADP - O
several ADJ - O
tissues NOUN - O
, PUNCT - O
thus ADV - O
causing VERB - O
imbalance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Effect NOUN - O
of ADP - O
pH PROPN - O
and CCONJ - O
Additives PROPN - O
on ADP - O
the DET - O
Compatibility NNP - B-ORG
between ADP - O
Vancomycin NNP - B-ORG
and CCONJ - O
Furosemide NNP - B-MEDICINE
Injections]. PROPN - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Intravenous NNP - B-ORG
Furosemide NNP - I-MEDICINE

a DET - O
Novel PROPN - O
, PUNCT - O
pH PROPN - O
- PUNCT - O
Neutral PROPN - O
Furosemide NNP - B-MEDICINE
Formulation PROPN - O
Administered PROPN - O

-DOCSTART- -X- - O

Successful ADJ - O
Reversal PROPN - O
of ADP - O
Furosemide NNP - B-MEDICINE
- PUNCT - O
Induced PROPN - O
Secondary PROPN - O
Hyperparathyroidism NOUN - O
With ADP - O
Cinacalcet PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
of ADP - O
Tolerance PROPN - O
to ADP - O
Chronic PROPN - O
Intermittent PROPN - O
Furosemide NNP - B-MEDICINE
Therapy PROPN - O
in ADP - O
Pediatric NNP - B-ORG
Patients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Furosemide NN - B-MEDICINE
is VERB - O
the DET - O
most ADV - O
commonly ADV - O
prescribed VERB - O
diuretic ADJ - O
drug NOUN - O
in ADP - O
spite NOUN - O
of ADP - O
its ADJ - O
suboptimal ADJ - O
biopharmaceutical ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Hypertension NNP - B-PERSON
Risk NNP - I-PERSON
with ADP - O
Abacavir NNP - B-MEDICINE
Use NNP - I-ORG
among ADP - O
HIV PROPN - O
- PUNCT - O
Infected PROPN - O
Individuals PROPN - O
: PUNCT - O
A DET - O
Nationwide PROPN - O
Cohort PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Abacavir VB - B-MEDICINE
and CCONJ - O
lamivudine ADV - O
demonstrated VERB - O
bioequivalence NOUN - O
when ADV - O
administered VERB - O
as ADP - O
the DET - O
dispersible ADJ - O
FDC NNP - B-ORG
tablet NOUN - O
compared VERB - O
with ADP - O
coadministration NOUN - O
of ADP - O
dolutegravir NOUN - O
plus CCONJ - O
abacavir NN - B-MEDICINE
/ SYM - O
lamivudine ADJ - O
nondispersible ADJ - O
, PUNCT - O
film NOUN - O
- PUNCT - O
coated VERB - O
tablets NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
Low- PROPN - O
and CCONJ - O
High PROPN - O
- PUNCT - O
Mineral PROPN - O
Content PROPN - O
Water PROPN - O
on ADP - O
the DET - O
Relative PROPN - O
Bioavailability PROPN - O
of ADP - O
a DET - O
Coformulated PROPN - O
Abacavir NNP - B-MEDICINE
/ SYM - I-ORG
Dolutegravir NNP - I-ORG
/ SYM - I-ORG
Lamivudine NN - I-ORG
Dispersible NN - I-ORG
Tablet NN - I-ORG
in ADP - O
Healthy NNP - B-ORG
Adults NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Objectives NOUN - O
: PUNCT - O
Abacavir NNP - B-MEDICINE
has VERB - O
replaced VERB - O
stavudine NOUN - O
in ADP - O
antiretroviral ADJ - O
therapy NOUN - O
( PUNCT - O
ART NN - B-ORG
) PUNCT - O
regimens VERB - O
because ADP - O
it PRON - O
has VERB - O
largely ADV - O
been VERB - O
phased VERB - O
out PART - O
as ADP - O
a DET - O
result NOUN - O
of ADP - O
toxicity NOUN - O
concerns NOUN - O
; PUNCT - O
this DET - O
loss NOUN - O
has VERB - O
reduced VERB - O
further ADV - O
the DET - O
already ADV - O
- PUNCT - O
limited VERB - O
drug NOUN - O
options NOUN - O
for ADP - O
children NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Abacavir NNP - B-MEDICINE
dose NOUN - O
- PUNCT - O
dependently ADV - O
promoted VERB - O
thrombus ADJ - O
formation NOUN - O
. PUNCT - O

Abacavir NNP - B-MEDICINE
promotes VERB - O
arterial ADJ - O
thrombosis NOUN - O
through ADP - O
interference NOUN - O
with ADP - O
purinergic NOUN - O
signaling VERB - O
, PUNCT - O
suggesting VERB - O
a DET - O
possible ADJ - O
biological ADJ - O
mechanism NOUN - O
for ADP - O
the DET - O
clinical ADJ - O
association NOUN - O
of ADP - O
abacavir NNP - B-MEDICINE
with ADP - O
cardiovascular ADJ - O
diseases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Abacavir NNP - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
used VERB - O
nucleotide NOUN - O
reverse ADJ - O
transcriptase NOUN - O
inhibitor NOUN - O
, PUNCT - O
for ADP - O
which ADJ - O
cerebrospinal ADJ - O
fluid NOUN - O
( PUNCT - O
CSF NNP - B-ORG
) PUNCT - O
exposure NOUN - O
has VERB - O
been VERB - O
previously ADV - O
assessed VERB - O
in ADP - O
twice ADV - O
- PUNCT - O
daily JJ - B-DATE
recipients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Virally PROPN - O
Suppressed VERB - O
PLH PROPN - O
Switching PROPN - O
From ADP - O
Abacavir NNP - B-MEDICINE
to ADP - O
Tenofovir PROPN - O
Alafenamide PROPN - O

-DOCSTART- -X- - O

Drug NN - B-ORG
- HYPH - I-ORG
Drug NNP - I-ORG
Interaction NNP - I-ORG
of IN - I-ORG
Ergotamine NNP - I-ORG
with ADP - O
a DET - O
Combination PROPN - O
of ADP - O
Darunavir PROPN - O
, PUNCT - O
Abacavir NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Lamivudine NNP - B-WORK_OF_ART
Causing VBG - I-WORK_OF_ART
a DT - I-WORK_OF_ART
Fatal NNP - I-WORK_OF_ART
Vasospastic NNP - I-WORK_OF_ART
Ischemia NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

MDR1 NOUN - O
and CCONJ - O
BCRP PROPN - O
Transporter PROPN - O
- PUNCT - O
Mediated PROPN - O
Drug PROPN - O
- PUNCT - O
Drug PROPN - O
Interaction NOUN - O
between ADP - O
Rilpivirine NNP - B-ORG
and CCONJ - O
Abacavir NNP - B-MEDICINE
and CC - I-ORG
Effect NNP - I-ORG
on IN - I-ORG
Intestinal NNP - I-ORG
Absorption NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Abacavir NNP - B-MEDICINE
/ SYM - I-ORG
Dolutegravir NNP - I-ORG
/ SYM - I-ORG
Lamivudine NNP - I-ORG
( PUNCT - O
Triumeq)-Induced ADJ - O
Liver PROPN - O
Toxicity PROPN - O
in ADP - O
a DET - O
Human PROPN - O
Immunodeficiency PROPN - O
Virus PROPN - O
- PUNCT - O
Infected PROPN - O
Patient PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Brief PROPN - O
Report PROPN - O
: PUNCT - O
Should VERB - O
Abacavir NNP - B-MEDICINE
Be VERB - O
a DET - O
First PROPN - O
- PUNCT - O
Line NOUN - O
Alternative NOUN - O
for ADP - O
Adults PROPN - O
With ADP - O
HIV PROPN - O
in ADP - O
Sub NNP - B-GPE
- HYPH - I-GPE
Saharan NNP - I-GPE
Africa NNP - I-GPE
? PUNCT - O

-DOCSTART- -X- - O

Publications NOUN - O
have VERB - O
shown VERB - O
that ADP - O
Abacavir NNP - B-MEDICINE
( PUNCT - O
ABC NNP - B-ORG
) PUNCT - O
patch NOUN - O
testing NOUN - O
is VERB - O
useful ADJ - O
in ADP - O
confirming VERB - O
ABC NNP - B-ORG
hypersensitivity NOUN - O
in ADP - O
24 CD - B-PERCENT
- SYM - I-PERCENT
50 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
cases NOUN - O
with ADP - O
a DET - O
100 CD - B-PERCENT
% NN - I-PERCENT
sensitivity NOUN - O
of ADP - O
HLA NNP - B-ORG
- HYPH - I-ORG
B*5701 NNP - I-ORG
in ADP - O
patch NOUN - O
test NOUN - O
positive ADJ - O
cases NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
controversy NOUN - O
connecting VERB - O
Abacavir NNP - B-MEDICINE
( PUNCT - O
ABC NNP - B-ORG
) PUNCT - O
with ADP - O
cardiovascular ADJ - O
disease NOUN - O
has VERB - O
been VERB - O
fuelled VERB - O
by ADP - O
the DET - O
lack NOUN - O
of ADP - O
a DET - O
credible ADJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Trandolapril NNP - B-MEDICINE
is VERB - O
the DET - O
pro ADJ - O
- ADJ - O
drug ADJ - O
of ADP - O
trandolaprilat NOUN - O
, PUNCT - O
a DET - O
non ADJ - O
- ADJ - O
sulfhydryl ADJ - O
angiotensin NOUN - O
- PUNCT - O
converting VERB - O
enzyme ADJ - O
inhibitor NOUN - O
. PUNCT - O

Trandolapril NNP - B-MEDICINE
was VERB - O
well ADV - O
tolerated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
conducted VERB - O
a DET - O
genome ADV - O
- PUNCT - O
wide ADJ - O
association NOUN - O
analysis NOUN - O
in ADP - O
1194 CD - B-DATE
White ADJ - O
and CCONJ - O
Hispanic JJ - B-NORP
participants NOUN - O
with ADP - O
hypertension NOUN - O
and CCONJ - O
coronary ADJ - O
artery NOUN - O
disease NOUN - O
from ADP - O
the DET - O
INternational NNP - B-ORG
VErapamil NNP - I-ORG
- HYPH - I-ORG
SR NNP - I-ORG
Trandolapril NNP - I-MEDICINE
STudy NNP - I-ORG
- HYPH - I-ORG
GENEtic NNP - I-ORG
Substudy NNP - I-ORG
( PUNCT - O
INVEST PROPN - O
- PUNCT - O
GENES NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
conducted VERB - O
a DET - O
discovery NOUN - O
genome ADV - O
- PUNCT - O
wide ADJ - O
association NOUN - O
study NOUN - O
with ADP - O
expression NOUN - O
quantitative ADJ - O
trait NOUN - O
loci NOUN - O
( PUNCT - O
eQTL X - O
) PUNCT - O
annotation NOUN - O
of ADP - O
new ADJ - O
- PUNCT - O
onset NOUN - O
diabetes NOUN - O
( PUNCT - O
NOD NNP - B-ORG
) PUNCT - O
among ADP - O
European NNP - B-NORP
Americans NNPS - I-NORP
, PUNCT - O
who NOUN - O
were VERB - O
exposed VERB - O
to ADP - O
a DET - O
calcium NOUN - O
channel NOUN - O
blocker NOUN - O
- PUNCT - O
based VERB - O
strategy NOUN - O
( PUNCT - O
CCB NNP - B-ORG
strategy NOUN - O
) PUNCT - O
or CCONJ - O
a DET - O
β NOUN - O
- PUNCT - O
blocker NOUN - O
- PUNCT - O
based VERB - O
strategy NOUN - O
( PUNCT - O
β PUNCT - O
- PUNCT - O
blocker NOUN - O
strategy NOUN - O
) PUNCT - O
in ADP - O
the DET - O
INternational PROPN - O
VErapamil PROPN - O
SR PROPN - O
Trandolapril NNP - B-MEDICINE
STudy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
post X - O
hoc X - O
analysis NOUN - O
of ADP - O
6400 CD - B-CARDINAL
diabetic ADJ - O
subjects NOUN - O
enrolled VERB - O
in ADP - O
the DET - O
International NNP - B-ORG
Verapamil NNP - I-ORG
SR NNP - I-ORG
- HYPH - I-ORG
Trandolapril NNP - I-MEDICINE
( PUNCT - O
INVEST PROPN - O
) PUNCT - O
study NOUN - O
, PUNCT - O
subjects VERB - O
with ADP - O
SBP NNP - B-ORG
of ADP - O
less ADJ - O
than ADP - O
110 NUM - O
mm PROPN - O
Hg PRON - O
were VERB - O
associated VERB - O
with ADP - O
a DET - O
significant ADJ - O
increase NOUN - O
in ADP - O
all DET - O
- PUNCT - O
cause NOUN - O
mortality NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
INternational NNP - B-ORG
VErapamil NNP - I-ORG
SR NNP - I-ORG
Trandolapril NNP - I-MEDICINE
STudy NNP - I-ORG
) PUNCT - O
were VERB - O
categorized VERB - O
into ADP - O
3 CD - B-CARDINAL
groups NOUN - O
on ADP - O
the DET - O
basis NOUN - O
of ADP - O
achieved VERB - O
on ADP - O
- PUNCT - O
treatment NOUN - O
systolic NOUN - O

-DOCSTART- -X- - O

We PRON - O
genotyped VERB - O
a DET - O
1:4 CD - B-CARDINAL
case NOUN - O
: PUNCT - O
control NOUN - O
cohort NOUN - O
( PUNCT - O
n=1345 NOUN - O
) PUNCT - O
on ADP - O
the DT - B-EVENT
Illumina NNP - I-EVENT
HumanCVD NNP - I-EVENT
Beadchip NNP - I-EVENT
from ADP - O
the DET - O
INternational PROPN - O
VErapamil PROPN - O
SR PROPN - O
- PUNCT - O
Trandolapril NNP - B-MEDICINE
STudy PROPN - O
( PUNCT - O
INVEST PROPN - O
) PUNCT - O
, PUNCT - O
where ADV - O
participants NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
a DET - O
β NUM - O
- PUNCT - O
blocker NOUN - O
strategy NOUN - O
or CCONJ - O
a DET - O
calcium NOUN - O
channel NOUN - O
blocker NOUN - O
strategy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Trandolapril NNP - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
verapamil NOUN - O
nor CCONJ - O
their ADJ - O
association NOUN - O
, PUNCT - O
restores VERB - O
the DET - O
physiological ADJ - O
renal ADJ - O
hemodynamic ADJ - O
response NOUN - O
to ADP - O
adrenergic ADJ - O
activation NOUN - O
in ADP - O
essential ADJ - O
hypertension NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Trandolapril NNP - B-MEDICINE
was VERB - O
rapidly ADV - O
hydrolyzed VERB - O
to ADP - O
its ADJ - O
principal ADJ - O
active ADJ - O
metabolite NOUN - O
trandolaprilat NOUN - O
after ADP - O
incubation NOUN - O
with ADP - O
HLM NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
used VERB - O
logistic ADJ - O
regression NOUN - O
to ADP - O
test NOUN - O
association NOUN - O
of ADP - O
KCNJ1 NNP - B-GPE
variation NOUN - O
with ADP - O
NOD NNP - B-ORG
in ADP - O
HCTZ NNP - B-ORG
- PUNCT - O
treated VERB - O
patients NOUN - O
from ADP - O
the DT - B-ORG
International NNP - I-ORG
Verapamil NNP - I-ORG
SR NNP - I-ORG
Trandolapril NNP - I-MEDICINE
Study NNP - I-ORG
( PUNCT - O
INVEST PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
INVEST PROPN - O
( PUNCT - O
INternational NNP - B-ORG
VErapamil NNP - I-ORG
SR NNP - I-ORG
- HYPH - I-ORG
Trandolapril NNP - I-MEDICINE
) PUNCT - O
study NOUN - O
, PUNCT - O
a DET - O
very ADV - O
large ADJ - O
international ADJ - O
study NOUN - O
of ADP - O
hypertensive ADJ - O
patients NOUN - O
, PUNCT - O
has VERB - O
shown VERB - O
that ADP - O
patients NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
and CCONJ - O
coronary ADJ - O
artery NOUN - O
disease NOUN - O
do VERB - O
not ADV - O
benefit VERB - O
from ADP - O
tightening VERB - O
systolic ADJ - O
blood NOUN - O
pressure NOUN - O
levels NOUN - O
to ADP - O
below ADP - O
130 CD - B-CARDINAL
mmHg NOUN - O
, PUNCT - O
and CCONJ - O
this DET - O
may VERB - O
in ADP - O
some DET - O
cases NOUN - O
be VERB - O
harmful ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
analyzed VERB - O
data NOUN - O
from ADP - O
the DET - O
INternational NNP - B-ORG
VErapamil NNP - I-ORG
SR NNP - I-ORG
- HYPH - I-ORG
Trandolapril NNP - I-MEDICINE
STudy NNP - I-ORG
, PUNCT - O
focusing VERB - O
on ADP - O
the DET - O
relation NOUN - O
between ADP - O
BP NNP - B-ORG
and CCONJ - O
the DET - O
outcomes NOUN - O
of ADP - O
6,166 CD - B-CARDINAL
previously ADV - O
revascularized VERB - O
patients NOUN - O
, PUNCT - O
using VERB - O
the DET - O
16,410 CD - B-CARDINAL
nonrevascularized VERB - O
patients NOUN - O
as ADP - O
a DET - O
reference NOUN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Trandolapril NNP - B-MEDICINE
/ SYM - O
verapamil NOUN - O
SR PROPN - O
combination NOUN - O
reverses VERB - O
drug NOUN - O
- PUNCT - O
induced VERB - O
new ADJ - O
- PUNCT - O
onset NOUN - O
diabetes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Lisinopril NNP - B-MEDICINE
inhibits VERB - O
nuclear ADJ - O
transcription NOUN - O
factor NOUN - O
kappa NOUN - O
B PROPN - O
and CCONJ - O
augments NOUN - O
sensitivity NOUN - O
to ADP - O
silymarin NOUN - O
in ADP - O
experimental ADJ - O
liver NOUN - O
fibrosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Daily NNP - B-ORG
Lisinopril NNP - I-MEDICINE
vs ADP - O
Placebo PROPN - O
for ADP - O
Prevention PROPN - O
of ADP - O
Chemoradiation PROPN - O
- PUNCT - O
Induced VERB - O
Pulmonary PROPN - O
Distress PROPN - O
in ADP - O
Patients PROPN - O
With ADP - O
Lung PROPN - O
Cancer PROPN - O
( PUNCT - O
Alliance PROPN - O
MC1221 PROPN - O
) PUNCT - O
: PUNCT - O

-DOCSTART- -X- - O

Superparamagnetic PROPN - O
γ PROPN - O
- PUNCT - O
Fe2O3@SiO2@lisinopril PROPN - O
( PUNCT - O
MNPs PROPN - O
- PUNCT - O
Lisinopril JJ - B-MEDICINE
) PUNCT - O
nanoparticles NOUN - O
are VERB - O
T2 NNP - B-ORG
and CCONJ - O
T2 NNP - B-ORG

Measurements NOUN - O
on ADP - O
the DET - O
relaxivities NOUN - O
( PUNCT - O
r1 PROPN - O
, PUNCT - O
r2 NOUN - O
and CCONJ - O
r2 NOUN - O
* PUNCT - O
) PUNCT - O
of ADP - O
the DET - O
MNPs PROPN - O
- PUNCT - O
Lisinopril NNP - B-MEDICINE
were VERB - O
determined VERB - O
in ADP - O
deionized ADJ - O
water NOUN - O
( PUNCT - O
in X - O
vitro X - O
) PUNCT - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
after ADP - O
subcutaneous ADJ - O
injection NOUN - O
of ADP - O
the DET - O
MNPs NOUN - O
- PUNCT - O
Lisinopril JJ - B-MEDICINE
into ADP - O
4T1 NNP - B-CARDINAL
( PUNCT - O
ATCC PROPN - O
® NOUN - O

MRI PROPN - O
images NOUN - O
of ADP - O
MNPs NNS - B-ORG
- : - I-ORG
Lisinopril NNP - I-MEDICINE
showed VERB - O
that ADP - O
the DET - O
MR NNP - B-ORG
signal NOUN - O
intensity NOUN - O
decreased VERB - O
significantly ADV - O
with ADP - O
increasing VERB - O
nanoparticle NOUN - O
concentration NOUN - O
in ADP - O
water NOUN - O
. PUNCT - O

With ADP - O
measured ADJ - O
r2 NOUN - O
values NOUN - O
up ADV - O
to ADP - O
236.66 CD - B-CARDINAL
  SPACE - O
mM-1s NOUN - O
  SPACE - O
-1 NOUN - O
, PUNCT - O
our ADJ - O
MNPs NOUN - O
- PUNCT - O
Lisinopril JJ - B-MEDICINE
show NOUN - O
better ADJ - O
performance NOUN - O
than ADP - O
commercial ADJ - O
alternatives NOUN - O
. PUNCT - O

Also ADV - O
we PRON - O
tested VERB - O
drug NOUN - O
release NOUN - O
of ADP - O
Lisinopril NNP - B-MEDICINE
coated VERB - O
MNPs NOUN - O
at ADP - O
two CD - B-CARDINAL
different ADJ - O
pHs NOUN - O
. PUNCT - O

The DT - B-ORG
MNPs- NNP - I-ORG
Lisinopril NNP - I-MEDICINE
is VERB - O
a DET - O
pH NOUN - O
- PUNCT - O
sensitive ADJ - O
drug NOUN - O
delivery NOUN - O
system NOUN - O
and CCONJ - O
releases VERB - O
different ADJ - O
amounts NOUN - O
of ADP - O
lisinopril NN - B-MEDICINE
from ADP - O
MNPs NNS - B-ORG
- : - I-ORG
Captopril NNP - I-ORG
in ADP - O
different ADJ - O
pHs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Randomized VERB - O
Controlled PROPN - O
Trial PROPN - O
of ADP - O
Lisinopril NNP - B-MEDICINE
to ADP - O
Decrease PROPN - O

-DOCSTART- -X- - O

Combined PROPN - O
Hydration PROPN - O
and CCONJ - O
Antibiotics PROPN - O
with ADP - O
Lisinopril NNP - B-MEDICINE
to ADP - O
Mitigate NNP - B-ORG
Acute NNP - I-ORG
and CCONJ - O
Delayed VBN - B-PERSON
High NNP - I-PERSON
- HYPH - I-PERSON
dose NN - I-PERSON
Radiation NN - B-ORG
Injuries NNPS - I-ORG
to ADP - O
Multiple NNP - B-ORG
Organs NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Effects NOUN - O
of ADP - O
Amlodipine NNP - B-ORG
/ SYM - I-ORG
Lisinopril NNP - I-MEDICINE
Fixed VBN - I-ORG
- HYPH - I-ORG
Dose NNP - I-ORG
Combination NN - I-ORG
on IN - I-ORG
Severity NNP - B-ORG
of IN - I-ORG
Left NNP - I-ORG
Ventricular NNP - I-ORG
Hypertrophy NNP - I-ORG
and CC - I-ORG
Parameters NNPS - I-ORG
of IN - I-ORG
Myocardial NNP - I-ORG
Stiffness NNP - I-ORG
in IN - I-ORG
Patients NNP - I-ORG
With IN - I-ORG
Hypertension]. NNP - I-ORG

-DOCSTART- -X- - O

Two CD - B-CARDINAL
standard ADJ - O
inhibitors NOUN - O
, PUNCT - O
Captopril NNP - B-ORG
and CCONJ - O
Lisinopril NNP - B-MEDICINE
, PUNCT - O
were VERB - O
checked VERB - O
through ADP - O
the DET - O
newly ADV - O
developed VERB - O
method NOUN - O
for ADP - O
their ADJ - O
inhibitory ADJ - O
potential NOUN - O
, PUNCT - O
and CCONJ - O
their ADJ - O
IC50 PROPN - O
values NOUN - O
were VERB - O
found VERB - O
to PART - O
be VERB - O
3.969 CD - B-CARDINAL
and CCONJ - O
0.852μM CD - B-GPE
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Medications NOUN - O
can VERB - O
also ADV - O
play VERB - O
a DET - O
role NOUN - O
, PUNCT - O
as ADP - O
randomized VERB - O
controlled VERB - O
trials NOUN - O
of ADP - O
biguanides NOUN - O
( PUNCT - O
metformin NOUN - O
) PUNCT - O
alpha NOUN - O
- PUNCT - O
glucosidase NOUN - O
inhibitors NOUN - O
( PUNCT - O
Acarbose PROPN - O
) PUNCT - O
, PUNCT - O
inhibitors NOUN - O
of ADP - O
pancreatic ADJ - O
lipase NOUN - O
( PUNCT - O
Orlistat NNP - B-ORG
) PUNCT - O
, PUNCT - O
PPAR PROPN - O
- PUNCT - O
gamma NOUN - O
agonists VERB - O
( PUNCT - O
Rosiglitazone NNP - B-ORG
, , - I-ORG
Pioglitazone NNP - I-ORG
) PUNCT - O
, PUNCT - O
meglitinides NOUN - O
( PUNCT - O
Nateglinide NNP - B-MEDICINE
) PUNCT - O
and CCONJ - O
GLP-1 PROPN - O
receptor NOUN - O
agonists VERB - O
( PUNCT - O
Liraglutide PROPN - O
) PUNCT - O
have VERB - O
all DET - O
shown VERB - O
benefits NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Co NNP - B-ORG
- NNP - I-ORG
Amorphous JJ - I-ORG
Combination NNP - I-ORG
of IN - I-ORG
Nateglinide NNP - I-MEDICINE
- PUNCT - O
Metformin PROPN - O
Hydrochloride PROPN - O
for ADP - O
Dissolution NNP - B-ORG
Enhancement NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
used VERB - O
baseline NOUN - O
and CCONJ - O
1-year CD - B-DATE
data NOUN - O
from ADP - O
the DET - O
Nateglinide NNP - B-MEDICINE
and CCONJ - O
Valsartan NNP - B-GPE
in ADP - O
Impaired NNP - B-ORG
Glucose NNP - I-ORG
Tolerance NNP - I-ORG
Outcomes NNP - I-ORG
Research NNP - I-ORG
( PUNCT - O
NAVIGATOR PROPN - O
) PUNCT - O

-DOCSTART- -X- - O

Nateglinide NNP - B-MEDICINE
is VERB - O
commonly ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
type NOUN - O
2 CD - B-CARDINAL
diabetes NOUN - O
mellitus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nateglinide NNP - B-MEDICINE
, PUNCT - O
N-(trans-4-isopropylcyclohexyl NNP - B-ORG
- HYPH - I-ORG
carbonyl)-d NNP - I-ORG
- PUNCT - O
phenylalanine NOUN - O
, PUNCT - O
is VERB - O
a DET - O
potent ADJ - O
insulin NOUN - O
secretagogue NOUN - O
designed VERB - O
to PART - O
restore VERB - O
early ADJ - O
- PUNCT - O
phase NOUN - O
insulin NOUN - O
secretion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Nateglinide NNP - B-MEDICINE
and CCONJ - O
Valsartan NNP - B-GPE
in ADP - O
Impaired NNP - B-ORG
Glucose NNP - I-ORG
Tolerance NNP - I-ORG
Outcomes NNP - I-ORG
Research NNP - I-ORG
( PUNCT - O
NAVIGATOR PROPN - O
) PUNCT - O
, PUNCT - O
9306 CD - B-DATE
research NOUN - O
participants NOUN - O
with ADP - O
impaired ADJ - O
glucose NOUN - O
tolerance NOUN - O
and CCONJ - O
≥1 VERB - O
cardiovascular ADJ - O
risk NOUN - O
factors NOUN - O
were VERB - O
randomized VERB - O
to PART - O
valsartan VERB - O
versus ADP - O
placebo NOUN - O
and CCONJ - O
nateglinide JJ - B-MEDICINE
versus ADP - O
placebo NOUN - O
in ADP - O
a DET - O
2×2 CD - B-CARDINAL
factorial ADJ - O
manner NOUN - O
, PUNCT - O
with ADP - O
a DET - O
median ADJ - O
follow NOUN - O
- PUNCT - O
up NOUN - O
of ADP - O
6.5 CD - B-DATE
years NNS - I-DATE
. PUNCT - O

-DOCSTART- -X- - O

Nateglinide NNP - B-MEDICINE
is VERB - O
Effective ADJ - O
for ADP - O
Diabetes PROPN - O
Mellitus PROPN - O
with ADP - O
Reactive NNP - B-ORG
Hypoglycemia NNP - I-ORG
in ADP - O
a DET - O
Child NN - B-ORG
with ADP - O
a DET - O
Compound PROPN - O
Heterozygous PROPN - O
ABCC8 PROPN - O
Mutation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Nateglinide RB - B-MEDICINE
, PUNCT - O
a DET - O
short ADJ - O
- PUNCT - O
acting NOUN - O
insulin NOUN - O
secretagogue NOUN - O
of ADP - O
the DET - O
meglitinide ADJ - O
class NOUN - O
of ADP - O
antidiabetic ADJ - O
agents NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
marketed VERB - O
for ADP - O
the DT - B-DATE
past JJ - I-DATE
decade NN - I-DATE
specifically ADV - O
to PART - O
address VERB - O
the DET - O
diminished ADJ - O
postprandial ADJ - O
insulin NOUN - O
secretion NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effects NOUN - O
of ADP - O
20 CD - B-PERCENT
% NN - I-PERCENT
Human NNP - B-PERSON
Serum NNP - I-PERSON
on ADP - O
Corneal NNP - B-ORG
Epithelial NNP - I-ORG
Toxicity NN - I-ORG
Induced VBN - I-ORG
by IN - I-ORG
Benzalkonium NNP - I-ORG
Chloride NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Synthesis PROPN - O
, PUNCT - O
Structure PROPN - O
and CCONJ - O
Antimicrobial PROPN - O
Properties PROPN - O
of ADP - O
Novel PROPN - O
Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
Analogues VERB - O
with ADP - O
Pyridine NNP - B-ORG
Rings NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Corrosive PROPN - O
Esophagitis PROPN - O
with ADP - O
Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
in ADP - O
a DET - O
Two NUM - O
Days PROPN - O
Old PROPN - O
Neonate PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
: PUNCT - O

-DOCSTART- -X- - O

With ADP - O
10 CD - B-PERCENT
% NN - I-PERCENT
Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
During ADP - O
Cataract PROPN - O
Surgery PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
a DET - O
Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
Surfactant PROPN - O
- PUNCT - O
Sodium PROPN - O
Hypochlorite PROPN - O
Combination PROPN - O
on ADP - O
Elimination PROPN - O
of ADP - O
Enterococcus PROPN - O
faecalis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Safety PROPN - O
and CCONJ - O
Efficacy PROPN - O
of ADP - O
Benzalkonium NNP - B-MEDICINE
Chloride NNP - I-MEDICINE
- PUNCT - O
optimized VERB - O
Tafluprost PROPN - O
in ADP - O
Japanese JJ - B-NORP
Glaucoma PROPN - O
Patients NOUN - O
With ADP - O
Existing VERB - O
Superficial PROPN - O
Punctate PROPN - O
Keratitis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Solid NNP - B-PERSON
Microneedles NNP - I-PERSON
for ADP - O
Transdermal NNP - B-ORG
Delivery NNP - I-ORG
of IN - I-ORG
Amantadine NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
and CCONJ - O
Pramipexole NNP - B-NORP
Dihydrochloride PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Comparative PROPN - O
Single PROPN - O
- PUNCT - O
Dose PROPN - O
Pharmacokinetics PROPN - O
of ADP - O
Amantadine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
and CCONJ - O
Rimantadine NNP - B-PERSON
Hydrochloride NNP - I-PERSON
in ADP - O
Young NNP - B-GPE
and CCONJ - O
Elderly PROPN - O
Adults PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Leader NN - B-MEDICINE
cells NOUN - O
initiate VERB - O
and CCONJ - O
organize VERB - O
the DET - O
migration NOUN - O
of ADP - O
follower NOUN - O
cells NOUN - O
, PUNCT - O
to PART - O
allow VERB - O
the DET - O
group NOUN - O
of ADP - O
cells NOUN - O
to PART - O
move VERB - O
as ADP - O
a DET - O
cohesive NOUN - O
and CCONJ - O
polarized ADJ - O
unit NOUN - O
. PUNCT - O

Leader NN - B-MEDICINE
- PUNCT - O
follower NOUN - O
specification NOUN - O
is VERB - O
essential ADJ - O
for ADP - O
coordinated ADJ - O
and CCONJ - O
directional ADJ - O
collective ADJ - O
movement NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Event PROPN - O
/ SYM - O
Self NOUN - O
- PUNCT - O
Triggered PROPN - O
Control NOUN - O
for ADP - O
Leader NNP - B-MEDICINE
- PUNCT - O
Following VERB - O
Consensus NNP - B-ORG
Over IN - I-ORG
Unreliable NNP - I-ORG
Network NNP - I-ORG

-DOCSTART- -X- - O

2018 CD - B-DATE
Visionary PROPN - O
Leader NNP - B-MEDICINE
Lori NNP - B-PERSON
A. NN - I-PERSON
Colineri NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Leaders NOUN - O
were VERB - O
also ADV - O
more ADV - O
likely ADJ - O
to PART - O
take VERB - O
actions NOUN - O
when ADV - O
external ADJ - O
disturbances NOUN - O
set VERB - O
task NOUN - O
states NOUN - O
back ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Leader NN - B-MEDICINE
- PUNCT - O
follower NOUN - O
controllability NOUN - O
on ADP - O
signed VERB - O
multiagent NOUN - O
networks NOUN - O
is VERB - O
investigated VERB - O
in ADP - O
this DET - O
paper NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Clarifying NNP - B-ORG
Role NNP - I-ORG
Expectations NNP - I-ORG
and CC - I-ORG
Practice PROPN - O
Standards PROPN - O
Using VERB - O
a DET - O
Clinical PROPN - O
Nurse PROPN - O
Leader NNP - B-MEDICINE
Professional PROPN - O
Practice PROPN - O
Model PROPN - O
Illustration PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Leader NN - B-MEDICINE
- PUNCT - O
centric ADJ - O
views NOUN - O
of ADP - O
leadership NOUN - O
tend VERB - O
to PART - O
regard VERB - O
followers NOUN - O
as ADP - O
passive ADJ - O
recipients NOUN - O
of ADP - O
leaders NOUN - O
' PART - O
influences NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Importance PROPN - O
of ADP - O
Authentic PROPN - O
Leadership PROPN - O
to ADP - O
all DET - O
Generations NNPS - B-WORK_OF_ART
Represented VBN - I-WORK_OF_ART
within IN - I-WORK_OF_ART
Academic NNP - I-WORK_OF_ART
Pharmacy NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Are VERB - O
Shaped VERB - O
by ADP - O
Leader NNP - B-MEDICINE
Behavior NNP - B-PERSON
and CCONJ - O
Follower NNP - B-ORG
Perceptions NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Statistical PROPN - O
Optimisation PROPN - O
of ADP - O
Buspirone NNP - B-MEDICINE
Hydrochloride NNP - I-MEDICINE
Buccoadhesive PROPN - O
Films PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
analyse NOUN - O
1 CD - B-CARDINAL
) PUNCT - O
the DET - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
orally ADV - O
disintegrating VERB - O
tablet NOUN - O
( PUNCT - O
ODT NNP - B-ORG
) PUNCT - O
compared VERB - O
to PART - O
olanzapine VB - B-MEDICINE
standard ADJ - O
oral ADJ - O
tablet NOUN - O
( PUNCT - O
SOT PROPN - O
) PUNCT - O
and CCONJ - O
2 LS - B-CARDINAL
) PUNCT - O
the DET - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT PROPN - O
compared VERB - O
to ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
for ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

The DET - O
average ADJ - O
bidding NOUN - O
prices NOUN - O
in ADP - O
China NNP - B-GPE
of ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT ADJ - O
, PUNCT - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
, PUNCT - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
, PUNCT - O
and CCONJ - O
other ADJ - O
switch NOUN - O
alternatives NOUN - O
were VERB - O
used VERB - O
. PUNCT - O

The DET - O
total ADJ - O
annual JJ - B-DATE
costs NOUN - O
per ADP - O
patient NOUN - O
in ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
arm NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
arm NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT NOUN - O
arm NOUN - O
are VERB - O
USD NNP - B-ORG
2,296.05 CD - I-ORG
, PUNCT - O
USD NN - B-ORG
1,940.05 CD - I-ORG
, PUNCT - O
and CCONJ - O
USD NN - B-ORG
2,292.81 CD - I-ORG
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
average ADJ - O
number NOUN - O
of ADP - O
relapses NOUN - O
per ADP - O
patient NOUN - O
in ADP - O
one CD - B-DATE
year NN - I-DATE
in ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
arm NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
arm NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT NOUN - O
arm NOUN - O
are VERB - O
0.734 CD - B-CARDINAL
, PUNCT - O
0.325 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
0.198 CD - B-DATE
, PUNCT - O
respectively ADV - O
. PUNCT - O

The DET - O
quality NOUN - O
- PUNCT - O
adjusted VERB - O
life NOUN - O
years NNS - B-DATE
( PUNCT - O
QALYs PROPN - O
) PUNCT - O
gained VERB - O
per ADP - O
patient NOUN - O
in ADP - O
one CD - B-DATE
year NN - I-DATE
in ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
arm NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
arm NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT NOUN - O
arm NOUN - O
are VERB - O
0.714 CD - B-CARDINAL
, PUNCT - O
0.737 CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
0.758 CD - B-CARDINAL
, PUNCT - O
respectively ADV - O
. PUNCT - O

Consequently ADV - O
, PUNCT - O
1 LS - B-CARDINAL
) PUNCT - O
the DET - O
incremental ADJ - O
cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
ratios NOUN - O
( PUNCT - O
ICERs PROPN - O
) PUNCT - O
of ADP - O
administrating VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT NOUN - O
over ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT PROPN - O
are VERB - O
USD PROPN - O
2,791.96 NUM - O
per ADP - O
relapse NOUN - O
avoided VERB - O
and CCONJ - O
USD NNP - B-ORG
16,798.39 CD - I-ORG
per IN - I-ORG
QALY NNP - I-ORG
gained VERB - O
; PUNCT - O
and CCONJ - O
2 LS - B-CARDINAL
) PUNCT - O
the DET - O
ICERs NUM - O
of ADP - O
using VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
over ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT PROPN - O
are VERB - O
USD PROPN - O
-870.39 PUNCT - O
per ADP - O
relapse NOUN - O
avoided VERB - O
and CCONJ - O
USD NN - B-ORG
-15,477.93 NOUN - O
per ADP - O
QALY NNP - B-ORG
gained VERB - O
. PUNCT - O

As ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
for ADP - O
schizophrenia NOUN - O
in ADP - O
China NNP - B-GPE
, PUNCT - O
olanzapine NN - B-MEDICINE
- PUNCT - O
ODT NOUN - O
is VERB - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
compared VERB - O
to ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT NOUN - O
and CCONJ - O
olanzapine NN - B-MEDICINE
- PUNCT - O
SOT PROPN - O
is VERB - O
cost NOUN - O
- PUNCT - O
effective ADJ - O
compared VERB - O
to ADP - O
aripiprazole NOUN - O
- PUNCT - O
SOT NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
in ADP - O
the DET - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
treatment NOUN - O
of ADP - O
schizophrenia NOUN - O
in ADP - O
China NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
purpose NOUN - O
of ADP - O
this DET - O
review NOUN - O
is VERB - O
to PART - O
summarize VERB - O
the DET - O
current ADJ - O
evidence NOUN - O
of ADP - O
the DET - O
off ADJ - O
- PUNCT - O
label NOUN - O
use NOUN - O
of ADP - O
intravenous ADJ - O
( PUNCT - O
IV NNP - B-ORG
) PUNCT - O
olanzapine NN - B-MEDICINE
and CCONJ - O
discuss VERB - O
its ADJ - O
risks NOUN - O
versus ADP - O
benefits NOUN - O
for ADP - O
the DET - O
management NOUN - O
of ADP - O
agitation NOUN - O
. PUNCT - O

A DET - O
literature NOUN - O
search NOUN - O
was VERB - O
conducted VERB - O
to PART - O
gather VERB - O
relevant ADJ - O
data NOUN - O
regarding VERB - O
IV NNP - B-ORG
use NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
for ADP - O
the DET - O
management NOUN - O
of ADP - O
acute ADJ - O
agitation NOUN - O
. PUNCT - O

PubMed NNP - B-ORG
, PUNCT - O
EMBASE NNP - B-ORG
, PUNCT - O
MEDLINE NNP - B-ORG
, PUNCT - O
and CCONJ - O
IPA NNP - B-ORG
were VERB - O
searched VERB - O
using VERB - O
the DET - O
keywords NOUN - O
and CCONJ - O
MESH NNP - B-ORG
terms NOUN - O
: PUNCT - O
olanzapine RB - B-MEDICINE
, PUNCT - O
intravenous ADJ - O
, PUNCT - O
IV NNP - B-ORG
, PUNCT - O
off ADP - O
- PUNCT - O
label NOUN - O
, PUNCT - O
and CCONJ - O
agitation NOUN - O
. PUNCT - O

All DET - O
case NOUN - O
reports VERB - O
, PUNCT - O
and CCONJ - O
retrospective ADJ - O
and CCONJ - O
prospective ADJ - O
studies NOUN - O
evaluating VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
IV NNP - B-ORG
olanzapine NN - B-MEDICINE
administration NOUN - O
for ADP - O
agitation NOUN - O
from ADP - O
January NNP - B-DATE
2004 CD - I-DATE
to IN - I-DATE
December NNP - I-DATE
2018 CD - I-DATE
were VERB - O
analyzed VERB - O
. PUNCT - O

Rates NOUN - O
of ADP - O
respiratory ADJ - O
depression NOUN - O
and CCONJ - O
airway NOUN - O
obstruction NOUN - O
are VERB - O
low ADJ - O
and CCONJ - O
similar ADJ - O
to ADP - O
that DET - O
of ADP - O
comparative ADJ - O
agents NOUN - O
, PUNCT - O
including VERB - O
intramuscular ADJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

: PUNCT - O
This DET - O
review NOUN - O
evaluated VERB - O
the DET - O
off ADP - O
- PUNCT - O
label NOUN - O
use NOUN - O
of ADP - O
IV NNP - B-ORG
olanzapine RB - B-MEDICINE
to PART - O
manage VERB - O
agitation NOUN - O
based VERB - O
on ADP - O
case NOUN - O
reports NOUN - O
, PUNCT - O
and CCONJ - O
retrospective ADJ - O
and CCONJ - O
prospective ADJ - O
data NOUN - O
. PUNCT - O

The DET - O
use NOUN - O
of ADP - O
IV NNP - B-ORG
olanzapine NN - B-MEDICINE
remains VERB - O
controversial ADJ - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
clear ADJ - O
evidence NOUN - O
evaluating VERB - O
safety NOUN - O
and CCONJ - O
efficacy NOUN - O
. PUNCT - O

Future ADJ - O
studies NOUN - O
are VERB - O
warranted VERB - O
comparing VERB - O
IV NNP - B-ORG
olanzapine RB - B-MEDICINE
with ADP - O
more ADV - O
commonly ADV - O
utilized VERB - O
and CCONJ - O
Food NNP - B-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
- PUNCT - O
approved VERB - O
treatment NOUN - O
modalities NOUN - O
for ADP - O
acute ADJ - O
agitation NOUN - O
in ADP - O
the DET - O
emergency NOUN - O
department NOUN - O
and CCONJ - O
other ADJ - O
settings NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
lurasidone NOUN - O
vs ADP - O
olanzapine NN - B-MEDICINE
on ADP - O
neurotrophic ADJ - O
biomarkers NOUN - O
in ADP - O
unmedicated ADJ - O
schizophrenia NOUN - O
: PUNCT - O
A DET - O
randomized ADJ - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ingestion NOUN - O
of ADP - O
the DET - O
prebiotic ADJ - O
Bimuno NNPS - B-ORG
™ NNP - I-ORG
galacto NOUN - O
- PUNCT - O
oligosaccharide NOUN - O
( PUNCT - O
B NNP - B-PRODUCT
- HYPH - I-PRODUCT
GOS NNP - I-PRODUCT
® NN - I-PRODUCT
) PUNCT - O
is VERB - O
one CD - B-CARDINAL
such ADJ - O
intervention NOUN - O
that ADJ - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
attenuate VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
improve VERB - O
cognitive ADJ - O
flexibility NOUN - O
in ADP - O
rats NOUN - O
, PUNCT - O
potentially ADV - O
through ADP - O
mechanisms NOUN - O
involving VERB - O
acetate ADJ - O
, PUNCT - O
the DET - O
major ADJ - O
short ADJ - O
- PUNCT - O
chain NOUN - O
fatty NOUN - O
acid NOUN - O
( PUNCT - O
SCFA NNP - B-ORG
) PUNCT - O
that ADJ - O
is VERB - O
produced VERB - O
by ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
fermentation NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
investigated VERB - O
the DET - O
individual ADJ - O
influences NOUN - O
of ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
and CCONJ - O
sodium NOUN - O
acetate NOUN - O
intake NOUN - O
on ADP - O
brain NOUN - O
histone NOUN - O
acetyltransferase NOUN - O
( PUNCT - O
HAT PROPN - O
) PUNCT - O
and CCONJ - O
histone NOUN - O
deacetylase NOUN - O
( PUNCT - O
HDAC NNP - B-ORG
) PUNCT - O
activities NOUN - O
, PUNCT - O
cortical ADJ - O
and CCONJ - O
hippocampal ADJ - O
expression NOUN - O
of ADP - O
HDAC1 NNP - B-DATE
- SYM - I-DATE
4 CD - I-DATE
and CCONJ - O
N NOUN - O
- PUNCT - O
methyl NOUN - O
- PUNCT - O
d NUM - O
- PUNCT - O
aspartate NOUN - O
receptor NOUN - O
subunits NOUN - O
in ADP - O
saline NOUN - O
or CCONJ - O
olanzapine NN - B-MEDICINE
injected VERB - O
female ADJ - O
rats NOUN - O
. PUNCT - O

The DET - O
effect NOUN - O
of ADP - O
sodium NOUN - O
acetate ADJ - O
on ADP - O
olanzapine RB - B-MEDICINE
- PUNCT - O
induced VERB - O
weight NOUN - O
gain NOUN - O
was VERB - O
also ADV - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Meta ADJ - O
- PUNCT - O
analysis NOUN - O
of ADP - O
ghrelin NOUN - O
alterations NOUN - O
in ADP - O
schizophrenia NOUN - O
: PUNCT - O
Effects NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
for ADP - O
therapeutic ADJ - O
drug NOUN - O
monitoring NOUN - O
in ADP - O
schizophrenia NOUN - O
patients NOUN - O
by ADP - O
LC NNP - B-ORG
/ SYM - I-ORG
MS NNP - I-ORG
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

High ADJ - O
prevalence NOUN - O
of ADP - O
prediabetes NOUN - O
and CCONJ - O
metabolic ADJ - O
abnormalities NOUN - O
in ADP - O
overweight ADJ - O
or CCONJ - O
obese ADJ - O
schizophrenia NOUN - O
patients NOUN - O
treated VERB - O
with ADP - O
clozapine NOUN - O
or CCONJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Antiemetic ADJ - O
use NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
advanced ADJ - O
cancer NOUN - O
: PUNCT - O
results NOUN - O
from ADP - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
multicenter NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Study NOUN - O
protocol NOUN - O
for ADP - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
, PUNCT - O
single ADJ - O
- PUNCT - O
arm NOUN - O
, PUNCT - O
multicentre ADJ - O
phase NOUN - O
II CD - B-ORG
trial NOUN - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
combined VERB - O
triplet NOUN - O
therapy NOUN - O
and CCONJ - O
olanzapine NN - B-MEDICINE
for ADP - O
prevention NOUN - O
of ADP - O
carboplatin ADJ - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
gynaecological ADJ - O
cancer NOUN - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
the DET - O
effect NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
on ADP - O
atherosclerosis NOUN - O
and CCONJ - O
the DET - O
mechanisms NOUN - O
in ADP - O
apolipoprotein NOUN - O
E NOUN - O
- NOUN - O
null ADJ - O
( PUNCT - O
apoE-/- NOUN - O
) PUNCT - O
mice NOUN - O
. PUNCT - O

Daily ADJ - O
treatment NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
( PUNCT - O
3 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
body NOUN - O
weight NOUN - O
) PUNCT - O
for ADP - O
four CD - B-DATE
weeks NNS - I-DATE
increased VERB - O
mean ADJ - O
arterial ADJ - O
blood NOUN - O
pressure NOUN - O
and CCONJ - O
the DET - O
whitening NOUN - O
of ADP - O
brown ADJ - O
adipose ADJ - O
tissue NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

In ADP - O
addition NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
impaired VERB - O
aortic ADJ - O
cholesterol NOUN - O
homeostasis NOUN - O
and CCONJ - O
exacerbated VERB - O
hyperlipidemia ADJ - O
and CCONJ - O
aortic ADJ - O
inflammation NOUN - O
, PUNCT - O
which ADJ - O
accelerated VERB - O
atherosclerosis NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

Moreover ADV - O
, PUNCT - O
lipid ADJ - O
accumulation NOUN - O
in ADP - O
liver NOUN - O
, PUNCT - O
particularly ADV - O
total ADJ - O
cholesterol NOUN - O
, PUNCT - O
free ADJ - O
cholesterol NOUN - O
, PUNCT - O
fatty ADJ - O
acids NOUN - O
, PUNCT - O
and CCONJ - O
glycerol NOUN - O
, PUNCT - O
was VERB - O
increased VERB - O
with ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
in ADP - O
apoE-/- NUM - O
mice NOUN - O
by ADP - O
upregulating VERB - O
the DET - O
expression NOUN - O
of ADP - O
de X - O
novo NOUN - O
lipid ADJ - O
synthesis NOUN - O
- PUNCT - O
related VERB - O
proteins NOUN - O
and CCONJ - O
downregulating VERB - O
that DET - O
of ADP - O
cholesterol NOUN - O
clearance- NOUN - O
or CCONJ - O
very ADV - O
low ADJ - O
- PUNCT - O
density NOUN - O
lipoprotein NOUN - O
secretion NOUN - O
- PUNCT - O
related VERB - O
proteins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
investigated VERB - O
whether ADP - O
upregulation NOUN - O
of ADP - O
macrophage NOUN - O
migration NOUN - O
inhibitory NOUN - O
factor NOUN - O
( PUNCT - O
MIF NNP - B-ORG
) PUNCT - O
underlies VERB - O
the DET - O
insulin NOUN - O
resistance NOUN - O
that ADJ - O
develops VERB - O
during ADP - O
treatment NOUN - O
with ADP - O
the DET - O
most ADV - O
commonly ADV - O
prescribed VERB - O
atypical ADJ - O
antipsychotic ADJ - O
, PUNCT - O
olanzapine NN - B-MEDICINE
. PUNCT - O

Global ADJ - O
MIF NNP - B-ORG
- PUNCT - O
gene NOUN - O
deletion NOUN - O
protected VERB - O
mice NOUN - O
from ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
insulin NOUN - O
resistance NOUN - O
, PUNCT - O
as ADP - O
did VERB - O
intracerebroventricular ADJ - O
injection NOUN - O
of ADP - O
neutralizing VERB - O
anti ADJ - O
- ADJ - O
MIF ADJ - O
antibody NOUN - O
, PUNCT - O
supporting VERB - O
the DET - O
role NOUN - O
of ADP - O
increased VERB - O
hypothalamic ADJ - O
MIF NN - B-ORG
expression NOUN - O
in ADP - O
metabolic NOUN - O
dysfunction NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
report NOUN - O
proposes VERB - O
a DET - O
pharmacotherapy NOUN - O
that ADJ - O
may VERB - O
qualify VERB - O
for ADP - O
treatment NOUN - O
- PUNCT - O
resistant ADJ - O
psychosis NOUN - O
, PUNCT - O
that ADV - O
is ADV - O
, PUNCT - O
high ADV - O
- PUNCT - O
dose NOUN - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
had VERB - O
sufficient ADJ - O
data NOUN - O
, PUNCT - O
however ADV - O
, PUNCT - O
to PART - O
undertake VERB - O
limited ADJ - O
meta NOUN - O
- PUNCT - O
analyses NOUN - O
for ADP - O
clozapine NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
, PUNCT - O
all DET - O
showing VERB - O
mildly ADV - O
elevated ADJ - O
associations NOUN - O
with ADP - O
dyslipidaemia NOUN - O
" PUNCT - O
caseness NOUN - O
" PUNCT - O
( PUNCT - O
clozapine NOUN - O
, PUNCT - O
odds VERB - O
ratio NOUN - O
1.26 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval ADJ - O
1.16 CD - B-CARDINAL
- SYM - I-CARDINAL
1.38 CD - I-CARDINAL
; PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
odds VERB - O
ratio NOUN - O
1.29 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval ADJ - O
0.89 CD - B-CARDINAL
- SYM - O
1.87 NUM - O
; PUNCT - O
risperidone NOUN - O
, PUNCT - O
odds NOUN - O
ratio NOUN - O
1.05 CD - B-CARDINAL
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval ADJ - O
0.80 CD - B-CARDINAL
- SYM - O
1.37 NUM - O
) PUNCT - O
compared VERB - O
with ADP - O
first JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antipsychotics NOUN - O
, PUNCT - O
but CCONJ - O
heterogeneity NOUN - O
was VERB - O
high ADJ - O
( PUNCT - O

Compared VERB - O
with ADP - O
haloperidol NOUN - O
, PUNCT - O
neither CCONJ - O
olanzapine NN - B-MEDICINE
nor CCONJ - O
risperidone NOUN - O
was VERB - O
associated VERB - O
with ADP - O
statistically ADV - O
significant ADJ - O
increases NOUN - O
in ADP - O
cholesterol NOUN - O
or CCONJ - O
triglycerides NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
subgroup NOUN - O
of ADP - O
these DET - O
patients NOUN - O
develops VERB - O
OCS NNP - B-ORG
during ADP - O
treatment NOUN - O
with ADP - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
antipsychotics NOUN - O
( PUNCT - O
SGAs NOUN - O
) PUNCT - O
, PUNCT - O
most ADV - O
importantly ADV - O
clozapine ADJ - O
and CCONJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

To PART - O
investigate VERB - O
the DET - O
role NOUN - O
of ADP - O
SGA NNP - B-ORG
treatment NOUN - O
on ADP - O
neural ADJ - O
activation NOUN - O
and CCONJ - O
connectivity NOUN - O
during ADP - O
emotional ADJ - O
processing NOUN - O
, PUNCT - O
patients NOUN - O
were VERB - O
stratified VERB - O
according VERB - O
to ADP - O
their ADJ - O
monotherapy NOUN - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
( PUNCT - O
group NOUN - O
I PRON - O
: PUNCT - O
clozapine VERB - O
or CCONJ - O
olanzapine NN - B-MEDICINE
, PUNCT - O
n DET - O
  SPACE - O
= SYM - O
  SPACE - O
20 CD - B-CARDINAL
; PUNCT - O
group NOUN - O
II CD - B-ORG
: PUNCT - O
amisulpride NOUN - O
or CCONJ - O
aripiprazole NOUN - O
, PUNCT - O
n CCONJ - O
  SPACE - O
= SYM - O
  SPACE - O
20 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Seizure NOUN - O
associated VERB - O
with ADP - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
J PROPN - O
- PUNCT - O
FORCE PROPN - O
) PUNCT - O
: PUNCT - O
a DET - O
randomized ADJ - O
, PUNCT - O
double ADJ - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
Phase PROPN - O
III NNP - B-PERSON
study NOUN - O
evaluating VERB - O
olanzapine NN - B-MEDICINE
( PUNCT - O
5 CD - B-CARDINAL
mg NUM - O
) PUNCT - O
plus CCONJ - O
standard ADJ - O
triple ADJ - O
antiemetic ADJ - O
therapy NOUN - O
for ADP - O
prevention NOUN - O
of ADP - O
chemotherapy NOUN - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
cisplatin ADV - O
- PUNCT - O
based VERB - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
regimens NOUN - O
containing VERB - O
olanzapine RB - B-MEDICINE
, PUNCT - O
the DET - O
available ADJ - O
and CCONJ - O
affordable ADJ - O
medication NOUN - O
in ADP - O
Sudan NNP - B-GPE
, PUNCT - O
were VERB - O
introduced VERB - O
as ADP - O
another DET - O
option NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
an DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimen NOUN - O
with ADP - O
the DET - O
antiemetic ADJ - O
regimen NOUN - O
that ADJ - O
was VERB - O
currently ADV - O
used VERB - O
in ADP - O
our ADJ - O
institute NOUN - O
for ADP - O
CINV PROPN - O
prophylaxis NOUN - O
in ADP - O
HEC NNP - B-ORG
/ SYM - I-ORG
MEC NNP - I-ORG
settings NOUN - O
. PUNCT - O

The DET - O
study NOUN - O
prospectively ADV - O
compared VERB - O
an DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimen NOUN - O
( PUNCT - O
acute ADJ - O
phase NOUN - O
: PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
ondansetron NOUN - O
, PUNCT - O
dexamethasone NOUN - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
: PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
ondansetron NOUN - O
) PUNCT - O
with ADP - O
an DET - O
ondansetron NOUN - O
/ SYM - O
dexamethasone ADJ - O
regimen NOUN - O
( PUNCT - O
acute ADJ - O
phase NOUN - O
: PUNCT - O
ondansetron NOUN - O
, PUNCT - O
dexamethasone NOUN - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
: PUNCT - O
ondansetron NOUN - O
) PUNCT - O
in ADP - O
adult NOUN - O
patients NOUN - O
with ADP - O
cancer NOUN - O
receiving VERB - O
HEC PROPN - O
or CCONJ - O
MEC NNP - B-ORG
. PUNCT - O

The DET - O
study NOUN - O
included VERB - O
131 CD - B-CARDINAL
patients NOUN - O
( PUNCT - O
olanzapine RB - B-MEDICINE
- PUNCT - O
containing VERB - O
: PUNCT - O
50 CD - B-CARDINAL
patients NOUN - O
; PUNCT - O
ondansetron NOUN - O
/ SYM - O
dexamethasone NOUN - O
: PUNCT - O
81 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
. PUNCT - O

CR NN - B-GPE
and CCONJ - O
nausea NOUN - O
control NOUN - O
were VERB - O
higher ADJ - O
in ADP - O
the DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
than ADP - O
in ADP - O
the DET - O
ondansetron NOUN - O
/ SYM - O
dexamethasone ADJ - O
regimen NOUN - O
( PUNCT - O
CR NOUN - O
: PUNCT - O
acute ADJ - O
phase NOUN - O
, PUNCT - O
86 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
71.6 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O
P NOUN - O
= SYM - O
.086 NUM - O
; PUNCT - O
delayed VERB - O
phase NOUN - O
, PUNCT - O
72 CD - B-PERCENT
% NN - I-PERCENT
v NOUN - O
30.9 CD - B-PERCENT
% NN - I-PERCENT
; PUNCT - O

The DET - O
major ADJ - O
toxicity NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
was VERB - O
grade NOUN - O
1 CD - B-CARDINAL
and CCONJ - O
2 CD - B-CARDINAL
sedation NOUN - O
or CCONJ - O
drowsiness NOUN - O
( PUNCT - O
25 CD - B-CARDINAL
patients NOUN - O
) PUNCT - O
. PUNCT - O

An DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimen NOUN - O
has VERB - O
better ADJ - O
efficacy NOUN - O
for ADP - O
prevention NOUN - O
of ADP - O
CINV PROPN - O
in ADP - O
the DET - O
HEC NNP - B-ORG
/ SYM - I-ORG
MEC NNP - I-ORG
setting VERB - O
. PUNCT - O

Oncologists NOUN - O
working VERB - O
in ADP - O
a DET - O
limited VERB - O
- PUNCT - O
resource NOUN - O
setting NOUN - O
should VERB - O
be VERB - O
familiar ADJ - O
with ADP - O
olanzapine RB - B-MEDICINE
- PUNCT - O
containing VERB - O
regimens NOUN - O
, PUNCT - O
because ADP - O
NK1RA NNP - B-ORG
agents NOUN - O
are VERB - O
not ADV - O
affordable ADJ - O
and CCONJ - O
not ADV - O
easily ADV - O
available ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
sensitive ADJ - O
, PUNCT - O
selective ADJ - O
rapid ADJ - O
bioanalytical NOUN - O
assay NOUN - O
method NOUN - O
was VERB - O
developed VERB - O
and CCONJ - O
quantification NOUN - O
of ADP - O
iloperidone NOUN - O
( PUNCT - O
ILP NNP - B-ORG
) PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
OLZ PROPN - O
) PUNCT - O
in ADP - O
rat NOUN - O
plasma NOUN - O
was VERB - O
done VERB - O
by ADP - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development NOUN - O
of ADP - O
a DET - O
population NOUN - O
pharmacokinetic ADJ - O
model NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
for ADP - O
Chinese JJ - B-NORP
health NOUN - O
volunteers NOUN - O
and CCONJ - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
growing VERB - O
number NOUN - O
of ADP - O
antiemetic ADJ - O
regimens NOUN - O
, PUNCT - O
and CCONJ - O
in ADP - O
particular ADJ - O
the DET - O
growing VERB - O
use NOUN - O
of ADP - O
regimens NOUN - O
containing VERB - O
antagonists NOUN - O
to ADP - O
the DET - O
Nk-1 NNS - B-ORG
receptor NOUN - O
( PUNCT - O
NK1RAs PROPN - O
) PUNCT - O
and CCONJ - O
the DET - O
antipsychotic ADJ - O
drug NOUN - O
olanzapine NN - B-MEDICINE
( PUNCT - O
OLZ PROPN - O
) PUNCT - O
, PUNCT - O
call VERB - O
for ADP - O
the DET - O
re NOUN - O
- NOUN - O
evaluation NOUN - O
of ADP - O
the DET - O
optimal ADJ - O
regimen NOUN - O
for ADP - O
CINV PROPN - O
. PUNCT - O

A DET - O
regimen NOUN - O
containing VERB - O
NEPA NNP - B-ORG
was VERB - O
more ADV - O
effective ADJ - O
in ADP - O
producing VERB - O
CR NNP - B-GPE
than ADP - O
conventional ADJ - O
regimens NOUN - O
without ADP - O
NEPA NNP - B-ORG
or CCONJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

Further ADJ - O
analysis NOUN - O
, PUNCT - O
based VERB - O
on ADP - O
the DET - O
surface NOUN - O
under ADP - O
the DET - O
cumulative ADJ - O
ranking VERB - O
probability NOUN - O
curve NOUN - O
, PUNCT - O
indicated VERB - O
that ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimens NOUN - O
were VERB - O
the DET - O
most ADV - O
effective ADJ - O
in ADP - O
producing VERB - O
CR NNP - B-GPE
. PUNCT - O

Our ADJ - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
supports VERB - O
the DET - O
conclusion NOUN - O
that ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
regimens NOUN - O
are VERB - O
the DET - O
most ADV - O
effective ADJ - O
for ADP - O
CINV PROPN - O
of ADP - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
. PUNCT - O

Substituting VERB - O
olanzapine NN - B-MEDICINE
for ADP - O
an DET - O
Nk-1 NNS - B-ORG
receptor NOUN - O
antagonist NOUN - O
may VERB - O
offer VERB - O
a DET - O
less ADV - O
costly ADJ - O
and CCONJ - O
more ADV - O
effective ADJ - O
alternative NOUN - O
for ADP - O
patients NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
the DET - O
70 CD - B-PERCENT
% NN - I-PERCENT
less ADV - O
costly ADJ - O
drug NOUN - O
, PUNCT - O
olanzapine RB - B-MEDICINE
, PUNCT - O
is VERB - O
suggested VERB - O
to PART - O
be VERB - O
equally ADV - O
effective ADJ - O
to PART - O
aprepitant VERB - O
in ADP - O
reducing VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
relative ADJ - O
bioavailability NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
in ADP - O
3 CD - B-CARDINAL
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
tablet NOUN - O
formulations NOUN - O
. PUNCT - O

ALKS PROPN - O
3831 NUM - O
is VERB - O
a DET - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
( PUNCT - O
OLZ PROPN - O
, PUNCT - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
) PUNCT - O
and CCONJ - O
samidorphan PROPN - O
( PUNCT - O
SAM NNP - B-ORG
, PUNCT - O
a DET - O
μ NOUN - O
- PUNCT - O
opioid NOUN - O
receptor NOUN - O
antagonist NOUN - O
with ADP - O
low ADJ - O
intrinsic ADJ - O
activity NOUN - O
at ADP - O
δ- XX - B-ORG
and CCONJ - O
κ ADJ - O
- PUNCT - O
opioid ADJ - O
receptors NOUN - O
) PUNCT - O
, PUNCT - O
intended VERB - O
to PART - O
provide VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
OLZ NNP - B-ORG
while ADP - O
mitigating VERB - O
its ADJ - O
known ADJ - O
weight NOUN - O
and CCONJ - O
metabolic ADJ - O
effects NOUN - O
. PUNCT - O

Relative ADJ - O
bioavailability NOUN - O
of ADP - O
OLZ NNP - B-PRODUCT
in IN - I-PRODUCT
ALKS NNP - I-PRODUCT
3831 CD - I-PRODUCT
, PUNCT - O
a DET - O
bilayer NOUN - O
tablet NOUN - O
containing VERB - O
OLZ NNP - B-PRODUCT
and CCONJ - O
SAM NNP - B-ORG
, PUNCT - O
a DET - O
matching VERB - O
bilayer NOUN - O
tablet NOUN - O
containing VERB - O
OLZ NNP - B-ORG
only ADV - O
( PUNCT - O
OLZ PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Zyprexa NNP - B-PERSON
( PUNCT - O
brand NOUN - O
olanzapine NN - B-MEDICINE
[ PUNCT - O
B PROPN - O
- PUNCT - O
OLZ PROPN - O
] PUNCT - O
) PUNCT - O
was VERB - O
assessed VERB - O
in ADP - O
an DET - O
open ADJ - O
- PUNCT - O
label NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
a DET - O
randomized VERB - O
trial NOUN - O
, PUNCT - O
we PRON - O
previously ADV - O
demonstrated VERB - O
that ADP - O
16 CD - B-CARDINAL
  SPACE - O
weeks NNS - B-DATE
of ADP - O
glucagon NOUN - O
- PUNCT - O
like ADJ - O
peptide-1 NN - B-ORG
receptor NOUN - O
agonist NOUN - O
liraglutide NOUN - O
treatment NOUN - O
vs. CCONJ - O
placebo NOUN - O
significantly ADV - O
reduced VERB - O
glucometabolic ADJ - O
disturbances NOUN - O
and CCONJ - O
body NOUN - O
weight NOUN - O
in ADP - O
prediabetic ADJ - O
, PUNCT - O
overweight ADJ - O
/ SYM - O
obese ADJ - O
schizophrenia NOUN - O
- PUNCT - O
spectrum NOUN - O
disorder NOUN - O
patients NOUN - O
treated VERB - O
with ADP - O
clozapine NOUN - O
or CCONJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Cost NOUN - O
- PUNCT - O
effectiveness NOUN - O
analysis NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
containing VERB - O
antiemetic ADJ - O
therapy NOUN - O
for ADP - O
managing VERB - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
in ADP - O
Southeast NNP - B-LOC
Asia NNP - I-LOC
: PUNCT - O
a DET - O
multinational ADJ - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
evaluate VERB - O
the DET - O
effectiveness NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
adjunctive ADJ - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
for ADP - O
low ADJ - O
weight NOUN - O
adolescents NOUN - O
with ADP - O
anorexia NOUN - O
nervosa NOUN - O
( PUNCT - O
AN).A ADJ - O
non ADJ - O
- ADJ - O
randomized ADJ - O
open ADJ - O
- PUNCT - O
label NOUN - O
trial NOUN - O
was VERB - O
conducted VERB - O
between IN - B-DATE
2010 CD - I-DATE
and CC - I-DATE
2014 CD - I-DATE
. PUNCT - O

Participants NOUN - O
received VERB - O
standard ADJ - O
treatment NOUN - O
and CCONJ - O
were VERB - O
invited VERB - O
to PART - O
take VERB - O
olanzapine NN - B-MEDICINE
at ADP - O
study NOUN - O
enrollment NOUN - O
. PUNCT - O

Participants NOUN - O
could VERB - O
accept VERB - O
, PUNCT - O
continue VERB - O
, PUNCT - O
or CCONJ - O
discontinue VERB - O
olanzapine RB - B-MEDICINE
as ADP - O
treatment NOUN - O
progressed VERB - O
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
two CD - I-CARDINAL
participants NOUN - O
took VERB - O
olanzapine NN - B-MEDICINE
( PUNCT - O
medication NOUN - O
group NOUN - O
) PUNCT - O
and CCONJ - O
ten CD - B-CARDINAL
participants NOUN - O
did VERB - O
not ADV - O
( PUNCT - O
comparison NOUN - O
group NOUN - O
) PUNCT - O
. PUNCT - O

Participants NOUN - O
in ADP - O
the DET - O
medication NOUN - O
group NOUN - O
demonstrated VERB - O
a DET - O
higher ADJ - O
rate NOUN - O
of ADP - O
weight NOUN - O
gain NOUN - O
compared VERB - O
to ADP - O
those DET - O
who NOUN - O
did VERB - O
not ADV - O
receive VERB - O
olanzapine NN - B-MEDICINE
( PUNCT - O
p VERB - O
= SYM - O
.012 NUM - O
) PUNCT - O
. PUNCT - O

No DET - O
serious ADJ - O
adverse ADJ - O
events NOUN - O
were VERB - O
noted VERB - O
, PUNCT - O
although ADP - O
seven CD - B-CARDINAL
participants NOUN - O
( PUNCT - O
31.8 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
discontinued VERB - O
olanzapine RB - B-MEDICINE
due ADP - O
to ADP - O
a DET - O
side NOUN - O
effect NOUN - O
. PUNCT - O

Preliminary ADJ - O
results NOUN - O
suggest VERB - O
that ADP - O
olanzapine NN - B-MEDICINE
may VERB - O
help VERB - O
facilitate VERB - O
weight NOUN - O
gain NOUN - O
in ADP - O
adolescents NOUN - O
with ADP - O
AN NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Patients NOUN - O
were VERB - O
treated VERB - O
with ADP - O
olanzapine NN - B-MEDICINE
for ADP - O
8 CD - B-DATE
  _SP - I-DATE
weeks NNS - I-DATE
. PUNCT - O

Further ADV - O
, PUNCT - O
SVM PROPN - O
analysis NOUN - O
showed VERB - O
that ADP - O
a DET - O
combination NOUN - O
of ADP - O
the DET - O
PAS NNP - B-ORG
scores NOUN - O
in ADP - O
these DET - O
two CD - B-CARDINAL
clusters NOUN - O
in ADP - O
patients NOUN - O
at ADP - O
baseline NOUN - O
was VERB - O
able ADJ - O
to PART - O
predict VERB - O
clinical ADJ - O
response NOUN - O
after ADP - O
8 CD - B-DATE
  _SP - I-DATE
weeks NNS - I-DATE
of ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
with ADP - O
77.27 CD - B-PERCENT
% NN - I-PERCENT
sensitivity NOUN - O
, PUNCT - O
72.73 CD - B-PERCENT
% NN - I-PERCENT
specificity NOUN - O
, PUNCT - O
and CCONJ - O
75.00 CD - B-PERCENT
% NN - I-PERCENT
accuracy NOUN - O
. PUNCT - O

The DET - O
present ADJ - O
study NOUN - O
suggests VERB - O
disrupted ADJ - O
asymmetry NOUN - O
of ADP - O
inter- NOUN - O
and CCONJ - O
intra ADJ - O
- PUNCT - O
hemispheric ADJ - O
FC NN - B-ORG
in ADP - O
drug NOUN - O
- PUNCT - O
naive ADJ - O
, PUNCT - O
first JJ - B-ORDINAL
- PUNCT - O
episode NOUN - O
schizophrenia NOUN - O
; PUNCT - O
in ADP - O
addition NOUN - O
, PUNCT - O
a DET - O
reduced ADJ - O
asymmetry NOUN - O
of ADP - O
inter ADJ - O
- ADJ - O
hemispheric ADJ - O
FC NNP - B-ORG
in ADP - O
the DET - O
left ADJ - O
MTG NNP - B-ORG
/ SYM - I-ORG
ITG NNP - I-ORG
and CCONJ - O
left VERB - O
PCC NNP - B-ORG
/ SYM - O
precuneus NOUN - O
may VERB - O
serve VERB - O
as ADP - O
an DET - O
endophenotype NOUN - O
for ADP - O
schizophrenia NOUN - O
, PUNCT - O
and CCONJ - O
may VERB - O
have VERB - O
clinical ADJ - O
utility NOUN - O
to PART - O
predict VERB - O
response NOUN - O
to ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Weight NOUN - O
change NOUN - O
over ADP - O
two CD - B-DATE
years NNS - I-DATE
in ADP - O
people NOUN - O
prescribed VERB - O
olanzapine RB - B-MEDICINE
, PUNCT - O
quetiapine NOUN - O
and CCONJ - O
risperidone NOUN - O
in ADP - O
UK NNP - B-GPE
primary ADJ - O
care NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Four CD - B-CARDINAL
studies NOUN - O
compared VERB - O
antipsychotic ADJ - O
drugs NOUN - O
( PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
lurasidone NOUN - O
, PUNCT - O
and CCONJ - O
ziprasidone NOUN - O
) PUNCT - O
with ADP - O
placebo NOUN - O
, PUNCT - O
and CCONJ - O
one CD - B-CARDINAL
study NOUN - O
assessed VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
combination NOUN - O
therapy NOUN - O
( PUNCT - O
olanzapine+fluoxetine NOUN - O
) PUNCT - O
in ADP - O
the DET - O
acute ADJ - O
phase NOUN - O
of ADP - O
BD NNP - B-ORG
with ADP - O
mixed ADJ - O
features NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
a DET - O
case NOUN - O
of ADP - O
gallbladder NOUN - O
carcinoma NOUN - O
who NOUN - O
presented VERB - O
to ADP - O
us PRON - O
with ADP - O
intractable ADJ - O
vomiting NOUN - O
which ADJ - O
was VERB - O
not ADV - O
relieved VERB - O
with ADP - O
a DET - O
combination NOUN - O
of ADP - O
traditional ADJ - O
antiemetics NOUN - O
but CCONJ - O
showed VERB - O
marked ADJ - O
improvement NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Oral ADJ - O
formulations NOUN - O
of ADP - O
the DET - O
antipsychotics NOUN - O
aripiprazole VERB - O
, PUNCT - O
asenapine NOUN - O
, PUNCT - O
lurasidone NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
paliperidone NOUN - O
, PUNCT - O
quetiapine NOUN - O
, PUNCT - O
and CCONJ - O
risperidone NOUN - O
are VERB - O
indicated VERB - O
for ADP - O
use NOUN - O
in ADP - O
pediatrics NOUN - O
for ADP - O
several ADJ - O
diagnoses NOUN - O
. PUNCT - O

The DET - O
primary ADJ - O
intent NOUN - O
of ADP - O
this DET - O
study NOUN - O
is VERB - O
to PART - O
provide VERB - O
descriptive ADJ - O
information NOUN - O
on ADP - O
the DET - O
use NOUN - O
of ADP - O
paliperidone NOUN - O
palmitate NOUN - O
, PUNCT - O
risperidone NOUN - O
microspheres NOUN - O
, PUNCT - O
aripiprazole NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
injection NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
pamoate NOUN - O
in ADP - O
pediatric ADJ - O
patients NOUN - O
within ADP - O
Indiana NNP - B-ORG
Medicaid NNP - I-ORG
. PUNCT - O

The DET - O
study NOUN - O
included VERB - O
the DET - O
prescription NOUN - O
medications NOUN - O
filled VERB - O
for ADP - O
all DET - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O
within ADP - O
Indiana NNP - B-ORG
Medicaid NNP - I-ORG
who NOUN - O
received VERB - O
the DET - O
LAI NNP - B-ORG
antipsychotics NOUN - O
paliperidone NOUN - O
palmitate VERB - O
, PUNCT - O
risperidone NOUN - O
microspheres NOUN - O
, PUNCT - O
aripiprazole NOUN - O
extended VERB - O
- PUNCT - O
release NOUN - O
injection NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
pamoate NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
used VERB - O
data NOUN - O
from ADP - O
1460 CD - B-DATE
participants NOUN - O
in ADP - O
the DET - O
CATIE PROPN - O
trial NOUN - O
, PUNCT - O
assigned VERB - O
to ADP - O
either CCONJ - O
perphenazine NOUN - O
( PUNCT - O
first JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
comparison NOUN - O
drug NOUN - O
) PUNCT - O
, PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
quetiapine NOUN - O
, PUNCT - O
risperidone NOUN - O
, PUNCT - O
or CCONJ - O
ziprasidone NOUN - O
. PUNCT - O

In ADP - O
the DET - O
scenario NOUN - O
of ADP - O
weight NOUN - O
change NOUN - O
being VERB - O
controlled VERB - O
between IN - B-PERCENT
-2 RB - I-PERCENT
% NN - I-PERCENT
and CC - I-PERCENT
1 CD - I-PERCENT
% NN - I-PERCENT
for ADP - O
all DET - O
participants NOUN - O
, PUNCT - O
patients NOUN - O
assigned VERB - O
to ADP - O
olanzapine NN - B-MEDICINE
would VERB - O
experience VERB - O
the DET - O
highest ADJ - O
significant ADJ - O
improvements NOUN - O
in ADP - O
both DET - O
PANSS+ NNP - B-PERSON
( PUNCT - O
-2.66 PUNCT - O
points NOUN - O
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Evidence NOUN - O
supports VERB - O
olanzapine NN - B-MEDICINE
for ADP - O
prophylaxis NOUN - O
of ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
/ SYM - O
vomiting NOUN - O
( PUNCT - O
CINV PROPN - O
) PUNCT - O
for ADP - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
most ADJ - O
studies NOUN - O
focus VERB - O
on ADP - O
solid ADJ - O
malignancies NOUN - O
and CCONJ - O
single ADJ - O
- PUNCT - O
day NOUN - O
regimens NOUN - O
. PUNCT - O

A DET - O
randomized ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blinded ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
trial NOUN - O
was VERB - O
conducted VERB - O
to PART - O
compare VERB - O
the DET - O
addition NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
to PART - O
triplet VERB - O
therapy NOUN - O
( PUNCT - O
fosaprepitant NOUN - O
, PUNCT - O
ondansetron NOUN - O
, PUNCT - O
dexamethasone NOUN - O
[ PUNCT - O
FOND PROPN - O
- PUNCT - O
O NOUN - O
] PUNCT - O
) PUNCT - O
versus ADP - O
triplet NOUN - O
therapy NOUN - O
alone ADV - O
( PUNCT - O
FOND PROPN - O
) PUNCT - O
in ADP - O
preventing VERB - O
CINV PROPN - O
in ADP - O
hematology NOUN - O
patients NOUN - O
receiving VERB - O
single ADJ - O
- PUNCT - O
day NOUN - O
and CCONJ - O
multiple ADJ - O
- PUNCT - O
day NOUN - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
and CCONJ - O
hematopoietic ADJ - O
cell NOUN - O
transplant NOUN - O
( PUNCT - O
HCT NNP - B-ORG
) PUNCT - O
regimens VERB - O
( PUNCT - O
NCT02635984 NNP - B-ORG
) PUNCT - O
. PUNCT - O

Mean VERB - O
duration NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
was VERB - O
7.7 CD - B-DATE
days NNS - I-DATE
( PUNCT - O
range NOUN - O
, PUNCT - O
4 CD - B-CARDINAL
to ADP - O
11 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Discontinuation NOUN - O
for ADP - O
possible ADJ - O
adverse ADJ - O
events NOUN - O
occurred VERB - O
in ADP - O
3 CD - B-CARDINAL
placebo NOUN - O
and CCONJ - O
0 CD - B-CARDINAL
olanzapine NN - B-MEDICINE
patients NOUN - O
. PUNCT - O

Addition NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
to ADP - O
an DET - O
NK-1-based PROPN - O
triplet NOUN - O
antiemetic ADJ - O
regimen NOUN - O
significantly ADV - O
improved VERB - O
clinically ADV - O
relevant ADJ - O
outcomes NOUN - O
in ADP - O
the DET - O
HCT NNP - B-ORG
population NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
role NOUN - O
of ADP - O
neuropeptide ADJ - O
CART NOUN - O
in ADP - O
hyperphagia NOUN - O
and CCONJ - O
weight NOUN - O
gain NOUN - O
induced VERB - O
by ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
in ADP - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Adjunctive ADJ - O
therapy NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
and CCONJ - O
fluoxetine NOUN - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
be VERB - O
beneficial ADJ - O
in ADP - O
treatment NOUN - O
- PUNCT - O
resistant ADJ - O
depression NOUN - O
and CCONJ - O
the DET - O
depressive ADJ - O
phase NOUN - O
of ADP - O
bipolar ADJ - O
disorder NOUN - O
. PUNCT - O

Pharmakopsychiatrie NNP - B-PERSON
strongly ADV - O
recommend VERB - O
that ADP - O
patients NOUN - O
taking VERB - O
olanzapine NN - B-MEDICINE
undergo ADJ - O
therapeutic ADJ - O
drug NOUN - O
monitoring NOUN - O
( PUNCT - O
TDM NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
suggest VERB - O
that ADP - O
TDM NNP - B-ORG
is VERB - O
useful ADJ - O
for ADP - O
patients NOUN - O
taking VERB - O
fluoxetine NOUN - O
. PUNCT - O

The DET - O
aim NOUN - O
of ADP - O
the DET - O
current ADJ - O
study NOUN - O
was VERB - O
to PART - O
develop VERB - O
and CCONJ - O
validate VERB - O
a DET - O
sensitive ADJ - O
, PUNCT - O
practical ADJ - O
, PUNCT - O
and CCONJ - O
robust ADJ - O
liquid ADJ - O
chromatography NOUN - O
- PUNCT - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
method NOUN - O
( PUNCT - O
LC PROPN - O
- PUNCT - O
MS PROPN - O
/ SYM - O
MS PROPN - O
) PUNCT - O
for ADP - O
simultaneous ADJ - O
determination NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
and CCONJ - O
norfluoxetine NOUN - O
in ADP - O
human ADJ - O
plasma NOUN - O
for ADP - O
routine ADJ - O
TDM NNP - B-ORG
. PUNCT - O

Simple ADJ - O
liquid NOUN - O
- PUNCT - O
liquid NOUN - O
extraction NOUN - O
using VERB - O
ethyl ADV - O
acetate ADJ - O
was VERB - O
used VERB - O
to PART - O
extract VERB - O
olanzapine NN - B-MEDICINE
, PUNCT - O
fluoxetine NOUN - O
, PUNCT - O
and CCONJ - O
norfluoxetine NOUN - O
from ADP - O
200 CD - B-CARDINAL
  SPACE - O
μL NN - B-ORG
of ADP - O
pre ADJ - O
- VERB - O
basified ADJ - O
human ADJ - O
plasma NOUN - O
. PUNCT - O

The DET - O
extraction NOUN - O
recoveries NOUN - O
were VERB - O
75%-85 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
olanzapine NN - B-MEDICINE
and CCONJ - O
olanzapine‑d3 NOUN - O
, PUNCT - O
and CCONJ - O
58%-69 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
fluoxetine NOUN - O
, PUNCT - O
norfluoxetine NOUN - O
, PUNCT - O
and CCONJ - O
their ADJ - O
deuterated ADJ - O
internal ADJ - O
standards NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

No DET - O
drugs NOUN - O
other ADJ - O
than ADP - O
olanzapine NN - B-MEDICINE
were VERB - O
taken VERB - O
under ADP - O
the DET - O
approved VERB - O
age NOUN - O
limit NOUN - O
in ADP - O
the DT - B-GPE
United NNP - I-GPE
States NNP - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Mice NOUN - O
were VERB - O
also ADV - O
pre VERB - O
- VERB - O
treated VERB - O
with ADP - O
antipsychotic ADJ - O
drugs NOUN - O
haloperidol NOUN - O
( PUNCT - O
0.25mg NUM - O
/ SYM - O
kg NOUN - O
) PUNCT - O
, PUNCT - O
clozapine NOUN - O
( PUNCT - O
2.5mg PROPN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
5mg NN - B-ORDINAL
/ SYM - O
kg NOUN - O
) PUNCT - O
. PUNCT - O

Clozapine ADJ - O
and CCONJ - O
olanzapine NN - B-MEDICINE
ameliorated VERB - O
the DET - O
PPI PROPN - O
deficit NOUN - O
in ADP - O
PLC NNP - B-ORG
- PUNCT - O
β1 PROPN - O
-/- PROPN - O
mice NOUN - O
, PUNCT - O
but CCONJ - O
not ADV - O
the DET - O
electrophysiology NOUN - O
abnormalities NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
was VERB - O
a DET - O
retrospective ADJ - O
review NOUN - O
of ADP - O
patients NOUN - O
receiving VERB - O
a DET - O
single ADJ - O
parenteral ADJ - O
dose NOUN - O
of ADP - O
droperidol NOUN - O
, PUNCT - O
haloperidol NOUN - O
, PUNCT - O
or CCONJ - O
olanzapine NN - B-MEDICINE
who NOUN - O
were VERB - O
acutely ADV - O
intoxicated ADJ - O
on ADP - O
alcohol NOUN - O
from ADP - O
2011 NUM - O
to ADP - O
2016 CD - B-DATE
. PUNCT - O

dL. ADP - O
Antipsychotics PROPN - O
administered VERB - O
were VERB - O
as ADP - O
follows VERB - O
: PUNCT - O
droperidol NOUN - O
( PUNCT - O
n VERB - O
  SPACE - O
= SYM - O
  SPACE - O
3,790 NUM - O
) PUNCT - O
, PUNCT - O
haloperidol PROPN - O
( PUNCT - O
n PROPN - O
  SPACE - O
= SYM - O
  SPACE - O
1,449 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
n VERB - O
  SPACE - O
= SYM - O
  SPACE - O
6,548 NUM - O
) PUNCT - O
. PUNCT - O

Median JJ - B-ORG
ED NNP - I-ORG
LOS NNP - I-ORG
was VERB - O
shortest ADJ - O
for ADP - O
droperidol NOUN - O
( PUNCT - O
499 CD - B-TIME
minutes NNS - I-TIME
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
confidence NOUN - O
interval NOUN - O
[ PUNCT - O
CI NNP - B-ORG
] PUNCT - O
  SPACE - O
= SYM - O
493 CD - B-TIME
- SYM - I-TIME
506 CD - I-TIME
minutes NNS - I-TIME
) PUNCT - O
, PUNCT - O
which ADJ - O
was VERB - O
significantly ADV - O
shorter ADJ - O
than ADP - O
both DET - O
haloperidol NOUN - O
( PUNCT - O
524 CD - B-TIME
minutes NNS - I-TIME
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
  SPACE - O
= SYM - O
515 CD - B-TIME
- HYPH - I-TIME
537 CD - I-TIME
minutes NNS - I-TIME
) PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
533 CD - B-TIME
minutes NNS - I-TIME
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
  SPACE - O
= SYM - O
528 CD - B-TIME
- HYPH - I-TIME
539 CD - I-TIME
minutes NNS - I-TIME
) PUNCT - O
. PUNCT - O

Droperidol NN - B-GPE
, PUNCT - O
when ADV - O
given VERB - O
as ADP - O
monotherapy NOUN - O
for ADP - O
sedation NOUN - O
of ADP - O
acute ADJ - O
agitation NOUN - O
secondary ADJ - O
to ADP - O
alcohol NOUN - O
intoxication NOUN - O
, PUNCT - O
was VERB - O
associated VERB - O
with ADP - O
significantly ADV - O
shorter ADJ - O
ED NNP - B-ORG
LOS NNP - I-ORG
than ADP - O
either CCONJ - O
parenteral ADJ - O
haloperidol NOUN - O
or CCONJ - O
parenteral ADJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

No DET - O
difference NOUN - O
in ADP - O
ED NNP - B-ORG
LOS NNP - I-ORG
was VERB - O
observed VERB - O
between ADP - O
haloperidol NOUN - O
and CCONJ - O
olanzapine NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Recently ADV - O
, PUNCT - O
neuromodulator NOUN - O
agents NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
tricyclic ADJ - O
antidepressants NOUN - O
, PUNCT - O
gabapentin NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
mirtazapine NOUN - O
, PUNCT - O
and CCONJ - O
benzodiazepines NOUN - O
, PUNCT - O
and CCONJ - O
cannabinoids NOUN - O
have VERB - O
been VERB - O
shown VERB - O
to PART - O
be VERB - O
efficacious ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
, PUNCT - O
and CCONJ - O
may VERB - O
be VERB - O
useful ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
chronic ADJ - O
symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
have VERB - O
determined VERB - O
whether ADP - O
B NNP - B-ORG
- HYPH - I-ORG
GOS NNP - I-ORG
® NN - I-ORG
influenced VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
associated VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
central ADJ - O
NMDA NNP - B-ORG
and CCONJ - O
serotonin ADJ - O
receptors NOUN - O
. PUNCT - O

( PUNCT - O
0.5 CD - B-CARDINAL
  SPACE - O
g NOUN - O
/ SYM - O
kg NOUN - O
/ SYM - O
day NOUN - O
) PUNCT - O
solution NOUN - O
or CCONJ - O
water NOUN - O
for ADP - O
21 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
and CCONJ - O
received VERB - O
a DET - O
single ADJ - O
, PUNCT - O
daily JJ - B-DATE
, PUNCT - O
intraperitoneal ADJ - O
injection NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
or CCONJ - O
saline VERB - O
on ADP - O
days NNS - B-DATE
8 CD - I-DATE
- SYM - I-DATE
21 CD - I-DATE
. PUNCT - O

The DET - O
intake NOUN - O
of ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
significantly ADV - O
attenuated VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
weight NOUN - O
gain NOUN - O
without ADP - O
altering VERB - O
frontal ADJ - O
cortex NOUN - O
5-HT2AR CD - B-CARDINAL
blockade NOUN - O
. PUNCT - O

Cortical PROPN - O
GluN1 PROPN - O
levels NOUN - O
were VERB - O
elevated VERB - O
by ADP - O
olanzapine NN - B-MEDICINE
in ADP - O
the DET - O
presence NOUN - O
of ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
. PUNCT - O

Plasma ADJ - O
acetate ADJ - O
concentrations NOUN - O
increased VERB - O
following VERB - O
B NNP - B-PRODUCT
- HYPH - I-PRODUCT
GOS NNP - I-PRODUCT
® NN - I-PRODUCT
or CCONJ - O
olanzapine NN - B-MEDICINE
administration NOUN - O
alone ADV - O
, PUNCT - O
but CCONJ - O
reduced VERB - O
when ADV - O
prebiotic ADJ - O
and CCONJ - O
drug NOUN - O
were VERB - O
administered VERB - O
in ADP - O
combination NOUN - O
. PUNCT - O

The DET - O
abundance NOUN - O
of ADP - O
WAT NNP - B-PERSON
GPR43 NNP - I-PERSON
mRNA PROPN - O
was VERB - O
reduced VERB - O
by ADP - O
olanzapine NN - B-MEDICINE
, PUNCT - O
only ADV - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
B NNP - B-PRODUCT
- HYPH - I-PRODUCT
GOS NNP - I-PRODUCT
® NN - I-PRODUCT
. PUNCT - O

Co NOUN - O
- NOUN - O
administration NOUN - O
of ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
and CCONJ - O
olanzapine NN - B-MEDICINE
also ADV - O
elevated VERB - O
plasma NOUN - O
TNFα NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
reported VERB - O
to PART - O
influence VERB - O
lipid NOUN - O
metabolism NOUN - O
. PUNCT - O

Finally ADV - O
, PUNCT - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
elevated VERB - O
faecal PROPN - O
Bifidobacterium NNP - B-ORG
spp NOUN - O
. PUNCT - O
and CCONJ - O
reduced VERB - O
some DET - O
bacteria NOUN - O
in ADP - O
the DET - O
Firmicutes NNPS - B-NORP
phylum NOUN - O
, PUNCT - O
whilst ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
either CCONJ - O
alone ADV - O
or CCONJ - O
with ADP - O
B NNP - B-PRODUCT
- HYPH - I-PRODUCT
GOS NNP - I-PRODUCT
® NN - I-PRODUCT
, PUNCT - O
was VERB - O
without ADP - O
effect NOUN - O
. PUNCT - O

These DET - O
data NOUN - O
suggest VERB - O
that ADP - O
inclusion NOUN - O
of ADP - O
B PROPN - O
- PUNCT - O
GOS PROPN - O
® NOUN - O
as ADP - O
an DET - O
adjunct NOUN - O
to PART - O
olanzapine VB - B-MEDICINE
treatment NOUN - O
in ADP - O
schizophrenia NOUN - O
may VERB - O
prevent VERB - O
weight NOUN - O
gain NOUN - O
and CCONJ - O
have VERB - O
benefits NOUN - O
on ADP - O
cognitive ADJ - O
function NOUN - O
in ADP - O
psychosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
most ADV - O
common ADJ - O
method NOUN - O
to PART - O
compare VERB - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
is VERB - O
by ADP - O
calculating VERB - O
the DET - O
score NOUN - O
of ADP - O
positive ADJ - O
and CCONJ - O
negative ADJ - O
syndromes NOUN - O
scale NOUN - O
( PUNCT - O
PANSS PROPN - O
) PUNCT - O
. PUNCT - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
compare VERB - O
the DET - O
treatment NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
using VERB - O
PANSS NN - B-ORG
, PUNCT - O
limited ADJ - O
to ADP - O
only ADJ - O
male ADJ - O
patients NOUN - O
receiving VERB - O
inpatient NOUN - O
treatment NOUN - O
to PART - O
obtain VERB - O
more ADV - O
significant ADJ - O
results NOUN - O
. PUNCT - O

These DET - O
participants NOUN - O
were VERB - O
divided VERB - O
into ADP - O
two CD - B-CARDINAL
groups NOUN - O
and CCONJ - O
treated VERB - O
with ADP - O
different ADJ - O
atypical ADJ - O
antipsychotics NOUN - O
( PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
20 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
day NOUN - O
[ PUNCT - O
n NOUN - O
= SYM - O
34 CD - B-CARDINAL
] PUNCT - O
; PUNCT - O
risperidone NOUN - O
, PUNCT - O
6 CD - B-DATE
mg NN - I-DATE
/ SYM - I-DATE
day NN - I-DATE
[ PUNCT - O
n NOUN - O
= SYM - O
34 CD - B-CARDINAL
] PUNCT - O
) PUNCT - O
. PUNCT - O

The DET - O
improvement NOUN - O
of ADP - O
the DET - O
schizophrenia NOUN - O
symptoms NOUN - O
measured VERB - O
by ADP - O
PANSS NN - B-ORG
after ADP - O
6 CD - B-DATE
weeks NNS - I-DATE
showed VERB - O
significant ADJ - O
differences NOUN - O
in ADP - O
the DET - O
scores NOUN - O
of ADP - O
PANSS PROPN - O
between ADP - O
the DET - O
male ADJ - O
patient ADJ - O
groups NOUN - O
treated VERB - O
with ADP - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
( PUNCT - O
p PUNCT - O
- PUNCT - O
value NOUN - O
< X - O
0.001).The CD - B-CARDINAL
group NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
shows VERB - O
a DET - O
higher ADJ - O
improvement NOUN - O
of ADP - O
the DET - O
scores NOUN - O
of ADP - O
PANSS PROPN - O
than ADP - O
that DET - O
the DET - O
group NOUN - O
of ADP - O
risperidone NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Here ADV - O
, PUNCT - O
we PRON - O
describe VERB - O
three CD - B-CARDINAL
cases NOUN - O
of ADP - O
refractory ADJ - O
epilepsy NOUN - O
with ADP - O
atypical ADJ - O
depression NOUN - O
in ADP - O
which ADJ - O
olanzapine NN - B-MEDICINE
, PUNCT - O
contrary ADJ - O
to ADP - O
its ADJ - O
earlier ADV - O
reported VERB - O
proconvulsant ADJ - O
effect NOUN - O
, PUNCT - O
showed VERB - O
excellent ADJ - O
antidepressant ADJ - O
action NOUN - O
and CCONJ - O
resulted VERB - O
in ADP - O
seizure NOUN - O
control NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
present VERB - O
one CD - B-CARDINAL
case NOUN - O
of ADP - O
a DET - O
woman NOUN - O
treated VERB - O
with ADP - O
the DET - O
intramuscular ADJ - O
depot NOUN - O
formulation NOUN - O
of ADP - O
the DET - O
atypical ADJ - O
antipsychotic ADJ - O
, PUNCT - O
olanzapine NN - B-MEDICINE
pamoate NOUN - O
( PUNCT - O
ZypAdhera NNP - B-PERSON
® NN - I-PERSON
) PUNCT - O
, PUNCT - O
during ADP - O
pregnancy NOUN - O
and CCONJ - O
breastfeeding NOUN - O
. PUNCT - O

Data NOUN - O
on ADP - O
olanzapine NN - B-MEDICINE
distribution NOUN - O
in ADP - O
breast NOUN - O
milk NOUN - O
as ADV - O
well ADV - O
as ADP - O
on ADP - O
plasma NOUN - O
concentration NOUN - O
in ADP - O
the DET - O
nursed VERB - O
infant NOUN - O
are VERB - O
provided VERB - O
. PUNCT - O

The DET - O
present ADJ - O
case NOUN - O
report NOUN - O
demonstrates VERB - O
that ADP - O
olanzapine NN - B-MEDICINE
was VERB - O
excreted VERB - O
in ADP - O
the DET - O
breast NOUN - O
milk NOUN - O
, PUNCT - O
but CCONJ - O
the DET - O
breast NOUN - O
- PUNCT - O
fed VERB - O
infant NOUN - O
had VERB - O
very ADV - O
low ADJ - O
olanzapine NN - B-MEDICINE
concentrations NOUN - O
, PUNCT - O
which ADJ - O
did VERB - O
not ADV - O
result VERB - O
in ADP - O
any DET - O
adverse ADJ - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
on ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
in ADP - O
patients NOUN - O
receiving VERB - O
moderately ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
( PUNCT - O
MEC NNP - B-ORG
) PUNCT - O
are VERB - O
limited ADJ - O
. PUNCT - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
evaluate VERB - O
and CCONJ - O
compare VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
versus ADP - O
placebo NOUN - O
in ADP - O
controlling VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
MEC NNP - B-ORG
. PUNCT - O

: PUNCT - O
We PRON - O
conducted VERB - O
a DET - O
randomized ADJ - O
, PUNCT - O
double ADJ - O
- PUNCT - O
blind ADJ - O
, PUNCT - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
study NOUN - O
to PART - O
determine VERB - O
whether ADP - O
olanzapine NN - B-MEDICINE
can VERB - O
reduce VERB - O
the DET - O
frequency NOUN - O
of ADP - O
chemotherapy NOUN - O
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
( PUNCT - O
CINV PROPN - O
) PUNCT - O
and CCONJ - O
improve VERB - O
the DET - O
quality NOUN - O
of ADP - O
life NOUN - O
( PUNCT - O
QOL NNP - B-ORG
) PUNCT - O
in ADP - O
patients NOUN - O
receiving VERB - O
palonosetron NOUN - O
and CCONJ - O
dexamethasone VERB - O
as ADP - O
prophylaxis NOUN - O
for ADP - O
MEC NNP - B-ORG
- PUNCT - O
induced VERB - O
nausea NOUN - O
and CCONJ - O
vomiting NOUN - O
. PUNCT - O

Fifty CD - B-CARDINAL
- HYPH - I-CARDINAL
six CD - I-CARDINAL
patients NOUN - O
were VERB - O
randomized VERB - O
to ADP - O
the DET - O
olanzapine NN - B-MEDICINE
( PUNCT - O
n=29 PROPN - O
) PUNCT - O
and CCONJ - O
placebo NOUN - O
( PUNCT - O
n=27 ADJ - O
) PUNCT - O
groups NOUN - O
. PUNCT - O

Complete ADJ - O
response NOUN - O
rates NOUN - O
were VERB - O
not ADV - O
significantly ADV - O
different ADJ - O
between ADP - O
the DET - O
olanzapine NN - B-MEDICINE
and CCONJ - O
placebo NOUN - O
groups NOUN - O
in ADP - O
the DET - O
acute ADJ - O
( PUNCT - O
96.5 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
88.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p=0.326 PROPN - O
) PUNCT - O
, PUNCT - O
delayed VERB - O
( PUNCT - O
69.0 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
48.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p=0.118 PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
overall ADJ - O
phases NOUN - O
( PUNCT - O
69.0 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
48.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p=0.118 PROPN - O
) PUNCT - O
. PUNCT - O

However ADV - O
, PUNCT - O
the DET - O
percentage NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
significant ADJ - O
nausea NOUN - O
( PUNCT - O
17.2 CD - B-PERCENT
% NN - I-PERCENT
vs. ADP - O
44.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
p=0.032 PROPN - O
) PUNCT - O
and CCONJ - O
the DET - O
use NOUN - O
of ADP - O
rescue NOUN - O
medications NOUN - O
( PUNCT - O
0.03±0.19 NUM - O
vs. ADP - O
1.88±2.88 CD - B-ORDINAL
, PUNCT - O
p=0.002 PROPN - O
) PUNCT - O
were VERB - O
lower ADJ - O
in ADP - O
the DET - O
olanzapine NN - B-MEDICINE
group NOUN - O
than ADP - O
in ADP - O
the DET - O
placebo NOUN - O
. PUNCT - O

Furthermore ADV - O
, PUNCT - O
the DET - O
olanzapine NN - B-MEDICINE
group NOUN - O
demonstrated VERB - O
better ADJ - O
QOL NNP - B-ORG
( PUNCT - O
p=0.015 PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Guidelines NOUN - O
all DET - O
recommend VERB - O
a DET - O
combination NOUN - O
of ADP - O
a DET - O
serotonin ADJ - O
( PUNCT - O
5-HT)3-receptor NUM - O
antagonist NOUN - O
, PUNCT - O
dexamethasone NOUN - O
, PUNCT - O
and CCONJ - O
a DET - O
NK1-receptor NNP - B-ORG
antagonist NOUN - O
in ADP - O
patients NOUN - O
receiving VERB - O
highly ADV - O
emetogenic ADJ - O
chemotherapy NOUN - O
( PUNCT - O
HEC PROPN - O
) PUNCT - O
with ADP - O
the DET - O
addition NOUN - O
of ADP - O
the DET - O
multireceptor NOUN - O
targeting VERB - O
agent NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
as ADP - O
an DET - O
option NOUN - O
in ADP - O
cisplatin ADJ - O
or CCONJ - O
anthracycline ADJ - O
- PUNCT - O
cyclophosphamide ADJ - O
chemotherapy NOUN - O
. PUNCT - O

The DET - O
addition NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
can VERB - O
be VERB - O
useful ADJ - O
in ADP - O
cisplatin NOUN - O
- PUNCT - O
based VERB - O
and CCONJ - O
anthracycline NOUN - O
- PUNCT - O
cyclophosphamide NOUN - O
- PUNCT - O
based VERB - O
chemotherapy NOUN - O
in ADP - O
particular ADJ - O
if ADP - O
the DET - O
main ADJ - O
problem NOUN - O
is VERB - O
nausea NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

As ADP - O
a DET - O
first JJ - B-ORDINAL
step NOUN - O
to PART - O
address VERB - O
this DET - O
question NOUN - O
, PUNCT - O
we PRON - O
evaluated VERB - O
whether ADP - O
chronic ADJ - O
exposure NOUN - O
to ADP - O
clinically ADV - O
comparable ADJ - O
doses NOUN - O
of ADP - O
haloperidol NOUN - O
or CCONJ - O
olanzapine NN - B-MEDICINE
resulted VERB - O
in ADP - O
the DET - O
immune ADJ - O
activation NOUN - O
of ADP - O
rat NOUN - O
adipose ADJ - O
tissue NOUN - O
. PUNCT - O

Samples NOUN - O
of ADP - O
visceral ADJ - O
adipose NOUN - O
tissue NOUN - O
were VERB - O
sampled VERB - O
from ADP - O
male ADJ - O
Sprague PROPN - O
- PUNCT - O
Dawley PROPN - O
rats NOUN - O
exposed VERB - O
to ADP - O
, PUNCT - O
haloperidol NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
or CCONJ - O
vehicle NOUN - O
( PUNCT - O
all DET - O
n ADP - O
  SPACE - O
= PUNCT - O
  SPACE - O
8) CD - B-CARDINAL
, PUNCT - O
for ADP - O
8 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Chronic ADJ - O
olanzapine NN - B-MEDICINE
exposure NOUN - O
resulted VERB - O
in ADP - O
significantly ADV - O
higher ADJ - O
adipose NOUN - O
IL-6 PROPN - O
levels NOUN - O
compared VERB - O
with ADP - O
vehicle NOUN - O
- PUNCT - O
controls NOUN - O
( PUNCT - O
ANOVA PROPN - O
p ADP - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.008 CD - B-CARDINAL
, PUNCT - O
Bonferroni JJ - B-GPE
post ADJ - O
- ADJ - O
hoc X - O
test NOUN - O
p X - O
  SPACE - O
= SYM - O
  SPACE - O
0.006 CD - B-CARDINAL
) PUNCT - O
; PUNCT - O
in ADP - O
parallel ADJ - O
, PUNCT - O
animals NOUN - O
exposed VERB - O
to ADP - O
olanzapine NN - B-MEDICINE
had VERB - O
significantly ADV - O
higher ADJ - O
F4/80 NUM - O
expression NOUN - O
when ADV - O
compared VERB - O
with ADP - O
vehicle NOUN - O
- PUNCT - O
controls NOUN - O
( PUNCT - O
Mann NNP - B-PERSON
Whitney NNP - I-PERSON
Test NNP - I-PERSON
, PUNCT - O
p X - O
  SPACE - O
= SYM - O
  SPACE - O
0.014 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
whereas ADP - O
there ADV - O
was VERB - O
no DET - O
difference NOUN - O
between ADP - O
haloperidol NOUN - O
and CCONJ - O
vehicle NOUN - O
groups NOUN - O
( PUNCT - O
Mann NNP - B-PERSON
Whitney NNP - I-PERSON
test NOUN - O
, PUNCT - O
p VERB - O
  SPACE - O
= SYM - O
  SPACE - O
0.1 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

Nevertheless ADV - O
, PUNCT - O
we PRON - O
found VERB - O
a DET - O
positive ADJ - O
correlation NOUN - O
between ADP - O
F4/80 PROPN - O
and CCONJ - O
TSPO NNP - B-ORG
adipose VERB - O
protein NOUN - O
levels NOUN - O
in ADP - O
the DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
exposed VERB - O
rats NOUN - O
( PUNCT - O
Spearman NNP - B-PERSON
's PART - O
rho VERB - O
  SPACE - O
= SYM - O
  SPACE - O
0.76 CD - B-CARDINAL
, PUNCT - O

Our ADJ - O
data NOUN - O
suggest VERB - O
that ADP - O
chronic ADJ - O
exposure NOUN - O
to ADP - O
olanzapine NN - B-MEDICINE
, PUNCT - O
but CCONJ - O
not ADV - O
haloperidol NOUN - O
, PUNCT - O
increases VERB - O
production NOUN - O
of ADP - O
the DET - O
pro ADJ - O
- ADJ - O
inflammatory ADJ - O
cytokine NOUN - O
IL-6 PROPN - O
in ADP - O
adipose NOUN - O
tissue NOUN - O
and CCONJ - O
increased VERB - O
macrophages NOUN - O
expression NOUN - O
( PUNCT - O
F4/80 PROPN - O
) PUNCT - O
, PUNCT - O
in ADP - O
the DET - O
absence NOUN - O
of ADP - O
measurable ADJ - O
changes NOUN - O
in ADP - O
TSPO NN - B-ORG
with ADP - O
respect NOUN - O
to ADP - O
vehicle NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
baseline ADJ - O
severity NOUN - O
adjustment NOUN - O
, PUNCT - O
quetiapine NOUN - O
( PUNCT - O
-5.00 NOUN - O
, PUNCT - O
-8.59 ADP - O
to ADP - O
-1.29 NUM - O
) PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
-8.28 NOUN - O
, PUNCT - O
-15.34 PUNCT - O
to ADP - O
-1.13 PUNCT - O
) PUNCT - O
became VERB - O
significantly ADV - O
superior ADJ - O
to ADP - O
placebo NOUN - O
. PUNCT - O

Topiramate NOUN - O
, PUNCT - O
lamotrigine NOUN - O
, PUNCT - O
aripiprazole NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
, PUNCT - O
risperidone NOUN - O
, PUNCT - O
memantine NOUN - O
, PUNCT - O
and CCONJ - O
quetiapine NOUN - O
are VERB - O
alternative ADJ - O
augmentation NOUN - O
drugs NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
a DET - O
definitive ADJ - O
conclusion NOUN - O
of ADP - O
the DET - O
best ADJ - O
drug NOUN - O
remains VERB - O
undetermined ADJ - O
because ADP - O
of ADP - O
the DET - O
considerable ADJ - O
heterogeneity NOUN - O
and CCONJ - O
limited ADJ - O
numbers NOUN - O
of ADP - O
studies NOUN - O
and CCONJ - O
patients NOUN - O
for ADP - O
each DET - O
agent NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
current ADJ - O
investigation NOUN - O
utilized VERB - O
an DET - O
animal NOUN - O
model NOUN - O
for ADP - O
early ADJ - O
APD NNP - B-ORG
treatment NOUN - O
with ADP - O
aripiprazole NOUN - O
, PUNCT - O
olanzapine RB - B-MEDICINE
, PUNCT - O
and CCONJ - O
risperidone NOUN - O
in ADP - O
male ADJ - O
and CCONJ - O
female ADJ - O
juvenile ADJ - O
rats NOUN - O
to PART - O
investigate VERB - O
potential ADJ - O
long ADJ - O
- PUNCT - O
term NOUN - O
changes NOUN - O
to ADP - O
the DET - O
adult NOUN - O
serotonin ADJ - O
( PUNCT - O
5-HT LS - B-ORG
) PUNCT - O
NT PROPN - O
system NOUN - O
. PUNCT - O

In ADP - O
the DET - O
male ADJ - O
cohort NOUN - O
, PUNCT - O
long ADJ - O
- PUNCT - O
term NOUN - O
changes NOUN - O
to ADP - O
5-HT2A CD - B-GPE
and CCONJ - O
5-HT2C CD - B-CARDINAL
receptors NOUN - O
were VERB - O
found VERB - O
mostly ADV - O
across ADP - O
hippocampal ADJ - O
and CCONJ - O
cortical ADJ - O
brain NOUN - O
regions NOUN - O
following VERB - O
early ADJ - O
aripiprazole NOUN - O
and CCONJ - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
, PUNCT - O
while ADP - O
early ADJ - O
risperidone NOUN - O
treatment NOUN - O
changed VERB - O
5-HT1A NNP - B-CARDINAL
receptor NOUN - O
levels NOUN - O
in ADP - O
the DET - O
NAc NOUN - O
and CCONJ - O
PFC NNP - B-ORG
. PUNCT - O

Lesser NNP - B-PERSON
effects NOUN - O
were VERB - O
uncovered VERB - O
in ADP - O
the DET - O
female ADJ - O
cohort NOUN - O
with ADP - O
aripiprazole NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
to PART - O
alter VERB - O
5-HT1A . - B-CARDINAL
and CCONJ - O
5-HT2A NNP - B-ORG
receptors NOUN - O
in ADP - O
NAc NOUN - O
and CCONJ - O
hippocampal ADJ - O
brain NOUN - O
regions NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

While ADP - O
effective ADJ - O
in ADP - O
reducing VERB - O
psychoses NOUN - O
, PUNCT - O
treatment NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
causes NOUN - O
rapid ADJ - O
increases NOUN - O
in ADP - O
blood NOUN - O
glucose NOUN - O
. PUNCT - O

We PRON - O
wanted VERB - O
to PART - O
determine VERB - O
if ADP - O
a DET - O
single ADJ - O
bout NOUN - O
of ADP - O
exercise NOUN - O
, PUNCT - O
immediately ADV - O
prior ADV - O
to ADP - O
treatment NOUN - O
, PUNCT - O
would VERB - O
attenuate VERB - O
the DET - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
rise NOUN - O
in ADP - O
blood NOUN - O
glucose NOUN - O
and CCONJ - O
if ADP - O
this DET - O
occurred VERB - O
in ADP - O
an DET - O
IL-6 PROPN - O
dependent ADJ - O
manner NOUN - O
. PUNCT - O

We PRON - O
found VERB - O
that ADP - O
exhaustive ADJ - O
, PUNCT - O
but CCONJ - O
not ADV - O
moderate ADJ - O
exercise NOUN - O
, PUNCT - O
immediately ADV - O
prior ADV - O
to ADP - O
treatment NOUN - O
, PUNCT - O
prevented VERB - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
hyperglycemia NOUN - O
and CCONJ - O
this DET - O
occurred VERB - O
in ADP - O
parallel NOUN - O
with ADP - O
increases NOUN - O
in ADP - O
serum ADJ - O
IL-6 NNP - B-GPE
. PUNCT - O

To PART - O
determine VERB - O
if ADP - O
IL-6 PROPN - O
was VERB - O
involved VERB - O
in ADP - O
the DET - O
mechanisms NOUN - O
through ADP - O
which ADJ - O
exhaustive ADJ - O
exercise NOUN - O
protected VERB - O
against ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
hyperglycemia NOUN - O
several ADJ - O
additional ADJ - O
experiments NOUN - O
were VERB - O
completed VERB - O
. PUNCT - O

Treatment NOUN - O
with ADP - O
IL-6 PROPN - O
( PUNCT - O
3 CD - B-CARDINAL
ng NOUN - O
/ SYM - O
g NOUN - O
bw NOUN - O
, PUNCT - O
IP NNP - B-ORG
) PUNCT - O
alone ADV - O
did VERB - O
not ADV - O
protect VERB - O
against ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
increases NOUN - O
in ADP - O
blood NOUN - O
glucose NOUN - O
. PUNCT - O

The DET - O
protective ADJ - O
effects NOUN - O
of ADP - O
exhaustive ADJ - O
exercise NOUN - O
against ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
increases NOUN - O
in ADP - O
blood NOUN - O
glucose NOUN - O
were VERB - O
intact ADJ - O
in ADP - O
whole ADJ - O
body NOUN - O
IL-6 PROPN - O
knockout NOUN - O
mice NOUN - O
. PUNCT - O

Similarly ADV - O
, PUNCT - O
treating VERB - O
mice NOUN - O
with ADP - O
an DET - O
IL-6 PROPN - O
neutralizing VERB - O
antibody NOUN - O
prior ADV - O
to ADP - O
exhaustive ADJ - O
exercise NOUN - O
did VERB - O
not ADV - O
negate VERB - O
the DET - O
protective ADJ - O
effect NOUN - O
of ADP - O
exercise NOUN - O
against ADP - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
hyperglycemia NOUN - O
. PUNCT - O

Our ADJ - O
findings NOUN - O
provide VERB - O
evidence NOUN - O
that ADP - O
a DET - O
single ADJ - O
bout NOUN - O
of ADP - O
exhaustive ADJ - O
exercise NOUN - O
protects NOUN - O
against ADP - O
acute ADJ - O
olanzapine NN - B-MEDICINE
- PUNCT - O
induced VERB - O
hyperglycemia NOUN - O
and CCONJ - O
that ADP - O
IL-6 PROPN - O
is VERB - O
neither CCONJ - O
sufficient ADJ - O
, PUNCT - O
nor CCONJ - O
required VERB - O
for ADP - O
exercise NOUN - O
to PART - O
protect VERB - O
against ADP - O
increases NOUN - O
in ADP - O
blood NOUN - O
glucose NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acute ADJ - O
and CCONJ - O
short ADJ - O
- PUNCT - O
term NOUN - O
administration NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
has VERB - O
a DET - O
favorable ADJ - O
effect NOUN - O
on ADP - O
sleep NOUN - O
in ADP - O
schizophrenia NOUN - O
patients NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
aimed VERB - O
to PART - O
clarify VERB - O
the DET - O
effect NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
on ADP - O
polysomnographic ADJ - O
profiles NOUN - O
of ADP - O
schizophrenia NOUN - O
patients NOUN - O
during ADP - O
the DET - O
acute ADJ - O
phase NOUN - O
of ADP - O
illness NOUN - O
after ADP - O
controlling VERB - O
for ADP - O
previous ADJ - O
drug NOUN - O
exposure NOUN - O
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
five CD - I-CARDINAL
drug NOUN - O
- PUNCT - O
naïve NOUN - O
or CCONJ - O
drug NOUN - O
- PUNCT - O
free ADJ - O
schizophrenia NOUN - O
patients NOUN - O
were VERB - O
assessed VERB - O
at ADP - O
baseline NOUN - O
and CCONJ - O
after ADP - O
six CD - B-DATE
weeks NNS - I-DATE
of ADP - O
olanzapine NN - B-MEDICINE
treatment NOUN - O
on ADP - O
Brief ADJ - O
Psychiatric PROPN - O
Rating PROPN - O
Scale NOUN - O
( PUNCT - O
BPRS PROPN - O
) PUNCT - O
, PUNCT - O
Positive PROPN - O
and CCONJ - O
Negative ADJ - O
Syndrome PROPN - O
Scale PROPN - O
( PUNCT - O
PANSS PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
Udvalg NNP - B-ORG
for ADP - O
Kliniske NNP - B-ORG
Undersogelser NNP - I-ORG
( PUNCT - O
UKU NNP - B-ORG
) PUNCT - O
side NOUN - O
- PUNCT - O
effect NOUN - O
rating NOUN - O
scale NOUN - O
and CCONJ - O
a DET - O
whole ADJ - O
- PUNCT - O
night NOUN - O
polysomnography NOUN - O
; PUNCT - O
fifteen CD - B-CARDINAL
patients NOUN - O
completed VERB - O
the DET - O
study NOUN - O
. PUNCT - O

In ADP - O
summary ADJ - O
, PUNCT - O
short ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
produced VERB - O
significant ADJ - O
improvement NOUN - O
in ADP - O
clinical ADJ - O
and CCONJ - O
polysomnography NOUN - O
profiles NOUN - O
of ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
with ADP - O
shorter ADJ - O
REM NN - B-ORG
latency NOUN - O
predicting VERB - O
a DET - O
good ADJ - O
clinical ADJ - O
response NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
describe VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
70-year CD - B-MONEY
- HYPH - I-MONEY
old JJ - I-MONEY
Alzheimer PROPN - O
patient NOUN - O
who NOUN - O
was VERB - O
taking VERB - O
olanzapine NN - B-MEDICINE
for ADP - O
2 CD - B-DATE
months NNS - I-DATE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
depression NOUN - O
, PUNCT - O
and CCONJ - O
developed VERB - O
peripheral ADJ - O
eosinophilia NOUN - O
and CCONJ - O
bilateral ADJ - O
EPE.Olanzapine PROPN - O
- PUNCT - O
induced VERB - O
peripheral ADJ - O
eosinophilia NOUN - O
and CCONJ - O
eosinophilic ADJ - O
pleural ADJ - O
effusion NOUN - O
was VERB - O
diagnosed VERB - O
. PUNCT - O

This DET - O
case NOUN - O
is VERB - O
a DET - O
reminder NOUN - O
that ADP - O
olanzapine NN - B-MEDICINE
may VERB - O
be VERB - O
a DET - O
potential ADJ - O
agent NOUN - O
for ADP - O
EPE NNP - B-ORG
, PUNCT - O
and CCONJ - O
that ADP - O
this DET - O
should VERB - O
be VERB - O
considered VERB - O
in ADP - O
clinical ADJ - O
practice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Data NOUN - O
of ADP - O
26 CD - B-CARDINAL
studies NOUN - O
were VERB - O
used VERB - O
in ADP - O
the DET - O
present ADJ - O
analysis NOUN - O
because ADP - O
sufficient ADJ - O
data NOUN - O
were VERB - O
available ADJ - O
only ADV - O
for ADP - O
olanzapine NN - B-MEDICINE
, PUNCT - O
risperidone NOUN - O
and CCONJ - O
the DET - O
no DET - O
- PUNCT - O
medication NOUN - O
group NOUN - O
. PUNCT - O

Both CCONJ - O
female ADJ - O
and CCONJ - O
male ADJ - O
patients NOUN - O
showed VERB - O
considerable ADJ - O
weight NOUN - O
gain NOUN - O
after ADP - O
switch NOUN - O
or CCONJ - O
initiate NOUN - O
of ADP - O
olanzapine NN - B-MEDICINE
or CCONJ - O
risperidone NOUN - O
, PUNCT - O
but CCONJ - O
meta ADJ - O
- PUNCT - O
regression NOUN - O
analyses NOUN - O
did VERB - O
not ADV - O
show VERB - O
significant ADJ - O
sex NOUN - O
differences NOUN - O
. PUNCT - O

In ADP - O
chronic ADJ - O
patients NOUN - O
switching VERB - O
to PART - O
olanzapine VB - B-MEDICINE
or CCONJ - O
risperidone VERB - O
receiving VERB - O
short ADJ - O
- PUNCT - O
or CCONJ - O
middle ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
, PUNCT - O
AP NNP - B-ORG
were VERB - O
associated VERB - O
with ADP - O
weight NOUN - O
gain NOUN - O
in ADP - O
both CCONJ - O
sex NOUN - O
subgroups NOUN - O
and CCONJ - O
no DET - O
significant ADJ - O
differences NOUN - O
were VERB - O
reported VERB - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
postnatal NOUN - O
rats NOUN - O
( PUNCT - O
PD23±1 ADV - O
) PUNCT - O
were VERB - O
administered VERB - O
aripiprazole NOUN - O
( PUNCT - O
1 LS - B-MONEY
  _SP - I-MONEY
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
, PUNCT - O
olanzapine NN - B-MEDICINE
( PUNCT - O
1 CD - B-MONEY
  _SP - I-MONEY
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
, PUNCT - O
risperidone NOUN - O
( PUNCT - O
0.3 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
or CCONJ - O
vehicle NOUN - O
( PUNCT - O
control NOUN - O
) PUNCT - O
for ADP - O
3 CD - B-DATE
weeks NNS - I-DATE
. PUNCT - O

Therefore ADV - O
, PUNCT - O
treatment NOUN - O
with ADP - O
aripiprazole NOUN - O
, PUNCT - O
olanzapine NN - B-MEDICINE
and CCONJ - O
risperidone NOUN - O
could VERB - O
induce VERB - O
differential ADJ - O
and CCONJ - O
gender NOUN - O
specific ADJ - O
effects NOUN - O
on ADP - O
the DET - O
binding VERB - O
density NOUN - O
of ADP - O
cannabinoid NOUN - O
receptors NOUN - O
in ADP - O
the DET - O
selected VERB - O
brain NOUN - O
regions NOUN - O
of ADP - O
childhood NOUN - O
/ SYM - O
adolescent ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
authors NOUN - O
examined VERB - O
the DET - O
risk NOUN - O
of ADP - O
developing VERB - O
gestational ADJ - O
diabetes NOUN - O
associated VERB - O
with ADP - O
the DET - O
continuation NOUN - O
of ADP - O
treatment NOUN - O
with ADP - O
aripiprazole NOUN - O
, PUNCT - O
ziprasidone NOUN - O
, PUNCT - O
quetiapine NOUN - O
, PUNCT - O
risperidone NOUN - O
, PUNCT - O
and CCONJ - O
olanzapine NN - B-MEDICINE
during ADP - O
pregnancy NOUN - O
compared VERB - O
with ADP - O
discontinuation NOUN - O
of ADP - O
these DET - O
antipsychotic ADJ - O
drugs NOUN - O
. PUNCT - O

Among ADP - O
1,543,334 CD - B-CARDINAL
pregnancies NOUN - O
, PUNCT - O
some DET - O
expectant ADJ - O
mothers NOUN - O
at ADP - O
baseline NOUN - O
were VERB - O
receiving VERB - O
treatment NOUN - O
with ADP - O
aripiprazole NOUN - O
( PUNCT - O
N=1,924 PROPN - O
) PUNCT - O
, PUNCT - O
ziprasidone NOUN - O
( PUNCT - O
N=673 PROPN - O
) PUNCT - O
, PUNCT - O
quetiapine NOUN - O
( PUNCT - O
N=4,533 PROPN - O
) PUNCT - O
, PUNCT - O
risperidone NOUN - O
( PUNCT - O
N=1,824 PROPN - O
) PUNCT - O
, PUNCT - O
or CCONJ - O
olanzapine NN - B-MEDICINE
( PUNCT - O
N=1,425 PROPN - O
) PUNCT - O
. PUNCT - O

The DET - O
crude ADJ - O
risk NOUN - O
of ADP - O
developing VERB - O
gestational ADJ - O
diabetes NOUN - O
among ADP - O
continuers NOUN - O
compared VERB - O
with ADP - O
discontinuers NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
was VERB - O
4.8 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
4.5 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
aripiprazole NOUN - O
, PUNCT - O
4.2 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
3.8 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
ziprasidone NOUN - O
, PUNCT - O
7.1 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
4.1 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
quetiapine NOUN - O
, PUNCT - O
6.4 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
4.1 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
risperidone NOUN - O
, PUNCT - O
and CCONJ - O
12.0 CD - B-PERCENT
% NN - I-PERCENT
and CCONJ - O
4.7 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
olanzapine NN - B-MEDICINE
. PUNCT - O

The DET - O
adjusted ADJ - O
relative ADJ - O
risks NOUN - O
were VERB - O
0.82 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=0.50 NNP - B-DATE
- HYPH - I-DATE
1.33 NNP - I-DATE
) PUNCT - O
for ADP - O
aripiprazole NOUN - O
, PUNCT - O
0.76 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=0.29 PROPN - O
- PUNCT - O
2.00 NUM - O
) PUNCT - O
for ADP - O
ziprasidone NOUN - O
, PUNCT - O
1.28 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=1.01 PROPN - O
- PUNCT - O
1.62 NUM - O
) PUNCT - O
for ADP - O
quetiapine NOUN - O
, PUNCT - O
1.09 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=0.70 PROPN - O
- PUNCT - O
1.70 NUM - O
) PUNCT - O
for ADP - O
risperidone NOUN - O
, PUNCT - O
and CCONJ - O
1.61 CD - B-CARDINAL
( PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=1.13 PROPN - O
- PUNCT - O
2.29 CD - B-CARDINAL
) PUNCT - O
for ADP - O
olanzapine NN - B-MEDICINE
. PUNCT - O

Compared VERB - O
with ADP - O
women NOUN - O
who NOUN - O
discontinued VERB - O
use NOUN - O
of ADP - O
an DET - O
atypical ADJ - O
antipsychotic ADJ - O
medication NOUN - O
before ADP - O
the DET - O
start NOUN - O
of ADP - O
pregnancy NOUN - O
, PUNCT - O
women NOUN - O
who NOUN - O
continued VERB - O
treatment NOUN - O
with ADP - O
olanzapine NN - B-MEDICINE
or CCONJ - O
quetiapine NOUN - O
had VERB - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
gestational ADJ - O
diabetes NOUN - O
that ADJ - O
may VERB - O
be VERB - O
explained VERB - O
by ADP - O
the DET - O
metabolic NOUN - O
effects NOUN - O
associated VERB - O
with ADP - O
these DET - O
two CD - B-CARDINAL
drugs NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tolazamide NN - B-MEDICINE
permitted VERB - O
expression NOUN - O
of ADP - O
normal ADJ - O
CH2O PROPN - O
; PUNCT - O
chlorpropamide ADJ - O
administration NOUN - O
predictably ADV - O
reduced VERB - O

-DOCSTART- -X- - O

Tolazamide NN - B-MEDICINE
may VERB - O
exhibit VERB - O
hepatic ADJ - O
cross ADJ - O
- ADJ - O
sensitivity NOUN - O
with ADP - O
chlorpropamide NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

WITH ADP - O
HYPERCHOLESTEROLEMIA ADJ - O
UNDER ADP - O
SIMVASTATIN NNP - B-MEDICINE
ADMINISTRATION PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A. NNP - B-PERSON
Delpino NNP - I-PERSON
, PUNCT - O
Walgreens NNP - B-MEDICINE
: PUNCT - O
Employee NOUN - O
and CCONJ - O
Shareholder NN - B-NORP
, PUNCT - O
Salary NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
describe VERB - O
the DET - O
population NOUN - O
of ADP - O
patients NOUN - O
who NOUN - O
received VERB - O
financial ADJ - O
assistance NOUN - O
from ADP - O
the DT - B-ORG
Good NNP - I-ORG
Days NNPS - I-ORG
Foundation NNP - I-ORG
( PUNCT - O
GDF NNP - B-ORG
) PUNCT - O
as ADP - O
facilitated VERB - O
by ADP - O
Walgreens NNP - B-MEDICINE
local ADJ - O
specialty NOUN - O
pharmacies NOUN - O
( PUNCT - O
LSPs).This NNP - B-ORG
was VERB - O
a DET - O
retrospective ADJ - O
descriptive ADJ - O
study NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
used VERB - O
a DET - O
joint ADJ - O
foundational NOUN - O
and CCONJ - O
pharmacy NOUN - O
claim NOUN - O
database NOUN - O
between IN - B-DATE
January NNP - I-DATE
1 CD - I-DATE
, , - I-DATE
2014 CD - I-DATE
, PUNCT - O
and CCONJ - O
December NNP - B-DATE
31 CD - I-DATE
, PUNCT - O
2016.Among CD - B-DATE
1572 CD - I-DATE
eligible ADJ - O
patients NOUN - O
who NOUN - O
received VERB - O
GDF NNP - B-ORG
financial ADJ - O
assistance NOUN - O
as ADP - O
facilitated VERB - O
by ADP - O
Walgreens NNP - B-MEDICINE
LSPs NNS - I-PERSON
, PUNCT - O
1524 CD - B-DATE
had VERB - O
disease NOUN - O
state NOUN - O
information NOUN - O
and CCONJ - O
14 CD - B-CARDINAL
of ADP - O
these DET - O
patients NOUN - O
receveived VERB - O
financial ADJ - O
assistance NOUN - O
for ADP - O
2 CD - B-CARDINAL
disease NOUN - O
states NOUN - O
( PUNCT - O
patient ADJ - O
count NOUN - O
denominator NOUN - O
, PUNCT - O
1538 CD - B-DATE
) PUNCT - O
. PUNCT - O

The DET - O
facilitation NOUN - O
of ADP - O
treatment NOUN - O
by ADP - O
GDF NNP - B-ORG
and CCONJ - O
Walgreens NNS - B-MEDICINE
LSPs NOUN - O
may VERB - O
be VERB - O
the DET - O
key NOUN - O
to ADP - O
many ADJ - O
patients NOUN - O
receiving VERB - O
their ADJ - O
treatment NOUN - O
and CCONJ - O
maintaining VERB - O
medication NOUN - O
persistence NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

One CD - B-CARDINAL
of ADP - O
the DET - O
most ADJ - O
prolific ADJ - O
systems NOUN - O
is VERB - O
Walgreens NNP - B-MEDICINE
Balance NNP - I-PERSON
Rewards NNPS - I-PERSON
for ADP - O
healthy ADJ - O
choices NOUN - O
( PUNCT - O
BRhc PROPN - O
) PUNCT - O
program NOUN - O
, PUNCT - O
an DET - O
incentivized ADJ - O
, PUNCT - O
Web NOUN - O
- PUNCT - O
based VERB - O
self NOUN - O
- PUNCT - O
monitoring VERB - O
program NOUN - O
. PUNCT - O

This DET - O
study NOUN - O
was VERB - O
performed VERB - O
to PART - O
evaluate VERB - O
health NOUN - O
data NOUN - O
self NOUN - O
- PUNCT - O
tracking VERB - O
characteristics NOUN - O
of ADP - O
individuals NOUN - O
enrolled VERB - O
in ADP - O
the DET - O
Walgreens NNP - B-MEDICINE
' PART - O
BRhc NNP - B-GPE
program NOUN - O
, PUNCT - O
including VERB - O
the DET - O
impact NOUN - O
of ADP - O
manual ADJ - O
versus ADP - O
automatic ADJ - O
data NOUN - O
entries NOUN - O
through ADP - O
a DET - O
supported VERB - O
device NOUN - O
or CCONJ - O
apps NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Walgreens NNP - B-MEDICINE
connected VERB - O
care NOUN - O
: PUNCT - O
impact NOUN - O
of ADP - O
managed VERB - O
therapy NOUN - O
on ADP - O
adherence NOUN - O
to ADP - O
medications NOUN - O
used VERB - O
to PART - O
treat VERB - O
multiple ADJ - O
sclerosis NOUN - O
and CCONJ - O
related ADJ - O
comorbid NOUN - O
conditions NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
study NOUN - O
was VERB - O
funded VERB - O
by ADP - O
Sanofi NNP - B-PERSON
U.S. NNP - I-PERSON
through ADP - O
a DET - O
grant NOUN - O
provided VERB - O
to ADP - O
Walgreens NNP - B-MEDICINE
for ADP - O
research NOUN - O
services NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Influence NOUN - O
of ADP - O
a DET - O
Xanthine PROPN - O
- PUNCT - O
Catechin PROPN - O
Chemical PROPN - O
Matrix PROPN - O
on ADP - O
in ADP - O
vitro X - O
Macrophage PROPN - O
- PUNCT - O
Activation PROPN - O
Triggered VERB - O
by ADP - O
Antipsychotic PROPN - O
Ziprasidone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NN - B-MEDICINE
and CCONJ - O
olanzapine NOUN - O
are VERB - O
also ADV - O
effective ADJ - O
, PUNCT - O
but CCONJ - O
the DET - O
evidence NOUN - O
is VERB - O
lacking VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NNP - B-MEDICINE
had VERB - O
no DET - O
effect NOUN - O
on ADP - O
the DET - O
mean ADJ - O
escape NOUN - O
latency NOUN - O
to PART - O
platform VERB - O
and CCONJ - O
the DET - O
number NOUN - O
of ADP - O
platform NOUN - O
area NOUN - O
crossings NOUN - O
in ADP - O
naïve NOUN - O
mice NOUN - O
, PUNCT - O
but CCONJ - O
haloperidol NOUN - O
, PUNCT - O
olanzapine NOUN - O
, PUNCT - O
and CCONJ - O
PHA-543613 NNP - B-PERSON
did VERB - O
not ADV - O
. PUNCT - O

Ziprasidone NNP - B-MEDICINE
and CCONJ - O
alpha-7 VB - B-ORG
nicotinic ADJ - O
acetylcholine NOUN - O
receptor NOUN - O
agonist NOUN - O
PHA-543613 NNPS - B-PERSON
might VERB - O
be VERB - O
helpful ADJ - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
CIAS PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro NNP - B-ORG
Drug NNP - I-ORG
- HYPH - I-ORG
Drug NNP - I-ORG
Interaction NNP - I-ORG
Potential NNP - I-ORG
of IN - I-ORG
Sulfoxide NNP - I-ORG
and/or CC - I-ORG
Sulfone NN - I-ORG
Metabolites NNPS - I-ORG
of IN - I-ORG
Albendazole NNP - I-ORG
, PUNCT - O
Triclabendazole NNP - B-PRODUCT
, PUNCT - O
Aldicarb NNP - B-ORG
, PUNCT - O
Methiocarb NNP - B-PERSON
, PUNCT - O
Montelukast NNP - B-NORP
and CCONJ - O
Ziprasidone NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NN - B-MEDICINE
- PUNCT - O
treated VERB - O
patients NOUN - O
had VERB - O
a DET - O
significantly ADV - O
greater ADJ - O
increase NOUN - O
in ADP - O
global ADJ - O
akathisia ADJ - O
scores NOUN - O
( PUNCT - O
P NOUN - O
= SYM - O
.01 PUNCT - O
) PUNCT - O
and CCONJ - O
significant ADJ - O
weight NOUN - O
increase NOUN - O
( PUNCT - O
mean VERB - O
[ PUNCT - O
SD PROPN - O
] PUNCT - O
= VERB - O
3.5 CD - B-CARDINAL
[ PUNCT - O
11.8 CD - B-CARDINAL
] PUNCT - O
kg NOUN - O
, PUNCT - O
or CCONJ - O
7.7 CD - B-CARDINAL
[ PUNCT - O
26.1 CD - B-CARDINAL
] PUNCT - O
lb NOUN - O
) PUNCT - O
compared VERB - O
to ADP - O
placebo NOUN - O
( PUNCT - O
1.0 CD - B-CARDINAL
[ PUNCT - O
6.4 CD - B-CARDINAL
] PUNCT - O
kg NOUN - O
, PUNCT - O
or CCONJ - O
2.2 CD - B-CARDINAL
[ PUNCT - O
14.1 CD - B-CARDINAL
] PUNCT - O
lb NOUN - O
) PUNCT - O
( PUNCT - O
P NOUN - O
= SYM - O
.03 PUNCT - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NNP - B-MEDICINE
( PUNCT - O
ZIP NNP - B-ORG
) PUNCT - O
is VERB - O
often ADV - O
used VERB - O
with ADP - O
olanzapine NOUN - O
( PUNCT - O
OLZ PROPN - O
) PUNCT - O
in ADP - O
' PUNCT - O
switch NOUN - O
' PUNCT - O
and CCONJ - O
combination NOUN - O
therapy NOUN - O
but CCONJ - O
empirical ADJ - O
evidence NOUN - O
to PART - O
support VERB - O
these DET - O
strategies NOUN - O
is VERB - O
limited ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NN - B-MEDICINE
- PUNCT - O
phospholipid NOUN - O
complex NOUN - O
was VERB - O
formulated VERB - O
by ADP - O
solvent NOUN - O
- PUNCT - O
evaporation NOUN - O
method NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Ziprasidone NN - B-MEDICINE
and CCONJ - O
aripiprazole NOUN - O
have VERB - O
been VERB - O
described VERB - O
to PART - O
be VERB - O
least ADV - O
commonly ADV - O
associated VERB - O
with ADP - O
weight NOUN - O
gain NOUN - O
or CCONJ - O
metabolic NOUN - O
changes NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Adjunctive ADJ - O
Ziprasidone NNP - B-MEDICINE
in ADP - O
Major PROPN - O
Depression PROPN - O
and CCONJ - O
the DT - B-ORG
Current NNP - I-ORG
Status NNP - I-ORG
of IN - I-ORG
Adjunctive NNP - I-ORG
Atypical NNP - I-ORG
Antipsychotics NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Survival NOUN - O
curves NOUN - O
of ADP - O
plasma NOUN - O
CGRP NNP - B-ORG
levels NOUN - O
also ADV - O
showed VERB - O
those DET - O
with ADP - O
higher ADJ - O
CGRP NNS - B-ORG
levels NOUN - O
responded VERB - O
better ADV - O
to ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

It PRON - O
may VERB - O
also ADV - O
serve VERB - O
as ADP - O
a DET - O
reference NOUN - O
for ADP - O
the DET - O
therapeutic ADJ - O
strategy NOUN - O
since ADP - O
it PRON - O
is VERB - O
higher ADJ - O
in ADP - O
patients NOUN - O
requiring VERB - O
migraine NOUN - O
prevention NOUN - O
and CCONJ - O
responsive ADJ - O
to ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
topiramate NN - B-MEDICINE
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
29-year CD - B-CARDINAL
- PUNCT - O
old ADJ - O
epileptic ADJ - O
woman NOUN - O
who NOUN - O
had VERB - O
been VERB - O
on ADP - O
treatment NOUN - O
with ADP - O
topiramate NN - B-MEDICINE
25mg NN - B-DATE
/ SYM - I-DATE
day NN - I-DATE
for ADP - O
9 CD - B-DATE
days NNS - I-DATE
. PUNCT - O

The DET - O
AACG NNP - B-ORG
is VERB - O
a DET - O
well ADV - O
- PUNCT - O
known VERB - O
side NOUN - O
effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
, PUNCT - O
but CCONJ - O
the DET - O
macular NOUN - O
striae NOUN - O
rarely ADV - O
accompanies VERB - O
it PRON - O
. PUNCT - O

Therefore ADV - O
, PUNCT - O
it PRON - O
is VERB - O
important ADJ - O
to PART - O
differentiate VERB - O
a DET - O
case NOUN - O
of ADP - O
AACG NNP - B-ORG
induced VERB - O
by ADP - O
topiramate NN - B-MEDICINE
from ADP - O
a DET - O
case NOUN - O
of ADP - O
primary ADJ - O
AACG NNP - B-ORG
, PUNCT - O
since ADP - O
they PRON - O
differ VERB - O
in ADP - O
their ADJ - O
clinical ADJ - O
presentation NOUN - O
, PUNCT - O
mechanism NOUN - O
of ADP - O
action NOUN - O
, PUNCT - O
and CCONJ - O
treatment NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

There ADV - O
were VERB - O
( PUNCT - O
i PUNCT - O
) PUNCT - O
dose NOUN - O
- PUNCT - O
related VERB - O
increased VERB - O
incidences NOUN - O
of ADP - O
pregnancies NOUN - O
carrying VERB - O
foetal ADJ - O
malformations NOUN - O
associated VERB - O
with ADP - O
maternal ADJ - O
intake NOUN - O
of ADP - O
valproate NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
when ADV - O
topiramate NN - B-MEDICINE
was VERB - O
a DET - O
component NOUN - O
of ADP - O
AED NNP - B-ORG
polytherapy NOUN - O

AED PROPN - O
polytherapy NOUN - O
did VERB - O
not ADV - O
increase VERB - O
foetal ADJ - O
hazard NOUN - O
unless ADP - O
valproate NOUN - O
or CCONJ - O
topiramate NN - B-MEDICINE
was VERB - O
involved VERB - O
in ADP - O
the DET - O
AED NNP - B-ORG
combination NOUN - O
. PUNCT - O

If ADP - O
it PRON - O
were VERB - O
not ADV - O
for ADP - O
the DET - O
importance NOUN - O
of ADP - O
maintaining VERB - O
seizure NOUN - O
control NOUN - O
, PUNCT - O
the DET - O
above ADJ - O
findings NOUN - O
suggest VERB - O
that ADP - O
it PRON - O
would VERB - O
be VERB - O
better ADJ - O
to PART - O
avoid VERB - O
using VERB - O
certain ADJ - O
AEDs NOUN - O
, PUNCT - O
particularly ADV - O
valproate ADJ - O
and CCONJ - O
topiramate NN - B-MEDICINE
, PUNCT - O
during ADP - O
pregnancy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

AIM PROPN - O
: PUNCT - O
Examine VERB - O
clinical ADJ - O
profile NOUN - O
of ADP - O
extended ADJ - O
- PUNCT - O
release NOUN - O
topiramate NN - B-MEDICINE
( PUNCT - O
Trokendi PROPN - O
  SPACE - O
XR PROPN - O
® NOUN - O
) PUNCT - O
and CCONJ - O
compare VERB - O
treatment NOUN - O
- PUNCT - O
emergent NOUN - O
adverse ADJ - O
events NOUN - O
( PUNCT - O
TEAEs NOUN - O
) PUNCT - O
associated VERB - O
with ADP - O
Trokendi PROPN - O
  SPACE - O
XR PROPN - O
versus ADP - O
previous ADJ - O
immediate ADJ - O
- PUNCT - O
release NOUN - O
topiramate NN - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
- HYPH - I-ORG
IR NNP - I-ORG
) PUNCT - O
treatment NOUN - O
. PUNCT - O

The DET - O
most ADV - O
common ADJ - O
TEAEs NOUN - O
recorded VERB - O
during ADP - O
topiramate NN - B-MEDICINE
treatment NOUN - O
were VERB - O
cognitive ADJ - O
symptoms NOUN - O
( PUNCT - O
word NOUN - O
- PUNCT - O
finding VERB - O
difficulty NOUN - O
, PUNCT - O
attention NOUN - O
/ SYM - O
concentration NOUN - O
difficulty NOUN - O
, PUNCT - O
slowed VERB - O
thinking VERB - O
) PUNCT - O
, PUNCT - O
paresthesia NOUN - O
, PUNCT - O
gastrointestinal ADJ - O
problems NOUN - O
and CCONJ - O
decreased VERB - O
appetite NOUN - O
/ SYM - O
weight NOUN - O
loss NOUN - O
. PUNCT - O

Trokendi PROPN - O
  SPACE - O
XR PROPN - O
use NOUN - O
and CCONJ - O
outcomes NOUN - O
in ADP - O
clinical ADJ - O
practice NOUN - O
were VERB - O
consistent ADJ - O
with ADP - O
established VERB - O
profile NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
29-year CD - B-PRODUCT
- HYPH - I-PRODUCT
old JJ - I-PRODUCT
man NOUN - O
with ADP - O
juvenile ADJ - O
myoclonic ADJ - O
epilepsy NOUN - O
and CCONJ - O
medically ADV - O
refractory ADJ - O
GTCS PROPN - O
on ADP - O
a DET - O
combination NOUN - O
of ADP - O
levetiracetam NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
was VERB - O
started VERB - O
on ADP - O
lacosamide ADJ - O
adjunctive ADJ - O
therapy NOUN - O
with ADP - O
the DET - O
plan NOUN - O
to PART - O
replace VERB - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
on ADP - O
sweat ADJ - O
chloride NOUN - O
level NOUN - O
while ADP - O
screening VERB - O
for ADP - O
cystic ADJ - O
fibrosis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Four CD - B-CARDINAL
new ADJ - O
medicines NOUN - O
- PUNCT - O
liraglutide NOUN - O
, PUNCT - O
lorcaserin NOUN - O
, PUNCT - O
bupropion NOUN - O
/ SYM - O
naltrexone NOUN - O
, PUNCT - O
and CCONJ - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
- PUNCT - O
have VERB - O
been VERB - O
recently ADV - O
added VERB - O
to ADP - O
the DET - O
pharmacological ADJ - O
arsenal NOUN - O
for ADP - O
obesity NOUN - O
treatment NOUN - O
and CCONJ - O
could VERB - O
represent VERB - O
important ADJ - O
tools NOUN - O
to PART - O
manage VERB - O
this DET - O
epidemic NOUN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
report VERB - O
our ADJ - O
recent ADJ - O
experience NOUN - O
with ADP - O
4 CD - B-CARDINAL
preterm NOUN - O
neonates NOUN - O
, PUNCT - O
born VERB - O
between IN - B-DATE
2015 CD - I-DATE
and CC - I-DATE
2017 CD - I-DATE
, PUNCT - O
who NOUN - O
developed VERB - O
radiographic ADJ - O
signs NOUN - O
of ADP - O
necrotizing VERB - O
enterocolitis NOUN - O
after ADP - O
receiving VERB - O
topiramate NN - B-MEDICINE
for ADP - O
seizures NOUN - O
. PUNCT - O

Each DET - O
was VERB - O
given VERB - O
oral ADJ - O
topiramate NN - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
electrographic ADJ - O
and CCONJ - O
clinical ADJ - O
seizures NOUN - O
and CCONJ - O
developed VERB - O
the DET - O
subsequent ADJ - O
diagnosis NOUN - O
of ADP - O
necrotizing VERB - O
enterocolitis ADJ - O
, PUNCT - O
with ADP - O
abdominal ADJ - O
distention NOUN - O
, PUNCT - O
hemoccult NOUN - O
- PUNCT - O
positive ADJ - O
stools NOUN - O
, PUNCT - O
and CCONJ - O
radiographic ADJ - O
signs NOUN - O
of ADP - O
intestinal ADJ - O
distention NOUN - O
and CCONJ - O
pneumatosis NOUN - O
. PUNCT - O

More ADJ - O
research NOUN - O
regarding VERB - O
the DET - O
risk NOUN - O
factors NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
use NOUN - O
in ADP - O
premature ADJ - O
infants NOUN - O
is VERB - O
needed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
characterize VERB - O
the DET - O
magnitude NOUN - O
and CCONJ - O
time NOUN - O
course NOUN - O
of ADP - O
pregnancy NOUN - O
- PUNCT - O
related VERB - O
clearance NOUN - O
changes NOUN - O
for ADP - O
different ADJ - O
antiepileptic ADJ - O
drugs NOUN - O
( PUNCT - O
AEDs NOUN - O
) PUNCT - O
: PUNCT - O
levetiracetam NOUN - O
, PUNCT - O
oxcarbazepine NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
phenytoin NOUN - O
, PUNCT - O
and CCONJ - O
valproate VERB - O
. PUNCT - O

AED NOUN - O
clearances NOUN - O
were VERB - O
calculated VERB - O
for ADP - O
levetiracetam NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
18 CD - B-CARDINAL
pregnancies NOUN - O
) PUNCT - O
, PUNCT - O
oxcarbazepine NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
4 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
topiramate NN - B-MEDICINE
( PUNCT - O
n NOUN - O
= SYM - O
10 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
valproate NOUN - O
( PUNCT - O
n NOUN - O
= SYM - O
5 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
phenytoin VERB - O
( PUNCT - O
n NOUN - O
= SYM - O
7 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

( PUNCT - O
p VERB - O
= SYM - O
0.0001 CD - B-DATE
) PUNCT - O
, PUNCT - O
and CCONJ - O
( PUNCT - O
3 LS - B-CARDINAL
) PUNCT - O
topiramate NN - B-MEDICINE
in ADP - O
second JJ - B-ORDINAL
trimester NOUN - O
( PUNCT - O
1.39-fold PROPN - O
) PUNCT - O

AED NOUN - O
clearance NOUN - O
significantly ADV - O
changes VERB - O
by ADP - O
the DET - O
first JJ - B-ORDINAL
trimester NOUN - O
for ADP - O
levetiracetam NOUN - O
and CCONJ - O
by ADP - O
the DET - O
second JJ - B-ORDINAL
trimester NOUN - O
for ADP - O
oxcarbazepine NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Increases NOUN - O
in ADP - O
heart NOUN - O
rate NOUN - O
were VERB - O
seen VERB - O
during ADP - O
the DET - O
clinical ADJ - O
program NOUN - O
for ADP - O
fixed VERB - O
- PUNCT - O
dose NOUN - O
combination NOUN - O
phentermine NOUN - O
( PUNCT - O
PHEN NNP - B-ORG
) PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
, PUNCT - O
an DET - O
oral ADJ - O
medication NOUN - O
indicated VERB - O
for ADP - O
weight NOUN - O
management NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
effect NOUN - O
on ADP - O
cardiovascular ADJ - O
( PUNCT - O
CV NNP - B-ORG
) PUNCT - O
outcomes NOUN - O
is VERB - O
uncertain ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Adults NOUN - O
treated VERB - O
with ADP - O
topiramate NN - B-MEDICINE
may VERB - O
develop VERB - O
nephrolithiasis NOUN - O
, PUNCT - O
but CCONJ - O
its ADJ - O
frequency NOUN - O
in ADP - O
children NOUN - O
on ADP - O
topiramate NN - B-MEDICINE
is VERB - O
unknown ADJ - O
. PUNCT - O

We PRON - O
studied VERB - O
40 CD - B-CARDINAL
consecutive ADJ - O
children NOUN - O
who NOUN - O
initiated VERB - O
topiramate NN - B-MEDICINE
therapy NOUN - O
for ADP - O
seizures NOUN - O
between ADP - O
January NNP - B-DATE
1997 CD - I-DATE
and CCONJ - O
February NNP - B-DATE
2003 CD - I-DATE
, PUNCT - O
followed VERB - O
for ADP - O
a DT - B-DATE
mean NN - I-DATE
of IN - I-DATE
36 CD - I-DATE
months NNS - I-DATE
. PUNCT - O

Serum PROPN - O
electrolytes NOUN - O
, PUNCT - O
urinary ADJ - O
calcium NOUN - O
/ PUNCT - O
creatinine NOUN - O
ratios NOUN - O
, PUNCT - O
and CCONJ - O
renal ADJ - O
ultrasonography NOUN - O
were VERB - O
performed VERB - O
before ADP - O
topiramate NN - B-MEDICINE
and CCONJ - O
every DT - B-DATE
6 CD - I-DATE
months NNS - I-DATE
thereafter ADV - O
. PUNCT - O

Four CD - B-CARDINAL
children NOUN - O
developed VERB - O
nephrolithiasis NOUN - O
and/or CCONJ - O
nephrocalcinosis NOUN - O
, PUNCT - O
which ADJ - O
resolved VERB - O
on ADP - O
discontinuation NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

Twenty CD - B-CARDINAL
- HYPH - I-CARDINAL
three CD - I-CARDINAL
children NOUN - O
had VERB - O
urinary ADJ - O
calcium NOUN - O
/ PUNCT - O
creatinine NOUN - O
ratios NOUN - O
before ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

Greater ADJ - O
urinary ADJ - O
calcium NOUN - O
excretion NOUN - O
was VERB - O
associated VERB - O
with ADP - O
increasing VERB - O
doses NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
( PUNCT - O
P NOUN - O
  SPACE - O
= SYM - O
0.039).Our CD - B-CARDINAL
study NOUN - O
shows VERB - O
that ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
therapy NOUN - O
with ADP - O
topiramate NN - B-MEDICINE
in ADP - O
children NOUN - O
is VERB - O
associated VERB - O
with ADP - O
  SPACE - O
persistent ADJ - O
hypercalciuria NOUN - O
and CCONJ - O
metabolic ADJ - O
acidosis NOUN - O
, PUNCT - O
which ADJ - O
can VERB - O
lead VERB - O
to ADP - O
nephrocalcinosis NOUN - O
and/or CCONJ - O
nephrolithiasis NOUN - O
. PUNCT - O

All DET - O
children NOUN - O
initiating VERB - O
topiramate NN - B-MEDICINE
therapy NOUN - O
should VERB - O
have VERB - O
baseline NOUN - O
and CCONJ - O
follow VERB - O
- PUNCT - O
up PART - O
urinary ADJ - O
calcium NOUN - O
/ SYM - O
creatinine NOUN - O
studies NOUN - O
, PUNCT - O
serum NOUN - O
electrolytes NOUN - O
, PUNCT - O
and CCONJ - O
periodic ADJ - O
renal ADJ - O
ultrasonography NOUN - O
, PUNCT - O
if ADP - O
the DET - O
urinary ADJ - O
calcium NOUN - O
/ SYM - O
creatinine NOUN - O
ratio NOUN - O
increases NOUN - O
to ADP - O
a DET - O
level NOUN - O
above ADP - O
normal ADJ - O
for ADP - O
age NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
total ADJ - O
, PUNCT - O
26,522 CD - B-CARDINAL
adult NOUN - O
patients NOUN - O
were VERB - O
identified VERB - O
as ADV - O
newly ADV - O
prescribed VERB - O
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
( PUNCT - O
44.0 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
mean VERB - O
age NN - B-DATE
47.1 CD - I-DATE
, PUNCT - O
80.5 CD - B-PERCENT
% NN - I-PERCENT
female NOUN - O
) PUNCT - O
, PUNCT - O
lorcaserin NOUN - O
( PUNCT - O
24.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
48.5 CD - B-CARDINAL
, PUNCT - O
79.3 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
extended VERB - O
release NOUN - O
( PUNCT - O
15.8 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
46.7 CD - B-CARDINAL
, PUNCT - O
82.2 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
or CCONJ - O
liraglutide VERB - O
3.0 CD - B-MONEY
  _SP - I-MONEY
mg NOUN - O
( PUNCT - O
15.4 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
46.9 CD - B-CARDINAL
, PUNCT - O
72.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

At ADP - O
6 CD - B-DATE
  _SP - I-DATE
months NNS - I-DATE
, PUNCT - O
41.8 CD - B-PERCENT
% NN - I-PERCENT
of ADP - O
patients NOUN - O
were VERB - O
still ADV - O
on ADP - O
liraglutide NOUN - O
3.0 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
, PUNCT - O
compared VERB - O
to ADP - O
15.9 CD - B-PERCENT
% NN - I-PERCENT
lorcaserin NOUN - O
( PUNCT - O
p VERB - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
18.1 CD - B-PERCENT
% NN - I-PERCENT
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
( PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.001 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
27.3 CD - B-PERCENT
% NN - I-PERCENT
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
( PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.001 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

After ADP - O
adjusting VERB - O
for ADP - O
baseline NOUN - O
factors NOUN - O
, PUNCT - O
patients NOUN - O
on ADP - O
liraglutide NOUN - O
3.0 CD - B-CARDINAL
  SPACE - O
mg PRON - O
had VERB - O
significantly ADV - O
lower ADJ - O
risk NOUN - O
of ADP - O
discontinuation NOUN - O
compared VERB - O
to ADP - O
those DET - O
on ADP - O
lorcaserin NOUN - O
( PUNCT - O
HR PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.46 CD - B-CARDINAL
, PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.0001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
( PUNCT - O
HR PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.48 CD - B-CARDINAL
, PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.0001 CD - B-CARDINAL
) PUNCT - O
, PUNCT - O
and CCONJ - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
( PUNCT - O
HR PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
0.64 CD - B-CARDINAL
, PUNCT - O
p X - O
  SPACE - O
< X - O
  SPACE - O
0.0001 CD - B-CARDINAL
) PUNCT - O
over ADP - O
the DET - O
course NOUN - O
of ADP - O
follow NOUN - O
- PUNCT - O
up NOUN - O
( PUNCT - O
mean ADJ - O
follow VERB - O
- PUNCT - O
up PART - O
duration NOUN - O
, PUNCT - O
342 CD - B-CARDINAL
- SYM - O
427 NUM - O
  SPACE - O
days NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Several ADJ - O
meta NOUN - O
- PUNCT - O
analyses NOUN - O
have VERB - O
been VERB - O
conducted VERB - O
to PART - O
review VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
in ADP - O
reducing VERB - O
weight NOUN - O
, PUNCT - O
however ADV - O
, PUNCT - O
several ADJ - O
issues NOUN - O
regarding VERB - O
the DET - O
methodology NOUN - O
had VERB - O
arisen VERB - O
of ADP - O
which ADJ - O
make VERB - O
the DET - O
results NOUN - O
remain VERB - O
ambiguous ADJ - O
. PUNCT - O

We PRON - O
conducted VERB - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
of ADP - O
randomised VERB - O
controlled VERB - O
trials NOUN - O
about ADP - O
the DET - O
use NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
in ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
for ADP - O
weight NOUN - O
reduction NOUN - O
. PUNCT - O

Patients NOUN - O
treated VERB - O
with ADP - O
topiramate NN - B-MEDICINE
experienced VERB - O
a DET - O
greater ADJ - O
reduction NOUN - O
in ADP - O
body NOUN - O
weight NOUN - O
and CCONJ - O
BMI NNP - B-ORG
. PUNCT - O

The DET - O
effects NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
augmentation NOUN - O
need VERB - O
further ADJ - O
investigations NOUN - O
in ADP - O
larger ADJ - O
definitive ADJ - O
studies NOUN - O
using VERB - O
methodological ADJ - O
rigor NOUN - O
and CCONJ - O
thorough ADJ - O
assessments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

CAS1 PROPN - O
was VERB - O
efficiently ADV - O
inhibited VERB - O
by ADP - O
tosylamide NOUN - O
, PUNCT - O
3-fluorosulfanilamide CD - B-CARDINAL
, PUNCT - O
and CCONJ - O
3-chlorosulfanilamide CD - B-GPE
( PUNCT - O
KIs NOUN - O
in ADP - O
the DET - O
range NOUN - O
of ADP - O
43.2 CD - B-CARDINAL
- SYM - O
79.6 NUM - O
  SPACE - O
nM SYM - O
) PUNCT - O
, PUNCT - O
whereas ADP - O
acetazolamide ADV - O
, PUNCT - O
methazolamide NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
ethoxzolamide NOUN - O
, PUNCT - O
dorzolamide VERB - O
, PUNCT - O
and CCONJ - O
brinzolamide NOUN - O
were VERB - O
medium ADJ - O
potency NOUN - O
inhibitors NOUN - O
( PUNCT - O
KIs NOUN - O
in ADP - O
the DET - O
range NOUN - O
of ADP - O
360 CD - B-CARDINAL
- SYM - O
445 NUM - O
  SPACE - O
nM PROPN - O
) PUNCT - O
. PUNCT - O

Acetazolamide PROPN - O
, PUNCT - O
dorzolamide VERB - O
, PUNCT - O
ethoxzolamide NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
sulpiride NOUN - O
, PUNCT - O
indisulam VERB - O
, PUNCT - O
celecoxib ADJ - O
, PUNCT - O
and CCONJ - O
sulthiame NOUN - O
were VERB - O
medium ADJ - O
potency NOUN - O
CAS2 PROPN - O
inhibitors NOUN - O
( PUNCT - O
KIs NOUN - O
of ADP - O
143 CD - B-CARDINAL
- SYM - O
857 NUM - O
  SPACE - O
nM SYM - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
this DET - O
review NOUN - O
, PUNCT - O
evidence NOUN - O
on ADP - O
the DET - O
food NOUN - O
and CCONJ - O
drug NOUN - O
administration NOUN - O
( PUNCT - O
FDA)-approved VERB - O
medications NOUN - O
, PUNCT - O
i.e. X - O
, PUNCT - O
orlistat ADJ - O
, PUNCT - O
lorcaserin NOUN - O
, PUNCT - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
, PUNCT - O
liraglutide NOUN - O
and CCONJ - O
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
, PUNCT - O
is VERB - O
summarized VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Although ADP - O
classic ADJ - O
anti ADJ - O
- ADJ - O
epileptic ADJ - O
drugs NOUN - O
have VERB - O
been VERB - O
associated VERB - O
with ADP - O
increased VERB - O
fracture NOUN - O
risk NOUN - O
, PUNCT - O
data NOUN - O
are VERB - O
lacking VERB - O
on ADP - O
the DET - O
outcomes NOUN - O
of ADP - O
newer ADJ - O
anti ADJ - O
- ADJ - O
epileptic ADJ - O
drugs NOUN - O
, PUNCT - O
such ADJ - O
as ADP - O
gabapentin NOUN - O
( PUNCT - O
GBP NNP - B-ORG
) PUNCT - O
, PUNCT - O
levetiracetam NOUN - O
, PUNCT - O
pregabalin NOUN - O
, PUNCT - O
oxcarbazepine NOUN - O
( PUNCT - O
OXC NNP - B-ORG
) PUNCT - O
, PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
. PUNCT - O

Phenobarbital PROPN - O
( PUNCT - O
OR CCONJ - O
= SYM - O
1.97 CD - B-CARDINAL
; PUNCT - O
95%CI NUM - O
= SYM - O
0.53 CD - B-CARDINAL
- SYM - O
7.34 NUM - O
) PUNCT - O
, PUNCT - O
phenytoin PROPN - O
( PUNCT - O
OR CCONJ - O
= SYM - O
0.52 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NN - B-ORG
= SYM - O
0.23 CD - B-CARDINAL
- PUNCT - O
1.16 NUM - O
) PUNCT - O
, PUNCT - O
levetiracetam NOUN - O
( PUNCT - O
OR CCONJ - O
= SYM - O
1.84 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI PROPN - O
= SYM - O
0.55 CD - B-CARDINAL
- SYM - O
6.16 NUM - O
) PUNCT - O
, PUNCT - O
valproic ADJ - O
acid NOUN - O
( PUNCT - O
OR CCONJ - O
= SYM - O
1.01 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
= SYM - O
0.53 CD - B-CARDINAL
- PUNCT - O
1.92 NUM - O
) PUNCT - O
, PUNCT - O
lamotrigine NOUN - O
( PUNCT - O
OR CCONJ - O
= SYM - O
1.44 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
= SYM - O
0.12 CD - B-CARDINAL
- PUNCT - O
16.65 NUM - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
( PUNCT - O
OR CCONJ - O
= SYM - O
0.47 CD - B-CARDINAL
; PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI NNP - B-ORG
= SYM - O
0.10 CD - B-CARDINAL
- SYM - O
2.31 NUM - O
) PUNCT - O
were VERB - O
not ADV - O
associated VERB - O
with ADP - O
fracture NOUN - O
risk NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

She PRON - O
had VERB - O
been VERB - O
started VERB - O
on ADP - O
topiramate NN - B-MEDICINE
for ADP - O
treatment NOUN - O
of ADP - O
migraine JJ - B-DATE
few JJ - I-DATE
months NNS - I-DATE
ago RB - I-DATE
. PUNCT - O

The DET - O
dose NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
was VERB - O
increased VERB - O
to ADP - O
100 CD - B-CARDINAL
  SPACE - O
mg PRON - O
twice ADV - O
daily JJ - B-DATE
2 CD - I-DATE
weeks NNS - I-DATE
ago RB - I-DATE
. PUNCT - O

Her ADJ - O
agranulocytosis NOUN - O
was VERB - O
attributed VERB - O
to ADP - O
topiramate NN - B-MEDICINE
after ADP - O
ruling VERB - O
out PART - O
other ADJ - O
possible ADJ - O
causes NOUN - O
. PUNCT - O

ANC NNP - B-ORG
improved VERB - O
after ADP - O
topiramate NN - B-MEDICINE
was VERB - O
stopped VERB - O
. PUNCT - O

ANC NNP - B-ORG
increased VERB - O
to ADP - O
1000 CD - B-CARDINAL
after ADP - O
5 CD - B-DATE
days NNS - I-DATE
of ADP - O
stopping VERB - O
topiramate NN - B-MEDICINE
. PUNCT - O

We PRON - O
also ADV - O
reviewed VERB - O
published VERB - O
cases NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
- PUNCT - O
associated VERB - O
agranulocytosis NOUN - O
. PUNCT - O

Agranulocytosis NOUN - O
is VERB - O
a DET - O
rare ADJ - O
side NOUN - O
effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
only RB - B-CARDINAL
3 CD - I-CARDINAL
case NOUN - O
reports NOUN - O
have VERB - O
been VERB - O
published VERB - O
so ADV - O
far ADV - O
. PUNCT - O

In ADP - O
all DET - O
cases NOUN - O
, PUNCT - O
agranulocytosis NOUN - O
developed VERB - O
after ADP - O
months NNS - B-DATE
of ADP - O
topiramate NN - B-MEDICINE
therapy NOUN - O
and CCONJ - O
when ADV - O
dose NOUN - O
was VERB - O
increased VERB - O
to ADP - O
200 CD - B-CARDINAL
  SPACE - O
mg PRON - O
daily RB - B-DATE
suggesting VERB - O
a DET - O
dose NOUN - O
- PUNCT - O
dependent ADJ - O
effect NOUN - O
. PUNCT - O

Next ADJ - O
steps NOUN - O
would VERB - O
be VERB - O
further ADJ - O
research NOUN - O
on ADP - O
the DET - O
pathogenesis NOUN - O
of ADP - O
agranulocytosis NOUN - O
associated VERB - O
with ADP - O
topiramate NN - B-MEDICINE
and CCONJ - O
creation NOUN - O
of ADP - O
registry NOUN - O
for ADP - O
data NOUN - O
synthesis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Chest NOUN - O
pain NOUN - O
is VERB - O
a DET - O
potential ADJ - O
adverse ADJ - O
effect NOUN - O
that ADP - O
to ADP - O
our ADJ - O
knowledge NOUN - O
has VERB - O
not ADV - O
been VERB - O
reported VERB - O
with ADP - O
the DET - O
use NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

We PRON - O
present VERB - O
the DET - O
case NOUN - O
of ADP - O
a DET - O
38-year CD - B-CARDINAL
- PUNCT - O
old ADJ - O
female NOUN - O
with ADP - O
a DET - O
seizure NOUN - O
disorder NOUN - O
who NOUN - O
experienced VERB - O
chest NOUN - O
pain NOUN - O
after ADP - O
the DET - O
first ADJ - O
dose NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

The DET - O
chest NOUN - O
pain NOUN - O
improved VERB - O
when ADV - O
the DET - O
topiramate NN - B-MEDICINE
was VERB - O
held VERB - O
. PUNCT - O

No DET - O
identifiable ADJ - O
causes NOUN - O
of ADP - O
chest NOUN - O
pain NOUN - O
were VERB - O
apparent ADJ - O
, PUNCT - O
other ADJ - O
than ADP - O
the DET - O
topiramate NN - B-MEDICINE
. PUNCT - O

The DET - O
Naranjo NNP - B-ORG
probability NOUN - O
scale NOUN - O
was VERB - O
utilized VERB - O
to PART - O
determine VERB - O
the DET - O
causality NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

The DET - O
resulting VERB - O
score NOUN - O
of ADP - O
3 CD - B-CARDINAL
indicates VERB - O
that ADP - O
it PRON - O
is VERB - O
possible ADJ - O
that ADP - O
the DET - O
chest NOUN - O
pain NOUN - O
was VERB - O
due ADJ - O
to ADP - O
the DET - O
topiramate NN - B-MEDICINE
. PUNCT - O

This DET - O
report NOUN - O
demonstrates VERB - O
an DET - O
example NOUN - O
of ADP - O
a DET - O
patient NOUN - O
who NOUN - O
experienced VERB - O
chest NOUN - O
pain NOUN - O
possibly ADV - O
caused VERB - O
by ADP - O
the DET - O
initiation NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

The DET - O
objective NOUN - O
of ADP - O
this DET - O
case NOUN - O
report NOUN - O
is VERB - O
to PART - O
increase VERB - O
the DET - O
awareness NOUN - O
of ADP - O
chest NOUN - O
pain NOUN - O
as ADP - O
an DET - O
adverse ADJ - O
effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Systematic ADJ - O
reviews NOUN - O
and CCONJ - O
meta NOUN - O
- PUNCT - O
analyses NOUN - O
on ADP - O
the DET - O
prevention NOUN - O
, PUNCT - O
treatment NOUN - O
, PUNCT - O
and CCONJ - O
monitoring NOUN - O
of ADP - O
body NOUN - O
weight NOUN - O
changes NOUN - O
as ADP - O
a DET - O
side NOUN - O
effect NOUN - O
of ADP - O
the DET - O
mood NOUN - O
stabilizers NOUN - O
valproate VERB - O
, PUNCT - O
lamotrigine NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
and CCONJ - O
carbamazepine NOUN - O
were VERB - O
identified VERB - O
in ADP - O
Embase NNP - B-GPE
( PUNCT - O
2010 CD - B-DATE
- SYM - I-DATE
2015 CD - I-DATE
, PUNCT - O
no DET - O
language NOUN - O
restrictions NOUN - O
) PUNCT - O
. PUNCT - O

Lamotrigine NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
are VERB - O
associated VERB - O
with ADP - O
weight NOUN - O
loss NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Levetiracetam NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
had VERB - O
no DET - O
effect NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Cinema PROPN - O
- PUNCT - O
like ADJ - O
sensory ADJ - O
phenomena NOUN - O
in ADP - O
a DET - O
migraine NOUN - O
patient NOUN - O
on ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Nine CD - B-CARDINAL
trials NOUN - O
compared VERB - O
topiramate NN - B-MEDICINE
, PUNCT - O
gabapentin NOUN - O
or CCONJ - O
pregabalin NOUN - O
to PART - O
placebo VERB - O
in ADP - O
859 CD - B-CARDINAL
unique ADJ - O
participants NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
was VERB - O
to PART - O
assess VERB - O
the DET - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
adjunctive ADJ - O
brivaracetam NOUN - O
( PUNCT - O
BRV PROPN - O
) PUNCT - O
with ADP - O
concomitant ADJ - O
use NOUN - O
of ADP - O
lamotrigine NOUN - O
( PUNCT - O
LTG NNP - B-ORG
) PUNCT - O
or CCONJ - O
topiramate NN - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
in ADP - O
patients NOUN - O
with ADP - O
uncontrolled ADJ - O
focal ADJ - O
seizures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
mechanism NOUN - O
of ADP - O
action NOUN - O
underlying VERB - O
the DET - O
preventive ADJ - O
effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
in ADP - O
migraine NOUN - O
remains VERB - O
largely ADV - O
unknown ADJ - O
. PUNCT - O

Using VERB - O
functional ADJ - O
magnetic ADJ - O
resonance NOUN - O
imaging NOUN - O
( PUNCT - O
fMRI PROPN - O
) PUNCT - O
we PRON - O
examined VERB - O
the DET - O
central ADJ - O
effects NOUN - O
of ADP - O
a DET - O
single ADJ - O
dose NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
( PUNCT - O
100 CD - B-CARDINAL
mg NOUN - O
) PUNCT - O
on ADP - O
trigeminal ADJ - O
pain NOUN - O
in ADP - O
humans NOUN - O
, PUNCT - O
compared VERB - O
to ADP - O
placebo NOUN - O
( PUNCT - O
mannitol NOUN - O
) PUNCT - O
. PUNCT - O

No DET - O
differences NOUN - O
in ADP - O
the DET - O
subjective ADJ - O
intensity NOUN - O
ratings NOUN - O
of ADP - O
the DET - O
painful ADJ - O
stimuli NOUN - O
were VERB - O
observed VERB - O
between ADP - O
topiramate NN - B-MEDICINE
and CCONJ - O
placebo NOUN - O
sessions NOUN - O
. PUNCT - O

In ADP - O
contrast NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
significantly ADV - O
decreased VERB - O
the DET - O
activity NOUN - O
in ADP - O
the DET - O
thalamus NOUN - O
and CCONJ - O
other ADJ - O
pain NOUN - O
processing NOUN - O
areas NOUN - O
. PUNCT - O

Additionally ADV - O
, PUNCT - O
topiramate NN - B-MEDICINE
increased VERB - O
functional ADJ - O
coupling NOUN - O
between ADP - O
the DET - O
thalamus NOUN - O
and CCONJ - O
several ADJ - O
brain NOUN - O
regions NOUN - O
such ADJ - O
as ADP - O
the DET - O
bilateral ADJ - O
precuneus NOUN - O
, PUNCT - O
posterior NOUN - O
cingulate NOUN - O
cortex NOUN - O
and CCONJ - O
secondary ADJ - O
somatosensory ADJ - O
cortex NOUN - O
. PUNCT - O

These DET - O
data NOUN - O
suggest VERB - O
that ADP - O
topiramate NN - B-MEDICINE
exhibits NOUN - O
modulating VERB - O
effects NOUN - O
on ADP - O
nociceptive ADJ - O
processing NOUN - O
in ADP - O
thalamo NOUN - O
- PUNCT - O
cortical ADJ - O
networks NOUN - O
during ADP - O
trigeminal ADJ - O
pain NOUN - O
and CCONJ - O
that ADP - O
the DET - O
preventive ADJ - O
effect NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
on ADP - O
frequent ADJ - O
migraine NOUN - O
is VERB - O
probably ADV - O
mediated VERB - O
by ADP - O
an DET - O
effect NOUN - O
on ADP - O
thalamo NOUN - O
- PUNCT - O
cortical ADJ - O
networks NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

This DET - O
review NOUN - O
presents VERB - O
detailed ADJ - O
safety NOUN - O
profiles NOUN - O
for ADP - O
orlistat ADJ - O
, PUNCT - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
, PUNCT - O
lorcaserin NOUN - O
, PUNCT - O
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
and CCONJ - O
liraglutide NOUN - O
3.0 CD - B-CARDINAL
  SPACE - O
mg PRON - O
, PUNCT - O
and CCONJ - O
discusses VERB - O
the DET - O
associated VERB - O
risk NOUN - O
- PUNCT - O
benefit NOUN - O
profiles NOUN - O
. PUNCT - O

Two CD - B-CARDINAL
anti ADJ - O
- ADJ - O
obesity ADJ - O
medications NOUN - O
presented VERB - O
safety NOUN - O
issues NOUN - O
that ADJ - O
warranted VERB - O
further ADJ - O
discussion NOUN - O
; PUNCT - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
( PUNCT - O
fetal ADJ - O
toxicity NOUN - O
) PUNCT - O
and CCONJ - O
liraglutide VERB - O
3.0 CD - B-CARDINAL
  SPACE - O
mg PRON - O
( PUNCT - O
risk NOUN - O
of ADP - O
gallstone NOUN - O
disease NOUN - O
and CCONJ - O
mild ADJ - O
, PUNCT - O
acute ADJ - O
pancreatitis NOUN - O
) PUNCT - O
, PUNCT - O
whereas ADP - O
the DET - O
adverse ADJ - O
events NOUN - O
associated VERB - O
with ADP - O
orlistat ADJ - O
, PUNCT - O
lorcaserin NOUN - O
, PUNCT - O
and CCONJ - O
naltrexone NOUN - O
/ SYM - O
bupropion NOUN - O
were VERB - O
mostly ADV - O
transient ADJ - O
tolerability NOUN - O
issues NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

LEV NN - B-ORG
, PUNCT - O
carbamazepine NOUN - O
, PUNCT - O
benzodiazepines NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
oxcarbazepine NOUN - O
, PUNCT - O
valproate NOUN - O
, PUNCT - O
and CCONJ - O
lamotrigine NOUN - O
were VERB - O
administered VERB - O
in ADP - O
48 CD - B-CARDINAL
, PUNCT - O
37 CD - B-DATE
, PUNCT - O
18 CD - B-DATE
, PUNCT - O
13 CD - B-DATE
, PUNCT - O
11 CD - B-DATE
, PUNCT - O
9 CD - B-DATE
, PUNCT - O
and CCONJ - O
9 CD - B-CARDINAL
patients NOUN - O
, PUNCT - O
singly ADV - O
or CCONJ - O
in ADP - O
combination NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
children NOUN - O
, PUNCT - O
aged VERB - O
between IN - B-DATE
7 CD - I-DATE
and CC - I-DATE
14 CD - I-DATE
years NNS - I-DATE
, PUNCT - O
had VERB - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
10 CD - I-CARDINAL
episodes NOUN - O
of ADP - O
seizures NOUN - O
per ADP - O
day NOUN - O
in ADP - O
spite NOUN - O
of ADP - O
polytherapy NOUN - O
with ADP - O
valproate NOUN - O
, PUNCT - O
lamotrigine NOUN - O
, PUNCT - O
clonazepam NOUN - O
, PUNCT - O
levetiracetam NOUN - O
, PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
in ADP - O
various ADJ - O
combinations NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Replacement NOUN - O
with ADP - O
topiramate NN - B-MEDICINE
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
proved VERB - O
to PART - O
be VERB - O
markedly ADV - O
effective ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

To PART - O
report VERB - O
two CD - B-CARDINAL
cases NOUN - O
of ADP - O
ciliochoroidal ADJ - O
effusion NOUN - O
after ADP - O
the DET - O
usage NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
. PUNCT - O

Two CD - B-CARDINAL
middle ADJ - O
- PUNCT - O
aged ADJ - O
women NOUN - O
experienced VERB - O
sudden ADJ - O
onset NOUN - O
of ADP - O
acute ADJ - O
glaucoma NOUN - O
and CCONJ - O
acquired VERB - O
myopia NOUN - O
after ADP - O
taking VERB - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
cycling VERB - O
acetazolamide NOUN - O
regimen NOUN - O
( PUNCT - O
2 CD - B-DATE
  _SP - I-DATE
days NNS - I-DATE
on ADV - O
, PUNCT - O
4 CD - B-CARDINAL
  SPACE - O
days NNS - B-DATE
off ADV - O
) PUNCT - O
plus CCONJ - O
low ADJ - O
- PUNCT - O
dose NOUN - O
topiramate NN - B-MEDICINE
maintained VERB - O
> X - O
95 CD - B-PERCENT
% NN - I-PERCENT
reduction NOUN - O
( PUNCT - O
0.5 CD - B-CARDINAL
  SPACE - O
± NUM - O
  SPACE - O
0.9/day CD - B-DATE
) PUNCT - O
in ADP - O
seizures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
group NOUN - O
of ADP - O
moderate ADJ - O
enzyme ADJ - O
- PUNCT - O
inducing VERB - O
drugs NOUN - O
includes VERB - O
eslicarbazepine NOUN - O
acetate NOUN - O
, PUNCT - O
oxcarbazepine NOUN - O
, PUNCT - O
rufinamide NOUN - O
, PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Multiple ADJ - O
therapies NOUN - O
that ADJ - O
target VERB - O
glutamate VERB - O
receptors NOUN - O
including VERB - O
magnesium NOUN - O
, PUNCT - O
topiramate NN - B-MEDICINE
, PUNCT - O
memantine NOUN - O
, PUNCT - O
and CCONJ - O
ketamine NOUN - O
have VERB - O
been VERB - O
reported VERB - O
to PART - O
have VERB - O
efficacy NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
migraine NOUN - O
, PUNCT - O
although ADP - O
with ADP - O
the DET - O
exception NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
, PUNCT - O
the DET - O
evidence NOUN - O
for ADP - O
the DET - O
efficacy NOUN - O
of ADP - O
these DET - O
therapies NOUN - O
is VERB - O
not ADV - O
strong ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

For ADP - O
short ADJ - O
- PUNCT - O
term NOUN - O
prevention NOUN - O
, PUNCT - O
both DET - O
syndromes NOUN - O
were VERB - O
highly ADV - O
responsive ADJ - O
to ADP - O
intravenous ADJ - O
lidocaine NOUN - O
by ADP - O
infusion NOUN - O
; PUNCT - O
for ADP - O
long ADJ - O
- PUNCT - O
term NOUN - O
prevention NOUN - O
, PUNCT - O
lamotrigine NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
were VERB - O
effective ADJ - O
for ADP - O
SUNCT NNP - B-ORG
, PUNCT - O
and CCONJ - O
lamotrigine NOUN - O
and CCONJ - O
gabapentin NOUN - O
were VERB - O
efficacious ADJ - O
in ADP - O
preventing VERB - O
SUNA NNP - B-ORG
attacks NOUN - O
. PUNCT - O

A DET - O
randomized ADJ - O
placebo NOUN - O
- PUNCT - O
controlled VERB - O
cross NOUN - O
- PUNCT - O
over ADP - O
trial NOUN - O
of ADP - O
topiramate NN - B-MEDICINE
in ADP - O
SUNCT NNP - B-ORG
using VERB - O
an DET - O
N PROPN - O
- PUNCT - O
of-1 NOUN - O
design NOUN - O
demonstrated VERB - O
it PRON - O
to PART - O
be VERB - O
an DET - O
effective ADJ - O
treatment NOUN - O
in ADP - O
line NOUN - O
with ADP - O
clinical ADJ - O
experience NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Drug NOUN - O
- PUNCT - O
resistant ADJ - O
epilepsy NOUN - O
and CCONJ - O
topiramate NN - B-MEDICINE
: PUNCT - O
Plasma ADJ - O
concentration NOUN - O
and CCONJ - O
frequency NOUN - O
of ADP - O
epileptic ADJ - O
seizures NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Influence NOUN - O
of ADP - O
treatment NOUN - O
with ADP - O
topiramate NN - B-MEDICINE
and CCONJ - O
zonisamide VERB - O
on ADP - O
levels NOUN - O
of ADP - O
the DET - O
peptide]. NOUN - O

-DOCSTART- -X- - O

Moderate ADJ - O
evidence NOUN - O
supports VERB - O
the DET - O
use NOUN - O
of ADP - O
nonsteroidal ADJ - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
drugs NOUN - O
, PUNCT - O
opioids NOUN - O
, PUNCT - O
and CCONJ - O
topiramate NN - B-MEDICINE
in ADP - O
the DET - O
short ADJ - O
- PUNCT - O
term NOUN - O
treatment NOUN - O
of ADP - O
mechanical ADJ - O
low ADJ - O
back NOUN - O
pain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

PCPs NOUN - O
were VERB - O
initially ADV - O
least ADV - O
comfortable ADJ - O
discussing VERB - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
extended VERB - O
release NOUN - O
( PUNCT - O
ER PROPN - O
) PUNCT - O
but CCONJ - O
developed VERB - O
significantly ADV - O
more ADJ - O
comfort NOUN - O
after ADP - O
the DET - O
trial NOUN - O
, PUNCT - O
to ADP - O
a DET - O
greater ADJ - O
degree NOUN - O
among ADP - O
PCP NNP - B-ORG
- HYPH - I-ORG
I NNP - I-ORG
( PUNCT - O
pre ADJ - O
/ SYM - O
post X - O
PCP NNP - B-ORG
- PUNCT - O
C PROPN - O
: PUNCT - O
2.86 CD - B-CARDINAL

Both DET - O
PCPs NOUN - O
rated VERB - O
phentermine NOUN - O
( PUNCT - O
pre ADJ - O
/ SYM - O
post X - O
PCP PROPN - O
- PUNCT - O
C PROPN - O
: PUNCT - O
5.03 CD - B-CARDINAL
[ PUNCT - O
2.05 CD - B-CARDINAL
] PUNCT - O
vs. ADP - O
5.50 CD - B-CARDINAL
[ PUNCT - O
2.12 CD - B-CARDINAL
] PUNCT - O
, PUNCT - O
P NOUN - O
= SYM - O
0.002 CD - B-CARDINAL
; PUNCT - O
pre ADJ - O
/ SYM - O
post VERB - O
PCP PROPN - O
- PUNCT - O
I PROPN - O
: PUNCT - O
5.70 CD - B-CARDINAL
[ PUNCT - O
1.64 CD - B-CARDINAL
] PUNCT - O
vs. ADP - O
6.83 CD - B-CARDINAL
[ PUNCT - O
1.18 CD - B-CARDINAL
] PUNCT - O
, PUNCT - O
P NOUN - O
= SYM - O
0.001 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
phentermine NOUN - O
/ SYM - O
topiramate NN - B-MEDICINE
ER PROPN - O
( PUNCT - O
pre ADJ - O
/ SYM - O
post X - O
PCP PROPN - O
- PUNCT - O
C PROPN - O
: PUNCT - O
3.91 CD - B-CARDINAL
[ PUNCT - O
2.33 CD - B-CARDINAL
] PUNCT - O
vs. ADP - O
5.47 CD - B-CARDINAL
[ PUNCT - O
2.54 CD - B-CARDINAL
] PUNCT - O
, PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
; PUNCT - O
pre ADJ - O
/ SYM - O
post X - O
PCP PROPN - O
- PUNCT - O
I PROPN - O
: PUNCT - O
5.58 CD - B-CARDINAL
[ PUNCT - O
2.21 CD - B-CARDINAL
] PUNCT - O
vs. ADP - O
7.02 CD - B-CARDINAL
[ PUNCT - O
1.47 CD - B-CARDINAL
] PUNCT - O
, PUNCT - O
P NOUN - O
< X - O
0.001 CD - B-CARDINAL
) PUNCT - O
significantly ADV - O
more ADV - O
effective ADJ - O
after ADP - O
the DET - O
trial NOUN - O
, PUNCT - O
though ADP - O
ratings NOUN - O
were VERB - O
higher ADJ - O
among ADP - O
PCP NNP - B-ORG
- HYPH - I-ORG
I. NN - I-ORG
CONCLUSIONS NOUN - O
: PUNCT - O
PCPs NOUN - O
initially ADV - O
overvalued VERB - O
exercise NOUN - O
and CCONJ - O
undervalued VERB - O
weight NOUN - O
- PUNCT - O
loss NOUN - O
medications NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Potential ADJ - O
Role PROPN - O
of ADP - O
Antipsychotic PROPN - O
- PUNCT - O
Galantamine NNP - B-MEDICINE
- PUNCT - O
Memantine PROPN - O
Combination PROPN - O
in ADP - O
the DET - O
Treatment PROPN - O
of ADP - O
Positive PROPN - O
, PUNCT - O
Cognitive PROPN - O
, PUNCT - O
and CCONJ - O
Negative NNP - B-PERSON
Symptoms NNPS - I-PERSON
of ADP - O
Schizophrenia NNP - B-GPE
. PUNCT - O

-DOCSTART- -X- - O

Can VERB - O
Galantamine NNP - B-MEDICINE
- PUNCT - O
Memantine PROPN - O
Combination PROPN - O
Prevent PROPN - O
Psychosis PROPN - O
? PUNCT - O

-DOCSTART- -X- - O

Galantamine NN - B-MEDICINE
improves VERB - O
cognition NOUN - O
, PUNCT - O
hippocampal ADJ - O
inflammation NOUN - O
, PUNCT - O
and CCONJ - O
synaptic ADJ - O
plasticity NOUN - O
impairments NOUN - O
induced VERB - O
by ADP - O
lipopolysaccharide NOUN - O
in ADP - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Top ADJ - O
ranking VERB - O
ten CD - B-CARDINAL
compounds NOUN - O
, PUNCT - O
which ADJ - O
have VERB - O
lower ADJ - O
Glide NNP - B-PERSON
Score NNP - I-PERSON
when ADV - O
compared VERB - O
to ADP - O
known VERB - O
drugs NOUN - O
( PUNCT - O
Tacrine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Galantamine NNP - I-MEDICINE
) PUNCT - O
for ADP - O
AChE. NNP - B-ORG

We PRON - O
report VERB - O
the DET - O
best ADJ - O
binding ADJ - O
compounds NOUN - O
with ADP - O
AChE NNP - B-ORG
compared VERB - O
to ADP - O
known VERB - O
drugs NOUN - O
( PUNCT - O
Taine NNP - B-ORG
and CC - I-ORG
Galantamine NNP - B-MEDICINE
) PUNCT - O
for ADP - O
AD NN - B-ORG
. PUNCT - O

Three CD - B-CARDINAL
molecules NOUN - O
( PUNCT - O
1-benzyl-3-(2- PROPN - O
hydroxyethyl)-N-[2-(3-pyridyl)ethyl]-3-pyrrolidinecarboxamide PROPN - O
, PUNCT - O
N-{3[benzyl(methyl)amino]propyl}-1,5-dimethyl-4-oxo-4,5-dihydro- PROPN - O
1H NNP - B-DATE
- HYPH - I-DATE
pyrrolo[3,2-c]quinoline-2-carboxamide NN - I-DATE
, PUNCT - O
and CCONJ - O
6-chloro CD - B-GPE
- HYPH - I-GPE
N-[2-(diethylamino)-2-phenylethyl]-4-oxo-4H NNP - I-GPE
- HYPH - I-GPE
chromene-2-carboxamide NNP - I-GPE
) PUNCT - O
have VERB - O
-196.36 PUNCT - O
, PUNCT - O
-204.27 INTJ - O
, PUNCT - O
-214.40 PUNCT - O
kJ PROPN - O
/ SYM - O
mol NOUN - O
, PUNCT - O
binding VERB - O
free ADJ - O
energy NOUN - O
values NOUN - O
respectively ADV - O
which ADJ - O
are VERB - O
much ADV - O
lower ADJ - O
than ADP - O
values NOUN - O
calculated VERB - O
for ADP - O
the DET - O
reference NOUN - O
ligands VERB - O
Tacrine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Galantamine NNP - B-MEDICINE
having VERB - O
-119.65 PUNCT - O
and CCONJ - O
-142.18 VERB - O
kJ VB - B-ORG
/ SYM - O
mol NOUN - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Galantamine NN - B-MEDICINE
not ADV - O
only ADV - O
is VERB - O
an DET - O
acetylcholinesterase ADJ - O
inhibitor NOUN - O
but CCONJ - O
has VERB - O
a DET - O
dual ADJ - O
mode NOUN - O
of ADP - O
action NOUN - O
as ADP - O
a DET - O
α-7nACh JJ - B-ORG
receptor NOUN - O
modulator NOUN - O
as ADV - O
well ADV - O
. PUNCT - O

Galantamine NN - B-MEDICINE
and CCONJ - O
memantine NOUN - O
are VERB - O
approved VERB - O
by ADP - O
the DT - B-ORG
US NNP - I-ORG
Food NNP - I-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
( PUNCT - O
FDA NNP - B-ORG
) PUNCT - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
Alzheimer PROPN - O
's PART - O
disease NOUN - O
( PUNCT - O
AD NN - B-ORG
) PUNCT - O
. PUNCT - O

Galantamine NN - B-MEDICINE
and CCONJ - O
memantine NOUN - O
have VERB - O
shown VERB - O
efficacy NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
ECT- NNP - B-ORG
and CCONJ - O
TBI NOUN - O
- PUNCT - O
induced VERB - O
cognitive ADJ - O
impairments NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Galantamine NNP - B-MEDICINE
- HYPH - I-ORG
Memantine NNP - I-ORG
Combination NNP - I-ORG
for IN - I-ORG
Cognitive NNP - I-ORG
Impairments NNS - I-ORG
Due IN - I-ORG
to ADP - O
Electroconvulsive NNP - B-ORG
Therapy NNP - I-ORG
, PUNCT - O
Traumatic NNP - B-PERSON
Brain NNP - I-PERSON
Injury NNP - I-PERSON
, PUNCT - O
and CCONJ - O
Neurologic NNP - B-ORG
and CCONJ - O
Psychiatric PROPN - O
Disorders NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Galantamine NNP - B-MEDICINE
( -LRB- - I-ORG
Gnt NNP - I-ORG
) PUNCT - O
is VERB - O
a DET - O
natural ADJ - O
alkaloid NOUN - O
inhibitor NOUN - O
of ADP - O
acetylcholinesterase NOUN - O
and CCONJ - O
is VERB - O
presently ADV - O
one CD - B-CARDINAL
of ADP - O
the DET - O
most ADV - O
used VERB - O
drugs NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
against ADP - O
Alzheimer PROPN - O
's PART - O
disease NOUN - O
during ADP - O
both CCONJ - O
the DET - O
initial ADJ - O
and CCONJ - O
intermediate ADJ - O
stages NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Neuroprotective PROPN - O
Effects PROPN - O
of ADP - O
Galantamine NNP - B-MEDICINE
on ADP - O
Nerve PROPN - O
Agent PROPN - O
- PUNCT - O
Induced PROPN - O
Neuroglial PROPN - O
and CCONJ - O
Biochemical PROPN - O
Changes PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Galantamine NNP - B-MEDICINE
, PUNCT - O
which ADJ - O
is VERB - O
currently ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
Alzheimer PROPN - O
's PART - O
disease NOUN - O
( PUNCT - O
AD NN - B-ORG
) PUNCT - O
, PUNCT - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
exert VERB - O
a DET - O
neuroprotective ADJ - O
effect NOUN - O
against ADP - O
beta NOUN - O
- PUNCT - O
amyloid NOUN - O
( PUNCT - O
Aβ PROPN - O
) PUNCT - O
peptide NOUN - O
- PUNCT - O
induced VERB - O
toxicity NOUN - O
, PUNCT - O
a DET - O
critical ADJ - O
component NOUN - O
involved VERB - O
in ADP - O
the DET - O
pathogenesis NOUN - O
of ADP - O
AD NN - B-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Galantamine NN - B-MEDICINE
is VERB - O
a DET - O
drug NOUN - O
used VERB - O
for ADP - O
the DET - O
therapy NOUN - O
of ADP - O
Alzheimer PROPN - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Compound NOUN - O
4a NUM - O
( PUNCT - O
IC50 PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
6.5 CD - B-CARDINAL
  SPACE - O
± X - O
  SPACE - O
0.1 CD - B-CARDINAL
) PUNCT - O
was VERB - O
found VERB - O
to PART - O
be VERB - O
most ADV - O
potent ADJ - O
compared VERB - O
with ADP - O
the DET - O
reference NOUN - O
compound NOUN - O
Galantamine NN - B-MEDICINE
( PUNCT - O
IC50 PROPN - O
  SPACE - O
= PUNCT - O
  SPACE - O
6.6 CD - B-CARDINAL
  SPACE - O
± PUNCT - O
  SPACE - O
0.00038 CD - B-CARDINAL
) PUNCT - O
and CCONJ - O
the DET - O
other ADJ - O
compounds NOUN - O
( PUNCT - O
4b,4c,4d NUM - O
) PUNCT - O
were VERB - O
also ADV - O
possess ADJ - O
that DET - O
activity NOUN - O
and CCONJ - O
hence ADV - O
can VERB - O
be VERB - O
employed VERB - O
for ADP - O
the DET - O
discovery NOUN - O
of ADP - O
lead ADJ - O
compounds NOUN - O
against ADP - O
Alzheimer PROPN - O
's PART - O
disease NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Efficacy NOUN - O
of ADP - O
Galantamine NNP - B-MEDICINE
on IN - I-ORG
Cognition NNP - I-ORG
in IN - I-ORG
Mild NNP - I-ORG
- HYPH - I-ORG
to NNP - I-ORG
- HYPH - I-ORG
Moderate PROPN - O
Alzheimer PROPN - O
's PART - O
Dementia NOUN - O
after ADP - O
Failure NOUN - O
to ADP - O
Respond NNP - B-PERSON
to ADP - O
Donepezil NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Lamivudine NNP - B-MEDICINE
's PART - O
efficacy NOUN - O
and CCONJ - O
safety NOUN - O
in ADP - O
preventing VERB - O
mother NOUN - O
- PUNCT - O
to ADP - O
- PUNCT - O
child NOUN - O
transmission NOUN - O
of ADP - O
hepatitis NOUN - O
B PROPN - O
: PUNCT - O
A DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Immunovirological ADJ - O
outcome NOUN - O
and CCONJ - O
HIV-1 PROPN - O
DNA NOUN - O
decay NOUN - O
in ADP - O
a DET - O
small ADJ - O
cohort NOUN - O
of ADP - O
HIV-1-infected JJ - B-ORG
patients NOUN - O
deintensificated VERB - O
from ADP - O
Abacavir NNP - B-ORG
/ SYM - I-ORG
Lamivudine NNP - I-MEDICINE
/ SYM - I-ORG
Dolutegravir NNP - I-ORG
to IN - I-ORG
Lamivudine NNP - I-MEDICINE
plus CC - I-ORG
Dolutegravir NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Lamivudine JJ - B-MEDICINE
plus CCONJ - O
tenofovir DET - O
combination NOUN - O
therapy NOUN - O
versus ADP - O
lamivudine JJ - B-MEDICINE
monotherapy NOUN - O
for ADP - O
HBV PROPN - O
/ SYM - O
HIV PROPN - O
coinfection NOUN - O
: PUNCT - O
a DET - O
meta ADJ - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Switch VERB - O
to ADP - O
Doravirine NNP - B-ORG
/ SYM - I-ORG
Lamivudine NNP - I-MEDICINE
/ SYM - I-ORG

-DOCSTART- -X- - O

The DET - O
most ADV - O
frequent ADJ - O
first JJ - B-ORDINAL
- PUNCT - O
line NOUN - O
regimens NOUN - O
were VERB - O
Tenofovir NNP - B-ORG
/ SYM - I-ORG
Emtricitabine NNP - I-ORG
/ SYM - I-ORG
Efavirenz NNP - I-ORG
( PUNCT - O
28.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
Zidovudine NNP - B-ORG
/ SYM - I-ORG
Lamivudine NNP - I-MEDICINE
/ SYM - I-ORG
Efavirenz NNP - I-ORG
( PUNCT - O
28.4 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
, PUNCT - O
and CCONJ - O
Abacavir NNP - B-ORG
/ SYM - I-ORG
Lamivudine NNP - I-MEDICINE
/ SYM - I-ORG
Efavirenz NNP - I-ORG
( PUNCT - O
15.9 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Lamivudine NNP - B-MEDICINE
( PUNCT - O
3TC NUM - O
) PUNCT - O
was VERB - O
recorded VERB - O
for ADP - O
more JJR - B-PERCENT
than IN - I-PERCENT
90 CD - I-PERCENT
% NN - I-PERCENT
of ADP - O
patients NOUN - O
in ADP - O
each DET - O
clinic NOUN - O
, PUNCT - O
and CCONJ - O
although ADP - O
there ADV - O
was VERB - O
variation NOUN - O
between ADP - O
clinics NOUN - O
in ADP - O
the DET - O
choice NOUN - O
of ADP - O
antiretroviral ADJ - O
therapy NOUN - O
( PUNCT - O
ART NNP - B-ORG
) PUNCT - O
, PUNCT - O
the DET - O
majority NOUN - O
were VERB - O
on ADP - O
first JJ - B-ORDINAL
line NOUN - O
drugs NOUN - O
consistent ADJ - O
with ADP - O
guidelines NOUN - O
. PUNCT - O
   SPACE - O

-DOCSTART- -X- - O

Lamivudine JJ - B-MEDICINE
monotherapy NOUN - O
in ADP - O
children NOUN - O
and CCONJ - O
adolescents NOUN - O

-DOCSTART- -X- - O

Clinical JJ - B-ORG
, , - I-ORG
Immunological NNP - I-ORG
and CC - I-ORG
Virological NNP - I-ORG
Responses NNPS - I-ORG
of IN - I-ORG
Zidovudine NNP - I-ORG
- HYPH - I-ORG
Lamivudine NNP - I-MEDICINE
- HYPH - I-ORG
Nevirapine NNP - I-ORG
versus IN - I-ORG
Zidovudine NNP - B-ORG
- HYPH - I-ORG
Lamivudine NNP - I-MEDICINE
- HYPH - I-ORG
Efavirenz NNP - I-ORG
Antiretroviral NNP - I-ORG
Treatment NNP - I-ORG
( PUNCT - O
ART NN - B-ORG
) PUNCT - O

-DOCSTART- -X- - O

[ PUNCT - O
Efficacy NOUN - O
and CCONJ - O
safety NOUN - O
of ADP - O
Entecavir NNP - B-PERSON
monotherapy NOUN - O
switched VERB - O
from ADP - O
Lamivudine NNP - B-MEDICINE
combined VERB - O
Adefovir NNP - B-PERSON
Dipivoxil NNP - I-PERSON
for ADP - O
chronic NOUN - O
hepatitis NOUN - O
B PROPN - O
virus NOUN - O
- PUNCT - O
related VERB - O
compensated ADJ - O
liver NOUN - O
cirrhosis]. NOUN - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
is VERB - O
a DET - O
commonly ADV - O
used VERB - O
antiepileptic ADJ - O
drug NOUN - O
( PUNCT - O
AED PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

T PROPN - O
Polymorphism PROPN - O
Is VERB - O
a DET - O
Risk NOUN - O
Factor PROPN - O
for ADP - O
Valproic NNP - B-MEDICINE
Acid PROPN - O
- PUNCT - O
Induced VERB - O
Abnormal PROPN - O
Liver PROPN - O
Function PROPN - O
in ADP - O
Chinese JJ - B-NORP
Patients NOUN - O
With ADP - O
Epilepsy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
and CCONJ - O
lithium NOUN - O
are VERB - O
widely ADV - O
used VERB - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
bipolar ADJ - O
disorder NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Transient ADJ - O
Gene PROPN - O
Expression PROPN - O
Using VERB - O
Valproic NNP - B-MEDICINE
Acid NOUN - O
in ADP - O
Combination NOUN - O
with ADP - O
Co PROPN - O
- NOUN - O
transfection NOUN - O
of ADP - O
SV40 PROPN - O
Large NNP - B-PERSON
T NNP - I-PERSON
Antigen NNP - I-PERSON
and CCONJ - O
human ADJ - O
p21CIP NOUN - O
/p27KIP PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
, PUNCT - O
a DET - O
widely ADV - O
used VERB - O
antiepileptic ADJ - O
drug NOUN - O
, PUNCT - O
exerts VERB - O
anti ADJ - O
- ADJ - O
angiogenic ADJ - O
effects NOUN - O
by ADP - O
inhibiting VERB - O
histone NOUN - O
deacetylase NOUN - O
( PUNCT - O
HDAC NNP - B-ORG
) PUNCT - O
. PUNCT - O

Valproic JJ - B-MEDICINE
acid NOUN - O
reduced VERB - O
the DET - O
pS6 NOUN - O
immunoreactivity NOUN - O
in ADP - O
neovascular ADJ - O
tufts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic NNP - B-MEDICINE
Acid NOUN - O
Poisoning NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
is VERB - O
an DET - O
inhibitor NOUN - O
of ADP - O
histone NOUN - O
deacetylases VERB - O
( PUNCT - O
HDACs PROPN - O
) PUNCT - O
that ADJ - O
can VERB - O
regulate VERB - O
differentiation NOUN - O
and CCONJ - O
proliferation NOUN - O
of ADP - O
stem NOUN - O
cells NOUN - O
by ADP - O
epigenetic ADJ - O
mechanisms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
attenuates VERB - O
global ADJ - O
cerebral ADJ - O
ischemia NOUN - O
/ SYM - O
reperfusion NOUN - O
injury NOUN - O
in ADP - O
gerbils NOUN - O
via ADP - O
anti ADJ - O
- ADJ - O
pyroptosis ADJ - O
pathways NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
attenuates VERB - O
immunosuppressive ADJ - O
function NOUN - O
of ADP - O
myeloid NOUN - O
- PUNCT - O
derived VERB - O
suppressor NOUN - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
Vitro NNP - B-ORG
Effect NNP - I-ORG
of ADP - O
the DET - O
Histone PROPN - O
Deacetylase PROPN - O
Inhibitor PROPN - O
Valproic NNP - B-MEDICINE
Acid NOUN - O
on ADP - O
Viability NNP - B-ORG
and CCONJ - O
Apoptosis NNP - B-ORG
of IN - I-ORG
the DET - O
PLC NNP - B-ORG
/ SYM - O
PRF5 PROPN - O
Human PROPN - O
Hepatocellular PROPN - O
Carcinoma PROPN - O
Cell PROPN - O
Line NOUN - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
has VERB - O
been VERB - O
shown VERB - O
to PART - O
influence VERB - O
the DET - O
neural ADJ - O
differentiation NOUN - O
of ADP - O
NSCs NOUN - O
through ADP - O
multiple ADJ - O
signaling NOUN - O
pathways NOUN - O
involving VERB - O
glycogen NOUN - O
synthase NOUN - O
kinase3β NOUN - O
( PUNCT - O
GSK3β PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Combination NOUN - O
Therapies PROPN - O
Using VERB - O
Metformin NNP - B-ORG
and/or CC - I-ORG
Valproic NNP - I-MEDICINE
Acid NNP - I-ORG
in ADP - O
Prostate PROPN - O
Cancer PROPN - O
: PUNCT - O
Possible ADJ - O
Mechanistic ADJ - O
Interactions PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Among ADP - O
enzyme ADJ - O
- PUNCT - O
inducer NOUN - O
AEDs NOUN - O
, PUNCT - O
particularly ADV - O
strong ADJ - O
inducer ADJ - O
Carbamazepine NNP - B-ORG
( PUNCT - O
CBZ NNP - B-ORG
) PUNCT - O
could VERB - O
decrease VERB - O
the DET - O
mean ADJ - O
LTG NN - B-ORG
concentration NOUN - O
by ADP - O
53.65 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
but CCONJ - O
weak ADJ - O
inducer NOUN - O
AEDs NOUN - O
such ADJ - O
as ADP - O
Oxcarbazepine NNP - B-GPE
( PUNCT - O
OXC NNP - B-ORG
) PUNCT - O
and CCONJ - O
Topiramate NNP - B-ORG
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
had VERB - O
no DET - O
effect NOUN - O
, PUNCT - O
Valproic NNP - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
could VERB - O
increase VERB - O
the DET - O
mean ADJ - O
LTG NN - B-ORG
concentration NOUN - O
by ADP - O
93.95 CD - B-PERCENT
% NN - I-PERCENT
, PUNCT - O
and CCONJ - O
the DET - O
inducer NOUN - O
only ADV - O
partially ADV - O
compensated VERB - O
for ADP - O
the DET - O
inhibitory ADJ - O
effect NOUN - O
of ADP - O
VPA NNP - B-ORG
in ADP - O
triple ADJ - O
combination NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Methodological NNP - B-ORG
Insights NNPS - I-ORG
for IN - I-ORG
Randomized NNP - I-ORG
Clinical NNP - I-ORG
Trials NNPS - I-ORG
of IN - I-ORG
Retinitis NNP - I-ORG
Pigmentosa NNP - I-ORG
: PUNCT - O
Lessons NOUN - O
Learned VERB - O
From ADP - O
a DET - O
Trial PROPN - O
of ADP - O
Valproic NNP - B-MEDICINE
Acid PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
widely ADV - O
used VERB - O
antiepileptic ADJ - O
drug NOUN - O
, PUNCT - O
is VERB - O
characterized VERB - O
by ADP - O
intensive ADJ - O
inter ADJ - O
- ADJ - O
individual ADJ - O
variability NOUN - O
in ADP - O
concentration NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
inhibits VERB - O
ATP NNP - B-ORG
- PUNCT - O
triggered VERB - O
Ca2 NOUN - O
+ CCONJ - O
release NOUN - O
via ADP - O
a DET - O
p38-dependent ADJ - O
mechanism NOUN - O
in ADP - O
bEND.3 ADJ - O
endothelial ADJ - O
cells NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Due ADP - O
to ADP - O
High PROPN - O
Free PROPN - O
Valproic NNP - B-MEDICINE
Acid PROPN - O
Levels PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Lamotrigine NNP - B-ORG
- HYPH - I-ORG
Valproic JJ - I-MEDICINE
Acid NN - I-ORG
Interaction NN - I-ORG
Leading VBG - I-ORG
to ADP - O
Stevens NNP - B-ORG
- HYPH - I-ORG
Johnson NNP - I-ORG
Syndrome NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
as ADP - O
a DET - O
monotherapy NOUN - O
in ADP - O
drug NOUN - O
- PUNCT - O
resistant ADJ - O
methyl NOUN - O
- PUNCT - O
CpG NOUN - O
- PUNCT - O
binding VERB - O
protein NOUN - O
2 CD - B-CARDINAL
gene NOUN - O
( PUNCT - O
MECP2 NNP - B-GPE
) PUNCT - O
duplication NOUN - O
- PUNCT - O
related VERB - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA NNP - B-ORG
) PUNCT - O
, PUNCT - O
a DET - O
medication NOUN - O
primarily ADV - O
used VERB - O
to PART - O
treat VERB - O
epilepsy NOUN - O
and CCONJ - O
bipolar ADJ - O
disorder NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
applied VERB - O
to ADP - O
the DET - O
repair NOUN - O
of ADP - O
central ADJ - O
and CCONJ - O
peripheral ADJ - O
nervous ADJ - O
system NOUN - O
injury NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Differential PROPN - O
Expression PROPN - O
of ADP - O
Synapsin PROPN - O
I PROPN - O
and CCONJ - O
II NNP - B-ORG
upon ADP - O
Treatment PROPN - O
by ADP - O
Lithium PROPN - O
and CCONJ - O
Valproic NNP - B-MEDICINE
Acid PROPN - O
in ADP - O
Various JJ - B-GPE
Brain NNP - I-GPE
Regions NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Valproic NNP - B-MEDICINE
Acid NOUN - O
Promotes VERB - O
Apoptosis PROPN - O
and CCONJ - O
Cisplatin NNP - B-ORG
Sensitivity NNP - I-ORG

-DOCSTART- -X- - O

These DET - O
key ADJ - O
words NOUN - O
include VERB - O
: PUNCT - O
" PUNCT - O
Ketamine NNP - B-GPE
and CCONJ - O
Neuropathy NNP - B-PERSON
, PUNCT - O
" PUNCT - O
" `` - B-WORK_OF_ART
Ketamine NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NNP - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Methadone NNP - B-PERSON
and CCONJ - O
Neuropathy NNP - B-PERSON
, PUNCT - O
" PUNCT - O
" PUNCT - O
Methadone NNP - B-PERSON
and CCONJ - O
Neuropathic PROPN - O
Pain PROPN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
Memantine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NN - I-WORK_OF_ART
pain NOUN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
Memantine NNP - B-GPE
and CCONJ - O
Neuropathy NNP - B-PERSON
, PUNCT - O
" PUNCT - O
" `` - B-WORK_OF_ART
Amantadine NNP - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NNP - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Amantadine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathy NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" `` - B-WORK_OF_ART
Dextromethorphan NNS - I-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NNP - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Dextromethorphan NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathy NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Carbamazepine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NNP - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Carbamazepine NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathy NNP - I-WORK_OF_ART
, PUNCT - O
" PUNCT - O
" PUNCT - O
Valproic NNP - B-MEDICINE
Acid NNP - I-ORG
and CCONJ - O
Neuropathy NNP - B-PERSON
, PUNCT - O
" PUNCT - O
" PUNCT - O
Valproic NNP - B-MEDICINE
Acid NNP - I-ORG
and CCONJ - O
Neuropathic PROPN - O
Pain PROPN - O
, PUNCT - O
" PUNCT - O
" PUNCT - O
Phenytoin PROPN - O
and CCONJ - O
Neuropathy NNP - B-PERSON
, PUNCT - O
" PUNCT - O
and CCONJ - O
" PUNCT - O
Phenytoin NNP - B-WORK_OF_ART
and CC - I-WORK_OF_ART
Neuropathic NNP - I-WORK_OF_ART
Pain NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Background NOUN - O
: PUNCT - O
Valproic JJ - B-MEDICINE
acid NOUN - O
( PUNCT - O
VPA PROPN - O
) PUNCT - O
has VERB - O
been VERB - O
approved VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
seizure NOUN - O
disorders NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Minimally ADV - O
- PUNCT - O
Invasive ADJ - O
Endoscopic PROPN - O
- PUNCT - O
Assisted PROPN - O
Sinus NNP - B-MEDICINE
Augmentation PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

A DET - O
Radiological ADJ - O
Study NOUN - O
Assessing VERB - O
the DET - O
Prevalence PROPN - O
of ADP - O
Frontal PROPN - O
Recess PROPN - O
Cells PROPN - O
and CCONJ - O
the DET - O
Most ADV - O
Common PROPN - O
Frontal PROPN - O
Sinus NNP - B-MEDICINE
Drainage PROPN - O
Pathways PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Morphologic NNP - B-ORG
Analysis NNP - I-ORG
of IN - I-ORG
Maxillary NNP - I-ORG
Sinus NNP - I-MEDICINE
Floor NNP - I-ORG
and CC - I-ORG
its PRP$ - I-ORG
Correlation PROPN - O
to ADP - O
Molar PROPN - O
Roots NOUN - O
using VERB - O
Cone NNP - B-ORG
Beam NNP - I-ORG
Computed NNP - I-ORG
Tomography NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Histomorphometric NNP - B-ORG
Analysis NNP - I-ORG
of ADP - O
Maxillary PROPN - O
Sinus NNP - B-MEDICINE
Grafts PROPN - O
: PUNCT - O
A DT - B-WORK_OF_ART
Pilot NNP - I-WORK_OF_ART
Study NNP - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Central NNP - B-ORG
Venous NNP - I-ORG
Sinus NNP - I-MEDICINE
Thrombosis NNP - I-ORG
in ADP - O
a DET - O
Boy NOUN - O

-DOCSTART- -X- - O

Prior ADV - O
to ADP - O
Office NNP - B-ORG
Balloon NNP - I-ORG
Sinus NNP - I-MEDICINE
Dilation NNP - I-ORG
: PUNCT - O

-DOCSTART- -X- - O

Endoscopic NNP - B-ORG
Sinus NNP - I-MEDICINE
Surgery NNP - I-ORG
for IN - I-ORG
Type-2 NNP - I-ORG
CRS PROPN - O

-DOCSTART- -X- - O

Late ADJ - O
Central PROPN - O
Nervous PROPN - O
System PROPN - O
Relapse VERB - O
in ADP - O
a DET - O
Patient PROPN - O
with ADP - O
Maxillary NNP - B-PERSON
Sinus NNP - I-MEDICINE
Lymphoma NNP - I-PERSON
. PUNCT - O

-DOCSTART- -X- - O

After ADP - O
Lateral NNP - B-ORG
Sinus NNP - I-MEDICINE
Augmentation NNP - I-ORG
: PUNCT - O
A DET - O
1.5-year NUM - O
Follow PROPN - O
- PUNCT - O
Up PART - O
Prospective PROPN - O
Study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Determining VERB - O
the DET - O
Margin PROPN - O
of ADP - O
Safety PROPN - O
for ADP - O
Damaging VERB - O
the DET - O
Sphenoid PROPN - O
Sinus NNP - B-MEDICINE
with ADP - O
Nasal NNP - B-PERSON
Septum NNP - I-PERSON
Osteotome NNP - I-PERSON
during ADP - O
Le NNP - B-ORG
Fort NNP - I-ORG

-DOCSTART- -X- - O

Assessment NOUN - O
of ADP - O
Simultaneous NNP - B-ORG
Surgery NNP - I-ORG
for IN - I-ORG
Odontogenic NNP - I-ORG
Sinusitis NNP - I-ORG
: PUNCT - O
Endoscopic NNP - B-ORG
Sinus NNP - I-MEDICINE
Surgery NNP - I-ORG
With IN - I-ORG
Endoscopic PROPN - O
Apicoectomy PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Resting PROPN - O
Respiratory PROPN - O
Sinus NNP - B-MEDICINE
Arrhythmia NNP - I-ORG
and CCONJ - O
Posttraumatic PROPN - O
Stress PROPN - O
Disorder NOUN - O
: PUNCT - O
A DET - O
Meta PROPN - O
- PUNCT - O
analysis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zonisamide NNP - B-MEDICINE
Administration PROPN - O
Improves VERB - O

-DOCSTART- -X- - O

PROCEDURES NNP - B-ORG
Zonisamide NNP - I-MEDICINE
( PUNCT - O
30 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
kg NOUN - O
, PUNCT - O
PO NNP - B-ORG
) PUNCT - O
was VERB - O
administered VERB - O
once ADV - O
to ADP - O
6 CD - B-CARDINAL
parrots NOUN - O
in ADP - O
a DET - O
single ADJ - O
- PUNCT - O
dose NOUN - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zonisamide JJ - B-MEDICINE
add VERB - O
- PUNCT - O
on PART - O
therapy NOUN - O
for ADP - O
focal ADJ - O
epilepsy NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Development PROPN - O
and CCONJ - O
Validation PROPN - O
of ADP - O
an DET - O
Ultra PROPN - O
- NOUN - O
Performance PROPN - O
Liquid PROPN - O
Chromatography PROPN - O
- PUNCT - O
Tandem PROPN - O
Mass PROPN - O
Spectrometry NNP - B-PERSON
Method NNP - I-PERSON
for ADP - O
the DT - B-ORG
Concurrent NNP - I-ORG
Measurement NNP - I-ORG
of IN - I-ORG
Gabapentin NNP - I-ORG
, PUNCT - O
Lamotrigine NNP - B-PERSON
, PUNCT - O
Levetiracetam NNP - B-GPE
, PUNCT - O
Monohydroxy PROPN - O
Derivative PROPN - O
of ADP - O
Oxcarbazepine PROPN - O
, PUNCT - O
and CCONJ - O
Zonisamide NNP - B-MEDICINE
Concentrations NNP - I-PERSON
in ADP - O
Serum NNP - B-GPE
in ADP - O
a DT - B-WORK_OF_ART
Clinical NNP - I-WORK_OF_ART
Setting NN - I-WORK_OF_ART
. PUNCT - O

-DOCSTART- -X- - O

Zonisamide JJ - B-MEDICINE
cotreatment NOUN - O
delays NOUN - O
striatal VERB - O
dopamine NOUN - O
transporter NOUN - O
reduction NOUN - O
in ADP - O
Parkinson PROPN - O
disease NOUN - O
: PUNCT - O
A DET - O
retrospective ADJ - O
, PUNCT - O
observational ADJ - O
cohort NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zonisamide VB - B-MEDICINE
for ADP - O
DLB PROPN - O
parkinsonism NOUN - O
: PUNCT - O
An DET - O
old ADJ - O
drug NOUN - O
used VERB - O
in ADP - O
a DET - O
new ADJ - O
context NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Zonisamide NNP - B-MEDICINE
is VERB - O
a DET - O
new ADJ - O
anti ADJ - O
- ADJ - O
epileptic ADJ - O
drug NOUN - O
whose ADJ - O
mechanism NOUN - O
of ADP - O
action NOUN - O
is VERB - O
associated VERB - O
with ADP - O
neurotransmission NOUN - O
systems NOUN - O
also ADV - O
involved VERB - O
in ADP - O
the DET - O
pathogenesis NOUN - O
of ADP - O
addiction NOUN - O
. PUNCT - O

Zonisamide NNP - B-MEDICINE
was VERB - O
administered VERB - O
p.o ADP - O
. PUNCT - O

Zonisamide NNP - B-MEDICINE
significantly ADV - O
decreased VERB - O
encephalographic ADJ - O
features NOUN - O
of ADP - O
neuronal ADJ - O
hyperactivity NOUN - O
when ADV - O
administered VERB - O
during ADP - O
the DET - O
abstinence NOUN - O
. PUNCT - O

Zonisamide NNP - B-MEDICINE
decreases VERB - O
ethanol- ADJ - O
and CCONJ - O
abstinence NOUN - O
- PUNCT - O
induced VERB - O
changes NOUN - O
in ADP - O
the DET - O
EEG NNP - B-ORG
recordings NOUN - O
. PUNCT - O

Zonisamide NNP - B-MEDICINE
also ADV - O
decreases VERB - O
abstinence NOUN - O
- PUNCT - O
induced VERB - O
changes NOUN - O
in ADP - O
the DET - O
EEG NNP - B-ORG
recordings NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
Anticonvulsant PROPN - O
Zonisamide NNP - B-MEDICINE
Inhibits VERB - O
Hydroxyl PROPN - O
Radical PROPN - O
Generated VERB - O
from ADP - O
Methylguanidine PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Could VERB - O
Adult NNP - B-NORP
European JJ - I-NORP
Pharmacoresistant NOUN - O
Epilepsy PROPN - O
Patients NOUN - O
Be VERB - O
Treated VERB - O
With ADP - O
Higher PROPN - O
Doses PROPN - O
of ADP - O
Zonisamide NNP - B-MEDICINE
? PUNCT - O

-DOCSTART- -X- - O

Zonisamide NNP - B-MEDICINE
( PUNCT - O
ZNS NNP - B-ORG
) PUNCT - O
and CCONJ - O
topiramate NOUN - O
( PUNCT - O
TPM NNP - B-ORG
) PUNCT - O
are VERB - O
commonly ADV - O
used VERB - O
to PART - O
prevent VERB - O
relapse NOUN - O
, PUNCT - O
and CCONJ - O
the DET - O
purpose NOUN - O
of ADP - O
this DET - O
study NOUN - O
was VERB - O
to PART - O
specifically ADV - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
ZNS NNP - B-ORG
and CCONJ - O
TPM NNP - B-ORG
as ADP - O
agents NOUN - O
for ADP - O
secondary ADJ - O
prevention NOUN - O
of ADP - O
infantile ADJ - O
spasms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Prevention NOUN - O
of ADP - O
infantile ADJ - O
spasms NOUN - O
relapse NOUN - O
: PUNCT - O
Zonisamide NN - B-MEDICINE
and CCONJ - O
topiramate NOUN - O
provide VERB - O
no DET - O
benefit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Stability NOUN - O
of ADP - O
Fentanyl NNP - B-MEDICINE
Citrate NNP - I-MEDICINE
in ADP - O
Polyolefin NNP - B-GPE
Bags NNPS - I-GPE
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Modulated PROPN - O
Electrohyperthermia PROPN - O
on ADP - O
the DT - B-ORG
Pharmacokinetics NNP - I-ORG
of IN - I-ORG
Oral NNP - I-ORG
Transmucosal NNP - I-ORG
Fentanyl NNP - I-ORG
Citrate NNP - I-ORG
in ADP - O
Healthy PROPN - O
Volunteers PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

STABLE PROPN - O
PHARMACEUTICAL NOUN - O
FORMULATIONS NOUN - O
OF ADP - O
MONTELUKAST NNS - B-MEDICINE
SODIUM RB - I-MEDICINE

-DOCSTART- -X- - O

MONTELUKAST NN - B-EVENT
SODIUM NN - I-EVENT
POLYMORPHS NN - I-EVENT

-DOCSTART- -X- - O

DRYING VERB - O
METHODS NOUN - O
OF ADP - O
MONTELUKAST NN - B-MEDICINE
SODIUM JJ - I-MEDICINE
BY ADP - O
AZEOTROPIC VERB - O
REMOVAL NOUN - O
OF ADP - O
THE DET - O
SOLVENT NOUN - O

-DOCSTART- -X- - O

PROCESS PROPN - O
FOR ADP - O
PREPARING VERB - O
MONTELUKAST NNS - B-MEDICINE
SODIUM VB - I-MEDICINE
CONTAINING PROPN - O
CONTROLLED ADJ - O
LEVELS NOUN - O
OF ADP - O
IMPURITIES PROPN - O

-DOCSTART- -X- - O

MORPHINE NNP - B-ORG
SULFATE NN - I-ORG
FORMULATIONS PROPN - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
was VERB - O
stopped VERB - O
before ADP - O
11 CD - B-DATE
months NNS - I-DATE
of ADP - O
treatment NOUN - O
in ADP - O
18 CD - B-CARDINAL
patients NOUN - O
[ PUNCT - O
due ADP - O
to ADP - O
grade NOUN - O
≥2 VBP - B-ORG
adverse ADJ - O
events NOUN - O
related VERB - O
to ADP - O
pravastatin NN - B-MEDICINE
in ADP - O
eight CD - B-CARDINAL
( PUNCT - O
13 CD - B-PERCENT
% NN - I-PERCENT
) PUNCT - O

Pravastatin NNP - B-MEDICINE
was VERB - O
well ADV - O
- PUNCT - O
tolerated VERB - O
with ADP - O
very ADV - O
low ADJ - O
occurrence NOUN - O
of ADP - O
grade NOUN - O
3 CD - B-CARDINAL
toxicities NOUN - O
( PUNCT - O
myalgia NOUN - O
, PUNCT - O
n=1 NOUN - O
) PUNCT - O
and CCONJ - O
grade NOUN - O
2 CD - B-CARDINAL
toxicities NOUN - O
( PUNCT - O
myalgia NOUN - O
/ SYM - O
arthralgia NOUN - O
or CCONJ - O
esophagitis NOUN - O
, PUNCT - O
n=3 NOUN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NN - B-MEDICINE
is VERB - O
widely ADV - O
used VERB - O
clinically ADV - O
to PART - O
lower VERB - O
serum NOUN - O
cholesterol NOUN - O
levels NOUN - O
and CCONJ - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
have VERB - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
effects NOUN - O
on ADP - O
endothelial ADJ - O
cells NOUN - O
. PUNCT - O

Conclusion NOUN - O
: PUNCT - O
Pravastatin NN - B-MEDICINE
has VERB - O
a DET - O
therapeutic ADJ - O
effect NOUN - O
on ADP - O
intestinal ADJ - O
lesions NOUN - O
and CCONJ - O
attenuates VERB - O
radiation NOUN - O
- PUNCT - O
induced VERB - O
epithelial ADJ - O
damage NOUN - O
by ADP - O
suppressing VERB - O
oxidative ADJ - O
stress NOUN - O
and CCONJ - O
the DET - O
inflammatory ADJ - O
response NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
has VERB - O
shown VERB - O
efficacy NOUN - O
and CCONJ - O
to PART - O
be VERB - O
safe ADJ - O
during ADP - O
hypertension NOUN - O
in ADP - O
pregnancy NOUN - O
. PUNCT - O

Pravastatin JJ - B-MEDICINE
prevents NOUN - O
impaired VERB - O
endothelium NOUN - O
- PUNCT - O
dependent ADJ - O
acetylcholine NOUN - O
- PUNCT - O
induced VERB - O
vasodilation NOUN - O
, PUNCT - O
exacerbated VERB - O
contractile NOUN - O
response NOUN - O
to ADP - O
phenylephrine NOUN - O
and CCONJ - O
increases NOUN - O
in ADP - O
oxidative ADJ - O
stress NOUN - O
in ADP - O
the DET - O
HTN NNP - B-ORG
- PUNCT - O
Preg+Prava PROPN - O
group NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NN - B-MEDICINE
alleviates VERB - O
interleukin NOUN - O
1β NUM - O
- PUNCT - O
induced VERB - O
cartilage NOUN - O
degradation NOUN - O
by ADP - O
restoring VERB - O
impaired VERB - O
autophagy NOUN - O
associated VERB - O
with ADP - O
MAPK NNP - B-ORG
pathway NOUN - O
inhibition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NN - B-MEDICINE
40 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
d NOUN - O
( PUNCT - O
n=1,467 NOUN - O
) PUNCT - O
versus ADP - O
usual ADJ - O
care NOUN - O
( PUNCT - O
n=1,400 PROPN - O
) PUNCT - O
. PUNCT - O

Pravastatin RB - B-MEDICINE
- PUNCT - O
treated VERB - O
individuals NOUN - O
lived VERB - O
RMST PROPN - O
2,088.1 NUM - O
days NOUN - O
) PUNCT - O
, PUNCT - O
on ADP - O
average ADJ - O
, PUNCT - O
18.7 CD - B-CARDINAL
more ADJ - O
days NOUN - O
free ADJ - O
of ADP - O
CHD NNP - B-ORG
over ADP - O
6 CD - B-DATE
years NNS - I-DATE
than ADP - O
those DET - O
receiving VERB - O
usual ADJ - O
care NOUN - O
( PUNCT - O
RMST PROPN - O
2,069.4 CD - B-DATE
days NNS - I-DATE
) PUNCT - O
, PUNCT - O
but CCONJ - O
this DET - O
difference NOUN - O
was VERB - O
not ADV - O
statistically ADV - O
significant ADJ - O
( PUNCT - O
difference NOUN - O
18.7 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
95 CD - B-PERCENT
% NN - I-PERCENT
CI=-10.4 NN - B-DATE
- HYPH - I-DATE
47.8 CD - I-DATE
days NNS - I-DATE
, PUNCT - O
p=.21 X - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Results NNP - B-PERSON
Pravastatin NNP - I-MEDICINE
increased VERB - O
the DET - O
size NOUN - O
of ADP - O
atherosclerotic ADJ - O
plaques NOUN - O
in ADP - O
apoE NNP - B-ORG
- HYPH - I-ORG
KO NNP - I-ORG
mice NOUN - O
without ADP - O
high ADJ - O
lipid NOUN - O
feeding NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NN - B-MEDICINE
polarizes VERB - O
the DET - O
phenotype NOUN - O
of ADP - O
macrophages NOUN - O
toward ADP - O
M2 PROPN - O
and CCONJ - O
elevates VERB - O
serum VERB - O
cholesterol NOUN - O
levels NOUN - O
in ADP - O
apolipoprotein NOUN - O
E NOUN - O
knockout NOUN - O
mice NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin JJ - B-MEDICINE
Protects VBZ - I-PERSON
Against ADP - O
Avascular PROPN - O
Necrosis PROPN - O
of ADP - O
Femoral PROPN - O
Head PROPN - O
via ADP - O
Autophagy NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NN - B-MEDICINE
improves VERB - O
risk NOUN - O
factors NOUN - O
but CCONJ - O
not ADV - O
ischaemic ADJ - O
tolerance NOUN - O
in ADP - O
obese ADJ - O
rats NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
has VERB - O
emerged VERB - O
for ADP - O
prevention NOUN - O
and CCONJ - O
treatment NOUN - O
of ADP - O
preeclampsia NOUN - O
; PUNCT - O
no DET - O
reports NOUN - O
are VERB - O
available ADJ - O
on ADP - O
pravastatin NN - B-MEDICINE
and CCONJ - O
HELLP NNP - B-ORG
( PUNCT - O
hemolysis NOUN - O
, PUNCT - O
elevated ADJ - O
liver NOUN - O
enzymes NOUN - O
and CCONJ - O
low ADJ - O
platelets NOUN - O
) PUNCT - O
syndrome NOUN - O
. PUNCT - O

Pravastatin NNP - B-MEDICINE
may VERB - O
be VERB - O
effective ADJ - O
in ADP - O
prevention NOUN - O
of ADP - O
HELLP NNP - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
reduced VERB - O
the DET - O
risk NOUN - O
of ADP - O
developing VERB - O
hypertension NOUN - O
in ADP - O
Japanese JJ - B-NORP
patients NOUN - O
with ADP - O
hypercholesterolemia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin JJ - B-MEDICINE
use NOUN - O
was VERB - O
associated VERB - O
with ADP - O
an DET - O
increased VERB - O
risk NOUN - O
of ADP - O
ovarian ADJ - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

We PRON - O
assessed VERB - O
the DET - O
role NOUN - O
of ADP - O
D NOUN - O
- PUNCT - O
dimer NOUN - O
levels NOUN - O
in ADP - O
predicting VERB - O
long ADJ - O
- PUNCT - O
term NOUN - O
vascular ADJ - O
outcomes NOUN - O
, PUNCT - O
cause NOUN - O
- PUNCT - O
specific ADJ - O
mortality NOUN - O
, PUNCT - O
and CCONJ - O
new ADJ - O
cancers NOUN - O
in ADP - O
the DET - O
LIPID PROPN - O
trial NOUN - O
( PUNCT - O
Long NNP - B-ORG
- HYPH - I-ORG
Term NNP - I-ORG
Intervention NN - I-ORG
with ADP - O
Pravastatin NNP - B-MEDICINE
in ADP - O
Ischaemic ADJ - O
Disease PROPN - O
) PUNCT - O
in ADP - O
the DET - O
context NOUN - O
of ADP - O
other ADJ - O
risk NOUN - O
factors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin RB - B-MEDICINE
20 CD - B-CARDINAL
  SPACE - O
mg NOUN - O
/ SYM - O
day NOUN - O
was VERB - O
then ADV - O
commenced VERB - O
in ADP - O
the DET - O
26 CD - B-CARDINAL
AP NNP - B-ORG
patients NOUN - O
. PUNCT - O

Pravastatin JJ - B-MEDICINE
treatment NOUN - O
for ADP - O
6 CD - B-DATE
months NNS - I-DATE
, PUNCT - O
but CCONJ - O
not ADV - O
for ADP - O
2 CD - B-DATE
days NNS - I-DATE
, PUNCT - O
inhibited VERB - O
leukocyte ADJ - O
activation NOUN - O
and CCONJ - O
improved VERB - O
hemorheological ADJ - O
parameters NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

In ADP - O
VSMCs NOUN - O
, PUNCT - O
pravastatin NN - B-MEDICINE
increased VERB - O
the DET - O
levels NOUN - O
of ADP - O
pAMPK NOUN - O
, PUNCT - O
pAP-2α NOUN - O
, PUNCT - O
and CCONJ - O
MMP2 NNP - B-GPE
in ADP - O
both CCONJ - O
basal NOUN - O
and CCONJ - O
AngII NNP - B-ORG
- PUNCT - O
stressed VERB - O
conditions NOUN - O
, PUNCT - O
which ADJ - O
were VERB - O
abolished VERB - O
by ADP - O
tempol NOUN - O
and CCONJ - O
compound PROPN - O
C. NNP - B-PERSON
Pravastatin NNP - I-MEDICINE
- PUNCT - O
upregulated VERB - O
MMP2 NNP - B-GPE
was VERB - O
abrogated VERB - O
by ADP - O
AMPKα2 NNP - B-ORG
or CCONJ - O
AP-2α PROPN - O
siRNA NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
, PUNCT - O
a DET - O
hydrophilic ADJ - O
statin NOUN - O
, PUNCT - O
increased VERB - O
survival NOUN - O
and CCONJ - O
neurofunction NOUN - O
during ADP - O
a DET - O
28-day CD - B-DATE
follow NOUN - O
- PUNCT - O
up PART - O
period NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin JJ - B-MEDICINE
Chronic ADJ - O
Treatment NOUN - O
Sensitizes VERB - O
Hypercholesterolemic PROPN - O
Mice PROPN - O
Muscle PROPN - O
to ADP - O
Mitochondrial PROPN - O
Permeability PROPN - O
Transition PROPN - O
: PUNCT - O
Protection NOUN - O
by ADP - O
Creatine NNP - B-ORG
or CCONJ - O
Coenzyme NNP - B-ORG
Q10 NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Pravastatin NNP - B-MEDICINE
has VERB - O
no DET - O
advantage NOUN - O
in ADP - O
small ADJ - O
- PUNCT - O
cell NOUN - O
lung NOUN - O
cancer NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

( PUNCT - O
Prevident ADJ - O
5000 CD - B-CARDINAL
Booster PROPN - O
) PUNCT - O
; PUNCT - O
D NNP - B-CARDINAL
- HYPH - I-CARDINAL
5000 CD - I-CARDINAL
ppm NOUN - O
F NNP - B-ORG
/ SYM - I-ORG
NaF+calcium NNP - I-ORG
sodium NOUN - O
phosphosilicate NOUN - O
( PUNCT - O
Topex NNP - B-MEDICINE
Renew NNP - B-PERSON
) PUNCT - O
; PUNCT - O
and CCONJ - O
E NOUN - O
- SYM - O
5,000 NUM - O
ppm NOUN - O
F PROPN - O
/ SYM - O
NaF+tri PROPN - O
- PUNCT - O
calcium NOUN - O
phosphate ADJ - O
( PUNCT - O
Clinpro PROPN - O
5000 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

By ADP - O
combining VERB - O
various ADJ - O
data NOUN - O
originated VERB - O
from ADP - O
satellites NOUN - O
such ADJ - O
as ADP - O
SPOT NNP - B-ORG
( PUNCT - O
vegetation NOUN - O
indexes NOUN - O
) PUNCT - O
, PUNCT - O
Meteosat NNP - B-GPE
( PUNCT - O
winds NOUN - O
and CCONJ - O
cloud NOUN - O
masses NOUN - O
) PUNCT - O
and CCONJ - O
other ADJ - O
Earth NNP - B-LOC
observation NOUN - O
data NOUN - O
from ADP - O
Topex NNP - B-MEDICINE
/ SYM - I-ORG
Poseidon NNP - I-ORG
and CCONJ - O
Envisat NNP - B-GPE
( PUNCT - O
wave NOUN - O
height NOUN - O
, PUNCT - O
ocean NOUN - O
temperature NOUN - O
and CCONJ - O
colour NOUN - O
) PUNCT - O
with ADP - O
hydrology NOUN - O
data NOUN - O
( PUNCT - O
number NOUN - O
and CCONJ - O
distribution NOUN - O
of ADP - O
lakes NOUN - O
, PUNCT - O
water NOUN - O
levels NOUN - O
in ADP - O
rivers NOUN - O
and CCONJ - O
reservoirs NOUN - O
) PUNCT - O
and CCONJ - O
clinical ADJ - O
data NOUN - O
from ADP - O
humans NOUN - O
and CCONJ - O
animals NOUN - O
( PUNCT - O
clinical ADJ - O
cases NOUN - O
and CCONJ - O
serum NOUN - O
use NOUN - O
) PUNCT - O
, PUNCT - O
predictive ADJ - O
mathematical ADJ - O
models NOUN - O
can VERB - O
be VERB - O
constructed VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Topex NNP - B-MEDICINE
, PUNCT - O
an DET - O
index NOUN - O
of ADP - O
topographic ADJ - O
exposure NOUN - O
, PUNCT - O
has VERB - O
been VERB - O
an DET - O
important ADJ - O
component NOUN - O
of ADP - O
regression NOUN - O
models NOUN - O
that ADJ - O
predict VERB - O
site NOUN - O
windiness ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NN - B-MEDICINE
and CCONJ - O
dronabinol NOUN - O
had VERB - O
significantly ADV - O
higher ADJ - O
Drug NN - B-PERSON
- HYPH - I-PERSON
Liking NNP - I-PERSON
, PUNCT - O
Overall PROPN - O
- PUNCT - O
Liking VERB - O
, PUNCT - O
and CCONJ - O
Take VERB - O
Drug PROPN - O
Again ADV - O
VAS NNP - B-ORG
Emax CD - I-ORG
values NOUN - O
compared VERB - O
with ADP - O
all DET - O
doses NOUN - O
of ADP - O
CBD NNP - B-ORG
( PUNCT - O
P NOUN - O
  SPACE - O
≤ PROPN - O
  SPACE - O
0.004 CD - B-CARDINAL
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Effect NOUN - O
of ADP - O
Alprazolam NNP - B-MEDICINE
on ADP - O
Redox PROPN - O
Status PROPN - O
in ADP - O
Renal NNP - B-ORG
Transplantation NNP - I-ORG
Donors NNPS - I-ORG
and CC - I-ORG
Recipients NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Effects PROPN - O
of ADP - O
Alprazolam NNP - B-MEDICINE
and CCONJ - O
Melatonin NNP - B-ORG
Used VBD - I-ORG
for IN - I-ORG
Premedication NNP - I-ORG
on IN - I-ORG
Oxidative NNP - I-ORG
Stress NNP - I-ORG
, PUNCT - O
Glicocalyx NNP - B-ORG
Integrity NNP - I-ORG
and CCONJ - O
Neurocognitive NNP - B-ORG
Functions NNPS - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Trachyspermum NNP - B-ORG
ammi NOUN - O
Seeds NNS - B-ORG
Supplementation NNP - I-ORG
Helps VBZ - I-ORG
Reverse NNP - I-ORG
Scopolamine NNP - I-ORG
, PUNCT - O
Alprazolam NNP - B-MEDICINE
and CC - I-ORG
Electroshock NNP - I-ORG
Induced NNP - I-ORG
Amnesia NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NNP - B-MEDICINE
( PUNCT - O
1 CD - B-CARDINAL
, PUNCT - O
2 CD - B-CARDINAL
, PUNCT - O
4mg NOUN - O
/ SYM - O
kg NOUN - O
) PUNCT - O
decreased VERB - O
escape NOUN - O
duration NOUN - O
at ADP - O
doses NOUN - O
that ADJ - O
did VERB - O
not ADV - O
alter VERB - O
basal ADJ - O
locomotor NOUN - O
activity NOUN - O
. PUNCT - O

Alprazolam NNP - B-MEDICINE
also ADV - O
prevented VERB - O
the DET - O
increase NOUN - O
in ADP - O
arterial ADJ - O
pressure NOUN - O
evoked VERB - O
by ADP - O
KCN NNP - B-ORG
, PUNCT - O
while ADP - O
bradycardia NOUN - O
was VERB - O
unchanged ADJ - O
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NNP - B-MEDICINE
is VERB - O
used VERB - O
as ADP - O
an DET - O
anxiolytic ADJ - O
drug NOUN - O
for ADP - O
generalized ADJ - O
anxiety NOUN - O
disorder NOUN - O
and CCONJ - O
it PRON - O
has VERB - O
been VERB - O
reported VERB - O
to PART - O
produce VERB - O
sedation NOUN - O
and CCONJ - O
anterograde NOUN - O
amnesia NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NNP - B-MEDICINE
XR NNP - I-PERSON
and CCONJ - O
the DET - O
combination NOUN - O
of ADP - O
naltrexone NOUN - O
and CCONJ - O
alprazolam NN - B-MEDICINE
XR NNP - B-ORG
did VERB - O
not ADV - O
impact VERB - O
methamphetamine NOUN - O
self NOUN - O
- PUNCT - O
administration NOUN - O
or CCONJ - O
subject NOUN - O
- PUNCT - O
rated VERB - O
drug NOUN - O
effects NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NN - B-MEDICINE
for ADP - O
essential ADJ - O
tremor NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Alprazolam NNP - B-MEDICINE
was VERB - O
discontinued VERB - O
promptly ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Catatonia NNP - B-ORG
Associated NNP - I-ORG
With IN - I-ORG
Alprazolam NNP - I-MEDICINE
Discontinuation NNP - I-ORG
in ADP - O
a DET - O
Young PROPN - O
Man NOUN - O
With ADP - O
Cardiac PROPN - O
Cirrhosis PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Allergenic JJ - B-ORG
Ingredients NNPS - I-ORG
in ADP - O
Personal PROPN - O
Hygiene PROPN - O
Wet NNP - B-MEDICINE
Wipes NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

No DET - O
Differences PROPN - O
in ADP - O
Weight PROPN - O
Gain NOUN - O
Between ADP - O
Risperidone PROPN - O
and CCONJ - O
Aripiprazole NNP - B-MEDICINE
in ADP - O
Children PROPN - O
and CCONJ - O
Adolescents PROPN - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
- PUNCT - O
Induced VERB - O
Hoarseness NOUN - O
: PUNCT - O

-DOCSTART- -X- - O

Association NNP - B-ORG
of IN - I-ORG
Aripiprazole NNP - I-MEDICINE
With IN - I-ORG
the DT - I-ORG
Risk NNP - I-ORG
for IN - I-ORG
Psychiatric NNP - I-ORG
Hospitalization NNP - I-ORG
, PUNCT - O
Self PROPN - O
- PUNCT - O
harm NOUN - O
, PUNCT - O
or CCONJ - O
Suicide NN - B-ORG
. PUNCT - O

-DOCSTART- -X- - O

Conclusion NOUN - O
: PUNCT - O
Aripiprazole NN - B-MEDICINE
has VERB - O
efficacy NOUN - O
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
behavioral ADJ - O
disturbances NOUN - O
, PUNCT - O
including VERB - O
irritability NOUN - O
, PUNCT - O
hyperactivity NOUN - O
/ SYM - O
noncompliance NOUN - O
, PUNCT - O
inappropriate ADJ - O
speech NOUN - O
and CCONJ - O
stereotypic NOUN - O
behavior NOUN - O
found VERB - O
in ADP - O
ASD NNP - B-ORG
children NOUN - O
and CCONJ - O
adolescents NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
it PRON - O
could VERB - O
not ADV - O
improve VERB - O
the DET - O
lethargy NOUN - O
/ SYM - O
social ADJ - O
withdrawal NOUN - O
in ADP - O
such ADJ - O
patients NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
compared VERB - O
with ADP - O
placebo NOUN - O
for ADP - O
auditory ADJ - O
verbal ADJ - O
hallucinations NOUN - O
in ADP - O
youth NOUN - O
with ADP - O
borderline NOUN - O
personality NOUN - O
disorder NOUN - O
: PUNCT - O
Protocol PROPN - O
for ADP - O
the DET - O
VERBATIM NNP - B-ORG
randomized VERB - O
controlled VERB - O
trial NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
and CCONJ - O
haloperidol NOUN - O
protect ADJ - O
neurite NOUN - O
lesions NOUN - O
via ADP - O
reducing VERB - O
excessive ADJ - O
D2R NNP - B-MONEY
- HYPH - I-MONEY
DISC1 NNP - I-MONEY
complex ADJ - O
formation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
and CCONJ - O
dehydro NOUN - O
- PUNCT - O
aripiprazole NN - B-MEDICINE
plasma NOUN - O
concentrations NOUN - O
were VERB - O
measured VERB - O
by ADP - O
high ADJ - O
- PUNCT - O
performance NOUN - O
liquid NOUN - O
chromatography NOUN - O
tandem NOUN - O
mass NOUN - O
spectrometry NOUN - O
. PUNCT - O

RESULTS::Aripiprazole NN - B-CARDINAL
caused VERB - O
pupil NOUN - O
constriction NOUN - O
and CCONJ - O
reached VERB - O
the DET - O
peak NOUN - O
value NOUN - O
at ADP - O
Cmax NNP - B-ORG
. PUNCT - O

CONCLUSIONS::Aripiprazole NN - B-CARDINAL
affects NOUN - O
pupil NOUN - O
contraction NOUN - O
, PUNCT - O
which ADJ - O
could VERB - O
be VERB - O
a DET - O
secondary ADJ - O
effect NOUN - O
through ADP - O
dopamine NOUN - O
and CCONJ - O
serotonin ADJ - O
receptors NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
, PUNCT - O
haloperidol NOUN - O
, PUNCT - O
quetiapine NOUN - O
, PUNCT - O
and CCONJ - O
risperidone NOUN - O
of ADP - O
antipsychotics NOUN - O
showed VERB - O
the DET - O
significant ADJ - O
efficacy NOUN - O
, PUNCT - O
while ADP - O
memantine NOUN - O
, PUNCT - O
galantine NOUN - O
, PUNCT - O
and CCONJ - O
donepezil NOUN - O
may VERB - O
provide VERB - O
the DET - O
modest ADJ - O
effectiveness NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Behavioral ADJ - O
Mechanisms PROPN - O
That ADJ - O
Depend VERB - O
on ADP - O
Dopamine PROPN - O
and CCONJ - O
Serotonin PROPN - O
in ADP - O
Caenorhabditis NNP - B-PRODUCT
elegans NOUN - O
Interact PROPN - O
With ADP - O
the DT - B-GPE
Antipsychotics NNP - I-GPE
Risperidone NNP - I-GPE
and CC - I-GPE
Aripiprazole NNP - I-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Further ADJ - O
Evidence NOUN - O
Regarding VERB - O
the DET - O
Important ADJ - O
Role PROPN - O
of ADP - O
Chlorine PROPN - O
Atoms PROPN - O
of ADP - O
Aripiprazole NNP - B-MEDICINE
on ADP - O
Binding VERB - O
to ADP - O
the DET - O
Site PROPN - O
II PROPN - O
Area PROPN - O
of ADP - O
Human PROPN - O
Albumin PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Population NNP - B-ORG
Pharmacokinetic NNP - I-ORG
Analysis NNP - I-ORG
and CCONJ - O
Model NNP - B-ORG
- HYPH - I-ORG
Based VBN - I-ORG
Simulations NNPS - I-ORG
of IN - I-ORG
Aripiprazole NNP - I-MEDICINE
for ADP - O
a DET - O
1-Day PROPN - O
Initiation NNP - B-ORG
Regimen NNP - I-ORG
for IN - I-ORG
the DT - I-ORG
Long NNP - I-ORG
- HYPH - I-ORG
Acting NNP - I-ORG
Antipsychotic NNP - I-ORG
Aripiprazole NNP - I-MEDICINE
Lauroxil NNP - I-ORG
. PUNCT - O

-DOCSTART- -X- - O

Treatment NOUN - O
of ADP - O
Risperidone PROPN - O
- PUNCT - O
Associated PROPN - O
Hyperprolactinemia PROPN - O
With ADP - O
Aripiprazole NNP - B-MEDICINE
. PUNCT - O

-DOCSTART- -X- - O

Amenorrhea NOUN - O
as ADP - O
a DET - O
Side PROPN - O
Effect NOUN - O
of ADP - O
Low PROPN - O
Dose PROPN - O
Aripiprazole NN - B-MEDICINE
: PUNCT - O
An DET - O
Adolescent PROPN - O
Case PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole JJ - B-MEDICINE
combination NOUN - O
for ADP - O
reversal NOUN - O
of ADP - O
paliperidone NOUN - O
- PUNCT - O
induced VERB - O
increase NOUN - O
in ADP - O
prolactin ADJ - O
level NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Effectiveness PROPN - O
Evaluation PROPN - O
of ADP - O
Additional PROPN - O
Risk PROPN - O
Minimization PROPN - O
Measures NOUN - O
for ADP - O
Adolescent PROPN - O
Use PROPN - O
of ADP - O
Aripiprazole NNP - B-MEDICINE
in ADP - O
the DT - B-ORG
European NNP - I-ORG
Union NNP - I-ORG
: PUNCT - O
Results NOUN - O
from ADP - O
a DET - O
Post PROPN - O
- PROPN - O
Authorization PROPN - O
Safety PROPN - O
Study PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Successful ADJ - O
Treatment PROPN - O
of ADP - O
Delusional PROPN - O
Disorder PROPN - O
With ADP - O
Aripiprazole NNP - B-MEDICINE
Long PROPN - O
- PUNCT - O
Acting PROPN - O
Injection PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
is VERB - O
a DET - O
third JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
atypical ADJ - O
antipsychotic ADJ - O
medication NOUN - O
, PUNCT - O
which ADJ - O
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
various ADJ - O
psychiatric ADJ - O
disorders NOUN - O
across ADP - O
the DET - O
lifespan NOUN - O
. PUNCT - O

Aripiprazole NN - B-MEDICINE
can VERB - O
cause VERB - O
side NOUN - O
effects NOUN - O
including VERB - O
headache NOUN - O
, PUNCT - O
insomnia NOUN - O
, PUNCT - O
agitation NOUN - O
, PUNCT - O
nervousness NOUN - O
, PUNCT - O
lightheadedness ADJ - O
, PUNCT - O
dizziness NOUN - O
, PUNCT - O
somnolence NOUN - O
, PUNCT - O
akathisia NOUN - O
, PUNCT - O
and CCONJ - O
weight NOUN - O
gain NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
sleep NOUN - O
- PUNCT - O
related VERB - O
eating NOUN - O
disorder NOUN - O
: PUNCT - O
a DET - O
case NOUN - O
report NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NNP - B-MEDICINE
's PART - O
effects NOUN - O
on ADP - O
cognitive ADJ - O
function NOUN - O
in ADP - O
patients NOUN - O
with ADP - O
schizophrenia NOUN - O
are VERB - O
unclear ADJ - O
because ADP - O
of ADP - O
the DET - O
difficulty NOUN - O
in ADP - O
disentangling VERB - O
specific ADJ - O
effects NOUN - O
on ADP - O
cognitive ADJ - O
function NOUN - O
from ADP - O
secondary ADJ - O
effects NOUN - O
due ADP - O
to ADP - O
the DET - O
improvement NOUN - O
in ADP - O
other ADJ - O
schizophrenic ADJ - O
symptoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Prolonged VERB - O
QRS PROPN - O
Widening VERB - O
After ADP - O
Aripiprazole NNP - B-MEDICINE
Overdose PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Hyperprolactinemic NNP - B-PERSON
Galactorrhea NNP - I-PERSON
as ADP - O
a DET - O
Side PROPN - O
Effect NOUN - O
of ADP - O
Aripiprazole NNP - B-MEDICINE
: PUNCT - O
An DET - O
Adolescent PROPN - O
Case PROPN - O
( PUNCT - O
Aripiprazole NNP - B-MEDICINE
- PUNCT - O
Related VERB - O
Hyperprolactinemic PROPN - O
Galactorrhea PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
reversed VERB - O
gastroparesis NOUN - O
in ADP - O
a DET - O
child NOUN - O
with ADP - O
1q21.1-q21.2 CD - B-CARDINAL
microdeletion NN - I-CARDINAL
. PUNCT - O

-DOCSTART- -X- - O

Add NOUN - O
- PUNCT - O
on ADP - O
Aripiprazole NNP - B-MEDICINE
for ADP - O
Atypical PROPN - O
Antipsychotic PROPN - O
- PUNCT - O
induced VERB - O
, PUNCT - O
Clinically PROPN - O
Significant PROPN - O
Hyperprolactinemia PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Aripiprazole NN - B-MEDICINE
- PUNCT - O
induced VERB - O
transient NOUN - O
myopia NOUN - O
: PUNCT - O
A DET - O
rare ADJ - O
entity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
is VERB - O
a DET - O
widely ADV - O
- PUNCT - O
used VERB - O
high ADJ - O
spectrum NOUN - O
antifungal NOUN - O
due ADP - O
to ADP - O
its ADJ - O
low ADJ - O
systemic ADJ - O
absorption NOUN - O
. PUNCT - O

Nystatin NNP - B-MEDICINE
was VERB - O
homogenously ADV - O
dispersed VERB - O
in ADP - O
the DET - O
surfactant ADJ - O
matrix NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Pseudonocardia NNP - B-GPE
autotrophica PROPN - O
was VERB - O
previously ADV - O
identified VERB - O
to PART - O
produce VERB - O
a DET - O
toxicity NOUN - O
- PUNCT - O
reduced VERB - O
and CCONJ - O
solubility NOUN - O
- PUNCT - O
improved VERB - O
disaccharide NOUN - O
- PUNCT - O
containing VERB - O
anti ADJ - O
- ADJ - O
fungal ADJ - O
compound NOUN - O
belonging VERB - O
to ADP - O
the DET - O
tetraene NOUN - O
- PUNCT - O
family NOUN - O
, PUNCT - O
Nystatin NNP - B-MEDICINE
- PUNCT - O
like ADP - O
Pseudonocardia NNP - B-PERSON
Polyene NNP - I-PERSON
A1 NNP - I-PERSON
( PUNCT - O
NPP NNP - B-ORG
A1 NNP - I-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Interactions NOUN - O
between ADP - O
Terpinen-4-ol NNP - B-ORG
and CCONJ - O
Nystatin NNP - B-MEDICINE
on ADP - O
biofilm NOUN - O
of ADP - O
Candida JJ - B-GPE
albicans NOUN - O
and CCONJ - O
Candida NNP - B-GPE
tropicalis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NN - B-MEDICINE
and CCONJ - O
chlorhexidine NOUN - O
are VERB - O
extensively ADV - O
used VERB - O
in ADP - O
oral ADJ - O
medicine NOUN - O
; PUNCT - O
however ADV - O
, PUNCT - O
there ADV - O
is VERB - O
some DET - O
controversy NOUN - O
about ADP - O
the DET - O
possibility NOUN - O
of ADP - O
these DET - O
drugs NOUN - O
showing VERB - O
antagonism NOUN - O
. PUNCT - O

Nystatin NNP - B-MEDICINE
/ SYM - O
chlorhexidine NOUN - O
combinations NOUN - O
showed VERB - O
lower ADJ - O
activity NOUN - O
against ADP - O
C. NNP - B-ORG
albicans NOUN - O
biofilms NOUN - O
, PUNCT - O
except ADP - O
for ADP - O
that DET - O
with ADP - O
a DET - O
30-min CD - B-CARDINAL
interval NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Amphotericin PROPN - O
B PROPN - O
, PUNCT - O
Nystatin NNP - B-MEDICINE
, PUNCT - O
and CCONJ - O
Fluconazole NNP - B-PERSON
were VERB - O
conjugated VERB - O
with ADP - O
silver NOUN - O
nanoparticles NOUN - O
, PUNCT - O
and CCONJ - O
synthesis NOUN - O
was VERB - O
confirmed VERB - O
using VERB - O
UV NOUN - O
- PUNCT - O
visible ADJ - O
spectrophotometry NOUN - O
. PUNCT - O

The DET - O
findings NOUN - O
revealed VERB - O
that ADP - O
silver NOUN - O
nanoparticles NOUN - O
conjugation NOUN - O
significantly ADV - O
enhanced VERB - O
antiamoebic ADJ - O
effects NOUN - O
of ADP - O
Nystatin NNP - B-MEDICINE
and CCONJ - O
Amphotericin PROPN - O
B PROPN - O
but CCONJ - O
not ADV - O
Fluconazole NNP - B-PERSON
at ADP - O
micromolar ADJ - O
concentrations NOUN - O
, PUNCT - O
compared VERB - O
with ADP - O
the DET - O
drugs NOUN - O
alone ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
molecular ADJ - O
mechanism NOUN - O
of ADP - O
Nystatin NNP - B-MEDICINE
action NOUN - O
is VERB - O
dependent ADJ - O
on ADP - O
the DET - O
membrane ADJ - O
biophysical ADJ - O
properties NOUN - O
and CCONJ - O
lipid ADJ - O
composition NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
, PUNCT - O
a DET - O
lipid ADJ - O
raft NOUN - O
inhibitor NOUN - O
, PUNCT - O
reduced VERB - O
ER PROPN - O
- PUNCT - O
c PROPN - O
- PUNCT - O
Src PROPN - O
- PUNCT - O
HER2 PROPN - O
complex ADJ - O
formation NOUN - O
and CCONJ - O
partially ADV - O
reversed VERB - O
tamoxifen NOUN - O
resistance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Additional ADJ - O
animals NOUN - O
were VERB - O
treated VERB - O
with ADP - O
Nystatin NNP - B-MEDICINE
( PUNCT - O
NYS NNP - B-ORG
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
rather ADV - O
than ADP - O
miconazole NOUN - O
should VERB - O
be VERB - O
preferred VERB - O
when ADV - O
treating VERB - O
warfarin NOUN - O
users NOUN - O
for ADP - O
oral ADJ - O
candidiasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Antifungal ADJ - O
polyene NOUN - O
macrolide NOUN - O
antibiotics NOUN - O
Amphotericin PROPN - O
B PROPN - O
( PUNCT - O
AmB NN - B-ORG
) PUNCT - O
and CCONJ - O
Nystatin NNP - B-MEDICINE
( PUNCT - O
NYS NNP - B-ORG
) PUNCT - O
were VERB - O
conjugated VERB - O
through ADP - O
the DET - O
ω NUM - O
- PUNCT - O
amino NOUN - O
acid NOUN - O
linkers NOUN - O
with ADP - O
diwalled ADJ - O
" PUNCT - O
molecular ADJ - O
umbrellas NOUN - O
" PUNCT - O
composed VERB - O
of ADP - O
spermidine NOUN - O
- PUNCT - O
linked VERB - O
deoxycholic NOUN - O
or CCONJ - O
cholic NOUN - O
acids NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
and CCONJ - O
miconazole NOUN - O
: PUNCT - O
pharmacological ADJ - O
and CCONJ - O
clinical ADJ - O
evidence NOUN - O
regarding VERB - O
interactions NOUN - O
with ADP - O
warfarin NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
A1 NNP - I-PERSON
, PUNCT - O
a DET - O
polyene NOUN - O
macrolide NOUN - O
antifungal NOUN - O
antibiotic NOUN - O
, PUNCT - O
in ADP - O
a DET - O
slightly ADV - O
basic ADJ - O
or CCONJ - O
acidic ADJ - O
solution NOUN - O
undergoes VERB - O
an DET - O
intramolecular ADJ - O
transformation NOUN - O
, PUNCT - O
yielding VERB - O
a DET - O
structural ADJ - O
isomer NOUN - O
, PUNCT - O
the DET - O
translactonization NOUN - O
product NOUN - O
, PUNCT - O
iso NOUN - O
- PUNCT - O
nystatin NN - B-MEDICINE
A1 PROPN - O
with ADP - O
lactone NOUN - O
ring NOUN - O
diminished VERB - O
by ADP - O
two CD - B-CARDINAL
carbon NOUN - O
atoms NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

● PUNCT - O
Support NOUN - O
for ADP - O
WHO PROPN - O
standards NOUN - O
on ADP - O
reporting VERB - O
clinical ADJ - O
trial NOUN - O
results NOUN - O
● PUNCT - O
Delayed VERB - O
antibiotic ADJ - O
prescription NOUN - O
for ADP - O
lower ADJ - O
respiratory ADJ - O
tract NOUN - O
infections NOUN - O
● PUNCT - O
Nystatin NNP - B-MEDICINE
dose VERB - O
change NOUN - O
- PUNCT - O
much ADJ - O
ado NOUN - O
about ADP - O
nothing NOUN - O
? PUNCT - O

-DOCSTART- -X- - O

Nystatin NNP - B-MEDICINE
induced VERB - O
significantly ADV - O
more ADV - O
biofilm ADJ - O
and CCONJ - O
overall ADJ - O
growth NOUN - O
than ADP - O
the DET - O
control NOUN - O
at ADP - O
all DET - O
concentrations NOUN - O
. PUNCT - O

Nystatin NNP - B-MEDICINE
provided VERB - O
an DET - O
increase NOUN - O
in ADP - O
biofilm NOUN - O
and CCONJ - O
growth NOUN - O
at ADP - O
each DET - O
concentration NOUN - O
tested VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Further ADV - O
, PUNCT - O
while ADP - O
the DT - B-ORG
Food NNP - I-ORG
and CC - I-ORG
Drug NNP - I-ORG
Administration NNP - I-ORG
has VERB - O
pointed VERB - O
out PART - O
that ADP - O
female ADJ - O
dosing NOUN - O
should VERB - O
be VERB - O
half PDT - B-CARDINAL
that ADV - O
given VERB - O
to ADP - O
males NOUN - O
, PUNCT - O
results NOUN - O
of ADP - O
this DET - O
population NOUN - O
testing NOUN - O
indicate VERB - O
that ADP - O
the DET - O
majority NOUN - O
of ADP - O
patients NOUN - O
( PUNCT - O
83 CD - B-PERCENT
% NN - I-PERCENT
male NOUN - O
and CCONJ - O
73 CD - B-PERCENT
% NN - I-PERCENT
female ADJ - O
) PUNCT - O
receive VERB - O
10 CD - B-DATE
mg NN - I-DATE
/ SYM - I-DATE
day NN - I-DATE
or CCONJ - O
12.5 CD - B-CARDINAL
mg NOUN - O
/ SYM - O
day NOUN - O
for ADP - O
Ambien NNP - B-FAC
CR NNP - I-FAC
® NN - I-FAC
with ADP - O
females NOUN - O
demonstrating VERB - O
statistically ADV - O
significantly ADV - O
higher ADJ - O
levels NOUN - O
of ADP - O
ZCA NNP - B-ORG
albeit ADP - O
zolpidem NOUN - O
levels NOUN - O
are VERB - O
not ADV - O
statistically ADV - O
significantly ADV - O
different ADJ - O
between ADP - O
men NOUN - O
and CCONJ - O
women NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
AUC(1.5-t NNP - B-PRODUCT
) PUNCT - O
parameter NOUN - O
ensured VERB - O
equivalence NOUN - O
with ADP - O
respect NOUN - O
to ADP - O
the DET - O
sustained ADJ - O
release NOUN - O
phase NOUN - O
of ADP - O
Ambien NNP - B-ORG
CR NNP - I-ORG
. PUNCT - O

In ADP - O
addition NOUN - O
to ADP - O
the DET - O
traditional ADJ - O
PK NNP - B-ORG
parameters NOUN - O
of ADP - O
AUCinf NNP - B-ORG
and CCONJ - O
Cmax NNP - B-ORG
, PUNCT - O
AUC(0 NNP - B-PRODUCT
- HYPH - I-PRODUCT
1.5 CD - I-PRODUCT
) PUNCT - O
and CCONJ - O
AUC(1.5-t NNP - B-ORG
) PUNCT - O
are VERB - O
recommended VERB - O
to PART - O
provide VERB - O
bioequivalence NOUN - O
measures NOUN - O
with ADP - O
respect NOUN - O
to ADP - O
label NOUN - O
indications NOUN - O
for ADP - O
Ambien NNP - B-FAC
CR NNP - I-FAC
: PUNCT - O
onset NOUN - O
of ADP - O
sleep NOUN - O
and CCONJ - O
sleep NOUN - O
maintenance NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
extended ADJ - O
- PUNCT - O
release NOUN - O
formulation NOUN - O
of ADP - O
zolpidem NOUN - O
( PUNCT - O
Ambien NNP - B-ORG
CR NNP - I-ORG
) PUNCT - O
is VERB - O
approved VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
insomnia NOUN - O
without ADP - O
a DET - O
treatment NOUN - O
duration NOUN - O
limit NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
was VERB - O
administered VERB - O
to ADP - O
73 CD - B-CARDINAL
, PUNCT - O
39 CD - B-DATE
, PUNCT - O
24 CD - B-DATE
, PUNCT - O
and CCONJ - O
six CD - B-CARDINAL
patients NOUN - O
for ADP - O
more JJR - B-CARDINAL
than IN - I-CARDINAL
1 CD - I-CARDINAL
, PUNCT - O
3 CD - B-CARDINAL
, PUNCT - O
5 CD - B-DATE
, PUNCT - O
and CCONJ - O
10 CD - B-CARDINAL
  SPACE - O
years NNS - B-DATE
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
combined VERB - O
with ADP - O
NB NNP - B-ORG
- HYPH - I-ORG
UVB NNP - I-ORG
in ADP - O
the DET - O
treatment NOUN - O
of ADP - O
cutaneous ADJ - O
CD30-positive ADP - O
anaplastic ADJ - O
large ADJ - O
cell NOUN - O
lymphoma NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
is VERB - O
a DET - O
second JJ - B-ORDINAL
- PUNCT - O
generation NOUN - O
synthetic ADJ - O
retinoid NOUN - O
, PUNCT - O
and CCONJ - O
is VERB - O
widely ADV - O
used VERB - O
for ADP - O
treating VERB - O
the DET - O
severe ADJ - O
psoriasis NOUN - O
vulgaris NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
did VERB - O
not ADV - O
induce VERB - O
HIV PROPN - O
reactivation NOUN - O
in ADP - O
latently ADV - O
infected VERB - O
cell NOUN - O
lines NOUN - O
( PUNCT - O
J PROPN - O
- PUNCT - O
Lat PROPN - O
and CCONJ - O
ACH-2 PROPN - O
) PUNCT - O
. PUNCT - O

Acitretin JJ - B-MEDICINE
induction NOUN - O
was VERB - O
insignificant ADJ - O
, PUNCT - O
however ADV - O
, PUNCT - O
compared VERB - O
to ADP - O
optimal ADJ - O
concentrations NOUN - O
of ADP - O
LRAs NOUN - O
. PUNCT - O

Acitretin NNP - B-MEDICINE
failed VERB - O
to PART - O
reactivate VERB - O
HIV PROPN - O
in ADP - O
a DET - O
model NOUN - O
of ADP - O
latently ADV - O
infected VERB - O
primary ADJ - O
CD4 PROPN - O
+ CCONJ - O
T PROPN - O
cells NOUN - O
but CCONJ - O
induced VERB - O
retinoic ADJ - O
acid NOUN - O
- PUNCT - O
inducible ADJ - O
gene NOUN - O
I PRON - O
( PUNCT - O
RIG PROPN - O
- PUNCT - O
I NOUN - O
) PUNCT - O
and CCONJ - O
mitochondrial ADJ - O
antiviral ADJ - O
signaling NOUN - O
( PUNCT - O
MAVS NOUN - O
) PUNCT - O
expression NOUN - O
in ADP - O
infected ADJ - O
and CCONJ - O
uninfected ADJ - O
cells NOUN - O
, PUNCT - O
confirming VERB - O
the DET - O
role NOUN - O
of ADP - O
acitretin NN - B-MEDICINE
as ADP - O
an DET - O
innate ADJ - O
immune ADJ - O
modulator NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Evaluation NOUN - O
of ADP - O
the DET - O
Innate PROPN - O
Immune PROPN - O
Modulator PROPN - O
Acitretin NNP - B-MEDICINE
as ADP - O
a DET - O
Strategy PROPN - O
To PART - O
Clear VERB - O
the DET - O
HIV PROPN - O
Reservoir PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
as ADP - O
a DET - O
Therapeutic PROPN - O
Option NOUN - O
for ADP - O
Chronic PROPN - O
Hand PROPN - O
Eczema PROPN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
has VERB - O
been VERB - O
a DET - O
valuable ADJ - O
option NOUN - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
psoriasis NOUN - O
, PUNCT - O
however ADV - O
, PUNCT - O
the DET - O
molecular ADJ - O
events NOUN - O
of ADP - O
acitretin NN - B-MEDICINE
leading VERB - O
to ADP - O
the DET - O
normalization NOUN - O
of ADP - O
keratinocytes NOUN - O
differentiation NOUN - O
on ADP - O
psoriasis NOUN - O
patients NOUN - O
have VERB - O
not ADV - O
been VERB - O
fully ADV - O
explored VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
is VERB - O
one CD - B-CARDINAL
of ADP - O
the DET - O
systemic ADJ - O
agents NOUN - O
used VERB - O
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
psoriasis NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin JJ - B-MEDICINE
for ADP - O
the DET - O
treatment NOUN - O
of ADP - O
recalcitrant ADJ - O
plantar NOUN - O
warts NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Acitretin NNP - B-MEDICINE
proved VERB - O
to PART - O
be VERB - O
a DET - O
highly ADV - O
effective ADJ - O
therapeutic ADJ - O
option NOUN - O
in ADP - O
an DET - O
infant NOUN - O
with ADP - O
annular ADJ - O
PP NN - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

Pivotal ADJ - O
role NOUN - O
of ADP - O
Acitretin JJ - B-MEDICINE
nanovesicular NOUN - O
gel NOUN - O
for ADP - O
effective ADJ - O
treatment NOUN - O
of ADP - O
psoriasis NOUN - O
: PUNCT - O
ex X - O
vivo NOUN - O
- PUNCT - O
in PART - O
vivo NOUN - O
evaluation NOUN - O
study NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
objective NOUN - O
was VERB - O
to PART - O
evaluate VERB - O
the DET - O
efficacy NOUN - O
of ADP - O
a DET - O
Northamerican JJ - B-NORP
Virginian PROPN - O
Witch NNP - B-PERSON
Hazel NNP - I-PERSON
( PUNCT - O
Hamamelis NNP - B-PERSON
virginiana)-based PROPN - O
shampoo NOUN - O
and CCONJ - O
tonic NOUN - O

-DOCSTART- -X- - O

Conversion NOUN - O
of ADP - O
phenolic NOUN - O
constituents NOUN - O
in ADP - O
aqueous ADJ - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
leaf NOUN - O
extracts VERB - O
during ADP - O
fermentation NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Since ADP - O
tannins NOUN - O
of ADP - O
different ADJ - O
classes NOUN - O
and CCONJ - O
molecular ADJ - O
weights NOUN - O
are VERB - O
often ADV - O
found VERB - O
together ADV - O
in ADP - O
plant NOUN - O
extracts NOUN - O
and CCONJ - O
may VERB - O
differ VERB - O
in ADP - O
their ADJ - O
antiviral ADJ - O
activity NOUN - O
, PUNCT - O
we PRON - O
have VERB - O
compared VERB - O
the DET - O
effect NOUN - O
against ADP - O
influenza NOUN - O
A DET - O
virus NOUN - O
( PUNCT - O
IAV PROPN - O
) PUNCT - O
of ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
L. NNP - B-PERSON
bark NOUN - O
extract NOUN - O
, PUNCT - O
fractions NOUN - O
enriched VERB - O
in ADP - O
tannins NOUN - O
of ADP - O
different ADJ - O
molecular ADJ - O
weights NOUN - O
and CCONJ - O
individual ADJ - O
tannins NOUN - O
of ADP - O
defined VERB - O
structures NOUN - O
, PUNCT - O
including VERB - O
pseudotannins NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Tannins NOUN - O
from ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
bark NOUN - O
extract NOUN - O
: PUNCT - O
characterization NOUN - O
and CCONJ - O
improvement NOUN - O
of ADP - O
the DET - O
antiviral ADJ - O
efficacy NOUN - O
against ADP - O
influenza NOUN - O
A DET - O
virus NOUN - O
and CCONJ - O
human ADJ - O
papillomavirus NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Witch NOUN - O
hazel NOUN - O
( PUNCT - O
Hamamelis NNP - B-NORP
virginiana PROPN - O
) PUNCT - O
fractions NOUN - O
and CCONJ - O
the DET - O
importance NOUN - O
of ADP - O
gallate ADJ - O
moieties NOUN - O
-- PUNCT - O
electron ADJ - O
transfer NOUN - O
capacities NOUN - O
in ADP - O
their ADJ - O
antitumoral ADJ - O
properties NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Polymeric ADJ - O
proanthocyanidins NOUN - O
were VERB - O
isolated VERB - O
from ADP - O
the DET - O
bark NOUN - O
of ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
L. NNP - B-PERSON
in ADP - O
yields NOUN - O
of ADP - O
about IN - B-PERCENT
5 CD - I-PERCENT
% NN - I-PERCENT
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
aqueous ADJ - O
ethanolic NOUN - O
extracts NOUN - O
of ADP - O
Polygonum NNP - B-ORG
bistorta NOUN - O
L. NNP - B-PERSON
Polygonaceae NNP - I-PERSON
, PUNCT - O
Guaiacum NNP - B-PERSON
officinale NOUN - O
L. NNP - B-PERSON
Zygophyllaceae NNP - I-PERSON
and CCONJ - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
L. NNP - B-PERSON
Hamamelidaceae NNP - I-PERSON
were VERB - O
screened VERB - O
for ADP - O
anti ADJ - O
- ADJ - O
inflammatory ADJ - O
activity NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Dual ADJ - O
inhibitory NOUN - O
activities NOUN - O
of ADP - O
tannins NOUN - O
from ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
and CCONJ - O
related ADJ - O
polyphenols NOUN - O
on ADP - O
5-lipoxygenase CD - B-PRODUCT
and CCONJ - O
lyso NOUN - O
- PUNCT - O
PAF PROPN - O
: PUNCT - O
acetyl NOUN - O
- PUNCT - O
CoA NOUN - O
acetyltransferase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Syzygium NN - B-ORG
aqueum NOUN - O
, PUNCT - O
Hamamelis NNP - B-NORP
virginiana NOUN - O
, PUNCT - O
Coccoloba NNP - B-ORG
pubescens NOUN - O
, PUNCT - O
Rhus PROPN - O
integrifolia NOUN - O
and CCONJ - O
Nuphar NNP - B-PERSON
luteum NOUN - O
were VERB - O
identified VERB - O
as ADV - O
highly ADV - O
potent ADJ - O
antitrypanosomal ADJ - O
extracts NOUN - O
with ADP - O
IC50 PROPN - O
values NOUN - O
< X - O
1 CD - B-CARDINAL
  SPACE - O

-DOCSTART- -X- - O

The DET - O
present ADJ - O
invention NOUN - O
relates VERB - O
to ADP - O
a DET - O
process NOUN - O
for ADP - O
preparing VERB - O
a DET - O
concentrated VERB - O
Hamamelis NNP - B-NORP
virginiana NOUN - O
extract NOUN - O
. PUNCT - O
  SPACE - O

-DOCSTART- -X- - O

Collagen NN - B-ORG
sponges NOUN - O
loaded VERB - O
with ADP - O
polyphenols NOUN - O
from ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
were VERB - O
investigated VERB - O
as ADP - O
active ADJ - O
materials NOUN - O
for ADP - O
chronic ADJ - O
wound NOUN - O
dressings NOUN - O
, PUNCT - O
evaluating VERB - O
in ADP - O
vitro NOUN - O
the DET - O
inhibition NOUN - O
of ADP - O
two CD - B-CARDINAL
major ADJ - O
enzymes NOUN - O
that ADJ - O
impair VERB - O
the DET - O
wound NOUN - O
healing VERB - O
process NOUN - O
- PUNCT - O
myeloperoxidase NOUN - O
( PUNCT - O
MPO NNP - B-ORG
) PUNCT - O
and CCONJ - O
collagenase NOUN - O
. PUNCT - O

-DOCSTART- -X- - O

Homologous ADJ - O
fractions NOUN - O
with ADP - O
galloylation NOUN - O
ranging VERB - O
from ADP - O
0.25 CD - B-CARDINAL
to ADP - O
< X - O
1 CD - B-CARDINAL
gallate ADJ - O
group NOUN - O
per ADP - O
molecule NOUN - O
were VERB - O
obtained VERB - O
from ADP - O
grape NOUN - O
( PUNCT - O
Vitis NNP - B-NORP
vinifera PROPN - O
) PUNCT - O
and CCONJ - O
witch NOUN - O
hazel NOUN - O
( PUNCT - O
Hamamelis NNP - B-NORP
virginiana PROPN - O
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Plant NOUN - O
extracts VERB - O
from ADP - O
witch NOUN - O
hazel NOUN - O
( PUNCT - O
Hamamelis NNP - B-NORP
virginiana PROPN - O
) PUNCT - O
, PUNCT - O
green ADJ - O
tea NOUN - O
( PUNCT - O
Camellia PROPN - O
sinensis NOUN - O
) PUNCT - O
, PUNCT - O
the DET - O
fern NOUN - O
Polypodium NNP - B-GPE
leucotomos NOUN - O
and CCONJ - O
others NOUN - O
contain VERB - O
antioxidant NOUN - O
polyphenolic ADJ - O
compounds NOUN - O
that ADJ - O
may VERB - O
protect VERB - O
the DET - O
skin NOUN - O
from ADP - O
sunburn NOUN - O
and CCONJ - O
photoaging NOUN - O
when ADV - O
administered VERB - O
topically ADV - O
or CCONJ - O
systemically ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
at RB - B-CARDINAL
least RBS - I-CARDINAL
one CD - I-CARDINAL
astringent NOUN - O
may VERB - O
comprise VERB - O
Hamamelis NNP - B-NORP
virginiana NOUN - O
extract NOUN - O
( PUNCT - O
Witch NNP - B-PERSON
Hazel NNP - I-PERSON
) PUNCT - O
. PUNCT - O

-DOCSTART- -X- - O

Hamamelitannin NNP - B-ORG
is VERB - O
a DET - O
natural ADJ - O
product NOUN - O
found VERB - O
in ADP - O
the DET - O
bark NOUN - O
of ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
( PUNCT - O
witch NOUN - O
hazel PROPN - O
) PUNCT - O
, PUNCT - O
and CCONJ - O
it PRON - O
has VERB - O
no DET - O
effect NOUN - O
on ADP - O
staphylococcal ADJ - O
growth NOUN - O
in ADP - O
vitro NOUN - O
; PUNCT - O
but CCONJ - O
like ADP - O
RIP NNP - B-ORG
, PUNCT - O
it PRON - O
does VERB - O
inhibit VERB - O
the DET - O
quorum NOUN - O
- PUNCT - O
sensing VERB - O
regulator NOUN - O
RNAIII NNP - B-PERSON
. PUNCT - O

-DOCSTART- -X- - O

An DET - O
extract NOUN - O
( PUNCT - O
I NOUN - O
) PUNCT - O
of ADP - O
parts NOUN - O
of ADP - O
the DET - O
plant NOUN - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
  SPACE - O

-DOCSTART- -X- - O

These DET - O
properties NOUN - O
seem VERB - O
to PART - O
be VERB - O
related VERB - O
to ADP - O
the DET - O
high ADJ - O
tannin NOUN - O
content NOUN - O
of ADP - O
S. NN - B-NORP
jambos NOUN - O
extracts NOUN - O
( PUNCT - O
77 NUM - O
and CCONJ - O
83 CD - B-PERCENT
% NN - I-PERCENT
for ADP - O
the DET - O
aqueous ADJ - O
and CCONJ - O
acetone NOUN - O
extracts NOUN - O
, PUNCT - O
respectively ADV - O
, PUNCT - O
determined VERB - O
according VERB - O
to ADP - O
the DT - B-ORG
European NNP - I-ORG
Pharmacopoeia NNP - I-ORG
method NOUN - O
) PUNCT - O
which ADJ - O
were VERB - O
generally ADV - O
more ADV - O
active ADJ - O
than ADP - O
Hamamelis NNP - B-NORP
virginiana NOUN - O
, PUNCT - O
Krameria NNP - B-GPE
triandra NOUN - O
, PUNCT - O
Alchemilla NNP - B-PERSON
vulgaris NOUN - O
and CCONJ - O
Rubus NNP - B-ORG
fruticosus NOUN - O
extracts NOUN - O
containing VERB - O
48 CD - B-CARDINAL
, PUNCT - O
44 CD - B-DATE
, PUNCT - O
46 CD - B-DATE
and CCONJ - O
28 CD - B-PERCENT
% NN - I-PERCENT
tannins NOUN - O
, PUNCT - O
respectively ADV - O
. PUNCT - O

-DOCSTART- -X- - O

The DET - O
protective ADJ - O
activities NOUN - O
of ADP - O
hamamelitannin PROPN - O
( PUNCT - O
2',5-di NUM - O
- PUNCT - O
O NOUN - O
- PUNCT - O
galloyl NOUN - O
- PUNCT - O
hamamelose NOUN - O
) PUNCT - O
in ADP - O
Hamamelis NNP - B-GPE
virginiana NOUN - O
L. NNP - B-PERSON
and CCONJ - O
its ADJ - O
related ADJ - O
compound NOUN - O
, PUNCT - O
gallic NOUN - O
acid NOUN - O
, PUNCT - O
on ADP - O
damaged VERB - O
murine NOUN - O
skin NOUN - O
fibroblasts NOUN - O
induced VERB - O
by ADP - O
UVB PROPN - O
irradiation NOUN - O
were VERB - O
investigated VERB - O
. PUNCT - O

-DOCSTART- -X- - O

Determination NOUN - O
of ADP - O
Escitalopram NNP - B-MEDICINE
Oxalate NNP - I-MEDICINE
and CCONJ - O
L PROPN - O
- PUNCT - O
Methylfolate PROPN - O
in ADP - O
Tablet NNP - B-ORG
by ADP - O
Spectrophotometric NNP - B-PERSON
and CCONJ - O
Reverse PROPN - O
Phase PROPN - O
High PROPN - O
- PUNCT - O
Performance PROPN - O
Liquid PROPN - O
Chromatographic NNP - B-PERSON
Methods NNP - I-PERSON
. PUNCT - O

